<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />



<title>Covid-19 trials</title>

<meta property="og:title" content="Covid-19 trials" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script src="site_libs/header-attrs-2.1/header-attrs.js"></script>
<script src="site_libs/jquery-1.12.4/jquery.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<script src="site_libs/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<script src="site_libs/htmlwidgets-1.5.1/htmlwidgets.js"></script>
<link href="site_libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="site_libs/datatables-binding-0.13/datatables.js"></script>
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="site_libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="site_libs/crosstalk-1.0.0/css/crosstalk.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.0.0/js/crosstalk.min.js"></script>
<link href="site_libs/nouislider-7.0.10/jquery.nouislider.min.css" rel="stylesheet" />
<script src="site_libs/nouislider-7.0.10/jquery.nouislider.min.js"></script>
<link href="site_libs/selectize-0.12.0/selectize.bootstrap3.css" rel="stylesheet" />
<script src="site_libs/selectize-0.12.0/selectize.min.js"></script>
<style type="text/css">

/*
 Dashboard CSS from Keen IO Dashboards
 (https://github.com/keen/dashboards)
*/

body {
  background: #f2f2f2;
  padding: 60px 0 0 8px; /* padding-top overridden by theme */
}

body hr {
  border-color: #d7d7d7;
  margin: 10px 0;
}

.navbar-inverse .navbar-nav > li > a,
.navbar .navbar-brand {
  text-decoration: none;
}

.navbar-logo {
  margin-top: 1px;
}

.navbar-logo img {
  margin-right: 12px;
}

.navbar-author {
  margin-left: 10px;
  font-size: 15px;
}

.navbar .dropdown-menu .fa {
  min-width: 20px;
}

.navbar .dropdown-menu {
  min-width: 150px;
  max-height: 500px;
  overflow: auto;
}

.chart-wrapper,
.nav-tabs-custom,
.sbframe-commentary
{
  background: #fff;
  border: 1px solid #e2e2e2;
  border-radius: 3px;
  margin-bottom: 8px;
  margin-right: 8px;
}

.chart-title {
  border-bottom: 1px solid #d7d7d7;
  color: #666;
  font-size: 14px;
  font-weight: 300;
  padding: 7px 10px 4px;
}

.chart-wrapper .chart-title:empty {
  display: none;
}

.chart-wrapper .chart-stage {
  overflow: hidden;
  padding: 5px 10px;
  position: relative;
}

.chart-wrapper .chart-notes {
  background: #fbfbfb;
  border-top: 1px solid #e2e2e2;
  color: #808080;
  font-size: 12px;
  padding: 8px 10px 5px;
}

/*
 CSS for handling flexbox layout
*/

#dashboard-container {
  visibility: hidden;
}

.tab-content>.dashboard-page-wrapper.active {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.dashboard-page-wrapper {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.dashboard-row-orientation {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.dashboard-row {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: horizontal;
  -webkit-box-direction: normal;
  -webkit-flex-direction: row;
      -ms-flex-direction: row;
          flex-direction: row;
}

.dashboard-row-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
}

.dashboard-column-orientation {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: horizontal;
  -webkit-box-direction: normal;
  -webkit-flex-direction: row;
      -ms-flex-direction: row;
          flex-direction: row;
}

.dashboard-column {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.chart-wrapper-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.chart-stage-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  position: relative;
}

.chart-shim {
  position: absolute;
  left: 8px; top: 8px; right: 8px; bottom: 8px;
}

.no-padding .chart-shim {
  left: 0; top: 0; right: 0; bottom: 0;
}

.flowing-content-shim {
  overflow: auto;
  left: 0; top: 0; right: 0; bottom: 0;
  padding-left: 8px;
  padding-right: 8px;
}

.flowing-content-container {
  padding-top: 8px;
  padding-bottom: 8px;
}

.chart-stage .table-bordered {
  border: none;
}

.chart-stage .table-bordered > tbody > tr > th,
.chart-stage .table-bordered > tfoot > tr > th,
.chart-stage .table-bordered > tbody > tr > td,
.chart-stage .table-bordered > tfoot > tr > td {
  border: none;
}

.chart-stage .table-bordered > tbody > tr > td {
  border-top: 1px solid #dddddd;
}

.chart-stage .table-bordered > thead > tr > th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.bootstrap-table table>thead {
  background-color: #fff;
}

.bootstrap-table table.data,
.bootstrap-table table.shiny-table {
  width: inherit !important;
}

.bootstrap-table table.data>tbody>tr>th,
.bootstrap-table table.shiny-table>tbody>tr>th {
  border-top: none;
  border-bottom: 2px solid #dddddd;
  padding: 5px;
}

.bootstrap-table .data td[align=right] {
  font-family: inherit;
}

.chart-wrapper form {
  padding-left: 5px;
  padding-right: 5px;
}

.shiny-input-container label {
  font-weight: normal;
}

.chart-stage .html-widget {
  width: 100% !important;
  height: 100% !important;
}

.chart-stage .html-widget-static-bound {
  width: 100% !important;
  height: 100% !important;
}

.chart-stage .shiny-bound-output {
  width: 100% !important;
  height: 100% !important;
}

/* Omit display of empty paragraphs */

.chart-shim>p:empty {
  display: none;
}

.chart-stage>p:empty {
  display: none;
}

/* Omit display of special knitr options div*/

.chart-stage .knitr-options {
  display: none;
}

/* Automatically resizing images */

.image-container {
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  margin: 0;
}

.image-container img {
  opacity: 0;
  overflow: hidden;
}

/* Value box */

.value-box {
  border-radius: 2px;
  position: relative;
  display: block;
  margin-right: 8px;
  margin-bottom: 8px;
  box-shadow: 0 1px 1px rgba(0, 0, 0, 0.1);
}

.value-box > .inner {
  padding: 10px;
  padding-left: 20px;
  padding-right: 20px;
}

.value-box .value {
  font-size: 38px;
  font-weight: bold;
  margin: 0 0 3px 0;
  white-space: nowrap;
  padding: 0;
}

.value-box .caption {
  font-size: 15px;
}
.value-box .caption > small {
  display: block;
  font-size: 13px;
  margin-top: 5px;
}

.value-box .icon i {
  position: absolute;
  top: 15px;
  right: 15px;
  font-size: 80px;
  color: rgba(0, 0, 0, 0.15);
}

.linked-value:hover {
  cursor: pointer;
}

.value-box.linked-value:hover {
  box-shadow: 0 2px 2px rgba(0, 0, 0, 0.3);
}

/* STORYBOARD */

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
  font-size: 50px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  background: #fff;
  border: 1px solid #e2e2e2;
  border-radius: 3px;
  color: #3a3c47;
  text-align: left;
  font-size: 14px;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.storyboard-nav .sbframelist ul li.active {
  color: #fff;
  background: #B8B8B8;
}

.sbframe-commentary {
  width: 300px;
  background: #fbfbfb;
  font-size: 14px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}

/* NAV TABS */

.nav-tabs-custom > .nav-tabs {
  margin: 0;
  border-bottom: 1px solid #d7d7d7;
  color: #666;
  font-size: 14px;
  font-weight: 300;
  border-top-right-radius: 3px;
  border-top-left-radius: 3px;
}
.nav-tabs-custom > .nav-tabs > li {
  border-top: 3px solid transparent;
  margin-bottom: -1px;
  margin-right: 5px;
}
.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:active {
  color: #666;
  font-weight: 300;
  font-size: 14px;
  border-radius: 0;
  padding: 3px 10px 5px;
  text-transform: none;
}

.nav-tabs-custom > .nav-tabs > li:not(.active) > a {
  border-bottom-color: transparent;
}

.nav-tabs-custom > .nav-tabs > li > a.text-muted {
  color: #999;
}
.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:hover {
  background: transparent;
  margin: 0;
}
.nav-tabs-custom > .nav-tabs > li > a:hover {
  color: #999;
}
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:hover,
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:focus,
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:active {
  border-color: transparent;
}
.nav-tabs-custom > .nav-tabs > li.active {
  border-top-color: #3c8dbc;
}
.nav-tabs-custom > .nav-tabs > li.active > a,
.nav-tabs-custom > .nav-tabs > li.active:hover > a {
  background-color: #fff;
  color: #666;
}
.nav-tabs-custom > .nav-tabs > li.active > a {
  border-top-color: transparent;
  border-left-color: #d7d7d7;
  border-right-color: #d7d7d7;
}
.nav-tabs-custom > .nav-tabs > li:first-of-type {
  margin-left: 0;
}
.nav-tabs-custom > .nav-tabs > li:first-of-type.active > a {
  border-left-color: transparent;
}
.nav-tabs-custom > .nav-tabs.pull-right {
  float: none !important;
}
.nav-tabs-custom > .nav-tabs.pull-right > li {
  float: right;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type {
  margin-right: 0;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type > a {
  border-left-width: 1px;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type.active > a {
  border-left-color: #d7d7d7;
  border-right-color: transparent;
}
.nav-tabs-custom > .nav-tabs > li.header {
  line-height: 35px;
  padding: 0 10px;
  font-size: 20px;
  color: #666;
}
.nav-tabs-custom > .nav-tabs > li.header > .fa,
.nav-tabs-custom > .nav-tabs > li.header > .glyphicon,
.nav-tabs-custom > .nav-tabs > li.header > .ion {
  margin-right: 5px;
}
.nav-tabs-custom > .tab-content {
  background: #fff;
  padding: 0;
  border-bottom-right-radius: 3px;
  border-bottom-left-radius: 3px;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.nav-tabs-custom > .tab-content > .chart-wrapper {
  background: #fff;
  border: none;
  margin: 0;
}


.nav-tabs-custom > .tab-content > .active {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.nav-tabs-custom .dropdown.open > a:active,
.nav-tabs-custom .dropdown.open > a:focus {
  background: transparent;
  color: #999;
}


@media (max-width: 767px) {
  .value-box {
    text-align: center;
    margin-right: 8px;
  }
  .value-box .icon {
    display: none;
  }
}

/* Fixed position sidebar */

.section.sidebar {
  position: fixed;
  top: 51px; /* overridden by theme */
  left: 0;
  bottom: 0;
  border-right: 1px solid #e2e2e2;
  background-color: white; /* overridden by theme */
  padding-left: 10px;
  padding-right: 10px;
  visibility: hidden;
  overflow: auto;
}

.section.sidebar form p:first-child {
  margin-top: 10px;
}

/* Embedded source code */

#flexdashboard-source-code {
  display: none;
}

.featherlight-content #flexdashboard-source-code {
  display: inline-block;
}

.featherlight-content {
  width: 80%;
  max-width: 800px;
  padding: 0 !important;
  border-bottom: none !important;
}

.featherlight:last-of-type {
  background: rgba(0, 0, 0, 0.7);
}

.featherlight-inner {
  width: 100%;
}

.featherlight-content pre {
  margin: 0;
  border: 0;
  background: #fff;
  font-size: 12px;
}

.unselectable {
  -ms-user-select: none;
  -webkit-user-select: none;
  -khtml-user-select: none;
  -moz-user-select: -moz-none;
  -o-user-select: none;
  user-select: none;
}

#flexdashboard-source-code code {
  -ms-user-select: text;
  -webkit-user-select: text;
  -khtml-user-select: text;
  -moz-user-select: text;
  -o-user-select: text;
  user-select: text;
}

/* DataTables Tweaks */

.dataTables_filter input[type="search"] {
  -webkit-appearance: searchfield;
  outline: none;
}

.dataTables_wrapper.no-footer
.dataTables_info {
  padding-top: 0;
}


table.dataTable thead th {
  border-bottom: 1px solid #d7d7d7;
}

.dataTables_wrapper.no-footer .dataTables_scrollBody {
  border-bottom: 1px solid #d7d7d7;
}

/* Mobile phone only CSS */

.desktop-layout div.section.mobile {
  display: none;
}

.mobile-layout div.section.no-mobile {
  display: none;
}

.mobile-figure {
  display: none;
}



body {
  padding-top: 60px;
}

.section.sidebar {
  top: 51px;
  background-color: rgba(39, 128, 227, 0.1);
}

.value-box {
  color: #f9f9f9;
}

.bg-primary {
  background-color: rgba(39, 128, 227, 0.7);
}

.storyboard-nav .sbframelist ul li.active {
  background-color: rgba(39, 128, 227, 0.7);
}

.nav-tabs-custom > .nav-tabs > li.active {
  border-top-color: rgba(39, 128, 227, 0.7);
}

.bg-info {
  background-color: rgba(153, 84, 187, 0.7);
}

.bg-warning {
  background-color: rgba(255, 117, 24, 0.7);
}

.bg-danger {
  background-color: rgba(255, 0, 57, 0.7);
}

.bg-success {
  background-color: rgba(63, 182, 24, 0.7);
}

.chart-title {
  font-weight: 500;
}

.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:active {
  font-weight: 500;
}

@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<button id="navbar-button" type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  Covid-19 trials
  <span class="navbar-author">
        </span>
</span>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.html(h1.html());
        h3.insertBefore(h1);
        h1.remove();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    $(window).on('resize', function() {
      if (_options.isMobile !== isMobilePhone() ||
          _options.isPortrait !== isPortrait()) {
        window.location.reload();
      }
    });

    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          li.append(navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target));
          menu.append(li);
        }
      } else {
        var li = $('<li></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover it's id and title, then remove it
    var h1 = wrapper.find('h1').first();
    var title = h1.html();
    h1.remove();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      menu.append(li);
    } else {
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = icon.substring(0, dashPos);
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "google-plus": "https://plus.google.com/share?url="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.html(h2.html());
      h3.insertBefore(h2);
      h2.remove();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.html(h3.html());
      h3.remove();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.html(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var navClass = "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      if (i === 0)
        li.attr('class', 'active');
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');
      if (i === 0) {
        tab.addClass('active');
        if (fade)
          tab.addClass('in');
      }

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.html();
    h3.remove();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.html(blockquote.children('p:first-child').html());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.html(caption.html());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.location.hash;
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.location.hash;
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }


  // get theme color
  var themeColors = {
    bootstrap: {
      primary: "rgba(51, 122, 183, 0.4)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    cerulean: {
      primary: "rgb(47, 164, 231)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    journal: {
      primary: "rgba(235, 104, 100, 0.70)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    flatly: {
      primary: "rgba(44, 62, 80, 0.70)",
      info: "rgba(52, 152, 219, 0.70)",
      success: "rgba(24, 188, 156, 0.70)",
      warning: "rgba(243, 156, 18, 0.70)",
      danger: "rgba(231, 76, 60, 0.70)"
    },
    readable: {
      primary: "rgba(69, 130, 236, 0.4)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    spacelab: {
      primary: "rgba(68, 110, 155, 0.25)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    united: {
      primary: "rgba(221, 72, 20, 0.30)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    cosmo: {
      primary: "rgba(39, 128, 227, 0.7)",
      info: "rgba(153, 84, 187, 0.7)",
      success: "rgba(63, 182, 24, 0.7)",
      warning: "rgba(255, 117, 24, 0.7)",
      danger: "rgba(255, 0, 57, 0.7)"
    },
    lumen: {
      primary: "rgba(21, 140, 186, 0.70)",
      info: "rgba(117, 202, 235, 0.90)",
      success: "rgba(40, 182, 44, 0.70)",
      warning: "rgba(255, 133, 27, 0.70)",
      danger: "rgba(255, 65, 54, 0.70)"
    },
    paper: {
      primary: "rgba(33, 150, 243, 0.35)",
      info: "rgb(225, 190, 231)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(255, 224, 178)",
      danger: "rgb(249, 189, 187)"
    },
    sandstone: {
      primary: "rgba(50, 93, 136, 0.3)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    simplex: {
      primary: "rgba(217, 35, 15, 0.25)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    yeti: {
      primary: "rgba(0, 140, 186, 0.298039)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    }
  }
  function themeColor(color) {
    return themeColors[_options.theme][color];
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage,
    themeColor: themeColor
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from anyone currently active
    $('.navbar ul.nav').find('li').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").parents('li').addClass('active');
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// datatables
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.find('.datatables');
  },
  flex: function(fillPage) {
    return fillPage;
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.html(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var components = chartIcon.split("-");
      if (components.length > 1)
        iconLib = components[0];
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // set color based on data-background if necessary
    var dataBackground = valueBox.attr('data-background');
    if (dataBackground)
      valueBox.css('background-color', bgColor);
    else {
      // default to bg-primary if no other background is specified
      if (!valueBox.hasClass('bg-primary') &&
          !valueBox.hasClass('bg-info') &&
          !valueBox.hasClass('bg-warning') &&
          !valueBox.hasClass('bg-success') &&
          !valueBox.hasClass('bg-danger')) {
        valueBox.addClass('bg-primary');
      }
    }

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // color
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        if (dataColor.indexOf('bg-') === 0) {
          valueBox.css('background-color', '');
          if (!valueBox.hasClass(dataColor)) {
             valueBox.removeClass('bg-primary bg-info bg-warning bg-danger bg-success');
             valueBox.addClass(dataColor);
          }
        } else {
          valueBox.removeClass('bg-primary bg-info bg-warning bg-danger bg-success');
          valueBox.css('background-color', dataColor);
        }
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});


</script>

<div id="dashboard-container">

<div id="column" class="section level2 sidebar">
<h2 class="sidebar">Column</h2>
<div id="ltima-atualizao" class="section level3">
<h3>ltima atualizao</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">2020-04-16 15:05</span>
<hr />
</div>
<div id="trials-na-base-americana" class="section level3">
<h3>Trials na base americana</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">621</span>
<hr />
</div>
<div id="trials-na-base-da-oms" class="section level3">
<h3>Trials na base da OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">1135</span>
</div>
</div>
<div id="column-1" class="section level2 tabset tabset-fade">
<h2 class="tabset tabset-fade">Column</h2>
<div id="remdios-lista-padronizada" class="section level3">
<h3>Remdios (lista padronizada)</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-c2632d75bbe476309a3f" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-c2632d75bbe476309a3f">{"x":{"filter":"none","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305"],["Hydroxychloroquine","Placebo","Placebo oral tablet","Azithromycin","Tocilizumab","Hydroxychloroquine Sulfate","Remdesivir","Lopinavir/ritonavir","Placebos","Losartan","Methylprednisolone","Favipiravir","Sarilumab","Anakinra","Chloroquine","Colchicine","Baricitinib","DAS181","Nitric Oxide Gas","Oseltamivir","placebo","Ruxolitinib","Standard of Care","Abidol hydrochloride","ACE inhibitor","Azithromycin Tablets","BCG Vaccine","Bevacizumab Injection","Camostat Mesilate","Chloroquine phosphate","Dexamethasone","Eculizumab","HB-adMSCs","Hydroxychloroquine + azithromycin","Hydroxychloroquine sulfate","Interferon Beta-1A","Interferon Beta-1B","Leronlimab (700mg)","Nitazoxanide","Nitric Oxide","Plasma","PUL-042 Inhalation Solution","Remdesivir placebo","Siltuximab","Tocilizumab (TCZ)"," continuation of RAS blocker therapy"," discontinuation of RAS blocker therapy"," Naproxen"," Standard of care"," Usual practice + SYMBICORT RAPIHALER","-Globulin","0.12% Chlorhexidine oral/nasal rinse","0.5% Povidone/Iodine oral/nasal rinse","Abidol Hydrochloride combined with Interferon atomization","Acalabrutinib","ACEIs","Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","Amoxicillin-clavulanate","Angiotensin 1-7","Angiotensin receptor blocker","Anluohuaxian","Arbidol","Arbidol Hydrochloride Granules","ASC09/ritonavir group","ASC09F+Oseltamivir","Ascorbic Acid","Aspirin","Aspirin 75mg","Atorvastatin 40mg","Atovaquone/Azithromycin","Aviptadil by intravenous infusion + maximal intensive care","azithromycin","Azithromycin 500Mg Oral Tablet","Baricitinib (janus kinase inhibitor)","Baricitinib Oral Tablet","basic treatment","Best supportive Care (BSC) + IFX-1","Best supportive care only","Bevacizumab","BLD-2660","BMS-986253","Bromhexine 8 MG","Bromhexine Hydrochloride Tablets","Calcium Channel Blockers","Canakinumab 150 MG/ML [Ilaris]","Carrimycin","CD24Fc","Ceftaroline","Ceftriaxone","Chemotherapy","chlorine dioxide 3000 ppm","chloroquine","Chloroquine analog (GNS651)","Chloroquine diphosphate","Chloroquine Diphosphate","Chloroquine or Hydroxychloroquine","Chloroquine Sulfate","cholecalciferol 200,000 IU","cholecalciferol 50,000 IU","Ciclesonide Metered Dose Inhaler [Alvesco]","Clazakizumab","Clazakizumab 12.5 mg","Clazakizumab 25 mg","Clevudine","Clopidogrel 75mg","CM4620-Injectable Emulsion","Control arm","Control group","Convalescent Serum","Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules","Conventional treatment","Danoprevir+Ritonavir","Darunavir and Cobicistat","DAS181 COVID-19","DAS181 OL","Deferoxamine","Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days","Defibrotide Injection","Dexamethasone and Hydroxychloroquine","Dexamethasone injection","Eicosapentaenoic acid gastro-resistant capsules","Emtricitabine/tenofovir disoproxil","Enoxaparin","Escin","favipiravir","Favipiravir Combined With Tocilizumab","Fingolimod 0.5 mg","Five-days oseltamivir","Fixed-duration higher dose Hydrocortisone","Fixed-duration Hydrocortisone","Fluvoxamine","Galidesivir","Ganovo+ritonavir+/-Interferon nebulization","Gargle/Mouthwash","Hidroxicloroquina","Hidroxicloroquine","High does chloroquine or hydroxychloroquine","Honey","Huaier Granule","Hydrocortisone","hydroxychloroquine","Hydroxychloroquine - Daily Dosing","Hydroxychloroquine - Weekly Dosing","Hydroxychloroquine (HCQ)","hydroxychloroquine + azithromycin","Hydroxychloroquine + Azithromycin","Hydroxychloroquine + lopinavir/ritonavir","Hydroxychloroquine + placebo","Hydroxychloroquine + Placebo","Hydroxychloroquine 200 Mg Oral Tablet","Hydroxychloroquine and azithromycin treatment arm.","Hydroxychloroquine as post exposure prophylaxis","Hydroxychloroquine Oral Product","hydroxychloroquine placebo","Hydroxychloroquine SAR321068","Hydroxychloroquine Sulfate (HCQ)","Hydroxychloroquine Sulfate 200 milligram (mg) Tab","Hydroxychloroquine Sulfate 400 mg twice a day","Hydroxychloroquine Sulfate 600 mg once a day","Hydroxychloroquine Sulfate 600 mg twice a day","Hydroxychloroquine Sulfate Loading Dose","Hydroxychloroquine Sulfate Regular dose","Hydroxychloroquine, Azithromycin","Hydroxychloroquine, Clindamycin","Hydroxychloroquine, Clindamycin, Primaquine - high dose.","Hydroxychloroquine, Clindamycin, Primaquine - low dose.","Hydroxychloroquine, Doxycycline","Hyperbaric oxygen","Ibuprofen","Imatinib tablets","Immunoglobulin of cured patients","Indomethacin","Inhaled nitric oxide gas","INO-4800","Insulin regimen","Interferon-Alpha2B","Interferon-1a","Intravenous Immunoglobulin","Isotonic saline 0.9%","Ivermectin","Ivermectine","Kevzara sc","L-ascorbic acid","Levamisole Pill + Budesonide+Formoterol inhaler","Liberase Enzyme (Roche)","Linagliptin","Lopinavir / Ritonavir","Lopinavir / ritonavir tablets combined with Xiyanping injection","Lopinavir / ritonavir, alpha-interferon nebulization","Lopinavir and ritonavir","lopinavir/ritonavir","Lopinavir/Ritonavir + hydoxychloroquine","lopinavir/ritonavir group","lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate","Lopinavir/ritonavir treatment","Low-dose chloroquine/hydroxychloroquine","LY3127804","Macrolide administered for 3-5 days","Macrolide administered for up to 14 days","Mavrilimumab","Mefloquine","Meplazumab for Injection","Methylprednisolone Sodium Succinate","methylprednisolone therapy","Mid dose chloroquine or hydroxychloroquine","Moxifloxacin or Levofloxacin","N-acetylcysteine+ Fuzheng Huayu Tablet","N-acetylcysteine+Placebo","Niclosamide","Nigella Sativa / Black Cumin","Nintedanib 150 MG","Nitazoxanide 500 MG","Nitazoxanide Tablets","Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Nivolumab","Nivolumab Injection","Normal Saline Infusion + Maximal intensive care","NORS (Nitric Oxide Releasing Solution)","Omeprazole 20mg","Oral","Patients with the treatment agains COVID19","PD-1 blocking antibody+standard treatment","Peginterferon Lambda-1a","Peginterferon lambda alfa-1a subcutaneous injection","Pegylated interferon lambda","Physiological saline solution","Piclidenoson","Piperacillin-tazobactam","Placebo 250 cc 24 hours continuous infusion for 15 days","Placebo of Hydroxychloroquine","Placebo of LPV/r Tablets","Placebo solution","Placebo: Emtricitabine/tenofovir disoproxil Placebo","Placebo: Hydroxychloroquine","Plaquenil 200Mg Tablet","Povidone-Iodine 0.5%","Povidone-Iodine 2%","Prednisone","Pyridostigmine Bromide","Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Recombinant human interferon 1","Recombinant Human Interferon 2b Spray","recombinant human interferon Alpha-1b","RhACE2 APN01","Ribavirin","Ritonavir+Oseltamivir","Rivaroxaban 2.5 MG","RoActemra iv","RoActemra sc","Ruxolitinib 10 MG","Ruxolitinib Oral Tablet","Ruxolitinib plus simvastatin","Saline oral/nasal rinse","Sargramostim","Sarilumab (anti-IL-6 receptor)","Sarilumab SAR153191","Selinexor","Shock-dependent hydrocortisone","Sildenafil citrate tablets","Simvastatin","Sirolimus","Sodium Chloride 9mg/mL","Spironolactone 100mg","Standard of care therapy","standard therapy","Standard therapy of COVID-19","Standard treatment","Stem Cell Product","Sterile Normal Saline for Intravenous Use","Sterile Water for Injection","Suspension of heat killed (autoclaved) Mycobacterium w","T3 solution for injection","T89","Tacrolimus","TCM prescriptions","Ten-days oseltamivir","Tetrandrine","thalidomide","Thalidomide","Thiazide or Thiazide-like diuretics","thymosin alpha 1","Thymosin+standard treatment","Tinzaparin or unfractionated heparin","TJ003234","Tocilizumab Injection","Tofacitinib","Tradipitant","Traditional Chinese Medicine Prescription","Tranexamic acid","Tranexamic acid tablets","Transfusion of COVID-19 convalescent plasma","Treatment and prophylaxis","Treatment with Dexmedetomidine","UNIKINON (Chloroquine phosphate) 200mg tablets","Valsartan (Diovan)","Vazegepant (BHV-3500)","VC","Vitamin C","Xiyanping injection","Yin Hu Qing Wen Granula(low does)","YinHu QingWen Decoction","YinHu QingWen Decoction(low dose)","Yinhu Qingwen Granula","Zithromax Oral Product"],[50,32,17,15,14,10,10,9,9,7,7,5,5,4,4,4,3,3,3,3,3,3,3,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug<\/th>\n      <th>n<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","columnDefs":[{"className":"dt-right","targets":2},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="remdios-dados-brutos" class="section level3">
<h3>Remdios (dados brutos)</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-afe7b45e07e2a9abf33f" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-afe7b45e07e2a9abf33f">{"x":{"filter":"none","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305"],["Hydroxychloroquine","Placebo","Placebo oral tablet","Azithromycin","Tocilizumab","Hydroxychloroquine Sulfate","Remdesivir","Lopinavir/ritonavir","Placebos","Losartan","Methylprednisolone","Favipiravir","Sarilumab","Anakinra","Chloroquine","Colchicine","Baricitinib","DAS181","Nitric Oxide Gas","Oseltamivir","placebo","Ruxolitinib","Standard of Care","Abidol hydrochloride","ACE inhibitor","Azithromycin Tablets","BCG Vaccine","Bevacizumab Injection","Camostat Mesilate","Chloroquine phosphate","Dexamethasone","Eculizumab","HB-adMSCs","Hydroxychloroquine + azithromycin","Hydroxychloroquine sulfate","Interferon Beta-1A","Interferon Beta-1B","Leronlimab (700mg)","Nitazoxanide","Nitric Oxide","Plasma","PUL-042 Inhalation Solution","Remdesivir placebo","Siltuximab","Tocilizumab (TCZ)"," continuation of RAS blocker therapy"," discontinuation of RAS blocker therapy"," Naproxen"," Standard of care"," Usual practice + SYMBICORT RAPIHALER","-Globulin","0.12% Chlorhexidine oral/nasal rinse","0.5% Povidone/Iodine oral/nasal rinse","Abidol Hydrochloride combined with Interferon atomization","Acalabrutinib","ACEIs","Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","Amoxicillin-clavulanate","Angiotensin 1-7","Angiotensin receptor blocker","Anluohuaxian","Arbidol","Arbidol Hydrochloride Granules","ASC09/ritonavir group","ASC09F+Oseltamivir","Ascorbic Acid","Aspirin","Aspirin 75mg","Atorvastatin 40mg","Atovaquone/Azithromycin","Aviptadil by intravenous infusion + maximal intensive care","azithromycin","Azithromycin 500Mg Oral Tablet","Baricitinib (janus kinase inhibitor)","Baricitinib Oral Tablet","basic treatment","Best supportive Care (BSC) + IFX-1","Best supportive care only","Bevacizumab","BLD-2660","BMS-986253","Bromhexine 8 MG","Bromhexine Hydrochloride Tablets","Calcium Channel Blockers","Canakinumab 150 MG/ML [Ilaris]","Carrimycin","CD24Fc","Ceftaroline","Ceftriaxone","Chemotherapy","chlorine dioxide 3000 ppm","chloroquine","Chloroquine analog (GNS651)","Chloroquine diphosphate","Chloroquine Diphosphate","Chloroquine or Hydroxychloroquine","Chloroquine Sulfate","cholecalciferol 200,000 IU","cholecalciferol 50,000 IU","Ciclesonide Metered Dose Inhaler [Alvesco]","Clazakizumab","Clazakizumab 12.5 mg","Clazakizumab 25 mg","Clevudine","Clopidogrel 75mg","CM4620-Injectable Emulsion","Control arm","Control group","Convalescent Serum","Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules","Conventional treatment","Danoprevir+Ritonavir","Darunavir and Cobicistat","DAS181 COVID-19","DAS181 OL","Deferoxamine","Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days","Defibrotide Injection","Dexamethasone and Hydroxychloroquine","Dexamethasone injection","Eicosapentaenoic acid gastro-resistant capsules","Emtricitabine/tenofovir disoproxil","Enoxaparin","Escin","favipiravir","Favipiravir Combined With Tocilizumab","Fingolimod 0.5 mg","Five-days oseltamivir","Fixed-duration higher dose Hydrocortisone","Fixed-duration Hydrocortisone","Fluvoxamine","Galidesivir","Ganovo+ritonavir+/-Interferon nebulization","Gargle/Mouthwash","Hidroxicloroquina","Hidroxicloroquine","High does chloroquine or hydroxychloroquine","Honey","Huaier Granule","Hydrocortisone","hydroxychloroquine","Hydroxychloroquine - Daily Dosing","Hydroxychloroquine - Weekly Dosing","Hydroxychloroquine (HCQ)","hydroxychloroquine + azithromycin","Hydroxychloroquine + Azithromycin","Hydroxychloroquine + lopinavir/ritonavir","Hydroxychloroquine + placebo","Hydroxychloroquine + Placebo","Hydroxychloroquine 200 Mg Oral Tablet","Hydroxychloroquine and azithromycin treatment arm.","Hydroxychloroquine as post exposure prophylaxis","Hydroxychloroquine Oral Product","hydroxychloroquine placebo","Hydroxychloroquine SAR321068","Hydroxychloroquine Sulfate (HCQ)","Hydroxychloroquine Sulfate 200 milligram (mg) Tab","Hydroxychloroquine Sulfate 400 mg twice a day","Hydroxychloroquine Sulfate 600 mg once a day","Hydroxychloroquine Sulfate 600 mg twice a day","Hydroxychloroquine Sulfate Loading Dose","Hydroxychloroquine Sulfate Regular dose","Hydroxychloroquine, Azithromycin","Hydroxychloroquine, Clindamycin","Hydroxychloroquine, Clindamycin, Primaquine - high dose.","Hydroxychloroquine, Clindamycin, Primaquine - low dose.","Hydroxychloroquine, Doxycycline","Hyperbaric oxygen","Ibuprofen","Imatinib tablets","Immunoglobulin of cured patients","Indomethacin","Inhaled nitric oxide gas","INO-4800","Insulin regimen","Interferon-Alpha2B","Interferon-1a","Intravenous Immunoglobulin","Isotonic saline 0.9%","Ivermectin","Ivermectine","Kevzara sc","L-ascorbic acid","Levamisole Pill + Budesonide+Formoterol inhaler","Liberase Enzyme (Roche)","Linagliptin","Lopinavir / Ritonavir","Lopinavir / ritonavir tablets combined with Xiyanping injection","Lopinavir / ritonavir, alpha-interferon nebulization","Lopinavir and ritonavir","lopinavir/ritonavir","Lopinavir/Ritonavir + hydoxychloroquine","lopinavir/ritonavir group","lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate","Lopinavir/ritonavir treatment","Low-dose chloroquine/hydroxychloroquine","LY3127804","Macrolide administered for 3-5 days","Macrolide administered for up to 14 days","Mavrilimumab","Mefloquine","Meplazumab for Injection","Methylprednisolone Sodium Succinate","methylprednisolone therapy","Mid dose chloroquine or hydroxychloroquine","Moxifloxacin or Levofloxacin","N-acetylcysteine+ Fuzheng Huayu Tablet","N-acetylcysteine+Placebo","Niclosamide","Nigella Sativa / Black Cumin","Nintedanib 150 MG","Nitazoxanide 500 MG","Nitazoxanide Tablets","Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Nivolumab","Nivolumab Injection","Normal Saline Infusion + Maximal intensive care","NORS (Nitric Oxide Releasing Solution)","Omeprazole 20mg","Oral","Patients with the treatment agains COVID19","PD-1 blocking antibody+standard treatment","Peginterferon Lambda-1a","Peginterferon lambda alfa-1a subcutaneous injection","Pegylated interferon lambda","Physiological saline solution","Piclidenoson","Piperacillin-tazobactam","Placebo 250 cc 24 hours continuous infusion for 15 days","Placebo of Hydroxychloroquine","Placebo of LPV/r Tablets","Placebo solution","Placebo: Emtricitabine/tenofovir disoproxil Placebo","Placebo: Hydroxychloroquine","Plaquenil 200Mg Tablet","Povidone-Iodine 0.5%","Povidone-Iodine 2%","Prednisone","Pyridostigmine Bromide","Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Recombinant human interferon 1","Recombinant Human Interferon 2b Spray","recombinant human interferon Alpha-1b","RhACE2 APN01","Ribavirin","Ritonavir+Oseltamivir","Rivaroxaban 2.5 MG","RoActemra iv","RoActemra sc","Ruxolitinib 10 MG","Ruxolitinib Oral Tablet","Ruxolitinib plus simvastatin","Saline oral/nasal rinse","Sargramostim","Sarilumab (anti-IL-6 receptor)","Sarilumab SAR153191","Selinexor","Shock-dependent hydrocortisone","Sildenafil citrate tablets","Simvastatin","Sirolimus","Sodium Chloride 9mg/mL","Spironolactone 100mg","Standard of care therapy","standard therapy","Standard therapy of COVID-19","Standard treatment","Stem Cell Product","Sterile Normal Saline for Intravenous Use","Sterile Water for Injection","Suspension of heat killed (autoclaved) Mycobacterium w","T3 solution for injection","T89","Tacrolimus","TCM prescriptions","Ten-days oseltamivir","Tetrandrine","thalidomide","Thalidomide","Thiazide or Thiazide-like diuretics","thymosin alpha 1","Thymosin+standard treatment","Tinzaparin or unfractionated heparin","TJ003234","Tocilizumab Injection","Tofacitinib","Tradipitant","Traditional Chinese Medicine Prescription","Tranexamic acid","Tranexamic acid tablets","Transfusion of COVID-19 convalescent plasma","Treatment and prophylaxis","Treatment with Dexmedetomidine","UNIKINON (Chloroquine phosphate) 200mg tablets","Valsartan (Diovan)","Vazegepant (BHV-3500)","VC","Vitamin C","Xiyanping injection","Yin Hu Qing Wen Granula(low does)","YinHu QingWen Decoction","YinHu QingWen Decoction(low dose)","Yinhu Qingwen Granula","Zithromax Oral Product"],[50,32,17,15,14,10,10,9,9,7,7,5,5,4,4,4,3,3,3,3,3,3,3,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>drug<\/th>\n      <th>n<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","columnDefs":[{"className":"dt-right","targets":2},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dados-brutos-eua" class="section level3">
<h3>Dados brutos EUA</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-a61b345b86acc5e6db2d" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-a61b345b86acc5e6db2d">{"x":{"filter":"top","filterHTML":"<tr>\n  <td><\/td>\n  <td data-type=\"integer\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n    <div style=\"display: none; position: absolute; width: 200px;\">\n      <div data-min=\"1\" data-max=\"621\"><\/div>\n      <span style=\"float: left;\"><\/span>\n      <span style=\"float: right;\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"integer\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n    <div style=\"display: none; position: absolute; width: 200px;\">\n      <div data-min=\"0\" data-max=\"10000000\"><\/div>\n      <span style=\"float: left;\"><\/span>\n      <span style=\"float: right;\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n<\/tr>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305","306","307","308","309","310","311","312","313","314","315","316","317","318","319","320","321","322","323","324","325","326","327","328","329","330","331","332","333","334","335","336","337","338","339","340","341","342","343","344","345","346","347","348","349","350","351","352","353","354","355","356","357","358","359","360","361","362","363","364","365","366","367","368","369","370","371","372","373","374","375","376","377","378","379","380","381","382","383","384","385","386","387","388","389","390","391","392","393","394","395","396","397","398","399","400","401","402","403","404","405","406","407","408","409","410","411","412","413","414","415","416","417","418","419","420","421","422","423","424","425","426","427","428","429","430","431","432","433","434","435","436","437","438","439","440","441","442","443","444","445","446","447","448","449","450","451","452","453","454","455","456","457","458","459","460","461","462","463","464","465","466","467","468","469","470","471","472","473","474","475","476","477","478","479","480","481","482","483","484","485","486","487","488","489","490","491","492","493","494","495","496","497","498","499","500","501","502","503","504","505","506","507","508","509","510","511","512","513","514","515","516","517","518","519","520","521","522","523","524","525","526","527","528","529","530","531","532","533","534","535","536","537","538","539","540","541","542","543","544","545","546","547","548","549","550","551","552","553","554","555","556","557","558","559","560","561","562","563","564","565","566","567","568","569","570","571","572","573","574","575","576","577","578","579","580","581","582","583","584","585","586","587","588","589","590","591","592","593","594","595","596","597","598","599","600","601","602","603","604","605","606","607","608","609","610","611","612","613","614","615","616","617","618","619","620","621"],[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621],["NCT04333550","NCT04336904","NCT04345445","NCT04331509","NCT04347915","NCT04343183","NCT04342637","NCT04333407","NCT04291053","NCT04336462","NCT04324489","NCT04347993","NCT04323228","NCT04335123","NCT04333420","NCT04342689","NCT04343755","NCT04329611","NCT04321421","NCT04344015","NCT04325633","NCT04323332","NCT04339660","NCT04306497","NCT04287686","NCT04344145","NCT04324996","NCT04348071","NCT04340232","NCT04321993","NCT04329832","NCT04343768","NCT04252118","NCT04348396","NCT04317092","NCT04346199","NCT04331171","NCT04344587","NCT04330586","NCT04348656","NCT04350073","NCT04275947","NCT04328285","NCT04331899","NCT04337996","NCT04315298","NCT04337762","NCT04330638","NCT04343690","NCT04343677","NCT04332081","NCT04304313","NCT04326920","NCT04337541","NCT04338347","NCT04348422","NCT04340544","NCT04334512","NCT04327674","NCT04341675","NCT04329923","NCT04330690","NCT04318418","NCT04333628","NCT04285801","NCT04304053","NCT04319315","NCT04334382","NCT04333355","NCT04335136","NCT04331366","NCT04331795","NCT04333225","NCT04344444","NCT04344080","NCT04348448","NCT04335084","NCT04344236","NCT04307693","NCT04345692","NCT04323631","NCT04348435","NCT04331834","NCT04337216","NCT04336254","NCT04313023","NCT04332094","NCT04292899","NCT04312997","NCT04334980","NCT04348409","NCT04343989","NCT04329572","NCT04347954","NCT04292730","NCT04341506","NCT04345523","NCT04345510","NCT04341168","NCT04347850","NCT04344171","NCT04346615","NCT04336956","NCT04347369","NCT04313322","NCT04346355","NCT04329650","NCT04331470","NCT04315987","NCT04305106","NCT04308317","NCT04244591","NCT04320615","NCT04344925","NCT04273529","NCT04273581","NCT04339608","NCT04312464","NCT04342221","NCT04347070","NCT04345679","NCT04338074","NCT04346017","NCT04344457","NCT04343742","NCT04345536","NCT04342182","NCT04347174","NCT04331600","NCT04325061","NCT04315896","NCT04280588","NCT04335201","NCT04341389","NCT04343248","NCT04329559","NCT04318301","NCT04337359","NCT04332107","NCT04349241","NCT04273646","NCT04331106","NCT04345991","NCT04334044","NCT04346147","NCT04328441","NCT04341116","NCT04346056","NCT04348240","NCT04252664","NCT04343781","NCT04346043","NCT04348214","NCT04328493","NCT04332913","NCT04330521","NCT04336332","NCT04344977","NCT04317040","NCT04347876","NCT04342897","NCT04338932","NCT04346368","NCT04313127","NCT04334005","NCT04336657","NCT04288102","NCT04303299","NCT04286503","NCT04329507","NCT04293692","NCT04339816","NCT04345276","NCT04291729","NCT04333472","NCT04343339","NCT04345315","NCT04344431","NCT04341688","NCT04338828","NCT04349631","NCT04335305","NCT04273321","NCT04347538","NCT04338360","NCT04343976","NCT04334252","NCT04339426","NCT04343794","NCT04341103","NCT04341285","NCT04331665","NCT04318444","NCT04344730","NCT04318015","NCT04341038","NCT04328272","NCT04348474","NCT04336774","NCT04338568","NCT04327531","NCT04323345","NCT03891420","NCT04349202","NCT04348877","NCT04344756","NCT04344782","NCT04335019","NCT04342663","NCT04347278","NCT04343001","NCT04348500","NCT04344288","NCT04348383","NCT04334291","NCT04333914","NCT04323644","NCT04341870","NCT04344951","NCT04261517","NCT04251767","NCT04330144","NCT04347824","NCT04347681","NCT04343144","NCT04348513","NCT04299724","NCT04346264","NCT04342104","NCT04338958","NCT04346797","NCT04338126","NCT04347928","NCT04257656","NCT04343092","NCT04298814","NCT04335097","NCT04324190","NCT04334850","NCT04348305","NCT04349540","NCT04335071","NCT04333693","NCT04349228","NCT04276896","NCT04343963","NCT04349410","NCT04341415","NCT04333862","NCT04328961","NCT04333953","NCT04345653","NCT04323514","NCT04322188","NCT04304690","NCT04342195","NCT04341207","NCT04316299","NCT04318431","NCT04336345","NCT04329546","NCT04344002","NCT04334460","NCT04320017","NCT04341441","NCT04344938","NCT04336384","NCT04330300","NCT04350086","NCT04331574","NCT04321265","NCT04333732","NCT04327206","NCT04326790","NCT04341142","NCT04345601","NCT04344184","NCT04338698","NCT04331054","NCT04339712","NCT04292964","NCT04325646","NCT04347980","NCT04337346","NCT04346212","NCT04342806","NCT04335786","NCT04338009","NCT04334265","NCT04334148","NCT04333589","NCT04330599","NCT04328480","NCT04311398","NCT04310228","NCT04302519","NCT04295551","NCT04345848","NCT04335552","NCT04337320","NCT04341792","NCT04346667","NCT04278963","NCT04303507","NCT04347941","NCT04347226","NCT04328012","NCT04320472","NCT04272710","NCT04335032","NCT04273763","NCT04331613","NCT04346810","NCT04310865","NCT04324021","NCT04344600","NCT04319445","NCT04339998","NCT04323761","NCT04319731","NCT04334967","NCT04321928","NCT04342884","NCT04347694","NCT04341766","NCT04336215","NCT04349982","NCT04298060","NCT04270383","NCT04348864","NCT04334954","NCT04332991","NCT04340050","NCT04320511","NCT04324528","NCT04336787","NCT04323878","NCT04343651","NCT04285190","NCT04324606","NCT04325048","NCT04344379","NCT04347239","NCT04349618","NCT04323800","NCT04321096","NCT04332380","NCT04325412","NCT04332666","NCT04268537","NCT04330495","NCT04349098","NCT04339881","NCT04334928","NCT04346277","NCT04329533","NCT04323787","NCT04332835","NCT04334876","NCT04306705","NCT04337424","NCT04312100","NCT04312009","NCT04323839","NCT04313946","NCT04315948","NCT04311177","NCT04350099","NCT04261426","NCT04337788","NCT04332016","NCT04255017","NCT04254874","NCT04340466","NCT04345159","NCT04316949","NCT04348929","NCT04275414","NCT04341935","NCT04339387","NCT04343053","NCT04261270","NCT04342169","NCT04332042","NCT04329195","NCT04316728","NCT04311697","NCT04321616","NCT04327349","NCT04328129","NCT04263402","NCT02735707","NCT04343261","NCT04341480","NCT04340349","NCT04252274","NCT04327505","NCT03042143","NCT04256395","NCT04325919","NCT04324866","NCT04305457","NCT04324463","NCT04347512","NCT04320277","NCT04333368","NCT04348695","NCT04327570","NCT04347889","NCT04339322","NCT04325867","NCT04347382","NCT04338100","NCT04342650","NCT04342156","NCT04339790","NCT04327401","NCT04279197","NCT04280705","NCT04284046","NCT04345861","NCT04345614","NCT04349592","NCT04344210","NCT04321174","NCT04322487","NCT04318314","NCT04323592","NCT04335747","NCT04335188","NCT04335773","NCT04334629","NCT04340219","NCT04348942","NCT04264858","NCT04321811","NCT04339634","NCT04348227","NCT04344249","NCT04337502","NCT04326452","NCT04335162","NCT04312243","NCT04322565","NCT04335279","NCT04344197","NCT04337047","NCT04341012","NCT04306055","NCT04340414","NCT04337008","NCT04331886","NCT04293887","NCT04320732","NCT04340921","NCT04333654","NCT04338945","NCT04346420","NCT04337489","NCT04296643","NCT04320238","NCT04343898","NCT04346342","NCT04319016","NCT04344561","NCT04346186","NCT04302688","NCT04347408","NCT04316884","NCT04333849","NCT04348461","NCT04279899","NCT04290871","NCT04337151","NCT04341493","NCT04315480","NCT04340479","NCT04328454","NCT03808922","NCT04346446","NCT04327804","NCT04345640","NCT04325906","NCT04344964","NCT04327388","NCT04346628","NCT04344535","NCT04325893","NCT04338906","NCT04326725","NCT04341714","NCT04321369","NCT04292340","NCT04346082","NCT04326114","NCT04322123","NCT04326387","NCT04346953","NCT04324047","NCT04315870","NCT04346589","NCT04342702","NCT04337918","NCT04326036","NCT04344548","NCT04322396","NCT04346693","NCT04341610","NCT04341519","NCT04274322","NCT04324073","NCT04344041","NCT04343664","NCT04345289","NCT04321278","NCT04344912","NCT04260594","NCT04314232","NCT04336748","NCT04330261","NCT04347460","NCT04326426","NCT04327180","NCT04345406","NCT04341922","NCT04334434","NCT04320862","NCT04345549","NCT04344834","NCT04324736","NCT04290858","NCT04283461","NCT04344327","NCT04346160","NCT04280224","NCT04290780","NCT04288713","NCT04343404","NCT04322513","NCT04318366","NCT04345887","NCT04320953","NCT04338802","NCT04299152","NCT04308187","NCT04322344","NCT04306393","NCT04322773","NCT04324684","NCT04346329","NCT04336410","NCT04337983","NCT04349163","NCT04345419","NCT04322786","NCT04336761","NCT04344119","NCT04342208","NCT04344106","NCT04338672","NCT04349371","NCT04327479","NCT04305574","NCT04347031","NCT04279795","NCT04279782","NCT04343729","NCT04341584","NCT04292327","NCT04340557","NCT04269525","NCT04261907","NCT04325672","NCT04326075","NCT04337190","NCT04061382","NCT04264533","NCT04338841","NCT04323527","NCT04275388","NCT04302766","NCT04348370","NCT04245631","NCT03331445","NCT04335630","NCT04322682","NCT04255940","NCT04281693","NCT04344509","NCT04259892","NCT04251871","NCT04260308","NCT04275245","NCT04307459","NCT04322279","NCT04339686","NCT04341727","NCT04335851","NCT04346927","NCT04319211","NCT04331808","NCT04328467","NCT04280913","NCT04333251","NCT04320056","NCT04347798","NCT04333875","NCT04316377","NCT04276688","NCT04346940","NCT04319172","NCT03680274","NCT04326309","NCT04346966","NCT04308668","NCT04262921","NCT04329897","NCT04346979","NCT04342728","NCT04339842","NCT04276987"],["Application of Desferal to Treat COVID-19","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19","Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","COVID-19 Symptom Tracker","The Randomized, Open, Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","COVID-19 Endoscopy Survey","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","DAS181 for Severe COVID-19: Compassionate Use","A Prospective \"Universal\" Observational Database for COVID-19","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","Study of Open Label Losartan in COVID-19","Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","The Role of Resistant Potato Starch in COVID-19 Infection","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","Hyperimmune Plasma for Critical Patients With COVID-19","COVID-19 Plasma Collection","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","Traditional Chinese Medicine for Severe COVID-19","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19","Safety and Efficacy of Ruxolitinib for COVID-19","Safety and Efficacy of Baricitinib for COVID-19","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19","Clinical and Biological Predictors of COVID-19 Disease in Older Patients","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI (Calquence Against the Virus)","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning","A Trial of Ciclesonide in Adults With Mild COVID-19","CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)","The COVID-19 Mobile Health Study (CMHS)","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","Mild COVID-19 Peginterferon Lambda","Dynamic Evaluation of COVID-19 Diagnostic Tests","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","Beat COVID-19 - Observational Trial","Treatment of COVID-19 Patients With Anti-interleukin Drugs","COPING With COVID-19( CWC-19)","Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study","Hyperbaric Oxygen for COVID-19 Patients","A Pilot Study of Sildenafil in COVID-19","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","CAP-1002 in Severe COVID-19 Disease","Evaluating the Immune Response for COVID-19","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","A Study of Quintuple Therapy to Treat COVID-19 Infection","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","Safety in Convalescent Plasma Transfusion to COVID-19","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients","The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19","PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment","Non-contact ECG Sensor System for COVID19","Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients","Testing for COVID-19 Infection in Asymptomatic Persons","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)","CovidDB: The Covid-19 Inpatient Database","Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen","Covid-19 Pediatric Observatory","A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Efficacy of Early Administration of Tocilizumab in COVID-19 Patients","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19","NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","Tetrandrine Tablets Used in the Treatment of COVID-19","Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","Max COVID19- Study","Myocardial Damage in COVID-19","Hydroxychloroquine for COVID-19","Implementation of Physiotherapy on COVID-19 Patients in ICU","Anti COVID-19 Convalescent Plasma Therapy","TXA and Corona Virus 2019 (COVID19) in Outpatients","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome","Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19","Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients","ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","Fingolimod in COVID-19","Defibrotide in COVID-19 Pneumonia","A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)","Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study","Hypertension in Patients Hospitalized With COVID-19","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","Efficacy and Safety of Favipiravir in Management of COVID-19","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","Survey of the Anxiety Associated With the COVID-19 Pandemic","Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","Treatment of SARS Caused by COVID-19 With Ruxolitinib","Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19","Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions","A Trial of Remdesivir in Adults With Mild and Moderate COVID-19","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database","Risk Assessment of Healthcare Workers and Infection Control in University and COVID-19 Quarantine Hospitals","The Vietnam Chloroquine Treatment on COVID-19","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","Impact of the Coronavirus (COVID-19) on Patients With Cancer","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","COVID-19 Plasma Collection","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?","A Study of LY3127804 in Participants With COVID-19","COVID-19 and Deep Venous Thrombosis","Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)","Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults","Vitamin D on Prevention and Treatment of COVID-19","Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?","Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","The Clinical Study of Carrimycin on Treatment Patients With COVID-19","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial","Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Evaluation of Ganovo Danoprevir  Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Piclidenoson for Treatment of COVID-19","Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment","Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","Checkpoint Blockade in COVID-19 Pandemic","Efficacy and Safety of Corticosteroids in COVID-19","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","Pegylated Interferon Lambda Treatment for COVID-19","Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection","Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19","CAPTION AI to Minimize Risk of COVID Exposure","Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19","Beaumont Health Large-scale Automated Serologic Testing for COVID-19","Plasma Rich Antibodies From Recovered Patients From COVID19","Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin/Zeribev) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease","Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","Defibotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.","International COVID19 Clinical Evaluation Registry,","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","Predict Adverse Events by Covid-19 Nephritis","Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","Trial Evaluating Efficacy and Safety of Nivolumab (Optivo) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.","Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection","Safety and Immunity of Covid-19 aAPC Vaccine","CoVid-19 - Infection and Antibody Formation in the Viennese Population","NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients","Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19","A Trial of Remdesivir in Adults With Severe COVID-19","Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","DIgital Online SuPport for COVID-19 StrEss","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","Hydrocortisone for COVID-19 and Severe Hypoxia","Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine","Pyridostigmine in Severe SARS-CoV-2 Infection","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Hydroxychloroquine for COVID-19 PEP","COVID-19 in Patients With HIV","Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers","Use of Ascorbic Acid in Patients With COVID 19","An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection","COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Acquiring Convalescent Specimens for COVID-19 Antibodies","Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","Acute Kidney Injury in Patients Hospitalized With COVID-19","Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","Outcomes of Patients With COVID-19 in the Intensive Care Unit","Understanding COVID-19","LunG canceR pAtients coVId19 Disease (GRAVID)","Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","Will Hydroxychloroquine Impede or Prevent COVID-19","Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality","Impact of Covid-19 in Congenital Heart Disease","Coronavirus (COVID-19) ACEi/ARB Investigation","Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","Renin-Angiotensin System Inhibitors and COVID-19","Outcomes and Prognostic Factors in COVID-19","CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION","BCG Vaccination to Protect Healthcare Workers Against COVID-19","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)","Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","Protective Role of Inhaled Steroids for Covid-19 Infection","Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction","Prognostic Factors of Patients With COVID-19","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome","Evaluation of Covid 19 Anxiety in Endometriosis Patients","Oropharyngeal Dysphagia in Patients With COVID-19","Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19","Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease","Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population","The ECLA PHRI COLCOVID Trial","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns","Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient","Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE","Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","Acute Encephalopathy in Critically Ill Patients With COVID-19","Prognositc Factors in COVID-19 Patients Complicated With Hypertension","EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS","Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection","Mindfulness During COVID-19","Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","COVID-19 Community Research Partnership","Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months","Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19","Rutgers COVID-19 Cohort Study","ICU Trial in Critical Ill COVID19 Patients","DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","COVID-19 Antibody Self-testing Using Virtual Point-of-care","SARS-COV2 Pandemic Serosurvey and Blood Sampling","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","COVID-19 Convalescent Plasma","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19","A Study of a Candidate COVID-19 Vaccine (COV001)","Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients","Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia","Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","The Impact of Camostat Mesilate on COVID-19 Infection","Convalescent Plasma for Patients With COVID-19: A Pilot Study","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Immunoregulatory Therapy for 2019-nCoV","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection","NOsocomial Dissemination Risk of SARS-Cov2","Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)","Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2","Sequential Oxygen Therapy Strategy for Patients With COVID-19","Losartan for Patients With COVID-19 Requiring Hospitalization","COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","Trial of Treatments for COVID-19 in Hospitalized Adults","Losartan for Patients With COVID-19 Not Requiring Hospitalization","Emotional Burden of Healthcare Professionals and Covid Infection 19","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease","COVID-19 Biological Samples Collection","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study","Prevalence of COVID-19 Symptoms History in Patients With Autoimmune Diseases","Predictors of Respiratory Failure in SARS-Cov-2 Infection","Birth Experience During COVID-19 Confinement","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","Effects of DPP4 Inhibition on COVID-19","COVID-19 Risk Stratification","Pro-thrombotic Status in Patients With SARS-Cov-2 Infection","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","University of Utah COVID-19 Hydrochloroquine Trial","TOFAcitinib in SARS-CoV2 Pneumonia","ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","Household Transmission Investigation Study for COVID-19 in French Guiana","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","Convalescent Plasma in the Treatment of COVID 19","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","Azithromycin-Hydroxychloroquine Combination in Sars-CoV-2 Pneumonia Study","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.","In-depth Immunological Investigation of COVID-19.","Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers:RCT","Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt","Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19","Efficacy of Nigella Sativa and Natural Honey Against COVID-19: an RCT","Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial","Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers","COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu","Adaptive COVID-19 Treatment Trial (ACTT)","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)","A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia","Qatar Prospective RCT Of Therapy Eliminating Covid Transmission","Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","Simple, Safe, Same: Lung Ultrasound for COVID-19","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases","COVID-19 Registry Rhineland-Palatinate (Germany)","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","LIBA Trial in COVID-19","Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic","A COVID-19 Symptom, Exposure and Immune Response Registry","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients","Behavior, Environment And Treatments for Covid-19","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy","How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?","Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic","Clinical and Radiomic Model of COVID-19","Treating COVID-19 With a Bidirectional Oxygenation Valve","Cardiovascular Complications and COVID-19 (CovCardioVasc)","NO Prevention of COVID-19 for Healthcare Providers","Colchicine Counteracting Inflammation in COVID-19 Pneumonia","Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey","Assessment of Distress in Crisis Situations During COVID-19","Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases","Blood Donor Recruitment During Epidemic of COVID-19","Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP","Renin Angiotesnin System - CoronaVirus","An Observational Study of Patients With Coronavirus Disease 2019","Efficacy and Safety of IFN-2 in the Treatment of Novel Coronavirus Patients","Risk Factors for Community- and Workplace Transmission of COVID-19","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury","Hydroxychloroquine in Outpatient Adults With COVID-19","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy","Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19","Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)","Medical Masks vs N95 Respirators for COVID-19","Experimental Trial of rhIFN Nasal Drops to Prevent 2019-nCOV in Medical Staff","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation","COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff","Accurate Classification System for Patients With COVID-19 Pneumonitis","Rapid Diagnostics, Antibody Testing and Host Response in Children With COVID-19","Mechanisms for Organ Dysfunction in Covid-19","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","BAttLe Against COVID-19 Using MesenchYmal Stromal Cells","The Investigation of the Neonates With or With Risk of COVID-19","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment","Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19","Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation","Clinical Characteristics and Prognostic Factors of Patients With COVID-19","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients","A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research","The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS","Endoscopy-related Phone Consultation During the COVID-19 Outbreak","Sarilumab COVID-19","Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19","Convalescent Plasma vs. Standard Plasma for COVID-19","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia","Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic","Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19","Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak","Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19","Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (COVID-19)","Evaluation of Novel Diagnostic Tests for COVID-19","Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients","A Study on the Prospective Cohort Library of COVID-19 in Southeran","Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19","An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19","ASC Therapy for Patients With Severe Respiratory COVID-19","Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)","Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia","Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)","Impact of COVID19 Outbreak in Cardiac Acute Care","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","Mechanisms to Morbidity and Mortality for Covid-19","HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers","Clinical Characteristics and Outcomes of Pediatric COVID-19","Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH","ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection","PREdiction of DIagnosed Covid-19 infecTion in IUC Patients","Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19","A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic","Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)","COVID-19 Pandemic Response Network","Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak","Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health","\"COVID-19 and Diabetes Outcomes\"","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)","COVID-19 in Cardiology Unit in France : Risk Factors for Mortality (CCF)","A Study to Assess the Virus, RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease","NK Cells Treatment for COVID-19","COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","Eculizumab (Soliris) in Covid-19 Infected Patients","PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2","Biomarkers for Identification of COVID-19 Infection","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Spironolactone in Covid-19 Induced ARDS","Non-contact Endoscopy at Covid-19 Outbreak","Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19","Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19","Influence of the COvid-19 Epidemic on STRESS","Escin in Patients With Covid-19 Infection","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","Prognostic Factors Keeping Track for Covid-19 Pneumonia","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19","Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Hemodynamic Characteristics of Patients With SARS-CoV-2","Resilience During Covid-19 Epidemic","A Real-life Experience on Treatment of Patients With COVID 19","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","Assessment of Chilbains Occuring During Covid-19 Infection","Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak","Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study","The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients","Saved From COVID-19","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection","Social Media Use During COVID-19","An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection","Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection","Convalescent Plasma to Limit Coronavirus Associated Complications","Early CPAP in COVID Patients With Respiratory Failure.","Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)","Sero-epidemiological Survey of England in 2019/2020","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia","HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection","Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia","Expanded Access Remdesivir (RDV; GS-5734)","BCG Vaccine for Health Care Workers as Defense Against SARS-COV2","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","Cardiovascular Manifestations of COVID-19","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","2019-nCoV Outbreak and Cardiovascular Diseases","A New Screening Strategy for 2019 Novel Coronavirus Infection","Microbial Etiology of Ventilator-associated Pneumonia in SARS-CoV-2 Infected Patients","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life","Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO)","Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.","Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","Video-Based Exercises and Well-Being During Social Isolation","Telerehabilitation for Patients Diagnosed With Coronavirus","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","Pre-exposure Prophylaxis for SARS-Coronavirus-2","Clinical Outcomes of Patients With COVID19","Study Testing Convalescent Plasma vs Best Supportive Care","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia","IMPACT: IMPact of Antimalarials on Covid Infections in RAPPORT","Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis","Norwegian Coronavirus Disease 2019 Study","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","The Effectiveness of Telerehabilitation-Based Exercises in Elderly People","Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients","Lessening Organ Dysfunction With VITamin C","Audio Data Collection for Identification and Classification of Coughing","The Effectiveness of Video-Based Exercises in Young Adults","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","Clinical Characterisation Protocol for Severe Emerging Infections","Acceptance and Commitment Therapy Delivered by Automated Software Messaging","Telerehabilitation-based Yoga and Mindfulness Home Program in Postmenopausal Women Having Social Isolation","Coronavirus 2019- Using Ascorbic Acid and Zinc Supplementation","Eating Habits of Adults During the Quarantine","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia"],[null,null,null,null,null,null,"COVID-19 Endo","C-19-ACS",null,"COVID-19",null,null,"ONSCOVID19",null,"PANAMO",null,null,null,"COV19-PLASMA",null,"ENACOVID",null,null,"CTOROTSADTOC",null,null,null,null,null,null,"HAHPS","DIC",null,null,"TOCIVID-19","ACE-ID-201","COVID CALL 15","CATNAP",null,"CONCOR-1",null,"CMHS","COVIDAXIS","COVID-Lambda","TRODVID-19",null,"JUPITER","COV-AID",null,null,null,null,"SARPAC",null,null,"COVIDIMMUNE","COMIHY","HAZDpaC",null,"SCOPE","PATCH","CATCO","CODIV-ACE",null,null,"HCQ4COV19",null,"HyAzOUT",null,"APN01-COVID-19","GO2 PEEP","COVIDOSE",null,"RCT","CYTOCOV-19",null,"HELPCOVID-19",null,null,"OAHU-COVID19",null,null,"PrEP_COVID",null,null,null,"TOCOVID",null,null,null,null,null,null,null,null,null,"ConPlas-19",null,null,"COVIDothque",null,null,"PANDOR",null,null,null,null,null,"HOPE","BEST-RCT","TT-NPC",null,"COVACTA",null,null,null,null,null,"COV-HCQ","PHYSIO-COVID",null,"TCOutpatient",null,"COVID-19",null,"CovidRegOUH","ConCoVid-19",null,"QUARANTINE2020","DEXA-COVID19","HYDRA",null,"DEFI-VID19","CTII-nCoV",null,null,"HT-COVID19",null,"ACTION","FAV-001",null,"CORA","CORIPLASM",null,"Covid-19HUF","BCG-CORONA",null,"Explore",null,null,"COVID19PUGG2","Strain",null,"VICO","TOSCA",null,null,"NIAID","SAC-COVID",null,null,null,null,"CTCOVID-19","COVITD-19",null,null,"THDMS-COVID-19",null,null,null,"AZIQUINE-ICU",null,null,null,"EPILOGUE","CORSA","OHB10cov","GARGLES","NO COV-ED",null,"COPERNICO",null,null,null,null,null,null,null,"Al-COVE","ECMO-VID",null,null,"COVIDICUS","PHYDRA","TACROVID","Covid",null,"CAPTION AI","SCOUT",null,null,null,"BLAST COVID-19","PRA-001","CORIMMUNO-COAG","CORIMMUNO-BEVA","eChoVid","STOP COVID","RegCOVID19","CRASH-19",null,"CORTI-Covid","DEFACOVID","HOPE COVID 19","IMMUNONCOVID","CovidSurg","CORIMUNO-VIRO","HOPE",null,null,null,null,null,"CORIMUNO-NIVO","Thy-Support",null,null,null,"RuxCoFlam","CORIMUNO19-ECU","TCInpatient","PHYSIO-COVID",null,null,null,"HSC19","DISPOSE","MultiCov","COVID STEROID","(COVID19_BMT)","CORON-ACT","Covid-VAS","COVID_2Pro",null,"PISCO","FMTVDM","SOS-COVID19","Covid-19",null,null,null,null,"SISCO","SEROCOV",null,"ONCOVID",null,"COVILLE","MexCOVID-19",null,"GRAVID",null,"JOCOVID","WHIP COVID-19",null,"COVID-CHD","CORONACION","PRODEX","SARS-RAS","COVIP","CROWN CORONA","BRACE","GRECCO-19","COVID-SER",null,null,"PROTECT","INHASCO","ESCAPE",null,"CORSER","DHYSCO",null,null,null,null,"REPLACECOVID",null,"HERO-HCQ",null,"COVIDENCE","COLCOVID",null,null,null,null,"COVID-HEP",null,null,"BIOCOVU","PEACE",null,"COPCOV","APPROVE-CARE",null,"COVIDMED","NeuroCOVID19",null,null,null,null,null,null,null,"PROTECT",null,null,null,null,null,"PROACTIVE-19",null,"CONEC",null,null,"POINT-C","STOP-Flu",null,null,null,"ORCHID",null,null,"CYCOV",null,"EC-COVID-PCS",null,null,null,null,"PREP-COVID",null,"VT4COVID","CSSC-001","CamoCO-19","CP-COVID-19","CAPACITY-COVID","ATCO",null,null,"Coronavirus","NODS-Cov2","EPICOS",null,null,"COVID-19","CP-COVID-19","COVID-Antibody","TACOS","EasyCoV","SOTSPC",null,"PRIORITY","AI-COVID-Xr","DisCoVeRy",null,"Emocovid",null,"COVIDeHPAD","COLCOV19-BX",null,null,"FRENCH CORONA","COVCALL",null,"CONFINE","BEST-CP",null,null,"ATTAC-Co",null,null,null,"ACORES-2",null,"COVID-AIV",null,null,"EPI-COVID-19",null,"REMAP-CAP",null,null,"HCQINRLGII","DC-COVID-19","COVID-19-HBO","REALIST","COVID-19",null,null,"NoCovid","ACT COVID19","TEACHCOVID","BARI-COVID","STROMA-CoV2","Ruxo-Sim-20","COntAGIouS",null,"COVID-19","eCardioCovid19","WUHAN Trail","POCUSCO","CloroCOVID19II","SHARP COVID-19",null,"CoDEX",null,null,null,"COVIDOC",null,"Q-PROTECT",null,"CORIPREV-LR","LUSCOVID19","COVID19-HCW","MP-C19",null,null,null,"LIBA","ONCOVID",null,null,"BEAT19",null,null,"IBD-COVID-19",null,null,"CovCardioVasc","NOpreventCOVID","ColCOVID-19","SPIN-CHAT",null,null,null,null,null,"SRA-COV","COVID-19",null,null,null,null,null,null,"REMOTE-COVID",null,null,"STOP-COVID",null,"COVID-preg","UPSAT",null,null,"RAPID-19","UMODCOVID19","TOVID-49",null,null,"NOSARSCOVID",null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HYCOVID","CLOCC",null,null,null,null,null,null,"Coalition-I","COVIDx",null,"CORIMUNO-19","I-COVID",null,null,"NOCOVID","GARM-COVID19",null,"ProPAC-COVID",null,"ASC COVID-19","BURDENCOV",null,"CORIMUNO-SARI",null,"New","CCAP",null,"CCU-COVID19",null,"COVID MECH",null,"PERN-COVID-19","COVIDHLH",null,"PREDICT",null,null,null,null,null,null,"CORONADO","NoCovid",null,"CCF",null,null,"NOSO-COR","SOLID-C19","ECMO-COVID-19","B-DT-COV2","COVID-BioB",null,null,null,null,"COVISTRESS","add-on-COV2","NOSARSCOVID","TOCIVID","NIKE_C19","Chloroquine UN",null,"PiCCOVID","Resi-CoV",null,null,"INCOVPED","ChilblainCOVID",null,"ProCov",null,null,null,null,null,null,null,"MetCOVID","CORIMUNO-ANA","2019-nCoV",null,null,null,null,"EC-COVID-RCT","COVID-ARA2","STORY",null,"HOME-CoV","CloroCOVID19",null,null,null,null,"NONTM",null,"COVID-19",null,null,null,"Cov-CONTACT",null,null,null,null,null,null,"WU352",null,"COVID-19","COVID-19","CORIMUNO-TOC",null,null,null,null,"IMPACT","AS DEFER","NO COVID-19",null,null,"COVIDSOT","LOVIT",null,null,"COVID-19 PEP","CCP-nCoV",null,null,"COVIDAtoZ",null,null],["Recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Active, not recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Withdrawn","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Available","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Completed","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Completed","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Active, not recruiting","Available","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Suspended","Completed","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Withdrawn","Not yet recruiting","Recruiting","Completed","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Recruiting","Not yet recruiting","Available","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Completed","Withdrawn","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Terminated","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Completed","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Completed","Recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Withdrawn","Not yet recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Available","Not yet recruiting","Enrolling by invitation","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Available","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Completed","Not yet recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Active, not recruiting","Recruiting","Not yet recruiting","Completed","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Enrolling by invitation","Enrolling by invitation","Recruiting","Completed","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Completed","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Withdrawn","Recruiting","Recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Not yet recruiting","Recruiting","Recruiting","Completed","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Enrolling by invitation","Not yet recruiting","Recruiting","Enrolling by invitation","Not yet recruiting","Not yet recruiting","Active, not recruiting","Active, not recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Completed","Not yet recruiting","Recruiting","Withdrawn","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Available","Recruiting","Recruiting","Recruiting","Not yet recruiting","Completed","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Enrolling by invitation","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Active, not recruiting","Recruiting","Recruiting","Not yet recruiting","Withdrawn","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Available","Not yet recruiting","Recruiting","Active, not recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Not yet recruiting","Recruiting","Withdrawn","Not yet recruiting","Not yet recruiting","Enrolling by invitation","Recruiting","Recruiting","Completed","Not yet recruiting","Not yet recruiting","Recruiting","Recruiting","Not yet recruiting","Recruiting","Recruiting","Enrolling by invitation","Not yet recruiting","Enrolling by invitation","Recruiting","Not yet recruiting"],["No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available","No Results Available"],["COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19 Pneumonia","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19 Pneumonia","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19 Infection","COVID-19|SARS-CoV-2","SARS-CoV-2|COVID-19","COVID-19","COVID-19 Infection","COVID-19","COVID-19 Disease","Use of Stem Cells for COVID-19 Treatment","COVID-19 Pneumonia","COVID-19","COVID-19","COVID-19 Pneumonia","COVID-19 Pneumonia","Corona Virus Disease 2019,COVID-19","COVID-19 Infections","COVID-19 Pneumonia","COVID-19","COVID-19 Thalidomide","COVID-19 Thalidomide","COVID-19","COVID-19|Cardiovascular Diseases","COVID-19, Hydroxychloroquine Sulfate","Sars-CoV2|COVID-19","COVID 19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","Acute Respiratory Distress Syndrome Caused by COVID-19","COVID-19|Severe Acute Respiratory Syndrome","Coronavirus Disease (COVID-19)","Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure","COVID-19","COVID-19|Viral Respiratory Illnesses","COVID-19|Liver Cirrhosis","COVID-19|Hypertension","Severe/Very Severe COVID-19 Illness","COVID-19|SARS-CoV-2","Coronavirus Disease (COVID-19)","2019 Novel Coronavirus Pneumonia|COVID-19","Anxiety Related to the COVID-19 Pandemic","Covid19","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2","COVID-19 Pneumonia","COVID-19","Coronavirus Disease 2019 COVID-19","Coronavirus Disease (COVID-19)","COVID-19","COVID-19|SARS-CoV-2","SARS-CoV-2|COVID-19","Coronavirus Disease (COVID-19)","Coronavirus Disease (COVID-19)","SARS-CoV-2 Infection|COVID-19","COVID-19 Pneumonia","Cancer|COVID-19","SARS-CoV-2|COVID-19","Coronavirus Disease 2019 (COVID-19)","Severe Coronavirus Disease (COVID-19)","COVID-19|BCG Vaccination","COVID-19|Pneumonia","COVID-19|Deep Vein Thrombosis (DVT)/Thrombophlebitis","Coronavirus Disease 2019 (COVID-19)","COVID-19","Patients Infected With COVID-19","COVID-19","Corona Virus Disease 2019(COVID-19)","SARS-COV-2 Infections|COVID-19","Novel Coronavirus Infectious Disease (COVID-19)","COVID-19|Respiratory Disease","COVID-19","COVID-19|Respiratory Failure","COVID-19","COVID-19","COVID-19|Coronavirus Infection","Addiction, Substance|COVID-19","COVID-19|SARS-CoV-2","Covid-19","Covid-19","COVID19","COVID-19","COVID-19|Pneumonia, Viral","COVID-19|Novel Coronavirus Pneumonia","COVID 19","COVID19","COVID-19|COVID","COVID 19","Covid19","COVID19","Solid Organ Transplant Rejection|COVID-19","ARDS, Human|COVID-19","COVID-19|Pneumonia","COVID-19|Corona Virus Infection","Acute Hypoxemic Respiratory Failure|COVID-19","COVID-19|Severe Acute Respiratory Syndrome","COVID-19|Lung Injury","COVID19","Covid-19","COVID-19","COVID-19 Pneumonia|Lung Ultrasound","COVID-19|Physician-Patient Relations","COVID-19","COVID-19|Yellow Fever","COVID-19|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2","Coronavirus Disease (COVID-19)","COVID19 Pneumonia","COVID19 Pneumonia","2019-nCoV (COVID-19)|Interstitial Pneumonia","COVID 19|Coronavirus","SARS-CoV-2","Covid-19","COVID19","Viral Pneumonia Human Coronavirus|COVID-19","COVID19","COVID 19","SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor","COVID-19|Coronavirus|Surgery","COVID19|SARS-CoV-2 Infection","Pneumonia, Viral|Covid-19","Pneumonia, Pneumocystis|Coronavirus|COVID-19","COVID-19 Complicated With Refractory Intestinal Infections","Contact Person From COVID-19 Confirmed Patient","Covid-19","Convalescent Plasma for COVID 19","COVID19- Infection With SARS-CoV-2 Virus","Pulmonary Infection|Covid-19","Treat and Prevent Covid-19 Infection","Virus Diseases|COVID-19","Respiratory Failure|Covid-19","Covid-19","SARS-CoV-2|COVID19","COVID19","COVID-19|ARDS|Sars-CoV2","COVID-19|Remdesivir|SARS-CoV-2","COVID 19","COVID-19|Endotracheal Intubation","COVID 19","COVID-19|Psychosocial Stress|Mental Health","Covid19|Pneumonia","Covid-19|Hypoxia","COVID19","SARS-CoV-2 Infection","Vascular Surgical Procedures|COVID-19|Postoperative Complications","COVID19","Pathogen Infection Covid-19 Infection","COVID-19|SARS-CoV-2","CoVid 19 Positive","Covid19|SARS-CoV Infection","SARS-CoV-2","COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)","HIV/AIDS|COVID-19|SARS-CoV-2","COVID19","Hospitalized Patients With Covid-19 Pneumonia","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection","Sars-CoV2","COVID-19|Coronavirus Infection|Corona Virus Infection","Cancer &amp; COVID 19","COVID-19|Acute Kidney Injury|Kidney Function","Covid19","Coronavirus Infections|COVID-19|Viral Pneumonia Human Coronavirus","SARS-CoV-2 Viral Kinetics and Host Immune Responses","Covid-19|Lung Cancer","Sars-CoV2","COVID-19|Myocardial Injury|Myocarditis","COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2","Covid 19 Pandemic From Ethical View","Congenital Heart Disease|Covid-19","Hypertension|COVID-19","COVID-19 Infection|Sars-cov-2|Respiratory Failure|Palliative Situation","COVID-19|Hypertension|Cardiovascular Diseases","COVID-19|Elderly Patients|Critical Illness|Survival|Old Age","COVID 19","Coronavirus Disease 2019 (COVID-19)|Febrile Respiratory Illness|Corona Virus Infection|COVID-19","Corona Virus Disease 19 (Covid 19)","Suspicion of Infection With SARS-CoV-2","Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19","COVID-19|Lung Injury, Acute","COVID 19","Covid-19 Infection|Hospitalization in Respiratory Disease Department","COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection","SARS-CoV-2|Outcome, Fatal","SARS (Severe Acute Respiratory Syndrome)|COVID-19","Respiratory Distress Syndrome, Adult|COVID-19","Endometriosis|Covid19","Oropharyngeal Dysphagia|COVID-19|Sars-CoV2|Nutrition","Health Care Worker (HCW)|COVID-19","Respiratory Distress Syndrome, Adult|SARS-CoV-2","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID-19","COVID|Sars-CoV2","SARS-CoV-2","Covid19|Newborn Morbidity","Infection Viral|Coronavirus|COVID-19","SARS-CoV-2|Coronavirus Infection|Asymptomatic Condition|COVID-19","CoVID-19|Chinese Medicine","COVID19|Coronavirus|Acute Respiratory Illnesses","ARDS, Human|Mechanical Ventilation Complication|COVID19","Solid Tumor|Sars-CoV2|Hematological Malignancy","SARS-CoV-2 Infection","COVID-19|Encephalopathy|Critically Ill","2019-nCoV","SARS-CoV-2","Novel Coronavirus Pneumonia|2019-nCoV","COVID-19|Acute Respiratory Distress Syndrome|Virus; Pneumonia|Acute Lung Injury","COVID-19|Burnout, Caregiver|Intensive Care Unit|Stress, Psychological","COVID-19|Severe Pneumonia|Chinese Medicine","SARS-CoV-2","Sars-CoV2","Migraine Disorders|Stress|Anxiety","Coronavirus Infection|COVID|Covid-19|SARS-CoV-2","SARS-CoV2 Infection","SARS CoV-2 Infection","COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus","SARS-CoV-2|Coronavirus|COVID-19|2019-nCoV|2019nCoV","Coronavirus|COVID","SARS-CoV 2|Immunization; Infection","Pneumonia, Viral|COVID-19","Coronavirus|SARS-CoV-2","Risk Factor, Cardiovascular|Covid19|Critical Illness|Course Illness","Influenza Infection|SAD-RV Infection and COVID-19","2019-nCoV","Communicable Disease|COVID-19|Sars-CoV2|Infectious Disease|Coronavirus|Virus Diseases","SARS-COV2 Virus","Coronavirus|Acute Respiratory Infection|SARS-CoV Infection","Coronavirus","SARS-COV2|Severe Acute Respiratory Syndrome|COVID-19","Coronavirus|COVID-19|SARS-CoV Infection|Respiratory Failure|Cytokine Storm","Covid-19|Coronavirus Infection|Pregnancy Related","Early CPAP Ventilation in COVID-19 Patients","Coronavirus Disease 2019","Coronavirus Disease 2019|Novel Coronavirus Pneumonia","Coronavirus","Coronavirus Infection","SARS-CoV-2 Infection","Coronavirus Disease 2019","Acute Respiratory Distress Syndrome|COVID19|Sars-CoV2|Pneumonia","Coronavirus|Convalescence","Corona Virus Infection","Coronavirus|Coronavirus Infection","COVID-19; Cardiovascular Diseases","Coronavirus|Respiratory Failure|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|SARS-CoV-2","2019 nCoV, PD-1","COVID 19|Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","Coronavirus Infection","Sars-CoV2","Coronavirus Infection","COVID|ARDS, Human|Ards|Sars-CoV2","Perceived Stress|Anxiety|Sleep Disturbance","Coronavirus","Coronavirus|Coronavirus Infection","SARS-CoV-2","Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab","SARS-CoV-2","Coronavirus Disease-2019","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Pregnancy|Coronavirus|COVID-19","COVID-19|Pneumonia, Viral|Influenza With Pneumonia|Flu Symptom|Flu Like Illness|Pneumonia, Interstitial|Pneumonia, Ventilator-Associated|Pneumonia Atypical","Corona Virus Infection","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Emotionnal Distress; COVID-19","2019-nCoV","Coronavirus Infection","Infection Viral","2019-nCoV","2019-nCoV","Pneumonia, Viral|Critically Ill|Corona Virus Infection","SARS-CoV-2|Systemic Lupus Erythematosus|Rheumatoid Arthritis|Sjogren's Syndrome|Psoriatic Arthritis","SARS-CoV-2 Pneumonia","Postpartum Depression","Coronavirus Infections","Coronavirus Infection|Type 2 Diabetes","Coronavirus|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere","Severe Acute Respiratory Syndrome Coronavirus 2","2019-nCoV Pneumonia","Coronavirus Infection|Coronavirus|Infectious Disease","SARS-COv2 Related Interstitial Pneumonia","History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","Coronavirus Infections","Acute Respiratory Distress Syndrome|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection","SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS","Coronavirus Infections","Coronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV Infection","2019-nCoV Severe Pneumonia","Community-acquired Pneumonia, Influenza, COVID-19","SARS-CoV-2|COVID|Coronavirus","Gynecological Cancer","Hydroxychloroquine|Antimalarials|Enzyme Inhibitors|Antirheumatic Agents","Pneumonia, Pneumocystis|Coronavirus","Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Cytokine Storm|Infection Viral","Acute Respiratory Distress Syndrome","Susceptibility to Viral and Mycobacterial Infection","Coronavirus Infections","Coronavirus Infection","Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Coronavirus|Severe Acute Respiratory Syndrome","Sars-CoV-2, Community-Acquired Pneumonia","Pharmacological Action","Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome","Coronavirus Infection","Coronavirus Infections","Covid-19","Characteristics Diseases|Outcome, Fatal","Angina Pectoris|Acute Coronary Syndrome|Coronary Syndrome|Coronary Artery Disease|Angioplasty|Stent Restenosis|Hypertension|Heart Failure, Systolic|Depression, Anxiety|Covid-19|Isolation, Social","Coronavirus Infection|Sars-CoV2","COVID|Coronavirus Infection","COVID-19|SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Clinical Trial","Coronavirus Infection|Hydroxychloroquine Adverse Reaction","Healthy Volunteer|Mood Disorder|Anxiety Disorder|Preexisting Medical Condition","Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Pulmonary Fibrosis Due to 2019-nCoV","Corona Virus Infection","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Coronavirus Infection|Pneumonia, Viral","Pneumonia","Covid19","COVID|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1","Coronavirus Infections|Post-exposure Prophylaxis","Coronavirus|Epidemic Disease|Pneumonia, Viral","Health Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological Abnormality","Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human","Rheumatoid Arthritis|Psoriatic Arthritis|Axial Spondyloarthritis|Systemic Lupus Erythematosus|Giant Cell Arteritis","COVID","Pediatric Respiratory Diseases|COVID|Fatigue Post Viral","Coronavirus|Respiratory Distress Syndrome|SARS-CoV Infection","Cancer","Open to All Adults in the US Who Have a Smart Phone and Reliable Internet Connection","2019-nCoV|Immunoglobulin of Cured Patients","Coronavirus","COVID|Drug Effect|Drug Interaction|Adverse Drug Event","Ventilator Associated Pneumonia","IBD|COVID","Coronavirus|Machine Learning","Coronavirus Infection","COVID|Acute Coronary Syndrome|Myocardial Infarction|Myocarditis|Venous Thromboembolism|Deep Vein Thrombosis|Pulmonary Embolism","Coronavirus Infections|Healthcare Associated Infection","Coronavirus Infections|Pneumonia, Viral","Scleroderma|Scleroderma, Systemic|Systemic Sclerosis","Surgery|COVID|Asymptomatic Patient|Covid-19|Preventive Measures","Stress, Psychological","Liver Diseases|Liver Cancer|COVID19","Blood Donation","COVID-19|ECMO","COVID 19","COVID-19|Coronavirus","COVID-19|Recombinant Human Interferon 1","Coronavirus","Cardiovascular Disease Acute|Cardiomyopathies|COVID","Coronavirus Infection","COVID","COVID|Hypoxemia","Coronavirus","Coronavirus|N95|Medical Mask","2019 Novel Coronavirus Infection","Coronavirus Infection","COVID|Mechanical Ventilation|Acute Respiratory Failure","Infection Viral","COVID|Hypoxic Respiratory Failure","COVID","Pneumonitis","COVID","COVID-19|Organ Dysfunction Syndrome Sepsis|Organ Dysfunction Syndrome, Multiple|Septic Shock|Acute Kidney Injury|Acute Respiratory Distress Syndrome","Coronavirus","COVID|Respiratory Distress Syndrome","Neonatal Infection|Perinatal Problems|Infectious Disease","Coronavirus|SARS (Severe Acute Respiratory Syndrome)","MAGEC Rod","Coronavirus Infection","SARS Pneumonia","COVID|Trauma|Ultrasound","Coronavirus","Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19","COVID","SARS-CoV Infection","Liver Cirrhoses","Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection","Colon Polyp|Colon Disease|Reflux, Gastroesophageal|Varices, Esophageal","Corona Virus Infection","COVID","COVID","Coronavirus","COVID","Pneumonitis|Coronavirus Infection","Efficacy, Self|Satisfaction, Patient|Telemedicine","Infections, Respiratory|Fever|Cough","Coronavirus","Stress","Disease, Infectious|Respiratory Disease|Safety Issues|Effectiveness","Coronavirus Infections","Acute Disease|Coronavirus|Respiratory Viral Infection","Healthy Lifestyle","Corona Virus Infection","Infection Viral","Pneumonia, Ventilator-Associated|Coronavirus Infection","Follow-up|COVID-19|Infectious Diseases|Respiratory","Corona Virus Infection","Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease","COVID","Virus Diseases|Infection Viral|Corona Virus Infection","Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia","Respiratory Tract Diseases","Corona Virus Infection|Post-traumatic Stress Disorder","Critically Ill|Coronavirus Infections","Corona Virus Infection","Coronavirus","Mental Stress|Mental Health Wellness 1|Depression|Anxiety|Behavior Problem|Emotional Problem","COVID|Corona Virus Infection|Viral Pneumonia","Coronavirus Infections|Pneumonia, Viral","Acute Coronary Syndrome|Heart Failure|COVID","2019-nCoV","Coronavirus|SARS","Sars-CoV2|Infection Viral|Healthcare Worker|Prophylaxis","COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response","COVID","Coronavirus Infection","Infection Viral|Coronavirus|ARDS|Pneumonia","COVID","Dysfunctional Worry","Telerehabilitation","COVID-19|SARS-CoV-2|Coronavirus|Influenza -Like Illness|Lower Resp Tract Infection|Upper Resp Tract Infection","Flu Like Symptom|Flu Like Illness","Mental Health Issue","Coronavirus|Diabetes","Coronavirus Infections|Pneumonia, Viral|Dyspnea","Corona Virus Infection|Immunisations","Infection Viral|Infection, Hospital|COVID","COVID|Conjunctivitis","Novel Coronavirus Pneumonia","Infection Viral","Coronavirus","Respiratory Distress Syndrome","Coronavirus","Coronavirus Infections","Respiratory Distress Syndrome, Adult","Gastrointestinal Disease|Infectious Disease","COVID-19|Nintedanib|Safety|Effect of Drugs","Severe Acute Respiratory Syndrome (SARS) Pneumonia","Stress, Psychological","Coronavirus Infections","SARS (Severe Acute Respiratory Syndrome)|Coronavirus","Corona Virus Disease","Pneumonia, Viral|Hypertension|Diabetes Mellitus|Obesity|Cardiovascular Diseases|Obstructive Lung Disease","COVID","Coronavirus Infection","Coronavirus|SARS-CoV-2|COVID-19|Acute Respiratory Distress Syndrome|Shock|Acute Circulatory Failure|Left Ventricular Dysfunction|Fluid Overload","Psychological","COVID","Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","Coronavirus|COVID|Infection Viral","Skin Manifestations|COVID|Chilblains","Musculoskeletal Pain","Coronavirus Infection|Oxygen Deficiency","Emergency Service, Hospital|General Surgery","COVID","Cardiovascular Diseases|Cardiovascular Risk Factor|SARS","Coronavirus|Depression|Anxiety|Stress","Pneumonia, Viral|Respiratory Failure","Coronavirus","Coronavirus","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Corona Virus Infection","Pneumonia Caused by Human Coronavirus","SARS-CoV Infection","Pneumonia, Viral|Pneumonia, Ventilator-Associated","2019-nCoV","Coronavirus","CPAP Ventilation|COVID-19|Emergency Departments","COVID|Acute Respiratory Distress Syndrome","Serogroup C Meningococcal Meningitis|Diphtheria|COVID-19","Vitamin C|Pneumonia, Viral|Pneumonia, Ventilator-Associated","Coronavirus Infection","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","2019 Novel Coronavirus Pneumonia","Coronavirus Disease 2019","Coronavirus|Coronavirus Infection|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|Coronavirus as the Cause of Diseases Classified Elsewhere","New Coronavirus","Respiratory Tract Infections|Corona Virus Infection","Cardiovascular Diseases|COVID","Corona Virus Infection","Cardiovascular Death; Major Adverse Cardiovascular Events","Novel Coronavirus Infection Pneumonia","Ventilator Associated Pneumonia","Coronavirus","Pneumonia Caused by Human Coronavirus (Disorder)","Virus; Pneumonia","2019-nCoVs Infection Pneumonia","Coronavirus Infections|Respiratory Failure|Ventilator Lung","Coronavirus","The Gold Standard for Current SARS CoV2 Detection is RT-PCR","Coronavirus Infection","Social Isolation|Physical Inactivity|Well-Being","Telerehabilitation|Coronavirus","Healthy People","Corona Virus Infection","COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome","Coronavirus Disease 2019","Pneumonia, Interstitial","Coronavirus|Pneumonia|Oxygen Toxicity","Covid-19 Infection|Rheumatoid Arthritis|Psoriatic Arthritis|Hydroxychloroquine","Aortic Valve Stenosis","Corona Virus Infection","Novel Coronavirus Infection","Telerehabilitation|Elderly People|Social Isolation","Transplant Recipient|Infections, Coronavirus","Sepsis|Vitamin C|Intensive Care Unit|COVID-19|Pandemic|Coronavirus","COVID-19|Coronavirus Infections|Hay Fever|Asthma|Chronic Obstructive Pulmonary Disease|Influenza|Common Cold|Respiratory Tract Infections|Healthy","Social Isolation|Exercise|Healthy","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections","Coronavirus Infections","Hip Osteoarthritis|Knee Osteoarthritis|Mental Stress|Coronavirus","Telerehabilitation","COVID|Corona Virus Infection","Health Behavior|Eating Behavior","Coronavirus"],["Drug: Deferoxamine","Drug: Favipiravir|Other: Placebo","Drug: Tocilizumab|Drug: Methylprednisolone","Other: No Intervention","Drug: Clevudine|Drug: Hydroxychloroquine","Device: Hyperbaric Oxygen Therapy","Other: Practice details","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","Drug: Huaier Granule","Device: oxyhydrogen|Device: Oxygen","Drug: DAS181",null,"Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|Dietary Supplement: isocaloric/isonutrigenous ONS","Drug: Losartan","Drug: Best supportive Care (BSC) + IFX-1|Drug: Best supportive care only","Dietary Supplement: Bob's Red Mill|Dietary Supplement: Control - Corn Starch","Biological: Convalescent Plasma","Drug: Hydroxychloroquine","Other: hyperimmune plasma","Other: Plasma Donation","Drug: 1: Naproxen|Drug: 2: Standard of care","Drug: Traditional Chinese Medicine Prescription","Biological: UC-MSCs|Other: Placebo","Drug: TCM prescriptions","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)",null,"Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Drug: Ruxolitinib","Drug: Baricitinib","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate|Drug: Baricitinib (janus kinase inhibitor)|Drug: Sarilumab (anti-IL-6 receptor)","Drug: Hydroxychloroquine|Drug: Azithromycin","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir|Drug: Interferon Beta-1A|Drug: Interferon Beta-1B","Biological: MSCs",null,"Drug: Tocilizumab Injection","Drug: Acalabrutinib","Device: Web application users","Other: Self-prone position recommendation|Other: Usual care","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine","Other: Convalescent plasma","Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy","Other: nCapp, a cell phone-based auto-diagnosis system","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","Drug: Peginterferon Lambda-1a|Other: Standard of Care Treatment","Diagnostic Test: COVID-19 diagnostic test","Drug: Sarilumab|Drug: Placebo",null,"Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab","Behavioral: Crisis management coaching","Drug: Hydroxychloroquine|Dietary Supplement: Placebo","Device: hyperbaric oxygen therapy (HBOT)","Drug: Sildenafil citrate tablets","Drug: Sargramostim|Other: Control","Other: Surgical facial mask","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: COVID-19 Serology|Other: Symptoms questionnare","Drug: Hydroxychloroquine|Drug: Placebo","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc",null,"Drug: Sirolimus|Drug: Placebo","Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet","Drug: Lopinavir/ritonavir",null,"Drug: chloroquine|Other: standard care",null,"Drug: Treatment and prophylaxis|Other: Standard Public Health measures","Other: survey","Drug: Hydroxychloroquine|Drug: Azithromycin","Biological: Convalescent Plasma","Drug: RhACE2 APN01|Drug: Physiological saline solution","Device: GO2 PEEP MOUTHPIECE","Drug: Tocilizumab","Drug: Hydroxychloroquine","Drug: Hydroxychloroquine|Drug: Azithromycin","Device: CytoSorb-Therapy","Drug: Canakinumab 150 MG/ML [Ilaris]","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Drug: Saline oral/nasal rinse|Drug: 0.5% Povidone/Iodine oral/nasal rinse|Drug: 0.12% Chlorhexidine oral/nasal rinse","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate","Drug: Hydroxychloroquine","Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine","Drug: HB-adMSCs|Drug: Placebos","Drug: Hydroxychloroquine|Drug: Placebos","Drug: Mavrilimumab","Biological: allogeneic human dental pulp stem cells (BSH BTC &amp; Utooth BTC)|Other: Intravenous saline injection (Placebo)","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","Drug: Remdesivir|Drug: Standard of Care","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Biological: bacTRL-Spike|Other: Placebo","Drug: Nitazoxanide Tablets|Drug: Placebo","Drug: Clazakizumab 12.5 mg|Drug: Clazakizumab 25 mg|Other: Placebo","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%","Drug: Remdesivir|Drug: Standard of Care","Device: Non-contact ECG","Other: Blood and derivatives.|Drug: Standard of Care",null,"Other: this study is non- interventional","Other: blood sample",null,"Drug: Vazegepant (BHV-3500)|Drug: Placebo","Other: hospitalized children with Covid19","Other: other","Biological: WJ-MSCs","Drug: Tocilizumab","Drug: Siltuximab|Drug: Methylprednisolone","Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine","Biological: NestCell","Drug: Bevacizumab","Drug: Tetrandrine","Drug: methylprednisolone therapy|Other: Standard care","Drug: Tocilizumab (TCZ)|Drug: Placebo","Device: Aerosol-reducing Mask|Device: Standard Mask","Drug: thalidomide|Drug: placebo","Drug: placebo|Drug: Thalidomide",null,"Other: non","Drug: Hydroxychloroquine Sulfate|Drug: Placebo","Other: Phsyiotherapy","Biological: anti-SARS-CoV-2 convalescent plasma","Drug: Tranexamic acid tablets|Drug: Placebo oral tablet","Diagnostic Test: Cytokines dosage|Diagnostic Test: Complement dosage","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Drug: chlorine dioxide 3000 ppm",null,"Biological: Convalescent plasma","Drug: Suspension of heat killed (autoclaved) Mycobacterium w|Drug: Standard therapy of COVID-19","Drug: Chloroquine phosphate|Other: Telemedicine","Drug: Dexamethasone","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Fingolimod 0.5 mg","Drug: Defibrotide Injection","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo","Drug: Nitazoxanide|Drug: Placebo",null,null,"Drug: Ruxolitinib","Drug: Azithromycin|Drug: Placebos","Drug: favipiravir|Drug: Standard of care therapy","Biological: UC-MSCs|Drug: Placebo","Diagnostic Test: Online Questionnaire","Drug: Transfusion of COVID-19 convalescent plasma","Drug: Ruxolitinib Oral Tablet","Drug: Hidroxicloroquine|Drug: Lopinavir/ritonavir|Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet","Drug: BCG Vaccine|Drug: Placebo","Drug: TJ003234|Drug: Placebo",null,null,"Drug: Remdesivir|Drug: Remdesivir placebo","Other: observation",null,null,"Drug: Chloroquine phosphate",null,null,"Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate",null,"Drug: CD24Fc|Drug: Placebo","Diagnostic Test: Tuberculin test","Drug: LY3127804|Drug: Placebo",null,"Biological: BM-MSCs|Biological: Placebo","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Dietary Supplement: Vitamin D","Other: Questionnaire|Diagnostic Test: IgG","Biological: MSCs|Biological: Saline containing 1% Human serum albuminsolution of MSC","Drug: Oral","Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment","Diagnostic Test: Breath test","Biological: UC-MSCs|Other: Placebo","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo","Drug: Danoprevir+Ritonavir","Drug: Ganovo+ritonavir+/-Interferon nebulization","Drug: Piclidenoson",null,"Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing (NGS) analysis|Other: serum chemistry analysis","Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Drug: Gargle/Mouthwash","Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen","Drug: HB-adMSCs","Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)","Drug: Methylprednisolone","Other: Saline Nasal Irrigation|Other: Saline with Baby Shampoo Nasal Irrigation","Biological: COVID-19 convalescent plasma","Drug: Pegylated interferon lambda","Other: Questionnaire","Drug: Atovaquone/Azithromycin","Device: BIOVITALS",null,"Procedure: ECMO Implantation","Drug: Ruxolitinib","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Dexamethasone injection|Drug: placebo|Procedure: conventional oxygen|Procedure: CPAP|Procedure: HFNO|Procedure: mechanical ventilation","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Tacrolimus|Drug: Methylprednisolone","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Device: Caption AI","Diagnostic Test: Lung ultrasound","Behavioral: turkish physicians","Dietary Supplement: Natural Honey|Other: Standard Care","Drug: Galidesivir|Drug: Placebo","Diagnostic Test: EUROIMMUN assay","Other: Antibody-Rich Plasma from COVID-19 recovered patients","Drug: Tinzaparin or unfractionated heparin","Drug: Bevacizumab Injection","Other: Pulmonary ultrasound","Drug: Fluvoxamine|Drug: Placebo","Drug: Patients with the treatment agains COVID19","Drug: Aspirin|Drug: Losartan|Drug: Simvastatin","Drug: Clazakizumab","Drug: Prednisone|Other: Control group","Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|Drug: Placebo 250 cc 24 hours continuous infusion for 15 days","Combination Product: Observational (registry)","Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care","Procedure: Surgery","Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets","Drug: Hydroxychloroquine","Other: washed microbiota transplantation|Other: placebo","Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)",null,"Other: convalescent plasma from recovered COVID 19 donor","Drug: Nivolumab Injection","Drug: T3 solution for injection|Drug: Placebo","Biological: Pathogen-specific aAPC","Diagnostic Test: NO intervention planned due to the observational study design only a diagnostic testing","Other: Monitoring for aggravation|Other: Evaluate HACOR score effectivity in this patients","Drug: Ruxolitinib 10 MG","Drug: Eculizumab","Drug: Tranexamic acid|Drug: Placebo oral tablet",null,"Drug: Remdesivir|Drug: Remdesivir placebo","Drug: Ivermectine|Drug: Hydroxychloroquine Sulfate|Drug: Placebos","Other: severe covid-19 pneumonia with ET","Device: Biosensors","Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition)","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment","Drug: Hydrocortisone|Drug: Sodium Chloride 9mg/mL","Other: no intervention","Drug: Tocilizumab (TCZ)|Drug: Placebo","Procedure: Vascular surgery","Drug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tablet","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Drug: Pyridostigmine Bromide|Drug: Placebo","Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum","Procedure: Auricular neuromodulation|Procedure: Control",null,"Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Other: No intervention","Drug: Hydroxychloroquine Sulfate (HCQ)","Dietary Supplement: Vitamin C",null,"Other: blood sample","Procedure: Blood draw","Drug: Hydroxychloroquine|Drug: Azithromycin",null,"Diagnostic Test: Data collection and rhinopharyngeal swab",null,"Other: NA (no intervention)",null,"Drug: BLD-2660","Diagnostic Test: Electrocardiogram and transthoracic echocardiography","Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment","Other: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality",null,"Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker","Drug: Treatment with Dexmedetomidine",null,null,"Drug: Low-dose chloroquine/hydroxychloroquine|Drug: Mid dose chloroquine or hydroxychloroquine|Drug: High does chloroquine or hydroxychloroquine|Drug: Placebo","Drug: BCG Vaccine","Drug: Colchicine|Drug: Standard treatment","Diagnostic Test: Serological tests will be applied on patients blood sampling","Genetic: Mesenchymal Stromal Cells","Drug: L-ascorbic acid","Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin","Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice","Drug: Anakinra|Drug: Tocilizumab",null,"Other: Human Biological samples","Drug: Dexamethasone and Hydroxychloroquine|Drug: Hydroxychloroquine",null,"Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)",null,"Drug: Valsartan (Diovan)|Drug: Placebo oral tablet","Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI","Drug: Anluohuaxian","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Favipiravir",null,"Drug: Colchicine|Other: Local standard of care","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab","Biological: Dental pulp mesenchymal stem cells","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment","Drug: Enoxaparin","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","Other: newborns from covid 19 positive mothers",null,"Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo","Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment","Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo","Procedure: Prone Positioning|Procedure: Standard of care.","Drug: BMS-986253","Drug: lopinavir/ritonavir|Drug: Hydroxychloroquine Sulfate|Drug: Losartan|Drug: Placebos","Other: Follow up",null,"Drug: Eicosapentaenoic acid gastro-resistant capsules","Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon 2b Spray","Biological: CAStem","Other: Patient management suffering of coronavirus infection","Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment","Biological: Emapalumab|Biological: Anakinra","Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline","Behavioral: Mindfulness session(s)","Diagnostic Test: Point-of-Care Ultrasonography (POCUS)","Drug: Remdesivir","Biological: Human Amniotic Fluid","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C","Behavioral: Personalized health education|Behavioral: General health education",null,null,"Other: No special intervention","Other: Non-Interventional","Diagnostic Test: Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)","Drug: DAS181|Drug: Placebo",null,"Diagnostic Test: COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine",null,"Drug: Hydroxychloroquine|Drug: Placebo","Biological: anti-SARS-CoV-2 convalescent plasma","Device: CT-V","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","Other: Survey",null,"Drug: Placebos|Drug: Leronlimab (700mg)","Drug: T89","Biological: ChAdOx1 nCoV-19|Biological: MenACWY Placebo","Device: Cordio App","Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo","Drug: Placebos|Drug: Leronlimab (700mg)","Other: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATION","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma","Drug: Camostat Mesilate|Drug: Placebo oral tablet","Drug: Plasma",null,"Drug: Angiotensin 1-7|Drug: Placebos","Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment","Drug: Hidroxicloroquina|Drug: Control group","Drug: Selinexor|Other: Placebo",null,"Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine","Biological: IC14, a monoclonal antibody against CD14","Other: \"Calm\" is a mindfulness meditation mobile app","Other: observational","Drug: Plasma|Drug: Hydroxychloroquine|Drug: Azithromycin","Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit","Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy","Diagnostic Test: Sampling salivary","Other: oxygen treatment","Drug: Losartan|Other: Placebo","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care","Drug: Losartan|Other: Placebo","Other: quetionnary","Drug: Intravenous Immunoglobulin|Other: Standard care","Other: telehealth applications","Other: biological samples collection","Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir","Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization","Other: No intervention","Other: Questionnaire by phone call",null,"Other: Self-administered questionnaires","Drug: Bevacizumab Injection","Drug: Linagliptin|Drug: Insulin regimen",null,"Other: SARS-Cov-2 infection","Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: Tofacitinib","Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy","Device: VivaDiag COVID-19 lgM/IgG Rapid Test","Drug: Aviptadil by intravenous infusion + maximal intensive care|Drug: Normal Saline Infusion + Maximal intensive care","Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC","Biological: Convalescent Plasma","Procedure: Human biological samples","Drug: Methylprednisolone","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab","Biological: Convalescent Plasma","Drug: Chemotherapy","Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG","Drug: Darunavir and Cobicistat","Drug: Hyperbaric oxygen","Biological: Human umbilical cord derived CD362 enriched MSCs|Biological: Placebo (Plasma-Lyte 148)","Other: mobile internet survey on self-test","Other: No intervention","Diagnostic Test: Nasopharyngeal swab","Drug: Nitric Oxide","Drug: Azithromycin|Drug: Chloroquine","Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm","Drug: Baricitinib","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Drug: Ruxolitinib plus simvastatin|Other: Standard of Care","Other: Patient sampling","Drug: Hydroxychloroquine|Other: Vitamin C","Other: Follow up","Other: Tele-medicine platform","Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos","Procedure: Follow-up at 14 days","Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab",null,"Drug: Dexamethasone","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet|Drug: N-acetylcysteine+Placebo","Other: Placebo|Drug: Remdesivir","Other: CT score","Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin","Drug: CM4620-Injectable Emulsion","Drug: Hydroxychloroquine + Azithromycin|Drug: Hydroxychloroquine + Placebo|Other: Placebo + Placebo","Behavioral: Tele-interventions related to diabetes management and mental well-being","Drug: Lopinavir/ritonavir","Diagnostic Test: Lung ultrasound","Diagnostic Test: COPAN swabbing and blood sample collection","Drug: Methylprednisolone|Other: standard care","Other: COVID-19 infection","Other: Prospective oberservational registry",null,"Drug: Ibuprofen","Other: Survey administration",null,"Drug: Immunoglobulin of cured patients|Drug: -Globulin","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Other: Simulation of Repurposed Drugs for COVID-19","Behavioral: Enhanced hygiene measures",null,"Diagnostic Test: Machine learning model","Device: bidirectional oxygenation mouthpiece",null,"Drug: Inhaled nitric oxide gas","Drug: Colchicine","Other: SPIN-CHAT Program","Other: global survey","Other: questionnaire assesment","Diagnostic Test: Collection of breath sample","Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information","Device: Low flow ECMO driving by CVVH machine","Other: blood draw",null,"Drug: Recombinant human interferon 1","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Biological: COVID-19 exposure","Drug: Hydroxychloroquine SAR321068|Drug: Placebo","Behavioral: COVID-surgRES questionaire","Other: Standard interface|Device: Double-Trunk Mask","Device: SensiumVitals wearable sensor","Device: Medical Mask|Device: N95 respirator","Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1","Other: No intervention",null,"Other: pregnant women with laboratory-confirmed 2019-n-CoV","Other: Postural Positioning","Diagnostic Test: IgM and IgG diagnostic kits to SARS-CoV-2|Diagnostic Test: Elisa-test for IgM and IgG to SARS-CoV-2",null,"Diagnostic Test: Loop mediated isothermal amplification COVID-19|Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)|Diagnostic Test: Cytokine profile",null,null,"Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells",null,"Drug: Nitric Oxide Gas","Device: MAGEC Spine Rod|Diagnostic Test: Titanium blood test","Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine","Drug: Tocilizumab","Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation","Other: retrospective analysis","Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL","Biological: Convalescent Plasma Transfusion|Other: Supportive Care","Diagnostic Test: Odd/Even birth year intervention groups","Other: no intervention","Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)","Other: None - NA","Drug: Sarilumab SAR153191|Drug: Placebo","Drug: Favipiravir|Other: Standard of care treatment","Biological: Convalescent Plasma|Biological: Standard Donor Plasma","Drug: Hydroxychloroquine|Drug: Placebo","Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine","Drug: Plaquenil 200Mg Tablet","Other: Satisfaction evaluation","Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals",null,"Behavioral: online mindfulness group","Device: Inspiratory training device|Device: Expiratory training device","Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin","Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection","Behavioral: Video based exercise",null,"Other: pregnant women with laboratory-confirmed 2019-n-CoV","Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients",null,"Drug: NORS (Nitric Oxide Releasing Solution)","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use","Biological: Allogeneic NK transfer","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","Drug: Stem Cell Product","Behavioral: PTSD|Behavioral: Burnout","Other: Nutrition support","Drug: Sarilumab","Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU",null,"Biological: Convalescent anti-SARS-CoV-2 plasma|Drug: Sarilumab|Drug: Baricitinib|Drug: Hydroxychloroquine|Other: Injective placebo|Other: Oral placebo","Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine","Other: Data collection","Drug: Arbidol|Other: basic treatment",null,"Drug: Hydroxychloroquine","Other: Exposure (not intervention) - SARS-CoV-2 infection",null,"Drug: Tradipitant|Drug: Placebo",null,"Drug: ACEIs|Drug: Conventional treatment","Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic","Other: Telerehabilitation",null,"Other: Individualised Ayurveda","Diagnostic Test: Online questionnaire","Other: no interventional study","Drug: Nitric Oxide","Biological: mRNA-1273",null,"Diagnostic Test: Schirmer Test I","Biological: NK Cells","Other: nosocomial infection/hospital acquired infection","Drug: Eculizumab",null,"Diagnostic Test: Biomarkers expression","Other: Observational Study","Drug: Spironolactone 100mg|Drug: Placebo oral tablet","Device: Non-contact MCE system","Drug: Nintedanib 150 MG|Other: Placebo","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis",null,"Drug: Escin|Drug: standard therapy","Drug: Nitric Oxide Gas","Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care",null,"Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Drug: INO-4800|Device: CELLECTRA 2000","Device: Transpulmonary thermodilution|Device: Echocardiography","Other: Questionnaire","Drug: Chloroquine|Drug: Favipiravir|Drug: Nitazoxanide|Drug: Ivermectin|Drug: Niclosamide","Drug: ACE inhibitor","Diagnostic Test: nasopharyngeal swab",null,null,"Procedure: Prone positioning","Other: COVID-19 Pandemic","Drug: Chloroquine|Drug: Placebo oral tablet","Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","Behavioral: Use of social media during COVID-19","Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab",null,"Other: Comprehensive treatment","Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution","Drug: Anakinra",null,"Drug: Losartan","Biological: UC-MSCs","Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group","Biological: Convalescent Plasma","Device: CPAP treatment","Biological: blood sampling","Procedure: venepuncture","Drug: VC|Drug: Sterile Water for Injection","Other: HOME-CoV rule implementation","Drug: Chloroquine diphosphate","Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization","Drug: Remdesivir","Biological: BCG Vaccine|Biological: Placebo Vaccine","Diagnostic Test: Recombinase aided amplification (RAA) assay","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values","Drug: Colchicine|Drug: Placebo oral tablet",null,"Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy","Other: Bacterial species isolated","Biological: 2019-nCoV PCR","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)",null,"Drug: Meplazumab for Injection","Other: standard operating procedures","Diagnostic Test: Serology|Genetic: Sequencing","Diagnostic Test: Thoracic CT Scan","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate","Other: Video based aerobic exercise","Other: Telerehabilitation|Other: exercise brochure","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","Drug: Tocilizumab","Drug: Hydroxychloroquine|Other: Placebo","Other: retrospective analysis","Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy","Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2","Other: Hydroxychloroquine/Chloroquine","Device: TAVR or SAVR","Drug: Hydroxychloroquine Sulfate","Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B","Other: Telerehabilitation|Other: Exercise brochure",null,"Drug: Vitamin C|Other: Control",null,"Other: Study Group","Drug: Hydroxychloroquine|Other: Placebo",null,"Behavioral: Software Messaging","Other: Telerehabilitation-Based|Other: Video-Based","Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care","Other: Assessment of Dietary Changes in Adults in the Quarantine","Biological: MSCs-derived exosomes"],["Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay","Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality","The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay","Physical health symptoms|Lack of physical health symptoms|Fever","The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)|The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load","Decrease incidence of intubation by 30% or greater|Decrease renal injury","Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number","All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate","Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function","Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme","Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death","Need for hospitalization|Duration of hospitalization|Need for ICU/Ventilator Support|Duration of ICU/Ventilator Support|Overall Survival","Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor- concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg","Change in PaO2/FiO2|Patients achieving early response","Rates of hospitalization for a COVID-19 related complication|Time to clinical recovery (TTCR)|Symptom Severity Score","For patients hospitalized for COVID-19 but not intubated|Primary objective for patients with COVID-19 already intubated|Duration of hospitalization|Duration of mechanical ventilation|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at day 10|Impact of donor titers level on efficacy|Impact of donor titers level on safety|Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60","Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased.","death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response","Number of patients who screen eligible for donation|Number of patients who consent to plasma donation|Number of plasma donations received|Safety of donation procedures","Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)","Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events","The immune function (TNF- IL-1IL-6TGF-IL-8PCTCRP)|Blood oxygen saturation|Rate of mortality within 28-days|Size of lesion area by chest imaging|CD4+ and CD8+ T cells count|Peripheral blood count recovery time|Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)|COVID-19 nucleic acid negative time","The relief / disappearance rate of main symptoms|Chest CT absorption|Virus antigen negative conversion rate|Clinical effective time: the average effective time|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor- (TNF-) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events","Burnout|Emotional Distress|Insomnia|Needs and difficulties in work situations","Clinical response|Side effects in the treatment group","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS 2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 2: Cumulative incidence of serious adverse events (SAEs)|Phase 2: Changes in white blood cell count (CBC) through Day 15|Phase 2: Changes in hemoglobin through Day 15|Phase 2: Changes in platelets through Day 15|Phase 2: Changes in creatinine through Day 15|Phase 2: Changes in glucose through Day 15|Phase 2: Changes in prothrombin time (PT) through Day 15|Phase 2: Changes in total bilirubin through Day 15|Phase 2: Changes in ALT through Day 15|Phase 2: Changes in AST through Day 15|Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 2: Changes in hemoglobin through End of Study (EOS)|Phase 2: Changes in platelets through End of Study (EOS)|Phase 2: Changes in creatinine through End of Study (EOS)|Phase 2: Changes in glucose through End of Study (EOS)|Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 2: Changes in total bilirubin through End of Study (EOS)|Phase 2: Changes in ALT through End of Study (EOS)|Phase 2: Changes in AST through End of Study (EOS)|Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15|Phase 2: Change in the 8-point ordinal scale|Phase 2: Change in National Early Warning Score (NEWS)|Phase 3: Change in the 8-point ordinal scale|Phase 3: Change in National Early Warning Score (NEWS)|Phase 3: Time to an improvement of one category using the 8-point ordinal scale|Phase 3: Time to an improvement of two categories using the 8-point ordinal scale|Phase 3: Time to discharge or to a NEWS 2 and maintained for 24 hours, whichever occurs first|Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Phase 3: Cumulative incidence of serious adverse events (SAEs)|Phase 3: Duration of hospitalization|Phase 3: Duration of new oxygen use|Phase 3: Duration of new ventilator or ECMO use|Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason|Phase 3: Incidence of new oxygen use|Phase 3: Incidence of new ventilator use|Phase 3: Number of oxygen free days|Phase 3: Number of ventilator or ECMO free days|Phase 3: 14 day mortality rate|Phase 3: 28 day mortality rate|Phase 3: Changes in white blood cell count (CBC) through Day 15|Phase 3: Changes in hemoglobin through Day 15|Phase 3: Changes in platelets through Day 15|Phase 3: Changes in creatinine through Day 15|Phase 3: Changes in glucose through Day 15|Phase 3: Changes in prothrombin time (PT) through Day 15|Phase 3: Changes in total bilirubin through Day 15|Phase 3: Changes in ALT through Day 15|Phase 3: Changes in AST through Day 15|Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)|Phase 3: Changes in hemoglobin through End of Study (EOS)|Phase 3: Changes in platelets through End of Study (EOS)|Phase 3: Changes in creatinine through End of Study (EOS)|Phase 3: Changes in glucose through End of Study (EOS)|Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)|Phase 3: Changes in total bilirubin through End of Study (EOS)|Phase 3: Changes in ALT through End of Study (EOS)|Phase 3: Changes in AST through End of Study (EOS)","Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score","Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events","Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase","Descriptive-epidemiological analysis of health conditions|Evaluation of frailty condition|Identification of biomarkers of inflammation|Assessment of functional capacity|Evaluation of drug consumption|Evaluation of inflamma-miRs","One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","Treatment failure rate|Number of days alive free of assisted ventilation|Number of days with assisted ventilator use|Number of days hospitalized|Number of days in ICU|Number of days alive outside of hospital|Occurrence of Adverse Events and Serious Adverse Events|Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Cmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Tmax)|Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (AUC)","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population","Change in respiratory status|Length of time participant spends in the prone position|Length of time participant spends in the supine position|Length of time participant spends lying on side|Length of time participant spends sitting up|Length of time participant spends standing or walking|Dyspnea or difficult/labored breathing|Discomfort with proning|Length of hospital stay|Invasive mechanical ventilation|Loss of IV access as a consequence of turning in bed|Acute respiratory distress syndrome (ARDS) diagnosis|Hospital mortality","Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure","Intubation or death in hospital|Intubation|Time to intubation|Ventilator-free days|In-hospital death|Time to in-hospital death|Death at 30 days|Length of stay in intensive care unit (ICU)|Length of stay in hospital|Need for extracorpeal membrane oxygenation (ECMO)|Need for renal replacement therapy|Myocarditis|Adverse events and serious adverse events|Transfusion-associated adverse events (AE)","Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device|Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device|Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients|Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3/Th3|Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles|Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy|Phase Angle in COVID-19 Patients: Measured via Multifrequency","Accuracy of nCapp COVID-19 risk diagnostic model","Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.|corrected QT interval (ms)","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","Positive or negative character of the three tests|sensitivity and specificity of the tests according to the time elapsed since the first symptoms","Percent change in C-reactive protein (CRP) levels|Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of 2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate &gt;24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation 94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Change in serum CRP levels|Incidence of serious adverse events|Incidence of Grade 4 neutropenia (ANC &lt;500/mm3)|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Incidence of gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level","Health Outcomes","Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score &lt;6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","Change in stress level as measured by survey|Change wellness as measured by survey","Incidence|Severity of Disease","Mortality|Days on invasive mechanical ventilation","Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event","Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function","Reduction in COVID-19 infection frequency|Antibody-screening",null,"Proportion of symptomatic patients with immune response (IgM/IgG/IgA)|Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)|Time to IgM|Time to IgG|Time to IgA|Serology kits inter-observer agreement","Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment|Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)|All-cause mortality within 28 days","Successful treatment as determined by Negative Test and resolution of symptoms|Safety of Quintuple Therapy","FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.","Progression to advanced respiratory support","Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events","Efficacy of Intervention|Time to improvement of one catergory from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)","Severe COVID-19|Death","change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease","28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement","Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3|The mortality rate of subjects at weeks 2|Proportion of participants that drop out of study|Proportion of participants that show non-compliance with study drug","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days","Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Lung infiltrates|Viral load of SARS-CoV-2","Cause of death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death","Change in Oxygen Saturation by Pulse Oximetry|Change in Respiratory Rate|Change in Heart Rate|Change in Blood Pressure|Change in Subjective Work of Breathing|Change in Partial Pressure of Oxygen (PaO2)|Change in Partial Pressure of Carbon Dioxide (PaCO2)|Change in pH|Change in Bicarbonate (HCO3)|Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test","Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days","Rate of COVID-19 positive conversion|Time-to-first clinical event","Most severe outcome","Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours|Change in organ dysfunction|Lactate clearance|Renal replacement therapy|Extracorporeal Membrane Oxygenation|ICU length of stay|Time on mechanical ventilation|Cumulative catecholamine dose|Overall and ICU mortality|Change of plasma Interleukin-6 (IL6) level|Change of plasma Interleukin-10 (IL10) level|Change of plasma Procalcitonin (PCT) level|Change of HLA-DR level|Change of TNF alpha level after ex-vivo stimulation","intensive care treatment|ICU stay times|% died after 1 month after treatment|hospitalization|adverse event","Prevention of COVID-19 measured by negative testing with RT-PCR|Safety as determined by blood pressure readings|Safety as determined by presence of side effects","Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx|Oxygen requirement of the patient|Oxygen saturation of the patient","Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine","i. Clinical status|Oxygenation|Mechanical Ventilation|Hospitalization|Mortality","Number patients developing severe infection or death","Incidence of hospitalization for COVID-19|Incidence of symptoms associated with COVID-19|Absence of upper/lower respiratory infection|Leukocyte differential|C Reactive protein|TNF alpha|IL-6|IL-10|Glucose|Calcium|Albumin|Total protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Total bilirubin|white blood cells|red blood cells|hemoglobin|hematocrit|mean corpuscular volume|mean corpuscular hemoglobin|mean corpuscular hemoglobin concentration|red cell distribution width|neutrophils|Lymphs|Monocytes|Eosinophils|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Platelets|Prothrombin time|INR|SF-36|PHQ-9","Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank","Time to resolution of fever|Change in clinical status|Mortality|Change in CRP|Change in IL-6","TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)","Severity of COVID-19|Incidence of SARS-CoV-2 infection|ICU admission|Mechanical ventilation|Mortality","In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events","Severity of COVID-19|SARS-CoV-2 infection|Severity of COVID-19 over 28 days|ICU admission|Mechanical Ventilation|Mortality","Frequency of Adverse Events|SARS-CoV-2 Antibodies|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination","Viral load|Evolution of acute respiratory syndrome|Change in Clinical Condition|Hospital discharge|Rate of mortality within 21-days|Need of mechanical ventilation","Incidence of serious adverse events associated with clazakizumab or placebo|Incidence of intubation|Time to extubation|Length of ICU stay|Number of patients who present a decrease in C-reactive protein|Patient survival","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days","Mean change in viral titers of SARS-CoV-2|Frequency of adverse effects of interest after nasal sprays|Frequency of symptoms related to SARS-CoV-2","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events","ECG changes associated with COVID-19","Category Changes in Ordinal Scale|Time to category 5, 6 or 7 of the ordinal scale|Mortality of any cause at 15 days|Mortality of any cause at 29 days|Oxygenation free days|Ventilator free days|Incidence of Treatment-Emergent Adverse Events|Antibodies levels in CP donors recovered from COVID-19|Viral load","COVID-19 infection","Clinical course of COVID-19|Analysis of development of antibodies to SARS-CoV-2|Estimation of viral load|Detection of viral coinfections|Measurement of cytokine and chemokine response|Characterisation of virus-host-interaction|Identification of disease patterns in proteome|Analysis of change in lymphocyte subtypes|Analysis of histological changes in severe lung disease|Detection of bacterial coinfections","Number of confirmed COVID-19|Number of severe COVID-19","Outcome comparison between different antiviral therapies|Outcome comparisons between ventilation types|Identification of risk factors|Number of days in hospital vs. clinical classification","To evaluate the safety and efficacy of vazegepant compared with placebo in patients hospitalized with COVID-19 infection requiring supplemental oxygen.|The number of unique subjects alive and off of oxygen. These are subjects in categories 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|A subject requiring initiation of mechanical ventilation, non-invasive ventilation, or a high flow nasal cannula is a subject that has any eCRF showing the use of any such device on any day.|The number of unique subjects admitted to an ICU verse those not admitted.|Subjects are alive and respiratory-failure free if they are categorized as being in categories 3, 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|Subjects are alive and free of either mechanical ventilation or non-invasive ventilation if they are categorized as being in categories 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.|Efficacy on Day 29 will be evaluated using the same 6-point severity scales that is used at Day 15.|Time to improvement of one category on the 6-point severity scale will be determined as the number of days from baseline to the first day that an eCRF indicates a one category improvement in the scale.|A 48-hour improvement in SpO2/FiO2 consists of two consecutive days where the case report forms show a clinically meaningful increase from baseline.|The time to improvement in the in the NEWS2 scale will be determined as the number of days from baseline to the first eCRF that shows an improvement.|A score &lt; 2 for 24 hours on the NEWS2 scale consists of a day where all of the reported NEWS2 scores are &lt; 2.|The change in NEWS2 scores will be determined as the change from baseline at Day 15 and at Day 29.|The number of unique subjects alive and off of oxygen.|A day with a resting respiratory rate &gt; 24 is a day in which all eCRFs collected for a subject indicate observed respiratory rates &gt; 24 breaths per minute.|A day with supplemental oxygen is one in which any case report form collected on that day indicates the use of any amount of supplemental oxygen.|Time to saturation greater than or equal to 90% on room air is measured by the number of days from baseline to the first day on which an eCRF indicates saturation greater than or equal to 90% without any supplemental oxygenation.|A ventilator free day is a day in which all of the eCRFs collected indicate that the subject was not using a ventilator.|SOFA scores will be determined from eCRFs. Values will be determined for subjects at admission to an ICU and for all subjects still in an ICU at the end of the study (Day 29).|The number of days of hospitalization will be determined from eCRFs. A hospitalization day is any day that it is shown that a subject spent at least spent part of the day in a hospital.|Time to fever resolution, without antipyretics, during two contiguous days .|The number of deaths, SAEs, severe AEs and Grade 3 or 4 laboratory abnormalities will be tabulated as the number of unique subjects meeting those criteria.|The incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infections will be tabulated as the number of unique subjects, reported in eCRFs, as having these conditions at any point in the study|The incidence of intranasal administration reactions will be tabulated, from eCRFs, as the number of unique subjects having such a condition at any point in the study.|The percentage of subjects who develop significant renal disease.|The percentage of subjects discharged to home on supplemental oxygen will determined from the unique number of subjects have eCRF pages indicating they were discharged to home while still on supplemental oxygen.","Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days","discrimination|Calibration|Net benefit","Clinical outcome|CT Scan|RT-PCR results","Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation|Death from any cause|Tocilizumab toxicity|Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment|Evaluate the progress of the PaO2 / FiO2 ratio|Evaluate the trend over time of the lymphocyte count","Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary  36.6  C, oral  37.2  C, or rectal or tympanic  37.8  C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 &lt;93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute &lt;500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT 3 times ULN (for patients with initial values normal) or&gt; 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.","Clear chest CT-scan|PCR test|Physical statues of patient","Change in Clinical Condition|Rate of mortality within 10-days|Change of Clinical symptoms - respiratory rate|Hypoxia|PaO2 / FiO2 ratio|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group|Complete blood count, cardiac, hepatic and renal profiles;","The time from randomization to clinical improvement","Survival rate|body temperature","Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality","Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of &lt;/= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Organ Failure-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ","Total Leak Volume of Non Invasive Ventilation Mask|Glasgow Coma Scale(GCS)|Respiratory Rate|Heart Rate|Metabolic Data: Blood Gas Measurements|Metabolic Data: Bicarbonate (HC03)|Metabolic Data: Partial Pressure of Carbon Dioxide (PaC02)|Metabolic Data: Partial Pressure of Oxygen (Pa02)","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence","Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of  2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-, IL-1, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1 and other cytokine expression levels before and after treatment","COVID-19 positive case","The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death","Effect of HCQ on in vivo viral clearance","Time of physiotherapy|Type of physiotherapy implemented","Changing of viral load of SARS-CoV2|Changes in immunglobulin G COVID-19 antibody titer|Changes at the cytokine pattern|Intensive Care Unit Admission|Length of hospital stay|Duration of mechanical ventilation|Clinical Status|Mortality","Hospitalization","IL6 concentration|IL6 concentration change from baseline value|Complement parameters|Complement parameters change from baseline values|Inflammatory cytokines baseline concentrations|Inflammatory cytokines change from baseline values|Concentration of markers of macrophage activation|Markers of macrophage activation change from baseline values","Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement","negative testing of covid19","Mortality|Severe disease","Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first|Impact of 250ml convP therapy on hospital days|Impact of 250ml convP on weaning from oxygen therapy|Impact of 250ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission|Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population|Impact of 250ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission|Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways","SOFA scores|Ordinal scale|All-cause mortality|Incidence of AE / SAE or event of clinical significance|SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample|ICU length of stay|Duration of mechanical ventilation|Duration of hospitalization|Clinical improvement|Time (in days) from treatment initiation to death","COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications","60-day mortality|Ventilator-free days","All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction","The change of pneumonia severity on X-ray images","to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival","Occurrence of adverse reactions|Anti SARS-CoV-2 S antibody response(ELISA)|Neutralizing antibody response to SARS-CoV-2|Occurrence of adverse events|Occurrence of serious adverse reaction|Neutralizing antibody response to Ad5-vector","Symptomatic laboratory-confirmed COVID-19|Symptomatic laboratory-confirmed VRI","All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis","Rate of Death|the severity of pneumonia",null,"Hospitalization|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)","Viral clearance|Clinical improvement|Radiological Improvement","Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio","Characteristics of COVID-19-related anxiety|COVID-19-related anxiety symptoms|Self-efficacy and coping with COVID-19|Consequences of COVID-19 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of COVID-19-related anxiety|Change in COVID-19-related anxiety symptoms","Survival without needs of ventilator utilization or use of immunomodulatory drugs|WHO progression scale 6|Severe adverse events|WHO progression scale|Overall survival|Time from randomization to discharge|Time to oxygen supply independency|Survival without needs of ventilator utilization|Survival without use of immunomodulatory drugs","Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate","time to clinical improvement|Safety of treatments|Tolerability of treatments","Health Care Workers absenteeism|The cumulative incidence of documented SARS-CoV-2 infection|The number of days of unplanned absenteeism, because of documented SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS-CoV-2 infection|The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|The number of days of self-reported fever (38 gr C)|The number of days of self-reported acute respiratory symptoms|The cumulative incidence of self-reported acute respiratory symptoms|The cumulative incidence of death for any reason|The cumulative incidence of death due to documented SARS-CoV-2 infection|The cumulative incidence of Intensive Care Admission for any reason|The cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection|The cumulative incidence of Hospital Admission for any reason|The cumulative incidence of Hospital Admission due to documented SARS-CoV-2 infection|The incidence and magnitude of SARS-CoV-2 antibodies at the end of the study period","Proportion (%) of subjects experiencing deterioration in clinical status|Treatment Emergent Adverse Events|Clinical status|Improvement in clinical status|Sequential Organ Failure Assessment (SOFA) score|Change from baseline in PaO2/ FiO2|Length of time to normalization of oxygen saturation|Change from baseline in percentage of subjects requiring mechanical ventilation|Change from baseline in Glucocorticoid use|Mortality rate from any cause|Length of hospitalization|Change from baseline in D-dimer|Serum concentration of TJ003234|Incidence and titer of anti-drug antibodies (ADA)","Exploring the presence of COVID-19","To determine SARS-CoV-2 viral load and infectivity insaliva that may contribute to asymptomatic transmission|Viral load of salivary droplets generated from speaking","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events","symptoms of COVID-19 in older patients","Dominant viral genome strain","Risk categorization of Healthcare workers'|Secondary COVID-19 infection rate|isolation rate among HCWs|adherence of HCWs to infection prevention|effectiveness of infection prevention|determine the emergency infection prevention","Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|Time to viral PCR negative from rectal swab|fever clearance time|Ordinal outcome scale|Development of ARDS","Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score &lt;3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases","Number of participants who fill out the survey and participate in the semi-structured interviews.","Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood","Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma","Improvement of COVID-19 disease status|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|All cause of death|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of oxygen therapy|Length of hospital stay|Absolute lymphocyte count","Pneumonia severity index|Need for ICU admission|COVID -19 test conversion|Mortality","Number of Ventilator Free Days|Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment|Oxygen Saturation (SpO)|Oxygen Flow Rate|Mortality|Length of Hospitalization|Number of Participants with any Serious Adverse Event (SAE)|Number of Participants with any Treatment Emergent Adverse Event (TEAE)","to investigate the prevalence and identify possible risk factors of the occurrence of a DVT in these patients at the ICU.","Changes of oxygenation index (PaO2/FiO2)|Side effects in the BM-MSCs treatment group|Clinical outcome|Hospital stay|CT Scan|Changes in viral load|Changes of CD4+, CD8+ cells count and concentration of cytokines|Rate of mortality within 28-days|Changes of C-reactive protein","Safety indexes of adverse reactions|Safety indexes of adverse events|Safety indexes of SAE|Safety indexes of lab measures|Immunogencity indexes of GMT(ELISA)|Immunogencity indexes of GMT(pseudoviral neutralization test method)|Immunogencity indexes of seropositivity rates(ELISA)|Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|Immunogencity indexes of GMI(ELISA)|Immunogencity indexes of GMI(pseudoviral neutralization test method)|Immunogencity indexes of GMC(Ad5 vector)|Immunogencity indexes of GMI(Ad5 vector)|Immunogencity indexes of cellular immune","Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery","Measure frequency of people suffered from unusual flu-like symptoms before December 2019|Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible","Size of lesion area and severity of pulmonary fibrosis by chest CT|mMRC (Modified Medical Research Council) dyspnea scale|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Duration of hospitalization(days)|Blood oxygen saturation|CD4+ T cell count and cytokine level|Side effects in the MSCs treatment group|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)","SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment","Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .","Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1, IL-6, IL-8,IL-10,TNF-)|Concentration of the myocardial enzymes","Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90","Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event","Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event","Duration of viral shedding in days|Time to clinical recovery (TTCR) in days|Treatment-emergent adverse events (AEs)|Requirement for non-invasive or mechanical ventilation|Length of hospital stay in days|Estimated PaO2/FiO2 ratio on day of discharge|All-cause mortality|Patients reaching undetectable COVID-19 virus levels in respiratory secretions|Duration of symptoms and signs of respiratory infection in days|Need for supportive respiratory management|Viral load|Treatment-emergent serious AEs (SAEs)|AEs leading to withdrawal|Treatment-emergent abnormalities in clinical laboratory parameters","Evolution of consumption|health care access","epidemiology|Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation|methods comparison|correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.|phylogenetic map|interactions between the virus and host cells","Time to normalize the oxygen requirement (oxygeno-dependence)|Days of hospitalization between the HBO group and the control group.|Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.|Days on invasive mechanical ventilation|Mortality","Intraoral viral load|Salivary cytokine profile","Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality","Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9","Percentage of patients with normalization of SpO2 96%|Proportion of patients with temperature &lt; 37,5 C armpit.|Proportion of patients discharged from the emergency department and classified as low risk|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in SARS-CoV-2 RT-PCR test|Change from baseline of ALC (absolute lymphocyte count),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)","the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days","Change in SARS-CoV-2 mucosal immune response in the nasopharynx|Change in microbial load in the nasopharynx|Change in Viral Load in the nasopharynx over the course of COVID-19 infection|Symptom assessment|Temperature assessment",null,"Undetectable COVID PCR at day 7|Undetectable COVID PCR at day 3, 10 and 14|Percentage of subjects on Lambda vs standard of care with symptomatic improvement|Percentage of subjects on Lambda vs standard of care with improved clinical outcomes","Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms","Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity","Time to diagnosis of COVID-19 by RT-PCR in subjects|Compliance to complete the study|Sensitivity and specificity of Biovitals Sentinel|Cross infection rate within the family cluster|Length of hospital stay of positive subjects|Length of ICU stay of positive patients|National Early Warning Score 2 rating of positive patients|Viral load of positive patients|Worsening of comorbidities|Mortality","Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19","28 day all cause mortality|90 day all cause mortality|Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days|duration of mechanical ventilation support|Ventilator Associated Pneumonia|Bleeding complications|Acute Renal Failure|Discharge Location","Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|Number of adverse events|All cause mortality rate|Average duration of hospital stay","Number of participants with symptomatic, lab-confirmed COVID-19.","The time-to-death from all causes|The time to need for mechanical ventilation (MV)|The viral load in the respiratory tract|Number of patient with at least one episode of healthcare-associated infections|Number of days alive without mechanical ventilation|Measure of SOFA score|Number of days alive without renal replacement therapy|Lengths of ICU-stay|Lengths of hospital-stay|Number of patients with severe hypoxemia,|Number of patients with cardiac arrest within 1 hour after intubation","Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel","Time to reach clinical stability|Time to reach an afebrile state for 48 hours.|Time to reach PaO2 / FiO2&gt; 400 and / or SatO2 / FiO2&gt; 300|Time to reach FR  24 rpm for 48 hours|Time to normalization of D-dimer (&lt;250 ug / L)|Time until PCR normalization (&lt;5mg / L).|Time until normalization of ferritin (&lt;400ug / L)|Study the impact of immunosuppressive treatment on viral load using quantitative PCR|Time until hospital discharge|Need for ventilatory support devices|Duration that it is necessary to maintain ventilatory support.|COVID-19 mortality|all-cause mortality|Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission|Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone.","National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers","Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity","Percent of patient echos that are not interpretable|Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)|Time to acquire images as measured by time stamps|Percent of agreement between AI calculate LVEF and LVEF read by physician","Accuracy of the diagnosis of interstitial syndrome by lung ultrasound|Inter-observer variability","Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future","Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results","number of subjects with treatment emergent adverse events and serious adverse events|number of subjects with change in laboratory parameters|exposure of galidesivir as measured by plasma concentrations|yellow fever virus (YFV) titer (Group A)|antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B)|changes in clinical status using 8-point ordinal scale in COVID-19 (Group B)|changes from baseline and time to improvement using NEWS in COVID-19 (Group B)|mortality","Prevalence COVID antibodies in employees of Beaumont Health","viral COVID-19 clearance|Decrease of radiological abnormalities|Clinical improvement","Survival without ventilation (VNI or mechanical ventilation)|ventilator free survival|World Health Organisation(WHO) progression scale 5|World Health Organisation(WHO) progression scale|overall survival|Length of hospital stay|Length of ICU stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to Renal Replacement Therapy (RRT) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|Rate of clinically overt arterial thrombosis|Rate of unscheduled central venous catheter replacement for catheter dysfunction|Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)|Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Incidence of adverse events","Proportion of surviving patients without need for intubation for respiratory support|Saturation of Oxygen in the blood (SaO2)|Arterial oxygen partial pressure (paO2)|Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)|CT-scan score|dyspnea|overall survival|admissionn to the intensive care unit (ICU)|incidence of mechanical ventilation|hospital length of stay|incidence of adverse event|VEGF plasma concentration","Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity|Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.|Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient|Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival","Time to clinical worsening|clinical deterioration on a Likert-type scale (1-6)|clinical deterioration measured by number of days|Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)","Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice|Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.|Information on the patterns of use of these drugs (dose, duration of treatment,|Adverse events|Time of hospital admission and/or stay in ICU and maximum severity reached.|Treatments for SARS-CoV-2 positive patients not described in the protocol|healthy survey for patients after their recovery/discharge from hospital.","Death|Myocardial infarction|Congestive cardiac failure|Severe cardiac arrythmia|Myocarditis|Respiratory failure including ARDS|Viral pneumonitis|Acute renal failure|Sepsis|Stroke|Gastrointestinal bleeding|Receipt of non invasive or mechanical ventilation|Ability to self care at hospital discharge","Evaluate the safety and efficacy of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement|Patient survival at 28 days|Patient survival at 60 days|Number of patients requiring the dose of open-label clazakizumab|Reduced duration of intensive care unit stay|Reduced duration of hospital stay","Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 &lt;90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.|disease severity assessed on a 7-level ordinal scale|number of patients with a supplemental oxygen use|radiological signs on chest imaging|number of patients transferred to intensive care unit|number of patients requiring invasive ventilation|Duration of oxygen therapy|number of adverse events induced by corticosteroid treatment|number of patients with infections other than SARS-CoV-2|number of deaths","1. Mortality rate|Clinical improvement by WHO|Clinical improvement by NEWS2 scales|Biologic response|Radiological response|Collection and storage of biological samples","Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.","28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)","30-day mortality|7-day mortality|30-day reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale &lt;= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines","50% reduction in symptom score for patients with lower respiratory tract infection|Lack of progression for patients with upper respiratory tract infection|Comparison of the primary endpoint with respective patients not receiving the treatment|Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment.|Frequency of AEs and SAEs","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2","Number of participants with improvement from severe type to common type","The rate of COVID-19","Disease-Aggrevation|Complications","ICU length of stay|Safety of convalescent plasma &amp; Serious adverse reactions.|Number of days on mechanical ventilation|30 days of mortality|Days to clinical recovery .","Time to clinical improvement|Overall survival|Cumulative incidence of ICU admission|Length of hospital stay|Positive nasal PCR|Incidence of adverse events|Incidence of grade 3-4 adverse events|World Health Organisation (WHO) progression scale","Assessment of weaning from cardiorespiratory support|Assessment of hemodynamic status|Assessment of pulmonary function|Assessment of hepatic function|Assessment of renal function|Assessment of cardiac function|Assessment of cardiac injury|Assessment of the course of COVID-19 infection|Assessment of clinical outcome and safety","Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable","Prevalence of SARS-CoV-2 antibody titres|Prevalence of SARS-CoV-2 antibody titres after 3 Months","HACOR score efficacy|HACOR score addaptation","overall response rate in reversal of hyperinflammation|efficacy of ruxolitinib + standard-of-care (SoC)","Survival without needs of intubation at day 14|Change in organ failure at day 3|OMS progression scale 5 at day 4|OMS progression scale at days 4, 7 and 14|Survival at 14, 28 and 90 days|Time to discharge|Time to oxygen supply independency|Time to negative viral excretion|Incidence of secondary infections|Vasopressor-free survival|Ventilator-free survival|28-day ventilator-free days|Incidence of dialysis|PaO2/FiO2 ratio|Rate of respiratory acidosis at day 4|Time to ICU discharge","Admission to Intensive Care Unit","intrapulmonary shunt ratio|Evolution of respiratory variables|Evolution of hemodynamic stability variables","Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of  2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events","Number of cured patients|Number of participants with treatment-related adverse events","Success rate of intubation|Infection rate of Anesthesiologist|Extubation time","Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative/peers evaluation of the patient|Serious of symptoms at admittance hospital","Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Chronic stress items (9 items)|Generalized Anxiety Disorder Scale (GAD-7)|Patient Health Questionnaire (PHQ8)|Somatic Symptom Disorder (SSD-12)|Somatic Symptom Scale (SSS-8)|Allgemeine Selbstwirksamkeit Kurzskala (ASKU)|Screening Tool for Psychological Distress (STOP-D) - selected items","Number of antibiotic free days|Mortality rates|Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.|Antibiotics duration at D28|Number of organ-failure free days (based on SOFA)|Incidence rates of bacterial super-infections|Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections|ICU and hospital lengths of stay|Quality of life Quality of life","Days alive without life support at day 28|All-cause mortality at day 28|Days alive without life support at day 90|All-cause mortality at day 90|Number of participants with one or more serious adverse reactions|Days alive and out of hospital at day 90|All-cause mortality at 1 year after randomisation|Health-related quality of life at 1 year","Comparison of inflammatory/immunological biomarkers &lt;72 hours after development of oxygen requirement|Overall survival at 30 and 100 days after development of oxygen requirement|Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression|Proportion of patients requiring mechanical ventilation|Incidence of secondary HLH (as defined by HS score)","Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)","30-days mortality|7-days mortality|30-days reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","Symptomatic COVID(+) infection rate","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine/CTL Events|Frequency of Serious vaccine/CTL Events","Critical condition or death|IL-6","Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status","Comparison of the percentage of clinically improved inpatients between D0 and D14","Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire","Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion","Mortality|Frequency of patients requiring hospital admissions|Frequency of patients requiring ICU admissions|Frequency of respiratory support use|Frequency of kidney injury|Frequency of liver injury","Recruitment Feasibility|Recourse utilization|Safety as reflected on the number and severity of adverse events and serious adverse events|Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.|Effect of basic inflammatory regulation","In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging","Cohort A: reduction of the need of invasive ventilation or 30-day mortality|Cohort B: reduction of mortality|Cohort A Reduction of the need of time of ventilatory support|Cohort B Percentage of patients that undergo to tracheostomy|Cohort B Improvement of the lung function assessed by radiologic findings","Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|\" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome \"","Number of antibodies against coronaviruses isolated and identified from patient samples","Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin","Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay","Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses|Sars-Cov2 IgM|Sars-Cov2 IgG","Hospital mortality|Length of stay in the intensive care unit","Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days|Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis","Clinical data of lung cancer patients with COVID-19 diagnoses|Diagnosis data|Treatments received|Prognostic factors","Antiviral Activity|Improvement of oxygenation|Safety &amp; Tolerability: incidence of TEAEs and serious adverse events (SAEs)","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes","Reduction in the number of COVID-19 infections in healthcare workers.","Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic","Prevalence of Covid-19 infection in the overall CHD population|Prevalence of Covid-19 infection per CHD sub-group|Cardiovascular complications|Other complications|Number of deaths","Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)|Number of Covid-19 positive participants who die|Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)|Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)|Number of SARS-CoV-2 positive participants|Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization|24 hour mean systolic BP (mmHg) on ambulatory BP monitoring|All-cause mortality","Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.|Overall survival of patients on Dexmedetomidine|Daily analgesic effect of Dexmedetomidine|Needs for other sedative pharmacological agents|Average dosage required for Dexmedetomidine to achieve mild to moderate sedation","Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity","Survival|Fragilty","Symptomatic COVID-19|Peak severity of COVID-19 over the study period","COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Febrile respiratory illness|Episodes of febrile respiratory illness|Work absenteeism due to febrile respiratory illness|Bed confinement due to febrile respiratory illness|Symptom duration of febrile respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with febrile respiratory illness|Unplanned work absenteeism|Hospitalisation cost to treat COVID-19|Local and systemic adverse events to BCG vaccination in healthcare workers","CRP increase to 3 x upper limit of normal|Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&amp;D committee|Maximal concentration of cardiac troponin","The positivity (Yes/No) of the serological test.","Incidence of unexpected adverse events|Improved oxygen saturations 93%|Decrease in oxygen supplementation by non-invasive or invasive interventions|Frequency of progression to mechanical ventilation or ECMO|Duration of mechanical ventilation|Duration of ICU stay|Duration of hospital stay|All-cause mortality at day 28","Number of ventilator-free days|All-cause-mortality|Acute-inflammation-free days|Organ-failure-free days","Laboratory Result|Clinical Outcome","Time (in days) to clinical improvement within 30 days after randomization|Mortality rate at D30|Time (in days) from randomization to death|Number of days alive outside ICU within 30 days|Number of days alive free of invasive or non-invasive ventilation within 30 days|Number of days alive with oxygen therapy within 30 days|Maximal oxygen rate within 30 days|Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)|Number of days alive outside hospital within 30 days|Use of antibiotics for respiratory (proved or suspected) infection within 30 days|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.","Change of baseline total sequential organ failure assessment (SOFA) score|Improvement of lung involvement measurements|Increase of pO2/FiO2 ratio|Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators|Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators|Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators|Change of sequential organ failure assessment (SOFA) score|Rate of Mortality|Cytokine stimulation|Gene expression|Serum/plasma proteins|Classification of the immune function","all-cause mortality|Severe state","Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.|Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies","Day-28 mortality|Ventilator-free days|Intensive Care Unit mortality|Day-60 mortality|Nosocomial pneumonia|Bacteremia","Covid 19 Anxiety levels in Endometriosis Patients","Prevalence of oropharyngeal dysphagia|Swallowing screening|Swallowing status.|Nutritonal status of study patient's.|Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).|Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).|Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions).|Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions).|Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department).|Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department).|Clinical complications at 6 months follow up from patient's medical history (respiratory complications).|Clinical complications at 6 months follow up from patient's medical history (mortality).","Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis|Distribution of COVID-19 risk factors by participant characteristics|Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization)|Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study|Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment","first occurrence of intensive care unit admission, mechanical ventilation or death|Death|Mechanical ventilation|Intensive care unit admission|Occurrence of acute kidney injury","Hierarchical composite endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, invasive mechanical ventilation or extracorporeal membrane oxygenation|AUC SOFA","Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung","Number of participants with clinical infection with COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events","Viral nucleic acid test negative conversion rate|Clinical cure rate","Incidence of suspected, probable or confirmed COVID-19|Incidence of confirmed COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of COVID-19 on participants' financial status|Incidence of physical complications of COVID-19|Impact of COVID-19 on participants' mental well-being","All-cause mortality|Composite outcome:composite of intubation for mechanical ventilation or death.","Sensitivity spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform","Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time","Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen","Clinical recovery time","Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality|Arterial thrombosis|Venous thromboembolism|Disseminated intravascular coagulation|All-cause mortality|Sepsis-induced coagulopathy|Acute respiratory distress syndrome|Durations of hospital stay, ICU stay, ventilation|Sequential organ failure assessment score|Clinical deterioration","World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events","Evaluation of apgar status of newborns from covid 19 positive mothers","Rate of secondary aggravation|Change of standart biological parameters|Change of Von willebrand factor (vWF) changes over time|Change of the Factor VIII (FVIII)|Prevalence of positivity of COVID-19 virus measured by PCR or serology","RT-PCR negative status|Progression of symptoms|Development of Symptoms|Adverse events","Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events","Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses","The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.|Length of time tolerating prone positioning|PaO2/FiO2 measured before prone positioning|PaO2/FiO2 ratio after 1 hours of prone positioning|SpO2/FiO2 ratio measured before prone positioning|SpO2/FiO2 ratio after 1 hours of prone positioning|Number requiring increase in ventilatory assistance (CPAP+BIPAP+IMV etc)|Work of breathing assessment (Respiratory distress scale)|Changes in bioimpedance measures of lung edema in patients in PP|Use of awake prone positioning as a rescue intervention in control patients","Time to Improvement in the 7-point ordinal scale|Time to Death|Time to Intubation|Proportion of patients requiring ICU admission|Mortality at 1 month","National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival","prevalence|Favorable outcome","Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery","Evaluation of EPA-FFA efficacy compared to standard of care|Increase in oxygen saturation|PaO2/FiO2 &gt;300mmHg increase|Reduction of IL-6|Mortality rate reduction|Reduction in ICU stays|Reducing hospitalisation days|reduction in need for mechanical ventilation|Fever reduction","Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality","Adverse reaction (AE) and severe adverse reaction (SAE)|Changes of lung imaging examinations|Time to SARS-CoV-2 RT-PCR negative|Duration of fever (Celsius)|Changes of blood oxygen (%)|Rate of all-cause mortality within 28 days|Lymphocyte count (*10^9/L)|Alanine aminotransferase (U/L)|Creatinine (umol/L)|Creatine kinase (U/L)|C-reactive protein (mg/L)|Procalcitonin (ng/L)|Lactate (mmol/L)|IL-1beta (pg/mL)|IL-2 (pg/mL)|IL-6 (pg/mL)|IL-8 (pg/mL)","Stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit","changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events","Treatment success|Time to mechanical ventilation|Change from baseline in Modified Early Warning system score|Change from baseline in resting peripheral capillary oxygen saturation (SpO2)|Change from baseline in partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2)|Change of pH in hemogasanalysis from baseline|Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline|Change of oxygen tension (pO2) in hemogasanalysis from baseline|Change of potassium in hemogasanalysis from baseline|Change of sodium in hemogasanalysis from baseline|Change of chloride in hemogasanalysis from baseline|Change of lactic acid in hemogasanalysis from baseline|Change of hemoglobin in hemogasanalysis from baseline|Change from baseline in oxygen supplementation|Change of findings of high-resolution computed tomography (CT) scan of the chest|Change from baseline in Ferritin|Change from baseline in lactate dehydrogenase (LDH)|Change from baseline in D-dimers|Change from baseline in White Blood Cells with differential counts|Change from baseline in Red Blood Counts|Change from baseline in Hemoglobin|Change from baseline in Platelet count|Change from baseline in Fibrinogen|Change from baseline in Complement factors C3/C4|Change from baseline in Prothrombin time|Change from baseline in Cardiac troponin|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in total bilirubin levels|Change from baseline in C-Reactive Protein|Change from baseline in Creatinine|Overall survival|Time to hospital discharge","Proportion of participants with no evidence of SARS-CoV-2 infection|Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples","Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference","POCUS Score - Lungs|POCUS Score - Heart",null,"Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation","Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality","Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases|The number of general practitioner visits|The number of emergency, hospital admission and intensive care admission|Length of hospitalization and intensive care unit stay|Organ dysfunction|Lifestyle changes|The cost of care","Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina|Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina|Cumulative incidence of SARS-CoV-2 infection|Monthly incidence of SARS-CoV-2 infection|Stratified incidence of SARS-CoV-2 infection by age group|Stratified incidence of SARS-CoV-2 infection by sex|Stratified incidence of SARS-CoV-2 by season|Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)|Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities|Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts|Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers|Relative risk of SARS-CoV-2 infection by age group|Relative risk of SARS-CoV-2 infection by sex|Relative risk of SARS-CoV-2 infection by season|Relative risk of SARS-CoV-2 infection by geographic area (zip code)|Relative risk of SARS-CoV-2 infection by preexisting comorbidities|Relative risk of SARS-CoV-2 infection by COVID-2 contacts|Relative risk of SARS-CoV-2 infection by use of PPE by health workers|Incidence of sequelae","Status of Immunization","Characteristics of pulmonary ultrasound for Covid-19 patients|Charateristics of pulmonary CT-scan for Covid-19 patients","Prevalence|Incidence","ICU CV risk and Biomarker (e.g. Troponin)|CV risk and Outcome during ICU stay","Percent of subjects who have returned to room air|Percent change of subjects return to baseline oxygen requirement","The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial","Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result|Clinical accuracy of the rapid tests based on Clinical diagnosis|Self-test interpretation of result vs expert clinical image interpretation of result|Ease of self-testing procedure","Number of people with detectable antibodies to SARS-COV2","COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28","Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients|Type of respiratory support|Cardiac arrest|Transfer to ICU|ICU mortality|ICU length of stay|Hospital mortality|Hospital length of stay|Ventilator-free days|Overall survival (28-day mortality)","Predictive association between CT-V, PBM score and disease progression","interleukin-6 (IL-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate","International Physical Activity Questionnaire|Pittsburgh Sleep Quality Index|Perceived Stress Scale|Numerical Pain Rating Scale","Death or need of intubation|30-day mortality","Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)|Time to clinical resolution (TTCR)|Change from baseline in National Early Warning Score 2 (NEWS2)|Change from baseline in pulse oxygen saturation (SpO2)|Change from baseline in the patient's health status on a 7-category ordinal scale|Incidence of hospitalization|Duration (days) of hospitalization|Incidence of mechanical ventilation supply|Duration (days) of mechanical ventilation supply|Incidence of oxygen use|Duration (days) of oxygen use|Mortality rate|Time to return to normal activity","The time to oxygen saturation recovery to normal level (97%)|The proportion of patients with normal level of oxygen saturation(97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment","Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19","Voice anaysis","To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events","All-cause mortality at Day 28|All-cause mortality at Day 14|Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)|Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)|Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.","A composite score based on all-cause mortality and the number of ventilator free-days (VFD)|All-cause mortality (intention to treat)|Ventilator-free days (VFD)|All-cause mortality with per protocol analysis|Time to successful extubation|Length of hospital stay|Respiratory parameters assessed daily from inclusion to weaning of deep sedation or 14 days whichever comes first|Daily sedation dose during the first 14 days of the study|Rate of use of rescue therapies|Incidence density rate of severe mixed acidosis|Incidence density rate of ventilator associated pneumonia|Incidence density rate of acute cor pulmonale|Incidence density rate of barotrauma|Incidence density rate of any serious adverse events|Cognitive impairment assessed by phone call using the Telephone Montreal Cognitive Assessment (T-MoCA) test|Quality of life assessed by the RAND 36-Item Health Survey (SF-36) score|Post-traumatic stress disorder assessed by the Impact of Event Scale - revised (IES-R) score by phone call|Cost-efficacy ratio of the innovative strategy compared to the reference strategy","Cumulative incidence of composite outcome of disease severity|Anti-SARS-CoV-2 titers|Rates of SARS-CoV-2 PCR positivity|Duration of SARS-CoV-2 PCR positivity|Peak quantity levels of SARS-CoV-2 RNA|Cumulative incidence of disease severity","Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Day 30 mortality|Change in NEW(2) score from baseline to day 30|Admission to ICU|Use of invasive mechanical ventilation or ECMO|Duration of supplemental oxygen (days)|Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30","Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","The incidence of cardiovascular complications in patients with COVID-19","ventilator free days|ICU free days|Hospital length of stay|Time to wean from mechanical ventilation|PaO2/FiO2 changes during drug administration|Deep vein thrombosis incidence|Changes in inflammatory markers|RAS effectors levels|Radiological findings","lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days","Incidence rate of new COVID-19 cases in both arms|Prevalence of COVID-19 cases in both arms|Mortality rate secondary to COVID-19 cases in both groups|Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups|Adverse events","Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale|Time to Clinical Improvement (TTCI)|Number of Participants with Overall Death Rate|Number of Participants With Rate of Mechanical Ventilation|Time to Mechanical Ventilation|Overall survival|Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale|Time to Intensive Care Unit (ICU) Admission|Rate of Intensive Care Unit (ICU) Admission|Length of Stay in Hospital|Percentage of Participants Discharged from Hospital|Length of Stay in Intensive Care Unit (ICU)|Duration of Oxygen Supplementation|Duration of Mechanical Ventilation|Change in Vienna Vaccine Safety Initiative (ViVI) Disease Severity Score|Time to Clinical Improvement in Participants  70 Years Old|Time to Clinical Improvement in Participants &gt; 70 Years Old|Time to Clinical Improvement in Participants with Pre-existing Diseases|Change in Oxygenation Index|Time to Improvement of One Point Using WHO Ordinal Scale Improvement|Percentage of Participants Experiencing WHO Ordinal Scale Improvement of &gt;1 point|Change from Baseline in C-reactive protein (CRP) Levels|Change from Baseline in Ferritin Levels|Change from Baseline in Lactate Dehydrogenase (LDH) Levels|Changes from Baseline in Blood Plasma Cytokines Levels|Number of Participants with Adverse Events (AE)","Understanding the dissemination of SARS Cov2 in hospital|Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2","Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days",null,"Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire","ICU and hospital mortality of COVID-19 patients|30 days mortality","Change in Viral Load|Change in Immunoglobulin M COVID-19 Titers|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1, IL-10, sIL-2R, IL-6, IL-8 and TNF-|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells","Specific detection of SARS-CoV-2 specific RNA|Analytical sensitivity of the LAMP test.|The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.|Evaluation of the use of saliva samples compared to nasopharyngeal samples","Incidence of respiratory failure|28 day mortality rate","Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days|Daily Hypotensive Episodes|Hypotension Requiring Vasopressors|Acute Kidney Injury|Sequential Organ Failure Assessment (SOFA) Total Score|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)|28-Day Mortality|90-Day Mortality|ICU Admission|Number of Ventilator-Free Days|Number of Therapeutic Oxygen-Free Days|Number of Vasopressor-Free Days|Length of ICU Stay|Length of Hospital Stay|Incidence of Respiratory Failure|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Disease Severity Rating|Viral Load by Nasopharyngeal Swab Day 9|Viral Load by Nasopharyngeal Swab Day 15|Viral Load by Blood Day 9|Viral Load by Blood Day 15","Clinical presentation|Disease prognosis outcomes|Pregnancy outcomes|Obstetric outcomes|Neonatal outcomes|Modes of transmission of COVID-19","COVID-19 positive X-Rays|COVID-19 negative X-Rays","Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of  2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Daily Maximum Temperature|Emergency Department/Clinic Presentations|Disease Severity Rating Day 7|Disease Severity Rating Day 15|Disease Severity Rating Day 28|Viral Load by Oropharyngeal Swab Day 9|Viral Load by Oropharyngeal Swab Day 15|Ventilator-Free Days|Therapeutic Oxygen-Free Days|Need for Hospital Admission at 15 Days|Need for Oxygen Therapy at 15 Days","anxiety","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events","Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).","COVID-19 desease description","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA","Mortality at day 28|severe complications|Imaging|Delay in Microbiological diagnosis|Antiviral therapy|Antibiotic therapy|Covid-19 treatments|Patients receiving renal replacement therapy|Patients receiving mechanical ventilation|Vital status","Adjusted Odds Ratio","Respiratory failure|Occurence of bacterial superinfection","\"Labor Agentry Scale questionnaire\" score in immediate post-partum (duration of hospital stay)|\"Labor Agentry Scale questionnaire\" score at two months after birth|Edinburg Postnatale Depression Scale questionnaire\" score at two months after birth|\"Impact of Event Scale - Revised questionnaire\" score at two months after birth|Breastfeeding statement at two months after birth|\"SF-12 Quality of life questionnaire\" score at two months after birth|\"SF-12 Quality of life questionnaire\" score in immediate post-partum","Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Degree of dyspnea (Liker scale)|Degree of dyspnea (VAS)|The area of lung lesions on Chest CT|The degree of lung exudation on Chest CT|SpO2|PaO2|CRP|hs-CRP|All-cause mortality","Changes in Glucose Llevels|Changes in SpO2 levels|Changes in Interleukin 6 (IL6)|Changes in chest structures","Suitable for discharge","on-treatment platelet reactivity|apoptosis rate in human umbilical vein endothelial cells (HUVEC)|Nitric oxide (NO) intracellular levels|reactive oxygen species (ROS) levels|coagulation factors levels|respiratory function|cardiac function|clinical outcome","Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery","Duration of viral shedding|Duration of COVID-19-attributable symptoms|Hospitalization|Adult household contact viral acquisition","need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events","Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge","Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients","Mortality|PaO2:FiO2 ratio|TNF alpha|Multi-system organ failure free days","In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction","Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization","Evaluation of the extent of the virus transmission within households|Characterization of the secondary cases","Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA","All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome","Mortality|Viral Load|Serum Antibody Titers","SARS-CoV-2 infection|Tumor response|Safety and tolerability|Patient-reported outcomes","Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.|Polymerase chain reaction assay (PCR) negative at day 30.|Polymerase chain reaction assay (PCR) negative at day 60.","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2","PO2/FiO2 (Safety)|PO2/FiO2 (Efficacy)|Early Warning Score (NEWS) (Safety)|Early Warning Score (NEWS) (Efficacy)|Immunological response (Efficacy)|Mechanical ventilation (Efficacy)|SAE|Serious ADR|AE|Oxygen dose|Pulmonary CT (low-dose CT)|Chest X-ray|Chest ultrasound|Secondary infections|Mortality|ICU free days|ICU mortality|Hospital mortality|Micro RNA plasma (Biomarker)|MicroRNA/RNA PBMC (Explanatory)|Immunological response (Explanatory)|Viral load","Oxygenation index (OI)|Incidence of Serious Adverse Events (SAEs)|Oxygenation index|Sequential Organ Failure Assessment (SOFA) score|Respiratory compliance (Crs)|Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)|Driving Pressure|Extubation and reintubation|Ventilation free days at day 28|Length of ICU and hospital stay|28-day and 90-day mortality","positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient","Clinical|Virological|Microbiological","Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery","Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality","Rate of patients reaching a significant hypoxemia, in each arms.","The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNF values at baseline and during the treatment course; the number of AEs.","Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 &gt; 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage","Percentage of patients who develop severe respiratory failure.|Length of ICU stay.|Length of hospital stay|Survival rate at 6 months|Survival rate at 12 months|Survival rate at 28 days|Percentage of patients with each AE by grade|Percentage of patients who discontinued due to AEs","Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome","COVID-19 Seroconversion rate|Admission for Covid-19","Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group|Clinical manifestations of Coronavirus Disease 2019 (COVID-19)|Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort|Radiological features of Coronavirus Disease 2019 (COVID-19) cohort|outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group","Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|Number of patients included in this platform|Number of consultations/sessions given","Days required to get a positive COVID-19 PCR to negative|HRCT/ X-ray findings of disease prgression|Severity of symptoms progression|Duration of Hospital Saty|30 day mortality|Oxygen Saturation at room air|Incidence of viral myocarditis|Incidence of Acute respiratory Distress Syndrome","Risk of unfavourable outcome at D14|Risk of unfavourable outcome over time|Risk-stratification threshold values|Adding value of POCUS score to previous risk-stratification clinical rules|POCUS score and patient clinical status at D14|POCUS and CT scan correlation|POCUS versus CT scan risk-stratification performances|POCUS score evolution performances","Proportion of patients with onset of severe acute respiratory syndrome (SARS)|Mortality rate|Number of participants in need of intensive care support|Viral concentration|Cumulative incidence of serious adverse events|Cumulative incidence of grade 3 and 4 adverse events|Proportion of patients with discontinued treatment|Incidence of cardiac lesions|Incidence of cardiac disfunctions|Change in respiratory capacity","positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.","NIMH COVID Study survey - adult responses|DSM XC and KS survey","Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score","High-resolution computed tomography (HRCT) score|Lung function including FVC, FVC as a percentage of projected value and DLco|Times of acute exacerbation|Six-minute walk distance|Dyspnea Scores|Composite physiological index","Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of infusions|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Number of non-invasive ventilation/high flow oxygen free days|Number of oxygenation free days|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of &lt;/= 2 and maintained for 24 hours, whichever occurs first|Ventilator/extracorporeal membrane oxygenation (ECMO) free days","7-day mortality","Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images","Improvement on a 7-point Ordinal Scale|Incidence of treatment-emergent adverse events (TEAE) (safety and tolerability)|Change in estimated PaO2/FiO2|Number of days alive and free of mechanical ventilation|Time to discharge alive from hospital|Number of patients alive on day 30 and day 60|Change in interleukin (IL)-6 level|Change in IL-17 level|Change in tumor necrosis factor-alpha level|Change in cytokine levels|CM4620-IE serum concentration","Proportion of virologically cured (no virus detected) cases at day 6|The dichotomous virologic shedding endpoint as assessed at two weeks after study entry|Quantitative viral load (assessed with each virology testing set)","Variation in HbA1c levels|COVID-19 infection|Variation in lipid profile|Variation in blood pressure levels|Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups|Comparison of eating disorders between groups|Comparison of adherence to the proposed clinical treatment between groups|Comparison of minor psychiatric disorders between groups|Comparison of sleep pattern changes between groups","Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life","Lung ultrasound grading system for COVID-19 pneumonia","Seroconversion to SARS-CoV-2 positivity","Composite primary end-point|death|Admission to ICU|Endotracheal intubation (invasive mechanical ventilation)|reduction of C-reactive protein or CRP|Reduction of mechanical ventilation","Disease activity|Immune modulating treatments|Biomarkers","Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge","Risk Factors|Immunulogical mechanisms|Long term outcome","Disease progression|Time to mechanical ventilation|Overall survival|Reduction in proportion of patients who require ventilation|Reduction in length of Critical Care stay|Reduction in length of Hospital stay|Modulation of serum pro- and anti-inflammatory cytokines|Reduction in duration of ventilation|Increase in ventilator-free days","Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs  29).|Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21Depression); in terms of proportions (0-4 vs  5).|Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21Anxiety); in terms of proportions (0-3 vs  4).|Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21Stress); in terms of proportions (0-7 vs  8).|Distress measured at baseline by the CPDI; in terms of continuous values.|Depression at baseline measured by the DASS-21Depression; in terms of continuous values.|Anxiety at baseline measured by the DASS-21Anxiety; in terms of continuous values.|Stress at baseline measured by the DASS-21Stress; in terms of continuous values.|Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREFPhysical health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREFPsychological health); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREFSocial relationships); in terms of continuous values.|Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREFEnvironment); in terms of continuous values.|Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnairein terms of continuous values.|Change from baseline in distress measured by CDPI; in terms of continuous values.|Change from baseline in depression measured by the DASS-21Depression; in terms of continuous values.|Change from baseline in anxiety measured by the DASS-21Anxiety; in terms of continues values.|Change from baseline in stress measured by the DASS-21Stress; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREFPhysical health; in terms of continuous values.|Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREFPsychological health; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREFSocial relationship; in terms of continuous values.|Change from baseline in domain-specific quality of life measured by the WHOQOL-BREFEnvironment; in terms of continuous values.|Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.|The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics","Registry Data","Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality","Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery","To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.|To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.|To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.|To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.|To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.|To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.","MDR pathogens in endotracheal aspirates|Microorganisms in endotracheal aspirates","IgG and IgM anti SARS-CoV-2|Clinical factors and severity of COVID-19 infection|demographic factors and severity of COVID-19 infection|pharmacologic factors and severity of COVID-19 infection","Predictive performance","Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide","Determine the incidence of cardiomyopathies and venous thromboembolism|Mortality|Duration of mechanical ventilation|shock at day 28|length of stay in the intensive care unit","COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test","Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical ventilhation|Hospitalization|Time from treatment initiation to death|Time to Negativization COVID 19|Fever","Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0|Depression symptoms: Patient Health Questionnaire (PHQ-8)|Stress: Perceived Stress Scale (PSS)|Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)|Boredom: Multidimensional State Boredom Scale (MSBS-8)|Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)|Frequency of social interactions|Adverse Effects","overview of surgical management on preventive measures of hospital infection spread during covid 19|testing policies and preventive measures for Covid-19, and their association with asymptomatic cases.","quantify and qualify distress over a large population in times of pandemic crisis.|qualify demographic data vs distress over a large population in times of pandemic crisis.","Breath volatile organic compound profiles|Utility of breath profiles for disease diagnosis or prognosis","Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks","PaCO2|Driving Pressure|Tidal volume","overactivity of the renin / aldosterone system","Natural history of COVID-19: Characteristics of COVID-19|Natural history of COVID-19: Participant demographics|Natural history of COVID-19: Treatment use|Time point of clinical response","The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.","Rate of COVID-19 infection","T-cell immunophenotype|Mortality|ITU admission|Myocardial injury","Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events","Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents","Change in O2 output|Comfort with the interfaces|Changes in PaO2|Changes in PaCO2|Changes in pH|Changes in respiratory rate","Deterioration resulting in healthcare review|Hospitalisation|Participant anxiety|Participant depression","RT-PCR confirmed COVID-19 infection|Acute respiratory illness|Absenteeism|Lower respiratory infection|Pneumonia|ICU admission|Mechanical ventilation|Death","new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect","14-Day Mortality|21-Day Mortality|28-Day Mortality|60-Day Mortality|90-Day Mortality|1-Year Mortality","Ventilation Mode|Tidal volume set|Expiratory tidal volume|Positive end-expiratory pressure|Maximum airway pressure or plateau pressure (Pplateau) or peak pressure (Ppeak) (cm H2O);|Level of pressure support above PEEP|Inspired fraction of oxygen|Set and measured respiratory rate|Inspiration to expiration ratio|Number of ventilation-free days and alive at day 28|Duration of ventilation in survivors;|Use of prone positioning|Use of recruitment maneuvers|Incidence of acute kidney injury|Duration of ICU stay|Duration of hospital stay|ICU mortality|Hospital mortality|28-day mortality|90-day mortality","Maternal and perinatal outcomes","Incidence of Mechanical Ventilation|Percentage of time in the assigned position|Number of participants with supplemental oxygen requirements|Change in mean oxyhemoglobin saturation|Change in Nocturnal Oxyhemoglobin saturation|Change in Heart Rate|Change in Respiratory Rate","Positive IgM/IgG tests|Comparison of the point of care test and Elisa|Re-infection rate|IgM/IgG positive participants on follow-up test","survival status","SARS-Cov2 positive molecular testing of throat/nasal swabs|Immunoglobulins (G and M) to SARS-Cov2 in plasma|Blood cytokine levels","Acute Kidney Injury|ARDS|30 day mortality|1 year mortality|Chronic Kidney Disease|SOFA-score","Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication.","Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)|Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate","The death of newborns with COVID-19|The SARS-CoV-2 infection of neonates born to mothers with COVID-19|The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19|The small for gestational age newborns in the neonates born to mothers with COVID-19|The preterm delivery of neonates born to mothers with COVID-19|The disease severity of neonates with COVID-19","SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2/FiO2 ratio in ambient air","Titanium level","Mechanical ventilation requirement","arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death","Correlation of FAST+ pulmonary findings with active COVID infection|Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes)","Proportion of patients remaining free of mechanical ventilation in both groups|Mortality in both groups|Improvement in Pa02/Fi02 ratio in both groups|Improvement in SOFA score in both groups|Duration of hospital Stay in both group.|Duration of Intensive Care Unit stay in both groups.|Requirements of Vasopressor in both groups.|Days free of dialysis in both groups.","Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development","Spontaneous recovery or death in both groups|Severity of prior as well as present decompensation in both groups|Duration of prior as well as present decompensation in both groups|Improvement in severity assessment Indices Model for End Stage Liver Disease (MELD) scores in both groups|Improvement in severity assessment Indices Child-Turcotte-Pugh (CTP) scores in both groups|Improvement in severity assessment Indices Sequential Organ Failure Assessment (SOFA) scores in both groups|Improvement in severity assessment Indices Acute Physiology And Chronic Health Evaluation (APACHE) scores II in both groups|Improvement in severity assessment Indices Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF SOFA) scores in both groups.","Treatment failure|Intubation rate|Efficacy of PP","Failed to attend patients|Patient satisfaction with the phone consult|Consultant satisfaction with the phone consult","Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner|Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale|Phase 2: The time to improvement in oxygenation|Phase 2: Mean change in 7-point ordinal scale from baseline to Day 15|Phase 2: Clinical status using the 7-point ordinal scale at Day 15|Phase 2: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3 : Time to resolution of fever|Phase 2 and 3 : Time to improvement in oxygenation|Phase 2 and 3: Time to resolution of fever and improvement in oxygenation|Phase 2 and 3:Time to change in NEWS2 from baseline|Phase 2 and 3: Time to NEWS2 of &lt;2 and maintained for 24 hours|Phase 2 and 3: Mean change from baseline to days 3, 5, 8, 11, 15, and 29 in NEWS2|Phase 2 and 3:Days with fever|Phase 2 and 3: Alive off supplemental oxygen at day 29|Phase 2 and 3: Days of resting respiratory rate &gt;24 breaths/min|Phase 2 and 3:Days of hypoxemia|Phase 2 and 3: Days of supplemental oxygen use|Phase 2 and 3: Time to saturation 94% on room air|Phase 2 and 3: Ventilator free days in the first 28 days (to day 29)|Phase 2 and 3: The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Phase 2 and 3: Proportion of patients requiring rescue medication during the 28-day period|Phase 2 and 3: The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Phase 2 and 3: Days of hospitalization among survivors|Phase 2 and 3: Incidence of death|Phase 3: Mean change in the 7-point ordinal scale from baseline to days 3, 5, 8, 11, 15, and 29 (or until discharge)|Phase 3: Clinical status using the 7-point ordinal scale at days 3, 5, 8, 11,15, and 29|Phase 3: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3: Incidence of serious adverse events|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|Phase 2 and 3: The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities","Time until cessation of oral shedding of SARS-CoV-2 virus|Count of participants with clinical worsening of COVID-19 disease|Sars-CoV-2 viral load|Count of participants with development of SARS-CoV-2 antibodies|Time until cessation of symptoms|Cmax of favipiravir|Cmin of favipiravir","28 day ventilator free days|90 day all-cause mortality","Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older","Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation &gt; 94% on room air for &gt;24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality","Protection against COVID-19","Efficiency of the telephone consultation|Satisfaction of the telephone consultation","Accuracy of patient administered tests","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0","rate of recruitment|rate of attendence|Depression, Anxiety and Stress Scale (DASS-21)|Sense of Coherence Scale","COVID-19 disease diagnosis|COVID-19 disease symptoms severity|Adverse effects","Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Presence of virus at day 10 in subset of 180 patients","SAMBA COVID-19 POC PCR Test|Patient acceptability|Immune Response Positivity","International Physical Activity Questionnaire - Short Form|Nottingham Health Profile|Beck Depression Inventory|Beck Anxiety Inventory|Pittsburgh Sleep Quality Index|Timed Get Up and Go Test|Flamingo Balance Test","Survival|WHO progression scale COVID 19","Maternal and perinatal outcomes","Number of mechanical ventilation days.|Survival|Shift to Continuous Positive Airway Pressure (CPAP) ventilation|Referral to a sub-intensive care unit or discharge","days to cure|Days of turning negative on RT-PCR test|36-Item Short Form Survey Instrument (SF-36)|C-reactive protein|number of cases returning to positive result in RT-PCR test|Number of positive outcome of IgG for antibody of COVID-19","Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19|Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19|Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19|Prevention Study: Measure the tolerability of NORS treatments|Treatment Sub Study: Measure the virucidal effect of NORS Treatments|Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery|Treatment Sub Study: Determine the reduction in clinical symptoms","Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry","Adverse effects and Safety|NK transfer Immunogenicity","Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement \"LTOT\")","The change of viral load in patients with SARS-COVID-19.|The frequency of development of Acute Respiratory Distress Syndrome (ADRS)|Duration of hospitalization|The frequency of early mortality|The frequency of late mortality|Clinical status at the time of completion of participation in the study","Changes in clinical critical treatment index|Days of respirator treatment|Improvement of clinical symptoms including duration of fever and respiratory need|Mortality|Marker of Immunological function -CD4+ and CD8+ T cell count|C-reactive protein and leucocyte|Cytokine profile|Glomerular Filtration Rate|Duration of hospitalization","PTSD Family members sup 22|PTSD Family members|PTSD Patients|PTSD healthcare providers|HADS Family members|HADS Patients|SF36 Patients|Questionnaire Family members|Questionnaire Patients|Questionnaire healthcare providers|MBI healthcare providers|Karasec instrument healthcare providers","28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation","Survival without needs of ventilator utilization at day 14.|WHO progression scale &lt;=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Number of death of any cause, during the 14 days following the inclusion and intervention.|Number of death of any cause, during the 28 days following the inclusion and intervention.|Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19|Rate of patients with at least one severe adverse event at day 28, according to the regulations|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at baseline|Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD75nmol/L)|Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or 75nmol/L)|Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or 75nmol/L)|Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or 75nmol/L)|Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or 75nmol/L)","Depression|Anxiety symptoms|Stress related problems|Behavior and emotional problem among children and adolescents","All-cause mortality or need of invasive mechanical ventilation|Frequency of adverse events|Frequency of severe adverse events|Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status|Ventilator-free days|Organ failure-free days|Duration of ICU stay|Mortality rate|Length of hospital stay|Duration of supplemental oxygen","Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death","Incidence of recurrent Major Cardiovascular Events (MACE) and urgent rehospitalization","Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count","Change in viral expression in association to organspecific biomarkers","Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR|Viral load during SARS-CoV-2 infection|Seroconversion during the study period|Incidence of any acute respiratory infection|Days of sick leave","Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies","Presence of sHLH as determined by expert chart review by two independent reviewers|Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection|Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin &gt; 10000 g/L) in Covid 19 viral infection|Characterization and incidence of the hyper-inflammatory state in COVID-19|all cause mortality assesed on day 15|all cause mortality assesed on day 29|immunophenotpye","Proportion of participants with normalization of fever and oxygen saturation by day 14|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough","Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU|Coinfections|Respiratory dysfunction requiring mechanical ventilation|Sequential Organ Failure Assessment (SOFA) Score|SAPS II score|Disseminated Intravascular Coagulation (DIC) score|Number of days on vasopressive amines|Occurrence of an event of venous or arterial thromboembolic disease|Number of days with extra renal treatment (ERA)|Number of patients alive after ICU stay less than 28 days will be tracked|Short Form 36|Hospital anxiety and depression scale (HADS)|Impact of Event Scale - revised (IES-R)|Post-traumatic stress disorder Checklist version DSM-5 (PSL-5)|Modified Medical Research Council (MMRC) Dyspnea Scale|Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters|Viral clearance","number of patients with virological cure","The self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)|Montgomery sberg Depression Rating Scale - Self report (MADRS-S)|Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)|Insomnia Severity Index (ISI)|Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)|Intolerance of uncertainty Scale (IUS)|Patient Satisfaction Questionnaire (PSQ)|Adverse events (AE)","Physical Activity Scale for the Elderly|Nottingham Health Profile|Loneliness Scale for the Elderly","Number of participants who experience inpatient admission|Number of participants admitted to the intensive care unit|Number of participants requiring mechanical ventilation|Number of deceased participants","Time to achieve afebrile|Severity of influenza symptom score","Depression|Anxiety|Obsessive compulsive disorder","Assess the prevalence of severe forms among hospitalized patients with diabtes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19","Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery","Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted","Death rate|Transfer to intensive care unit|Ventilation analysis|Construction of a predictive score for COVID-19 severe form","virus RNA and miRNA levels in tears|inflammatory response in tears|Epidemiologic data","Improvement of clinical symptoms including duration of fever|Improvement of clinical symptoms including respiratory frequency|Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0|Time of virus nucleic acid test negative|CD4+ and CD8+ T cell count|Rate of mortality within 28-days|Size of lesion area by thoracic imaging","nosocomial infection",null,"Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them","Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","p/f ratio|SOFA","Technical success|Clinical success|Adverse events","Changes in forced vital capacity (FVC)|Changes in carbon monoxide dispersion (DLco%)|Changes in the six-minute walk test (6MWT)|Changes in High resolution CT score","Determine the number of Covid-19 patients who were unable to complete SCE Therapy|Examine the percentage of activated T cells after SCE therapy by flow cytometry|Assess the percentage of Th17 cells after SCE therapy by flow cytometry|Chest imaging changes by computed tomography (CT) scan of the chest|Quantification of the SARS-CoV-2 viral load by real time RT-PCR","Stress|Perception and knowledge of the epidemic|Feeling of information on the part of companies / establishments / governments|Means of protection|Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|Sociodemographic factors and lifestyle habits","Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function","Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment","Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events","rate of recovery|time to improvement|efficacy of treatments|organ failure","Adverse effects|Immune-score|COVID-19 prevention|Clinical response","Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Administration (Injection) Site Reactions|Percentage of Participants with Adverse Events of Special Interest (AESIs)|Change from Baseline in Antigen-Specific Binding Antibody Titers|Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-) Cellular Immune Response","Body temperature|Blood pressure|Pulse (heart rate)|Respiratory rate|Data provided by transpulmonary thermodilution-CI|Data provided by transpulmonary thermodilution-GEDV|Data provided by transpulmonary thermodilution-EVLW|Data provided by transpulmonary thermodilution-PVPI|Incidence of abnormal laboratory test results|Incidence of new-onset or reversible systolic left ventricular dysfunction|Changes of extravascular lung water measured by transpulmonary thermodilution|Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution|Correlation between the hemodynamic characteristics and 90-day mortality","compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.","Number of patients with decreased viral load","Incidence of influenza","Prevalence of positivity of COVID-19 virus measured by rt-PCR|Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients|Respiratory signs of children tested within 28 day|Percentage of children hospitalized tested within 28 day|Contact frequency|Prevalence of positivity of other respiratory viruses measured by rt-PCR","Clinical skin manifestations|Histology and biological data|Non invasive vascular examination","The Rapid Office Strain Assessment (ROSA)|The Standardised Nordic Questionnaries (NMQ)","Proportion of \"responder\" patients to prone position|proportion of \"persistent responders\" patients after prone position|Evolution of PaO2|Duration of prone positioning and PaO2 evolution|Evolution of Spo2|EVA Dyspnea|Intolerance to prone positioning|Tolerance to prone positioning","Rates of emergency visits needing surgical consult|The ratio of severe presentations to non-severe presentations|The impact of age on ED attendance rates|Differences in ED surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbidity","Number of symptomatic illness in at risk healthcare workers|Number of healthcare workers with symptomatic COVID infections|Number of severe illness in at risk healthcare workers|Number of sero-conversions in at risk healthcare workers|Percentage of patients with adverse events Grade 3 or higher|Percentage of patients with GI intolerance","All-cause mortality|30-day mortality|Major adverse cardiovascular events","Assessment of COVID-19 situation|Depression, Anxiety and Stress Scale|Familiarity and trust in COVID-related rumours|Availability heuristic","1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2","Positive rate of 2019 Novel Coronavirus RNA|Survival rate","Survival rate|Chest computed tomography|Recovery Time|Depression evaluation","Mortality rate at day 28|Proportion of patients with SARS|Mortality rate on days 7, 14 and 28|Incidence of orotracheal intubation|Change in oxygenation index","Survival without needs of ventilator utilization at day 14|WHO progression scale  5|Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) or withdrawal of NIV or high flow (for &gt; 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge","Mortality|The time interval of Nucleic acid detection become negative","Mechanical ventilation|ICU transfer|Oxygen therapy","Oxygenation index|28 day mortality|Hospital stay|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Lymphocyte percentage|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-8|IL-10|tumor necrosis factor(TNF)-|-interferon(IFN)","The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal","RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support","Death or need of intubation|30-day mortality","ACE2 level change over time|ACE2 activity over time|Mortality at day 28|ARDS severity|Duration of mechanical ventilation|Need for prone positionning|Need for extracorporeal membran oxygenation|Use of paralytic agents|Need for renal replacement therapy|Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)|Sequential Organ Failure Assessment (SOFA) score|Number of session(s) of prone positionning|Duration of extracorporeal membran oxygenation treatment|Type of vasoactive drugs|Duration of vasoactive treatment","Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds|Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds|Recruitment rate|Cost|To assess, in relevant age groups, immunity against infections and vaccine preventable diseases|Sera collection","Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores","the composite rate of adverse outcomes|The rate of hospitalization","Mortality rate reduction of 50% by day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable)","Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia",null,"incidence (measured by confirmed positive test) of SARS-CoV2 infection following BCG vaccination compared to placebo|COVID19-related disease severity (measured by ordinal severity scale) following BCG vaccination compared to placebo","Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%","Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects|Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects|Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum|Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score","Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications","Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation","Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety","Screening accuracy|Cost-effectiveness analysis","Prevalence of the microorganisms responsible for VAP among patients infected or not by the SARS-CoV-2|Prevalence of multi-drug resistant bacteria responsible for VAP among patients infected or not by the SARS-CoV-2","Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab|For each participant, time (days) between the last contact with the laboratory-confirmed 2019-nCoV case and the first positive PCR|For each participant, time (days) between the first positive PCR and the first negative PCR|Number of Participants with presence of at least one of the following symptoms: fever &gt; 38C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhe|Number of Participants with positive serology in the 90 days following last contact","Time to complete remission of 2019-nCoV infection-associated symptoms|The incidence of dyspnea with low oxygen saturation level and high respiratory rate|Number of subjects who develop complications of 2019-nCoV infection|Time to virus shedding|Time to improvement of abnormalities in Chest radiology|The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment","GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)","2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status","Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management","Number of Participants with positive serology in the 90 days following last contact|fever &gt; 38C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea","Diagnostic performance of chest CT in screening for pulmonary lesions in clinical suspicions of COVID.|Compare the diagnostic performance of chest CT and RT-PCR in COVID 19 at the initial consultation (screening).","Hours to recovery|Time fever resolution","World Health Organization Quality of Life Questionnaire Bref|Rapid Assessment of Physical Activity|Global Rating of Change Scale","Visual Analogue Scale|Modified Borg Scale|Leicester Cough Questionnaire|Timed Up and Go|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory","International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|Beck Depression Scale","Survival without needs of ventilator utilization at day 14.|WHO progression scale &lt;=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","reduction in oxygen and ventilation support","The number of interventions|Duration of interventions|Mean oxygen flow|Time within theSpO2 target|Time with hypoxemia|Time with hyperoxemia|Rate of ICU admission|Rate of needed non invasive respiratory support|Rate of intubation|NEWS 2 score evolution|EWSO2 score evolution|Cost-effectiveness|length of stay","Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group|Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action","Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure","Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status","Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens","Standardized Mini Mental Test|Mini Nutritional Assesment|Short Physical Performance Test|Single Leg Stance Test|Charlson Comorbidity Index|Clinic Fragility Scale|Pittsburgh Sleep Quality Index|Social Isolation Survey|Quality of life scale in the elderly|The Physical Activity Scale for the Elderly|Timed Up and Go Test|30 Second Chair Stand Test|The Beck Depression Inventory|The Beck Anxiety Inventory","Incidence of coronavirus infection in Solid Organ Transplant Recipients|Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients|Presence of other risk factors|Establish the frequency and type of complications related to the net state of the patient immunosuppression|Frequency of co-infections|Mortality|Laboratory characteristics|Determination of coronavirus viral load|Microbiological testing","Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration","Dataset size|Cough sound identification|Improvement of the existing model|Evaluate the usability of the application","International Physical Activity Questionnaire (Short Form)|Short Form-36 (SF-36)|The Pittsburgh Sleep Quality Index|Distress Tolerance Scale|Beck Anxiety Inventory|Nottingham Health Profile|Sit And Reach Test|Shoulder Flexibility Test|Curl-Up Test|Repetitive Squat Test|Side Plank Test|Timed Up and Go Test|Single Leg Stance Test","Incidence of COVID19 Disease among those who are asymptomatic at trial entry|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 day","Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants","Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.","The Brief Resilience Scale|Nottingham Health Profile|Mindful Attention Awareness Scale|The Body Awareness Questionnaire|Richard-Campbell Sleep Questionnaire|Lateral bridge test|Functional reach test|Beck Depression Scale","Symptom Reduction|Symptom Resolution: Fever|Symptom Resolution: Cough|Symptom Resolution: Shortness of Breath|Symptom Resolution: Fatigue|Day 5 Symptoms|Hospitalizations|Severity of Symptoms|Adjunctive Medications|Supplementation Side Effects","Changes in the Eating Habits of Adults during the Quarantine","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality"],["Kermanshah University of Medical Sciences","Giuliano Rizzardini|ASST Fatebenefratelli Sacco","University of Malaya","King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University","Bukwang Pharmaceutical","Ochsner Health System","Al-Azhar University","Imperial College London","Tongji Hospital","Shanghai Asclepius Meditec Inc.|Shanghai Public Health Clinical Center|Henan Provincial People's Hospital|Shenzhen Third People's Hospital|The First People's Hospital of Yunnan|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine","Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.","Hackensack Meridian Health|Cota Inc.","King Saud University","University of Kansas Medical Center","InflaRx GmbH","Yale University|University of Michigan|University of Minnesota","Hackensack Meridian Health","Dr. Michael Hill|Alberta Health Services|University of Alberta|University of Calgary|Calgary Health Trust|Alberta Innovates Health Solutions|Government of Alberta","Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA|OSPEDALE MAGGIORE LODI|OSPEDALE ASST CREMONA","Thomas Jefferson University","Assistance Publique - Hpitaux de Paris","Xiyuan Hospital of China Academy of Chinese Medical Sciences","Puren Hospital Affiliated to Wuhan University of Science and Technology|Shanghai University|Qingdao Co-orient Watson Biotechnology group co. LTD|Basic Medical Sciences, Chinese Academy of Medical Sciences","Jiangsu Famous Medical Technology Co., Ltd.","The First Affiliated Hospital of Guangzhou Medical University","Universit Libre de Bruxelles","Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd.","University of Colorado, Denver","University of Colorado, Denver","Lisa Barrett|Nova Scotia Health Authority|Dalhousie University","Intermountain Health Care, Inc.|University of Utah","Shahid Beheshti University of Medical Sciences","Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Huoshenshan Hospital|Tianjin Haihe Hospital|VCANBIO CELL &amp; GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University","Istituto Nazionale di Ricovero e Cura per Anziani","National Cancer Institute, Naples","AstraZeneca|Acerta Pharma B.V.","Weprom|Institut Pasteur|Assistance Publique - Hpitaux de Paris|DOCAPOST|Direction Gnrale de l'Offre de Soins","Boston University","Korea University Guro Hospital","Hamilton Health Sciences Corporation|Canadian Blood Services|Hma-Qubec|University of Toronto|Universit de Montral|McMaster University","Duke University","Chinese Alliance Against Lung Cancer|Shanghai Respiratory Research Institution","Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur","Stanford University","Tourcoing Hospital","Regeneron Pharmaceuticals|Sanofi","Beat COVID LLC","University Hospital, Ghent|Belgium Health Care Knowledge Centre","Duke University","United States Department of Defense","NYU Langone Health","Tongji Hospital","University Hospital, Ghent|Flanders Institute of Biotechnology","Rigshospitalet, Denmark|Nordsjaellands Hospital|Hvidovre University Hospital|Herlev Hospital|Technical University of Denmark","Capricor Inc.","Assaf-Harofeh Medical Center","University Hospital Tuebingen|Robert Bosch Medical Center|Universittsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","ProgenaBiome","University of Aarhus","University of Cincinnati","Ravi Amaravadi, MD|University of Pennsylvania","Sunnybrook Health Sciences Centre|AbbVie","Neuromed IRCCS","HaEmek Medical Center, Israel|T MAY BIOPHARMA LTD.","Chinese University of Hong Kong","Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|FUNDACIN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIN DE LA SALUD Y LA CIENCIA|Laboratorios Gebro Pharma SA|Laboratorios Rubi|Institut Catala de Salut","Assiut University","Intermountain Health Care, Inc.|University of Utah|Utah Department of Health","Hospital San Jose Tec de Monterrey|Tecnologico de Monterrey","Apeiron Biologics","Emory University","University of Chicago","Baylor Research Institute","LCMC Health","Universittsklinikum Hamburg-Eppendorf","AUSL Romagna Rimini","ProgenaBiome","NYU Langone Health","Asan Medical Center","Queen's Medical Centre","Rambam Health Care Campus|Rabin Medical Center","Hope Biosciences|Hope Biosciences Stem Cell Research Foundation","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubi","Virginia Commonwealth University","Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)","Pulmotect, Inc.","Fundaci Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III","Gilead Sciences","Pulmotect, Inc.","Symvivo Corporation","Azidus Brasil|Farmoquimica S.A.|Hospital Vera Cruz|Hospital Casa de Sade - Vera Cruz - Campinas - SP - Brazil|Centro de Genomas - UNIFESP|Emilio Ribas Institute of Infectious Diseases","NYU Langone Health","Azidus Brasil|PREVENT SENIOR PRIVATE OPERADORA DE SADE LTDA","Stanford University","Gilead Sciences","Northwestern Medicine","Cristina Avendao Sol|Puerta de Hierro University Hospital","German Cancer Research Center","University Hospital of Cologne|Clinic for Internal Medicine I, University Hospital Cologne, Germany|Institute of Virology, University Hospital Cologne, Germany|Center for Molecular Medicine Cologne (CMMC) Cologne, Germany","University Hospital, Montpellier","ClarData","Biohaven Pharmaceuticals, Inc.","Centre Hospitalier Intercommunal Creteil|ACTIV|GPIP|Socit Franaise de Pdiatrie|GFRUP","Xinqiao Hospital of Chongqing","Stem Cells Arabia","Azienda Unit Sanitaria Locale Reggio Emilia","Judit Pich Martnez|Fundacion Clinic per a la Recerca Biomdica","Fasa University of Medical Sciences","Azidus Brasil|Cellavita Pesquisa Cientfica Ltda|Hospital Vera Cruz","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital","Henan Provincial People's Hospital","Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University","Hoffmann-La Roche","Lawson Health Research Institute","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","Max Healthcare Insititute Limited","Wuhan Union Hospital, China","University Hospital Tuebingen|Robert Bosch Medical Center|Universittsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine","University Hospital, Montpellier|Socit espagnole de pneumologie (SEPAR)|Societe franaise de kinsithrapie en ranimation (SKR)","Orthosera Kft.|Semmelweis University|University of Pcs|Hungarian National Blood Service","University of Alabama at Birmingham","Francis Corazza|Brugmann University Hospital","Perseverance Research Center, LLC|Athena Medical Group","Genesis Foundation","Oslo University Hospital","Erasmus Medical Center|Maasstad Hospital","Cadila Pharnmaceuticals|Council of Scientific and Industrial Research, India","Wroclaw Medical University","Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigacin Biomdica en Red, M.P.","National Institute of Respiratory Diseases, Mexico|Sanofi","First Affiliated Hospital of Fujian Medical University","IRCCS San Raffaele","Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China|CanSino Biologics Inc.|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Zhongnan Hospital","Romark Laboratories L.C.","Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|Sixth Peoples Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth Peoples Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine","Zhenhua Zen|Nanfang Hospital of Southern Medical University","Novartis Pharmaceuticals|Novartis","University of California, San Francisco","Ain Shams University","Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.","Charite University, Berlin, Germany","Assistance Publique - Hpitaux de Paris|Etablissement Franais du Sang","Grupo Cooperativo de Hemopatas Malignas","Hospital Universitario de Fuenlabrada|Centro Nacional de Investigaciones Oncologicas CARLOS III","UMC Utrecht|Radboud University","I-Mab Biopharma Co. Ltd.","Sara Hassan Agwa|Ain Shams University","National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)","Capital Medical University|Chinese Academy of Medical Sciences","University Hospital, Angers","Ain Shams University","Fatma Soliman Elsayed Ebeid|Ain Shams University","Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city","University of L'Aquila","Stanford University","Rutgers, The State University of New Jersey","National Institutes of Health Clinical Center (CC)","OncoImmune, Inc.","Assiut University","Eli Lilly and Company","Jessa Hospital","Guangzhou Institute of Respiratory Disease|Guangzhou Eighth People's Hospital|Tongji Hospital, Huazhong University of Science &amp; Technology|Guangzhou Cellgenes Biotechnology Co.,Ltd","CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital","Universidad de Granada","Assiut University","Beijing 302 Hospital|Huoshenshan Hospital|Maternal and Child Health Hospital of Hubei Province|General Hospital of Central Theater Command, Wuhan, China|VCANBIO CELL &amp; GENE ENGINEERING CORP.,LTD, China","Rajavithi Hospital","Beijing YouAn Hospital|Shenyang Tonglian Group Co., Ltd.|Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences|Huangshi Central Hospital|Shenyang Pharmaceutical University|First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Harbin Medical University|No.2 People's Hospital of Fuyang City|First Affiliated Hospital Bengbu Medical College|Renmin Hospital of Wuhan University|The sixth people's hospital of Shenyang|Nanyang Central Hospital","NHS Lothian","Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd","Frantisek Duska, MD, PhD|Masaryk Hospital Usti nad Labem|University Hospital Pilsen|The Faculty Hospital Na Bulovce|St. Anne's University Hospital Brno, Czech Republic|University Hospital, Motol|General University Hospital, Prague|University Hospital Olomouc|Charles University, Czech Republic","Huoshenshan Hospital|Ascletis Pharmaceuticals Co., Ltd.","The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.","Can-Fite BioPharma|Rabin Medical Center","University Hospital, Montpellier","Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|AUSL Romagna","Direction Centrale du Service de Sant des Armes","Aga Khan University|University of Karachi","Massachusetts General Hospital|Department of Anesthesia, Critical Care and Pain Medicine (DACCPM), Massachusetts General Hospital","Hope Biosciences","MedSIR","Beijing Chao Yang Hospital","Vanderbilt University Medical Center","Mayo Clinic","Raymond Chung|Eiger BioPharmaceuticals|Massachusetts General Hospital","Jessa Hospital","HonorHealth Research Institute","The University of Hong Kong","CareDx","University Hospital Tuebingen|University Hospital Freiburg|RWTH Aachen University|University Hospital Muenster","University Health Network, Toronto","Columbia University","Assistance Publique - Hpitaux de Paris","National Institute of Respiratory Diseases, Mexico|Sanofi","Hospital Universitari de Bellvitge|Institut d'Investigaci Biomdica de Bellvitge","Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad","Azidus Brasil|PREVENT SENIOR PRIVATE OPERADORA DE SADE LTDA","Duke University|Caption Health, Inc.","Hasselt University|Ziekenhuis Oost-Limburg","Kanuni Sultan Suleyman Training and Research Hospital","Misr University for Science and Technology","BioCryst Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID)","William Beaumont Hospitals","Ain Shams University","Assistance Publique - Hpitaux de Paris","Assistance Publique - Hpitaux de Paris","Assistance Publique - Hpitaux de Paris","Washington University School of Medicine","Instituto de Investigacin Marqus de Valdecilla","London School of Hygiene and Tropical Medicine","Cedars-Sinai Medical Center","Hospices Civils de Lyon","Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","IVAN J NUEZ GIL|St Carlos Hospital, Madrid, Spain","Centre Leon Berard","University of Birmingham","Assistance Publique - Hpitaux de Paris","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|Athens General Hospital Hippokrateio|Athens General Hospital of Thoracic Diseases SOTIRIA|General Hospital of Athens Sismanoglio|Divine Providence Hospital Pammakaristos","Shanghai Public Health Clinical Center","The Second Hospital of Nanjing Medical University","Gangnam Severance Hospital","University Hospital Goettingen|Universittsklinikum Hamburg-Eppendorf|University Hospital, Aachen|Transplantationszentrum Kln-Merheim","King Fahad Specialist Hospital Dammam|King Fahad Medical City|King Faisal Specialist Hospital And Research Center|King Abdulaziz Medical City|King Fahad University Hospital|John Hopkins Aramco Healthcare|Taibah University|King Saud University|King Khaled University Hospital|King Fahad Military Medical Complex|Qatif Central Hospital","Assistance Publique - Hpitaux de Paris","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.|ATTIKON University Hospital","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","Ludwig Boltzmann Institute for Lung Health","Hospital General Universitario Morales Meseguer","Prof. Dr. med. Andreas Hochhaus|University of Jena","Assistance Publique - Hpitaux de Paris","University of Alabama at Birmingham","University Hospital, Lille","Capital Medical University","University of Baghdad","Tongji Hospital","Lars Wik|University of Stavanger|Oslo University Hospital|Norwegian Telemedicine|Basque Country University","Gunther Meinlschmidt|Selfapy GmbH|International Psychoanalytic University Berlin","Assistance Publique - Hpitaux de Paris|BioMrieux","Scandinavian Critical Care Trials Group|Rigshospitalet, Denmark|Copenhagen Trial Unit, Center for Clinical Intervention Research|University of Copenhagen|Aarhus University Hospital","Great Ormond Street Hospital for Children NHS Foundation Trust","University Hospital Inselspital, Berne|Roche Pharma AG","Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","Abderrahmane Mami Hospital","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","The Camelot Foundation","Fondation Ophtalmologique Adolphe de Rothschild","University Hospital Inselspital, Berne","University of Washington|New York University|Bill and Melinda Gates Foundation","University of Missouri-Columbia","Hackensack Meridian Health","University of Palermo","A.O. Ospedale Papa Giovanni XXIII","Assistance Publique - Hpitaux de Paris","Columbia University","Gustave Roussy, Cancer Campus, Grand Paris","Zhenhua Zen|Nanfang Hospital of Southern Medical University","Centre Hospitalier Intercommunal Creteil|ACTIV","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","University Hospital, Geneva|University of Geneva, Switzerland","Spanish Lung Cancer Group","Blade Therapeutics","Groupe Hospitalier Pitie-Salpetriere","Henry Ford Health System","Assiut University|Doaa M.EL Shehaby","University Hospital, Montpellier|Pr. Jean-Benot THAMBO, Bordeaux (prsident)|Dr. Cline GRUNENWALD GRONIER, Strasbourg|Dr. Sbastien HASCOET, Le Plessis-Robinson|Dr. Adeline BASQUIN, Rennes|Dr. Nicolas COMBES, Toulouse|Dr. Xavier IRIART, Bordeaux|Dr. Daniela LAUX, Paris|Dr. Magalie LADOUCEUR, Paris|Pr. BERTRAND LEOBON, Toulouse|Pr. Caroline OVAERT, Marseille|Dr. Karine WARIN-FRESSE, Nantes|Alexis BLANC, Montpellier|Pr. Roland HENAINE, Lyon|Hamouda ABASSI, Montpellier","National University of Ireland, Galway, Ireland","University Hospital, Limoges","Societa Italiana dell'Ipertensione Arteriosa","Heinrich-Heine University, Duesseldorf","Washington University School of Medicine|Bill and Melinda Gates Foundation","Murdoch Childrens Research Institute|Royal Children's Hospital","National and Kapodistrian University of Athens","Hospices Civils de Lyon","Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System","Virginia Commonwealth University","Shehnoor Azhar|Federal Task Force on Science &amp; Technology notified by Government of Pakistan|University of Health Sciences Lahore","Assistance Publique - Hpitaux de Paris","Hellenic Institute for the Study of Sepsis","Chongqing Medical University","Institut Pasteur","Centre Chirurgical Marie Lannelongue","Kanuni Sultan Suleyman Training and Research Hospital","Hospital de Matar","Duke University|Patient-Centered Outcomes Research Institute","Radboud University","University of Pennsylvania|Jordana B. Cohen, MD, MSCE|Thomas C. Hanff, MD, MPH|Vicente Corrales-Medina, MD, PhD|James Brian Byrd, MD|Roberto Viau Colindres","Peking University First Hospital","Duke University|Patient-Centered Outcomes Research Institute","Peking University First Hospital","Queen Mary University of London|King's College London|London School of Hygiene and Tropical Medicine","Estudios Clnicos Latino Amrica|Population Health Research Institute","Huashan Hospital","Peking University First Hospital","CAR-T (Shanghai) Biotechnology Co., Ltd.","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","University Hospital, Geneva","Duke University","Kanuni Sultan Suleyman Training and Research Hospital","University Hospital, Lille","Government of Punjab, Specialized Healthcare and Medical Education Department|Mayo Hospital Lahore|Services Institute of Medical Sciences, Pakistan|Pakistan Kidney and Liver Institute|Forman Christian College|Harvard School of Public Health","China Academy of Chinese Medical Sciences","University of Oxford","University College Hospital Galway","Matthew Dallos|Bristol-Myers Squibb|Columbia University","Bassett Healthcare","Ictal Group","Chongqing Medical University","S.L.A. Pharma AG","Second Affiliated Hospital of Wenzhou Medical University|WanBangDe Pharmaceutical Group Co.,Ltd.","Chinese Academy of Sciences|Beijing YouAn Hospital","Hpital Raymond Poincar|Dominique FLETCHER MD-PhD|Guillaume GERI MD-PhD|Clement DURET MD","Zhong Wang|Wuhan Leishenshan Hospital|The First Affiliated Hospital of Dalian Medical University|Tanshan People's Hospital|North China University of Science and Technology Affiliated Hospital|Jizhong Energy Fengfeng Group Hospital|China Academy of Chinese Medical Sciences","Swedish Orphan Biovitrum","Johns Hopkins University|Eiger BioPharmaceuticals","Wake Forest University Health Sciences","University of Minnesota","Gilead Sciences","University of Utah","Providence Health &amp; Services|Center for Outcomes Research and Education|Providence Cancer Center, Earle A. Chiles Research Institute","University of Pecs","Wake Forest University Health Sciences","Medical University of Vienna","Centre Hospitalier Intercommunal Creteil","Rutgers, The State University of New Jersey","Medical University of Graz","Ansun Biopharma, Inc.","Beijing Children's Hospital|Capital Institute of Pediatrics, China|The First Affiliated Hospital of Anhui Medical University|China-Japan Friendship Hospital|The First Affiliated Hospital of Xiamen University|Guangzhou Women and Children's Medical Center|Shenzhen Children's Hospital|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan People's Hospital|Children's Hospital of Hebei Province|Wuhan Women and Children's Medical Center|Changchun Children's Hospital|Childrens Hospital of Nanjing Medical University|Jiangxi Province Children's Hospital|Shengjing Hospital|Shanxi Provincial Maternity and Children's Hospital|Xian Children's Hospital|Children's Hospital of Chongqing Medical University|Tianjin Children's Hospital|Tianjin Medical University Second Hospital|Kunming Children's Hospital|Second Affiliated Hospital of Wenzhou Medical University","Neuroganics LLC","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","University of Chicago","William Beaumont Hospitals","Dr. Alexander Supady|University Hospital Freiburg","Istanbul Kltr University|Istanbul University-Cerrahpasa","Mario Negri Institute for Pharmacological Research","CytoDyn, Inc.","Tasly Pharmaceuticals, Inc.","University of Oxford","Cordio Medical","Assistance Publique - Hpitaux de Paris","CytoDyn, Inc.","Hospices Civils de Lyon","Johns Hopkins University","University of Aarhus","Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundacin Universitaria de Ciencias de la Salud","UMC Utrecht","Erasme University Hospital|Fonds Erasme pour la Recherche Mdicale","Southeast University, China","Instituto de Investigacin Marqus de Valdecilla","Karyopharm Therapeutics Inc","Assistance Publique - Hpitaux de Paris","Plan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.","Implicit Bioscience","University of Arizona","Mayo Clinic","Universidad del Rosario|Fundacin Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnologa e Innovacion en Salud","Indiana University","Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital","University Hospital, Montpellier|SkillCell|Sys2Diag (CNRS-Alcediag UMR9005)","Henan Provincial People's Hospital","University of Minnesota","University of California, San Francisco|University of California, Los Angeles","Professor Adrian Covic|Falcon Trading Iasi|Grigore T. Popa University of Medicine and Pharmacy","Institut National de la Sant Et de la Recherche Mdicale, France","University of Minnesota","University Hospital, Limoges","Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","University Hospital, Limoges","University Hospital, Bordeaux","Tongji Hospital","Tongji Hospital","Centre Hospitalier Universitaire de Nmes","Fondation Ophtalmologique Adolphe de Rothschild","University of Bologna","Central Hospital, Nancy, France","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital","University of Miami","Brigham and Women's Hospital","University Hospital of Ferrara","Tongji Hospital","University of Utah","Universit Politecnica delle Marche","Assistance Publique - Hpitaux de Paris|Groupe Hospitalier Piti-Salptrire","Centro Studi Internazionali, Italy|VivaChek Laboratories, Inc.","NeuroRx, Inc.|Relief Therapeutics Holding SA|Target Health Inc.|Lavin Consulting, LLC","Oslo University Hospital","Mazandaran University of Medical Sciences","Institut Pasteur|Institut Pasteur de la Guyane|Centre Hospitalier Andre Rosemon de Cayenne","Tongji Hospital","MJM Bonten|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|Berry Consultants|Global Coalition for Adaptive Research|University of Pittsburgh Medical Center|UMC Utrecht","Saint Francis Care","Tongji Hospital","Instituto Nacional de Rehabilitacion","Shanghai Public Health Clinical Center","Karolinska University Hospital|Karolinska Institutet|University of California, San Diego|Blekinge County Council Hospital","Belfast Health and Social Care Trust|Queen's University, Belfast|Northern Ireland Clinical Trials Unit|NHS Blood and Transplant","Beijing Tsinghua Chang Gung Hospital|Institute for precision medicine of Tsinghua University|Institute for artificial intelligent of Tsinghua University|Chinese Medical Doctor Association|Institute for network behavior of Tsinghua University|school of clinical medicine of Tsinghua University","Chinese University of Hong Kong","Universita di Verona|Azienda Ospedaliera Universitaria Integrata Verona","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Population Health Research Institute","University Hospital, Strasbourg, France","Hospital of Prato","Assistance Publique - Hpitaux de Paris","Fundacin de investigacin HM|Apices Soluciones S.L.","Universitaire Ziekenhuizen Leuven","Stony Brook University","Assiut University","Professor Adrian Covic|Medical Sciences Academy - Romania|Victor Babes Clinical Hospital of Infectious Diseases - Bucharest|Grigore T. Popa University of Medicine and Pharmacy","Sheikh Zayed Federal Postgraduate Medical Institute|Mayo Hospital Lahore","University Hospital, Angers","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado","Tan Tock Seng Hospital|National Center for Infectious Diseases|Singapore Clinical Research Institute|Singapore Eye Research Institute|Saw Swee Hock School of Public Health|Duke-NUS Graduate Medical School|Netherlands: Ministry of Health, Welfare and Sports","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","Luiz F. L. Reis, Ph.D.|Hospital Israelita Albert Einstein|Hospital do Coracao|Brazilian Research In Intensive Care Network|Ache Laboratorios Farmaceuticos S.A.|Hospital Sirio-Libanes","ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 Peoples Hospital|Tongji Hospital","National Institute of Allergy and Infectious Diseases (NIAID)","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","University Hospital, Montpellier","CalciMedica, Inc.","Hamad Medical Corporation","Federal University of Rio Grande do Sul","Darrell Tan|St. Michael's Hospital, Toronto","Catholic University of the Sacred Heart|Valle del Serchio General Hospital, Lucca, Italy|University of Trento, Trento, Italy|Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy|Bresciamed, Brescia, Italy|118 USL Nordovest Toscana, Lucca, Italy|General Hospital, Voghera, Italy|Lodi General Hospital, Lodi, Italy","University College, London|St. Bartholomew's Hospital|Royal Free Hospital NHS Foundation Trust|UCLH","University of Trieste","Salome Kristensen|Aalborg University Hospital","IHF GmbH - Institut fr Herzinfarktforschung|Ministerium fr Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz","University Hospital, Akershus|St. Olavs Hospital|Helse Stavanger HF|Haukeland University Hospital|University Hospital of North Norway|Alesund Hospital|Norwegian Institute of Public Health|The University of New South Wales|University of Bristol|Sykehuset Ostfold|Nordlandssykehuset HF|Vestre Viken Hospital Trust|Helse Fonna|Levanger Hospital|Oslo University Hospital|Sykehuset Innlandet HF","King's College London|Guy's &amp; St Thomas NHS Foundation Trust","University Hospital, Ghent","ObvioHealth","Wuhan Union Hospital, China","xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud","Tabula Rasa HealthCare","Hpital Universitaire Fattouma Bourguiba","Nantes University Hospital","Maastricht University|The Central Hospital of Wuhan","TMC HealthCare|PEEP Medical, LLC","Centre Hospitalier Universitaire de Nice","Massachusetts General Hospital","Azienda Ospedaliero-Universitaria di Parma","Lady Davis Institute","University of Rome Tor Vergata","Wefight","Mayo Clinic","Guangzhou Blood Center","Peking Union Medical College Hospital","Assistance Publique Hopitaux De Marseille","Target PharmaSolutions, Inc.","Tongji Hospital","Oslo University Hospital|Age Labs AS","Barts &amp; The London NHS Trust|Queen Mary University of London","Sanofi","Ospedale Policlinico San Martino","Cliniques universitaires Saint-Luc- Universit Catholique de Louvain","Imperial College London|CW+ Charity","McMaster University|Vancouver Coastal Health|University of Alberta|Dalhousie University","Shanghai Jiao Tong University School of Medicine","Brigham and Women's Hospital","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","Federico II University","Johns Hopkins University","Herlev Hospital|Nordsjaellands Hospital|Hvidovre University Hospital|Rigshospitalet, Denmark|Mental Health Services in the Capital Region, Denmark|University Hospital Bispebjerg and Frederiksberg","Renmin Hospital of Wuhan University","Queen's University, Belfast|Belfast Health and Social Care Trust","Uppsala University","University Hospital, Angers","Instituto de Investigacin Sanitaria de la Fundacin Jimnez Daz|Instituto de Investigacin Sanitaria y Biomdica de Alicante|Hospital General Universitario Gregorio Maraon|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Universitario de Salamanca|Hospital General Universitario de Alicante|Hospital Clnico Universitario Virgen de la Arrixaca","Children's Hospital of Fudan University","Xijing Hospital|Massachusetts General Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","Royal National Orthopaedic Hospital NHS Trust","Hugo Mendieta Zeron|Materno-Perinatal Hospital of the State of Mexico","Universit Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord","University of Colorado, Denver","Shanghai 10th People's Hospital|Chibi People's Hospital, Hubei Province","Ansun Biopharma, Inc.","Institute of Liver and Biliary Sciences, India","Dr. Deneen Vojta|PATH|Mayo Clinic|Bill and Melinda Gates Foundation|UnitedHealth Group","Institute of Liver and Biliary Sciences, India","Rush University Medical Center|Medical College of Wisconsin","Austin Health","Sanofi|Regeneron Pharmaceuticals","Stanford University","Stony Brook University|Chembio Diagnostic Systems, Inc.","University Hospital, Angers","Heinrich-Heine University, Duesseldorf|Universittsklinikum Hamburg-Eppendorf|University Hospital, Frankfurt|St. Georg Hospital Leipzig, Germany|Hospital Schwabing Munich, Germany|Missioklinik, Wuerzburg, Germany","Istinye University","Pierre and Marie Curie University","Dr. Deneen Vojta|Quest Diagnostics|Bill and Melinda Gates Foundation|UnitedHealth Group","Shanghai Public Health Clinical Center","Chinese University of Hong Kong","Universidad Complutense de Madrid","Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS","CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust","Istinye University","Assistance Publique - Hpitaux de Paris","Federico II University","A.O. Ospedale Papa Giovanni XXIII|Aferetica - Italy (BO)","Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Medical University|First Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital And Sixth People's Hospital of Wenzhou Medical University|Yueqing Hospital of Wenzhou Medical University|Ruian Hospital of Wenzhou Medical University|Cangnan Hospital of Wenzhou Medical University|Pingyang Hospital of Wenzhou Medical University|Yongjia People's Hospital","Sanotize Research and Development corp.|The Emmes Company, LLC","Healeon Medical Inc|Robert W. Alexander, MD","Universidad Nacional de Colombia|Fundacin Salud de los Andes","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","Burnasyan Federal Medical Biophysical Center","Rigshospitalet, Denmark","Assistance Publique - Hpitaux de Paris","Peking University Third Hospital|School of Pharmaceutical Sciences, Peking University, Beijing, China|Department of Medicine, Queen's University, Kingston, Ontario, Canada","Assistance Publique - Hpitaux de Paris","University Hospital, Angers|Mylan Laboratories","Tjhin Wiguna|Fakultas Kedokteran Universitas Indonesia|Dr Cipto Mangunkusumo General Hospital","Thomas Benfield|Hvidovre University Hospital","Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|Cristlia Produtos Qumicos Farmacuticos Ltda.","Assistance Publique - Hpitaux de Paris|Action, France","Jieming QU|Ruijin Hospital","University Hospital, Akershus","Medical University of Vienna","University of Calgary","Technische Universitt Mnchen","Vanda Pharmaceuticals","University Hospital, Lille","Tanta University","Karolinska Institutet","Kubra Koce, MSc PT|Istanbul University-Cerrahpasa","Duke University","Aarogyam UK","Assiut University","Nantes University Hospital","Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","National Institute of Allergy and Infectious Diseases (NIAID)","French Cardiology Society|Institut National de la Sant Et de la Recherche Mdicale, France","G. d'Annunzio University","Xinxiang medical university|First Affiliated Hospital of Xinjiang Medical University","Hospices Civils de Lyon","Hudson Medical","University Hospital, Strasbourg, France","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico \"Mater Domini\"","Universit Vita-Salute San Raffaele","Istanbul University-Cerrahpasa","Changhai Hospital","Huilan Zhang|Tongji Hospital","Tianhe Stem Cell Biotechnologies Inc.","University Hospital, Clermont-Ferrand|Faculty of Medicine, Clermont-Ferrand, France|UMR CNRS 6024 LaPSCo, Clermont-Ferrand, France|Wittyfit, Paris, France","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico \"Mater Domini\"","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital","Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital","Catholic University of the Sacred Heart","Universidad Nacional de Colombia|Fundacin Salud de los Andes","Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations (CEPI)","Bicetre Hospital","University Hospital, Angers","Tanta University","University College, London","University Hospital, Lille","Centre Hospitalier Universitaire de Nice","Istanbul University-Cerrahpasa","ELHARRAR Xavier|Centre Hospitalier Intercommunal Aix-Pertuis","Sheba Medical Center","Columbia University","University Hospital, Essen","Jean Liu|Yale-NUS College","Burnasyan Federal Medical Biophysical Center","Third Affiliated Hospital, Sun Yat-Sen University","Third Affiliated Hospital, Sun Yat-Sen University","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado","Assistance Publique - Hpitaux de Paris","Fujian Provincial Hospital","Sharp HealthCare","ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital","First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.","Mayo Clinic","Mario Negri Institute for Pharmacological Research","University Hospital, Angers","University of Oxford","ZhiYong Peng|Zhongnan Hospital","University Hospital, Angers","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus Vincius Guimares de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes Mouro|Ludmila Abraho Hajjar|Jorge Souza Mendona","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","U.S. Army Medical Research and Development Command","Andrew Dinardo|Radbound University Medical Center|M.D. Anderson Cancer Center|Harvard University|Baylor College of Medicine","Beijing Ditan Hospital","University of British Columbia|Mallinckrodt","Memorial Hermann Health System","Montreal Heart Institute|DACIMA Software","Qilu Hospital of Shandong University","Affiliated Hospital to Academy of Military Medical Sciences|The Fifth Medical Center of Chinese PLA General Hospital","Poitiers University Hospital","Institut National de la Sant Et de la Recherche Mdicale, France","Beijing 302 Hospital","Huazhong University of Science and Technology","Tang-Du Hospital","University of Milan","Institut National de la Sant Et de la Recherche Mdicale, France","Poitiers University Hospital","Washington University School of Medicine","Biruni University|Istanbul University-Cerrahpasa","Yasemin rak|Istinye University","Istanbul University-Cerrahpasa","Assistance Publique - Hpitaux de Paris","University of Minnesota","Guangzhou Institute of Respiratory Disease|Huizhou Municipal Central Hospital","Baylor Research Institute","Laval University","University of Alberta","University Hospital Inselspital, Berne","University Hospital, Akershus","The University of Hong Kong|Hospital Authority, Hong Kong","Istinye University","Fundacin Pblica Andaluza para la gestin de la Investigacin en Sevilla|Spanish Network for Research in Infectious Diseases|GESITRA-IC","Universit de Sherbrooke|Lotte &amp; John Hecht Memorial Foundation","HealthMode Inc.","Istinye University","University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta","Institut National de la Sant Et de la Recherche Mdicale, France","University of Iowa","Istinye University","The Cleveland Clinic","Eliz Arter|Cyprus Science University|Eastern Mediterranean University","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd."],["All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All"],["3 Years to 99 Years  (Child, Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","19 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","30 Years to 70 Years  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","up to 85 Years  (Child, Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 89 Years  (Adult, Older Adult)","18 Years to 89 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","65 Years and older  (Older Adult)","Child, Adult, Older Adult","18 Years to 130 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 64 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 110 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","6 Months and older  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","25 Years to 65 Years  (Adult, Older Adult)","45 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","35 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 79 Years  (Adult, Older Adult)","16 Years to 99 Years  (Child, Adult, Older Adult)","18 Years to 95 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","19 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","15 Years to 100 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","19 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","65 Years to 120 Years  (Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","6 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","1 Year to 80 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","70 Years and older  (Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years to 80 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","40 Years to 70 Years  (Adult, Older Adult)","8 Years to 80 Years  (Child, Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","16 Years to 100 Years  (Child, Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 95 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 50 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","25 Years to 55 Years  (Adult)","5 Years to 75 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","1 Year to 100 Years  (Child, Adult, Older Adult)","50 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","14 Years to 70 Years  (Child, Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 85 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","6 Months to 80 Years  (Child, Adult, Older Adult)","6 Years to 85 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 69 Years  (Adult, Older Adult)","19 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","3 Months and older  (Child, Adult, Older Adult)","30 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","6 Months to 80 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 99 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","6 Months to 15 Years  (Child)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","Child, Adult, Older Adult","60 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 120 Years  (Adult, Older Adult)","70 Years and older  (Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","5 Years and older  (Child, Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 45 Years  (Adult)","Child, Adult, Older Adult","18 Years to 89 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","16 Years to 100 Years  (Child, Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","up to 15 Minutes  (Child)","18 Years and older  (Adult, Older Adult)","20 Years to 50 Years  (Adult)","18 Years and older  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","30 Years to 79 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","12 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","45 Years and older  (Adult, Older Adult)","60 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 100 Years  (Adult, Older Adult)","18 Years to 105 Years  (Adult, Older Adult)","20 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years to 45 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 110 Years  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 60 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","75 Years and older  (Older Adult)","up to 100 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","30 Years to 70 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 90 Years  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 85 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","5 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Months and older  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","up to 18 Years  (Child, Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","55 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 100 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","14 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 95 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","up to 15 Years  (Child)","18 Years and older  (Adult, Older Adult)","70 Years and older  (Older Adult)","18 Years and older  (Adult, Older Adult)","up to 28 Days  (Child)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","5 Years and older  (Child, Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 65 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 70 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","20 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","40 Years to 60 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 50 Years  (Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","19 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","70 Years and older  (Older Adult)","4 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 90 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","16 Years and older  (Child, Adult, Older Adult)","65 Years and older  (Older Adult)","Child, Adult, Older Adult","18 Years to 60 Years  (Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","14 Years to 75 Years  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","Child, Adult, Older Adult","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 99 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 50 Years  (Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","up to 18 Years  (Child, Adult)","up to 90 Years  (Child, Adult, Older Adult)","18 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","21 Years and older  (Adult, Older Adult)","18 Years to 60 Years  (Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","up to 24 Years  (Child, Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 70 Years  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 74 Years  (Adult, Older Adult)","1 Year to 90 Years  (Child, Adult, Older Adult)","14 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","40 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","Child, Adult, Older Adult","18 Years to 100 Years  (Adult, Older Adult)","Child, Adult, Older Adult","14 Years to 80 Years  (Child, Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 75 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years to 100 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 35 Years  (Adult)","18 Years to 70 Years  (Adult, Older Adult)","18 Years to 55 Years  (Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","60 Years and older  (Adult, Older Adult)","16 Years and older  (Child, Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 40 Years  (Adult)","18 Years and older  (Adult, Older Adult)","Child, Adult, Older Adult","18 Years and older  (Adult, Older Adult)","45 Years to 65 Years  (Adult, Older Adult)","18 Years and older  (Adult, Older Adult)","18 Years to 80 Years  (Adult, Older Adult)","18 Years to 75 Years  (Adult, Older Adult)"],["Phase 1|Phase 2","Phase 3","Phase 3",null,"Phase 2","Not Applicable",null,"Not Applicable","Phase 2|Phase 3","Not Applicable","Not Applicable",null,"Phase 4","Phase 1","Phase 2|Phase 3","Not Applicable","Phase 2","Phase 3","Not Applicable","Not Applicable","Phase 3","Phase 3","Phase 1|Phase 2",null,"Not Applicable",null,"Phase 1|Phase 2","Phase 2|Phase 3","Phase 2|Phase 3","Phase 2","Phase 2","Phase 4","Phase 1",null,"Phase 2","Phase 2",null,"Not Applicable","Phase 2","Phase 3","Not Applicable",null,"Phase 3","Phase 2","Not Applicable","Phase 2|Phase 3",null,"Phase 3","Not Applicable","Phase 2","Not Applicable","Phase 3","Phase 4","Not Applicable",null,null,"Phase 3","Phase 2",null,"Phase 2","Phase 2","Phase 2",null,"Phase 2|Phase 3",null,"Phase 3",null,"Phase 3","Phase 1","Phase 2","Not Applicable","Phase 2","Phase 2","Phase 3","Not Applicable",null,"Phase 2","Phase 2","Phase 2","Phase 3","Early Phase 1","Phase 2","Phase 3","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 3","Phase 2","Phase 1","Not Applicable","Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 3",null,"Phase 2",null,null,null,null,"Phase 2|Phase 3",null,null,"Phase 1","Phase 2","Phase 2","Phase 2|Phase 3","Phase 1","Not Applicable","Phase 4","Phase 2|Phase 3","Phase 3",null,"Phase 2","Phase 2",null,null,"Phase 3",null,"Early Phase 1","Phase 2","Not Applicable","Phase 1|Phase 2",null,null,"Phase 2|Phase 3","Not Applicable","Phase 4","Phase 4","Phase 3","Phase 2","Phase 2","Phase 2","Phase 3",null,null,null,"Phase 3","Phase 3","Not Applicable",null,"Phase 2","Phase 1|Phase 2","Phase 2","Phase 3","Phase 1|Phase 2",null,null,"Phase 3",null,null,null,"Phase 2",null,null,"Phase 2",null,"Phase 3",null,"Phase 2",null,"Phase 1|Phase 2","Phase 1","Not Applicable",null,"Phase 2","Phase 3","Phase 4",null,"Not Applicable","Phase 3","Phase 4","Phase 4","Phase 2",null,null,"Phase 2|Phase 3","Not Applicable","Phase 2","Phase 2","Phase 2","Not Applicable","Not Applicable",null,"Phase 2",null,"Not Applicable","Not Applicable",null,"Not Applicable","Not Applicable","Phase 2|Phase 3","Not Applicable","Phase 3","Phase 3","Phase 3","Early Phase 1","Not Applicable","Not Applicable",null,"Phase 3","Phase 1",null,"Not Applicable","Phase 2","Phase 2",null,"Phase 2",null,"Phase 3","Phase 2","Phase 2","Phase 2",null,"Phase 2",null,"Phase 2|Phase 3","Phase 2","Phase 3","Not Applicable","Phase 3",null,"Phase 2","Phase 2","Phase 2","Phase 1",null,null,"Phase 2","Phase 2","Phase 2",null,"Phase 3","Phase 1",null,"Not Applicable","Not Applicable","Not Applicable","Phase 3",null,"Phase 2",null,"Phase 3","Phase 1|Phase 2","Phase 2|Phase 3","Phase 2|Phase 3","Not Applicable",null,"Phase 1",null,"Phase 2","Not Applicable",null,"Not Applicable",null,"Phase 2",null,"Not Applicable",null,null,null,"Phase 2",null,"Phase 3",null,null,"Phase 4","Phase 4",null,null,"Phase 3","Phase 3","Phase 2","Not Applicable","Early Phase 1","Phase 2","Phase 3","Phase 3","Phase 2",null,null,"Phase 3",null,null,null,"Phase 4","Not Applicable","Not Applicable","Phase 3","Not Applicable",null,"Phase 3",null,"Not Applicable","Early Phase 1","Not Applicable","Phase 3","Phase 2",null,null,"Phase 4","Phase 2|Phase 3","Not Applicable","Not Applicable","Phase 2","Phase 2|Phase 3",null,null,"Phase 3","Not Applicable","Phase 1|Phase 2",null,"Phase 2|Phase 3","Phase 2|Phase 3","Phase 2","Not Applicable",null,null,"Early Phase 1","Phase 4","Not Applicable",null,null,null,null,null,"Phase 2",null,"Not Applicable",null,"Phase 3","Early Phase 1",null,"Not Applicable",null,null,"Phase 2","Not Applicable","Phase 1|Phase 2",null,"Phase 3","Phase 2","Not Applicable","Phase 2","Phase 1|Phase 2","Phase 2",null,"Phase 2|Phase 3","Phase 2","Phase 4","Phase 2",null,"Phase 3",null,"Not Applicable",null,"Phase 2|Phase 3",null,null,null,null,"Phase 2",null,null,"Phase 3","Phase 2",null,"Phase 2|Phase 3","Not Applicable",null,"Phase 4","Phase 4",null,null,null,"Not Applicable","Phase 2|Phase 3","Phase 4",null,"Not Applicable","Phase 3","Phase 2","Phase 2","Phase 3","Not Applicable","Phase 2","Phase 2|Phase 3","Not Applicable","Not Applicable","Phase 4","Phase 4","Phase 2",null,"Early Phase 1","Phase 3","Phase 2|Phase 3","Phase 1|Phase 2",null,null,null,"Phase 2","Phase 3","Phase 3","Phase 3","Phase 1|Phase 2","Phase 2",null,"Phase 2",null,"Not Applicable","Phase 3",null,"Phase 2","Phase 3",null,"Phase 3","Phase 2","Phase 3",null,"Phase 2|Phase 3","Phase 2","Not Applicable","Not Applicable","Phase 3",null,null,"Phase 2|Phase 3",null,null,null,"Phase 4",null,null,"Not Applicable",null,null,null,null,null,"Not Applicable",null,"Phase 2","Phase 2","Not Applicable",null,null,null,"Not Applicable","Not Applicable","Not Applicable",null,"Early Phase 1",null,null,"Phase 1",null,"Not Applicable",null,"Not Applicable","Phase 3",null,null,null,"Not Applicable",null,null,null,null,null,"Phase 2",null,"Phase 2",null,"Phase 4","Phase 2",null,null,"Phase 3","Phase 2",null,null,"Not Applicable",null,"Phase 2|Phase 3","Phase 2","Phase 1|Phase 2","Phase 3","Phase 4",null,null,null,null,"Not Applicable","Not Applicable","Phase 3",null,"Not Applicable",null,null,"Not Applicable",null,"Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 2","Phase 3","Phase 1|Phase 2",null,null,"Phase 2|Phase 3","Phase 3",null,"Phase 3","Phase 3",null,"Phase 4",null,"Phase 3",null,null,"Phase 3",null,"Phase 3","Not Applicable","Not Applicable",null,"Not Applicable",null,null,"Phase 2","Phase 1",null,null,"Phase 1",null,null,null,null,null,"Phase 4","Not Applicable","Phase 2","Phase 2",null,"Phase 2|Phase 3","Phase 2","Phase 2",null,"Phase 3","Phase 1",null,null,"Phase 2|Phase 3",null,null,null,null,"Not Applicable",null,"Phase 2",null,null,"Phase 2",null,null,"Phase 2","Phase 2",null,"Phase 4","Phase 2","Not Applicable","Phase 2","Not Applicable",null,null,"Phase 2","Not Applicable","Phase 2","Not Applicable",null,"Phase 4",null,"Phase 2",null,"Phase 3",null,"Not Applicable",null,null,"Not Applicable",null,"Phase 1|Phase 2",null,null,null,"Phase 3","Not Applicable","Not Applicable",null,"Phase 2","Phase 3",null,"Phase 1","Not Applicable",null,null,"Phase 4","Phase 2","Not Applicable",null,"Phase 3",null,"Not Applicable","Phase 3",null,"Not Applicable","Not Applicable","Not Applicable",null,"Phase 1"],[50,100,310,10000000,60,48,40,3170,550,100,4,5000,30,50,130,1300,55,1660,49,2000,584,50,30,340,0,200,90,80,80,1000,300,60,20,300,400,428,3000000,380,141,1200,120,450,1200,120,176,400,100000,342,100,1450,40,10,80,6000,null,1000,2700,600,375,30,400,440,5000,210,8,3040,400,1550,20,200,5,50,360,600,24,100,600,48,150,350,1116,100,440,10,20,200,276,2400,100,84,50,30,400,45,1600,100,278,500,160,500,5000,120,250,1000,5,398,100,30,66,140,60,80,330,50,100,40,10000,500,220,150,20,100,200,80,20,400,426,40,400,200,500,30,50,500,600,50,275,null,2271,100,48,6000,120,20,165,1500,144,500,30,308,353,100,3000,250,30,50,160,2800,230,100,200,12,20,108,200,100,90,320,520,200,0,240,40,11,40,100,500,100,40,260,56,24,400,90,null,40,5000,25,200,500,200,64,1600,550,400,84,75,200,500,50,200,1000,66,50000,20,808,130,300,152,100,10000,60,304,120,2500,273,1000,60,60,30,0,2486,100,40,92,60,100,5500,100,200,120,60,15,237,50,120,214,600,194,1000,40,100,50,530,100,436,500,60,500,2000,500,45,500,50,1000,12,1000,287,600,150,250,200,120,500,3000,874,5000,2414,10,2000,4000,55000,4170,180,400,30,200,500,436,20,201,1000,122,80,100,100000,651,152,750,15000,210,12000,2500,100,150,24,80,200,500,70,1000,400,300,40000,200,138,4000,250,0,240,60,9,100,116,54,164,200,500,null,10,1250,7576,150000,400,200,750,50,280,500,100,1000,510,10,25,30,100,3000,75,120,510,5000,900,390,200,150,180,10,1000,60,120,800,230,100,4000,null,150,50000,80,340,120,180,30,200,1000,200,3100,580,200,80,200,2000,400,100,220,1500,350,600,20,20,1500,60,60,400,50,554,200,120,700,30,450,100,7100,15,207,100,30,200,75,300000,170,300,240,1500,405,60,60,94,100,1212,200,200,30,300,210,3000,5000,290,136,440,39,150,60,456,149,1220,100,400,104,333,4000,350,230,180,10000,10,100000,12123,120,850,300,15,100,470,310,162,1200,2000,120,19491,10,50,5000,328,50000,140,210,1200,15,200,576,2944,2000,1000,20,70,30000,669,150,100,100,100,100,0,100,86,38,20,120,250,20,120,100,346,150,300,120,500,1300,334,80,400,533,15,30,240,630,200,128,1000,20,10,504,200,10,10,226,320,40,1464,117,239,260,10000,1500,440,500,380,200,440,12500,20,300,500,60,670,30,200000,18,300,1000,0,45,500,25,30,300,null,100,110,1000,60,1,96,20,50000,120,200,200,198,86,40,200,280,100,1302508,914,30,500,25,1000000,350,630,5000,320,20,100,420,240,400,200,10,160,0,900,100,2300,140,4000,440,348,null,700,50,20,500,6000,12000,230,10000,300,150,30000,20,50,300,56000,500,30,30,200,240,3500,0,115,216,500,100,202,127,30,50,800,1000,128,3000,500,82,50,520,400,30],["Other","Other","Other","Other","Industry","Other","Other","Other","Other","Industry|Other","Other|Industry","Other|Industry","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other|Industry","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Industry","Industry","Other","Other","U.S. Fed","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Industry","Other","Industry","Industry","Industry","Industry|Other","Other","Industry|Other","Other","Industry","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other|Industry","Other","Other","Other|Industry","Industry","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","NIH","Other","Other","Other","Other","Other","Other","Other","Other","NIH","Industry","Other","Industry","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other|Industry","Industry|Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Industry","Other","Other","Other","Other","Other|Industry","Other","Other","Industry|Other","Other|Industry","Other","Other","Other","Industry|NIH","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Industry","Other","Other","Other","Other","Industry","Other|Industry","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Industry","NIH","Other|NIH","Other","Other","Other","Other","Other","Industry","Industry","Other","Industry","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other|Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","NIH","Other|Industry","Other","NIH","Other","Other","Industry","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Industry|Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Industry","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Industry|Other","Other","Other","Other","Industry","Other","Other|Industry","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Industry","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","NIH","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Industry|Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Industry","U.S. Fed","Other","Other","Other|Industry","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Other","Industry","Other","Other","Other","Other","Other","Other","Other","Other|Industry"],["Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Observational","Observational","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Expanded Access:Intermediate-size Population","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Expanded Access:Intermediate-size Population","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Observational","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Expanded Access:Treatment IND/Protocol","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Expanded Access:Intermediate-size Population","Interventional","Observational","Interventional","Observational","Observational","Observational","Observational","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Observational","Interventional","Observational","Observational","Interventional","Observational","Observational","Observational","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Observational","Observational","Interventional","Observational","Observational","Observational","Observational","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Expanded Access:Individual Patients|Treatment IND/Protocol","Observational","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Observational","Observational","Interventional","Observational","Interventional","Observational","Observational","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Expanded Access:Intermediate-size Population|Treatment IND/Protocol","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional"],["Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention",null,"Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Observational Model: Case-Only|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Control|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Cross-Sectional","Observational Model: Case-Control|Time Perspective: Retrospective",null,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Cross-Sectional","Observational Model: Case-Only|Time Perspective: Other","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment",null,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Ecologic or Community|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Other","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Case-Only|Time Perspective: Retrospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Observational Model: Case-Only|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Cohort|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Observational Model: Cohort|Time Perspective: Prospective",null,"Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",null,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Ecologic or Community|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Prospective","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Other|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Other","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Retrospective","Observational Model: Case-Only|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Other","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","Observational Model: Cohort|Time Perspective: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Retrospective","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective",null,"Observational Model: Case-Only|Time Perspective: Retrospective","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Cross-Sectional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Prospective","Observational Model: Case-Only|Time Perspective: Other","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment",null,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Observational Model: Cohort|Time Perspective: Prospective","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Control|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","Observational Model: Case-Control|Time Perspective: Retrospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Prospective","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Retrospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Observational Model: Case-Control|Time Perspective: Prospective","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Cohort|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Observational Model: Other|Time Perspective: Prospective","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Observational Model: Case-Only|Time Perspective: Cross-Sectional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment"],["1398.1224","HS216C17-PHASE III","TVCS-COVID19","COVID-19 Symptom tracker","BK-CLV-201","STUDY00001051","WES-2","20HH5868","TJ-IRB20200205","JT202002LZ","DAS181-SARS-CoV-2","Pro2020-0342","ONS_COVID-19","STUDY00145514","IFX-1-P2.9","2000027887","Pro2020-0375","ABCOV-01 version 1.1","IRCCSSanMatteoH","20D.346","APHP200387","2020XLA015-1","Pr20200402","JSZYJ202001","GIRH-APN01","PSY-ENCOVID19","ChongqingPublicHMC","20-0869","20-0738","SAIL-004","1051355","Different Interferons in COVID","2020003D","INRCA_01_2020","TOCIVID-19|2020-001110-38","D822FC00001","WP-2020-02","H-40070","KUMC-COVID-19","CONCOR-1","Pro00105221","CAALC-008-CMHS","20PH061|2020-001188-96","55619","RIPH_2020_6","6R88-COV-2040","20200835","COV-AID","Pro00105319","Pentagon 20-1","s20-00399","GST-G1","SARPAC","2020-04-02","CAP-1002-COVID-19","105-20-ASF","COMIHY","PRG-044","COVID-FLUS","2020-0337","842838","2114","DEP_012020","EMC 0045-20","2020.059","HCQ4COV19|2020-001031-27","AssiutU-3-2020","1051360","PC-TecSalud Fase I","APN01-01-COVID19","STUDY00000381","IRB20-0515","020-132","COVID 2020-001","CYTOCOV-19|U1111-1250-2078|DRKS00021199","CANASCOV","PRG-042","s20-00444","S2020-0472-0001","RA-2020-018","0154-20-RMB","Allogeneic COVID-19 Protection","PrEP_COVID","HM20019145","2020K-G005|hDPSC-CoVID-2019-02-2020","PUL-042-501","IIBSP-COV-2020-23","GS-US-540-5773|2020-000841-15","PUL-042-502","bacTRL-Spike-1","NITFQM0320OR","s20-00392","HIAPRE0320OR","IRB-56134","GS-US-540-5774|2020-000842-32","20-0407","ConPlas-19","COVID-19-1.0-DKFZ","KICC19","RECHMPL20_0185","CovidDB","BHV3500-203","PANDOR","XQonc-015","COVID-19","RCT-TCZ-COVID-19|2020-001386-37","SILCOR-COVID-19","97548","HOPE","QLEmer","TT-NPC","Glucocorticoid COVID-19","WA42380|2020-001154-22","137654","20200214-COVID-19-M-T","20200214-COVID-19-S-T","Covid-19/MHC/2020","MD-COVID-19","COV-HCQ|2020-001224-33","RECHMPL20_0175","AntiCOVID19ORT","TXACOVID1","CHUB-IL6-COVID-19","HIZ-PRC-COVID-19","Genesis AKCOVID- FG-1","CovidRegOUH","NL73489.078.20","CRSC20004","QUARANTINE2020","2020-001278-31","HidroxycloroquinaCOVID19","MRCTA, ECFAH of FMU [2020]027","DEFI-VID19","JSVCT089","RM08-3006","CHESS2002","HT-COVID19","CINC424A2001M","20-30504","FMASU P14 / 2020","202001","EA1/071/20","APHP200375-10|2020-001246-18","HAL 345/2020","24032020","NL73249.041.20","TJ003234COV201","FMASU P17a/ 2020","200094|20-D-0094","CAP-China remdesivir 1","ar20-0031v1","FMASU P16a/ 2020","FMASU P18a/ 2020","COVID","0064468/20","55596","002011|Pro2020000712","200081","CD24Fc-007|20200674","AssiutU12","17824|I7W-MC-UDAA","JessaH_COVID19_DVT","SC-2020-01","JSVCT088","COVITD-19","AssiutU11","2020-013-D","TH-DMS-COVID19 study","BeijingYouan Hospital","282014","Pr20200225","AZIQUINE-ICU-25032020|2020-001456-18","ASC-CTP-HS-01","ASC-CTP-NC-01","CAN-COR-1","RECHMPL20_0195","IRSTB113","2020PPRC03","2020-Sur-ERC-20","2019P00XXXX","Protection Against COVID-19","MedOPP376","Methylprednisolone in COVID-19","pending IRB","20-003312","2020p00xxxx","JessaH_COVID19_prescreening","HRI-COVID-19-Anti-Malarial-001","COVID19_Biovitals_Protocol_1","Al-COVE","ECMO-VID","U-DEPLOY: RUX-COVID|20-5315","AAAS9676","APHP200388|2020-001457-43","ProfilaxisCOVID","TACRO-BELL-COVID|2020-001445-39","Ath/ct101/22/3","HIAPRE0420OR","pro00105212","CTU2020032","turkishcovid19","MUST23032020","BCX4430-108|272201300017C-18-0-1|DMID18-0022","2020-134","FMASU P15/ 2020","APHP200389-6","APHP200389-7","APHP200390|2020-A00768-31","202004023","IDI-REM-2020-1","2020-KEP-420","00000644","69HCL20_0321|2020-001553-48","IMIB-DFC-2020-02","20/241-E|EUPAS34399","ET20-076 - IMMUNONCOVID-20|2020-001373-70","CS-20200324","APHP200375-3","UNIKINON-01/HOPE","HC-COVID-19","WMT-YJ-202001","3-2020-0036","UMG_Co19-Nephritis","HAEM0321","APHP200389-5","T3inj-02/ThySupport","GIMI-IRB-20002","LEAD CoVid-19","08-04-2020","RuxCoFlam","APHP200375-4","TXACOVID2","2020_32|2020-A00957-32","CAP-China remdesivir 2","PRO20040001","COVEI","127157","IPUB_2020_01","APHP200392|2020-001324-33","RH-ITA-008|2020-001395-15","20BO08","2020-00691|2020DR2044","RIV-2020-1","AbderrahmaneMH","GIMI-IRB-20001","Inf-3323","FMTVDM2020","CRN_2020_8","2020-00563","STUDY00009750","262095","Pro2020-0356","3143","v 0.9 16th March 2020","APHP200310","AAAS9517","2020-001250-21|2020/3078","hkyy2020-005 AKI","COVILLE|2020-A00724-35","TEI-3336-20-20-1","2020-00516","GECP 20/02_GRAVID","B-2660-204","CIC1421-20-05","1410401","2020A10","RECHMPL20_0155","C.A. 2348","87RI20_0011 (PRODEX)","SARS-RAS","20-004","202004099","62586","906295542","69HCL20_0329","H-47561 MSC for COVID-19","HM20018977","12(06)/2016-Coord","P 200394|2020-001306-35","ESCAPE|2020-001039-29","2020-02-2","2020-007","2037815010","endocovid19","COVID_OD","Pro00105284","NL73547.091.20|2020-001320-34","842810","2020 research 110","Pro00105274","2020 research 112","COVIDENCE","COLCOVID version1.2","KY2020-COVID-19","2020YFC0844100","KT005HB001","QF-XYP1990-1","2020-00794","PRO00105339","covid19pregnancynewborn","2020_33|2020-A00906-33","NBC-COVID19-02","YHQW-V3.0","VIR20001","APPROVE-CARE-2020","AAAS9881","1581969","Neuro-COVID-19","2020-02","EPA-COV-001","2019NCP1.0","ChineseASZQ-006","CSC19APR","YHQW-Severe-V2.0","Sobi.IMMUNO-101|2020-001167-93","IRB00248163","IRB00064587","STUDY00009429","GS-US-540-5821|2020-001453-49","131618","2020000186","IV/2428- 2 /2020/EKU","IRB00064912","1375/2020","COVID-ECHO","2020000679","250320","DAS181-2-07","BCH Lung 012","2020/03/18","200083|20-I-0083","PETAL 05 Orchid","IRB20-0523","2020-087","CYCOV","FADP-2","EC-COVID-PCS-Fenice","CD10_COVID-19","T89-NCP-01","COV001","COV001","APHP200386|2020-001273-73","CD12_COVID-19","69HCL20_0322","IRB00245634","2020-001200-42","ABN011-1","20-161/C","P2020/201","2020YFC0841300-03","EnCOVID-HidroxiCLOROQUINA","XPORT-CoV-1001|2020-001411-25","APHP200417","PrEP COVID-19","COV02","Pending UA IRB Approval","20-002610","ABN011-2","2003973826","WHTJCOVID-19","RECHMPL20_0170","SOT-C","SURG-2020-28675","20-30410","0110","C20-15","SURG-2020-28683","87RI20_0015/Emocovid","IVIG-001","87RI20_0013","CHUBX 2020/11","TJ20200128","TJ20200131","2020-A00797-32","GDE_2020_11","PREDI-CO","2020-A00881-38","QLEmer20200214","20200384","2020P000944","250320","ASC09F-CTP-TJ-01","IRB_00131893","TOFACoV","APHP200409","VivaDiag-2020","COVID-AIV","118684","IR.MAZUMS.REC.1399.7330|IRCT20181104041551N1","2020-009","TJ20200201","U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584","SFH-20-23","2020-TJ-COVID-19","20/20","DC-COVID-19","K-2020-2611|2020-001349-37|4-1199/2020","16154DMcA-AS","RWS-BTCH-002","COVID-19 study 2020.076","Gisondi 4","NOgas mildCOVID-19","PHRI.ACT.COVID19","7783","HPrato-3","APHP200395|2020-001287-28","Ruxo-Sim-20|2020-001405-23","COntAGIouS","IRB2020-00222","COVID-19 in Egypt","GTP0032","1.6/M.Edu/141/2020","2020-A00782-37","CAAE: 30504220.5.0000.0005","2020/00402","999920085|20-M-N085","CAAE: 30227020.5.1001.0008","Fzhy-ncp-2","20-0006","CT2019-nCoV","RECHMPL20_168","CM4620-204","MRC-05-001","2020241093","CORIPREV-1","0013226/20","130852","MP-19 023_2020","20200401","COVID-19 Registry","20/03794","282009","BC-07505-LGE","OBVIO-OBV-001","WuhanUH-2019 nCoV-Ig","XC-PCOR-COVID19","COVID-PACE-2020-001","Malek Khemili","RC20_0150","UM_2020_GY_COVID-19","COVID19PEEP2020|GO2 PEEP Study","20reamedcovid19","NOpreCOVID-19","ColCOVID-19","SPIN-CHAT-001","s-covid survey","WefightDistress20","19-001971","Blood donor recruitment","Low flow-ECMO by CVVH in NCP","2020-16|2020-A00795-34","TARGET-COVID-19","Zhaojp","REK-124170","282289","EFC16855|2020-001269-35|U1111-1249-6168","COVID-ItaliansurgRES-SPIGC","DTM-001","REMOTE-COVID","20006014","Interferon_prophylaxis","2007P000003","PRoVENT-COVID","145/20","IRB00246834","RegHCOVIDScreening","COVID-19 WU1","282617","EPN 2017/043 Covid19","2020/29","BALMYS-19","CHFudanU_NNICU14","NO-SARS-COVID-19","RNOH MAGEC","2020-03-681","TOCICOV-1","20-0751","HBCBH-IEC-2020-101","DAS181-3-01|2018-004318-16","ILBS-COVID-02","20-002","ILBS-COVID-01","COVID-19-HFNC+PP","38839","EFC16844|U1111-1249-6021","56032","SBU-COVID19-ConvalescentPlasma","49RC20_0071","CLOCC-2020","2020-2/1","GREEN GRC01","20-001","Anti-SARS-CoV-2","online-mind","Covid_ISCIII 20/265-E_BS","Brazil COVID Coalition I Trial","COVIDx","002","APHP200375|2020-001246-18","5/20","DFPP COVID 19","SAHoWMU-CR2020-NCP-202","COVID-CTP-01","GARM COVID19","UNAL FSA COVID","KronLungesyg_COVID_19_protokol","DAL-05-04-2020","EudraCT number: 2020-001330-36","APHP200389","COV_NUTRIC","APHP200375-2","2020-001602-34","MH-Covid19","25032020|2020-001367-88","30155020.5.1001.0071","INDS 0522070420","Abdrcspc202001","117589","HCQ prophylaxis for COVID19","REB18-0107_MOD9","161/20 S","VLY-686-3501","2020_20|2020-A00763-36","ACEIS COVID 19","Put in EPN","002","Pro00105189","AU08","Covid-19 mental health","RC20_0148","COVID19 NOgas mild","20-0003|1UM1AI148373-01","2020-02","UChieti03","xinxiangM","69HCL20_0214","COVID19","7772","covid-19 biomarkers","COVID-BioB/OSR","10042020","ncMCE1","huilanz Zhang","2020-TH-001","2020 COVISTRESS","covid-19 add-on therapy","NO-SARS-COVID-19","APPI2-CV-2020-01","20202503","UNAL-COVID-CP","COVID19-001","2020-A00793-36","2020-A00831-39","COVID 19 treatment","ISAC17_205R","2020_21|2020-A00811-38","20dermatocovid.02","GPA1347","20202703-2","SMC-20-7078-YZ-CTIL","AAAS9992","20-9213-BO","2020-CERC-001","FL-01/20","PL11","XWX3","CAEE: 30615920.2.0000.0005","APHP200375-5","KY-2020-24.01","COVID-ARB|2003902","2020002","ASC09F-CTP-ZY-01","20-002864","EC-COVID-RCT-Fenice","COVID-ARA2","ID 263097","2020001","2020-A00831-38","CAAE: 30152620.1.0000.0005","QF-XYP2001-1","S-20-01","H-47454","DTXY022","NTM-CTP-01: H17-02107","HSC-MS-20-0286","MHIPS-2020-001","2019nCoV-CVD","307-nCoV","PAVM COVID","C20-06|2020-A00280-39","2020001D","IRBID:TJ-C 20200107","20200101","02-PNSNP-2020","C20-16|2020-A00609-30","POWER-COVID_CT","202003188","Physical Activity Project","009","EAvcil|pek Yeldan","APHP200375-1","STUDY00009414","GZHZ-COVID19","020-123","21909","Pro00100000","2020-00672","REC 121446","UW-20-074","007","COVIDSOT","MP-31-2019-2945","HM070102","001","STUDY00009267","C20-05|2020-A00256-33","201412701-1","0001","IRB 20-361","Nutr2020","MEXCOVID"],["April 2020","March 25, 2020","April 15, 2020","March 23, 2020","April 24, 2020","April 2020","April 10, 2020","April 3, 2020","April 1, 2020","February 15, 2020","March 6, 2020","March 27, 2020","May 1, 2020","March 25, 2020","March 31, 2020","May 1, 2020","April 2020","April 13, 2020","March 17, 2020","April 13, 2020","April 13, 2020","March 2020","February 1, 2020","March 2, 2020","February 2020","April 15, 2020","March 21, 2020","April 2020","April 2020","April 2020","March 30, 2020","April 10, 2020","January 27, 2020","April 2020","March 19, 2020","December 18, 2020","March 17, 2020","April 2020","April 1, 2020","April 27, 2020","April 17, 2020","February 14, 2020","April 14, 2020","April 15, 2020","April 2020","March 18, 2020","April 6, 2020","April 2020","April 13, 2020","April 2020","April 6, 2020","February 9, 2020","March 24, 2020","April 2, 2020",null,"April 20, 2020","April 10, 2020","April 2020","March 14, 2020","April 2020","April 9, 2020","March 18, 2020","March 23, 2020","April 2020","February 14, 2020","March 18, 2020","March 11, 2020","April 2, 2020","April 15, 2020","April 2020","April 8, 2020","April 4, 2020","April 3, 2020","April 10, 2020","April 1, 2020","April 2020","April 2020","April 9, 2020","March 11, 2020","March 26, 2020","March 2020","April 23, 2020","April 3, 2020","April 2020","April 6, 2020","April 2020","April 2, 2020","March 6, 2020","April 2020","April 30, 2020","April 12, 2020","March 31, 2020","April 23, 2020","May 2020","March 15, 2020","April 15, 2020","April 3, 2020","April 20, 2020","April 2020","February 1, 2020","March 30, 2020","April 2020","April 7, 2020","January 17, 2020","March 16, 2020","March 31, 2020","April 1, 2020","April 4, 2020","April 2020","March 17, 2020","March 5, 2020","January 26, 2020","April 3, 2020","April 2020","February 20, 2020","February 18, 2020","April 2, 2020","January 1, 2020","March 29, 2020","April 1, 2017","April 14, 2020","April 15, 2020","March 20, 2020","April 16, 2020","April 1, 2020","March 15, 2020","April 1, 2020","April 20, 2020","April 6, 2020","April 3, 2020","March 23, 2020","February 22, 2020","April 6, 2020","April 12, 2020","April 30, 2020","March 30, 2020","March 21, 2020",null,"April 1, 2020","April 20, 2020","April 20, 2020","March 27, 2020","April 14, 2020","April 1, 2020","April 13, 2020","March 25, 2020","April 11, 2020","April 20, 2020","April 21, 2020","February 12, 2020","March 22, 2020","April 20, 2020","April 20, 2020","April 1, 2020","April 1, 2020","April 2020","April 1, 2020","April 15, 2020","April 8, 2020","April 11, 2020","April 18, 2020","April 17, 2020","April 2020","March 16, 2020","April 10, 2020","April 2020","March 5, 2020","April 15, 2020","February 23, 2020","March 25, 2020","February 24, 2020","April 20, 2020","March 18, 2020","February 17, 2020","April 6, 2020","April 8, 2020","March 27, 2020","April 2020","July 1, 2020","April 2020","April 16, 2020","April 14, 2020","February 14, 2020","May 2020",null,"May 1, 2020","April 17, 2020","April 2020","April 1, 2020","April 1, 2020","June 1, 2020","April 20, 2020","March 2020","April 10, 2020","April 1, 2020","April 1, 2020","March 28, 2020","April 20, 2020","April 2020","April 13, 2020","March 26, 2020","March 25, 2020","April 9, 2020","April 2020","April 20, 2020","April 20, 2020","April 15, 2020","April 2020","April 10, 2020","April 15, 2020","April 2020","April 21, 2020","April 2020","April 8, 2020","March 23, 2020","April 2020","March 31, 2020","April 11, 2020","April 6, 2020","February 6, 2020","February 5, 2020","April 1, 2020","April 13, 2020","April 12, 2020","April 15, 2020","May 2, 2020","February 15, 2020","April 27, 2020","April 1, 2020","May 1, 2020","April 2020","April 15, 2020","April 2020","February 6, 2020","April 8, 2020","March 7, 2020","April 7, 2020","April 8, 2020","April 2020","April 15, 2020","April 15, 2020","April 2020","April 1, 2020","April 15, 2020","March 24, 2020","April 4, 2020","April 11, 2020","April 2020","March 19, 2020","March 2020","April 1, 2020","April 14, 2020","March 13, 2020","March 19, 2020","March 16, 2020","March 25, 2020","April 3, 2020","February 26, 2020","April 14, 2020","April 1, 2020","March 27, 2020","May 15, 2020","May 2020","March 20, 2020","April 7, 2020","April 2020","March 1, 2020","March 30, 2020","April 20, 2020","March 10, 2020","March 19, 2020","April 2020","March 30, 2020","April 6, 2020","April 9, 2020","May 2020","April 22, 2020","April 7, 2020","April 2020","April 2, 2020","March 1, 2020","March 13, 2020","April 2020","April 5, 2020","April 2020","April 10, 2020","April 2020","March 31, 2020","April 1, 2020","April 2020","April 1, 2020","April 2, 2020","March 2020","March 14, 2020","March 8, 2020","March 5, 2020","March 14, 2020","April 14, 2020","April 2020","April 1, 2020","April 2020","April 14, 2020","February 27, 2020","April 2020","April 11, 2020","April 2020","April 6, 2020","March 23, 2020","January 25, 2020","April 13, 2020","February 16, 2020","January 27, 2020","April 15, 2020","March 20, 2020","April 2, 2020","April 2020","March 22, 2020","April 15, 2020",null,"March 20, 2020","March 30, 2020","April 1, 2020","April 2020","April 11, 2020","March 31, 2020","April 7, 2020","April 8, 2020","April 2020","February 15, 2020","April 2020","April 21, 2020","April 2, 2020","April 10, 2020","April 2020","March 27, 2020","April 12, 2020","April 6, 2020","April 1, 2020","February 26, 2020","April 2020","April 2020","April 14, 2020","April 15, 2020","April 14, 2020","May 1, 2020","March 31, 2020","April 1, 2020","March 23, 2020","March 31, 2020","February 10, 2020","April 6, 2020","April 30, 2020","April 13, 2020","April 1, 2020",null,"April 1, 2020","March 30, 2020","April 1, 2020","April 1, 2020","February 20, 2020","April 7, 2020","February 1, 2020","April 13, 2020","March 20, 2020","March 18, 2020","March 22, 2020","April 9, 2020","April 15, 2020","February 10, 2020","April 2020","April 2, 2020","February 1, 2020","February 1, 2020","April 3, 2020","April 2020","March 20, 2020","April 16, 2020","February 15, 2020","April 30, 2020","March 1, 2020","April 8, 2020","February 1, 2020","April 14, 2020","April 10, 2020","April 9, 2020","March 2020","April 2020","March 28, 2020","March 28, 2020","March 23, 2020","February 1, 2020","April 11, 2016","April 10, 2020","April 10, 2020","April 10, 2020","January 30, 2020","April 25, 2020","January 7, 2019","February 1, 2020","February 24, 2020","April 1, 2020","March 21, 2020","April 1, 2020","May 1, 2020","March 16, 2020","April 1, 2020","April 13, 2020","March 27, 2020","April 20, 2020","May 1, 2020","March 31, 2020","April 15, 2020","April 6, 2020","April 8, 2020","April 2020","April 20, 2020","April 13, 2020","February 15, 2020","February 21, 2020","January 31, 2020","April 10, 2020","April 8, 2020","April 14, 2020","April 17, 2020","March 30, 2020","April 1, 2020","March 18, 2020","March 23, 2020","April 8, 2020","April 6, 2020","April 1, 2020","April 6, 2020","March 30, 2020","April 20, 2020","March 17, 2020","March 21, 2020","April 7, 2020","March 1, 2020","April 15, 2020","December 23, 2019","March 27, 2020","February 28, 2020","April 2, 2020","April 20, 2020","April 15, 2020","April 2, 2020","March 31, 2020","September 10, 2019","March 13, 2020","March 3, 2020","April 3, 2020","April 2020","March 1, 2020","March 27, 2020","April 10, 2020","March 31, 2020","March 15, 2020","April 9, 2020","April 1, 2020","April 1, 2020","January 21, 2020","April 1, 2020","March 6, 2020","January 1, 2020","April 20, 2020","April 15, 2020","December 10, 2019","April 13, 2020","March 12, 2020","March 27, 2020","April 6, 2020","February 1, 2020","March 23, 2020","April 2020","April 6, 2020","March 12, 2020","May 1, 2020","January 30, 2020","May 23, 2019","April 14, 2020","March 25, 2020","April 14, 2020","April 6, 2020","April 15, 2020","March 29, 2020","April 2020","April 8, 2020","April 2020","June 1, 2020","March 20, 2020","March 16, 2020","March 9, 2020","February 1, 2020","May 1, 2020","April 26, 2020","April 1, 2020","April 6, 2020","April 20, 2020","March 27, 2020","January 1, 2020","April 2020","March 16, 2020","April 6, 2020","March 25, 2020","April 13, 2020","April 6, 2020","April 8, 2020","April 20, 2020","April 9, 2020","February 19, 2020","March 27, 2020","April 2020","April 12, 2020","April 20, 2020","March 28, 2020","March 20, 2020","February 7, 2020","March 23, 2020","April 2020","March 18, 2020","March 27, 2020","April 1, 2020","March 30, 2020","April 15, 2020","April 10, 2020","April 20, 2020","April 3, 2020","February 26, 2020","May 2020","March 10, 2020","March 1, 2020","March 3, 2020","April 10, 2020","April 14, 2020","February 15, 2020","March 9, 2020",null,"April 1, 2020","March 24, 2020","March 19, 2020","April 21, 2020","March 16, 2020","April 2, 2020","May 10, 2020","March 11, 2020","March 23, 2020","March 21, 2020","April 5, 2020","March 31, 2020","April 20, 2020","April 3, 2020","April 15, 2020","April 15, 2020","April 15, 2020","January 1, 1998","April 2020","April 9, 2020","April 10, 2020","April 1, 2020","April 5, 2020","April 2020","March 26, 2020","March 8, 2020","April 8, 2020","January 20, 2020","January 20, 2020","April 2020","April 2020","January 1, 2020","March 27, 2020","February 6, 2020","February 7, 2020","April 1, 2020","April 6, 2020","April 3, 2020","October 15, 2019","February 14, 2020","April 9, 2020","March 23, 2020","February 14, 2020",null,"April 2020","January 1, 2020","October 24, 2017","March 30, 2020","March 23, 2020","January 20, 2020","February 2020","April 2020","February 4, 2020","January 22, 2020","February 3, 2020","February 3, 2020","March 19, 2020","March 9, 2020","April 2020","April 4, 2020","April 6, 2020","April 10, 2020","March 25, 2020","March 31, 2020","April 6, 2020","February 22, 2020","April 1, 2020","April 6, 2020","April 15, 2020","March 20, 2020","March 25, 2020","February 10, 2020","April 10, 2020","March 2020","November 8, 2018","March 25, 2020","April 20, 2020","March 17, 2020","February 7, 2020","April 5, 2020","May 1, 2020","April 8, 2020","April 10, 2020","February 15, 2020"],["September 2020","July 2020","October 31, 2020","March 23, 2022","September 30, 2020","June 2020","October 10, 2020","March 30, 2021","August 1, 2020","February 21, 2020","April 25, 2020","April 2021","October 1, 2020","September 2020","October 31, 2020","October 1, 2020","April 2021","July 31, 2020","May 31, 2020","April 12, 2021","May 13, 2021","March 2020","June 30, 2020","May 2020","April 2020","June 15, 2020","May 31, 2020","August 2020","August 2020","February 2021","December 31, 2020","April 20, 2020","December 2020","December 2020","December 19, 2020","January 28, 2022","March 31, 2020","July 2020","June 30, 2020","October 31, 2020","October 1, 2020","April 30, 2020","November 30, 2020","May 31, 2021","July 2020","March 9, 2021","December 2020","September 2020","June 30, 2020","June 2020","July 2020","March 1, 2020","October 31, 2020","July 1, 2020",null,"December 1, 2020","November 30, 2021","April 2021","May 15, 2020","July 2020","April 1, 2021","March 18, 2022","April 10, 2020","April 2021","February 25, 2020","June 15, 2020","April 1, 2020","December 31, 2020","December 20, 2020","September 2020","May 2020","July 2020","July 30, 2020","April 10, 2021","December 2020","July 2020","April 2021","May 1, 2020","May 2020","December 31, 2021","December 2020","December 31, 2020","October 3, 2020","July 2020","December 31, 2020","September 2020","September 2020","May 2020","September 2020","August 31, 2021","May 31, 2020","July 1, 2020","May 31, 2020","July 2020","May 2020","July 15, 2020","July 2020","May 31, 2020","October 2020","December 1, 2022","December 31, 2022","July 2020","June 30, 2021","April 30, 2020","June 30, 2020","May 30, 2020","May 20, 2020","April 20, 2020","May 2020","June 30, 2020","March 1, 2021","April 13, 2020","August 31, 2021","June 2020","May 30, 2020","April 30, 2020","May 30, 2020","March 15, 2020","March 2021","September 1, 2020","June 1, 2020","October 15, 2020","December 2020","June 20, 2020","April 7, 2020","January 1, 2021","July 1, 2020","June 30, 2020","September 30, 2020","October 30, 2020","October 31, 2020","July 1, 2020","September 30, 2020","January 31, 2021","August 31, 2020","June 29, 2020","March 28, 2020",null,"July 30, 2020","October 1, 2020","June 30, 2020","September 2020","May 15, 2020","June 1, 2020","August 2020","October 25, 2020","September 2020","October 1, 2020","July 1, 2020","April 10, 2020","April 5, 2020","October 1, 2020","October 1, 2020","April 1, 2021","December 31, 2020","May 2022","April 30, 2021","July 1, 2024","May 2021","June 16, 2020","July 10, 2020","September 30, 2020","December 2020","December 30, 2020","June 30, 2020","May 2020","July 15, 2020","October 31, 2020","February 28, 2021","March 25, 2020","February 25, 2020","December 31, 2021","April 30, 2020","March 19, 2020","June 6, 2020","July 30, 2020","March 2021","April 2021","December 31, 2020","April 2021","December 31, 2020","May 15, 2020","May 1, 2020","June 2021",null,"October 1, 2020","December 20, 2022","October 2020","December 31, 2021","December 1, 2020","June 1, 2024","October 30, 2020","March 2021","December 31, 2020","December 31, 2020","June 1, 2020","May 28, 2020","June 30, 2020","November 1, 2020","April 30, 2020","April 26, 2020","April 25, 2020","May 31, 2021","June 2021","October 2020","July 31, 2020","September 30, 2020","April 2020","June 1, 2020","October 15, 2020","April 2021","December 31, 2020","November 2020","July 8, 2020","May 1, 2020","June 2020","September 30, 2020","May 2020","April 1, 2021","February 25, 2020","April 30, 2020","March 30, 2021","December 31, 2020","December 31, 2020","July 31, 2020","May 2, 2021","July 31, 2023","June 1, 2020","June 1, 2020","January 31, 2021","May 2020","October 15, 2020","September 2020","March 30, 2020","August 1, 2020","May 30, 2020","April 8, 2021","June 2020","July 2020","March 30, 2021","October 15, 2020","October 2020","October 1, 2020","July 15, 2020","July 31, 2023","September 30, 2020","October 11, 2020","June 2020","June 30, 2020","September 30, 2020","October 1, 2020","April 8, 2021","March 13, 2021","May 19, 2020","July 16, 2020","March 2021","April 2022","February 28, 2020","June 2020","April 30, 2020","January 31, 2022","May 15, 2021","August 2020","May 20, 2020","June 30, 2020","June 2020","December 1, 2020","January 31, 2021","November 20, 2020","April 10, 2020","September 2020","February 2021","October 30, 2020","August 31, 2020","September 9, 2020","February 2022","April 2021","September 1, 2020","July 2020","April 1, 2022","March 13, 2020","February 28, 2021","June 2020","April 20, 2020","July 2020","December 31, 2099","July 2020","December 31, 2020","June 1, 2020","July 2020","June 1, 2020","April 1, 2025","May 30, 2020","June 1, 2020","May 2020","June 30, 2021","July 14, 2020","November 30, 2020","August 1, 2020","June 15, 2020","August 2020","April 28, 2020","January 2021","April 2021","March 11, 2021","September 2021","January 1, 2021","December 2020","March 31, 2020","July 13, 2020","April 15, 2020","December 2020","August 15, 2020","March 30, 2021","July 2020","December 2020","December 2020","October 2020",null,"March 20, 2021","September 30, 2021","April 21, 2021","December 2021","April 11, 2021","May 1, 2020","September 1, 2020","June 30, 2020","March 2021","December 31, 2020","April 2021","March 31, 2022","April 2021","December 31, 2020","March 2021","September 26, 2020","May 10, 2020","October 5, 2020","December 4, 2020","June 15, 2020","May 2021","June 2021","July 31, 2020","December 31, 2020","July 14, 2021","December 31, 2022","December 31, 2020","August 31, 2020","March 23, 2021","May 30, 2020","April 30, 2020","November 6, 2020","August 31, 2020","May 15, 2020","June 30, 2020",null,"June 30, 2020","April 30, 2021","August 31, 2020","November 1, 2020","May 30, 2020","April 17, 2020","October 2020","April 1, 2021","March 31, 2024","August 16, 2020","March 2023","April 1, 2021","December 15, 2020","April 30, 2020","July 2020","March 2023","June 1, 2020","June 1, 2020","June 30, 2020","October 2020","April 30, 2020","August 16, 2021","April 2020","June 30, 2020","April 15, 2020","June 30, 2020","May 1, 2020","April 2022","June 20, 2020","May 9, 2020","September 2020","August 2020","August 2020","May 20, 2020","March 23, 2022","June 1, 2020","December 2021","December 1, 2020","July 10, 2020","June 9, 2020","August 31, 2020","October 31, 2021","September 2020","July 31, 2020","February 28, 2021","November 2020","April 1, 2021","September 30, 2020","August 1, 2021","April 30, 2020","June 30, 2020","May 13, 2020","September 30, 2020","December 30, 2020","July 30, 2020","October 1, 2020","May 25, 2020","December 29, 2020","September 2020","August 2020","March 1, 2022","August 30, 2020","December 2022","April 1, 2023","February 18, 2020","September 6, 2020","July 2020","May 14, 2020","August 20, 2020","March 31, 2021","December 31, 2020","December 31, 2020","May 20, 2020","August 1, 2021","July 31, 2021","December 31, 2030","August 5, 2020","April 2020","May 1, 2021","April 30, 2020","March 20, 2021","July 7, 2020","April 30, 2020","September 30, 2020","January 20, 2020","May 1, 2020","August 28, 2020","March 20, 2021","June 20, 2020","June 3, 2020","April 8, 2020","April 30, 2020","December 31, 2021","March 13, 2020","August 15, 2020","June 3, 2020","March 2021","May 30, 2020","March 27, 2022","April 10, 2020","May 2020","April 15, 2020","June 30, 2020","April 1, 2021","December 1, 2020","May 2020","April 15, 2020","May 2020","April 30, 2020","May 2021","October 1, 2020","February 10, 2020","October 13, 2020","December 31, 2020","September 2020","September 15, 2020","November 30, 2020","March 1, 2021","January 2021","August 30, 2020","April 9, 2020","May 1, 2021","April 2, 2020","April 30, 2021","June 30, 2020","April 3, 2020","June 30, 2020","May 31, 2020","June 15, 2020","July 2020","April 2021","April 30, 2021","September 2020","June 1, 2021","July 1, 2020","May 30, 2020","March 23, 2020","July 31, 2020","April 30, 2021","September 26, 2020","August 30, 2020","April 7, 2021","June 1, 2020","March 27, 2021","April 20, 2020","July 2020","March 2021","July 31, 2020","November 1, 2021","June 10, 2020","October 31, 2020","December 2020","January 30, 2021","November 30, 2020","April 4, 2020","March 27, 2021","July 2020","June 30, 2020","June 15, 2021","August 30, 2020","June 2020","July 1, 2020","December 31, 2021","July 2020","March 17, 2021","July 1, 2020","August 1, 2020","September 2021","December 1, 2029","June 10, 2021","June 1, 2020","December 31, 2021","March 30, 2020","October 2020","April 10, 2020","March 1, 2021","June 1, 2021","April 19, 2020","April 30, 2020","September 30, 2020","October 10, 2020",null,"April 15, 2020","June 30, 2020","March 19, 2022","July 21, 2020","March 16, 2020","May 4, 2020","October 9, 2020","March 2022","June 30, 2020","March 21, 2021","June 1, 2021","May 5, 2020","June 1, 2020","November 2020","October 2020","May 15, 2020","December 2029","May 31, 2016","December 2020","June 30, 2020","June 1, 2020","April 15, 2020","April 1, 2021","April 2021","March 25, 2026","May 31, 2020","August 1, 2020","January 31, 2021","January 31, 2021","September 2020","May 2020","April 30, 2020","October 6, 2020","April 30, 2020","May 31, 2020","December 31, 2022","October 5, 2020","October 6, 2020","April 30, 2020","September 30, 2020","June 1, 2020","August 31, 2020","May 14, 2020",null,"May 2021","December 31, 2020","December 31, 2020","March 2021","September 2020","April 30, 2020","March 2020","September 2020","October 4, 2020","January 22, 2021","April 15, 2020","December 31, 2020","April 19, 2020","May 1, 2020","September 2020","April 1, 2021","May 13, 2020","June 10, 2020","May 15, 2020","March 31, 2021","August 2020","March 31, 2020","December 31, 2022","April 30, 2021","April 2021","December 2020","April 1, 2021","March 30, 2020","June 10, 2020","March 2022","December 31, 2021","September 25, 2022","June 20, 2020","April 21, 2020","August 7, 2020","May 30, 2020","July 1, 2020","September 30, 2020","May 31, 2020","May 31, 2020"],["March 2021","July 2020","October 31, 2020","March 23, 2022","December 31, 2020","June 2020","December 10, 2020","March 30, 2021","September 1, 2020","August 1, 2020","April 30, 2020","April 2021","October 30, 2020","October 2020","December 31, 2020","May 1, 2021","April 2021","August 31, 2020","May 31, 2020","April 12, 2021","July 13, 2021","April 2020","June 30, 2020","May 2020","April 2020","July 15, 2020","September 30, 2020","October 2020","October 2020","July 2021","December 31, 2021","April 24, 2020","December 2021","December 2020","December 19, 2022","January 28, 2022","July 31, 2020","July 2020","September 30, 2020","December 31, 2020","December 1, 2020","May 31, 2020","November 30, 2020","May 31, 2022","October 2020","April 1, 2021","July 2021","December 2020","June 30, 2020","August 2020","July 2020","November 9, 2020","December 31, 2020","July 1, 2020",null,"December 31, 2020","September 30, 2022","July 2021","May 15, 2020","September 2020","December 1, 2021","May 18, 2022","April 30, 2020","December 2021","February 25, 2020","June 15, 2020","April 16, 2020","December 31, 2021","April 30, 2021","November 2020","May 2020","December 2020","July 30, 2020","December 10, 2021","February 2021","September 2020","July 2021","May 9, 2020","May 2020","December 31, 2021","December 2020","April 30, 2021","October 30, 2020","July 2020","March 31, 2021","October 2020","October 2020","May 2020","October 2020","December 31, 2021","June 30, 2020","July 1, 2020","June 30, 2020","August 2020","May 2020","September 15, 2020","July 2020","December 31, 2020","October 2020","December 30, 2022","June 30, 2023","July 2020","June 30, 2021","May 31, 2020","September 30, 2020","May 30, 2020","May 20, 2020","May 20, 2020","June 2020","July 31, 2020","May 1, 2021","April 13, 2020","September 30, 2021","August 2020","June 30, 2020","May 30, 2020","June 30, 2020","March 18, 2020","February 2022","December 1, 2022","April 1, 2021","October 30, 2020","December 2020","September 30, 2020","June 1, 2020","May 1, 2021","July 1, 2020","July 30, 2020","December 31, 2020","October 30, 2020","March 22, 2021","July 1, 2020","December 31, 2020","January 31, 2021","August 31, 2020","June 29, 2021","March 30, 2020",null,"July 30, 2021","December 1, 2020","February 15, 2022","September 2021","June 1, 2020","June 1, 2020","September 2020","December 25, 2020","September 2020","December 1, 2020","July 1, 2020","April 27, 2020","April 5, 2020","December 1, 2020","December 1, 2020","April 1, 2022","March 31, 2021","May 2022","April 30, 2021","April 1, 2025","May 2022","June 30, 2020","July 10, 2020","December 30, 2020","December 2020","December 20, 2022","June 30, 2020","May 2020","July 31, 2020","November 30, 2020","February 28, 2021","March 25, 2020","February 25, 2020","June 30, 2022","May 31, 2020","March 19, 2020","July 6, 2020","September 30, 2020","March 2022","May 2021","March 31, 2021","April 2022","December 31, 2020","May 15, 2020","May 30, 2020","June 2022",null,"December 31, 2021","December 20, 2023","April 2021","January 31, 2022","March 1, 2021","December 1, 2025","January 31, 2021","March 2022","December 31, 2020","March 31, 2021","July 1, 2020","June 28, 2020","July 31, 2020","November 9, 2020","April 30, 2020","April 28, 2020","May 10, 2020","May 31, 2021","June 2021","December 2020","September 30, 2020","November 30, 2020","May 2020","July 1, 2020","January 1, 2021","August 2021","March 31, 2021","November 2020","August 8, 2020","May 5, 2020","August 2020","September 30, 2020","July 2020","April 30, 2021","February 25, 2020","April 30, 2020","March 30, 2022","December 31, 2021","April 11, 2021","September 30, 2020","May 31, 2021","December 31, 2024","September 30, 2020","July 1, 2020","August 31, 2021","August 2020","December 15, 2020","September 2020","April 10, 2020","August 1, 2020","July 30, 2020","December 20, 2025","December 2021","August 2020","December 30, 2021","January 15, 2021","October 2020","November 1, 2020","July 15, 2020","December 31, 2024","April 30, 2021","November 11, 2020","June 2020","December 31, 2021","October 31, 2020","October 1, 2020","April 8, 2022","March 13, 2021","May 19, 2020","October 16, 2020","March 2021","April 2022","March 8, 2020","June 2020","May 30, 2020","March 31, 2022","May 15, 2022","September 2020","May 20, 2020","April 30, 2021","July 2020","December 30, 2020","March 1, 2021","November 20, 2020","April 30, 2020","December 2020","February 2021","March 30, 2022","September 30, 2020","September 9, 2020","February 2022","May 2021","November 30, 2020","July 2020","April 1, 2022","March 13, 2020","February 28, 2023","August 2020","April 25, 2020","August 2020","December 31, 2099","August 2021","December 31, 2020","December 1, 2020","July 2020","September 15, 2020","April 1, 2025","June 30, 2020","December 1, 2020","May 2020","July 30, 2021","April 14, 2021","November 30, 2020","August 1, 2020","June 20, 2020","August 2020","May 28, 2021","January 2021","April 2021","May 11, 2021","September 2022","April 1, 2021","December 2020","April 30, 2020","July 31, 2020","April 30, 2020","December 2020","September 1, 2020","June 30, 2021","September 2020","June 2021","December 2020","October 2020",null,"March 20, 2021","September 30, 2023","August 21, 2021","December 2021","April 11, 2021","September 30, 2020","October 21, 2021","July 31, 2020","September 2022","December 31, 2020","April 2021","March 31, 2022","July 2021","December 31, 2021","March 2022","November 26, 2020","June 10, 2020","November 9, 2020","April 4, 2021","September 15, 2020","May 2021","September 2021","August 31, 2020","April 1, 2021","April 14, 2022","January 2023","May 1, 2021","December 31, 2020","June 23, 2021","June 15, 2020","October 31, 2020","November 6, 2020","August 31, 2020","June 15, 2020","July 31, 2020",null,"July 30, 2020","April 30, 2021","December 31, 2020","January 1, 2021","June 20, 2020","April 17, 2020","February 2021","April 1, 2021","March 31, 2024","August 18, 2020","March 2023","April 1, 2021","June 15, 2021","June 30, 2020","September 2020","March 2023","July 1, 2020","July 1, 2020","April 30, 2021","October 2020","May 31, 2020","November 1, 2021","May 2020","September 30, 2020","April 15, 2020","June 30, 2021","July 1, 2020","April 2023","July 10, 2020","May 9, 2020","November 2020","September 2020","November 2020","September 30, 2020","March 23, 2022","July 1, 2020","December 2023","April 1, 2021","July 10, 2020","July 10, 2020","December 31, 2020","December 31, 2022","October 2022","July 31, 2020","June 17, 2021","December 2020","April 1, 2022","December 31, 2020","August 1, 2021","April 30, 2020","May 31, 2021","May 13, 2020","September 30, 2020","December 30, 2020","July 30, 2020","October 1, 2020","May 30, 2020","January 29, 2021","September 2020","October 2020","April 1, 2022","August 30, 2020","December 2022","April 1, 2023","February 18, 2020","April 6, 2021","September 2020","May 30, 2020","August 30, 2020","March 31, 2022","January 15, 2021","December 31, 2021","May 30, 2020","September 1, 2021","September 30, 2021","December 31, 2030","November 5, 2020","September 2020","May 1, 2021","May 31, 2020","March 20, 2022","April 6, 2021","July 4, 2020","September 1, 2021","March 3, 2020","June 1, 2020","August 28, 2020","March 20, 2022","July 20, 2020","June 3, 2020","April 15, 2020","May 31, 2020","December 31, 2021","April 3, 2020","October 15, 2020","July 31, 2020","March 2021","June 30, 2020","March 20, 2030","June 10, 2020","May 2020","May 1, 2020","June 30, 2020","April 1, 2021","January 1, 2021","June 2020","June 1, 2022","August 2020","May 1, 2020","May 2021","August 1, 2021","March 4, 2020","October 13, 2020","December 31, 2021","September 2020","September 30, 2020","December 31, 2020","March 1, 2022","March 2021","December 30, 2020","May 2020","May 1, 2021","April 15, 2020","December 28, 2021","June 30, 2020","April 10, 2020","June 30, 2020","June 30, 2020","June 15, 2020","June 2021","April 2021","August 31, 2021","September 2020","December 31, 2021","September 1, 2020","June 15, 2020","March 23, 2020","December 31, 2020","April 30, 2021","October 12, 2020","August 30, 2020","October 7, 2021","July 31, 2020","December 31, 2021","April 30, 2020","July 2020","March 2021","September 30, 2020","December 31, 2021","November 10, 2020","March 31, 2021","December 2020","April 30, 2021","December 31, 2021","July 2020","December 31, 2021","July 2020","December 31, 2020","June 15, 2021","August 30, 2020","August 2020","December 30, 2020","December 31, 2021","August 2020","March 17, 2022","August 31, 2020","August 31, 2020","September 2021","December 1, 2029","June 10, 2021","July 31, 2020","December 31, 2021","March 30, 2020","October 2020","May 8, 2020","February 1, 2022","June 1, 2021","July 9, 2020","April 30, 2020","December 30, 2020","October 30, 2020",null,"April 15, 2020","August 30, 2020","March 19, 2022","October 21, 2020","March 16, 2020","August 1, 2020","November 10, 2020","March 2022","August 30, 2020","March 21, 2022","June 1, 2021","May 30, 2020","October 1, 2020","November 2020","April 2021","May 25, 2020","December 2029","March 31, 2020","December 2020","June 30, 2020","July 1, 2020","May 1, 2020","April 1, 2022","April 2021","March 25, 2026","May 31, 2020","August 1, 2020","February 28, 2021","February 28, 2021","September 2020","December 31, 2020","July 31, 2020","December 31, 2020","September 30, 2020","June 30, 2020","December 31, 2022","November 9, 2020","December 6, 2020","November 30, 2020","September 30, 2020","June 1, 2020","August 31, 2020","December 14, 2021",null,"November 2021","December 31, 2020","March 31, 2021","March 2022","September 2020","April 30, 2020","March 2020","December 2020","February 4, 2021","January 22, 2021","April 20, 2020","December 31, 2020","December 31, 2020","May 1, 2020","November 2020","August 1, 2021","June 30, 2020","July 31, 2020","July 20, 2020","December 31, 2021","August 2020","March 31, 2020","December 31, 2022","October 31, 2021","April 2021","December 2020","March 3, 2025","March 31, 2020","July 31, 2020","April 2022","December 31, 2022","September 25, 2022","October 20, 2020","May 12, 2020","August 7, 2023","June 30, 2020","August 1, 2020","April 30, 2021","May 31, 2020","July 31, 2020"],["April 3, 2020","April 7, 2020","April 14, 2020","April 2, 2020","April 15, 2020","April 13, 2020","April 13, 2020","April 3, 2020","March 2, 2020","April 7, 2020","March 27, 2020","April 15, 2020","March 26, 2020","April 6, 2020","April 3, 2020","April 13, 2020","April 13, 2020","April 1, 2020","March 25, 2020","April 14, 2020","March 27, 2020","March 26, 2020","April 9, 2020","March 13, 2020","February 27, 2020","April 14, 2020","March 27, 2020","April 15, 2020","April 9, 2020","March 26, 2020","April 1, 2020","April 13, 2020","February 5, 2020","April 16, 2020","March 20, 2020","April 15, 2020","April 2, 2020","April 14, 2020","April 1, 2020","April 16, 2020","April 16, 2020","February 19, 2020","March 31, 2020","April 2, 2020","April 8, 2020","March 19, 2020","April 8, 2020","April 1, 2020","April 13, 2020","April 13, 2020","April 2, 2020","March 11, 2020","March 30, 2020","April 7, 2020","April 8, 2020","April 16, 2020","April 9, 2020","April 6, 2020","March 31, 2020","April 10, 2020","April 1, 2020","April 1, 2020","March 24, 2020","April 3, 2020","February 26, 2020","March 11, 2020","March 24, 2020","April 6, 2020","April 3, 2020","April 6, 2020","April 2, 2020","April 2, 2020","April 3, 2020","April 14, 2020","April 14, 2020","April 16, 2020","April 6, 2020","April 14, 2020","March 13, 2020","April 14, 2020","March 26, 2020","April 16, 2020","April 2, 2020","April 7, 2020","April 7, 2020","March 18, 2020","April 2, 2020","March 3, 2020","March 18, 2020","April 6, 2020","April 16, 2020","April 14, 2020","April 1, 2020","April 15, 2020","March 3, 2020","April 10, 2020","April 14, 2020","April 14, 2020","April 10, 2020","April 15, 2020","April 14, 2020","April 15, 2020","April 7, 2020","April 15, 2020","March 18, 2020","April 15, 2020","April 1, 2020","April 2, 2020","March 20, 2020","March 12, 2020","March 16, 2020","January 28, 2020","March 25, 2020","April 14, 2020","February 18, 2020","February 18, 2020","April 9, 2020","March 18, 2020","April 10, 2020","April 15, 2020","April 14, 2020","April 8, 2020","April 15, 2020","April 14, 2020","April 13, 2020","April 14, 2020","April 10, 2020","April 15, 2020","April 2, 2020","March 27, 2020","March 20, 2020","February 21, 2020","April 6, 2020","April 10, 2020","April 13, 2020","April 1, 2020","March 23, 2020","April 7, 2020","April 2, 2020","April 16, 2020","February 18, 2020","April 2, 2020","April 15, 2020","April 3, 2020","April 15, 2020","March 31, 2020","April 10, 2020","April 15, 2020","April 16, 2020","February 5, 2020","April 13, 2020","April 15, 2020","April 16, 2020","March 31, 2020","April 3, 2020","April 1, 2020","April 7, 2020","April 14, 2020","March 20, 2020","April 15, 2020","April 13, 2020","April 8, 2020","April 15, 2020","March 18, 2020","April 3, 2020","April 7, 2020","February 28, 2020","March 11, 2020","February 27, 2020","April 1, 2020","March 3, 2020","April 9, 2020","April 14, 2020","March 2, 2020","April 3, 2020","April 13, 2020","April 14, 2020","April 14, 2020","April 10, 2020","April 8, 2020","April 16, 2020","April 6, 2020","February 18, 2020","April 15, 2020","April 8, 2020","April 14, 2020","April 6, 2020","April 9, 2020","April 13, 2020","April 10, 2020","April 10, 2020","April 2, 2020","March 24, 2020","April 14, 2020","March 23, 2020","April 10, 2020","March 31, 2020","April 16, 2020","April 7, 2020","April 8, 2020","March 31, 2020","March 26, 2020","March 27, 2019","April 16, 2020","April 16, 2020","April 14, 2020","April 14, 2020","April 6, 2020","April 13, 2020","April 15, 2020","April 13, 2020","April 16, 2020","April 14, 2020","April 16, 2020","April 6, 2020","April 3, 2020","March 26, 2020","April 10, 2020","April 14, 2020","February 7, 2020","February 5, 2020","April 1, 2020","April 15, 2020","April 15, 2020","April 13, 2020","April 16, 2020","March 9, 2020","April 15, 2020","April 10, 2020","April 8, 2020","April 15, 2020","April 8, 2020","April 15, 2020","February 6, 2020","April 13, 2020","March 6, 2020","April 6, 2020","March 27, 2020","April 6, 2020","April 16, 2020","April 16, 2020","April 6, 2020","April 3, 2020","April 16, 2020","February 19, 2020","April 14, 2020","April 16, 2020","April 10, 2020","April 3, 2020","April 1, 2020","April 3, 2020","April 14, 2020","March 26, 2020","March 26, 2020","March 11, 2020","April 10, 2020","April 10, 2020","March 20, 2020","March 24, 2020","April 7, 2020","April 1, 2020","April 14, 2020","April 6, 2020","March 24, 2020","April 10, 2020","April 14, 2020","April 7, 2020","April 1, 2020","April 16, 2020","April 2, 2020","March 25, 2020","April 3, 2020","March 31, 2020","March 30, 2020","April 10, 2020","April 14, 2020","April 14, 2020","April 8, 2020","April 2, 2020","April 9, 2020","March 3, 2020","March 27, 2020","April 15, 2020","April 7, 2020","April 15, 2020","April 13, 2020","April 6, 2020","April 8, 2020","April 6, 2020","April 6, 2020","April 3, 2020","April 1, 2020","March 31, 2020","March 17, 2020","March 17, 2020","March 10, 2020","March 4, 2020","April 15, 2020","April 6, 2020","April 7, 2020","April 10, 2020","April 15, 2020","February 20, 2020","March 11, 2020","April 15, 2020","April 15, 2020","March 31, 2020","March 25, 2020","February 17, 2020","April 6, 2020","February 18, 2020","April 2, 2020","April 15, 2020","March 17, 2020","March 27, 2020","April 14, 2020","March 24, 2020","April 9, 2020","March 27, 2020","March 24, 2020","April 6, 2020","March 25, 2020","April 13, 2020","April 15, 2020","April 10, 2020","April 7, 2020","April 16, 2020","March 6, 2020","February 17, 2020","April 16, 2020","April 6, 2020","April 3, 2020","April 9, 2020","March 25, 2020","March 27, 2020","April 7, 2020","March 27, 2020","April 13, 2020","February 26, 2020","March 27, 2020","March 27, 2020","April 14, 2020","April 15, 2020","April 16, 2020","March 27, 2020","March 25, 2020","April 2, 2020","March 27, 2020","April 3, 2020","February 13, 2020","April 1, 2020","April 16, 2020","April 9, 2020","April 6, 2020","April 15, 2020","April 1, 2020","March 27, 2020","April 3, 2020","April 6, 2020","March 13, 2020","April 7, 2020","March 18, 2020","March 17, 2020","March 27, 2020","March 18, 2020","March 20, 2020","March 17, 2020","April 16, 2020","February 7, 2020","April 8, 2020","April 2, 2020","February 5, 2020","February 5, 2020","April 9, 2020","April 14, 2020","March 20, 2020","April 16, 2020","February 19, 2020","April 10, 2020","April 9, 2020","April 13, 2020","February 7, 2020","April 10, 2020","April 2, 2020","April 1, 2020","March 20, 2020","March 17, 2020","March 25, 2020","March 31, 2020","March 31, 2020","February 10, 2020","April 13, 2016","April 13, 2020","April 10, 2020","April 9, 2020","February 5, 2020","March 31, 2020","February 3, 2017","February 5, 2020","March 30, 2020","March 27, 2020","March 12, 2020","March 27, 2020","April 15, 2020","March 24, 2020","April 3, 2020","April 16, 2020","March 31, 2020","April 15, 2020","April 9, 2020","March 30, 2020","April 15, 2020","April 8, 2020","April 13, 2020","April 10, 2020","April 9, 2020","March 31, 2020","February 21, 2020","February 21, 2020","February 25, 2020","April 15, 2020","April 14, 2020","April 16, 2020","April 14, 2020","March 25, 2020","March 26, 2020","March 23, 2020","March 26, 2020","April 6, 2020","April 6, 2020","April 6, 2020","April 6, 2020","April 9, 2020","April 16, 2020","February 11, 2020","March 25, 2020","April 9, 2020","April 16, 2020","April 14, 2020","April 7, 2020","March 30, 2020","April 6, 2020","March 18, 2020","March 26, 2020","April 6, 2020","April 14, 2020","April 7, 2020","April 10, 2020","March 12, 2020","April 9, 2020","April 7, 2020","April 2, 2020","March 3, 2020","March 25, 2020","April 10, 2020","April 3, 2020","April 8, 2020","April 15, 2020","April 7, 2020","March 5, 2020","March 24, 2020","April 13, 2020","April 15, 2020","March 24, 2020","April 14, 2020","April 15, 2020","March 10, 2020","April 15, 2020","March 20, 2020","April 3, 2020","April 16, 2020","February 21, 2020","March 2, 2020","April 7, 2020","April 10, 2020","March 19, 2020","April 9, 2020","March 31, 2020","January 18, 2019","April 15, 2020","March 31, 2020","April 14, 2020","March 30, 2020","April 14, 2020","March 31, 2020","April 15, 2020","April 14, 2020","March 30, 2020","April 8, 2020","March 30, 2020","April 10, 2020","March 25, 2020","March 3, 2020","April 15, 2020","March 30, 2020","March 26, 2020","March 30, 2020","April 15, 2020","March 27, 2020","March 20, 2020","April 15, 2020","April 13, 2020","April 8, 2020","March 30, 2020","April 14, 2020","March 26, 2020","April 15, 2020","April 10, 2020","April 10, 2020","February 18, 2020","March 27, 2020","April 14, 2020","April 13, 2020","April 14, 2020","March 25, 2020","April 14, 2020","February 7, 2020","March 19, 2020","April 7, 2020","April 1, 2020","April 15, 2020","March 30, 2020","March 30, 2020","April 14, 2020","April 10, 2020","April 6, 2020","March 25, 2020","April 14, 2020","April 14, 2020","March 27, 2020","March 2, 2020","February 25, 2020","April 14, 2020","April 15, 2020","February 21, 2020","March 2, 2020","February 28, 2020","April 13, 2020","March 26, 2020","March 24, 2020","April 15, 2020","March 25, 2020","April 8, 2020","March 6, 2020","March 13, 2020","March 26, 2020","March 12, 2020","March 26, 2020","March 27, 2020","April 15, 2020","April 7, 2020","April 8, 2020","April 16, 2020","April 14, 2020","March 26, 2020","April 7, 2020","April 14, 2020","April 10, 2020","April 14, 2020","April 8, 2020","April 16, 2020","March 31, 2020","March 12, 2020","April 15, 2020","February 21, 2020","February 21, 2020","April 13, 2020","April 10, 2020","March 3, 2020","April 9, 2020","February 13, 2020","February 10, 2020","March 27, 2020","March 30, 2020","April 7, 2020","August 19, 2019","February 11, 2020","April 8, 2020","March 26, 2020","February 19, 2020","March 10, 2020","April 16, 2020","January 29, 2020","November 6, 2017","April 6, 2020","March 26, 2020","February 5, 2020","February 24, 2020","April 14, 2020","February 7, 2020","February 5, 2020","February 7, 2020","February 19, 2020","March 13, 2020","March 26, 2020","April 9, 2020","April 10, 2020","April 6, 2020","April 15, 2020","March 24, 2020","April 2, 2020","March 31, 2020","February 21, 2020","April 3, 2020","March 24, 2020","April 15, 2020","April 3, 2020","March 20, 2020","February 19, 2020","April 15, 2020","March 24, 2020","September 21, 2018","March 30, 2020","April 15, 2020","March 16, 2020","February 10, 2020","April 1, 2020","April 15, 2020","April 13, 2020","April 9, 2020","February 19, 2020"],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["April 6, 2020","April 8, 2020","April 14, 2020","April 7, 2020","April 15, 2020","April 13, 2020","April 13, 2020","April 9, 2020","March 17, 2020","April 7, 2020","April 2, 2020","April 15, 2020","April 15, 2020","April 14, 2020","April 16, 2020","April 16, 2020","April 16, 2020","April 15, 2020","March 25, 2020","April 16, 2020","April 14, 2020","March 26, 2020","April 9, 2020","March 17, 2020","March 17, 2020","April 14, 2020","March 27, 2020","April 15, 2020","April 9, 2020","April 7, 2020","April 9, 2020","April 16, 2020","April 15, 2020","April 16, 2020","April 7, 2020","April 15, 2020","April 6, 2020","April 14, 2020","April 1, 2020","April 16, 2020","April 16, 2020","February 19, 2020","April 16, 2020","April 2, 2020","April 8, 2020","April 6, 2020","April 9, 2020","April 8, 2020","April 13, 2020","April 13, 2020","April 9, 2020","March 17, 2020","April 2, 2020","April 7, 2020","April 8, 2020","April 16, 2020","April 9, 2020","April 13, 2020","March 31, 2020","April 10, 2020","April 13, 2020","April 16, 2020","March 24, 2020","April 14, 2020","March 10, 2020","April 16, 2020","April 7, 2020","April 9, 2020","April 3, 2020","April 6, 2020","April 14, 2020","April 9, 2020","April 10, 2020","April 14, 2020","April 14, 2020","April 16, 2020","April 6, 2020","April 14, 2020","March 13, 2020","April 14, 2020","March 26, 2020","April 16, 2020","April 7, 2020","April 7, 2020","April 7, 2020","April 14, 2020","April 7, 2020","April 14, 2020","April 14, 2020","April 10, 2020","April 16, 2020","April 14, 2020","April 16, 2020","April 15, 2020","April 16, 2020","April 10, 2020","April 15, 2020","April 14, 2020","April 14, 2020","April 16, 2020","April 14, 2020","April 16, 2020","April 10, 2020","April 15, 2020","March 18, 2020","April 15, 2020","April 13, 2020","April 13, 2020","April 15, 2020","March 26, 2020","March 16, 2020","April 15, 2020","April 8, 2020","April 14, 2020","February 21, 2020","February 21, 2020","April 9, 2020","March 18, 2020","April 10, 2020","April 16, 2020","April 14, 2020","April 8, 2020","April 15, 2020","April 16, 2020","April 13, 2020","April 14, 2020","April 13, 2020","April 15, 2020","April 2, 2020","April 9, 2020","March 20, 2020","February 21, 2020","April 6, 2020","April 15, 2020","April 16, 2020","April 1, 2020","April 7, 2020","April 7, 2020","April 8, 2020","April 16, 2020","April 14, 2020","April 13, 2020","April 15, 2020","April 3, 2020","April 16, 2020","April 3, 2020","April 16, 2020","April 16, 2020","April 16, 2020","April 15, 2020","April 14, 2020","April 16, 2020","April 16, 2020","March 31, 2020","April 13, 2020","April 1, 2020","April 13, 2020","April 14, 2020","April 10, 2020","April 15, 2020","April 15, 2020","April 8, 2020","April 15, 2020","April 14, 2020","April 7, 2020","April 7, 2020","April 7, 2020","April 10, 2020","February 27, 2020","April 1, 2020","March 18, 2020","April 13, 2020","April 14, 2020","April 13, 2020","April 3, 2020","April 15, 2020","April 15, 2020","April 14, 2020","April 16, 2020","April 8, 2020","April 16, 2020","April 15, 2020","April 1, 2020","April 15, 2020","April 8, 2020","April 14, 2020","April 9, 2020","April 13, 2020","April 15, 2020","April 10, 2020","April 16, 2020","April 13, 2020","March 25, 2020","April 14, 2020","March 23, 2020","April 10, 2020","April 2, 2020","April 16, 2020","April 7, 2020","April 15, 2020","April 2, 2020","March 26, 2020","April 15, 2020","April 16, 2020","April 16, 2020","April 15, 2020","April 14, 2020","April 6, 2020","April 15, 2020","April 15, 2020","April 13, 2020","April 16, 2020","April 15, 2020","April 16, 2020","April 6, 2020","April 7, 2020","March 26, 2020","April 14, 2020","April 14, 2020","April 13, 2020","March 17, 2020","April 1, 2020","April 15, 2020","April 15, 2020","April 14, 2020","April 16, 2020","March 9, 2020","April 16, 2020","April 13, 2020","April 8, 2020","April 15, 2020","April 8, 2020","April 15, 2020","April 15, 2020","April 13, 2020","March 6, 2020","April 16, 2020","April 14, 2020","April 6, 2020","April 16, 2020","April 16, 2020","April 8, 2020","April 3, 2020","April 16, 2020","March 19, 2020","April 15, 2020","April 16, 2020","April 10, 2020","April 3, 2020","April 1, 2020","April 7, 2020","April 16, 2020","March 26, 2020","March 31, 2020","April 13, 2020","April 13, 2020","April 10, 2020","March 30, 2020","April 16, 2020","April 7, 2020","April 13, 2020","April 15, 2020","April 6, 2020","March 24, 2020","April 15, 2020","April 14, 2020","April 14, 2020","April 13, 2020","April 16, 2020","April 2, 2020","April 8, 2020","April 15, 2020","April 7, 2020","April 2, 2020","April 10, 2020","April 14, 2020","April 14, 2020","April 10, 2020","April 13, 2020","April 15, 2020","March 17, 2020","March 31, 2020","April 15, 2020","April 7, 2020","April 15, 2020","April 15, 2020","April 8, 2020","April 8, 2020","April 6, 2020","April 15, 2020","April 10, 2020","April 1, 2020","March 31, 2020","March 17, 2020","April 10, 2020","March 10, 2020","March 4, 2020","April 15, 2020","April 13, 2020","April 7, 2020","April 10, 2020","April 15, 2020","March 17, 2020","March 27, 2020","April 15, 2020","April 15, 2020","April 8, 2020","April 14, 2020","March 17, 2020","April 13, 2020","March 23, 2020","April 2, 2020","April 15, 2020","March 17, 2020","April 9, 2020","April 14, 2020","April 8, 2020","April 9, 2020","April 15, 2020","March 24, 2020","April 6, 2020","March 27, 2020","April 13, 2020","April 15, 2020","April 10, 2020","April 15, 2020","April 16, 2020","April 2, 2020","February 17, 2020","April 16, 2020","April 16, 2020","April 7, 2020","April 14, 2020","March 31, 2020","March 31, 2020","April 13, 2020","March 31, 2020","April 14, 2020","February 26, 2020","April 15, 2020","April 14, 2020","April 14, 2020","April 15, 2020","April 16, 2020","April 8, 2020","April 6, 2020","April 2, 2020","March 27, 2020","April 6, 2020","February 13, 2020","April 13, 2020","April 16, 2020","April 9, 2020","April 9, 2020","April 16, 2020","April 13, 2020","April 14, 2020","April 3, 2020","April 6, 2020","March 17, 2020","April 7, 2020","March 18, 2020","April 16, 2020","April 7, 2020","April 2, 2020","March 25, 2020","April 13, 2020","April 16, 2020","February 7, 2020","April 8, 2020","April 3, 2020","March 17, 2020","March 17, 2020","April 14, 2020","April 14, 2020","April 7, 2020","April 16, 2020","April 3, 2020","April 10, 2020","April 9, 2020","April 13, 2020","March 17, 2020","April 16, 2020","April 2, 2020","April 14, 2020","March 20, 2020","April 10, 2020","April 14, 2020","March 31, 2020","April 16, 2020","March 17, 2020","April 16, 2020","April 14, 2020","April 10, 2020","April 9, 2020","April 13, 2020","March 31, 2020","April 15, 2020","February 20, 2020","March 30, 2020","March 27, 2020","April 9, 2020","March 27, 2020","April 15, 2020","March 24, 2020","April 3, 2020","April 16, 2020","March 31, 2020","April 15, 2020","April 9, 2020","April 1, 2020","April 15, 2020","April 8, 2020","April 14, 2020","April 10, 2020","April 15, 2020","April 15, 2020","February 21, 2020","April 6, 2020","February 25, 2020","April 15, 2020","April 14, 2020","April 16, 2020","April 14, 2020","March 25, 2020","March 27, 2020","March 26, 2020","March 27, 2020","April 7, 2020","April 8, 2020","April 6, 2020","April 6, 2020","April 9, 2020","April 16, 2020","March 17, 2020","April 2, 2020","April 14, 2020","April 16, 2020","April 14, 2020","April 7, 2020","April 1, 2020","April 6, 2020","April 3, 2020","April 15, 2020","April 6, 2020","April 14, 2020","April 7, 2020","April 13, 2020","April 13, 2020","April 9, 2020","April 7, 2020","April 9, 2020","March 3, 2020","March 31, 2020","April 10, 2020","April 13, 2020","April 10, 2020","April 15, 2020","April 7, 2020","March 5, 2020","March 31, 2020","April 16, 2020","April 15, 2020","April 10, 2020","April 14, 2020","April 15, 2020","March 10, 2020","April 16, 2020","March 20, 2020","April 8, 2020","April 16, 2020","February 21, 2020","March 24, 2020","April 7, 2020","April 10, 2020","April 13, 2020","April 10, 2020","March 31, 2020","April 2, 2020","April 15, 2020","April 14, 2020","April 15, 2020","April 3, 2020","April 15, 2020","April 9, 2020","April 15, 2020","April 14, 2020","April 8, 2020","April 8, 2020","April 10, 2020","April 10, 2020","April 13, 2020","March 3, 2020","April 15, 2020","March 30, 2020","April 13, 2020","April 10, 2020","April 15, 2020","April 1, 2020","March 20, 2020","April 15, 2020","April 13, 2020","April 9, 2020","March 31, 2020","April 14, 2020","April 13, 2020","April 15, 2020","April 10, 2020","April 10, 2020","April 8, 2020","April 15, 2020","April 14, 2020","April 14, 2020","April 14, 2020","April 1, 2020","April 14, 2020","February 7, 2020","March 19, 2020","April 7, 2020","April 1, 2020","April 15, 2020","April 6, 2020","April 6, 2020","April 14, 2020","April 10, 2020","April 16, 2020","April 13, 2020","April 14, 2020","April 15, 2020","April 14, 2020","March 24, 2020","April 13, 2020","April 14, 2020","April 15, 2020","April 14, 2020","April 13, 2020","March 30, 2020","April 13, 2020","April 13, 2020","March 31, 2020","April 15, 2020","March 25, 2020","April 8, 2020","April 14, 2020","March 13, 2020","March 27, 2020","April 7, 2020","April 7, 2020","April 13, 2020","April 15, 2020","April 9, 2020","April 8, 2020","April 16, 2020","April 14, 2020","March 26, 2020","April 7, 2020","April 14, 2020","April 10, 2020","April 14, 2020","April 8, 2020","April 16, 2020","April 15, 2020","March 17, 2020","April 15, 2020","February 21, 2020","February 24, 2020","April 14, 2020","April 14, 2020","March 3, 2020","April 9, 2020","February 17, 2020","February 10, 2020","April 8, 2020","March 31, 2020","April 10, 2020","March 24, 2020","March 10, 2020","April 13, 2020","April 15, 2020","February 19, 2020","April 10, 2020","April 16, 2020","April 10, 2020","March 31, 2020","April 7, 2020","April 9, 2020","February 5, 2020","February 24, 2020","April 14, 2020","February 17, 2020","February 5, 2020","February 7, 2020","February 19, 2020","March 17, 2020","March 26, 2020","April 13, 2020","April 10, 2020","April 6, 2020","April 15, 2020","March 24, 2020","April 8, 2020","April 10, 2020","March 19, 2020","April 6, 2020","March 27, 2020","April 15, 2020","April 7, 2020","April 3, 2020","April 15, 2020","April 15, 2020","March 24, 2020","April 10, 2020","March 30, 2020","April 15, 2020","April 8, 2020","February 11, 2020","April 8, 2020","April 15, 2020","April 14, 2020","April 15, 2020","February 25, 2020"],["Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of","Asst Fatebenefratelli Sacco, Milano, Italy","University Malaya Medical Centre, Kuala Lumpur, Malaysia","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom",null,"Ochsner Medical Center, New Orleans, Louisiana, United States","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of","Charing Cross Hospital, London, United Kingdom",null,"First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States",null,"University of Kansas Medical Center, Kansas City, Kansas, United States","University Amsterdam, Amsterdam, Netherlands|University Amsterdam, Amsterdam, Netherlands|University Maastricht, Maastricht, Netherlands",null,"Hackensack University Medical Center, Hackensack, New Jersey, United States","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada","Catherine Klersy, Pavia, PV, Italy","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",null,"Hao Li, Beijing, Beijing, China","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China","Huai'an fourth people's Hospital, Huaian, Jiangsu, China","GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",null,"Chongqing Public Health Medical Center, Chongqing, China",null,"University of Colorado, Denver, Aurora, Colorado, United States","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","Beijing 302 Military Hospital of China, Beijing, China","IRCCS INRCA Hospital, Ancona, Italy","Azienda Ospedaliera \"SS. Antonio e Biagio e C. Arrigo\" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialit Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialit Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",null,"All French Emergency services, Le Mans, France",null,null,"University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Royal Jubilee Hospital, Victoria, British Columbia, Canada|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Centre, Winnipeg, Manitoba, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Jospeh's Healthcare Hamtilon, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Thunder Bay Regional Health Sciences Centre - Cancer Centre, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health Toronto, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Hpital de la Cit-de-la-Sant, Laval, Quebec, Canada|Hpital Maisonneuve-Rosemont, Montral, Quebec, Canada|Centre hospitalier de l'Universit de Montral, Montral, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montral, Quebec, Canada|Jewish General Hospital, Montral, Quebec, Canada|McGill University Health Centre, Montral, Quebec, Canada|Hpital du Sacr-Coeur de Montreal, Montral, Quebec, Canada|Centre hospitalier universitaire de Qubec, Quebec City, Quebec, Canada|Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre hospitalier affili universitaire rgional de Trois-Rivires, Trois-Rivires, Quebec, Canada","Duke University Medial Center, Durham, North Carolina, United States","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","CHU d'Angers, Angers, France|AP-HP - Hpital Bichat, Paris, France|CHU de Saint-Etienne, Saint-tienne, France",null,null,"Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Facility 2, Manhasset, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States","Beat COIVD, LLC, Chicago, Illinois, United States","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|University Hospital Ghent, Gent, Belgium|University Hospital Brussels, Jette, Belgium|University Hospital Lige, Lige, Belgium","Duke University, Durham, North Carolina, United States","Pentagon, Arlington, Virginia, United States","NYU Winthrop Hospital, Mineola, New York, United States","Department and Institute of Infectious Disease, Wuhan, Hubei, China","AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium","Rigshospitalet, Copenhagen, Denmark","Cedars-Sinai Medical Center, Los Angeles, California, United States",null,"Institute for Tropical Medicine, Tbingen, Germany","ProgenaBiome, Ventura, California, United States","Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark",null,"University of Pennsylvania, Philadelphia, Pennsylvania, United States","Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada|St Paul's Hospital, Vancouver, British Columbia, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|McGill University Health Centre-Glen Site Royal Victoria Hospital, Montral, Quebec, Canada|CHU de Qubec - Universit Laval, Qubec, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Qubec- Universit Laval, Qubec, Quebec, Canada|Centre Intgr Universitaire de Sant et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada","IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy",null,"Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong","Departament de Salut, Barcelona, Spain","Assiut University Hospitals, Assiut, Egypt","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States","Hospital San Jos, Monterrey, Nuevo Leon, Mexico","Medizinische Universitt Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universitt Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjllands Hospital, Hillerd, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universittsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universitt Mnchen, Mnchen, Germany","Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States","University of Chicago Medicine, Chicago, Illinois, United States","Baylor University Medical Center, Dallas, Texas, United States","University Medical Center New Orleans, New Orleans, Louisiana, United States","University Medical Center Hamburg-Eppendorf, Hamburg, Germany",null,"ProgenaBiome, Ventura, California, United States","NYU Langone Health, New York, New York, United States","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of","Queen's Medical Center, Honolulu, Hawaii, United States",null,"Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States","ISGlobal, Barcelona, Spain","Virginia Commonwealth University, Richmond, Virginia, United States","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",null,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland, 2425 Geary Blvd, San Francisco, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals &amp; Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham &amp; Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, 270-05 76th Ave, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|CHU de BORDEAUX, Bordeaux, France|Chu Montpellier, Montpelier Cedex 5, France|CHU de Nantes, Nantes, France|Saint Louis hospital, Paris, France|Hopital Saint Antoine, Paris, France|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Dsseldorf, WA, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universittsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik fr Hmatologie, Onkologie, Immunologie, Mnchen, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcal De Henares, Madrid, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramn y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Mlaga, Mlaga, Spain|Hopitaux Universitaires de Genve, Genve 14, Switzerland|Ospedale Regionale di Locarno La Carit, Lugano, Switzerland|Universittsspital Zrich, Zrich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester Royal, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",null,"Vaccine Evaluation Center, BC Children's Research Institute, University of British Columbia., Vancouver, British Columbia, Canada|Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada","Centro de Genomas, So Paulo, Brazil|Hospital Emlio Ribas, So Paulo, Brazil","New York University School of Medicine, New York, New York, United States",null,"Stanford Health Care, Stanford, California, United States","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente-Oakland/San Francisco, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals &amp; Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham &amp; Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UTSW Medical Center, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU de BORDEAUX, Bordeaux, France|Chu Montpellier, Montpelier Cedex 5, France|CHU de Nantes, Nantes, France|Saint Louis hospital, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Dsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universittsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik fr Hmatologie, Onkologie, Immunologie, Mnchen, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City Easter Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcal De Henares, Madrid, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramn y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Mlaga, Mlaga, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genve, Genve 14, Switzerland|Ospedale Regionale di Locarno La Carit, Lugano, Switzerland|Universittsspital Zrich, Zrich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|Manchester Royal, Manchester, M13 9wl, United Kingdom|Royal infirmary edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",null,"Hospital Clnico Universitario Lozano Blesa, Zaragoza, Aragn, Spain|Hospital Universitario Severo Ochoa, Legans, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Prncipe de Asturias, Meco, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Maran, Madrid, Spain|Hospital Universitario Ramn y Cajal, Madrid, Spain|Hospital Clnico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain",null,"University Hospital Cologne, Cologne, NRW, Germany","Uh Montpellier, Montpellier, France","Universittsklinikum Ulm, Ulm, Germany|Klinikum Altmhlfranken, Weienburg, Germany|Municipal Clinical Emergency Hospital of Timisoara, Timisoara, Romania",null,"Centre Hospitalier intercommunal de Creteil, Creteil, France|Assistance Publique Hpitaux de Paris, Paris, France","Xinqiao Hospital of Chongqing, Chongqing, China","Stem Cells Arabia, Amman, Jordan","Ospedale di Guastalla, Guastalla, RE, Italy|Azienda Unit Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|ASST Cremona, Cremona, Italy|Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy|Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Ospedale Evangelico Internazionale di Genova, Genova, Italy|Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy|Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|IRCCS Istituto Auxologico Italiano Milano, Milano, Italy|Azienda Ospedaliero-Universitaria \"Maggiore della Carit\" di Novara, Novara, Italy|Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy|Azienda Ospedaliero-Universitaria Parma, Parma, Italy|Azienda Unit Sanitaria Locale di Piacenza, Piacenza, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|AO Ordine Mauriziano di Torino, Torino, Italy|ASST Bergamo Ovest -Treviglio, Treviglio, Italy|AULSS 2 Marca Trevigiana, Treviso, Italy|AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy|AULSS 3 Serenissima Ospedale \"Dell'Angelo\", Venezia, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy|IRCCS Sacro Cuore Don Calabria, Verona, Italy","Hospital Clnic de Barcelona, Barcelona, Spain","Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of","Hospital Vera Cruz, Campina Grande, So Paulo, Brazil","Qilu Hospital of Shandong University, Jinan, Shandong, China","Tetrandrine Tablets, Jinhua, Zhejiang, China","Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|New York University Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Baylor University Medical Center; Valdez/ Rhone, Dallas, Texas, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|McMaster University Medical Centre, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjllands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany|Uniklinik Kln, Kln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",null,null,null,"Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","Institute for Tropical Medicine, Tbingen, Germany","Uhmontpellier, Montpellier, France",null,"University of Alabama at Birmingham, Birmingham, Alabama, United States","CHU Brugmann, Brussels, Belgium","Perseverance Research Center, Scottsdale, Arizona, United States","San Carlos Hospital, Bogota, Cundinamarca, Colombia","Oslo University Hospital, Oslo, Norway","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands","Postgraduate Institute of Medical Education and Research, Chandigarh, India",null,"ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clnic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundacin Jimnez Daz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clnico Universitario, Valladolid, Spain|Anesthesia, Hospital Universitario Ro Hortega, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Ro Hortega, Valladolid, Spain",null,"Wan-Jin Chen, Fuzhou, China",null,"Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China",null,"Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China","Hankou Hospital, Hankou, Hubei, China",null,"University of California San Francisco, San Francisco, California, United States",null,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","Charit-Universittsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany","SMIT, Saint Antoine hospital, Paris, France","Grupo Cooperativo de Hemopatas Malignas, Huixquilucan, Estado De Mxico, Mexico","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain","Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands","OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Oschner Medical Center, New Orleans, Louisiana, United States",null,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States","Jin Yin-tan hospital, Wuhan, Hubei, China","Angers University Hospital, Angers, France",null,null,"National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam","Ospedale San Salvatore, L'Aquila, Italy",null,"Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States",null,"Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States","AssiutU, Assiut, Egypt",null,null,"Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China","Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain","AssiutU, Assiut, Egypt","Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand",null,null,"Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",null,"Huoshenshan Hostipal, Wuhan, Hubei, China","The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China","Rabin Medical Center, Petah tikva, Israel","Uhmontpellier, Montpellier, France","UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italy","Sainte Anne Military Teaching Hospital, Toulon, France",null,"Massachusetts General Hospital, Boston, Massachusetts, United States","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States","Hospital Quirnsalud Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Ruber Juan Bravo, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Arnau de Vilanova-Lliria, Valencia, Spain|Hospital Universitario Doctor Peset, Valencia, Spain","Hubei province hospital of integrated Chinese &amp; Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China","Vanderblt University Medical Center, Nashville, Tennessee, United States","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States","Massachusetts General Hospital, Boston, Massachusetts, United States",null,null,"The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",null,"University Hospital Tuebingen, Tuebingen, Germany","Princess Margaret Cancer Centre, Toronto, Ontario, Canada","Columbia University Irving Medical Center, New York, New York, United States","Hopital Bichat - Aphp, Paris, France",null,"Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain","Ayub Teaching Institution, Abbottbd, K.p.k, Pakistan","Prevent Senior Private Operadora de Sade LTDA., So Paulo, Brazil","Duke University Medical Center, Durham, North Carolina, United States","Ziekenhuis Oost Limburg, Genk, Limburg, Belgium","Pinar Yalcin Bahat, Istanbul, stanbul, Turkey","Mahmoud Tantawy, Cairo, Egypt","Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clnicas, School of Medicine, USP, So Paulo, SP, Brazil","Beaumont Health System, Royal Oak, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States",null,"Ranimation hpital Louis Mourier, Colombes, Hauts De Seine, France|ranimation hpital Cochin, Paris, France|Mdecine vasculaire, Hpital Europen Georges Pompidou, Paris, France",null,null,"BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",null,"University College Hospital, Ibadan, Oyo, Nigeria|Shifa Tameer-e-Millat University, Rawalpindi, Pakistan",null,"Hpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France","Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain","Hospital Lclinico San Carlos, Madrid, Spain","Centre Lon Brard, Lyon, Rhne, France",null,"AP-HP Hpital Europen George Pompidou, Paris, France|AP-HP Hpital Lariboisire, Paris, France|AP-HP Hpital Piti Salptrire, Paris, France|AP-HP Hpital Saint Antoine, Paris, France","Divine Providence Hospital \"Pammakaristos\", Athens, Greece|Athens General Hospital \"Hippokrateio\", Athens, Greece|Athens General Hospital of Thoracic Diseases \"SOTIRIA\", 1st University Pulmonary Clinic, Athens, Greece|Athens General Hospital of Thoracic Diseases \"SOTIRIA\", 3rd University Pathology Clinic, Athens, Greece|General Hospital of Athens \"Sismanoglio\", Marosi, Greece","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China","Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",null,"University Medical Center Goettingen, Gttingen, Germany","John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia|Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia|king Fahad specialist hospital, Dammam, Saudi Arabia|DHahran Military Medical Complex, Dhahran, Saudi Arabia|Taibah University, Madinah, Saudi Arabia|Qatif Central Hospital, Qatif, Saudi Arabia|King Abdulaziz Medical City, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|King Faisal Specialist Hospital &amp; Research Center, Riyadh, Saudi Arabia|King Khalid University Hospital, Riyadh, Saudi Arabia","Pneumologie hpital Tenon, Paris, France","Attikon University General Hospital, Haidari/Athens, Greece","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China","The LEAD Study Center, Vienna, Austria","Hospital General Universitario Morales Meseguer, Murcia, Spain","University Hospital Jena, Jena, Germany",null,"University of Alabama at Birmingham, Birmingham, Alabama, United States",null,"Bin Cao, Beijing, Beijing, China",null,null,null,"Selfapy GmbH, Berlin, Germany","Intensive care department-Hospital Tenon, Paris, France",null,"Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|University Hospital Zurich, Zurich, Switzerland","Spanish Society for Angiology and Vascular Surgery, Madrid, Spain",null,"Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China","Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn, Ciudad de Mxico, Tlalpan, Mexico","FHHI-OI-Camelot; QME, Los Angeles, California, United States","Fondation Adolphe de Rothschild, Paris, France","Guido Beldi, Bern, Switzerland","NYU Langone Health, New York, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","University of Missouri-Columbia, Columbia, Missouri, United States","Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States","A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy","ASST - Papa Giovanni XXIII, Bergamo, Italy","Hopital Piti Salpetrire, Paris, France","Columbia University Irving Medical Center/NYP, New York, New York, United States","Gustave Roussy, Villejuif, Val De Marne, France","Hankou Hospital, Wuhan, Hubei, China","Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevires-sur-Marne, France|Cabinet du Dr Corrard, Combs-la-Ville, France|53 Boulevard De La Libert, Les Lilas, France|157 Avenue du Gnral Leclerc, Maisons-Alfort, France|Cabinet du Dr Bodin, Montgeron, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|Cabinet du Dr D'acremont, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|Cabinet du Dr Michot, Paris, France|Cabinet du Dr Cohen, Saint-Maur-des-Fosss, France|Cabinet de Pdiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beausjour, Vincennes, France","Instituto Nacional de Ciencias Mdicas y Nutricin Salvador Zubirn, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico","University Hospitals of Geneva, Geneva, Switzerland","H. Universitario Quirn Dexeus, Barcelona, Spain|H.U. Puerta de Hierro, Madrid, Spain",null,"Clinical Investigation Center Piti-Salptrire, Paris, France","Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department &amp; Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States",null,"Uh Montpellier, Montpellier, France","University Hospital Galway, Galway, Ireland","University Hospital, Limoges, France","Spedali Civili di Brescia, Brescia, Italy","Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark|Hpitaux de Paris, Hpital Saint-Antoine, service de ranimation mdicale, Paris, France|INSERM, UMR_S 1136, Institut Pierre Louis d'Epidmiologie et de Sant Publique, Paris, France|Sorbonne Universits, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidmiologie et de Sant Publique, Paris, France|Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany|Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway|Department of Clinical Medecine,University of Bergen, Bergen, Norway","Washington University School of Medicine, Saint Louis, Missouri, United States|Melbourne Medical School, Melbourne, Victoria, Australia|Population Health Resarch Institute, Hamilton, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|St James's Hospital, Dublin, Leinster, Ireland|Universitas Academic Hospital, Bloemfontein, Free State, South Africa|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa|Tygerberg Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|University College London, London, United Kingdom|Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia","Epworth Victoria Parade, Melbourne, Victoria, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Epworth Eastern, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia",null,null,"Houston Methodist Hospital, Houston, Texas, United States","Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States",null,"Hpital Bichat - Service de Pneumologie, Paris, France","2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ionnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, \"Latsio\", Thriasio Elefsis General Hospital, Elefsna, Greece|Intensive Care Unit, \"Koutlimbaneio &amp; Triantafylleio\" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China","CHU Amiens-Picardie, Amiens, France|CHU Franois Mitterand, Dijon, France|CHU Limoges, Limoges, France|Hpital de la Croix Rousse, Lyon, France|Hpitaux de Brabois, Nancy, France|CHR Orlans, Orlans, France|Institut Pasteur, Paris, France|CHU Poitiers, Poitiers, France|Hpital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-tienne, France|CH de Tourcoing, Tourcoing, France|Hpital Bretonneau, Tours, France",null,"Pinar Yalcin Bahat, Istanbul, stanbul, Turkey","Consorci Sanitari del Maresme (Hospital de Matar), Matar, Barcelona, Spain","Duke Clinical Research Institute, Durham, North Carolina, United States",null,null,"The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",null,"The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",null,null,"Huashan Hospital of Fudan University, Shanghai, Shanghai, China","Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China",null,null,"Geneva University Hospitals, Geneva, Switzerland","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States","Pinar Yalcin Bahat, Istanbul, stanbul, Turkey",null,null,"Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China",null,"Galway University Hospital, Galway, Ireland","Columbia University Irving Medical Center, New York, New York, United States","Bassett Medical Center, Cooperstown, New York, United States","Centre Hospitalier d'Argenteuil, Argenteuil, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre Hospitalier Universitaire Ambroise Par, Boulogne, France|Centre Hospitalier Rgional Universitaire de Brest, Brest, France|Centre Hospitalier de Brives, Brive-la-Gaillarde, France|Centre Hospitalier Universitaire Beaujon, Clichy, France|Centre Hospitalier Universitaire Louis Mourier, Colombes, France|Centre hospitalier de Dieppe, Dieppe, France|Centre Hospitalier Universitaire de Dijon, Dijon, France|Centre Hospitalier d'Etampes, Etampes, France|Grand Hpital de l'Est Francilien - Site de Marne-la-Valle, Jossigny, France|Centre Hospitalier de la Roche-sur-Yon, La Roche-sur-Yon, France|Centre Hospitalier de La Rochelle, La Rochelle, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire Hpital Edouard Herriot, Lyon, France|Hpital priv Jacques Cartier, Massy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalier Rgional d'Orlans, Orlans, France|Centre Hospitalier Universitaire Cochin, Paris, France|Groupe hospitalier Paris Saint-Joseph, Paris, France|Hpital Fondation Adolphe de Rothschild, Paris, France|Hopital Priv Claude Galien, Quincy-sous-Snart, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Centre Hospitalier de Roanne, Roanne, France|Hopital Foch, Suresnes, France|Centre Hospitalier de Toulon, Toulon, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Tours, Tours, France|Gustave-Roussy, Villejuif, France","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",null,"The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China","Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China",null,"Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China","ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensit di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy","Johns Hopkins Hospital, Baltimore, Maryland, United States","Wake Forest Health Sciences, Winston-Salem, North Carolina, United States","University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States","Community Medical Centers, Fresno, California, United States|MemorialCare Medical Group Long Beach, Long Beach, California, United States|Huntington Hospital, Pasadena, California, United States|California Pacific Medical Center, San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|San Mateo County Medical Center Foundation, San Mateo, California, United States|PIH Health Whittier Hospital, Whittier, California, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Sarasota Memorial Hospital Clinical Research Center, Sarasota, Florida, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|St. Joseph Mercy Hospital Health System, Ann Arbor, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|CentraState Medical Center, Freehold, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|St. Michael's Medical Center, Newark, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Virtua Voorhees, Voorhees, New Jersey, United States|Maimonides Medical Center, Brooklyn, New York, United States|New York Presbyterian Hospital, Flushing, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Ellis Hospital, Schenectady, New York, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|Hpitaux Civils de Colmar, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|Hpital Raymond Poincar, Garches, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Universitatsklinikum Regensburg, Regensburg, Germany|Klinikum Wrzburg Mitte, Wrzburg, Germany|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Ospedaliero Universitaria, Bologna, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|University Hospital Basel, Basel, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland|University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom|Southampton University Hospital, Southampton, United Kingdom",null,"Portland Providence Medical Center, Portland, Oregon, United States",null,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States",null,"CHG de Chambery, Chambry, France|Centre Hospitalier Intercommunal de Crteil, Crteil, France|CHU de Limoges, Limoges, France|APHM - Hopital Nord, Marseille, France|CHU de Nancy, Nancy, France|Hopital priv de la Loire, Saint-tienne, France|CHU de Tours, Tours, France","Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States","Medical University of Graz, Graz, Styria, Austria","Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China","Beijing Children's Hospital,, Beijing, China","Neuroganics, Northglenn, Colorado, United States","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States","University of Chicago Medicine, Chicago, Illinois, United States","Beaumont Health, Royal Oak, Michigan, United States","University Clinic Freiburg, Freiburg, Germany","Istanbul University - Cerrahpaa, Istanbul, Turkey",null,"Montefiore Medical Center, Bronx, New York, United States",null,"NIHR WTCRF, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",null,"Hpital GHU Paris Saclay, Boulogne-Billancourt, France|Hpital Saint Antoine, Paris, France|Hpital Broca, Paris, France|Hpital La Piti-Salptrire, Paris, France|Hpital Cochin, Paris, France|Hpital europen Georges Pompidou, Paris, France|Hpital Necker, Paris, France","Montefiore Medical Center, Bronx, New York, United States","Service de Mdecine Intensive Ranimation CHU Gabriel Montpied, Clermont-Ferrand, France|Service de Mdecine Intensive Ranimation Hpital Michallon - CHU Grenoble Alpes, La Tronche, France|Service de Mdecine Intensive Ranimation Hpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Ranimation Chirurgicale Hpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Mdecine Intensive Ranimation Hpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de Ranimation Chirurgicale Hpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de ranimation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France|Service de Ranimation Clinique de la Sauvegarde, Lyon, France|Service de Ranimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bnite, France|Service de Ranimation Centre hospitalier Annecy Genevois, Pringy, France|Service de Mdecine Intensive Ranimation Hpital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, France",null,"Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerd, Hillerd, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, Kbenhavn, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark","Universidad del Rosario, Bogota, Cundinamarca, Colombia","University Medical Center Utrecht, Utrecht, Netherlands",null,null,null,null,null,"Hospital Universitario Ramn y Cajal, Madrid, Spain","IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy",null,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States","Universidad del Rosario, Bogota, Cundinamarca, Colombia",null,"Tongji Hospital, Wuhan, Hubei, China",null,"Henan Provincial People's Hospital, Zhengzhou, Henan, China","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States","University of California, San Francisco, San Francisco, California, United States","U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Universit degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Iai, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom","CHRU Lille, Lille, France|CHU Nantes, Nantes, France|APHP - Bichat Claude Bernard, Paris, France","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States","CH Esquirol, Limoges, France|CHU de Limoges, Limoges, France",null,null,"Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France","Department and Institute of Infectious Disease, Wuhan, Hubei, China","Department and Institute of Infectious Disease, Wuhan, Hubei, China","CHU Nimes, Nmes, France","Fondation Adolphe de Rothschild, Paris, France","University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy","Centre Hospitalier Rgional Universitaire de Nancy, Nancy, France","Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy","University of Miami, Miami, Florida, United States","Brigham and Women's Hospital, Boston, Massachusetts, United States","Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy","Department and Institute of Infectious Disease, Wuhan, Hubei, China","University of Utah, Salt Lake City, Utah, United States","Ospedali Riuniti di Ancona, Ancona, Marche, Italy","Cardiologie, Groupe Hospitalier Piti-Salptrire, Paris, France","Unit' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy","Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Rambam Health Care Campus, Haifa, Israel","Andreas Barratt-Due, Oslo, Norway","Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of","Centre Hospitalier Andre Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana","Department and Institute of Infectious Disease, Wuhan, Hubei, China","St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Universit de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Poega, Poega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charit - Universittsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charit - Universittsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neuklln, Berlin, Germany|Universittsklinikum Kln, Cologne, Germany|Universittsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universittsklinikum Jena, Jena, Germany|Universittsklinikum Leipzig, Leipzig, Germany|Universitts Klinikum Tbingen, Tbingen, Germany|Universittsklinikum Wrzburg, Wrzburg, Germany|Jsa Andrs County Hospital, Nyregyhza, Hungary|Csolnoky Ferenc Krhz - Veszprem County Hospital, Veszprm, Hungary|Almsi Balogh Pl Krhz, zd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases \"Dr. Victor Babes\", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Crdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom","Trinity Health Of New England, Hartford, Connecticut, United States","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","National Institute of Rehabilitation, Mexico City, Cdmx, Mexico","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",null,"Belfast Health and Social Care Trust, Royal Hospitals, Belfast, Northern Ireland, United Kingdom","Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China","Prince of Wales Hospital, Sha Tin, Hong Kong",null,"Massachusetts General Hospital, Boston, Massachusetts, United States","Hamilton Health Sciences, Hamilton, Ontario, Canada",null,"Fabrizio Cantini, Prato, Tuscany, Italy","Hpital Piti-Salptrire - APHP, Paris, France|Hpital Europen Georges Pompidou - APHP, Paris, France","Hospital Universitario Madrid Sanchinarro, Madrid, Spain",null,null,null,"Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania","Mayo Hospital, Kingedward Medical University, Lahore, Punjab, Pakistan",null,"Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",null,"National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Braslia, Distrito Federal, Brazil|Fundao Social Rural de Colatina, Colatina, Esorito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poos De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paran, Brazil|Eurolatino Natal Pesquisas Mdicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Cricima, Santa Catarina, Brazil|Fundao Pio XII, Barretos, So Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, So Paulo, Brazil|Associacao Beneficente Siria, So Paulo, Brazil|Hospital das Clnicas da Faculdade de Medicina de Ribeiro Preto da USP - HCFMRP, So Paulo, Brazil|Hospital Israelita Albert Einstein, So Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, So Paulo, Brazil|Real e Benemrita Associao Portuguesa de Beneficncia/SP, So Paulo, Brazil|Santa Casa de Misericrdia, So Paulo, Brazil|Secretaria de Sade do Estado de So Paulo, So Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Srio-Libans, So Paulo, Brazil|Universidade Federal de So Paulo, So Paulo, Brazil","Shuguang Hospital, Shanghai, Shanghai, China","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health Sciences Center, College of Public Health- Epidemiology, Gainesville, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universittsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Coso Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom","Wuhan third hospital, Wuhan, Hubei, China","Montpellier University hospital, Montpellier, France","Henry Ford Hospital, Detroit, Michigan, United States|Regions Hospital, Saint Paul, Minnesota, United States",null,"Hospital de Clnicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil","Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada","Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy","Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom","Marco Confalonieri, Trieste, TS, Italy","Aalborg University Hospital, Aalborg, Denmark","Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik fr Herzchirurgie, Ludwigshafen, RLP, Germany",null,null,"University Hospital Gent, Gent, Belgium",null,"Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","BEAT19.org, San Francisco, California, United States","Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States","Department of anesthesia and intensive care, Fattouma Bourguiba Hospital, Monastir, Tunisia","Chu Nantes, Nantes, France","The central hospital of Wuhan, Wuhan, Hubei, China","TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States","CHU de Nice, Nice, France|Hpitaux Universitaires Paris Centre - Hpital Cochin, Paris, France",null,null,null,"Tor Vergata Hospital, Rome, Italy","Wefight, Montpellier, France","Mayo Clinic Florida, Jacksonville, Florida, United States","Guangzhou Blood Center, Guangzhou, Guangdong, China","Yun Long, Beijing, Beijing, China","ASSISTANCE PUBLIQUE HPITAUX de MARSEILLE, Marseille, France",null,null,"Oslo University Hospital, Oslo, Norway",null,"Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 2501001, Bordeaux Cedex, France","U.O.C. Chirurgia Generale Universitaria \"V. Bonomo\", Bari, Italy|Ospedale Perrino Asl Brindisi, Brindisi, Italy|Dipartimento di scienze mediche e chirurgiche, Universit di Catanzaro, Catanzaro, Italy|Ospedale Policlinico San Martino, Genova, Italy|Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy|IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale Cristo re, Roma, Italy","Cliniques universitaires Saint-Luc, Brussels, Brussels Capital, Belgium",null,null,"Taihe Hospital, Shiyan, Hubei, China","Brigham and Women's Hospital, Boston, Massachusetts, United States","Flevoziekenhuis, Almere, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre hospitals, Apeldoorn, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Hospital, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Haga Hospital, Den Haag, Netherlands|Medical Center Haaglanden, Den Haag, Netherlands|Gelderse Vallei Hospital, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medical Center, Eindhoven, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Dijklander Ziekenhuis, Hoorn, Netherlands|Medical Centre Leeuwarden, Leeuwarden, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Zuyderland Medical Centre, Sittard, Netherlands|UMC Utrecht, Utrecht, Netherlands","Gabriele Saccone, Napoli, Italy",null,"Herlev Hospital, Herlev, Region Hovedstaden, Denmark|Bispebjerg Hospital, Kbenhavn NV, Region Hovedstaden, Denmark|Psykiatrisk Center Ballerup, Ballerup, Denmark|Psykiatrisk Center Kbenhavn, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Psykiatrisk Center Amager, Copenhagen, Denmark|Psykiatrisk Center Stolpegaard, Gentofte, Denmark|Brne- og Ungdomspsykiatrisk Center, Glostrup, Denmark|Psykiatrisk Center Glostrup, Glostrup, Denmark|Nordsjaellands Hospital, Hillerd, Denmark|Psykiatrisk Center Nordsjlland, Hillerd, Denmark|Psykiatrisk Center Sankt Hans, Roskilde, Denmark|Bornholms Hospital, Rnne, Denmark|Psykiatrisk Center Bornholm, Rnne, Denmark","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","Royal Belfast Hospital for Sick Children, Belfast, United Kingdom","Uppsala University Hospital, Uppsala, Sweden","Angers University Hospital, Angers, France",null,"Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China",null,"Royal National Orthopaedic Hospital, Stanmore, United Kingdom","Materno-Perinatal Hospital \"Mnica Pretelini\", Toluca, Mexico","Universit Politecnica delle Marche, Ancona, AN, Italy","Children's Hospital Colorado, Aurora, Colorado, United States","Shanghai 10th People's Hospital, Shanghai, Shanghai, China","City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health &amp; Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India","Everett Clinic, Seattle, Washington, United States","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India","Rush University Medical Center, Chicago, Illinois, United States|Medical College of Wisconsin, Wauwatosa, Wisconsin, United States",null,"Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain","Stanford University, Stanford, California, United States","Stony Brook University Hospital, Stony Brook, New York, United States","CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|APHP Henri Mondor, Crteil, France|CHU Dijon, Dijon, France|CHD Vende, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hpital Priv du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orlans, Orlans, France|APHP Saint-Antoine, Paris, France|La Piti-Salptrire, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-tienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco",null,"Istinye University Medical School, Istanbul, Turkey","Department of Neuro- Urology, Hpital Tenon, Paris, France","Everett Clinic, Seattle, Washington, United States","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China","School of public health and primary care, Hong Kong, Hong Kong",null,"Hospital Geral Clriston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitria Da Conquista, BA, Brazil|Hospital Geral de Vitria da Conquista, Vitria Da Conquista, BA, Brazil|Hospital de Braslia, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Braslia, DF, Brazil|Hospital Maternidade So Jos - UNESC - Fundao Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericrdia de So Joo Del Rei, So Joo Del Rei, MG, Brazil|Associao Evanglica Beneficente de Londrina - Hospital Evanglico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Crebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital So Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital So Jos, Criciuma, SC, Brazil|Hospital Baa Sul - Baa Sul Medical Center, Florianpolis, SC, Brazil|Hospital Nereu Ramos, Florianpolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundao PIO XII), Barretos, SP, Brazil|Casa de Sade Santa Marcelina, So Paulo, SP, Brazil|Hospital Albert Einstein, So Paulo, SP, Brazil|Hospital Beneficncia Portuguesa - Real e Benemrita Associao Portuguesa de Beneficncia, So Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemrita, So Paulo, SP, Brazil|Hospital das Clnicas da FMUSP, So Paulo, SP, Brazil|Hospital do Servidor Pblico Estadual - HSPE - IAMSPE, So Paulo, SP, Brazil|Hospital So Paulo - UNIFESP, So Paulo, SP, Brazil|Hospital Srio-Libans, So Paulo, SP, Brazil|Hospital SEPACO, So Paulo, S, Brazil","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",null,"Kremlin Bictre APHP, Le Kremlin-Bictre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France","University of Naples Federico II, Napoli, Italy","IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy|ASST HPG23 - Unit of Nephrology, Bergamo, Italy|ASST Papa Giovanni XXIII - Microbiology and Virology Unit, Bergamo, Italy|Asst Pg23 - S.I.M.T, Bergamo, Italy|ASST-PG23 - Intensive Care Unit, Bergamo, Italy","Wenzhou Medical University, Wenzhou, Zhejiang, China|The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",null,"Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States","Fundacion Salud De Los Andes, Bogot, Bogot Distrito Capital, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia","Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjllands Hospital, Hillerd, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation","2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark","Saint-Louis Hospital, Paris, Ile De France, France","Peking University Third Hospital, Beijing, China","Kremlin Bicetre hospital APHP, Le Kremlin-Bictre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France","CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Lille, Lille, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France","dr. Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Arhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Herning Hospital, Herning, Denmark|Nordsjllands Hospital, Hillerd, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Vejle Hospital, Vejle, Denmark","Instituto de Cardiologia do Distrito Federal, Braslia, Distrito Federal, Brazil|Fundao Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poos De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paran, Brazil|Hospital Universitrio Onofre Lopes, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Cricima, Santa Catarina, Brazil|Fundao Pio XII, Barretos, So Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, So Paulo, Brazil|Hospital Israelita Albert Einstein, So Paulo, Brazil|AMICO Saude LTDA, So Paulo, Brazil|Associacao Beneficente Siria, So Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, So Paulo, Brazil|Real e Benemrita Associao Portuguesa de Beneficncia/SP, So Paulo, Brazil|Real e Benemrita Associao Portuguesa de Beneficncia/SP, So Paulo, Brazil|Santa Casa de Misericrdia, So Paulo, Brazil|Secretaria de Sade do Estado de So Paulo, So Paulo, Brazil|Serv Social da Industria do papel, papelo e cortia do estado de SP, So Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Srio-Libans, So Paulo, Brazil|Universidade Federal de So Paulo, So Paulo, Brazil","Unit de Soins Intensifs de Cardiologie, Piti Salptrire Hospital, AP-HP, Paris, France",null,null,null,"University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada","Department of nephrology, Klinikum rechts der Isar, Mnchen, Bavaria, Germany",null,"Hpital Roger Salengro, ICU, CHU Lille, Lille, France","Tanta University, Tanta, Egypt","Karolinska Institutet, Stockholm, Sweden","Istanbul university Cerrahpasa, Istanbul, Turkey","Duke University Medical Center, Durham, North Carolina, United States","Aarogyam, Leicester, United Kingdom",null,"CHU Nantes, Nantes, France",null,"Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States","CHU de Lille, Lille, France|APHM, Marseille, France|CHU de Massy, Massy, France|APHP - Bichat, Paris, France|Aphp - Hegp, Paris, France|IMM, Paris, France|CHU de Rouen, Rouen, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|CHU de Nancy, Vanduvre-ls-Nancy, France","Ophtalmology Clinic, G.d'Annunzio University, Chieti, Italy","The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China","Service Hygine, Epidmiologie et Prvention, Lyon, France|Service Hygine, Epidmiologie et Prvention, Lyon, France",null,"Service de Chirurgie Thoracique Nouvel Hpital Civil Hpitaux Universitaires de Strasbourg, Strasbourg, France","Luca Gallelli, Catanzaro, Italy","Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Universit Vita-Salute San Raffaele, Milano, Mi, Italy","Istanbul University-Cerrahpaa, Istanbul, Turkey","Changhai Hospital, Shanghai, China",null,null,"University Hospital, Clermont-Ferrand, Clermont-Ferrand, France","Luca Gallelli, Catanzaro, Italy","University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerd Hospital, Hillerd, Denmark","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy","Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia","Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","Bicetre Hospital, Paris, Val-de-Marne, France",null,"Tanta university hospital, Tanta, Egypt",null,"CH Louis MOURIER, Colombes, France|Hpital Mre Enfant CHU, Nantes, France|Hpitaux Pdiatriques de Nice CHU-Lenval, Nice, France|Hpital des enfants - CHU, Toulouse, France|CHU de Tours, Tours, France","CHU de Nice, Nice, France",null,"CHI Aix-Pertuis, Aix-en-Provence, France","Sheba Medical Center, Ramat Gan, Israel","Columbia University Irving Medical Center/NYP, New York, New York, United States","University Hospital Essen, Essen, NRW, Germany","Yale-NUS College, Singapore, Singapore","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",null,"Fujian Provincial Hospital, Fuzhou, Fujian, China","Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",null,null,null,"University Hospital Angers, Angers, France","Centre for Clinical Vaccinology &amp; Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China","Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Lige, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CHU Brest, Brest, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Hospices Civils de Lyon (University Hospital of Lyon), Lyon, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|Hpital Bichat, Paris, France|Hpital Lariboisire, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",null,null,"Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Harris Health System - Ben Taub Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States","Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China","Diamond Centre, Vancouver, British Columbia, Canada","Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States","New York University School of Medecine, New York, New York, United States|Montreal Heart Institute, Montreal, Quebec, Canada","Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China","the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China",null,"CIC 1425, Paris, France","The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China","Tongji HospitalTongji Medical College AffiliatedHuazhong University of Science  Technology, Wuhan, Hubei, China","Tangdu Hospital, Xi'an, Shaanxi, China","Luigi Sacco University Hospital, Milan, Lombardia, Italy","CIC 1425, Paris, France",null,"Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States","Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",null,"Istanbul University Cerrahpasa, Istanbul, Turkey",null,"Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States","HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China",null,null,"University of Alberta, Edmonton, Alberta, Canada","Department of Cardiology, Bern University Hospital, Bern, Switzerland","Akershus University Hospital, Lrenskog, Norway","University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",null,null,"Research Center of the CHUS, Sherbrooke, Quebec, Canada","Virtual Facility, Bronx, New York, United States",null,"Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Internet, New York, New York, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montral, Quebec, Canada","CHU Pellegrin, service des Maladies Infectieuses et Tropicales, Bordeaux, France|APHP La Piti Salptrire, service des Maladies Infectieuses et Tropicales, Paris, France|APHP Bichat, Service de ranimation mdicale et infectieuse, Paris, France|APHP Bichat, Service des Maladies Infectieuses et Tropicales, Paris, France","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",null,"Cleveland Clinic, Cleveland, Ohio, United States","Online, Nicosia, Cyprus",null],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf",null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf",null,null,null,null,null,null,null,"\"Study Protocol and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04339842/Prot_SAP_000.pdf",null],["https://ClinicalTrials.gov/show/NCT04333550","https://ClinicalTrials.gov/show/NCT04336904","https://ClinicalTrials.gov/show/NCT04345445","https://ClinicalTrials.gov/show/NCT04331509","https://ClinicalTrials.gov/show/NCT04347915","https://ClinicalTrials.gov/show/NCT04343183","https://ClinicalTrials.gov/show/NCT04342637","https://ClinicalTrials.gov/show/NCT04333407","https://ClinicalTrials.gov/show/NCT04291053","https://ClinicalTrials.gov/show/NCT04336462","https://ClinicalTrials.gov/show/NCT04324489","https://ClinicalTrials.gov/show/NCT04347993","https://ClinicalTrials.gov/show/NCT04323228","https://ClinicalTrials.gov/show/NCT04335123","https://ClinicalTrials.gov/show/NCT04333420","https://ClinicalTrials.gov/show/NCT04342689","https://ClinicalTrials.gov/show/NCT04343755","https://ClinicalTrials.gov/show/NCT04329611","https://ClinicalTrials.gov/show/NCT04321421","https://ClinicalTrials.gov/show/NCT04344015","https://ClinicalTrials.gov/show/NCT04325633","https://ClinicalTrials.gov/show/NCT04323332","https://ClinicalTrials.gov/show/NCT04339660","https://ClinicalTrials.gov/show/NCT04306497","https://ClinicalTrials.gov/show/NCT04287686","https://ClinicalTrials.gov/show/NCT04344145","https://ClinicalTrials.gov/show/NCT04324996","https://ClinicalTrials.gov/show/NCT04348071","https://ClinicalTrials.gov/show/NCT04340232","https://ClinicalTrials.gov/show/NCT04321993","https://ClinicalTrials.gov/show/NCT04329832","https://ClinicalTrials.gov/show/NCT04343768","https://ClinicalTrials.gov/show/NCT04252118","https://ClinicalTrials.gov/show/NCT04348396","https://ClinicalTrials.gov/show/NCT04317092","https://ClinicalTrials.gov/show/NCT04346199","https://ClinicalTrials.gov/show/NCT04331171","https://ClinicalTrials.gov/show/NCT04344587","https://ClinicalTrials.gov/show/NCT04330586","https://ClinicalTrials.gov/show/NCT04348656","https://ClinicalTrials.gov/show/NCT04350073","https://ClinicalTrials.gov/show/NCT04275947","https://ClinicalTrials.gov/show/NCT04328285","https://ClinicalTrials.gov/show/NCT04331899","https://ClinicalTrials.gov/show/NCT04337996","https://ClinicalTrials.gov/show/NCT04315298","https://ClinicalTrials.gov/show/NCT04337762","https://ClinicalTrials.gov/show/NCT04330638","https://ClinicalTrials.gov/show/NCT04343690","https://ClinicalTrials.gov/show/NCT04343677","https://ClinicalTrials.gov/show/NCT04332081","https://ClinicalTrials.gov/show/NCT04304313","https://ClinicalTrials.gov/show/NCT04326920","https://ClinicalTrials.gov/show/NCT04337541","https://ClinicalTrials.gov/show/NCT04338347","https://ClinicalTrials.gov/show/NCT04348422","https://ClinicalTrials.gov/show/NCT04340544","https://ClinicalTrials.gov/show/NCT04334512","https://ClinicalTrials.gov/show/NCT04327674","https://ClinicalTrials.gov/show/NCT04341675","https://ClinicalTrials.gov/show/NCT04329923","https://ClinicalTrials.gov/show/NCT04330690","https://ClinicalTrials.gov/show/NCT04318418","https://ClinicalTrials.gov/show/NCT04333628","https://ClinicalTrials.gov/show/NCT04285801","https://ClinicalTrials.gov/show/NCT04304053","https://ClinicalTrials.gov/show/NCT04319315","https://ClinicalTrials.gov/show/NCT04334382","https://ClinicalTrials.gov/show/NCT04333355","https://ClinicalTrials.gov/show/NCT04335136","https://ClinicalTrials.gov/show/NCT04331366","https://ClinicalTrials.gov/show/NCT04331795","https://ClinicalTrials.gov/show/NCT04333225","https://ClinicalTrials.gov/show/NCT04344444","https://ClinicalTrials.gov/show/NCT04344080","https://ClinicalTrials.gov/show/NCT04348448","https://ClinicalTrials.gov/show/NCT04335084","https://ClinicalTrials.gov/show/NCT04344236","https://ClinicalTrials.gov/show/NCT04307693","https://ClinicalTrials.gov/show/NCT04345692","https://ClinicalTrials.gov/show/NCT04323631","https://ClinicalTrials.gov/show/NCT04348435","https://ClinicalTrials.gov/show/NCT04331834","https://ClinicalTrials.gov/show/NCT04337216","https://ClinicalTrials.gov/show/NCT04336254","https://ClinicalTrials.gov/show/NCT04313023","https://ClinicalTrials.gov/show/NCT04332094","https://ClinicalTrials.gov/show/NCT04292899","https://ClinicalTrials.gov/show/NCT04312997","https://ClinicalTrials.gov/show/NCT04334980","https://ClinicalTrials.gov/show/NCT04348409","https://ClinicalTrials.gov/show/NCT04343989","https://ClinicalTrials.gov/show/NCT04329572","https://ClinicalTrials.gov/show/NCT04347954","https://ClinicalTrials.gov/show/NCT04292730","https://ClinicalTrials.gov/show/NCT04341506","https://ClinicalTrials.gov/show/NCT04345523","https://ClinicalTrials.gov/show/NCT04345510","https://ClinicalTrials.gov/show/NCT04341168","https://ClinicalTrials.gov/show/NCT04347850","https://ClinicalTrials.gov/show/NCT04344171","https://ClinicalTrials.gov/show/NCT04346615","https://ClinicalTrials.gov/show/NCT04336956","https://ClinicalTrials.gov/show/NCT04347369","https://ClinicalTrials.gov/show/NCT04313322","https://ClinicalTrials.gov/show/NCT04346355","https://ClinicalTrials.gov/show/NCT04329650","https://ClinicalTrials.gov/show/NCT04331470","https://ClinicalTrials.gov/show/NCT04315987","https://ClinicalTrials.gov/show/NCT04305106","https://ClinicalTrials.gov/show/NCT04308317","https://ClinicalTrials.gov/show/NCT04244591","https://ClinicalTrials.gov/show/NCT04320615","https://ClinicalTrials.gov/show/NCT04344925","https://ClinicalTrials.gov/show/NCT04273529","https://ClinicalTrials.gov/show/NCT04273581","https://ClinicalTrials.gov/show/NCT04339608","https://ClinicalTrials.gov/show/NCT04312464","https://ClinicalTrials.gov/show/NCT04342221","https://ClinicalTrials.gov/show/NCT04347070","https://ClinicalTrials.gov/show/NCT04345679","https://ClinicalTrials.gov/show/NCT04338074","https://ClinicalTrials.gov/show/NCT04346017","https://ClinicalTrials.gov/show/NCT04344457","https://ClinicalTrials.gov/show/NCT04343742","https://ClinicalTrials.gov/show/NCT04345536","https://ClinicalTrials.gov/show/NCT04342182","https://ClinicalTrials.gov/show/NCT04347174","https://ClinicalTrials.gov/show/NCT04331600","https://ClinicalTrials.gov/show/NCT04325061","https://ClinicalTrials.gov/show/NCT04315896","https://ClinicalTrials.gov/show/NCT04280588","https://ClinicalTrials.gov/show/NCT04335201","https://ClinicalTrials.gov/show/NCT04341389","https://ClinicalTrials.gov/show/NCT04343248","https://ClinicalTrials.gov/show/NCT04329559","https://ClinicalTrials.gov/show/NCT04318301","https://ClinicalTrials.gov/show/NCT04337359","https://ClinicalTrials.gov/show/NCT04332107","https://ClinicalTrials.gov/show/NCT04349241","https://ClinicalTrials.gov/show/NCT04273646","https://ClinicalTrials.gov/show/NCT04331106","https://ClinicalTrials.gov/show/NCT04345991","https://ClinicalTrials.gov/show/NCT04334044","https://ClinicalTrials.gov/show/NCT04346147","https://ClinicalTrials.gov/show/NCT04328441","https://ClinicalTrials.gov/show/NCT04341116","https://ClinicalTrials.gov/show/NCT04346056","https://ClinicalTrials.gov/show/NCT04348240","https://ClinicalTrials.gov/show/NCT04252664","https://ClinicalTrials.gov/show/NCT04343781","https://ClinicalTrials.gov/show/NCT04346043","https://ClinicalTrials.gov/show/NCT04348214","https://ClinicalTrials.gov/show/NCT04328493","https://ClinicalTrials.gov/show/NCT04332913","https://ClinicalTrials.gov/show/NCT04330521","https://ClinicalTrials.gov/show/NCT04336332","https://ClinicalTrials.gov/show/NCT04344977","https://ClinicalTrials.gov/show/NCT04317040","https://ClinicalTrials.gov/show/NCT04347876","https://ClinicalTrials.gov/show/NCT04342897","https://ClinicalTrials.gov/show/NCT04338932","https://ClinicalTrials.gov/show/NCT04346368","https://ClinicalTrials.gov/show/NCT04313127","https://ClinicalTrials.gov/show/NCT04334005","https://ClinicalTrials.gov/show/NCT04336657","https://ClinicalTrials.gov/show/NCT04288102","https://ClinicalTrials.gov/show/NCT04303299","https://ClinicalTrials.gov/show/NCT04286503","https://ClinicalTrials.gov/show/NCT04329507","https://ClinicalTrials.gov/show/NCT04293692","https://ClinicalTrials.gov/show/NCT04339816","https://ClinicalTrials.gov/show/NCT04345276","https://ClinicalTrials.gov/show/NCT04291729","https://ClinicalTrials.gov/show/NCT04333472","https://ClinicalTrials.gov/show/NCT04343339","https://ClinicalTrials.gov/show/NCT04345315","https://ClinicalTrials.gov/show/NCT04344431","https://ClinicalTrials.gov/show/NCT04341688","https://ClinicalTrials.gov/show/NCT04338828","https://ClinicalTrials.gov/show/NCT04349631","https://ClinicalTrials.gov/show/NCT04335305","https://ClinicalTrials.gov/show/NCT04273321","https://ClinicalTrials.gov/show/NCT04347538","https://ClinicalTrials.gov/show/NCT04338360","https://ClinicalTrials.gov/show/NCT04343976","https://ClinicalTrials.gov/show/NCT04334252","https://ClinicalTrials.gov/show/NCT04339426","https://ClinicalTrials.gov/show/NCT04343794","https://ClinicalTrials.gov/show/NCT04341103","https://ClinicalTrials.gov/show/NCT04341285","https://ClinicalTrials.gov/show/NCT04331665","https://ClinicalTrials.gov/show/NCT04318444","https://ClinicalTrials.gov/show/NCT04344730","https://ClinicalTrials.gov/show/NCT04318015","https://ClinicalTrials.gov/show/NCT04341038","https://ClinicalTrials.gov/show/NCT04328272","https://ClinicalTrials.gov/show/NCT04348474","https://ClinicalTrials.gov/show/NCT04336774","https://ClinicalTrials.gov/show/NCT04338568","https://ClinicalTrials.gov/show/NCT04327531","https://ClinicalTrials.gov/show/NCT04323345","https://ClinicalTrials.gov/show/NCT03891420","https://ClinicalTrials.gov/show/NCT04349202","https://ClinicalTrials.gov/show/NCT04348877","https://ClinicalTrials.gov/show/NCT04344756","https://ClinicalTrials.gov/show/NCT04344782","https://ClinicalTrials.gov/show/NCT04335019","https://ClinicalTrials.gov/show/NCT04342663","https://ClinicalTrials.gov/show/NCT04347278","https://ClinicalTrials.gov/show/NCT04343001","https://ClinicalTrials.gov/show/NCT04348500","https://ClinicalTrials.gov/show/NCT04344288","https://ClinicalTrials.gov/show/NCT04348383","https://ClinicalTrials.gov/show/NCT04334291","https://ClinicalTrials.gov/show/NCT04333914","https://ClinicalTrials.gov/show/NCT04323644","https://ClinicalTrials.gov/show/NCT04341870","https://ClinicalTrials.gov/show/NCT04344951","https://ClinicalTrials.gov/show/NCT04261517","https://ClinicalTrials.gov/show/NCT04251767","https://ClinicalTrials.gov/show/NCT04330144","https://ClinicalTrials.gov/show/NCT04347824","https://ClinicalTrials.gov/show/NCT04347681","https://ClinicalTrials.gov/show/NCT04343144","https://ClinicalTrials.gov/show/NCT04348513","https://ClinicalTrials.gov/show/NCT04299724","https://ClinicalTrials.gov/show/NCT04346264","https://ClinicalTrials.gov/show/NCT04342104","https://ClinicalTrials.gov/show/NCT04338958","https://ClinicalTrials.gov/show/NCT04346797","https://ClinicalTrials.gov/show/NCT04338126","https://ClinicalTrials.gov/show/NCT04347928","https://ClinicalTrials.gov/show/NCT04257656","https://ClinicalTrials.gov/show/NCT04343092","https://ClinicalTrials.gov/show/NCT04298814","https://ClinicalTrials.gov/show/NCT04335097","https://ClinicalTrials.gov/show/NCT04324190","https://ClinicalTrials.gov/show/NCT04334850","https://ClinicalTrials.gov/show/NCT04348305","https://ClinicalTrials.gov/show/NCT04349540","https://ClinicalTrials.gov/show/NCT04335071","https://ClinicalTrials.gov/show/NCT04333693","https://ClinicalTrials.gov/show/NCT04349228","https://ClinicalTrials.gov/show/NCT04276896","https://ClinicalTrials.gov/show/NCT04343963","https://ClinicalTrials.gov/show/NCT04349410","https://ClinicalTrials.gov/show/NCT04341415","https://ClinicalTrials.gov/show/NCT04333862","https://ClinicalTrials.gov/show/NCT04328961","https://ClinicalTrials.gov/show/NCT04333953","https://ClinicalTrials.gov/show/NCT04345653","https://ClinicalTrials.gov/show/NCT04323514","https://ClinicalTrials.gov/show/NCT04322188","https://ClinicalTrials.gov/show/NCT04304690","https://ClinicalTrials.gov/show/NCT04342195","https://ClinicalTrials.gov/show/NCT04341207","https://ClinicalTrials.gov/show/NCT04316299","https://ClinicalTrials.gov/show/NCT04318431","https://ClinicalTrials.gov/show/NCT04336345","https://ClinicalTrials.gov/show/NCT04329546","https://ClinicalTrials.gov/show/NCT04344002","https://ClinicalTrials.gov/show/NCT04334460","https://ClinicalTrials.gov/show/NCT04320017","https://ClinicalTrials.gov/show/NCT04341441","https://ClinicalTrials.gov/show/NCT04344938","https://ClinicalTrials.gov/show/NCT04336384","https://ClinicalTrials.gov/show/NCT04330300","https://ClinicalTrials.gov/show/NCT04350086","https://ClinicalTrials.gov/show/NCT04331574","https://ClinicalTrials.gov/show/NCT04321265","https://ClinicalTrials.gov/show/NCT04333732","https://ClinicalTrials.gov/show/NCT04327206","https://ClinicalTrials.gov/show/NCT04326790","https://ClinicalTrials.gov/show/NCT04341142","https://ClinicalTrials.gov/show/NCT04345601","https://ClinicalTrials.gov/show/NCT04344184","https://ClinicalTrials.gov/show/NCT04338698","https://ClinicalTrials.gov/show/NCT04331054","https://ClinicalTrials.gov/show/NCT04339712","https://ClinicalTrials.gov/show/NCT04292964","https://ClinicalTrials.gov/show/NCT04325646","https://ClinicalTrials.gov/show/NCT04347980","https://ClinicalTrials.gov/show/NCT04337346","https://ClinicalTrials.gov/show/NCT04346212","https://ClinicalTrials.gov/show/NCT04342806","https://ClinicalTrials.gov/show/NCT04335786","https://ClinicalTrials.gov/show/NCT04338009","https://ClinicalTrials.gov/show/NCT04334265","https://ClinicalTrials.gov/show/NCT04334148","https://ClinicalTrials.gov/show/NCT04333589","https://ClinicalTrials.gov/show/NCT04330599","https://ClinicalTrials.gov/show/NCT04328480","https://ClinicalTrials.gov/show/NCT04311398","https://ClinicalTrials.gov/show/NCT04310228","https://ClinicalTrials.gov/show/NCT04302519","https://ClinicalTrials.gov/show/NCT04295551","https://ClinicalTrials.gov/show/NCT04345848","https://ClinicalTrials.gov/show/NCT04335552","https://ClinicalTrials.gov/show/NCT04337320","https://ClinicalTrials.gov/show/NCT04341792","https://ClinicalTrials.gov/show/NCT04346667","https://ClinicalTrials.gov/show/NCT04278963","https://ClinicalTrials.gov/show/NCT04303507","https://ClinicalTrials.gov/show/NCT04347941","https://ClinicalTrials.gov/show/NCT04347226","https://ClinicalTrials.gov/show/NCT04328012","https://ClinicalTrials.gov/show/NCT04320472","https://ClinicalTrials.gov/show/NCT04272710","https://ClinicalTrials.gov/show/NCT04335032","https://ClinicalTrials.gov/show/NCT04273763","https://ClinicalTrials.gov/show/NCT04331613","https://ClinicalTrials.gov/show/NCT04346810","https://ClinicalTrials.gov/show/NCT04310865","https://ClinicalTrials.gov/show/NCT04324021","https://ClinicalTrials.gov/show/NCT04344600","https://ClinicalTrials.gov/show/NCT04319445","https://ClinicalTrials.gov/show/NCT04339998","https://ClinicalTrials.gov/show/NCT04323761","https://ClinicalTrials.gov/show/NCT04319731","https://ClinicalTrials.gov/show/NCT04334967","https://ClinicalTrials.gov/show/NCT04321928","https://ClinicalTrials.gov/show/NCT04342884","https://ClinicalTrials.gov/show/NCT04347694","https://ClinicalTrials.gov/show/NCT04341766","https://ClinicalTrials.gov/show/NCT04336215","https://ClinicalTrials.gov/show/NCT04349982","https://ClinicalTrials.gov/show/NCT04298060","https://ClinicalTrials.gov/show/NCT04270383","https://ClinicalTrials.gov/show/NCT04348864","https://ClinicalTrials.gov/show/NCT04334954","https://ClinicalTrials.gov/show/NCT04332991","https://ClinicalTrials.gov/show/NCT04340050","https://ClinicalTrials.gov/show/NCT04320511","https://ClinicalTrials.gov/show/NCT04324528","https://ClinicalTrials.gov/show/NCT04336787","https://ClinicalTrials.gov/show/NCT04323878","https://ClinicalTrials.gov/show/NCT04343651","https://ClinicalTrials.gov/show/NCT04285190","https://ClinicalTrials.gov/show/NCT04324606","https://ClinicalTrials.gov/show/NCT04325048","https://ClinicalTrials.gov/show/NCT04344379","https://ClinicalTrials.gov/show/NCT04347239","https://ClinicalTrials.gov/show/NCT04349618","https://ClinicalTrials.gov/show/NCT04323800","https://ClinicalTrials.gov/show/NCT04321096","https://ClinicalTrials.gov/show/NCT04332380","https://ClinicalTrials.gov/show/NCT04325412","https://ClinicalTrials.gov/show/NCT04332666","https://ClinicalTrials.gov/show/NCT04268537","https://ClinicalTrials.gov/show/NCT04330495","https://ClinicalTrials.gov/show/NCT04349098","https://ClinicalTrials.gov/show/NCT04339881","https://ClinicalTrials.gov/show/NCT04334928","https://ClinicalTrials.gov/show/NCT04346277","https://ClinicalTrials.gov/show/NCT04329533","https://ClinicalTrials.gov/show/NCT04323787","https://ClinicalTrials.gov/show/NCT04332835","https://ClinicalTrials.gov/show/NCT04334876","https://ClinicalTrials.gov/show/NCT04306705","https://ClinicalTrials.gov/show/NCT04337424","https://ClinicalTrials.gov/show/NCT04312100","https://ClinicalTrials.gov/show/NCT04312009","https://ClinicalTrials.gov/show/NCT04323839","https://ClinicalTrials.gov/show/NCT04313946","https://ClinicalTrials.gov/show/NCT04315948","https://ClinicalTrials.gov/show/NCT04311177","https://ClinicalTrials.gov/show/NCT04350099","https://ClinicalTrials.gov/show/NCT04261426","https://ClinicalTrials.gov/show/NCT04337788","https://ClinicalTrials.gov/show/NCT04332016","https://ClinicalTrials.gov/show/NCT04255017","https://ClinicalTrials.gov/show/NCT04254874","https://ClinicalTrials.gov/show/NCT04340466","https://ClinicalTrials.gov/show/NCT04345159","https://ClinicalTrials.gov/show/NCT04316949","https://ClinicalTrials.gov/show/NCT04348929","https://ClinicalTrials.gov/show/NCT04275414","https://ClinicalTrials.gov/show/NCT04341935","https://ClinicalTrials.gov/show/NCT04339387","https://ClinicalTrials.gov/show/NCT04343053","https://ClinicalTrials.gov/show/NCT04261270","https://ClinicalTrials.gov/show/NCT04342169","https://ClinicalTrials.gov/show/NCT04332042","https://ClinicalTrials.gov/show/NCT04329195","https://ClinicalTrials.gov/show/NCT04316728","https://ClinicalTrials.gov/show/NCT04311697","https://ClinicalTrials.gov/show/NCT04321616","https://ClinicalTrials.gov/show/NCT04327349","https://ClinicalTrials.gov/show/NCT04328129","https://ClinicalTrials.gov/show/NCT04263402","https://ClinicalTrials.gov/show/NCT02735707","https://ClinicalTrials.gov/show/NCT04343261","https://ClinicalTrials.gov/show/NCT04341480","https://ClinicalTrials.gov/show/NCT04340349","https://ClinicalTrials.gov/show/NCT04252274","https://ClinicalTrials.gov/show/NCT04327505","https://ClinicalTrials.gov/show/NCT03042143","https://ClinicalTrials.gov/show/NCT04256395","https://ClinicalTrials.gov/show/NCT04325919","https://ClinicalTrials.gov/show/NCT04324866","https://ClinicalTrials.gov/show/NCT04305457","https://ClinicalTrials.gov/show/NCT04324463","https://ClinicalTrials.gov/show/NCT04347512","https://ClinicalTrials.gov/show/NCT04320277","https://ClinicalTrials.gov/show/NCT04333368","https://ClinicalTrials.gov/show/NCT04348695","https://ClinicalTrials.gov/show/NCT04327570","https://ClinicalTrials.gov/show/NCT04347889","https://ClinicalTrials.gov/show/NCT04339322","https://ClinicalTrials.gov/show/NCT04325867","https://ClinicalTrials.gov/show/NCT04347382","https://ClinicalTrials.gov/show/NCT04338100","https://ClinicalTrials.gov/show/NCT04342650","https://ClinicalTrials.gov/show/NCT04342156","https://ClinicalTrials.gov/show/NCT04339790","https://ClinicalTrials.gov/show/NCT04327401","https://ClinicalTrials.gov/show/NCT04279197","https://ClinicalTrials.gov/show/NCT04280705","https://ClinicalTrials.gov/show/NCT04284046","https://ClinicalTrials.gov/show/NCT04345861","https://ClinicalTrials.gov/show/NCT04345614","https://ClinicalTrials.gov/show/NCT04349592","https://ClinicalTrials.gov/show/NCT04344210","https://ClinicalTrials.gov/show/NCT04321174","https://ClinicalTrials.gov/show/NCT04322487","https://ClinicalTrials.gov/show/NCT04318314","https://ClinicalTrials.gov/show/NCT04323592","https://ClinicalTrials.gov/show/NCT04335747","https://ClinicalTrials.gov/show/NCT04335188","https://ClinicalTrials.gov/show/NCT04335773","https://ClinicalTrials.gov/show/NCT04334629","https://ClinicalTrials.gov/show/NCT04340219","https://ClinicalTrials.gov/show/NCT04348942","https://ClinicalTrials.gov/show/NCT04264858","https://ClinicalTrials.gov/show/NCT04321811","https://ClinicalTrials.gov/show/NCT04339634","https://ClinicalTrials.gov/show/NCT04348227","https://ClinicalTrials.gov/show/NCT04344249","https://ClinicalTrials.gov/show/NCT04337502","https://ClinicalTrials.gov/show/NCT04326452","https://ClinicalTrials.gov/show/NCT04335162","https://ClinicalTrials.gov/show/NCT04312243","https://ClinicalTrials.gov/show/NCT04322565","https://ClinicalTrials.gov/show/NCT04335279","https://ClinicalTrials.gov/show/NCT04344197","https://ClinicalTrials.gov/show/NCT04337047","https://ClinicalTrials.gov/show/NCT04341012","https://ClinicalTrials.gov/show/NCT04306055","https://ClinicalTrials.gov/show/NCT04340414","https://ClinicalTrials.gov/show/NCT04337008","https://ClinicalTrials.gov/show/NCT04331886","https://ClinicalTrials.gov/show/NCT04293887","https://ClinicalTrials.gov/show/NCT04320732","https://ClinicalTrials.gov/show/NCT04340921","https://ClinicalTrials.gov/show/NCT04333654","https://ClinicalTrials.gov/show/NCT04338945","https://ClinicalTrials.gov/show/NCT04346420","https://ClinicalTrials.gov/show/NCT04337489","https://ClinicalTrials.gov/show/NCT04296643","https://ClinicalTrials.gov/show/NCT04320238","https://ClinicalTrials.gov/show/NCT04343898","https://ClinicalTrials.gov/show/NCT04346342","https://ClinicalTrials.gov/show/NCT04319016","https://ClinicalTrials.gov/show/NCT04344561","https://ClinicalTrials.gov/show/NCT04346186","https://ClinicalTrials.gov/show/NCT04302688","https://ClinicalTrials.gov/show/NCT04347408","https://ClinicalTrials.gov/show/NCT04316884","https://ClinicalTrials.gov/show/NCT04333849","https://ClinicalTrials.gov/show/NCT04348461","https://ClinicalTrials.gov/show/NCT04279899","https://ClinicalTrials.gov/show/NCT04290871","https://ClinicalTrials.gov/show/NCT04337151","https://ClinicalTrials.gov/show/NCT04341493","https://ClinicalTrials.gov/show/NCT04315480","https://ClinicalTrials.gov/show/NCT04340479","https://ClinicalTrials.gov/show/NCT04328454","https://ClinicalTrials.gov/show/NCT03808922","https://ClinicalTrials.gov/show/NCT04346446","https://ClinicalTrials.gov/show/NCT04327804","https://ClinicalTrials.gov/show/NCT04345640","https://ClinicalTrials.gov/show/NCT04325906","https://ClinicalTrials.gov/show/NCT04344964","https://ClinicalTrials.gov/show/NCT04327388","https://ClinicalTrials.gov/show/NCT04346628","https://ClinicalTrials.gov/show/NCT04344535","https://ClinicalTrials.gov/show/NCT04325893","https://ClinicalTrials.gov/show/NCT04338906","https://ClinicalTrials.gov/show/NCT04326725","https://ClinicalTrials.gov/show/NCT04341714","https://ClinicalTrials.gov/show/NCT04321369","https://ClinicalTrials.gov/show/NCT04292340","https://ClinicalTrials.gov/show/NCT04346082","https://ClinicalTrials.gov/show/NCT04326114","https://ClinicalTrials.gov/show/NCT04322123","https://ClinicalTrials.gov/show/NCT04326387","https://ClinicalTrials.gov/show/NCT04346953","https://ClinicalTrials.gov/show/NCT04324047","https://ClinicalTrials.gov/show/NCT04315870","https://ClinicalTrials.gov/show/NCT04346589","https://ClinicalTrials.gov/show/NCT04342702","https://ClinicalTrials.gov/show/NCT04337918","https://ClinicalTrials.gov/show/NCT04326036","https://ClinicalTrials.gov/show/NCT04344548","https://ClinicalTrials.gov/show/NCT04322396","https://ClinicalTrials.gov/show/NCT04346693","https://ClinicalTrials.gov/show/NCT04341610","https://ClinicalTrials.gov/show/NCT04341519","https://ClinicalTrials.gov/show/NCT04274322","https://ClinicalTrials.gov/show/NCT04324073","https://ClinicalTrials.gov/show/NCT04344041","https://ClinicalTrials.gov/show/NCT04343664","https://ClinicalTrials.gov/show/NCT04345289","https://ClinicalTrials.gov/show/NCT04321278","https://ClinicalTrials.gov/show/NCT04344912","https://ClinicalTrials.gov/show/NCT04260594","https://ClinicalTrials.gov/show/NCT04314232","https://ClinicalTrials.gov/show/NCT04336748","https://ClinicalTrials.gov/show/NCT04330261","https://ClinicalTrials.gov/show/NCT04347460","https://ClinicalTrials.gov/show/NCT04326426","https://ClinicalTrials.gov/show/NCT04327180","https://ClinicalTrials.gov/show/NCT04345406","https://ClinicalTrials.gov/show/NCT04341922","https://ClinicalTrials.gov/show/NCT04334434","https://ClinicalTrials.gov/show/NCT04320862","https://ClinicalTrials.gov/show/NCT04345549","https://ClinicalTrials.gov/show/NCT04344834","https://ClinicalTrials.gov/show/NCT04324736","https://ClinicalTrials.gov/show/NCT04290858","https://ClinicalTrials.gov/show/NCT04283461","https://ClinicalTrials.gov/show/NCT04344327","https://ClinicalTrials.gov/show/NCT04346160","https://ClinicalTrials.gov/show/NCT04280224","https://ClinicalTrials.gov/show/NCT04290780","https://ClinicalTrials.gov/show/NCT04288713","https://ClinicalTrials.gov/show/NCT04343404","https://ClinicalTrials.gov/show/NCT04322513","https://ClinicalTrials.gov/show/NCT04318366","https://ClinicalTrials.gov/show/NCT04345887","https://ClinicalTrials.gov/show/NCT04320953","https://ClinicalTrials.gov/show/NCT04338802","https://ClinicalTrials.gov/show/NCT04299152","https://ClinicalTrials.gov/show/NCT04308187","https://ClinicalTrials.gov/show/NCT04322344","https://ClinicalTrials.gov/show/NCT04306393","https://ClinicalTrials.gov/show/NCT04322773","https://ClinicalTrials.gov/show/NCT04324684","https://ClinicalTrials.gov/show/NCT04346329","https://ClinicalTrials.gov/show/NCT04336410","https://ClinicalTrials.gov/show/NCT04337983","https://ClinicalTrials.gov/show/NCT04349163","https://ClinicalTrials.gov/show/NCT04345419","https://ClinicalTrials.gov/show/NCT04322786","https://ClinicalTrials.gov/show/NCT04336761","https://ClinicalTrials.gov/show/NCT04344119","https://ClinicalTrials.gov/show/NCT04342208","https://ClinicalTrials.gov/show/NCT04344106","https://ClinicalTrials.gov/show/NCT04338672","https://ClinicalTrials.gov/show/NCT04349371","https://ClinicalTrials.gov/show/NCT04327479","https://ClinicalTrials.gov/show/NCT04305574","https://ClinicalTrials.gov/show/NCT04347031","https://ClinicalTrials.gov/show/NCT04279795","https://ClinicalTrials.gov/show/NCT04279782","https://ClinicalTrials.gov/show/NCT04343729","https://ClinicalTrials.gov/show/NCT04341584","https://ClinicalTrials.gov/show/NCT04292327","https://ClinicalTrials.gov/show/NCT04340557","https://ClinicalTrials.gov/show/NCT04269525","https://ClinicalTrials.gov/show/NCT04261907","https://ClinicalTrials.gov/show/NCT04325672","https://ClinicalTrials.gov/show/NCT04326075","https://ClinicalTrials.gov/show/NCT04337190","https://ClinicalTrials.gov/show/NCT04061382","https://ClinicalTrials.gov/show/NCT04264533","https://ClinicalTrials.gov/show/NCT04338841","https://ClinicalTrials.gov/show/NCT04323527","https://ClinicalTrials.gov/show/NCT04275388","https://ClinicalTrials.gov/show/NCT04302766","https://ClinicalTrials.gov/show/NCT04348370","https://ClinicalTrials.gov/show/NCT04245631","https://ClinicalTrials.gov/show/NCT03331445","https://ClinicalTrials.gov/show/NCT04335630","https://ClinicalTrials.gov/show/NCT04322682","https://ClinicalTrials.gov/show/NCT04255940","https://ClinicalTrials.gov/show/NCT04281693","https://ClinicalTrials.gov/show/NCT04344509","https://ClinicalTrials.gov/show/NCT04259892","https://ClinicalTrials.gov/show/NCT04251871","https://ClinicalTrials.gov/show/NCT04260308","https://ClinicalTrials.gov/show/NCT04275245","https://ClinicalTrials.gov/show/NCT04307459","https://ClinicalTrials.gov/show/NCT04322279","https://ClinicalTrials.gov/show/NCT04339686","https://ClinicalTrials.gov/show/NCT04341727","https://ClinicalTrials.gov/show/NCT04335851","https://ClinicalTrials.gov/show/NCT04346927","https://ClinicalTrials.gov/show/NCT04319211","https://ClinicalTrials.gov/show/NCT04331808","https://ClinicalTrials.gov/show/NCT04328467","https://ClinicalTrials.gov/show/NCT04280913","https://ClinicalTrials.gov/show/NCT04333251","https://ClinicalTrials.gov/show/NCT04320056","https://ClinicalTrials.gov/show/NCT04347798","https://ClinicalTrials.gov/show/NCT04333875","https://ClinicalTrials.gov/show/NCT04316377","https://ClinicalTrials.gov/show/NCT04276688","https://ClinicalTrials.gov/show/NCT04346940","https://ClinicalTrials.gov/show/NCT04319172","https://ClinicalTrials.gov/show/NCT03680274","https://ClinicalTrials.gov/show/NCT04326309","https://ClinicalTrials.gov/show/NCT04346966","https://ClinicalTrials.gov/show/NCT04308668","https://ClinicalTrials.gov/show/NCT04262921","https://ClinicalTrials.gov/show/NCT04329897","https://ClinicalTrials.gov/show/NCT04346979","https://ClinicalTrials.gov/show/NCT04342728","https://ClinicalTrials.gov/show/NCT04339842","https://ClinicalTrials.gov/show/NCT04276987"]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Rank<\/th>\n      <th>NCT Number<\/th>\n      <th>Title<\/th>\n      <th>Acronym<\/th>\n      <th>Status<\/th>\n      <th>Study Results<\/th>\n      <th>Conditions<\/th>\n      <th>Interventions<\/th>\n      <th>Outcome Measures<\/th>\n      <th>Sponsor/Collaborators<\/th>\n      <th>Gender<\/th>\n      <th>Age<\/th>\n      <th>Phases<\/th>\n      <th>Enrollment<\/th>\n      <th>Funded Bys<\/th>\n      <th>Study Type<\/th>\n      <th>Study Designs<\/th>\n      <th>Other IDs<\/th>\n      <th>Start Date<\/th>\n      <th>Primary Completion Date<\/th>\n      <th>Completion Date<\/th>\n      <th>First Posted<\/th>\n      <th>Results First Posted<\/th>\n      <th>Last Update Posted<\/th>\n      <th>Locations<\/th>\n      <th>Study Documents<\/th>\n      <th>URL<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","columnDefs":[{"className":"dt-right","targets":[1,14]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dados-brutos-oms" class="section level3">
<h3>Dados brutos OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-d758d851ba85f7fbedb5" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-d758d851ba85f7fbedb5">{"x":{"filter":"top","filterHTML":"<tr>\n  <td><\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"integer\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n    <div style=\"display: none; position: absolute; width: 200px;\">\n      <div data-min=\"20150713\" data-max=\"20200414\"><\/div>\n      <span style=\"float: left;\"><\/span>\n      <span style=\"float: right;\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"disabled\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n<\/tr>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305","306","307","308","309","310","311","312","313","314","315","316","317","318","319","320","321","322","323","324","325","326","327","328","329","330","331","332","333","334","335","336","337","338","339","340","341","342","343","344","345","346","347","348","349","350","351","352","353","354","355","356","357","358","359","360","361","362","363","364","365","366","367","368","369","370","371","372","373","374","375","376","377","378","379","380","381","382","383","384","385","386","387","388","389","390","391","392","393","394","395","396","397","398","399","400","401","402","403","404","405","406","407","408","409","410","411","412","413","414","415","416","417","418","419","420","421","422","423","424","425","426","427","428","429","430","431","432","433","434","435","436","437","438","439","440","441","442","443","444","445","446","447","448","449","450","451","452","453","454","455","456","457","458","459","460","461","462","463","464","465","466","467","468","469","470","471","472","473","474","475","476","477","478","479","480","481","482","483","484","485","486","487","488","489","490","491","492","493","494","495","496","497","498","499","500","501","502","503","504","505","506","507","508","509","510","511","512","513","514","515","516","517","518","519","520","521","522","523","524","525","526","527","528","529","530","531","532","533","534","535","536","537","538","539","540","541","542","543","544","545","546","547","548","549","550","551","552","553","554","555","556","557","558","559","560","561","562","563","564","565","566","567","568","569","570","571","572","573","574","575","576","577","578","579","580","581","582","583","584","585","586","587","588","589","590","591","592","593","594","595","596","597","598","599","600","601","602","603","604","605","606","607","608","609","610","611","612","613","614","615","616","617","618","619","620","621","622","623","624","625","626","627","628","629","630","631","632","633","634","635","636","637","638","639","640","641","642","643","644","645","646","647","648","649","650","651","652","653","654","655","656","657","658","659","660","661","662","663","664","665","666","667","668","669","670","671","672","673","674","675","676","677","678","679","680","681","682","683","684","685","686","687","688","689","690","691","692","693","694","695","696","697","698","699","700","701","702","703","704","705","706","707","708","709","710","711","712","713","714","715","716","717","718","719","720","721","722","723","724","725","726","727","728","729","730","731","732","733","734","735","736","737","738","739","740","741","742","743","744","745","746","747","748","749","750","751","752","753","754","755","756","757","758","759","760","761","762","763","764","765","766","767","768","769","770","771","772","773","774","775","776","777","778","779","780","781","782","783","784","785","786","787","788","789","790","791","792","793","794","795","796","797","798","799","800","801","802","803","804","805","806","807","808","809","810","811","812","813","814","815","816","817","818","819","820","821","822","823","824","825","826","827","828","829","830","831","832","833","834","835","836","837","838","839","840","841","842","843","844","845","846","847","848","849","850","851","852","853","854","855","856","857","858","859","860","861","862","863","864","865","866","867","868","869","870","871","872","873","874","875","876","877","878","879","880","881","882","883","884","885","886","887","888","889","890","891","892","893","894","895","896","897","898","899","900","901","902","903","904","905","906","907","908","909","910","911","912","913","914","915","916","917","918","919","920","921","922","923","924","925","926","927","928","929","930","931","932","933","934","935","936","937","938","939","940","941","942","943","944","945","946","947","948","949","950","951","952","953","954","955","956","957","958","959","960","961","962","963","964","965","966","967","968","969","970","971","972","973","974","975","976","977","978","979","980","981","982","983","984","985","986","987","988","989","990","991","992","993","994","995","996","997","998","999","1000","1001","1002","1003","1004","1005","1006","1007","1008","1009","1010","1011","1012","1013","1014","1015","1016","1017","1018","1019","1020","1021","1022","1023","1024","1025","1026","1027","1028","1029","1030","1031","1032","1033","1034","1035","1036","1037","1038","1039","1040","1041","1042","1043","1044","1045","1046","1047","1048","1049","1050","1051","1052","1053","1054","1055","1056","1057","1058","1059","1060","1061","1062","1063","1064","1065","1066","1067","1068","1069","1070","1071","1072","1073","1074","1075","1076","1077","1078","1079","1080","1081","1082","1083","1084","1085","1086","1087","1088","1089","1090","1091","1092","1093","1094","1095","1096","1097","1098","1099","1100","1101","1102","1103","1104","1105","1106","1107","1108","1109","1110","1111","1112","1113","1114","1115","1116","1117","1118","1119","1120","1121","1122","1123","1124","1125","1126","1127","1128","1129","1130","1131","1132","1133","1134","1135"],["ChiCTR2000029953","ChiCTR2000029935","NCT04246242","ChiCTR2000029949","ChiCTR2000029850","ChiCTR2000029814","ChiCTR2000029947","ChiCTR2000029896","ChiCTR2000029811","ChiCTR2000029810","NCT04252885","NCT04255940","NCT04260308","ChiCTR2000029883","ChiCTR2000029805","ChiCTR2000029789","ChiCTR2000029779","ChiCTR2000029778","ChiCTR2000029869","ChiCTR2000029867","ChiCTR2000029777","ChiCTR2000029776","NCT04251871","NCT04260594","NCT04261426","NCT04261907","ChiCTR2000029782","ChiCTR2000029764","ChiCTR2000029941","ChiCTR2000029939","ChiCTR2000029849","ChiCTR2000029822","ChiCTR2000029907","ChiCTR2000029905","ChiCTR2000029695","ChiCTR2000029656","ChiCTR2000029815","ChiCTR2000029813","ChiCTR2000029742","ChiCTR2000029741","ChiCTR2000029870","ChiCTR2000029855","ChiCTR2000029806","ChiCTR2000029790","ChiCTR2000029626","ChiCTR2000029624","ChiCTR2000029788","ChiCTR2000029765","ChiCTR2000029637","ChiCTR2000029636","ChiCTR2000029853","ChiCTR2000029839","ChiCTR2000029763","ChiCTR2000029758","ChiCTR2000029601","ChiCTR2000029569","ChiCTR2000029589","ChiCTR2000029578","ChiCTR2000029821","ChiCTR2000029819","ChiCTR2000029542","ChiCTR2000029539","ChiCTR2000029518","ChiCTR2000029517","ChiCTR2000029804","ChiCTR2000029769","ChiCTR2000029756","ChiCTR2000029747","ChiCTR2000029495","ChiCTR2000029493","ChiCTR2000029768","ChiCTR2000029754","ChiCTR2000029462","ChiCTR2000029438","ChiCTR2000029432","ChiCTR2000029431","ChiCTR2000029751","ChiCTR2000029735","ChiCTR2000029739","ChiCTR2000029732","ChiCTR2000029436","ChiCTR2000029418","ChiCTR2000029639","ChiCTR2000029628","ChiCTR2000029734","ChiCTR2000029621","ChiCTR2000029625","ChiCTR2000029602","ChiCTR2000029609","ChiCTR2000029606","ChiCTR2000030173","ChiCTR2000030166","ChiCTR2000029600","ChiCTR2000029572","ChiCTR2000029605","ChiCTR2000029603","ChiCTR2000029559","ChiCTR2000029544","ChiCTR2000029558","ChiCTR2000029548","ChiCTR2000029541","ChiCTR2000029487","ChiCTR2000030118","ChiCTR2000030116","ChiCTR2000029468","ChiCTR2000029437","ChiCTR2000029461","ChiCTR2000029460","ChiCTR2000029459","ChiCTR2000029439","ChiCTR2000029435","ChiCTR2000029430","ChiCTR2000030093","ChiCTR2000030084","ChiCTR2000030043","ChiCTR2000030041","NCT04259892","NCT04268537","ChiCTR2000030179","ChiCTR2000029400","NCT04244591","ChiCTR2000030164","ChiCTR2000030113","ChiCTR2000030034","ChiCTR2000030032","ChiCTR2000029381","NCT04269525","ChiCTR2000030185","ChiCTR2000030167","ChiCTR2000030096","ChiCTR2000030094","ChiCTR2000030165","ChiCTR2000030117","ChiCTR2000030115","ChiCTR2000030092","ChiCTR2000030188","ChiCTR2000030170","ChiCTR2000030046","ChiCTR2000030030","ChiCTR2000030029","ChiCTR2000030027","ChiCTR2000030090","ChiCTR2000030058","ChiCTR2000030138","ChiCTR2000030137","ChiCTR2000030016","ChiCTR2000030007","ChiCTR2000030056","ChiCTR2000030033","ChiCTR2000030136","ChiCTR2000030102","ChiCTR2000030017","ChiCTR2000030015","ChiCTR2000030012","ChiCTR2000030010","ChiCTR2000030089","ChiCTR2000030088","ChiCTR2000030008","ChiCTR2000030006","ChiCTR2000030000","ChiCTR2000029956","ChiCTR2000030087","ChiCTR2000030086","ChiCTR2000030054","ChiCTR2000030039","ChiCTR2000029996","ChiCTR2000029995","ChiCTR2000030001","ChiCTR2000029999","ChiCTR2000030021","ChiCTR2000030020","ChiCTR2000030019","ChiCTR2000030004","ChiCTR2000030003","ChiCTR2000030002","ChiCTR2000029994","ChiCTR2000029978","ChiCTR2000029992","ChiCTR2000029990","ChiCTR2000029989","ChiCTR2000029988","ChiCTR2000029960","ChiCTR2000029959","ChiCTR2000029781","ChiCTR2000029740","ChiCTR2000029985","ChiCTR2000029972","ChiCTR2000029866","ChiCTR2000029865","ChiCTR2000029981","ChiCTR2000029974","ChiCTR2000029803","ChiCTR2000029780","ChiCTR2000029851","NCT04252664","ChiCTR2000029954","NCT04279899","NCT04256395","NCT04273529","NCT04273581","ChiCTR2000030433","ChiCTR2000030418","NCT04270383","NCT04273646","NCT04275947","ChiCTR2000030420","NCT04257656","NCT04275245","NCT04275388","NCT04279197","ChiCTR2000030386","ChiCTR2000030382","ChiCTR2000030390","ChiCTR2000030363","ChiCTR2000030322","ChiCTR2000030314","NCT04280588","ChiCTR2000030432","ChiCTR2000030398","ChiCTR2000030389","NCT04279782","NCT04279795","NCT04280224","ChiCTR2000030442","ChiCTR2000030334","ChiCTR2000030333","ChiCTR2000030305","ChiCTR2000030262","ChiCTR2000030424","ChiCTR2000030391","ChiCTR2000030387","ChiCTR2000030263","ChiCTR2000030317","ChiCTR2000030315","ChiCTR2000030327","ChiCTR2000030325","ChiCTR2000030300","ChiCTR2000030283","ChiCTR2000030324","ChiCTR2000030293","ChiCTR2000030265","ChiCTR2000030264","ChiCTR2000030290","ChiCTR2000030259","ChiCTR2000030258","ChiCTR2000030257","ChiCTR2000030260","ChiCTR2000030255","ChiCTR2000030261","ChiCTR2000030222","ChiCTR2000030253","ChiCTR2000030219","ChiCTR2000030226","ChiCTR2000030225","ChiCTR2000030215","ChiCTR2000030196","ChiCTR2000030223","ChiCTR2000030162","ChiCTR2000030091","ChiCTR2000030042","ChiCTR2000030022","ChiCTR2000030013","ChiCTR2000029899","ChiCTR2000029898","ChiCTR2000029975","ChiCTR2000029762","ChiCTR2000030218","ChiCTR2000029952","ChiCTR2000029991","ChiCTR2000029755","ChiCTR2000029728","ChiCTR2000029387","ChiCTR2000029900","ChiCTR2000029761","ChiCTR2000029759","ChiCTR2000029386","ChiCTR2000029760","NCT04286503","ChiCTR2000029829","ChiCTR2000030552","NCT04276688","NCT04281693","NCT04282902","NCT04252118","NCT04276987","ChiCTR2000030593","ChiCTR2000030559","ChiCTR2000030557","ChiCTR2000030535","ChiCTR2000030522","NCT04284046","NCT04285190","ChiCTR2000030627","ChiCTR2000030581","ChiCTR2000030574","ChiCTR2000030579","ChiCTR2000030578","ChiCTR2000030503","ChiCTR2000030487","ChiCTR2000030564","ChiCTR2000030544","ChiCTR2000030485","ChiCTR2000030472","ChiCTR2000030543","ChiCTR2000030541","ChiCTR2000030556","ChiCTR2000030542","ChiCTR2000030493","ChiCTR2000030480","ChiCTR2000030540","ChiCTR2000030492","ChiCTR2000030471","ChiCTR2000030469","ChiCTR2000030518","ChiCTR2000030491","ChiCTR2000030479","ChiCTR2000030477","ChiCTR2000030490","ChiCTR2000030481","ChiCTR2000030489","ChiCTR2000030484","ChiCTR2000030468","ChiCTR2000030453","ChiCTR2000030482","ChiCTR2000030475","ChiCTR2000030467","ChiCTR2000030465","ChiCTR2000030436","ChiCTR2000029958","ChiCTR2000030312","ChiCTR2000030304","ChiCTR2000030464","ChiCTR2000030163","ChiCTR2000030014","ChiCTR2000029580","ChiCTR2000029993","ChiCTR2000029638","ChiCTR2000029550","ChiCTR2000029549","ChiCTR2000029579","ChiCTR2000029433","ChiCTR2000029757","NCT04292340","ChiCTR2000029434","NCT04292327","ChiCTR2000029479","ChiCTR2000030896","ChiCTR2000030895","ChiCTR2000030894","NCT04293887","ChiCTR2000030902","ChiCTR2000030893","ChiCTR2000030863","NCT04295551","NCT04296643","NCT04299711","ChiCTR2000030897","ChiCTR2000030862","ChiCTR2000030861","ChiCTR2000030901","ChiCTR2000030854","ChiCTR2000030853","ChiCTR2000030852","ChiCTR2000030892","ChiCTR2000030883","ChiCTR2000030860","ChiCTR2000030812","ChiCTR2000030865","ChiCTR2000030858","ChiCTR2000030810","ChiCTR2000030809","ChiCTR2000030838","ChiCTR2000030836","ChiCTR2000030856","ChiCTR2000030849","ChiCTR2000029308","EUCTR2015-002340-14-NL","ChiCTR2000030835","ChiCTR2000030834","ChiCTR2000030833","ChiCTR2000030831","ChiCTR2000030819","ChiCTR2000030818","ChiCTR2000030816","ChiCTR2000030814","ChiCTR2000030795","ChiCTR2000030778","ChiCTR2000030807","ChiCTR2000030805","ChiCTR2000030803","ChiCTR2000030802","ChiCTR2000030798","ChiCTR2000030796","ChiCTR2000030801","ChiCTR2000030800","NCT04298814","ChiCTR2000030898","ChiCTR2000030759","ChiCTR2000030758","ChiCTR2000030782","ChiCTR2000030773","ChiCTR2000030784","ChiCTR2000030768","ChiCTR2000030866","ChiCTR2000030864","ChiCTR2000030757","ChiCTR2000030756","ChiCTR2000030764","ChiCTR2000030762","ChiCTR2000030859","ChiCTR2000030857","ChiCTR2000030760","ChiCTR2000030755","ChiCTR2000030751","ChiCTR2000030718","ChiCTR2000030855","ChiCTR2000030850","ChiCTR2000030753","ChiCTR2000030744","ChiCTR2000030742","ChiCTR2000030741","ChiCTR2000030717","ChiCTR2000030716","ChiCTR2000030740","ChiCTR2000030708","ChiCTR2000030739","ChiCTR2000030721","ChiCTR2000030841","ChiCTR2000030839","ChiCTR2000030707","ChiCTR2000030706","ChiCTR2000030719","ChiCTR2000030703","ChiCTR2000030832","ChiCTR2000030830","ChiCTR2000030806","ChiCTR2000030804","ChiCTR2000030799","ChiCTR2000030797","ChiCTR2000030687","ChiCTR2000030545","ChiCTR2000030690","ChiCTR2000030580","ChiCTR2000030701","ChiCTR2000030700","ChiCTR2000030779","ChiCTR2000030763","ChiCTR2000030466","ChiCTR2000030388","ChiCTR2000030761","ChiCTR2000030754","ChiCTR2000030558","ChiCTR2000030329","ChiCTR2000030683","ChiCTR2000030681","ChiCTR2000030114","ChiCTR2000030082","ChiCTR2000030306","ChiCTR2000030221","ChiCTR2000029984","ChiCTR2000029957","ChiCTR2000030619","ChiCTR2000030483","ChiCTR2000030752","ChiCTR2000030747","ChiCTR2000030187","ChiCTR2000029895","ChiCTR2000030478","ChiCTR2000030055","ChiCTR2000030722","ChiCTR2000030720","ChiCTR2000029817","ChiCTR2000029812","ChiCTR2000029837","ChiCTR2000029826","ChiCTR2000030031","ChiCTR2000030005","ChiCTR2000030702","ChiCTR2000030697","ChiCTR2000030686","ChiCTR2000030679","ChiCTR2000030606","ChiCTR2000030597","ChiCTR2000030528","ChiCTR2000030509","ChiCTR2000029820","NCT04264533","ChiCTR2000029592","NCT04307693","ChiCTR2000030476","ChiCTR2000030417","ChiCTR2000030381","ChiCTR2000030135","ChiCTR2000030085","ChiCTR2000029818","ChiCTR2000029816","ChiCTR2000029770","NCT04302519","ChiCTR2000031163","NCT04308187","ChiCTR2000031115","ChiCTR2000031140","ChiCTR2000031138","ChiCTR2000031104","ChiCTR2000031088","ChiCTR2000030992","ChiCTR2000030989","ChiCTR2000031090","ChiCTR2000030996","ChiCTR2000031023","ChiCTR2000031014","ChiCTR2000030941","ChiCTR2000030939","ChiCTR2000030947","ChiCTR2000030946","ChiCTR2000030986","ChiCTR2000030961","NCT04285801","NCT04299724","NCT04302688","ChiCTR2000031150","ChiCTR2000030933","ChiCTR2000030932","ChiCTR2000030952","ChiCTR2000030950","ChiCTR2000031139","ChiCTR2000031089","ChiCTR2000030922","ChiCTR2000030906","ChiCTR2000030943","ChiCTR2000030934","ChiCTR2000030931","ChiCTR2000030771","ChiCTR2000030993","ChiCTR2000030987","ChiCTR2000030519","ChiCTR2000030254","ChiCTR2000030765","ChiCTR2000029658","ChiCTR2000030985","ChiCTR2000030951","ChiCTR2000030929","ChiCTR2000030920","ChiCTR2000030224","ChiCTR2000030168","ChiCTR2000030944","ChiCTR2000030942","ChiCTR2000029955","ChiCTR2000029830","ChiCTR2000029573","ChiCTR2000029496","ChiCTR2000030919","ChiCTR2000030539","ChiCTR2000030095","ChiCTR2000029868","EUCTR2020-000890-25-FR","DRKS00021134","IRCT20100228003449N27","IRCT20200316046792N1","IRCT20100228003449N28","IRCT20160625028622N1","IRCT20151227025726N12","IRCT20100228003449N29","IRCT20200128046294N2","NCT04263402","IRCT20100228003449N30","JPRN-jRCTs031190227","TCTR20200321001","NCT04251767","JPRN-jRCTs031190226","JPRN-jRCTs041190120","NCT04273763","NCT04283396","NCT04287686","NCT04254874","NCT04255017","NCT04261270","JPRN-UMIN000039686","NCT04276896","NCT04264858","NCT04278963","NCT04292964","NCT04306497","JPRN-UMIN000039873","TCTR20200324001","NCT04291053","NCT04293692","NCT04305574","NCT04310865","NCT04272710","NCT04304313","NCT04306705","NCT04314232","NCT04314817","NCT04308317","NCT04312464","NCT04313322","ChiCTR2000031366","NCT04312100","NCT04318015","NCT04318418","ChiCTR2000031356","NCT04316884","ChiCTR2000031361","NCT04311398","NCT04314271","NCT04315870","NCT04315896","ChiCTR2000031330","ChiCTR2000031329","ChiCTR2000031365","ChiCTR2000031319","ChiCTR2000031336","ChiCTR2000031324","ChiCTR2000031328","ChiCTR2000031327","NCT04316728","ChiCTR2000031337","ChiCTR2000031272","ChiCTR2000031252","ChiCTR2000031271","ChiCTR2000031245","ChiCTR2000031301","ChiCTR2000031247","ChiCTR2000031296","ChiCTR2000031293","ChiCTR2000031246","ChiCTR2000031244","ChiCTR2000031204","ChiCTR2000031187","ChiCTR2000031203","ChiCTR2000031176","ChiCTR2000031227","ChiCTR2000030940","ChiCTR2000031214","ChiCTR2000031198","ChiCTR2000030962","ChiCTR2000030938","ChiCTR2000030936","ChiCTR2000030923","ChiCTR2000030937","ChiCTR2000030704","ChiCTR2000031196","ChiCTR2000030988","ChiCTR2000030817","ChiCTR2000029982","ChiCTR2000030330","ChiCTR2000030288","ChiCTR2000030256","ChiCTR2000030198","ChiCTR2000030028","EUCTR2020-001243-15-BE","ChiCTR2000029976","EUCTR2020-001162-12-FR","EUCTR2020-000919-69-NL","EUCTR2020-001224-33-DE","EUCTR2020-000982-18-NO","EUCTR2020-001023-14-GB","NCT04312997","NCT04315948","NCT04319900","NCT04061382","NCT04288713","NCT04290871","NCT04303507","NCT04305106","NCT04321928","NCT04322786","NCT04323228","NCT04313023","NCT04316299","NCT04318314","NCT04318444","NCT04320017","NCT04322565","NCT04323514","NCT04323631","NCT04319211","NCT04320056","NCT04320277","NCT04320953","NCT04322344","NCT04323644","ChiCTR2000031630","NCT04321174","NCT04321421","NCT04322487","NCT04323332","ChiCTR2000031589","ChiCTR2000031587","NCT04324996","NCT04325412","NCT04325633","NCT04326309","ChiCTR2000031627","ChiCTR2000031533","NCT04325919","NCT04327570","ChiCTR2000031539","ChiCTR2000031540","ChiCTR2000031538","NCT04323345","NCT04323592","NCT04324463","NCT04324866","ChiCTR2000031504","ChiCTR2000031499","ChiCTR2000031494","ChiCTR2000031465","ChiCTR2000031453","ChiCTR2000031438","ChiCTR2000031454","ChiCTR2000031439","NCT04327479","NCT04331860","ISRCTN14966673","ChiCTR2000031429","ChiCTR2000031427","ChiCTR2000031199","EUCTR2020-000936-23-FR","ChiCTR2000031639","ChiCTR2000031503","ChiCTR2000031428","ChiCTR2000031376","ChiCTR2000031501","ChiCTR2000031500","ChiCTR2000031432","ChiCTR2000031430","EUCTR2020-001254-22-BE","EUCTR2020-001345-38-GR","EUCTR2020-001236-10-NL","EUCTR2020-001010-38-NO","EUCTR2020-001172-15-DK","EUCTR2020-001386-37-IT","NCT03331445","NCT04261517","NCT04273321","NCT04298060","EUCTR2020-001271-33-FR","EUCTR2020-001281-11-FR","NCT04303299","NCT04305457","NCT04312243","ACTRN12620000421932","NCT03808922","ACTRN12620000417987","NCT03680274","NCT04316377","NCT04321096","NCT04321265","NCT04322396","EUCTR2020-001275-32-DK","NCT04290780","NCT04245631","NCT04275414","NCT04292730","NCT04324489","NCT04324528","NCT04324606","NCT04328272","NCT04252274","NCT04274322","NCT04280705","NCT04283461","NCT04310228","NCT04315987","NCT04318301","NCT04319445","NCT04292899","NCT04304690","NCT04306055","NCT04308668","NCT04328480","NCT04328493","NCT04328961","NCT04329611","NCT04288102","NCT04291729","NCT04302766","NCT04304053","NCT04320238","NCT04320472","NCT04320862","NCT04321278","NCT04329832","NCT04330261","NCT04330495","NCT04311177","NCT04313127","NCT04315298","NCT04315480","NCT04306393","NCT04311697","NCT04312009","NCT04313946","NCT04321369","NCT04322123","NCT04322188","NCT04323787","NCT04330690","NCT04331106","NCT04331366","NCT04331574","NCT04317040","NCT04317092","NCT04318366","NCT04319016","NCT04323839","NCT04324190","NCT04325672","NCT04325893","NCT04331795","NCT04332016","NCT04332666","NCT04333550","NCT04319315","NCT04320511","NCT04320732","NCT04322513","NCT04320615","NCT04321616","NCT04321811","NCT04321993","NCT04326387","NCT04326452","NCT04326790","NCT04327206","NCT04333732","NCT04333953","NCT04334382","NCT04334629","NCT04322682","NCT04323800","NCT04323878","NCT04324684","NCT04322773","NCT04324021","NCT04324047","NCT04327388","NCT04327505","NCT04327531","NCT04328441","NCT04334850","NCT04335032","NCT04335071","NCT04325061","NCT04325646","NCT04325906","NCT04326036","NCT04324073","NCT04325867","NCT04326075","NCT04326114","NCT04328467","NCT04329546","NCT04329572","NCT04330521","NCT04335279","NCT04336345","NCT04336384","NCT04336774","NCT04326725","NCT04327180","NCT04327349","NCT04327674","NCT04330638","NCT04331054","NCT04331171","NCT04326426","NCT04326920","NCT04327401","NCT04336787","NCT04337008","NCT04337216","NCT04337489","NCT04328012","NCT04328129","NCT04328454","NCT04329533","NCT04331613","NCT04332835","NCT04333251","NCT04333693","NCT04329507","NCT04329923","NCT04330144","NCT04330586","NCT04337502","NCT04337918","NCT04338347","NCT04338360","NCT04334252","NCT04334434","NCT04334460","NCT04334967","NCT04329559","NCT04329650","NCT04330300","NCT04331509","NCT04331600","NCT04331808","NCT04331834","NCT04330599","NCT04331470","NCT04331665","NCT04331886","NCT04338568","NCT04338802","NCT04339426","NCT04339660","NCT04335019","NCT04335084","NCT04335201","NCT04335851","NCT04331899","NCT04332094","NCT04332107","NCT04332081","NCT04332380","NCT04332913","NCT04333355","NCT04340349","NCT04340544","NCT04341168","NCT04341389","NCT04336215","NCT04336332","NCT04336657","NCT04336956","NCT04341415","NCT04341610","NCT04341870","NCT04332991","NCT04333225","NCT04333407","NCT04337047","NCT04337190","NCT04337541","NCT04337996","NCT04333472","NCT04333589","NCT04334005","NCT04334148","NCT04342689","NCT04342702","NCT04342728","NCT04343144","NCT04338828","NCT04338945","NCT04339387","NCT04339608","NCT04334980","NCT04335097","NCT04335123","NCT04335188","NCT04343781","NCT04343794","ACTRN12620000468921","NCT04333420","NCT04333628","NCT04333654","NCT04333849","ACTRN12620000443998","ISRCTN10077335","NCT04339634","NCT04339816","NCT04340050","NCT04340466","NCT04335305","NCT04335630","NCT04335747","NCT04335773","ISRCTN15281137","ISRCTN40092247","NCT04336410","NCT04336761","NCT04337151","NCT04337320","NCT04333862","NCT04334044","NCT04334265","NCT04334291","NCT04341116","NCT04341142","NCT04341441","NCT04341493","ChiCTR2000031772","ChiCTR2000031770","NCT04337762","NCT04337983","NCT04338074","NCT04338100","NCT04334512","NCT04334928","NCT04335136","NCT04335162","ChiCTR2000031752","ChiCTR2000031751","NCT04341584","NCT04341675","NCT04341766","NCT04341792","NCT04338932","NCT04338958","NCT04340479","NCT04340921","ChiCTR2000031712","ChiCTR2000031707","NCT04335786","NCT04336254","NCT04336462","NCT04341012","NCT04341480","NCT04341688","NCT04341922","ChiCTR2000031672","ChiCTR2000030750","NCT04336904","NCT04337346","NCT04337359","NCT04337788","NCT04342104","NCT04342221","NCT04342637","NCT04342663","NCT04342208","NCT04342650","NCT04342884","NCT04343001","NL8490","NL8501","NCT04338009","NCT04338672","NCT04338698","NCT04338906","NCT04342897","NCT04343339","NCT04343404","NCT04343664","EUCTR2020-001250-21-FR","EUCTR2020-001500-41-BE","NCT04343755","ACTRN12620000444987","NCT04343092","NCT04343183","NCT04343651","NCT04343742","NCT04339322","NCT04339790","NCT04339998","NCT04340219","EUCTR2020-001039-29-GR","ACTRN12620000447954","ISRCTN50189673","NCT04343768","ACTRN12620000448943","ISRCTN13694948","ISRCTN51287266","NCT04340232","NCT04340414","NCT04341103","NCT04341285","ACTRN12620000445976","ACTRN12620000470998","ISRCTN16912075","ISRCTN83971151","NCT04341506","NCT04341519","NCT04341714","NCT04341935","ChiCTR2000031860","ChiCTR2000031834","ChiCTR2000031794","ChiCTR2000031783","ChiCTR2000031735","ChiCTR2000031675","NCT04342156","NCT04342169","NCT04342182","NCT04342195","ChiCTR2000031734","ChiCTR2000031705","ChiCTR2000030328","NL8512","NCT04342806","NCT04343248","NCT04343261","NCT04343677","ChiCTR2000030494","ChiCTR2000030331","NL8513","NL8498","NL8460","NL8483","NCT04343690","NCT04343898","ACTRN12620000438954","EUCTR2020-001381-11-FR","ACTRN12620000449932","ACTRN12620000457943","NL8491","EUCTR2020-001310-38-DE","EUCTR2020-001435-27-FR","EUCTR2020-001333-13-FR","ACTRN12620000454976","ISRCTN43900695","EUCTR2020-001366-11-ES","EUCTR2020-001409-21-ES","ISRCTN77353041","ISRCTN86534580","EUCTR2020-001421-31-ES","EUCTR2020-001606-33-ES","EUCTR2020-001492-33-FR","EUCTR2020-001194-69-ES","ChiCTR2000031836","ChiCTR2000031782","EUCTR2020-001565-37-ES","ChiCTR2000031781","ChiCTR2000031779","ChiCTR2000031700","ChiCTR2000031699","NL8473","NL8485","NL8497","NL8504","EUCTR2020-001301-23-FR","EUCTR2020-001335-28-NL","EUCTR2020-001188-96-FR","EUCTR2020-001373-70-FR","EUCTR2020-001457-43-FR","EUCTR2020-001445-39-ES","EUCTR2020-001442-19-ES","EUCTR2020-001385-11-ES","EUCTR2020-001270-29-GB","EUCTR2020-001307-16-ES"],["17 February 2020","17 February 2020","3 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","25 February 2020","25 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","25 February 2020","25 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","17 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","24 February 2020","24 February 2020","25 February 2020","17 February 2020","24 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","17 February 2020","24 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","25 February 2020","2 March 2020","25 February 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","2 March 2020","9 March 2020","2 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","9 March 2020","16 March 2020","9 March 2020","16 March 2020","9 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","9 March 2020","11 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","23 March 2020","16 March 2020","23 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","16 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","23 March 2020","24 March 2020","24 March 2020","24 March 2020","24 March 2020","24 March 2020","24 March 2020","24 March 2020","30 March 2020","24 March 2020","23 March 2020","25 March 2020","30 March 2020","23 March 2020","23 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","23 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","23 March 2020","25 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","30 March 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","6 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","6 April 2020","6 April 2020","14 April 2020","14 April 2020","14 April 2020","6 April 2020","14 April 2020","6 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","6 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","13 April 2020","13 April 2020","14 April 2020","13 April 2020","13 April 2020","13 April 2020","13 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020","14 April 2020"],["Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)","Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)","Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical study of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19) based on CRISPR-cas protein","The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection","2019-nCoV Outbreak and Cardiovascular Diseases","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia","A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR","Analysis of clinical characteristics of severe novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)","Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection","Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)","Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection","Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients","A medical records based study of novel coronavirus pneumonia (COVID-19) and influenza virus co-infection","Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Exhaled Breath","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study","Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Immune Repertoire (TCR &amp; BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19)","A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)","The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial","Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of ovel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial","Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation","Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19) patients","Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial","Chinese medicine prevention and treatment program for suspected novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial","Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19)","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency","Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People","Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)","Impact of vitamin D deficiency on prognosis of patients with novel coronavirus pneumonia (COVID-19)","A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial","Study for Mental health and psychological status of doctors, nurses and patients in novel coronavirus pneumonia (COVID-19) designated hospital and effect of interventions","A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)","Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)","Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19)","Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19)","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)","A real-world  study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19)","A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","The effect of pulmonary rehabilitation for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Combination of traditional Chinese medicine and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population","Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-19)","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Immunoregulatory Therapy for 2019-nCoV","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)","Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure","A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU","Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial","Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia","The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)","Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)","A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients","Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)","A medical records based study for acute kidney injury in novel coronavirus pneumonia (COVID-19)","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Humanistic Care in Healthcare Workers in Novel Coronavirus Pneumonia (COVID-19)","Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of Novel coronavirus pneumonia (COVID-19)","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)","Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19)","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)","Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)","Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women","Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19)","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)","A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)","Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)","Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae","A prospective, open label, randomized, control trial for chloroquine or hydroxychloroquine in patients with mild and common novel coronavirus pulmonary (COVIP-19)","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Study on anxiety of different populations under novel coronavirus (COVID-19) infection","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)","A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)","The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp","Effect of Novel Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students","Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the Treatment for Novel Coronavirus Pneumonia (COVID-19)","Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus pneumonia (COVID-19)","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)","A prospective, randomized, open label, controlled trial for chloroquine and hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Clinical observation and research of  Severe acute respiratory syndrome coronavirus 2(COVID-19) infection in perinatal newborns","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)","Study for mental health status and influencing factors of nurses during epidemic prevention of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics","Descriptive study on the clinical characteristics and outcomes of novel coronavirus pneumonia (COVID-19) in cardiovascular patients","Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)","Mild/Moderate 2019-nCoV Remdesivir RCT","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","The Investigation of the Neonates With or With Risk of COVID-19","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia","The COVID-19 Mobile Health Study (CMHS)","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Severe 2019-nCoV Remdesivir RCT","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia","Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)","Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet","Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology","Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome","Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)","Fingolimod in COVID-19","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19).","A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations","NK Cells Treatment for Novel Coronavirus Pneumonia","Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19)","microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)","A randomized, open-label controlled trial for the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus pneumonia (COVID-19)","Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)","Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients","Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)","Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic","Clinical study for a new type of Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)","A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang","Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel coronavirus pneumonia (COVID-19) patients","Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)","Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients","Study for continuous renal replacement therapy with adsorption filter in the treatment of the novel coronavirus pneumonia (COVID-19)","ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)","Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus pneumonia (COVID-19) from two hospitals in China","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial","A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients","The coagulation function of novel coronavirus pneumonia (COVID-19) patients","Clinical study for individualized nutritional assessment and supportive treatment of novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)","Cancelled due to lack of participants                                        Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People","Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)","Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey","Cancelled by the investigator                     Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)","Cancelled due to lack of patient                                                                A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive&amp;","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A prospective clinical study for recombinant human interferon alpha 1b spray in the prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)","Cancelled due to lack of patient                                                                              Clinical study for the effect and","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)","Cancelled due to lack of patient                         Medical records based study for epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)","A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy","Cancelled due to lack of patient                Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Retracted due to lack of patient                               A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm","Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: a randomized controlled trial","Cancelled due to lack of patient                              A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases","The Clinical Study of Carrimycin on Treatment Patients With COVID-19","Cancelled due to lack of patient                                 Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)","Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","A New Screening Strategy for 2019 Novel Coronavirus Infection","A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia","Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study","A medical records based study for the safety of artificial liver cluster nursing in critically ill patients with novel coronavirus pneumonia (COVID-19)","A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)","CT Scores Predict Mortality in 2019-nCoV Pneumonia","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19","Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases","The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope","Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)","Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)","Extracorporeal blood purification therapy using Li's Artifical Liver System for patients with severe novel coronavirus pneumonia (COVID19) patient","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)","Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)","Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A medical records based retrospective Cohort study","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country","Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)","A clinical study about the diagnosis and prognosis evaluation of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.","Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy","Retrospective study for integrate Chinese and conventional medicine  treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial","A medical records based study for Comparing Differences of Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients between Sichuan Province and Wuhan City","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)","Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia (COVID-19): the TCM symptoms and treatment regulation","Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)","A Multicenter, Long- term Follow-up and Registration Study for Myocardial Injury and Prognosis of Novel coronavirus pneumonia (COVID-19)","Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19)","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Cancelled by the investigator                        Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Application of flash glucose monitoring to evaluate the effect of blood glucose changes on prognosis in patients with novel coronavirus pneumonia (COVID-19)","A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department","Cancelled, due to modify the protocol                                          A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment&amp;","Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)","Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)","A Medical Based Retrospective Real World Study for Assessment of Effectiveness of Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Cancelled due to lack of patient                               Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial","A pilot study for Integrated Chinese and Western Medicine in the treatment of non-critical novel coronavirus pneumonia (COVID-19)","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of 2019 Novel Coronavirus (2019-nCoV) Infected Pneumonia","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)","The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population","Clinical Application and Theoretical Discussion of Fu-Zheng Qing-Fei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)","Retrospective and Prospective Study for Nosocomial infection in Stomatology Department under the Background of novel coronavirus pneumonia (COVID-19) epidemic period","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial","Efficacy and Safety of IFN-a2 in the Treatment of Novel Coronavirus Patients","Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors","Study for effects of crisis intervention based on positive psychology for medical staffs working in the novel coronavirus pneumonia (COVID-19) field","Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19): An Multicenter Cohort Study","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","Medical Masks vs N95 Respirators for COVID-19","Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)","Correlation analysis of blood eosinophil cell levels and clinical type category of novel coronavirus pneumonia (COVID-19): a medical records based retrospective study","Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling","Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong","A clinical multicenter study for the occurrence, development and prognosis of novel coronavirus pneumonia (COVID-19)","Evaluation of the protective effect of dexmedetomidine on patients with severe novel coronavirus pneumonia (COVID-19)","Factors associated with death in patients with novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19) Fibrosis: a prospective exploratory experimental medical study","Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)","A medical records based study for investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid of novel coronavirus pneumonia (COVID-19) patients","Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients","Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection","Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","A medical records based study for clinical outcomes and follow-up of novel coronavirus pneumonia (COVID-19) patients","Development of warning system with clinical differential diagnosis and prediction for severe type of novel coronavirus pneumonia (COVID-19) patients based on artificial intelligence and CT images","Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy","An artificial intelligence assistant system for suspected novel coronavirus pneumonia (COVID-19) based on chest CT","Investigation on psychological status of novel coronavirus pneumonia (COVID-19) rehabilitation patients in Zhengzhou City and research on coping strategies","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Adaptive trial in severe pneumonia (REMAP-CAP)","Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)","Epidemiological Characteristics and Antibody Levels of novel coronavirus pneumonia (COVID-19) of Pediatric Medical Staff working in Quarantine Area","Clinical validation and application of high-throughput novel coronavirus (2019-nCoV) screening detection kit","The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia (COVID-19): a single center and descriptive study in Wuhan","Retrospective analysis of digestive system symptoms in 600 cases of novel coronavirus pneumonia (COVID-19) in Guanggu district, Wuhan","A medical records based study for the value of Lymphocyte subsets in the diagnose and treatment of novel coronavirus pneumonia (COVID-19)","Nutritional risk assessment and outcome prediction of critically ill novel coronavirus pneumonia (COVID-19) patients","A medical records based analysis of clinical evidence of human-to-human transmission of 2019 novel coronavirus pneumonia (COVID-19) by conjunctival route","A multicenter retrospective study of rheumatic  patients with novel coronavirus pneumonia (COVID-19)","A medical records based study for epidemic and clinical features of novel coronavirus pneumonia (COVID-19) in Ningbo First Hospital","Clinical characteristics and prognosis of cancer patients with novel coronavirus pneumonia (COVID-19)","Quantitative CT characteristic estimate the severity of novel coronavirus pneumonia (COVID-19)","Collection and analysis of clinical data in severe and critically ill patients with novel coronavirus pneumonia (COVID-19)","A retrospective study of clinical drug therapy in patients with novel coronavirus pneumonia (COVID-19)","A medical records based study for clinical characteristics of novel coronavirus pneumonia (COVID-19)","Clinical characteristics and treatment of novel coronavirus pneumonia (COVID-19)","Analysis of risk factors affecting prognosis of elderly patients infected with novel coronavirus pneumonia (COVID-19): a single-center retrospective observational study","Cancelled by the investigator                Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their diagnostic and prognostic value","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based study for sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)","The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia (COVID-19)","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)","A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi","Study for the Psychological Status of Medical Staff of Otolaryngology Head and Neck Surgery in Hubei Province under the Epidemic of novel coronavirus pneumonia (COVID-19)","Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19)","Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers","Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)","Research for the influence of epidemic of novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations","Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''","A medical based analysis for influencing factors of death of novel coronavirus pneumonia (COVID-19) patients in Wuhan third hospital","Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)","A medical records based study for clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China","A medical records based study for characteristics, prognosis of ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe novel coronavirus pneumonia (COVID-19)","Study for the physical and mental health status of medical workers under the novel coronavirus pneumonia (COVID-19) epidemic","A medical records based analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)","Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19)","Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)","A medical records based study for risk assessment and treatment timing of invasive fungal infection in novel coronavirus pneumonia (COVID-19) critical patients","Shedding of SARS-CoV-2 in human semen and evaluation of reproductive health of novel coronavirus pneumonia (COVID-19) male patients","Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19).","Cross sectional study of dialysis treatment and mental status under the outbreak of novel coronavirus pneumonia (COVID-2019) in China","Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS","A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)","Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19)","Preliminary screening of novel coronavirus pneumonia (COVID-19) by special laboratory examination and CT imaging before surgery","Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau","Cancelled by the investigator                       Application of cas13a-mediated RNA detection in the assay of novel coronavirus nucleic acid (COVID-19)","A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)","Study for the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)","Development and application of novel coronavirus pneumonia (COVID-19) intelligent image classification system based on deep learning","Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial","Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia (COVID-19)","clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia (COVID-19) patients","Novel coronavirus pneumonia (COVID-19) associated kidney injury in children","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Study for immune cell subsets in convalescent patients with novel coronavirus pneumonia (COVID-19)","Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19)","A randomized, parallel controlled open-label trial for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel coronavirus pneumonia (COVID-19)","Study for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in treatment of novel coronavirus pneumonia (COVID-19) adult common patients","A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","A Medical Records Based analysis for Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)","Cancelled due to lack of patients                                       Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study","Medical records based study for the accuracy of SARS-CoV-2 IgM antibody screening for diagnosis of novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator             Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital","Cancelled by the investigator                          Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)","The prediction value of prognosis of novel coronavirus pneumonia (COVID-19) in elderly patients by modified early warning score (MEWS): a medical records based retrospective observational study","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of Novel Coronavirus Pneumonia (COVID-19) and other infectious viruses in the operating Room","Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator             Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                               Mechanism of novel coronavirus pneumonia (COVID-19) virus with silent latent immune system induced by envelope protein and vaccine development","Cancelled by the investigator               Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator              Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                         An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","A medical records based real world study for the characteristics and correlation mechanism of traditional Chinese medicine combined with western medicine in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator         A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)","A medical records based analysis for risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)","A prospective cohort  study for comprehensive treatment of Chinese medicine in the treatment of convalescent patients of novel coronavirus pneumonia (COVID-19)","Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Cancelled by investigator                Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                                    Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)","Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management","Cancelled by the investigator                    Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator               Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator          A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator            A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                              A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COV","Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test","Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-19) common patient: a prospective clinical trial","A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals","The effects of prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak","Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator           Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Cancelled by investigator                                      A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia","Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)","Cancelled by the investigator                               Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Cancelled by investigator           A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","Cancelled by the investigator                  A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients","Cancelled by the investigator               Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients","Cancelled by the investigator            Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Cancelled by the investigator                      Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","The relationship between Vitamin D andnovel coronavirus pneumonia (COVID-19)","Influence of the COvid-19 Epidemic on STRESS","A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)","Study for the impact on fetus and neonates of vertical transmission of 2019-nCoV","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)","Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)","A prognosis study of novel coronavirus pneumonia (COVID-19)","A medical records based study for the diagnosis and prognosis prediction AI model of novel coronavirus pneumonia (COVID-19)","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)","Effect of Auricular point pressing on insomnia of novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial.","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period","A Study for SARS-COV-2 RNA Level in Blood and Excrement of Novel Coronavirus Pneumonia (COVID-19) Convalescent Patients","A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggan, Hubei in Huanggang.","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based study for clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia (COVID-19)","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19)","Correlation of T lymphocytes level and clinical severity in novel coronavirus pneumonia (COVID-19) patients: a medical records based retrospective study","A Medical Records Based Retrospective Study for Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19) in WuHan","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","Safety and Immunity of Covid-19 aAPC Vaccine","Accurate Classification System for Patients With COVID-19 Pneumonitis","Application of radiology in the prevention and control system of emergency respiratory infectious diseases","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in novel coronavirus pneumonia (COVID-19) patients: a randomized controlled trial","Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)","Myocardial injury and arrythmias in the novel coronavirus pneumonia (COVID-19) patients","Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19)","A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild and moderate patients with novel coronavirus pneumonia (COVID-19)","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with novel coronavirus pneumonia (COVID-19)","A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector)","Venous Thrombosis Risk of novel coronavirus pneumonia (COVID-19) Patients: A Prospective Study","A Platform for Rapid Immuno-detection and Emergency Vaccine Development of Novel Coronavirus (2019-COV)","A Medical Records Based Study for Clinical Characteristic and Outcomes of Hospitalized Patients With Novel Coronavirus Pneumonia (COVID-19)","Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies","A medical records based study for the value of Upper Respiratory Tract Virus Detection in the assessment of rehabilitation of novel coronavirus pneumonia (COVID-19) patient","A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia (COVID-19)","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study","Cancelled by the investigator                 Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Psychological Responses of Medical Staff during the Metaphase of novel coronavirus pneumonia (COVID-19) Outbreak in Hubei, China","Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.","Cancelled by the investigator                Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                   A real world study for Compound Houttuyniae Mixture for prevention of novel coronavirus pneumonia (COVID-19)","Clinical study of human NK cells and MSCs transplantation for severe novel coronavirus pneumonia (COVID-19)","Combined diagnostic value of novel coronavirus (2019-CoV) infection detected by NLR and CRP","Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging","A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection","A randomized, open label, parallel controlled trial of evaluating the efficacy of recombinant cytokine gene-derived protein injection for clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)","An observational study for cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)","Study for clinical oral characteristics of patients with novel coronavirus pneumonia (COVID-19) and Effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus","A medical records based study for optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial","Hydroxychloroquine as a treatment for coronavirus disease COVID-19","Identification of host cell respiratory tract cell gene expression and epigenetic pattern after human SARS-CoV-2 infection","Interferon  in treatment  of COVID-19","Effect of herbal syrup and solution in treatment of COVID-19","Interferon in treatment of COVID-19","The effect of Noscapine  on clinical and pulmonary manifestations of COVID-19 patients","Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with novel Coronavirus(COVID-19)","?Effect of sofosbuvir/ ledipasvir on COVID-19","Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants with Moderate to Severe Coronavirus Disease (COVID-19)","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia","Combination therapy in COVID 19","Triple combination therapy in patients infected with COVID-19","ED Response against Covid-19 pandemic","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection","Favipiravir in patients infected with COVID-19","Favipiravir for SARS-CoV-infected patients","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Study for Novel Coronavirus Pneumonia (NCP)","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19","Prognostic Factors of Patients With COVID-19","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.","COVID-19 Registry","Covid-19 preparedness among Emergency Departments: a cross-sectional study in France.","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus","Social Media Use During COVID-19","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","Prognositc Factors in COVID-19 Patients Complicated With Hypertension","A Pilot Study of Sildenafil in COVID-19","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","Mechanisms to Morbidity and Mortality for Covid-19","Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","Tetrandrine Tablets Used in the Treatment of COVID-19","Myocardial Damage in COVID-19","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis","Sequential Oxygen Therapy Strategy for Patients With COVID-19","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","Study for the changes of the brain structure and function in healed patients of novel coronavirus pneumonia (COVID-19)","Mechanisms for Organ Dysfunction in Covid-19","Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation","Influence of novel coronavirus pneumonia (COVID-19) on disease activity, medical and mental condition of patients with rheumatic diseases","To explore the pathogenesis and course prediction of novel coronavirus pneumonia (COVID-19) severe patients","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe novel coronavirus pneumonia (COVID-19) patients","AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)","The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of novel coronavirus pneumonia (COVID-19)","The protective effect of sleep psychology and music therapy of novel coronavirus pneumonia (COVID-19) mild and moderate type patients","Clinical characteristics and death risk factors in severe novel coronavirus pneumonia (COVID-19) patients: a single-center respective analysis based on medical records","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19","The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak","Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)","Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients: a medical records based retrospective study","A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury","Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)","A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death","Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk","Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)","Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a medical records based study","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)","Study on home pharmaceutical care for chronic patients over the novel coronavirus pneumonia (COVID-19) epidemic","Clinical features and prognosis of invasive echanicalventilation patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)","Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis","A medical records based study for clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)","Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study","Clinical investigation and reseach on TCM syndrome of novel coronavirus pneumonia (COVID-19)","A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the treatment of novel coronavirus pneumonia (COVID-19)","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery phase with Fei-Pi-Qi-Xu Zhen","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)","Efficacy and optimization of antiviral therapy for novel coronavirus pneumonia (COVID-19) patients","A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19)","Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound","Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism","Cancelled by the investigator                               Clinical research of 6-minute walk training on motor function of novel coronavirus pneumonia (COVID-19)","Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial","Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China","Clinical research of pulmonary rehabilitation in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.","The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life in patients with mild novel coronavirus pneumonia (COVID-19)","Sarilumab COVID-19","Reducing health care workers absenteeism in Coronavirus 2019 pandemic nu enhancement of the immune system through vaccination with Bacillus Calmette-Gurin","Systematic study of the medicine hydroxychloroquine against placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19","A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19)","a trial of an inhaled antiviral drug to treat or prevent severe respiratory difficulties in patients with COVID-19","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","Trial of Treatments for COVID-19 in Hospitalized Adults","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","Sero-epidemiological Survey of England in 2019/2020","Eculizumab (Soliris) in Covid-19 Infected Patients","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2","Acute Kidney Injury in Patients Hospitalized With COVID-19","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","Colchicine Efficacy in COVID-19 Pneumonia","Use of Ascorbic Acid in Patients With COVID 19","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","Non-contact Endoscopy at Covid-19 Outbreak","Escin in Patients With Covid-19 Infection","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","Hyperimmune Plasma for Critical Patients With COVID-19","Simple, Safe, Same: Lung Ultrasound for COVID-19","Traditional Chinese Medicine for Severe COVID-19","Investigation for the sleep quality in non-health care workers during the pandemic of novel coronavirus pneumonia (COVID-19)","A paired clinical study for novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","Audio Data Collection for Identification and Classification of Coughing","Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune","Survey of psychological status and related factors of emergency medical staff in the country during the novel coronavirus pneumonia (COVID-19) pandemic","Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong","In-depth Immunological Investigation of COVID-19.","A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and  the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19)","Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)","Assessment of mental health status of first-line dental emergency medical personnel during novel coronavirus pneumonia (COVID-19) pandemic","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","A multi-center telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province","Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study","Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial","Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial","Analysis of changes in high risk factors of cervical spondylosis during novel coronavirus pneumonia (COVID-19) pandemic","Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)","A medical records based study for novel coronavirus pneumonia (COVID-19) patients undergoing endotracheal intubation","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection","COVID-19 Public Image Registry","Does point-of-care testing for coronavirus in hospital improve patient care compared to laboratory testing?","The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of  Immunological, biochemical, and Metabolic Parameters: a Retrospective Observational Study","Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial","A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy","Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)","Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)","A medical records based study for safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy","The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study","Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19)","A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adults","Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis","Sargramostim in patients with acute hypoxic respiratory failure due to COVID-19","CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS","Countering Lung Damage in COVID-19 infection: the CounterCovid Study","NORWEGIAN CORONAVIRUS DISEASE 2019 [NO-COVID-19] STUDY: A TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION","Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19","Efficacy of Tocilizumab - COVID-19","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","Efficacy and Safety of Corticosteroids in COVID-19","DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19  risque daggravation secondaire : tude prospective multicentrique randomise en double aveugle","Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit..","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","NO Prevention of COVID-19 for Healthcare Providers","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","Chloroquine Chemorophylaxis Countermeasure against COVID-19","Lessening Organ Dysfunction With VITamin C","Norwegian Coronavirus Disease 2019 Study","The Impact of Camostat Mesilate on COVID-19 Infection","Outcomes and Prognostic Factors in COVID-19","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19","Anti-il6 treatment of serious COVID-19 disease with threatening respiratory failure","COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment","DAS181 for Severe COVID-19: Compassionate Use","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","A Study of a Candidate COVID-19 Vaccine (COV001)","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool","Adaptive COVID-19 Treatment Trial (ACTT)","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Hypertension in Patients Hospitalized With COVID-19","Mindfulness During COVID-19","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19)","COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Blood Donor Recruitment During Epidemic of COVID-19","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","The ECLA PHRI COLCOVID Trial","The Vietnam Chloroquine Treatment on COVID-19","Hydroxychloroquine for COVID-19 PEP","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)","Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Expanded Access Remdesivir (RDV; GS-5734)","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","Experimental Trial of rhIFNa Nasal Drops to Prevent 2019-nCOV in Medical Staff","Acute Encephalopathy in Critically Ill Patients With COVID-19","COVID-19 Pandemic Response Network","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","Clinical Characteristics and Outcomes of Pediatric COVID-19","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","Losartan for Patients With COVID-19 Not Requiring Hospitalization","A Phase I Clinical Trial in 18-60 Adults","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","Losartan for Patients With COVID-19 Requiring Hospitalization","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals","Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus (COVID-19)","An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID19 Registry","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","Survey of the Anxiety Associated With the COVID-19 Pandemic","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","Renin-Angiotensin System Inhibitors and COVID-19","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","DIgital Online SuPport for COVID-19 StrEss","Convalescent Plasma to Limit Coronavirus Associated Complications","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","COVID-19 Biological Samples Collection","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Application of Desferal to Treat COVID-19","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","Risk Factors for Community- and Workplace Transmission of COVID-19","Biomarkers for Identification of COVID-19 Infection","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2","Behavior, Environment And Treatments for Covid-19","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Evaluation of Novel Diagnostic Tests for COVID-19","Treating COVID-19 With a Bidirectional Oxygenation Valve","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","BCG Vaccination to Protect Healthcare Workers Against COVID-19","CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION","COVID-19 in Patients With HIV","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","LIBA Trial in COVID-19","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","Prognostic Factors Keeping Track for Covid-19 Pneumonia","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","Sarilumab COVID-19","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19","Early CPAP in COVID Patients With Respiratory Failure.","Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19","Pre-exposure Prophylaxis for SARS-Coronavirus-2","Understanding COVID-19","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19","Impact of the Coronavirus (COVID-19) on Patients With Cancer","Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","Outcomes of Patients With COVID-19 in the Intensive Care Unit","Impact of Covid-19 in Congenital Heart Disease","CAPTION AI to Minimize Risk of COVID Exposure","Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia","PREdiction of DIagnosed Covid-19 infecTion in IUC Patients","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19","Treatment of COVID-19 Patients With Anti-interleukin Drugs","Protective Role of Inhaled Steroids for Covid-19 Infection","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","Renin Angiotesnin System - CoronaVirus","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation","Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","Household Transmission Investigation Study for COVID-19 in French Guiana","Clinical Characteristics and Prognostic Factors of Patients With COVID-19","Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic","Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Study Testing Convalescent Plasma vs Best Supportive Care","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","A Trial of Ciclesonide in Adults With Mild COVID-19","Clinical and Radiomic Model of COVID-19","Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","CAP-1002 in Severe COVID-19 Disease","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia","Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)","Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia","Coronavirus (COVID-19) ACEi/ARB Investigation","COVID-19 Symptom Tracker","ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia","An Observational Study of Patients With Coronavirus Disease 2019","Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study","Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19","Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","Defibrotide in COVID-19 Pneumonia","Video-Based Exercises and Well-Being During Social Isolation","Mild COVID-19 Peginterferon Lambda","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","Hyperbaric Oxygen for COVID-19 Patients","Convalescent Plasma for Patients With COVID-19: A Pilot Study","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","Safety in Convalescent Plasma Transfusion to COVID-19","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)","Rutgers COVID-19 Cohort Study","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?","Covid-19 Pediatric Observatory","Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome","ASC Therapy for Patients With Severe Respiratory COVID-19","Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","Assessment of Distress in Crisis Situations During COVID-19","Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","Dynamic Evaluation of COVID-19 Diagnostic Tests","Piclidenoson for Treatment of COVID-19","Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","Vitamin D on Prevention and Treatment of COVID-19","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","The Role of Resistant Potato Starch in COVID-19 Infection","A Study on the Prospective Cohort Library of COVID-19 in Southeran","COVID-19 Using Ascorbic Acid and Zinc Supplementation","CORIMUNO19-NIVO: TRIAL EVALUATING EFFICACY and SAFETY OF NIVOLUMAB (OPDIVO) IN PATIENTS WITH COVID-19 INFECTION, NESTED IN THE CORIMUNO-19 COHORT","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy","COVID-19 Risk Stratification","Max COVID19- Study","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","Study of Open Label Losartan in COVID-19","COVID-19 Registry Rhineland-Palatinate (Germany)","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","Effect of a Brief Problem Management Intervention on Covid 19-Related Anxiety and Depression","Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19","Hydroxychloroquine in Outpatient Adults With COVID-19","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","Home rehabilitation for people with COVID-19: Implementing telehealth approaches to care","Comparison of lung water in COVID-19 patients and other patients with acute respiratory failure","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial","COVID-19 Convalescent Plasma","French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study","Checkpoint Blockade in COVID-19 Pandemic","Cardiovascular Manifestations of COVID-19","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","A phase I/II study to determine efficacy, safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers","UKOSS: Pandemic COVID-19 in pregnancy","Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment","Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Treatment of SARS Caused by COVID-19 With Ruxolitinib","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019","International COVID19 Clinical Evaluation Registry,","Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","Will Hydroxychloroquine Impede or Prevent COVID-19","Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19","Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)","Experiences in nursing care for patients with suspected novel coronavirus pneumonia (COVID-19) in Shanghai","Beat COVID-19 - Observational Trial","Hemodynamic Characteristics of Patients With SARS-CoV-2","TXA and Corona Virus 2019 (COVID19) in Outpatients","Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","A Study of Quintuple Therapy to Treat COVID-19 Infection","Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Cardiovascular Complications and COVID-19 (CovCardioVasc)","A medical records based observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function","CORIMUNO-ANA: TRIAL EVALUATING EFFICACY OF ANAKINRA IN PATIENTS WITH COVID-19 INFECTION, NESTED IN THE CORIMUNO-19 COHORT","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia","Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19","Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient","COVID-19 and Deep Venous Thrombosis","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury","Study for investigation of contamination by novel coronavirus pneumonia (COVID-19) in the clinical environment","Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic","Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19","A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load in COVID-19 Patients","A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic","Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19","Evaluation of Covid 19 Anxiety in Endometriosis Patients","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease","NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure","Hydroxychloroquine for COVID-19","COVID-19 Endoscopy Survey","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak","Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","COVID-19 Community Research Partnership","Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19\n","Using eHealth to support COVID-19 self-assessment and collection of self-reported health data","Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","A Study of LY3127804 in Participants With COVID-19","Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containement","PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2","Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia","COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients","Treatment of COVID-19 patients with anti-interleukin drugs","Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","COVID-19 Research Response (ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial)","Ivermectin Adjuvant to Hydroxychloroquin in COVID19 Patients","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19","Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt","Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers","Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)","Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic","MANAGEMENT OF NOVEL SARS CORONAVIRUS","Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19","A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease","Distress and resilience of healthcare professionals during the COVID-19 (coronavirus) pandemic","Aspergillosis in patients with severe influenza or coronavirus","Safety and Efficacy of Baricitinib for COVID-19","Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP","AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","To compare the effectiveness of two drugs (hydroxychloroquine and lopinavir/ritonavir alone or combined in treating hospitalized patients with confirmed COVID-19 compared to standard of care\r\n\r\n","Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.","RECOVERY Respiratory Support: Respiratory Strategies in patients with coronavirus COVID-19  CPAP, high-flow nasal oxygen, and standard care","Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients","Non-contact ECG Sensor System for COVID19","Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic","Effects of DPP4 Inhibition on COVID-19","Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients","A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)","A medical records based retrospective study for analysis clinical characteristics and risk factors of death in patients with novel coronavirus pneumonia (COVID-19)","Investigation for Prevention Awareness against COVID-19","Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based retrospective analysis of maternal and infant outcomes in Cesarean delivery in Hangzhou non pneumonia Hospital during pandemic of Novel coronovirus pneumonia(COVID-19)","Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial","University of Utah COVID-19 Hydrochloroquine Trial","Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","Acquiring Convalescent Specimens for COVID-19 Antibodies","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial","Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19)","Cancelled by the investigator                            Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)","The use of ACE2 receptor increasing medication at hospital admission and\nmortality rates in COVID-19 patints \n","Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19","A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","CONVALESCENT PLASMA IN THE TREATMENT OF COVID 19","Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study","Early risk stratification of the novel coronavirus infected diseases (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)","Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui","COVID-19 in rheumatic patients: a prospective cohort study","Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients","Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort study","A weapon against COVID-19: (Social) media and influencers","COPING With COVID-19( CWC-19)","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","Utilizing lung ultrasound in COVID-19 patients in ICU  comparison of management strategies on survival and time on ventilation.","COVID-19 - ACORES-2 study: ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection","Maternal and neonatal outcomes from women infected with SARS-COV2 (COVID-19) during pregnancy","Hydroxychloroquine for the Community-Based Treatment of COVID-19","Countering Lung Damage in COVID-19 infection (CounterCovid) study","Clinical Study to assess positive value of blood plasma from donors having built immunity against the new corona virus (SARS-CoV-2) transfused to patients suffering from SARS-CoV-2 infection","Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety\nof several experimental treatments to reduce the risk of hospitalization or death\n(COVERAGE trial)","Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial","Can intravenous high dose zinc improve clinical outcomes in patients with COVID-19 infection?","Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care","DEFIBROTIDE AS PREVENTION AND TREATMENT OF RESPIRATORY DISTRESS AND CYTOKINE RELEASE SYNDROME OF COVID-19","Cohort study for predicting severe disease courses in patients presenting for coronavirus testing to the University of Zurich COVID-19 Testing Center","A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above","Clinical trial for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.","Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection","Interest in the administration of Dornase alpha aerosol in Acute Respiratory Distress Syndrome secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19","Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the new SARS-CoV-2 coronavirus (COVID-19)","A Medical Records Based study for the Clinical Characteristics Of Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome","A questionnaire investigation of hydroxychloroquine for its potential protective effect against novel coronavirus infection (COVID-19)","Prevention of novel Coronavirus infection with hydroxychloroquine","A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector)","Effect of novel coronavirus pneumonia (COVID-19) upon male reproductive system","Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent","Study for immune antibody and multi-group function of novel coronavirus pneumonia (COVID-19) patients","Immunity against SARS-CoV-2 in Dutch population","COVID-19 during pregnancy: a prospective observational cohort","Lung ultrasound vs CT scan in COVID-19 disease","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial","Efficacy of Addition of Naproxen for COVID-19 Infection / Enacovid Study","An open label phase II/III study of IFX-1 in patients with severe COVID-19 Pneumonia","Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial","Study comparing the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection","Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia","CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)","Clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of COVID-19","EPICOS - Experimental clinical trial for PreventIon or COronavirus in health Care professionalS","Hydroxychloroquine for COVID 19 in moderately to severely ill hospitalized patients","Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to coronavirus infection."],["Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)","Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)","Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Development and application of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19)  based on CRISPR-cas protein","A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection","Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia in Wuhan, China","A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR","Optimization of treatment and diagnosis plan for critically ill patients","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)","Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)","Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial","Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).","A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia","A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection","Clinical study for the changes in mental state of medical staff in the department of radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the epidemic of novel coronavirus infection (COVID-19)","Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a Multicenter Study","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection","Study for construction and assessment of early warning score of the clinical risk of novel coronavirus (COVID-19) infected patients","Co-infection of novel coronavirus pneumonia (COVID-19) and influenza virus: a single-center, two-phase, observational study","Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Volatile Organic Compounds in Exhaled Breath","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Psychological survey of frontline medical staff in various regions of China during the epidemic of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study","Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Optimization of treatment and diagnosis plan for critically ill patients","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Immune Repertoire (TCR &amp; BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19) Patients","A real world study for traditional Chinese Medicine in the treatment of novel coronavirus pneumonia ((COVID-19)","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","An observational study for Xin-Guan-1 formula  in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","An observational study on the clinical characteristics, treatment and outcome of novel coronavirus pneumonia (COVID-19)","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation","Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network","A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)","A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","Optimization of treatment and diagnosis plan for critically ill patients","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency","Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of Different People","Study for clinical characteristics and distribution of TCM syndrome of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia (COVID-19)","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)","Impact of vitamin D deficiency on prognosis of patients novel coronavirus pneumonia (COVID-19)","The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial","Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study","Observational study of Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)","Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)","Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)","The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study","A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Pulmonary rehabilitation to improve pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population","An epidemiology study for TCM syndrome  of novel coronavirus pneumonia (COVID-19)","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)","Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV: a Prospective, Randomized Controlled Trial","A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial","Study on ultrasonographic manifestations of new type of novel coronavirus pneumonia (covid-19) in non-critical stage of pulmonary lesions","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection","The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for establishment of correlation between virological dynamics and clinical features in noveal coronavirus pneumonia (COVID-19)","Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body construction and psychological state for female at different ages","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)","A clinical research for the changes of Blood cortisol ACTH level and adrenal morphology in blood cortisol to guide the application of individualized hormone in severe novel coronavirus pneumonia (COVID-19) patients","Assessment of cardiac function in patients with Novel Coronavirus Pneumonia (COVID-19) by echocardiography and its new techniques","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)","The risk factor and prognosis of acute kidney injury in novel coronavirus pneumonia (COVID-19)","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","The Effect of Humanistic Care in Healthcare Workers Participated in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the effect of early endotracheal intubation on the outcome of novel coronavirus pneumonia (COVID-19) patients","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)","The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With  Novel Coronavirus Pneumonia (COVID-19)","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)","Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)","Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women","Development of 2019-nCoV  therapeutic antibody","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Correalation between anxiety as well as depression and gut microbiome among staff of hospital during the novel coronavirus pneumonia (COVID-19) outbreak","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)","Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus pneumonia (COVID-19)","Study for the effects on medical providers' infection rate and mental health after performing different anesthesia schemes in cesarean section for novel coronavirus pneumonia (COVID-19) puerperae","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Study on anxiety of different populations under novel coronavirus (COVID-19) infection","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)","A medical records based analysis for the clinical characteristics of novel coronavirus pneumonia (COVID-19) in immunocompromised patients","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)","The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational registration study using nCapp","Effect of New Coronavirus Pneumonia (COVID-19) on the Mental Health of College Students","Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19)","Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Clinical observation of the novel coronavirus pneumonia (COVID-19) in neonatal","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)","Study on mental health status and influencing factors of nurses during epidemic prevention of Novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics","Clinical characteristics and outcomes of cardiovascular disease patients infected by COVID-19 in Wuhan, China: a descriptive study","Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)","A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease.","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","A Multicenter Observational Study of the Perinatal-neonatal Population With or With Risk of COVID-19 in China","Registry Study on the Efficacy of a Self-test and Self-alert Applet in Detecting Susceptible Infection of COVID-19 a Population Based Mobile Internet Survey","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","The Application of Rehabilitation and Lung Eight-segment Exercise in  Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)","A Multicenter Observational Study About the Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children","Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia","The COVID-19 Mobile Health Study, a Large-scale Clinical Observational Study Using nCapp","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease.","Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia","A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)","Construction and application of non-contact doctor-patient interactive diagnosis and treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19) based on mobile internet","Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology","Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical features and treatment outcome","Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-19) Patients","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)","Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)","Investigation on Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection in Isolation Unit","Study on Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations in Patients","Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus","The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)","microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)","Multiomics study and emergency plan optimization of spleen strengthening clearing damp and stomach therapy combined with antiviral therapy for novel coronavirus pneumonia (COVID-19)","Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A medical records based analysis for antiviral therapy effect on novel coronavirus pneumonia COVID-19 patients","Clinical observation and research of multiple organs injury in severe patients with novel coronavirus pneumonia (COVID-19)","Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic","A prospective randomized controlled trial for a Self-made Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period","Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)","A survey of mental health of first-line medical service providers and construction of crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang","Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia  (COVID-19): a single-center, prospective, open clinical study","Correlation between imaging characteristics and laboratory tests of new coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)","Clinical observation and research plan of novel coronavirus pneumonia (COVID-19) patients","Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)","ICU healthcare personnel burnout investigation during the fight against novel coronavirus pneumonia (COVID-19)","Health related quality of life and its influencing factors among front line nurses caring patients with new coronavirus infection (COVID-19) from two hospitals in China","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial","A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients","The coagulation function of novel coronavirus pneumonia (COVID-19) patients","Clinical study on novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau promoted by individualized nutritional assessment and supportive treatment","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the Impact of Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People","Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","The treatment status and risk factors related to prognosis of hospitalized patients with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a descriptive study","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)","Quality of life among Chinese residents during and after novel coronavirus pneumonia (COVID19) outbreak: an online survey","Cancelled                         Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)","A Medical Records Based Study for Construction and Analysis of Diagnosis Predictive Model of Novel Coronavirus Pneumonia (COVID-19)","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)","Epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Chongqing","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)","A Retrospective Study for Preventive Medication in Tongji Hospital During the Epidemic of Novel Coronavirus Pneumonia (COVID-19)","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the Hospital Workers and Nosocomial  Prevention and Control Strategy","Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)","A study on treatment strategies of novel coronavirus pnueumonia patients","A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases","The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study","Medical records based study for Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia (COVID-19)","Critical ultrasound in evaluating cardiopulmonary function in critical patients infected with 2019 novel coronavirus pneumonia (COVID-19)","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection","Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection","A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection","Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus","A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia","Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a multicenter, retrospective, observational study","Retrospective study to assess the safety of in vitro blood purification treatment in critically ill patients with novel coronavirus pneumonia COVID-19","A retrospective study on virus typing, Hematological Immunology and case Review of novel coronavirus infected and convalescent patients (COVID-19)","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)","CT Scores Predict Mortality in 2019-nCoV Pneumonia","A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)","Study on the application of convalescent plasma therapy in severe COVID-19","The immediate psychological impact of novel coronavirus pneumonia (COVID-19) outbreak on medical students in anesthesiology and how the cope","Research on peripheral immunity function monitoring and its clinical application in patients with novel coronavirus pneumonia (COVID-19)","Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)","Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)","Study for the risk factors of critically ill patients with novel coronavirus pneumonia (COVID-19)","Study for timing of mechanical ventilation for critically ill patients with novel coronavirus pneumonia (COVID-19): A case records based retrospective Cohort study","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Detection of coronavirus in simultaneously collecting tears and throat swab samples collected from the patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in various provinces and municipalities throughout the country","Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)","A clinical study about the diagnosis and prognosis of novel coronacirus pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative cytokines and other laboratory indexes.","Survey for sleep, anxiety and depression status of Chinese residents during the outbreak of novel coronavirus infected disases (COVID-19)","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy","Retrospective studyfor integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial","Comparative Study for Clinical Features and Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients in Sichuan Province and Wuhan","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","The Effect and Safety of oXiris Membrane Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19): a Single Center Prospective Open-label Study","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)","Key techniques of combination therapy of Novel Coronavirus Pneumonia (COVID-19) - Study on TCM symptoms and treatment law","Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus pneumonia (CoVID-19)","SARS-CoV-2 Infection on Myocardial Injury and Prognosis: a Multicenter, Long- term Follow-up and Registration Study","The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Application of flash glucose monitoring to evaluate the effect of hyperglycemia and glycemic variability on prognosis in patients with novel coronavirus pneumonia (COVID-19)","A medical records based study for the clinical characteristics of anesthesia novel coronavirus pneumonia (COVID-19) patients during perioperative period and assessment of infection and mental health of Anesthesiology Department","A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","Protective factors of mental resilience in first-line nurses with novel coronavirus pneumonia (COVID-19)","Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)","The Real World Study to Evaluate the Added Treatment Effectiveness of Comprehensive Traditional Chinese Medicine for Novel Coronavirus Pneumonia (COVID-19)","Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial","A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)","The investigation of cytokine expression profile of novel coronavirus pneumonia (COVID-19) and its clinical significance","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","The Efficacy and Safety of Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of Novel Coronavirus Pneumonia Patient (COVID-19) : An Observational Study","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus(2019-nCoV)","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population","Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)","Retrospective and Prospective Study on Nosocomial infection in Stomatology Department under the Background of COVID-19","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial","Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1 in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan","Analysis for the mental health status of residents in Jingzhou during the outbreak of the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors","Study of effects of crisis intervention on medical staff based on positive psychology","Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19)9: An Multicenter Cohort Study","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial","Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel Coronavirus Disease 2019: A Longitudinal Study Protocol","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)","Correlation analysis of blood eosinophil cell levels and clinical novel coronavirus pneumonia type: a single-center, retrospective study","Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling","Retrospective analysis of epidemiology and transmission dynamics of patients confirmed with Coronavirus Disease (COVID-19) in Hong Kong","A clinical multicenter study on the occurrence, development and prognosis of 2019 ncov infection","Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia","Factors associated with death patients with novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study","Clinical research and preparation development of qingfei detoxification decoction (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)","Investigation of dynamic profile of RT-PCR test for SARS-CoV-2 nucleic acid","Study for the virus molecular evolution which driven the immune-pathological responses and the protection mechanisms of novel coronavirus pneumonia (COVID-19) patients","Establishment of an early warning model for maternal and child vertical transmission of COVID-19 infection","Clinical characteristics and outcomes of 483 mild patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center, retrospective study from the mobile cabin hospital","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Clinical outcomes and follow-up study of COVID-19 patients","Development of warning system with clinical differential diagnosis and prediction for severe type of SARS-Cov-2 patients based on artificial intelligence and CT images","Novel covid-19 pneumonia combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy","An artificial intelligence assistant system for suspected new coronavirus pneumonia based on chest CT","Investigation on psychological status of COVID-19 rehabilitation patients in Zhengzhou City and research on coping strategies","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) - REMAP-CAP","Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)","Epidemiological Characteristics and Antibody Levels of COVID-19 Infection of Pediatric Medical Staff working in Quarantine Area","Clinical validation and application of high-throughput novel coronavirus (2019-ncov) screening detection kit","The analysis of related factors on improving oxygenation status by endotracheal intubation ventilation in severe patients suffered from novel coronavirus pneumonia: a single center and descriptive study in Wuhan","Retrospective analysis of digestive system symptoms in 600 cases of 2019-ncov pneumonia in Guanggu district, Wuhan","The value of Lymphocyte subsets in Coronavirus Disease 2019","Nutritional risk assessment and outcome prediction of critically ill COVID-19 patients","Ocular dectection of SARS-CoV-2 in 114 cases of COVID-19 pneumonia in Wuhan, China: an observational study","A multicenter retrospective study of rheumatic  patients with COVID-19","Epidemiologic and Clinical features of COVID-19 in Ningbo","Screening and Identification of SARS-CoV-2 Infection and Progression in Cancer Patients Based on Bioinformatics Analysis","Quantitative CT characteristic estimate the severity of 2019-nCoV","Clinical characteristics of severe or critically ill patients infected with 2019-nCoV","A retrospective study of clinical drug therapy in patients with COVID-19","Clinical characteristics of COVID-19","Clinical characteristics and treatment of COVID-19","Analysis of risk factors affecting prognosis of elderly patients infected with COVID-19 pneumonia: a single-center retrospective observational study","Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia and their diagnostic and prognostic value","Analysis of Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia","Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus pneumonia (COVID-19)","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Sedation and Analgesia Usage in critically ill patients with novel coronavirus pneumonia (COVID-19)","The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)","A study for clinical characteristics of novel coronavirus pneumonia (COVID-19) patients follow-up in Guangxi","Risk Factors for Anxiety of Otolaryngology Workers in Hubei Province Fighting Against novel coronavirus pneumonia (COVID-19)","Open-label, observational study of human umbilical cord derived mesenchymal stem cells in the treatment of severe and critical COVID-1","Clinical study for TCM Decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the Management of investigator-initiated clinical trial and the resilience of medical service providers","Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus pneumonia (COVID-19)","Research for the influence of epidemic of  novel coronavirus pneumonia (COVID-19) on sleep, psychological and chronic diseases among different populations","Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''","Analysis of influencing factors of death of COVID-19 patients in wuhan third hospital","Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea intubation patients with new coronavirus pneumonia (COVID-19)","Clinical characteristics of 2019 novel coronavirus pneumonia (COVID-19) in Zhejiang province, China","Characteristics, prognosis of  ederly patients with Novel Coronavirus Pneumonia (COVID-19) in Wuhan area: a dual-center, retrospective, cohort study","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe new coronavirus pneumonia","Study for the physical and mental health status of medical workers under the situation of COVID-19","Analysis of the Incidence and Risk Factors of Ventilator-associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)","Characteristics, prognosis, and treatments effectiveness of critically ill patients with Novel Coronavirus Pneumonia (COVID-19): a dual-center, retrospective, cohort study","Observational Study for Prone Position Ventilation and Conventional Respiratory Support in ARDS Patients with  Novel Coronavirus Pneumonia (COVID-19)","Risk assessment and treatment timing of invasive fungal infection in critically ill covid-19 patients: medical records based study","Shedding of SARS-CoV-2 in human semen and reproductive health evaluation of ever infected males","Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus Pneumonia (COVID-19)","Cross sectional study of dialysis treatment and mental status under the outbreak of COVID-2019 in China","Exploration of the Clinical Characteristics of Patients with Novel Coronavirus Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and MERS","A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)","Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients","Preliminary screening of Coronavirus Disease (COVID-19) by special laboratory examination and CT imaging before surgery","Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau","Application of cas13a-mediated RNA detection in the detection of novel coronavirus nucleic acid","A retrospective cohort study for integrated traditional Chinese and western medicine in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in Wuhan","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)","Study on the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)","Development and application of COVID-19 intelligent image classification system based on deep learning","Retrospective study for the efficacy of ulinastatin combined with ''clear lung detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial","Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia","clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus pneumonia patients","COVID-19 infection associated kidney injury in children","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","Study on immune cell subsets in convalescent patients with SARS-CoV-2 infection","Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial","A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)","An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Analysis of Risk Factors for Outcomes After Respiratory Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)","Investigation on Mental Health Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus Pneumonia (COVID-19)","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study","Accuracy analysis of SARS-CoV-2 IgM antibody screening for diagnosis of COVID-19","Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital","Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)","The prediction value of prognosis of COVID-19 in elderly patients by modified early warning score (MEWS): a retrospective observational study","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of SARS-CoV-2 and other infectious viruses in the operating Room","Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia(COVID-19)","Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19) in asymptomatic patients: a single center, prospective, open clinical study","Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)","Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)","An observational study of high-dose Vitamin C in the treatment of severe and critical patients with novel coronavirus pneumonia (COVID-19)","Analysis of the characteristics of traditional Chinese medicine combined with western medicine and its correlation mechanism based on real-world patients with  novel coronavirus pneumonia (COVID-19)","A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)","Analysis of risk factors for death in patients with Novel Coronavirus Pneumonia (COVID-19)","A prospective cohort  study on recovering patients with novel coronavirus pneumonia (COVID-19) by comprehensive treatment of Chinese medicine","Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)","Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)","Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management","Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)","Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test","Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial","A multi-center, open-label observation study for psychological status and intervention efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia (COVID-19) designated hospitals","The effects of  prevention and control measures on treatment and psychological status of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak","Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children","Medical records based study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Study for the correlation between Chinese medicine certificate and lung image of novel coronavirus pneumonia (COVID-19)","Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","A cox regression analysis of prognosis of novel coronavirus pneumonia (COVID-19)","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial","Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-nCoV in High-risk Population Including Medical Staff","Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)","Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients","Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients","Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of  Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","The correlation between Vitamin D deficient and severe status of novel coronavirus pneumonia (COVID-19) patients","The COVISTRESS Study: Influence of the COvid-19 Epidemic on STRESS","A medical records based study of peripheral blood T lymphocyte subsets in patients with novel coronavirus pneumonia (COVID-19)","Study on the impact on fetus and neonates of vertical transmission of 2019-nCoV","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)","Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)","The Cohotr of COVID-19","The Diagnosis and prognosis prediction of novel coronavirus pneumonia (COVID-19) based on AI and Radiomics","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)","Effect of Auricular point pressing on insomnia of 2019 new coronavirus pneumonia patients: a randomized controlled trial.","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period","Detection of SARS-COV-2 RNA Level in Blood and Excrement of Patients Infected with 2019-nCOV in Recovery Period","A medical records based study for clinical features and prognosis of severe patients with novel coronavirus pneumonia (COVID-19) in Huanggang.","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia","Clinical application of extracorporeal membrane oxygenation in the treatment of severe respiratory failure patients with novel coronavirus pneumonia","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia","association of T lymphocytes level and clinical severity in patients of NCP: a single-center retrospective data","The Retrospective Study about Clinical Characteristics, Treatments and Prognosis of Patients with Novel Coronavirus Pneumonia in WuHan","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study","Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine","Accurate Classification System for Patients With COVID-19 Based on Prognostic Nomogram","Application of radiology in the prevention and control system of emergency respiratory infectious diseases","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in COVID-19 patients: a demonstration study for the key techniques","Correlation between virological negative conversion and clinical factors and prognosis in patients with novel coronavirus pneumonia (COVID-19)","Myocardial injury and arrythmias in the COVID-19 patients","Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)","Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection","A single-center, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) in healthy adults aged between 18 and 60 years","Venous Thrombosis Risk of 2019-nCoV Pneumonia(COVID-19) Patients: A Prospective Study","A Platform for Rapid Immuno-detection and Emergency Vaccine Development of  Coronavirus SARS-CoV-2","Clinical Characteristic and Outcomes of Hospitalized Patients With Coronavirus Disease 2019","Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies","Upper Respiratory Tract Virus Detection of Corona Virus Disease 2019(COVID-19)to Evaluation the value of rehabilitation patients","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)","Study for the clinical characteristics and digestive system damage of novel coronavirus pneumonia COVID-19","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study","Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial","Psychological Responses of Medical Staff during the Metaphase of Coronavirus Disease 2019 Outbreak in Hubei, China","Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.","Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)","A prospective real world study on Compound Houttuyniae Mixture used in people of the observation period in close contact with novel coronavirus pneumonia (COVID-19)","An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia","Combined diagnostic value of novel coronavirus infection detected by NLR and CRP","Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging","A study for the psychological status, social support, and care needs of tumor patients admitted to a general hospital during the novel coronavirus pneumonia (COVID-19) outbreak","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection","A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)","An observational study of cardiac and pulmonary ultrasound and evaluation of treatment of severe patients with novel coronavirus pneumonia (COVID-19)","Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)","Optimization and evaluation of the comprehensive diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the assessment of risk factors for severe pneumonia","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial","Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - SARS-CoV2quine","Identification of host cell respiratory tract cell gene expression and epigenetic pattern after human SARS-CoV-2 infection - SC2","Evaluating efficacy and safety of interferone -1b (IFN -1b) in the treatment of COVID-19","Formulation of two natural products (syrup and solution) and evaluation of their effects in patients with coronavirus disease 2019 (COVID-19): A randomized controlled trial","Evaluating efficacy and safety of interferone -1a in the treatment COVID-19 infection","The effect of  NOSCOVID on pulmonary &amp; other clinical manifestations of COVID-19 patients","Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)","Evaluating efficacy and safety of sofosbuvir/ ledipasvir in  treatment of COVID-19","A prospective randomized controlled trial comparing Sovodak (Sofosbuvir+Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia","Evaluating efficacy and safety of Hydroxychloroquine + Oseltamivir + Lopinavir or Atazanavir/ritonavir combination  in patients with COVID-19","A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of  lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.","Response adjustment of emergency deparytment against Covid-19 pandemic: experience of 5-French academic hospitals.","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study","A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.","Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Study for Clinical Epidemiology and Methods of Diagnosis and Treatment of Novel Coronavirus Pneumonia (NCP)","A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease - ECMOCARD Study","Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus","An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients","Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","Prognostic Factors of Patients With COVID-19","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19 in Jiangsu Province","COVID-19 Registry - COVID-19 Registry","Preparedness and Responsiveness among Emergency Department against Covid-19 during a rapid growth epidemic phase.","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study","Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus","Getting it Right: Towards Responsible Social Media Use During a Pandemic","An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China","A Pilot Study of Sildenafi in the Treatment of COVID-19","A Retrospective Study of Evaluating Safety and Efficacy of Tocilizumab Compared to Continuous Renal Replacement Therapy in Controlling CRS Triggered by COVID-19","Changes in Organ Specific Biomarkers, Virus Expression and Prognosis for Covid-19","Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19","Retrospective Study of Myocardial Damage in COVID-19","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Causes of fever in outpatient outside Wuhan during novel coronavirus pneumonia pandemic: a medical records based retrospective analysis","Sequential Oxygen Therapy Strategy for Patients With COVID-19","Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","Altered brain structure and function in patients with COVID-19 after rehabilitation","Uppsala Intensive Care Study of Mechanisms for Organ Dysfunction in Covid-19","Retrospective analysis of anesthesia management of emergency cesarean section in non-pneumonia hospital of Wuhan during pandemic of novel coronavirus pneumonia (COVID-19)","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy","Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)","Analysis for prevention and control effects of orthokeratology lens on myopia adolescents during the novel coronavirus pneumonia (COVID-19) pandemic situation","Influence of COVID-19 on disease activity, medical and mental condition of patients with rheumatic diseases","Serum and urine proteins and metabolomic markers in patients with COVID-19","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","AI based prognostic evaluation of novel coronavirus pneumonia (COVID-19)","The investigation on medical adhesive-related skin injury caused by protective dressings of medical staffs during the period of COVID-19","The protective effect of sleep psychology and music therapy in patients with new coronary pneumonia (mild and moderate type)","Clinical characteristics and death risk factors in COVID-19 patients","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19","The relationship between habits of using eyes, degree of visual fatigue and myopia progression in students during the novel coronavirus pneumonia (COVID-19) pandemic","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak","Outcomes and infectivity of patients with asymptomatic novel coronavirus (COVID-19) infection","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)","Epidemiologic and Clinical Characteristics of novel coronavirus pneumonia (COVID-19) in surgical patients","A retrospective study of clinical characteristics and prognosis of novel coronavirus pneumonia (COVID-19) patients with myocardial injury","Study on the mental state of medical staff  during the epidemic period of novel coronavirus pneumonia (COVID-19)","A medical records based study for clinical features of novel coronavirus pneumonia (COVID-19) patients and risk factors of death","Epidemiological study of novel coronavirus infection (COVID-19) in children at medium/low risk","Epidemiological survey of close contacts of novel coronavirus pneumonia (COVID-19)","Shedding virus and functional prognosis in patients with novel coronavirus pneumonia (COVID-19): a cohort study","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia","A medical records based retrospective study for novel coronavirus pneumonia (COVID-19)","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)","Study on home pharmaceutical care for chronic patients over the new coronavirus pneumonia epidemic","Clinical features and prognosis of  invasive mechanicalventilation patients  with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a single-centered, retrospective, observational study","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)","Clinical study on the correlation between novel coronavirus pneumonia (COVID-19) clinical rehabilitation assessment and prognosis","Clinical characteristics and risk factors of novel coronavirus pneumonia (COVID-19)","Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-arm clinical study","Clinical investigation and reseach on TCM syndrome of COVID-19","Hospital of Chengdu University of Traditional Chinese Medicine jointly launched a real-world study on the clinical efficacy evaluation of the Inner hospital preparation","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)","Gu-Shen Ding-Chuan-Wan used in the recovery phase of 2019-nCoV pneumonia(FeiPiQiXuZheng): a randomized, open-label, controlled clinical trial","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)","Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets","Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial","Multicenter clinical study of evaluation of multi-organ function in patients with novel coronavirus pneumonia (COVID-19) by ultrasound","Prediction of prognosis and antiviral effect of patients with neocoronavirus infected pneumonia based on Peripheral blood exosomal metabolomics analysis and radiomics in CT of lung and its mechanism","the effects of 6-minute walk training on walking distance, oxygen saturation, heart rate and global rating of change of normal or critial novel coronavirus pneumonia (COVID-19)","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China","Effect of pulmonary rehabilitation on pulmonary function, exercise capacity, activity of daily living and quality of life in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19","Novel coronavirus pneumonia (COVID-19) emergency research project tackled by Shanghai University of Traditional Chinese Medicine","An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19","Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Gurin vaccination, a randomized controlled trial (COVID-19). - BCG-CORONA","Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19","The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - N-ReCOVID 19","A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) - Phase II trial of inhaled anti-viral (SNG001) for SARS-CoV-2 infection","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","Serum Testing of Representative Youngsters: Sero- Epidemiological Survey of England in 2019/2020","Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.","Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)","The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial","Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19)","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing COVID-19 Infection in Adults Exposed to COVID-19","Acute Kidney Injury in Patients Hospitalized With COVID-19 in Wuhan, China: a Single-center Retrospective Observational Study","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA","Use of Ascorbic Acid in Patients With COVID 19","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","Investigation of Physical Activity, Quality of Life and Stress Levels of Individuals Who Live in Their Homes Isolated Because of Coronavirus (COVID-19) Disease","Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia)","Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study","Non-contact Endoscopy at Covid-19 Outbreak","Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19","Proposal for International Standardization of the Use of Lung Ultrasound for COVID-19 Patients; a Simple, Quantitative, Reproducible Method","A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19","What happens to non-health care workers' sleep of China during the pandemic of novel coronavirus pneumonia (COVID-19)","A paired clinical study of novel coronavirus pneumonia (COVID-19) patients with ordinary, severe, critical, and deceased patients in Tongji Hospital","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","Audio Data Collection for Identification and Classification of Coughing","Study for the Mechanism of the Relationship between Infection of novel coronavirus pneumonia (COVID-19) and Host Innate Immune","Survey of psychological status and related factors of emergency medical staff in the country during the COVID-19 pandemic","Comprehensive Clinical, Virological, Microbiological, Immunological and Laboratory Monitoring of Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)","In-depth Characterisation of the Dynamic Host Immune Response to Coronavirus SARS-CoV-2","A Medical Records Based Study for the Correlation between Angiotensin II Type 1 Receptor Blockers (ARBs) and  the Progression and Outcome of Novel Coronavirus Pneumonia (COVID-19)","Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)","Assessment of mental health status of first-line dental emergency medical personnel during novel coronavirus pneumonia (COVID-19) pandemic","The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial","Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","A multi-center telephone follow-up study of disease management and infection in rheumatic patients during novel coronavirus pneumonia (COVID-19) pandemic in Hubei province","Sleep quality of patients with novel coronavirus pneumonia (COVID-19) treated in mobile cabin hospital: a retrospective study","Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Novel coronavirus (2019-nCOV) IgG detection kit (magnetic particle chemiluminescence) clinical trial","Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial","Analysis of changes in high risk factors of cervical spondylosis during novel coronavirus pneumonia (COVID-19) pandemic","Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)","Clinical experience of 59 novel coronavirus pneumonia patients with intensive endotracheal intubation: a single center, retrospective, descriptive study","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection","COVID-19 Public Image Registry","Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised pre and post implementation study (CoV-19POC)","The Effects of novel coronavirus pneumonia (COVID-19) Risk Factors on Dynamic Changes of  Immunological, biochemical, and Metabolic Parameters: a Retrospective Observational Study","Novel coronavirus infection (COVID-19) IgM detection kit (magnetic particle chemiluminescence) clinical trial","A Medical Records Based Retrospective Study for Clinical Characteristics of severe Novel Coronavirus Pneumonia (COVID-19)","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy","Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)","Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical application value of multiple tests for novel coronavirus pneumonia (COVID-19)","Safety and effectiveness analysis of data from novel coronavirus pneumonia (COVID-19) patients with conventional therapy","The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study","Impact of measuring distance and cold outdoor environment on the screening of novel coronavirus pneumonia (COVID-19)","A clinical study evaluating the safety and tolerability of microRNA2911 plasmids in healthy adults","Evaluation of  the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis","A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - SARPAC","CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL - HOPE","COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19  a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease - CounterCovid Study","NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION - NO-COVID-19","Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 - APN01-01-COVID19","Uno studio randomizzato multicentrico in aperto per valutare lefficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. - TOCI-RE","An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults &amp; Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails","A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection","HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19  risque daggravation secondaire : tude prospective multicentrique randomise en double aveugle - HYCOVID","Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19","Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial","Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers","ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (COVID-19)","A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects","Multi-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2/COVID-19 in Healthcare Workers at High-Risk of Exposure","Lessening Organ Dysfunction With VITamin C (LOVIT)","Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection","The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial","Outcomes and Prognostic Factors in Coronavirus Disease (COVID-19) in Very Old Intensive Care Patients","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial","Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV","A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment","DAS181 for Severe COVID-19: Compassionate Use","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool (COV_NUTRIC)","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults","Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study","Exploratory Clinical Study to Assess the Efficacy of NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Hypertension in Patients Hospitalized With COVID-19 in Wuhan, China: A Single-center Retrospective Observational Study","Mindfulness During COVID-19 - Remote Mindfulness Sessions","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic","Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China","Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","The ECLA PHRI COLCOVID Trial","A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam","Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study","A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.","A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence","An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734)","Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)","An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area","Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection","Pandemic Response Network: Duke Community Health Watch","Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - Severely-ill Patients","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial","Clinical Characteristics and Outcomes of Children Potentially Infected by Severe Acute Respiratory Distress Syndrome (SARS)-CoV-2 Presenting to Pediatric Emergency Departments","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization","A Single-center,Open-label,Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19","Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia","Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization","The Benefits of Artificial Intelligence Algorithms (CNNs) for Discriminating Between COVID-19 and Influenza Pneumonitis in an Emergency Department Using Chest X-Ray Examinations","Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals","An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azytromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients","An Observational Case-control Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry and Validation of C2D2 (Critical Care Data Dictionary)","A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients","Online-based Survey of the Anxiety Associated With the COVID-19 Pandemic in the General Population in Germany","GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19","A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment","Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia","Study to Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","PRIORITY (Pregnancy Coronavirus Outcomes Registry)","Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic","Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19","Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study","Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis","Biological Samples Collection From Patients and Caregivers Treated at Bordeaux University Hospital for Asymptomatic and Symptomatic Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Infection (COVID-19).","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations","Impact of Social Media on Knowledge Dissemination Between Physicians During COVID-19 Virus Outbreak","COVID CT, Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","Risk Factors for Community- and Workplace Transmission of COVID-19","Biomarkers Identification for Diagnosis and Treatment of SARS-COV-2 Infection","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients","A PATIENT-CENTRIC OUTCOMES REGISTRY OF PATIENTS WITH KNOWN OR SUSPECTED NOVEL CORONAVIRUS INFECTION SARS-COV-2 (COVID-19)","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Evaluation of Novel Diagnostic Tests for 2019-nCOV","The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial","A Phase 2, International Multi-site, Bayesian Adaptive, Randomised, Double-blinded, Placebo-controlled Trial Assessing the Effectiveness of Varied Doses of Oral Chloroquine in Preventing or Reducing the Severity of COVID-19 Disease in Healthcare Workers","Prospective Observational Study for Patients With HIV and Confirmed SARS-CoV-2","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial","Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","EC-COVID-PCS - Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","Time of Recovery and Prognostic Factors of Covid19 Pneumonia","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial","A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","An Adaptive Phase 2/3, Randomized, Double-blind, Placebo Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19","Safety and Efficacy of Hyperbaric Oxygen for Improvement of Acute Respiratory Distress Syndrome in Adult Patients With COVID-19; a Randomized, Controlled, Open Label, Multicentre Clinical Trial","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study","Reducing Health Care Workers Absenteeism in SARS-CoV-2 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Gurin Vaccination, a Randomized Controlled Trial.","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial","A Randomized Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalized Subjects With Confirmed SARS-CoV-2","CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS","Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic","EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial","Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial","Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","How Immune Responses Shape Virological and Clinical Characteristics of COVID-19: a Prospective Cohort Study","Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus","Impact of the Coronavirus (COVID-19) on Patients With Cancer","A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients","Outcomes of Patients With COVID-19 in the Intensive Care Unit: A National Observational Study (Mexico COVID-19 ICU Study)","Impact of Covid-19 in Congenital Heart Disease - COVID-CHD","Use of Caption AI to Perform a Clinically Indicated Transthoracic Echocardiogram in Patients Being Evaluated for or Positive for COVID-19","Proflaxis for Healthcare Professionals Using Hydroxychloroquine Plus Vitamin Combining Vitamins C, D and Zinc During COVID-19 Pandemia: An Observational Study","PCR-COVID-19 Predictors of Positivity in Patients Admitted to ICU for Respiratory Infection: A Prospective Observational Cohort Study","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19","A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome","Protective Role of Inhaled Steroids for Covid-19 Infection","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection","A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.","COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CODEX (Alliance Covid-19 Brasil III)","Determination Of Physical Activity, Sleep And Stress Level Of Pregnant Women In The Covid-19 Quarantine Period","Renin Angiotesnin System - CoronaVirus","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation","REmote MOniToring usE in Suspected Cases of COVID-19 (Coronavirus): REMOTE-COVID Trial","Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)","Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana","Clinical Characteristics and Prognostic Factors of Patients With COVID-19 in Chibi Hospital of Hubei Province","Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial","Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study (Covid-VAS)","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19","A Clinical and Radiological Model to Predict the Prognosis for COVID-19 Patients","Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection","CAP-1002 Treatment in Patients With Severe COVID-19 and in Critical Condition as Indicated by Life Support Measurements","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19","Descriptive Study Regarding the Ambulant Screening Protocol for COVID-19 in Times of High SARS CoV-2 Prevalence","Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic","Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment","Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment","Clinical Characteristics of COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study","Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia","The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial","COVID-19 Symptom Tracker","Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Effectiveness and Safety of Chloroquine Phosphate in Combination With Telemedicine in the Reduction of Risk of Disease-related Hospitalization or Death, in Ambulatory Patients With COVID-19 at Particular Risk of Serious Complications","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial","Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population","Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease","A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia","An Observational Study of Patients With Coronavirus Disease 2019","Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia","Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study","Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","An Open Label Phase II Pilot Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia","Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation","A Phase 2 Randomized, Open Label Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)","Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19","Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19","Convalescent Plasma for Patients With COVID-19: A Pilot Study","Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study","Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Cohort Study of SARS-CoV-2 Incidence, Transmission, and Disease Severity in Healthcare Workers","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","COVID-19-Like Illness: Did we Have Unusual Severe Respiratory Tract Infections October-December 2019 Before WHO Announcement ?","Covid-19 Pediatric Observatory","Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.","Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study","Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","Assessment of Distress in Crisis Situations During COVID-19","Impact of Previous Treatment With Angiotensin II Receptor Blockers in Patients With SARS-Cov2 Infection Admitted to the Intensive Care Unit on Survival and Severity of the Disease (COVID-ARA2)","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","Dynamic Evaluation of COVID-19 Diagnostic Tests","Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial","The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)","The Role of Resistant Potato Starch in COVID-19 Infection","A Study on the Prospective Cohort Library of Novel Coronavirus Pneumonia in Southeran","CORONAVIRUS DISEASE 2019- USING ASCORBIC ACID AND ZINC SUPPLEMENTATION (COVIDAtoZ) Research Study A RANDOMIZED, OPEN LABEL SINGLE CENTER STUDY","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department","Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy: an Italian Polispecialistic Society of Young Surgeons (S.P.I.G.C.) Survey","COVID-19 Risk Stratification","A Prospective, Longitudinal, Observational Study of Healthcare Workers and the General Population to Watch for Flu-like Symptoms in Suspicion of COVID 19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults","Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study","An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19","COVID-19 Registry Rhineland-Palatinate (Germany) - COVID-19 Disease Registry a National, Multicentre, Non-interventional, Prospective Observational Study","National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","Randomised Controlled Trial of Problem Management Plus versus Enhanced Treatment as Usual on Anxiety and Depression in People Distressed by Covid 19","A Pragmatic Adaptive Open Label, Randomized Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial","A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","Home telerehabilitation for people with COVID-19: Implementing telehealth approaches to care and its effect on reintegration into the community","EVALUATION: Extravascular lung water index in patients with COVID-19: A prospective comparison to a recent cohort with non-COVID-19 ARDS","Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial","Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center","French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study","A Multicenter, Randomized, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Checkpoint Blockade in Patients With Coronavirus Disease 2019 (COVID-19)-Related Mild Acute Respiratory Syndrome Nonresponsive to Frontline Therapy","Cardiovascular Manifestations of Hospitalized Patients With Coronavirus Disease 2019","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology","A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers","Maternal and perinatal outcomes of pandemic COVID-19 in pregnancy","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment","Postnatal Outcomes of Covid 19 Positive Mothers Newborns","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study","International COVID19 Clinical Evaluation Registry: HOPECOVID19. (Health Outcome Predictive Evaluation for COVID19)","A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study","Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome","Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)","Public health emergencies of hospital emergency nursing human resource database to development and construction","A Virtual Observational Protocol to Gain Longitudinal Data in Participants to Help Understand COVID-19 Spread and Disease Progression","Hemodynamic Characteristics of Patients With SARS-CoV-2: PiCCOVID Study","Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients","Point Of Care UltraSonography to Perform Risk-stratification of Patients With Suspected or Confirmed COVID-19 - POCUSCO Study","A Phase II Pilot Study of Quintuple Therapy to Treat COVID-19 Infection","Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Screening of Cardiovascular Complications in Patients With COVID-19","Observational study for myocardial injury and cardiac function in critically ill patients with novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-2019) patients' prognosis and their influence on heart and lung function","CORIMUNO-ANA: TRIAL EVALUATING EFFICACY OF ANAKINRA IN PATIENTS WITH COVID-19 INFECTION, NESTED IN THE CORIMUNO-19 COHORT","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)","Prospective Descriptive Study on the Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid19","Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic","COVID-19 and Deep Venous Thrombosis: a Cross-sectional Study","A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation","The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation","The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury","A cross-sectional observation study to delineate the degree of environmental contamination by SARS-CoV-2 in the clinical environment","Study for sleep quality of medical teams members moved to Hubei for the fighting of novel coronavirus pneumonia (COVID-19) pandemic","PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","Development of a Breath Analysis Test for Disease Diagnosis and Prognosis","The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19, a Prospective Cohort Study","A Double Blind, Randomized Controlled Trial of Three Gargling Agents in Reducing Intraoral Viral Load in Subjects With Laboratory Confirmed Coronavirus Disease (COVID-19)","Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial","Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","Endometriosis Patients Covid 19 Anxiety","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With Symptoms of Confirmed or Probable COVID-19 Disease","NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure","Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19","Gastrointestinal Endoscopy in the Era of COVID-19: a Multinational Survey","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak","Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial","A Multicenter, Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records","Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial","An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19\n","Using eHealth to support COVID-19 self-assessment and collection of self-reported health data","The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019","The Impact of the Coronavirus Disease 2019 (Covid-19) Outbreak on Emergency Room Attendances of Surgical Patients at a Tertiary Medical Center","Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment","Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection","A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19","Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containement - EPILOGUE","STUDY ECMO-COVID-19 : PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2","Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia","COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVID","A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AID","Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection","ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections COVID-19 Research Response Trial","Adjuvant Use of Ivermectin To Hydroxychloroquine in Patients With Covid19: A Novel Double Blind Placebo Controlled Pilot Study","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19","Characteristics and Outcome of COVID-19 Among Egyptian Patients","Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers","Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)","A Prospective Cohort Study Investigating Oncology-patient-reported Anxiety, Mood, and Quality of Life During the COVID-19 Pandemic (ONCOVID Trial)","EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTION","Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19","Randomized evaluation of COVID-19 therapy","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease","Distress And Resilience of healthcare professionals during the COVID-19 pandemic","Incidence and pathogenesis of invasive aspergillosis in intensive care patients with severe influenza or COVID-19 (AspiFlu)","Safety and Efficacy of Baricitinib for COVID-19","Safety and Effectiveness Study of Low Flow Extracorporeal Membrane Oxygenation(CO2 Removal) Driving by Continuous Hemofiltration Machine the Severe New Corovirus Pneumonia (NCP)","AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care","Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.","In adult patients with known or suspected COVID-19, does the use of Continuous Positive Airway Pressure (CPAP) or high-flow nasal oxygen (HFNO), compared with standard care reduce mortality or need for tracheal intubation?","\n                An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care\n","Evaluating Non-contact ECG Sensor System for Early Detection of COVID19","\"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers\" \"Impact Psychologique de l'pidmie COVID-19 Chez Les Patients, Familles et Soignants de Reanimation\" \"BURDENCOV\"","Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic","Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes","Study for the exercise rehabilitation therapy for the dysfunction of cured discharged novel coronavirus pneumonia (COVID-19) patients","A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)","Clinical features and outcomes of critically ill adult patients with COVID-19 admitted to ICUs of non-Wuhan city, China: a medical records based retrospective study","The impact of Information Sources over behaviors and preventive measures against COVID-19","Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19)","Retrospective analysis of maternal and infant outcomes in Cesarean delivery in Hangzhou non pneumonia Hospital during pandemic of Novel coronovirus pneumonia(COVID-19)","Safety And Efficacy Of Hydroxychloroquine As COVID-19 Prophylaxis For At-Risk Population (SHARP): A Cluster Randomized Controlled Trial","Hydroxychloroquine for Outpatients With Confirmed COVID-19","Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19","Acquiring Convalescent Specimens to Isolate and Identify Potent Monoclonal Antibodies Against COVID-19","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial","Study for early biological warning signals in patients with acute renal injury caused by novel coronavirus pneumonia (COVID-19)","Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)","The use of ACE2 receptor increasing medication at hospital admission and\nmortality rates in COVID-19 patints \n","Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study","A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","CONVALESCENT PLASMA IN THE TREATMENT OF COVID 19","Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study","Early risk stratification of the novel coronavirus disease 2019 (COVID-19): a multicenter retrospective study  (ERS-COVID-19 study)","Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui","COVID-19 in rheumatic patients: a prospective cohort study","Lung ultrasound (LUS) as a tool to determine the clinical course in COVID-19 patients","Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort study","The use of (social) media","Effectiveness of Crisis Management Coaching on Faculty and Trainee Wellness During COVID-19 Crisis","Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","Utilizing lung ultrasound in COVID-19 patients in ICU  comparison of management strategies on survival and time on ventilation.","COVID-19 - ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection: the randomized ACORES-2 study - ACORES-2","Prospective registry of maternal, perinatal and neonatal outcomes from pregnancies infected with SARS-COV2 (COVID-19)","A Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19\r\n","Countering Lung Damage in COVID-19 infection (CounterCovid) study","A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19","Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety\nof several experimental treatments to reduce the risk of hospitalization or death\n(COVERAGE trial) - COVERAGE","Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCO","High-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients: A pilot randomized controlled trial","Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19)","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity","A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19. - DEFACOVID","Predicting hospitalization and poor clinical outcomes in patients presenting for SARS-CoV-2 testing in an outpatient testing center in Switzerland - a prospective cohort study","Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE)","Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.","Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infection","Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 - COVID19-COVIDornase","Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19","Clinical Characteristics Of 45 Hospitalized Novel Coronavirus Pneumonia (COVID-19) Patients With Acute Respiratory Distress Syndrome: A Single-Centered, Retrospective, Observational Study","A questionnaire investigation of hydroxychloroquine for its potential protective effect against Severe Acute Respiratory Syndromes-coronavirus-2 infection","PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. - PrEP_COVID","A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years","Effect of novel coronavirus pneumonia (COVID-19) upon male reproductive system","Development and clinical application of novel coronavirus pneumonia (COVID-19) antigen reagent","Serum, faeces and sputum proteins and metabolomic markers in patients with novel coronavirus pneumonia (COVID-19)","Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2","COVID-19 during pregnancy: a prospective observational cohort","A prospective observational multi-center trial assessingthe diagnostic value of lungultrasound (LUS) vs CT-scan in patientswith COVID-19Infection","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial","Efficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study - ENACOVID","A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - \"PANAMO\" - Panamo","Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial - COVIDAXIS","IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection\r\n\r\n - IMMUNONCOVID-20","Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUS","PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)","Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) - TCOVID","Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled with placebo - EPICOS","An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19","Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. - Steroids In Coronavirus (SIC)"],[null,null,null,null,null,null,null,null,null,null,"ELACOI",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Cov-CONTACT",null,null,null,"Steroids-SARI",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"COVID-19",null,null,null,null,null,null,"CMHS",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"2019-nCoV",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"COVISTRESS",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"CTOROTSADTOC",null,null,null,null,null,null,null,null,"TACOS","COVID MECH","CovidTox","TT-NPC",null,null,null,"SOTSPC","PHYDRA","CODIV-ACE",null,"UMODCOVID19",null,null,null,"I-COVID","HYDRA",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"DisCoVeRy",null,"STORY","SOLID-C19","NOSARSCOVID","COPCOV","BEST-RCT","PROACTIVE-19",null,"ONSCOVID19",null,null,"COVID19-HCW",null,"JOCOVID",null,null,null,"COVID-19",null,"BARI-COVID",null,"add-on-COV2","CovidSurg",null,"CORIPREV-LR","COV19-PLASMA","LUSCOVID19",null,null,null,null,"CAPACITY-COVID","ENACOVID",null,null,null,null,"COntAGIouS",null,null,null,null,"MP-C19","ACT COVID19",null,null,null,null,null,null,null,null,null,null,"C19REG",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"NONTM",null,null,"STOP-Flu",null,null,"THDMS-COVID-19","NoCovid","NOpreventCOVID",null,null,null,"LOVIT","NO COVID-19","CamoCO-19","COVIP","ProPAC-COVID",null,"NOSO-COR",null,"BEST-CP",null,null,"CYCOV",null,"Covid","DC-COVID-19",null,null,null,null,"HOPE","HT-COVID19",null,null,"SEROCOV",null,"COVID-19 PEP","COLCOVID","VICO",null,null,null,null,null,"HCQ4COV19",null,"NeuroCOVID19",null,null,"HAHPS","PERN-COVID-19",null,null,"APICTH",null,null,"NOSARSCOVID","COVID-AIV",null,"AI-COVID-Xr",null,"Coalition-I","SISCO","VIRUS","CATCO","CORA","GO2 PEEP","SARS-RAS","SAC-COVID","TOCIVID-19","COVID-BioB","COVID-preg","PRIORITY","DISPOSE",null,"HYCOVID","COVIDOSE","COLCOV19-BX","ATCO",null,null,null,null,"B-DT-COV2","COVACTA",null,"BEAT19",null,"COVIDx",null,"GRECCO-19","BRACE","CROWN CORONA",null,"HyAzOUT","LIBA","COVID-19","CSSC-001","EC-COVID-PCS","NIKE_C19","TOCIVID",null,"CORIMUNO-19",null,"COVID-19-HBO",null,"BCG-CORONA","MultiCov",null,"CORON-ACT","DEXA-COVID19","CORSER",null,"GARM-COVID19","CORIMUNO-SARI","eCardioCovid19","EC-COVID-RCT",null,null,null,null,null,"SPIN-CHAT","MexCOVID-19","COVID-CHD","CAPTION AI",null,"PREDICT",null,null,"COV-AID","INHASCO","COVID CALL 15",null,"SARPAC","CODEX",null,"SRA-COV",null,"REMOTE-COVID","COVIDMED","EPI-COVID-19",null,null,null,"CP-COVID-19",null,"Covid-VAS",null,"PATCH",null,null,null,"NOCOVID",null,null,null,null,null,null,null,null,"CORONACION",null,"QUARANTINE2020","CORIMUNO-TOC","PrEP_COVID","COVIDENCE",null,null,"COVID-19","SCOUT",null,null,null,"eChoVid","HELPCOVID-19","DEFI-VID19",null,"COVID-Lambda","TOCOVID","ACTION",null,"CP-COVID-19","TOSCA",null,"HCQINRLGII","COMIHY",null,"CTII-nCoV",null,null,null,"PANDOR","SOS-COVID19","ASC COVID-19","CORIMUNO-VIRO","ORCHID",null,"C-19-ACS",null,"COVID-ARA2",null,"TRODVID-19",null,null,"COVITD-19","HERO-HCQ",null,null,"COVIDAtoZ","CORIMUNO-NIVO","NO COV-ED",null,null,null,null,"HSC19",null,null,"COVID19PUGG2",null,null,"PANAMO",null,null,"TOVID-49",null,null,null,"AZIQUINE-ICU",null,"FRENCH CORONA","COPERNICO",null,null,null,null,null,null,"INCOVPED",null,null,"Covid-19",null,null,"HOPE COVID 19",null,"COVID-SER","WHIP COVID-19",null,null,null,"JUPITER","PiCCOVID","TCOutpatient","POCUSCO","HAZDpaC","EPICOS","APN01-COVID-19","CovCardioVasc",null,null,"CORIMUNO-ANA","SCOPE",null,"BIOCOVU",null,"RuxCoFlam",null,null,null,null,null,null,"COVID-19",null,null,"COVID-19",null,null,null,null,null,null,"COVIDeHPAD",null,"COV-HCQ","COVID-19 Endo","STOP COVID",null,"CloroCOVID19II",null,"CRASH-19",null,null,"REPLACECOVID",null,"PROTECT","CLOCC",null,"EPILOGUE","ECMO-COVID-19","New",null,null,null,null,null,null,null,null,"COVID-19",null,null,"ONCOVID",null,null,null,"DIC",null,null,null,null,null,"Al-COVE","ECMO-VID",null,null,null,null,null,"BURDENCOV",null,null,null,null,null,null,null,null,"SHARP COVID-19",null,"ConCoVid-19",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"STOP-COVID",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["Zhongnan Hospital of Wuhan University","HwaMei Hospital, University of Chinese Academy of Sciences","Xiangya Hospital of Central South University","Emergency Department of Zhongnan hospital of Wuhan University","The First Affiliated Hospital of Zhejiang University School of Medicine","Children's Hospital of Fudan University","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","Affiliated Hospital of Changchun University of traditional Chinese Medicine","Guangzhou reborn health management consultation co., LTD","Shenzhen Second People's Hospital","Guangzhou 8th People's Hospital","Qilu Hospital of Shandong University","Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","The First Affiliated Hospital of He'nan University of Chinese Medicine","Wuxi People's Hospital","Shanghai University of TCM","Huangshi Hospital of Traditional Chinese Medicine","Beijing You'an Hospital, Capital Medical University","Huangshi Hospital of Traditional Chinese Medicine","The First Affiliated of Wenzhou Medical University","Beijing 302 Hospital","Jieming QU","Peking Union Medical College Hospital","First Affiliated Hospital of Zhejiang University","Zhejiang Provincial People's Hospital","West China Hospital, Sichuan University","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","HwaMei Hospital, University of Chinese Academy of Sciences","The First Affiliated Hospital of Zhengzhou University","Nanjing Second Hospital","West China Hospital, Sichuan University","Zhongnan Hospital of Wuhan University","Shenzhen Third People's Hospital","Wuhan Pulmonary Hosptial","Guangdong Provincial Hospital of Chinese Medicine","Shanghai Public Health Clinical Center","Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology","The Fifth Affiliated Hospital Sun Yat-Sen University","Jiangsu Institute of Parasitic Diseases","The First Affiliated Hospital of Medical College of Zhejiang University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Shanghai Pulmonary Hospital","The First Affiliated Hospital of Zhejiang University School of Medicine","Shanghai Public Health Clinical Center","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Guangdong Provincial Hospital of Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","People's Hospital of Guangshan County","Ningbo First Hospital","China Academy of Chinese Medical Sciences; Zhongnan Hospital of Wuhan University","Department of Critical Care Medicine, West China Hospital of Sichuan University","Hubei Provincial Hospital of TCM","Xiangyang 1st People's Hospital","Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital","Zhejiang Chinese Medical University","Deyang Integrated Traditional Chinese and Western Medicine Hospital","Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University","Sun Yat sen Memorial Hospital of Sun Yat sen University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Zhejiang Chinese Medical University","Zhejiang Chinese Medical University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Enze Hospital of Taizhou Enze Medical Center (Group)","Renmin Hospital of Wuhan University","The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine","1. Xinhua Affiliated Hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Zhongnan Hospital of Wuhan University","West China Hospital, Sichuan University","The First Affiliated Hospital of He'nan University of Chinese Medicine","Beijing hospital of Traditional Chinese medicine; Hubei integrated traditional Chinese and Western Medicine Hospital","The First Afflicated Hospital of Guangzhou University of Chinese Medicine","Affiliated Zhongshan Hospital of Dalian University","The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of Guangzhou Medical University","West China Hospital, Sichuan University","The First Hospital of He'nan University of Chinese Medicine","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","The Fifth Affiliated Hospital Sun Yat-Sen University","Guangdong Provincial Hospital of Chinese Medicine","The First People's Hospital of Huaihua","Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","The First Affiliated Hospital of Zhejiang University School of Medicine","Hubei Provincial Hospital of TCM","The Fifth Affiliated Hospital of Sun Yat-Sen University","The First Affiliated Hospital, College of Medicine, Zhejiang University","Hunan yuanpin Cell Biotechnology Co., Ltd","The 5th Medical Center Chinese PLA General Hospital","The Third People's Hospital of Shenzhen","Xiangyang First People's Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of Zhejiang University School of Medicine","Renmin Hospital of Wuhan University","The First Hospital Affiliated to Zhejiang University's Medical School","Hospital of Chengdu University of Traditional Chinese Medicine","The First Affiliated Hospital, Zhejiang University School of Medicine","Zhongnan Hospital of Wuhan University","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","Shenzhen national medicine inheritance medical research institute co. LTD","The First Affiliated Hospital of Nanchang University","Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences","Hubei Provincial Integrated Hospital of traditional Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1.Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese MedHubei integrated traditional Chinese and Western Medicine Hospital","Wuhan 1st Hospital","Hubei Integrated Hospital of Traditional Chinese and Western Medicine","The Second Hospital of Shanxi Medical University","The First Hospital of Shanxi Medical University","Peking University Third Hospital","Zhongnan Hospital of Wuhan University","Institut National de la Sant Et de la Recherche Mdicale, France","Southeast University, China","The First Affiliated Hospital of Nanchang University","China Academy of Chinese Medical Sciences","Peking Union Medical College Hospital","Wuhan Jin Yin-tan hospital","The Third People's Hospital of Shenzhen","Tongde Hospital of Zhejiang Province","Xi'an Chest Hospital","The First Affiliated Hospital of Guangzhou Medical University","ZhiYong Peng","West China Hospital of Sichuan University","Renmin Hospital of Wuhan University","Peking University First Hospital","Chengdu University of Traditional Chinese Medicine","Tianjin University","Shanghai Public Health Clinical Center","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Department of Ultrasound, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital","Shanghai Public Health Clinical Center","First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of Zhejiang University School of Medicine","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","West China Hospital, Sichuan University","Renmin Hospital of Wuhan University","Chinese PLA General Hospital","The Second Affiliated Hospital of Xi'an Jiaotong University","Guangxi medical uniwresity","The First Affiliated Hospital of Guangzhou Medical University","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","The First Affiliated Hospital of Guangzhou Medical University","the Second Affiliated hospital of Xi'an Jiaotong University","Tianjin Huanhu Hospital","Department of Ultrasound Imaging, Renmin Hospital of Wuhan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Shanghai Changzheng Hospital","The Sixth Medical Center of PLA General Hospital","The Fifth Affiliated Hospital of Sun Yat-Sen University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Nanchang Ninth Hospital","Hospital of Chengdu University of Traditional Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Zhongshan Hospital Affiliated to Xiamen University","Affiliated Hospital of Xuzhou Medical University","Beijing Chaoyang Hospital, Capital Medical University","Shanghai General Hospital of Shanghai Jiaotong University","Health commission of Heilongjiang province","Shanghai 10th people's hospital","Department of respiratory and critical care medicine, Tongji Hospital, Tongji Medical College, Huazhong University of science and technology","Second Hospital of University of South China, Hengyang","Zhongshan Hospital Fudan University","West China Hospital, Sichuan University","Hospital of Chengdu University of Traditional Chinese Medicine","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Shanghai University of TCM","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine,","Zhongshan Hospital Affiliated to Xiamen University","Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences","Chinese PLA General Hospital","Zhongnan Hospital of Wuhan University","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","West China Second Hospital, Sichuan University","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","The First Hospital of Peking University","Sichuan Academy of Medical Sciences &amp; Sichuan Provincial Peoples Hospital","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Enze Hospital of Taizhou Enze Medical Center (Group)","Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Qingdao East Sea Pharmaceutical Co., Ltd.","Renmin Hospital of Wuhan University","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Zhongshan Hospital, Fudan University","Capital Medical University","Hubei Hospital of Traditional Chinese Medicine","Children's Hospital of Fudan University","Beijing Tsinghua Chang Gung Hospital","First Affiliated Hospital of Wenzhou Medical University","First Affiliated Hospital of Wenzhou Medical University","The First Affiliated Hospital of Fujian Medical University","The First Affiliated Hospital of Fujian Medical University","Beijing Children's Hospital","Wuhan Union Hospital, China","Chinese Alliance Against Lung Cancer","Institute of Integrative Medicine of Dalian Medical University, Dalian, China.","Capital Medical University","Tang-Du Hospital","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","ShuGuang Hospital","Hu'nan university of chinese medicine","Hubei Provincial Hospital of TCM","Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of science and technology","Xinyang Central Hospital","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","First Affiliated Hospital of Fujian Medical University","The First Affiliated Hospital of Fujian Medical University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Hubei Provincial Hospital Of TCM","Third Affiliated Hospital, Sun Yat-Sen University","Third Affiliated Hospital, Sun Yat-Sen University","Xinxiang medical university","the Second Affiliated hospital of Xi'an Jiaotong University","Nanjing Second Hospital","Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University","Li Caixia","Shanghai Public Health Clinical Center","Henan Provincial People's Hospital","Lishui Central Hospital","Tongji Hospital of Tongji University","Beijing Geriatric Hospital","West China Hospital of Sichuan University","Affiliated Hospital of Changchun University of traditional Chinese Medicine","The Second Affiliated hospital of Anhui Medical University","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Nanjing Second Hospital","Xianning Central Hospital","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Shanghai Public Health Clinical Center","The First Affiliated Hospital of Harbin Medical University","Department of critical care, Zhongnan Hospital of Wuhan University","Xiamen University","Shanghai Changzheng Hospital","The Fourth Affiliated Hospital of Harbin Medical University","Puren Hospital of Wuhan City","Ganzi Hospital of West China Hospital, Sichuan University","Shanghai University of Traditional Chinese Medicine","Wuxi Fifth People's Hospital","The Thirteenth People's Hospital of Chongqing","Ganzi Hospital of West China Hospital, Sichuan University","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","The Fourth Hospital of Hebei Medical University","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","The First Affiliated Hospital of Nanchang University, Ten layers pulse Research Institute of traditional Chinese medicine, Nanchang University","Central South Hospital of Wuhan University",null,"Cancelled","West China Hospital, Sichuan University","Chongqing Liangjiang New Area first people's Hospital","First Affiliated Hospital of Anhui Medical University","Chinese PLA General Hospital","Peking University Third Hospital","Peking University Third Hospital","The First Hospital of Jilin University","The First Affiliated Hospital of Chongqing Medical University","Fifth People's Hospital of Ganzhou","Chongqing Three Gorges Central Hospital(Chongqing University Three Gorges Hospital  )","The First Affiliated Hospital of Nanchang University","Tongji Hospital, Tongji Medical College of HUST","Tongji Hospital affiliated to Tongji medical college of HUST","Chongqing Public Health Medical Center","Renmin Hospital of Wuhan University","The First Affiliated Hospital of Chongqing Medical University","The Second Affiliated Hospital of Chongqing Medical University","Chongqing Public Health Medical Center","The Second Affiliated Hospital of Chongqing Medical University","Beijing YouAn Hospital","Chongqing Three Gorges Central Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The University of Hong Kong","Affiliated Hospital to Academy of Military Medical Sciences","Huilan Zhang","Beijing 302 Hospital","Ruijin Hospital","The First Affiliated Hospital, College of Medicine of Zhejiang University","The First Affiliated Hospital of Zhejiang University School of Medicine","The Third Affiliated Hospital of the Second Military Medical University","Wuhan Red Cross Hospital","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","Tasly Pharmaceuticals, Inc.","The First Affiliated Hospital of Zhengzhou University","West China Hospital, Sichuan University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shandong Provincial Hospital","Shandong Provincial Hospital","The First Affiliated Hospital of Zhejiang University School of Medicine","The First Affiliated Hospital of HeNan University of CM","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shenyang Sixth People's Hospita","Central Theater General Hospital of PLA","Xiamen Medical College,Shijiazhuang Medical College","Anhui Cancer Hospital","West China Hospital of Sichuan University","Renmin Hospital of Wuhan University","Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","Maoming People's Hospital","Shanghai University of TCM","The Second Affiliated Hospital of Wenzhou Medical University","West China Hospital of Sichuan University","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.","Huo-Shen-Shan Hospital","Zhongnan Hospital of Wuhan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Hubei Shiyan Taihe hospital","Affiliated Hospital of Shandong University of Traditional Chinese Medicine","The First Affiliated Hospital of Wenzhou Medical University","Peking University First Hospital","Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Dalian Medical University, Dalian, China.","The First Affiliated Hospital of Guangzhou University of TCM","Shanghai Sixth People's Hospital","Department of Anesthesiology, Zhongnan Hospital of Wuhan University","First people's hospital of Jiangxi district,Wuhan","The Third Affiliated Hospital of Sun Yat-sen University","The Third Xiangya Hospital, Central South University","Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Tranditional Medicine","Wuhan Fourth Hospital","Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of Guangzhou Medical University","West China Hospital, Sichuan University","Hospital of Chengdu University of Traditional Chinese Medicine","Hospital of Chengdu University of Traditional Chinese Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Hebei Yiling Hospital?Renmin Hospital of Wuhan University","China-Japan friendship hospital","Shanghai Public Health Clinical Center","Hebei Yiling Hospital, Renmin Hospital of Wuhan University","Fujian Provincial Hospital","Hospital of Chengdu University of Traditional Chinese Medicine","Zhengzhou People's Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Peking University First Hospital","Tongji Hospital","Jingzhou Mental Health Center","Zhengzhou People's Hospital","Jinling Hospital, Medical School of Nanjing University","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","McMaster University","University of Macau","HwaMei Hospital, University of Chinese Academy of Sciences","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of the Guangzhou Medical University","The Chinese University of Hong Kong","Li Lanjuan","Department of critical care medicine, the third affiliated hospital of zunyi medical university","Beijing An Zhen Hospital, Capital Medical University","State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University","Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Ninth People's Hospital","Tongji Hospital, Huazhong university of science and technology","Hubei Cancer Hospital","Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Zhongnan Hospital of Wuhan University","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology","Zhengzhou People's Hospital","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","University Medical Center Utrecht","the First Affiliated Hospital of Xinxiang Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Third Hospital","Department of Critical Care Medicine, The First Affiliated Hospital, Henan Traditional Chinese Medicine University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji hospital, Tongji medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Ningbo First Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Tongji Hospital, Tongji medical college of HUST","Wuhan 3rd Hospital","The Second Hospital of Hebei Medical University","The Third Hospital of Wuhan","The Third Affiliated Hospital of Zunyi Medical University","Tongji Hospital","The affiliated Hospital to Changchun University of Traditional Chinese Medicine","The First Affiliated Hospital of Wenzhou Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Cangzhou People's Hospital","Huashan Hospital Fudan Universtiy","The People's Hospital of Guangxi Zhuang Autonomous Region","Zhongnan Hospital of Wuhan University","The First Hospital of Changsha","Xiangyang 1st people's Hospital","Clinical Research Institute, Shenzhen-Peking University-The Hong Kong University of Science &amp; Technology Medical Center","Shenzhen Hospital of Southern Medical University","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Wuhan Third Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Zhejiang Hospital","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Affiliated Hospital of Inner Mongolia University for the Nationalities","Zhongnan Hospital of Wuhan University","Department of Critical Care Medicine, the Third Affiliated Hospital of Zunyi Medical University","The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine","Shandong Provincial Chest hospital","Shandong Provincial Chest Hospital","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Shandong Provincial Chest hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China","Tongji Medical College, HUST","Shandong Provincial Chest hospital","West China Hospital, Sichuan University","Shandong Provincial Chest hospital","Affiliated Hospital of Guangdong Medical University","Union hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongren Hospital, Shanghai Jiao Tong University School of Medicine","Ganzi Hospital of West China Hospital, Sichuan University","Affiliated Hospital of Zunyi Medical University","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","Xiangya Hospital of Central South University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Hwa Mei Hospital, University of Chinese Academy of Sciences","Wuhan Third Hospital","Maoming People's Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Fifth People's Hospital, Fudan University","Department of Nephrology, Wuhan children's Hospital","Hubei Hospital of Traditional Chinese Medicine","The Third Affiliated Hospital of the Second Military Medical University","Shanghai General Hospital","The Third People's Hospital of Shenzhen","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Shanghai Changzheng Hospital","Shandong Provincial Chest hospital","Yongchuan Hospital,Chongqing Medical University","Jingzhou First People's Hospital","Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine","The Third Affiliated Hospital of Sun Yat-sen University","Guangzhou Panyu Central Hospital","The Second Affiliated Hospital of Xi'an Medical University","The Sixth Affiliated Hospital of Sun Yat-sen University","Liaocheng People's Hospital","Peking University People's Hospital","The First Affiliated Hospital of Nanchang University","Luohu hospital group medical center of Shenzhen University","Guangzhou Panyu Central Hospital","Guangzhou reborn health management consultation co., LTD","The Second Affiliated Hospital Of Xi'an Jiaotong University","The First Affiliated Hospital of Bengbu Medical College","The first affiliated hospital of guangzhou university of Chinese medicine","Shandong Provincial Chest hospital","Hubei Provincial Hospital of TCM","Jingzhou First People's Hospital","Guangzhou Eighth People's Hospital","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","The First Affiliated Hospital of Guangzhou Medical University","Shanghai First People's Hospital","Hubei Provincial Hospital of TCM","Guangzhou reborn health management consultation co., LTD","Guangzhou reborn health management consultation co., LTD","Jingzhou Central Hospital","Jingzhou Central Hospital","The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","China-Japan friendship hospital","Ningbo First Hospital, Ningbo Hospital of Zhejiang University","Peking University Third Hospital","Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","China Academy of Chinese Medical Science","The Second Clinical College of Guangzhou University of Chinese Medicine","The First Hospital of Harbin Medical University","Wuhan Asia General Hospital","ZhiYong Peng","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Asan Medical Center","Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","Harbin infectious diseases hospital","First people's hospital of Jiangxi district,Wuhan","The Second Affiliated Hospital Of Xi'an Jiaotong University","Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University","Guangzhou reborn health management consultation co., LTD","Guangzhou reborn health management consultation co., LTD","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","CAR-T (Shanghai) Biotechnology Co., Ltd.","The People's Hospital of GuangXi Zhuang Autonomous Region","University Hospital, Clermont-Ferrand","Zhengzhou People's Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","The third xiangya hospital of Central South University","The Fifth Affiliated Hospital of Sun Yat-Sen University","Xiangyang 1st People's Hospital","Changzheng Hospital, Naval Military Medical University, Shanghai","Beijing Normal University","Ningbo Kangning Hospital","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Hu'nan Cancer Hospital","HwaMei Hospital, University of Chinese Academy of Sciences","Hu'nan Provincial People's Hospital, Hu'nan Normal University","PLA General Hospital","Beijing Chaoyang Hospital, Capital Medical University","The First Affiliated Hospital of Guangzhou Medical University","Shenzhen Third People's Hospital","Changzheng Hospital, Naval Military Medical University, Shanghai","Chinese University of Hong Kong","Shenzhen Geno-Immune Medical Institute","Renmin Hospital of Wuhan University","Hwa Mei Hospital, University of Chinese Academy of Sciences","The First Affiliated Hospital of Nanchang University","Anqing Municipal Hospital","The Fifth Hospital Affiliated to Sun Yat-sen University","West China Hospital of Sichuan University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Guangzhou Eighth People's Hospital","Foshan First People's Hospital","Jiangsu Provincial Center for Disease Control and Prevention","Shandong Provincial Hospital","The Fifth Affiliated Hospital of Sun Yat-sen University","HuiZhou Municipal Central Hospital","The Second Xiangya Hospital of CSU","Renmin Hospital of Wuhan University","Beijing Chao-yang Hospital, Capital Medical University","Guangzhou Eighth People's Hospital","Zhongnan Hospital of Wuhan University","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Central Theater General Hospital of PLA","Renmin Hospital of Wuhan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Renmin Hospital of Wuhan University","HwaMei Hospital, University of Chinese Academy of Sciences","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","The Second Affiliated Hospital of Nanchang University","Shanghai Kongjiang Hospital","West China Second University Hospital, Sichuan University","The Fifth Affiliated Hospital of Sun Yat-Sen University","The First Affiliated Hospital of Medical College of Zhejiang University","The First Hospital of Changsha; The Second Xiangya Hospital of Central South University","Xiangya Hospital, Central South University (West Campus of Wuhan Union Hospital)","Guangzhou Eighth People's Hospital","The First Affiliated Hospital of Nanchang University","Ruijin Hospital, Shanghai Jiaotong University School of Medicine","Fondation Mditerrane Infection (FMI) - IHU Mditerrane Infection","Klinik fr Ansthesiologie und Intensivtherapie; Universittsklinikum Leipzig","Tehran University of Medical Sciences","Iran University of Medical Sciences","Tehran University of Medical Sciences","Qazvin University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Tehran University of Medical Sciences","Digestive Disease Research Institute","Tongji Hospital","Tehran University of Medical Sciences","Tokue Yutaka","Study Group for Efficiency and Quality of Emergency Departments and Non-Scheduled Activities Departm","The Second Hospital of Nanjing Medical University","Tokue Yutaka","Doi Yohei","Second Affiliated Hospital of Wenzhou Medical University","Wuhan Union Hospital, China","The First Affiliated Hospital of Guangzhou Medical University","Tongji Hospital","Tongji Hospital","Tongji Hospital","Critical Care Research Group\nThe Prince Charles Hospital","Shenzhen Geno-Immune Medical Institute","Wuhan Union Hospital, China","China Academy of Chinese Medical Sciences","Chongqing Medical University","Jiangsu Famous Medical Technology Co., Ltd.","National Center for Global Health and Medicine","Study Group for Efficiency and Quality of Emergency Departments and Non-Scheduled Activities Departm","Tongji Hospital","Puren Hospital Affiliated to Wuhan University of Science and Technology","Jean Liu","Zhong Wang","Chongqing Medical University","Tongji Hospital","Tongji Hospital","University Hospital, Akershus","Groupe Hospitalier Pitie-Salpetriere","Henan Provincial People's Hospital","Wuhan Union Hospital, China","Stem Cells Arabia","Chinese PLA General Hospital","Henan Provincial People's Hospital","National Institute of Respiratory Diseases, Mexico","Neuromed IRCCS","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Uppsala University","Hubei Maternal and Child Health Care Hospital","Huashan Hospital","Xiangya Hospital of Central South University","Federico II University","National Institute of Respiratory Diseases, Mexico","Shandong Eye Institute","Guangdong Second Provincial General Hospital","WESTLAKE UNIVERSITY","Renmin Hospital of Wuhan University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Nanjing University Medical College Affiliated Drum Tower Hospital","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology","Centro Studi Internazionali, Italy","Shandong Eye Institute","China European International Business School (CEIBS)","Chongqing Medical University","The Third Affiliated Hospital of Sun Yat-sen University","Renmin Hospital of Wuhan University","China-Japan Union Hospital of Jilin Unversity","West China Hospital, Sichuan University","Yichang Central people's Hospital","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","School of Public Health and Management, Chongqing Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Beijing you'an Hospital, Capital Medical University","Wuhan Third Hospital &amp; Tongren Hospital of Wuhan University","Zhengzhou People's Hospital","People's hospital of Zhengzhou","Renmin Hospital of Wuhan University","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","Wuhan Third Hospital","Nothern Jiangsu People's Hospital","Hospital of Chengdu University of Traditional Chinese Medicine","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Hospital of Chengdu University of Traditional Chinese Medicine.","Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine","The First Affiliated Hospital of Guangzhou Medical University","The First People's Hospital of Jiangxia District, Wuhan","Diagnosis, treatment and Research Center for infectious diseases, the fifth medical center of the PLA","Guangdong Provincial Hospital of Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","China Academy of Chinese Medical Sciences","Daping Hospital,Army Medical University","West China Hospital of Sichuan University","West China Hospital","UZLeuven","Shanghai University of Traditional Chinese Medicine","Sanofi-aventis Recherche et Dveloppement","University Medical Center","Universittsklinikum Tbingen","Oslo University Hospital","Synairgen Research Limited","Pulmotect, Inc.","Institut National de la Sant Et de la Recherche Mdicale, France","Beijing Chao Yang Hospital","University of Oxford","Hudson Medical","Xijing Hospital","University of Oxford","Qilu Hospital of Shandong University","University of Pecs","University College, London","King Saud University","Pulmotect, Inc.","Zhenhua Zen","University College, London","Columbia University","Groupe Hospitalier Pitie-Salpetriere","Lucio Manenti","University of Palermo","Rambam Health Care Campus","Istanbul University-Cerrahpasa","Laval University","Hospital of Prato","Changhai Hospital","University of Catanzaro","University of Birmingham","Guangzhou Eighth People's Hospital","Darrell Tan","Foundation IRCCS San Matteo Hospital","Catholic University of the Sacred Heart","Xiyuan Hospital of China Academy of Chinese Medical Sciences","Renmin Hospital of Wuhan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Chongqing Public Health Medical Center","UMC Utrecht","Assistance Publique - Hpitaux de Paris","HealthMode Inc.","N0.2 People's Hospital of Fuyang City","Peking Union Medical College Hospital","Chinese University of Hong Kong","Universitaire Ziekenhuizen Leuven","Wuhan Women and Children's Health Care Center","Affiliated Hospital of Zunyi Medical University","Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine","Misr University for Science and Technology","University of Trieste","Population Health Research Institute","Universita di Verona","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Oriental Hospital","Huangshi Hospital of Traditional Chinese Medicine (Municipal Infectious Disease Hospital)","The First People's Hospital of Jiangxia District, Wuhan","Tongji Hospital of Tongji Medical College, Huazhong Science and Technology University","Affiliated Hospital of Southwest Medical University","Infection prevention and treatment center of The Fifth Affiliated Hospital of Sun Yat-Sen University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","University Hospital, Essen","RAD-AID International","University Hospital Southampton NHS Foundation Trust","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First People's Hospital of Jiangxia District, Wuhan","Xiangya Hospital, Central South University (West Campus of Wuhan Union Hospital)","INSERM","Peking University Sixth Hospital","Shanghai Sixth People's Hospital","Wuhan Asia heart Hospital","Peking University Third Hospital","Eastern theater General Hospital","Dermatology Department of Peking University First Hosptal","Nanjing University","The Fifth Medical Center of PLA General Hospital","University Hospital Ghent","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.","Amsterdam UMC","Akershus University Hospital","APEIRON Respiratory Therapies GmbH","Azienda Unit Sanitaria Locale-IRCCS di Reggio Emilia","University of British Columbia","Shanghai Public Health Clinical Center","Beijing Chao Yang Hospital","Ansun Biopharma, Inc.","CHU Angers","CHU de Saint Etienne","Rajavithi Hospital","Massachusetts General Hospital","Massachusetts General Hospital","The Prince Charles Hospital","Ansun Biopharma, Inc.","Australian Defence Force Malaria and Infectious Disease Institute","Universit de Sherbrooke","University Hospital, Akershus","University of Aarhus","Heinrich-Heine University, Duesseldorf","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark","Hospices Civils de Lyon","Beijing Ditan Hospital","Qilu Hospital of Shandong University","Gilead Sciences","Renmin Hospital of Wuhan University","Dr. Alexander Supady","University of Oxford","Prof. Dr. Umar Farooq","Shanghai Public Health Clinical Center","Peking University Third Hospital","National Institute of Allergy and Infectious Diseases (NIAID)","National Institute of Allergy and Infectious Diseases (NIAID)","Peking University First Hospital","Azidus Brasil","Zhenhua Zen","Wake Forest University Health Sciences","Gilead Sciences","Assistance Publique - Hpitaux de Paris","Guangzhou Blood Center","University of Minnesota","Estudios Clnicos Latino Amrica","Oxford University Clinical Research Unit, Vietnam","University of Washington","Dr. Michael Hill","Beijing 302 Hospital","The Ninth Hospital of Nanchang","U.S. Army Medical Research and Development Command","Fundacio Lluita Contra la SIDA","Shanghai Jiao Tong University School of Medicine","Ictal Group","Duke University","Hospital Israelita Albert Einstein","Intermountain Health Care, Inc.","University of Calgary","Instituto de Investigacin Marqus de Valdecilla","University of Minnesota","CanSino Biologics Inc.","Regeneron Pharmaceuticals","Universit Politecnica delle Marche","Massachusetts General Hospital","NeuroRx, Inc.","University of Minnesota","Professor Adrian Covic","Dr. Deneen Vojta","Hospital do Coracao","A.O. Ospedale Papa Giovanni XXIII","Mayo Clinic","Sunnybrook Health Sciences Centre","Charite University, Berlin, Germany","Emory University","Societa Italiana dell'Ipertensione Arteriosa","OncoImmune, Inc.","National Cancer Institute, Naples","Universit Vita-Salute San Raffaele","Federico II University","University of California, San Francisco","Gunther Meinlschmidt","Mayo Clinic","University Hospital, Angers","University of Chicago","University Hospital, Bordeaux","Erasme University Hospital","Kermanshah University of Medical Sciences","Assiut University","William Beaumont Hospitals","Oslo University Hospital","University of Catanzaro","Hoffmann-La Roche","Oslo University Hospital","xCures","Lisa Barrett","CCTU- Cancer Theme","TMC HealthCare","National and Kapodistrian University of Athens","Murdoch Childrens Research Institute","Washington University School of Medicine","University of Missouri-Columbia","Intermountain Health Care, Inc.","King's College London","Montreal Heart Institute","Johns Hopkins University","Mario Negri Institute for Pharmacological Research","Catholic University of the Sacred Heart","Marius Henriksen","Swedish Orphan Biovitrum","Assistance Publique - Hpitaux de Paris","Sanofi","Karolinska University Hospital","Kanuni Sultan Suleyman Training and Research Hospital","UMC Utrecht","Assistance Publique - Hpitaux de Paris","S.L.A. Pharma AG","University Hospital Inselspital, Berne","Dr. Negrin University Hospital","Institut Pasteur","Rush University Medical Center","Healeon Medical Inc","Assistance Publique - Hpitaux de Paris","Professor Adrian Covic","Mario Negri Institute for Pharmacological Research","Universidad Complutense de Madrid","University of Minnesota","University Hospital, Geneva","Azidus Brasil","Stanford University","Lady Davis Institute","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","University Hospital, Montpellier","Duke University","Istinye University","University Hospital, Lille","Mazandaran University of Medical Sciences","University of Aarhus","University Hospital, Ghent","Assistance Publique - Hpitaux de Paris","Weprom","Vanda Pharmaceuticals","University Hospital, Ghent","Luiz F. L. Reis, Ph.D.","Istanbul Kltr University","Assistance Publique Hopitaux De Marseille","Virginia Commonwealth University","Imperial College London","Bassett Healthcare","Institut Pasteur","Shanghai 10th People's Hospital","University of Arizona","Chinese Academy of Sciences","Universidad del Rosario","Baylor Research Institute","Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","NHS Lothian","Ravi Amaravadi, MD","Gangnam Severance Hospital","Korea University Guro Hospital","Maastricht University","Sanotize Research and Development corp.","Capricor Inc.","Mayo Clinic","Jessa Hospital","Kubra Koce, MSc PT","Blade Therapeutics","Providence Health &amp; Services","Hepatopancreatobiliary Surgery Institute of Gansu Province","Judit Pich Martnez","National University of Ireland, Galway, Ireland","King's College London","Wroclaw Medical University","Assistance Publique - Hpitaux de Paris","Barcelona Institute for Global Health","Queen Mary University of London","Fasa University of Medical Sciences","University Health Network, Toronto","Target PharmaSolutions, Inc.","Hasselt University","Huilan Zhang","HonorHealth Research Institute","Puren Hospital Affiliated to Wuhan University of Science and Technology","Assistance Publique - Hpitaux de Paris","ProgenaBiome","IRCCS San Raffaele","Biruni University","Stanford University","Fundaci Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","University of California, San Francisco","NYU Langone Health","Universidad del Rosario","University of L'Aquila","Hospital San Jose Tec de Monterrey","Instituto Nacional de Rehabilitacion","University Hospital Tuebingen","University Hospital of Cologne","Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China","Rutgers, The State University of New Jersey","Rutgers, The State University of New Jersey","Assiut University","Centre Hospitalier Intercommunal Creteil","Fondation Ophtalmologique Adolphe de Rothschild","Rigshospitalet, Denmark","Assistance Publique - Hpitaux de Paris","Massachusetts General Hospital","Baylor Research Institute","Imperial College London","Wefight","University Hospital, Angers","Rigshospitalet, Denmark","Tourcoing Hospital","Can-Fite BioPharma","Peking University First Hospital","Universidad de Granada","Duke University","Yale University","Second Affiliated Hospital of Wenzhou Medical University","The Cleveland Clinic","Assistance Publique - Hpitaux de Paris","Massachusetts General Hospital","Ospedale Policlinico San Martino","Brigham and Women's Hospital","Max Healthcare Insititute Limited","Symvivo Corporation","Lars Wik","University of Kansas Medical Center","IHF GmbH - Institut fr Herzinfarktforschung","University Hospital, Angers","The University of Hong Kong","UNSW Sydney","InflaRx GmbH","HaEmek Medical Center, Israel","Sanofi","University Hospital, Angers","Flinders Medical Centre","Klinikum der Universitt Mnchen","Tabula Rasa HealthCare","Frantisek Duska, MD, PhD","University of Chicago","Centre Hospitalier Universitaire de Nimes","MedSIR","Memorial Hermann Health System","Salome Kristensen","University Hospital, Akershus","University of Oxford","University of Oxford","Inovio Pharmaceuticals","University Hospital, Lille","Royal National Orthopaedic Hospital NHS Trust","Kanuni Sultan Suleyman Training and Research Hospital","University Hospital Inselspital, Berne","Grupo Cooperativo de Hemopatas Malignas","Peking University First Hospital","IVAN J NUEZ GIL","I-Mab Biopharma Co. Ltd.","Hospices Civils de Lyon","Henry Ford Health System","Hugo Mendieta Zeron","Fujian Provincial Maternity and Child Health Hospital","Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Beat COVID LLC","Bicetre Hospital","University of Alabama at Birmingham","University Hospital, Angers","ProgenaBiome","Plan Nacional sobre el Sida (PNS)","Apeiron Biologics","Centre Hospitalier Universitaire de Nice","the First Affiliated Hospital of Nanjing Medical University","Wuhan Fourth Hospital","Assistance Publique - Hpitaux de Paris","University of Cincinnati","Centre Hospitalier Intercommunal Creteil","University Hospital, Lille","Jessa Hospital","Prof. Dr. med. Andreas Hochhaus","University of Colorado, Denver","Barts &amp; The London NHS Trust","The Chinese University of Hong Kong","Shanghai Orient Hospital","Radboud University","Renmin Hospital of Wuhan University","Shanghai Asclepius Meditec Inc.","Mayo Clinic","Tongji Hospital","Aga Khan University","Karolinska Institutet","Beijing University of Chinese Medicine","Shenzhen Third People's Hospital","Giuliano Rizzardini","Kanuni Sultan Suleyman Training and Research Hospital","Novartis Pharmaceuticals","University Hospital, Limoges","Hospital General Universitario Morales Meseguer","University Hospital Tuebingen","Al-Azhar University","Washington University School of Medicine","Istanbul University-Cerrahpasa","Fundao de Medicina Tropical Dr. Heitor Vieira Dourado","Wake Forest University Health Sciences","London School of Hygiene and Tropical Medicine","UMC Utrecht","Interactive Studios","University of Pennsylvania","Sheba Medical Center","Shehnoor Azhar","Heinrich-Heine University, Duesseldorf","Eli Lilly and Company","University Hospital, Montpellier","University Hospital, Strasbourg, France","Tjhin Wiguna","GUSTAVE ROUSSY","University Hospital Ghent","Hackensack Meridian Health","South Metropolitan Health Service","University of Baghdad","Ochsner Health System","CytoDyn, Inc.","Genesis Foundation","Assiut University","National Institute of Mental Health (NIMH)","University of Minnesota","University Hospital, Ghent","HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS","Royal Brisbane &amp; Women's Hospital","University of Oxford","Shahid Beheshti University of Medical Sciences","Deakin University","University Hospital of Bern","St George's University Hospitals NHS Foundation Trust","University of Colorado, Denver","Peking Union Medical College Hospital","CareDx","University Hospital Tuebingen","University of Melbourne","Firebrick Pharma Pty Ltd","University of Warwick","World Health Organization","Northwestern Medicine","Assistance Publique - Hpitaux de Paris","Pierre and Marie Curie University","University of Miami","Beijing Sports University","Jiangsu Province Hospital","Huanggang Central Hospital","N/A","Huzhou Central Hospital","Women's Hospital, Medical School of Zhejiang University","Tan Tock Seng Hospital","University of Utah","Erasmus Medical Center","Columbia University","Huoshenshan Hospital","Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","nonen","Duke University","Romark Laboratories L.C.","Saint Francis Care","United States Department of Defense","West China Hospital, Sichuan University","the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China","Reade Research BV","Radboudumc","none","Fred Foundation ; Noaber Foundation","Duke University","Brigham and Women's Hospital","Griffith University","ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)","University of Melbourne","Medical Research Institute of New Zealand","Amsterdam UMC","DRK-Bluspendedienst Baden-Wrttemberg - Hessen gGmbH","CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC","Groupe Hospitalier Paris Saint-Joseph","Austin Health","Northumbria University","FIB-HCSC","FFIS","University of Zurich","University of Oxford","Sociedad Espaola de Farmacia Hospitalaria","Instituto Investigacin Sanitario Biocruces Bizkaia","Hpital Fondation Adolphe de Rothschild","Flix Gutirrez Rodero","The First Affiliated Hospital of Yangtze University","The 2nd Xiangya Hospital of Central South Uinvercity","ISGlobal","Jiangsu Provincial Center for Disease Control and Prevention","Shandong Provincial Hospital","Chinese PLA General Hospital","Wenzhou Central Hospital","National Institute for Public Health and the Environment (RIVM)","Mxima MC","Radboudumc","UMCG, Roche","Assistance Publique - Hpitaux de Paris","InflaRx GmbH","CHU de Saint Etienne","Centre Lon Brard","APHP","Dr. Xavier Solanich Moreno. Servei Medicina Interna. Hospital de Bellvitge","INSTITUT DE RECERCA H. SANTA CREU I SANT PAU","Plan Nacional  Sobre SIDA","sanofi-aventis recherche &amp; dveloppement","Fundacin para la Investigacin Biomdica Hospital Ramn y Cajal"],["2020-02-17","2020-02-16","27/01/2020","2020-02-16","2020-02-15","2020-02-14","2020-02-16","2020-02-16","2020-02-14","2020-02-14","30/01/2020","03/02/2020","03/02/2020","2020-02-16","2020-02-14","2020-02-13","2020-02-13","2020-02-13","2020-02-15","2020-02-15","2020-02-13","2020-02-13","28/01/2020","06/02/2020","06/02/2020","06/02/2020","2020-02-13","2020-02-13","2020-02-16","2020-02-16","2020-02-15","2020-02-14","2020-02-16","2020-02-16","2020-02-10","2020-02-09","2020-02-14","2020-02-14","2020-02-11","2020-02-11","2020-02-15","2020-02-15","2020-02-14","2020-02-13","2020-02-07","2020-02-07","2020-02-13","2020-02-13","2020-02-08","2020-02-08","2020-02-15","2020-02-15","2020-02-12","2020-02-12","2020-02-06","2020-02-04","2020-02-05","2020-02-05","2020-02-14","2020-02-14","2020-02-03","2020-02-03","2020-02-03","2020-02-03","2020-02-14","2020-02-13","2020-02-12","2020-02-11","2020-02-02","2020-02-02","2020-02-13","2020-02-12","2020-02-02","2020-02-01","2020-02-01","2020-02-01","2020-02-12","2020-02-10","2020-02-11","2020-02-10","2020-02-01","2020-01-30","2020-02-08","2020-02-07","2020-02-10","2020-02-07","2020-02-07","2020-02-06","2020-02-06","2020-02-07","2020-02-24","2020-02-24","2020-02-06","2020-02-05","2020-02-07","2020-02-06","2020-02-04","2020-02-03","2020-02-04","2020-02-04","2020-02-03","2020-02-02","2020-02-23","2020-02-23","2020-02-02","2020-02-01","2020-02-02","2020-02-02","2020-02-02","2020-02-01","2020-02-01","2020-02-01","2020-02-23","2020-02-22","2020-02-21","2020-02-21","05/02/2020","08/02/2020","2020-02-24","2020-01-29","23/01/2020","2020-02-24","2020-02-23","2020-02-21","2020-02-21","2020-01-27","07/02/2020","2020-02-24","2020-02-24","2020-02-23","2020-02-23","2020-02-24","2020-02-23","2020-02-23","2020-02-23","2020-02-24","2020-02-24","2020-02-21","2020-02-20","2020-02-21","2020-02-20","2020-02-22","2020-02-22","2020-02-24","2020-02-24","2020-02-19","2020-02-19","2020-02-22","2020-02-21","2020-02-24","2020-02-23","2020-02-20","2020-02-20","2020-02-19","2020-02-19","2020-02-22","2020-02-22","2020-02-19","2020-02-19","2020-02-19","2020-02-17","2020-02-22","2020-02-22","2020-02-22","2020-02-21","2020-02-20","2020-02-19","2020-02-19","2020-02-19","2020-02-20","2020-02-20","2020-02-20","2020-02-19","2020-02-19","2020-02-19","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-18","2020-02-17","2020-02-17","2020-02-13","2020-02-11","2020-02-18","2020-02-17","2020-02-15","2020-02-15","2020-02-18","2020-02-18","2020-02-14","2020-02-13","2020-02-15","31/01/2020","2020-02-17","18/02/2020","01/02/2020","14/02/2020","14/02/2020","2020-03-01","2020-03-01","11/02/2020","14/02/2020","17/02/2020","2020-03-01","31/01/2020","06/02/2020","17/02/2020","15/02/2020","2020-02-18","2020-02-17","2020-03-01","2020-02-29","2020-02-28","2020-02-28","20/02/2020","2020-03-01","2020-03-01","2020-03-01","15/02/2020","19/02/2020","13/02/2020","2020-03-02","2020-02-28","2020-02-28","2020-02-28","2020-02-26","2020-03-01","2020-03-01","2020-03-01","2020-02-26","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-28","2020-02-27","2020-02-28","2020-02-27","2020-02-26","2020-02-26","2020-02-27","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-26","2020-02-25","2020-02-26","2020-02-25","2020-02-26","2020-02-26","2020-02-25","2020-02-25","2020-02-26","2020-02-24","2020-02-23","2020-02-21","2020-02-20","2020-02-19","2020-02-16","2020-02-16","2020-02-18","2020-02-12","2020-02-25","2020-02-17","2020-02-18","2020-02-12","2020-02-10","2020-01-29","2020-02-16","2020-02-12","2020-02-12","2020-01-29","2020-02-12","25/02/2020","2020-02-15","2020-03-07","11/02/2020","20/02/2020","10/02/2020","27/01/2020","16/02/2020","2020-03-08","2020-03-07","2020-03-07","2020-03-06","2020-03-06","22/02/2020","19/02/2020","2020-03-08","2020-03-08","2020-03-07","2020-03-08","2020-03-08","2020-03-05","2020-03-04","2020-03-07","2020-03-06","2020-03-03","2020-03-03","2020-03-06","2020-03-06","2020-03-07","2020-03-06","2020-03-04","2020-03-03","2020-03-06","2020-03-04","2020-03-02","2020-03-02","2020-03-05","2020-03-04","2020-03-03","2020-03-03","2020-03-04","2020-03-03","2020-03-04","2020-03-03","2020-03-02","2020-03-02","2020-03-03","2020-03-03","2020-03-02","2020-03-02","2020-03-01","2020-02-17","2020-02-28","2020-02-28","2020-03-02","2020-02-24","2020-02-20","2020-02-05","2020-02-18","2020-02-08","2020-02-04","2020-02-04","2020-02-05","2020-02-01","2020-02-12","25/02/2020","2020-02-01","23/02/2020","2020-02-02","2020-03-16","2020-03-16","2020-03-16","15/02/2020","2020-03-16","2020-03-16","2020-03-16","03/03/2020","03/03/2020","04/03/2020","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-16","2020-03-15","2020-03-16","2020-03-16","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-16","2020-03-15","2020-01-23","13/07/2015","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-14","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","26/02/2020","2020-03-16","2020-03-13","2020-03-13","2020-03-14","2020-03-14","2020-03-14","2020-03-14","2020-03-16","2020-03-16","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-16","2020-03-16","2020-03-13","2020-03-13","2020-03-13","2020-03-11","2020-03-16","2020-03-15","2020-03-13","2020-03-13","2020-03-13","2020-03-13","2020-03-11","2020-03-11","2020-03-13","2020-03-11","2020-03-13","2020-03-12","2020-03-15","2020-03-15","2020-03-11","2020-03-11","2020-03-11","2020-03-10","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-15","2020-03-09","2020-03-06","2020-03-10","2020-03-08","2020-03-10","2020-03-10","2020-03-14","2020-03-13","2020-03-02","2020-03-01","2020-03-13","2020-03-13","2020-03-07","2020-02-28","2020-03-09","2020-03-09","2020-02-23","2020-02-22","2020-02-28","2020-02-25","2020-02-18","2020-02-17","2020-03-08","2020-03-03","2020-03-13","2020-03-13","2020-02-24","2020-02-16","2020-03-03","2020-02-22","2020-03-12","2020-03-11","2020-02-14","2020-02-14","2020-02-15","2020-02-14","2020-02-21","2020-02-19","2020-03-10","2020-03-10","2020-03-09","2020-03-09","2020-03-08","2020-03-08","2020-03-06","2020-03-05","2020-02-14","04/02/2020","2020-02-05","10/03/2020","2020-03-03","2020-03-01","2020-02-29","2020-02-24","2020-02-22","2020-02-14","2020-02-14","2020-02-13","27/02/2020","2020-03-23","12/03/2020","2020-03-22","2020-03-22","2020-03-22","2020-03-22","2020-03-22","2020-03-20","2020-03-20","2020-03-22","2020-03-20","2020-03-21","2020-03-21","2020-03-18","2020-03-18","2020-03-19","2020-03-19","2020-03-20","2020-03-20","24/02/2020","05/03/2020","07/03/2020","2020-03-23","2020-03-18","2020-03-18","2020-03-19","2020-03-19","2020-03-22","2020-03-22","2020-03-17","2020-03-17","2020-03-18","2020-03-18","2020-03-18","2020-03-14","2020-03-20","2020-03-20","2020-03-05","2020-02-26","2020-03-13","2020-02-09","2020-03-20","2020-03-19","2020-03-17","2020-03-17","2020-02-26","2020-02-24","2020-03-18","2020-03-18","2020-02-17","2020-02-15","2020-02-05","2020-02-03","2020-03-17","2020-03-06","2020-02-23","2020-02-15","10/03/2020","19/03/2020","2020-03-16","2020-03-17","2020-03-19","2020-03-22","2020-03-23","2020-03-19","2020-03-14","02/02/2020","2020-03-22","27/02/2020","20/03/2020","30/01/2020","27/02/2020","02/03/2020","14/02/2020","13/02/2020","21/02/2020","02/02/2020","02/02/2020","04/02/2020","06/03/2020","17/02/2020","08/02/2020","19/02/2020","01/03/2020","01/03/2020","19/03/2020","21/03/2020","27/02/2020","24/02/2020","08/03/2020","15/03/2020","12/02/2020","14/02/2020","08/03/2020","17/03/2020","17/03/2020","04/03/2020","04/03/2020","15/03/2020","2020-03-29","13/03/2020","19/03/2020","19/03/2020","2020-03-28","13/03/2020","2020-03-28","14/03/2020","16/03/2020","18/03/2020","18/03/2020","2020-03-27","2020-03-27","2020-03-29","2020-03-27","2020-03-28","2020-03-27","2020-03-27","2020-03-27","14/03/2020","2020-03-28","2020-03-26","2020-03-25","2020-03-26","2020-03-25","2020-03-27","2020-03-25","2020-03-27","2020-03-27","2020-03-25","2020-03-25","2020-03-24","2020-03-23","2020-03-24","2020-03-23","2020-03-25","2020-03-18","2020-03-24","2020-03-23","2020-03-20","2020-03-18","2020-03-18","2020-03-17","2020-03-18","2020-03-10","2020-03-23","2020-03-20","2020-03-15","2020-02-18","2020-02-28","2020-02-27","2020-02-26","2020-02-25","2020-02-20","27/03/2020","2020-02-18","20/03/2020","17/03/2020","24/03/2020","24/03/2020","17/03/2020","16/03/2020","13/03/2020","20/03/2020","30/07/2019","27/02/2020","27/02/2020","06/03/2020","09/03/2020","20/03/2020","23/03/2020","23/03/2020","16/03/2020","17/03/2020","17/03/2020","20/03/2020","20/03/2020","24/03/2020","18/03/2020","25/03/2020","20/03/2020","19/03/2020","20/03/2020","21/03/2020","23/03/2020","25/03/2020","2020-04-05","18/03/2020","23/03/2020","23/03/2020","08/03/2020","2020-04-05","2020-04-04","25/03/2020","25/03/2020","26/03/2020","26/03/2020","2020-04-05","2020-04-03","24/03/2020","26/03/2020","2020-04-03","2020-04-03","2020-04-03","23/03/2020","19/03/2020","25/03/2020","24/03/2020","2020-04-03","2020-04-02","2020-04-02","2020-04-02","2020-04-01","2020-04-01","2020-04-01","2020-04-01","26/03/2020","30/03/2020","18/03/2020","2020-03-31","2020-03-31","2020-03-23","09/03/2020","2020-04-05","2020-04-03","2020-03-31","2020-03-29","2020-04-02","2020-04-02","2020-03-31","2020-03-31","24/03/2020","31/03/2020","31/03/2020","16/03/2020","23/03/2020","02/04/2020","25/10/2017","06/02/2020","15/02/2020","28/02/2020","24/03/2020","26/03/2020","24/02/2020","09/03/2020","15/03/2020","30/03/2020","16/01/2019","30/03/2020","19/09/2018","13/03/2020","23/03/2020","19/03/2020","23/03/2020","24/03/2020","27/02/2020","26/01/2020","14/02/2020","28/02/2020","25/03/2020","25/03/2020","20/03/2020","25/03/2020","29/01/2020","16/02/2020","20/02/2020","21/02/2020","09/03/2020","18/03/2020","20/03/2020","20/03/2020","28/02/2020","09/03/2020","08/03/2020","11/03/2020","30/03/2020","27/03/2020","23/03/2020","29/03/2020","24/02/2020","27/02/2020","02/03/2020","05/03/2020","21/03/2020","22/03/2020","23/03/2020","23/03/2020","30/03/2020","30/03/2020","31/03/2020","13/03/2020","15/03/2020","15/03/2020","14/03/2020","10/03/2020","14/03/2020","13/03/2020","17/03/2020","23/03/2020","24/03/2020","24/03/2020","24/03/2020","23/03/2020","27/03/2020","31/03/2020","30/03/2020","19/03/2020","19/03/2020","19/03/2020","20/03/2020","24/03/2020","26/03/2020","26/03/2020","25/03/2020","01/04/2020","30/03/2020","27/03/2020","01/04/2020","16/03/2020","23/03/2020","23/03/2020","23/03/2020","23/03/2020","23/03/2020","23/03/2020","24/03/2020","26/03/2020","25/03/2020","26/03/2020","25/03/2020","31/03/2020","31/03/2020","02/04/2020","02/04/2020","23/03/2020","24/03/2020","25/03/2020","25/03/2020","24/03/2020","25/03/2020","25/03/2020","26/03/2020","25/03/2020","27/03/2020","27/03/2020","02/04/2020","01/04/2020","02/04/2020","25/03/2020","26/03/2020","26/03/2020","26/03/2020","25/03/2020","21/03/2020","26/03/2020","26/03/2020","27/03/2020","29/03/2020","29/03/2020","30/03/2020","01/04/2020","02/04/2020","30/03/2020","03/04/2020","26/03/2020","25/03/2020","24/03/2020","27/03/2020","31/03/2020","29/03/2020","30/03/2020","26/03/2020","24/03/2020","26/03/2020","03/04/2020","03/04/2020","01/04/2020","01/04/2020","27/03/2020","23/03/2020","27/03/2020","26/03/2020","06/02/2020","31/03/2020","27/03/2020","31/03/2020","26/03/2020","30/03/2020","30/03/2020","31/03/2020","06/04/2020","06/04/2020","31/03/2020","03/04/2020","02/04/2020","02/04/2020","02/04/2020","02/04/2020","29/03/2020","31/03/2020","30/03/2020","31/03/2020","30/03/2020","31/03/2020","01/04/2020","31/03/2020","30/03/2020","01/04/2020","31/03/2020","04/04/2020","01/04/2020","07/04/2020","02/04/2020","02/04/2020","02/04/2020","31/03/2020","02/04/2020","27/03/2020","31/03/2020","30/03/2020","30/03/2020","30/03/2020","26/03/2020","31/03/2020","02/04/2020","03/04/2020","03/04/2020","07/04/2020","02/04/2020","31/03/2020","03/04/2020","30/03/2020","07/04/2020","07/04/2020","06/04/2020","31/03/2020","01/04/2020","01/04/2020","03/04/2020","03/04/2020","02/04/2020","01/04/2020","01/04/2020","01/04/2020","29/03/2020","02/04/2020","08/04/2020","04/04/2020","08/04/2020","09/04/2020","05/04/2020","07/04/2020","06/04/2020","07/04/2020","31/03/2020","01/04/2020","31/03/2020","31/03/2020","09/04/2020","20/02/2020","14/04/2020","01/04/2020","01/04/2020","01/04/2020","01/04/2020","06/04/2020","07/04/2020","07/04/2020","06/04/2020","07/04/2020","07/04/2020","31/03/2020","02/04/2020","03/04/2020","03/04/2020","06/04/2020","01/04/2020","03/04/2020","03/04/2020","03/04/2020","05/04/2020","01/04/2020","01/04/2020","01/04/2020","01/04/2020","04/04/2020","08/04/2020","07/04/2020","07/04/2020","2020-04-09","2020-04-09","06/04/2020","30/03/2020","06/04/2020","31/03/2020","02/04/2020","02/04/2020","01/04/2020","03/04/2020","2020-04-09","2020-04-08","07/04/2020","05/04/2020","01/04/2020","07/04/2020","07/04/2020","07/04/2020","06/04/2020","03/04/2020","2020-04-07","2020-04-07","02/04/2020","28/03/2020","25/03/2020","07/04/2020","07/04/2020","06/04/2020","07/04/2020","2020-04-06","2020-03-13","03/04/2020","05/04/2020","03/04/2020","03/04/2020","08/04/2020","08/04/2020","07/04/2020","08/04/2020","07/04/2020","04/04/2020","08/04/2020","08/04/2020","31/03/2020","01/04/2020","01/04/2020","04/04/2020","04/04/2020","03/04/2020","10/04/2020","08/04/2020","08/04/2020","09/04/2020","24/03/2020","04/04/2020","08/04/2020","06/04/2020","05/04/2020","07/04/2020","31/03/2020","07/04/2020","07/04/2020","08/04/2020","06/04/2020","31/03/2020","31/03/2020","06/04/2020","02/04/2020","08/04/2020","06/04/2020","01/04/2020","06/12/2019","03/04/2020","03/03/2020","16/03/2020","30/03/2020","06/04/2020","14/04/2020","06/04/2020","25/03/2020","07/04/2020","07/04/2020","08/04/2020","06/04/2020","2020-04-12","2020-04-11","2020-04-10","2020-04-10","2020-04-08","2020-04-06","08/04/2020","07/04/2020","31/03/2020","08/04/2020","2020-04-08","2020-04-07","2020-02-28","02/04/2020","08/04/2020","08/04/2020","08/04/2020","09/04/2020","2020-03-05","2020-02-28","07/04/2020","31/03/2020","16/03/2020","26/03/2020","09/04/2020","09/04/2020","06/04/2020","29/03/2020","06/04/2020","08/04/2020","31/03/2020","31/03/2020","01/04/2020","02/04/2020","08/04/2020","08/04/2020","26/03/2020","03/04/2020","07/04/2020","22/03/2020","07/04/2020","07/04/2020","01/04/2020","07/04/2020","2020-04-11","2020-04-10","07/04/2020","2020-04-10","2020-04-10","2020-04-07","2020-04-07","23/03/2020","27/03/2020","31/03/2020","03/04/2020","26/03/2020","27/03/2020","24/03/2020","29/03/2020","02/04/2020","03/04/2020","03/04/2020","03/04/2020","30/03/2020","08/04/2020"],[20200217,20200216,20200127,20200216,20200215,20200214,20200216,20200216,20200214,20200214,20200130,20200203,20200203,20200216,20200214,20200213,20200213,20200213,20200215,20200215,20200213,20200213,20200128,20200206,20200206,20200206,20200213,20200213,20200216,20200216,20200215,20200214,20200216,20200216,20200210,20200209,20200214,20200214,20200211,20200211,20200215,20200215,20200214,20200213,20200207,20200207,20200213,20200213,20200208,20200208,20200215,20200215,20200212,20200212,20200206,20200204,20200205,20200205,20200214,20200214,20200203,20200203,20200203,20200203,20200214,20200213,20200212,20200211,20200202,20200202,20200213,20200212,20200202,20200201,20200201,20200201,20200212,20200210,20200211,20200210,20200201,20200130,20200208,20200207,20200210,20200207,20200207,20200206,20200206,20200207,20200224,20200224,20200206,20200205,20200207,20200206,20200204,20200203,20200204,20200204,20200203,20200202,20200223,20200223,20200202,20200201,20200202,20200202,20200202,20200201,20200201,20200201,20200223,20200222,20200221,20200221,20200205,20200208,20200224,20200129,20200123,20200224,20200223,20200221,20200221,20200127,20200207,20200224,20200224,20200223,20200223,20200224,20200223,20200223,20200223,20200224,20200224,20200221,20200220,20200221,20200220,20200222,20200222,20200224,20200224,20200219,20200219,20200222,20200221,20200224,20200223,20200220,20200220,20200219,20200219,20200222,20200222,20200219,20200219,20200219,20200217,20200222,20200222,20200222,20200221,20200220,20200219,20200219,20200219,20200220,20200220,20200220,20200219,20200219,20200219,20200218,20200218,20200218,20200218,20200218,20200218,20200217,20200217,20200213,20200211,20200218,20200217,20200215,20200215,20200218,20200218,20200214,20200213,20200215,20200131,20200217,20200218,20200201,20200214,20200214,20200301,20200301,20200211,20200214,20200217,20200301,20200131,20200206,20200217,20200215,20200218,20200217,20200301,20200229,20200228,20200228,20200220,20200301,20200301,20200301,20200215,20200219,20200213,20200302,20200228,20200228,20200228,20200226,20200301,20200301,20200301,20200226,20200228,20200228,20200228,20200228,20200228,20200227,20200228,20200227,20200226,20200226,20200227,20200226,20200226,20200226,20200226,20200226,20200226,20200225,20200226,20200225,20200226,20200226,20200225,20200225,20200226,20200224,20200223,20200221,20200220,20200219,20200216,20200216,20200218,20200212,20200225,20200217,20200218,20200212,20200210,20200129,20200216,20200212,20200212,20200129,20200212,20200225,20200215,20200307,20200211,20200220,20200210,20200127,20200216,20200308,20200307,20200307,20200306,20200306,20200222,20200219,20200308,20200308,20200307,20200308,20200308,20200305,20200304,20200307,20200306,20200303,20200303,20200306,20200306,20200307,20200306,20200304,20200303,20200306,20200304,20200302,20200302,20200305,20200304,20200303,20200303,20200304,20200303,20200304,20200303,20200302,20200302,20200303,20200303,20200302,20200302,20200301,20200217,20200228,20200228,20200302,20200224,20200220,20200205,20200218,20200208,20200204,20200204,20200205,20200201,20200212,20200225,20200201,20200223,20200202,20200316,20200316,20200316,20200215,20200316,20200316,20200316,20200303,20200303,20200304,20200316,20200316,20200316,20200316,20200316,20200316,20200316,20200316,20200316,20200316,20200315,20200316,20200316,20200315,20200315,20200315,20200315,20200316,20200315,20200123,20150713,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200314,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200315,20200226,20200316,20200313,20200313,20200314,20200314,20200314,20200314,20200316,20200316,20200313,20200313,20200313,20200313,20200316,20200316,20200313,20200313,20200313,20200311,20200316,20200315,20200313,20200313,20200313,20200313,20200311,20200311,20200313,20200311,20200313,20200312,20200315,20200315,20200311,20200311,20200311,20200310,20200315,20200315,20200315,20200315,20200315,20200315,20200309,20200306,20200310,20200308,20200310,20200310,20200314,20200313,20200302,20200301,20200313,20200313,20200307,20200228,20200309,20200309,20200223,20200222,20200228,20200225,20200218,20200217,20200308,20200303,20200313,20200313,20200224,20200216,20200303,20200222,20200312,20200311,20200214,20200214,20200215,20200214,20200221,20200219,20200310,20200310,20200309,20200309,20200308,20200308,20200306,20200305,20200214,20200204,20200205,20200310,20200303,20200301,20200229,20200224,20200222,20200214,20200214,20200213,20200227,20200323,20200312,20200322,20200322,20200322,20200322,20200322,20200320,20200320,20200322,20200320,20200321,20200321,20200318,20200318,20200319,20200319,20200320,20200320,20200224,20200305,20200307,20200323,20200318,20200318,20200319,20200319,20200322,20200322,20200317,20200317,20200318,20200318,20200318,20200314,20200320,20200320,20200305,20200226,20200313,20200209,20200320,20200319,20200317,20200317,20200226,20200224,20200318,20200318,20200217,20200215,20200205,20200203,20200317,20200306,20200223,20200215,20200310,20200319,20200316,20200317,20200319,20200322,20200323,20200319,20200314,20200202,20200322,20200227,20200320,20200130,20200227,20200302,20200214,20200213,20200221,20200202,20200202,20200204,20200306,20200217,20200208,20200219,20200301,20200301,20200319,20200321,20200227,20200224,20200308,20200315,20200212,20200214,20200308,20200317,20200317,20200304,20200304,20200315,20200329,20200313,20200319,20200319,20200328,20200313,20200328,20200314,20200316,20200318,20200318,20200327,20200327,20200329,20200327,20200328,20200327,20200327,20200327,20200314,20200328,20200326,20200325,20200326,20200325,20200327,20200325,20200327,20200327,20200325,20200325,20200324,20200323,20200324,20200323,20200325,20200318,20200324,20200323,20200320,20200318,20200318,20200317,20200318,20200310,20200323,20200320,20200315,20200218,20200228,20200227,20200226,20200225,20200220,20200327,20200218,20200320,20200317,20200324,20200324,20200317,20200316,20200313,20200320,20190730,20200227,20200227,20200306,20200309,20200320,20200323,20200323,20200316,20200317,20200317,20200320,20200320,20200324,20200318,20200325,20200320,20200319,20200320,20200321,20200323,20200325,20200405,20200318,20200323,20200323,20200308,20200405,20200404,20200325,20200325,20200326,20200326,20200405,20200403,20200324,20200326,20200403,20200403,20200403,20200323,20200319,20200325,20200324,20200403,20200402,20200402,20200402,20200401,20200401,20200401,20200401,20200326,20200330,20200318,20200331,20200331,20200323,20200309,20200405,20200403,20200331,20200329,20200402,20200402,20200331,20200331,20200324,20200331,20200331,20200316,20200323,20200402,20171025,20200206,20200215,20200228,20200324,20200326,20200224,20200309,20200315,20200330,20190116,20200330,20180919,20200313,20200323,20200319,20200323,20200324,20200227,20200126,20200214,20200228,20200325,20200325,20200320,20200325,20200129,20200216,20200220,20200221,20200309,20200318,20200320,20200320,20200228,20200309,20200308,20200311,20200330,20200327,20200323,20200329,20200224,20200227,20200302,20200305,20200321,20200322,20200323,20200323,20200330,20200330,20200331,20200313,20200315,20200315,20200314,20200310,20200314,20200313,20200317,20200323,20200324,20200324,20200324,20200323,20200327,20200331,20200330,20200319,20200319,20200319,20200320,20200324,20200326,20200326,20200325,20200401,20200330,20200327,20200401,20200316,20200323,20200323,20200323,20200323,20200323,20200323,20200324,20200326,20200325,20200326,20200325,20200331,20200331,20200402,20200402,20200323,20200324,20200325,20200325,20200324,20200325,20200325,20200326,20200325,20200327,20200327,20200402,20200401,20200402,20200325,20200326,20200326,20200326,20200325,20200321,20200326,20200326,20200327,20200329,20200329,20200330,20200401,20200402,20200330,20200403,20200326,20200325,20200324,20200327,20200331,20200329,20200330,20200326,20200324,20200326,20200403,20200403,20200401,20200401,20200327,20200323,20200327,20200326,20200206,20200331,20200327,20200331,20200326,20200330,20200330,20200331,20200406,20200406,20200331,20200403,20200402,20200402,20200402,20200402,20200329,20200331,20200330,20200331,20200330,20200331,20200401,20200331,20200330,20200401,20200331,20200404,20200401,20200407,20200402,20200402,20200402,20200331,20200402,20200327,20200331,20200330,20200330,20200330,20200326,20200331,20200402,20200403,20200403,20200407,20200402,20200331,20200403,20200330,20200407,20200407,20200406,20200331,20200401,20200401,20200403,20200403,20200402,20200401,20200401,20200401,20200329,20200402,20200408,20200404,20200408,20200409,20200405,20200407,20200406,20200407,20200331,20200401,20200331,20200331,20200409,20200220,20200414,20200401,20200401,20200401,20200401,20200406,20200407,20200407,20200406,20200407,20200407,20200331,20200402,20200403,20200403,20200406,20200401,20200403,20200403,20200403,20200405,20200401,20200401,20200401,20200401,20200404,20200408,20200407,20200407,20200409,20200409,20200406,20200330,20200406,20200331,20200402,20200402,20200401,20200403,20200409,20200408,20200407,20200405,20200401,20200407,20200407,20200407,20200406,20200403,20200407,20200407,20200402,20200328,20200325,20200407,20200407,20200406,20200407,20200406,20200313,20200403,20200405,20200403,20200403,20200408,20200408,20200407,20200408,20200407,20200404,20200408,20200408,20200331,20200401,20200401,20200404,20200404,20200403,20200410,20200408,20200408,20200409,20200324,20200404,20200408,20200406,20200405,20200407,20200331,20200407,20200407,20200408,20200406,20200331,20200331,20200406,20200402,20200408,20200406,20200401,20191206,20200403,20200303,20200316,20200330,20200406,20200414,20200406,20200325,20200407,20200407,20200408,20200406,20200412,20200411,20200410,20200410,20200408,20200406,20200408,20200407,20200331,20200408,20200408,20200407,20200228,20200402,20200408,20200408,20200408,20200409,20200305,20200228,20200407,20200331,20200316,20200326,20200409,20200409,20200406,20200329,20200406,20200408,20200331,20200331,20200401,20200402,20200408,20200408,20200326,20200403,20200407,20200322,20200407,20200407,20200401,20200407,20200411,20200410,20200407,20200410,20200410,20200407,20200407,20200323,20200327,20200331,20200403,20200326,20200327,20200324,20200329,20200402,20200403,20200403,20200403,20200330,20200408],["4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM","4/15/2020 4:11:24 PM"],["ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","German Clinical Trials Register","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","IRCT","ClinicalTrials.gov","IRCT","JPRN","TCTR","ClinicalTrials.gov","JPRN","JPRN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","JPRN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","JPRN","TCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ISRCTN","ChiCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","EU Clinical Trials Register","EU Clinical Trials Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","EU Clinical Trials Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ISRCTN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ISRCTN","ISRCTN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","Netherlands Trial Register","Netherlands Trial Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","EU Clinical Trials Register","EU Clinical Trials Register","ClinicalTrials.gov","ANZCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","EU Clinical Trials Register","ANZCTR","ISRCTN","ClinicalTrials.gov","ANZCTR","ISRCTN","ISRCTN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","ANZCTR","ISRCTN","ISRCTN","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ChiCTR","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","ChiCTR","Netherlands Trial Register","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ClinicalTrials.gov","ChiCTR","ChiCTR","Netherlands Trial Register","Netherlands Trial Register","Netherlands Trial Register","Netherlands Trial Register","ClinicalTrials.gov","ClinicalTrials.gov","ANZCTR","EU Clinical Trials Register","ANZCTR","ANZCTR","Netherlands Trial Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","ANZCTR","ISRCTN","EU Clinical Trials Register","EU Clinical Trials Register","ISRCTN","ISRCTN","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","ChiCTR","ChiCTR","EU Clinical Trials Register","ChiCTR","ChiCTR","ChiCTR","ChiCTR","Netherlands Trial Register","Netherlands Trial Register","Netherlands Trial Register","Netherlands Trial Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register","EU Clinical Trials Register"],["http://www.chictr.org.cn/showproj.aspx?proj=49217","http://www.chictr.org.cn/showproj.aspx?proj=49607","https://clinicaltrials.gov/show/NCT04246242","http://www.chictr.org.cn/showproj.aspx?proj=49181","http://www.chictr.org.cn/showproj.aspx?proj=49533","http://www.chictr.org.cn/showproj.aspx?proj=49387","http://www.chictr.org.cn/showproj.aspx?proj=49599","http://www.chictr.org.cn/showproj.aspx?proj=49432","http://www.chictr.org.cn/showproj.aspx?proj=49355","http://www.chictr.org.cn/showproj.aspx?proj=49407","https://clinicaltrials.gov/show/NCT04252885","https://clinicaltrials.gov/show/NCT04255940","https://clinicaltrials.gov/show/NCT04260308","http://www.chictr.org.cn/showproj.aspx?proj=49549","http://www.chictr.org.cn/showproj.aspx?proj=49188","http://www.chictr.org.cn/showproj.aspx?proj=49348","http://www.chictr.org.cn/showproj.aspx?proj=49378","http://www.chictr.org.cn/showproj.aspx?proj=49422","http://www.chictr.org.cn/showproj.aspx?proj=49486","http://www.chictr.org.cn/showproj.aspx?proj=49514","http://www.chictr.org.cn/showproj.aspx?proj=49380","http://www.chictr.org.cn/showproj.aspx?proj=49342","https://clinicaltrials.gov/show/NCT04251871","https://clinicaltrials.gov/show/NCT04260594","https://clinicaltrials.gov/show/NCT04261426","https://clinicaltrials.gov/show/NCT04261907","http://www.chictr.org.cn/showproj.aspx?proj=49445","http://www.chictr.org.cn/showproj.aspx?proj=49388","http://www.chictr.org.cn/showproj.aspx?proj=49596","http://www.chictr.org.cn/showproj.aspx?proj=49612","http://www.chictr.org.cn/showproj.aspx?proj=49530","http://www.chictr.org.cn/showproj.aspx?proj=49502","http://www.chictr.org.cn/showproj.aspx?proj=49587","http://www.chictr.org.cn/showproj.aspx?proj=49595","http://www.chictr.org.cn/showproj.aspx?proj=49219","http://www.chictr.org.cn/showproj.aspx?proj=49086","http://www.chictr.org.cn/showproj.aspx?proj=49346","http://www.chictr.org.cn/showproj.aspx?proj=49425","http://www.chictr.org.cn/showproj.aspx?proj=49297","http://www.chictr.org.cn/showproj.aspx?proj=49263","http://www.chictr.org.cn/showproj.aspx?proj=49563","http://www.chictr.org.cn/showproj.aspx?proj=49543","http://www.chictr.org.cn/showproj.aspx?proj=49161","http://www.chictr.org.cn/showproj.aspx?proj=49453","http://www.chictr.org.cn/showproj.aspx?proj=49170","http://www.chictr.org.cn/showproj.aspx?proj=49132","http://www.chictr.org.cn/showproj.aspx?proj=49452","http://www.chictr.org.cn/showproj.aspx?proj=49409","http://www.chictr.org.cn/showproj.aspx?proj=49127","http://www.chictr.org.cn/showproj.aspx?proj=49215","http://www.chictr.org.cn/showproj.aspx?proj=49532","http://www.chictr.org.cn/showproj.aspx?proj=49439","http://www.chictr.org.cn/showproj.aspx?proj=49408","http://www.chictr.org.cn/showproj.aspx?proj=49295","http://www.chictr.org.cn/showproj.aspx?proj=48988","http://www.chictr.org.cn/showproj.aspx?proj=49062","http://www.chictr.org.cn/showproj.aspx?proj=49104","http://www.chictr.org.cn/showproj.aspx?proj=49080","http://www.chictr.org.cn/showproj.aspx?proj=49306","http://www.chictr.org.cn/showproj.aspx?proj=49490","http://www.chictr.org.cn/showproj.aspx?proj=48968","http://www.chictr.org.cn/showproj.aspx?proj=48991","http://www.chictr.org.cn/showproj.aspx?proj=48860","http://www.chictr.org.cn/showproj.aspx?proj=48861","http://www.chictr.org.cn/showproj.aspx?proj=49178","http://www.chictr.org.cn/showproj.aspx?proj=49415","http://www.chictr.org.cn/showproj.aspx?proj=49222","http://www.chictr.org.cn/showproj.aspx?proj=49287","http://www.chictr.org.cn/showproj.aspx?proj=48971","http://www.chictr.org.cn/showproj.aspx?proj=48931","http://www.chictr.org.cn/showproj.aspx?proj=49131","http://www.chictr.org.cn/showproj.aspx?proj=49370","http://www.chictr.org.cn/showproj.aspx?proj=48922","http://www.chictr.org.cn/showproj.aspx?proj=48911","http://www.chictr.org.cn/showproj.aspx?proj=48881","http://www.chictr.org.cn/showproj.aspx?proj=48907","http://www.chictr.org.cn/showproj.aspx?proj=49354","http://www.chictr.org.cn/showproj.aspx?proj=49279","http://www.chictr.org.cn/showproj.aspx?proj=49283","http://www.chictr.org.cn/showproj.aspx?proj=49302","http://www.chictr.org.cn/showproj.aspx?proj=48884","http://www.chictr.org.cn/showproj.aspx?proj=48886","http://www.chictr.org.cn/showproj.aspx?proj=49187","http://www.chictr.org.cn/showproj.aspx?proj=49155","http://www.chictr.org.cn/showproj.aspx?proj=48868","http://www.chictr.org.cn/showproj.aspx?proj=49165","http://www.chictr.org.cn/showproj.aspx?proj=49177","http://www.chictr.org.cn/showproj.aspx?proj=48985","http://www.chictr.org.cn/showproj.aspx?proj=49145","http://www.chictr.org.cn/showproj.aspx?proj=49146","http://www.chictr.org.cn/showproj.aspx?proj=49229","http://www.chictr.org.cn/showproj.aspx?proj=49696","http://www.chictr.org.cn/showproj.aspx?proj=49042","http://www.chictr.org.cn/showproj.aspx?proj=41760","http://www.chictr.org.cn/showproj.aspx?proj=49051","http://www.chictr.org.cn/showproj.aspx?proj=49075","http://www.chictr.org.cn/showproj.aspx?proj=48880","http://www.chictr.org.cn/showproj.aspx?proj=49013","http://www.chictr.org.cn/showproj.aspx?proj=48792","http://www.chictr.org.cn/showproj.aspx?proj=49015","http://www.chictr.org.cn/showproj.aspx?proj=48992","http://www.chictr.org.cn/showproj.aspx?proj=48965","http://www.chictr.org.cn/showproj.aspx?proj=49594","http://www.chictr.org.cn/showproj.aspx?proj=49901","http://www.chictr.org.cn/showproj.aspx?proj=48919","http://www.chictr.org.cn/showproj.aspx?proj=48913","http://www.chictr.org.cn/showproj.aspx?proj=48927","http://www.chictr.org.cn/showproj.aspx?proj=48930","http://www.chictr.org.cn/showproj.aspx?proj=48929","http://www.chictr.org.cn/showproj.aspx?proj=48904","http://www.chictr.org.cn/showproj.aspx?proj=48827","http://www.chictr.org.cn/showproj.aspx?proj=48902","http://www.chictr.org.cn/showproj.aspx?proj=49932","http://www.chictr.org.cn/showproj.aspx?proj=49952","http://www.chictr.org.cn/showproj.aspx?proj=49866","http://www.chictr.org.cn/showproj.aspx?proj=49891","https://clinicaltrials.gov/show/NCT04259892","https://clinicaltrials.gov/show/NCT04268537","http://www.chictr.org.cn/showproj.aspx?proj=50059","http://www.chictr.org.cn/showproj.aspx?proj=48824","https://clinicaltrials.gov/show/NCT04244591","http://www.chictr.org.cn/showproj.aspx?proj=49983","http://www.chictr.org.cn/showproj.aspx?proj=49988","http://www.chictr.org.cn/showproj.aspx?proj=49647","http://www.chictr.org.cn/showproj.aspx?proj=49816","http://www.chictr.org.cn/showproj.aspx?proj=48768","https://clinicaltrials.gov/show/NCT04269525","http://www.chictr.org.cn/showproj.aspx?proj=50058","http://www.chictr.org.cn/showproj.aspx?proj=49567","http://www.chictr.org.cn/showproj.aspx?proj=49794","http://www.chictr.org.cn/showproj.aspx?proj=49970","http://www.chictr.org.cn/showproj.aspx?proj=49947","http://www.chictr.org.cn/showproj.aspx?proj=49762","http://www.chictr.org.cn/showproj.aspx?proj=49964","http://www.chictr.org.cn/showproj.aspx?proj=49880","http://www.chictr.org.cn/showproj.aspx?proj=50025","http://www.chictr.org.cn/showproj.aspx?proj=50017","http://www.chictr.org.cn/showproj.aspx?proj=49861","http://www.chictr.org.cn/showproj.aspx?proj=49841","http://www.chictr.org.cn/showproj.aspx?proj=49824","http://www.chictr.org.cn/showproj.aspx?proj=49852","http://www.chictr.org.cn/showproj.aspx?proj=49910","http://www.chictr.org.cn/showproj.aspx?proj=49831","http://www.chictr.org.cn/showproj.aspx?proj=50004","http://www.chictr.org.cn/showproj.aspx?proj=50007","http://www.chictr.org.cn/showproj.aspx?proj=49799","http://www.chictr.org.cn/showproj.aspx?proj=49619","http://www.chictr.org.cn/showproj.aspx?proj=49904","http://www.chictr.org.cn/showproj.aspx?proj=49703","http://www.chictr.org.cn/showproj.aspx?proj=50005","http://www.chictr.org.cn/showproj.aspx?proj=49747","http://www.chictr.org.cn/showproj.aspx?proj=49798","http://www.chictr.org.cn/showproj.aspx?proj=49800","http://www.chictr.org.cn/showproj.aspx?proj=49718","http://www.chictr.org.cn/showproj.aspx?proj=49777","http://www.chictr.org.cn/showproj.aspx?proj=49889","http://www.chictr.org.cn/showproj.aspx?proj=49902","http://www.chictr.org.cn/showproj.aspx?proj=49426","http://www.chictr.org.cn/showproj.aspx?proj=49737","http://www.chictr.org.cn/showproj.aspx?proj=49748","http://www.chictr.org.cn/showproj.aspx?proj=49618","http://www.chictr.org.cn/showproj.aspx?proj=49919","http://www.chictr.org.cn/showproj.aspx?proj=49934","http://www.chictr.org.cn/showproj.aspx?proj=49869","http://www.chictr.org.cn/showproj.aspx?proj=49544","http://www.chictr.org.cn/showproj.aspx?proj=49510","http://www.chictr.org.cn/showproj.aspx?proj=49418","http://www.chictr.org.cn/showproj.aspx?proj=49723","http://www.chictr.org.cn/showproj.aspx?proj=49717","http://www.chictr.org.cn/showproj.aspx?proj=49690","http://www.chictr.org.cn/showproj.aspx?proj=49812","http://www.chictr.org.cn/showproj.aspx?proj=49768","http://www.chictr.org.cn/showproj.aspx?proj=49783","http://www.chictr.org.cn/showproj.aspx?proj=49770","http://www.chictr.org.cn/showproj.aspx?proj=49738","http://www.chictr.org.cn/showproj.aspx?proj=49309","http://www.chictr.org.cn/showproj.aspx?proj=49702","http://www.chictr.org.cn/showproj.aspx?proj=49574","http://www.chictr.org.cn/showproj.aspx?proj=49674","http://www.chictr.org.cn/showproj.aspx?proj=49720","http://www.chictr.org.cn/showproj.aspx?proj=49218","http://www.chictr.org.cn/showproj.aspx?proj=49639","http://www.chictr.org.cn/showproj.aspx?proj=49636","http://www.chictr.org.cn/showproj.aspx?proj=49138","http://www.chictr.org.cn/showproj.aspx?proj=49317","http://www.chictr.org.cn/showproj.aspx?proj=49711","http://www.chictr.org.cn/showproj.aspx?proj=49664","http://www.chictr.org.cn/showproj.aspx?proj=49519","http://www.chictr.org.cn/showproj.aspx?proj=49545","http://www.chictr.org.cn/showproj.aspx?proj=49692","http://www.chictr.org.cn/showproj.aspx?proj=49321","http://www.chictr.org.cn/showproj.aspx?proj=49428","http://www.chictr.org.cn/showproj.aspx?proj=49220","http://www.chictr.org.cn/showproj.aspx?proj=49534","https://clinicaltrials.gov/show/NCT04252664","http://www.chictr.org.cn/showproj.aspx?proj=49402","https://clinicaltrials.gov/show/NCT04279899","https://clinicaltrials.gov/show/NCT04256395","https://clinicaltrials.gov/show/NCT04273529","https://clinicaltrials.gov/show/NCT04273581","http://www.chictr.org.cn/showproj.aspx?proj=50273","http://www.chictr.org.cn/showproj.aspx?proj=50341","https://clinicaltrials.gov/show/NCT04270383","https://clinicaltrials.gov/show/NCT04273646","https://clinicaltrials.gov/show/NCT04275947","http://www.chictr.org.cn/showproj.aspx?proj=50286","https://clinicaltrials.gov/show/NCT04257656","https://clinicaltrials.gov/show/NCT04275245","https://clinicaltrials.gov/show/NCT04275388","https://clinicaltrials.gov/show/NCT04279197","http://www.chictr.org.cn/showproj.aspx?proj=50323","http://www.chictr.org.cn/showproj.aspx?proj=50325","http://www.chictr.org.cn/showproj.aspx?proj=50224","http://www.chictr.org.cn/showproj.aspx?proj=49984","http://www.chictr.org.cn/showproj.aspx?proj=50240","http://www.chictr.org.cn/showproj.aspx?proj=50248","https://clinicaltrials.gov/show/NCT04280588","http://www.chictr.org.cn/showproj.aspx?proj=50268","http://www.chictr.org.cn/showproj.aspx?proj=50173","http://www.chictr.org.cn/showproj.aspx?proj=50278","https://clinicaltrials.gov/show/NCT04279782","https://clinicaltrials.gov/show/NCT04279795","https://clinicaltrials.gov/show/NCT04280224","http://www.chictr.org.cn/showproj.aspx?proj=50380","http://www.chictr.org.cn/showproj.aspx?proj=49491","http://www.chictr.org.cn/showproj.aspx?proj=48801","http://www.chictr.org.cn/showproj.aspx?proj=50223","http://www.chictr.org.cn/showproj.aspx?proj=50136","http://www.chictr.org.cn/showproj.aspx?proj=50174","http://www.chictr.org.cn/showproj.aspx?proj=30796","http://www.chictr.org.cn/showproj.aspx?proj=50329","http://www.chictr.org.cn/showproj.aspx?proj=50140","http://www.chictr.org.cn/showproj.aspx?proj=50247","http://www.chictr.org.cn/showproj.aspx?proj=50255","http://www.chictr.org.cn/showproj.aspx?proj=50214","http://www.chictr.org.cn/showproj.aspx?proj=50227","http://www.chictr.org.cn/showproj.aspx?proj=50022","http://www.chictr.org.cn/showproj.aspx?proj=50119","http://www.chictr.org.cn/showproj.aspx?proj=50231","http://www.chictr.org.cn/showproj.aspx?proj=50195","http://www.chictr.org.cn/showproj.aspx?proj=49691","http://www.chictr.org.cn/showproj.aspx?proj=50161","http://www.chictr.org.cn/showproj.aspx?proj=50175","http://www.chictr.org.cn/showproj.aspx?proj=49918","http://www.chictr.org.cn/showproj.aspx?proj=49887","http://www.chictr.org.cn/showproj.aspx?proj=50006","http://www.chictr.org.cn/showproj.aspx?proj=50130","http://www.chictr.org.cn/showproj.aspx?proj=50089","http://www.chictr.org.cn/showproj.aspx?proj=49963","http://www.chictr.org.cn/showproj.aspx?proj=50048","http://www.chictr.org.cn/showproj.aspx?proj=50143","http://www.chictr.org.cn/showproj.aspx?proj=50110","http://www.chictr.org.cn/showproj.aspx?proj=49855","http://www.chictr.org.cn/showproj.aspx?proj=49945","http://www.chictr.org.cn/showproj.aspx?proj=50107","http://www.chictr.org.cn/showproj.aspx?proj=49883","http://www.chictr.org.cn/showproj.aspx?proj=50026","http://www.chictr.org.cn/showproj.aspx?proj=49570","http://www.chictr.org.cn/showproj.aspx?proj=49914","http://www.chictr.org.cn/showproj.aspx?proj=49899","http://www.chictr.org.cn/showproj.aspx?proj=49797","http://www.chictr.org.cn/showproj.aspx?proj=49796","http://www.chictr.org.cn/showproj.aspx?proj=49536","http://www.chictr.org.cn/showproj.aspx?proj=49482","http://www.chictr.org.cn/showproj.aspx?proj=49592","http://www.chictr.org.cn/showproj.aspx?proj=49404","http://www.chictr.org.cn/showproj.aspx?proj=50115","http://www.chictr.org.cn/showproj.aspx?proj=49630","http://www.chictr.org.cn/showproj.aspx?proj=49666","http://www.chictr.org.cn/showproj.aspx?proj=49301","http://www.chictr.org.cn/showproj.aspx?proj=49250","http://www.chictr.org.cn/showproj.aspx?proj=48782","http://www.chictr.org.cn/showproj.aspx?proj=49377","http://www.chictr.org.cn/showproj.aspx?proj=49400","http://www.chictr.org.cn/showproj.aspx?proj=49352","http://www.chictr.org.cn/showproj.aspx?proj=48777","http://www.chictr.org.cn/showproj.aspx?proj=49369","https://clinicaltrials.gov/show/NCT04286503","http://www.chictr.org.cn/showproj.aspx?proj=49520","http://www.chictr.org.cn/showproj.aspx?proj=49708","https://clinicaltrials.gov/show/NCT04276688","https://clinicaltrials.gov/show/NCT04281693","https://clinicaltrials.gov/show/NCT04282902","https://clinicaltrials.gov/show/NCT04252118","https://clinicaltrials.gov/show/NCT04276987","http://www.chictr.org.cn/showproj.aspx?proj=50228","http://www.chictr.org.cn/showproj.aspx?proj=50583","http://www.chictr.org.cn/showproj.aspx?proj=50667","http://www.chictr.org.cn/showproj.aspx?proj=49790","http://www.chictr.org.cn/showproj.aspx?proj=44213","https://clinicaltrials.gov/show/NCT04284046","https://clinicaltrials.gov/show/NCT04285190","http://www.chictr.org.cn/showproj.aspx?proj=50727","http://www.chictr.org.cn/showproj.aspx?proj=50394","http://www.chictr.org.cn/showproj.aspx?proj=49953","http://www.chictr.org.cn/showproj.aspx?proj=50692","http://www.chictr.org.cn/showproj.aspx?proj=50690","http://www.chictr.org.cn/showproj.aspx?proj=49632","http://www.chictr.org.cn/showproj.aspx?proj=50507","http://www.chictr.org.cn/showproj.aspx?proj=50653","http://www.chictr.org.cn/showproj.aspx?proj=50134","http://www.chictr.org.cn/showproj.aspx?proj=50459","http://www.chictr.org.cn/showproj.aspx?proj=49753","http://www.chictr.org.cn/showproj.aspx?proj=50541","http://www.chictr.org.cn/showproj.aspx?proj=50623","http://www.chictr.org.cn/showproj.aspx?proj=50672","http://www.chictr.org.cn/showproj.aspx?proj=50608","http://www.chictr.org.cn/showproj.aspx?proj=50547","http://www.chictr.org.cn/showproj.aspx?proj=50470","http://www.chictr.org.cn/showproj.aspx?proj=50658","http://www.chictr.org.cn/showproj.aspx?proj=50549","http://www.chictr.org.cn/showproj.aspx?proj=50421","http://www.chictr.org.cn/showproj.aspx?proj=50082","http://www.chictr.org.cn/showproj.aspx?proj=50586","http://www.chictr.org.cn/showproj.aspx?proj=50552","http://www.chictr.org.cn/showproj.aspx?proj=50450","http://www.chictr.org.cn/showproj.aspx?proj=50458","http://www.chictr.org.cn/showproj.aspx?proj=50487","http://www.chictr.org.cn/showproj.aspx?proj=50453","http://www.chictr.org.cn/showproj.aspx?proj=50490","http://www.chictr.org.cn/showproj.aspx?proj=50263","http://www.chictr.org.cn/showproj.aspx?proj=50390","http://www.chictr.org.cn/showproj.aspx?proj=50381","http://www.chictr.org.cn/showproj.aspx?proj=50353","http://www.chictr.org.cn/showproj.aspx?proj=50452","http://www.chictr.org.cn/showproj.aspx?proj=50378","http://www.chictr.org.cn/showproj.aspx?proj=50388","http://www.chictr.org.cn/showproj.aspx?proj=50297","http://www.chictr.org.cn/showproj.aspx?proj=49635","http://www.chictr.org.cn/showproj.aspx?proj=50258","http://www.chictr.org.cn/showproj.aspx?proj=49653","http://www.chictr.org.cn/showproj.aspx?proj=50382","http://www.chictr.org.cn/showproj.aspx?proj=50031","http://www.chictr.org.cn/showproj.aspx?proj=49802","http://www.chictr.org.cn/showproj.aspx?proj=49088","http://www.chictr.org.cn/showproj.aspx?proj=49435","http://www.chictr.org.cn/showproj.aspx?proj=49224","http://www.chictr.org.cn/showproj.aspx?proj=48775","http://www.chictr.org.cn/showproj.aspx?proj=49014","http://www.chictr.org.cn/showproj.aspx?proj=49045","http://www.chictr.org.cn/showproj.aspx?proj=48898","http://www.chictr.org.cn/showproj.aspx?proj=49081","https://clinicaltrials.gov/show/NCT04292340","http://www.chictr.org.cn/showproj.aspx?proj=48889","https://clinicaltrials.gov/show/NCT04292327","http://www.chictr.org.cn/showproj.aspx?proj=48773","http://www.chictr.org.cn/showproj.aspx?proj=51028","http://www.chictr.org.cn/showproj.aspx?proj=51034","http://www.chictr.org.cn/showproj.aspx?proj=51126","https://clinicaltrials.gov/show/NCT04293887","http://www.chictr.org.cn/showproj.aspx?proj=51130","http://www.chictr.org.cn/showproj.aspx?proj=51073","http://www.chictr.org.cn/showproj.aspx?proj=50767","https://clinicaltrials.gov/show/NCT04295551","https://clinicaltrials.gov/show/NCT04296643","https://clinicaltrials.gov/show/NCT04299711","http://www.chictr.org.cn/showproj.aspx?proj=50462","http://www.chictr.org.cn/showproj.aspx?proj=51107","http://www.chictr.org.cn/showproj.aspx?proj=51103","http://www.chictr.org.cn/showproj.aspx?proj=51064","http://www.chictr.org.cn/showproj.aspx?proj=51083","http://www.chictr.org.cn/showproj.aspx?proj=51081","http://www.chictr.org.cn/showproj.aspx?proj=51077","http://www.chictr.org.cn/showproj.aspx?proj=51118","http://www.chictr.org.cn/showproj.aspx?proj=50960","http://www.chictr.org.cn/showproj.aspx?proj=51102","http://www.chictr.org.cn/showproj.aspx?proj=50947","http://www.chictr.org.cn/showproj.aspx?proj=49933","http://www.chictr.org.cn/showproj.aspx?proj=51097","http://www.chictr.org.cn/showproj.aspx?proj=50986","http://www.chictr.org.cn/showproj.aspx?proj=51015","http://www.chictr.org.cn/showproj.aspx?proj=51071","http://www.chictr.org.cn/showproj.aspx?proj=51054","http://www.chictr.org.cn/showproj.aspx?proj=51091","http://www.chictr.org.cn/showproj.aspx?proj=51086","http://www.chictr.org.cn/showproj.aspx?proj=48684","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14","http://www.chictr.org.cn/showproj.aspx?proj=51050","http://www.chictr.org.cn/showproj.aspx?proj=51047","http://www.chictr.org.cn/showproj.aspx?proj=51035","http://www.chictr.org.cn/showproj.aspx?proj=51036","http://www.chictr.org.cn/showproj.aspx?proj=51039","http://www.chictr.org.cn/showproj.aspx?proj=51037","http://www.chictr.org.cn/showproj.aspx?proj=51048","http://www.chictr.org.cn/showproj.aspx?proj=51042","http://www.chictr.org.cn/showproj.aspx?proj=50982","http://www.chictr.org.cn/showproj.aspx?proj=50987","http://www.chictr.org.cn/showproj.aspx?proj=51019","http://www.chictr.org.cn/showproj.aspx?proj=51026","http://www.chictr.org.cn/showproj.aspx?proj=51007","http://www.chictr.org.cn/showproj.aspx?proj=51004","http://www.chictr.org.cn/showproj.aspx?proj=50994","http://www.chictr.org.cn/showproj.aspx?proj=50991","http://www.chictr.org.cn/showproj.aspx?proj=50998","http://www.chictr.org.cn/showproj.aspx?proj=50997","https://clinicaltrials.gov/show/NCT04298814","http://www.chictr.org.cn/showproj.aspx?proj=50780","http://www.chictr.org.cn/showproj.aspx?proj=49284","http://www.chictr.org.cn/showproj.aspx?proj=50590","http://www.chictr.org.cn/showproj.aspx?proj=50976","http://www.chictr.org.cn/showproj.aspx?proj=50934","http://www.chictr.org.cn/showproj.aspx?proj=50307","http://www.chictr.org.cn/showproj.aspx?proj=50968","http://www.chictr.org.cn/showproj.aspx?proj=50299","http://www.chictr.org.cn/showproj.aspx?proj=50662","http://www.chictr.org.cn/showproj.aspx?proj=50648","http://www.chictr.org.cn/showproj.aspx?proj=50705","http://www.chictr.org.cn/showproj.aspx?proj=50852","http://www.chictr.org.cn/showproj.aspx?proj=50950","http://www.chictr.org.cn/showproj.aspx?proj=51025","http://www.chictr.org.cn/showproj.aspx?proj=51040","http://www.chictr.org.cn/showproj.aspx?proj=50955","http://www.chictr.org.cn/showproj.aspx?proj=50945","http://www.chictr.org.cn/showproj.aspx?proj=50941","http://www.chictr.org.cn/showproj.aspx?proj=50843","http://www.chictr.org.cn/showproj.aspx?proj=51090","http://www.chictr.org.cn/showproj.aspx?proj=51056","http://www.chictr.org.cn/showproj.aspx?proj=50901","http://www.chictr.org.cn/showproj.aspx?proj=50910","http://www.chictr.org.cn/showproj.aspx?proj=50857","http://www.chictr.org.cn/showproj.aspx?proj=50907","http://www.chictr.org.cn/showproj.aspx?proj=50860","http://www.chictr.org.cn/showproj.aspx?proj=50850","http://www.chictr.org.cn/showproj.aspx?proj=50900","http://www.chictr.org.cn/showproj.aspx?proj=50083","http://www.chictr.org.cn/showproj.aspx?proj=50896","http://www.chictr.org.cn/showproj.aspx?proj=50759","http://www.chictr.org.cn/showproj.aspx?proj=51072","http://www.chictr.org.cn/showproj.aspx?proj=50904","http://www.chictr.org.cn/showproj.aspx?proj=50160","http://www.chictr.org.cn/showproj.aspx?proj=50001","http://www.chictr.org.cn/showproj.aspx?proj=50867","http://www.chictr.org.cn/showproj.aspx?proj=50251","http://www.chictr.org.cn/showproj.aspx?proj=51044","http://www.chictr.org.cn/showproj.aspx?proj=51009","http://www.chictr.org.cn/showproj.aspx?proj=51029","http://www.chictr.org.cn/showproj.aspx?proj=51018","http://www.chictr.org.cn/showproj.aspx?proj=50995","http://www.chictr.org.cn/showproj.aspx?proj=50988","http://www.chictr.org.cn/showproj.aspx?proj=50572","http://www.chictr.org.cn/showproj.aspx?proj=50126","http://www.chictr.org.cn/showproj.aspx?proj=50261","http://www.chictr.org.cn/showproj.aspx?proj=50693","http://www.chictr.org.cn/showproj.aspx?proj=50795","http://www.chictr.org.cn/showproj.aspx?proj=50786","http://www.chictr.org.cn/showproj.aspx?proj=50973","http://www.chictr.org.cn/showproj.aspx?proj=50921","http://www.chictr.org.cn/showproj.aspx?proj=50387","http://www.chictr.org.cn/showproj.aspx?proj=50306","http://www.chictr.org.cn/showproj.aspx?proj=50956","http://www.chictr.org.cn/showproj.aspx?proj=50824","http://www.chictr.org.cn/showproj.aspx?proj=50678","http://www.chictr.org.cn/showproj.aspx?proj=49779","http://www.chictr.org.cn/showproj.aspx?proj=50633","http://www.chictr.org.cn/showproj.aspx?proj=50763","http://www.chictr.org.cn/showproj.aspx?proj=49987","http://www.chictr.org.cn/showproj.aspx?proj=49915","http://www.chictr.org.cn/showproj.aspx?proj=50222","http://www.chictr.org.cn/showproj.aspx?proj=50071","http://www.chictr.org.cn/showproj.aspx?proj=49712","http://www.chictr.org.cn/showproj.aspx?proj=49633","http://www.chictr.org.cn/showproj.aspx?proj=50656","http://www.chictr.org.cn/showproj.aspx?proj=50495","http://www.chictr.org.cn/showproj.aspx?proj=50925","http://www.chictr.org.cn/showproj.aspx?proj=50000","http://www.chictr.org.cn/showproj.aspx?proj=50057","http://www.chictr.org.cn/showproj.aspx?proj=49569","http://www.chictr.org.cn/showproj.aspx?proj=50460","http://www.chictr.org.cn/showproj.aspx?proj=49864","http://www.chictr.org.cn/showproj.aspx?proj=50338","http://www.chictr.org.cn/showproj.aspx?proj=50793","http://www.chictr.org.cn/showproj.aspx?proj=49384","http://www.chictr.org.cn/showproj.aspx?proj=49374","http://www.chictr.org.cn/showproj.aspx?proj=49495","http://www.chictr.org.cn/showproj.aspx?proj=49481","http://www.chictr.org.cn/showproj.aspx?proj=49806","http://www.chictr.org.cn/showproj.aspx?proj=49669","http://www.chictr.org.cn/showproj.aspx?proj=50537","http://www.chictr.org.cn/showproj.aspx?proj=50781","http://www.chictr.org.cn/showproj.aspx?proj=50714","http://www.chictr.org.cn/showproj.aspx?proj=50730","http://www.chictr.org.cn/showproj.aspx?proj=50713","http://www.chictr.org.cn/showproj.aspx?proj=50702","http://www.chictr.org.cn/showproj.aspx?proj=50641","http://www.chictr.org.cn/showproj.aspx?proj=49956","http://www.chictr.org.cn/showproj.aspx?proj=49492","https://clinicaltrials.gov/show/NCT04264533","http://www.chictr.org.cn/showproj.aspx?proj=49069","https://clinicaltrials.gov/show/NCT04307693","http://www.chictr.org.cn/showproj.aspx?proj=50455","http://www.chictr.org.cn/showproj.aspx?proj=50279","http://www.chictr.org.cn/showproj.aspx?proj=50290","http://www.chictr.org.cn/showproj.aspx?proj=50002","http://www.chictr.org.cn/showproj.aspx?proj=49948","http://www.chictr.org.cn/showproj.aspx?proj=49382","http://www.chictr.org.cn/showproj.aspx?proj=49389","http://www.chictr.org.cn/showproj.aspx?proj=49412","https://clinicaltrials.gov/show/NCT04302519","http://www.chictr.org.cn/showproj.aspx?proj=51390","https://clinicaltrials.gov/show/NCT04308187","http://www.chictr.org.cn/showproj.aspx?proj=51032","http://www.chictr.org.cn/showproj.aspx?proj=50605","http://www.chictr.org.cn/showproj.aspx?proj=51416","http://www.chictr.org.cn/showproj.aspx?proj=51185","http://www.chictr.org.cn/showproj.aspx?proj=51132","http://www.chictr.org.cn/showproj.aspx?proj=51338","http://www.chictr.org.cn/showproj.aspx?proj=51331","http://www.chictr.org.cn/showproj.aspx?proj=51148","http://www.chictr.org.cn/showproj.aspx?proj=51349","http://www.chictr.org.cn/showproj.aspx?proj=50984","http://www.chictr.org.cn/showproj.aspx?proj=51348","http://www.chictr.org.cn/showproj.aspx?proj=51000","http://www.chictr.org.cn/showproj.aspx?proj=51059","http://www.chictr.org.cn/showproj.aspx?proj=51267","http://www.chictr.org.cn/showproj.aspx?proj=51265","http://www.chictr.org.cn/showproj.aspx?proj=51316","http://www.chictr.org.cn/showproj.aspx?proj=51291","https://clinicaltrials.gov/show/NCT04285801","https://clinicaltrials.gov/show/NCT04299724","https://clinicaltrials.gov/show/NCT04302688","http://www.chictr.org.cn/showproj.aspx?proj=51021","http://www.chictr.org.cn/showproj.aspx?proj=51184","http://www.chictr.org.cn/showproj.aspx?proj=51230","http://www.chictr.org.cn/showproj.aspx?proj=51278","http://www.chictr.org.cn/showproj.aspx?proj=51272","http://www.chictr.org.cn/showproj.aspx?proj=51404","http://www.chictr.org.cn/showproj.aspx?proj=51136","http://www.chictr.org.cn/showproj.aspx?proj=51141","http://www.chictr.org.cn/showproj.aspx?proj=51154","http://www.chictr.org.cn/showproj.aspx?proj=50898","http://www.chictr.org.cn/showproj.aspx?proj=51160","http://www.chictr.org.cn/showproj.aspx?proj=51212","http://www.chictr.org.cn/showproj.aspx?proj=50961","http://www.chictr.org.cn/showproj.aspx?proj=51342","http://www.chictr.org.cn/showproj.aspx?proj=51329","http://www.chictr.org.cn/showproj.aspx?proj=50604","http://www.chictr.org.cn/showproj.aspx?proj=50137","http://www.chictr.org.cn/showproj.aspx?proj=50964","http://www.chictr.org.cn/showproj.aspx?proj=49074","http://www.chictr.org.cn/showproj.aspx?proj=51311","http://www.chictr.org.cn/showproj.aspx?proj=51283","http://www.chictr.org.cn/showproj.aspx?proj=50696","http://www.chictr.org.cn/showproj.aspx?proj=50476","http://www.chictr.org.cn/showproj.aspx?proj=49968","http://www.chictr.org.cn/showproj.aspx?proj=49433","http://www.chictr.org.cn/showproj.aspx?proj=50199","http://www.chictr.org.cn/showproj.aspx?proj=50981","http://www.chictr.org.cn/showproj.aspx?proj=49531","http://www.chictr.org.cn/showproj.aspx?proj=49511","http://www.chictr.org.cn/showproj.aspx?proj=49065","http://www.chictr.org.cn/showproj.aspx?proj=48809","http://www.chictr.org.cn/showproj.aspx?proj=51149","http://www.chictr.org.cn/showproj.aspx?proj=50660","http://www.chictr.org.cn/showproj.aspx?proj=49845","http://www.chictr.org.cn/showproj.aspx?proj=49524","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25","http://www.drks.de/DRKS00021134","http://en.irct.ir/trial/46545","http://en.irct.ir/trial/46554","http://en.irct.ir/trial/46538","http://en.irct.ir/trial/46576","http://en.irct.ir/trial/46561","http://en.irct.ir/trial/46567","http://en.irct.ir/trial/46463","https://clinicaltrials.gov/show/NCT04263402","http://en.irct.ir/trial/46536","https://jrct.niph.go.jp/latest-detail/jRCTs031190227","http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=5975","https://clinicaltrials.gov/show/NCT04251767","https://jrct.niph.go.jp/latest-detail/jRCTs031190226","https://jrct.niph.go.jp/latest-detail/jRCTs041190120","https://clinicaltrials.gov/show/NCT04273763","https://clinicaltrials.gov/show/NCT04283396","https://clinicaltrials.gov/show/NCT04287686","https://clinicaltrials.gov/show/NCT04254874","https://clinicaltrials.gov/show/NCT04255017","https://clinicaltrials.gov/show/NCT04261270","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045268","https://clinicaltrials.gov/show/NCT04276896","https://clinicaltrials.gov/show/NCT04264858","https://clinicaltrials.gov/show/NCT04278963","https://clinicaltrials.gov/show/NCT04292964","https://clinicaltrials.gov/show/NCT04306497","https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045453","http://www.clinicaltrials.in.th/index.php?tp=regtrials&amp;menu=trialsearch&amp;smenu=fulltext&amp;task=search&amp;task2=view1&amp;id=5976","https://clinicaltrials.gov/show/NCT04291053","https://clinicaltrials.gov/show/NCT04293692","https://clinicaltrials.gov/show/NCT04305574","https://clinicaltrials.gov/show/NCT04310865","https://clinicaltrials.gov/show/NCT04272710","https://clinicaltrials.gov/show/NCT04304313","https://clinicaltrials.gov/show/NCT04306705","https://clinicaltrials.gov/show/NCT04314232","https://clinicaltrials.gov/show/NCT04314817","https://clinicaltrials.gov/show/NCT04308317","https://clinicaltrials.gov/show/NCT04312464","https://clinicaltrials.gov/show/NCT04313322","http://www.chictr.org.cn/showproj.aspx?proj=51692","https://clinicaltrials.gov/show/NCT04312100","https://clinicaltrials.gov/show/NCT04318015","https://clinicaltrials.gov/show/NCT04318418","http://www.chictr.org.cn/showproj.aspx?proj=51499","https://clinicaltrials.gov/show/NCT04316884","http://www.chictr.org.cn/showproj.aspx?proj=51385","https://clinicaltrials.gov/show/NCT04311398","https://clinicaltrials.gov/show/NCT04314271","https://clinicaltrials.gov/show/NCT04315870","https://clinicaltrials.gov/show/NCT04315896","http://www.chictr.org.cn/showproj.aspx?proj=51504","http://www.chictr.org.cn/showproj.aspx?proj=51667","http://www.chictr.org.cn/showproj.aspx?proj=51694","http://www.chictr.org.cn/showproj.aspx?proj=51647","http://www.chictr.org.cn/showproj.aspx?proj=51517","http://www.chictr.org.cn/showproj.aspx?proj=51668","http://www.chictr.org.cn/showproj.aspx?proj=51425","http://www.chictr.org.cn/showproj.aspx?proj=51669","https://clinicaltrials.gov/show/NCT04316728","http://www.chictr.org.cn/showproj.aspx?proj=51170","http://www.chictr.org.cn/showproj.aspx?proj=51455","http://www.chictr.org.cn/showproj.aspx?proj=51559","http://www.chictr.org.cn/showproj.aspx?proj=51194","http://www.chictr.org.cn/showproj.aspx?proj=51518","http://www.chictr.org.cn/showproj.aspx?proj=51603","http://www.chictr.org.cn/showproj.aspx?proj=51540","http://www.chictr.org.cn/showproj.aspx?proj=51584","http://www.chictr.org.cn/showproj.aspx?proj=51629","http://www.chictr.org.cn/showproj.aspx?proj=51535","http://www.chictr.org.cn/showproj.aspx?proj=51486","http://www.chictr.org.cn/showproj.aspx?proj=49420","http://www.chictr.org.cn/showproj.aspx?proj=51442","http://www.chictr.org.cn/showproj.aspx?proj=51030","http://www.chictr.org.cn/showproj.aspx?proj=51443","http://www.chictr.org.cn/showproj.aspx?proj=51473","http://www.chictr.org.cn/showproj.aspx?proj=51061","http://www.chictr.org.cn/showproj.aspx?proj=51509","http://www.chictr.org.cn/showproj.aspx?proj=51488","http://www.chictr.org.cn/showproj.aspx?proj=51254","http://www.chictr.org.cn/showproj.aspx?proj=51239","http://www.chictr.org.cn/showproj.aspx?proj=51100","http://www.chictr.org.cn/showproj.aspx?proj=51139","http://www.chictr.org.cn/showproj.aspx?proj=51240","http://www.chictr.org.cn/showproj.aspx?proj=50778","http://www.chictr.org.cn/showproj.aspx?proj=51112","http://www.chictr.org.cn/showproj.aspx?proj=51317","http://www.chictr.org.cn/showproj.aspx?proj=50631","http://www.chictr.org.cn/showproj.aspx?proj=49724","http://www.chictr.org.cn/showproj.aspx?proj=50274","http://www.chictr.org.cn/showproj.aspx?proj=50202","http://www.chictr.org.cn/showproj.aspx?proj=50078","http://www.chictr.org.cn/showproj.aspx?proj=50066","http://www.chictr.org.cn/showproj.aspx?proj=49840","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001243-15","http://www.chictr.org.cn/showproj.aspx?proj=49631","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000919-69","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001224-33","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14","https://clinicaltrials.gov/show/NCT04312997","https://clinicaltrials.gov/show/NCT04315948","https://clinicaltrials.gov/show/NCT04319900","https://clinicaltrials.gov/show/NCT04061382","https://clinicaltrials.gov/show/NCT04288713","https://clinicaltrials.gov/show/NCT04290871","https://clinicaltrials.gov/show/NCT04303507","https://clinicaltrials.gov/show/NCT04305106","https://clinicaltrials.gov/show/NCT04321928","https://clinicaltrials.gov/show/NCT04322786","https://clinicaltrials.gov/show/NCT04323228","https://clinicaltrials.gov/show/NCT04313023","https://clinicaltrials.gov/show/NCT04316299","https://clinicaltrials.gov/show/NCT04318314","https://clinicaltrials.gov/show/NCT04318444","https://clinicaltrials.gov/show/NCT04320017","https://clinicaltrials.gov/show/NCT04322565","https://clinicaltrials.gov/show/NCT04323514","https://clinicaltrials.gov/show/NCT04323631","https://clinicaltrials.gov/show/NCT04319211","https://clinicaltrials.gov/show/NCT04320056","https://clinicaltrials.gov/show/NCT04320277","https://clinicaltrials.gov/show/NCT04320953","https://clinicaltrials.gov/show/NCT04322344","https://clinicaltrials.gov/show/NCT04323644","http://www.chictr.org.cn/showproj.aspx?proj=50474","https://clinicaltrials.gov/show/NCT04321174","https://clinicaltrials.gov/show/NCT04321421","https://clinicaltrials.gov/show/NCT04322487","https://clinicaltrials.gov/show/NCT04323332","http://www.chictr.org.cn/showproj.aspx?proj=51969","http://www.chictr.org.cn/showproj.aspx?proj=51952","https://clinicaltrials.gov/show/NCT04324996","https://clinicaltrials.gov/show/NCT04325412","https://clinicaltrials.gov/show/NCT04325633","https://clinicaltrials.gov/show/NCT04326309","http://www.chictr.org.cn/showproj.aspx?proj=51865","http://www.chictr.org.cn/showproj.aspx?proj=51835","https://clinicaltrials.gov/show/NCT04325919","https://clinicaltrials.gov/show/NCT04327570","http://www.chictr.org.cn/showproj.aspx?proj=51893","http://www.chictr.org.cn/showproj.aspx?proj=51684","http://www.chictr.org.cn/showproj.aspx?proj=51938","https://clinicaltrials.gov/show/NCT04323345","https://clinicaltrials.gov/show/NCT04323592","https://clinicaltrials.gov/show/NCT04324463","https://clinicaltrials.gov/show/NCT04324866","http://www.chictr.org.cn/showproj.aspx?proj=51781","http://www.chictr.org.cn/showproj.aspx?proj=51915","http://www.chictr.org.cn/showproj.aspx?proj=51904","http://www.chictr.org.cn/showproj.aspx?proj=51538","http://www.chictr.org.cn/showproj.aspx?proj=51859","http://www.chictr.org.cn/showproj.aspx?proj=51815","http://www.chictr.org.cn/showproj.aspx?proj=51693","http://www.chictr.org.cn/showproj.aspx?proj=51837","https://clinicaltrials.gov/show/NCT04327479","https://clinicaltrials.gov/show/NCT04331860","http://isrctn.com/ISRCTN14966673","http://www.chictr.org.cn/showproj.aspx?proj=51816","http://www.chictr.org.cn/showproj.aspx?proj=51809","http://www.chictr.org.cn/showproj.aspx?proj=51478","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23","http://www.chictr.org.cn/showproj.aspx?proj=51119","http://www.chictr.org.cn/showproj.aspx?proj=51911","http://www.chictr.org.cn/showproj.aspx?proj=51813","http://www.chictr.org.cn/showproj.aspx?proj=51724","http://www.chictr.org.cn/showproj.aspx?proj=50254","http://www.chictr.org.cn/showproj.aspx?proj=51897","http://www.chictr.org.cn/showproj.aspx?proj=51646","http://www.chictr.org.cn/showproj.aspx?proj=49254","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001254-22","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001345-38","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001236-10","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001010-38","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001172-15","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001386-37","https://clinicaltrials.gov/show/NCT03331445","https://clinicaltrials.gov/show/NCT04261517","https://clinicaltrials.gov/show/NCT04273321","https://clinicaltrials.gov/show/NCT04298060","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001271-33","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001281-11","https://clinicaltrials.gov/show/NCT04303299","https://clinicaltrials.gov/show/NCT04305457","https://clinicaltrials.gov/show/NCT04312243","https://anzctr.org.au/ACTRN12620000421932.aspx","https://clinicaltrials.gov/show/NCT03808922","https://anzctr.org.au/ACTRN12620000417987.aspx","https://clinicaltrials.gov/show/NCT03680274","https://clinicaltrials.gov/show/NCT04316377","https://clinicaltrials.gov/show/NCT04321096","https://clinicaltrials.gov/show/NCT04321265","https://clinicaltrials.gov/show/NCT04322396","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001275-32","https://clinicaltrials.gov/show/NCT04290780","https://clinicaltrials.gov/show/NCT04245631","https://clinicaltrials.gov/show/NCT04275414","https://clinicaltrials.gov/show/NCT04292730","https://clinicaltrials.gov/show/NCT04324489","https://clinicaltrials.gov/show/NCT04324528","https://clinicaltrials.gov/show/NCT04324606","https://clinicaltrials.gov/show/NCT04328272","https://clinicaltrials.gov/show/NCT04252274","https://clinicaltrials.gov/show/NCT04274322","https://clinicaltrials.gov/show/NCT04280705","https://clinicaltrials.gov/show/NCT04283461","https://clinicaltrials.gov/show/NCT04310228","https://clinicaltrials.gov/show/NCT04315987","https://clinicaltrials.gov/show/NCT04318301","https://clinicaltrials.gov/show/NCT04319445","https://clinicaltrials.gov/show/NCT04292899","https://clinicaltrials.gov/show/NCT04304690","https://clinicaltrials.gov/show/NCT04306055","https://clinicaltrials.gov/show/NCT04308668","https://clinicaltrials.gov/show/NCT04328480","https://clinicaltrials.gov/show/NCT04328493","https://clinicaltrials.gov/show/NCT04328961","https://clinicaltrials.gov/show/NCT04329611","https://clinicaltrials.gov/show/NCT04288102","https://clinicaltrials.gov/show/NCT04291729","https://clinicaltrials.gov/show/NCT04302766","https://clinicaltrials.gov/show/NCT04304053","https://clinicaltrials.gov/show/NCT04320238","https://clinicaltrials.gov/show/NCT04320472","https://clinicaltrials.gov/show/NCT04320862","https://clinicaltrials.gov/show/NCT04321278","https://clinicaltrials.gov/show/NCT04329832","https://clinicaltrials.gov/show/NCT04330261","https://clinicaltrials.gov/show/NCT04330495","https://clinicaltrials.gov/show/NCT04311177","https://clinicaltrials.gov/show/NCT04313127","https://clinicaltrials.gov/show/NCT04315298","https://clinicaltrials.gov/show/NCT04315480","https://clinicaltrials.gov/show/NCT04306393","https://clinicaltrials.gov/show/NCT04311697","https://clinicaltrials.gov/show/NCT04312009","https://clinicaltrials.gov/show/NCT04313946","https://clinicaltrials.gov/show/NCT04321369","https://clinicaltrials.gov/show/NCT04322123","https://clinicaltrials.gov/show/NCT04322188","https://clinicaltrials.gov/show/NCT04323787","https://clinicaltrials.gov/show/NCT04330690","https://clinicaltrials.gov/show/NCT04331106","https://clinicaltrials.gov/show/NCT04331366","https://clinicaltrials.gov/show/NCT04331574","https://clinicaltrials.gov/show/NCT04317040","https://clinicaltrials.gov/show/NCT04317092","https://clinicaltrials.gov/show/NCT04318366","https://clinicaltrials.gov/show/NCT04319016","https://clinicaltrials.gov/show/NCT04323839","https://clinicaltrials.gov/show/NCT04324190","https://clinicaltrials.gov/show/NCT04325672","https://clinicaltrials.gov/show/NCT04325893","https://clinicaltrials.gov/show/NCT04331795","https://clinicaltrials.gov/show/NCT04332016","https://clinicaltrials.gov/show/NCT04332666","https://clinicaltrials.gov/show/NCT04333550","https://clinicaltrials.gov/show/NCT04319315","https://clinicaltrials.gov/show/NCT04320511","https://clinicaltrials.gov/show/NCT04320732","https://clinicaltrials.gov/show/NCT04322513","https://clinicaltrials.gov/show/NCT04320615","https://clinicaltrials.gov/show/NCT04321616","https://clinicaltrials.gov/show/NCT04321811","https://clinicaltrials.gov/show/NCT04321993","https://clinicaltrials.gov/show/NCT04326387","https://clinicaltrials.gov/show/NCT04326452","https://clinicaltrials.gov/show/NCT04326790","https://clinicaltrials.gov/show/NCT04327206","https://clinicaltrials.gov/show/NCT04333732","https://clinicaltrials.gov/show/NCT04333953","https://clinicaltrials.gov/show/NCT04334382","https://clinicaltrials.gov/show/NCT04334629","https://clinicaltrials.gov/show/NCT04322682","https://clinicaltrials.gov/show/NCT04323800","https://clinicaltrials.gov/show/NCT04323878","https://clinicaltrials.gov/show/NCT04324684","https://clinicaltrials.gov/show/NCT04322773","https://clinicaltrials.gov/show/NCT04324021","https://clinicaltrials.gov/show/NCT04324047","https://clinicaltrials.gov/show/NCT04327388","https://clinicaltrials.gov/show/NCT04327505","https://clinicaltrials.gov/show/NCT04327531","https://clinicaltrials.gov/show/NCT04328441","https://clinicaltrials.gov/show/NCT04334850","https://clinicaltrials.gov/show/NCT04335032","https://clinicaltrials.gov/show/NCT04335071","https://clinicaltrials.gov/show/NCT04325061","https://clinicaltrials.gov/show/NCT04325646","https://clinicaltrials.gov/show/NCT04325906","https://clinicaltrials.gov/show/NCT04326036","https://clinicaltrials.gov/show/NCT04324073","https://clinicaltrials.gov/show/NCT04325867","https://clinicaltrials.gov/show/NCT04326075","https://clinicaltrials.gov/show/NCT04326114","https://clinicaltrials.gov/show/NCT04328467","https://clinicaltrials.gov/show/NCT04329546","https://clinicaltrials.gov/show/NCT04329572","https://clinicaltrials.gov/show/NCT04330521","https://clinicaltrials.gov/show/NCT04335279","https://clinicaltrials.gov/show/NCT04336345","https://clinicaltrials.gov/show/NCT04336384","https://clinicaltrials.gov/show/NCT04336774","https://clinicaltrials.gov/show/NCT04326725","https://clinicaltrials.gov/show/NCT04327180","https://clinicaltrials.gov/show/NCT04327349","https://clinicaltrials.gov/show/NCT04327674","https://clinicaltrials.gov/show/NCT04330638","https://clinicaltrials.gov/show/NCT04331054","https://clinicaltrials.gov/show/NCT04331171","https://clinicaltrials.gov/show/NCT04326426","https://clinicaltrials.gov/show/NCT04326920","https://clinicaltrials.gov/show/NCT04327401","https://clinicaltrials.gov/show/NCT04336787","https://clinicaltrials.gov/show/NCT04337008","https://clinicaltrials.gov/show/NCT04337216","https://clinicaltrials.gov/show/NCT04337489","https://clinicaltrials.gov/show/NCT04328012","https://clinicaltrials.gov/show/NCT04328129","https://clinicaltrials.gov/show/NCT04328454","https://clinicaltrials.gov/show/NCT04329533","https://clinicaltrials.gov/show/NCT04331613","https://clinicaltrials.gov/show/NCT04332835","https://clinicaltrials.gov/show/NCT04333251","https://clinicaltrials.gov/show/NCT04333693","https://clinicaltrials.gov/show/NCT04329507","https://clinicaltrials.gov/show/NCT04329923","https://clinicaltrials.gov/show/NCT04330144","https://clinicaltrials.gov/show/NCT04330586","https://clinicaltrials.gov/show/NCT04337502","https://clinicaltrials.gov/show/NCT04337918","https://clinicaltrials.gov/show/NCT04338347","https://clinicaltrials.gov/show/NCT04338360","https://clinicaltrials.gov/show/NCT04334252","https://clinicaltrials.gov/show/NCT04334434","https://clinicaltrials.gov/show/NCT04334460","https://clinicaltrials.gov/show/NCT04334967","https://clinicaltrials.gov/show/NCT04329559","https://clinicaltrials.gov/show/NCT04329650","https://clinicaltrials.gov/show/NCT04330300","https://clinicaltrials.gov/show/NCT04331509","https://clinicaltrials.gov/show/NCT04331600","https://clinicaltrials.gov/show/NCT04331808","https://clinicaltrials.gov/show/NCT04331834","https://clinicaltrials.gov/show/NCT04330599","https://clinicaltrials.gov/show/NCT04331470","https://clinicaltrials.gov/show/NCT04331665","https://clinicaltrials.gov/show/NCT04331886","https://clinicaltrials.gov/show/NCT04338568","https://clinicaltrials.gov/show/NCT04338802","https://clinicaltrials.gov/show/NCT04339426","https://clinicaltrials.gov/show/NCT04339660","https://clinicaltrials.gov/show/NCT04335019","https://clinicaltrials.gov/show/NCT04335084","https://clinicaltrials.gov/show/NCT04335201","https://clinicaltrials.gov/show/NCT04335851","https://clinicaltrials.gov/show/NCT04331899","https://clinicaltrials.gov/show/NCT04332094","https://clinicaltrials.gov/show/NCT04332107","https://clinicaltrials.gov/show/NCT04332081","https://clinicaltrials.gov/show/NCT04332380","https://clinicaltrials.gov/show/NCT04332913","https://clinicaltrials.gov/show/NCT04333355","https://clinicaltrials.gov/show/NCT04340349","https://clinicaltrials.gov/show/NCT04340544","https://clinicaltrials.gov/show/NCT04341168","https://clinicaltrials.gov/show/NCT04341389","https://clinicaltrials.gov/show/NCT04336215","https://clinicaltrials.gov/show/NCT04336332","https://clinicaltrials.gov/show/NCT04336657","https://clinicaltrials.gov/show/NCT04336956","https://clinicaltrials.gov/show/NCT04341415","https://clinicaltrials.gov/show/NCT04341610","https://clinicaltrials.gov/show/NCT04341870","https://clinicaltrials.gov/show/NCT04332991","https://clinicaltrials.gov/show/NCT04333225","https://clinicaltrials.gov/show/NCT04333407","https://clinicaltrials.gov/show/NCT04337047","https://clinicaltrials.gov/show/NCT04337190","https://clinicaltrials.gov/show/NCT04337541","https://clinicaltrials.gov/show/NCT04337996","https://clinicaltrials.gov/show/NCT04333472","https://clinicaltrials.gov/show/NCT04333589","https://clinicaltrials.gov/show/NCT04334005","https://clinicaltrials.gov/show/NCT04334148","https://clinicaltrials.gov/show/NCT04342689","https://clinicaltrials.gov/show/NCT04342702","https://clinicaltrials.gov/show/NCT04342728","https://clinicaltrials.gov/show/NCT04343144","https://clinicaltrials.gov/show/NCT04338828","https://clinicaltrials.gov/show/NCT04338945","https://clinicaltrials.gov/show/NCT04339387","https://clinicaltrials.gov/show/NCT04339608","https://clinicaltrials.gov/show/NCT04334980","https://clinicaltrials.gov/show/NCT04335097","https://clinicaltrials.gov/show/NCT04335123","https://clinicaltrials.gov/show/NCT04335188","https://clinicaltrials.gov/show/NCT04343781","https://clinicaltrials.gov/show/NCT04343794","https://anzctr.org.au/ACTRN12620000468921.aspx","https://clinicaltrials.gov/show/NCT04333420","https://clinicaltrials.gov/show/NCT04333628","https://clinicaltrials.gov/show/NCT04333654","https://clinicaltrials.gov/show/NCT04333849","https://anzctr.org.au/ACTRN12620000443998.aspx","http://isrctn.com/ISRCTN10077335","https://clinicaltrials.gov/show/NCT04339634","https://clinicaltrials.gov/show/NCT04339816","https://clinicaltrials.gov/show/NCT04340050","https://clinicaltrials.gov/show/NCT04340466","https://clinicaltrials.gov/show/NCT04335305","https://clinicaltrials.gov/show/NCT04335630","https://clinicaltrials.gov/show/NCT04335747","https://clinicaltrials.gov/show/NCT04335773","http://isrctn.com/ISRCTN15281137","http://isrctn.com/ISRCTN40092247","https://clinicaltrials.gov/show/NCT04336410","https://clinicaltrials.gov/show/NCT04336761","https://clinicaltrials.gov/show/NCT04337151","https://clinicaltrials.gov/show/NCT04337320","https://clinicaltrials.gov/show/NCT04333862","https://clinicaltrials.gov/show/NCT04334044","https://clinicaltrials.gov/show/NCT04334265","https://clinicaltrials.gov/show/NCT04334291","https://clinicaltrials.gov/show/NCT04341116","https://clinicaltrials.gov/show/NCT04341142","https://clinicaltrials.gov/show/NCT04341441","https://clinicaltrials.gov/show/NCT04341493","http://www.chictr.org.cn/showproj.aspx?proj=52165","http://www.chictr.org.cn/showproj.aspx?proj=52148","https://clinicaltrials.gov/show/NCT04337762","https://clinicaltrials.gov/show/NCT04337983","https://clinicaltrials.gov/show/NCT04338074","https://clinicaltrials.gov/show/NCT04338100","https://clinicaltrials.gov/show/NCT04334512","https://clinicaltrials.gov/show/NCT04334928","https://clinicaltrials.gov/show/NCT04335136","https://clinicaltrials.gov/show/NCT04335162","http://www.chictr.org.cn/showproj.aspx?proj=52135","http://www.chictr.org.cn/showproj.aspx?proj=52130","https://clinicaltrials.gov/show/NCT04341584","https://clinicaltrials.gov/show/NCT04341675","https://clinicaltrials.gov/show/NCT04341766","https://clinicaltrials.gov/show/NCT04341792","https://clinicaltrials.gov/show/NCT04338932","https://clinicaltrials.gov/show/NCT04338958","https://clinicaltrials.gov/show/NCT04340479","https://clinicaltrials.gov/show/NCT04340921","http://www.chictr.org.cn/showproj.aspx?proj=51650","http://www.chictr.org.cn/showproj.aspx?proj=52079","https://clinicaltrials.gov/show/NCT04335786","https://clinicaltrials.gov/show/NCT04336254","https://clinicaltrials.gov/show/NCT04336462","https://clinicaltrials.gov/show/NCT04341012","https://clinicaltrials.gov/show/NCT04341480","https://clinicaltrials.gov/show/NCT04341688","https://clinicaltrials.gov/show/NCT04341922","http://www.chictr.org.cn/showproj.aspx?proj=51940","http://www.chictr.org.cn/showproj.aspx?proj=50928","https://clinicaltrials.gov/show/NCT04336904","https://clinicaltrials.gov/show/NCT04337346","https://clinicaltrials.gov/show/NCT04337359","https://clinicaltrials.gov/show/NCT04337788","https://clinicaltrials.gov/show/NCT04342104","https://clinicaltrials.gov/show/NCT04342221","https://clinicaltrials.gov/show/NCT04342637","https://clinicaltrials.gov/show/NCT04342663","https://clinicaltrials.gov/show/NCT04342208","https://clinicaltrials.gov/show/NCT04342650","https://clinicaltrials.gov/show/NCT04342884","https://clinicaltrials.gov/show/NCT04343001","https://trialregister.nl/trial/8490","https://trialregister.nl/trial/8501","https://clinicaltrials.gov/show/NCT04338009","https://clinicaltrials.gov/show/NCT04338672","https://clinicaltrials.gov/show/NCT04338698","https://clinicaltrials.gov/show/NCT04338906","https://clinicaltrials.gov/show/NCT04342897","https://clinicaltrials.gov/show/NCT04343339","https://clinicaltrials.gov/show/NCT04343404","https://clinicaltrials.gov/show/NCT04343664","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001250-21","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001500-41","https://clinicaltrials.gov/show/NCT04343755","https://anzctr.org.au/ACTRN12620000444987.aspx","https://clinicaltrials.gov/show/NCT04343092","https://clinicaltrials.gov/show/NCT04343183","https://clinicaltrials.gov/show/NCT04343651","https://clinicaltrials.gov/show/NCT04343742","https://clinicaltrials.gov/show/NCT04339322","https://clinicaltrials.gov/show/NCT04339790","https://clinicaltrials.gov/show/NCT04339998","https://clinicaltrials.gov/show/NCT04340219","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29","https://anzctr.org.au/ACTRN12620000447954.aspx","http://isrctn.com/ISRCTN50189673","https://clinicaltrials.gov/show/NCT04343768","https://anzctr.org.au/ACTRN12620000448943.aspx","http://isrctn.com/ISRCTN13694948","http://isrctn.com/ISRCTN51287266","https://clinicaltrials.gov/show/NCT04340232","https://clinicaltrials.gov/show/NCT04340414","https://clinicaltrials.gov/show/NCT04341103","https://clinicaltrials.gov/show/NCT04341285","https://anzctr.org.au/ACTRN12620000445976.aspx","https://anzctr.org.au/ACTRN12620000470998.aspx","http://isrctn.com/ISRCTN16912075","http://isrctn.com/ISRCTN83971151","https://clinicaltrials.gov/show/NCT04341506","https://clinicaltrials.gov/show/NCT04341519","https://clinicaltrials.gov/show/NCT04341714","https://clinicaltrials.gov/show/NCT04341935","http://www.chictr.org.cn/showproj.aspx?proj=52198","http://www.chictr.org.cn/showproj.aspx?proj=52216","http://www.chictr.org.cn/showproj.aspx?proj=52193","http://www.chictr.org.cn/showproj.aspx?proj=51832","http://www.chictr.org.cn/showproj.aspx?proj=50613","http://www.chictr.org.cn/showproj.aspx?proj=52037","https://clinicaltrials.gov/show/NCT04342156","https://clinicaltrials.gov/show/NCT04342169","https://clinicaltrials.gov/show/NCT04342182","https://clinicaltrials.gov/show/NCT04342195","http://www.chictr.org.cn/showproj.aspx?proj=52103","http://www.chictr.org.cn/showproj.aspx?proj=51793","http://www.chictr.org.cn/showproj.aspx?proj=50241","https://trialregister.nl/trial/8512","https://clinicaltrials.gov/show/NCT04342806","https://clinicaltrials.gov/show/NCT04343248","https://clinicaltrials.gov/show/NCT04343261","https://clinicaltrials.gov/show/NCT04343677","http://www.chictr.org.cn/showproj.aspx?proj=50077","http://www.chictr.org.cn/showproj.aspx?proj=50271","https://trialregister.nl/trial/8513","https://trialregister.nl/trial/8498","https://trialregister.nl/trial/8460","https://trialregister.nl/trial/8483","https://clinicaltrials.gov/show/NCT04343690","https://clinicaltrials.gov/show/NCT04343898","https://anzctr.org.au/ACTRN12620000438954.aspx","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001381-11","https://anzctr.org.au/ACTRN12620000449932.aspx","https://anzctr.org.au/ACTRN12620000457943.aspx","https://trialregister.nl/trial/8491","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001310-38","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001435-27","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001333-13","https://anzctr.org.au/ACTRN12620000454976.aspx","http://isrctn.com/ISRCTN43900695","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001366-11","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001409-21","http://isrctn.com/ISRCTN77353041","http://isrctn.com/ISRCTN86534580","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001421-31","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001606-33","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001492-33","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001194-69","http://www.chictr.org.cn/showproj.aspx?proj=52213","http://www.chictr.org.cn/showproj.aspx?proj=51934","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001565-37","http://www.chictr.org.cn/showproj.aspx?proj=52006","http://www.chictr.org.cn/showproj.aspx?proj=52051","http://www.chictr.org.cn/showproj.aspx?proj=52052","http://www.chictr.org.cn/showproj.aspx?proj=51924","https://trialregister.nl/trial/8473","https://trialregister.nl/trial/8485","https://trialregister.nl/trial/8497","https://trialregister.nl/trial/8504","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001301-23","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001335-28","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001188-96","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001373-70","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001457-43","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001445-39","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001442-19","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001385-11","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001270-29","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001307-16"],["Not Recruiting","Recruiting","Not recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not recruiting","Not Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Authorised","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting",null,"Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting",null,"Recruiting","Not Recruiting","Not Recruiting",null,"Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting",null,null,"Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting",null,"Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting",null,"Recruiting","Not Recruiting","Recruiting","Recruiting",null,"Not Recruiting","Not Recruiting",null,"Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Not Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting",null,"Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Authorised","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Not Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting",null,"Recruiting","Not Recruiting","Recruiting","Recruiting",null,"Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Authorised","Recruiting","Authorised","Authorised","Authorised","Authorised","Authorised","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Not Recruiting","Recruiting","Not Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Not Recruiting","Recruiting","Authorised","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Not recruiting","Not recruiting","Recruiting","Not recruiting","Authorised","Authorised","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Authorised","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not Recruiting","Not Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Authorised","Authorised","Not recruiting","Not Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Recruiting","Authorised","Recruiting","Recruiting","Not recruiting","Not Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not recruiting","Not recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Not recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Not recruiting","Not recruiting","Recruiting","Recruiting","Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Not recruiting","Not recruiting","Not recruiting","Not Recruiting","Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Not recruiting","Recruiting","Not Recruiting","Authorised","Not Recruiting","Not Recruiting","Recruiting","Authorised","Authorised","Authorised","Not Recruiting","Recruiting","Authorised","Authorised","Recruiting","Recruiting","Authorised","Authorised","Authorised","Authorised","Not Recruiting","Not Recruiting","Authorised","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Not Recruiting","Recruiting","Recruiting","Recruiting","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised","Authorised"],["No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","No","Yes","Yes","No","Yes","No","No","Yes","No"],[null,null,"N/A","18","16","0","18",null,"18","1","18 Years","N/A","N/A","18",null,"18",null,"15","18","18","18",null,"14 Years","18 Years","18 Years","18 Years","18",null,"18",null,"18","0","0",null,"1","18","18","18","18",null,null,"18","18","18","18",null,"18","18",null,"18","18","18","18",null,"18","18",null,null,"3","18","18","18","14","14",null,"18","18","12","18","18","18",null,"18",null,null,null,null,null,"18",null,null,"18","14",null,null,"18","18","18","18","1","18","18","16","18","18","18","30","18",null,"18","18",null,null,"18","18",null,"18","18","18",null,"18","18","18","18","18","18","N/A","18 Years","18","18","18 Years",null,"16","18","1","18","18 Years",null,"18","16","16","18","18","18",null,"18","50","18",null,"18","18","15","18","16","15","18","15",null,"18","0","18",null,null,"18","18",null,"18","18",null,"18",null,null,null,"18","18","18",null,"18","18",null,"18","18","16",null,"18","18","18","18",null,"60","18",null,"0","18","16","22","18","18",null,"18","18","18","18","35","18 Years",null,"N/A","N/A","18 Years","18 Years",null,"18","N/A","18 Years","18 Years",null,"18 Years","18 Years","18 Years","18 Years","0","18",null,"0","18","1","18 Years","20","18","18","N/A","N/A","18 Years","20","0","18","18","18","18",null,null,null,"18","18",null,null,"18",null,null,"16",null,"18","18","18","18",null,null,"18",null,"60",null,"8",null,"18","18",null,"18",null,"15","14","18",null,"18","18","18","18","18","0","18","18","18","18","18","18","18","18",null,"18 Years","0","18","18 Years","N/A","18 Years","18 Years","18 Years","18","18","18",null,"18","N/A","18 Years",null,"18","18",null,null,"18","18","0","14","14","18",null,"16","18",null,"18","18","18",null,"18","18","18",null,"18","18","18","18","18",null,null,null,null,"18",null,"18","18","18","18","20",null,"0","18","18","18","18",null,null,"18","18","18","N/A","18","18 Years",null,"18",null,"18","18 Years","16","18",null,"18 Years","18 Years","10 Years",null,"0","18","0",null,"18","18","18","10","18","18",null,"18","18","13","18","18","20","7","18",null,"16",null,null,"18","1","0","14","10","12",null,"23",null,"18",null,"30",null,"65","0","18 Years","18",null,"14","2","18",null,null,"18",null,null,"20","18","1",null,null,"18","65","18","18",null,"18","14","14","18","14","14","22","14","24","14",null,"18","12",null,"1",null,"18",null,null,"18","18",null,"18","0","18","18","18","18","18",null,"14","18","18","16","18","1","18","60","2","18","18","18","18",null,"18",null,null,"14",null,"18","18","18","18","18","18","18","18","18","18","18","18","18","18","18","0","18","18","18","18","1","18 Years","18","16 Years","14","18","18","18","12","18","18",null,"18 Years","0.1","N/A","18","20",null,"0","0",null,"11","18","33",null,null,null,"14","38","18",null,null,"18 Years","6 Months","N/A",null,"18","16","15",null,"18","18","18","18",null,null,null,"0","18","18","18","18","1","18","18","0","18",null,"18","18","4","20",null,null,null,"18","18","18",null,"18",null,"18 Years","18 years","18 years","18 years","2 years","18 years","18 years","18 years","18 Years","no limit","&gt;= 20age old","18 Years","14 Years","&gt;= 20age old","&gt;= 16age old","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","1years-old","6 Months","18 Years","18 Years","18 Years","18 Years","Not applicable","30 Years","18 Years","18 Years","21 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years",null,"18 Years","18 Years","N/A","18","18 Years","18","16 Years","18 Years","18 Years","18 Years","8","18","1","18","18",null,"18","18","18 Years","8","22",null,"18","25","18",null,"18","0",null,"18",null,"7","18","45","0","18","18","18",null,"18","18","0","18","7","16","18",null,null,"18","18",null,null,"18",null,"25",null,null,null,null,null,"18 Years","18 Years","18 Years","N/A","18 Years","18 Years","16 Years","18 Years","60 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","16 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18","18 Months","18 Years","N/A","N/A","18","18","18 Years","18 Years","18 Years","18 Years","10","18","18 Years","18 Years","18","18","20","5 Years","18 Years","18 Years","18 Years","18",null,"18","/","18","18","18","30","18 Years","18 Years",null,"13","/","18",null,"18","18","1","18","18","20","18","18",null,null,null,null,null,null,"14 Years","18 Years","18 Years","18 Years",null,null,"16 Years","18 Years","18 Years","No limit","N/A","18 Years","18 Years","18 Years","18 Years","70 Years","N/A",null,"N/A","1 Year","18 Years","12 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","12 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","N/A","18 Years","18 Years","N/A","6 Months","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","3 Years","25 Years","18 Years","18 Years","14 Years","18 Years","18 Years","18 Years","18 Years","16 Years","18 Years","18 Years","18 Years","18 Years","N/A","45 Years","18 Years","40 Years","18 Years","18 Years","18 Years","18 Years","30 Years","18 Years","18 Years","18 Years","25 Years","18 Years","18 Years","18 Years","30 Years","18 Years","5 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","20 Years","18 Years","30 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","19 Years","18 Years","18 Years","18 Years","65 Years","18 Years","45 Years","18 Years","18 Years","60 Years","18 Years","18 Years","18 Years","18 Years","16 Years","15 Years","12 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","20 Years","18 Years","8 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","40 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","19 Years","18 Years","18 Years","N/A","70 Years","18 Years","18 Years","18 Years","18 Years","18 Years","70 Years","18 Years",null,"55 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A",null,null,"18 Years","N/A","N/A","N/A","18 Years","18 Years","18 Years","N/A","18 Years","18 Years","18 Years","5 Years","2","17","18 Years","N/A","19 Years","18 Years","18 Years","18 Years","35 Years","18 Years","29","18","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","N/A","18 Years","0","28","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","16 Years","18","25","18 Years","18 Years","6 Years","75 Years","18 Years","18 Years","30 Years","18 Years","18 Years","18 Years","N/A","50 Years",null,null,"18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","18 Years","4 Years",null,null,"18 Years","18 Years","18 Years","18 Years","18 Years","N/A","N/A","18 Years","18 Years","18 Years",null,"18 Years",null,"18 Years","18 Years",null,null,"18 Years","14 Years","N/A","18 Years","18 Years","18 Years",null,null,"18 Years","18 Years","18 Years","18 Years","18","18","18","17",null,"18","18 Years","18 Years","18 Years","18 Years","18","14","18",null,"18 Years","65 Years","18 Years","18 Years","18","0",null,null,null,null,"18 Years","18 Years","18 Years",null,"18 Years","18 Years",null,null,null,null,"18 Years",null,null,null,null,null,null,null,null,null,"18",null,null,"18","18","10","6",null,null,null,null,null,null,null,null,null,null,null,null,null,null],[null,null,"N/A",null,"99","18","75",null,null,"100","80 Years","N/A","N/A","75",null,"90",null,"85","80","75","80",null,"80 Years","75 Years","N/A","75 Years","80",null,"75",null,"75","100","100",null,"100",null,"75","75","70",null,null,"75",null,"80","90",null,"80","85",null,null,null,null,"75",null,"65",null,null,null,"85","90","80",null,"80","80",null,"80","60","80","70","70","75",null,"90",null,null,null,null,null,"85",null,null,null,"??",null,null,null,"90","65","80","99","70",null,"75",null,null,"75","65","75",null,"75","65",null,null,"75","80",null,"70","70","70",null,"60","90","65","75","75",null,"N/A","N/A","65",null,"N/A",null,"75","85","90","75","75 Years",null,"75",null,"50","80","70",null,null,null,"100","80",null,"75",null,"35","70","75","60","80","80",null,"80","90","80",null,null,"60","70",null,"80","65",null,"75",null,null,null,"75","60",null,null,null,"100",null,"70","90","30",null,"85","80","60","75",null,null,"70",null,"1",null,"99","55","65","85",null,null,null,"60",null,"74","N/A",null,"28 Days","N/A","N/A","N/A",null,"80","18 Years","65 Years","90 Years",null,"N/A","75 Years","70 Years","65 Years","0","65",null,"18","90","15","80 Years","45","75",null,"N/A","N/A","65 Years","90","100",null,"90","70",null,null,null,null,"79",null,null,null,"75",null,null,"92",null,null,"60","75","70",null,null,"75",null,null,null,"91",null,"80","65",null,"100",null,"35","99","80",null,null,"75",null,"80",null,"79","75",null,null,"65",null,"80","80",null,null,"75 Years","90","90","N/A","N/A","N/A","70 Years","75 Years","100",null,"80",null,"75","N/A","85 Years",null,"35","90",null,null,null,null,"18","90","90","75",null,"30","-",null,"65","110","90",null,"75","65",null,null,"75",null,"75",null,"70",null,null,null,null,null,null,"90","80","99","70","55",null,"100","65","75",null,"75",null,null,"75",null,"-","N/A",null,"75 Years",null,"75",null,"65","N/A","65","70",null,"100 Years","N/A","19 Years",null,"99","85","100",null,null,"100","80","75","85","100",null,"82",null,"90","80","80","88","70",null,null,"75",null,null,"99","100","86","90","88",null,null,"94",null,null,null,"85",null,"100","86","90 Years","80",null,"90","89","80",null,null,"85",null,null,"80",null,"99",null,null,"74","90","70",null,null,"??","90","90","90","90","90","55","90","89","90",null,null,"85",null,"100",null,"75",null,null,"75","75",null,"80","18","75","80","80",null,null,null,"90","55","80",null,"70","80","65","110","65",null,"80","60","60",null,null,null,null,"90",null,"80",null,"75","70",null,"65",null,null,"65","75","65","85","-","96",null,"18","ND","ND",null,"80","90","N/A","65","99 Years","70","65","70",null,null,null,null,null,"75 Years","85","N/A","80","50",null,"90","100",null,"18","65","75",null,null,null,null,"70","80",null,null,"N/A","80 Years","N/A",null,"75","90","80",null,"80","80","65","60",null,null,null,"100","100","75","85","100","99","80","65","99","70",null,"100","??","80","90",null,null,null,"70","-","85",null,null,null,"no maximum age","65 years","65 years","75 years","no limit","no limit","75 years","no limit","N/A","no limit","Not applicable","95 Years","70 Years","Not applicable","Not applicable","80 Years","90 Years","80 Years","N/A","N/A","55 Years","100years-old","80 Years","N/A","N/A","N/A","75 Years","Not applicable","70 Years","75 Years","75 Years","N/A","N/A","100 Years","N/A","80 Years","N/A","N/A","75 Years","N/A","N/A",null,"75 Years","N/A","N/A","80","N/A","50","100 Years","N/A","50 Years","80 Years","25","100","80","65","90",null,null,"100","N/A","25","47",null,"65","77","100",null,"98","18",null,"99",null,"101","75","80","100","80","80","90",null,"??","75","??",null,"90","85","85",null,null,null,"75",null,null,null,null,"65",null,null,null,null,null,"N/A","N/A","75 Years","24 Years","N/A","N/A","N/A","80 Years","N/A","N/A","65 Years","N/A","N/A","N/A","N/A","N/A","85 Years","N/A","N/A","55 Years","N/A","85 Years","80 Years","75 Years","N/A",null,"N/A","N/A","N/A","85 Years","65","100","N/A","N/A","N/A","N/A","85","80","N/A","N/A","80","80","65","75 Years","80 Years","N/A","75 Years","N/A",null,"90","/","70","70","75","90","N/A","100 Years",null,"N/A","/","100",null,"60","80","90","?","85","30","70","80",null,null,null,null,null,null,"N/A","N/A","N/A","N/A",null,null,"100 Years","N/A","99 Years","No limit","N/A","64 Years","N/A","N/A","110 Years","N/A","N/A",null,"N/A","90 Years","80 Years","N/A","70 Years","100 Years","55 Years","50 Years","N/A","N/A","99 Years","55 Years","65 Years","N/A","100 Years","N/A","N/A","N/A","60 Years","N/A","N/A","N/A","80 Years","N/A","75 Years","75 Years","N/A","N/A","65 Years","N/A","N/A","N/A","N/A","18 Years","75 Years","N/A","60 Years","N/A","90 Years","99 Years","100 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","120 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","100 Years","N/A","99 Years","65 Years","N/A","N/A","75 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","100 Years","N/A","79 Years","N/A","N/A","90 Years","55 Years","N/A","N/A","80 Years","80 Years","N/A","N/A","N/A","90 Years","N/A","N/A","70 Years","N/A","N/A","N/A","N/A","99 Years","N/A","N/A","N/A","N/A","90 Years","N/A","70 Years","N/A","N/A","75 Years","N/A","90 Years","80 Years","N/A","45 Years","N/A","N/A","95 Years","N/A","N/A","N/A","99 Years","70 Years","60 Years","N/A","N/A","N/A","N/A","99 Years","80 Years","N/A","N/A","N/A","N/A","N/A","N/A","65 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","100 Years","N/A","N/A","N/A","70 Years","95 Years","75 Years","N/A","N/A","N/A","35 Years","64 Years","N/A","N/A","N/A","60 Years","N/A","N/A","N/A","99 Years","N/A","N/A","N/A","N/A","80 Years","18 Years","N/A","80 Years","80 Years","N/A","75 Years","85 Years","N/A","N/A","N/A","N/A","N/A","80 Years","70 Years","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","55 Years","N/A","N/A","N/A","N/A","N/A","No limit","N/A","N/A","N/A","N/A","No limit",null,"N/A","N/A","N/A","N/A","N/A","N/A","N/A","18 Years",null,null,"50 Years","18 Years","N/A","15 Minutes","N/A","N/A","80 Years","N/A","N/A","N/A","75 Years","N/A","7","80","110 Years","N/A","N/A","N/A","N/A","65 Years","80 Years","N/A","91","45","N/A","N/A","105 Years","N/A","N/A","N/A","N/A","N/A","100","54","N/A","65 Years","85 Years","N/A","80 Years","65 Years","N/A","70","65","75 Years","45 Years","N/A","N/A","N/A","99 Years","70 Years","N/A","65 Years","N/A","N/A","N/A",null,null,"N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A",null,null,"N/A","No limit","N/A","N/A","99 Years","N/A","N/A","N/A","N/A","N/A",null,"No limit",null,"N/A","No limit",null,null,"89 Years","N/A","N/A","N/A","No limit","65 Years",null,null,"N/A","N/A","N/A","N/A","80","75","100","35",null,"50","80 Years","N/A","N/A","65 Years","75","75",null,null,"89 Years","120 Years","90 Years","N/A","100","120",null,null,null,null,"N/A","N/A","80 Years",null,"60 Years","75 Years",null,null,null,null,"No limit",null,null,null,null,null,null,null,null,null,"88",null,null,null,"80","90","61",null,null,null,null,null,null,null,null,null,null,null,null,null,null],["Both","Both","All","Both","Male","Both","Both","Both","Both","Both","All","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","All","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","All","Both","Both","All","Both","Both","Both","Both","Both","All","Both","Both","Both","Female","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Female","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Female","Both","Both","Both","Both","All","Both","All","All","All","All","Both","Male","All","All","All","Both","All","All","All","All","Both","Both","Both","Both","Both","Both","All","Both","Both","Both","All","All","All","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","Both","Both","All","All","All","All","All","Both","Both","Both","Both","Both","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","Both","All","Both","Both","Male","Both","All","Both","Both","Both","All","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","&lt;br&gt; Female: yes&lt;br&gt; Male: yes&lt;br&gt;","Both","Both","Male","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","All","Both","All","Both","Both","Both","Both","Both","Both","Both","Both","All","Male","All","Both","Female","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","All","All","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Male","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both, male and female","Both","Both","Both","Both","Both","Both","Both","All","Both","Both","Both","All","Both","Both","All","All","All","All","All","All","Male and Female","All","All","All","All","All","Male and Female","Both","All","All","All","All","All","All","All","All","All","All","All","All","Both","All","All","All","Both","All","Female","All","All","Female","All","Both","Both","Both","Both","Both","Both","Both","Both","All","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Both","All","All","All","All","Both","Both","All","All","All","All","Both","Both","All","All","Both","Both","Both","All","All","All","All","Both","Both","Both","Both","Both","Both","Both","Male","All","All","Both","Both","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both","Both","Both","Both","Both","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","All","All","All","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","All","All","Both males and females","All","Both males and females","All","All","All","All","All","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Female","All","All","All","All","All","All","Female","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","All","Both males and females","All","All","All","All","Both males and females","Both","All","All","All","All","All","All","All","All","Both","Female","All","All","All","All","All","All","All","All","All","All","All","All","Both","Both","All","All","All","All","All","All","All","All","Both","Both","All","All","All","All","All","All","All","All","Both","Male","All","All","All","All","Female","All","All","Both","Both","All","Female","All","All","All","All","All","All","All","All","All","All",null,null,"All","All","All","All","All","All","All","All","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","All","Both males and females","All","All","All","All","All","All","All","All","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both males and females","Both","All","Both males and females","Both","Both","All","All","All","All","Both males and females","Both males and females","Both","Both","All","All","All","All","Both","Both","Both","Both","Both","Female","All","All","All","All","Both","Both","Both",null,"All","All","All","All","Both","Both",null,null,null,null,"All","All","Both males and females","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Females","Both males and females",null,"&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both males and females","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Both","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","Both","Male","Both","Both",null,null,null,null,"&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;","&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;"],["2020-02-01","2020-02-06","January 25, 2020","2020-02-16","2020-02-15","2020-02-14","2020-03-01","2020-01-31","2020-02-20","2020-02-16","January 28, 2020","January 20, 2020","February 3, 2020","2020-02-17","2020-02-12","2020-02-15","2020-02-14","2020-02-14","2020-02-10","2020-02-15","2020-02-05","2020-02-11","January 22, 2020","February 7, 2020","February 10, 2020","February 7, 2020","2020-01-30","2020-02-16","2020-03-01","2020-02-10","2020-02-01","2020-02-07","2020-02-16","2020-02-10","2020-03-01","2020-02-14","2020-02-01","2020-02-14","2020-02-10","2020-02-12","2020-02-15","2020-02-15","2020-02-12","2020-02-17","2020-02-17","2020-02-08","2020-03-01","2020-02-10","2020-02-07","2020-02-09","2020-02-16","2020-02-10","2020-02-13","2020-02-03","2020-02-01","2020-02-05","2020-02-06","2020-02-06","2020-02-14","2020-02-11","2020-02-03","2020-02-04","2020-02-04","2020-02-04","2020-02-12","2020-02-15","2020-02-15","2020-02-11","2020-02-03","2020-02-03","2020-02-12","2020-02-10","2020-02-01","2020-02-04","2020-02-01","2020-01-29","2020-02-01","2020-01-26","2020-02-12","2020-02-10","2020-02-01","2020-02-03","2020-02-10","2020-02-07","2020-02-08","2020-02-07","2020-02-17","2020-02-01","2020-02-10","2020-01-25","2020-02-17","2020-02-25","2020-01-30","2020-02-05","2020-02-06","2020-02-06","2020-01-31","2020-02-04","2020-01-29","2020-02-04","2020-02-10","2020-02-10","2020-02-24","2020-02-01","2020-02-01","2020-02-03","2020-02-03","2020-02-02","2020-02-03","2020-02-02","2020-02-01","2020-02-03","2020-03-01","2020-02-24","2020-02-21","2020-02-25","February 4, 2020","February 10, 2020","2020-02-24","2020-01-29","January 26, 2020","2020-02-24","2020-02-22","2020-02-07","2020-02-10","2020-01-24","February 6, 2020","2020-02-24","2020-03-02","2020-02-17","2020-03-01","2020-02-24","2020-02-15","2020-02-27","2020-02-12","2020-02-15","2020-02-15","2020-02-07","2020-02-20","2020-02-20","2020-02-20","2020-02-22","2020-03-10","2020-02-24","2020-02-24","2020-02-04","2020-02-03","2020-02-23","2020-02-24","2020-02-24","2020-02-24","2020-02-17","2020-02-19","2020-02-19","2020-02-19","2020-02-28","2020-03-01","2020-02-12","2020-02-19","2020-02-16","2020-02-18","2020-02-12","2020-02-24","2020-02-22","2020-05-31","2020-02-20","2020-02-20","2020-02-15","2020-02-20","2020-02-20","2020-02-06","2020-02-28","2020-02-20","2020-02-19","2020-02-15","2020-02-19","2020-02-21","2020-02-17","2020-01-30","2020-02-20","2020-02-13","2020-02-28","2020-01-25","2020-02-14","2020-02-11","2020-02-10","2020-02-17","2020-02-17","2020-02-20","2020-02-18","2020-02-09","2020-02-20","2020-02-14","2020-02-19","February 12, 2020","2020-04-30","February 1, 2020","February 1, 2020","February 20, 2020","February 18, 2020","2020-03-01","2020-03-01","February 15, 2020","February 16, 2020","February 14, 2020","2020-03-01","February 6, 2020","February 3, 2020","February 14, 2020","February 15, 2020","2020-03-01","2020-03-01","2020-01-01","2020-02-23","2020-02-01","2020-02-28","February 22, 2020","2020-03-02","2020-02-27","2020-02-29","January 20, 2020","January 20, 2020","February 20, 2020","2020-03-05","2020-02-19","2020-03-04","2020-03-09","2020-02-01","2020-03-02","2020-03-01","2020-03-01","2020-02-20","2020-03-01","2020-01-01","2020-01-21","2020-02-28","2020-02-20","2020-02-27","2020-02-28","2020-03-01","2020-02-24","2020-02-28","2020-02-11","2020-02-22","2020-02-21","2020-03-09","2020-02-27","2020-03-01","2020-03-01","2020-02-21","2020-02-27","2020-01-21","2020-02-01","2020-02-22","2020-02-26","2020-02-20","2020-02-20","2020-03-01","2020-02-22","2020-02-21","2020-02-22","2020-02-20","2020-02-17","2020-02-17","2020-02-24","2020-02-12","2020-01-22","2020-02-17","2020-02-18","2020-02-15","2020-02-15","2020-01-25","2020-02-17","2020-02-13","2020-02-15","2020-01-29","2020-02-12","February 23, 2020","2020-02-15","2020-03-08","February 10, 2020","February 2020","February 4, 2020","January 27, 2020","February 15, 2020","2020-03-10","2020-03-07","2020-03-10","2020-02-20","2020-03-09","January 31, 2020","February 26, 2020","2020-02-01","2020-02-02","2020-03-08","2020-02-15","2020-03-07","2020-01-20","2020-03-04","2020-03-15","2020-02-24","2020-03-03","2020-02-25","2020-02-14","2020-03-06","2020-03-15","2020-03-09","2020-03-04","2020-03-03","2020-03-08","2020-03-04","2020-03-02","2020-02-27","2020-02-29","2020-03-03","2020-02-26","2020-03-04","2020-02-01","2020-03-01","2020-02-01","2020-02-02","2020-02-28","2020-03-02","2020-03-06","2020-03-04","2020-03-01","2020-03-02","2020-03-06","2020-02-17","2020-02-29","2020-03-10","2020-03-03","2020-02-25","2020-02-19","2020-01-31","2020-02-20","2020-02-03","2020-01-29","2020-02-03","2020-01-31","2020-02-01","2020-02-14","February 1, 2020","2020-02-01","January 1, 2020","2020-01-30","2020-02-06","2020-03-14","2020-03-01","March 1, 2020","2020-02-10","2020-03-19","2020-01-22","March 14, 2020","April 1, 2020","October 15, 2020","2020-02-10","2020-01-24","2019-02-27","2020-03-09","2020-01-22","2020-02-01","2020-01-27","2020-03-06","2020-02-18","2020-03-16","2020-01-31","2020-02-01","2020-02-06","2020-02-23","2020-02-22","2020-01-20","2020-02-01","2020-02-15","2020-03-16","2020-01-10","16/09/2015","2020-02-14","2020-03-16","2020-03-22","2020-01-01","2020-03-01","2020-01-31","2020-02-24","2020-02-20","2020-03-20","2020-01-20","2020-02-15","2020-02-15","2020-01-31","2020-01-27","2020-02-10","2020-01-29","2020-01-23","2020-02-01","March 7, 2020","2020-01-27","2020-02-15","2020-03-10","2020-02-01","2020-02-12","2020-01-17","2020-02-01","2020-02-01","2020-02-01","2020-03-13","2020-02-20","2020-03-07","2019-12-01","2020-03-01","2020-03-01","2020-03-13","2020-03-15","2020-01-25","2020-02-12","2020-02-01","2020-03-15","2020-02-01","2020-02-01","2020-03-15","2020-02-01","2020-04-01","2020-03-05","2020-02-01","2020-03-10","2020-02-01","2020-03-16","2020-02-17","2020-03-01","2020-03-20","2020-02-09","2020-03-01","2020-03-10","2020-03-16","2020-01-01","2020-02-01","2020-02-01","2020-01-20","2020-03-07","2020-02-01","2020-02-04","2020-02-10","2020-02-01","2020-03-10","2020-03-09","2020-03-16","2020-02-01","2020-02-26","2020-02-18","2020-05-31","2020-03-11","2020-03-07","2020-03-05","2020-03-09","2020-03-16","2020-02-24","2020-02-23","2020-03-19","2020-01-31","2020-03-01","2020-02-24","2020-02-01","2020-03-01","2020-02-01","2020-02-22","2020-02-25","2020-02-16","2020-02-26","2020-02-10","2020-03-09","2020-03-01","2020-02-20","2020-02-20","2020-02-17","2020-02-17","2020-02-20","2020-02-21","2020-02-15","2020-03-10","2020-03-03","2020-01-28","2020-03-09","2020-03-09","2020-03-06","2020-03-13","2020-02-01","February 14, 2020","2020-02-07","March 11, 2020","2020-03-03","2020-03-01","2020-02-29","2020-02-25","2020-02-22","2020-02-20","2020-02-20","2020-02-13","March 5, 2020","2020-02-16","March 11, 2020","2020-05-01","2020-02-01","2020-02-26","2020-02-05","2020-02-09","2020-03-10","2020-03-20","2020-03-23","2020-03-18","2020-03-16","2020-03-19","2020-01-28","2020-03-16","2020-02-11","2020-02-10","2020-03-20","2020-01-01","February 14, 2020","February 15, 2020","December 10, 2019","2020-04-01","2020-03-31","2020-02-01","2020-01-18","2020-02-10","2020-03-20","2020-03-13","2020-02-26","2020-03-10","2020-03-31","2020-03-01","2020-03-23","2020-03-01","2020-03-12","2020-03-05","2020-03-06","2020-02-20","2019-12-01","2020-02-10","2020-03-04","2020-03-20","2020-03-17","2020-02-20","2020-02-26","2020-02-29","2020-09-01","2020-01-20","2020-03-01","2020-02-14","2020-02-06","2020-01-29","2020-03-20","2020-03-06","2020-02-23","2020-02-11","05/03/2020","20/03/2020","2020-03-15","2020-03-16","2020-03-15","2020-03-19","2020-03-03","2020-03-18","2020-03-26","February 1, 2020","2020-03-15","27/02/2020","20/03/2020","February 5, 2020","27/02/2020","02/03/2020","February 16, 2020","February 21, 2020","February 2020","February 1, 2020","February 1, 2020","February 1, 2020","2020/02/01","March 24, 2020","March 17, 2020","February 27, 2020","March 1, 2020","March 2, 2020","2020/03/19","24/03/2020","April 1, 2020","February 24, 2020","March 8, 2020","March 20, 2020","January 25, 2020","February 9, 2020","February 20, 2020","March 23, 2020","March 17, 2020","March 5, 2020","January 1, 2020","March 16, 2020","2020-04-01","February 1, 2020","April 1, 2020","March 23, 2020","2020-04-12","March 12, 2020","2020-03-31","March 14, 2020","March 20, 2020","January 1, 2020","March 23, 2020","2020-03-18","2020-03-11","2020-01-17","2020-04-01","2020-04-12","2020-04-10","2020-03-13","2020-04-01","March 2020","2020-03-18","2020-02-18","2020-02-10","2020-04-01","2020-01-25","2020-02-01","2020-03-01","2020-01-14","2020-03-16","2020-02-01","2020-03-25","2020-01-30","2020-03-23","2020-03-16","2020-02-20","2020-03-26","2020-02-01","2020-03-31","2020-04-01","2020-03-01","2020-02-28","2020-03-10","2020-02-15","2020-03-19","2020-02-10","2020-01-10","2020-03-23","2020-02-28","2020-03-26","2020-02-28","2020-02-27","2020-02-01","2020-02-24","2020-02-24","26/03/2020","2020-02-18","26/03/2020","17/03/2020","25/03/2020","26/03/2020","17/03/2020","April 2020","March 22, 2020","March 5, 2020","October 15, 2019","February 25, 2020","March 23, 2020","April 2020","March 17, 2020","April 1, 2020","January 1, 1998","April 1, 2020","April 2020","February 26, 2020","March 18, 2020","March 2020","March 20, 2020","April 1, 2020","March 13, 2020","March 2020","March 25, 2020","April 6, 2020","March 16, 2020","March 16, 2020","March 23, 2020","March 31, 2020","2020-02-17","March 30, 2020","March 17, 2020","April 1, 2020","March 2020","2020-03-06","2020-01-27","March 21, 2020","March 23, 2020","March 27, 2020","March 25, 2020","2020-04-20","2020-04-10","February 24, 2020","March 27, 2020","2020-03-15","2020-02-05","2020-04-03","March 25, 2020","March 23, 2020","April 1, 2020","April 1, 2020","2019-12-01","2020-02-10","2020-02-01","2020-03-25","2020-04-01","2020-04-01","2020-01-25","2020-03-20","March 26, 2020","March 30, 2020","20/03/2020","2020-04-01","2020-03-25","2020-02-04","09/03/2020","2020-03-27","2020-04-01","2020-02-05","2020-03-28","2020-03-17","2020-03-05","2020-05-01","2020-03-20","24/03/2020","02/04/2020","31/03/2020","23/03/2020","03/04/2020","27/03/2020","October 24, 2017","February 6, 2020","February 14, 2020","April 2020","31/03/2020","30/03/2020","April 15, 2020","March 21, 2020","April 2, 2020","05/03/2020","May 23, 2019","30/03/2020","November 8, 2018","March 25, 2020","March 31, 2020","March 19, 2020","April 6, 2020","03/04/2020","March 9, 2020","January 1, 2020","February 15, 2020","March 15, 2020","March 6, 2020","March 27, 2020","April 2020","March 28, 2020","January 30, 2020","February 19, 2020","February 21, 2020","March 3, 2020","March 8, 2020","April 2020","March 21, 2020","March 22, 2020","March 6, 2020","March 16, 2020","March 13, 2020","March 17, 2020","March 2020","April 1, 2020","March 2020","April 15, 2020","March 5, 2020","February 17, 2020","January 1, 2018","March 18, 2020","January 21, 2020","March 23, 2020","April 3, 2020","March 28, 2020","March 30, 2020","March 18, 2020","April 6, 2020","April 9, 2020","March 16, 2020","March 18, 2020","March 12, 2020","March 21, 2020","April 2020","April 2, 2020","March 18, 2020","March 9, 2020","April 1, 2020","March 19, 2020","March 30, 2020","March 18, 2020","March 27, 2020","April 2020","March 10, 2020","April 8, 2020","March 19, 2020","March 19, 2020","January 1, 2020","March 20, 2020","April 2020","April 1, 2020","April 2020","April 4, 2020","April 2, 2020","March 31, 2020","April 2020","March 11, 2020","April 2020","March 27, 2020","March 24, 2020","April 3, 2020","March 26, 2020","March 21, 2020","April 2020","April 6, 2020","March 27, 2020","April 6, 2020","March 30, 2020","April 2020","April 1, 2020","April 2, 2020","April 6, 2020","March 23, 2020","May 1, 2020","April 6, 2020","March 31, 2020","April 5, 2020","April 2, 2020","March 27, 2020","March 29, 2020","April 25, 2020","March 26, 2020","March 25, 2020","April 2020","April 13, 2020","April 2020","April 3, 2020","March 13, 2020","April 6, 2020","March 25, 2020","March 27, 2020","March 31, 2020","April 6, 2020","April 26, 2020","April 6, 2020","March 27, 2020","April 3, 2020","April 2020","April 15, 2020","April 1, 2020","March 1, 2020","April 2020","March 20, 2020","March 30, 2020","March 28, 2020","March 14, 2020","April 2020","April 2020","March 17, 2020","April 1, 2020","March 24, 2020","April 1, 2020","April 12, 2020","April 3, 2020","April 2020","April 1, 2020","April 6, 2020","March 23, 2020","January 30, 2020","April 1, 2020","January 27, 2020","April 1, 2020","April 1, 2020","April 1, 2020","March 25, 2020","April 9, 2020","April 1, 2020","April 1, 2020","December 23, 2019","April 6, 2020","January 10, 2019","January 10, 2019","April 17, 2020","April 1, 2020","May 2020","March 30, 2020","March 30, 2020","April 1, 2020","March 30, 2020","March 23, 2020","April 6, 2020","March 31, 2020","April 3, 2020","April 2, 2020","April 4, 2020","April 20, 2020","April 2020","April 13, 2020","April 2, 2020","April 2020","February 1, 2020","April 2020","April 2020","April 6, 2020","April 6, 2020","April 15, 2020","April 2, 2020","April 1, 2020","April 6, 2020","April 1, 2020","April 1, 2020","April 15, 2020","April 10, 2020","April 10, 2020","April 2020","April 12, 2020","March 28, 2020","April 1, 2020","April 2020","April 7, 2020","April 2020","April 20, 2020","April 2020","April 2, 2020","April 3, 2020","April 3, 2020","March 31, 2020","April 3, 2020","April 2, 2020","April 2020","April 6, 2020","April 1, 2020","April 10, 2020","April 2020","May 1, 2020","March 16, 2020","April 8, 2020","April 15, 2020","April 2020","March 15, 2020","March 1, 2020","April 2, 2020","April 30, 2020","April 7, 2020","March 25, 2020","April 6, 2020","March 22, 2020","April 1, 2020","20/04/2020","March 31, 2020","April 2020","March 31, 2020","March 27, 2020","01/05/2020","19/03/2020","April 7, 2020","April 20, 2020","April 30, 2020","April 3, 2020","March 30, 2020","March 30, 2020","April 8, 2020","April 1, 2020","26/03/2020","20/03/2020","April 3, 2020","April 2020","April 2020","April 1, 2020","March 19, 2020","April 1, 2020","April 1, 2020","March 23, 2020","April 2020","April 9, 2020","April 7, 2020","April 6, 2020","2020-01-10","2020-01-22","April 6, 2020","April 15, 2020","April 15, 2020","April 6, 2020","April 2020","April 1, 2020","April 2020","February 28, 2020","2020-01-01","2020-04-01","April 2020","April 2020","March 31, 2020","April 2020","April 17, 2020","May 1, 2020","May 1, 2020","April 10, 2020","2020-04-01","2020-03-01","April 2020","April 6, 2020","February 15, 2020","September 10, 2019","April 10, 2020","July 1, 2020","April 10, 2020","2020-04-01","2020-03-01","March 25, 2020","April 5, 2020","April 5, 2020","April 2020","April 1, 2020","March 29, 2020","April 10, 2020","April 10, 2020","April 10, 2020","April 2020","April 2020","April 2020","12/04/2020","23/03/2020","March 31, 2020","April 5, 2020","April 7, 2020","June 1, 2020","April 18, 2020","April 8, 2020","April 1, 2020","April 12, 2020","03/04/2020","03/04/2020","April 2020","07/04/2020","April 8, 2020","April 2020","April 1, 2020","April 1, 2020","May 1, 2020","April 16, 2020","April 15, 2020","March 30, 2020","01/04/2020","31/03/2020","19/03/2020","April 10, 2020","01/06/2020","02/04/2020","13/12/2019","April 2020","March 3, 2020","April 1, 2020","June 1, 2020","10/04/2020","20/04/2020","06/04/2020","26/03/2020","April 15, 2020","April 9, 2020","March 16, 2020","April 30, 2020","2020-04-27","2020-04-20","2020-04-08","2020-03-24","2020-03-01","2020-04-06","April 2020","April 14, 2020","April 1, 2020","March 25, 2020","2020-03-19","2020-03-10","2020-03-02","18/03/2020","April 10, 2020","April 30, 2020","April 10, 2020","April 2020","2020-03-01","2020-02-01","13/04/2020","15/03/2020","16/03/2020","16/03/2020","April 13, 2020","April 1, 2020","20/04/2020","08/04/2020","10/04/2020","14/04/2020","31/03/2020","06/04/2020","10/04/2020","09/04/2020","09/04/2020","06/04/2020","27/03/2020","01/04/2020","08/04/2020","25/03/2020","06/04/2020","07/04/2020","10/04/2020","30/03/2020","2020-01-23","2020-04-13","03/04/2020","2020-04-09","2020-01-01","2020-04-21","2020-02-01","23/03/2020","27/03/2020","15/03/2020","06/04/2020","10/04/2020","29/03/2020","07/04/2020","01/04/2020","10/04/2020","31/03/2020","02/04/2020","28/03/2020","02/04/2020","01/04/2020"],["survival group:200;died:200;","Case series:100;","500","Case series:40;","experimental group:10;control group:10;","control group:15;experimental group:15;","experimental group :100;control group :100;","Case series:100;","Experimental group:30;Control group:30;","Target condition:10000;Difficult condition:300","125","12000","30000","Target condition:200;Difficult condition:0","case series:100;","Experimental group:50;Control group:50;","Target condition:0;Difficult condition:0","TCM Group:150;QFPD decoction group:150;SFJD capsuale group:150;control group:150;","experimental group:150;control group:150;","Experimental group:260;Control group:260;","experimental group:80;control group:80;","experimental group:20;control group:20;","150","380","80","160","Case series:27;","case series:100;","experimental group :100;control group:100;","Conventional treatment group:50;Experimental group:50;","Experimental group:30;Control group:30;","Experimental group:70;Control group:40;","Case series:1000;","Case series:271;","Target condition:300;Difficult condition:300","control group:50;experimental group:50;","Case series:800;","Experimental group:36;Control Group:36;","General patients treated with normal treatment:30;General patients experimental group:30;Severe patients control group 1:10;Severe patients control group 2:10;Severe patients experimental group:10;","experimental group:56;control group:56;","Target condition:500;Difficult condition:100","Chinese traditional medicine group 1:60;Chinese traditional medicine group 2:60;Control group:60;","Thymosin treatment group:40;PD-1 treatment group:40;Conventional treatment group:40;","Control group:60;Experimental group:60;","Normal group:10;Severe group:10;","Case series:500;","Control group :30;Intervention group :30;","control group:94;Experience group:94;","Experimental group:50;Control group:50;","Case series:40;","Experimental group:10;Control group:10;","Case series:100;","experimental group:204;control group:204;","Case series:100;","Control group:200;Experimental group:200;","control group :15;Experimental group :15;","control group:30;experimental group:30;","Treatment group:1000;","Observation  group:300;Health  education unit:100;","Experimental group:40;Control group:40;","Experimental group:10;control group:10;","experimental group:164;control group:164;","(ordinary) Western medicine group:40;(ordinary) Chinese and Western Medicine Group:40;(severe) Western medicine group:30;(severe) Chinese and Western Medicine Group:30;","treament group:50;placebo group:50;","Case series:100;","Experimental group:20;Control group:20;","experimental group:119;control group:119;","Experimental group:100;control group:100;","experimental group:30;\t Control group:30;Control group:30;","experimental group \t:50;control group :50;","experimental group:30;control group:30;","Epilepsy group:500;Health Control group:1000;","Case series:200;","control group:50;Experimental group:50;","Case series:72;","A:15;B:15;C:15;","Suspected patient control group:100;Suspected patient Treatment group:100;Common NCP patient control group:50;Common NCP patient Treatment group:50;Severe NCP patient:50;","non-severe group and severe gorup:500;","Experimental group:220;Control group:220;","Vitamin D deficiency group:104;Vitamin D normal group:52;","Group 1:50;Group 2:50;","Experimental Group:28;Control Group:14;","doctors group:48;nurses group:48;suspected cases group:48;cases group:48;","Experimental group:50;Control group:50;","Case series:40;","Experimental group:190;Control group:190;","Target condition:80;Difficult condition:0","Experimental group:300;Control group:300;","mild-moderate chloroquine group:59;mild-moderate Lopinavir/ritonavir group:59;mild-moderate combination group:59;severe-chloroquine group :14;severe- Lopinavir/ritonavir group:14;","experimental group A:18;control gorup A:15;Experimental Group B1:10;Experimental Group B2:10;Control Gorup A:10;","Experimental group:30;control group:30;","Control group:10;Investigation group:10;","Group A:30;Group B:30;Group C:30;","control group:15;experimental group:15;","Low dose group:100;Medium dose of group:100;High dose of group:100;Control group:100;","Experimental group:80;Control group:80;","experimental group 1:100;experimental group 2:100;Placebo control group:100;","Experimental group 1:10;Experimental group 2:10;Control group:10;","single arm:200;","A:10;B:10;C:10;","DRV/c group:40;LPV/r group:40;other group:20;","Experimental group:100;Control group:100;","Experimental group:60;Control group:60;","Two groups:16;","experimental group:60;Historical Control:60;","Case series:300;","experimental group:50;Control group:50;","experimental group:50;Control group:50;","experimental group:50;control group:50;","control group:60;experimental group:60;","Community exposure TCM intervention group:20;Community exposure control group:20;Hospital exposure TCM intervention group:20;Hospital exposure control group:20;Community suspected TCM intervention group:20;Community suspected control group:20;Hospital su","Case series:600;","1:30;2:30;","Psychological Intervention Group:90;Control Group :90;","Experimental:150;control:150;","Case series:40;","300","120","Experimental group:50;Control group:50;","Group A:20;Group B:20;Group C:20;","80","Case series:10;","Control group:15;Experimental group:15;","Experimental group:88;Control group:44;","Case series:20;","Group 1:200;Group 2:200;","10","Target condition:40;Difficult condition:0","Experimental Group:40;Control Group:40;","Case series:120;","Adolescent group:50;Childbearing group:100;Climacterium group:50;","control group:30;mild ill patients:15;severe/critical ill patients:15;","Combination therapy group:232;Conventional treatment group:116;","Case series:50;","Severe group:200;Critical group:200;Light group:200;Common group:200;","Experimental group:80;Control group:40;","severe NCP group:8;Acute exacerbation NCP group:8;","Case series:10;","Case series:2000;","Case series:20;","Case series:60;","Exercise prescription group:200;Control group:200;","Experimental group :100;Control group:100;","Experimental group:30;Control group:30;","Case series:130;","1:30;2:30;","Experimental group:100;Control group:100;","case series:100;","Intervention group 1:276;Intervention group 2:276;Control group:276;","Humanistic care:100;Control group:30;","control group with common NCP:30;experimental group with common NCP:30;experimental group with severe NCP:30;control group with severe NCP:30;experimental group with critical NCP:30;control group with critical NCP:30;","Severe group:100;Non-severe group:100;","Case series:300;","Case series:20;","Experimental group:50;Control group:50;","Experimental group:30;Control group:30;","Experimental group:20;Control group:20;","Case series:100;","Experimental group:30;Control group:30;","Ganovo / ritonavir group:10;Pegasys group:10;Novaferon group:10;Coriolus group:10;Comparator:10;","Experimental group:60;Control group:60;","Light group:200;Common group:200;Severe group:200;Critical group:200;","general anesthesia group vs. intraspinal anesthesia group:30;Health care goup:180;","Hydroxychloroquine sulfate gloup:40;Chloroquine phosphate gloup:40;Control group:20;","Experimental group:30;control group:60;","Low-dose group:20;Middle-dose group:20;High-dose group:20;","pneumonia patients group:100;medical staff group:100;","Experimental group:120;Control group:120;","Mild Group:30;Severe Group:30;","Case series:10;","Case series:20;","Training:150;Vaidation:450;","college students:150000;","Group 1:120;Group 2:240;Group 3:120;","control group:30;Experience group:30;","Control group:100;Experimental group:100;","Control group:93;Experimental group:93;","Chloroquine phosphate gloup:40; Hydroxychloroquine sulfate gloup:40;Routine treatment group:20;","experimental group:60;control group:60;","experimental group.:150;Control group:150;","Experimental group:40;Control group:40;","Control group:30;Experimental group:70;","COVID-19 pregnant women and normal pregnant women and infants born to them:30;","experimental group:80;control group:80;","hydroxychloroquine group:54;control group:24;","Case series:1853;","Experimental group:20;control:20;","Target condition:120;Difficult condition:0","common group:400;severe group:400;critical group:400;","Target condition:60;Difficult condition:0","Experimental group:150;Control group:150;","A1:80;A2:80;B1:80;B2:80;","experimental group:80;control group:80;","control group:34;Experience group:34;","308","Control group:100;Experimental group 1:100;Experimental group 2:100;","100","300000","100","40","one group:80;","Group 1:40;Group 2:40;","500","48","450","Control group:30;Experimental group:30;","453","20","348","136","Case series:1000;","Case series:50;","Target condition:3000;Difficult condition:0","Monitor cases, suspected cases and diagnosed cases:120;","Light and common type group:80;Severe group:40;Western medicine treatment group:30;Chinese and western medicine combined treatment group:30;Non-invasive mechanical ventilation group:15;Nasal high flow oxygen therapy group:15;","Case series:40;","30","Case series:40;Control group:40;","Experimental group:170;Control group:170;","Exposure group:60;Control group:60;","100","20","30","Case series:100;","Target condition:25;Difficult condition:25","Pirfenidone group:147;Control group:145;","Case series:20;","Group 2:10;Group 3:10;Group 1:10;","Case series:30;","Case series:100;","Mild group:100;Serere group:30;","Case series:200;","The experimental group:150;Control group:150;","Case series:120;","Case series:200;","Intervention group:500;","Case series:9;","case series:100;","Two groups:40;","Case series:300;","High inflammation oXiris CRRT treatment group:10;High inflammation Conventional treatment group:10;Low inflammation conventional treatment group:10;","Burnout positive group versus burnout negative group:1000;","Case series:2000;","Experimental group:30;Control group:30;","Experimental group:30;Control group:30;","Case series:100;","Experimental group:10;Control group:10;","Routine treatment +  Jing-Yin Granule:200;Routine treatment :100;","Exocrine group:13;Control group:13;","the elderly population:658;","Target condition:30;Difficult condition:30","Case series:120;","Case series:40;","Experimental group:93;Control Group:93;","Experimental group 1:20;Control group (Mild patients):20;Experimental group 2:20;Control group (general patient):20;Experimental group 3:20;Control group (severe patients):20;","Case series:60;","General population:5000;",null,"Experimental group:100;Control group:100;","Case series:240;","Experimental group:50;Control group:50;","Experimental group:300;Control group:150;","hydroxychloroquine sulfate:50;phosphate chloroquine:50;","hydroxychloroquine sulfate:50;phosphate chloroquine:50;","Experimental group:10;","Experimental group:30;Control group:30;","Experimental group of ordinary COVID-19:30;Control group of ordinary COVID-19:30;Experimental group of severe COVID-19:20;","Case series:0;","Kesuting syrup group:24;Keqing capsule group:24;control group:24;","experimental group:60;control group:60;","Case series:500;","arm A:36;arm B:36;arm C:36;","Case series:200;","Low-dose group:60;Medium-dose group:60;High-dose group:60;control group:60;","control group 1:20;control group 2:20;Experimental group:20;","Experimental group:24;Control group:24;","Experimental group:120;Control group:120;","520","Case series:40;","Case series:70;","70","230","294","20","30","Case series:150;","Case series:12;","Case series:1030;","experimental group:50;control group:50;","experimental group:50;control group:50;","39","120","Experimental group:15;Control group:15;","Case series:192;","case series:500;","Case series:200;","Experimental group:20;Control group:20;","Experimental group:30;Control group:30;","Azvudine Plus Symptomatic treatment:10;","monitor cases, suspected cases and diagnosed cases:120;","Case series:1500;","Group 2:50;Group 1:40;","Experimental group:10;Control group:10;","Case series:35;","Medical students group; Non-medical students group:1300;","Target condition:200;Difficult condition:200","Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:600;","cross-sectional study:1300;","Interferon Therapy Group:164;Control group:164;","CRRT group:76;Control group:76;","Control group:30;Experimental group:170;","Lipoic acid group:197;Blank control group:197;","Control group:48;Experimental group:48;","Experimental group:30;Control group:30;","Patients in Wuhan versus Sichuan:100;","Control group:50;Experimental group:50;","Case series:19;","Case series:100;","Early corticosteroid intervention group:75;Middle-late corticosteroid intervention group:75;Control group:50;","COVID-2019 patients in Tongji Hospital:250;COVID-2019 patients in Mobile field hospital:250;Medical staff in Tongji Hospital:250;Control:250;","treatment group1:30;treatment group 2:30;control group:30;","PRE-GROUP1:400;PRE-GROUP2:400;TRE-GROUP1:100;TRE-GROUP2:50;","ACEIs/ARBs:100;","Case series:8000;","Case series:19;","Control group:30;Experimental group:30;","Group 2:35;Group 1:35;","Case series:100;","patient group:200;Health care team:60;","Case series:24;","Case series:300;","Case series:200;","Case series:256;","Experimental group:150;control group:150;","Experimental group:35;control group:35;","group A:20;control group:20;","Treatment group:50;Control group:50;","Experimental group 1 (mild):150;Experimental group 1 (moderate):150;","Experimental group:200;Control group:200;","Case series:200;","Routine treatment + Lianhua Qingwen Capsules/granules:120;Conventional treatment:120;","Experimental group:100;Control group:100;","15","Routine treatment + Lianhua Qingwen Capsules/granules:120;Conventional treatment:120;","400","Experimental group:10000;blank cntrol group:10000;","Case series:24;","Case series:1000;","Group 1:90;Group 2:30;Group 3:30;","328","Case series:1000;","Observation group:50;","Case series:5000;","80","576","3428","Control group:10;Experimental group:10;","Ordinary COVID-19 patients:100;Heavy COVID-19 patients:50;","Case series:90;","Case series:100;","The triple combination antiviral therapy:196;The dual combination antiviral therapy:41;","Case series:200;","Case series:150;","Experimental group:20;Control group:20;","Case series:100;","Case series:100;","Case series:50;","Case series:200;","Case series:483;","Experimental group:50;control group:50;","Case series:1000;","Target condition:1000;Difficult condition:0","Group 2:150;Group 1:150;","Target condition:600;Difficult condition:100","Case series:81;","intervention group:80;Control group:80;","4000","High dose group:10;Low dose group:10;","Case series:500;","Target condition:400;Difficult condition:0","Case series:75;","Case series:600;","\t Case series:10;","Case series:200;","Case series:100;","Case series:90;","Case series:40;","non-cancer COVID-19 versus cancer with COVID-19:100;","Case series:200;","severe patients:400;","Case series:2000;","Case series:100;","Case series:500;","discharge group:100;","Target condition:22;Difficult condition:57","120","Population under risk:1000;","control group:14;experimental group:56;","NIV group:150;MV group:50;","Case series:20;","Case series:20;","Case series:150;","Case series:450;","MSC group:30;","Case series:50;","Case series:100;","Case series:60;","4 groups:2800;","Case series:100;","Group 1:700;Group 2:605;","Case series:30;","two groups:74;","Case series:400;","Case series:60;","Experimental group:40;Control group:40;","Case series:200;","Observation group:113;Control group:113;","case series:100;","ECMO group:10;the conventional treatment group:20;","Case series:200;","transnasal high-flow oxygen therapy:50;noninvasive mechanical ventilation:30;invasive mechanical ventilation:20;","Exposed group:130;Control group:130;","in hospital:50;Recovered:100;","case series:100;","Case series:1000;","case series:100;","Target condition:50;Difficult condition:0","Experimental group:5;Control group:5;","Case series:100;","Case series:78;","Target condition:300;Difficult condition:200","Integrated traditional Chinese and western medicine group:771;Western medicine group:300;","experimental group:20;control group:20;","Group 1:200;Group 2:200;Group 3:200;Group 4:200;","Case series:150;","experimental group:20;","Exocarpium Citri Grandis Group:64;Placebo Group:64;","Target condition:1000;Difficult condition:0","Case series:100;","Infection without renal injury group:30;Infection with proteinuria group:30;Infection with hematuria group:30;Infection with impaired renal function group:30;","Control group:100;Experimental group 1:100;Experimental group 2:100;","Two groups:30;","experimental group:30;control group:30;","experimental group:30;control group:30;","experimental group:30;control group:30;","Experimental group:50;Control group:50;","case series:100;","Case series:50;","Experimental group:30;Control group:30;","Case series:20;","Target condition:30;Difficult condition:0","1:132;2:132;","Control group:30;CIK group:30;NK group:30;","Target condition:234;Difficult condition:0","Group A:60;Group B:60;Group C:60;Group D:60;","Target condition:150;Difficult condition:0","experimental group:20;control group:20;","Case series:15;","Case series:960;","Experimental group:30;Control group:30;","Case series:66;","Case series:160;","treatment group :16;","case series:500;","Control group :750;Comprehensive treatment group:750;","Experimental group:30;control group:30;","Case series:160;","Positive drug control group:60;Compound Yuxingcao Mixture Group:60;","Routine treatment group:230;Dipyridamole treatment group:230;","Case series:30;","Group 2:60;Group 1:60;","High dose group:20;Conventional dose group:20;Preventive dose group:20;","Experimental group:30;Control group:30;","Phosphoric chloroquine:80;Placebo:40;","Phosphoric chloroquine:30;Placebo:15;","Phosphoric chloroquine:80;Placebo:40;","Target condition:200;Difficult condition:0","eperimental group:25;control group:25;","Case series:1500;","tumor patients group:300;","case series:500;","Chinese medicine treatment cohort:40;Integrated Chinese and western medicine treatment cohort:40;Western medicine treatment cohort:40;","Case series:150;","Group 1:30;Group 2:30;","experimental group:20;control group:20;","Case series:410;","140","Two cohorts:1000;","150","1:100;2:100;","Experimental group:15;control group:15;","Experimental group:20;Control group:20;","Experimental group:26;Control group:13;","Target condition:400;Difficult condition:100","Experimental group :30;Control group:30;","Experimental group:30;Control group :30;","Case series:500;","24","Case series:80;","50000","Case series:30;","Case series:300;","Pirfenidone group:20;Support treatment group:20;","Diagnosed Group:98;Suspending Group:102;","COVID-19  patients:314;","Target condition:1000;Difficult condition:0","SFBT group:38;Waiting Group:38;","Group 1:30;Group 2:30;","Experimental group:30;control group:30;","Group 2:160;Group 1:160;","SARS-COV-2 RNA Positive group:50;SARS-COV-2 RNA Negative group:50;","Case series:200;","Case series:10;","Case series:34;","1:80;2:40;","Critical group/ Ordinary group:200;","Case series:2000;","8","100","669","Case series:150;","Group 1:36;Group 2:36;Group 3:36;","COVID-19 patients:100;","Case series:93;","the patients of 2019 new coronavirus pneumonia:50;","Case series:20;","experimental group:150;control group:150;","A:15;B:15;","1:36;2:36;3:36;","Case series:200;","Case series:90;","COVID-19 patients:60;","Target condition:30;Difficult condition:0","Target condition:300;Difficult condition:0","Experimental group 1:50;Experimental group 2:50;Control group:50;","Case series:40;","Experimental group:120;Control group:120;",null,"experimental group:30;control group:30;","cross-sectional study:1300;","Target condition:2500;Difficult condition:500","Experimental group:30;Control group:30;","Tricholoma matsutake group:25;Cannabis sativa capsule group:25;Dendrobium candidum group:25;Routine treatment group:25;","1 the critical group :8;2 the severe group:8;3 the control group of the critical group:8;4 the control group of the severe group:8;","Experimental group:1000;Control group:1000;","Experimental group:10;Control group:10;","Case series:191;","Target condition:80;Difficult condition:20","tumor patients group:200;non tumor patients group:200;","Mild Type Group A:80;Mild Type Group B:80;Common and Heavy Type Group C:160;Common and Heavy Type Group C:160;","Intervention A:30;intervention B:30;intervention C:30;","observational:80;","control group:20;Experimental group (mild and normal type in patients with new coronavirus pneumonia):20;","Case series:94;","Experimental group:180;Control group:180;","25","60","30","150","30","125","20","50","70","100","50","50","5000","0","50","86","60","2000","0","100","400","60","500","100","10","300","201","340","9999","650","550","0","5000","116","0","10","120","200","1000","60","500","5","Case series:5000;","30","400","5000","mild recovery:200;severe recovery:200;control:200;","100","Cesarean section:2000;","100","80","20","500","Case series:160;","Case series:120;","Target condition:0;Difficult condition:0","hDPSCs group:10;Control group:10;","Target condition:1000;Difficult condition:0","Case series:300;","Group M:30;Group C:30;","Case series:120;","200","Case series:400;","mindfulness intervention group:60;control group:50;","Case series:60;","Control group:40;Experimental group:40;","Case series:2000;","Case series:100;","Case series:500;","Survival and D:200;","Case series:240;","Case series:68;","Case series:200;","Experimental treatment group:150;control group:150;","Case series:1292;","1:14;2:14;","Homeopathic patient:100;","Case series:40;","Experimental group:38;control group:38;","Case series:60;","Case series:150;","Case series:60;","confirmed group:100;control group:60;","CM group:2130;WM group:710;","Suspected case treatment group:150;Suspected case control group:150;Confirmed case  treatment group:50;Confirmed case control group:50;","Experimental group:72;Control group:72;","Experimental group:25;Control group:25;","treatment group:60;control group:30;","Experimental group:102;control group:102;","Light group:200;Common group:200;Severe group:200;Critical group:200;","COVID-19 group:100;Healthy people:50;","Case series:10;","experimental group:102;control group:102;","Case series:1000;","experimental group:30;control group:30;","Experimental group:20;Control group:20;","200","experimental group:40;control group:40;","460","1000","220","443","400","100","3100","150","2300",null,"0","40000","140","7576","1302508","30","200","287","400","1600","500","100","500","1116","200","216","60","1","120","1000","Experimental group:30;control group:30;","1220","49","100","50","cross-sectional study:462;","ordinary group versus severe group versus critical group versus deceased patients group:2000;","90","1000","584","1000","Control group :20;normal group:20;severe group:20;","Case series:7000;","170","100","ARBs Group:60;non-ARBs Group:120;","Experimental group:50;Control group:50;","Medical personnel group:123;","1000","104","1500","300","Rheumatic disease with COVID-19:1000;Rheumatic disease without COVID-19:1000;","eye patch and earplugs:16;eye patch:39;","Experimental group:18;Control group:18;","Target condition:200;Difficult condition:0","Nintedanib group:40;Control group:40;","Case series:820;","experimental group:28;control group :28;",null,"6000","500000","500","COVID-19 with risk factors:800;COVID-19 without risk factors:1200;","Target condition:200;Difficult condition:0","Case series:120;","3100","Group 1:96;Group 2:96;","Control:50;Noninvasive cardiopulmonary monitoring group:50;","Target condition:500;Difficult condition:0","Mild:400;severe:200;","Group 1:10;Group 2:10;","experiment group:29;experiment group :29;","Different dose groups:15;","Experimental group:100;Control group:100;","80","60","304","200","200",null,"20","30","400","280","1300","50","320","240","470","400","250","680","800","202","180","4000","226","200","300","50","20","1600","4","30","510","75","30","117","440","45","150","66","275","200","2400","1000","19491","3000","2500","250","2000","1660","90","11",null,"3040","2944","250","200000","440","300","12500","800","580","108","400","38","200","120","200","200","533","630","50","50000","440","6000","5","2000","230","400","1000","20","1000","600","0","1300","50","2000","60","50","400","25","50000","110","330","700","100000","1000","200","15","180","4170","55000","500","1550","230","6000","150","3000","198","200","54","1000","300","200","200","1500","194","240","100","200","1000","346","10","240","200","900","240","3500","250","400","50","162","150","5000","500","80","500","30","375","342","436","3000000","300","80","290","100","50","10","200","4000","450","120","150","9","80","115","50","200","400","2486","141","300","200",null,null,"5000","30","120","1250","50","100","2414","10000000","400","240","440","12000","30","64","5000","50","96","25","30","300","600","50","30","120","276","2271","40","10","30","20","100","2700","160","500","750","160","100","250","60","40","60","510","360","3170","2000","100","6000","176","40","210","200","15000","1300","504","520","92","260","1200","1500","10000","84","214","50","4000","353","200","140","130","210","210","100","58","25","12123","240","10","220","24","500","333","350","510","500","40","914","100","70","500","20","750","2500","144","400","3000","86","Experimental group:45;Control groop:60;","Case series:119;","100000","200","100","300","600","4000","200","100","survival group:39;death group:36;","Case group:30;control group:30;","240","30","200","1000","12","200","20","140","Patient:30;Healthcare providers:30;","For the mild new coronary pneumonia: General Ward Group:20;For the severe new coronary pneumonia: ICU Group:17;Support staff: Logistics group:10;","651","20","100","120","207","5","670","Experimental Group:75;Control Group:75;","common type :30;Latent period group:30;Normal control group:30;Blank vaccine control group:30;","100","80",null,"200","100","220","40","152","500","210","150000","10000","950","2000","152","1000000","500","334","200","100","100","10000","1000","342","55","100000","50","48","75","20","200","5000","500","180","40","150","5000","60","154","400","70","80","10","500","200","2500","20","4002","10000","100","1464","400","20","intervention group:72;Control group:78;","Experimental group:60;Control group:60;","Case series:130;","Case series:883;","NK cell group:10;Control group:10;","Case series:2000;","3000","400","426","12","Case series:40;","Case series:200;","Experimental group:30;Control group:30;","400","100000","300","15","1450","Novel coronavirus pneumonia:600;","Case series:498;","8000","20","100","17000","100","2000","60","554","200","70","386","106","1057","122","160","75","100000","120","2000","3000","1530","132","100","200","mild, moderate, severe ARDS:45;","Patients with LE and are taking hydroxychloroquine:200;Patients with LE and are not taking hydroxychloroquine:50;Patients with dermatomyositis and are taking hydroxychloroquine:200;Patients with dermatomyositis and are not taking hydroxychloroquine:100;P","440","1:250;2:125;3:125;","1:50;","Target condition:600;Difficult condition:0","Target condition:33;Difficult condition:30","4000","20","200","354","584","130","1200","273","550","84","276","4000","350","104"],["Observational study","Interventional study","Interventional","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Diagnostic test","Interventional","Observational","Observational","Diagnostic test","Observational study","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional","Interventional","Interventional","Interventional","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Diagnostic test","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional study","Basic Science","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Prevention","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Prognosis study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Prevention","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Observational","Interventional","Interventional study","Interventional study","Interventional","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional","Diagnostic test","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Basic Science","Treatment study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Diagnostic test","Observational study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Interventional","Interventional study","Observational","Observational","Interventional","Interventional","Interventional study","Interventional study","Observational","Interventional","Observational","Interventional study","Interventional","Interventional","Interventional","Interventional","Interventional study","Observational study","Diagnostic test","Observational study","Observational study","Interventional study","Interventional","Interventional study","Interventional study","Observational study","Observational","Observational","Interventional","Interventional study","Diagnostic test","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Observational study","Epidemilogical research","Interventional study","Observational study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Treatment study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Diagnostic test","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Health services reaserch","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional","Observational study","Observational study","Interventional","Interventional","Interventional","Interventional","Interventional","Observational study","Observational study","Observational study","Interventional study","Interventional study","Observational","Interventional","Interventional study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Observational study","Observational study","Diagnostic test","Observational study","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Epidemilogical research","Interventional study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Epidemilogical research","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Interventional study","Observational","Interventional study","Observational","Interventional study","Interventional study","Observational study","Interventional study","Interventional","Observational study","Observational study","Observational study","Interventional","Interventional","Observational","Interventional study","Observational study","Health services reaserch","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Interventional study","Observational study","Diagnostic test","Interventional study","Diagnostic test","Interventional study","Interventional study","Interventional clinical trial of medicinal product","Interventional study","Observational study","Diagnostic test","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Observational","Observational study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Epidemilogical research","Observational study","Interventional study","Observational study","Observational study","Observational study","Epidemilogical research","Observational study","Observational study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Diagnostic test","Interventional study","Screening","Observational study","Diagnostic test","Observational study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Diagnostic test","Observational study","Basic Science","Interventional study","Basic Science","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Diagnostic test","Epidemilogical research","Interventional study","Diagnostic test","Interventional study","Diagnostic test","Interventional study","Observational study","Health services reaserch","Interventional study","Observational study","Observational study","Interventional study","Observational study","Observational study","Interventional study","Interventional study","Interventional study","Prognosis study","Observational study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Diagnostic test","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Interventional study","Observational study","Interventional","Observational study","Interventional","Interventional study","Interventional study","Interventional study","Interventional study","Diagnostic test","Interventional study","Interventional study","Observational study","Interventional","Observational study","Observational [Patient Registry]","Observational study","Observational study","Interventional study","Observational study","Observational study","Diagnostic test","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational","Interventional","Observational","Health services reaserch","Interventional study","Observational study","Observational study","Basic Science","Interventional study","Interventional study","Interventional study","Prevention","Observational study","Observational study","Observational study","Diagnostic test","Diagnostic test","Interventional study","Observational study","Interventional study","Epidemilogical research","Interventional study","Observational study","Diagnostic test","Interventional study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Diagnostic test","Observational study","Interventional study","Interventional study","Observational study","Interventional study","Observational study","Interventional study","Interventional clinical trial of medicinal product","observational","interventional","interventional","interventional","interventional","interventional","interventional","interventional","Interventional","interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational","Observational","Interventional","Observational","Interventional","Observational study","Observational","Interventional","Observational","Observational study","Observational","Observational study","Observational","Observational [Patient Registry]","Observational [Patient Registry]","Interventional","Observational study","Observational study","Diagnostic test","Interventional study","Diagnostic test","Observational study","Interventional study","Observational study","Interventional","Observational study","Interventional study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Observational study","Interventional study","Epidemilogical research","Interventional study","Observational study","Observational study","Interventional study","Observational study","Observational study","Observational study","Observational study","Treatment study","Interventional study","Interventional study","Interventional study","Interventional study","Interventional study","Observational study","Observational study","Observational study","Interventional study","Epidemilogical research","Interventional study","Interventional study","Interventional clinical trial of medicinal product","Interventional study","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional","Observational","Expanded Access","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational [Patient Registry]","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional study","Interventional","Interventional","Observational","Interventional","Observational study","Observational study","Interventional","Observational [Patient Registry]","Interventional","Observational","Basic Science","Health Services Research","Observational","Observational [Patient Registry]","Observational study","Interventional study","Health Services Research","Interventional","Interventional","Interventional","Observational","Observational study","Observational study","Interventional study","Diagnostic test","Interventional study","Observational study","Interventional study","Observational study","Observational [Patient Registry]","Observational [Patient Registry]","Interventional","Observational study","Diagnostic test","Observational study","Interventional clinical trial of medicinal product","Interventional study","Interventional study","Diagnostic test","Observational study","Interventional study","Health Services Research","Basic Science","Interventional study","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional","Interventional","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional clinical trial of medicinal product","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Expanded Access","Interventional","Interventional","Observational [Patient Registry]","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Observational","Observational","Interventional","Observational","Interventional","Observational [Patient Registry]","Interventional","Interventional","Observational","Observational [Patient Registry]","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Observational","Observational","Observational","Interventional","Interventional","Observational [Patient Registry]","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Observational [Patient Registry]","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational [Patient Registry]","Observational","Interventional","Observational","Observational","Interventional","Observational [Patient Registry]","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational [Patient Registry]","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Expanded Access","Expanded Access","Observational","Interventional","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Observational","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Interventional","Observational","Observational","Interventional","Interventional","Observational [Patient Registry]","Interventional","Observational","Observational","Observational [Patient Registry]","Interventional","Observational","Interventional","Observational","Observational","Observational [Patient Registry]","Observational","Interventional","Interventional","Observational [Patient Registry]","Interventional","Interventional","Interventional","Interventional","Interventional study","Observational study","Observational","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational study","Observational study","Interventional","Interventional","Observational [Patient Registry]","Observational","Observational","Interventional","Observational [Patient Registry]","Observational","Observational study","Observational study","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Interventional study","Interventional study","Interventional","Observational [Patient Registry]","Expanded Access","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Observational","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational [Patient Registry]","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional","Observational","Interventional","Interventional","Interventional","Observational","Observational","Observational","Observational","Observational","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Interventional","Interventional","Observational","Interventional","Interventional","Interventional","Interventional","Interventional","Observational","Observational","Observational","Interventional","Observational study","Interventional study","Observational study","Observational study","Interventional study","Observational study","Interventional","Interventional","Interventional","Observational","Interventional study","Observational study","Interventional study","Observational","Observational [Patient Registry]","Interventional","Interventional","Interventional","Observational study","Epidemilogical research","Observational","Observational","Observational","Interventional","Interventional","Observational","Observational","Interventional clinical trial of medicinal product","Observational","Interventional","Interventional","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional","Interventional","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Observational","Interventional","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Observational study","Observational study","Interventional clinical trial of medicinal product","Interventional study","Observational study","Diagnostic test","Diagnostic test","Observational","Observational","Observational","Interventional","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product","Interventional clinical trial of medicinal product"],["Factorial","Single arm","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Sequential","Non randomized control","Non randomized control","Parallel","Sequential","Parallel","Factorial","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Sequential","Sequential","Parallel","Factorial","Non randomized control","Parallel","Parallel","Parallel","Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Sequential","Parallel","Parallel","Parallel","Parallel","Sequential","Factorial","Sequential","Parallel","Sequential","Parallel","Parallel","Parallel","Sequential","Parallel","Parallel","Parallel","Factorial","Sequential","Parallel","Parallel","Sequential","Single arm","Parallel","Sequential","Parallel","Sequential","Parallel","Parallel","Non randomized control","Single arm","Non randomized control","Non randomized control","Non randomized control","Parallel","Parallel","Parallel","Cohort study","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Factorial","Sequential","Parallel","Sequential","Parallel","Non randomized control","Factorial","Parallel","Factorial","Non randomized control","Parallel","Factorial","Non randomized control","Sequential","Parallel","Sequential","Parallel","Non randomized control","Parallel","Parallel","Parallel","Non randomized control","Parallel","Parallel","Parallel","Parallel","Parallel","Single arm","Parallel","Parallel","Case-Control study","Parallel","Dose comparison","Non randomized control","Single arm","Parallel","Parallel","Parallel","Parallel","Parallel","Sequential","Non randomized control","Parallel","Parallel","Single arm",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Parallel","Non randomized control","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Parallel","Parallel","Sequential","Non randomized control","Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Sequential","Parallel","Sequential","Factorial","Factorial","Parallel","Single arm","Factorial","Parallel","Factorial","Single arm","Sequential","Single arm","Single arm","Parallel","Parallel","Parallel","Single arm","Parallel","Parallel","Sequential","Parallel","Non randomized control","Parallel","Factorial","Sequential","Sequential","Parallel","Parallel","Parallel","Sequential","Parallel","Non randomized control","Parallel","Factorial","Factorial","Parallel","Non randomized control","Parallel","Factorial","Parallel","Factorial","Sequential","Sequential","Factorial","Sequential","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Non randomized control","Factorial","Parallel","Parallel","Sequential","Parallel","Factorial","Factorial","Sequential","Parallel","Parallel","Parallel","Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Parallel",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Single arm","Parallel",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).","Sequential","Single arm","Sequential","Sequential","Factorial","Single arm","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Parallel","Non randomized control",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Non randomized control","Factorial","Parallel","Single arm","Sequential","Single arm","Sequential","Factorial","Sequential","Parallel","Sequential","Sequential","Sequential","Non randomized control","Single arm","Non randomized control","Sequential","Parallel","Sequential","Sequential","Parallel","Single arm","Sequential","Parallel","Parallel","Parallel","Sequential","Cross-sectional","Sequential","Sequential","Parallel","Parallel","Single arm","Sequential","Parallel","Parallel","Sequential","Parallel","Non randomized control","Parallel","Parallel","Single arm","Parallel","Parallel","Sequential","Parallel","Parallel","Sequential","Parallel","Sequential","Parallel","Parallel","Parallel","Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Screening. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Single arm","Sequential","Sequential","Parallel","Parallel",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Sequential","Sequential","Sequential","Parallel","Non randomized control","Single arm","Sequential","Sequential","Factorial","Non randomized control","Sequential","Sequential","Sequential","Factorial","Sequential","Parallel","Parallel","Non randomized control","Parallel","Parallel","Parallel","Cross-sectional","Parallel","Single arm","Single arm","Parallel","Sequential","Parallel","Non randomized control","Sequential","Sequential","Single arm","Parallel","Parallel","Single arm","Factorial","Single arm","Sequential","Sequential","Sequential","Parallel","Parallel","Parallel","Parallel","Factorial","Parallel","Sequential","Parallel","Parallel",null,"Parallel",null,"Cluster randomization","Single arm","Sequential","Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Single arm","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).",null,"Parallel","Sequential","Sequential","Sequential","Cohort study","Sequential","Sequential","Parallel","Sequential","Sequential","Cohort study","Sequential","Sequential","Cross-sectional","Sequential","Sequential","Non randomized control","Sequential","Sequential","Parallel","&lt;br&gt;                Controlled: yes&lt;br&gt;                Randomised: yes&lt;br&gt;                Open: yes&lt;br&gt;                Single blind: no&lt;br&gt;                Double blind: no&lt;br&gt;                Parallel group: no&lt;br&gt;                Cross over: no&lt;br&gt;                Other: no&lt;br&gt;                If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;                Placebo: no&lt;br&gt;                Other: no&lt;br&gt;                Number of treatment arms in the trial: 20&lt;br&gt;","Single arm","Sequential","Sequential","Sequential","Sequential","Sequential","Sequential","Sequential","Factorial","Sequential","Factorial","Sequential","Sequential","Case study","Sequential","Sequential","Case study","Sequential",null,"Sequential","Parallel","Factorial","Case-Control study","Cohort study","Sequential","Sequential","Single arm","Non randomized control","Sequential","Sequential","Factorial","Single arm","Factorial","Sequential","Case-Control study","Sequential","Sequential","Parallel","Sequential","Factorial","Sequential","Non randomized control","Sequential","Sequential","Factorial","Sequential","Sequential","Sequential","Case study","Sequential","Non randomized control","Sequential","Sequential","Sequential","Cohort study","Parallel","Parallel","Sequential","Sequential","Parallel","Sequential","Sequential","Factorial","Parallel","Factorial","Parallel","Parallel","Parallel","Parallel","Sequential","Sequential","Parallel","Single arm","Sequential","Sequential","Parallel","Sequential","Parallel","Sequential","Parallel","Sequential","Sequential","Parallel","Sequential","Sequential","Parallel","Sequential","Non randomized control","Parallel","Single arm","Parallel","Parallel","Sequential","Parallel","Parallel","Parallel","Parallel","Parallel","Parallel","Sequential","Parallel","Non randomized control","Sequential","Sequential","Factorial","Sequential","Non randomized control","Parallel","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).","Factorial","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Parallel","Parallel","Parallel","Factorial","Parallel","Parallel","Sequential","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential",null,"Sequential","Sequential","Parallel","Sequential","Cohort study","Sequential","Parallel","Parallel","Parallel","Historical control","Factorial","Sequential","Non randomized control","Cohort study","Non randomized control","Factorial","Sequential",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Sequential","Parallel","Sequential","Sequential","Sequential","Sequential","Non randomized control","Parallel","Non randomized control","Sequential","Sequential","Sequential","Sequential","Sequential","Parallel","Sequential","Parallel","Sequential","Parallel","Sequential","Sequential","Parallel","Parallel","Parallel","Non randomized control","Parallel","Sequential","Sequential","Factorial","Parallel","Parallel","Single arm","Case-Control study","Sequential","Parallel","Controlled: no\nRandomised: no\nOpen: no\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: no\n","Allocation: Non-randomized controlled trial;. Masking: Open (masking not used). Control: Other. Assignment: Other. Study design purpose: Prognosis;","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients with inclusion criteria of the study will be recruited in the intervention or the control group according the permuted block randomization (5 blocks and 3 patients in each block).","Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomized in a 1:1 ratio into one of the treatment groups and standard of care group using computer generated randomization plan. The date and time of randomization will be recorded. Allocation concealment will be done with the sealed envelope method, Blinding description: The treatment assignment will remain unknown until the patient is randomized. Physicians who treat patients and the patients will not be blinded. Radiologists, physicians who assess outcomes and the statistician analyzing the data all will be blinded.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done according to the blocks randomization method. Regarding to the sample size, 3 patients will be include in each block. Random sequences will be created  by SAS software. This is a non-blinded randomized clinical trial.","Randomization: Not randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: In this study  patients,  nurse , supervisor and researcher don't know which group of patients will use  the medicine.\nPhysician and clinicians team know about the drug and group who use the drug.","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization will be done according to the blocks randomization method. Regarding to the sample size, 5 patients will be include in each block. SAS procedure PROC PLAN will be applied to generate the randomization schedule. \nThis is a non-blinded randomized clinical trial.","Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomized in a 1:1 ratio into one of the treatment groups and standard of care group using computer generated randomization plan. The date and time of randomization will be recorded. Allocation concealment will be done with the sealed envelope method, Blinding description: The treatment assignment will remain unknown until the patient is randomized. Physicians who treat patients and the patients will not be blinded. Radiologists, physicians who assess outcomes and the statistician analyzing the data all will be blinded.","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment.","single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose","N/A","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose","randomized controlled trial, open(masking not used), no treatment control, parallel assignment, treatment purpose","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Not selected Not selected","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).",null,null,"Not selected Not selected","N/A","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Factorial",null,"Sequential",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Sequential","Sequential","Sequential","Parallel","Sequential","Sequential","Parallel","Sequential","Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Sequential","Quasi-randomized controlled","Cohort study","Parallel","Sequential","Sequential","Sequential","Sequential","Sequential","Sequential","Sequential","Parallel","Case-Control study","Parallel","Sequential","Case-Control study","Non randomized control","Sequential","Sequential","Single arm","Factorial","Quasi-randomized controlled","Parallel","Parallel","Cross-over","Non randomized control","Parallel","Factorial","Factorial","Sequential","Parallel","Sequential","Parallel","Parallel","Controlled: yes\nRandomised: yes\nOpen: yes\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: no\nOther: yes\nOther specify the comparator: Best clinical practice\nNumber of treatment arms in the trial: 2\n","Parallel","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 3\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: yes\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: no\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: yes\nPlacebo: no\nOther: yes\nOther specify the comparator: Standard of care\nNumber of treatment arms in the trial: 2\n","Controlled: yes\nRandomised: yes\nOpen: no\nSingle blind: no\nDouble blind: yes\nParallel group: no\nCross over: no\nOther: no\nIf controlled, specify comparator, Other Medicinial Product: no\nPlacebo: yes\nOther: no\nNumber of treatment arms in the trial: 2\n","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Care Provider).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Care Provider).",null,"Non randomized control","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Sequential","Factorial","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Factorial","Sequential",null,null,"Factorial","Case-Control study","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator).","Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Factorial","Factorial","Single arm","Sequential","Parallel","Sequential","Parallel","Sequential",null,null,"Prospective interventional non-randomised pre and post implementation study (Diagnostic)","Factorial","Sequential","Sequential","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;","Parallel","Parallel","Sequential","Factorial","Non randomized control","Diagnostic test for accuracy","Dose comparison","Case-Control study","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: standard of care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Prospective, multicenter, open, phase 2 study, one arm-non randomized&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard of care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: no&lt;br&gt;Randomised: &lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Both;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Parallel;Type of endpoint: Efficacy;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Usual care&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;",null,null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).","Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Single (Care Provider).","Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).","Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",null,null,"Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Health Services Research. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).",null,null,"Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).",null,null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Screening. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Outcomes Assessor).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).",null,"Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Single (Participant).","Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Single Group Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;","Observational single-centre cohort study; comparison to a recent cohort of non-COVID-19 patients with ARDS (see ISRCTN32938630) (Diagnostic)",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,null,"Interventional randomized controlled trial (Prevention)","Observational cohort study (Other)","Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).",null,null,null,null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).","Non randomized control","Sequential",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,"Factorial","Factorial","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,null,"Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,null,"Sequential","Cross-sectional","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Triple (Participant, Care Provider, Outcomes Assessor).","Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Parallel","Parallel","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",null,null,"Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,"Allocation: Randomized. Intervention model: Factorial Assignment. Primary purpose: Treatment. Masking: None (Open Label).","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: 2 or more arms, randomized&lt;br&gt;","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: Unknown, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: Not applicable&lt;br&gt;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).",null,null,null,"Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: standard treatment&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard of Care&lt;br&gt;Number of treatment arms in the trial: 6&lt;br&gt;","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective;","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",null,null,null,null,null,"Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Pharmacokinetics;","Randomised adaptive trial (Treatment)","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;","Mixed-methods observational (Other)","Observational; Design type: Cohort study (Other)","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Factorial;Type of endpoint: Efficacy;","Purpose: Prevention; Allocation: Non-randomised trial;","Adaptive (group-sequential), pragmatic, randomised controlled, open-label, multi-centre, effectiveness trial (Treatment)","Open-label randomized multicountry clinical trial  (Treatment)",null,null,null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Non randomized control","Parallel","Sequential","Sequential","Parallel","Sequential","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).",null,"Single arm","Factorial","Sequential","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: Not applicable&lt;br&gt;",null,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).","Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Triple (Participant, Care Provider, Investigator).","Sequential","Sequential","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: Not applicable&lt;br&gt;","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: Not applicable&lt;br&gt;","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: Single arm&lt;br&gt;","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Active, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: 2 or more arms, non-randomized&lt;br&gt;","Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).",null,"Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: discontinuation&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective;","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: Double, &lt;br&gt;                        Control: Placebo, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: 2 or more arms, randomized&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Cross-over allowed for patients with progressive COVID-19&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Best supportive care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: AZINC FORME ET VITALITE (vitamins supplements)&lt;br&gt;Number of treatment arms in the trial: 5&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Dexamethasone associated with hydroxychloroquine will be compared to hydroxychloroquine alone&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy;","Interventional cluster randomized trial (Treatment)","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Local standard of care&lt;br&gt;Number of treatment arms in the trial: 5&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: conventional treatment&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Single-center, prospective cohort study (Diagnostic)","Pragmatic open prospective individually randomised platform randomised controlled clinical trial in community care (Treatment)","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Other doses regimen&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: IBUPROFEN, PARACETAMOL&lt;br&gt;Number of treatment arms in the trial: 3&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: usual treatment&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Sequential","Factorial","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Parallel","Sequential","Sequential","Sequential","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: Single arm&lt;br&gt;","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: Single arm&lt;br&gt;","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Not applicable, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: Not applicable&lt;br&gt;","&lt;br&gt;                        Randomized: No, &lt;br&gt;                        Masking: None, &lt;br&gt;                        Control: Active, &lt;br&gt;                        Group: undefined, &lt;br&gt;                        Type: 2 or more arms, randomized&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard of care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Best Supportive Care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 8&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: antiviral standard treatment&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 4&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Standard of care&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;","Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;Number of treatment arms in the trial: 2&lt;br&gt;"],["N/A","N/A","Phase 4","Retrospective study","0","0","N/A","N/A","0","0","Phase 4","Phase 4","N/A","0","N/A","0","0","0","4","4","0","4","N/A","Phase 4","Phase 2/Phase 3","N/A","N/A","0","N/A","N/A","0","0","0","N/A","0","0","N/A","0","4","4","0","N/A","N/A","N/A","0","N/A","N/A","4","0","0","0","4","N/A","0","0","0","0","0","N/A","4","4","0","0","0","Retrospective study","0","0","0","0","0","0","N/A","N/A","4","4","0","N/A","N/A","N/A","0","0","0","0","0","N/A","4","0","0","4","0","0","0","0","0","4","0","4","0","0","0","N/A","N/A","0","N/A","N/A","N/A","0","0","0","0","0","N/A","N/A","0","4","N/A","N/A","Phase 2","New Treatment Measure Clinical Study","0","Phase 2/Phase 3","N/A","0","N/A","0","4","Phase 2","0","0","N/A","N/A","0","4","N/A","0","N/A","0","0","Retrospective study","0","N/A","N/A","3","2","0","4","0","N/A","New Treatment Measure Clinical Study","0","0","0","0","0","N/A","4","0","N/A","N/A","4","N/A","0","Retrospective study","0","N/A","2","N/A","3","0","Retrospective study","N/A","N/A","N/A","N/A","4","0","0","4","1-2","4","4","0","N/A","4","4","N/A","N/A","Retrospective study","N/A","0","0","0","4","4","Phase 3","4","N/A","N/A","Phase 2","Phase 2","1","N/A","Phase 1","N/A","N/A","N/A","Phase 3","Phase 1/Phase 2","N/A","Phase 2","0","0","Retrospective study","N/A","0","0","Phase 2","0","N/A","0","Phase 1","Phase 1","Phase 1","0","0","0","0","0","0","Retrospective study","Retrospective study","N/A","N/A","0","Retrospective study","N/A","1","Retrospective study","0","Retrospective study","0","N/A","N/A","N/A","0","Retrospective study","0","4","0","N/A","1","New Treatment Measure Clinical Study","Retrospective study","0","0","2","N/A","0","N/A","Retrospective study","4","4","4","4","4","4","N/A","Retrospective study","4","4","Retrospective study","N/A","Retrospective study","4","0","N/A","4","Phase 4","Retrospective study","0","Phase 2","N/A","Phase 3","Phase 1","Phase 1","Retrospective study","Retrospective study","N/A","4","0","N/A","N/A","0","N/A","0","Retrospective study","N/A","0","0","N/A","Retrospective study","Retrospective study","N/A","N/A","N/A","0","Retrospective study","N/A","4","0","Retrospective study","4","0","0","0","0","0","0","4","0","N/A","N/A","Retrospective study","N/A","0","N/A","N/A","N/A","Retrospective study","N/A","0","Retrospective study","N/A","0","0","0","0","N/A","N/A","0","4","0","Phase 2/Phase 3","4","Phase 2/Phase 3","N/A","0","1","4","Early Phase 1","N/A","N/A","Retrospective study","N/A","N/A","N/A","N/A","Retrospective study","0","Retrospective study","N/A","0","Retrospective study","0","N/A","0","N/A","Retrospective study","N/A","1","N/A","N/A","4","0","0","N/A","\n                Human pharmacology (Phase I): no\n                Therapeutic exploratory (Phase II): no\n                Therapeutic confirmatory - (Phase III): no\n                Therapeutic use (Phase IV): yes\n","New Treatment Measure Clinical Study","N/A","0","Retrospective study","N/A","N/A","Retrospective study","N/A","Retrospective study","Retrospective study","Retrospective study","Retrospective study","Retrospective study","Retrospective study","1","Retrospective study","1","0","N/A","N/A","0","Retrospective study","N/A","N/A","N/A","N/A","0","N/A","N/A","0","Retrospective study","Retrospective study","N/A","Retrospective study","Retrospective study","Retrospective study","N/A","4","1","N/A","Retrospective study","Retrospective study","Retrospective study","0","Retrospective study","N/A","Retrospective study","N/A","Retrospective study","0","0","0","Retrospective study","0","Retrospective study","0","0","N/A","1","4","Retrospective study","N/A","0","4","N/A","4","0","0","4","Retrospective study","N/A","0","N/A","Retrospective study","Retrospective study","0","Retrospective study","0","0","4","0","0","0","N/A","Retrospective study","1","Retrospective study","0","0","1-2","0","4","N/A","0","0","0","4","4","4","N/A","0","Retrospective study","N/A","N/A","Retrospective study","Retrospective study","N/A","0","N/A","Phase 2","4","Phase 2","0","0","N/A","N/A","0","0","0","N/A","Early Phase 1","N/A","Phase 2","0","0","0","N/A","Retrospective study","Retrospective study","N/A","N/A","0","N/A","Retrospective study","N/A","0","N/A","4","Retrospective study","Retrospective study","N/A","Phase 1","N/A","N/A","0","Retrospective study","Retrospective study","0","0","N/A","N/A","1","0","Retrospective study","Retrospective study","0","Retrospective study","2-3","0","0","Retrospective study","N/A","N/A","Retrospective study","N/A","N/A","N/A","N/A","1","Retrospective study","0","0","4","4","N/A","0","0","4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","2-3","2-3","2-3","2","3","2-3","3","Phase 4","2-3","2","N/A","N/A","2","2","N/A","N/A","N/A","Phase 4","Phase 4","Phase 3","Not applicable","Phase 1/Phase 2","N/A","Phase 2/Phase 3","N/A","Phase 2","Not applicable","N/A","Phase 2/Phase 3","N/A","Phase 2","Phase 2/Phase 3","N/A","Phase 3","Phase 4","Phase 3","Phase 1","Phase 4","N/A","Phase 1","Retrospective study","N/A","Phase 3","Phase 1","N/A","Phase 4","Retrospective study","N/A","N/A","N/A","Phase 3","N/A","N/A","0","N/A","N/A","N/A","N/A","Retrospective study","N/A","N/A","N/A","N/A","0","Retrospective study","Retrospective study","N/A","Retrospective study","N/A","N/A","N/A","2","Retrospective study","0","N/A","Retrospective study","N/A","0","Retrospective study","N/A","0","N/A","0","4","4","Retrospective study","N/A","0","0","N/A","N/A","Retrospective study","0","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 3","Phase 2/Phase 3","Phase 2","Phase 2","Phase 2","N/A","N/A","N/A","Phase 2","Phase 4","Phase 2","Phase 2","Phase 2","Phase 2/Phase 3","N/A","Phase 2","N/A","Early Phase 1","Phase 3","N/A","Phase 3","N/A","Phase 2/Phase 3","Early Phase 1","0","Phase 3","N/A","N/A","Phase 3","N/A","0","Phase 1/Phase 2","N/A","Phase 3","Phase 1","0","N/A","N/A","N/A","Retrospective study","1","N/A","Phase 3","Phase 2/Phase 3","Phase 3","Phase 1/Phase 2","Retrospective study","Retrospective study","1","0","4","N/A","0","N/A","N/A","Phase 3","Not Applicable","Retrospective study","0","Retrospective study","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","N/A","Retrospective study","N/A","0","0","1","2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 3","N/A","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 3","Phase 2","Phase 2","Not Applicable","Phase 3","Phase 4","Phase 3","Phase 4","Phase 1/Phase 2","Phase 1/Phase 2","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Phase 1","Phase 2/Phase 3","Phase 3","N/A","N/A","Phase 1/Phase 2","Phase 3","Phase 3","Phase 2","Phase 3","Phase 1","N/A","Phase 1","Phase 2","N/A","Phase 3","N/A","N/A","Phase 3","Phase 3","Phase 2","Phase 1","Phase 3","Phase 2","Phase 4","N/A","Phase 3","Phase 3","Phase 3","N/A","Phase 3","Phase 2","Phase 1","Phase 4","Phase 2","Phase 1","Phase 2/Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","N/A","N/A","Phase 3","N/A","N/A","Phase 2","Phase 2","N/A","N/A","Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","N/A","Phase 2","Phase 3","Phase 2","N/A","Phase 2/Phase 3","Phase 1/Phase 2","N/A","Phase 3","N/A","Phase 2","Phase 3","Phase 2/Phase 3","Phase 2/Phase 3","Phase 2","Phase 3","N/A","Phase 2","Phase 3","Phase 2","N/A","Phase 3","Phase 4","Phase 3","Phase 2","Phase 2","Phase 1/Phase 2","Phase 2","Phase 2/Phase 3","Phase 2/Phase 3","Phase 2/Phase 3","Phase 2/Phase 3","N/A","Phase 3","N/A","Phase 3","Phase 2","Phase 4","N/A","N/A","Early Phase 1","Phase 2/Phase 3","N/A","N/A","N/A","Phase 3","N/A","Early Phase 1","Phase 4","N/A","Phase 2","N/A","N/A","N/A","N/A","N/A","N/A","Phase 3","Phase 3","N/A","Phase 3","Phase 4","Phase 3","N/A","N/A","Phase 2","N/A","Phase 2/Phase 3","N/A","Phase 3","N/A","Phase 1/Phase 2","Phase 2/Phase 3","Phase 1","Early Phase 1","Phase 1","Phase 2","Phase 3","Phase 2","N/A","Phase 2","N/A","N/A","Phase 1","N/A","Phase 2","Phase 4","N/A","Phase 2","Phase 4","N/A","Phase 4","Phase 2","Phase 3","Phase 2","Phase 2/Phase 3","N/A","N/A","N/A","Phase 2","N/A","Phase 1/Phase 2","Phase 3","Phase 2","Phase 2","N/A","Phase 2","Phase 2","Phase 3","N/A","Phase 2","N/A","Phase 1","Early Phase 1","Phase 3","Phase 2","Phase 2","N/A","Phase 2","N/A","Phase 2","N/A","Phase 1/Phase 2","Phase 2/Phase 3","Phase 3","Phase 2","N/A","N/A","Phase 1","N/A","N/A","Phase 2","N/A","N/A","Phase 3","N/A","N/A","N/A","Phase 2","Phase 2","N/A","Phase 4","Phase 4","Phase 1","N/A","Phase 1","Phase 2","Phase 4","N/A","Not Applicable","Phase 2/Phase 3","Phase 2/Phase 3","Phase 1","N/A","Not Applicable","Not Applicable","Phase 4","Phase 3","Early Phase 1","N/A","Phase 2","Phase 3","N/A","N/A","Phase I/II","Not Applicable","Phase 1","Phase 3","N/A","N/A","N/A","Phase 1/Phase 2","N/A","N/A","Phase 1/Phase 2","N/A","Phase 3","Phase 4","0","N/A","Phase 4","Phase 1/Phase 2","Phase 2","Phase 2","Phase 2","Phase 3","Phase 2","Phase 2","Retrospective study","N/A","Phase 2","Phase 2","N/A","N/A","N/A","Phase 2","N/A","Phase 4","N/A","N/A","Phase 4","Phase 1/Phase 2","N/A","N/A","N/A","N/A","N/A","0","1-2","Phase 3","N/A","N/A","N/A","N/A","Phase 3","N/A","Phase 2","Phase 2/Phase 3","Phase 2","N/A","Phase 3",null,null,"N/A","Phase 1","Phase 3","Phase 4","Phase 2","Phase 2/Phase 3","N/A","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2","Not Applicable","Phase 1","N/A","Phase 2","Phase 2","N/A","Phase 2","Phase 2","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Not Applicable","Phase II/III","Phase 4","Not Applicable","Not Applicable","Not Applicable","Phase 2/Phase 3","N/A","Phase 1","N/A","Phase 3","Phase 0","Not Applicable","Phase III","Phase 4","Phase 4","N/A","Phase 4","0","N/A","N/A","N/A","0","Retrospective study","Phase 3","Phase 2","Phase 2/Phase 3","Phase 2/Phase 3","N/A","N/A","4",null,"Phase 2","Phase 3","Phase 2","Phase 2","Retrospective study","N/A",null,null,null,null,"N/A","Phase 2","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Not Applicable","Phase 2",null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 1 / Phase 2","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Not Applicable","Phase III","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Retrospective study","Retrospective study","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","2","Retrospective study","N/A","0",null,null,null,null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): \nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): \nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n"],["China","China",null,"China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,null,null,"China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","Wuhan","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","France",null,"China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","Chinese","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,null,"China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China",null,"China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","china","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","Hong Kong","China","China","China",null,"China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China",null,null,null,"China","China",null,"China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","Portugal;Greece;Spain;Ireland;United Kingdom;Czech Republic;Hungary;Belgium;Romania;Croatia;Australia;Denmark;Netherlands;Germany;New Zealand","China","China","China","China","China","China","China","China","China","China","China",null,null,"China","China",null,"China","China",null,"China","China","China",null,"China","China","China","China","China","China","China","China","China","Chian","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China?","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,null,"China","China","China","China","China","China","China","China","China","China","China",null,null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","Korea, Republic of","China","China","China","China","China",null,null,"China",null,"China","France","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China",null,"Hong Kong","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","France","Germany","Iran (Islamic Republic of)","Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","Iran (Islamic Republic of)","China","Iran (Islamic Republic of)","Japan","France;France","China","Japan","Japan","China","China","China","China","China","China","Japan,Asia(except Japan),Australia,Europe","China","China","China","China","China","Japan","France",null,"China","Singapore","China","China","China","China",null,"France","China","China","Jordan","China","China",null,"Italy","China","Sweden","China","China","China","Italy",null,"China",null,"China","China","China",null,"China","China","Italy","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","Belgium","China","France;Canada;Spain;Russian Federation;Israel;Germany;Japan;Italy","Netherlands","Germany","Norway","United Kingdom","United States","France","China","United Kingdom",null,null,null,"China",null,null,null,null,"China","United Kingdom","United States","France",null,"Italy",null,"Turkey",null,"Italy","China","Italy",null,"China","Canada","Italy","Italy","China","China","China","China","Netherlands",null,"United States","China","China","Hong Kong",null,"China","China","China","Egypt","Italy","Canada",null,"China","China","China","China","China","China","China",null,"Germany","United States","United Kingdom","China","China","China","France;Belgium;Luxembourg;Netherlands;Germany;United Kingdom;Spain","China","China","China","China","China","China","China","China","Belgium","Greece","Netherlands","Norway","Denmark","Italy","Canada","China","China","China","France","France","Thailand","United States",null,"Australia;Hong Kong;Taiwan, Province Of China;Indonesia;Korea, Republic Of;Japan;Italy;Singapore;Viet Nam;Thailand;United Kingdom;United States of America","United States;Australia;Korea, Republic of;Taiwan;Australia;Korea, Republic of;Taiwan;United States","Australia","Canada","Norway","Denmark","Denmark;France;Germany;Norway;Denmark;France;Germany;Norway","Denmark","Denmark","France","China","China;Italy;China;Italy","United States;China;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Singapore;Spain;Switzerland;Taiwan;United Kingdom;China;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Singapore;Spain;Switzerland;Taiwan;United Kingdom;United States;Iran, Islamic Republic of","China","Germany","United Kingdom","Pakistan","China","China","United States;Denmark;Germany;Japan;Korea, Republic of;Mexico;Singapore;United Kingdom;Denmark;Germany;Japan;Korea, Republic of;Mexico;Singapore;United Kingdom;United States","United States","China","Brazil","China","United States","United States;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Singapore;Spain;Switzerland;Taiwan;United Kingdom;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Singapore;Spain;Switzerland;Taiwan;United Kingdom;United States","France","China","United States;Canada;United States",null,"Vietnam","United States","Canada","China","China",null,"Spain","China","France","United States","Brazil","United States","Canada",null,"United States","China","United States","Italy","United States","United States;Israel;United States","United States","Italy;Romania;United Kingdom;Italy;Romania;United Kingdom","United States","Brazil","Italy","United States","Canada","Germany","United States","Italy","United States","Italy","Italy","Italy","United States","Germany","United States","France;Monaco;France;Monaco","United States","France",null,"Iran, Islamic Republic of","Egypt","United States","Norway","Italy","United States;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States",null,"United States","Canada","United Kingdom","United States",null,"Australia","United States;Australia;Canada;Ireland;South Africa;United Kingdom;Australia;Canada;Ireland;South Africa;United Kingdom;United States","United States","United States",null,"United States;Canada;United States",null,null,"Italy","Denmark","Italy","France","Canada;France;Italy;Spain;Canada;France;Italy;Spain",null,"Turkey","Netherlands","France",null,"Switzerland","Spain","France","United States","United States","France","Romania",null,null,"United States","Switzerland",null,null,null,"Mexico","France","United States","Turkey","France","Iran, Islamic Republic of","Denmark","Belgium","France","France",null,"Belgium;Italy","Brazil","Turkey","France","United States",null,"United States","French Guiana","China",null,"China","Colombia",null,"Spain",null,"United States",null,null,"China",null,"United States","United States",null,null,null,"United States","China","Spain","Ireland","United States;United Kingdom;United States",null,null,"Spain",null,"Iran, Islamic Republic of","Canada",null,"Belgium",null,null,"China",null,"United States",null,"Turkey",null,"Spain","United States","United States","Colombia","Italy","Mexico","Mexico","Germany","Germany",null,"United States","United States","Egypt","France","France","Denmark",null,"United States","United States","United Kingdom","France","France","Denmark",null,"Israel","China","Spain",null,null,"China","United States","France","United States","Italy","United States","India","Canada",null,"United States","Germany","France",null,"Australia","Netherlands",null,"United States;France;United States","France","Australia","Germany","United States",null,"United States","France",null,"United States","Denmark",null,"United Kingdom","United Kingdom","United States","France","United Kingdom","Turkey","Switzerland","Mexico","China","Spain","United States",null,"United States","Mexico",null,"China","United States","France","United States",null,"United States","Spain","Austria;Denmark;Germany;Austria;Denmark;Germany","France","China","China",null,null,"France",null,null,"Germany","United States",null,null,"China",null,"China","China","United States","China",null,"Sweden","China","China","Italy","Turkey",null,null,"Spain","Germany","United States;Egypt;Iran, Islamic Republic of;Egypt;Iran, Islamic Republic of;United States","United States",null,"Brazil","United States","Nigeria;Pakistan;Nigeria;Pakistan","The Netherlands","The Netherlands",null,"Israel",null,null,null,"France","France","Indonesia","France","Belgium",null,"Australia",null,"United States","United States","Colombia",null,"United States","United States","Belgium","Greece","Australia","United Kingdom",null,"Australia","Australia;Austria;Belgium;Brazil;Bulgaria;Croatia;Cyprus;Czech Republic;Denmark;Finland;France;French Southern Territories;Germany;Greece;Ireland;Isle of Man;Israel;Italy;Lebanon;Liechtenstein;Lithuania;Luxembourg;Malta;Netherlands;New Zealand;Norway;Portugal;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States of America","United Kingdom","United States","China",null,"Germany","Australia;New Zealand","Australia","United Kingdom","Indonesia;Iran;Norway;Peru;Qatar;South Africa;Spain;Switzerland;Thailand;Argentina;Brazil;Canada;Germany",null,"France","France","United States","China","China","China","Bolivia","China","China",null,"United States","Netherlands","United States","China","China","China","The Netherlands","United States",null,"United States","United States","China","China","The Netherlands","The Netherlands","The Netherlands","The Netherlands","United States","United States","Australia","France","Australia","New Zealand","The Netherlands","Germany","France","France","Australia","United Kingdom","Spain","Spain","Switzerland","United Kingdom","Spain","Spain","France","Spain","China","China","Spain","China","??","China","China","The Netherlands","The Netherlands","The Netherlands","The Netherlands","France","Netherlands","France","France","France","Spain","Spain","Spain","France;Hungary;Czech Republic;Denmark;Germany;United Kingdom","Spain"],["Yan Zhao","Ting Cai",null,"Yan, Zhao","Xiaowei Xu","Zhai Xiaowen","LU Zhenhui","Wang Tan","Chao Xu","Weiren Huang",";",null,";","Xu Shuyun","Wu Wenjuan","Li Jiansheng","Xiangming Fang","Wei Zhang","Tingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang","Ronghua Jin","Tingrong Huang, Bangjiang Fang, Jun Feng, Jianguo Zuo, Gang Wang","Xiaoyin Huang","; ;",null,null,";","Yongshi Jia","Bin Song","LU Zhenhui","Ting Cai","Huaqi Wang","Yongxiang Yi","Yao, Rong","Zhao Yan","Deng Guofang","Ronghui Du","Zhan Jie","Hongzhou Lu, Xiaorong Chen","Qin Ning, Meifang Han","Xia Jinyu","Cao Jun","Wu Guolin","Xia Jiaan","Lixin Wang","Fang Xueling","Lu Hongzhou","Yaosheng Zhang, Jianwei Shang","Xiaoling Xu","Zhang Zhongde","Hu bo, Li wei","Pei Guangzhong","Chao Cao","Huang Luqi; Li Zhiqiang","Kang Yan","Tong Xiaolin","Pei Bin","LIU QINGQUAN","Chengping Wen","Qiu Jun","Ying Kejing","Jiang Shanping","Jianping Zhao","Wen Chengping","Chengping Wen","Wu Wenjuan","Lv Dongqing","Zhan Zhang","Nianzhi Zhang","Min Huang","Jixian Zhang","Jun Lin","Chen Lei","Li Jiansheng","LIU QINGQUAN, MIAO QING, ZHANG BOLI","Zhongqi Yang, Minyong Wen","Dewei Zhao","Mao Wei","Min Xie","Nanshan Zhong, Zeguang Zheng","Jun Guo","Li Jiansheng, Li Suyun","Tengxiao Liang, Tong Wang, Xuezeng Hao, Jingfeng Zhang, Yaosheng  Zhang","Wen Shenglin, Xia Jinyu","Zhang Zhongde","Chengfeng Qiu","Qu Jieming","Cai Hongliu","Xiaolin Tong","Hong Shan","Lanjuan Li /Xiaowei Xu/Charile Xiang","Xue Zhigang","Yanling Zhao","Liu Yingxia","Pei Bei","Wang Daowen, Zhao Jianping","Qiu Yunqing","Zhang Zhan","Qiu Yunqing","Xie Chunguang","Yunqing Qiu","Wang Xinghuan/Ke Hengning","Su Wen","Yuan Yongming","Zhang Wei","Jiang Hua","Xia Wenguang, An Changqing, Zhang Boli","Wenguang Xia","Chanjuan Zheng","Wenguang Xia","WANG YUGUANG, LI XUCHENG, ZHANG BOLI","Wei Li","ZHANG ZHONGDE, ZHANG BOLI","Tian Feng","Xu Yong","Ma Penglin","Cheng Zhenshun","; ;",null,"Le Aiping","Huang Luqi",null,"You Shang","Liu Yingxia","Kequn Chai","Huang Yi","Zhong Nanshan / Song Yuanlin/Qiu Haibo/Li Yimin/Liu Xiaoqinqing","; ;","Wanhong Yin","Qianxue Chen","Hong Zhao","Hua Lu","Yu Hongzhi","Hongzhou Lu","Wang Shaogang","Mingxing Xie","Donghui Huang","Lu Hongzhou","Bende Liu","Gang Xu","Shentu Jianzhong?Wu Lihua","Yao-sheng Zhang/Ting-rong Huang/Chun-yan Ji/Jian-wei Shang","XIONG YAN","Ke Hu","Jian Bo and Chuanzhu Li","Gong Shouping","Chaoqian Li","Nanshan Zhong","Qingping Wu","Feng WANG","Gong Shouping","Xiaoguang Tong","Qing Zhou","Shixuan Wang","XiaoWang Qu","Zhang Dingyu","Huji Xu","Lianru Gao","Jing Liu","Chen Xiangdong","Hongyi Chen","Tang Jianyuan","Mingxing Xie","Haifa Xia, Xiangdong Chen","Yin Zhenyu","Xuebing Yan","Zhaohui Tong","Jiang Hong","Baofeng Yang","Peng Hu","Zhou Min","Luo Zhigang","Chunxue Bai","Tao Li","Tang Jianyuan","Hongliang He","Fang Lei","Fang Min","Yin Zhenyu","Robert Chunhua Zhao/Ronghua Jin","Feng Cao","Zhao Yan","CHEN Xinyu","Jun Tang","Xin Zheng","Zhuoli Zhang","Caixia Xie","Chen Hong","Lyu Dongqing","Peng Yudong","Shixuan Wang","Dong Liang","Zhan Zhang","Xin Zheng","Junbo Ge",";","Yang Yi",null,"; ;",";",";","Nijun","Ni Jun","; ; ; ;",null,"; ;","Dong Shang",null,";",null,";","Xiaorong Chang","Zhongyu Zhou","Kunlun He","Yan Hao; Xiaoping Luo","Lu Yibin","Rui Pan",";","RongJin Lin","Zhang Dingyu","Jianzhong Liu","; ;","; ;",";","Ma Xiaorong","Yongxiang Yi","Huilan Zhang","Li Caixia","Jianqing Xu","Shao Fengmin","Chuxiao Shao","Ziqiang Zhang","Jihui Lyu","Hu Bing","Wang Tan","Zhenhua Zhang","Ming Chen","Yongxiang Yi","Kaihu Yu","Ming Chen","Feng Li","Kaijiang Yu","WANG Jing","Jiemin Zhu","Junxue Wang","Wei Yang","Li Jiangping","Lijia Deng","Liu Hua/Wang Qian","Meiping Chu","Bin Zhan","Lijia Deng","Bi Ying-fei","Zhenjie Hu","Zhou Jia","Shao Yi","Zhiyong Peng","Daisy Dexing Zhang","Cancelled","XIONG YAN","Chen Hao","Liangdan Sun","Feng Cao","Shen Ning","Shen Ning","Hua Shucheng","Wenxiang Huang","Xie Liangdong","Kaihu Xiao","Wei Zhang","Liu Dong","Liu Dong","Yaokai Chen","Yu Jia","Wenxiang Huang","Peng Hu","Yaokai Chen","Huawei Mao",";","Wang Hailong","Li Shusheng","; ;","; ;",";",";",";","Xiaoyang Lu","Zhang Huafen","Wang Hongyang","Xu Zhihua","Chuantao Zhang",null,";","Guojun Zhang","Yunxia Zuo","Mei Heng","Jiang Shujuan","Liu Yi","Xiaowei XU","Li Suyun","Yan Hao; Xiaoping Luo","Minghao Fang","Shusheng Li","Ye Gu","Chen Xiao","Ye Wan","Hu Liu","Ying binwu","Zhongyuan Xia","Huilan Zhang","Li Shusheng","CHEN Xinyu","Chen Chunbo","Xiuming Song","Yuanrong Dai","Kang Yan","Zhijun Fang","Xuemei Li","Wang Hao","Chen Zhenshun","Xufang Sun","Jie Luo","Zhang Wei","Yanling Shi","Yong Huo","Xuemei Li","Wei Yao","Wu Caineng","ZHOU JIAN","Zongze Zhang","Bende Liu","Pang Yong-li","Chengxian Guo","Bin Li","CAI YU","Jianfeng Zhou","Ye Feng/ Yang Zifeng/ Xu Xuyan/ Zhu Jun/ Jiang Lihong/ Zhang Yunhui/ Yuan Bing/ Chen Shi/ Fan Jie","Lunxu Liu","Xie Chunguang","Xie Chunguang","Jianfeng Zhou","Zhong Nanshan/Zhang Boli/Li Lanjuan/Duan Zhongping/Li Xingwang/Liu Qingquan/Song Yuanlin/Jia Zhenhua","Cao Bin","; ;","Zhong Nanshan/Zhang Boli/Li Lanjuan/Duan Zhongping/Li Xingwang/Liu Qingquan/Song Yuanlin/Jia Zhenhua",null,"Tang Jianyuan","Wang Dazhong","Jingzhi Ma","Guiqiang Wang",null,"Deng Xiaopeng","Wang He","Lu Guangming",null,";",null,"Honghua Ye","Feng Gao","Shiyue Li","Prof. Christopher CK Lai","Li Lanjuan","Wen Jianli","Jiang Xie","Qun Luo","Yang Si-Jin","Zhang Sheng","Xu Jie","Luo Xiaoping","Tiejun Wang","Li Xugui","Xu Shuyun","Xu Haibo","Bangjiang Fang","Liming Xia","Yibin Hao","Zhang Dingyu","W.W. van Bentum-Puijk","Dou Qifeng","Yan Hao, Xiaoping Luo","Ning Qin","Ye Tu","Xia Tian","Zhengrong Mao","Yi Bian","Junming Wang","Lingli Dong","Qian Guoqing","Zhihua Wang, Xianglin Yuan","Liang Wang","Xin Li","LIU DONG","Wang Hua-bing","Yuan Yadong","Peng Jian","Wu Kaifeng",null,"Wang Tan","Jing-Guo Cheng","Zhigang He","Lihui Wang","Jing Chen","Guo Zhang","Xiong Chen","Xie yuanlin","Zhu Bo","Zhang Yue","Qingyou Zheng","Xia Hong","GuoLin Song","Guoqin Sun","Shusheng Li","Hong Wang","Cuntai Zhang","Burenbatu","Zhao Yan","Wen Jianli","Fengbin Liu","Fenglin Liu","Fenglin Liu","Hongyu Gao","Fenglin Liu","Minghao Fang","HONGGANG LI","Fenglin Liu","Hui Zhong","Fenglin Liu","Huanqin Han","Xiang Cheng","Peng Sun","Lijia Demi","Guangtao huang","Wei Li","Pinhua Pan, Yehong Kuang","Yuan Yang","Jingfeng Zhang","JIAN PENG","Hu Linhui","TAO WANG","Yingjia Xu","Wang Xiaowen","Yang Yi","Wang Hongyang","Min Zhang","Cai Qingxian","Zhang Yu","Zhaofen Lin,Wansheng Chen,Weifen Xie","Fenglin Liu","Song Ying","xiao wei","Qin Wang","Zhanlian Huang","Hanwei Chen","Gao Jun","Chen Lei","Zunyuan Liu","Zhu Fengxue","Hong tao","Bi Xiaohui","Zhu Haibing","Wei Wei","Gao Dengfeng","Qingping Shi","He jing","Fenglin Liu","Li Xiaodong","Wei Xiao","Weiping Cai","Haibin Ni","Qingling Zhang","Zhi Zhang","Xiaodong Li","Chao Xu","Chao Xu","Jinghua Mao","Jinghua Mao","Ying Deng","Jingzhi Ma","Cao Bin","Zhongze Lou","Baoshan Cao","Liu Zhisheng","Miao Qing","Miao Qing","Meizhen Lin","Kaijiang Yu","Huang Keqiang","; ;","Xin Zheng",null,"Jia Lijun","Jing Xu","Bende Liu","Gao Dengfeng","Zairong Wei","Chao Xu","Chao Xu","Jin Yang",";","Kun Ye","; ;","Jiao Xianfa","CHEN Hui","Meng Jie","Pengfei Pang","Pei Bin","Fan Li","Shitao Chen","Haihang Yu","Jing Li","Yang Jinfeng","Rengbin Ji","YY Chen","Gang Sun","Zhaohui Tong","Chunli Liu","GAO Hong","Tang Hao",null,"; ;",null,"Jie Lin","Feng Zhen","Changqing Hu","Chen Jian","Liujie","Zhang Dingyu","Luping Lin","Bin Zhang/Yinong Ye","Zhu Fengcai","Jiang Shujuan","Tian Lin","Huang Hui","Qianjin Lu","Binru Wang","Zhaohui Tong","Chuo Li","Xinghuan Wang","GuoLin  Song","Li Bixi","Zhongyuan Xia","Wei Wang","Binghong Zhang","Ting Cai","Chengyun Liu","Dawei Wang","Ye Xiaoqun","MINGLI LIU","Ying-kun Guo","Hongmei Tao","Li Lanjuan","Gong Guozhong","Zhang Lina","Fan Zhong","Wei Zhang","Guochao Shi","IHU Mditerrane Infection","Sven","Hossein Khalili","Amir Hossein Jamshidi","Hossein Khalili","Dr Ehsan Aali","Farzaneh Dastan","Hossein Khalili","Dr Hossein Poustchi",";","Hossein Khalili","Tetsuya","Enrique",null,"Tetsuya","Masashi",null,";",null,";",";",";","Keibun","; ;",null,"; ;",null,";","Junko","Enrique",null,null,"; ;","; ; ; ;",null,";","; ;",null,"; ;",null,null,";","Kun Xiao","; ;","; ; ; ; ; ; ; ;","; ;","Wenliang Fan","; ;","Shen Chan",";","; ;",null,"; ; ; ; ; ; ;","Xianli Du","Tianwang Li","Haixiao Chen","Prof. Qingsong Ye; Dr. Chenliang Zhou","Fan Yang","Wei Min","Yuan-hao Wu","Hong Qiu","; ;","Xianli Du","Zheng Xue","Qiuling Shi","Zhuang-Gui Chen","Zhongyuan Xia","Daoyuan Si","Xiandong Meng","Zhang Rong","Yan Hao, Xiaoping Luo","Xiaojun Tang","Wei Wang","Jin Ronghua","Pengcheng Luo","Fu Liran","Zhang Yi","Qingta Meng","Wei Lu","GAO Tian-lin","Jun Shao","Peiyang Gao","Sun Hongyuan","Peiyang Gao","Lei Genping","Li Shi-yue","Hu Xingxing","Zhe Xu","Zhongde Zhang","Mingxing Xie","Jin Yang","Ming Wu","Huang Luqi; Ruan Lianguo","Cao Guoqiang","Chengqi He","Yan Kang","Laurens Liesenborghs","Shan Chunlei","Direction des Oprations Cliniques","Marc J. M. Bonten","Project management,Diane Egger-Adam","Sect. Clin. Imm. &amp; Infect. Diseases","Jody Brookes",";",";",";","; ;",null,";",null,"; ; ;",";",null,null,";",null,"; ; ; ; ; ; ; ;",";",";",null,";",";","; ;",null,"; ;",null,";",null,"Hong wenxin","; ;",null,"; ; ; ;","; ;","Zhongyuan Xia","Xiaomei Guo","; ;",";",";",";","Xiuyong Li","Xuezhong Yu",";",";","Zhang Hua-nian","Jiang ZhiXia","Yaqin Zhu",";","; ;","; ; ;",null,"Lingli Dong","Li Chen","Feng Ganzhu","Xiang Changgang","Xianglin Yuan","Ou Cehua","Xiao Fei","Li Wan","; ;","; ;",null,"Lingli Dong","Xiang Changgang","Fan Rong","Christelle DELMAS","Hongqiang Sun","Shen Chengxing","Zejin Liu","Dongyang Liu","Weiqin Li","LI HANG","Chenyu Zhang","Fu-Sheng Wang","HIRUZ CTU","Regulatory Affairs department","Jurjan Aman","Department of Infectious Diseases","CRO","Trial Information Support Line-TISL",null,null,null,";","chef de projets","project manager",null,";",null,null,";",null,"; ; ;","; ;",";",null,null,"Sponsor/Investigator",";","; ;",";",";","; ;","; ;",";","; ;",null,null,null,null,";",";",null,"; ;",";",null,null,";",null,";","; ;","; ; ;",";",null,null,";",";","; ;",";",";",";","; ;",null,"; ;","; ;",";",null,"; ;",";","; ;","; ;",null,"; ;","; ;",null,null,"; ; ;",";","; ; ; ; ; ; ; ;",";",";",null,null,"; ;",";",null,null,"; ;",";","; ;","; ; ; ;","; ;","; ;",";",";",";","; ; ; ; ; ; ;","; ;",null,"; ;",null,null,";","; ; ;",null,";",";","; ;",";",";","; ;",";",";",null,";",";",null,null,"; ;",null,";",";",null,";",null,null,"; ;",";",null,";","; ;",";",null,";","; ; ;","; ;","; ;",";","; ;",null,";",";","; ;","; ;",null,";",";",";","; ;",null,";","; ;","; ;",null,";",";","; ;",null,";",null,"; ;",";",null,null,";","; ;",";",null,null,null,";","; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;","; ;","; ;",";",null,null,";",null,"; ;","; ; ;",null,"; ;",null,";",";",";",";",null,"; ; ;",";",";","; ; ;",";","; ;",";",";",null,null,"; ; ; ;",";","; ;","; ;",";",null,"; ;",null,null,";",null,"; ;",null,"; ;","; ; ; ; ;","; ;",";",";",";",";",";",null,null,";",";",null,";","; ;","; ; ;",null,"; ;","; ;",null,null,null,"; ;",";",";",null,null,null,"; ; ;",null,"; ;","; ;",";",";","; ;",null,null,null,";",";",null,null,"; ;",null,";",";",";",null,"; ; ;",";","Guihua Liu","Sanlian Hu",null,null,"; ;","; ; ; ; ; ; ; ; ;",";",";",";",";","Yun Liu","zhu pengfei",null,";",null,";",null,"; ;","; ;","; ;","Christopher KC Lai","Chen Li",";","; ;",";","; ;",";",";","; ;","Yingshuai Li","Zhenlin Zhao",null,null,";",null,"; ; ;","; ;",null,";",null,null,";","; ;","Jesper","Thomas",null,";",";",null,";","; ;","; ;","; ;",null,"HIRUZ CTU",";",null,null,";",null,"; ; ;",null,"; ;",";","; ;","President of the Board",null,"Michelle","; ; ; ; ;",null,null,null,";","; ;",null,";",null,null,"Keith",null,null,"; ;","; ;",";","Jinghua Qian","Li Jianan","Liping Jia","DIANA MARIA CESPEDES ARCANI","Enhai Cui","Bai Xiaoxia",";","; ;",";","; ;","Junxue Wang","Ying Fan","Yun Lin","Diederik","; ;",null,";","; ; ; ; ;","Rui Zeng","Weng Jianping","Femke","Frank","JAH","Hamza","; ; ;",";",null,"Carla VANDENABELE",null,null,"Harm Jan","Sixten Krper","REC","Clinical research project manager",null,"Greg","SCREN-UICEC","LOLA SERNA GUIRAO","Jan","Emma;Julie","Emilio Garcia Cabrera","Epidemiologist","Clinical Research Director","Unidad de Enfermedades Infecciosas","Jinzhi Lu","Qianjin Lu","Jose Muoz Gutirrez","Zhu Fengcai","Shengtian Zhao","Zhang Chunyan","Tangshaohua","Alienke","Marion","Frank","Margriet","Eldoie SOLER","Clinical Research and Development","Project manager","Julien GAUTIER","DRCI","Xavier Solanich Moreno","UICEC Sant Pau","Clinical Trials Department","Medical Information","Anabel Snchez"],[null,null,"Pinhua Pan, Medical PhD",null,null,null,null,null,null,null,"Yueping Li, MD, Master;Linghua Li, MD, PhD","Panpan Hao, MD","Yuhong Dai;Yuhong Dai",null,null,null,null,null,null,null,null,null,"Xiao-he Xiao, PD.;Rui-lin Wang, Dr.;Rui-lin Wang, Dr.",null,"Taisheng Li","Yunqing Qiu, Master;Xiaowei Xu, Master",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Xavier Duval, MD;Xavier Duval, MD;Xavier Duval, MD",null,null,null,"Bin Du, MD",null,null,null,null,null,"XingHuan Wang, professor;XingHuan Wang, professor;XingHuan Wang, professor",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Bin Cao, Professor;Ying Liu",null,null,"Jiahong Dong, M.D;Xiaobin Feng, M.D;Xiaobin Feng, M.D","Jinglin Xia, MD;Jinglin Xia, MD","Jinglin Xia, MD;Jinglin Xia, MD",null,null,"Kunling Shen, MD,PhD;Tianyou Wang, MD,PhD;Baoping Xu, MD,PhD;Baoping Xu, MD,PhD;Lina Wang","Yang Jin, MD","Chunxue Bai;Chunxue Bai;Chunxue Bai",null,"Bin Cao, Professor","Jianqi Lian, MD;Sicao Li","Hongzhou Lu, Master","Chenghai Liu, PhD;Chenghai Liu, PhD",null,null,null,null,null,null,"Ying Fu;Wan-Jin Chen, MD",null,null,null,"Liang Peng, Doctor;Wenxiong Xu, Doctor;Liang Peng, Doctor","Liang Peng, Doctor;Wenxiong Xu, Doctor;Liang Peng, Doctor","ZHU, Professor;GUO, Professor",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Ronghua Jin;Huiguo Ding",null,null,"Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP;Ivan FN Hung, MD FRCP","Yan Liu;Xiaotian Sun;Yan Liu, Ph.D.","Huilan Zhang, PD;Huilan Zhang, PD","Lei Shi, MD,PhD;Lei Shi, MD, PhD","Jie-ming Qu, MD.,PhD.;Jie-ming Qu, MD.,PhD.",null,null,null,null,null,null,"Shuiping Zhou, PhD;Yi He, PhD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Hongzhou Lu, Ph.D;Hongzhou Lu, Ph.D;Jun Chen",null,"Xiuling Shang",null,null,null,null,"Jianping Zhao, Ph.D.",null,null,null,null,"Mark B Loeb;Mark Loeb, MD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Zhiyong Peng, professor;Zhiyong Peng, professor;Zhiyong Peng, professor",null,"Sung-Han Kim, MD.PhD",null,null,null,null,null,null,null,null,"Liwei cheng, doctor;Xiaoyang Zhou, doctor",null,"Frderic DUTHEIL;Lise Laclautre;Lise Laclautre",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Lung-Ji Chang;Lung-Ji Chang;Lung-Ji Chang","Qiong Gong, MD.",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Laudi",null,null,null,null,null,null,null,"Qing Ning, Professor;Qin Ning, professor",null,"Nakamura","Casalino","Faming Zhang, MD; PHD","Nakamura","Kondo","XIAN SHEN, phd","Yang Jin;Yang Jin","Yimin Li, PhD, MD","Qing Ning, Professor;Qin Ning, professor","Qing Ning, Professor;Qin Ning, professor","Qing Ning, Professor;Qin Ning, professor","Liu","Lung-Ji Chang, PhD;Lung-Ji Chang, PhD;Lung-Ji Chang, PhD",null,"Wei Zhang;Jiang-Rong Huang, M.D.;Xiao-Dong Li, M.D.",null,"Haibo Cheng, phD;Lei Cui, phD","Terada","Casalino","Lin Chen",null,"Jean Liu, PhD;Jean Liu, PhD;Jean Liu, PhD","Dong Shang, M.D.;Jiang-Rong Huang, M.D.;Xiao-Dong Li, M.D.;Zhong Wang, M.D.;Jun Liu, M.D.",null,"Qing Ning, Professor;Qin Ning, professor","SHAOXIAN HU, M.D;YIKAI YU, M.D;AIHUA DU, M.D",null,"Joe-Elie Salem, MD, PhD;Lee S Nguyen, MD, PhDc;Lee S Nguyen, MD, PhDc",null,null,"Adeeb M AlZoubi, Ph.D.;Adeeb M Alzoubi, Ph.D.",null,"Xiaoju Zhang, PhD;Ziqi Wang, MD;Li Li, Master","Jorge Rojas-Serrano, MD, PhD.;Rogelio Perez-Padilla, MD;Felipe Jurado-Camacho, MD. MSc;Ireri Thirion-Romero, MD, MSc;Sebastian Rodrguez-Llamazares, MD, MPH;Carmen Hernandez Crdenas, MD, MSc;Cristobal Guadarrama-Prez, MD;Alejandra Ramrez-Venegas, MD, MSc;Felipe Camacho-Jurado, MD","Augusto Di Castelnuovo, MSc, PhD;Augusto Di Castelnuovo, MSc, PhD;Augusto Di Castelnuovo",null,"Robert Frithiof, MD. PhD;Robert Frithiof, MD. PhD.;Robert Frithiof, MD. PhD.",null,"Wenhong Zhang, Doctor;Wenhong Zhang, PhD,MD","Zhang Li Na, MD;Zhao Ch Guang, MD;Xiao","Gabriele Saccone, MD","Carmen Hernandez-Crdenas, MD. MSc.;Luis-Felipe Jurado-Camacho, MD;Ireri Thirion-Romero, MD. MSc;Sebastian Rodriguez-Llamazares, MD.MPH;Rogelio Perez-Padilla, MD. PhD;Cristobal Guadarrama, MD MSc;Joel Vasquez-Prez, MD;Carmen Hernandez-Crdenas, MD. MSc",null,null,null,null,null,null,null,null,"Maurizio Cipolla, MD;Antonio V Gaddi, MD, MSc;Maurizio Cipolla, MD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Colin Broom, MD;Colin Broom, MD","Florence Ader, MD;Florence Ader, MD","Shumin Wang, Phd.;Shumin Wang, Phd.","Matthew Snape, Professor;Iason Vichos;Iason Vichos","Thomas C Pitts, M.D.","Chong Lei, MD, PhD;Lorenzo Berra, MD","William Schilling, MD","Yihai Cao, Dr;Yuguo Chen, Dr;Jiaojiao Pang, Dr;Jiaojiao Pang, Dr","Pter Hegyi, MD, PhD, DSc;Pter Hegyi, MD, PhD, DSc",null,"Mahmoud M.A. Abulmeaty, M.D., FACN","Colin Broom, MD;Colin Broom, MD",null,"James C Moon;Gabriella Captur;Charlotte Manisty;Ben O'Brien;Hugh Montgomery;Steffen Petersen;Thomas Treibel;James C Moon, MD MBBS MRCP;James Moon","Elizabeth Oelsner, MD, MPH;Elizabeth Oelsner, MD, MPH","Joe-Elie Salem, MD-PhD;Joe-Elie Salem, MD-PhD","Lucio Manenti, MD","Salvatore Corrao, MD;Salvatore Corrao, MD","Paul;Paul","Ipek Yeldan, Prof.;Eren Avcil, M.Sc,Pt;Eren Avcil, M.Sc,Pt","Franois Lellouche","Fabrizio Cantini, MD;Fabrizio Cantini, MD;Fabrizio Cantini","Zhuan Liao, MD","LUCA GALLELLI;LUCA GALLELLI","Aneel Bhangu",null,"Darrell Tan, MD FRCPC PhD;Attia Qamar, BEng;Adrienne Chan, MD MPH FRCPC","Cesare Perotti, MD","Riccardo Inchingolo, MD, PhD;Andrea Smargiassi, MD, PhD;Libertario Demi, PhD;Gino Soldati, MD;Libertario Demi, PhD","Hao Li, Professor;Hao Li, Professor;Hao Li, Prof.",null,null,"Min Liu, A.B;Min Liu, A.B;Min Liu, A.B","Folkert W. Asselbergs, MD, PhD;Marijke Linschoten, MD","Frdric ADNET, MD, PhD;Frdric ADNET, MD, PhD","Daniel R Karlin, MD, MA;Daniel R Karlin, MD, MA",null,null,"Paul CHAN;","Joost Wauters, MD PhD;Joost Wauters, MD PhD",null,null,null,"Mahmoud Tantawy, MD;Mahmoud Tantawy, MD","Francesco Salton, MD;Francesco Salton, MD;marco confalonieri, MD","Richard Whitlock, MD PhD;Emilie Belley-Cote, MD PhD;ACT COVID-19 Study Coordinator;ACT COVID-19 Study Coordinator","Paolo Gisondi",null,null,null,null,null,null,null,null,"Tienush Rassaf, MD;Matthias Totzeck, MD;Amir A Mahabadi, MD","Daniel Mollura, MD;Dan Gebow, PhD;TBD TBD",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Jeremy D Road, MD",null,"Bing Sun, MD","Jennifer Ho, MD, PhD;Ivy Fan",null,null,"Subsai Kongsaengdao, M.D.","Lorenzo Berra;Lorenzo Berra, MD","Lorenzo Berra, MD",null,"Stanley Lewis, M.D;Jennifer Ho, M.D",null,"Franois Lamontagne, MD FRCPC MSc;Neill Adhikari, MDCM FRCPC MSc;Marie-Helene Masse;Marie-Helene Masse","Olav Dalgard, MD PhD;Olav Dalgard, MD PhD;Olav Dalgard, MD PhD","Lars stergaard, Professor;Ole S Sgaard, MD PhD","Christian Jung, MD","Jens-Ulrik Sthr Jensen, MD, PhD",null,"Philippe VANHEMS, MD, PhD;Philippe VANHEMS, MD, PhD","Yao Xie, Doctor;Yao Xie, Doctor;Yao Xie, Doctor","Yuguo Chen, Dr;Jiaojiao Pang, Dr","Gilead Study Director;Gilead Clinical Study Information Center","Zuojiong Gong, MD;Zuojiong Gong, MD;Zuojiong Guong, MD","Alexander Supady, Dr., MPH;Alexander Supady, Dr., MPH;Alexander Supady, Dr., MPH","Andrew Pollard, Prof;Volunteer Recruitment Co-ordinator","Umar Farooq, PhD;Umar Farooq, PhD;Umer Farooq, PhD","Hongzhou Lu, Ph.D",null,"20-0006 Central Contact","20-0003 Central Contact","Guiqiang Wang;Guiqiang Wang","Florentino de Araujo Cardoso Filho;Alvaro Razuk Filho, MD, PhD",null,"Rebecca E Wells, MD, MPH;Rebecca E Wells, MD, MPH;Rebecca Wells, MD","Gilead Study Director;Gilead Clinical Study Information Center","Pierre HAUSFATER, MD PHD",null,"David Boulware, MD, MPH;David Boulware (Please email), MD, MPH","Andres Orlandini, MD","Guy Thwaites, PhD. MD;Jeremy Day, PhD. MD","Ruanne V. Barnabas, MBChB, DPhil;Anna Bershteyn, PhD;Meighan Krows","Luanne Metz, MD;Michael D Hill, MD;Dr. L Metz, MD;Carol C Kenney, RN, CCRP","Fu-Sheng Wang, MD, PhD;Lei Shi, MD,PhD","Yahong Chen, MD","Sandi K Parriott","oriol Mitja, PhD;Oriol Mitj","Zhongji Meng;Zhongji Meng","Stephane LEGRIEL, MD, PhD;Stephane LEGRIEL, MD, PhD;Stephane LEGRIEL, MD, PhD","Becky Smith, MD;Mark Sendak, MD, MPP","Otvio Berwanger, PhD;ARO-HIAE Academic Research Organization HIAE","Samuel M Brown, MD MS;Valerie T Aston, MBA","Stephen Freedman, MD;Stephen Freedman, MDCM, MSc;Stephen Freedman, MDCM, MSc","Javier Crespo, MDPhD","Christopher Tignanelli, MD;Michael Puskarich, MD, MS;Christopher Tignanelli, MD","Zhu Fengcai;Guan Xuhua;Wang Wei","Clinical Trial Management;Clinical Trials Administrator",null,"Lorenzo Berra, MD;Lorenzo Berra, MD;Lorenzo Berra, MD","Jonathan C Javitt, MD, MPH;Robert E Besthof, MIM","Christopher Tignanelli, MD;Michael Puskarich, MD, MS;Christopher Tignanelli, MD","Alexandru Burlacu, Lecturer;Radu Dabija, Lecturer;Alexandru Burlacu, MD, PhD","Ethan Berke, MD","Alexandre Biasi, PhD;Fernando G Zampieri;Fernando G Zampieri, PhD","Giuseppe GRITTI, MD;GIUSEPPE GRITTI, MD;Alessandro Rambaldi, MD","Rahul Kashya, MBBS",null,"Andreas Strhle, Prof.Dr.;Antonia Bendau, M.Sc.Psych.;Antonia Bendau, M.Sc.Psych.;","Jeffrey Miller, MD;Jeffrey Miller, MD","Guido Iaccarino, MD;Guido Grassi, MD;MariaLorenza Muiesan, MD;Claudio Borghi, MD;Claudio Ferri, MD;MASSIMO VOLPE, MD;Leonardo Sechi;Guido Iaccarino, MD, PhD;Marialorenza Muiesan","Shyamasundaran Kottilil;Pan Zheng, MD, PhD","Francesco Perrone, MD, PhD;Francesco Perrone, MD, PhD","Giovanni Landoni, Professor","Gabriele Saccone","Vanessa Vacoby, MD, MAS;Ruth Gebrezghi;Study Coordinator","Gunther Meinlschmidt, Prof. Dr.;Kati Bermbach","Michael Joyner, MD","Vincent DUBEE","Pankti Reid, MD, MPH;Pankti Reid, MD, MPH;Pankti Reid, MD, MPH","Isabelle PELLEGRIN;Isabelle PELLEGRIN","Filippo Annoni, MD;Robson AS Santos, MD,PhD;filippo annoni, MD","Alireza Ghaffarieh, MD;Yadollah Shakiba, MD, PhD;Amir Kiani, PhD;Alireza Ghaffarieh, MD;Yadollah Shakiba, MD, PhD","Aliae Mohamed-Hussein;Aliae Mohamed-Hussein;Aliae Hussein, MD","Girish B Nair, MD;Joanne Gondert, RN, BSN;Joanne Gondert, RN, BSN","Arne Sraas, MD, PhD;Arne Sraas, PhD","LUCA GALLELLI;LUCA GALLELLI","Clinical Trials;Reference Study ID Number: WA42380 www.roche.com/about_roche/roche_worldwide.htm","Paul Aukrust, MD, Professor;Andreas Barratt-Due, MD, PhD;Trine Ksine, MD;Katerina Nezvalova-Henriksen, Pharm D, PhD;Anne Margarita Dyrhol Riise, MD, Professor;Marius Trseid, MD, PhD;Inge Christoffer Olsen, PhD;Paul Aukrust, MD, Professor","Mark Shapiro;BEAT19.org;BEAT19.org","Barbara Goodall","Ravindra Prof. Gupta, BMBCh;Richard D. Skells, BSc.;Ravi K Gupta, PhD",null,"Spyridon Deftereos","Prof Nigel Curtis;Prof Nigel Curtis, MBBS PhD","Michael S. Avidan, MBBCh;Ramani Moonesinghe, MD;Helen Rees, MD;Linda Yun, BS","Dima Dandachi, MD","Brandon Webb, MD;Valerie T Aston, MBA","Manu Shankar-Hari, MBBS;Ndaba Mazibuko, MD","Jean-Claude Tardif, MD;Zohar Bassevitch, B.SC.;Jean-Claude Tardif, MD","Shmuel Shoham, MD;Shmuel Shoham, MD","Guido Bertolini, MD;Guido Bertolini, MD","Geltrude Mingrone, MD PhD;Anna Caprodossi;Anna Caprodossi","Lars Erik Kristensen, PhD;Lars Erik Kristensen, PhD","Emanuele Nicastri, MD;Cristina de Min, MD / CMO","Olivier HERMINE, MD-PhD","Clinical Sciences &amp; Operations;Trial Transparency email recommended (Toll free number for US &amp; Canada)","Anders Kjellberg, MD;Anders Kjellberg, MD",null,"Thijs ten Doesschate, MD","Muriel FARTOUKH, PU-PH MD PHD;Muriel FARTOUKH, PU-PH MD PHD;Muriel FARTOUKH, PU-PH MD PHD","Justin Slagel","Peter M. Villiger, Prof. Dr. med.;Stephan Reichenbach, Prof. Dr.med.","Jess Villar, MD;Jess Villar, MD","Bruno HOEN, Pr","Jie Li, PhD;Jie Li, PhD","Robert W Alexander, MD","Olivier HERMINE, MD-PhD","Alexandru Burlacu, MD, PhD;Cristina Plesoianu, PhD;Alexandru Burlacu, MD, PhD","Guido Bertolini, MD;Guido Bertolini, MD","Csar Calvo Lobo, PhD","Radha Rajasingham, MD;Radha Rajasingham (Please Email), MD","Claire-Anne Siegrist, MD;Claire-Anne Siegrist, MD;Claire-Anne Siegrist, MD","Luciana Ferrara;Carla Morales Guerra Godoy, MD, PhD",null,"Brett D Thombs, PhD;Marie-Eve Carrier, MSc","Silvio A. amendys-Silva, MD, MSc;Guillermo Dominguez-Cherit, MD;Eduardo Rivero-Sigarroa, MD;Silvio A. amendys-Silva, MD, MSc","Pascal AMEDRO, MD-PhD;Pascal AMEDRO, MD-PhD;Pascal AMEDRO, MD-PHD","Sreekanth Vemulapallli, MD;Kristine Arges, BSN;Kristine Arges, BSN","Mahir M Ozmen, Professor;Istinye University M ozmen, Prof","Julien Poissy, MD,PhD;Julien Poissy, MD,PhD;","Majid Saeedi, Ph.D.","Sren H Skaarup;Sren H Skaarup","Bart Lambrecht, MD, PhD;Anja Delporte","Camille TAILLE, MD, PhD;Camille TAILLE, MD, PhD;Camille TAILLE, MD, PhD","Fabrice DENIS, MD;Fabrice DENIS, MD;Fabrice DENIS, MD","Vasilios Polymeropoulos, MD","Bart Lambrecht;Anja Delporte","Luciano Cesar Pontes Azevedo, Ph.D;Luciano Cesar Pontes Azevedo, Ph.D","Ayse Zengin Alpzgen, assistant professor;Ayse Zengin Alpzgen, Assistant Professor","Emilie Garrido-Pradalie;Franois Silhol, MD;Francois Silhol, MD","Antonio Abbate, MD, PhD","Ara Darzi, Prof;Fahad M Iqbal, MBChB (hons)","Daniel Freilich, MD;Jennifer Victory, RN;Kristin Pullyblank, RN, MS","Claude Flamand, PhD;Claude Flamand, Phd;Claude Flamand, PhD","Ming Li, M.D.","Mike Foley;Rachael Smith, DO","Zhou Qi, Doctor;Wang Liu, Doctor","Juan M Anaya Cabrera, MD, PhD;Juan M Anaya Cabrera, MD, PhD;Gustavo Quintero, MD, MSc",null,"Enrique M San Norberto, MD, PhD, MsC;Enrique M San Norberto, MD, PhD, MsC","Michael Eddleston","Ravi Amaravadi, MD;Amelia Anderson;Amelia Anderson","Yong Goo Song, Professor;Yong Goo Song, Professor","Joon Young Song, MD, PhD",null,"Jeremy Road, MD;Chris Miller, Ph.D.","Raj Makkar, MD;Siegfried Rogy, PhD;Mitch Gheoghiu, MD","Michael Joyner, MD;Michael Joyner, MD","Janneke Cox, Dr",null,null,"Brian Kendal, MD;Trista Johnson, PhD, MPH","Mingkai Chen, MD;Xiaolong Qi, MD;Fengmei Wang, MD;Ye Gu, MD;Zicheng Jiang, MD;Guo Zhang, MD;Yong Zhang, MD;Dengxiang Liu, MD;Qing He, MD;Hua Yang, MD;Zhengyan Wang, MD;Bin Xiong, MD;Xiaodan Li, MD;Hongguang Zhang, MD;Chuxiao Shao, MD;Hongmei Yue, MD;Xiaolong Qi, MD","Felipe Garca, MD;Felipe Garca, MD;Felipe Garca, MD","John William McEvoy, MBBCh MHS;John William McEvoy, MBBCh MHS;John William McEvoy, MBBCh MHS","Tim D Spector;Victoria Vazquez","Marta Duda-Sikula, MBA","Olivier HERMINE, MD-PhD","Jose Muoz Gutirrez, MD, PhD;Jose F Muoz Gutirrez, MD, PhD","Adrian Martineau, PhD","Siamack Afazeli;Siamack Afazeli, Pharm.D;Jalal Karimi, PhD","Steven Chan, M.D.;Vikas Gupta, M.D.;Steven Chan, M.D.;Steven Chan, M.D.","Chuck Moser","Michiel Thomeer, MD,PhD;Michiel J Thomeer, MD,PhD;Michiel J Thomeer, MD, PhD","Huilan Zhang, PD","Michael Gordon, MD;Karen Lewandowski, RN","Yan Liu, MD;Yan Liu, MD","Mehdi BENCHOUFI, MD;Mehdi BENCHOUFI, MD","Sabine Hazan, MD;Sabine Hazan, MD","Fabio Ciceri, MD","Ayse Zengin Alpzgen, Assistant Professor, PhD;Begum Kara Kaya, MSc;Ayse Zengin Alpzgen, Assistant Professor, PhD;Ayse Zengin Alpozgen, Assistant Professor, PhD","Upinder Singh;Upinder Singh","Pere Domingo, MD, PhD;Pere Domingo, MD, PhD","Catherine Oldenburg, ScD, MPH;Thuy Doan, MD, PhD;Jessica M Brogdon, MPH;Jessica M Brogdon, MPH","Scott Gorenstein;David Lee, MD","Juan M Anaya Cabrera, MD, PhD;Juan M Anaya Cabrera, MD, PhD;Gustavo Quintero, MD, MSc","Roberto Giacomelli, MD, PhD;Roberto Giacomelli, MD","Jos Fe Castilleja-Leal, MD.;Servando Cardona-Huerta, MD., Ph. D.",null,"Diane Egger-Adam, Dr.","Robert W Krner, Dr.;Jan Rybniker, PD Dr. Dr.;Miguel A Alejandre Alcazar, Prof. Dr. Dr.;Robert W Krner, Dr.;Robert W Koerner, Dr.","Fengcai Zhu, MD;Wenjuan Wang, MD","Jeffrey L Carson, MD;Reynold A Panettieri, MD;Jeffrey L Carson, MD","Sabiha Hussain, MD;Steven K. Libutti, MD, FACS;Sabiha Hussain, MD","Aliae Mohamed-Hussein;Aliae AR Mohamed-Hussein","Corinne Levy, MD","Claire-Marie RANGON;Amlie YAVCHITZ;Claire-Marie RANGON","Jens Kastrup, Professor MD","David Saadoun, MD PhD","Boyd Taylor Thompson, MD;Katie Oldmixon, RN","Peter A McCullough, MD, MPH","Prapa Kanagaratnam, FRCP, PhD;Alena Marynina, BSc, MSc;Alena Marynina, BSc, MSc",null,"Pierre Asfar, MD, PhD;Pierre Asfar, MD, PhD;Julien Demiselle, M.D.","Henrik Ullum, Prof., DMSc;Kasper Karmark Iversen, Prof., DMSc;Thomas Benfield, Prof., DMSc;Christian Torp-Pedersen, Prof., DMSc;Henning Bundgaard, Prof., DMSc;Henning Bundgaard, Prof., DMSc","Pierre PATOZ, PharmD;Barthelemy LAFONDESMURS, MD;Pierre PATOZ, PharmD","Zivit Harpaz;Zivit Harpaz","Guiqiang Wang;Guiqiang Wang","Manuel J Castillo, MD, PhD;Manuel J Castillo, MD, PhD","Adrian Hernandez, MD;Rachel Olson, RN","Sherry Mansour, MD, MS;Sherry Mansour, MD, MS",null,"Milind Desai, M. D.","Jacques Cadranel, MD PhD;Jacques Cadranel, MD PhD","N. Stuart Harris, MD, MFA;N. Stuart Harris, MD, MFA",null,"David Levine, MD;David M Levine, MD MPH MA","Sujeet Jha, MRCP (U.K);Sujeet Jha, MRCP (U.K);Samreen Siddiqui, PhD","Eric L Sievers, MD;Manish Sadarangani, MRCPCH, DPHIL;Joanne Langley, MD, FRCPSC;Alexander Graves, PhD, MBA","Lars Wik, MD","Matthias Salathe;Matthias Salathe, MD;Matthias Salathe, MD","Anselm Gitt, MD;Anselm Gitt, MD;Anselm Gitt, MD","Cdric Annweiler, M.D., Ph.D.",null,null,"A Vlaar, MD;Korinna Pilz, MD;A. V., MD, PhD","Lee Goldstein, MD;Lee Goldstein, MD","Clinical Sciences &amp; Operations;Trial Transparency email recommended (Toll free number for US &amp; Canada)","Cedric ANNWEILER, MD, PhD",null,null,"Veronique Michaud, PhD;Malavika Deodhar, PhD;Sweilem B Al Rihani, PharmD, PhD;Jacques Turgeon, PhD",null,"Maria Lucia Madariaga, MD;Maria Lucia Madariaga, MD;Maria Lucia Madariaga","CLAIRE ROGER;CLAIRE ROGER, MD, PhD;Claire Roger, MD, PhD","Javier Corts;Alicia Garca","Efstratios Koutroumpakis, MD;Efstratios Koutroumpakis, MD","Salome Kristensen, MD, PhD;Line Uhrenholt, MD;Line Uhrenholt, MD","Christopher Inchley, Phd",null,null,"ShuPing Yang, MD, PhD;Inovio Call Center","Franois Dubos, MD,PhD;Franois DUBOS, MD,PhD","Harry Hothi, PhD",null,"Guido Beldi, Prof. Dr.;Guido Beldi;Guido Beldi",null,"Guiqiang Wang;Guiqiang Wang","IVAN J NUNEZ GIL, MD, PhD, MSc;IVAN J NUEZ J NUEZ GIL, MD","Claire Xu, MD, PhD;US Site Head","Jean-Baptiste Mr FASSIER, Dr","William W O'Neill, MD;Dee Dee Wang, MD;Dee Dee Wang, MD;Dee Dee Wang, MD","Jos Meneses Caldern, MD;Hugo Mendieta Zern, PhD.",null,null,"Rama Jager, M.D.","Xavier Monnet, MD.PhD","Timothy J Ness, MD PhD;Timothy J Ness, MD PhD;Timothy J Ness","Philippe LE CONTE, Pr;Thomas FLAMENT, Dr;Louis SOULAT, Pr;Nicolas MARJANOVIC, Dr;Francis COUTURAUD, Dr;Laure BAUDIN, Dr;Karim TAZAROURTE, Pr;Thomas DELOMAS, Dr;Luc-Marie JOLY, Pr;Franois MORIN, Dr","Sabine Hazan, MD;Sabine Hazan, MD","Rosa Polo, MD,PhD;Miguel Hernn, MD,PhD","Sonja Hller, Dr.;Henning Bundgaard, Prof. Dr. med.","Denis DOYEN;Denis DOYEN",null,null,"Xavier Mariette, MD, PhD","Nishant Gupta, MD;Nishant Gupta, MD","Gilles MANGIAPAN, MD","Delphine Garrigue, MD;Delphine Garrigue, MD","Bjorn Stessel, Dr","Andreas Hochhaus, Prof. Dr.;Andreas Hochhaus, Prof. Dr.;Andreas Hochhaus, Prof. Dr.","Jose L Diaz-Miron, MD;Jose L Diaz-Miron, MD;Jose L Diaz-Miron, MD","Sam (Saidi) Mohiddin, MD;Federica Marelli-Berg, PhD;Daniel E Harding, BM BCh",null,null,"Niels van Royen, MD PhD;Roland RJ van Kimmenade, MD PhD","Prof. Qingsong Ye, PhD,DDS;Qingsong Ye, PhD,DDS;Chenliang Zhou, PhD","Zhang Ze Guang, doctor;Zheng Z Guang, doctor","Tushar Patel;Robert Brannock;Robert Brannock","Qinglei Gao, Dr.;Qinglei Gao, Dr.","Syed MR Kazmi, FCPS;Farhan R Khan, MS, FCPS","Erik M Andersson, PhD;Erik M Andersson, PhD;Erik M Andersson, PhD",null,null,"Giuliano Rizzardini, Md",null,"Novartis Pharmaceuticals;Novartis Pharmaceuticals","Achille TCHALLA, MD","Miguel Guia;Antonio Esquinas;Miguel Guia;Antonio Esquinas","Benjamin Mordmller, Prof.;Diane Egger-Adam, Dr.;Diane Egger-Adam, Dr.","Mohamed Alboraie, MD, MRCP(UK)","Eric J Lenze, MD;Angela Stevens","Ayse Zengin Alpzgen","Marcus Lacerda, MD","John W Sanders, MD, MPH&amp;TM;Wake Forest Baptist Medical Center","Haleema Shakur-Still;Ian Roberts;Haleema Shakur-Still","Weehuizen","Timmers","Julio A Chirinos","Roi Anteby, MD;Roi Anteby, MD","Javed Akram, FRCP;Shehnoor Azhar, MPH",null,"Call 1-877-CTLILLY (1-877-265-4559 or 1-317-615-4559) Mon - Fri 9AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST);There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or","Hlne Donnadieu-Rigole, MD PhD;Hlne Donnadieu-Rigole, MD PhD;hlne Donnadieu-Rigole, doctor","Pierre-Emmanuel FALCOZ, MD, PhD;Pierre-Emmanuel FALCOZ, MD, PhD;Pierre-Emmanuel FALCOZ, MD, PhD","Tjhin Wiguna, PhD;Tjhin Wiguna, PhD;Tjhin Wiguna, PhD",null,null,"Michele L Donato, MD;Mariefel Vendivil",null,null,"Jeffery S Kuo, MD;John F Engle, MD","Kush Dhody, MBBS, MS, CCRA","yohanny andrade, researcher;oswaldo leyva, researcher;EDUARDO INSIGNARES-CARRIONE, Research Direc.;YOHANNY ANDRADE, INVESTIGATOR",null,"Joyce Y Chung, M.D.;Alison Gibbons;Alison Gibbons","Matthew Yocum, MD;Matthew Yocum, MD","Hannelore Denys, MD, PhD;Heini Kanervo, RN;Hannelore Denys",null,null,"Nunn","Ilad Alavi Darazam, MD;Shervin Shokouhi, MD;Minoosh Shabani, MD;Mohammadreza Haji Esmaelie, MD;Seyed Sina Naghibi Irvani, MD, MPH, MBA;Seyed Sina Naghibi Irvani, MD, MPH, MBA",null,null,null,"Joaquin Espinosa, PhD;Angela Rachubinski, PhD","Yun Long;Yun Long, MD;Yun Long","Alana Burns","Peter Rosenberger, Prof.;Peter Rosenberger, Prof.",null,null,"Couper",null,"Andrew Gostine, MD","Elie AZOULAY, MD PhD;Nancy KENTISH-BARNES, PhD;Nancy KENTISH-BARNES, MD PHD","Grard Amarenco, PhD;Camille Chesnel, MD;Camille Chesnel, MD","Gianluca Iacobellis, MD PhD;Gianluca Iacobellis, MD PhD",null,null,null,null,null,null,"Rupesh Agrawal, MD;Rupesh Agrawal, MD","Adam Spivak, MD;Christina Pacchia, PhD;Christina Pacchia, PhD","Bart Rijnders, MD, PhD;Bart Rijnders, MD, PhD","David Ho, M.D,;Yang Luo, PhD;Brett Gray",null,null,null,"van Wijk","Emily O'Brien, PhD;Laura Webb;Laura Webb","Matthew Bardin, PharmD, BCPS","Latha Dulipsingh;Latha Dulipsingh, MD","Angela Phillips, PhD;Scott A Wallace, MD;David S Robinson, MD;John S Baxter, MD, JD;Scott A Wallace, MD;Scott A Wallace, MD",null,null,"Hooijberg","Bosch","VAN Oers","Yousuf","Patty Lee, MD;Sangeeta Joshi, MD;Erika Ratcliffe;Erika Ratcliffe","David E Leaf, MD, MMSc;David E Leaf, MD, MMSc",null,null,null,null,"Bogaard",null,null,null,null,"Elder",null,null,"Fehr","Ogburn;Allen",null,null,null,null,null,null,null,null,null,null,null,"Wijmenga-Monsuur","Frenken","Bosch","Dijkstra",null,null,null,null,null,null,null,null,null,null],["169 Donghu Road, Wuchang District, Wuhan, Hubei, China","41 Xibei Street, Ningbo, Zhejiang, China",null,"169 Donghu Road, Wuchang District, Wuhan, Hubei, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","399 Wanyuan Road, Minhang District, Shanghai","725 Wanping Road South, Xuhui District, Shanghai, China","1478 Gongnong Road, Changchun, Jilin, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","3002 Sungang Road West, Futian District, Shenzhen",null,null,null,"1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","156 Jinshui Road East, Zhengzhou, He'nan, China","299 Qingyang Road, Liangxi District, Wuxi, Jiangsu","Pulmonary Department, 5A Ward, 528 Zhanghen Road, Pudong New Area District, Shanghai, China","6 Guangchang Road, Huangshi, Hubei, China","8 Xitoutou, You'anmen, Fengtai District, Beijing","6 Guangchang Road, Huangshi, Hubei","Nanbaixiang, Ouhai District, Wenzhou, Zhejiang",null,null,null,null,"158 Shangtang Road, Xiacheng District, Hangzhou, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","725 Wanping Road South, Xuhui District, Shanghai, China","41 Xibei Street, Ningbo, Zhejiang, China","1 Jianshe Road East, Zhengzhou, He'nan, China","1 Kangfu Road, Tangshan Street, Jiangning District, Nanjing, China","37 Guoxue Lane, Chengdu, Sichuan, China","169 Donghu Road, Wuhan, Hubei, China","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","28 Baofeng Road, Qiaokou District, Wuhan, Hubei, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","2901 Caolang Road, Jinshan District, Shanghai","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","52 Meihua Road East, Xiangzhou District, Zhuhai, China","117 Meiyuan Yangxiang, Wuxi, Jiangsu, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","507 Zhengmin Road, Yangpu District, Shanghai, China","79 Qingchun Road, Hangzhou, China","2901 Caolang Road, Jinshan District, Shanghai, China","5 Hai-Yun-Cang Lane, Dongcheng District, Beijing, China","17 Lujiang Road, Luyang District, Hefei, Anhui, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","222 Zhengda Street, Guangshan County, He'nan, China","59 Liuting Road, Ningbo, Zhejiang, China","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China","23 Art Gallery Back Street, Dongcheng District, Beijing, China","548 Binwen Road, Hangzhou, Zhejiang, China","159 Tianshan Road South, Jingyang District, Deyang, Sichuan, China","3 Qingchun Road East, Jianggan District, Hangzhou, Zhejiang, China","102 Yanjiang Road West, Guangzhou, Guangdong, China","1095 Jiefang Avenue, Wuhan, Hubei","548 Binwen Road, Binjiang District, Hangzhou, Zhejiang","548 Binwen Road, Hangzhou, Zhejiang, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","1 Tongyang Road East, Luqiao District, Taizhou, Zhejiang, China","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","117 Meishan Road, Hefei, Anhui, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","169 Donghu Road, Wuchang District, Wuhan, Hubei","37 Guoxuexiang, Wuhou District, Chengdu, Sichuan, China","156 Jinshui East Road, Zhengzhou, He'nan, China","23 Back Street of Art Gallery, Dongcheng District, Beijing, China","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China","6 Jiefang Street, Dalian, Liaoning, China","54 Youdian Road, Shangcheng District, Hangzhou, Zhejiang, China","1095 Jiefang Avenue, Wuhan, Hubei, China","151 Yanjing Road, Yuexiu District, Guangzhou, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","19 Renmin Road, Zhengzhou, He'nan, China","5 Haiyuncang Lane, Dongcheng District, Beijing","52 Meihua Road East, Zhuhai, Guangdong, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","144 Jinxi Road South, Hecheng District, Huaihua, Hu'nan, China","197 Second Ruijin Road, Huangpu District, Shanghai, China","79 Qingchun Road, Hangzhou, Zhejiang, China","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","52 Meihua Road East, Zhuhai, Guangdong, China","79 Qingchun Road, Hangzhou, Zhejiang, China","102 South Dongwu Road, Changsha Economic and Technological Development Zone, Changsha, Hu'nan, China","100 West Fourth Ring Road, Fengtai District, Beijing, China","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","79 Qingchun Road, Hangzhou, Zhejiang, China","238 Jiefang Road, Wuchang District, Wuhan, Hubei, China","79 Qingchun Road, Hangzhou, Zhejiang, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","79 Qingchun Road, Hangzhou, Zhejiang, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China","Room 18A 03-2, Anlian Building, 4018 Jintian Road, Fuzhong Community, Lianhua Street, Futian District, Shenzhen, Guangdong, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","32 Second Section, First Ring Road West, Chengdu, Sichuan, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","23 Back Street of Art Gallery, Dongcheng District, Beijing/11 Lingjiao Lake Road, Jianghan District, Wuhan, Hubei, China","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China","10 Poyang Lake Road, Jinghai District, Tianjin, China","382 Wuyi Road, Xinghualing District, Taiyuan, Shanxi, China","85 Jiefang Road South, Yingze District, Taiyuan, Shanxi, China","49 North Huayuan Road, Haidian District, Beijing, China","169 Donghu Road, Wuhan, Hubei, China",null,null,"17 Yongwai Main Street, Nanchang, Jiangxi, China","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China",null,"1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","29 Bulan Road, Logngang District, Shenzhen, Guangdong, China","234 Gucui Road, Xihu District, Hangzhou, Zhejiang, China","Xi'an Chest Hospital, East Section of Hangtian Avenue, Chang'an District, Xi'an, Shaanxi, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China",null,"37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","99 Jiefang Road, Wuchang District, Wuhan, Hubei, China","8 Xi-Shi-Ku Street, Xicheng District, Beijing, China","37 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","890 Jin'gu Road, Jinnan District, Tianjin, China","9th Floor, Block 3, Lufthansa Center, 16 Xinyuanli Street, Chaoyang District, Beijing, China","1095 Jiefang Avenue, Wuhan, Hubei, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","53 Jidajingle Road, Zhuhai, Guangdong, China","2901 Caolang Road, Jinshan District, Shanghai, China","1 Culture Avenue, Jiangxia District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","79 Qingchun Road, Hangzhou, Zhejiang, China","5 Hai-Yun-Cang Lane, Dongcheng District, Beijing, China","363 Furong Avenue, Wenjing District, Chengdu, Sichuan, China","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","28 Fuxing Road, Haidian Distract, Beijing, China","157 West 5th Road, Xi'an, Shaanxi, China","6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region, China","151 Yanjiang Road, Yuexiu District, Guangzhou","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China","151 Yanjiang Road, Guangzhou, Guangdong, China","157 West 5th Road, Xi'an, Shaanxi, China","6 Jizhao Road, Jinnan District, Tianjin","238 Jiefang Road, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","102 Luo-Jia-Jing, Beihu District, Chenzhou, Hu'nan, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","415 Fengyang Road, Huangpu District, Shanghai, China","6 Fucheng Road, Haidian District, Beijing, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China.","1277 Jiefang Avenue, Wuhan, Hubei, China","167 Hongdu Middle Avenue, Qingshanhu District, Nanchang, Jiangxi, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","1277 Jiefang Avenue, Wuhan, Hubei, China","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China","Room 507, Xianyue Haijing Building, 195 Xianyue Road, Siming Square, Xiamen, Fujian, China","9 Kunpeng Road, Gulou District, Xuzhou, Jiangsu, China","8 Workers Stadium Road South, Chaoyang District, Beijing","650 Xinsongjiang Road, Songjiang District, Shanghai, China","194 Xuefu Road, Nangang District, Harbin, Heilongjiang, China","301 Yanchang Middle Road, Shanghai, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","35 Jiefang Avenue, Zhengxiang District, Hengyang, Hu'nan, China","180 Fenglin Road, Xuhui District, Shanghai, China","28 South Dianxin Street, Wuhou District, Chengdu, Sichuan, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","17 Lujiang Road, Luyang District, Hefei, Anhui, China","1200 Cailun Road, Pudong New District, Shanghai, China","110 Ganhe Road, Hongkou District, Shanghai, China","201-209 Hubin Road South, Siming District, Xiamen, Fujian","5 Shantiao Street, Dongdan, Dongcheng District, Beijing, China","28 Fuxing Road, Haidian District, Beijing, China","169 Donghu Road, Wuhan, Hubei, China","95 Shaoshan Middle Road, Yuhua District, Changsha, Hu'nan, China","20 Third Section, Renmin Road South, Chengdu, Sichuan, China","1277 Jiefang Avenue, Wuhan, Hubei","8 Xishiku Street, Beijing, China","32 West Second Section, First Ring Road, Chengdu, Sichuan, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1 Tongyang Road East, Luqiao District, Taizhou, Zhejiang","1277 Jiefang Avenue, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","1377 Jiao-Zhou-Wan Road West, Yinzhou Street, Huangdao District, Qingdao, Shandong, China","99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","1277 Jiefang Avenue, Wuhan, Hubei, China","180 Fenglin Road, Xuhui District, Shanghai, China",null,"4 Garden Hill, Wuchang District, Wuhan, Hubei, China",null,null,null,null,"20 Chazhong Road, Taijiang District, Fuzhou, Fujian, China","20 Chazhong Road, Fuzhou, Fujian, China",null,null,null,"9 West Section, Lushun Road South, Lushunkou District, Dalian, Liaoning, China",null,null,null,null,"Hanpu Science and Teaching Road, Yuelu District, Changsha, Hu'nan, China","4 Huayuan Hill, Wuchang District, Wuhan, Hubei, China","28 Fuxing Road, Haidian District, Beijing, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1 Siyi Road, Shihe District, Xinyang, He'nan, China","136 Jingzhou Street, Xiangcheng, Xiangyang, Hubei, China",null,"20 Chazhong Road, Taijiang District, Fuzhou, Fujian, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","4 Garden Hill, Wuchang District, Wuhan, Hubei, China",null,null,null,"157 West 5th Road, Xi'an, Shaanxi, China","1 Kangfu Road, Tangshan Street, Jiangning District, Nanjing, China","1095 Jiefang Avenue, Wuhan, Hubei, China","N1 Shangcheng Road, Yiwu, Zhejiang, China","2901 Caolang Road, Jinshan District, Shanghai, China","7 Weiwu Road, Jinshui District, Zhengzhou, He'nan, China","289 Kuocang Road, Liandu District, Lishui, Zhejiang, China","389 Xincun Road, Putuo District, Shanghai, China","118 Wenquan Road, Haidian District, Beijing, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China.","1478 Gongnong Road, Chaoyang  District, Changchun, Jilin, China","678 Furong Road, Jingkai District, Hefei, Anhui, China","136 Jingzhou Street, Xiangcheng, Xiangyang, Hubei, China","1-1 Zhongfu Road, Gulou District, Nanjingy, Jiangsu, China","228 Jingui Road, Xianning, Hubei, China","136 Jingzhou Street, Xiangcheng DIstrict, Xiangyang, Hubei, China","2901 Caolang Road, Jinshan District, Shanghai, China","23 Youzheng Street, Nangang District, Harbin, Heilongjiang, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","Room 222, Alice Lee Building, Xiangan Campus, Xiamen University, Fujian, China","415 Fengyang Road, Huangpu District, Shanghai, China","37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, China","1 Benxi Street, Fouth Jianshe Road, Qinshan District, Wuhan, Hubei, China","94 West Street, Kangding City, Ganzi Prefecture, Sichuan, China","1200 Cailun Road, Zhangjiang Hi-TechPark, Pudong New Area, Shanghai, China","1215 Guangrui Road, Wuxi, Jiangsu, China","16 Railway New Village, Jiulongpo Districts, Chongqing, China","94 West Street, Kangding City, Ganzi Prefecture, Sichuan, China","88 Changling Road, Xiqing District, Tianjin, China","12 Jiankang Road, Shi-Jia-Zhuang, Hebei, China","110 Ganhe Road, Hongkou District, Shanghai, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","4/F, School of Public Health and Primary Care","Cancelled","363 Furong Avenue, Wenjing District, Chengdu, Sichuan","116 North Street, Guixi Street, Dianjiang, Chongqing, China","218 Jixi Road, Hefei, Anhui, China","28 Fuxing Road, Haidian District, Beijing, China","49 Huayuan Road North, Haidian District, Beijing, China","49 Huayuan Road North, Haidian District, Beijing, China","71 Xinmin Street, Changchun, Jilin, China","1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, China","Chizhuling Fifth People's Hospital, Shuixi Town, Ganzhou, Jiangxi, China","165 Xincheng Road, Wanzhou District, Chongqing, China","17 Yongwai Main Street, Nanchang, Jiangxi","1095 Jiefang Avenue, Wuhan, Hubei","1095 Jiefang Avenue, Wuhan, Hubei, China","109 Baoyu Road, Shapingba District, Chongqing, China","99 Zhang-Zhi-Dong Road, Wuchang District, Wuhan, Hubei, China","1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing","74 Lingjiang Road, Yuzhong District, Chongqing, China","109 Baoyu Road, Shapingba District, Chongqing, China","136 Second Zhongshan Road, Yuzhong District, Chongqing, China",null,"165 Xincheng Road, Wanzhou, Chongqing, China","1095 Jiefang Avenue, Wuhan, Hubei.",null,null,null,null,null,"79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","225 Changhai Road, Yangpu District, Shanghai, China","Mianyang Central Hospital of Sichuan province","39 Shi-Er-Qiao Road, Chengdu, Sichuan, China",null,null,"1 Jianshe Road East, Zhengzhou, He'nan, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei",", Jinan, Shandong,Shandong,PR China","324 Jing-Wu-Wei-Qi Road, Huaiyin District, Ji'nan, Shandong, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","19 Renmin Road, Zhengzhou, He'nan, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","85 Heping Street South, Heping District, Shenyang, Liaoning, China","627 Wuluo Road, Wuchang District, Wuhan, Hubei, China","1999 Guankou Middle Road, Jimei District, Xiamen, Fujian, China","107 Huanhu Road East, Hefei, Anhui, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","238 Jiefang Road, 99 Zhangzhidong Raod, Wuchang, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","95 Shaoshan Middle Road, Yuhua District, Changsha, Hu'nan, China","101 Weimin Road, Maoming, Guangdong, China","528 Zhanghen Road, Pudong New Area District, Shanghai, China","109 Xueyuan Road West, Lucheng District, Wenzhou, Zhejiang, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","100 Cross Street, Hongshan Road, Nanjing, Jiangsu, China","1 Shuai-Fu-Yuan,  Dongdan, Dongcheng District, Beijing, China","Zhiyin Aveneu, Caidian District, Wuhan, Hubei, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","32 Renmin Road South, Shiyan, Hubei, China","42 Wenhua Road West, Lixia District, Ji'nan, Shandong, China","Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.Zhejiang, China","No.8 Xishiku Street, West city District, Peking","1 Shuai-Fu-Yuan, Dongcheng District, Beijing, China","9 West Section, Lushun Road South, Lushunkou District, Dalian, Liaoning, China","16 Jichang Road, Guangzhou, Guangdong, China","600 Yishan Road, Xuhui District, Shanghai, China","169 Donghu Road, Wuhan, Hubei, China","1 Culture Avenue, Jiangxia District, Wuhan, Hubei, China","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","138 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China","110 Ganhe Road, Hongkou District, Shanghai, China","473 Hanzheng Street, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","No.37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, 610041, P.R China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","385 North Xinshi Road, Qiaoxi District, Shijiazhuang, Hebei, China","Cherry Blossom Garden East Street, Chaoyang District, Beijing",null,"385 Xinshi Road North, Qiaoxi District, Shijiazhuang, Hebei, China",null,"39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","1095 Jiefang Avenue, Wuhan, Hubei, China","8 Xishiku Street, Xicheng District, Beijing, China",null,"47 Taqiao Road North, Shashi District, Jingzhou, Hubei, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","305 East Zhongshan Road, Nanjing, Jiangsu, China",null,null,null,"41 Xibei Street, Haisu District, Ningbo, Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","Department of Microbiology Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin , NT, Hong Kong SAR","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","98 Fenghuang Road, Huichuan District, Zunyiy, Guizhou, China","2 Anzhen Road, Chaoyang District, Beijing, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","182 Chunhui Road, Longmatan District, Luzhou, Sichuan, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","280 Mohe Road, Baoshan District, Shanghai, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","116 Zhuodaoquan Road South, Hongshan District, Wuhan, Hubei, China","279 Luoyu Road, Hongshan District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","725 Wanping Road South, Xuhui District, Shanghai, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","Universiteitsweg 100","88 Jiankang Road, Weihui, Xinxiang, He'nan, China","1095 Jiefang Avenue, Qiaokou DIstrict, Wuhan, Hubei, China","1095 Jiefang Avenue, Hankou, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","19 Renmin Road, Jinshui District, Zhengzhou, He'nan, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","59 Liuting  Street, Ningbo, Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1277 Jiefang Avenue, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","215 Heping Road West, Shijiazhuang, Hebei, China","241 Peng-Liu-Yang Road, Wuchang, Wuhan, Hubei, China","98 Fenghuang Road, Huichuan District, Zunyi, Guizhou, China",null,"1478 Gongnong Road, Changchun, Jilin, China","Wenzhou Medical University, Chashan Higher Education Park, Wenzhou, Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","13 North Qingchi Avenue, Xinhua District, Cangzhou, Hebei, China","12 Wulumuqi Road Middle, Jin'an District, Shanghai, China","6 Taoyuan Road, Nanning, Guangxi Zhuang Autonomous Region, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","311 Yingpan Road, Kaifu District, Changsha, Hu'nan, China","3 Yunxing Road, Fancheng District, Xiangyang, Hubei, China","1120 Lianhua Road, Futian District, Shenzhen, Guangdong, China","1333 Xinhu Road, Bao'an District, Shenzhen, Guangdong, China","1 Xiyuan Playground, Haidian District, Beijing, China","32 Feishan Street, Guiyang, Guizhou, China","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1229 Gudun Road, Xihu District, Hangzhou, Zhejiang, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1742 Huolinhe Street, Keerqin District, Tongliao, Inner Mongolia Autonomous Region, China","169 Donghu Road, Wuhan, Hubei, China","98 Fenghuang Road, Huichuan District, Zunyiy, Guizhou, China","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China","12 Lieshishan Road East, Licheng District, Jinan, Shandong, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","1095 Jiefang Road, Wuhan, Hubei, China","13 Hangkong Road, Qiaokou District, Wuhan, Hubei, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","57 South Renmin Road, Zhanjiang, Guangdong, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","1111 Xianxia Road, Changning District, Shangha","94 West Street, Kangding, Ganzi Prefecture, Sichuan, China","149 Dalian Road, Zunyi, Guizhou, China","215 Zhongshan Avenue, Qiaokou District, Wuhan, Hubei, China","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","Room 711, Building 4, 41 Xibei Street, Haishu Distruct, Ningbo, Zhejiang, China","216 Guanshan Avenue, Hongshan District, Wuhan, Hubei, China","101 Weimin Road, Maoming, Guangdong, China","1095 Jiefang Avenue, Wuhan, Hubei, China","801 Heqing Road, Shanghai, China","100 Hongkong Road, Jiang'an District, Wuhan, Hubei, China","4 Garden Hill, Wuchang District, Wuhan, Hubei, China","225 Changhai Road, Yangpu District, Shanghai, China","NO.85 Wujin Road, Hongkou District, Shanghai, China","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China","415 Fengyang Road, Huangpu District, Shanghai, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","439 Xuanhua Road, Yongchuan District, Chongqing, China","8 Hangkong Road, Shashi District, Jingzhou, Hubei, China","1630 Dongfang Road, Pudong District, Shanghai, China","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","8 Fuyu Road East, Qiaonan Street, Panyu District ,Guangzhou, Guangdong, China","167 Fangdong Street, Baqiao District, Xi'an, Shaanxi, China","26 Yuancun Erheng Road, Tianhe District, Guangzhou, Guangdong, China","67 Dongchang Road West, Liaocheng, Shandong, China","11 Xizhimen Street South, Xicheng District, Beijing, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","33 Zhongyuan Road, Buji Town, Longgang District, Shenzhen, Guangdong, China","8 East Fuyu Road, South Bridge Street, Panyu District, Guangzhou, Guangdong, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","157 Xiwu Road, Xi'an, Shaanxi, China","287 Changhuai Road, Longzihu District, Bengbu, Anhui, China","16 Jichang Road, Baiyun District, Guangzhou, Guangdong, China","12 East Lieshishan Road, Licheng District, Ji'nan, Shandong, China","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","8 Hangkong Road, Shashi District, Jingzhou, Hubei, China","627 Dongfeng Road East, Guangzhou, Guangdong, China","100 Cross Street, Hongshan Road, Nanjing, Jiangsu, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","100 Haining Road, Hongkou District, Shanghai, China","856 Luoyu Road, Hongshan District, Wuhan, Hubei, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","60 Jingjing Road, Jingzhou District, Jingzhou, Hubei, China","60 Jingjing Road, Jingzhou District, Jingzhou, Hubei, China","22 Second Shuguang Road, Qingcheng District, Qingyuan, Guangdong, China","1095 Jiefang Avenue, Wuhan, Hubei, China","2 Yinghua Street East, Chaoyang District, Beijing, China","59 Liuting Street, Haishu, Ningbo, Zhejiang, China","49 North Garden Road, Haidian District, Beijing, China","100 Hongkong Road, Jiang'an District, Wuhan, Hubei, China","1 Xiyuan Playground, Haidian District, Beijing, China","1 Xiyuan Playground, Haidian District, Beijing, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","23 Youzheng Street, Harbin, Heilongjiang, China","300 Taizihu north Road, Wuhan Economic and Technological Development Zone, Wuhan, Hubei, China",null,"1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China",null,"725 Wanping Road South, Xuhui District, Shanghai, China","Room 319, life medicine venture building, Limin biomedical R &amp; D center, East Shenyang Street and South Zhuhai Road, Harbin, Heilongjiang, China","1 Wenhua Avenue, Jiangxia District, Wuhan, Hubei, China","157 Xiwu Road, Xi'an, Shaanxi, China","149 Dalian Road, Huichuan District, Zunyi, Guizhou, China","1 Fourth Nanyun Road, Hi-Tech District, Guangzhou, Guangdong, China","85 Kefeng Road, Hi-Tech Development District, Guangzhou, Guangdong, China","1277 Jiefang Avenue, Wuhan, Hubei, China",null,"6 Taoyuan Road, Qingxiu District, Nanning, Guangxi Zhuang Autonomous Region, China",null,"33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","58 Shenlong Avenue, Wuhan, Hubei, China","138 Tong-Zi-Po Road, Yuelu District, Changsha, Hu'nan, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","15 Jiefang Road, Fancheng District, Xiangyang, Hubei, China","415 Fengyang Road, Huangpu District, Shanghai, China","19 Xin-Jie-Kou-Wai Street, Haidian District, Beijing, China","Zhuangyu Road South, Zhenhai District, Ningbo, China","1 Xiyuan Playground, Haidian District, Beijing","283 Tongzipo Road, Yuelu District, Changsha, Hu'nan, China","41 Xibei Street, Ningbo, Zhejiang, China","61 West Jiefang Road, Changsha, Hu'nan, China","28 Fuxing Road, Haidian District, Beijing, China","8 Worker Stadium Road South, Chaoyang District, Beijing, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","29 Bulan Road, Longgang District, Shenzhen, Guangdong, China","415 Fengyang Road, Huangpu District, Shanghai, China",null,null,null,"41 Xibei Street, Haishu Distruct, Ningbo, Zhejiang, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","352 Renmin Road, Yingjiang District, Anqing, Anhui, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","1 Yintan Road, Dongxihu District, Wuhan, Hubei, China","627 Dongfeng Road, Yuexiu District, Guangzhou, Guangdong, China","81 Lingnan Avenue North, Foshan, Guangdong, China","172 Jiangsu Road, Gulou District, Nanjing District, Jiangsu, China","324 Jing-Wu-Wei-Qi Road, Huaiyin District, Ji'nan, Shandong, China","52 Meihua Road, Xiangzhou District, Zhuhai, Guangdong, China","41 Erling Road, Huizhou, Guangdong, China","139 Renmin Middle Road, Furong District, Changsha, Hu'nan, China","241 Pengliuyang Road, Wuchang District, Wuhan, Hubei, China","8 Worker Stadium Road South, Chaoyang District, Beijing, China","8 Huaying Road, Baiyun District, Guangzhou, Guangdong, China","169 Donghu Road, Wuchang District, Wuhan, Hubei, China","32 Feishan Street, Guiyang, Guizhou, China","627 Wuluo Road, Wuchang District, Wuhan, Hubei, China","238 Jiefang Road/99 Zhangzhidong Raod, Wuchang, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","99 Zhang-Zhi-Dong Road, Wuchang District, Wuhan, Hubei, China","41 Xibei Street, Ningbo, Zhejiang, China","1277 Jiefang Avenue, Wuhan, Hubei, China","100 Shizhi Street, Hongshan Road, Nanjing, Jiangsu, China","1 Minde Road, Donghu District, Nanchang, Jiangxi, China","480 Shuangyang Road, Yangpu District, Shanghai, China","20 South Renmin Road, Chengdu, Sichuan, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China","139 Renmin Road, Furong District, Changsha, Hu'nan, China","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China","8 Huaying Road, Baiyun District, Guangzhou, Guangdong, China","17 Yongwai Main Street, Donghu District, Nanchang, Jiangxi, China","197 Second Ruijin Road, Huangpu District, Shanghai, China","19-21 Boulevard Jean Moulin","Liebigstrasse 20","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","No 847, Behesht St. South Side of Shahr Park, Vahdat-e-Islami St., Hasan Abad Sq., Tehran, Iran","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","Bahonar","Dr. Masih Daneshvari Hospital, Daar-Abad, Niavaran","Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","Shariati Hospital, Kargar Street, Tehran",null,"Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran","3-39-15 Showa-mchi, Maebashi-shi,Gunma","46 rue Henri Huchard Paris 75018",null,"3-39-15 Showa-mchi, Maebashi-shi, Gunma","1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi 470-1192, Japan",null,null,null,null,null,null,"Takebayashi 911-1, Utsunomiya-shi, Tochigi",null,null,null,null,null,"1-21-1, Toyama, Shinjuku-ku, Japan","46 rue Henri Huchard Paris 75018",null,null,null,null,null,null,null,null,null,null,null,null,"28 Fuxing Road, Beijing, China",null,null,null,"1277 Jiefang Avenue, Jianghan District, Wuhan, Hubei, China",null,"745 Wuluo Road, Hongshan District, Wuhan, Hubei, China",null,null,null,null,"5 Yan-Er-Dao Road, Qingdao, Shandong, China","466 Xingang Middle Road, Guangzhou, Guangdong, China","150 Ximen Street, Linhai, Zhejiang, China","238 Jiefang Road, Wuchang District, Wuhan, Hubei, China","1277 Jiefang Avenue, Wuhan, Hubei, China","321 Zhongshan Road, Gulou District, Nanjing, Jiangsu, China","314 West Anshan Road, Nankai District, Tianjin, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China",null,"5 Yan-Er-Dao Road, Shi'nan District, Qingdao, Shandong, China","699 Hongfeng Road, Pudong New District, Shanghai, China","1 Yi-Xue-Yuan Road, Yuzhong District, Chongqing, China","600 Tianhe Road, Tianhe District, Guangzhou, Guangdong, China","99 Zhangzhidong Road, Wuhan, Hubei, China","126 Xiantai Street, Erdao District, Changchun, Jilin, China","28 Dianxin Road South, Wuhou District, Chengdu, Sichuan, China","183 Yiling Road, Yichang, Hubei, China","1095 Jiefang Avenue, Wuhan, Hubei, China","1 Yi-Xue-Yuan Road, Yuzhong District, Chongqing, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","8 Xi-Tou-Tiao Lane West, You'anmen Street, Fengtai District, Beijing, China","241 Peng-Liu-Yang Road, Wuchang District, Wuhan, Hubei, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","33 Huanghe Road, Jinshui District, Zhengzhou, He'nan, China","238 Jiefang Road / 99 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China","725 Wanping Road South, Xuhui District, Shanghai, China","349 Hangzhou Road, Yangpu District, Shanghai, China","98 Nantong Road West, Guangling District, Yangzhou, Jiangsu, China","39 Shi-Er-Qiao Road, Chengdu, Sichuan, China","88 Changling Road, Xiqing District, Tianjin, China","39 Shi-er-qiao Road, Chengdu, Sichua, China","Plus 2 Weiyang Road West, Xianyang, Shaanxi, China","151 Yanjiang Road West, Yuexiu District, Guangzhou, Guangdong, China","100 Shizi Street, Hongshan Road, Qixia District, Nanjing, Jiangsu, China","100 West 4th Ring Middle Road, Fengtai District, Beijing, China","111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China","1277 Jiefang Avenue, Wuhan, Hubei, China","1277 Jiefang Avenue, Wuhan, Hubei, China","17 Lujiang Road, Luyang District, Hefei, Anhui, China","16 Nanxiao Street, Dongzhimennei, Dongcheng District, Beijing, China","10 Changjiang Branch Road, Yuzhong District, Chongqing, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China","Herestraat 49","1200 Cailun Road, Pudong New District, Shanghai, China","1 avenue Pierre Brossolette","Heidelberglaan 100","Wilhelmstr. 27","Sognsvannsveien 20","Mailpoint 810, Level F, Southampton General Hospital, Tremona Road",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"627 Dongfeng Road East, Yuexiu District, Guangzhou, Guangdong, China",null,null,null,null,"238 Jiefang Road/99 Zhangzhidong Raod, Wuchang, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China",null,null,null,null,"1088 Yinghe Road West, Yinzhou District, Fuyang, Anhui, China","1 Shuai-Fu-Yuan,  Dongdan, Dongcheng District, Beijing, China",null,null,"100 Hong Kong Road, Jiang'an District, Wuhan, Hubei, China","149 Dalian Road, Huichuan District, Zunyi, Guizhou, China","500 Quxi Road, Huangpu District, Shanghai, China",null,null,null,null,"1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","150 Jimo Road, Pudong New Area, Shanghai","12 Guangchang Road, Huangshigang District, Huangshi, Hubei, China","1 Wenhua Avenue, Jiangxia District, Wuhan, Hubei, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","25 Taiping Street, Jiangyang District, Chuzhou, Sichuan, China","52 Meihua Road East, Xiangzhou District, Zhuhai, Guangdong, China","1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China",null,null,null,"1095 Jiefang Avenue, Qiaokou District, Wuhan, Hubei, China","1 Wenhua Avenue, Jiangxia District, Wuhan, Hubei, China","87 Xiangya Road, Kaifu District, Changsha, Hu'nan, China","8 rue de la Croix Jarry","51 Huayuan Road North, Haidian District, Beijing","600 Yishan Road, Xuhui District, Shanghai, China","300 Taizi Lake Road North, Economic and Technological Development Zone, Wuhan, Hubei, China","49 North Huayuan Road, Haidian District, Beijing, China","305 Zhongshandong road, Xuanwu district, Nanjing, Jiangsu, China.","8 Cao-Lan-Zi hutong, Xi-Shi-Ku Street, Xicheng District, Beijing, China","163 Xianling Avenue, Qixia District, Nanjing, Jiangsu, China","100 West Fourth Ring Road Middle, Fengtai District, Beijing, China","C. Heymanslaan 10","14th Km National Road 1","De Boelelaan 1117","Sykehusveien 25","Martinistrasse 64","Grenzacherstrasse 124",null,null,null,null,"4 rue Larrey","URCIP - Batiment Recherche - Hpital Nord",null,null,null,null,null,null,null,null,null,null,null,"Nordre Fasanvej 57, vej 8, Indg 19",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"18 Daoshan Road, Gulou District, Fuzhou, Fujian, China","600 Yishan Road, Xuhui District, Shanghai, China",null,null,null,null,null,null,null,null,"300 Guangzhou Road, Nanjing, Jiangsu, China","473 Hanzheng Street, Qiaokou District, Wuhan, Hubei, China",null,null,null,null,null,null,null,null,"1/F Lui Che Woo Clinical Science Building, Prince of Wales Hospital, N.T. Hong Kong","149 Jimo Road, Pudong New District, Shanghai, China",null,null,null,null,null,null,null,"11 Beisanhuan Road East, Chaoyang District, Beijing, China","Floor 10, Building 10, Biomedical Innovation Industrial Park, 14 Jinhui Road, Kengzi street, Pingshan District, Shenzhen, Guangdong, China",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"C. Heymanslaan 10",null,null,null,null,null,null,null,null,null,null,"88 Michalakopoulou Street",null,"\n                    CTSU, Nuffield Department of Population Health\n                    University of Oxford\n                    Richard Doll Building\n                    Old Road Campus\n",null,null,null,null,null,null,null,null,null,null,"\n                    Clinical Trials Unit\n                    Warwick Medical School\n                    University of Warwick\n",null,null,null,null,null,"48 Xinxi Road, Haidian District, Beijing, China","300 Guangzhou Road, Nanjing, Jiangsu, China","11 Kaopeng Street, Huangzhou District, Huanggang, Hubei, China","Suit 29, Unit 1, 2nd Building, Donghu Guoji, Wuchang, Wuhan, Hubei, China","198 Hongqi Road, Wuxing District, Huzhou, Zhejiang, China","1 Xueshi Road, Shangcheng District, Hangzhou, Zhejiang, China",null,null,null,null,"Zhiyinhu Avenue, Caidian District, Wuhan, Hubei, China","600 Yishan Road, Xuhui District, Shanghai, China","1277 Jiefang Road, Jianghan District, Wuhan, Hubei, China",null,null,null,null,null,"37 Guoxue Lane, Wuhou District, Chengdu, Sichuan","17 Lujiang Road, Luyang District, Hefei, Anhui, China",null,null,null,null,null,null,null,"DRCI Hpital St Louis, 1 av. Claude Vellefaux",null,null,null,"Helmholtzstr. 10","12 rue dubernat","133 Avenue de la rsistance",null,"\n                    Northumbria Sleep Research Laboratory\n                    Northumbria University\n","profesor martin lagos s/n","LUIS FONTES PAGAN 9","\n                    Epidemiology, Biostatistics and Prevention Institute (EBPI)\n                    University of Zurich\n                    Hirschengraben 84\n","\n                    Nuffield Department of Primary Care Health Sciences, University of Oxford\n                    Radcliffe Observatory Quarter, Woodstock Road\n                ;\n                    Nuffield Department of Primary Care Health Sciences, University of Oxford\n                    Radcliffe Observatory Quarter, Woodstock Road\n","Calle Castilla 135 2C","Plaza de Cruces N12 Edificio 1 Planta 0","29 rue Manin","Camino de la Almazara 11","8 Hangkong Road, Shashi District, Jingzhou, Hubei, China","139 Renmin Middle Road, Furong District, Changsha, Hu'nan, China","Calle Rossell 132 42","172 Jiangsu Road, Gulou District, Nanjing District, Jiangsu, China","324 Jing-Wu-Wei-Qi Road, Ji'nan, Shandong, China","28 Fuxing Road, Haidian District, Beijing, China","Kang-Le-Fang-Kou, Jiangbin Road West, Lucheng District, Wenzhou, Zhejiang, China",null,null,null,null,"DRCI, 1 avenue Claude Vellefaux","Winzerlaer Strasse 2","URCIP - Batiment Recherche - Hpital Nord","28 rue Laennec","1, Avenues Claude Vellefaux","Feixa Llarga","Sant Quint 77-79","P Castellana 127-1D","410 Thames Valley Park Drive","Carretera de Colmenar Viejo Km 9,100"],["doctoryanzhao@whu.edu.cn","caiting@ucas.ac.cn","pinhuapan668@126.com","doctoryanzhao@whu.edu.cn","xxw69@126.com","zhaixiaowendy@163.com","tcmdoctorlu@163.com","Wangtan215@sina.com","164972769@qq.com","pony8980@163.com","lipipi007@163.com;","panda.how@sdu.edu.cn","eier_dai@163.com;eier_dai@163.com","sxu@hust.edu.cn","88071718@qq.com","li_js8@163.com","xiangming_fang@njmu.edu.cn","zhangw1190@sina.com","fangbji@163.com","dinghuiguo@medmail.com.cn","fangbji@163.com","zjwzhxy@126.com",";wrl7905@163.com;wrl7905@163.com",null,"litsh@263.net",";xxw69@126.com","jiayongshi@medmail.com.cn","songlab_radiology@163.com","tcmdoctorlu@163.com","caiting@ucas.ac.cn","wanghuaqi2004@126.com","ian0126@126.com","1037070596@qq.com","doctoryanzhao@whu.edu.cn","jxxk1035@yeah.net","bluesearh006@sina.com","zhanjie34@126.com","luhongzhou@fudan.edu.cn","31531955@qq.com","xiajinyu@mail.sysu.edu.cn","caojuncn@hotmail.com","wuguolin28@163.com","3131862959@qq.com","wlx1126@hotmail.com","13588867114@163.com","Luhongzhou@shphc.org.cn","zysjsgzs@163.com","xxlahh08@163.com","doctorzzd99@163.com","hubo@mail.hust.edu.cn","503818505@qq.com","caocdoctor@163.com","huangluqi01@126.com","Kangyan@scu.edu.cn","252417083@qq.com","xyxzyxzh@163.com","Liuqingquan2003@126.com","wengcp@163.com","973007530@qq.com","yingsrrsh@163.com","shanpingjiang@126.com","zhaojp@tjh.tjmu.edu.cn","wengcp@163.com","wengcp@163.com","1346801465@qq.com","lvdq@enzemed.com","doctorzhang2003@163.com","13505615645@163.com","1025823309@qq.com","jxzhang1607@163.com","wdznyy@126.com","leilei_25@126.com","li_js8@163.com","ZJHTCM@FOXMAIL.COM","yang_zhongqi@163.com","zhaodewei2016@163.com","maoweilw@163.com","xie_m@126.com","zheng862080@139.com","guojun@wchscu.cn","lisuyun2000@126.com","shanghongcai@126.com","wenshl@mail.sysu.edu.cn","doctorzzd99@163.com","qiuchengfeng0721@163.com","jmqu0906@163.com","caiicu@163.com","Xiaolintong66@sina.com","shanhong@mail.sysu.edu.cn","ljli@zju.edu.cn","xuezg@tongji.edu.cn","zhaoyl2855@126.com","yingxialiu@hotmail.com","xyxzyxzh@163.com","dwwang@tjh.tjmu.edu.cn","qiuyq@zju.edu.cn","doctorzhang2003@163.com","qiuyq@zju.edu.cn","xcg718@aliyun.com","qiuyq@zju.edu.cn","wangxinghuan@whu.edu.cn","784404524@qq.com","64699629@qq.com","zhangweiliuxin@163.com","cdjianghua@qq.com","DOCXWG@16.COM","docxwg@163.com","chanjuanzheng@163.com","docxwg@163.com","ZJHTCM@FOXMAIL.COM","whsdyyykjc@126.com","ZJHTCM@FOXMAIL.COM","tflook@163.com","xuyongsmu@vip.163.com","mapenglin1@163.com","chzs1990@163.com",";xavier.duval@aphp.fr;xavier.duval@aphp.fr",null,"leaiping@126.com","huangluqi01@126.com","dubin98@gmail.com","you_shang@126.com","yingxialiu@hotmail.com","ckqmzygzs@163.com","huang-yi-1980@163.com","ylsong70@163.com",";znyylcsy@126.com;","doctorwhy@126.com","chenqx666@whu.edu.cn","zhaohong_pufh@bjmu.edu.cn","1924238034@qq.com","ykb@tju.edu.cn","luhongzhou@shphc.org.cn","lingqing1985@163.com","xiemx@hust.edu.cn","13600001163@139.com","luhongzhou@shphc.org.cn","liubende99@outlook.com","xugang@tjh.tjmu.edu.cn","stjz@zju.edu.cn","ysz3129@163.com","luyibingli@163.com","hukejx@163.com","boj301@sina.com","shpingg@126.com","2534776680@qq.com","linling@gird.cn","wqp1968@163.com","412475734@qq.com","shpingg@126.com","Tongxg@yahoo.com","qingzhou.wh.edu@hotmail.com","sxwang@tjh.tjmu.edu.cn","quxiaowang@163.com","1813886398@qq.com","xuhuji@smmu.edu.cn","lianru666@163.com","liujing25@mail.sysu.edu.cn","xiangdongchen2013@163.com","Chenhongyi8660@163.com","tangjianyuan163@163.com","xiemx@hust.edu.cn","xiangdongchen2013@163.com","Yinzy@xmu.edu.cn","yxbxuzhou@126.com","13910930309@163.com","jhong.pku@163.com","yangbf@ems.hrbmu.edu.cn","18917683122@189.cn","minzhou@tjh.tjmu.edu.cn","706885399@qq.com","bai.chunxue@zs-hospital.sh.cn","xuntao26@hotmail.com","tangjianyuan163@163.com","44271370@qq.com","fanglei586@126.com","fangmin19650510@163.com","Yinzy@xmu.edu.cn","zhaochunhua@vip.163.com","fengcao8828@163.com","doctoryanzhao@whu.edu.cn","chenxinyuchen@163.com","tj1234753@sina.com","Xin11@hotmail.com","zhuoli.zhang@126.com","8999578@qq.com","chenhong1129@hotmail.com","lvdq@enzemed.com","am-penicillin@163.com","sxwang@tjh.tjmu.edu.cn","dl5506@126.com","doctorzhang2003@163.com","Xin11@hotmail.com","jbge@zs-hospital.sh.cn","caobin@zryhyy.com.cn;","153267742@qq.com",null,";fengxiaobin200708@aliyun.com;",";xiajinglin@fudan.edu.cn",";xiajinglin@fudan.edu.cn","nijun1000@126.com","nijun1000@126.com",";;;xubaopingbch@163.com;","whuhjy@sina.com",";bai.chunxue@zs-hospital.sh.cn;","shangdongdalian@163.com","caobin@zryhyy.com.cn","liangjq@fmmu.edu.cn;","lunliweiyuanhui2009@126.com","chenghailiu@hotmail.com;","xrchang1956@163.com","2209447940@qq.com","hekl301@aliyun.com","haoyaner@163.com","luyb6810@163.com","55815147@qq.com","fuying1995@163.com;wanjinchen75@fjmu.edu.cn","nplrj@126.com","1813886398@qq.com","ljzwd@163.com",";xwx1983@163.com;pzp33@hotmail.com",";xwx1983@163.com;pzp33@hotmail.com","wulingzhu@xxmu.edu.cn;guomh@163.com","maxr0910@163.com","ian0126@126.com","huillanz_76@163.com","li_caixia@zju.edu.cn","xujianqing@shphc.org.cn","guyuesunny@163.com","scx1818@126.com","zzq1419@126.com","lvjihui@139.com","hubingnj@163.com","Wangtan215@sina.com","zzh1974cn@163.com","55815147@qq.com","hcm200702@163.com","2066255602@qq.com","55815147@qq.com","dr_lif08@126.com","drkaijiang@163.com","wangjing9279@163.com","jieminzhu@xmu.edu.cn","docd1@sina.com","hydyangwei@tom.com","1078404424@qq.com","27216302@qq.com","yyliuhua@126.com","chump1981@163.com","406302524@qq.com","27216302@qq.com","yingfei1981@163.com","syicu@vip.sina.com","pdzhoujia@163.com","freebee99@163.com","Pengzy5@hotmail.com","zhangdxdaisy@cuhk.edu.hk","wdxjy@whu.edu","luyibingli@163.com","1041863309@qq.com","ahmusld@163.com","fengcao8828@163.com","shenning1972@126.com","shenning1972@126.com","shuchenghua@126.com","wenxiang_huang@163.com","2590410004@qq.com","xiaokh1@163.com","zhangweiliuxin@163.com","ld_2069@163.com","ld_2069@163.com","yaokaichen@hotmail.com","yogaqq116@whu.edu.cn","wenxiang_huang@163.com","hp_cq@163.com","yaokaichen@hotmail.com","maohwei@qq.com",";dinghuiguo@medmail.com.cn","wangjinlong2007666@163.com","shushengli16@sina.com",";ivanfn@gmail.com;ivanfn@gmail.com",";xiaotian-sun@hotmail.com;13911798288@163.com","huilanz_76@163.com;","shilei302@126.com;shilei302@126.com",";jmqu0906@163.com","luxiaoyang@zju.edu.cn","zhanghuafen@zju.edu.cn","hywangk@vip.sina.com","1121733818@qq.com","1035788783@qq.com",null,";heyi@tasly.com","zlgj-001@126.com","zuoyunxiahxa@qq.com","hmei@hust.edu.cn","docjiangshujuan@163.com","15168888626@163.com","xxw69@126.com","38797527@qq.com","haoyaner@163.com","Fangmh@tjh.tjmu.edu.cn","shushengli16@sina.com","sylykjk@163.com","cxfn817@163.com","417433835@qq.com","drliuhu@gmail.com","binwuying@126.com","wenqin-1987@163.com","huilanz_76@163.com","shushengli16@sina.com","chenxinyuchen@163.com","gghicu@163.com","Xiumingsong@sina.com","13968888872@163.com","Kangyan@scu.edu.cn","fangzjnj@hotmail.com","lixmpumch@126.com","wanghaohh@vip.126.com","chzs1990@163.com","s_1862777@163.com","182190248@qq.com","zhagnweijinan@126.com","akidney_doctor@hotmail.com","drhuoyong@163.com","lixmpumch@126.com","411484335@qq.com","wucaineng861010@163.com","zhoujian@sjtu.edu.cn","zhangzz@whu.edu.cn","liubende99@outlook.com","pangi88@126.com","gchxyy@163.com","18930568129@163.com","caiy_kf@163.com","zhougene@medmail.com.cn","yefeng@gird.cn","lunxu_liu@aliyun.com","xcg718@aliyun.com","xcg718@aliyun.com","zhougene@medmail.com.cn","jiactm@163.com","caobin_ben@163.com",";luhongzhou@fudan.edu.cn;","jiactm@163.com",null,"tangjianyuan163@163.com","13803818341@163.com","majingzhi2002@163.com","john131212@126.com","Zhaojp88@126.com","49637569@qq.com","WH9400@163.com","cjr.luguangming@vip.163.com",null,";loebm@mcmaster.ca",null,"yehonghua@medmail.com.cn","13971587381@163.com","lishiyue@188.com","chris.kclai@cuhk.edu.hk","ljli@zju.edu.cn","zywenjianli@163.com","frank782008@aliyun.com","luoqunx@163.com","lykyk3160823@126.com","aloof3737@126.com","dr.xu@aliyun.com","xpluo@tjh.tjmu.edu.cn","tiejunwanghp@163.com","spine672@163.com","sxu@hust.edu.cn","xuhaibo1120@hotmail.com","fangbji@163.com","Lmxia@tjh.tjmu.edu.cn","haoyibin0506@126.com","1813886398@qq.com","w.w.puijk-2@umcutrecht.nl","douqifeng@126.com","haoyaner@163.com","qning@vip.sina.com","whtuye@163.com","hcwy100@163.com","maozhengrong1971@163.com","bianyi2526@163.com","eyedrwjm@163.com","tjhdongll@163.com","guoqing.qian@foxmail.com","zhwang_hust@hotmail.com","wang6@tjh.tjmu.edu.cn","314440820@qq.com","ld_2069@163.com","273225540@qq.com","yuanyd1108@163.com","541163409@qq.com","kiphoonwu@126.com",null,"Wangtan215@sina.com","wzwsjcjg@126.com","1097685807@qq.com","849614995@qq.com","money_0921@163.com","zhangguogx@hotmail.com","zn_chenxiong@126.com","1286779459@qq.com","274770142@qq.com","zyzy1933@163.com","zhengqingyou@163.com","970236538@qq.com","ant000999@126.com","707986890@qq.com","Shushengli16@sina.com","hongwang71@yahoo.com","ctzhang0425@163.com","nmbrbt8989@163.com","doctoryanzhao@whu.edu.cn","zywenjianli@163.com","liufb163@163.com","xkyylfl@163.com","xkyylfl@163.com","hygao@tjh.tjmu.edu.cn","xkyylfl@163.com","fangmh@tjh.tjmu.edu.cn","lhgyx@hotmail.com","xkyylfl@163.com","zhonghui39@126.com","xkyylfl@163.com","huanqinhan@126.com","nathancx@hust.edu.cn","SP2082@shtrhospital.com","27216302@qq.com","haitao3140@sina.com","784404524@qq.com","pinhuapan668@126.com","yuanyang70@hotmail.com","jingfengzhang73@163.com","137585260@qq.com","hulinhui@live.cn","wt7636@126.com","xuyingjia@5thhospital.com","b5477@163.com","153267742@qq.com","hywangk@vip.sina.com","maggie_zhangmin@163.com","41180423@qq.com","whxhzy@163.com","linzhaofen@sina.com","xkyylfl@163.com","164738059@qq.com","99xw@sina.com","qinwang_1975@126.com","zhanlianh@163.com","docterwei@sina.com","13816012151@163.com","chenlei0nan@163.com","ly29.love@163.com","fxzhu72@163.com","ht2000@vip.sina.com","524712958@qq.com","zhb-ck@163.com","wwei@chinacord.org","gaomedic@163.com","sir_shi@126.com","sakeonel@126.com","xkyylfl@163.com","lixiaodong555@126.com","99xw@sina.com","gz8hcwp@126.com","nhb_2002@126.com","zqling68@hotmail.com","16683890@qq.com","lixiaodong555@126.com","164972769@qq.com","164972769@qq.com","hbjzyyywlc@163.com","hbjzyyywlc@163.com","surewin001@126.com","majingzhi2002@163.com","caobin_ben@163.com","lorenzo_87@163.com","caobaoshan0711@aliyun.com","liuzsc@126.com","miaoqing55@sina.com","miaoqing55@sina.com","lmzmay@163.com","drkaijiang@163.com","hkq123123@163.com",";pengzy5@hotmail.com;","xin11@hotmail.com","shkimmd@amc.seoul.kr","ljjia@shutcm.edu.cn","18604501911@163.com","liubende99@outlook.com","gaomedic@163.com","188116999@qq.com","164972769@qq.com","164972769@qq.com","whuhjy@sina.com",";xiaoyangzh@hotmail.com","yezi5729@163.com",";promo_interne_drci@chu-clermontferrand.fr;","278353780@qq.com","chenhhust@126.com","mengjie@csu.edu.cn","pangpf@mail.sysu.edu.cn","xyxzyxzx@163.com","fanli0930@163.com","kittychen36@gmail.com","yuhaihang0414@sina.com","xyyylijing@sina.com","315977705@qq.com","rengbinji@163.com","chenyinyin1212@hunnu.edu.cn","sunok301@126.com","tongzhaohuicy@sina.com","chunli@gird.cn","13603035264@139.com","tanghao_0921@126.com",null,";c@szgimi.org;c@szgimi.org",null,"linjie1992@zju.edu.cn","fengzhenly@sina.com","13966906638@139.com","chenjn@mail.sysu.edu.cn","liudr@outlook.com","1813886398@qq.com","13533550083@163.com","FSYYN001@126.com","iszfc@sina.com","docjiangshujuan@163.com","tianlin@mail.sysu.edu.cn","393406816@qq.com","qianlu5860@gmail.com","wanbr2000@sina.com","tongzhaohuicy@sina.com","gz8hlc@126.com","wangxinghuan@whu.edu.cn","ant000999@126.com","bxlee@sohu.com","wenqin-1987@163.com","wwang@vip.126.com","zbhong6288@163.com","caiting@ucas.ac.cn","chengyunliu@hust.edu.cn","cleverwdw@126.com","511201663@qq.com","395956184@qq.com","gykpanda@163.com","13926946929@163.com","ljli@zju.edu.cn","gongguozhong@csu.edu.cn","zln7095@163.com","gz8hzf@126.com","zhangweiliuxin@163.com","shi_guochao2010@qq.com","line.meddeb@ap-hm.fr","anaesthesie@medizin.uni-leipzig.de","khalilih@tums.ac.ir","jamshidi.ah@iums.ac.ir","khalilih@tums.ac.ir","en.aali@gmail.com","f_dastan@sbmu.ac.ir","khalilih@tums.ac.ir","h.poustchi@gmail.com","qning@vip.sina.com;qning@vip.sina.com","khalilih@tums.ac.ir","nakamurt@gunma-u.ac.jp","enrique.casalino@aphp.fr",null,"nakamurt@gunma-u.ac.jp","mkond@fujita-hu.ac.jp",null,"whunjy@126.com;whuhjy@126.com",null,"qning@vip.sina.com;qning@vip.sina.com","qning@vip.sina.com;qning@vip.sina.com","qning@vip.sina.com;qning@vip.sina.com","keiliu0406@gmail.com",";c@szgimi.org;c@szgimi.org",null,";;",null,"363994906@qq.com;houy@famousmed.net","registry.covid@hosp.ncgm.go.jp","enrique.casalino@aphp.fr","chenlin_tj@126.com",null,";jeanliu@yale-nus.edu.sg;jeanliu@yale-nus.edu.sg",";;;;franlj1104@aliyun.com",null,"qning@vip.sina.com;qning@vip.sina.com",";yuyikai@163.com;",null,";nguyen.lee@icloud.com;",null,null,"adeebalzoubi@stemcellsarabia.net;adeebalzoubi@stemcellsarabia.net","455957898@qq.com",";13781919609@163.com;sykyxmbgs@163.com",";;;;;;;;lfjcamacho@comunidad.unam.mx",";dicastel@ngi.it;","fwl@hust.edu.cn",";robert.frithiof@surgsci.uu.se;robert.frithiof@surgsci.uu.se","sunnyabs1215@163.com","zhangwenhong@fudan.edu.cn;zhangwenhong@fudan.edu.cn",";562122649@qq.com;xyyyllwyh@126.com","gabriele.saccone@unina.it",";;;;;;;cmhcar@hotmail.com","lilibestever@126.com","litian-wang@163.com","chenhx@enzemed.com","20215851@qq.com","fyang@vip.163.com","824647903@qq.com","doctor.wuyh@gmail.com","tjqiuhong@163.com",";antonio.gaddi@ehealth.study;maurizio.cipolla@ehealth.study","lilibestever@126.com","zhengxue.academic@gmail.com","qshi@cqmu.edu.cn","chenzhuanggui@126.com","wanzimili@sina.com","sidaoyuan1984@sina.com","wchmhcmxd@163.com","13972046539@163.com","haoyaner@163.com","tangxiaoj0726@qq.com","wwang@vip.126.com","jin_eagle@sina.com","pluo@whu.edu.cn","fuliran@126.com","nicole8611@163.com","mengqt2013@hotmail.com","icuwei@163.com","2235658154@qq.com","sjun1982@163.com","gaopy930@126.com","sunhongyuan12@163.com","gaopy930@126.com","leigenping2006@163.com","lishiyue@188.com","huxingxing82@163.com","xuzhe302@139.com","doctorzzd99@163.com","xiemx@hust.edu.cn","whuhjy@sina.com","ahslyywm@163.com","huangluqi01@126.com","cgq1963@163.com","hxkfhcq@126.com","kangyan_hx@163.com","laurens.liesenborghs@uzleuven.be","shanclhappy@163.com","Public-Registry-MA-France@sanofi.com","M.J.M.Bonten@umcutrecht.nl","diane.egger-adam@uni-tuebingen.de","andreas.barrattdue@gmail.com","jody.brookes@synairgen.com",";clinicaltrials@pulmotect.com",";florence.ader@chu-lyon.fr","shuminwang7000@163.com;shuminwang7000@163.com",";info@ovg.ox.ac.uk;info@ovg.ox.ac.uk","Drpitts@hudsonmedical.com",";","William@tropmedres.ac",";;jiaojiaopang@126.com;jiaojiaopang@126.com",";hegyi2009@gmail.com",null,"mabulmeaty@ksu.edu.sa",";clinicaltrials@pulmotect.com",null,";;;;;;;bartshealth.covid-hcw@nhs.net;",";eco7@cumc.columbia.edu","joe-elie.salem@aphp.fr;joe-elie.salem@aphp.fr","lmanenti@ao.pr.it","s.corrao@tiscali.it;s.corrao@tiscali.it",";M_paul@rambam.health.gov.il",";erenavcil@gmail.com;erenavcil@gmail.com","francois.lellouche@criucpq.ulaval.ca",";fbrzcantini@gmail.com;fbrzcantini@gmail.com",null,"gallelli@unicz.it;gallelli@unicz.it","A.A.Bhangu@bham.ac.uk","winsonhong@126.com",";Attia.Qamar@unityhealth.to;adrienne.chan@sunnybrook.ca",null,";;;;libertario.demi@unitn.it",";xyhplihao1965@126.com;xyhplihao1965@126.com","wenqin-1987@163.com","xmguo@tjh.tjmu.edu.cn",";gwzxliumin@foxmail.com;gwzxliumin@foxmail.com","f.w.asselbergs@umcutrecht.nl;m.p.m.linschoten@umcutrecht.nl",";frederic.adnet@aphp.fr",";","lxy7111@126.com","yxzpumch@126.com","paulkschan@cuhk.edu.hk;",";joost.wauters@uzleuven.com","whet_ctr@163.com","jzxhl@126.com","zyq1590@163.com",";drmtantaway@yahoo.com",";francesco.salton@gmail.com;mconfalonieri@units.it",";;ACT.ProjectTeam@PHRI.ca;ACT.ProjectTeam@PHRI.ca","paolo.gisondi@univr.it","393176736@qq.com","leetangbaba@163.com","zhu1635253@163.com","18971327286@163.com","yuanxianglin@hust.edu.cn","oucehua@swmu.edu.cn","xiaof35@sysu.edu.cn","wanli0604@163.com",";matthias.totzeck@uk-essen.de;amir-abbas.mahabadi@uk-essen.de",";dgebow@gmail.com;TBD@TBD.com",null,"393176736@qq.com","18971327286@163.com","fanrong3463@163.com","rqrc.siege@inserm.fr","sunhq@bjmu.edu.cn","shencx@sjtu.edu.cn","zejinliu@163.com","liudongyang@vip.sina.com","liweiqindr@vip.163.com","drlihang@126.com","cyzhang@nju.edu.cn","fswang302@163.com","hiruz.ctu@uzgent.be","soumelas@uni-pharma.gr","j.aman@amsterdamumc.nl","jan.erik.berdal@medisin.uio.no","s.borregaard@ctc-north.com","global.rochegenentechtrials@roche.com",null,null,"ricusunbing@126.com",";ifan@ansunbiopharma.com","DRCI-Promotion-Interne@chu-angers.fr","carine.labruyere@chu-st-etienne.fr","skhongsa@gmail.com","lberra@mgh.harvard.edu;lberra@mgh.harvard.edu","lberra@mgh.harvard.edu",null,";jho@ansunbiopharma.com",null,";;marie-helene.masse3@usherbrooke.ca;marie-helene.masse3@usherbrooke.ca",";odalgard@uio.no;odalgard@uio.no",";olesoega@rm.dk","contact@vipstudy.org","jens.ulrik.jensen@regionh.dk","lars.erik.kristensen@regionh.dk",";philippe.vanhems@chu-lyon.fr",";xieyao00120184@sina.com;xieyao00120184@sina.com",";jiaojiaopang@126.com",";GileadClinicalTrials@gilead.com",";zjgong@163.com;",";alexander.supady@universitaets-herzzentrum.de;",";vaccinetrials@ndm.ox.ac.uk",";dean@ayubmed.edu.pk;dean@ayubmed.edu.pk","luhongzhou@fudan.edu.cn",null,"DMIDClinicalTrials@niaid.nih.gov","KPWA.vaccine@kp.org",";john131212@sina.com","florentino.cardoso@hospitalcare.com.br;alvaro.filho@preventsenior.com.br",null,";rewells@wakehealth.edu;rewells@wakehealth.edu",";GileadClinicalTrials@gilead.com","pierre.hausfater@aphp.fr",null,";covid19@umn.edu","aorlandinimd@eclainternational.org",";jday@oucru.org",";;meigs@uw.edu",";;luanne.metz@ahs.ca;ckenney@ucalgary.ca",";shilei302@126.com",null,"sandi.k.parriott.mil@mail.mil","oriolmitja@hotmail.com;omitja@flsida.org","zhongji.meng@163.com;zhongji.meng@163.com",";neurocovid19study@ictalgroup.org;neurocovid19study@ictalgroup.org",";mark.sendak@duke.edu",";aro.clinicaltrials@einstein.br",";Valerie.Aston@imail.org",";stephen.freedman@ahs.ca;stephen.freedman@ahs.ca","javiercrespo1991@gmail.com",";;Covid19trial@umn.edu",";;",";clinicaltrials@regeneron.com",null,";lberra@mgh.harvard.edu;",";rbesthof@neurorxpharma.com",";;Covid19trial@umn.edu",";;alexandru.burlacu@umfiasi.ro",null,";;fzampieri@hcor.com.br",";g.gritti@asst-pg23.it;arambaldi@asst-pg23.it",null,null,";;antonia.bendau@charite.de;corona-angst@charite.de",";jeffrey.miller@emory.edu",";;;;;;;guiaccar@unina.it;",";pzheng@oncoimmune.com",";f.perrone@istitutotumori.na.it","landoni.giovanni@hsr.it","gabriele.saccone@libero.it",";PRIORITYCOVID19@ucsf.edu;PRIORITYCOVID19@ucsf.edu","gunther.meinlschmidt@ipu-berlin.de;contact@selfapy.com",null,"vincent.dubee@chu-angers.fr",";pankti.reid@uchospitals.edu;","isabelle.pellegrin@chu-bordeaux.fr;isabelle.pellegrin@chu-bordeaux.fr",";;filippo.annoni@erasme.ulb.ac.be",";;;alireza_ghaffarieh@meei.harvard.edu;",";aliaehussein@aun.edu.eg;aliaehussein@aun.edu.eg",";joanne.gondert@beaumont.org;joanne.gondert@beaumont.org","Arne.Vasli.Lund.Soraas@rr-research.no;Arne.Vasli.Lund.Soraas@rr-research.no","gallelli@unicz.it;gallelli@unicz.it",";global-roche-genentech-trials@gene.com",";;;;;;;paukrust@ous-hf.no",";info@beat19.org;info@beat19.org","barbara.goodall@nshealth.ca",";richard.skells@addenbrookes.nhs.uk;rkg20@cam.ac.uk",null,"spdeftereos@gmail.com",";nigel.curtis@rch.org.au",";;;lindayun@wustl.edu","dandachid@health.missouri.edu",";Valerie.Aston@imail.org",";ndaba.mazibuko@nhs.net",";;jean-claude.tardif@icm-mhi.org",";TOID_CRC@jhmi.edu",";Guido.bertolini@marionegri.it",";anna.caprodossi@policlinicogemelli.it;anna.caprodossi@policlinicogemelli.it",";lars.erik.kristensen@regionh.dk",";sobi.immuno@sobi.com","ohermine@gmail.com",";Contact-US@sanofi.com",";anders.kjellberg@ki.se",null,"t.tendoesschate@umcutrecht.nl",";muriel.fartoukh@aphp.fr;muriel.fartoukh@aphp.fr","jslagel@slapharma.com",";stephan.reichenbach@ispm.unibe.ch",";jesus.villar54@gmail.com","bruno.hoen@pasteur.fr",";Jie_Li@rush.edu",null,"ohermine@gmail.com",";;alexandru.burlacu@umfiasi.ro",";guido.bertolini@marionegri.it","cescalvo@ucm.es",";covid19prep@umn.edu",";claire-anne.siegrist@unige.ch;",";carla.ccih@gmail.com",null,";carrier.marie.eve@gmail.com",";;;snamendys@gmail.com",";p-amedro@chu-montpellier.fr;p-amedro@chu-montpellier.fr",";kristine.arges@duke.edu;kristine.arges@duke.edu","ozmenmm@gmail.com;mahir.ozmen@istinye.edu.tr",";julien.poissy@chru-lille.fr;",null,";soeska@rm.dk",";anja.delporte@uzgent.be",";camille.taille@aphp.fr;camille.taille@aphp.fr",";f.denis@cjb72.org;","vasilios.polymeropoulos@vandapharma.com",";anja.delporte@uzgent.be",";luciano.azevedo@hsl.org.br","azengin@istanbul.edu.tr;",";francois.silhol@ap-hm.fr;francois.silhol@ap-hm.fr",null,";f.iqbal@imperial.ac.uk",";jennifer.victory@bassett.org;kristin.pullyblank@bassett.org",";cflamand@pasteur-cayenne.fr;cflamand@pasteur-cayenne.fr","mlid163@163.com",";rachael.smith@bannerhealth.com",";wangliu@ioz.ac.cn",";anayajm@gmail.com;gustavo.quintero@urosario.edu.co",null,"esannorberto@hotmail.com;esannorberto@hotmail.com","m.eddleston@ed.ac.uk",";amelia.anderson@pennmedicine.upenn.edu;amelia.anderson@pennmedicine.upenn.edu",";imfell@yuhs.ac","infection@korea.ac.kr",null,";chris@sanotize.com",";srogy@capricor.com;Mitch.Gheorghiu@cshs.org",";USCOVIDplasma@mayo.edu","janneke.cox@jessazh.be",null,null,";",";;;;;;;;;;;;;;;;qixiaolong@vip.163.com",";fgarcia@clinic.cat;",";johnwilliam.mcevoy@nuigalway.ie;johnwilliam.mcevoy@nuigalway.ie",";victoria.vazquez@kcl.ac.uk","marta.duda-sikula@umed.wroc.pl","ohermine@gmail.com",";jose.munoz@isglobal.org","a.martineau@qmul.ac.uk",";Dr.afazeli@gmail.com;info@fums.ac.ir",";;steven.chan@uhn.ca;steven.chan@uhn.ca","cmoser@targetpharmasolutions.com",";michiel.thomeer@zol.be;michiel.thomeer@zol.be","Huilanz_76@163.com",";klewandowski@honorhealth.com","447822853@qq.com;447822853@qq.com",";mehdi.benchoufi@aphp.fr",";sabinehazan@aim.com","ciceri.clinicaltrials@hsr.it",";;azengin@istanbul.edu.tr;azengin@istanbul.edu.tr",";usingh@stanford.edu","pdomingo@santpau.cat;pdomingo@santpau.cat",";;ACTIONTrial@ucsf.edu;ACTIONTrial@ucsf.edu","Scott.Gorenstein@nyulangone.org;David.Lee@nyulangone.org",";anayajm@gmail.com;gustavo.quintero@urosario.edu.co","roberto.giacomelli@univaq.it;roberto.giacomelli@univaq.it",";servandocardona@tec.mx",null,"diane.egger-adam@uni-tuebingen.de",";;;robert.koerner@uk-koeln.de;robert.koerner@uk-koeln.de",";wangwj@jscdc.cn",";;jeffrey.carson@rutgers.edu",";;hussaisa@rwjms.rutgers.edu","aliaehussein@aun.edu.eg;aliaehussein@gmail.com","corinne.levy@activ-france.fr",";ayavchitz@for.paris;cmrangon@for.paris","jens.kastrup@regionh.dk","david.saadoun@aphp.fr",";coldmixon@mgh.harvard.edu",null,";alena.marynina@nhs.net;alena.marynina@nhs.net",null,";piasfar@chu-angers.fr;julien.demiselle@chu-angers.fr",";;;;henning.bundgaard@regionh.dk;henning.bundgaard@regionh.dk",";;ppatoz@ch-tourcoing.fr",";Zivit@canfite.co.il",";john131212@sina.com",";mcgarzon@ugr.es",";rachel.e.olson@duke.edu",";sherry.mansour@yale.edu",null,null,"jacques.cadranel@aphp.fr;jacques.cadranel@aphp.fr","nsharris@mgh.harvard.edu;nsharris@mgh.harvard.edu",null,"dmlevine@bwh.harvard.edu;dmlevine@bwh.harvard.edu",";sujeet.jha@maxhealthcare.com;samreensiddiqui@maxhealthcare.com",";;;bd@symvivo.com","lars.wik@medisin.uio.no",";msalathe@kumc.edu;msalathe@kumc.edu",";gitta@klilu.de;gitta@klilu.de",null,null,null,";korinna.pilz@inflarx.de;",";goldstein_le@clalit.org.il",";Contact-US@sanofi.com","ceannweiler@chu-angers.fr",null,null,";;;",null,";mlmadariaga@bsd.uchicago.edu;",";claire.roger@chu-nimes.fr;claire.roger@chu-nimes.fr",";alicia.garcia@medsir.org","Efstratios.Koutroumpakis@uth.tmc.edu;Efstratios.Koutroumpakis@uth.tmc.edu",";l.uhrenholt@rn.dk;l.uhrenholt@rn.dk","chris.inchley@gmail.com",null,null,";clinical.trials@inovio.com",";francois.dubos@chru-lille.fr","harry.hothi@nhs.net",null,";Guido.Beldi@insel.ch;Guido.Beldi@insel.ch",null,";john131212@sina.com","ibnsky@yahoo.es;ibnsky@yahoo.es",";US.Info@I-MabBiopharma.com","jean-baptiste.fassier@chu-lyon.fr",";;whipcovid19@hfhs.org;whipcovid19@hfhs.org",";drmendietaz@yahoo.com","lgh19870628@126.com","liuliu9027@163.com","rjager@beatcovidtrial.com","xavier.monnet@aphp.fr",";tness@uabmc.edu;tness@uabmc.edu",";;;;;;;;;Francois.Morin@chu-angers.fr",";sabinehazan@aim.com",";","sonja.hoeller@apeiron-biologics.com;",";doyen.d@chu-nice.fr","yanggang201301@163.com","happyzhupengfei@163.com","xavier.mariette@aphp.fr",";guptans@ucmail.uc.edu","gilles.mangiapan@chicreteil.fr",";Delphine.garrigue@chru-lille.fr","bjorn.stessel@jessazh.be",";ruxcoflam@med.uni-jena.de;ruxcoflam@med.uni-jena.de",";jose.diaz-miron@childrenscolorado.org;jose.diaz-miron@childrenscolorado.org",";;d.harding@qmul.ac.uk","chris.kclai@cuhk.edu.hk","leetangbaba@163.com",";Roland.vanKimmenade@radboudumc.nl",";qingsongye@foxmail.com;","zheng862080@139.com;zheng862080@139.com",";brannock.robert@mayo.edu;brannock.robert@mayo.edu","qingleigao@hotmail.com;qingleigao@hotmail.com",";farhan.raza@aku.edu",";erik.m.andersson@ki.se;erik.m.andersson@ki.se","liyingshuai2013@163.com","zhaozl2006@163.com",null,null,";novartis.email@novartis.com","achille.tchalla@chu-limoges.fr",";;miguelguia7@gmail.com;antmesquinas@gmail.com",";diane.egger-adam@uni-tuebingen.de;diane.egger-adam@uni-tuebingen.de","alboraie@azhar.edu.eg",";stevens.a@wustl.edu","azengin@istanbul.edu.tr","marcuslacerda.br@gmail.com",";jwsander@wakehealth.edu",";;haleema.shakur-still@lshtm.ac.uk","j.m.weehuizen-2@umcutrecht.nl","thomas@interactivestudios.nl","juliochi@pennmedicine.upenn.edu","roi.anteby@sheba.health.gov.il;roi.anteby@sheba.health.gov.il",";shehnoor.azhar@gmail.com",null,";ClinicalTrials.gov@lilly.com",";h-donnadieu_rigole@chu-montpellier.fr;h-donnadieu_rigole@chu-montpellier.fr",";pierre-emmanuel.falcoz@chru-strasbourg.fr;pierre-emmanuel.falcoz@chru-strasbourg.fr",";;twiga00@yahoo.com",null,"hiruz.ctu@uzgent.be",";Marifiel.Vendivil@HackensackMeridian.org",null,null,";englemd94@gmail.com","kushd@amarexcro.com",";;eduardoinsignarescarrione@gmail.com;yohanny.andrade2@gmail.com",null,";alison.gibbons@nih.gov;alison.gibbons@nih.gov",";yocum007@umn.edu",";heini.kanervo@uzgent.be;","insepsis@otenet.gr",null,"recoverytrial@ndph.ox.ac.uk",";;;;;sina.irvani@gmail.com",null,null,null,";bari-covid19@cuanschutz.edu",";ly_icu@aliyun.com;ly_icu@aliyun.com","aburns@caredx.com",";peter.rosenberger@med.uni-tuebingen.de",null,null,"k.couper@warwick.ac.uk",null,"andrew.gostine@nm.org",";nancy.kentish@aphp.fr;nancy.kentish@aphp.fr",";greengrc01@gmail.com;greengrc01@gmail.com",";giacobellis@med.miami.edu","ydkfedu@163.com","lijianan@njmu.edu.cn","41025513@qq.com","dicespedes2@hotmail.com","kjkceh@126.com","baixiaoxia@zju.edu.cn",";rupesh_agrawal@ttsh.com.sg",";christina.pacchia@hsc.utah.edu;christina.pacchia@hsc.utah.edu",";b.rijnders@erasmusmc.nl",";yl4459@cumc.columbia.edu;","docd1@sina.com","fanyingsh@126.com","frank0130@126.com","DF.van.Wijk@nwz.nl",";laura.webb@duke.edu;laura.webb@duke.edu","matthew.bardin@romark.com","Latha.Dulipsingh@trinityhealthofne.org;",";;;;usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil;usaf.pentagon.11-mdg.mbx.flight-med-clinic@mail.mil","zengrui_0524@126.com","wengjp@ustc.edu.cn","f.hooijberg@reade.nl","frank.bosch@radboudumc.nl","jah.vanoers@etz.nl","hamza@hamzayousuf.nl",";;erika.ratcliffe@duke.edu;erika.ratcliffe@duke.edu",";deleaf@bwh.harvard.edu",null,"carla.vandenabele@aphp.fr",null,null,"hj.bogaard@amsterdamumc.nl","s.koerper@blutspende.de","patrick.cassai@chu-bordeaux.fr","l.lamrani@hml.fr",null,"g.elder@northumbria.ac.uk","fibucicec.hcsc@salud.madrid.org","lola.serna@carm.es","jan.fehr@uzh.ch","principle@phc.ox.ac.uk;principle@phc.ox.ac.uk","secretaria@delosclinical.com","eunate.aranaarri@osakidetza.eus","pvachey@for.paris","gutierrez_fel@gva.es","jinzhilu2015@163.com","qianlu5860@gmail.com","jose.munoz@isglobal.org","jszfc@sina.com","398139849@qq.com","rebrcca@126.com","tsh006@163.com","alienke.wijmenga@rivm.nl","marion.frenken@mmc.nl","frank.bosch@radboudumc.nl","m.j.dijkstra-tiekstra@umcg.nl","elodie.soler@aphp.fr","korinna.pilz@inflarx.de","arnauld.garcin@chu-st-etienne.fr","julien.gautier@lyon.unicancer.fr","fadila.amerali@aphp.fr","xsolanich@bellvitgehospital.cat","epenag@santpau.cat",null,"uk-medicalinformation@sanofi.com","anabelsanchez.hrc@gmail.com"],["+86 13995577963","+86 13738498188","+86 13574810968","+86 13995577963","+86 13605708066","+86 64931902","+86 13817729859","+86 13756858523","+86 15018720816","+86 13923781386","020- 36052117;","86-18560086593","+86 13476229575;+86 13476229575","+86 13517248539","+86 13397192695","+86 371-65676568","+86 13861779030","+86 13601733045","+86 0714-6224162","+86 13811611118","+86 0714-6224162","+86 13819711719",";+86 10 66933436;+86 66933323",null,"010-69155086",";+86 13605708066","+86 13605813177","86 28 85423680","+86 13817729859","+86 13738498188","+86 15890689220","+86 13338628626","+86 18980601415","+86 13995577963","+86 13530027001","+86 15337110926","+86 15818136908","+86 18930810088","+86 27 83662688","+86 13823078064","+86 0510-68781007","+86 13136150848","+86 13871120171","+86 18917962300","+86 13588867114","+86 18930810088","+86 18134048843","+86 18963789002","+86 13903076359","+86 13707114863","+86 13839708181","+86 574-87089878","+86 010-64089801","+86 18980601566","+86 18908628577","+86 18995678520","+86 010-52176520","+86 571 86613587","+86 13881070630","+86 13588706900","+86 13922738892","+86 13507138234","+86 13906514781","+86 13601331063","+86 13397192695","+86 13867622009","+86 18062567610","+86 13505615645","+86 13307161995","+86 13377897297","+86 13971156723","+86 18980605819","+86 371 65676568","+86 13902020873","+86 13688867618","+86 0411-62893509","+86 0571-87068001","+86 18602724678","+86 18928868242","+86 15388178461","+86 371 66248624","+86 010 84012510","+86 13312883618","+86 13903076359","+86 14786531725","+86 21 64370045","+86 13505811696","+86 13910662116","+86 0756 2528573","+86 0571-87236426","+86 15000285942","+86 13681208998","+86 755 61238922","+86 18995678520","+86 13971301060","+86 13588189339","+86 18962567610","+86 13588189339","+86 18980880132","+86 13588189339","+86 18971387168/+86 15729577635","+86 13659897175","+86 18664556429","+86 13707089183","+86 028 87393881","+86 13902020873","+86 13377897278","+86 18971317115","+86 13377897278","+86 13902020873","+86 13163283819","+86 13902020873","+86 13934570253","+86 18234016125","+86 13810339898","+86 02767812787",";01 40 25 71 48;01 40 25 71 48",null,"+86 13707089009","+86 010-64089801","8610-6915-5036","+86 15972127819","+86 755 61238922","+86 13906503739","+86 13319184133","+86 020 34294311",";18971387168;","+86 13518106758","+86 027-88041911-82237","+86 13810765943","+86 18980880525","+86 22 58830026","+86 21-37990333","+86 15827257012","+86 13607108938","+86 0756-3325892","+86 18930810088","+86 13907191851","+86 13507181312","13957111817","+86 18610329658","+86 18328737998","+86 18971035988","+86 13801257802","+86 13709206398","+86 13807887867","+86 13902233092","+86 13971605283","+86 13710801606","+86 13709206398","+86 13820088121","+86 13971358226","+86 027-83663078","+86 15526272595","+86 13507117929","+86 13671609764","+86 18600310121","+86 13844021812","+86 15071096621","+86 13807088660","+86 13910768464","+86 13607108938","+86 15071096621","+86 13950120518","+86 15205215685","+86 13910930309","+86 15301655562","+86 133 0451 2381","+86 18917683122","+86 15002749377","+86 13907342350","+86 18621170011","+86 18980601817","+86 13910768464","+86 15956927046","+86 021-51323092","+86 18930568005","+86 13950120518","+86 010-65125311","+86 13911798280","+86 13995577963","+86 13807312410","+86 18180609287","+86 18602724981","+86 13901094780","+86 13699093647","+86 13296508243","+86 13867622009","+86 13886157176","+86 02783663078","+86 18560082787","+86 18062567610","+86 18602724981","+86-21-64041990","+01084206264;","+86 18971163518",null,";+86 13228683243;",";0577-55578166",";0577-55578166","+86 19890572216","+86 19890572216",";;;861059616308;","+8613554361146",";+8618621170011?;","+86 18098875933","+01084206264","+86-13571892829;+86-029-84777631","021-37990333","8621-20256521;","+86 0731 88458187","+86 18672308659","+86 010 66939107","+86 13971679960","+86 13937642780","+86 13986394739","+86;+1386061359","+86 13809508580","+86 13507117929","+86 13307173928",";+8613760783281;+8613533978874",";+8613760783281;+8613533978874","00863733029089;00863734402517","+86 13992856156","+86 13338628626","+86 15391532171","+86 15268118258","+86 18964630206","+86 15037167775","+86 0578 2285102","+86 18721335536","+86 010 62402842","+86 18980601278","+86 13756858523","+86 13215510411","+86 13797625096","+86 13584010516","+86 13508649926","+86 13797625096","+86 18121150282","+86 13303608899","+86 18186161668","+86 15960212649","+86 18917387623","+86 13845099775","+86 18602764053","+86 17723451376","+86 18930568010","+86 15052103816","+86 13678494357","+86 17723451376","+86 13920648942","+86 13933856908","+86 18017306677","+86 13576955700","+86 18672396028","+852 22528451","123","+86 18328737998","+86 023 61103649","+86 13856985045","+86 13911798280","+86 15611908958","+86 15611908958","+86 13756661209","+86 13883533808","+86 13707077997","+86 19923204040","+86 0791-88693401","+86 13507183749","+86 13507183749","+86 023-65481658","+86 18062586860","+86 13883533808","+86 13608338064","+86 13638352995","+86 13928459556",";+86-13911683832","+86 15923859880","+86 13971086498",";+862 22554049;852 22554049",";+86-01066823480;010-66947473","15391532171;","86-10-66933333;86-10-66933333",";+86-21-64370045","+86 13605715886","+86 13757120681","+86 13801955367","+86 18508160990","+86 13880336152",null,";86-022-86343860","+86 13673665268","+86 18980601541","+86 13886160811","+86 15168887199","+86 18660117915","+86 13605708066","13938415502","+86 13971679960","+86 15071157405","+86 13971086498","+86 18502468189","+86 13986156712","+86 13806086169","+86 13866175691","+86 18980601655","+86 13808628560","+86 15391532171","+86 13971086498","+86 13807312410","+86 13922745788","+86 13817525012","+86 13857715778","+86 18980601566","+86 13372018676","+86 13911467356","+86 13901883868","+86 13627288300","+86 18627770651","+86 0719 8801713","+86 13505319899","+86 0577 55579261","+86 13901333060","+86 13911467356","+86 17709877386","+86 13580315308","+86 18930172033","+86 13971687403","+86 13907191851","+86 15626235237","+86 0731-88618338","+86 18930568129","+86 18702745799","+86 027 83665506","+86 13710494278; +86 13622273918","+86 18980601525","+86 18980880132","+86 18980880132","+86 027-83665506","+86 0311-83855881","13911318339",";+86-021-37990333;008602137990333","+86 0311 83855881",null,"+86 13910768464","+86 13803818341","+86 13871257728","+86 13911405123","13507138234","+86 13872250922","+86 15937129400","+86 13951608346",null,";9053340010",null,"+86 13505743664","+86 13971587381","+86 13902233925","+852 3505 3333","+86 13906514210","+86 15186660001","+86 13161985564","+86 13710658121","+86 15228218357","+86 18971201115","+86 13501722091","+86 027-83662684","+86 13277914596","+86 13807172756","+86 13517248539","+86 13545009416","+86 18917763257","+86 13607176908","+86 15903715671","13507117929","+31(0)8875 55196","+86 13503735556","+86 13971679960","+86 027-83662391","+86 18986152706","+86 13871480868","+86 18695808321","+86 15102710366","+86 13886169836","+86 18672912727","+86 15888193663","+86 13607195518","+86 13971625289","+86 13797062903","+86 13507183749","+86 15377628125","+86 15833119392","+86 18627151212","+86 13788989286",null,"+86 13756858523","+86 13857797188","+86 18827001384","+86 13832102657","+86 13816108686","+86 13978839646","+86 13995599373","+86 13975137399","+86 13995789500","+86 18823361933","+86 18601085226","+86 13699207252","+86 13985004689","+86 18971163158","+86 13971086498","+86 0571 87377780","+86 15927668408","+86 18804758989","+86 13995577963","+86 15186660001","+86 020-36591782","+86 13953116564","+86 13953116564","+86 13886188018","+86 13953116564","+86 15071157405","+86 13871402927","+86 13953116564","+86 18980601215","+86 13953116564","+86 13828291023","+86 15972061080","+86 18121225835","+86 17723451376","+86 18085287828","+86 18995598097","+86 13574171102","+86 13995561816","+86 15706855886","+86 13907105212","+86 13580013426","+86 13971477320","+86 18017321696","+86 15907190882","+86 18971163518","+86 13801955367","+86 18121288279","+86 13760857996","+86 13971292838","+86 13601605100, 13301833859, 13701682806","+86 13953116564","+86 13668077090","+86 071 68494565","+86 13621964604","+86 13580584031","+86 18922238906","+86 13816012151","+86 13570236595","+86 18263511977","+86 13911005275","+86 13803535961","+86 15618795225","+86 13826041759","+86 13729856651","+86 15091544672","+86 13855288331","+86 13760661654","+86 13953116564","+86 13908658127","+86 18972161798","+86 020-83710825","+86 15312019183","+86 13609068871","+86 13621759762","+86 13908658127","+86 15018720816","+86 15018720816","+86 071 68497225","+86 071 68497225","+86 13500296796","+86 13871257728","+86 13911318339","+86 0574-87085111","+86 15611963362","+86 027-82433145","+86 13910812309","+86 13910812309","+86 18922108136","+86 0451-53602290","+86 15287110369",";+8618672396028;","+86 027 85726732","82-2-3010-3114","+86 13585779708","+86 18604501911","+86 13907191851","+86 15091544672","+86 15208660008","+86 15018720816","+86 15018720816","+86 13554361146",";18986033792","+86 18978817899",";0473754963;0473754963","+86 13674950311","+86 13437171877","+86 13607492399","+86 18902536585","+86 18995678520","+86 13564684699","+86 15967196694","+8613605880185","+86 15901203883","+86 13875985950","+86 13989370664","+86 13637403483","+86 13501078679","+86 13910930309","+86 13560158649","+86 13603035264","+86 13816033045",null,";+86(755)8672 5195;86-755-86725195",null,"+86 15258871484","+86 13970038111","+86 13966906638","+86 13926931713","+86 18980606533","+86 13507117929","+86 13533550083","+86 18038860666","+86 025 83759418","+86 15168887199","+86 0756 2528222","+86 13825498648","+86 731-85295860","+86 13554260702","+86 13910930309","+86 15989096626","+86 027 67813096","+86 13985004689","+86 13397192089","+86 13808628586","+86 13871143176","+86 13886009855","+86 13738498188","+86 18007117616","+86 025-52362054","+86 0791 86300047","+86 13761153836","+86 18180609256","+86 13926946929","+86 13906514210","+86 13873104819","+86 15874875763","+86 18122317900","+86 13707089183","+86 13918462035","00334 13 73 23 47","+49 341 97 17700","+98 21 6695 4715","+98 21 5563 9666","0098216654715","+98 28 3333 6001","+98 21 2610 9490","+98 21 6695 4715","+98 21 8241 5000","+8613971521450;","+98 21 6695 4715","+81-27-220-8740","33140257761",null,"+81-27-220-8740","+81-562-93-9407",null,"13554361146;13554361146",null,"+8613971521450;","+8613971521450;","+8613971521450;","028-626-5500",";+86(755)8672 5195;86-755-86725195",null,";;",null,"13815857118;13951266803","0332027181","33140257761","+8613517260864",null,";66013694;",";;;;8610-64093207",null,"+8613971521450;",";+1 (484) 995-5917;+86 2783662886",null,";0033158414143;",null,null,"+962795337575;+962795337575","+86 13716608331",";+86-13781919609;+86-13619842879",";;;;;;;;+52 55871700",";3289035621;","+86 027 85726727",";0736563473;073-6563473","+86 18986161976","13801844344;+86 21 52889999",";+86136673520046;","0817462202",";;;;;;;54871700","+86 15192552255","+86 13710874687","+86 13706760666","+86 027 88041919-83920","+86 027 85726309","+86 15850531741","+86 022 27986625","+86 13986296106",";+393920039246;","+86 15192552255","+86 17717830223","+86 023-68485008","+86 13600009221","+86 17762551726","+86 13578949866","+86 18980605046","+86 13972046539","+86 13971679960, 13387522645","+86 13668023656","+86 13871143176","+86 13901374552","+86 13507191363","+86 15837117112","+86 13837167212","+86 13995569560","+86 18917763194","+86 18930132792","+86 18051061365","+86 18980025566","+86 18222521385","+86 18980025566","+86 13609219205","+86 13902233925","+86 17327006987","+86 15001111836","+86 13903076359","+86 13607108938","+86 13554361146","+86 18655106697","+86 010-64089801","+86 023 68757780","+86 18980601618","+86 18980601556",null,"+86 18616974986",null,"00318875 503 50","+4970712982191","+4723071916","02380512800",";713-579-9226",";+33 (0)4 72 07 15 60","+86 13488760399;+86 13488760399",";01865611400;01865 611 400","6465967386",";","+66 2 203-6333",";;18560089129;+86 18560089129",";+36703751031",null,"00966548155983",";713-579-9226",null,";;;;;;;07570911438;",";212-305-9056","01 42 17 85 31;01 42 17 85 31","00393400732913","+390916662717;+390916662717",";+972-50-2062140",";+9005320683378;+9005320683378","418-656-8711",";+393408075607;+39 3408075607",null,"3339245656;3339245656","+44 1216272949","+86 13729834533",";416-864-6060;",null,";;;;00390461283942",";+0086-133113382093;01062835088","+86 27 88041911","+86 13971518978",";13668072999;13668072999","+31 (0) 88 755 5555;+31 (0)88 755 5555",";+33 1-48-96-44-08","+1 (201) 212-6643;","+86 13505581239","+86 13601262164","+852 35053339;+852 35053555",";003216344275","+86 027 82308909","+86 19385219073","+86 13817091896",";+201221865587",";3486986287;+393356895168",";;905-297-3479;","+39 0458122547","+86 02783665518","+86 13585808910","+86 18951762691","+86 18971327286","+86 13667241722","+86 15608089909","+86 13380600018","+86 13638670601",";+49201723;+49201723",";415-244-1481;415-244-1481",null,"+86 027-83665518","+86 18971327286","+86 13808454319","33182533368","+86 10 82805960","+86 18501664545","+86 18963980043","+86 18610966092","+86 13951839654","+86 13693058190","+86 13913994223","+86 010-66933332","+3293320500","3021080725121374","+31610738910","+4767960000","+4940524719200",null,null,null,"86013911151075",";+86 186 2190 9313","0241353342","33(0)477120469","66818180890","+16176437733;","+16176437733",null,";858-452-2631",null,";;819-346-1110;819-346-1110",";+47 92616800;+47 92 61 68 00",";+45 2499 4962","+2118118800","004528938168","4538164157",";04 72 11 07 20",";8610-84322200;8610-84322200",";(086)0531-82166843",";1-833-445-3230 (GILEAD-0)",";027-88999120;",";+49761270;",";01865 611424",";00923219111681;00929929311100","+86-021-37990333",null,"13017617948","12062872061",";13911405123","+55 19 991232882;+55 11 981797949",null,";336-716-2357;",";1-833-445-3230 (GILEAD-0)","33142177240",null,";6126249996","+ 54 341 4450210",";+84 8 39237954",";;206-520-3833",";;403-944-4241;403-944-4286",";86-10-66933333",null,"301-619-6824","0034 934651072;","18971905757;+86-18971905757",";33139638839;33139638839",";919-684-3234",";+55 (11) 2151-1233",";8015074606",";4039557740;4039557740","942202520",";;612-624-4373",";;",";844-734-6643",null,";+16176437733;",";+14842546134",";;612-624-4373",";;0040744488580",null,";;+55 11 99882-9343",";+39.0352673684;+39 035 2673683",null,null,";;+4930450517274;+49 30 450 517 285",";404-778-7200",";;;;;;;+390817464717;",";(202) 7516823",";+390815903571","+390226436151","3394685179",";(415) 754-3749;415-754-3749","+49 30 300117;+49 (0) 30 - 3982031",null,"241353872",";7737021220;","05 57 82 11 50;05 57 82 11 50",";;0032(0)483141483",";;;+1-608-698-7334;",";01222302352;01222302352",";248-898-0343;248-898-0343","+4790652904;+4790652904","3339245656;3339245656",";888-662-6728",";;;;;;;0047 46778374",";(415) 754-9290;","(902) 292-0132",";01223 349707;07500792984",null,"00306944699901",";+613 93456366",";;;314-273-2240","573-884-8728",";8015074606",";07961949717",";;514-376-3330",";410-614-6702",";+39 035 4535 313",";+390630154395;",";0045 38164157",";+46 8 697 20 00","603707920",";800-633-1610",";+46812375212",null,"+31621197660",";01 56 01 65 74;01 56 01 65 74","01923681001",";+41 31 631 56 98",";+34606860027","+33 1 40 61 37 60",";312-947-0065",null,"603707920",";;0040744488580",";+39 035 4554 313","91 394 1544",";612-626-8171",";+41795533396;+4179 553 4676",";+55 11 991893404",null,";514-340-8222",";;;+52 55 54870900",";04 67 33 66 43;467336643",";919-668-0927;919-668-0927","+905324246838;+905324246838",";0320444495;0320445962",null,";28911869",";+32-9-3320228",";+33 1 40 25 68 63;+33 1 40 25 68 63",";241682940;","2027343400",";+32-9-3320228",";+5511992383611","(212) 866 37 00 43144;",";;",null,";07588550244",";6075476965;607-547-6711",";+33 5 94 29 26 15;+33 5 94 29 26 15","+8613524348108",";1-541-601-9106",";+86-01064807858",";+57 321 233 9828;+57 318 3606458",null,"0034686754618;0034686754618","0131 242 3867",";215-509-5690;215-509-5690",";82-2-2019-3310","82-2-2626-3052",null,";778-899-0607",";818-618-5774;310-423-6152",";507-255-4288","03211 33 76 51",null,null,";",";;;;;;;;;;;;;;;;+86-18588602600",";+34932275400;",";+353 9 154 4331;+353 9 154 4331",";02071886765","48 71 784 00 34","603707920",";608774071","+442078822551",";+989121392982;+987153314026",";;416-946-2000;","984-234-0268",";+3289327171;+3289327171","15391532171",";480-583-0760","+8613387517458;+8613387517458",";+33(0) 6 30 37 11 00",";805-200-7426","+39 02 2643",";;+90 (212) 866 37 00;+90(212) 866 37 00",";6507234045",";",";;(415) 514-1582;415-514-1582","516-663-8498;212-562-6561",";+57 321 233 9828;+57 318 3606458","0039 0862 434742;0862434742",";+5218112121946",null,"+4970712982191",";;;+49 221 478;+49221478",";8625-83759911",";;732-235-7122",";;732-235-7840","01222302352;+201222302352","148850404",";(0)1 48 03 64 54;(0)1 48 03 64 54","+4535452819","673081143",";617 726-4777",null,";07776 224520;07776 224520",null,";+33241355865;33 (0)241355865",";;;;+4526112290;+4526112290",";;0320694540",";+972-3-9241114",";13911405123",";+34 649440850",";919-668-5590",";412 716 0497",null,null,"1 56 01 66 73;01 56 01 66 73","617-724-3290;617-724-3290",null,"617-732-7063;617-732-7063",";+919910609000;+919582865898",";;;(604) 428-7474","91728966",";9135886000;913-588-6000",";+49 621 5032944;0621 - 5032944",null,null,null,";+49 89 4141 89 78;",";972-4-6494143",";800-633-1610","(+33)241354725",null,null,";;;",null,";773-270-2004;",";0033466683050;+33466683331",";+34 611 261 467","4123203161;412-320-3161",";+45 21707727;+45 21707727","90069276",null,null,";(267) 440-4237",";020445982","+44 (0) 20 8909 5847?",null,";0316328275;0316328275",null,";13911405123","0034 913303002;913303002",";240-767-6981","04 78 86 12 05",";;313-574-2651;313-574-2651",";+52-722-276-5540","18359186153","+86 18930177147","(708) 620-4608","+33 01 45 21 35 39",";2059079743;205-907-9743",";;;;;;;;;33 (0)2 41 35 00 81",";805-200-7436",";","43 1 865 65 77 128;",";0033492035510","+86 18601406982","+8613720162185","145213751",";5135584831","0033157022087",";03 20 44 67 97","003211222107",";+49 3641;+49 3641",";720-777-6571;720-777-6571",";;020 7377 7000","+852 55696828","+86 13585808910",";+31243616785",";+8615858242516;+86 027 88041919","18928868242;86-20-83062843",";904-953-2000;904-953-2000","+86-13871127473;+86-13871127473",";03052225117",";+46736716335;08-524 824 46","+86 13681410020","+86 13828895409",null,null,";41613241111","+33 5 55 05 86 26",";;00351915774975;0034609321966",";+4970712982191;+4970712982191","00201155019700",";(314)362-6291","+905526830479","+55 92 99114 7633",";336-70-COVID",";;+44 207 958 8113","0887555678","0031650617047","215-573-6606","19293011120;+972545882207",";+92 321 4090221",null,";1-317-615-4559",";0467337020;0467337020",";33 3 69 55 11 34;33 3 69 55 11 34",";;+628129005599",null,"+3293320500",";551-996-5828",null,null,";985-768-8918","301-956-2536",";;+573007191994;+573012629694",null,";(240) 665-0697;240-665-0697",";612-626-8015",";+32 9 332 26 19;","302107480662",null,"-",";;;;;+989141182825",null,null,null,";(720) 507-9107",";+8610169152300;+8610169152300","415.287.2420",";+49707129",null,null,"+442476151179",null,"(312) 695-0061",";142499995;142499995",";0156017500;0156017500",";3052433636","+86 18600819602","+86 13705161766","+86 15171346752","+86 15549450300","+86 13857281688","+86 13957152365",";6357100",";8012138735;801-213-8735",";+31107033510",";2123046205;","18917387623","+86 13918307508","+86 13986268403","088-085-7589",";+1 919 668 8977;919-668-8977","813-282-8544","860-714-4402;860-714-4402",";;;;703-697-3255;703-697-3255","+86 028-85423248","+86 0551-62286223","0202421633","+31243619880","0132213808","00 31 20 444 22 44",";;919-681-5006;919-681-5006",";617-525-7612",null,"+33140 27 57 27",null,null,"+31020 444 1896","0049731150519","+33057820334","0033140942554",null,"+44 (0)191 227 3241","+349133030007360",null,"+41 44 634 46 79","+44 (0)800 138 0880;+44 (0)800 138 0880",null,"0034946182646","33148036433","34966616234","+86 18163138632","+86 13797097676","+349322754001825","+86-025-83759418","+86 15153169567","+86 18810882866","+86 13858825280",null,"040-8888380","+31243619880","+31 50 3610468","+3301 44 84 17 35","+4989414 1897897","33(0)477120286","+33426 55 68 29",null,"0034932602324","34935537636","+34912948910","+448450230441","+34913368825"],["Emergency Department of Zhongnan Hospital of Wuhan University","HwaMei Hospital, University of Chinese Academy of Sciences",null,"Emergency Department of Zhongnan hospital of Wuhan University","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","Children's Hospital of Fudan University","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","Affiliated Hospital of Changchun University of traditional Chinese Medicine",null,"Shenzhen Second People's Hospital",null,null,null,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","He'nan University of Chinese Medicine","Wuxi People's Hospital","Shuguang Hospital Affiliated to Shanghai University of TCM.","Huangshi Hospital of Traditional Chinese Medicine","Beijing You'an Hospital, Capital Medical University","Huangshi Hospital of Traditional Chinese Medicine","The First Affiliated of Wenzhou Medical University","302 Military Hospital;",null,null,"First Affiliated Hospital of Zhejiang University;","Zhejiang Provincial People's Hospital","West China Hospital, Sichuan University","Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine","HwaMei Hospital, University of Chinese Academy of Sciences","The First Affiliated Hospital of Zhengzhou University","Nanjing Second Hospital","West China Hospital, Sichuan University","Zhongnan Hospital of Wuhan University","Pulmonary Diseases Department, Shenzhen Third People's Hospital","Wuhan Pulmonary Hospital","Guangdong Provincial Hospital of Chinese Medicine","Shanghai Public Health Clinical Center","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The Fifth Affiliated Hospital Sun Yat-Sen University","Jiangsu Institute of Parasitic Diseases","The First Affiliated Hospital of Medical College of Zhejiang University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Shanghai Pulmonary Hospital","The First Affiliated Hospital of Zhejiang University School of Medicine","Shanghai Public Health Clinical Center","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Guangdong Provincial Hospital of Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","People's Hospital of Guangshan County","Ningbo First Hospital","China Academy of Chinese Medical Sciences","Department of Critical Care Medicine, West China Hospital of Sichuan University","Hubei Provincial Hospital of TCM","Xiangyang 1st People's Hospital","Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital","Zhejiang Chinese Medical University","Deyang integrative medicine hospital","Sir Run Run Show Hospital, School of Medicine, Zhejiang University","Sun Yat sen Memorial Hospital of Sun Yat sen University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Zhejiang Chinese Medical University","Zhejiang Chinese Medical University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Enze Hospital of Taizhou Enze Medical Center (Group)","Renmin Hospital of Wuhan University","The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Zhongnan Hospital of Wuhan University","West China Hospital, Sichuan University","The First Affiliated Hospital of He'nan University of Chinese Medicine","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine","The First Afflicated Hospital of Guangzhou University of Chinese Medicine","Affiliated Zhongshan Hospital of Dalian University","The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of Guangzhou Medical University","West China Hospital, Sichuan University","The First Hospital of He'nan University of Chinese Medicine","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine","Department of Psychology, the Fifth Affiliated Hospital Sun Yat-Sen University","Guangdong Provincial Hospital of Chinese Medicine","The First People's Hospital of Huaihua","Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","The First Affiliated Hospital of Zhejiang University School of Medicine","Hubei Provincial Hospital of TCM","The Fifth Affiliated Hospital of Sun Yat-Sen University","The First Affiliated Hospital, College of Medicine, Zhejiang University","Hu'nan Yuanpin Cell Biotechnology Co., Ltd","The 5th Medical Center Chinese PLA General Hospital","The Third People's Hospital of Shenzhen","Xiangyang First People's Hospital","Department of Cardiovascular Medicine, Tongji Hospital","The First Affiliated Hospital of Zhejiang University School of Medicine","Renmin Hospital of Wuhan University","The First Hospital Affiliated to Zhejiang University's Medical School","Hospital of Chengdu University of Traditional Chinese Medicine","The First Affiliated Hospital, Zhejiang University School of Medicine","Zhongnan Hospital of Wuhan University","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","Shenzhen national medicine inheritance medical research institute co. LTD","The First Affiliated Hospital of Nanchang University","Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital","Hubei integrated hospital of traditional Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1. Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","1.Xinhua affiliated hospital, Hubei University of Chinese Medicine; 2. Hubei Provincial Hospital of Integrated Chinese and Western Medicine","Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine","Wuhan 1st Hospital","Tianjin University of Traditional Chinese Medicine","The Second Hospital of Shanxi Medical University","The First Hospital of Shanxi Medical University","Peking University Third Hospital","Zhongnan Hospital of Wuhan University","Institut National de la Sant Et de la Recherche Mdicale, France;",null,"The First Affiliated Hospital of Nanchang University","China Academy of Chinese Medical Sciences",null,"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shenzhen the 3rd People's Hospital","Tongde Hospital of Zhejiang Province","Xi'an Chest Hospital","The First Affiliated Hospital of Guangzhou Medical University","Wuhan University;","Department of Critical Care Medicine, West China Hospital of Sichuan University","Renmin Hospital of Wuhan University","Peking University First Hospital","Chengdu University of Traditional Chinese Medicine","Haihe hospital, Tianjin University","Jiangxi Qingfeng Pharmaceutical Co., Ltd.","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Guangdong Provincial Hospital of Chinese Medicine - Zhuhai Hospital","Shanghai Public Health Clinical Center","First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital)","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of Zhejiang University School of Medicine","Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing China","West China Hospital, Sichuan University","Renmin Hospital of Wuhan University","Chinese PLA General Hospital","The Second Affiliated Hospital of Xi'an Jiaotong University","Department of respiratory medicine, the First Affiliated Hospital of Guangxi Medical University","The First Affiliated Hospital of Guangzhou Medical University","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","The First Affiliated Hospital of Guangzhou Medical University","the Second Affiliated hospital of Xi'an Jiaotong University","Tianjin Huanhu Hospital","Renmin Hospital of Wuhan University","Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology","The First People's Hospital of Chenzhou, Institute of Translational Medicine,University of South China","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Shanghai Changzheng Hospital","The Sixth Medical Center of PLA General Hospital","The Fifth Affiliated Hospital of Sun Yat-Sen University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Nanchang Ninth Hospital","Hospital of Chengdu University of Traditional Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Zhongshan Hospital Affiliated to Xiamen University","Affiliated Hospital of Xuzhou Medical University","Beijing Chaoyang Hospital, Capital Medical University","Shanghai General hospital of Shanghai Jiaotong University","Heilongjiang Province hospital","Shanghai 10th People's Hospital, Tongji University","Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Second Hospital of University of South China, Hengyang","Zhongshan Hospital Fudan University","West China Hospital, Sichuan University","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","Faculty of Rehabilitation Medicine, Shanghai University of Chinese Medicine","Tuina Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","Zhongshan Hospital Affiliated to Xiamen University","institute of basic medicine, Chinese Academy of medical sciences","Chinese PLA General Hospital","Zhongnan Hospital of Wuhan University","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","West China Second Hospital, Sichuan University, Chengdu, China","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","The First hospital of Peking University","Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Enze Hospital of Taizhou Enze Medical Center (Group)","Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Qilu Hospital of Shandong University","Renmin Hospital of Wuhan University","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Zhongshan Hospital, Fudan University",null,"Hubei Hospital of Traditional Chinese Medicine",null,"Beijing Tsinghua Changgung Hospital;","First Affiliated Hospital of Wenzhou Medical University;","First Affiliated Hospital of Wenzhou Medical University;","The First Affiliated Hospital of Fujian Medical University","The First Affiliated Hospital of Fujian Medical University","Beijing Children's Hospital of Capital Medical University, China;Beijing Children's Hospital of Capital Medical University, China;Beijing Children's Hospital of Capital Medical University, China;",null,"Shanghai Respiratory Research Institution;","Institute of Integrative Medicine of Dalian Medical University",null,null,null,null,"Hu'nan University of Chinese Medicine","Hubei Provincial Hospital of TCM","Key Laboratory of Ministry of Industry and Information Technology of Biomedical Engineering and Translational Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Xinyang Central Hospital","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences",null,"The First Affiliated Hospital of Fujian Medical University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Hubei Provincial Hospital of TCM","Third Affiliated Hospital of Sun Yat-sen University;","Third Affiliated Hospital of Sun Yat-sen University;",null,"the Second Affiliated hospital of Xi'an Jiaotong University","Nanjing Second Hospital","Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University","The Fourth Affiliated Hospital of Zhejiang University School of Medicine","Shanghai Public Health Clinical Center","He'nan Provincial People's Hospital","Lishui Central Hospital","Tongji Hospital of Tongji University","Beijing Geriatric Hospital","West China Hospital of Sichuan University","Affiliated Hospital of Changchun University of traditional Chinese Medicine","The Second Affiliated hospital of Anhui Medical University","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Nanjing Second Hospital","Xianning Central Hospital","Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Sciences","Shanghai Public Health Clinical Center","The First Affiliated Hospital of Harbin Medical University","Department of critical care, Zhongnan Hospital of Wuhan University","Xiamen University","Shanghai Changzheng Hospital","The Fourth Affiliated Hospital of Harbin Medical University","Puren Hospital of Wuhan City","Ganzi Hospital of West China Hospital, Sichuan University","Shanghai University of Traditional Chinese Medicine","Wuxi Fifth People's Hospital","The Thirteenth People's Hospital of Chongqing","Ganzi Hospital of West China Hospital, Sichuan University","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","The Fourth Hospital of Hebei Medical University","Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine","The First Affiliated Hospital of Nanchang University","Central South Hospital, Wuhan University","JC School Of Public Health And Primary Care, The Chinese University Of Hong Kong","Cancelled","West China Hospital, Sichuan University","Chongqing Dianjiang County People's Hospital","First Affiliated Hospital of Anhui Medical University","Chinese PLA General Hospital","Peking University Third Hospital","Peking University Third Hospital","The First Hospital of Jilin University","The First Affiliated Hospital of Chongqing Medical University","Fifth People's Hospital of Ganzhou","Chongqing Three Gorges Central Hospital","The First Affiliated Hospital of Nanchang University","Institutional Review Board, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital affiliated to Tongji Medical College of HUST","Chongqing Public Health Medical Center","Renmin Hospital of Wuhan University","The First Affiliated Hospital of Chongqing Medical University","The Second Affiliated Hospital of Chongqing Medical University","Chongqing Public Health Medical Center","Chongqing Medical University","Beijing YouAn Hospital;","Three Gorges Central Hospital","Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The University of Hong Kong;","The Fifth Medical Center of Chinese PLA General Hospital;",null,null,"Ruijin Hospital, Medical School of Shanghai Jiaotong University Shanghai, China;","The First Affiliated Hospital, College of Medicine of Zhejiang University","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","The Third Affiliated Hospital of the Second Military Medical University","Mianyang Central Hospital","Affiliated Hospital of Chengdu University of Traditional Chinese Medicine",null,"Tasly Pharmaceutical Group Co., Ltd.;","The First Affiliated Hospital of Zhengzhou University","Department of Anesthesiology, West China School of Medicine, Sichuan University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Department of Respiratory Medicine, Shandong Provincial Hospital","Shandong Provincial Hospital","The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease","The First Affiliated Hospital of HeNan University of CM","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Emergency / Intensive Care Department of Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Eergency / Intensive Care Department of Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology","Shenyang Sixth People's Hospital","Central Theater General Hospital of PLA","Xiamen Medical College","Anhui Cancer Hospital","West China Hospital, Sichuan University","Renmin Hospital of Wuhan University","Department of Respiratory and Critical Care Medicine, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology","The First Affiliated Hospital of Hu'nan University of traditional Chinese Medicine","Maoming People's Hospital","Shuguang Hospital Affiliated to Shanghai University of T.C.M.","the Second Affiliated Hospital of Wenzhou Medical University","West China Hospital, Sichuan University","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Huo-Shen-Shan Hospital","Zhongnan Hospital of Wuhan University","Department of Ophthalmology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shiyan Taihe hospital","Affiliated Hospital of Shandong University of Traditional Chinese Medicine","The First Affiliated Hospital of Wenzhou Medical University","Peking University First Hospital","Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","Dalian Medical University","The First Affiliated Hospital of Guangzhou University of TCM","Shanghai Sixth People's Hospital","Zhongnan Hospital of Wuhan University","First People's Hospital of Jiangxi District","The Third Affiliated Hospital of Sun Yat-sen University","The Third Xiangya Hospital, Central South University","Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine Affiliated to Shanghai University of Tranditional Medicine","Wuhan Fourth Hospital","Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of Guangzhou Medical University","West China Hospital, Sichuan University","Hospital of Chengdu University of Traditional Chinese Medicine","Hospital of Chengdu University of Traditional Chinese Medicine","Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shijiazhuang Yiling Pharmaceutical Co., Ltd.","China-Japan friendship hospital","Shanghai Public Health Clinical Center;","Hebei Yiling Hospital","Fujian Provincial Hospital","Hospital of Chengdu University of Traditional Chinese Medicine","Zhengzhou People's Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Peking University First Hospital",null,"Jingzhou Mental Health Center","Zhengzhou People's Hospital","Jinling Hospital, Medical School of Nanjing University",null,"McMaster University;",null,"HwaMei Hospital, University of Chinese Academy of Sciences","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of the Guangzhou Medical University","The Chinese University of Hong Kong","The First Affiliated Hospital, College of Medicine,Zhejiang University","The Third Affiliated Hospital of Zunyi Medical University","Beijing Anzhen Hospital, Capital Medical University","State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University","Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Ninth People's Hospital","Tongji Hospital, Huazhong University of Science and Technology","Department of Breast Surgery, Hubei Cancer Hospital","Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan University Central South Hospital","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology","Zhengzhou people's hospital","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","University Medical Center Utrecht, Julius Centrum UMCU","the First Affiliated Hospital of Xinxiang Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan Third Hospital","The First Affiliated Hospital, He'nan Traditional Chinese Medicine University","Eergency / Intensive Care Department of Tongji Hospital","Tongji hospital, Tongji medical College, Huazhong University of Science and Technology","Tongji Hospital","Ningbo First Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(HUST)","Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Tongji Hospital, Tongji Medical College of HUST","Wuhan 3rd Hospital","The Second Hospital of Hebei Medical University","The Third Hospital of Wuhan","The Third Affiliated Hospital of Zunyi Medical University",null,"Affiliated Hospital of Changchun University of Traditional Chinese Medicine","WenZhou Medical University","Eergency / Intensive Care Department of Tongji Hospital","Cangzhou People's Hospital","Huashan Hospital Fudan University","The People's Hospital of Guangxi Zhuang Autonomous Region","Zhongnan Hospital of Wuhan University","The First Hospital of Changsha","Xiangyang 1st People's Hospital","Clinical Research Institute, Shenzhen-Peking University-The Hong Kong University of Science &amp; Technology Medical Center","Shenzhen Hospital of Southern Medical University","Xiyuan Hospital of China Academy of Chinese Medical Sciences","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Wuhan Third Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Zhejiang Hospital","Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Affilated Hospital of Inner Mongolia University for the Nationalities","Zhongnan Hospital of Wuhan University","The Third Affiliated Hospital of Zunyi Medical University","the First Affiliated Hospital, Guangzhou University of Chinese Medicine","Shandong Provincial Chest hospital","Shandong Provincial Chest Hospital","Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shandong Provincial Chest Hospital","Department of Emergency, Tongji Hospital","Huazhong University of Science and Technology","Shandong Provincial Chest Hospital","West China Hospital, Sichuan University","Shandong Provincial Chest hospital","Affiliated Hospital of Guangdong Medical University","Union hospital of Tongji Medical College, Huazhong University of Science and Technology","Tongren Hospital, Shanghai Jiao Tong University School of Medicine","Ganzi Hospital of West China Hospital, Sichuan University","Affiliated Hospital of Zunyi Medical University","Wuhan Hospital of Integrated Traditional Chinese and Western Medicine","Xiangya Hospital of Central South University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology(HUST)","Hwa Mei Hospital, University of Chinese Academy of Sciences","Wuhan third hospital","Maoming People's Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Fifth People's Hospital, Fudan University","Department of Nephrology, Wuhan Children's Hospital","Hubei Hospital of Traditional Chinese Medicine","The Third Affiliated Hospital of the Second Military Medical University","Shanghai General Hospital","The Third People's Hospital of Shenzhen","Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology","Shanghai Changzheng Hospital","Shandong Provincial Chest Hospital","Yongchuan Hospital, Chongqing Medical University","Jingzhou First People's Hospital","Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine","The Third Affiliated Hospital of Sun Yat-sen University","Guangzhou Panyu central hospital","The Second Affiliated Hospital of Xi'an Medical University","The Sixth Affiliated Hospital of Sun Yat-sen University","Liaocheng People's Hospital","Peking University People's Hospital","The First Affiliated Hospital of Nanchang University","Luohu hospital group medical center of Shenzhen University","Central Hospital of Panyu District, Guangzhou City","Guangzhou reborn health management consultation co., LTD","The Second Affiliated Hospital of Xi'an Jiaotong University","The First Affiliated Hospital of Bengbu Medical College","The First Affiliated Hospital of Guangzhou University of Chinese Medicine","Shandong Provincial Chest hospital","Hubei Provincial Hospital of TCM","Jingzhou First People's Hospital","Guangzhou Eighth People's Hospital","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","The First Affiliated Hospital of Guangzhou Medical University","Shanghai First People's Hospital","Hubei Provincial Hospital of TCM","Guangzhou reborn health management consultation co., LTD","Guangzhou reborn health management consultation co., LTD","Jingzhou Central Hospital","Jingzhou Central Hospital","The Sixth Affiliated Hospital of Guangzhou Medical University (Qingyuan People's Hospital)","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","China-Japan Friendship Hospital","Ningbo First Hospital, Ningbo Hospital of Zhejiang University","Peking University Third Hospital","Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","The Second Clinical College of Guangzhou University of Chinese Medicine","The First Hospital of Harbin Medical University","Wuhan Asia General Hospital","Wuhan University;","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",null,"Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine","Harbin Peiyou Jiandi Biotechnology Co., Ltd","First people's hospital of Jiangxi district, Wuhan","The Second Affiliated Hospital of Xi'an Jiaotong University","Affiliated Hospital of Zunyi Medical University","Guangzhou reborn health management consultation co., LTD","Guangzhou reborn health management consultation co., LTD","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Research office of wuhan renmin university;","The People's Hospital of GuangXi Zhuang Autonomous Region","University Hospital, Clermont-Ferrand;","Zhengzhou People's Hospital","Union Hospital West Campus, Tongji Medical College, Huazhong University of Science and Technology","The Third Xiangya Hospital of Central South University","The Fifth Affiliated Hospital of Sun Yat-Sen University","Xiangyang 1st People's Hospital","Department of Respiratory Medicine, Changzheng Hospital, Naval Military Medical University","Mental Health Service Center, Beijing Normal University","Ningbo Kangning Hospital","Nursing Department of Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine","Hu'nan Cancer Hospital","HwaMei Hospital, University of Chinese Academy of Sciences","Hu'nan Provincial People's Hospital, Hu'nan Normal University","PLA General Hospital","Beijing Chaoyang Hospital","The First Affiliated Hospital of Guangzhou Medical University","Shenzhen Third People's Hospital","Department of Respiratory Medicine, Changzheng Hospital, Naval Military Medical University",null,"Shenzhen Geno-Immune Medical Institute;","Renmin Hospital of Wuhan University","Hwa Mei Hospital, University of Chinese Academy of Sciences","The First Affiliated Hospital of Nanchang University","Department of Infectious Diseases, Anqing Municipal Hospital","The Fifth Hospital Affiliated to Sun Yat-sen University","West China Hospital of Sichuan University","Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital)","Guangzhou Eighth People's Hospital","Department of Infectious Diseases, Foshan First People's Hospital","Jiangsu Provincial Center for Disease Control and Prevention","Shandong Provincial Hospital","The Fifth Affiliated Hospital of Sun Yat-sen University","HuiZhou Municipal Central Hospital","The 2nd Xiangya Hospital of CSU","Wuhan Third Hospital","Beijing Chao-yang Hospital, Capital Medical University","Guangzhou Eighth People's Hospital","Zhongnan Hospital of Wuhan University","The Second Affiliated Hospital of Guizhou University of traditional Chinese Medicine","Central Theater General Hospital of PLA","Renmin Hospital of Wuhan University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Renmin Hospital of Wuhan University","HwaMei Hospital, University of Chinese Academy of Sciences","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine","The Second Affiliated Hospital of Nanchang University","Shanghai Kongjiang Hospital","West China Second University Hospital, Sichuan University","The Fifth Affiliated Hospital of Sun Yat-Sen University","The First Affiliated Hospital of Medical College of Zhejiang University","The Second Xiangya Hospital of Cental South University","Intensive Care Unit, XiangYa Hospital, Central South University","Guangzhou Eighth People's Hospital","The First Affiliated Hospital of Nanchang University","Ruijin Hospital, Shanghai Jiaotong University School of Medicine","Fondation Mditerrane Infection (FMI) - IHU Mditerrane Infection","Klinik fr Ansthesiologie und Intensivtherapie; Universittsklinikum Leipzig","Tehran University of Medical Sciences","Iran University of Medical Sciences","Tehran University of Medical Sciences","Qazvin University of Medical Sciences","Shahid Beheshti University of Medical Sciences","Tehran University of Medical Sciences","Tehran University of Medical Sciences",null,"Tehran University of Medical Sciences","Gunma University Hospital","APHP","The Second Hospital of Nanjing Medical University","Gunma Universty Hospital","Fujita Health University Hospital","The 2nd Affiliated Hospital of Wenzhou Medical University",null,"The First Affiliated Hospital of Guangzhou Medical University",null,null,null,"Saiseikai Utsunomiya Hospital Department of emergency medicine and intensive care unit","Shenzhen Geno-Immune Medical Institute;",null,"Jingzhou Hospital of Traditional Chinese Medicine;Yangtze University Health Science Center;Hubei Hospital of Traditional Chinese Medicine",null,null,"National Center for Global Health and Medicine Center for Clinical Sciences","Assistance Publique Hopitaux de Paris",null,null,"Yale-NUS College;","Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University;Yangtze University Health Science Center;Hubei Hospital of Traditional Chinese Medicine;China Academy of Chinese Medical Sciences;",null,null,"Tongji Hospital;",null,"Clinical Investigations Center;",null,null,null,null,"Henan Provincial People's Hospital;","National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;","IRCCS Neuromed;","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Uppsala University Hospital;","Maternal and Child Health Hospital of Hubei Province",null,"Xiangya Hospital;",null,"National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;National Institute of Respiratory Diseases - Mxico;","Shandong Eye Institute","Guangdong Second Provincial General Hospital","Taizhou Hospital of Zhejiang Province","Center for Regenerative Medicine, Renmin Hospital of Wuhan University","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Nanjing University Medical College Affiliated Drum Tower Hospital","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Tongji Hosptial, Tongji Medical College, Huazhong University of Science and Technology","Medical director of UCCP CATANZARO, Italy;","Shandong Eye Institute","China European International Business School (CEIBS)","Department of Public Health and Management, Chongqing Medical University","Department of Pediatrics, The Third Affiliated Hospital of Sun Yat-sen University","Renmin Hospital of Wuhan University","China-Japan Union hospital of Jilin University","West China Hospital, Sichuan University","Yichang Central People's Hospital",null,"School of Public Health and Management, Chongqing Medical University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Beijing You'an Hospital, Capital Medical University","Wuhan Third Hospital &amp; Tongren Hospital of Wuhan University","Zhengzhou People's Hospital","People's hospital of Zhengzhou","Department of anesthesiology, Renmin Hospital of Wuhan University","Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine","The First Rehabilitation Hospital of Shanghai","Nothern Jiangsu People's Hospital","Hospital of Chengdu University of Traditional Chinese Medicine","First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","Hospital of Chengdu University of Traditional Chinese Medicine","Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine","the First Affiliated Hospital of Guangzhou Medical University","Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine","Diagnosis, treatment and Research Center for infectious diseases, the fifth medical center of the PLA","Guangdong Provincial Hospital of Chinese Medicine","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)","China Academy of Chinese Medical Sciences","Daping Hospital, Army Medical University","West China Hospital, Sichuan University","West China Hospital, Sichuan University","UZ Leuven","Shanghai University of Traditional Chinese Medicine","Sanofi-aventis France","University Medical Center Utrecht","Universittsklinikum Tbingen","Oslo university hospital","Synairgen Research Ltd","Pulmotect, Inc.;","Hospices Civils de Lyon;",null,"University of Oxford;",null,"Fourth Military Medical University;Massachusetts General Hospital",null,"Qilu Hospital of Shandong University, Karolinska Institutet;Qilu Hospital of Shandong University;","Insitute for Translational Medicine, University of Pcs, HU;",null,null,"Pulmotect, Inc.;",null,"BHC &amp; UCL;RFH &amp; UCL;BHC &amp; UCL;BHC &amp; QMUL;UCL;BHC &amp; QMUL;Barts Heart Center;","Columbia University Irving Medical Center;",null,null,null,"Rambam MC;","Istanbul University-Cerrahpasa;",null,"Hospital of Prato, Italy;","Changhai Hospital",null,null,"Guangzhou Eighth People's Hospital","St. Michael's Hospital, Toronto;","Foundation IRCCS San Matteo Hospital","Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy;Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy;Dept. of Information Engineering and Computer Science, University of Trento, Italy;Diagnostic and Interventional Ultrasound Unit, Valle del Serchio Hospital, Lucca, Italy;","Xiyuan Hospital of China Academy of Chinese Medical Sciences;","Wuhan University Renmin Hospital","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Chongqing Public Health Center;",null,"Assistance Publique - Hpitaux de Paris;",null,"2nd People's Hospital of Fuyang City","Peking Union Medical College Hospital",null,"UZ Leuven;","Wuhan Women and Children's Health Care Center","Affiliated Hospital of Zunyi Medical University","Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine","Misr University for Science and Technology","University of Trieste;","Population Health Research Institute;Population Health Research Institute;",null,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Shanghai Oriental Hospital","Huangshi Hospital of Traditional Chinese Medicine","The First People's Hospital of Jiangxia District, Wuhan","Tongji Hospital of Tongji Medical College; Huazhong Science and Technology University","Affiliated Hospital of Southwest Medical University","The Fifth Affiliated Hospital of Sun Yat-Sen University","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","University Hospital Essen, Deparment of Cardiology and Vascular Medicine;","Rad-AID;",null,"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","the First People's Hospital of Jiangxia District","Department of Integrated Traditional Chinese &amp; Western Medicine, Xiangya Hospital, Central South University","INSERM","Peking University Sixth Hospital","Shanghai Sixth People's Hospital","Wuhan Asia General Hospital","Peking University Third Hospital","Eastern theater General Hospital","Peking University First Hospital","Nanjing University","The Fifth Medical Center of PLA General Hospital","University Hospital Ghent","Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories SA","Amsterdam UMC","Akershus University Hospital","CTC North GmbH &amp; CO.KG","F. Hoffmann-La Roche Ltd","Professor",null,null,"Ansun Biopharma, Inc.;","CHU Angers","URCIP- CHU Saint Etienne",null,null,null,null,"Ansun Biopharma, Inc.;",null,"Universit de Sherbrooke and CIUSSS de l'Estrie - CHUS;Sunnybrook Health Sciences Centre, University of Toronto;","Akerhus University Hospital;","Head of Department;",null,null,"The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark","Service Hygine, Epidmiologie et Prvention;","Department of Hepatology, Division 2, Beijing Ditan Hospital;","Qilu Hospital of Shandong University;","Gilead Sciences;","Renmin Hospital of Wuhan University;","University Clinic Freiburg;","University of Oxford;","Khyber Medical University Peshawer;",null,null,null,null,"Peking University First Hospital;",null,null,"Wake Forest University Health Sciences;","Gilead Sciences;",null,null,"University of Minnesota;",null,"University of Oxford, UK;","University of Washington;NYU Langone Health;","University of Calgary;University of Calgary;","The fifth medical center of PLA general hospital;","Ascletis Pharmaceuticals Co., Ltd.",null,null,null,"Ictal Group;","Duke University;","Hospital Israelita Albert Einstein;","Intermountain Health Care, Inc.;","University of Calgary;",null,"University of Minnesota;University of Minnesota;","Jiangsu Province Centers for Disease Control and Prevention;Hubei Provincial Center for Disease Control and Prevention;Tongji Hospital","Regeneron Pharmaceuticals;",null,"Massachusetts General Hospital;","NeuroRx, Inc.;","University of Minnesota;University of Minnesota;","University of Medicine and Pharmacy Gr T Popa - Iasi;University of Medicine and Pharmacy Gr T Popa - Iasi;","UnitedHealth Group","Hospital do Corao;Hospital do Corao;","ASST PAPA GIOVANNI XXIII;","Mayo Clinic",null,"Charit-Universittsmedizin Berlin - Department of Psychiatry and Psychotherapy;Charit-Universittsmedizin Berlin - Department of Psychiatry and Psychotherapy;","Emory University;","Federico II University;Inversity of Milan, BICOCCA;Universit degli Studi di Brescia;University of Bologna;University of L'Aquila;Univerity of Rome \"La Sapienza\";University of Udine;","Institute of Human Virology, University of Maryland Baltimore;","Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale;",null,null,"University of California, San Francisco;",null,"Mayo Clinic",null,"University of Chicago, Department of Medicine, Section of Rheumatology;",null,"Erasme hospital;Minas Gerais University;","Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran;","Assiut University;","William Beaumont Hospitals;",null,null,"Hoffmann-La Roche;","Oslo University Hospital;Oslo University Hospital;Oslo University Hospital;Oslo Hospital Pharmacies;Oslo University Hospital;Oslo University Hospital;NorCRIN;","xCures;",null,"University of Cambridge &amp; Cambridge University Hospitals NHS Foundation Trust;",null,null,"Murdoch Children's Research Institute;","Washington Univeristy School of Medicine;University College, London;Wits University;",null,"Intermountain Health Care, Inc.;","Guys and St Thomas' NHS Foundation Trust;","Montreal Heart Institute;Montreal Health Innovations Coordinating Center;","Johns Hopkins University;","Istituto di Ricerche Farmacologiche Mario Negri IRCCS;","Fondazione Policlinico Universitario A. Gemelli IRCCS;","The Parker Institute;","Direttore Dipartimento di Malattie Infettive;",null,"Sanofi;","Karolinska University Hospital (and karolinska Insitutet);",null,null,"Assistance Publique - Hpitaux de Paris;",null,"University Hospital Bern (Inselspital);","Hospital Universitario Dr. Negrin;",null,"Rush University Medical Center;","Global Alliance Regenerative Medicine",null,"University of Medicine and Pharmacy \"Gr. T. Popa\" Iasi, Romania;Medical Sciences Academy from Romania;","Istituto di Ricerche Farmacologiche Mario Negri IRCCS;",null,"University of Minnesota;","Professor of vaccinology;","Azidus Brasil;",null,"Lady Davis Institute for Medical Research, McGill University;","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran;","UH MONTPELLIER;","Duke University;",null,"University Hospital, Lille;","Vice-Chancellor for Research, Mazandaran University of Medical Sciences","Aarhus Universitets Hospital;","University Hospital, Ghent;","Assistance Publique - Hpitaux de Paris;","Jean Bernard Center - LE MANS;",null,"University Hospital, Ghent;","Teaching Director of Teaching &amp; Research Institute Srio-Libans Hospital;",null,"ASSISTANCE PUBLIQUE HPITAUX de MARSEILLE;","Virginia Commonwealth University","Institute of Global Health Innovation;","Bassett Medical Center;","Institut Pasteur de la Guyane, Head of Epidemiology Unit;",null,"Director Department of Obstetrics and Gynecology BUMCP;","Institute of zoology, Chinese Academy of Sciences;","Universidad del Rosario;",null,null,null,"University of Pennsylvania;","Gangnam Severance Hospital;",null,null,"Vancouver Coastal Health;","Cedars-Sinai Medical Center, Los Angeles, CA 90048;","Mayo Clinic;",null,null,null,"Providence Medical Group Infectious Disease;Providence Ambulatory Quality and Clinical Services","Renmin Hospital of Wuhan University;LanZhou University;Tianjin Second People's Hospital;Sixth Peoples Hospital of Shenyang;Ankang Central Hospital;Guangxi Zhuang Autonomous Region;Dalian Sixth Peoples Hospital;Xingtai People's Hospital;Shenzhen Third People's Hospital;Minda Hospital Affiliated to Hubei University for Nationalities;Suizhou Hospital, Hubei University of Medicine;Wuhan Union Hospital, China;The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture;The Affiliated Third Hospital of Jiangsu University;The Central Hospital of Lishui City;LanZhou University;","Hospital Clnic de Barcelona;","National University of Ireland, Galway, Ireland;","King's College London;",null,null,"Barcelona Institute for Global Health",null,"Fasa University of Medical Sciences;","Princess Margaret Cancer Centre;Princess Margaret Cancer Centre;",null,"Ziekenhuis Oost-Limburg;",null,"HonorHealth Research Institute;",null,"Assistance Publique - Hpitaux de Paris;","ProgenaBiome;",null,"Istanbul University-Cerrahpasa;Biruni University;","Professor (Medicine -Infectious Diseases);",null,"University of California, San Francisco;University of California, San Francisco;",null,"Universidad del Rosario;",null,"Hospital San Jos;",null,null,"Children's University Hospital Cologne;Department I of Internal Medicine University Hospital Cologne;Children's University Hospital Cologne;","Jiangsu Province Centers of Disease Control and Prevention;","Rutgers Biomedical Health Sciences;Rutgers Institute for Translational Medicine and Science;","Rutgers, The State University of New Jersey;Rutgers Cancer Institute of New Jersey;",null,null,"Fondation Adolphe de Rothschild;",null,null,"Massachusetts General Hospital;","Baylor Health Care System","Imperial College Healthcare NHS Trust;",null,"CHU Angers, service de mdecine intensive ranimation;","Rigshospitalet, Denmark;Herlev Hospital;Hvidovre University Hospital;Nordsjllands Hospital;","CH Tourcoing;CH Tourcoing;","Can-Fite BioPharma Ltd;","Peking University First Hospital;","Universidad de Granada;","Duke University;","Yale University;",null,"The Cleveland Clinic",null,null,null,null,"Max Healthcare;","Chief Medical Officer;Principal Investigator;Principal Investigator;",null,"University of Kansas Medical Center;","Stiftung IHF and Klinikum der Stadt Ludwigshafen;","University Hospital, Angers",null,null,"University Amsterdam;","HaEmek Medical Center, Israel;","Sanofi;",null,null,null,"Tabula Rasa HealthCare;Tabula Rasa HealthCare;Tabula Rasa HealthCare;Tabula Rasa HealthCare",null,"University of Chicago Biological Sciences Division Department of Surgery;","Nimes University Hospital;","IOB Institute of Oncology, Vall dHebron Institute of Oncology (VHIO);",null,"Department of Rheumatology, Aalborg University Hospital;",null,null,null,"Inovio Pharmaceuticals;","University Hospital, Lille;",null,null,"University Hospital Inselspital, Berne;",null,"Peking University First Hospital;",null,"I-Mab Biopharma US Limited;",null,"Henry Ford Health System;Henry Ford Health System;","Hospital Materno-Perinatal \"Mnica Pretelini Senz\";",null,"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",null,null,"University of Alabama at Birmingham;","University Hospital of Nantes;University Hospital of Tours;University Hospital of Rennes;University Hospital of Poitiers;University Hospital of Brest;Hospital of Cholet;Hospices Civils de Lyon (University Hospital of Lyon);Hospital of Saint-L;University Hospital, Rouen;","ProgenaBiome;","Plan Nacional sobre el Sida (PNS);Harvard School of Public Health",";The Capital Region's Unit of Inherited Cardiac Diseases Faculty of Health and Medical Sciences University of Copenhagen Rigshospitalet, University of Copenhagen","CHU de NICE - Archet 1;","the First Affiliated Hospital of Nanjing Medical University","Wuhan Fourth Hospital",null,"University of Cincinnati;",null,"University Hospital, Lille;",null,"University Hospital Jena;","University of Colorado/Children's Hospital Colorado;","Barts &amp; The London NHS Trust;Queen Mary University of London;","Chinese University of Hong Kong","Shanghai Orient Hospital","Radboud University;","Center for Regenerative Medicine, Renmin Hospital of Wuhan University;",null,"Mayo Clinic;",null,"Aga Khan University;","Karolinska Institutet;","Beijing University of Chinese Medicine","Shenzhen Ruipuxun Academy for Stem Cell &amp; Regenerative Medicine","ASST Fatebenefratelli Sacco",null,"Novartis Pharmaceuticals;",null,"Hospital General Universitario Morales Meseguer;Hospital General Universitario Morales Meseguer;","University Hospital Tbingen;",null,"Washington University School of Medicine;",null,null,"Wake Forest University Health Sciences;","London School of Hygiene and Tropical Medicine;London School of Hygiene and Tropical Medicine;",null,null,null,null,"University of Health Sciences Lahore;",null,"Eli Lilly and Company;","University Hospital, Montpellier;","Service de Chirurgie Thoracique Nouvel Hpital Civl Hpitaux Univesitaires de Strasbourg;","Dr Cipto Mangunkusumo General Hospital;Fakultas Kedokteran Univeristas Indonesia;",null,"University Hospital Ghent","Hackensack Meridian Health;",null,null,"Ochsner Health System;",null,"Genesis Foundation;Genesis Foundation;",null,"National Institute of Mental Health (NIMH);","University of Minnesota;","Medical Oncologist;","HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS",null,null,"Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;Shahid Beheshti University of Medical Sciences;",null,null,null,"University of Colorado, Denver;","Peking Union Medical College Hospit;",null,"+4970712986622;",null,null,null,null,null,"APHP;","Sorbonne Universit, GRC 001, GREEN Groupe de Recherche en Neuro-Urologie, AP-HP, Hpital Tenon, F-75020, Paris, France;","University of Miami;","Beijing Sports University","Jiangsu Provincial Hospital","Huanggang Central Hospital","Wuhan University","Huzhou Central Hospital","Women's Hospital, Medical School of Zhejiang University","Tan Tock Seng Hospital;","University of Utah;","Erasmus Medical Center;","Columbia University Irving Medical Center;","Huoshenshan Hospital","Shanghai Jiao Tong University Affiliated Sixth People's Hospital","Union Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology",null,"Duke University;",null,null,"11 MDG;NMRTC Bethesda;11 MDG;11 MDG;","West China Hospital, Sichuan University","the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China",null,null,null,null,"Duke University;Duke University;","Brigham and Women's Hospital;",null,"ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)",null,null,null,"IKT Ulm","CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC","Groupe Hospitalier Paris Saint Joseph - Hpital Marie Lannelongue",null,null,"FIB-HCSC","FFIS",null,";","Delos Clinical","Eunate Arana Arri (Instituto Investigacin Biocruces Bizkaia)","Hpital Fondation Adolphe de Rothschild","FISABIO","The First Affiliated Hospital of Yangtze University","The Second Xiangya Hospital of Central South University","ISGlobal","Jiangsu Provincial Center for Disease Control and Prevention","Shandong Provincial Hospital","Chinese PLA General Hospital","Wenzhou Central Hospital",null,null,null,null,"Assistance Publique - Hpitaux de Paris","InflaRX GmbH","CHU Saint Etienne","Centre Lon Brard","APHP","Dr. Xavier Solanich Moreno. Servei Medicina Interna. Hospital de Bellvitge","INSTITUT DE RECERCA H. SANTA CREU I SANT PAU","Effice","sanofi-aventis recherche &amp; dveloppement","Fundacin para la Investigacin Biomdica Hospital Ramn y Cajal"],["Inclusion criteria: 2019-nCoV-infected pneumonia diagnosed patients, the diagnostic criteria refer to \"guideline of the diagnose and treatment of 2019-nCoV (trial)\" published by National Health Committees of Peoples' Republic Country \"","Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission.\r&lt;br&gt;Criteria for diagnosis (meet all the following criteria):\r&lt;br&gt;1. Epidemiologic history.\r&lt;br&gt;2. Clinical manifestations (meet any 2 of the following): fever, normal or decreased white blood cell count or lymphopenia in the early stage of onset, and Chest radiology in the early stage shows multiple small patchy shadowing and interstitial changes which is especially significant in periphery pulmonary. Furthermore, it develops into bilateral multiple ground-glass opacity and infiltrating shadowing. Pulmonary consolidation occurs in severe cases. Pleural effusion is rare;\r&lt;br&gt;3. Confirmed case (suspected case obtained one of the following etiologic evidences): a positive result to real-time reverse-transcriptase PCR for respiratory specimen or blood specimen, or Genetic sequencing result of virus in respiratory or blood specimens are highly homologous to SARS-CoV-2.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Patients diagnosed with RT-PCR for 2019 Novel Coronavirus (2019-nCoV)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Patients infected with other viruses\r&lt;br&gt;","Inclusion criteria: 1. Aged &gt;=18 years; \r&lt;br&gt;2. Diagnosed of 2019-nCoV infection with \"guideline of the diagnose and treatment of 2019-nCoV (tested the fourth edition)\" published by National Health Committees of Peoples' Republic Country.\r&lt;br&gt;3. Failed by conventional treatment needing ECMO support.","Inclusion criteria: 1. Laboratory confirmed diagnosis of COVID19 infection by RT-PCR;\r&lt;br&gt;2. Aged &gt; 18 years;\r&lt;br&gt;3. Written informed consent given by the patient or next-of-kin;\r&lt;br&gt;4. Clinical deterioration despite conventional treatment that required intensive care.","Inclusion criteria: Children diagnosed with novel coronavirus pneumonia through epidemiological history, clinical symptoms, and nucleic acid test results.","Inclusion criteria: 1. Meet the diagnostic criteria forconfirmed cases  in the Diagnosis and Treatment of Pneumonia of New Coronavirus Pneumonia (Trial Version 5);\r&lt;br&gt;2. The acute stage is complicated by sepsis, respiratory failure, ARDS and so on. The patients are with multiple organ damage when improved and tended to recover after organ support and other treatments; \r&lt;br&gt;3. Meet the TCM diagnostic criteria for the recovery period;\r&lt;br&gt;4. Aged 18-75 years-old men or women;\r&lt;br&gt;5. Patients who volunteer to participate in this study and sign informed consent.","Inclusion criteria: 1. Suspected, mild, normal and severe cases diagnosed in accordance with the diagnosis and treatment scheme for pneumonia of novel coronavirus infection (trial version 5);\r&lt;br&gt;2. The expert team of consultation in our hospital will participate in the diagnosis and treatment.","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;\r&lt;br&gt;2. Voluntarily sign written informed consent.","Inclusion criteria: Pneumonia cases with suspected SARS-CoV-2have either of the following epidemiological histories consistent with the following two clinical manifestations:\r&lt;br&gt;A comprehensive analysis was conducted based on the following epidemiological history and clinical manifestations\r&lt;br&gt;1. Epidemiological history\r&lt;br&gt;(1) Travel history or residence history of wuhan and surrounding areas or other communities shall provide case reports within 14 days before the onset of the disease;\r&lt;br&gt;(2) Cases have been reported in the past 14 days in patients with fever or respiratory symptoms in community residents of wuhan and surrounding areas;\r&lt;br&gt;(3) Aggressive attack;\r&lt;br&gt;(4) History of exposure to new coronavirus infections people with new coronavirus infections are those who have tested positive for nucleic acid;\r&lt;br&gt;2. Clinical manifestations\r&lt;br&gt;(1) Fever and/or respiratory symptoms;\r&lt;br&gt;(2) Pneumonia with the above imaging features;\r&lt;br&gt;(3) The total number of white blood cells was normal or decreased or the number of lymphocytes decreased at the initial stage of the disease.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  In sputum, throat swab, lower respiratory tract secretion, blood and other samples,\r&lt;br&gt;             the nucleic acid of the novel coronavirus was positive, or the sequencing of the virus\r&lt;br&gt;             gene was highly homologous with the known novel coronavirus\r&lt;br&gt;\r&lt;br&gt;          -  Age is between 18-80 years old, the weight is more than 30kg, and there is no limit\r&lt;br&gt;             for men and women\r&lt;br&gt;\r&lt;br&gt;          -  The following conditions were met: creatinine = 110 umol / L, creatinine clearance\r&lt;br&gt;             rate (EGFR) = 60 ml / min / 1.73m2, AST and ALT = 5  ULN, TBIL = 2  ULN;\r&lt;br&gt;\r&lt;br&gt;          -  The subjects should fully understand the purpose, nature, method and possible reaction\r&lt;br&gt;             of the study, voluntarily participate in the study and sign the informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Have a clear history of lopinavir or ritonavir or arbidol allergy\r&lt;br&gt;\r&lt;br&gt;          -  Severe nausea, vomiting, diarrhea and other clinical manifestations affect the oral or\r&lt;br&gt;             absorption of the drugs\r&lt;br&gt;\r&lt;br&gt;          -  At the same time, take drugs that may interact with lopinavir or ritonavir or arbidol\r&lt;br&gt;\r&lt;br&gt;          -  Patients with serious underlying diseases, including but not limited to heart disease\r&lt;br&gt;             (including history of angina pectoris or coronary heart disease or myocardial\r&lt;br&gt;             infarction, atrioventricular block), lung, kidney, liver malfunction and mental\r&lt;br&gt;             diseases that cannot be treated together\r&lt;br&gt;\r&lt;br&gt;          -  ancreatitis or hemophilia\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant and lactating women\r&lt;br&gt;\r&lt;br&gt;          -  Suspected or confirmed history of alcohol and drug abuse\r&lt;br&gt;\r&lt;br&gt;          -  Participated in other drug trials in the past month\r&lt;br&gt;\r&lt;br&gt;          -  The researchers judged that patients were not suitable for the study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients visiting emergency department.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        -\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  can use mobil phone or computer\r&lt;br&gt;\r&lt;br&gt;          -  volunteer to take part in the investigation\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  can not use phone or computer\r&lt;br&gt;\r&lt;br&gt;          -  unwilling to take part in the investigation\r&lt;br&gt;","Inclusion criteria: Confirmed or suspected case of COVID-19 in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.\r&lt;br&gt;1. Aged &lt;= 75 years;\r&lt;br&gt;2. Patients with newly diagnosed and suspected coronavirus pneumonia;\r&lt;br&gt;3. Willing and able to sign informed consent.","Inclusion criteria: (1) Patients diagnosed with 2019-nCoV pneumonia;\r&lt;br&gt;(2) Patients admitted to the ICU during the study period.","Inclusion criteria: 1. General/severe/critical patients who meet the diagnostic criteria of new coronavirus pneumonia;\r&lt;br&gt;2. Patients whose viral nucleic acid has turned negative after treatment;\r&lt;br&gt;3. Patients who are characterized by respiratory symptoms such as cough, shortness of breath, chest tightness or corresponding chest imaging features;\r&lt;br&gt;4. Patients who meet TCM syndrome; \r&lt;br&gt;5. Patients who voluntarily participate in the study and sign informed consent.","Inclusion criteria: Patients diagnosed by nucleic acid and/or genetic test in Wuxi (later expanded to southern Jiangsu and Jiangsu Province) with novel coronavirus pneumonia, and other types of viral pneumonia confirmed by nucleic acid and/or genetic testing and/or pathological testing, cases of mycoplasma pneumonia, fungal pneumonia, hypersensitivity pneumonia, and mixed pulmonary infections with similar imaging findings that need to be differentiated from novel coronavirus pneumonia.","Inclusion criteria: Meet the diagnostic criteria of Novel Coronavirus Pneumonia (COVID-19).","Inclusion criteria: 1. patients with novel coronavirus pneumonia confirmed by pathogenic detection;\r&lt;br&gt;2. Fever, respiratory tract and other symptoms, the change of pneumonia can be seen in imaging;\r&lt;br&gt;3. Aged 18 to 80 years;\r&lt;br&gt;4. Signed informed consent.","Inclusion criteria: 1. Subjects have signed informed consent; agree not to participate in other clinical studies within 30 days from the first administration of the research drug to the last administration.\r&lt;br&gt;2. Aged &gt;= 18 and &lt;= 75 years.\r&lt;br&gt;3. Met the diagnostic criteria for COVID-19 (fifth edition, China).\r&lt;br&gt;4. SOFA score: 2 to 13 points.\r&lt;br&gt;COVID-19 clinical stratifications:\r&lt;br&gt;1. Mild (n = 200): The clinical symptoms are mild or asymptomatic, and no pneumonia is seen on imaging, but the throat swab or mouthwash 2019-nCOV is positive.\r&lt;br&gt;2. General type (n = 160): with fever, respiratory tract symptoms, etc. Imaging shows pneumonia.\r&lt;br&gt;3. Severe type (n = 80): Meet any of the following criteria.\r&lt;br&gt;(1) Respiratory distress, RR &gt;= 30 times / minute.\r&lt;br&gt;(2) In the resting state, the oxygen saturation is &lt;= 93%.\r&lt;br&gt;(3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;= 300mmHg (1mmHg = 0.133kPa).\r&lt;br&gt;4. Critical type (n = 80): One of the following criteria:\r&lt;br&gt;(1) Respiratory failure (ARDS) occurs and requires mechanical ventilation.\r&lt;br&gt;(2) Shock.\r&lt;br&gt;(3) Combined failure of other organs requires ICU monitoring and treatment.","Inclusion criteria: 1. Hospitalized patients with novel coronavirus pneumonia confirmed by pathogenic detection\r&lt;br&gt;2. Meet any one of the criteria for severe type:\r&lt;br&gt;1) Respiratory distress: RP &gt;= 30/min;\r&lt;br&gt;2) At rest, the oxygen saturation &lt;= 93%;\r&lt;br&gt;3) Arterial partial pressure of oxygen (PaO2)/Fraction of inspiration (FiO2)(Oxygenation Index, P/F) &lt;= 300mmHg.\r&lt;br&gt;3. Aged 18 to 75 years;\r&lt;br&gt;4. Signed informed consent.","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;\r&lt;br&gt;2. Above 18 years old (inclusive);\r&lt;br&gt;3. Voluntarily sign written informed consent.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed 2019-nCoV infection case in term of laboratory evidence;\r&lt;br&gt;\r&lt;br&gt;          -  80 years = age = 14years;\r&lt;br&gt;\r&lt;br&gt;          -  Within 72 hours after the onset of abnormalities shown by Chest radiology or several\r&lt;br&gt;             symptoms (fever and cough).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt; 14 years or &gt; 80 years;\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or lactating female;\r&lt;br&gt;\r&lt;br&gt;          -  One of the following items occurred at the enrollment: (i) respiratory failure\r&lt;br&gt;             necessitating mechanical ventilation; (ii) liver failure: total bilirubin = 10mg/dL\r&lt;br&gt;             and/or severe coagulation disorders; (iii) renal function failure: although adequate\r&lt;br&gt;             circulating blood and cardiac output, urine = 0.5ml/kgh, Cr or BUN = 1.5 times normal\r&lt;br&gt;             elevation;\r&lt;br&gt;\r&lt;br&gt;          -  Intake of Chinese medicinal herbs during the past 2 weeks;\r&lt;br&gt;\r&lt;br&gt;          -  Refused to sign an informed consent form prior to study participation;\r&lt;br&gt;\r&lt;br&gt;          -  Unwilling and unable to comply with protocol request.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Sign the informed consent form;\r&lt;br&gt;\r&lt;br&gt;          2. Age =18 years, regardless of gender;\r&lt;br&gt;\r&lt;br&gt;          3. Subjects with pneumonia diagnosed as 2019-nCoV infection; A) Detection of 2019-nCoV\r&lt;br&gt;             nucleic acid positive by RT-PCR in respiratory tract or blood samples.\r&lt;br&gt;\r&lt;br&gt;             B) The virus gene sequence of respiratory tract or blood samples is highly homologous\r&lt;br&gt;             to the known 2019-nCoV.\r&lt;br&gt;\r&lt;br&gt;          4. According to the standard of \"pneumonia diagnosis and treatment Program of New\r&lt;br&gt;             Coronavirus infection (trial Fifth Edition)\" issued by National Health Commission of\r&lt;br&gt;             the People's Republic of China, clinical classification: mild, ordinary subjects; A)\r&lt;br&gt;             Mild type, the clinical symptoms were mild and no pneumonia was found in imaging.\r&lt;br&gt;\r&lt;br&gt;        B) Common type, With fever, respiratory tract and other symptoms, the manifestations of\r&lt;br&gt;        pneumonia can be seen on imaging.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Critical type:\r&lt;br&gt;\r&lt;br&gt;             If one of the following conditions is met:\r&lt;br&gt;\r&lt;br&gt;             A) Respiratory failure occurs and mechanical ventilation is needed; B) Shock occurred;\r&lt;br&gt;             C) Patients with other organ failure need ICU monitoring treatment.\r&lt;br&gt;\r&lt;br&gt;          2. Severe type:\r&lt;br&gt;\r&lt;br&gt;             If one of the following conditions is met:\r&lt;br&gt;\r&lt;br&gt;             A) Respiratory distress, RR = 30 beats / min; B) In resting state, finger oxygen\r&lt;br&gt;             saturation (SaO2) = 93%; C) Partial pressure of arterial oxygen (PaO2) / concentration\r&lt;br&gt;             of oxygen inhaled (FiO2)=300mmHg)\r&lt;br&gt;\r&lt;br&gt;          3. Those who have a history of allergy to this class of drugs and / or severe allergic\r&lt;br&gt;             constitution;\r&lt;br&gt;\r&lt;br&gt;          4. The results of laboratory tests are abnormal:\r&lt;br&gt;\r&lt;br&gt;             A) Hematological dysfunction is defined as:\r&lt;br&gt;\r&lt;br&gt;             i) Platelet (PLT) count: &lt;100  109 / L; ii) hemoglobin (Hb) level &lt;90g/L.\r&lt;br&gt;\r&lt;br&gt;             B) abnormal liver function is defined as:\r&lt;br&gt;\r&lt;br&gt;             i) level of total bilirubin(TBil) : &gt;2 times Upper Limits of Normal(ULN); ii) the\r&lt;br&gt;             levels of aspartate aminotransferase (AST) and Alanine transaminase (ALT):&gt;3 times of\r&lt;br&gt;             ULN.\r&lt;br&gt;\r&lt;br&gt;             C) definition of renal dysfunction:\r&lt;br&gt;\r&lt;br&gt;             Serum creatinine&gt;1.5 times of ULN, or calculated creatinine clearance&lt;50ml / min;\r&lt;br&gt;\r&lt;br&gt;             D) definition of abnormal blood coagulation:\r&lt;br&gt;\r&lt;br&gt;             International normalized ratio(INR) &gt;1.5 times of ULN, and the prothrombin time ((PT))\r&lt;br&gt;             or activated partial thromboplastin time (aPTT) is 1.5 times of ULN, unless the\r&lt;br&gt;             subject is receiving anticoagulant therapy.\r&lt;br&gt;\r&lt;br&gt;          5. Abidor was used before inclusion(Tablets, capsules, granules).\r&lt;br&gt;\r&lt;br&gt;          6. Women who are nursing or pregnant.\r&lt;br&gt;\r&lt;br&gt;          7. Serum or urine pregnancy tests were positive for women of child-bearing age.\r&lt;br&gt;\r&lt;br&gt;          8. Immunodeficient patient(Patients with malignant tumors, Organ or bone marrow\r&lt;br&gt;             transplant, HIV patient, those who took immunosuppressive drugs within 3 months before\r&lt;br&gt;             the screening test ).\r&lt;br&gt;\r&lt;br&gt;          9. With the following history of present illness:\r&lt;br&gt;\r&lt;br&gt;               1. Neurological and neurodevelopmental disorders, These include diseases of the\r&lt;br&gt;                  brain, spinal cord, peripheral nerves and muscles(Such as cerebral palsy,\r&lt;br&gt;                  epilepsy, stroke, mental retardation, moderate to severe developmental delay,\r&lt;br&gt;                  muscular malnutrition or spinal cord injury ).\r&lt;br&gt;\r&lt;br&gt;               2. circulation system disease( congenital heart disease, Congestive heart failure or\r&lt;br&gt;                  coronary artery disease).\r&lt;br&gt;\r&lt;br&gt;               3. Severe heart disease or a history of clinically significant arrhythmias that the\r&lt;br&gt;                  researchers believe will affect participants' safety (According to the ECG or\r&lt;br&gt;                  medical history).\r&lt;br&gt;\r&lt;br&gt;         10. Other patients considered ineligible for this study were considered ineligible by the\r&lt;br&gt;             investigators\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult aged &gt;=18years old;\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory (RT-PCR) confirmed 2019-nCoV infection in throat swab and/or sputum and/or\r&lt;br&gt;             lower respiratory tract samples;\r&lt;br&gt;\r&lt;br&gt;          -  The interval between the onset of symptoms and randomized is within 7 days. The onset\r&lt;br&gt;             of symptoms is mainly based on fever. If there is no fever, cough or other related\r&lt;br&gt;             symptoms can be used;\r&lt;br&gt;\r&lt;br&gt;          -  Meet any of the following criteria for severe or critical ill conditions:\r&lt;br&gt;\r&lt;br&gt;               1. Respiratory rate &gt;=30/min; or\r&lt;br&gt;\r&lt;br&gt;               2. Rest SPO2&lt;=90%; or\r&lt;br&gt;\r&lt;br&gt;               3. PaO2/FiO2&lt;=300mmHg; or\r&lt;br&gt;\r&lt;br&gt;               4. Respiratory failure and needs mechanical ventilation; or\r&lt;br&gt;\r&lt;br&gt;               5. Shock occurs; or\r&lt;br&gt;\r&lt;br&gt;               6. Multiple organ failure and needs ICU monitoring;\r&lt;br&gt;\r&lt;br&gt;          -  Sign the Informed Consent Form on a voluntary basis.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Exist of other evidences that can explain pneumonia including but not limited to:\r&lt;br&gt;\r&lt;br&gt;        influenza A virus, influenza B virus, bacterial pneumonia, fungal pneumonia, noninfectious\r&lt;br&gt;        causes, etc.;\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to Intravenous Immunoglobulin or its preparation components;\r&lt;br&gt;\r&lt;br&gt;          -  Patients with selective IgA deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Women who are pregnant or breast-feeding;\r&lt;br&gt;\r&lt;br&gt;          -  Researchers consider unsuitable.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Aged between 18 and 75 years, extremes included, male or female\r&lt;br&gt;\r&lt;br&gt;          -  2. Laboratory (RT-PCR) and clinical symptoms confirmed case of 2019-nCoV pneumonia,\r&lt;br&gt;             according to the official guideline \"Pneumonia Diagnosis and Treatment Scheme for\r&lt;br&gt;             Novel Coronavirus Infection (Trial Version 5)\"\r&lt;br&gt;\r&lt;br&gt;          -  3. Hospitalised with a new onset respiratory illness (=7 days since illness onset)\r&lt;br&gt;\r&lt;br&gt;          -  4. No family planning within six months, and agree to take effective contraceptive\r&lt;br&gt;             measures throughout the study and for at least 30 days after the final study drug dose\r&lt;br&gt;\r&lt;br&gt;          -  5. Must agree not to enroll in another study of an investigational agent prior to\r&lt;br&gt;             completion of Day 30 of study\r&lt;br&gt;\r&lt;br&gt;          -  6. Informed Consent Form (ICF) signed voluntarily\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Severe 2019-nCoV pneumonia met one of the following criteria: respiratory distress,\r&lt;br&gt;             RR = 30 times / min, or SaO2 / SpO2 = 93% in resting state, or arterial partial\r&lt;br&gt;             pressure of oxygen (PaO2) /concentration of oxygen (FiO2) = 300mmHg (1mmHg = 0.133kpa)\r&lt;br&gt;\r&lt;br&gt;          -  2. Critical severe 2019-nCoV pneumonia met one of the following criteria: respiratory\r&lt;br&gt;             failure and mechanical ventilation required, or shock, or combined with other organ\r&lt;br&gt;             failure required ICU monitoring treatment\r&lt;br&gt;\r&lt;br&gt;          -  3. Severe liver disease (e.g. Child Pugh score = C, AST &gt; 5 times upper limit)\r&lt;br&gt;\r&lt;br&gt;          -  4. Known allergic reaction to any of components of ASC09 / ritonavir compound tablets\r&lt;br&gt;\r&lt;br&gt;          -  5. Patients with definite contraindications in the label of ritonavir\r&lt;br&gt;\r&lt;br&gt;          -  6. Positive serum pregnancy test result for women with childbearing potential at\r&lt;br&gt;             screening\r&lt;br&gt;\r&lt;br&gt;          -  7. Using HIV protease inhibitor drugs\r&lt;br&gt;\r&lt;br&gt;          -  8. Not suitable for the study, in the opinion of the Investigator (e.g. patient may be\r&lt;br&gt;             transferred to another hospital during the study period, patient with multiple basic\r&lt;br&gt;             diseases, etc.)\r&lt;br&gt;","Inclusion criteria: Medical staff who are currently working during the epidemic of new coronavirus (Covid-19)","Inclusion criteria: 1. Patients diagnosed with COVID-19;\r&lt;br&gt;2. Underwent chest CT scan during the treatment and at least one chest CT scan during follow-up;\r&lt;br&gt;3. Able to complete the study.","Inclusion criteria: 1. Meet the diagnostic criteria for suspected and confirmed cases (including mild, general, and severe) in the Diagnosis and Treatment of Pneumonia of New Coronavirus Pneumonia (Trial Version 5);\r&lt;br&gt;2. Meet the TCM diagnostic criteria for each stage of the novel coronavirus pneumonia;\r&lt;br&gt;3. Aged 18-75 years-old men or women;\r&lt;br&gt;4. Patients who volunteer to participate in this study and sign informed consent.","Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission.\r&lt;br&gt;Criteria for diagnosis (meet all the following criteria):\r&lt;br&gt;1. With epidemiological history;\r&lt;br&gt;2. Clinical manifestations (meet any 2 of the following): fever, normal or decreased white blood cell count or lymphopenia in the early stage of onset, and Chest radiology in the early stage shows multiple small patchy shadowing and interstitial changes which is especially significant in periphery pulmonary. Furthermore, it develops into bilateral multiple ground-glass opacity and infiltrating shadowing. Pulmonary consolidation occurs in severe cases. Pleural effusion is rare;\r&lt;br&gt;3. Confirmed case (suspected case obtained one of the following etiologic evidences): a positive result to real-time reverse-transcriptase PCR for respiratory specimen or blood specimen, or Genetic sequencing result of virus in respiratory or blood specimens are highly homologous to SARS-CoV-2.","Inclusion criteria: Participants with 18 to 75 years of age who have been diagnosed with NCP by nucleic acid testing and meet the clinical classification of severe NCP referring to the clinical classification standard in the General Office of the National Health and Health Commission-Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 4).","Inclusion criteria: 1. Age is not limited;\r&lt;br&gt;2. Clinical diagnosis is in accordance with the \"Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)\" on the diagnosis of a new type of coronavirus infection;\r&lt;br&gt;3. potable decoction;\r&lt;br&gt;4. no honeysuckle allergy;\r&lt;br&gt;5. child-bearing age female subjects pregnancy test negative person;\r&lt;br&gt;6. child-bearing age female subjects pregnancy test positive person needs targeted communication, the patient's consent can be included;\r&lt;br&gt;7. pregnancy or breast-feeding subjects need targeted communication, the patient's consent can be included in the voluntary informed consent signed by the person under the age of 16.","Inclusion criteria: Patients who meet the suspected or confirmed diagnostic criteria of COVID-19.","Inclusion criteria: 1. Influenza patients diagnosed in our center from December 1 to February 28 in the past 5 years (positive throat swab antigens of influenza A, B and H7 subtypes);\r&lt;br&gt;2. From December 1, 2019 to February 13, 2020, patients with positive detection of SARS-COV-2 (throat swab) in our center;\r&lt;br&gt;3. novel coronavirus (COVID-19) (throat swab) positive patients admitted to our hospital after February 13, 2020\r&lt;br&gt;4. Influenza virus antigen/nucleic acid positive patients admitted to our hospital after February 13, 2020","Inclusion criteria: Suspected cases of pneumonitis with the novel coronavirus infection. Suspected case criteria: Any one of the following epidemiological histories meets any two of the clinical manifestations:\r&lt;br&gt;Comprehensive analysis based on the following epidemiological history and clinical manifestations: \r&lt;br&gt;1. Epidemiological history:\r&lt;br&gt;(1) Travel history or residence history of Wuhan and surrounding areas or other communities with case reports within 14 days before the onset of illness; \r&lt;br&gt;(2) Onset of illness Patients with fever or respiratory symptoms from Wuhan and surrounding areas, or from communities with case reports in the previous 14 days; \r&lt;br&gt;(3) Aggressive onset; \r&lt;br&gt;(4) History of contact with new coronavirus infection. People with a new coronavirus infection are those who test positive for nucleic acid. \r&lt;br&gt;2. Clinical manifestations \r&lt;br&gt;(1) fever and/or respiratory symptoms; \r&lt;br&gt;(2) with the imaging mentioned above characteristics of pneumonia; \r&lt;br&gt;(3) the total number of white blood cells is normal or decreased in the early stage of onset, or the lymphocyte count is decreased.","Inclusion criteria: 1. Adults (defined as age &gt;= 18 years); \r&lt;br&gt;2. Patients with new type of coronavirus infection confirmed by PCR / serum antibodies; \r&lt;br&gt;3. The time interval between symptom onset and random enrollment is within 10 days.The onset of symptoms is mainly based on fever. If there is no fever, cough or other related symptoms can be used;\r&lt;br&gt;4. Imaging confirmed pneumonia;\r&lt;br&gt;5. In the state of no oxygen at rest, the patient's blood oxygen saturation SPO2 &lt;= 94% or shortness of breath (breathing frequency &gt;= 24) or oxygenation index &lt;= 300mmHg.","Inclusion criteria: 1. Aged&gt; 18 years old;\r&lt;br&gt;2. Working time in the front line of novel coronavirus pneumonia prevention and control =1 week;\r&lt;br&gt;3. The working department is the hot spot for the sample hospital, the ward for the suspected cases, and the ward for the confirmed cases;\r&lt;br&gt;4. No previous history of mental illness or mental illness;\r&lt;br&gt;5. Voluntarily participate in this research.","Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium;\r&lt;br&gt;(2) Those who have been diagnosed with TCM as epidemic-closed lungs;\r&lt;br&gt;(3) Inpatients aged 18 to 75 years, regardless of gender;\r&lt;br&gt;(4) Voluntarily receive treatment with the drug and sign informed consent. The informed consent process complies with relevant GCP regulations.","Inclusion criteria: 1. Aged &gt;=18 to 70 years;\r&lt;br&gt;2. Diagnosed 2019-nCoV infected patients by viral nucleic acid,or although the test was negative and even not be detected, the reseachers judged it to be a novel coronavirus pneumonia;\r&lt;br&gt;3. Understand and agree to participate in this study and sign informed consent;\r&lt;br&gt;4. According to the guideline of clinical classification of novel coronavirus pneumonia (2019-nCoV) diagnosis and treatment plan (trial version fifth), the general patients were included in the selection criteria: fever, respiratory tract symptoms, imaging findings of pneumonia; Severe patients were selected according to the following criteria: \r&lt;br&gt;1) respiratory distress, RR &gt;= 30 times / minute; \r&lt;br&gt;2) resting state, mean oxygen saturation less than 93%;\r&lt;br&gt;3) artery. PaO2 / FiO2 &lt;= 300MMHG (1mmhg = 0.133kpa).","Inclusion criteria: (All the following criteria are met before being selected):\r&lt;br&gt;1. Aged &gt;= 18 years;\r&lt;br&gt;2. Meet all the following criteria (refer to confirmed cases in the 5th edition of the diagnosis and treatment plan):\r&lt;br&gt;(1) Epidemiological history;\r&lt;br&gt;(2) Clinical manifestations (according to any of the following 2): fever; normal or decreased white blood cell count or reduced lymphocyte count in the early stages of onset; multiple small patchy shadows and interstitial changes in early chest imaging, which are evident in the extrapulmonary zone. Furthermore, it develops multiple ground glass infiltration and infiltrates in both lungs. In severe cases, pulmonary consolidation and pleural effusion are rare.\r&lt;br&gt;(3) Confirmed: Suspected cases have one of the following pathogenic evidence: respiratory specimens, blood specimens, or fecal specimens are detected by real-time fluorescent RT-PCR to detect novel coronavirus nucleic acid; the above-mentioned specimens are genetically sequenced and highly homologous to known new coronaviruses .\r&lt;br&gt;(4) Light or ordinary patients;\r&lt;br&gt;(5) With or without anti-viral drugs other than chloroquine phosphate, lopinavir/ritonavir.","Inclusion criteria: Confirmed and suspected cases of novel Coronavirus pneumonia","Inclusion criteria: 1) common type pneumonia patients with confirmed new coronavirus infection;\r&lt;br&gt;2) aged 18 to 75 years old;\r&lt;br&gt;3) voluntary signing of written informed consent.","Inclusion criteria: 1. 2019 adult patients with new-type coronavirus pneumonia diagnosed with 2019-nCoV infection by PCR according to the \"Pneumonitis Diagnosis and Treatment Protocol for New-type Coronavirus Infection (Trial Version 5)\"\r&lt;br&gt;2. The absolute value of lymphocytes &lt;0.6x10^9/L;\r&lt;br&gt;3. Severe respiratory failure does not exceed 48 hours and requires ICU treatment. Among them, severe respiratory failure is defined as PaO2 / FiO2 &lt;200 mmHg and requires positive pressure mechanical ventilation (including non-invasive and invasive mechanical ventilation, PEEP &gt;=5 cmH2O);\r&lt;br&gt;4. Sign the informed consent.","Inclusion criteria: (1) Comply with the standards of diagnosis and classification of western medicine, and the standards of syndromes of traditional Chinese medicine.\r&lt;br&gt;(2) Aged 18-80 years.\r&lt;br&gt;(3) Those who voluntarily participated in this research and signed written informed consent.","Inclusion criteria: 1. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnosic criteria refer to \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)\";\r&lt;br&gt;2. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days);\r&lt;br&gt;3. Patients who voluntarily signed informed consent.","Inclusion criteria: 1. Suspected case:\r&lt;br&gt;Patients in observation period of traditional Chinese medicine who are in line with the diagnostic criteria for suspected cases of pneumonia caused by 2019 novel coronavirus infection in the \"diagnosis and treatment plan for pneumonia caused by 2019 novel coronavirus infection (trial version IV)\", formulated by the National Health Commission, and in accordance with the \"diagnosis and treatment plan for pneumonia caused by 2019 nove coronavirus infection in Shanghai (Trial Implementation)\",formulated by the office of the leading group for the prevention and control of pneumonia caused by 2019 novel coronavirus infection in Shanghai,.\r&lt;br&gt;Any one with epidemiological history and any two with clinical manifestations.\r&lt;br&gt;(1) Epidemiological history\r&lt;br&gt;1) Within 14 days before the onset of the disease, there was a travel history or residential history in Wuhan or other areas where the local cases continued to spread;\r&lt;br&gt;2) Within 14 days before the onset of the disease, the patient had been exposed to fever or respiratory symptoms from Wuhan city or other areas where local cases continue to spread;\r&lt;br&gt;3) There is a clustering disease or an epidemiological association with the new coronavirus infection.\r&lt;br&gt;(2) Clinical manifestations:\r&lt;br&gt;1) Fever;\r&lt;br&gt;2) It has the imaging characteristics of pneumonia: in the early stage, there are multiple small spot shadow and interstitial changes, especially in the extrapulmonary zone. In severe cases, lung consolidation and pleural effusion are rare;\r&lt;br&gt;3) In the early stage of the disease, the total number of leukocytes was normal or decreased, or the lymphocyte count was decreased.","Inclusion criteria: 1. Meet the diagnostic criteria of the \"New Coronavirus Pneumonia Diagnosis and Treatment Scheme\", patients with pneumonia confirmed by new coronavirus infection; \r&lt;br&gt;2. Pneumonia Severity Index (PSI) grade is I ~ II; \r&lt;br&gt;3. Aged 18-80 years; \r&lt;br&gt;4. Those who have signed the informed consent voluntarily.","Inclusion criteria: 1. The patients who were diagnosed with the common type of NCP (including   severe risk factors) and severe cases of new coronavirus pneumonia;\r&lt;br&gt;2. Aged 18 to 85 years;\r&lt;br&gt;3. IL-6 elevated (using Elisa method, using the same company kit);\r&lt;br&gt;4. Patients or authorized family members volunteered to participate in this study and signed informed consent.\r&lt;br&gt;Definition of Novel Coronavirus Pneumonia (NCP) clinical cases:\r&lt;br&gt;1. Regular patients with NCP (including severe risk factors): patients with dual pulmonary lesions based on common NCP clinical symptoms accompanied by fever or no fever;\r&lt;br&gt;2. Critical NCP patient: Refer to the \"New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)\" formulated by the National Health Commission.","Inclusion criteria: Patients who meet the diagnostic criteria of Hubei Province pneumonia infected by novel coronavirus(2019-nCoV), and clinical classification of mild, moderate and severe were included.","Inclusion criteria: 1) Aged &gt;=18 years, gender unlimited, inpatient;\r&lt;br&gt;2) Patients with new coronavirus infection were confirmed: respiratory or blood samples were positive for 2019 ncov nucleic acid by real-time fluorescent RT-PCR, or respiratory or blood samples were highly homologous with known 2019 ncov gene sequencing;\r&lt;br&gt;3) According to the standard of \"diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5)\", the clinical types are common type or severe type;\r&lt;br&gt;4) The time interval between symptom onset and enrollment was within 7 days. The symptom onset was mainly based on fever. If there was no fever, coughing or other related symptoms could be used, such as fatigue, nasal obstruction, runny nose, chest distress, sore throat, muscle ache, diarrhea, etc;\r&lt;br&gt;5) Informed consent has been signed.","Inclusion criteria: (1) aged &gt;=18 years old;\r&lt;br&gt;(2) real-time fluorescence rt-pcr of respiratory or blood samples presents the positive nucleic acid of COVID-19, or the viral gene sequencing of respiratory or blood samples was highly homologous with the known COVID-19.\r&lt;br&gt;(3) patients diagnosed with novel coronavirus meet the diagnostic criteria of the latest clinical guidelines for novel coronavirus issued by the world health organization (WHO) on January 28, 2020 and the diagnostic criteria of the pneumonia diagnosis and treatment program for novel coronavirus infection (trial version 5) issued by National Health commission of the People's Republic of China.","Inclusion criteria: 1. Aged &gt;= 18 years; \r&lt;br&gt;2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV;\r&lt;br&gt;3. Pneumonia confirmed with chest CT;\r&lt;br&gt;4. &lt;= 8 days since illness onset and hospitalization with feverat, cough, or dyspnea; \r&lt;br&gt;5. Willing to participant in this study and sign the informed consent.","Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the \"Diagnosis and Treatment Program for COVID-19\"(trial version 5th).\r&lt;br&gt;(2) Agree to participate in the study and the patient or legal guardian signs the informed consent form.","Inclusion criteria: Patients who meet the diagnostic criteria of pneumonia caused by novel coronavirus.","Inclusion criteria: 1. Suspected and confirmed cases of pneumonia in accordance with the above new signs of coronavirus infection and the standard of clinical common diagnosis;\r&lt;br&gt;2. Aged 18-65 years old;\r&lt;br&gt;3. Signing the general informed consent form.","Inclusion criteria: On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial version 4).\r&lt;br&gt;1. patients with severe 2019-ncov according to the clinical stage met any of the following criteria: \r&lt;br&gt;(1) Respiratory distress, RR&gt;=30 times/min; \r&lt;br&gt;(2) In resting state, oxygen saturation is less than 93%;\r&lt;br&gt;(3) Partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;=300mmHg (1mmHg= 0.133kpa);\r&lt;br&gt;2. according to the clinical stage of critical 2019-ncov, meet one of the following conditions:\r&lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is required;\r&lt;br&gt;(2) Shock;\r&lt;br&gt;(3) Combined with other organ failure, intensive care unit is required;\r&lt;br&gt;3. other inclusion criteria: good compliance, willingness to cooperate with the study, and informed consent signed by the patient.","Inclusion criteria: (1) Comply with the diagnostic criteria of \"Pneumonitis Diagnosis and Treatment Scheme for New Coronavirus Infection (Trial Version 5)\";\r&lt;br&gt;(2) The classification was judged as common type;\r&lt;br&gt;(3) Body temperature &gt; 37.3 degree C;\r&lt;br&gt;(4) Subjects are &gt;= 18 years of age.","Inclusion criteria: 1. Patients who meet the diagnostic criteria of the fifth edition of pneumonia diagnosis and treatment plan for new coronavirus infection issued by the national health and health commission (annex 1) for the confirmed cases of light (medical observation period), common (early stage of TCM clinical treatment) or heavy (middle stage of TCM clinical treatment);\r&lt;br&gt;2. Prospective study patients informed and consented to participate in this study.","Inclusion criteria: 1. Non suspected cases and non confirmed cases;\r&lt;br&gt;2. Participate in novel coronavirus front-line prevention and control of medical staff, street community office staff;\r&lt;br&gt;3. Novel coronavirus pneumonia is recommended by people who voluntarily accept TCM technology.","Inclusion criteria: 1. Aged &gt;=18 years, unlimited for men and women;\r&lt;br&gt;2. A novel coronavirus infection confirmed by pathogenic detection;\r&lt;br&gt;3. According to novel coronavirus infection pneumonia treatment plan (trial version fifth), severe patients should comply with any of the following: respiratory distress (RR&gt;30 times / points); resting state, refers to oxygen saturation less than 93%; arterial oxygen partial pressure (PaO2) / oxygen inhalation concentration (FiO2) is less than 300 mmHg;\r&lt;br&gt;4. Sign the informed consent voluntarily.","Inclusion criteria: 1. Aged &gt;=18 years old; \r&lt;br&gt;2. Patients has been diagnosed with 2019-nCoV pneumonia according to WHO interim guidance*.\r&lt;br&gt;* WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Jan 11, 2020. https://www.who.int/internalpublications-detail/clinical-management-of-severe-acute-respiratoryinfection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed Jan 29, 2020).","Inclusion criteria: 1. Adult aged &gt;= 18 years old;\r&lt;br&gt;2. Patients with unexplained viral pneumonia that have been clinically diagnosed or patients with novel coronavirus serum antibody (IgM or IgG) positive or patients with novel coronavirus infection confirmed by PCR when no rapid diagnostic kit has been developed;\r&lt;br&gt;3. The interval between the onset of symptoms and randomized is within 7 days. The onset of symptoms is mainly based on fever. If there is no fever, cough or other related symptoms can be used;","Inclusion criteria: (1) Patients who meet the diagnostic criteria of the common type of confirmed cases (the initial stage of clinical treatment of traditional Chinese medicine) or the severe cases of confirmed cases (the middle stage of clinical treatment of traditional Chinese medicine);\r&lt;br&gt;(2) The cases of common type (the initial stage of clinical treatment of traditional Chinese medicine) belong to the type of cold-dampness stagnant lung;\r&lt;br&gt;(3) The confirmed cases were severe (in the middle stage of clinical treatment of traditional Chinese medicine).\r&lt;br&gt;(4) The patients knew and agreed to participate in this study.","Inclusion criteria: (1) Conforming to the diagnostic criteria of suspected cases (Chiese medicine observation period) in the fourth edition of pneumonia diagnosis and treatment program for new coronavirus infection issued by the national health and health commission;\r&lt;br&gt;(2) Age between 14 and 80 years old;\r&lt;br&gt;(3) Patients informed and agreed to participate in the study.","Inclusion criteria: 1. Patients who meet the requirements of the \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (Trial Version 4)\" which issued by the General Office of the National Health Commission.\r&lt;br&gt;2. ECMO-treated patients with severe hypoxic respiratory failure.","Inclusion criteria: Severe patients (according to any of the following): respiratory distress (RR&gt; 30 beats / min); at rest, means oxygen saturation &lt;= 93%; arterial oxygen pressure (PaO2) / oxygen concentration (FiO2) &lt; = 300 mmHg","Inclusion criteria: 1. 18 years old &lt;= age &lt;= 60 years old at the time of screening;\r&lt;br&gt;2. Pharyngeal swabs, alveolar lavage fluid, or sputum specimens during screening showed that 2019-nCoV virus nucleic acid test results were positive for at least two of nCov-EP, nCov-NP, and nCovORF1ab, in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment plan (trial version 5);\r&lt;br&gt;3. The investigator determined that aerosolized inhalation treatment was appropriate, and volunteered to participate in the study and signed informed consent.","Inclusion criteria: Conforming to the diagnostic standard of COVID-19; Participants in the first and second trials need to meet the diagnostic criteria of traditional Chinese medicine for epidemic diseases; Participants in the third trial need to meet the diagnostic criteria of deficiency of qi in lung and spleen of epidemic diseases.","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV); \r&lt;br&gt;2. virus turned negative after treatment; \r&lt;br&gt;3. aged 18-70 years old; \r&lt;br&gt;4. patients with clear consciousness \r&lt;br&gt;5. Signing the informed consent form.","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);\r&lt;br&gt;2. virus turned negative after treatment;\r&lt;br&gt;3. Patients diagnosed with pulmonary fibrosis; \r&lt;br&gt;4. aged 18-70 years old;\r&lt;br&gt;5. patients with clear consciousness;\r&lt;br&gt;6. Signing the informed consent form.","Inclusion criteria: 1. Aged 18-75 years male or female;\r&lt;br&gt;2. Body weight 40-100 kg and BMI &gt;= 18kg/m2;\r&lt;br&gt;3. Been Confirmed with commom 2019-nCoV pneumonia inpatient;\r&lt;br&gt;4. With fever, respiratory tract and other symptoms, imaging shows pneumonia;\r&lt;br&gt;5. 2019-nCoV nucleic acid test was positive by pathogenic detection within 72 hours;\r&lt;br&gt;6. Have undergone surgical sterilization or take effective contraception during the trial;\r&lt;br&gt;7. Written the informed consent.","Inclusion criteria: Long-term follow-up of patients with epilepsy and healthy subjects in the natural population cohort study of west China hospital, sichuan university.","Inclusion criteria: 1. Patients with pneumonia infected by new coronavirus; \r&lt;br&gt;2. To sign informed consent.","Inclusion criteria: 1) Pneumonia patients diagnosed as new coronavirus infection;\r&lt;br&gt;2) The type of pneumonia was judged as severe and critical;\r&lt;br&gt;3) Informed consent.","Inclusion criteria: 1. Confirmed or suspected cases who are comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the \"Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4)\";\r&lt;br&gt;2. Inpatients aged 18-75 years;\r&lt;br&gt;3. Obtain the informed consent form.","Inclusion criteria: 1. 2019-nCoV infected patients treated at Affiliated Zhongshan Hospital of Dalian University and Zhongnan Hospital of Wuhan University from January 2020 to December 2020\r&lt;br&gt;2. nCoV nucleic acid positive;\r&lt;br&gt;3. Aged &gt;=18 years;\r&lt;br&gt;4. Patients understand the purpose of the trial, voluntarily sign informed consent, and agree to complete the rectification research process.","Inclusion criteria: 1. Patients diagnosed with suspected or confirmed NCP (divided into ordinary type and severe type according to their clinical classification);\r&lt;br&gt;2. Be between 18-85 years of age;\r&lt;br&gt;3. Informed consent and signed informed consent.","Inclusion criteria: SARI\r&lt;br&gt;1. An ARI with history of fever or measured temperature &gt;= 38 degree C and cough; onset within the last ~10 days; and requiring hospitalization. However, the absence of fever does NOT exclude viral infection.\r&lt;br&gt;2. Surveillance case definitions for 2019-nCoV:\r&lt;br&gt;(1) Patients with severe acute respiratory infection (fever, cough, and requiring admission to hospital), AND with no other etiology that fully explains the clinical presentation1 AND at least one of the following:\r&lt;br&gt;A. a history of travel to or residence in the city of Wuhan, Hubei Province, China in the 14 days prior to symptom onset, or\r&lt;br&gt;B. patient is a health care worker who has been working in an environment where severe acute respiratory infections of unknown etiology are being cared for.\r&lt;br&gt;(2) Patients with any acute respiratory illness AND at least one of the following:\r&lt;br&gt;A. close contact2 with a confirmed or probable case of 2019-nCoV in the 14 days prior to illness onset, or\r&lt;br&gt;B. visiting or working in a live animal market in Wuhan, Hubei Province, China in the 14 days prior to symptom onset, or\r&lt;br&gt;C. worked or attended a health care facility in the 14 days prior to onset of symptoms where patients with hospital-associated 2019-nCov infections have been reported.","Inclusion criteria: Subjects participating in this clinical study must meet all of the following criteria:\r&lt;br&gt;1. General- severe hospitalized patients who meet the diagnostic criteria of the \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan (Trial Version 5)\". That is, one of the following three conditions is met on the premise that the general diagnostic criteria are met:\r&lt;br&gt;1) Respiratory frequency (RR): 20-30 times / minute;\r&lt;br&gt;2) Peripheral oxygen saturation: 93-95%;\r&lt;br&gt;3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2): 300-400mmHg (1mmHg = 0.133kPa).\r&lt;br&gt;2. Patients aged &gt;= 18 and &lt;= 85 years, with normal autonomous judgment ability, regardless of gender and region;\r&lt;br&gt;3. Patients who voluntarily participated in the study and signed informed consent.","Inclusion criteria: 1. Aged &gt;= 18 years.\r&lt;br&gt;2. Patients who meet the diagnostic criteria of suspected cases of pneumonia caused by novel coronavirus infection.","Inclusion criteria: 1. patients with 2019-nCoV pneumonia;\r&lt;br&gt;2. Sign informed consent.","Inclusion criteria: 1) Aged  &gt;= 18 years;\r&lt;br&gt;2) Meet the diagnostic criteria of severe pneumonia patients with new coronavirus;\r&lt;br&gt;3) The informed consent form.","Inclusion criteria: 1) Medical staff involved in the diagnosis and treatment of new coronavirus pneumonia;\r&lt;br&gt;2) 2019-nCoV infection suspected or confirmed cases;\r&lt;br&gt;3) Voluntarily participate in this research project and sign informed consent;\r&lt;br&gt;4) Able to cooperate with the scale assessor.","Inclusion criteria: Patients who meet the diagnostic criteria of suspected cases of pneumonia caused by novel coronavirus infection.","Inclusion criteria: Patients who are positive for novel coronary virus detected by RC-PCR and  second-generation sequencing.","Inclusion criteria: 1. Sign the informed consent form;\r&lt;br&gt;2. Aged &gt;=18 years;\r&lt;br&gt;3. Subjects diagnosed as 2019-nCoV pneumonia;\r&lt;br&gt;(1) Detection of 2019-nCoV nucleic acid positive by RT-PCR in respiratory tract or blood samples;\r&lt;br&gt;(2) The virus gene sequence of respiratory tract or blood samples is highly homologous to the known 2019-nCoV;\r&lt;br&gt;4. According to the standard of \"2019-nCoV pneumonia diagnosis and treatment Program of New Coronavirus infection (trial Fifth Edition)\" issued by National Health Commission of China, clinical classification: mild, ordinary subjects;\r&lt;br&gt;(1) Mild type, the clinical symptoms were mild and no pneumonia was found in imaging;\r&lt;br&gt;(2) Common type, With fever, respiratory tract and other symptoms, the manifestations of pneumonia can be seen on imaging.","Inclusion criteria: 1. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnosic criteria refer to \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)\";\r&lt;br&gt;2. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days);\r&lt;br&gt;3. Patients who voluntarily signed informed consent.","Inclusion criteria: 1. Conforming to the diagnostic criteria for the above close contacts;\r&lt;br&gt;2. Aged between 18 and 65 years old;\r&lt;br&gt;3. Signing the generalized informed consent form.  (The intervention objects is incorporated in the clinical study as desired).","Inclusion criteria: 1. Aged &gt;=18 years old; \r&lt;br&gt;2. Patients has been diagnosed with 2019-nCoV pneumonia according to the fifth version of 2019-nCoV pneumonia management guideline made by the national health commission of the People's Repulic of China.\r&lt;br&gt;More details see: http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml","Inclusion criteria: 1. Diagnosed as novel coronavirus pneumonia (NCP) Patient:\r&lt;br&gt;1) Basis of diagnostic criteria: \"Notice on Printing and Distributing Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Implementation Fourth Edition)\" (National Health Office Medical Letter C2020377)\r&lt;br&gt;2019-nCoV diagnosis of pneumonia: \r&lt;br&gt;(1) Epidemiological history: A. Travel history or residence history in Wuhan area or other areas with continuous local case transmission within 14 days before onset; B. Contact history within 14 days before onset Patients with fever or respiratory symptoms from Wuhan City or other areas where local case transmission is ongoing; C. Aggregative onset or epidemiological association with new coronavirus infection. \r&lt;br&gt;(2) Clinical manifestations: A. fever; B. imaging characteristics of pneumonia: multiple small patchy shadows and interstitial changes in the early stage, which are obvious in the extrapulmonary zone, and then develop into multiple ground glass infiltrates and infiltrates, which are severe Patients may have pulmonary consolidation, and pleural effusion is rare; C. The total number of white blood cells is normal or reduced in the early stage of onset, or the lymphocyte count is reduced. \r&lt;br&gt;(3) Any one of the epidemiological history meets any two of the clinical manifestations as suspected cases, and those who have one of the following pathogenic evidence are confirmed cases: A. A new type of real-time fluorescence RT-PCR test for respiratory specimens or blood specimen Coronavirus-positive nucleic acid; B. Sequencing of viral genes in respiratory specimens or blood specimens, highly homologous to known new coronaviruses. \r&lt;br&gt;(4) It is severe if it meets any of the following: A. Respiratory distress, RR &gt; 30 beats / min; B. In resting state, means oxygen saturation &lt; 93%; C. Arterial partial pressure of oxygen (PaO2) / oxygen Concentration (FiO2) &lt;= 300mmHg (lmmHg = 0.133kPa).\r&lt;br&gt;(5) It is critical if it meets any of the following: 1) respiratory failure occurs and requires mechanical ventilation; 2) shock occurs; 3) combined organ failure requires ICU monitoring and treatment\r&lt;br&gt;2. The patient or legal donor agrees to participate in the study and signs an informed consent form.","Inclusion criteria: 1. Aged 18-60 years old;\r&lt;br&gt;2. Patients with clinical symptoms, signs, auxiliary detection combined with 1 or more nucleic acid test to confirm the diagnosis of new coronavirus pneumonia;\r&lt;br&gt;3. Voluntarily sign the informed consent to comply with the requirements of the  program.","Inclusion criteria: Inclusion of case criteria (pneumonia diagnosis and treatment protocol for COVID-19 (trial 6th edition))\r&lt;br&gt;1. Common type patient: with fever, respiratory tract and other symptoms, and imaging findings of pneumonia.\r&lt;br&gt;2. Severe patients: patients who meet any of the following criteria\r&lt;br&gt;(1) respiratory distress, RR&gt;=30 times/min;\r&lt;br&gt;(2) in resting state, oxygen saturation is less than 93%;\r&lt;br&gt;(3) partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) =300mmHg (1mmHg = 0.133kpa);\r&lt;br&gt;3. TCM syndrome differentiation conforms to the clinical diagnostic criteria for patients in the early, middle, severe and convalescent stages of the pneumonia diagnosis and treatment program forCOVID-2019 (trial version 6);\r&lt;br&gt;4. Signed informed consent voluntarily.","Inclusion criteria: 1. 16 to 75 years of age, male or female;\r&lt;br&gt;2. Respiratory or blood samples tested positive for novel coronavirus;\r&lt;br&gt;3. Within 7 days of onset: Onset is defined as body temperature exceeding 38 degree C (armpit temperature) or at least one 2019-nCoV pneumonia related systemic or respiratory symptom;\r&lt;br&gt;4. Willing to take contraception during the study and within 7 days after treatment;\r&lt;br&gt;5. No difficulty in swallowing the Pills;\r&lt;br&gt;6. Willing to sign informed consent form.","Inclusion criteria: On January 27, 2020, the general office of the national health commission and the office of the state administration of traditional Chinese medicine issued the pneumonia diagnosis and treatment plan for new coronavirus infection (trial version 4).\r&lt;br&gt;Only patients with severe and critical 2019-ncov were included in this study. \r&lt;br&gt;1. Patients with severe 2019-ncov according to the clinical stage met any of the following criteria: \r&lt;br&gt;(1) Respiratory distress, RR &gt;= 30 times/min; \r&lt;br&gt;(2) In resting state, oxygen saturation is less than 93%;\r&lt;br&gt;(3) Partial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;= 300mmHg (1mmHg= 0.133kpa);\r&lt;br&gt;2. According to the clinical stage of critical 2019-ncov, one of the following conditions is met: \r&lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is required; \r&lt;br&gt;(2) Shock;\r&lt;br&gt;(3) Combined with other organ failure, intensive care unit is required.\r&lt;br&gt;3. Other inclusion criteria: good compliance, willingness to cooperate with the study, and informed consent signed by the patient.","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;\r&lt;br&gt;2. Above 18 years old (inclusive);\r&lt;br&gt;3. Voluntarily sign written informed consent.","Inclusion criteria: 1. Aged 18-75 years old;\r&lt;br&gt;2. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnostic criteria refer to \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)\";\r&lt;br&gt;3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);\r&lt;br&gt;4. Women and partners who have no planned pregnancy within the past six months, and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;5. Agree not to participate in other clinical studies within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;6. Patients who voluntarily signed informed consent.","Inclusion criteria: Patients with novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent form.","Inclusion criteria: 1. 18 to 75 years of age, male or female, willing to sign informed consent;\r&lt;br&gt;2. Tested positive for novel coronavirus infection after the onset of symptoms using a real time polymerase chain reaction (RT-PCR)-based diagnostic assay;\r&lt;br&gt;3. At least 2 viral nucleic acid tests are still positive under current antiviral therapy;\r&lt;br&gt;4. No difficulty in swallowing the pills;\r&lt;br&gt;5. Willing to abide by the protocol.","Inclusion criteria: Patients who meet the suspected and confirmed diagnostic criteria for the 2019-nCoV pneumonia version 4.0 of the National Health and Medical Commission (released 2020.01.27).","Inclusion criteria: 1. Aged 18 to 75 years male or female, willing to sign the informed consent;\r&lt;br&gt;2. Tested positive for novel coronavirus infection after the onset of symptoms using a real time polymerase chain\r&lt;br&gt;reaction (RT-PCR)-based diagnostic assay;\r&lt;br&gt;3. Enrollment and initiation of study drug treatment &lt;=96 hours after onset of symptoms;\r&lt;br&gt;4. No difficulty in swallowing the pills;\t\r&lt;br&gt;5. Willing to abide by the protocol.","Inclusion criteria: 1. Aged 18-65 years;\r&lt;br&gt;2. been Confirmed with 2019-nCoV pneumonia, hospitalized or will be hospitalized;\r&lt;br&gt;3. Sign the ICF;\r&lt;br&gt;4. no more than 10 days from the occurrence of relevant clinical symptoms to the diagnosis been confirmed.","Inclusion criteria: Healthy children between the ages of 1 and 18 who meet the TCM constitutional doctrine:\r&lt;br&gt;(1) Main features: moderate body shape, ruddy complexion, energetic, etc .;\r&lt;br&gt;(2) Common manifestations: Symmetric body shape, complexion, moisturized complexion, thick and shiny hair, bright eyes, clear nose, moist olfactory, rosy lips, not easy to fatigue, energetic, cold and heat tolerance, good sleep, stomach Najia, the second stool is normal, the tongue is reddish, the moss is thin and white, the veins are gentle and strong, and the fingerprint is faint purple. Lively and cheerful character. Usual disease is less common.","Inclusion criteria: (1) All patients were diagnosed with a new type of coronavirus pneumonia;\r&lt;br&gt;(2) Clear mind, cooperation and communication; \r&lt;br&gt;(3) Men and women aged 18 and 80 years; \r&lt;br&gt;(4) informed consent has been signed and is willing to be assessed.","Inclusion criteria: Patients are eligible for admission if they meet all of the following criteria within 5-7 days of their first ICU admission. \r&lt;br&gt;1) Aged 18-75 years; \r&lt;br&gt;2) The patient meets the ARDS diagnostic standard (Berlin standard) and needs intubation ventilator-assisted or ECMO-assisted treatment; \r&lt;br&gt;3) The primary disease caused by 2019-nCoV virus infection; \r&lt;br&gt;4) Imaging data suggest bilateral lung lesions; \r&lt;br&gt;5) Voluntarily participate in clinical research; fully understand, know, and sign informed consent.","Inclusion criteria: 1. diagnosis of 2019-new coronavirus (2019-nCoV) pneumonia;\r&lt;br&gt;2. adult patients aged 18-80 years old.","Inclusion criteria: Inpatient patients diagnosed as neumonia caused by new coronavirus infection.","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);The classification was judged as common type;\r&lt;br&gt;2. aged 18-70 years old;\r&lt;br&gt;3. patients with clear consciousness;\r&lt;br&gt;4. Signing the informed consent form.","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);\r&lt;br&gt;2. virus turned negative after treatment;\r&lt;br&gt;3. aged 18-70 years old;\r&lt;br&gt;4. patients with clear consciousness\r&lt;br&gt;5. Signing the informed consent form.","Inclusion criteria: 1. patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);\r&lt;br&gt;2. virus turned negative after treatment;\r&lt;br&gt;3. aged 18-70 years old;\r&lt;br&gt;4. patients with clear consciousness;\r&lt;br&gt;5. Signing the informed consent form.","Inclusion criteria: 1) patients diagnosed as Pneumonia caused by new coronavirus infection (2019-nCoV);\r&lt;br&gt;2) The classification was judged as common type;\r&lt;br&gt;3) Informed consent.","Inclusion criteria: 1. aged 18 to 60 years\r&lt;br&gt;2. to be confirmed with a exposure history of diagnosed population within last 14 days;\r&lt;br&gt;3. with fever, positive results of blood routine examination and positive findings in CT examination, any two in three items met.","Inclusion criteria: Patients with Confirmed 2019-nCoV infected pneumonia","Inclusion criteria: Including front-line medical staff for COVID-19 epidemic prevention and control, including front-line medical staff responsible for epidemic prevention and control in Wuhan or other regions, and front-line staff responsible for epidemic prevention and control in communities.\r&lt;br&gt;Enrollment criteria: \r&lt;br&gt;1. Voluntarily participated in and sign the informed consent form; \r&lt;br&gt;2. The generalized anxiety scale (GAD-7) score is greater than 5 points, and the patient health questionnaire-depressive symptoms group scale (PHQ-9) score is greater than 5 points;\r&lt;br&gt;3. Aged 18-65 years old male or female; \r&lt;br&gt;4. Education level at or above primary school.","Inclusion criteria: 1. Age between 18 and 75 years old (including threshold), regardless of gender;\r&lt;br&gt;2. The patient under isolation observation is diagnosed with mild or common type of 2019-nCoV acute respiratory disease and can cooperate to complete corresponding psychological intervention;\r&lt;br&gt;3. The total score of Hamilton depression scale (HAMD17) and Hamilton anxiety scale (HAMA14) at baseline is both at least 7;\r&lt;br&gt;4. The patient has sufficient compliance to complete the experiment according to the protocol;\r&lt;br&gt;5. The patient and his/her family or guardian sign the informed consent to participate voluntarily in this clinical study.","Inclusion criteria: 1. Confirmed and suspected cases of pneumonia from novel coronavirus infection;\r&lt;br&gt;2. Meet the diagnostic criteria for community - acquired pneumonia;\r&lt;br&gt;3. Clinical classification is \"heavy\" or \"critical\";\r&lt;br&gt;4. Aged 18 to 75 years;\r&lt;br&gt;5. Obtain informed consent.","Inclusion criteria: (1) Aged &gt;=18 years old inpatient;\r&lt;br&gt;(2) novel coronavirus nucleic acid positive was detected by real-time fluorescent RT-PCR in throat swabs;\r&lt;br&gt;(3) The clinical types were common type or severe type;\r&lt;br&gt;(4) Informed consent has been signed.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  High/moderate risk contact with a laboratory-confirmed 2019-nCoV case\r&lt;br&gt;\r&lt;br&gt;          -  Undergoing standard sanitary surveillance by Sant Publique France\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent for patients = 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent of both parents for patients &lt; 18 years\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Subject deprived of freedom\r&lt;br&gt;\r&lt;br&gt;          -  Subject under a legal protective measure\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Adult SARI patients with 2019-ncov infection confirmed by PCR;\r&lt;br&gt;\r&lt;br&gt;          2. Absolute value of lymphocytes &lt; 0. 6x 109/L;\r&lt;br&gt;\r&lt;br&gt;          3. Severe respiratory failure within 48 hours and requires admission to ICU. (severe\r&lt;br&gt;             respiratory failure was defined as PaO2/FiO2 &lt; 200 mmHg and was supported by positive\r&lt;br&gt;             pressure mechanical ventilation (including non-invasive and invasive mechanical\r&lt;br&gt;             ventilation, PEEP&gt;=5cmH2O))\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age &lt; 18\r&lt;br&gt;\r&lt;br&gt;          2. Pregnant\r&lt;br&gt;\r&lt;br&gt;          3. Allergic to experimental drugs\r&lt;br&gt;\r&lt;br&gt;          4. The underlying disease is very serious and the expected survival time is less than 6\r&lt;br&gt;             months (such as advanced malignant tumor);\r&lt;br&gt;\r&lt;br&gt;          5. COPD or end-stage lung disease requires home oxygen therapy\r&lt;br&gt;\r&lt;br&gt;          6. Expected survival time not exceeding 48 hours\r&lt;br&gt;\r&lt;br&gt;          7. Participated in other clinical intervention trials within the last 3 months\r&lt;br&gt;\r&lt;br&gt;          8. Autoimmune diseases\r&lt;br&gt;\r&lt;br&gt;          9. A history of organ, bone marrow or hematopoietic stem cell transplantation 10.\r&lt;br&gt;             Received radiotherapy and chemotherapy for malignant tumor within 6 months\r&lt;br&gt;\r&lt;br&gt;        11.HIV infected patients or diagnosed with acquired immunodeficiency within the past year\r&lt;br&gt;        (CD4 T cells &lt;=200/mm3) 12. Patients receiving anti-hcv treatment 13.90 days of retinal\r&lt;br&gt;        detachment or eye surgery 14. Permanent blindness in one eye 15. History of iritis,\r&lt;br&gt;        endophthalmitis, scleral inflammation or retinitis 16. The competent physician considered\r&lt;br&gt;        it inappropriate to participate in the study\r&lt;br&gt;","Inclusion criteria: 1) The confirmed patient (or legal guardian) agrees to participate in the study and signs the informed consent form;\r&lt;br&gt;2) aged 18 to 65 years;\r&lt;br&gt;3) Real-time fluorescent RT-PCR of respiratory specimens or blood specimens to detect patients with new type of coronavirus positive;\r&lt;br&gt;4) Patients diagnosed as severe and critically ill and with rapid disease progression according to the \"Diagnosis and Treatment Program for Pneumonia of New Coronavirus Infection (Trial Version 6)\".","Inclusion criteria: 1) Comply with the diagnostic criteria for pneumonia caused by novel coronavirus infection in the \"Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 4)\";\r&lt;br&gt;2) Agree to participate in the study and the patient or legal guardian signs the informed consent form.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult\r&lt;br&gt;\r&lt;br&gt;          -  PCR confirmed noval coronavirus infection\r&lt;br&gt;\r&lt;br&gt;          -  Symptoms developed more than 7 days\r&lt;br&gt;\r&lt;br&gt;          -  PaO2/FiO2 &lt; 200 mmHg\r&lt;br&gt;\r&lt;br&gt;          -  Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula\r&lt;br&gt;             (HFNC) higher than 45 L/min for less than 48 hours\r&lt;br&gt;\r&lt;br&gt;          -  Requiring ICU admission\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  pregnancy;\r&lt;br&gt;\r&lt;br&gt;          -  patients currently taking corticosteroids (cumulative 400 mg prednisone or\r&lt;br&gt;             equivalent);\r&lt;br&gt;\r&lt;br&gt;          -  Severe underlying disease, i.e. end stage of malignancy disease or end stage of\r&lt;br&gt;             pulmonary disease;\r&lt;br&gt;\r&lt;br&gt;          -  Severe adverse events before ICU admission, i.e. cardiac arrest;\r&lt;br&gt;\r&lt;br&gt;          -  Underlying disease requiring corticosteroids;\r&lt;br&gt;\r&lt;br&gt;          -  Contraindication for corticosteroids;\r&lt;br&gt;\r&lt;br&gt;          -  Recruited in other clinical intervention trial\r&lt;br&gt;","Inclusion criteria: All patients with SARS-CoV-2 pneumonia in the ICU","Inclusion criteria: 1. 16 to 75 years of age, male or female;\r&lt;br&gt;2. Respiratory or blood samples tested positive for novel coronavirus;\r&lt;br&gt;3. A novel coronavirus nucleic acid was detected in respiratory or anal swabs after 10 days of standard treatment with roranavir / ritonavir;\r&lt;br&gt;4. Willing to take contraception during the study and within 7 days after treatment;\r&lt;br&gt;5. No difficulty in swallowing the Pills;\r&lt;br&gt;6. Willing to sign informed consent form.","Inclusion criteria: (1) Patients in accordance with the diagnostic criteria of \"Quick reference guide for diagnosis and treatment of novel coronavirus pneumonia(2019-nCoV)(Standard Edition)\" and \"Diagnostic and treatment protocols of novel coronavirus pneumonia(Trial version 5)\" issued by National Health Commission;\r&lt;br&gt;(2) Patients in accordance with the TCM syndrome differentiation standard;\r&lt;br&gt;(3) Aged 18 to 85 years;\r&lt;br&gt;(4) Before the trial begins, patients or their legal representatives voluntarily agree to participate by giving written informed consent approved by ethic committee.","Inclusion criteria: 1. novel coronavirus: \r&lt;br&gt;(1) 1 days before onset, 14 had travel history or residence history in Wuhan or other areas with local cases;\r&lt;br&gt;(2) during the 14 days before onset, patients with fever or respiratory symptoms from Wuhan or other areas with persistent local cases were exposed;\r&lt;br&gt;(3) there was an epidemiological association between clustering onset or new coronavirus infection;\r&lt;br&gt;2. Clinical manifestations: \r&lt;br&gt;(1) fever; \r&lt;br&gt;(2) radiographically characteristic of ground glass or patchy consolidation pneumonia in the lung; \r&lt;br&gt;(3) normal or reduced leukocyte count or lymphocyte count in the early stage of the disease.\r&lt;br&gt;3. novel coronavirus nucleic acid positive novel coronavirus was detected by real-time fluorescence RT-PCR based on the standard of suspected cases: \r&lt;br&gt;(1) positive result of nCoV nucleic acid test;\r&lt;br&gt;(2) sequencing of the virus gene was highly homologous to the known new coronavirus. Patients included in the study need to meet the above three criteria and be clinically diagnosed as non critical patients.","Inclusion criteria: 1. New coronavirus-infected pneumonia confirmed by pathogenic detection;\r&lt;br&gt;2. Meet the diagnostic criteria for community-acquired pneumonia (based on 2019 ATS/IDSA diagnostic criteria);\r&lt;br&gt;3. Pneumonia Severity Index (PSI) III-V or Oxygenation Index (P/F)&lt;=300 mmHg;\r&lt;br&gt;4. Aged 18 to 75 years;\r&lt;br&gt;5. Obtain informed consent.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  18-75 years old ,no gender restriction\r&lt;br&gt;\r&lt;br&gt;          -  According to Diagnosis and Clinical Management of Pneumonia caused by 2019-nCoV\r&lt;br&gt;             infection(Trial Version 4), patients are diagnosed with severe or critical 2019-nCoV\r&lt;br&gt;             pneumonia with stay in the ICU of less than 48 hours\r&lt;br&gt;\r&lt;br&gt;          -  Women of childbearing age should have a negative blood pregnancy test before the start\r&lt;br&gt;             of dosing and agree to take effective contraceptive measures during the trial until\r&lt;br&gt;             the last follow-up (28 days)\r&lt;br&gt;\r&lt;br&gt;          -  Sequential Organ Failure Assessment(SOFA) score between 2-13 point\r&lt;br&gt;\r&lt;br&gt;          -  Voluntarily participate in this clinical study and sign a written informed consent. If\r&lt;br&gt;             the patient cannot obtain informed consent, he can authorize his legal representative.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Liver or kidney SOFA score of more than 3 points;\r&lt;br&gt;\r&lt;br&gt;          -  HIV positive\r&lt;br&gt;\r&lt;br&gt;          -  Highly allergic constitution or history of severe allergies;\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant and lactating women;\r&lt;br&gt;\r&lt;br&gt;          -  Patients with malignant tumors;\r&lt;br&gt;\r&lt;br&gt;          -  Patients with previous history of pulmonary embolism;\r&lt;br&gt;\r&lt;br&gt;          -  Participating in clinical trials of other drugs within 3 months before enrollment.\r&lt;br&gt;\r&lt;br&gt;          -  be thought by researchers to be inappropriate to participate in this clinical study.\r&lt;br&gt;","Inclusion criteria: Patients who meet the diagnostic criteria of pneumonia caused by novel coronavirus.","Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium;\r&lt;br&gt;(2) Inpatients aged 18 to 75 years;\r&lt;br&gt;(3) Voluntarily receive treatment with the drug and sign informed consent. The informed consent process complies with relevant GCP regulations.","Inclusion criteria: 1. COVID-19 diagnosed based on the interim guidelines of the World Health Organization;\r&lt;br&gt;2. Excess specimens for clinical testing (sputum, nasopharyngeal swabs, blood specimens, urine, anal swabs).\r&lt;br&gt;3. Sign the informed consent form (WeChat or electronic signature record).","Inclusion criteria: 1. aged between 16 and 50 years;\r&lt;br&gt;2. no history of gynecological diseases before;\r&lt;br&gt;3. willing to join this research and sign an informed consent form.","Inclusion criteria: (1) Confirmed patients (or legal guardian) sign a written informed consent form;\r&lt;br&gt;(2) Aged from 18 to 80 years, male or female;\r&lt;br&gt;(3) Patients with positive detection of 2019 Novel Coronavirus Pneumonia fluorescence RT-PCR in respiratory specimens or blood samples;\r&lt;br&gt;(4) Mild ill, severe ill and critical ill patients are grouped based on the fifth edition of the treatment and diagnosis plan published by the National Health Commission of the Peoples Republic of China.","Inclusion criteria: 1. Aged 18-70 years old;\r&lt;br&gt;2. Meet the diagnostic criteria for confirmed cases in the diagnosis and treatment plan of new coronavirus-infected pneumonia (trial version 5); and the clinical symptoms before admission or screening must meet the following conditions:\r&lt;br&gt;Fever (armpit temperature &gt;=37.3 degree C, or mouth temperature &gt;=38.0 degree C, or anal or ear temperature &gt;=38.6 degree C) &lt;=7 days; and breathing rate&gt; 24 beats / min or cough (at least one of the two);\r&lt;br&gt;3. Confirmed 2019-nCoV infection by Laboratory inspection (RT-PCR);\r&lt;br&gt;4. Have not previously received treatment or experimental treatment for COVID-19. Patients who have been treated with proprietary Chinese medicine or lopinavir / ritonavir tablets for less than 3 days can be enrolled;\r&lt;br&gt;5. Subjects volunteerly participate in this study and agree to sign informed consent;\r&lt;br&gt;6. According to the researcher's judgment, the subject / legal guardian is considered reliable and able to comply with this plan, visit plan and medication arrangement.","Inclusion criteria: 1. Aged &gt;=18 years;\r&lt;br&gt;2. Severed COVID-19 patients, matched the requirements of &lt;COVID-19 diagnosis and treatment programme (trial sixth edition)&gt; launched by NHC, which is meeting any of the following:\r&lt;br&gt;RR&gt;=30 times/min;\r&lt;br&gt;Rest SaO2&lt;=93%;\r&lt;br&gt;PaO2/FiO2&lt;=300mmHg;\r&lt;br&gt;Lung lesion area increasing &gt;50% with 24-28h via imaging examination;\r&lt;br&gt;3. Be able to work with researchers and be willing to comply with the entire research requirements.","Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19)","Inclusion criteria: (1) Comply with the diagnostic criteria for COVID-19 in the \"Diagnosis and Treatment Program for pneumonia caused by novel coronavirus infection (Trial Version 5)\", meet the the criteria of severe and critical type;\r&lt;br&gt;(2) Agree to participate in the study and the patient or legal guardian signs the informed consent form.","Inclusion criteria: (1) Inpatients aged 50 and over, regardless of gender, voluntarily signed informed consent;\r&lt;br&gt;(2) Persons diagnosed with 2019-nCoV infection: respiratory specimens or blood specimens are tested positive for 2019-nCoV nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens or blood specimens are sequenced for viral genes, which are highly homologous with known 2019-nCoV;\r&lt;br&gt;(3) Severe NCP group: meets (\"New Coronavirus Infected Pneumonia Diagnosis and Treatment Plan (Trial Fifth Edition)\") diagnostic criteria for heavy NCP.\r&lt;br&gt;(4) NCP group in acute exacerbation period: NCP patients with acute exacerbation period in general to severe and critically severe (for definition of severe and critically severe, see \"Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Fifth Edition)\");\r&lt;br&gt;Remarks: \"Judgment Criteria for NCP Patients with Acute Exacerbation in General to Severe and Critical Severity\"\r&lt;br&gt;1) Aged 50 years or older;\r&lt;br&gt;2) Dyspnea (those who inhale oxygen in a mask);\r&lt;br&gt;3) Combined with basic diseases, such as COPD, diabetes, hypertension, coronary heart disease;\r&lt;br&gt;4) White blood cell count is less than 4  109 / L or has a tendency to decrease continuously;\r&lt;br&gt;5) Lymphocyte count &lt;1.5x10^9 / L or a trend of continuous decrease;\r&lt;br&gt;6) Platelet count is less than 150x10^9/L or has a tendency to decrease continuously;\r&lt;br&gt;7) Hemoglobin has continued to decrease;\r&lt;br&gt;8) C-reactive protein &gt;=10 mg / L or a trend of continuous increase;\r&lt;br&gt;9) Procalcitonin &gt;=0.5 ng / mL or a tendency of continuous increase;\r&lt;br&gt;10) Lactate dehydrogenase &gt;=250 U/L or a trend of continuous increase;\r&lt;br&gt;11) Aspartate aminotransferase and alanine aminotransferase have a tendency to increase continuously;\r&lt;br&gt;12) Creatinine &gt;=133 umol/L or a tendency of continuous increase;\r&lt;br&gt;13) D-dimer &gt;=0.5 mg/L or a trend of continuous increase;\r&lt;br&gt;14) There is a continuous decrease in serum potassium;\r&lt;br&gt;15) IL-6 has a tendency to increase continuously;\r&lt;br&gt;16) Any of IL-2, IL-4, IL-10, TNF, IFN-r, and IL-17A has a tendency to increase continuously;\r&lt;br&gt;17) Imaging findings consistent with NCP progression.\r&lt;br&gt;Remarks: (1) If 9 or more of the above 17 items are met, they are judged to be \"normal-to-severe, severely severe NCP patients with acute exacerbation period\"; (2) continuous increase or decrease trend: at least 3 consecutive measurements, specific trends Determined by the research doctor; (3) In view of the special circumstances of the NCP, during the trial implementation, the selection criteria of the protocol can be appropriately updated and adjusted according to the clinical progress.","Inclusion criteria: 1. Inpatients aged 18 to 80 years old, male or female;\r&lt;br&gt;2. Confirmed patient diagnosed according to the guideline for Diagnosis and Treatment for COVID-19 (5th version), whose clinical classification is common or severe case;\r&lt;br&gt;Clinically diagnosed cases (suspected cases with radiological characteristics of pneumonia) or suspected cases have one of the following pathogenic evidences:\r&lt;br&gt;1) positive sputum or blood SARS-CoV-2 real-time RT-PCR assay;\r&lt;br&gt;2) Virus gene sequence from respiratory tract samples or blood samples, is highly homologous with SARS-CoV-2;\r&lt;br&gt;3. All subjects with childbearing ages must take effective contraceptive measures within 3 months after enrolling the screening period and after this clinical trial;\r&lt;br&gt;4. Full evaluation of the patient's condition, and confirmation that the patient can be transfused into convalescent plasma by doctors;\r&lt;br&gt;5. Volunteer to transfuse convalescent plasma, and sign the informed transfusion form and sign the notice of infusion (when neither the subject nor the legal guardian can read and understand the agreed contents of the notice of infusion, they need to sign it together with a third-party witness or/and his legal guardian or his legal representative to sign it together).","Inclusion criteria: COVID-19 patients admitted to Tongji Hospital ,Tongji Medical College, Huazhong University of Science and Technology","Inclusion criteria: 1. Aged 18 to 75 years male or female, willing to sign the informed consent; \r&lt;br&gt;2. Patients with novel coronavirus infection pneumonia were confirmed by epidemiology and clinical symptoms. The diagnostic criteria refer to \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)\";\r&lt;br&gt;3.Tested positive for novel coronavirus infection using a real time polymerase chain reaction (RT-PCR)-based diagnostic assay; or highly homologous to COVID-19 according to Virus gene sequencing;\r&lt;br&gt;4. Patients with pneumonia were confirmed by Chest imaging;\r&lt;br&gt;5. Enrollment and initiation of study drug treatment &lt;=10 days after onset of symptoms; Symptom are mainly fever, or cough on patients without fever;\r&lt;br&gt;6. Willing to abide by the protocol according investigators.","Inclusion criteria: 1. Meet the diagnostic criteria of the \"New Coronavirus Pneumonia Diagnosis and Treatment Scheme\" and patients diagnosed with new coronavirus infection; \r&lt;br&gt;2. Meet the diagnostic criteria for severe cases in the \"Plan\", namely: respiratory distress, RR &gt;=30 times / min; Below, refers to oxygen saturation &lt;=93%; arterial blood oxygen partial pressure (PaO2 / oxygen concentration (FiO2) &lt;=300mmHg;\r&lt;br&gt;3. aged &gt;=18 years old;\r&lt;br&gt;4. those who have voluntarily signed informed consent.","Inclusion criteria: All students from China University will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent.","Inclusion criteria: 1. aged 18-70 years male or female;\r&lt;br&gt;2. 2019 new coronavirus nucleic acid test positive;\r&lt;br&gt;3. meet the national diagnosis criteria;\r&lt;br&gt;4. subjects onset within 8 days (severe cases can be delayed to 14 days);\r&lt;br&gt;5. subjects or agency personnel agree to sign the informed consent;\r&lt;br&gt;6. subjects who can take oral medication or who receive oral medication;\r&lt;br&gt;7. subjects agree to collect clinical samples;\r&lt;br&gt;8. female subjects of child-bearing age are not pregnant and agree to take effective contraceptive measures within 7 days of the last oral medication to ensure that they will not pregnant;\r&lt;br&gt;9. men agree not to have sex with women for seven days after taking their last oral medication.","Inclusion criteria: Subjects who met all of the following conditions entered the trial:\r&lt;br&gt;1. Male or female patients aged 16 to 75 years;\r&lt;br&gt;2. willing to sign informed consent;\r&lt;br&gt;3. Based on the criteria for suspected cases of COVID-19 infection, sputum, throat swabs, lower respiratory tract secretions and other specimens were tested for positive COVID-19 nucleic acid by real-time fluorescent RT-PCR; or viral gene sequencing was performed with known COVID- 19 highly homologous;\r&lt;br&gt;4. The imaging findings are consistent with pneumonia.","Inclusion criteria: Healthcare-personnel who are working for treating COVID-19","Inclusion criteria: Patients aged &gt;=18 years with novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent.","Inclusion criteria: 1. Patients aged  15-80 years,diagnosed with mild, common, and severe novel coronavirus pneumonia in accordance with the diagnostic criteria for the diagnosis and treatment of novel coronavirus pneumonia issued by the National Health Commission (trial version 5);\r&lt;br&gt;2. White blood cell Count &lt; 15.0 x 10^9/L and Lymphocyte Count &lt; 0.8 x10^9/L.","Inclusion criteria: 1. In line with the diagnosis and treatment plan of pneumonia infected by novel coronavirus of the National Health Commission (Fifth Edition) Hubei Province Diagnostic criteria: including clinical diagnosis and etiological diagnosis;\r&lt;br&gt;2. Obtain the informed consent signed by the patient or the legally authorized agent of the patient.","Inclusion criteria: 1. Aged 18 to 80 years (inclusive);\r&lt;br&gt;2. People who had ineffective protection, i.e.:\r&lt;br&gt;1) living, studying, working together with, or having close contacts with confirmed cases and positive testers, such as working at close distances or sharing the same classroom or living in the same house;\r&lt;br&gt;2) had close contacts with medical personnel, family members or people who have similar close contact during the diagnosis, treatment, and visits, such as visiting or staying in a closed environment with other patients in the ward and their accompanying staff personnel;\r&lt;br&gt;3) people who took the same transportation and have close contact with the cases, including carers on the transportation vehicle;\r&lt;br&gt;4) people traveled together (e.g., family, colleagues, friends, etc.);\r&lt;br&gt;5) Other passengers or flight attendants who possibly had close contact with confirmed cases and positive testers after investigation and evaluation;\r&lt;br&gt;3. People who were considered as having close contacts with cases after an assessment by onsite investigators.","Inclusion criteria: Inpatients with 2019 Novel Coronavirus infection in the severe case section running by national medical team from the Second Affiliated hospital of Xian Jiaotong University","Inclusion criteria: 1. Aged 18-80 years;\r&lt;br&gt;2. Within 1 week of onset;\r&lt;br&gt;3. Meet the diagnostic criteria of common, severe and critical NCP, according to \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Pneumonia (Trial Version 6)\".\r&lt;br&gt;4. Sign informed consent.","Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19)","Inclusion criteria: 1. Female of after menarche;\r&lt;br&gt;2. Meet the pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of hubei province: including clinical diagnosis and etiological diagnosis;\r&lt;br&gt;4. Patients who signed the informed consent","Inclusion criteria: 1)2019-nCoV-cured patients that over 18 years of age\r&lt;br&gt;2)Sign informed consent.","Inclusion criteria: 1. Aged 18 to 70 years old, inpatients, male or female;\r&lt;br&gt;2. Patients with severe novel coronavirus infection: According to the \"Pneumonitis Diagnosis and Treatment Guideline for the Novel Coronavirus Infection (Trial Version 5)\", clinically diagnosed cases (suspected cases with pneumonia imaging features) or suspected cases.\r&lt;br&gt;Severe patients must also meet any of the following:\r&lt;br&gt;1) Respiratory distress, RR&gt;=30 times / minute\r&lt;br&gt;2) In the resting state, the oxygen saturation is &lt;=93%;\r&lt;br&gt;3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;=300 mmHg (1mm Hg = 0.133 kPa).\r&lt;br&gt;3. Subjects and / or legal guardians of the subjects volunteered to participate in the study and voluntarily signed informed consent.","Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:\r&lt;br&gt;1. Will sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;\r&lt;br&gt;2. Chinese aged &gt;=18 years;\r&lt;br&gt;3. In accordance with NCP criteria for severe and critical illness, namely \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 6)\". Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment.\r&lt;br&gt;4. The course of disease is within 14 days after the onset of illness;\r&lt;br&gt;5. Will take nasopharyngeal or oropharyngeal swabs before administration.","Inclusion criteria: 1) age 18-80 years old, regardless of gender: 2) the diagnosis criteria of severe nCoV pneumonia in line with the 6th edition of China's new coronavirus pneumonia diagnosis scheme: a.B. Real-time fluorescence rt-pcr of respiratory tract specimens or blood samples was used to detect positive nCoV nucleic acid;3) critical cases of nCoV pneumonia: meet one of the following criteria: a. respiratory failure and mechanical ventilation required;B. shock;C. Combined with other organ failure, intensive care unit is required;4) patients with poor treatment response: that is, the above critically ill patients have undergone active modern medicine to fight against shock, correct acidosis, improve multi-organ function rescue and ECMO assisted breathing, and have not been improved by circulation assisted treatment and hormone application;5) those who signed the informed consent and agreed to participate in the initial clinical trial were selected.","Inclusion criteria: 1. Volunteer to participate in the study and sign informed consent;\r&lt;br&gt;2. Aged 18-65 years, male or female;\r&lt;br&gt;3. Weight &gt;= 40kg and &lt;=100kg, and BMI &gt;= 18kg/m2;\r&lt;br&gt;4. Medical staff during the novel coronavirus (COVID-19) outbreak.","Inclusion criteria: (1) In line with ethics, sign a written informed consent form;\r&lt;br&gt;(2) Patients with positive detection of new coronavirus nucleic acid;\r&lt;br&gt;(3) Chest CT confirmed pulmonary lesions;\r&lt;br&gt;(4) Hospitalized patients with fever or respiratory symptoms;\r&lt;br&gt;(5) Patients who did not participate in other clinical studies within three months.","Inclusion criteria: 1. Aged 18-75 years old;\r&lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 4);\r&lt;br&gt;3. patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);\r&lt;br&gt;4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration.\r&lt;br&gt;6.Patients who voluntarily sign informed consent.","Inclusion criteria: cured patients of 2019 novel coronavirus.","Inclusion criteria: The COVID-19 patients are confirmed according to the novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) issued by the National Health Protection Commission and the Chinese medicine administration.","Inclusion criteria: 1) The NCP puerperae undergoing cesarean section (The diagnosis and treatment plan of pneumonia infected by novel coronavirus of the National Health Commission (Fifth Edition) Hubei Province Diagnostic criteria: including clinical diagnosis and etiological diagnosis);\r&lt;br&gt;2) Contact medical staff related to cesarean section of NCP puerperae;\r&lt;br&gt;3) Voluntary participation in the test and signing of informed consent.","Inclusion criteria: 1. Aged 18-75 years old;\r&lt;br&gt;2. RT-PCR positive for 2019-nCoV or Confirmed lung involvement with chest imaging;\r&lt;br&gt;3. The clinical symptoms are slight, and there is no obvious manifestation of pneumonia (mild disease) or clinical symptoms such as fever and respiratory tract in imaging. The manifestation of pneumonia (common type) can be seen in imaging;\r&lt;br&gt;4. &lt;=7 days since onset of the disease;\r&lt;br&gt;5. Willingness of study participant to accept randomization to any assigned treatment arm;\r&lt;br&gt;6. Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study.","Inclusion criteria: 1. The diagnosis conforms to the diagnostic criteria of \"pneumonia diagnosis and treatment program for new coronavirus infection (trial version 5)\";\r&lt;br&gt;2. Clinical classification is normal,severe or critical;\r&lt;br&gt;3. Subject aged &gt;=18 years old;\r&lt;br&gt;4. The patient or his/her legal guardian will participate voluntarily and sign the informed consent.","Inclusion criteria: 1. Voluntarily sign the Consent Form;\r&lt;br&gt;2. Male or female aged 18 and over;\r&lt;br&gt;3. According to the \"Diagnosis and Treatment Scheme for Pneumonia of Novel coronavirus pneumonia Infection-Trial Fifth Edition\", inpatient diagnosed with Novel coronavirus pneumonia diagnosed and clinical classification of ordinary type: Inpatients with fever (underarm temperature &gt;= 37.0 degree C), respiratory tract, etc. Imaging shows pneumonia.","Inclusion criteria: 1. First-line medical staff: doctors and nurses who enter the fixed-point pneumonia treatment hospital in Hubei Province for first-line clinical work, or clinical doctors and nurses who have treated COVID19 pneumonia cases in local designated pneumonia treatment hospitals, and clinical first-line medical staff who are exposed to/receive suspected cases of fever and confirmed cases of COVIP19 in hospital fever clinics\r&lt;br&gt;2. Confirmed and suspected cases: In the time of this investigation, in accordance with the latest version of the country's \"new coronavirus pneumonia diagnosis and treatment program\" confirmed and clinically confirmed patients. Suspected cases: In the time of this investigation, in accordance with the latest version of the country's \"new coronavirus pneumonia treatment program\" of suspected patients, but has not yet reached the diagnosis of patients. If the patient is eventually diagnosed but is suspected in the investigation, it is still classified as a suspected case.","Inclusion criteria: (1) Adult aged &gt;=18 years and agrees to sign the informed consent;\r&lt;br&gt;(2) Laboratory-confirmed 2019-nCoV infection by real-time RT-PCR;\r&lt;br&gt;(3) Chest imaging (CT) confirmed lung damage: multiple small plaques and stromal changes in the lungs, which were obvious in the outer lung, or multiple ground-glass shadows and infiltration shadows in both lungs, the changes may not be present in mild patients;\r&lt;br&gt;(4) Hospitalized patients with fever (axillary temperature &gt;=37.0 degree C) or respiratory symptoms;\r&lt;br&gt;(5) The interval between symptom onset and randomization was within 12 days;\r&lt;br&gt;(6) Did not participate in other clinical researches within 3 months;\r&lt;br&gt;(7) Do not participate other antiviral studies within 28 days of follow-up.","Inclusion criteria: 1. aged &gt;=18 years;\r&lt;br&gt;2. Gender limitation;\r&lt;br&gt;3. Patients must be able to sign informed consent and understand the possible risks of microecological intervention;\r&lt;br&gt;4. Be willing to provide stool and blood samples on time.","Inclusion criteria: Diagnostic criteria refers to the WHO standards, including clinically diagnosed cases and laboratory confirmed cases","Inclusion criteria: (1) Age 18-70 years\r&lt;br&gt;(2) Clinical symptoms, signs, and lung CT suggest changes in lung inflammation. Patients diagnosed with new type of coronavirus pneumonia combined with more than one nucleic acid test\r&lt;br&gt;(3) Clinical symptoms, signs, and lung CT suggest lung inflammation changes. Combined with more than one respiratory or blood specimen virus gene sequencing, it is highly homologous to known new coronaviruses.\r&lt;br&gt;(4) Negative nucleic acid or viral gene test, but New Crown Pneumonia expert group discusses cases with high suspicion of New Crown Pneumonia\r&lt;br&gt;(5) Voluntarily sign the informed consent and agree to comply with the requirements of the test protocol\r&lt;br&gt;(6) Patients can communicate in words or words. Sign informed consent\r&lt;br&gt;(7) The patient agrees and has the ability to complete auxiliary tests related to the trial","Inclusion criteria: 1. Aged 18-90 years;\r&lt;br&gt;2. With risk factor of COVID-19;\r&lt;br&gt;3. Access to nCapp platform;\r&lt;br&gt;4. to be able to complete a 1 year follow up.","Inclusion criteria: All students from Sichuan University will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent.","Inclusion criteria: (1) Patients with mild who are in compliance with the \"Pneumonitis Diagnosis and Treatment Program for COVID-19(Trial Fifth Edition)\" (released on 2020.2.4);\r&lt;br&gt;(2) Aged more than 18 years old;\r&lt;br&gt;(3) Informed consent of the patient.","Inclusion criteria: 1. The patients who were diagnosed with the common type of NCP (including severe risk factors) and severe cases of new coronavirus pneumonia;\r&lt;br&gt;2. Aged 18 to 85 years;\r&lt;br&gt;3. IL-1 elevated (using Elisa method, using the same company kit);\r&lt;br&gt;4. Patients or authorized family members volunteered to participate in this study and signed informed consent;\r&lt;br&gt;Definition of Novel Coronavirus Pneumonia (NCP) clinical cases:\r&lt;br&gt;1. Regular patients with NCP (including severe risk factors): patients with dual pulmonary lesions based on common NCP clinical symptoms accompanied by fever or no fever;\r&lt;br&gt;2. Critical NCP patient: Refer to the \"New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)\" formulated by the National Health Commission.","Inclusion criteria: (1) Meet NCP critical diagnosis criteria;\r&lt;br&gt;(2) Volunteer to participate in this study, cooperate with examination and treatment;\r&lt;br&gt;(3) The selected patients were basically stable, conscious and cooperative;\r&lt;br&gt;(4) No serious mental disorder;\r&lt;br&gt;(6) Aged between 20-80 years.","Inclusion criteria: 1. Aged 18 to 60 years old;\r&lt;br&gt;2. Inpatients who meet the diagnostic criteria for mild, general and neonatal pneumonia in western medicine, and early and recovery stages of traditional Chinese medicine;\r&lt;br&gt;3. Understand and agree to participate in this study and sign the informed consent.","Inclusion criteria: 1. The age at the time of signing the informed consent is &gt;= 18 years old and &lt;= 75 years old, both male and female; \r&lt;br&gt;2. The change of typical viral pneumonia in lung was detected by RT-PCR test of novel coronavirus nucleic acids or lung CT; \r&lt;br&gt;3. SaO2 / SpO2 &lt;= 94% or pa02 / fi02 ratio &lt; 300mghg at room temperature at admission; \r&lt;br&gt;4. Onset &lt;=12 days; \r&lt;br&gt;5. Willing to participate in the trial and randomly assigned to any treatment group; \r&lt;br&gt;6. Cannot participate in another experiment during the study period.","Inclusion criteria: 1. Male or female, 18-95 years old;\r&lt;br&gt;2. 2019 new coronavirus nucleic acid test positive;\r&lt;br&gt;3. Diagnosed as moderate to severe cases of new coronavirus pneumonia in 2019, which meets the following clinical manifestations:\r&lt;br&gt;4. With fever and respiratory symptoms, imaging shows pneumonia;\r&lt;br&gt;5. A severe case diagnosed with 2019 new coronavirus pneumonia, that is, any of the following:\r&lt;br&gt;(1) Increased breathing rate (&gt;=30 beats / min), difficulty breathing, cyanosis of lips;\r&lt;br&gt;(2) In the resting state, it means that oxygen saturation &lt;=93%; or blood oxygen drops rapidly;\r&lt;br&gt;(3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;=300mmHg (1mmHg = 0.133kPa);\r&lt;br&gt;6. I or the authorized agent signed the informed consent form;\r&lt;br&gt;7. Agree to collect clinical samples.","Inclusion criteria: 1. Aged &gt;=60 years;\r&lt;br&gt;2. Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)\";\r&lt;br&gt;3. Those without broad-spectrum antibacterial, antifungal, and antiviral treatment;\r&lt;br&gt;4. Imaging revealed pneumonia in patients with a diagnosis of pathogen: influenza, CAP/HAP bacterial infection, and fungal infection;\r&lt;br&gt;5. Participants signed informed consent before the study;\r&lt;br&gt;6. It must be agreed not to participate in other clinical studies until the 28th day of completion.","Inclusion criteria: 1) Male and female, 18-70 years old;\r&lt;br&gt;2) Severe patients (in any case: respiratory distress, RR &gt;= 30 times / min; in resting state, oxygen saturation &lt;= 93%; PaO2 / FiO2 &lt;= 300MMHG);\r&lt;br&gt;3) Within 12 days after illness onset;\r&lt;br&gt;4) Agree to sign the informed consent;\r&lt;br&gt;5) Able to ingest, absorb and tolerate oral medication;\r&lt;br&gt;6) Agree to collect clinical samples;\r&lt;br&gt;7) Consent to contraceptive measures for sex within 7 days of the last oral medication.","Inclusion criteria: The diagnostic criteria of novel coronavirus infection pneumonia can be observed and agreed by the patients themselves.","Inclusion criteria: 1. The neonates delivered by the mother who were suspected or confirmed infection of COVID-19;\r&lt;br&gt;2. The newborn,whose mother had no diagnosis of COVID-19 before delivery, had a history of epidemiological exposure (including diagnosis of COVID-19 of their mother after delivery or other people who had a close contacts with neonates), and the newborn tested positive for SARS-Cov-2 nucleic acid after birth, whether they had clinical symptom or not.","Inclusion criteria: 1) Aged &gt;= 18 years;            \r&lt;br&gt;2) In line with the diagnostic criteria of \"new coronavirus pneumonia diagnosis program\", the patient was diagnosed as pneumonia infected by the new coronavirus;\r&lt;br&gt;3) Severe pneumonia index (PSI) class for I ~ II;            \r&lt;br&gt;4) Hospitalized for:            \r&lt;br&gt;Fever: axillary temperature &gt;= 36.7 degree C, oral temperature &gt;= 38.0 degree C, Anal temperature &gt;= 38.6 degree C;            \r&lt;br&gt;respiratory rate &gt; 24 times / min or cough (at least one of them);            \r&lt;br&gt;5) The course of symptoms should be less than or equal to 8 days;            \r&lt;br&gt;6) Volunteers and comply with the hospital regulations, can cooperate with the completion of the prescribed inspection;           \r&lt;br&gt;7) Voluntary informed consent was signed prior to the trial.","Inclusion criteria: Patients with novel coronavirus infection who agreed to participate in this trial and signed the informed consent form. The diagnose criteria was according to Diagnostic and treatment protocol of COVID-19 pneumonia published by Chinese General Office of National Health Committee(6th and further edition).","Inclusion criteria: (1) nurses with working years &gt;=1 year;\r&lt;br&gt;(2) registered nurses who are qualified to practice;\r&lt;br&gt;(3) nurses who volunteered to participate in this study.","Inclusion criteria: (1) Aged 18-65 years;\r&lt;br&gt;(2) Virus nucleic acid test is positive;\r&lt;br&gt;(3) Lung CT showed multiple patchy, lumpy ground glass opacity(GGO) or consolidation in both lungs.","Inclusion criteria: 1. Aged &gt;18 years; \r&lt;br&gt;2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV; \r&lt;br&gt;3. Lung involvement confirmed with chest imaging.","Inclusion criteria: All patients who were diagnosed as COVID-19 according to the interim guidance of China National Health Commission (NHC)  were screened in this study. CVD included hypertension, coronary heart disease or/and heart failure confirmedly diagnosed in the past.","Inclusion criteria: 1. Aged &gt;=18 years old female;\r&lt;br&gt;2. A history of fertility or sexual activity\r&lt;br&gt;3. Meet the pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of Hubei province: including clinical diagnosis and etiological diagnosis;\r&lt;br&gt;4. Sign the informed consent.","Inclusion criteria: 1. Patients or his/her legal representatives agreed to participate the study and signed the informed consent. \r&lt;br&gt;2. Those diagnosed with mild or moderate novel coronavirus pneumonia (NCP) or those with severe NCP but can take medicines orally or via stomach tube. The confirmed patients were defined as those NCP suspects with one of the following pathogenic evidences:\r&lt;br&gt;1) The novel coronavirus in respiratory or blood specimens were confirmed by real time RT-PCR.\r&lt;br&gt;2) The genetic sequence of the virus detected in respiratory or blood specimen are highly homologous with the known coronavirus;\r&lt;br&gt;3. Adult patient aged&gt;=18 years;\r&lt;br&gt;4. Those who are able to communicate well with investigators and to complete the study according to the protocol.","Inclusion criteria: 1. 18 years old &lt;= age &lt;= 60 years old when screening, not limited to men and women;\r&lt;br&gt;2. Who are in close contact with suspected cases, confirmed cases, and positive test of new coronavirus nucleic acid, and those who have not taken effective protection, that is, close contacts;\r&lt;br&gt;3. Study subjects are willing to be randomly assigned to any designated treatment group;\r&lt;br&gt;4. Must agree to not participate in another study of study drugs until day 24 of completion of the study.\r&lt;br&gt;5. Participants volunteered to participate in this study and signed informed consent.","Inclusion criteria: 1) Aged &gt;= 18 years;\r&lt;br&gt;2) In line with the diagnostic criteria of \"new coronavirus pneumonia diagnosis program\", the patient was diagnosed as pneumonia infected by the new coronavirus;\r&lt;br&gt;3) Severe pneumonia index (PSI) class for III ~ IV;\r&lt;br&gt;4) The course of symptoms should be less than or equal to 8 days;\r&lt;br&gt;5) Volunteers and comply with the hospital regulations, can cooperate with the completion of the prescribed inspection;\r&lt;br&gt;6) Voluntary informed consent was signed prior to the trial.","Inclusion criteria: 1. Severe patients diagnosed with novel coronavirus pneumonia (COVID-19);\r&lt;br&gt;2. Aged 35 years old to 74 years old;\r&lt;br&gt;3. Patients or authorized family members volunteered to participate in this study and signed informed consent.\r&lt;br&gt;Note: Case definition: Severe NCP: Refer to the \"New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)\" formulated by the National Health Commission.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years at time of signing Informed Consent Form\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.\r&lt;br&gt;\r&lt;br&gt;          3. Lung involvement confirmed with chest imaging\r&lt;br&gt;\r&lt;br&gt;          4. Hospitalised with:\r&lt;br&gt;\r&lt;br&gt;               -  Fever - =36.7? -axilla or Oral temperature = 38.0 ? or =38.6C tympanic or rectal\r&lt;br&gt;                  or\r&lt;br&gt;\r&lt;br&gt;               -  And at least one of Respiratory rate &gt;24/min Or Cough\r&lt;br&gt;\r&lt;br&gt;          5. =8 days since illness onset\r&lt;br&gt;\r&lt;br&gt;          6. Willingness of study participant to accept randomization to any assigned treatment\r&lt;br&gt;             arm.\r&lt;br&gt;\r&lt;br&gt;          7. Must agree not to enroll in another study of an investigational agent prior to\r&lt;br&gt;             completion of Day 28 of study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Physician makes a decision that trial involvement is not in patients' best interest,\r&lt;br&gt;             or any condition that does not allow the protocol to be followed safely.\r&lt;br&gt;\r&lt;br&gt;          2. Severe liver disease (e.g. Child Pugh score = C, AST&gt;5 times upper limit)\r&lt;br&gt;\r&lt;br&gt;          3. SaO2/SPO2=94% in room air condition, or the Pa02/Fi02 ratio &lt;300mgHg\r&lt;br&gt;\r&lt;br&gt;          4. Known allergic reaction to remdesivir\r&lt;br&gt;\r&lt;br&gt;          5. Patients with known severe renal impairment (estimated glomerular filtration rate =30\r&lt;br&gt;             mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis,\r&lt;br&gt;             peritoneal dialysis\r&lt;br&gt;\r&lt;br&gt;          6. Pregnant or breastfeeding, or positive pregnancy test in a predose examination\r&lt;br&gt;\r&lt;br&gt;          7. Will be transferred to another hospital which is not the study site within 72 hours.\r&lt;br&gt;\r&lt;br&gt;          8. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or\r&lt;br&gt;             trial related) within the 30 days prior to the time of the screening evaluation.\r&lt;br&gt;","Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients in Hubei Province;\r&lt;br&gt;2. Aged 18 to 65 years;\r&lt;br&gt;3. The time interval between symptom onset and randomization was within 7 days (the onset of symptom was mainly determined by the time of fever);\r&lt;br&gt;4. Sign the written informed consent before the study.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The neonates with COVID-19,or neonates born by infected mothers\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The neonates with major anomalies\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  people who lived in or out of China at present and threatened by the infection and\r&lt;br&gt;             spread of COVID-19\r&lt;br&gt;\r&lt;br&gt;               -  without gender and age restriction\r&lt;br&gt;\r&lt;br&gt;               -  people who have concerns of his health\r&lt;br&gt;\r&lt;br&gt;               -  voluntary completion of the self-test and evaluation.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  people who are not internet accessible or can not use this Mobile Applet.\r&lt;br&gt;\r&lt;br&gt;          -  people who can not recognize the questionnaire.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years;\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory (RT-PCR) diagnosis of common patients infected with COVID-19 (refer to the\r&lt;br&gt;             fifth edition of the Chinese Guidelines for Diagnosis and Treatment);\r&lt;br&gt;\r&lt;br&gt;          3. chest imaging confirmed lung damage;\r&lt;br&gt;\r&lt;br&gt;          4. The diagnosis is less than or equal to 8 days;\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Severe liver disease (such as Child Pugh score = C, AST&gt; 5 times the upper limit);\r&lt;br&gt;             severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less)\r&lt;br&gt;\r&lt;br&gt;          2. Positive pregnancy or breastfeeding or pregnancy test;\r&lt;br&gt;\r&lt;br&gt;          3. In the 30 days before the screening assessment, have taken any experimental treatment\r&lt;br&gt;             drugs for COVID-19 (including off-label, informed consent use or trial-related);\r&lt;br&gt;\r&lt;br&gt;          4. Those with a history of thromboembolism, except for those caused by PICC.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years;\r&lt;br&gt;\r&lt;br&gt;          2. The laboratory (RT-PCR) confirmed the diagnosis of severe patients infected with\r&lt;br&gt;             CoVID-19 (refer to the fifth edition of the Chinese diagnosis and treatment guideline\r&lt;br&gt;             for trial); the diagnosis of new coronavirus pneumonia was confirmed, and any of the\r&lt;br&gt;             following: 1) Respiratory distress, breathing =30 beats / min; 2) In the resting\r&lt;br&gt;             state, the oxygen saturation is =93%; 3) Arterial blood oxygen partial pressure /\r&lt;br&gt;             oxygen concentration =300mmHg\r&lt;br&gt;\r&lt;br&gt;          3. The diagnosis is less than or equal to 12 days;\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Severe liver disease (such as Child Pugh score = C, AST&gt; 5 times the upper limit);\r&lt;br&gt;             severe renal dysfunction (the glomerulus is 30ml / min / 1.73m2 or less)\r&lt;br&gt;\r&lt;br&gt;          2. Pregnancy or breastfeeding or positive pregnancy test;\r&lt;br&gt;\r&lt;br&gt;          3. In the 30 days before the screening assessment, have taken any experimental treatment\r&lt;br&gt;             drugs for CoVID-19 (including off-label, informed consent use or trial-related);\r&lt;br&gt;\r&lt;br&gt;          4. Those with a history of thromboembolism, except for those caused by PICC.\r&lt;br&gt;","Inclusion criteria: 1. aged between 18-70 years old;\r&lt;br&gt;2. clinical dignosied 2019-nCov pneumonia and clinical recovery,diagnostic criteria according to the   2019-nCov pneumonia-6th edition;\r&lt;br&gt;3. Cured within one month of discharge;\r&lt;br&gt;4. consious,emotionormal,able to communicate well with medical staff and finish the exercise;\r&lt;br&gt;5. Understand and be willing to participate in this clinical trial and provide signed informed consent.","Inclusion criteria: 1. Aged 18-80 years;\r&lt;br&gt;2. Meet the diagnostic criteria of \"New Coronavirus Infected Pneumonia Sixth Edition\";\r&lt;br&gt;3. Blood pressure 90-150 / 60-100mmHg, respiratory rate 12-20 beats / min, heart rate 60-100 beats / min;\r&lt;br&gt;4. Extremity muscle strength examination is more than 5-grade;\r&lt;br&gt;5. Accept the study with the consent of the patient or family, and sign an informed consent form before the study","\r&lt;br&gt;        1. For the 2019-nCoV infection group\r&lt;br&gt;\r&lt;br&gt;             Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;             Diagnosed with 2019-nCoV infection (with direct laboratory evidence).\r&lt;br&gt;\r&lt;br&gt;               1. Respiratory or blood samples tested positive for novel coronavirus nucleic acid\r&lt;br&gt;                  with RT-PCR.\r&lt;br&gt;\r&lt;br&gt;               2. Gene sequencing of respiratory or blood samples show highly homologous with known\r&lt;br&gt;                  novel coronaviruses.\r&lt;br&gt;\r&lt;br&gt;             Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;             Subjects will be excluded if the children or their parents disagree to conduct this\r&lt;br&gt;             study.\r&lt;br&gt;\r&lt;br&gt;          2. For the control group\r&lt;br&gt;\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Diagnosed with pneumonia, and excepted of novel coronavirus infection.\r&lt;br&gt;\r&lt;br&gt;          2. The hospitalization time is the same as that of novel coronavirus pneumonia.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Subject will be excluded if she or he has one of the following:\r&lt;br&gt;\r&lt;br&gt;          1. First diagnosis is not pneumonia.\r&lt;br&gt;\r&lt;br&gt;          2. Any one of the novel coronavirus laboratory test results show positive.\r&lt;br&gt;\r&lt;br&gt;          3. Children or their parents disagree to conduct this study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. CT image is characteristic of viral pneumonia;\r&lt;br&gt;\r&lt;br&gt;          2. 2019-ncov infection (positive nucleic acid test) is confirmed by pathogenic test;\r&lt;br&gt;\r&lt;br&gt;          3. In compliance with the 2019-nCoV infection severe pneumonia diagnosis standard\r&lt;br&gt;             (according to the novel coronavirus infection pneumonia diagnosis and treatment\r&lt;br&gt;             program (Trial Implementation Version 5) issued by the National Health and Medical\r&lt;br&gt;             Commission, and WHO 2019 new coronavirus guidelines standards). It is severe if it\r&lt;br&gt;             meets any of the following: (A) Increased breathing rate (=30 beats / min), difficulty\r&lt;br&gt;             breathing, cyanosis of the lips; (B) When inhaling, means oxygen saturation =93%; (C)\r&lt;br&gt;             Partial pressure of arterial oxygen (PaO2) / Fraction of inspired oxygen (FiO2) =300\r&lt;br&gt;             mmHg (1mmHg = 0.133kPa);\r&lt;br&gt;\r&lt;br&gt;          4. 18 years old = age = 65 years old, regardless of gender;\r&lt;br&gt;\r&lt;br&gt;          5. The patient or legal donor agrees to participate in the study and signs the informed\r&lt;br&gt;             consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with severe allergies or allergies to stem cell preparations and their\r&lt;br&gt;             components;\r&lt;br&gt;\r&lt;br&gt;          2. Patients with serious basic diseases that affect survival, including: blood diseases,\r&lt;br&gt;             cachexia, active bleeding, severe malnutrition, etc .;\r&lt;br&gt;\r&lt;br&gt;          3. Patients with pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis,\r&lt;br&gt;             alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or\r&lt;br&gt;             bacterial pneumonia;\r&lt;br&gt;\r&lt;br&gt;          4. Continuous use of immunosuppressive agents or organ transplants in the past 6 months;\r&lt;br&gt;\r&lt;br&gt;          5. In vitro life support (ECMO, ECCO2R, RRT);\r&lt;br&gt;\r&lt;br&gt;          6. Expected deaths within 48 hours, uncontrolled infections;\r&lt;br&gt;\r&lt;br&gt;          7. Patients with malignant blood-borne diseases such as HIV or syphilis;\r&lt;br&gt;\r&lt;br&gt;          8. Patient with pregnancy, are planning to become pregnant or breastfeeding;\r&lt;br&gt;\r&lt;br&gt;          9. Patients with poor compliance and unable to complete the full study;\r&lt;br&gt;\r&lt;br&gt;         10. The investigator determines that there may be increased risk of the subject or other\r&lt;br&gt;             conditions that interfere with the clinical trial and the judgment of the results\r&lt;br&gt;             (such as excessive stress, sensitivity or cognitive impairment, etc.);\r&lt;br&gt;\r&lt;br&gt;         11. There are other situations that the researchers think are not suitable to participate\r&lt;br&gt;             in this clinical study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  High risk of COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  RT-PCR test result of SAR2-CoV-19\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Not available for RT-PCR test result of SAR2-CoV-19\r&lt;br&gt;","Inclusion criteria: 1) confirmed or suspected cases of new coronavirus pneumonia;\r&lt;br&gt;2) be able to understand the content of this study, and have the ability of normal communication and understanding;\r&lt;br&gt;3) voluntarily participate in this study and obtain written informed consent from the guardian or the patient.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years at time of signing Informed Consent Form\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.\r&lt;br&gt;\r&lt;br&gt;          3. Lung involvement confirmed with chest imaging\r&lt;br&gt;\r&lt;br&gt;          4. Hospitalized with a SaO2/SPO2=94% on room air or Pa02/Fi02 ratio &lt;300mgHg\r&lt;br&gt;\r&lt;br&gt;          5. =12 days since illness onset\r&lt;br&gt;\r&lt;br&gt;          6. Willingness of study participant to accept randomization to any assigned treatment\r&lt;br&gt;             arm.\r&lt;br&gt;\r&lt;br&gt;          7. Must agree not to enroll in another study of an investigational agent prior to\r&lt;br&gt;             completion of Day 28 of study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Physician makes a decision that trial involvement is not in patients' best interest,\r&lt;br&gt;             or any condition that does not allow the protocol to be followed safely.\r&lt;br&gt;\r&lt;br&gt;          2. Severe liver disease (e.g. Child Pugh score = C, AST&gt;5 times upper limit)\r&lt;br&gt;\r&lt;br&gt;          3. Pregnant or breastfeeding, or positive pregnancy test in a predose examination\r&lt;br&gt;\r&lt;br&gt;          4. Patients with known severe renal impairment (estimated glomerular filtration rate =30\r&lt;br&gt;             mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis,\r&lt;br&gt;             peritoneal dialysis\r&lt;br&gt;\r&lt;br&gt;          5. Will be transferred to another hospital which is not the study site within 72 hours.\r&lt;br&gt;\r&lt;br&gt;          6. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or\r&lt;br&gt;             trial related) within the 30 days prior to the time of the screening evaluation.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Men and women aged 18 to 75 years (inclusive)\r&lt;br&gt;\r&lt;br&gt;          -  In line with the new coronavirus infection pneumonia diagnosis and treatment plan\r&lt;br&gt;             (trial version 4) issued by the Health Commission, patients with new coronavirus (2019\r&lt;br&gt;             ncov) pneumonia were clinically diagnosed;\r&lt;br&gt;\r&lt;br&gt;          -  The subjects must be able to understand the study and willing to participate in the\r&lt;br&gt;             study, and sign the informed consent (if the subjects with no behavioral ability think\r&lt;br&gt;             it is in their own interests to participate in the test, they should sign the informed\r&lt;br&gt;             consent by their legal guardian, or notify the consent by phone (recording) and\r&lt;br&gt;             explain it in the original medical record and other relevant documents).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Known or expected to have allergic reactions or a history of allergy to any of the\r&lt;br&gt;             ingredients treated in this trial;\r&lt;br&gt;\r&lt;br&gt;          -  In the judgment of the investigator, there are other reasons that the patient is not\r&lt;br&gt;             suitable to participate in this study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Aged between 18 and 70 years, extremes included, male or female\r&lt;br&gt;\r&lt;br&gt;          2. Fever (armpit temperature =37.3  C, or mouth temperature =38.0  C, or anal or ear\r&lt;br&gt;             temperature =38.6  C) =7 days according to the official guideline \"Pneumonia\r&lt;br&gt;             Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)\"\r&lt;br&gt;\r&lt;br&gt;          3. Laboratory test (RT-PCR) confirms infection 2019-nCoV\r&lt;br&gt;\r&lt;br&gt;          4. No previous or experimental treatment for pneumonia associated with a novel\r&lt;br&gt;             coronavirus infection. Patients who have been treated with proprietary Chinese\r&lt;br&gt;             medicines or lopinavir / ritonavir tablets for less than 3 days can be enrolled\r&lt;br&gt;\r&lt;br&gt;          5. Informed Consent Form (ICF) signed voluntarily\r&lt;br&gt;\r&lt;br&gt;          6. Based on the investigator's judgment, the subject / legal guardian is considered\r&lt;br&gt;             reliable and able to comply with this program, visit plan and medication arrangement\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Suffer from diseases that need to be distinguished from new coronavirus infection\r&lt;br&gt;             pneumonia, such as tuberculosis, bacterial or viral pneumonia other than new\r&lt;br&gt;             coronavirus pneumonia, hospital-acquired pneumonia, and other pathogenic\r&lt;br&gt;             microorganisms pneumonia;\r&lt;br&gt;\r&lt;br&gt;          2. Patients with basic diseases such as primary immunodeficiency disease, acquired\r&lt;br&gt;             immunodeficiency syndrome, congenital respiratory malformations, abnormal lung\r&lt;br&gt;             development, aspiration pneumonia, lung malignant tumors, etc .;\r&lt;br&gt;\r&lt;br&gt;          3. Researchers have judged that previous or current diseases may affect patients'\r&lt;br&gt;             participation in the trial or influence the outcome of the study, including: malignant\r&lt;br&gt;             disease, autoimmune disease, liver and kidney disease, blood disease, neurological\r&lt;br&gt;             disease, and endocrine Disease; currently suffering from diseases that seriously\r&lt;br&gt;             affect the immune system, such as: human immunodeficiency virus (HIV) infection, or\r&lt;br&gt;             the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;\r&lt;br&gt;          4. Subjects with: asthma requiring daily treatment, any other chronic respiratory\r&lt;br&gt;             disease, respiratory bacterial infections such as purulent tonsillitis, acute\r&lt;br&gt;             tracheobronchitis, sinusitis, otitis media, and other respiratory tracts that affect\r&lt;br&gt;             clinical trial evaluation Disease: Chest CT confirmed patients with basic lung\r&lt;br&gt;             diseases such as severe interstitial lung disease and bronchiectasis;\r&lt;br&gt;\r&lt;br&gt;          5. Patients diagnosed with severe, critically recurrent coronavirus infection, pneumonia,\r&lt;br&gt;             or need mechanical ventilation or need systemic antihormonal treatment;\r&lt;br&gt;\r&lt;br&gt;          6. Breastfeeding or pregnancy test result is positive during the screening period or\r&lt;br&gt;             test;\r&lt;br&gt;\r&lt;br&gt;          7. The research drug Xiyanping injection or a drug with similar efficacy (see Prohibition\r&lt;br&gt;             of Medication) has been used for more than 3 days during screening.\r&lt;br&gt;\r&lt;br&gt;          8. Allergic constitution (persons who are allergic to more than 2 kinds of substances),\r&lt;br&gt;             people who are allergic to similar drugs in the past or those who are known to be\r&lt;br&gt;             allergic to the ingredients and auxiliary materials in the test drugs;\r&lt;br&gt;\r&lt;br&gt;          9. Patients who have participated in other clinical trials in the past 3 months;\r&lt;br&gt;\r&lt;br&gt;         10. The investigator determines that it is not appropriate to participate in a clinical\r&lt;br&gt;             trial.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with pulmonary fibrosis after standard treatment of COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Age 18-65\r&lt;br&gt;\r&lt;br&gt;          -  2019-nCoV nucleic acid negative in respiratory tract or blood samples were detected by\r&lt;br&gt;             real-time fluorescence PCR for more than 2 times\r&lt;br&gt;\r&lt;br&gt;          -  The patient did not participant in other drug clinical studies within 1 month.\r&lt;br&gt;\r&lt;br&gt;          -  The patient or the patient's guardian agrees to participate the trial and sign the\r&lt;br&gt;             informed Consent Form\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Gestation or lactation period women and women who plan to get pregnant during the\r&lt;br&gt;             study period\r&lt;br&gt;\r&lt;br&gt;          -  Those who are unable to communicate, such as patients in unconsciousness or with\r&lt;br&gt;             dementia, various mental , etc.\r&lt;br&gt;\r&lt;br&gt;          -  Severe background disease like severe cardiac insufficiency (cardiac function grade\r&lt;br&gt;             IV), severe liver and kidney diseases, bronchial asthma, COPD, neurological diseases,\r&lt;br&gt;             tumors,etc.\r&lt;br&gt;\r&lt;br&gt;          -  Long-term bedridden for various reasons\r&lt;br&gt;\r&lt;br&gt;          -  Patient who are allergy to the experimental drug\r&lt;br&gt;","Inclusion criteria: Moxibustion intervention study plan for 14 days of NCP close contact with forced home isolation:\r&lt;br&gt;Participants inclusion criteria:\r&lt;br&gt;1. Aged 18 to 75 years old;\r&lt;br&gt;2. Those that meet one or more of the following:\r&lt;br&gt;(1)In the past 1 month, there is a history of contact with patients with pneumonia diagnosed by new coronavirus;\r&lt;br&gt;(2) People who have lived or stayed in Wuhan or the affected area in the past month;\r&lt;br&gt;3. Those who have had close contacts with returnees from Hubei in the past month;\r&lt;br&gt;4. Persons who live or work in 2 or more confirmed cases of novel coronavirus infection pneumonia;\r&lt;br&gt;5. Take the same transportation with the newly diagnosed cases of Novel Coronary Pneumonia and have close contact with people, including those who have taken care of the patient on the transportation and the patient's colleagues (family, colleagues, friends, etc.);\r&lt;br&gt;6. The area is limited to Hunan Province;\r&lt;br&gt;7. Voluntarily participate in this research and sign the informed consent.\r&lt;br&gt;Patient who meet the above 4 items can be included in this study.\r&lt;br&gt;Research Program on Moxibustion Intervention in NCP Home Isolation Population:\r&lt;br&gt;1. Aged 18 to 75 years old;\r&lt;br&gt;2. Those that meet one or more of the following:\r&lt;br&gt;(1) There is no contact history of patients with pneumonia diagnosed with new-type coronavirus in the past month;\r&lt;br&gt;(2) The corpus callosum is weak, susceptible to wind and cold, and has a history of chronic respiratory diseases;\r&lt;br&gt;3. The area is limited to Hunan Province;\r&lt;br&gt;4. Voluntarily participate in this research and sign the informed consent.\r&lt;br&gt;Patient who meet the above 4 items can be included in this study.\r&lt;br&gt;Research Program on Moxibustion Intervention in NCP Home Isolation Medical Care Group:\r&lt;br&gt;1. Aged 18 to 75 years old;\r&lt;br&gt;2. Those that meet one or more of the following:\r&lt;br&gt;(1) Occupation is doctor and patient;\r&lt;br&gt;(2) There is no contact history of patients with pneumonitis diagnosed with new-type coronavirus in the past 1 month;\r&lt;br&gt;3. The area is limited to Hu'nan Province;\r&lt;br&gt;4. Voluntarily participate in this research and sign the informed consent.\r&lt;br&gt;Participants who meet the above 4 items can be included in this study.","Inclusion criteria: 1. Meet the diagnostic criterias for novel coronavirus pneumonia during the medical observation period, light type (the syndrome of cold and damp stagnating lungs), ordinary type (the syndrome of lung block by cold and damp), and recovery period  (qi deficiency of the spleen and the lung syndrome); \r&lt;br&gt;2. Aged 18 to 65 years old; 10-day spacer\r&lt;br&gt;3. Voluntarily received inderect moxibustion for at least 10 days;\r&lt;br&gt;4. Voluntarily test and abide by the relevant management regulations of the hospital, and be able to cooperate in completing the various inspections.","Inclusion criteria: 1. confirmed clinical records in the database of the hospital;\r&lt;br&gt;2. inpatients have confirmed clinical diagnosis and relevant laboratory tests;\r&lt;br&gt;3. the CT images are complete, the image quality meets the diagnostic and measurement requirements;\r&lt;br&gt;4. the format of image storage and transmission is DICOM file.","Inclusion criteria: This study intends to select surveillance cases, suspected cases, and diagnosed cases of COVID-19 for children aged 0-18 who were admitted to the Department of Pediatrics, Tongji Hospital from December 2019 to June 2020.\r&lt;br&gt;1. Epidemiological classification: All Participants divided into three levels: high, medium and low risk according to the epidemiological history:\r&lt;br&gt;(1) high risk: the participants are close to suspected or confirmed cases of COVID-19 within 14 days before the onset of illness;\r&lt;br&gt;(2) medium risk: cluster cases of COVID-19 in the residence or community;\r&lt;br&gt;(3) low risk: the residence or community has no cluster cases or not from epidemic place;\r&lt;br&gt;2. Monitoring cases: high-risk children with no symptom and medium-risk or low-risk children with the following symptoms:\r&lt;br&gt;(1) Fever;\r&lt;br&gt;(2) respiratory symptoms or weakness, nausea, vomiting, abdominal discomfort and diarrhea;\r&lt;br&gt;3. Suspected cases: If the high-risk children meet any 2 of the following 3 conditions, they are suspected cases. Any 2 of the following 3 surveillance cases in medium and low risk were suspected cases after elimination of influenza (no effect of oseltamivir phosphate for 2 days) and other common respiratory pathogenic infections:\r&lt;br&gt;(1) Persistent fever, obvious respiratory symptoms, shortness of breath, pulse oxygen saturation decreased, or gastrointestinal symptoms such as nausea, vomiting, abdominal discomfort and diarrhea;\r&lt;br&gt;(2) laboratory tests: white blood cells level normal or decreased , lymphocyte count decreased, CRP normal or slightly elevated;\r&lt;br&gt;(3) chest radiology shows signs of COVID-19;\r&lt;br&gt;4. Diagnosed cases: all suspected cases who respiratory swabs or secretions, blood, feces and urine SARS-CoV-2 nucleic acid test is positive; viral gene sequencing is highly homologous with SARS-CoV -2.","Inclusion criteria: According to the \"Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (Trial Version 6)\" issued by the General Office of the State Health Committee of the People's Republic of China, newly diagnosed patients with pneumonia have been diagnosed.  Clinical classification: \r&lt;br&gt;(1) mild: clinical symptoms are mild, and no pneumonia is found on imaging;\r&lt;br&gt;(2) Common type: with fever, respiratory tract and other symptoms, pneumonia can be seen on imaging;\r&lt;br&gt;(3) Heavy duty.  \r&lt;br&gt;Comply with any of the following: \r&lt;br&gt;1. shortness of breath, RR&gt;=30 times/min;\r&lt;br&gt;2. In the resting state, oxygen saturation &lt;=93%;\r&lt;br&gt;3. arterial partial pressure of oxygen (PaO2)/ oxygen concentration (FiO2)&lt;=300mmHg(1mmHg=0.133kPa). In areas with high altitude (over 1,000 meters above sea level), PaO2/FiO2 shall be corrected according to the following formula: PaO2/FiO2*[ atmospheric pressure (mmHg)/760];  Pulmonary imaging showed that patients with obvious lesion progress &gt; 50% within 24-48 hours should be managed according to heavy duty;\r&lt;br&gt;4. Critical type: one of the following conditions is met: \r&lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is required;\r&lt;br&gt;(2) Shock;\r&lt;br&gt;(3) ICU monitoring and treatment are required for patients with other organ failure.","Inclusion criteria: 1. Confirmed or clinically diagnosed cases;\r&lt;br&gt;2. Aged &gt; 1 year;\r&lt;br&gt;3. Volunteers.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The patients who were diagnosed with the common type of NCP (including severe risk\r&lt;br&gt;             factors) and severe cases of new coronavirus pneumonia;\r&lt;br&gt;\r&lt;br&gt;          -  Aged 18 to 85 years;\r&lt;br&gt;\r&lt;br&gt;          -  Patients or authorized family members volunteered to participate in this study and\r&lt;br&gt;             signed informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with any history of bradyarrhythmia or atrioventricular blocks\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are participating in other drug clinical trials;\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or lactating women;\r&lt;br&gt;\r&lt;br&gt;          -  ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;\r&lt;br&gt;\r&lt;br&gt;          -  Definite diagnosis of rheumatic immune-related diseases;\r&lt;br&gt;\r&lt;br&gt;          -  Long-term oral anti-rejection or immunomodulatory drugs;\r&lt;br&gt;\r&lt;br&gt;          -  Patients with active pulmonary tuberculosis, with definite bacterial and fungal\r&lt;br&gt;             infections.\r&lt;br&gt;","Inclusion criteria: (1) Aged 20-45 years old;\r&lt;br&gt;(2) Understand and willing to participate in this clinical trial and provide signed informed consent.","Inclusion criteria: 1. Aged 18 to 75 years men and women;\r&lt;br&gt;2. Inpatients with novel coronavirus(SARS-CoV-2) infection confirmed by PCR;\r&lt;br&gt;3. Agree and sign the informed consent form.","Inclusion criteria: Patients with Novel coronavirus pneumonia who are mainly admitted to hospitals in Hubei Province and whose temperature is normal for at least 5 days after treatment, whose vital signs are stable (including to be discharged) or who have been discharged, but whose lung damage has not improved.\r&lt;br&gt;1. Aged &gt;=18 years male and female;\r&lt;br&gt;2. Clinically diagnosed and confirmed cases;\r&lt;br&gt;3. Classification: clinically diagnosed cases, confirmed cases of ordinary, severe, critical.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Epidemiological history including resident of Hubei province, or travel history to\r&lt;br&gt;             Hubei province or exposure to suspected patients in the past two weeks.\r&lt;br&gt;\r&lt;br&gt;          2. Symptoms like fever, fatigue, myalgia, headache, cough, sputum production, chest\r&lt;br&gt;             tightness, dyspnea, etc.\r&lt;br&gt;\r&lt;br&gt;          3. White blood cells decreased or were normal, or lymphocytes decreased, and chest CT\r&lt;br&gt;             images showed typical findings of viral pneumonia.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients can not follow-up;\r&lt;br&gt;\r&lt;br&gt;          2. Investigator considering inappropriate.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Epidemiological history including resident of Hubei province, or travel history to\r&lt;br&gt;             Hubei province or exposure to suspected patients in the past two weeks.\r&lt;br&gt;\r&lt;br&gt;          2. Symptoms like fever, fatigue, myalgia, headache, cough, sputum production, chest\r&lt;br&gt;             tightness, dyspnea, etc.\r&lt;br&gt;\r&lt;br&gt;          3. White blood cells decreased or were normal, or lymphocytes decreased, and chest CT\r&lt;br&gt;             images showed typical findings of viral pneumonia.\r&lt;br&gt;\r&lt;br&gt;          4. Detection of 2019 Novel Coronavirus nucleic acid is positive by local Center for\r&lt;br&gt;             Disease Control and Prevention (CDC).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients can not follow-up;\r&lt;br&gt;\r&lt;br&gt;          2. Investigator considering inappropriate.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Male or female, aged at 18 years-65 years old\r&lt;br&gt;\r&lt;br&gt;          -  2. Pneumonia that is judged by chest radiograph or computed tomography\r&lt;br&gt;\r&lt;br&gt;          -  3. Laboratory confirmation of NCP infection by reverse-transcription polymerase chain\r&lt;br&gt;             reaction(RT-PCR) from any diagnostic sampling source\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Pregnancy or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  2. Known HIV, HBV or HCV infection\r&lt;br&gt;\r&lt;br&gt;          -  3. Patients with malignant tumor, other serious systemic diseases and psychosis\r&lt;br&gt;\r&lt;br&gt;          -  4. Patients who are participating in other clinical trials\r&lt;br&gt;\r&lt;br&gt;          -  5. Inability to provide informed consent or to comply with test requirements\r&lt;br&gt;","Inclusion criteria: severe case of COVID-19","Inclusion criteria: 1. Age is not limited; \r&lt;br&gt;2. Confirmed group:clinical diagnosis is in accordance with the \"Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)\" on the diagnosis of a new type of coronavirus infection; \r&lt;br&gt;3. Suspected group: clinical diagnosis is in accordance with the \"Notice on issuing a new type of coronavirus pneumonia diagnosis and treatment program (Fifth edition)\" on the diagnosis of suspecting a new type of coronavirus infection.","Inclusion criteria: 1. First diagnosis of novel coronavirus infection\r&lt;br&gt;2. Epidemiological history Travel history or residence history of Wuhan City within two weeks before the onset of illness; or patients who have had fever from Wuhan with respiratory symptoms within 14 days before the onset of illness, or have cluster Onset;\r&lt;br&gt;3. Clinical manifestations:\r&lt;br&gt;(1) fever;\r&lt;br&gt;(2) with the following imaging characteristics of pneumonia; early lesions are limited, showing patchy, subsegmental or segmental ground glass shadows, with or without thickening of lobular septum; progression Increased lesions and expanded scope, involving multiple lung lobes, some lesions consolidation, coexistence of ground glass shadows and consolidation shadows or strip shadows; diffuse lung lesions in severe stages, a few of which show \"white lung\", mainly consolidation , Combined with ground glass shadow, multiple cord shadow, air bronchus sign. Pleural effusion or lymphadenopathy are rare;\r&lt;br&gt;(3) The total number of white blood cells is normal or decreased, or the lymphocyte count is decreased in the early stage of onset.\r&lt;br&gt;On the basis of confirmed cases meeting the criteria for suspected cases, sputum, throat swabs, lower respiratory tract secretions, and other specimens were tested by real-time fluorescent RT-PCR to detect positive nucleic acid of the new coronavirus; or viral gene sequencing was highly similar to known new coronavirus source. Trial diagnosis and treatment plan according to the fourth edition of the new Coronavirus Infected Pneumonia issued by the National Health and Health Commission;\r&lt;br&gt;Diagnosis criteria for severe pneumonia:\r&lt;br&gt;One of the following:\r&lt;br&gt;(1) respiratory distress (&gt;=30 beats / min);\r&lt;br&gt;(2) In a resting state, SPO2&lt;=93% under inhaled air;\r&lt;br&gt;(3) PaO2 / FiO2&lt;=300mmHg;\r&lt;br&gt;Criteria for critical pneumonia:\r&lt;br&gt;One of the following:\r&lt;br&gt;(1) Respiratory failure, requiring mechanical ventilation;\r&lt;br&gt;(2) shock;\r&lt;br&gt;(3) complicated with other organ failure requires intensive care unit.","Inclusion criteria: Adult patients with confirmed 2019-nCoV","Inclusion criteria: 1. Aged from 18 to 70 years old;\r&lt;br&gt;2. According with the clinical diagnosis of viral pneumonia symptoms,including fever, Low white blood cells or platelets infiltration shadow in CT;\r&lt;br&gt;3. Positive result for  nucleic acid of 2019-nCov;\r&lt;br&gt;4. Patients can receive aerosol inhalation\r&lt;br&gt;5. Consent to sign a written informed statement prior to the beginning of the study.","Inclusion criteria: (1) aged &gt;=18 years;\r&lt;br&gt;(2) positive COVID-19 nucleic acid was detected by RT-PCR in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, or viral gene sequencing was detected in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, which was highly homologous with known COVID-19;\r&lt;br&gt;(3) Confirmed to be diagnosed as COVID-19, meeting the diagnostic criteria for moderate and severe patients in the diagnosisin line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment plan (trial version 6), and not significantly improved after treatment with the triple antiviral program;\r&lt;br&gt;(4) Informed consent has been signed.","Inclusion criteria: Confirmed cases of novel coronavirus pneumonia","Inclusion criteria: According to the \"Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (Trial Version 6)\" issued by the General Office of the State Health Committee of the People's Republic of China, newly diagnosed patients with pneumonia have been diagnosed. Clinical classification: \r&lt;br&gt;(1) mild: clinical symptoms are mild, and no pneumonia is found on imaging;\r&lt;br&gt;(2) Common type: with fever, respiratory tract and other symptoms, pneumonia can be seen on imaging;\r&lt;br&gt;(3) Heavy duty. \r&lt;br&gt;Comply with any of the following: \r&lt;br&gt;1. shortness of breath, RR&gt;=30 times/min;\r&lt;br&gt;2. In the resting state, oxygen saturation &lt;=93%;\r&lt;br&gt;3. arterial partial pressure of oxygen (PaO2)/ oxygen concentration (FiO2)&lt;=300mmHg(1mmHg=0.133kPa). In areas with high altitude (over 1,000 meters above sea level), PaO2/FiO2 shall be corrected according to the following formula: PaO2/FiO2*[ atmospheric pressure (mmHg)/760]; Pulmonary imaging showed that patients with obvious lesion progress &gt; 50% within 24-48 hours should be managed according to heavy duty;\r&lt;br&gt;4. Critical type: one of the following conditions is met: \r&lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is required;\r&lt;br&gt;(2) Shock;\r&lt;br&gt;(3) ICU monitoring and treatment are required for patients with other organ failure.","Inclusion criteria: staff working in hospital during the epidemic of COVID-19","Inclusion criteria: Patients undergoing painless gastroscopy in our hospital.","Inclusion criteria: 1. Suspected, mild, normal and severe cases diagnosed in accordance with the diagnosis and treatment scheme for pneumonia of novel coronavirus infection (trial version 5);\r&lt;br&gt;2. Aged &gt;= 18 years;\r&lt;br&gt;3. Patients who voluntarily participate in the study and sign informed consent.","Inclusion criteria: A total of 200 2019-new coronavirus infections were included, regardless of age or sex.","Inclusion criteria: 1. Front line medical staff;\r&lt;br&gt;2. Participate in the prevention and treatment of COVID-19;\r&lt;br&gt;3. Voluntary to finish psychological survey;\r&lt;br&gt;4. without psychological history.","Inclusion criteria: 1. Upon the judgment of the researcher, the subject or his legal representative can understand and comply with the requirements of the program, and voluntarily sign the informed consent;\r&lt;br&gt;2. According to the new type of coronavirus pneumonia diagnosis and treatment scheme (trial version 5) diagnostic criteria, accord with standard of new coronavirus pneumonia confirmed cases, clinical diagnostic criteria for classification to heavy (pneumonia severity index (PSI) III - V level, or arterial blood oxygen partial pressure (PaO2 / oxygen concentration (FiO2) (P/F) 300 mmHg) or less;\r&lt;br&gt;3. Aged 18 to 75 years male or female.","Inclusion criteria: 1. Patients diagnosed with COVID-19;\r&lt;br&gt;2. Underwent chest CT scan during the treatment and at least one chest CT scan during follow-up;\r&lt;br&gt;3. Able to complete the study.","Inclusion criteria: 1. Confirmed or clinically diagnosed cases;\r&lt;br&gt;2. Aged &gt;= 2 years;\r&lt;br&gt;3. Volunteers.","Inclusion criteria: 1. be over 18 years of age;\r&lt;br&gt;2. 2019-nCoV infected patients confirmed by viral nucleic acid testing;\r&lt;br&gt;3. Subjects and their families (or guardians) have fully read, understood, and signed informed consent.","Inclusion criteria: 1. Aged 18 to 85 years old;\r&lt;br&gt;2. It conforms to the diagnostic criteria of severe and critical type in \"Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus (6th Edition)\";\r&lt;br&gt;3. Sign the informed consent form.","Inclusion criteria: All ICU staff involved in the fight against the new coronary pneumonia for at least 1 week","Inclusion criteria: The front line nurses who were taking care of the nCoV infected patients in the participating hospitals","Inclusion criteria: 1. Aged 18 to 75 years old;\r&lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the current diagnosis and treatment plan for pneumonia with new coronavirus infection;\r&lt;br&gt;3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);\r&lt;br&gt;4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;6. Patients who voluntarily sign informed consent.","Inclusion criteria: (1) Adults aged &gt;=18 years understand and agree to sign informed consent;\r&lt;br&gt;(2) a novel coronavirus infection confirmed by laboratory RT-PCR.\r&lt;br&gt;(3) Hospitalized patients with fever (axillary temperature &gt;=37.0 degree C) or respiratory symptoms;\r&lt;br&gt;(4) The interval between symptom onset and immediate enrollment is within 14 days;\r&lt;br&gt;(5) Those who did not participate in other clinical trials within 3 months;\r&lt;br&gt;(6) No other antiviral drugs were involved in the follow-up study within 14 days.","Inclusion criteria: the diagnosed COVID-19 pneumonia inpatients","Inclusion criteria: 1. novel coronavirus pneumonia patients with nutritional malnutrition diagnosed by nutritional assessment;\r&lt;br&gt;2. enteral nutrition support treatment for at least 5 days;\r&lt;br&gt;3. No use of Fat emulsion taboo;","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia, clinical classification is ordinary or heavy;\r&lt;br&gt;2. TCM syndrome differentiation is wind-heat syndrome;\r&lt;br&gt;3. Aged between 18-75 years old, regardless of gender;\r&lt;br&gt;4. Voluntarily sign written informed consent.","Inclusion criteria: Patients meet the diagnostic criteria \"Diagnosis and treatment of novel coronavirus pneumonia (trial version fifth)\"for suspected cases outside Hubei Province: combined with the following epidemiological and clinical manifestations: epidemiological history \r&lt;br&gt;1. Patients with travel or residence history in Wuhan and surrounding areas or other communities with case reports within 14 days before the onset of the disease; \r&lt;br&gt;2. Patients with a novel coronavirus infection (positive for nucleic acid detection) within 14 days before onset;,\r&lt;br&gt;3. Patients with fever or respiratory symptoms from Wuhan and surrounding areas or from the community with case report had been contacted within 14 days before the onset of the disease; \r&lt;br&gt;4.  Clustering disease; clinical manifestations:\r&lt;br&gt; (1) fever and / or respiratory symptoms;\r&lt;br&gt; (2) having the above-mentioned imaging characteristics of pneumonia;\r&lt;br&gt; (3) normal or reduced leukocyte count or lymphocyte count in the early stage of the disease. \r&lt;br&gt;There is any one in the epidemiological history, and it is consistent with any two in the clinical manifestations. \r&lt;br&gt;If there is no clear epidemiological history, it is in line with 3 of the clinical manifestations.","Inclusion criteria: subjects who are over 60 years old, and willing to participate in the investigation.","Inclusion criteria: suspected infection and Confirmed novel coronavirus patients","Inclusion criteria: 1) Any age;\r&lt;br&gt;2) Meet the diagnostic standard of COVID-19;\r&lt;br&gt;3) Voluntarily accept TCM syndrome differentiation treatment;\r&lt;br&gt;4) Agree to sign informed consent.","Inclusion criteria: All patients with 2019 novel coronavirusinfected pneumonia enrolled in this study were diagnosed according to guidance(trial version 5) of China,and met the standard of Heavy or critically ill.","Inclusion criteria: 1. Aged 18 to 80 years;\r&lt;br&gt;2. Patients with novel coronavirus pneumonia who were diagnosed as general type or severe type according to the western medicine classification general type, severe type and Chinese medicine classification criteria;\r&lt;br&gt;3. Understand and agree to participate in the study and sign the informed consent.","Inclusion criteria: 1) The confirmed patient (or legal guardian) agrees to participate in the study and signs the informed consent form;\r&lt;br&gt;2) aged 18 to 65 years;\r&lt;br&gt;3) The time interval between the onset of symptoms and random enrollment is within 8 days (the onset of symptoms is mainly based on the occurrence of fever);\r&lt;br&gt;4) Real-time fluorescent RT-PCR of respiratory specimens or blood specimens to detect patients with 2019-nCoV nucleic acid positive;\r&lt;br&gt;5) Patients were diagnosed as type 3 patients with mild, common and severe cases according to the \"Diagnosis and Treatment Scheme for 2019-nCoV (Trial Version 6)\".","Inclusion criteria: 1. Patients volunteered to sign the informed consent;\r&lt;br&gt;2. Patients who were diagnosed with the common type of NCP and severe cases of new coronavirus pneumonia, Referring to the New Coronavirus Pneumonia Diagnosis and Treatment Plan, with elevation of IL-6, and grade 2-3 CRS.In the case of atypical signs of CRS, he or she should be judged by the investigator;\r&lt;br&gt;3. Aged &gt;=18 years.","Inclusion criteria: The inclusion criteria are: aged 18 or above; those who can understand Chinese language; be able to give access to the online survey and answer questions.","Inclusion criteria: Cancelled","Inclusion criteria: Nursing student will be invited to participate in this research. Students will voluntarily participate in the study and ask for an informed consent.","Inclusion criteria: Novel coronavirus pneumonia real-time fluorescence RT-PCR virus nucleic acid detection cases were detected in all centers.","Inclusion criteria: (1) Age 18 to 80 years old (including threshold), sex unlimited, inpatient\r&lt;br&gt;(2) Respiratory specimen were positive for COVID-19 nucleic acid by RT-PCR;\r&lt;br&gt;(3) Clinical classification is mild or moderate type (with symptoms of fever, respiratory tract, imaging findings of pneumonia);\r&lt;br&gt;(4) Hospitalization for the following reasons:Fever (axillary temperature &gt;= 36.7 degrees C, or mouth temperature &gt;= 38.0 degrees C, or anal or ear temperature &gt;= 38.6 degrees C) and respiratory frequency &gt; 24 beats/min or cough (Shortness of breath and cough at least one);\r&lt;br&gt;(5) Informed consent signed.","Inclusion criteria: 1. Aged 18 to 70 years old;\r&lt;br&gt;2. Non-suspected and non-confirmed cases;\r&lt;br&gt;3. Front-line medical staffs in designated hospitals during the outbreak of pneumonia caused by COVID-19;\r&lt;br&gt;4. Participate voluntarily and sign the informed consent.","Inclusion criteria: 1. Aged &gt;=18 years at time of signing Informed Consent Form;\r&lt;br&gt;2. Patients with confirmed cases meeting the following criteria\r&lt;br&gt;(1) Epidemiology history;\r&lt;br&gt;(2) Clinical manifestations (epidemiological history and in accordance with any of the following 2 items; no clear epidemiology history, conforms to  3 items in clinical manifestations):\r&lt;br&gt;Fever and / or respiratory symptoms;\r&lt;br&gt;In the early stage of the disease, the total leukocyte count was normal or decreased, or the lymphocyte count decreased;\r&lt;br&gt;Early chest imaging showed multiple small plaques and interstitial changes, which were evident in the extraneous lung. Further, multiple ground-glass shadows and infiltration shadows were found in both lungs, and lung consolidation and pleural effusion were rare in severe cases;\r&lt;br&gt;(3) Having one of the following etiological evidence:\r&lt;br&gt;Respiratory tract, blood or fecal samples RT-PCR confirmed infection with 2019-nCoV;\r&lt;br&gt;The virus genes of the above samples were sequenced and highly homologous to the 2019-nCoV;\r&lt;br&gt;3. Patients who meet the following mild and normal criteria;\r&lt;br&gt;Mild: mild clinical symptoms, no signs of pneumonia on imaging;\r&lt;br&gt;Normal: fever, respiratory symptoms, imaging manifestations of pneumonia;\r&lt;br&gt;4. Antimalarial drugs such as chloroquine and hydroxychloroquine were not used within 3 months;\r&lt;br&gt;5. Agree not to participate in other clinical researchers within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;6. Eligible fertile subjects (male and female) must agree to use effective birth control (hormone or barrier or abstinence) with their partner during the trial period and for at least 3 months after the last dose;\r&lt;br&gt;7. Patients who agree to participate in this study and are willing to sign the informed consent form voluntarily.","Inclusion criteria: 1.  Age 18 to 75 Yearsmale or female subjects\r&lt;br&gt;2.  Diagnosed with COVID-19,according to \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (Pilot  Sixth Edition);\r&lt;br&gt;3.  Sever COVID-19, except shock and ICU care with organ failure;\r&lt;br&gt;4.  Antimalarial drugs such as chloroquine and hydroxychloroquine sulfate were not used within 3 months.;\r&lt;br&gt;5.  Agreed not to participate in other clinical trials in the period of 30 days from first dose;\r&lt;br&gt;6.  Eligible subjects (male and female) agree to use effective birth-control method (hormone or barrier or abstinence) during the trial and at least 3 month after the last dose;\r&lt;br&gt;7.  Willingness of participant the study with inform consent form","Inclusion criteria: A novel coronavirus pneumonia patient who was more than 18 years old and agreed to participate in the trial and signed informed consent.","Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:\r&lt;br&gt;1. Sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;\r&lt;br&gt;2. Chinese aged &gt;=18 years;\r&lt;br&gt;3. It complies with the NCP Critical and Critical Diagnostic Standards, namely \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5). Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment.\r&lt;br&gt;4. The course of disease is within 14 days after the onset of illness;\r&lt;br&gt;5. Will take nasopharyngeal or oropharyngeal swabs before administration.","Inclusion criteria: (1) Aged &gt;=18 years;\r&lt;br&gt;(2) Novel coronavirus pneumonia patients diagnosed by pathogenic testing;\r&lt;br&gt;(3) The patient himself participated in the study voluntarily, agreed and signed the informed consent.","Inclusion criteria: All patients diagnosed with novel coronavirus pneumonia by nucleic acid detection.","Inclusion criteria: 1. Patients withmild and moderate novel coronavirus pneumonia (COVID-19) diagnosed  refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5);\r&lt;br&gt;2. Patient cough score &gt; 1;\r&lt;br&gt;3. Aged 18- 80 years old; \r&lt;br&gt;4. The subjects (including male subjects) had no pregnancy, sperm donor, egg donor for nearly half a year, and were willing to take effective contraception from the first dose until three months after the last;\r&lt;br&gt;5. Subjects are fully aware of the purpose, nature, content, process and possible adverse reactions of the study and voluntarily sign the informed consent.","Inclusion criteria: 1. Patients who  were confirmed diagnosis of 2019-ncov virus pneumonia, according to the \"pneumonia diagnosis and treatment program for novel coronavirus infection (trial version 5)\",including clinical symptoms, pulmonary CT manifestations and positive nucleic acid test;\r&lt;br&gt;2. Inpatients 18 years old (including 18), regardless of gender;\r&lt;br&gt;3. Willing to participate in this clinical trial and sign the informed consent.","Inclusion criteria: 1. Staff of tongji hospital willing to participate this study;\r&lt;br&gt;2. Aged &gt;=18 years.","Inclusion criteria: (1) 1865 years of age; \r&lt;br&gt;(2) Diagnosed as mild to moderate COVID-19; \r&lt;br&gt;(3) Be willing to sign informed consent;\r&lt;br&gt;(4) The clinical assessment and condition of the subject does not influence the completion of the study.","Inclusion criteria: 1. Hospital workers with diagnosis of new coronavirus pneumonia in Wuhan;\r&lt;br&gt;2. Aged &gt;=18 years old.","Inclusion criteria: Subjects who meet the following conditions can become subjects of this study:\r&lt;br&gt;1. Sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian;\r&lt;br&gt;2. Chinese who are &gt;= 18 years of age;\r&lt;br&gt;3. It complies with the diagnostic criteria for NCP diagnosis of common patients, that is, the \"Pneumonitis Diagnosis and Treatment Scheme for New Coronavirus Infection (Trial Fifth Edition)\".\r&lt;br&gt;Comprehensive analysis based on the following epidemiological history, clinical manifestations and etiological examination:\r&lt;br&gt;a. Epidemiological history\r&lt;br&gt;(1)Travel history or residence history of Wuhan and surrounding areas or other communities with case reports within 14 days before the onset of illness;\r&lt;br&gt;(2)Have a history of contact with a new coronavirus infected person (positive nucleic acid test) within 14 days before the onset of illness;\r&lt;br&gt;(3)Patients with fever or respiratory symptoms from Wuhan and surrounding areas or from communities with case reports within 14 days before the onset of illness;\r&lt;br&gt;(4)Aggressive onset;\r&lt;br&gt;b. clinical manifestations\r&lt;br&gt;(1)Fever and / or respiratory symptoms;\r&lt;br&gt;(2)NCP imaging features (early multiple small patchy shadows and interstitial changes, obvious in the extrapulmonary zone. Then developed into multiple lungs with ground glass and infiltrates. In severe cases, pulmonary consolidation and pleural effusion Rare\r&lt;br&gt;(3)The total number of early white blood cells is normal or decreased, or the lymphocyte count is decreased.\r&lt;br&gt;c. Real-time fluorescent RT-PCR of respiratory or blood specimens for detection of novel coronavirus nucleic acid;\r&lt;br&gt;NCP confirmed case criteria:\r&lt;br&gt;(1)Have any one of the epidemiological history, and meet any two of the clinical manifestations, and at the same time, the pathogenic test is positive;\r&lt;br&gt;(2)If there is no clear epidemiological history, it meets any three of the clinical manifestations, and at the same time, the pathogenic examination is positive.\r&lt;br&gt;4. The course of disease is within 10 days after the onset of illness;\r&lt;br&gt;5. Will take nasopharyngeal or oropharyngeal swabs before administration.","Inclusion criteria: 1. Aged 18- 80 years old; \r&lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5);\r&lt;br&gt;3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days);\r&lt;br&gt;4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;6. Patients who voluntarily sign informed consent.","Inclusion criteria: 1. Male or female over 18 years of age;\r&lt;br&gt;2. Novel coronavirus infection is confirmed by pathogenic detection;\r&lt;br&gt;3. The diagnosis of severe coronavirus pneumonia will have to meet at least one of the following criteria: \r&lt;br&gt;(1) Respiratory distress, RR&gt;30 times/minute\r&lt;br&gt;(2) In the state of no oxygen at rest, the patient's SPO2&lt;=93%\r&lt;br&gt;(3) Oxygenation Index (PaO2/FiO2)&lt;=300 mmHg (1mmHg=0.133kPa);\r&lt;br&gt;(4) Respiratory failure requiring mechanical ventilation; \r&lt;br&gt;(5) Sepsis; \r&lt;br&gt;(6) Other organ failure requiring ICU care.\r&lt;br&gt;4. Be willing to give the informed consent.","Inclusion criteria: 1. Informed consent offered;\r&lt;br&gt;2. Confirmed infection with 2019-nCoV by RT-PCR;\r&lt;br&gt;3. Compliance with the intervention of study.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Subjects or their legal representatives have signed the informed consent form(ICF);\r&lt;br&gt;             agree not to participate in other clinical studies within 30 days after the last\r&lt;br&gt;             administration from the first administration of the study drug.\r&lt;br&gt;\r&lt;br&gt;          2. Subjects are aged = 18 and = 75;\r&lt;br&gt;\r&lt;br&gt;          3. Meet the diagnostic criteria for 2019-nCoV pneumonia (V5.0);\r&lt;br&gt;\r&lt;br&gt;          4. SOFA score: 1 ~ 13 points.\r&lt;br&gt;\r&lt;br&gt;          5. A retreated patient or the relapsed patient meets any of the following criteria:\r&lt;br&gt;\r&lt;br&gt;               -  Have fever again or aggravated clinical symptoms; ? 2019nCOVRNA in the throat\r&lt;br&gt;                  swabs converts from negative to positive; ? The clinical symptoms don't improve\r&lt;br&gt;                  or 2019nCOVRNA continues to be positive; ? The chest CT shows pneumonia or\r&lt;br&gt;                  fibrosis progression.\r&lt;br&gt;\r&lt;br&gt;        Clinical stratification:\r&lt;br&gt;\r&lt;br&gt;          1. Mild type: clinical symptoms mild or asymptomatic, no pneumonia performance in CT, but\r&lt;br&gt;             positive 2019-nCoV in throat swabs or gargle.\r&lt;br&gt;\r&lt;br&gt;          2. Ordinary type: fever, respiratory symptoms, etc., pneumonia performance visible in CT.\r&lt;br&gt;\r&lt;br&gt;          3. Severe type: meeting any of the following criteria:\r&lt;br&gt;\r&lt;br&gt;        (1) Respiratory distress, RR=30 times/min; (2) Finger oxygen saturation =93% in rest state;\r&lt;br&gt;        (3) Arterial partial pressure of oxygen (PaO2)/concentration of oxygen inhalation\r&lt;br&gt;        (FiO2)=300mmHg (1mmHg=0.133kPa).\r&lt;br&gt;\r&lt;br&gt;        4. Critical type: meeting any of the following criteria:(1)Respiratory failure occurs and\r&lt;br&gt;        mechanical ventilation is required;(2)Patients go into shock;(3)ICU is needed for other\r&lt;br&gt;        organ failure.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Other viral pneumonia\r&lt;br&gt;\r&lt;br&gt;          2. Patients who have received tumor immunotherapy (such as PD-1/L1, CTLA4, etc.) in the\r&lt;br&gt;             past 1 month, and inflammatory factor modulators such as Ulinastatin;\r&lt;br&gt;\r&lt;br&gt;          3. Patients who have taken anti-bacterial drugs such as macrolide in the past 1 week;\r&lt;br&gt;\r&lt;br&gt;          4. Patients who have received organ transplantation or surgery planning in the past 6\r&lt;br&gt;             months;\r&lt;br&gt;\r&lt;br&gt;          5. Patients who can't take food or drugs due to coma or intestinal obstruction;\r&lt;br&gt;\r&lt;br&gt;          6. Patients who have severe underlying diseases that affects survival, including\r&lt;br&gt;             uncontrolled malignant tumor with multiple metastases that cannot be resected, blood\r&lt;br&gt;             diseases, dyscrasia, active bleeding, severe malnutrition, etc.\r&lt;br&gt;\r&lt;br&gt;          7. Women subjects that are pregnant or lactating, or subjects (including male subjects)\r&lt;br&gt;             having a pregnancy plan (including plans for sperm donation or egg donation), or\r&lt;br&gt;             subjects that may fail to take effective contraceptive measures within the next 6\r&lt;br&gt;             months;\r&lt;br&gt;\r&lt;br&gt;          8. Patients with allergic constitution, or patients allergic to macrolides and\r&lt;br&gt;             lopinavir/ritonavir tablets;\r&lt;br&gt;\r&lt;br&gt;          9. Patients with contraindications to lopinavir/ritonavir tablets who plan or are using\r&lt;br&gt;             drugs that interact with the drug (including: drugs that are highly dependent on CYP3A\r&lt;br&gt;             clearance and whose elevated plasma concentrations can be associated with severe\r&lt;br&gt;             and/or life-threatening events [with a narrow therapeutic index], CYP3A inducer [see\r&lt;br&gt;             instruction for details]) and cannot stop using or use other drugs instead;\r&lt;br&gt;\r&lt;br&gt;         10. Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total\r&lt;br&gt;             bilirubin is 3 times higher than the upper limit of normal, or patients with\r&lt;br&gt;             child-Pugh grade C cirrhosis.\r&lt;br&gt;\r&lt;br&gt;         11. ECLS (ECMO, ECCO2R, RRT)\r&lt;br&gt;\r&lt;br&gt;         12. Critical patients with expected life&lt;48 hours\r&lt;br&gt;\r&lt;br&gt;         13. Patients who have participated in any other clinical study within 1 month;\r&lt;br&gt;\r&lt;br&gt;         14. The investigators conclude that the patients not suitable for the study.\r&lt;br&gt;","Inclusion criteria: 2020.01.01 Patients who have tested positive for new coronavirus in our hospital","Inclusion criteria: 1. Aged &gt; 18 years; \r&lt;br&gt;2. COVID-19 coronavirus nucleic acid positive (including throat swabs, sputum, bronchoalveolar lavage fluid, stool and other specimens); \r&lt;br&gt;3. Chest imaging has clear viral pneumonia changes; \r&lt;br&gt;4. Respiratory dysfuntion, which meets the following criteria: \r&lt;br&gt;(1) Respiratory distress, respiratory rate (RR) is greater than 30 times /min; \r&lt;br&gt;(2) Finger pulse oxygen saturation &lt;= 93% at resting state;\r&lt;br&gt;(3) PaO2 / FiO2 &lt;= 300 mmHg (1 mmHg = 0.133 kPa); and \r&lt;br&gt;(4) Pulmonary imaging showed that the lesions progressed more than 50% within 24-48 hours.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Recruited subjects include all adult patients =18 years hospitalised for virologically\r&lt;br&gt;             confirmed 2019-n-CoV infection.\r&lt;br&gt;\r&lt;br&gt;          2. NEWS of =1 upon recruitment\r&lt;br&gt;\r&lt;br&gt;          3. Auditory temperature =38C with at least one of the following symptoms (cough, sputum\r&lt;br&gt;             production, sore-throat, nasal discharge, myalgia, headache or fatigue) upon admission\r&lt;br&gt;\r&lt;br&gt;          4. Symptom duration =10 days\r&lt;br&gt;\r&lt;br&gt;          5. All subjects give written informed consent.\r&lt;br&gt;\r&lt;br&gt;          6. Subjects must be available to complete the study and comply with study procedures.\r&lt;br&gt;             Willingness to allow for serum samples to be stored beyond the study period, for\r&lt;br&gt;             potential additional future testing to better characterize immune response.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Inability to comprehend and to follow all required study procedures.\r&lt;br&gt;\r&lt;br&gt;          2. Allergy or severe reactions to the study drugs\r&lt;br&gt;\r&lt;br&gt;          3. Patients with known prolonged QT or PR interval, second- or third-degree heart block,\r&lt;br&gt;             or ventricular cardiac arrhythmias, including torsade de pointes\r&lt;br&gt;\r&lt;br&gt;          4. Patients taking medication that will potentially interact with lopinavir/ ritonavir,\r&lt;br&gt;             ribavirin or interferon-beta1b\r&lt;br&gt;\r&lt;br&gt;          5. Patients with known history of severe depression\r&lt;br&gt;\r&lt;br&gt;          6. Pregnant or lactation women\r&lt;br&gt;\r&lt;br&gt;          7. Inability to comprehend and to follow all required study procedures\r&lt;br&gt;\r&lt;br&gt;          8. Received an experimental agent (vaccine, drug, biologic, device, blood product, or\r&lt;br&gt;             medication) within 1 month prior to recruitment in this study or expect to receive an\r&lt;br&gt;             experimental agent during this study. Unwilling to refuse participation in another\r&lt;br&gt;             clinical study through the end of this study.\r&lt;br&gt;\r&lt;br&gt;          9. Have a history of alcohol or drug abuse in the last 5 years.\r&lt;br&gt;\r&lt;br&gt;         10. Have any condition that the investigator believes may interfere with successful\r&lt;br&gt;             completion of the study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Who agree to participate in the study and sign written informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed NCIP patients\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        (1) Age = 18 years. (2) Clinically diagnosed patients with new type of coronavirus\r&lt;br&gt;        pneumonia include: on the basis of meeting the criteria for suspected cases, one of the\r&lt;br&gt;        following pathogenic evidence: ? real-time fluorescent RT-PCR of respiratory specimens or\r&lt;br&gt;        blood specimens for detection of new coronavirus nucleic acid; Respiratory or blood\r&lt;br&gt;        specimens are genetically sequenced and highly homologous to known new coronaviruses. (3)\r&lt;br&gt;        The time interval between the suspected neocoronary pneumonia pneumonia case and the random\r&lt;br&gt;        enrollment is determined within 4 days to 7 days according to the history symptoms and\r&lt;br&gt;        chest CT imaging. Cough, diarrhea, or other related symptoms can be used. The imaging\r&lt;br&gt;        changes are mainly based on chest CT.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        (1) AST and ALT&gt; 1.5 x ULN at visit 1; (2) bilirubin&gt; 1.5 x ULN at visit 1; (3) creatinine\r&lt;br&gt;        clearance rate calculated by Cockcroft-Gault formula at visit 1 &lt;30 mL / min; (4) patients\r&lt;br&gt;        with potential chronic liver disease (Child Pugh A, B or C liver injury; (5) previous\r&lt;br&gt;        treatment with nidanib or pirfenidone; (6) screening visits (interviews 1) Received other\r&lt;br&gt;        research drug treatment within 1 month or 6 half-lives (whichever is greater); (7) IPF\r&lt;br&gt;        diagnosis based on ATS / ERS / JRS / ALAT 2011 guidelines (P11-07084); (8 ) Significant\r&lt;br&gt;        pulmonary hypertension (PAH) defined by any of the following standards: ? Clinical /\r&lt;br&gt;        echocardiographic evidence of previously significant right heart failure; ? Medical history\r&lt;br&gt;        including right heart catheter showing a cardiac index = 2l / min / m2; ? Prostaglandol /\r&lt;br&gt;        qu Parenteral administration of prostacyclin in the treatment of PAH; (9) other clinically\r&lt;br&gt;        significant lung abnormalities considered by the investigator; (10) major extrapulmonary\r&lt;br&gt;        physiological limitations (such as chest wall deformity, large amount of pleural effusion);\r&lt;br&gt;        (11) Cardiovascular diseases, any of the following diseases: ? Severe hypertension within 6\r&lt;br&gt;        months of Visit 1, uncontrollable after treatment (=160 / 100 mmHg); ? myocardial\r&lt;br&gt;        infarction within 6 months of visit 1; ? unstable angina within 6 months of visit 1; (12)\r&lt;br&gt;        history of severe central nervous system (CNS) events; (13) known trials Drug allergies;\r&lt;br&gt;        (14) Other diseases that may interfere with the testing process or as judged by the\r&lt;br&gt;        investigator may interfere with the trial participation or may put the patient at risk when\r&lt;br&gt;        participating in the trial; (15) Women who are pregnant, breastfeeding, or planning\r&lt;br&gt;        pregnancy in this trial (16) Patients are unable to understand or follow the trial\r&lt;br&gt;        procedures, including completing the questionnaires themselves without assistance.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female, aged at 18 years (including) -70 years old\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase\r&lt;br&gt;             chain reaction (RT-PCR) from any diagnostic sampling source; and\r&lt;br&gt;\r&lt;br&gt;          3. Pneumonia that is judged by chest radiograph or computed tomography.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Pregnancy, lactation and those who are not pregnant but do not take effective\r&lt;br&gt;             contraceptives measures;\r&lt;br&gt;\r&lt;br&gt;          2. Patients with malignant tumor, other serious systemic diseases and psychosis;\r&lt;br&gt;\r&lt;br&gt;          3. Patients who are participating in other clinical trials;\r&lt;br&gt;\r&lt;br&gt;          4. Inability to provide informed consent or to comply with test requirements.\r&lt;br&gt;\r&lt;br&gt;          5. Co-Infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory\r&lt;br&gt;             infection virus.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1.Willingness of study participant to accept this treatment arm, and signed informed\r&lt;br&gt;        consent; 2.Male or female, aged at 18 years (including) to 75 years old; 3.Patients with\r&lt;br&gt;        confirmed novel coronavirus pneumonia; 4.Confirmation of SARS-CoV-2 infection by\r&lt;br&gt;        reverse-transcription polymerase chain reaction (RT-PCR) from respiratory tract or blood\r&lt;br&gt;        specimens; 5.Diagnostic criteria of \"Severe\" or \" Critical\":\r&lt;br&gt;\r&lt;br&gt;          1. Severe, comply with any of the following:\r&lt;br&gt;\r&lt;br&gt;               1. Respiratory distress, Respiratory rate (RR) = 30 times/min\r&lt;br&gt;\r&lt;br&gt;               2. Pulse oxygen saturation (SpO2) at rest = 93%\r&lt;br&gt;\r&lt;br&gt;               3. Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) = 300mmHg\r&lt;br&gt;\r&lt;br&gt;          2. Critical, comply with any of the following:\r&lt;br&gt;\r&lt;br&gt;               1. Respiratory failure, and requirement for mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;               2. Shock\r&lt;br&gt;\r&lt;br&gt;               3. Other organ failure and requirement for ICU monitoring\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Allergic or hypersensitive to any of the ingredients;\r&lt;br&gt;\r&lt;br&gt;          2. Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other\r&lt;br&gt;             viruses;\r&lt;br&gt;\r&lt;br&gt;          3. Obstructive HABP/VABP induced by lung cancer or other known causes;\r&lt;br&gt;\r&lt;br&gt;          4. Carcinoid syndrome;\r&lt;br&gt;\r&lt;br&gt;          5. History of long-term use of immunosuppressive agents;\r&lt;br&gt;\r&lt;br&gt;          6. History of epilepsy and requirement for continuous anticonvulsant treatment or\r&lt;br&gt;             anticonvulsant treatment received within the last 3 years;\r&lt;br&gt;\r&lt;br&gt;          7. History of severe chronic respiratory disease and requirement for long-term oxygen\r&lt;br&gt;             therapy;\r&lt;br&gt;\r&lt;br&gt;          8. Undergoing hemodialysis or peritoneal dialysis;\r&lt;br&gt;\r&lt;br&gt;          9. Estimated or actual rate of creatinine clearance &lt; 15 ml/min;\r&lt;br&gt;\r&lt;br&gt;         10. History of moderate and severe liver disease (Child-Pugh score &gt;12);\r&lt;br&gt;\r&lt;br&gt;         11. Expectation of receiving any of following medications during the study:\r&lt;br&gt;\r&lt;br&gt;               1. Receiving continuous valproic acid or sodium valproate within the first 2 weeks\r&lt;br&gt;                  prior to screening\r&lt;br&gt;\r&lt;br&gt;               2. Receiving 5-transtryptamine reuptake inhibitors, tricyclic antidepressants, 5-HT1\r&lt;br&gt;                  receptor agonists or monoamine oxidase inhibitors within the first 2 weeks prior\r&lt;br&gt;                  to screening\r&lt;br&gt;\r&lt;br&gt;         12. Incapable of understanding study protocol;\r&lt;br&gt;\r&lt;br&gt;         13. History of deep venous thrombosis or pulmonary embolism within the last 3 years;\r&lt;br&gt;\r&lt;br&gt;         14. Undergoing ECMO or high-frequency oscillatory ventilation support;\r&lt;br&gt;\r&lt;br&gt;         15. HIV, hepatitis virus, or syphilis infection;\r&lt;br&gt;\r&lt;br&gt;         16. Period of pregnancy or lactation, or planned pregnancy within 6 months;\r&lt;br&gt;\r&lt;br&gt;         17. Any condition of unsuitable for the study determined by investigators.\r&lt;br&gt;","Inclusion criteria: (1) Aged &gt;=18 years;\r&lt;br&gt;(2) novel coronavirus pneumonia novel coronavirus pneumonia diagnosis and treatment plan (trial version sixth) is diagnosed as new type coronavirus pneumonia common, heavy and critical patients;\r&lt;br&gt;(3) Patients who used antiviral drugs such as lopinavir / ritonavir, abidol, darunavir / corbistadine and fabiravir for more than 72 hours.","Inclusion criteria: Critically ill patients with SARS-CoV-2 infection who had perform blood purificationtherapy using artificial liver suppoer system and underwent clustering nusing progremm","Inclusion criteria: COVID-19 patients were diagnosed and cured as convalescent patients with disappearance of clinical symptoms and convalescent patients who met the discharge criteria after imaging examination and viral nucleic acid test.","Inclusion criteria: 1. Aged 18 to 75 years;\r&lt;br&gt;2. Real-time fluorescence RT-PCR detection of nucleic acid positive of novel coronavirus in respiratory tract specimens or blood preparation;\r&lt;br&gt;3. Sequencing of virus genes in respiratory tract specimens or blood preparation, highly homologous to known novel coronavirus ;\r&lt;br&gt;4. The patients are diagnosed with common type of novel coronavirus pneumonia according to the Pneumonia Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6), and have fever and/or respiratory symptoms, and shows pneumonia in the chest CT.\r&lt;br&gt;5. Can be included in some severe patients, consistent with any of the following:\r&lt;br&gt;(1) Respiratory distress, RR &gt;= 30 times/min;\r&lt;br&gt;(2) Under quiescent condition, Oxygen saturation &lt;= 93%;\r&lt;br&gt;(3) Arterial partial pressure of oxygen(PaO2)/oxygen concentration(FiO2)&lt;= 300mmHg.","Inclusion criteria: 1. Laboratory confirmed infection with 2019-nCoV;\r&lt;br&gt;2. Clinical classification is mild or common;\r&lt;br&gt;3. Lung involvement confirmed with chest imaging;\r&lt;br&gt;4. Hospitalised with: Fever: axilla temperature &gt;= 36.7 degrees C, or Oral temperature &gt;= 38.0 degrees C, or rectal temperature &gt;= 38.6 degrees C.And at least one of Respiratory rate &gt; 24/min Or Cough;\r&lt;br&gt;5. TCM syndrome differentiation is phlegm-heat obstructing the lung syndrome; \r&lt;br&gt;6. Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study;\r&lt;br&gt;7. Aged between 18-75 years of signing Informed Consent Form.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  all patients suspected of 2019 novel coronavirus infection.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  patients' data are not available.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Adult male or female patients aged 18-85 years old;\r&lt;br&gt;\r&lt;br&gt;          2. The newly diagnosed COVID-19 patients who meet the diagnostic criteria set forth in\r&lt;br&gt;             the \"Guidance of Diagnosis and Treatment for Patients with Coronavirus Disease 2019\r&lt;br&gt;             (COVID-19) (Procedural Version 5 Amendment)\", issued by the National Health Commission\r&lt;br&gt;             of the People's Republic of China on 8 February 2020;\r&lt;br&gt;\r&lt;br&gt;          3. Patients whose blood oxygen saturation is not less than 90%.\r&lt;br&gt;\r&lt;br&gt;          4. Patients who agree to participate in the study and voluntarily comply with the\r&lt;br&gt;             relevant requirements of the study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with other diseases that may affect, in the opinion of study researchers, the\r&lt;br&gt;             implementation of the study or the observation of the efficacy data;\r&lt;br&gt;\r&lt;br&gt;          2. Patients with severe Coronavirus Disease 2019 (COVID-19), that is based on \"Guidance\r&lt;br&gt;             of Diagnosis and Treatment for Patients with Coronavirus Disease 2019 (COVID-19)\r&lt;br&gt;             (Procedural Version 5 Amendment)\" with respect to the criteria for clinical severity\r&lt;br&gt;             classification;\r&lt;br&gt;\r&lt;br&gt;          3. Female patients with known pregnancy and in lactation at screening;\r&lt;br&gt;\r&lt;br&gt;          4. Patients with previous allergies to T89 or Radix Salvia Miltiorrhizae, Radix\r&lt;br&gt;             Notoginseng and Borneol;\r&lt;br&gt;\r&lt;br&gt;          5. Any other condition that, in the opinion of the investigator, may affect the conduct\r&lt;br&gt;             of the study, reduce compliance or increase the risk of patients.\r&lt;br&gt;","Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test and were in accordance with the clinical classification of severe or critically illness. (refer to the clinical classification criteria in the pneumonia diagnosis and treatment program of novel coronavirus infection, General Office of the National Health Commission (trial version 4)).","Inclusion criteria: medical students in anesthesiology department","Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients;\r&lt;br&gt;2. Aged 18 to 90 years;\r&lt;br&gt;3. Sign the written informed consent before the study.","Inclusion criteria: 1. Patients who were diagnosed with novel coronavirus pneumonia by the nucleic acid test;\r&lt;br&gt;2. Patients who agreed to enrollment.","Inclusion criteria: Patients with new type of coronavirus pneumonia admitted to the designated hospital of Jinan City have the same diagnostic criteria as \"Pneumonitis diagnosis and treatment plan for new type of coronavirus infection (latest version)\r&lt;br&gt;during 2020.02-2020.05","Inclusion criteria: 1. aged &gt;=18 years old;\r&lt;br&gt;2. laboratory conformed SARS-CoV-2 infection;\r&lt;br&gt;3. critically ill and require intensive care.","Inclusion criteria: (1) aged &gt;=18 years; \r&lt;br&gt;(2) positive COVID-19 nucleic acid was detected by RT-PCR in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, or viral gene sequencing was detected in sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions, which was highly homologous with known COVID-19; \r&lt;br&gt;(3) Confirmed to be diagnosed as COVID-19, meeting the diagnostic criteria for moderate and severe patients in the diagnosisin line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment plan (trial version 6), and not significantly improved after treatment with the triple antiviral program; \r&lt;br&gt;(4) Informed consent has been signed.","Inclusion criteria: This study intends to select surveillance cases, suspected cases and diagnosed cases of COVID-19 for children aged 0-18 who were admitted to the department of Pediatrics in Tongji Hospital from December 2019 to June 2020.\r&lt;br&gt;1. Epidemiological classification: all children are divided into three levels: high, medium and low risk according to their epidemiological history:\r&lt;br&gt;(1) high risk: participant was close to suspected or confirmed case of COVID-19 within 14 days before the onset of illness;\r&lt;br&gt;(2) intermediate risk: cluster of COVID-19 cases in the place of residence or the community;\r&lt;br&gt;(3) low risk: The residence or community has no cluster cases or not from epidemic area;\r&lt;br&gt;2. Surveillance cases: high-risk children who do not show symptoms are surveillance cases, and intermediate or low risk children who have any of the following symptoms are surveillance cases:\r&lt;br&gt;(1) Fever;\r&lt;br&gt;(2) Respiratory symptoms or weakness, nausea, vomiting, abdominal discomfort and diarrhea.\r&lt;br&gt;3. Suspected cases: Newborns born to pregnant women diagnosed with COVID-19 are suspected cases. High-risk children and surveillance cases at intermediate and low risk are suspected cases after excluding influenza (standardized administration of oseltamivir phosphate for 2 days) and other common respiratory pathogen infections who meet any two of the following three conditions are suspected cases:\r&lt;br&gt;(1) persistent Fever, obvious respiratory symptoms, shortness of breath or decreased pulse oxygen saturation, or gastrointestinal manifestations such as nausea, vomiting, abdominal discomfort and diarrhea;\r&lt;br&gt;(2) Laboratory tests: normal or decreased white blood cells, decreased lymphocyte count, normal or slightly elevated CRP;\r&lt;br&gt;(3) pulmonary imaging with signs of COVID-19.\r&lt;br&gt;4. Confirmed cases: meeting the criteria for suspected cases, positive result on COVID-19 nucleic acid test with samples of respiratory swabs or secretions, blood, feces and urine ; highly homologous viral gene sequencing with known COVID-19.","Inclusion criteria: 1. Have any of the following epidemiological history: \r&lt;br&gt;(1) travel history or residence history of Wuhan and surrounding areas, or other communities with case reports within 14 days before the onset of illness; \r&lt;br&gt;(2) close contact with febrile patients from Wuhan and surrounding areas, or other communities with case reports within 14 days before the onset of illness; \r&lt;br&gt;(3) Aggressive onset; \r&lt;br&gt;(4) History of close contact with novel coronavirus infections. People with a novel coronavirus infection are those who test positive for a nucleic acid.\r&lt;br&gt;2. Have any two of the following clinical manifestations: \r&lt;br&gt;(1) fever and / or respiratory symptoms; \r&lt;br&gt;(2) have the above-mentioned imaging characteristics of pneumonia; \r&lt;br&gt;(3) the total number of white blood cells is normal or decreased in the early stage of onset, or the lymphocyte count is decreased.\r&lt;br&gt;3. Evidence of any of the following pathogens: \r&lt;br&gt;(1) Real-time fluorescent RT-PCR of respiratory specimens or blood specimens to detect novel coronavirus nucleic acid is positive; \r&lt;br&gt;(2) The sequence of genes in the respiratory tract or blood specimens is homologous to known novel coronavirus.\r&lt;br&gt;Meet the above three cases as confirmed cases and be included in the study.","Inclusion criteria: 1. Meets 2019 novel coronavirus pneumonia diagnosis criteria;\r&lt;br&gt;2. Under non-invasive ventilation, finger oxygen saturation&lt;90%.","Inclusion criteria: 1. Aged 18-75 years old;\r&lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection;\r&lt;br&gt;3. patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days);\r&lt;br&gt;4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;6. Patients who voluntarily sign informed consent.","Inclusion criteria: All enrolled patients with confirmed NCIP according to both clinical way ( include  symptoms,blood routine test and chest computed tomography) and labotatory way (the revere-transcriptase-polymerase-chain-rection (RT-PCR) reaction from throat swab sample) .The patients signed consent was obtained for each sample collection.","Inclusion criteria: Full-time college and graduate students are willing to participate in the research.","Inclusion criteria: COVID-19 group: \r&lt;br&gt;1. Age&gt; = 18 years old, no gender restriction; \r&lt;br&gt;2. Patients with covid-19 determined by gold standard; \r&lt;br&gt;3. Total bilirubin &lt;=1.5 UNL, aspartate aminotransferase AST (SGOT) and alanine aminotransferase ALT (SGPT) &lt;=2.5 UNL; \r&lt;br&gt;4. The patients had no smoking or drinking in the past week;\r&lt;br&gt;5. All patients should be informed.\r&lt;br&gt;Similar symptoms group: \r&lt;br&gt;1. Age&gt; = 18 years old;\r&lt;br&gt;2. Patients with negative nucleic acid test;\r&lt;br&gt;3. Blood biochemical urea nitrogen &lt;=1.25 UNL, creatinine &lt;=1.25 UNL; Total bilirubin &lt;=1.5 UNL, aspartate aminotransferase AST (SGOT) and alanine aminotransferase ALT (SGPT) &lt;=2.5 UNL;\r&lt;br&gt;4. With Symptoms of fever and cough; \r&lt;br&gt;5. No smoking or drinking in the past week;\r&lt;br&gt;6. All patients should be informed.\r&lt;br&gt;Healthy control group:\r&lt;br&gt;1. Healthy patients who were screened by the physical examination center;\r&lt;br&gt;2. Had no history of acute disease in the past two weeks;\r&lt;br&gt;3. No smoking and drinking history in the past week;\r&lt;br&gt;4. Patients with informed consent.","Inclusion criteria: Patients diagnosed with COVID-19\r&lt;br&gt;Mild group\r&lt;br&gt;Diagnosed patients classified as mild and ordinary types according to the National Health Commission of the Peoples Republic of China. Report of Novel Coronavirus-Infected Pneumonia in China by January 18, 2020. \r&lt;br&gt;Severe group\r&lt;br&gt;Diagnosed patients classified as severe type according to the National Health Commission of the Peoples Republic of China. Report of Novel Coronavirus-Infected Pneumonia in China by January 18, 2020.\r&lt;br&gt;Healthy control\r&lt;br&gt;RT-PCR test of novel coronavirus nucleic acid was negative. A healthy person is confirmed by a comprehensive physical examination.","Inclusion criteria: (1) Chinese residents who experienced the noval coronavirus;\r&lt;br&gt;(2) People aged between 18 and 65 years old;\r&lt;br&gt;(3) People have electronic social software such as WeChat, QQ and Email.","Inclusion criteria: 1. Aged &gt;=18 years;\r&lt;br&gt;2. Clinically diagnosed patients with COVID-19, including: on the basis of meeting the criteria for suspected cases, one of the following etiology evidence:\r&lt;br&gt;(1) real-time fluorescent RT-PCR detection of SARS-Cov-2 nucleic acid samples in respiratory or blood samples;\r&lt;br&gt;(2) Sequencing of viral genes in respiratory specimens or blood specimens, highly homologous to known SARS-Cov-2;\r&lt;br&gt;3. The interval between the onset of symptoms and random enrollment is within 7 days. The onset of symptoms is mainly based on fever. Cough, diarrhea or other related symptoms can be used for the evidence of onset symptoms if without fever.","Inclusion criteria: 1. Adult patients confirmed by 2019-nCov throat swab or other samples of nucleic acid positive; \r&lt;br&gt;2. Patients with clear manifestations of pulmonary exudation on chest imaging; \r&lt;br&gt;3. Patients requiring oxygen therapy or mechanical ventilation,  ARDS (oxygenation index &lt; 200mmHg) was diagnosed according to the Berlin standard in 2012.","Inclusion criteria: The diagnostic criteria of novel coronavirus infection pneumonia can be observed and agreed by the patients themselves.","Inclusion criteria: (1) Patients aged from 18 to 75 years old;\r&lt;br&gt;(2) Mild patients with confirmed COVID-19 according to the diagnostic criteria of \"novel coronavirus Infection Diagnosis and Treatment Plan (Trial 6th Edition)\" issued by the National Health and Safety Commission;\r&lt;br&gt;(3) Patients and their families voluntarily participated in the study and signed an informed consent form.","Inclusion criteria: 1. Real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive, or viral gene sequencing is highly homologous with known new coronavirus;\r&lt;br&gt;2. Confirmed as a novel coronavirus pneumonia common and severe patients, meets the diagnostic criteria of the \"novel coronavirus pneumonia diagnosis and treatment plan (trial implementation of the sixth edition)\"\r&lt;br&gt;3. aged 18 to 65 years;\r&lt;br&gt;4. Learn about the significance of the study before the trial also the possible inconveniences and potential risk.","Inclusion criteria: (1) Aged 18 years or older, male or female;\r&lt;br&gt;(2) Real-time fluorescent RT-PCR of pharyngeal swab samples was positive for novel coronavirus nucleic acid;\r&lt;br&gt;(3) Clinical classification is common or severe;\r&lt;br&gt;(4) Signed informed consent.","Inclusion criteria: Patients diagnosed with new coronavirus pneumonia","Inclusion criteria: 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;\r&lt;br&gt;2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;\r&lt;br&gt;3) Inpatients aged 18 to 75 years male or female;\r&lt;br&gt;4) Volunteer to receive treatment under their own scheme and sign informed consent.","Inclusion criteria: 1. Written informed consent from patients or representative;\r&lt;br&gt;2. Aged over 18 years;\r&lt;br&gt;3. Fullfill the diagnostic criteria of critically ill 2019-nCoV Respiratory Disease;\r&lt;br&gt;2019-nCoV diagnosis confirmed by the combination of epidemiology, clinical manifestation and virus PCR results of respiratory specimen;\r&lt;br&gt;Critically ill patients should include one of the followings at least:\r&lt;br&gt;1) respritary failure, mechanical ventilation required;\r&lt;br&gt;2) shock;\r&lt;br&gt;3) complicated with other organ failures, require ICU admission.","Inclusion criteria: Must meet all of the following criteria\r&lt;br&gt;1. aged 18 to 75 years male or female;\r&lt;br&gt;2. Body Weight 40-100kg, and BMI &gt;=18kg/M2;\r&lt;br&gt;3. to meet the diagnostic criteria in the fourth edition of the diagnostic protocol for pneumonia caused by 2019-ncov infection issued by the National Health Commission, and to identify patients with pneumonia caused by common type of 2019-ncov infection.\r&lt;br&gt;Note: suspected patient with one of the following etiological evidence:\r&lt;br&gt;(1) Respiratory Specimens or blood samples were positive for 2019-ncov acid by real-time fluorescent RT-PCR;\r&lt;br&gt;(2) Respiratory Specimens or blood samples were genetically sequenced and highly homologous to known 2019-ncov.\r&lt;br&gt;4. has fever, respiratory symptoms, imaging can see the performance of pneumonia.\r&lt;br&gt;5. the positive test result of etiological evidence within 72 hours;\r&lt;br&gt;6. A woman must:\r&lt;br&gt;(1) Surgical sterilization has been performed. \r&lt;br&gt;(2) Menopause, menopause at least 1 year; \r&lt;br&gt;(3) The following conditions must be met for the child to be fertile;\r&lt;br&gt;The pre-trial Serum / urine pregnancy test was negative in the study group, and during the study period (interview 1-5), consenting to an approved method of contraception (E. G. Oral, injectable or implantable, barrier-forming, spermicide and condom, or intrauterine device) , contraceptive methods remained the same throughout the study period.\r&lt;br&gt;Men must meet one of the following requirements:\r&lt;br&gt;(1) Surgical sterilization has been performed; \r&lt;br&gt;(2) An approved method of contraception must be used throughout the study period and the method remains the same throughout the study period;\r&lt;br&gt;7. those who agree to take part in the test and sign the informed consent form voluntarily.","Inclusion criteria: Patients who are more than 18 years are definitely diagnosed with COVID-19. [That is, the diagnosis of 2019-nCoV-infected pneumonia patients was diagnosed according to the diagnostic criteria for novel coronavirus pneumonia diagnosis and treatment program (trial version 5) issued by the National Health and Health Commission on February 5, 2020.","Inclusion criteria: 1. COVID-19 suspected or confirmed patients: meet the following suspected or confirmed case diagnostic criteria; aged between 18 and 70 years old;\r&lt;br&gt;1.1 Diagnostic criteria for suspected cases;\r&lt;br&gt;1.1.1 History of Epidemiology:\r&lt;br&gt;(1) travel history or residence history within 14 days before the morbidity in Wuhan and its surrounding areas, or in other communities with reported cases;\r&lt;br&gt;(2) History of contact with new coronavirus infection (positive nucleic acid test) within 14 days before morbidity;\r&lt;br&gt;(3) Patients with fever or respiratory symptoms from Wuhan and its surrounding areas, or from communities with reported cases, had been contacted within 14 days before the morbidity;\r&lt;br&gt;(4) Clustered morbidity (2 or more cases of fever and/or respiratory symptoms in a small area such as home, office, school class, etc. Within 2 weeks);\r&lt;br&gt;1.1.2 Clinical manifestations:\r&lt;br&gt;(1) Fever and/or respiratory symptoms;\r&lt;br&gt;(2) Having the above novel coronavirus pneumonia imaging features;\r&lt;br&gt;(3) In the early stage of morbidity, the total number of white blood cells is normal or reduced, or the number of lymphocytes is normal or reduced;\r&lt;br&gt;1.1.3 Have any of the epidemiological history, and meet any 2 of the clinical signs. If there was no clear epidemiological history, it was in accordance with the 3 items in the clinical signs;\r&lt;br&gt;1.2 Diagnostic criteria for confirmed case\r&lt;br&gt;Suspected cases also have one of the following etiological or serological evidence:\r&lt;br&gt;(1) Detection of High Homology of Novel Coronavirus by Real-time Fluorescence RT-PCR; \r&lt;br&gt;(2) Sequencing of the viral genome, which is highly homologous to known novel coronaviruses;\r&lt;br&gt;(3) Serum specific IgM antibody and IgG antibody of new type coronavirus were positive; the specific IgG antibody of new type coronavirus in serum changed from negative to positive or increased by 4 times or more in recovery stage than in acute stage;\r&lt;br&gt;2. non-COVID healthy residents: Wuhan residents; non-COVID-2019 patients;\r&lt;br&gt;3. medical staff: age 18-70 years old and in-service hospital staff.","Inclusion criteria: (1) The novel coronavirus was detected at the age of 18~70 years when signing the informed consent; (2) the nucleic acid test of the pharyngeal test, sputum, lower respiratory tract secretions, blood and so on (RT-PCR detection of the new coronavirus nucleic acid positive) and the sequencing of the virus gene, which were highly homologous with the known new coronavirus, and confirmed that the 2019-nCoV was detected. Chest X * ray and CT imaging confirmed pneumonia (manifested as pulmonary infiltration, single lung or multiple lung lesions, mainly located in the lung field and subpleural area of the Chinese and foreign countries. Lesions were presented as \"mosaic\" sign caused by small patch glass, consolidation and coexistence of small nodules, ground glass shadow and air retention). Lung imaging showed significant progress in 24-48 hours. The patients had no improvement or progressive aggravation after standard anti bacteria treatment; ? had fever, fatigue, cough, shortness of breath and other symptoms, because of fever (body temperature = 37.3 ?), respiratory rate &gt; 30 times / min, SpO2 = 93% (quiet, resting state), oxygenation index = 300; ? The total number of leukocytes in the early stage of onset was normal / decreased, or lymphocyte count decreased. C reactive protein and ESR increased, PCT was normal. (6) epidemiological history (two weeks before onset, Hubei or other higher incidence rate of travel history, or contact with persons from above regions, or the removal of other suspected and confirmed cases), the time from onset to less than 14 days. The subjects are willing to be randomly assigned to any designated treatment group; ? on the basis of current routine treatment, the patients are still in progress, fully informed and signed with the patients and their families; ? they must agree not to participate in another study of the drug under study before the 28th day after the completion of the study.","Inclusion criteria: 1. Criteria for inclusion of confirmed patients:\r&lt;br&gt;(1) Comply with the diagnostic criteria of \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Pneumonia (COVID-19) (Trial Version 5)\";\r&lt;br&gt;(2) Above 2 years old;\r&lt;br&gt;2. Inclusion criteria for close contacts:\r&lt;br&gt;One of the following contact situations after the onset of the case, but did not take effective protection:\r&lt;br&gt;(1) People who live, study, work or have close contact with the case, such as working close to the case or sharing the same classroom or living in the same house as the case;\r&lt;br&gt;(2) Medical staff, family members, or other people who have close contact with the case, such as direct treatment and care of the case, visiting or staying in the closed environment where the case is located, and the case is the same as other cases in the ward. Patients and their caregivers;\r&lt;br&gt;(3) People who are in the same transportation as the case and have close contact with them, including those who have taken care of the patient on the transportation, and the patient's colleagues (family, colleagues, friends, etc.) are found to be likely to be near Distance from other passengers and flight attendants who are in contact with the patient;\r&lt;br&gt;(4) On-site investigators evaluate that they are qualified to meet other contacts with close contacts.","Inclusion criteria: confirmed cases of novel coronavirus(COVID-19) by real time fluorescent RT-PCR in Wenzhou City from January 2020","Inclusion criteria: (1) All confirmed and diagnosed SARS-CoV-2 infection patients (including the clinical diagnosis case of the New Coronavirus Pneumonia HUBEI) (Fifth Edition)\r&lt;br&gt;(2) Voluntarily agree to enter the trial and sign the written informed consent.","Inclusion criteria: 1. Written informed consent from patients or representative;\r&lt;br&gt;2. Aged over 18\r&lt;br&gt;3. Fullfill the diagnostic criteria of critically ill 2019-nCoV Respiratory Disease;\r&lt;br&gt;2019-nCoV diagnosis confirmed by the combination of epidemiology, clinical manifestation and virus PCR results of respiratory specimen;\r&lt;br&gt;Critically ill patients should include one of the followings at least:\r&lt;br&gt;1) respritary failure, mechanical ventilation required;\r&lt;br&gt;2) shock;\r&lt;br&gt;3) complicated with other organ failures, require ICU admission.","Inclusion criteria: 1) confirmed or suspected cases of new coronavirus pneumonia;\r&lt;br&gt;2) be able to understand the content of this study, and have the ability of normal communication and understanding;\r&lt;br&gt;3) voluntarily participate in this study and obtain written informed consent from the guardian or the patient.","Inclusion criteria: 1. Eligible patients were adults ((aged 18-80 years); \r&lt;br&gt;2. Were identified as laboratory-confirmed COVID-19 infection; \r&lt;br&gt;3. Those who need intubation in ICU, and with no severe hypoxemia.","Inclusion criteria: 1. patient with novel coronavirus pneumonia (including nucleic acid positive case or clinically diagnosed case);\r&lt;br&gt;2. patients with type 2 diabetes;\r&lt;br&gt;3. Aged between 18-80 years old;\r&lt;br&gt;4. With effective flash glucose monitoring data.","Inclusion criteria: 1. Confirmed and suspected patients undergoing new crown anesthesia;\r&lt;br&gt;2. Medical staff of anesthesiology department contacted with patients suspected of new crown in operating room;\r&lt;br&gt;3. Voluntary participation in the test and signing of informed consent.","Inclusion criteria: 1. Aged 18 to 70 years old;\r&lt;br&gt;2. Patients with pneumonia infected by new coronavirus: confirmed cases in compliance with the Diagnosis and Treatment Plan for Pneumonia Infected by New Coronavirus (Sixth Edition);\r&lt;br&gt;3. Confirmed cases who can be transfused into anti-SARS-CoV-2 virus inactivated plasma after fully assessing patients condition;\r&lt;br&gt;4. Cases who score 3 or 4 according to 6-grade scale;\r&lt;br&gt;5. The subjects and/or their legal guardians voluntarily participated in the study and voluntarily signed an informed consent form.","Inclusion criteria: (1) registered nurse;\r&lt;br&gt;(2) to combat the new coronavirus pneumonia of the first line of nurses (infection department, fever clinic, emergency);\r&lt;br&gt;(3) volunteer to participate in this study.","Inclusion criteria: Novel Coronavirus Pneumonia (COVID-19) patients","Inclusion criteria: Observational study, no inclusion criteria","Inclusion criteria: pneumoniaits were diagnosed by chest CT findings and positive nucleic acid tests","Inclusion criteria: 1. Aged &gt;= 18 years and &lt;= 75 years;\r&lt;br&gt;2. Patients clinically diagnosed as novel coronavirus infection; or with positive serum antibodies (IgM or IgG); or with novel coronavirus infection confirmed by PCR; \r&lt;br&gt;3. Severe/critical patients.","Inclusion criteria: 1. Aged&gt;= 18, male or female;\r&lt;br&gt;2. Fever, axillary temperature &gt; 37.3 degrees;\r&lt;br&gt;3. Consistent with the clinical diagnosis of COVID-19 mild, normal, severe case;\r&lt;br&gt;4. Patients who sign informed consent form freely and voluntarily.","Inclusion criteria: (1) Aged 18 to 75 years old;\r&lt;br&gt;(2) Real-time fluorescent RT-PCR for respiratory or blood specimens to detect novel coronavirus nucleic acid positive;\r&lt;br&gt;(3) The sequence of virus genes in respiratory or blood samples was highly homologous with the known novel coronavirus;\r&lt;br&gt;(4) According to the \"Pneumonitis Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Fifth Edition)\", the common patients diagnosed with novel coronavirus pneumonia that have fever, respiratory symptoms, and imaging shows pneumonia.\r&lt;br&gt;(5) Some severe patients could be included. Accord with any of the following: ? Respiratory distress, RR = 30 times / minute; ? In resting state, means oxygen saturation = 93%; ? Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) = 300mmHg.","Inclusion criteria: 1. Conform to the western medicine influenza diagnostic criteria\r&lt;br&gt;2. Conform to the diagnostic criteria of TCM wind-heat clip dampness syndrome\r&lt;br&gt;3. Over 18 years old","Inclusion criteria: Patients with suspected and confirmed diagnosis of 2019-nCoV Pneumonia Version 4.0 (published at 2020.01.27) of the National Health Commission","Inclusion criteria: 1.No age restriction.\r&lt;br&gt;2. Clinically confirmed 2019-nCoV infected patients.\r&lt;br&gt;3. Patients with willingness and ability to sign the informed consent.","Inclusion criteria: 1. Those who meet the diagnostic criteria for suspected cases in the diagnosis and treatment scheme;\r&lt;br&gt;2. Over 18 years old (including 18 years old), male or female;\r&lt;br&gt;3. At the time of enrollment, the patient had any of the main symptoms (fever, cough, fatigue);\r&lt;br&gt;4. Voluntarily sign a written informed consent before the study begins.","Inclusion criteria: 1. The patient signed an informed consent form to participate in the study of convalescent plasma therapy;\r&lt;br&gt;2.The age of the patient is 18 or more than18 years old;\r&lt;br&gt;3. COVID-19 patients diagnosed by PCR;\r&lt;br&gt;4. Nucleic acid positive within 72 hours before blood transfusion;\r&lt;br&gt;5. Pneumonia confirmed by imaging;\r&lt;br&gt;6. The clinical symptoms reach the standard of severe or critical.\r&lt;br&gt;Severe patients meet any of the following:\r&lt;br&gt;a) respiratory distress, RR = 30 beats / min;\r&lt;br&gt;b) in resting state, oxygen saturation = 93%;\r&lt;br&gt;c) partial pressure of oxygen in arterial blood (PaO2) / oxygen concentration (FiO2) \r&lt;br&gt;= 300mmHg (1mmHg=0.133kPa)\r&lt;br&gt;Critically ill patients meet any of the following:\r&lt;br&gt;a) respiratory failure and need mechanical ventilation;\r&lt;br&gt;b) shock;\r&lt;br&gt;c) patients with other organ failure need ICU monitoring treatment.\r&lt;br&gt;7. Accept random grouping into any group;\r&lt;br&gt;8. The patient was hospitalized before the end of the clinical study.\r&lt;br&gt;9. Willing to participate in all necessary research directions and be able to participate in follow-up;\r&lt;br&gt;10. During the period of participating in this study, they will no longer participate in clinical trials such as other antiviral drugs.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The participants were diagnosed as COVID-19;\r&lt;br&gt;\r&lt;br&gt;          -  Participants received anti-SARS-CoV-2 inactivated convalescent plasma\r&lt;br&gt;\r&lt;br&gt;          -  Written the informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participants lacked detailed medical history\r&lt;br&gt;","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;\r&lt;br&gt;2. Above 18 years old (inclusive);\r&lt;br&gt;3. At the time of enrollment, the patient had any of the main symptoms (fever, cough, fatigue);\r&lt;br&gt;4. Voluntarily sign written informed consent.","\r&lt;br&gt;        Inclusion criteria.\r&lt;br&gt;\r&lt;br&gt;          1. 2019-nCov (SARA-Cov-2) nucleic acid positive detected by PCR.\r&lt;br&gt;\r&lt;br&gt;          2. Older than 18 years old and younger than 75 years old.\r&lt;br&gt;\r&lt;br&gt;          3. Meet the diagnostic criteria of COVID-19 for different types (including ordinary type,\r&lt;br&gt;             heavy type and critical type)\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria.\r&lt;br&gt;\r&lt;br&gt;          1. the age is less than 18 years old;\r&lt;br&gt;\r&lt;br&gt;          2. pregnant or lactating women;\r&lt;br&gt;\r&lt;br&gt;          3. severe underlying diseases, such as advanced malignant tumor, end-stage lung disease,\r&lt;br&gt;             etc.\r&lt;br&gt;","Inclusion criteria: 1. No physical discomfort;\r&lt;br&gt;2. Aged 16 years old and above;\r&lt;br&gt;3. Take the medicine recommended by this research voluntarily.","Inclusion criteria: 1. Pneumonitis patients infected with new coronavirus;\r&lt;br&gt;2. Meet the standard of TCM syndrome differentiation;\r&lt;br&gt;3. Sign the informed consent.","Inclusion criteria: Patients of stomatology department in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 4 to January 23, 2020.\r&lt;br&gt;1. The visiting data of patients could be backtracked;\r&lt;br&gt;2. The patients could be connected;\r&lt;br&gt;3. The patients or the guardians could understand the content of investigation;\r&lt;br&gt;4. The patients or the guardians signed informed consent.","Inclusion criteria: 1. Male and female aged 18-65 years;\r&lt;br&gt;2. Clinically diagnosed with Corona Virus Disease 2019;\r&lt;br&gt;3. Increased interleukin-6;\r&lt;br&gt;4. Sign the informed consent;\r&lt;br&gt;5. Subjects who can take medicine orally;\r&lt;br&gt;6. Agree to collect clinical samples;\r&lt;br&gt;7. Female subjects of childbearing age are not pregnant and agree to take effective contraception within 7 days of the last oral medication to ensure that they are not pregnant within 3-6 months;\r&lt;br&gt;8. Male patients agree to effective contraception within 7 days of last oral medication.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age = 18 years;\r&lt;br&gt;\r&lt;br&gt;          2. Clinically diagnosed patients with new type of coronavirus pneumonia, including: in\r&lt;br&gt;             accordance with the criteria for suspected cases, have one of the following etiology\r&lt;br&gt;             evidence:\r&lt;br&gt;\r&lt;br&gt;             ? Real-time fluorescence RT-PCR of respiratory specimens or blood specimens for\r&lt;br&gt;             detection of new coronavirus nucleic acid;\r&lt;br&gt;\r&lt;br&gt;             ? Sequencing of viral genes in respiratory specimens or blood specimens, highly\r&lt;br&gt;             homologous to known new coronavirus\r&lt;br&gt;\r&lt;br&gt;          3. The time interval between the onset of symptoms and random enrollment is within 7\r&lt;br&gt;             days. The onset of symptoms is mainly based on fever. If there is no fever, cough,\r&lt;br&gt;             diarrhea or other related symptoms can be used.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Any situation where the programme cannot be carried out safely;\r&lt;br&gt;\r&lt;br&gt;          2. Patients who have used interferon or remedesivir;\r&lt;br&gt;\r&lt;br&gt;          3. No clinical manifestations and chest imaging findings\r&lt;br&gt;\r&lt;br&gt;          4. Known allergy or hypersensitivity to interferon (including asthma);\r&lt;br&gt;\r&lt;br&gt;          5. Disabled in patients with uncontrolled autoimmune diseases;\r&lt;br&gt;\r&lt;br&gt;          6. Patients with severe heart disease, decompensated liver disease, renal insufficiency\r&lt;br&gt;             (CrCL &lt;50ml / min), and those with abnormal bone marrow function are prohibited;\r&lt;br&gt;\r&lt;br&gt;          7. Epilepsy and impaired central nervous system function;\r&lt;br&gt;\r&lt;br&gt;          8. Pregnancy: Positive pregnancy test for women of childbearing age;\r&lt;br&gt;\r&lt;br&gt;          9. Breastfeeding women have not stopped breastfeeding;\r&lt;br&gt;\r&lt;br&gt;         10. The patient may be transferred to a non-participating hospital within 72 hours.\r&lt;br&gt;","Inclusion criteria: 1. including confirmed, suspected patients, isolated observers, ordinary residents and frontline staff;\r&lt;br&gt;2. residence in Jingzhou for more than 14 days during the outbreak;\r&lt;br&gt;3. Aged 16-65 years;\r&lt;br&gt;4. self-volunteered.","Inclusion criteria: Positive Screening for the SCL-90; Voluntary participation in this research","Inclusion criteria: 1. Suspected COVID-19 patients with chest CT scannings(including follow-up scanning);\r&lt;br&gt;2. Patients confirmed with etiological detection and clinical following data.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Aged &gt;=18 years;\r&lt;br&gt;\r&lt;br&gt;          2. Novel coronavirus pneumonia patients diagnosed by pathogenic testing;\r&lt;br&gt;\r&lt;br&gt;          3. The patient himself participated in the study voluntarily, agreed and signed the\r&lt;br&gt;             informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;\r&lt;br&gt;\r&lt;br&gt;          2. Severe primary diseases that affect survival, including: uncontrolled malignant\r&lt;br&gt;             tumors, hematological diseases, and HIV that have not been metastasized in multiple\r&lt;br&gt;             places;\r&lt;br&gt;\r&lt;br&gt;          3. Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and\r&lt;br&gt;             allergic alveolitis caused by lung tumors;\r&lt;br&gt;\r&lt;br&gt;          4. Women who are breastfeeding or pregnant;\r&lt;br&gt;\r&lt;br&gt;          5. Those who are known to be allergic to the ingredients contained in the research\r&lt;br&gt;             medication, or patients with allergies;\r&lt;br&gt;\r&lt;br&gt;          6. Those who have continued to use immunosuppressive agents or organ transplants in the\r&lt;br&gt;             past 6 months;\r&lt;br&gt;\r&lt;br&gt;          7. Patients who have participated in other drug clinical trials within 3 months before\r&lt;br&gt;             the screening test;\r&lt;br&gt;\r&lt;br&gt;          8. The investigator judges that he or she cannot complete or should not participate in\r&lt;br&gt;             the study (expected death within 48 hours, and the patient refuses active treatment)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Nurses who work &gt; 37 hours per week in medical, emergency, pediatric units\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Nurses with one or more comorbidities\r&lt;br&gt;\r&lt;br&gt;          -  Nurses who cannot pass an N95 respirator fit-test\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. age range: 10-19;\r&lt;br&gt;\r&lt;br&gt;          2. full-time students in these targets high or middle schools;\r&lt;br&gt;\r&lt;br&gt;          3. nationality: China;\r&lt;br&gt;\r&lt;br&gt;          4. exposure context: COVID-19;\r&lt;br&gt;\r&lt;br&gt;          5. able to adequately understand the content of consent form and questionnaire;\r&lt;br&gt;\r&lt;br&gt;        (d) able to sufficiently state the purpose of the research and acknowledge the potential\r&lt;br&gt;        risks and benefits based on the questionnaire\r&lt;br&gt;","Inclusion criteria: 1. Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission. Criteria for diagnosis (meet all the following criteria): \r&lt;br&gt;(1) With epidemiological history;\r&lt;br&gt;(2) Clinical manifestations (meet any 2 of the following): fever, normal or decreased white blood cell count or lymphopenia in the early stage of onset, and Chest radiology in the early stage shows multiple small patchy shadowing and interstitial changes which is especially significant in periphery pulmonary. Furthermore, it develops into bilateral multiple ground-glass opacity and infiltrating shadowing. Pulmonary consolidation occurs in severe cases. Pleural effusion is rare;\r&lt;br&gt;(3) Confirmed case (suspected case obtained one of the following etiologic evidences): a positive result to real-time reverse-transcriptase PCR for respiratory specimen or blood specimen, or Genetic sequencing result of virus in respiratory or blood specimens are highly homologous to SARS-CoV-2; \r&lt;br&gt;2. The person is treated with de-isolation and meets hospital discharge criteria according to the 'Diagnosis and treatment of novel coronavirus pneumonia (trial edition 5)'. However, the respiratory nucleic acid turned positive and there were changes in lung imaging;\r&lt;br&gt;3. Gastrointestinal anatomy and function allowed and use safely, without nausea, vomiting and other gastrointestinal symptoms.","Inclusion criteria: COVID-19 nucleic acid testing positive non-critically ill hospitalized patients.","Inclusion criteria: Stage I and ii healthy subjects\r&lt;br&gt;Stage 3:\r&lt;br&gt;1. Clinical manifestations:\r&lt;br&gt;(1) Fever;\r&lt;br&gt;(2) normal or decreased white blood cells;\r&lt;br&gt;(3) CT pulmonary exudation; Or a suspected patient with an epidemiological history;\r&lt;br&gt;2. Isolation ward: patients with novel coronavirus (mild, common).","Inclusion criteria: All patients with laboratory confirmed diagnosis of COVID-19 and are listed in the Centre for Health Protection (CHP) database will be included in the study.","Inclusion criteria:  From January 22 to February 16, 2020,Patients diagnosed with new coronavirus infection in 15 medical institutions in Zhejiang Province.","Inclusion criteria: 1. Aged &gt;=18 years old;\r&lt;br&gt;2. Symptoms of novel coronavirus infection;\r&lt;br&gt;3. Positive nucleic acid test of novel coronavirus.","Inclusion criteria: 1. positiveness of nucleic acid of COVID-19 in a in throat swab nucleic acid positive;\r&lt;br&gt;2. newly-onset pneumonia in a CT scan;\r&lt;br&gt;3. typical symptoms of pneumonia, i.e., fever, cough, dyspnea, etc.;\r&lt;br&gt;4. live in Wuhan in the past one month.","Inclusion criteria: 1. Patients aged from 18 to 80 years;\r&lt;br&gt;2. conformed to epidemic history;\r&lt;br&gt;3. fever and respiratory symptoms;\r&lt;br&gt;4. normal or decreased leukocyte count in peripheral blood; or decreased lymphocyte count;\r&lt;br&gt;5. conformed to imaging features of COVID-19 pneumonia;\r&lt;br&gt;6. positive for COVID-19 nucleic acid test or second-generation sequencing of pathogens;\r&lt;br&gt;7. serum KL- 61500U / ml;\r&lt;br&gt;8. and conforms to any of the following:\r&lt;br&gt;(1) respiratory distress, RR &gt;=30 beats / min;\r&lt;br&gt;(2) oxygen saturation &lt;=93% at rest;\r&lt;br&gt;(3) partial pressure of arterial oxygen (PaO2) / oxygen concentration (FiO2) &lt;=300mmHg (1mmHg=0.133kPa).","Inclusion criteria: Based on the diagnostic criteria of provinces other than hubei province in the latest diagnosis and treatment program of novel coronavirus pneumonia issued by the national health commission, the light, common, severe and critical types of suspected and confirmed cases were determined by combining epidemiological history, clinical manifestations and laboratory examination.","Inclusion criteria: Patients with confirmed COVID-19","Inclusion criteria: 1. Aged &gt;=18 years Chinese people;\r&lt;br&gt;2. Clinical diagnosis of 2019 - nCoV suspected cases: clinical diagnosis of 2019 - nCoV suspected cases: according to the national health committee office of the general office of the state administration of traditional Chinese medicine on February 3, 2020 promulgated the new coronavirus infection pneumonia diagnosis and treatment scheme (trial version 5) notice, will be suspected cases are defined as any article 1 has a history of epidemiology, conform to the clinical manifestation of 2:1) history of epidemiology: in 14 days before the onset of Wuhan city and surrounding areas, or other cases reported history of history of travel or live in the community; In the 14 days before onset, the patient had been exposed to fever or respiratory symptoms from wuhan city and surrounding areas or from the case reporting community.Cluster disease; With the new coronavirus infection has a history of contact, the new coronavirus infection refers to the pathogen nucleic acid test positive.(2) clinical manifestations: fever and/or respiratory symptoms;The imaging features of pneumonia were as follows: multiple small patches and stromal changes were observed in the early stage, and the lung exhalation was obvious. Then, multiple ground glass and infiltrating shadows were found in both lungs.\r&lt;br&gt;3. In severe cases, lung consolidation could occur, and pleural effusion was rare.The total number of white blood cells in the early stage of the disease is normal or decreased, or the lymphocyte count is reduced.The clinical diagnosis was confirmed as 2019-ncov cases: based on the suspected cases, sputum, pharyngeal swab, secretions of the lower respiratory tract and other specimens were tested for positive nucleic acid of the novel coronavirus by real-time fluorescence rt-pcr. Or virus gene sequencing, and known new coronavirus highly homologous.Mild cases or severe cases were included in the study.","Inclusion criteria: All patients who meet one or two of the followings will be included in this study(pregnant women and newborns delivered):\r&lt;br&gt;Epidemiological history: \r&lt;br&gt;1. travel or residence history of Wuhan or other areas with continuous transmission of local cases within 14 days before the onset of the disease; or contact with local cases from Wuhan or other areas within 14 days before the onset of the disease; or associated with the occurrence of clustering disease;\r&lt;br&gt;2. Clinical manifestations: fever; or chest CT imaging features: multiple small patches and interstitial changes at the early stage, showing clearly in the lung. In severe cases, lung consolidation and pleural effusion are rare. or In the early stage of infection, the total number of white blood cells was normal or decreased, or the lymphocyte count was decreased.","Inclusion criteria: The mild cases were defined as those with mild clinical symptoms and no abnormalities on imaging examination; critical cases were those that met any of the following conditions: \r&lt;br&gt;1) respiratory failure requiring mechanical ventilation; \r&lt;br&gt;2) shock;\r&lt;br&gt;3) combined with another organ failure, the need for intensive care unit (ICU) monitoring and treatment. The process of classified management of mild and severe cases is shown in Figure 1. Among the patients we followed, 62 patients progressed to severe cases; they were transferred to designated hospitals for further treatment. \r&lt;br&gt;Moreover, the discharge diagnostic criteria were as follows: \r&lt;br&gt;1) body temperature returned to normal for more than 3 d; \r&lt;br&gt;2) respiratory symptoms improved significantly; \r&lt;br&gt;3) significant improvement in lung imaging; \r&lt;br&gt;4) negative nucleic acid test for nasal and pharyngeal swabs twice.","Inclusion criteria: (1) mild / general patients who meet the diagnostic criteria of the Protocol;\r&lt;br&gt;(2) Aged &gt;=18 years;\r&lt;br&gt;(3) Obtain patients' informed consent.","Inclusion criteria: According to the clinical diagnostic criteria of the fifth edition \"diagnosis and treatment of pneumonia with novel coronavirus infection\", COVID 19 pneumonia was clinically diagnosed.","Inclusion criteria: (1) Patients diagnosed with COVID-19 infection; the diagnostic criteria are as follows: SARS-COV-2 nucleic acid RT-PCR test results of respiratory specimens are positive;\r&lt;br&gt;(2) There are CT image examination data and manifestations of viral pneumonia;\r&lt;br&gt;(3) There are clinical laboratory examination data and follow-up data.","Inclusion criteria: 1. patients with novel coronavirus pneumonia confirmed by pathogenic detection;\r&lt;br&gt;2. Fever, respiratory tract and other symptoms, the change of pneumonia can be seen in imaging;\r&lt;br&gt;3. Aged 18 to 80 years;\r&lt;br&gt;4. Signed informed consent.","Inclusion criteria: 1. COVID-19 patients with positive SARS-COV-2 nucleic acid RT-PCR test results;\r&lt;br&gt;2. Viral pneumonia manifestation on CT.","Inclusion criteria: 1. Above 7 years old, understand the purpose and significance of the research, and be able to cooperate with the research;\r&lt;br&gt;2. Meet the diagnostic criteria of the COVID-19;\r&lt;br&gt;3. Clear consciousness and stable vital signs;\r&lt;br&gt;4. Voluntarily participate in this study and sign the informed consent.","Inclusion criteria: 1. Adult aged &gt;=18years old;\r&lt;br&gt;2. Patients infected with new coronavirus confirmed by PCR\r&lt;br&gt;3. In the state of no oxygen at rest, the patient's SPO2&lt;=94% or the oxygenation index is less than 300mmHg.","Inclusion criteria: &lt;br&gt;                General REMAP-CAP Inclusion Criteria:&lt;br&gt;                1. Adult patient admitted to an ICU for acute severe CAP within 48 hours of hospital admission with&lt;br&gt;                a. symptoms or signs or both that are consistent with lower respiratory tract infection (for example, acute onset of dyspnea, cough, pleuritic chest pain) AND&lt;br&gt;                b. Radiological evidence of new onset infiltrate of infective origin (in patients with pre-existing radiological changes, evidence of new infiltrate)&lt;br&gt;                2. Up to 48 hours after ICU admission, receiving organ support with one or more of:&lt;br&gt;                a. Non-invasive or invasive ventilatory support;&lt;br&gt;                b. Receiving infusion of vasopressor or inotropes or both&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;                Are the trial subjects under 18? no&lt;br&gt;                Number of subjects for this age range:&lt;br&gt;                F.1.2 Adults (18-64 years) yes&lt;br&gt;                F.1.2.1 Number of subjects for this age range 2000&lt;br&gt;                F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;                F.1.3.1 Number of subjects for this age range 2000&lt;br&gt;","Inclusion criteria: 1. Male or female patients aged 16-75 years;\r&lt;br&gt;2. Willing to sign informed consent;\r&lt;br&gt;3. novel coronavirus novel coronavirus is highly novel correlate with the novel coronavirus, based on the standard of suspected cases of new coronavirus infection, real-time fluorescence RT-PCR detection of new coronavirus nucleic acid positive, and sequencing of the virus gene;\r&lt;br&gt;4. novel coronavirus pneumonia novel coronavirus infection was diagnosed according to the new coronavirus pneumonia diagnosis and treatment plan (trial version sixth). Severe pneumonia is defined by compliance with any of the following:\r&lt;br&gt;(1) Dyspnea, RR &gt;=30 times / min;\r&lt;br&gt;(2) At rest, the oxygen saturation &lt;=93%;\r&lt;br&gt;(3) PaO2 / FiO2 &lt;=300MMHG (lmmhg = o.133kpa). Pa02 / fi02 should be corrected according to the formula: PaO2 / FiO2 x[atmospheric pressure (mmHg) / 760] The pulmonary imaging showed that the lesions progressed more than 50% within 24-48 hours, and the patients were managed as severe.","Inclusion criteria: This study intends to recruit all doctors, nurses, and care workers who have been in clinical work for more than half a month from January to March 2020 in pediatric fever clinic, pediatric buffer clinic, pediatric emergency department, PICU, NICU, neonatal specialty, pediatric infectious and digestive disorders specialty, pediatric kidney and vascular disease specialty, pediatric hematology specialty, children's genetic endocrinology and respiratory specialty, and children's health care specialty.","Inclusion criteria: Patients with novel coronavirus pneumonia and suspending patients","Inclusion criteria: (1) patients who were diagnosed to NCP;\r&lt;br&gt;(2) patients who received with invasive mechanical ventilation","Inclusion criteria: Novel coronavirus pneumonia patients","Inclusion criteria: Acorrding to  Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected Jan 11, 2020.","Inclusion criteria: 1) Meets COVID-19 diagnosis criteria from WHO;\r&lt;br&gt;2) Critically ill COVID-19 patients who admiteed to ICUs;\r&lt;br&gt;3) length of stay in ICU &gt;=24 hours","Inclusion criteria: (1) Subjects must understand the clinical trial requirements and potential risks, with voluntarily participation, and sign the informed consent;\r&lt;br&gt;(2) Fever and/or respiratory symptoms, normal or reduced total white blood cell count in the early stage of disease, or reduced lymphocyte count;\r&lt;br&gt;(3) With an epidemiological history and radiological features of viral pneumonia;\r&lt;br&gt;(4) Respiratory tract specimens were detected positive for sars-cov-2 virus nucleic acid by RT-PCR","Inclusion criteria: Patients must meet all of the following inclusion criteria before they can join this study: \r&lt;br&gt;1. Patients admitted to hospital from December 2019 to March 2020;\r&lt;br&gt;2. Patients identified as any rheumatic disease according to the latest international diagnostic standards for the respective disease;\r&lt;br&gt;3. COVID-19 patients have been diagnosed according to the Chinese New Coronavirus Pneumonia Diagnosis and Treatment Program (trial version 7).","Inclusion criteria: All confirmed COVID-19 followed  by  the guidance of NHC.","Inclusion criteria: 1. tumor group:\r&lt;br&gt;(1) Aged &gt;=18 years;\r&lt;br&gt;(2) Diagnosed as a malignant tumor or has a history of malignant tumors before enrollment;\r&lt;br&gt;(3) The diagnosis and treatment of new coronavirus pneumonia was issued in the seventh edition of the New Coronary Virus Pneumonia Diagnosis and Treatment Plan (trial implementation of the seventh edition) issued by the seventh edition of the National Health Committee in March 2020;\r&lt;br&gt;(4) Life expectancy is at least 2 years.\r&lt;br&gt;2. Control group (non-tumor group):\r&lt;br&gt;(1) Aged &gt;=18 years;\r&lt;br&gt;(2) no history of malignant tumors;\r&lt;br&gt;(3) No basic diseases such as diabetes, coronary heart disease, pneumonia, chronic bronchitis;\r&lt;br&gt;(4) The diagnosis and treatment of new coronavirus pneumonia was issued by the Seventh Edition of the National Health Committee of the People's Republic of China in March 2020 in the \"Diagnosis and Treatment of New Coronavirus Pneumonia (Trial Version 7)\";\r&lt;br&gt;(5) Life expectancy is at least 2 years.","Inclusion criteria: This study was a retrospective single-center study, which included patients suspected of novel coronavirus infection and underwent both chest CT imaging and laboratory virus nucleic acid test (RT-PCR assay with throat swab samples) from February 15, 2020 to February 29, 2020.","Inclusion criteria: The patients who had been confirmed with SARS-CoV-2 infection by a nucleic acid-positive test and identified as severe or critical according to the diagnosis and treatment protocol for novel coronavirus pneumonia , were enrolled in this study","Inclusion criteria: 1. Those who meet the diagnosis of COVID-19;\r&lt;br&gt;2. In-patients admitted in designated hospitals.","Inclusion criteria: 1. Confirmed case: any one of the epidemiological history, and in line with the two clinical manifestations, with one of the following etiological evidence:\r&lt;br&gt;(1) epidemiological history:\r&lt;br&gt;1) travel history or residence history of wuhan and surrounding areas or other communities with reported cases within 14 days before onset;\r&lt;br&gt;2) within 14 days prior to onset, the patient had been exposed to fever or respiratory symptoms from wuhan city and surrounding areas, or from communities with reported cases;\r&lt;br&gt;3) cluster disease;\r&lt;br&gt;4) a history of contact with a new type of coronavirus infection (positive in the detection of pathogen nucleic acid);\r&lt;br&gt;(2) clinical manifestations:\r&lt;br&gt;1) fever and/or respiratory symptoms;\r&lt;br&gt;2) the total number of white blood cells in the early stage of the disease is normal or decreased, or the lymphocyte count is reduced;\r&lt;br&gt;(3) pathogenic evidence:\r&lt;br&gt;1) real-time fluorescence rt-pcr detection of positive nucleic acid of novel coronavirus in respiratory tract or blood samples;\r&lt;br&gt;2) the gene sequencing of the respiratory or blood specimen virus is highly homologous to the known novel coronavirus;\r&lt;br&gt;2. Suspected cases: any one of them has an epidemiological history and conforms to any three of the clinical manifestations;\r&lt;br&gt;(1) epidemiological history:\r&lt;br&gt;1) travel history or residence history of wuhan and surrounding areas or other communities with reported cases within 14 days before onset;\r&lt;br&gt;2) within 14 days prior to onset, the patient had been exposed to fever or respiratory symptoms from wuhan city and surrounding areas, or from communities with reported cases;\r&lt;br&gt;3) cluster disease;\r&lt;br&gt;4) a history of contact with a new type of coronavirus infection (positive in the detection of pathogen nucleic acid).\r&lt;br&gt;(2) clinical manifestations:\r&lt;br&gt;1) fever and/or respiratory symptoms;\r&lt;br&gt;2) imaging features of the above pneumonia;\r&lt;br&gt;3) the total number of white blood cells in the early stage of the disease was normal or decreased, or the lymphocyte count was decreased.","Inclusion criteria: Patients who meet the diagnostic criteria for confirmed cases of pneumonia in the diagnosis and treatment program for novel coronavirus infection (trial seventh edition) issued by the national health commission on March 3, 2020","Inclusion criteria: Aged &gt;=65 years patient with novel coronavirus pneumonia COVID-19","Inclusion criteria: Refer to the national health commission document \"diagnosis and treatment plan of new coronavirus pneumonia (trial seven edition)\".","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Wuhan residents;\r&lt;br&gt;\r&lt;br&gt;          -  novel coronavirus pneumonia was found to be characterized by fever and cough.\r&lt;br&gt;             Laboratory tests revealed leukocyte or lymphocyte decrease, chest CT examination\r&lt;br&gt;             showed viral pneumonia changes, and was diagnosed as COVID-19 pneumonia according to\r&lt;br&gt;             the national health and Health Committee's new coronavirus pneumonia diagnosis and\r&lt;br&gt;             treatment plan (trial version fifth Revision).\r&lt;br&gt;\r&lt;br&gt;          -  Severe and critical patients with covid-19 pneumonia in urgent need of tracheal\r&lt;br&gt;             intubation;\r&lt;br&gt;\r&lt;br&gt;          -  Sign informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Suspected patients with covid-19 pneumonia;\r&lt;br&gt;\r&lt;br&gt;          -  Patients who need emergency endotracheal intubation due to other causes of respiratory\r&lt;br&gt;             failure;\r&lt;br&gt;\r&lt;br&gt;          -  The family refused to sign the informed consent.\r&lt;br&gt;","Inclusion criteria: Vulnerable and high risk groups such as health care workers and non health care workers in health care settings. 2019-ncov.","Inclusion criteria: (1) Patients with Novel coronavirus pneumonia diagnosed according to &lt;diagnosis and treatment scheme for pneumonia of new coronavirus infection (trial version 5)&gt;;\r&lt;br&gt;(2) Inpatients aged &gt;18 years old;\r&lt;br&gt;(3) Patients Know the informed consent, voluntary participate in this clinical trial and sign informed consent.","Inclusion criteria: 1) The diagnosis meets the diagnostic criteria for new coronavirus pneumonia;\r&lt;br&gt;2) Patients receiving NIV or MV treatment.","Inclusion criteria: New Coronavirus Patients Meeting the Criteria for the Diagnosis and Treatment of New Coronavirus Infected Pneumonia (Trial Version 5)","Inclusion criteria: 1. Aged 18 to 80 years;\r&lt;br&gt;2. Diagnosed as COVID-19 pneumonia (according to the latest diagnostic criteria of The novel coronavirus pneumonia diagnosis and treatment plan formulated by the State Health Protection Committee);\r&lt;br&gt;3. admitted into ICU;\r&lt;br&gt;4. Rapid increase of serum IL-6 level.","Inclusion criteria: Inclusion criteria Patients confirmed to be infected with 2019-nCoV.","Inclusion criteria: otolaryngology healthcare workers in Hubei Province","Inclusion criteria: 1. Patients diagnosed as severe or critical COVID-19; or patients who have turned negative for viral nucleic acid detection but still have the following severe or critical manifestations:\r&lt;br&gt;According to the \"New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 6)\" promulgated by the National Health Commission, any of the following is confirmed to be diagnosed as severe COVID-19: \r&lt;br&gt;1) shortness of breath, RR &gt;=30 times / minute; \r&lt;br&gt;2) in a resting state , Oxygen saturation&lt;=93%; \r&lt;br&gt;3) arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;=300mmHg (1mmHg = 0.133kPa). \r&lt;br&gt;The diagnosis of critical COVID-19 is consistent with any of the following: \r&lt;br&gt;1) respiratory failure occurs and requires mechanical ventilation; \r&lt;br&gt;2) shock occurs; \r&lt;br&gt;3) combined organ failure requires ICU monitoring and treatment;\r&lt;br&gt;2. Informed consent, voluntary participation and signing of informed consent by patients (or entrusted agents).","Inclusion criteria: 1. novel coronavirus pneumonia diagnostic criteria;\r&lt;br&gt;2. age unlimited, male and female unlimited.","Inclusion criteria: (1) Currently participating in or responsible for an investigator-initiated clinical trial;\r&lt;br&gt;(2) Voluntarily participate in this study.","Inclusion criteria: we collected 30 mild and common type patients who have positive SARS-CoV-2 of throat swab and 30 suspected patients who have negative nucleic acid but have some symptoms (fever, cough, etc) as controls","Inclusion criteria: (1) Aged &gt;18 years old; \r&lt;br&gt;(2) can complete the wechat questionnaire independently.","Inclusion criteria: Common and severe new coronavirus pneumonia","Inclusion criteria: 1) Comply with the diagnostic criteria for patients with new pneumonia virus in the Pneumonitis Diagnosis and Treatment Program for Corona Virus Disease 2019(7th Edition);\r&lt;br&gt;(2) Complete clinical data of patients.","Inclusion criteria: 1. Critical patients with COVID-19 confirmed by etiology test;\r&lt;br&gt;2. airway intubation with mechanical ventilation is used;\r&lt;br&gt;3. voluntarily joined this study with informed consents.","Inclusion criteria: According to the sixth edition of the Chinese New Coronary Virus Pneumonia Diagnosis and Treatment Guidelines, patients with suspected novel coronavirus pneumonia were included in the study.","Inclusion criteria: 1. confirmed with COVID-19;\r&lt;br&gt;2 olderer than 65 years;\r&lt;br&gt;3. meet the critically ill criteria according to Chinese management guideline for COVID-19 (version 7).","Inclusion criteria: (1) novel coronavirus pneumonia novel coronavirus pneumonia is diagnosed according to the new pneumonia diagnosis and treatment plan (trial version fifth);\r&lt;br&gt;(2) According to the diagnostic standard of \"lung invasion\" in Mongolian medicine \"myxosis\", the patients were diagnosed as Mongolian medicine \"myxosis\" acute fever;\r&lt;br&gt;(3) RT-PCR was used to detect the new coronavirus in respiratory or blood samples;\r&lt;br&gt;(4) Aged 18 to 70 years old;\r&lt;br&gt;(5) subjects' informed consent and signing informed consent.","Inclusion criteria: 1. Male and female, older than 18 years; \r&lt;br&gt;2. Patients with confirmed COVID19;\r&lt;br&gt;3. Need to continue the antivirus therapy;\r&lt;br&gt;4. Agree to sign the informed consent;\r&lt;br&gt;5. Able to ingest, absorb and tolerate oral medication;\r&lt;br&gt;6. Agree to collect clinical samples;\r&lt;br&gt;7. Consent to contraceptive measures for sex within 7 days of the last oral medication.","Inclusion criteria: 1. Aged &gt;=18 years;\r&lt;br&gt;2. Endotracheal intubation patients with positive nucleic acid test of novel coronavirus;\r&lt;br&gt;3. Patients with off-line extubation.","Inclusion criteria: 1. Aged 18-65 years, gender without limitation;\r&lt;br&gt;2. Meical workers normal working during the period of COVID-19;\r&lt;br&gt;3. Auqired the informed consent and willing to be a volunteer.","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;\r&lt;br&gt;2. ARDS patients according to the Berlin definition;\r&lt;br&gt;3. Patients in ICU met the VAP criteria and were not associated with other site infection.","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;\r&lt;br&gt;2. Severe ARDS patients according to the Berlin definition.","Inclusion criteria: 1. confirmed with COVID-19;\r&lt;br&gt;2. ICU admission;\r&lt;br&gt;3. meet the critically ill criteria  according to Chinese management guideline for COVID-19 (version 7)","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;\r&lt;br&gt;2. aged 14 years or more;\r&lt;br&gt;3. diagnosis of  ARDS according to Berlin definition.","Inclusion criteria: 1. confirmed critically ill covid-19;\r&lt;br&gt;2. grouping criteria: meet the clinical risk factor combination criteria for invasive candidiasis in critically ill patients proposed by ostrosky-zeichner et al in 2009:\r&lt;br&gt;(1) the length of stay in ICU exceeds 4 days;\r&lt;br&gt;(2) in line with two of the following three conditions: broad-spectrum antibiotics; Central venous catheterization; Mechanical ventilation;\r&lt;br&gt;(3) meeting one of the following six criteria: total parenteral nutrition (day 1 to day 3); Dialysis (1-3 days); Major surgery or pancreatitis or immunosuppression or glucocorticoids (within 7 days).","Inclusion criteria: Men with diagnosed COVID-19, aged 22-55 years old. 50 inpatients and 100 males after recovery.","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;\r&lt;br&gt;2. ARDS patients are defined According to the Berlin definition.","Inclusion criteria: Hemodialysis and peritoneal dialysis patients","Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test and were in accordance with the clinical classification of severe or critically illness. (refer to the clinical classification criteria in the pneumonia diagnosis and treatment program of novel coronavirus infection, General Office of the National Health Commission (trial version 7)).","Inclusion criteria: 1. Aged 15-79 years;\r&lt;br&gt;2. Patients with COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;","Inclusion criteria: 1. Volunteers who have understood and signed the informed consent;\r&lt;br&gt;2. Aged &gt;=18 years;\r&lt;br&gt;3. Patients diagnosed with acute severe 2019-nCoV pneumonia:\r&lt;br&gt;(1) Laboratory (RT-PCR) confirmed infection with 2019-nCoV.\r&lt;br&gt;(2) Lung involvement confirmed with pulmonary CT scan;\r&lt;br&gt;(3) At least one of the following conditions should be met: respiratory distress, RR &gt;=30 times/min; oxygen saturation &lt;=93% in resting state; PaO2/FiO2 &lt;=300mmHg; respiratory failure and mechanical ventilation are required; shock occurs; ICU monitoring and treatment is required in combination with other organ failure.","Inclusion criteria: Surgical admission patients requires emergency or scheduled surgery.","Inclusion criteria: Patients diagnosed with NCIP in Tibetan Plateau were included in the study","Inclusion criteria: Pneumonia cases with suspected SARS-CoV-2 have either of the following epidemiological histories consistent with the following two clinical manifestations:\r&lt;br&gt;A comprehensive analysis was conducted based on the following epidemiological history and clinical manifestations\r&lt;br&gt;1. Epidemiological history\r&lt;br&gt;(1) Travel history or residence history of wuhan and surrounding areas or other communities shall provide case reports before the onset of the disease;\r&lt;br&gt;(2) Cases have been reported in patients with fever or respiratory symptoms in community residents of wuhan and surrounding areas;\r&lt;br&gt;(3) Aggressive attack;\r&lt;br&gt;(4) History of exposure to new coronavirus infections people with new coronavirus infections are those who have tested positive for nucleic acid;\r&lt;br&gt;2. Clinical manifestations\r&lt;br&gt;(1) Fever and/or respiratory symptoms;\r&lt;br&gt;(2) Pneumonia with the above imaging features;\r&lt;br&gt;(3) The total number of white blood cells was normal or decreased or the number of lymphocytes decreased at the initial stage of the disease.","Inclusion criteria: (1) Comply with the diagnostic criteria for patients with new pneumonia virus in the The Pneumonitis Diagnosis and Treatment Program for Corona Virus Disease 2019(Sixth Edition); \r&lt;br&gt;(2) Complete clinical data of patients.","Inclusion criteria: 1. Aged 18 to 75 years old;\r&lt;br&gt;2. The diagnosis of new-type coronavirus pneumonia was confirmed by RT-PCR or gene sequencing according to the \"Diagnosis and Treatment Scheme for Pneumonia of New Coronavirus Infection (Trial Version 6 and Updated)\", and the clinical type was general (including severe high-risk factors) and severe;\r&lt;br&gt; Note: Patients with common new type of coronavirus pneumonia (including severe high-risk factors): patients with common type with multiple lung multiple lesions, or pulmonary imaging shows that the lesion progresses significantly within 50% within 24 to 48 hours;\r&lt;br&gt;3. IL-6 is elevated (Roche chemiluminescence detection is recommended);\r&lt;br&gt;4. The patient voluntarily signed the informed consent.","Inclusion criteria: 1. Intervention group:\r&lt;br&gt;(1) Aged 18 to 50 years;\r&lt;br&gt;(2) Diagnosed as a depression or anxiety by Diagnostic and Statistical Manual of Mental Disorders (DSM-5); the score of HAMD-17&gt;17,or HAMA&gt;7;\r&lt;br&gt;2. Non-intervention group:\r&lt;br&gt;(1) Aged 18 to 50 years;\r&lt;br&gt;(2) Diagnosed as a depression or anxiety by Diagnostic and Statistical Manual of Mental Disorders (DSM-5); the score of HAMD-17&gt;17,or HAMA&gt;7.","Inclusion criteria: All patients hospitalized for novel coronavirus pneumonia in Hwa Mei Hospital, University of Chinese Academy Sciences from January 2020 were enrolled. The subjects were included the confirmed cases following the latest guideline of diagnostic and treatment Covid-19 issued by China Health Committee, and suspected patients admitting in isolation and observation ward during the same study period.","Inclusion criteria: The confirmed patients with common type of new coronavirus pneumonia were selected, and the diagnostic criteria were shown in [diagnosis and treatment scheme 5.0 for pneumonia caused by new coronavirus infection].","Inclusion criteria: (1) aged between 18 and 75 years old;\r&lt;br&gt;(2) Common type patients with confirmed COVID-19 according to the diagnostic criteria of \"novel coronavirus Infection Diagnosis and Treatment Plan (Trial 6th Edition)\" issued by the National Health and Safety Commission;\r&lt;br&gt;(3) Patients and their families voluntarily participated in the study and signed an informed consent form.","Inclusion criteria: 1. Patients who were confirmed diagnosis of COVID-19 pneumonia, according to the \"pneumonia diagnosis and treatment program for novel coronavirus infection (trial version seven)\", including clinical symptoms, pulmonary CT manifestations and positive nucleic acid test;\r&lt;br&gt;2. Patients who admitted to the designated hospitals.","Inclusion criteria: 1. Aged 18 to 80 yrs;\r&lt;br&gt;2. Diagnosed as COVID-19 pneumonia(according to the latest diagnostic criteria of The novel coronavirus pneumonia diagnosis and treatment plan formulated by the State Health Protection Committee)","Inclusion criteria: 1. COVID-19 infection;\r&lt;br&gt;2. Children with kidney injury: Hematuria, Proteinuria, renal dysfunction.","Inclusion criteria: 1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients in Hubei Province;\r&lt;br&gt;2. Aged 18 to 65 years;\r&lt;br&gt;3. The time interval between symptom onset and randomization was within 7 days (the onset of symptom was mainly determined by the time of fever);\r&lt;br&gt;4. Sign the written informed consent before the study.","Inclusion criteria: COVID-19 confirmed that the clinical symptoms of patients disappeared, after imaging examination, virus nucleic acid test, in line with the discharge criteria of convalescent patients.","Inclusion criteria: (1) aged 18-80 years old;\r&lt;br&gt;(2) severe (including critical risk factors) and critical patients with confirmed novel coronavirus pneumonia;\r&lt;br&gt;(3) blood CRP and ESR were more than twice higher than normal or TNFa and Il-6 were higher than normal;\r&lt;br&gt;(4) sign the informed consent.","Inclusion criteria: 1. Those who agree to take part in the test and sign the informed consent form voluntarily;\r&lt;br&gt;2. Adult aged &gt;=18years old, male or female;\r&lt;br&gt;3. The inpatients with mild or common type of COVID-19 confirmed according to the diagnostic criteria \"COVID-19 diagnosis and treatment plan -  Sixth trial edition\" issued by the National Health Commission.\r&lt;br&gt;4. Respiratory Specimens (including but not limited to sputum, nasopharyngeal swab and secretion of lower respiratory tracts) were positive for 2019-ncov nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens were genetically sequenced and highly homologous to known 2019-ncov.","Inclusion criteria: 1. Those who agree to take part in the test and sign the informed consent form voluntarily;\r&lt;br&gt;2. Adults aged &gt;=18years old, male or female;\r&lt;br&gt;3. The inpatients with mild or common type of COVID-19 confirmed according to the diagnostic criteria \"COVID-19 diagnosis and treatment plan -  Sixth trial edition\" issued by the National Health Commission.\r&lt;br&gt;4. Respiratory Specimens (including but not limited to sputum, nasopharyngeal swab and secretion of lower respiratory tracts) are positive for 2019-nCoV nucleic acid by real-time fluorescent RT-PCR; or respiratory specimens are genetically sequenced and highly homologous to known 2019-nCoV.","Inclusion criteria: 1. Aged between 18 and 75 years;\r&lt;br&gt;2. In accordance with NCP criteria for severe and critical illness. Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment;\r&lt;br&gt;3. Will not participate in other drug clinical trials since the first day of Ulinastatin Injection admission;\r&lt;br&gt;4. Will sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian.","Inclusion criteria: 1. Patients who were diagnosed as COVID-19 by nucleic acid test;\r&lt;br&gt;2. ARDS patients according to the Berlin definition.","Inclusion criteria: All patients meet the diagnostic criteria for neo-coronary pneumonia (New Coronavirus Infected Pneumonia Diagnosis and Treatment Program, Fifth Edition)","Inclusion criteria: 1. The patient signs the written informed consent;\r&lt;br&gt;2. Aged 18-80 years;\r&lt;br&gt;3. the novel coronavirus novel coronavirus infection diagnostic criteria for pneumonia, namely, the new coronavirus pneumonia diagnosis and treatment plan (trial version sixth). It conforms to any of the following:\r&lt;br&gt;1) in case of shortness of breath, RR &gt;=30 times / min;\r&lt;br&gt;2) in case of resting state, oxygen saturation &lt;=93%;\r&lt;br&gt;3) in case of arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;=300MMHG (1mmhg = 0.133kpa). PaO2 / FiO2 should be corrected according to the following formula in high altitude (over 1000m above sea level): PaO2 / FiO2 * [atmospheric pressure (mmHg) / 760]; pulmonary imaging showed that in 24-48 hours, patients with obvious progress of lesions &gt; 50% should be treated as severe management;\r&lt;br&gt;4. The course of disease is within 14 days after onset.","Inclusion criteria: 1. Patients who agree to join the study and signed the informed consent;\r&lt;br&gt;2. Aged &gt;16 years old;\r&lt;br&gt;3. Patients with CRP more than twice the upper limit of laboratory test;\r&lt;br&gt;4. The severe or critial patients with COVID-19 according to the sixth edition of guideline for diagnosis and treatment of COVID-19 from national health council;\r&lt;br&gt;5. With renal injury: \r&lt;br&gt;(1) CKD 5 stage;\r&lt;br&gt;(2) Acute kidney injury: increase in SCr by &gt;26.5umol/L within 48 hours; or increase in SCr to &gt;1.5 times baseline; or urine volume &lt;0.5ml/Kg/h for 6 hours.","Inclusion criteria: patients with positive SARS-CoV-2 IgM antibody","Inclusion criteria: Epidemiological history:\r&lt;br&gt;1. History of residence or travel in Hubei province within 14 day before the onset of illness;\r&lt;br&gt;2. Exposure history to resident or traveler in Hubei province within 14 days before the onset of illness.\r&lt;br&gt;Suspected features:\r&lt;br&gt;1. fever;\r&lt;br&gt;2. Lymphopenia;\r&lt;br&gt;3. typical CT pneumonia features.\r&lt;br&gt;Inclusion criteria for cases admitted to the hospital: \r&lt;br&gt;all patients with fever, outpatient, emergency and in-patient.","Inclusion criteria: 1. New-type coronavirus infection is diagnosed as mild or common (diagnosed according to the \"Notice on the Issuance of a New Coronavirus-Infected Pneumonia Diagnosis and Treatment Plan (Trial Implementation of the Sixth Edition)\") or patients with poor immune function (cured discharged patients but peripheral hemolymph Cell count and classification are abnormal).\r&lt;br&gt;2. Aged 18-65 years;\r&lt;br&gt;3. Sign informed consent.","Inclusion criteria: 1. From January 1, 2020 to March 31, 2020, the elderly patients who aged 60 or over were clinically diagnosed as new coronavirus pneumonia by the Guangdong medical team of Hankou hospital, Wuhan city, Hubei province;\r&lt;br&gt;2. From January 1, 2020 to March 31, 2019, the elderly patients who aged 60 years or above were diagnosed with new coronavirus pneumonia by the Guangdong medical team of hankou hospital, Wuhan city, Hubei province (See schedule 1 of the study protocol for details).","Inclusion criteria: Aged 2-65 years, with a BMI of 18-28, who underwent otolaryngological surgery. The patients were ASA grade I-III.","Inclusion criteria: Patients with severe cases of newly diagnosed novel coronavirus pneumonia, aged over 18 years old, meeting the diagnostic criteria for confirmed cases and patients with severe and critical types in the sixth edition of the diagnosis and treatment program for novel coronavirus pneumonia.","Inclusion criteria: Patients with mild/common novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent form","Inclusion criteria: 1. Upon the judgment of the researcher, the subject or his legal representative can understand and comply with the requirements of the program, and voluntarily sign the informed consent;\r&lt;br&gt;2. According to the new type of coronavirus pneumonia diagnosis and treatment scheme (trial version 5) diagnostic criteria, accord with standard of new coronavirus pneumonia confirmed cases, clinical diagnostic criteria for classification to heavy (pneumonia severity index (PSI) III - V level, or arterial blood oxygen partial pressure (PaO2 / oxygen concentration (FiO2) (P/F) 300 mmHg) or less;\r&lt;br&gt;3. Aged 18 to 75 years male or female.","Inclusion criteria: All staff, excluding the internship and probationer, who aged from 18y to 60y and volunteered for this survey, were included in this survey.","Inclusion criteria: 1. Patients with confirmed novel coronavirus-infected pneumonia; \r&lt;br&gt;2. Voluntarily sign written informed consent.","Inclusion criteria: 1. Aged&gt;=18 years old;\r&lt;br&gt;2. Diagnosed as severe and critical patients with novel coronavirus pneumonia;\r&lt;br&gt;3. Being treated in the ICU.","Inclusion criteria: Patients were diagnosed with a new type of coronavirus pneumonia when they were discharged or admitted to the hospital. The diagnostic criteria were based on the New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial) (First to Sixth Edition).","Inclusion criteria: (1) age: 18-75 years old (including threshold), regardless of gender;\r&lt;br&gt;(2) compliance with the pneumonia diagnosis and treatment protocol for novel coronavirus infection - the diagnostic criteria for the trial version 6 (the latest version, which is currently updated to version 6).\r&lt;br&gt;(3) the sixth version of the reference treatment scheme meets the common type standard;\r&lt;br&gt;(4) no participation in traditional health exercise (ba duan jin, tai chi, wu qin xi or other fitness qigong) within 7 days;\r&lt;br&gt;(5) steady gait and clear consciousness;\r&lt;br&gt;(6) patients who agreed to participate in this study and voluntarily signed the informed consent.","Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test","Inclusion criteria: (1) Corresponding to diagnosis standards of convalescence of COVID-19 mentioned above;\r&lt;br&gt;(2) Imaging manifestations Fibrous cable-like shadow (patchy) ground glass changes in the lungs,honeycomb sign,reticular changes, increased bronchovascular shadows, pleural effusion,nodular change, any one or more of the above;\r&lt;br&gt;(3) Aged 18-65 years;\r&lt;br&gt;(4) Signing of informed consent.","Inclusion criteria: 1. Sign the written informed consent;\r&lt;br&gt;2. Aged 18-80 years old;\r&lt;br&gt;3. Meet the diagnostic criteria for novel coronavirus infection(trial version sixth), confirmed by combining with the epidemiological history, clinical manifestations and etiology examination;\r&lt;br&gt;4. Course of disease within 14 days after onset.","Inclusion criteria: (1)Aged &gt;=18 years old, gender unlimited, inpatient;\r&lt;br&gt;(2) Novel coronavirus nucleic acid positive in pharyngeal swab specimen by real-time fluorescent RT-PCR;\r&lt;br&gt;(3) Clinical classification is ordinary or severe patients;\r&lt;br&gt;(4) Informed consent has been signed.","Inclusion criteria: 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;\r&lt;br&gt;2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;\r&lt;br&gt;3) Inpatients aged 18 to 75 years male or female;\r&lt;br&gt;4) Volunteer to receive treatment under their own scheme and sign informed consent.","Inclusion criteria: Suspected cases of neo-coronary pneumonia (outside Hubei province), clinically diagnosed cases (in Hubei province), and light / general confirmed cases, severe/critical confirmed cases, aged 18-70 years, each center enrolls cases in a competitive manner.\r&lt;br&gt;The diagnostic criteria for the new coronavirus pneumonia conform to the diagnostic criteria issued by the National Health and Medical Commission for the diagnosis and treatment of pneumonia in the new coronavirus infection (trial version 5):\r&lt;br&gt;(1) Suspected cases.\r&lt;br&gt;Comprehensively analyze combinations of the following epidemiological history and clinical presentations:\r&lt;br&gt;1.1.1.Epidemiological history\r&lt;br&gt;(1) Within 14 days prior to onset, had history of travel or residence in Wuhan or surrounding regions, or other communities reporting cases;\r&lt;br&gt;(2) Within 14 days prior to symptom onset, having had contact with patients infected with 2019-nCoV (positive nucleic acid test).\r&lt;br&gt;(3) Within 14 days prior to onset, had contact with patients who had a fever or respiratory tract symptoms that had come from Wuhan, its surrounding regions, or other communities reporting cases.\r&lt;br&gt;(4) Clustered onset (Within a span of 2 weeks, 2 or more cases with fever and/or respiratory symptoms appear in a small area, such as a family, an office, or a school class)\r&lt;br&gt;2. Clinical presentations\r&lt;br&gt;(1) Fever and/or respiratory tract symptoms;\r&lt;br&gt;(2) Having the imaging features of novel coronavirus pneumonia discussed above;\r&lt;br&gt;(3) During the early stages of the disease, white blood cell count is normal or reduced, while the lymphocyte count is normal or reduced.\r&lt;br&gt;Where there are any of the epidemiologic history items, and any 2 of the clinical presentions are met.\r&lt;br&gt;Where there is no clear epidemiological history, and at least 3 of the clinical presentations are met.\r&lt;br&gt;(2) Confirmed cases.\r&lt;br&gt;A 2019-nCoV diagnosis is confirmed if the suspected cases also have one of the following etiological or serological evidence.\r&lt;br&gt;1.1.Positive result in real-time fluorescence RT-PCR detection of novel coronavirus nucleic acid;\r&lt;br&gt;2.The sequence of the virus is highly homologues to that of 2019-nCoV.\r&lt;br&gt;3.Specific IgM and IgG antibodies against 2019-nCoV test positive in the serum; IgG antibodies specific to 2019-nCoV test positive after previous negative results, or increased by more than 4 times in the recovery phase compared to the acute phase.\r&lt;br&gt;VI. Clinical classifications\r&lt;br&gt;(1) Mild form.\r&lt;br&gt;Clinical symptoms are minor, imaging does not show signs of lung inflammation.\r&lt;br&gt;(2) Regular form.\r&lt;br&gt;Has fever and respiratory tract symptoms, imaging shows visible lung inflammation.\r&lt;br&gt;(3) Severe form.\r&lt;br&gt;Adults who meet any one of the following:\r&lt;br&gt;1.1.Shortness of breath, RR &gt; 30 breaths/minute; 2. Oxygen saturation &lt; 93% at rest\r&lt;br&gt;2.Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) &lt; 300mmHg (1mmHg=0.133kPa).\r&lt;br&gt;For high altitude (altitude over 1000 meters) regions, (PaO2/FiO2) should be corrected according to the following formula: PaO2/FiO2 x [ atmospheric pressure (mmHg)/760]\r&lt;br&gt;The patient should be managed as a severe case if lung imaging shows a substantial progression of lesions (greater than 50%) within 24-48 hours.\r&lt;br&gt;Children who meet any one of the following:\r&lt;br&gt;1. Show shortness of breath (&lt; 2 months old, RR&gt; 60 times/min; 2~12 months old, RR&gt;50 times/min; 1~5 years old, RR&gt;40 times/min; 55 years old, RR&gt;0 times/min), except the effects of fever and crying;\r&lt;br&gt;2. Oxygen saturation &lt; 92% at rest.\r&lt;br&gt;3. Laboured breathing (wheezing, flaring o","Inclusion criteria: 1. over 18 years old;\r&lt;br&gt;2. Patients diagnosed with Covid-19 pneumonia (those who meet the clinical diagnosis above the common type or have a positive nucleic acid test);\r&lt;br&gt;3. Have 64-row high-resolution CT examination of the chest within 24 hours;\r&lt;br&gt;4. There is no clear history of other cardiopulmonary diseases (such as with COPD, massive pleural effusion, tuberculosis, pulmonary hypertension, severe heart failure, pulmonary heart disease, etc.);\r&lt;br&gt;5. Able to cooperate with lung auscultation and agree to participate in the examination;\r&lt;br&gt;6. Be able to sign informed consent.","Inclusion criteria: 1. Conforming to the Chinese and Western Medicine Diagnostic Standards of patients with novel coronavirus pneumonia (COVID-19) in recovery period;\r&lt;br&gt;2. Aged between 18 and 65 years old;\r&lt;br&gt;3. Signing the generalized informed consent form (The intervention objects is incorporated in the clinical study as desired).","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;\r&lt;br&gt;2. Voluntarily sign written informed consent.","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;\r&lt;br&gt;2. Voluntarily sign written informed consent.","Inclusion criteria: Subjects who meet the all of the following criterion to be elegiable for this study:\r&lt;br&gt;1. Meet the requirements of the \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)\";\r&lt;br&gt;2. Aged 18 to 65 years male or female; \r&lt;br&gt;3. The interval from the onset of symptoms to enrollment is within 7days: onset of symptoms is defined as onset of at least one systematic symtom(such as fever(temperature&gt;=37.3 degree C) or shivering,headache,hypodynamia,muscle pain or joint pain) or respiratory symptom(such as cough,pharyngodynia,nasal obstruction,rhinorrhea);\r&lt;br&gt;4. Agree to participate in this study and write informed content.","Inclusion criteria: 1. Patients who meet the requirements of the New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);\r&lt;br&gt;2. Aged 18-75 years male or female;\r&lt;br&gt;3. Serious patient meet one of the following:\r&lt;br&gt;(1) respiratory distress wiht respiratory rate &gt;=30 breaths/min;\r&lt;br&gt;(2) oxygen saturation&lt;=93% on quiet status;\r&lt;br&gt;(3) Arterial partial pressure of oxygen(PaO2)/oxygen concentration&lt;=300mmHg;\r&lt;br&gt;4. critically ill patients meet one of the following:\r&lt;br&gt;(1) Experience respiratory failure and need to receive mechanical ventilation;\r&lt;br&gt;(2) Experience shock;\r&lt;br&gt;(3) Complicated with other organs failure and need intensive care and therapy in ICU;\r&lt;br&gt;5. Agree to particapate this study and write the informed consent.","Inclusion criteria: 1. Meet the requirements of the \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)\";\r&lt;br&gt;2. Aged 18 to 65 years male or female; \r&lt;br&gt;3. The interval from the onset of symptoms to enrollment is within 7days: onset of symptoms is defined as onset of at least one systematic symtom(such as fever(temperature&gt;=37.3 degree C) or shivering,headache,hypodynamia,muscle pain or joint pain) or respiratory symptom(such as cough,pharyngodynia,nasal obstruction,rhinorrhea);\r&lt;br&gt;4. Agree to participate in this study and write informed content.","Inclusion criteria: Confirmed or suspected case of COVID-19 in Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.\r&lt;br&gt;1. Aged between 18-85 years old;\r&lt;br&gt;2. Patients with newly diagnosed and suspected COVID-19;\r&lt;br&gt;3. Willing and able to sign informed consent;\r&lt;br&gt;4. Before having breakfast in the morning.","Inclusion criteria: 1. The patient signed an informed consent form to participate in the study of convalescent plasma therapy;\r&lt;br&gt;2. patient aged &gt;=18 years old;\r&lt;br&gt;3. COVID-19 patients diagnosed by PCR;\r&lt;br&gt;4. Nucleic acid positive within 72 hours before blood transfusion;\r&lt;br&gt;5. Pneumonia confirmed by imaging; \r&lt;br&gt;6. Hospitalization for the following reason:\r&lt;br&gt;Fever: axillary temperature&gt;=36.7 degree C, or oral temperature&gt;=38.0 degree C, or anal or ear temperature=38.6 ?\r&lt;br&gt;And respiratory rate&gt; 24 beats / min or cough (at least one of the two);\r&lt;br&gt;7. There are severe clinical warning indicators: such as a progressive decrease in peripheral blood lymphocytes, a progressive increase in peripheral blood inflammatory factors, a progressive increase in lactic acid, and rapid progress of lung lesions in the short term, et al.\r&lt;br&gt;8. Accept random grouping into any group;\r&lt;br&gt;9. The patient was hospitalized before the end of the clinical study.\r&lt;br&gt;10. Willing to participate in all necessary research directions and be able to participate in follow-up;\r&lt;br&gt;11. During the period of participating in this study, they will no longer participate in clinical trials such as other antiviral drugs.","Inclusion criteria: 1. Medical staff of designated hospitals for new crown pneumonia in Ningbo area;\r&lt;br&gt;2. Patients with new-coronary pneumonia infection, suspected cases, patients in fever observation ward, forced isolation and home isolation in Ningbo area;\r&lt;br&gt;3. Medical staff and staff entering isolation ward and fever observation ward;\r&lt;br&gt;4. Medical staff and staff who went to Wuhan to participate in the aid of Hubei to fight the epidemic;\r&lt;br&gt;5. Family members of medical staff involved in fighting the epidemic;\r&lt;br&gt;6. Ordinary people participating in this survey.","Inclusion criteria: 1. patients diagnosed as malignant tumor by pathology or cytology inpatient or outpatient in general hospital during the outbreak of 2019-nCOV;\r&lt;br&gt;2. aged 18 or above;\r&lt;br&gt;3. informed consent and ability to cooperate with research.","Inclusion criteria: 1. Children aged 0-18 years and met the guideline for the diagnosis and treatment of COVID-19;\r&lt;br&gt;2. Agreed to participant in the study;\r&lt;br&gt;3. Can cooperate with the later on follow-up.","Inclusion criteria: 1. Compliance with NCP diagnostic criteria; \r&lt;br&gt;2. Aged &gt;=18 years.","Inclusion criteria: 1. Compliance with NCP diagnostic criteria;\r&lt;br&gt;2. Aged &gt;=18 years.","Inclusion criteria: Refer to the National Health and Health Commission's \"Diagnosis and Treatment Plan for New Coronavirus Infected Pneumonia (Trial Version 5)\" (hereinafter referred to as \"Diagnosis and Treatment Plan\") to confirm the diagnosis of adult patients with new coronavirus infection.","Inclusion criteria: 1. Male or female aged 18-80 years old;\r&lt;br&gt;2. Patients with confirmed novel coronavirus-infected pneumonia;\r&lt;br&gt;3. Diagnosed as moderate cases of COVID-19 with fever and respiratory symptoms and image showing pneumonia;\r&lt;br&gt;4. Voluntarily sign written informed consent.","Inclusion criteria: 2020.01.01 Patients who have tested positive for new coronavirus in our hospital","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. = 18 years old;\r&lt;br&gt;\r&lt;br&gt;          2. Diagnosed as serious or critical SARI (according to the 4th version of Diagnosis and\r&lt;br&gt;             Clinical management of 2019-nCoV infected pneumonia);\r&lt;br&gt;\r&lt;br&gt;          3. Being treated in the ICU.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Allergic to vitamin C;\r&lt;br&gt;\r&lt;br&gt;          2. Dyspnea due to cardiogenic pulmonary edema;\r&lt;br&gt;\r&lt;br&gt;          3. Pregnant or breastfeeding;\r&lt;br&gt;\r&lt;br&gt;          4. Expected life is less than 24 hours;\r&lt;br&gt;\r&lt;br&gt;          5. There is a state of tracheotomy or home oxygen therapy in the past;\r&lt;br&gt;\r&lt;br&gt;          6. Previously complicated with end-stage lung disease, end-stage malignancy,\r&lt;br&gt;             glucose-6-phosphate dehydrogenase deficiency, diabetic ketoacidosis, and active kidney\r&lt;br&gt;             stone disease;\r&lt;br&gt;\r&lt;br&gt;          7. The patient participates in another clinical trial at the same time.\r&lt;br&gt;","Inclusion criteria: High-risk population including medical staff on duty during the outbreak of 2019-nCoV pneumonia.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  confirmed mild COVID-19 (NEWS scoring system 0-4)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  unable to take oral medication\r&lt;br&gt;\r&lt;br&gt;          -  pregnancy or breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  immunocompromised patients\r&lt;br&gt;\r&lt;br&gt;          -  creatinine clearance (CCL) &lt; 30 mL/min\r&lt;br&gt;\r&lt;br&gt;          -  aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 5 times Upper limit of\r&lt;br&gt;             normal (ULN)\r&lt;br&gt;","Inclusion criteria: (1) diagnosed as a mild and common type of the new coronavirus pneumonia, meeting the diagnostic criteria of the new coronavirus pneumonia diagnosis plan (trial version 6), both male and female;\r&lt;br&gt;(2) aged 14 to 70 years old;\r&lt;br&gt;(3) body temperature &gt; 37.3 degree C; \r&lt;br&gt;(4) understand the nature, significance, possible benefits, inconvenience and potential dangers of the test in detail before the test;\r&lt;br&gt;(5) understand the study procedure and voluntarily sign the written informed consent (signed by both the patient and the legal guardian for the minor patient).","Inclusion criteria: 1. Aged 18 to 65 years old, both male and female;\r&lt;br&gt;2. The eligible subjects (male and female) with fertility must agree to take effective contraceptive measures from the beginning of self-sufficiency with their partners to 6 months after drug withdrawal;\r&lt;br&gt;3. Novel coronavirus pneumonia diagnosis novel coronavirus pneumonia novel coronavirus pneumonia diagnosis and treatment plan (latest edition) is confirmed;\r&lt;br&gt;4. Drugs without chloroquine and its derivatives within three months;\r&lt;br&gt;5. Sign the informed consent.","Inclusion criteria: 1. Aged 18 to 70 years old;\r&lt;br&gt;2. Patients with pneumonia infected by new coronavirus: confirmed cases in compliance with the Diagnosis and Treatment Plan for Pneumonia Infected by New Coronavirus (Sixth Edition);\r&lt;br&gt;3. Confirmed cases who can be transfused into anti-SARS-CoV-2 virus inactivated plasma after fully assessing patients condition; \r&lt;br&gt;4. Cases who score 3 or 4 according to 6-grade scale;\r&lt;br&gt;5. The subjects and/or their legal guardians voluntarily participated in the study and voluntarily signed an informed consent form.","Inclusion criteria: 1. Aged&gt;=18 years old;\r&lt;br&gt;2. Diagnosed as severe and critical patients with novel coronavirus pneumonia;\r&lt;br&gt;3. Being treated in the ICU.","Inclusion criteria: 1. Common inpatient, volunteer and fever patient;\r&lt;br&gt;2. Patients who are older than 12 years, gender unlimited;\r&lt;br&gt;3. Consenting or the guardian of a minor is willing to participate in this trial and will sign the informed consent.","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;\r&lt;br&gt;2. Voluntarily sign written informed consent.","Inclusion criteria: 1. Patients with confirmed new coronavirus-infected pneumonia;\r&lt;br&gt;2. Voluntarily sign written informed consent.","Inclusion criteria: Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)\"","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Age = 18, age = 75, gender unlimited;\r&lt;br&gt;\r&lt;br&gt;          -  2. novel coronavirus diagnosed severe pneumonia and confirmed no effective treatment\r&lt;br&gt;             plan. (severe patients meet any of the following: (1) respiratory distress, RR &gt; 30\r&lt;br&gt;             times / minute; (2) resting state, oxygen saturation is less than 93%; (3) arterial\r&lt;br&gt;             oxygen partial pressure (PaO2) / oxygen inhalation (FiO2) is less than 300 mmHg (1mm\r&lt;br&gt;             Hg=0.133 kPa).\r&lt;br&gt;\r&lt;br&gt;          -  3. Those who voluntarily participate in the clinical study and can cooperate with\r&lt;br&gt;             researchers to carry out the study, and the patients themselves or their legal\r&lt;br&gt;             representatives voluntarily sign the informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Patients with autoimmune diseases in the past or screening;\r&lt;br&gt;\r&lt;br&gt;          -  2. Those who have serious basic diseases that affect their survival, including:\r&lt;br&gt;             malignant tumor, hematopathy, malignant fluid, active hemorrhage, severe malnutrition,\r&lt;br&gt;             etc. which have not been controlled and can not be removed due to multiple metastasis;\r&lt;br&gt;\r&lt;br&gt;          -  3. Known or self-reported HIV or syphilis infected persons;\r&lt;br&gt;\r&lt;br&gt;          -  4. Have participated in stem cell clinical research;\r&lt;br&gt;\r&lt;br&gt;          -  5. Pregnant or lactating women or those who have fertility plans in the past year;\r&lt;br&gt;\r&lt;br&gt;          -  6. The estimated life cycle is less than 48 hours;\r&lt;br&gt;\r&lt;br&gt;          -  7. Those who participated in other clinical trials within 3 months before screening;\r&lt;br&gt;\r&lt;br&gt;          -  8. Other conditions that the researcher thinks are not suitable for participating in\r&lt;br&gt;             the experiment.\r&lt;br&gt;","Inclusion criteria: Patinets diagnosed with COVID-19 according to Diagnosis and treatment of novel coronavirus pneumonia (trial version sixth)","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Anyone volunteer to participate\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Anyone non-voluntary to participate\r&lt;br&gt;","Inclusion criteria: COVID-19 patient","Inclusion criteria: Pregnant women confirmed with COVID-19 and admitted in our department from February,2020 to August, 2020","Inclusion criteria: (1) Patients aged 18-80 years;\r&lt;br&gt;(2) Clear diagnosis of patients with severe COVID-19;\r&lt;br&gt;(3) Voluntarily join the trial and sign the informed consent.","Inclusion criteria: (1) Fever patients;\r&lt;br&gt;(2) peoples who need to screen the novel coronavirus;\r&lt;br&gt;(3) patients for possible infection with novel coronavirus through High throughput sequencing of pathogens;\r&lt;br&gt;(4) Age and gender are not limited;\r&lt;br&gt;(5) Patients has been diagnosed with 2019-nCoV pneumonia according to the latest version of 2019-nCoV pneumonia management guideline made by the national health commission of the People's Repulic of China.","Inclusion criteria: We recruited patients with positive real-time RT-PCR results who were admitted to Xiangyang No.1 Peoples Hospital before February 9th, 2020.","Inclusion criteria: (1) To include confirmed, suspected and clinically diagnosed cases according to the fifth edition of the diagnosis and treatment guidelines for COVID-19 issued by the national health and construction commission;\r&lt;br&gt;(2) Among the patients included in the general outpatient and emergency department, CT findings suggested cases of viral pneumonia.","Inclusion criteria: 1. Aged 11-18 years middle school students;\r&lt;br&gt;2. GAD-7 score above 10;\r&lt;br&gt;3. willing to participate this study and receive their legal guardian's informed consent;\r&lt;br&gt;4. Have stable internet and quiet space to receive internet based counseling.","Inclusion criteria: Positive result in nucleic acid test, medical diagnosis is Corona Virus Disease 2019","Inclusion criteria: (1) Patients with mild, common, and severe neocoronary pneumonia; \r&lt;br&gt;(2) Those who meet the diagnostic criteria for insomnia with traditional Chinese medicine; \r&lt;br&gt;(3) Those who meet the diagnostic criteria for insomnia with western medicine; \r&lt;br&gt;(4) Those aged 18-75 years; \r&lt;br&gt;(5) Agree to receive treatment, and the patient or legal guardian signs the information through mobile phone software and voice authorization Consent; \r&lt;br&gt;(6) During this period, the patient did not take drugs and other treatments for the disease, or the drug dose did not increase based on the original treatment.","Inclusion criteria: (1) aged 18-60 years;\r&lt;br&gt;(2) BMI in the normal range (1+/-20%);\r&lt;br&gt;(3) diagnosis of lung cancer, breast cancer, cervical cancer, colorectal cancer, with surgical indications, no distant metastasis;\r&lt;br&gt;(4) ASA grade I-II;\r&lt;br&gt;(5) no thymosin A1, Chinese Medicine (Bazhen Tang) use contraindications;\r&lt;br&gt;(6) before the test, the patients or their legal representatives understand and voluntarily sign the ethics Informed consent approved by the Committee.","Inclusion criteria: 1. Aged &gt;14years old;\r&lt;br&gt;2. The diagnosis conforms to the \"Diagnosis and Treatment Plan for Pneumonia Infected in novel coronavirus\"","Inclusion criteria: Severe patients diagnosed with novel coronavirus pneumonia (COVID-19) in Huanggang City, and admitted to the Dabie mountain regional treatment center in huanggang from Jan.28th,2020 to Mar.12th,2020.","Inclusion criteria: (1) all patients with clearly diagnosed NCP who voluntarily receive treatment and do not participate in other clinical trials;\r&lt;br&gt;(2) aged &gt;=18 years, approved by the ethics committee, fully understand and sign the informed consent.","Inclusion criteria: 1. patients who meet the requirements of the \"diagnosis and treatment plan for pneumonia caused by novel coronavirus infection (the fourth edition)\" issued by the general office of the national health commission;\r&lt;br&gt;2. patients with severe hypoxic respiratory failure treated with ECMO.","Inclusion criteria: 1. Patients diagnosed with new coronavirus pneumonia and in need of hospitalization: they meet the diagnostic criteria of the diagnosis and treatment program for new coronavirus pneumonia (trial fifth edition) issued by the national health commission;\r&lt;br&gt;2. Pneumonia with novel coronavirus confirmed by aetiological nucleic acid test;\r&lt;br&gt;3. Aged 18 to 80 years;\r&lt;br&gt;4. Sign the informed consent;\r&lt;br&gt;5. VTE score was greater than or equal to 4, and there were no higher blood risk factors.","Inclusion criteria: 1. Patients diagnosed with COVID-19;\r&lt;br&gt;2. Aged older than 18 years.","Inclusion criteria: (1) Patients with novel coronavirus pneumonia in Wuhan Hankou Hospital\r&lt;br&gt;(2) Patients with novel coronavirus pneumonia in Wuhan Huoshenshan Hospital\r&lt;br&gt;(3) Patients meet the clinical suspicion and diagnosis of new type of coronavirus pneumonia (diagnostic criteria refer to the trial version 7 diagnosis and treatment program of novel coronavirus pneumonia) and aggregate cases;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  admission to ICU\r&lt;br&gt;\r&lt;br&gt;          -  adult (=18 years old)\r&lt;br&gt;\r&lt;br&gt;          -  confirmed case of 2019-nCov infection by 2019-nCov RNA by reverse transcription\r&lt;br&gt;             polymerase chain reaction , isolation in cell culture of 2019-nCov from a clinical\r&lt;br&gt;             specimen or serum antibody to 2019-nCov\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - none\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Healthy and Covid-19-positive volunteers\r&lt;br&gt;\r&lt;br&gt;          -  The interval between the onset of symptoms and randomized is within 7 days in Covid-19\r&lt;br&gt;             patients. The onset of symptoms is mainly based on fever. If there is no fever, cough\r&lt;br&gt;             or other related symptoms can be used;\r&lt;br&gt;\r&lt;br&gt;          -  White blood cells = 3,500/l, lymphocytes = 750/l;\r&lt;br&gt;\r&lt;br&gt;          -  Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)\r&lt;br&gt;             or tuberculosis (TB) test negative;\r&lt;br&gt;\r&lt;br&gt;          -  Sign the Informed Consent voluntarily;\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Subject with active HCV, HBV or HIV infection.\r&lt;br&gt;\r&lt;br&gt;          -  Subject is albumin-intolerant.\r&lt;br&gt;\r&lt;br&gt;          -  Subject with life expectancy less than 4 weeks.\r&lt;br&gt;\r&lt;br&gt;          -  Subject participated in other investigational vaccine therapies within the past 60\r&lt;br&gt;             days.\r&lt;br&gt;\r&lt;br&gt;          -  Subject with positive pregnancy test result.\r&lt;br&gt;\r&lt;br&gt;          -  Researchers consider unsuitable.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with novel coronavirus pneumonia should be examined and diagnosed by CT and\r&lt;br&gt;             swab test of viral nucleic acid.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who should have died during the course of the disease, but the cause of death\r&lt;br&gt;             was unrelated to viral pneumonia.\r&lt;br&gt;\r&lt;br&gt;          -  Suspected patient review refers to the negative nucleic acid test.\r&lt;br&gt;","Inclusion criteria: All patients hospitalized for novel coronavirus pneumonia in Hwa Mei Hospital, University of Chinese Academy Sciences from January 2020 were enrolled. The subjects were included the confirmed cases following the latest guideline of diagnostic and treatment Covid-19 issued by China Health Committee, and suspected patients admitting in isolation and observation ward during the same study period.","Inclusion criteria: 1. Patients diagnosed with COVID-19 [in accordance with the diagnostic criteria of the Notice on Printing and Distributing COVID-19 Diagnosis and Treatment Plan (Trial Implementation Version 6th) issued by the National Health and Medical Commission], and meets the discharge criterion;\r&lt;br&gt;2. Aged 18 to 75 years old;\r&lt;br&gt;3. Be consious;\r&lt;br&gt;4. Volunteer to participate in the study and sign the informed consent form, and be able to understand, receive rehabilitation guidance and implement it.","Inclusion criteria: Patients with COVID-19 confirmed by CDC","Inclusion criteria: 1. Diagnosed COVID-19 patients;\r&lt;br&gt;2. Suspending COVID-19 patients.","Inclusion criteria: Patients diagnosed with new coronavirus pneumonia","Inclusion criteria: 1. Aged 18 to 80 years old;\r&lt;br&gt;2. Patients diagnosed with novel coronavirus pneumonia (COVID-19);\r&lt;br&gt;3. Patients &gt;=21 days since the first symptoms ;\r&lt;br&gt;4. The diagnosis of pulmonary fibrosis is based on the chest CT (such as fibrotic changes in multiple lungs with patchy ground glass or with consolidation, lobular septal thickening, grid, stripe shadow, etc.) or other examination results;\r&lt;br&gt;5. The subject must meet at least one of the following two criteria:\r&lt;br&gt;(1) Pulmonary function examination, showing restricted ventilation dysfunction and / or impaired gas exchange, FVC &lt;80% predicted value, FEV1 / FVC&gt; 70%, DLCO &lt;80% predicted value;\r&lt;br&gt;(2) Shortness of breath after exercise or need oxygen therapy support;\r&lt;br&gt;6. Voluntarily participate in this study, agree to comply with the requirements of the clinical research protocol, and sign an informed consent.","Inclusion criteria: 1. Patients who have been diagnosed as COVID-19 according to The Diagnosis and Treatment Plan for 2019-nCoV(The Fifth Trial Edition);\r&lt;br&gt;2. aged between 18 to 80 years old, male or female;\r&lt;br&gt;3. the subjects participating the clinical trial are voluntary and sign the informed consent, thoroughly informed the purpose, method, possible reaction.","Inclusion criteria: (1) Aged 18 to 65 years old;\r&lt;br&gt;(2) Patients with mild or normal type who have been diagnosed with new type of coronavirus infection [in accordance with the diagnostic criteria of the Notice on Printing and Distributing New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Implementation) issued by the National Health and Medical Commission];\r&lt;br&gt;(3) According to the National Health and Health Commission's antiviral treatment for more than 10 days, the COVID-19 nucleic acid examination of the throat swabs/putum /stool samples was still positive or weakly positive.","Inclusion criteria: 1. Aged between 18 and 60 years;\r&lt;br&gt;2. Able to understand the content of informed consent and willing to sign the informed consent;\r&lt;br&gt;3. Able and willing to complete all the secluded study process during the whole follow-up period of 6 months.\r&lt;br&gt;4. Negative in HIV diagnostic test;\r&lt;br&gt;5. Negative in serum antibodies (IgG and IgM) screening of COVID-19.\r&lt;br&gt;6. Normal in lung CT images (no imaging features of COVID-19);\r&lt;br&gt;7. Axillary temperature &lt;=37.0 degree C;\r&lt;br&gt;8. The BMI index 18.5-30.0;\r&lt;br&gt;9. Negative in Nasopharyngeal swabs / sputum and anal swabs through RTPCR;\r&lt;br&gt;10. Laboratory tests such as hematological examination and clinical biochemistry examination are in the normal range or without meaning judged by clinical doctor;\r&lt;br&gt;11. General good health as established by medical history and physical examination.","Inclusion criteria: 1. Patients who were diagnosed with novel coronavirus pneumonia by the nucleic acid test;\r&lt;br&gt;2. Patients who agreed to enrollment.","Inclusion criteria: 1. novel coronavirus pneumonia confirmed patients, and clinical classification is common, heavy or severe;\r&lt;br&gt;2. Willing to participate in rapid immunoassay research.","Inclusion criteria: Hospitalized patients with COVID19","Inclusion criteria: 1. Patients with COVID-19 infection that meet the diagnostic criteria of \"the 5th edition Pneumonitis diagnosis and treatment guideline for COVID-19 infection of China\";\r&lt;br&gt;2. Age- and sex-matched normal people and patients with influenza A and B.","Inclusion criteria: Meet the criteria for confirmed cases in the \"Diagnosis and Treatment of New Coronavirus Pneumonia (Trial Version 7)\" issued by the National Health and Health Committee of the People's Republic of China:\r&lt;br&gt;1. clinical manifestations:\r&lt;br&gt;(1) fever and / or respiratory symptoms;\r&lt;br&gt;(2) It has the imaging characteristics of new coronavirus pneumonia;\r&lt;br&gt;(3) The total number of white blood cells is normal or decreased, and the lymphocyte count is decreased in the early stage of onset. \r&lt;br&gt;2. Etiological evidence is available:\r&lt;br&gt;(1) real-time fluorescent RT-PCR detection of new coronavirus nucleic acid positive;\r&lt;br&gt;(2) viral gene sequencing, which is highly homologous with known new coronaviruses.","Inclusion criteria: 1. Male and female aged 18-75 years old;\r&lt;br&gt;2. Patients previously diagnosed with COVID-2019: the course of illness is no more than 14 days;If the course of disease was more than 14 days, patients meeting one of the following conditions could also be included:\r&lt;br&gt;(1) no obvious absorption or progression of chest lesions within 7 days;\r&lt;br&gt;(2) respiratory symptoms (chest tightness, or cough, or breathing difficulties); Nucleic acid positive within 3 days\r&lt;br&gt;3. sign the informed consent;\r&lt;br&gt;4. Agree to collect clinical samples;\r&lt;br&gt;5. Female or male subjects of childbearing age agree to take effective contraceptive measures within 3 months of the last oral medication to ensure that female or male partners of childbearing age are not pregnant.","Inclusion criteria: 1. Pharyngeal swabs and / or anal swab specimens are positive for new coronavirus nucleic acids, or viral gene sequencing is highly homologous to known new coronaviruses;\r&lt;br&gt;2. Males and females aged 18 to 85 years;\r&lt;br&gt;3. Participants should fully understand the purpose, nature, methods and possible complications of the trial, volunteer to participate in this study and sign the informed consent.","Inclusion criteria: (1) Aged 18 years or older; \r&lt;br&gt;(2) Voluntarily signed informed consent;\r&lt;br&gt;(3) Hospitalized patients diagnosed as COVID-19.","Inclusion criteria: Common and severe new coronavirus pneumonia","Inclusion criteria: 1. Eligible patients were adults ((aged 18-80 years);\r&lt;br&gt;2. Were identified as laboratory-confirmed 2019-nCoV infection;\r&lt;br&gt;3. Those who need intubation in ICU, and with no severe hypoxemia.","Inclusion criteria: (1) Medical staff in Hubei province;\r&lt;br&gt;(2) People aged between 18 and 65 years old;\r&lt;br&gt;(3) People have electronic social software such as WeChat, QQ and Email.","Inclusion criteria: (1) The patients with covid-19 were diagnosed;\r&lt;br&gt;(2) CT was positive for the first time.","Inclusion criteria: 1. Aged 18 to 70 years old, inpatients, male or female;\r&lt;br&gt;2. Patients with severe COVID-19: confirmed cases shall be in compliance with guideline of \"Diagnosis and Treatment Plan for COVID-19 (Version 7)\" or updated versions.Confirmed cases can be defined if suspected cases have characteristic of following pathogeny or serology:\r&lt;br&gt;1) Detect nucleic acid of novel coronavirus positive by real-time fluorescence RT-PCR;\r&lt;br&gt;2) Have highly homologous to known novel coronavirus by sequencing;\r&lt;br&gt;3) Detect sero specific lgM and lgG positive; IgG specific against new coronavirus positive conversion or the titer of IgG is 4 times higher in convalescent period than in acute period;\r&lt;br&gt; Adult patients with severe COVID-19 shall meet any of the following:\r&lt;br&gt;1) Respiratory distress, RR&gt;=30 times / minute;\r&lt;br&gt;2) In the resting state, the oxygen saturation is &lt;=93%;\r&lt;br&gt;3) For lung radiology, the lesion has obtained more than 50% obvious improvement within 24-48 hours;\r&lt;br&gt;4) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;=300 mmHg (1mm Hg = 0.133 kPa);\r&lt;br&gt;3. Subjects and / or legal guardians of the subjects volunteered to participate in the study and voluntarily signed informed consent.","Inclusion criteria: 1. Aged &gt;=18 years old;\r&lt;br&gt;2. The person, who is diagnosed as COVID-19 according to the 'Diagnosis and treatment of novel coronavirus pneumonia (trial edition 5)', is treated with de-isolation and meets hospital discharge criteria:\r&lt;br&gt;Temperature returned to normal over 3 days, respiratory symptoms improved obviously, two consecutive respiratory tract pathogenic nucleic acid detection negative (sampling time interval at least 1 day), can be removed from isolation and discharged or transferred to the corresponding department to treat other diseases;\r&lt;br&gt;3. The gastrointestinal structure and function of the patient are permitted and can be used safely and should be actively supported by enteral nutrition.","Inclusion criteria: 1. Female patients aged &gt;=18 years who were of childbearing years were excluded from pregnancy and agreed to use non-drug contraceptive measures during the study period;\r&lt;br&gt;2. SARS-CoV-2 nucleic acid test positive;\r&lt;br&gt;3. Lung CT examination showed evaluable lesions;\r&lt;br&gt;4. Meet the diagnostic criteria for severe or critical illness in the diagnosis and treatment program for new coronavirus pneumonia (trial version 6);\r&lt;br&gt;5. Subjects voluntarily participate in the study and sign the informed consent.","Inclusion criteria: 1) Those who have close contact with patients with novel coronavirus pneumonia;\r&lt;br&gt;2) Be over 18 years old (including 18 years old);\r&lt;br&gt;3) Voluntarily sign written informed consent.","Inclusion criteria: 1. Patients are eligible for inclusion if they meet all of the following criteria within 5-7 days after the first admission to the ICU.\r&lt;br&gt;2. The patients met the diagnostic criteria of 2019-nCoV pneumonia (new coronavirus infection) pneumonia treatment plan (Fifth version), the National Health Office [2020] No.103.;\r&lt;br&gt;3. The primary disease is 2019 nCoV infection;\r&lt;br&gt;4. Respiratory distress, RP &gt;=30 times/unit;\r&lt;br&gt;5. Under resting state, blood oxygen saturation &lt;=93%;\r&lt;br&gt;6. PaO2 / FiO2 &lt;=300nnhg (1mmhg = 0.133kpa);\r&lt;br&gt;7. Imaging data suggest bilateral lesions\r&lt;br&gt;8. Volunteer to participate in clinical research, understand and sign informed consent.","Inclusion criteria: A novel coronavirus infection was treated in 191 hospitals in Wuhan Third Hospital from January 21, 2020 to February 20, 2020. Among them, 83 cases were common group, 20 cases were severe group, 43 cases were critical group, 45 cases were death group, 50 healthy people were selected as healthy control group, blood routine test and C reactive protein (CRP) were detected.","Inclusion criteria: 1. novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV and the Chinese medicine authority;\r&lt;br&gt;2. No contraindications for MR examination;\r&lt;br&gt;3. understand the potential risks / benefits, patients or guardians agree to participate in the study, understand all the study procedures, agree  the plan of follow-up.","Inclusion criteria: 1. Patients diagnosed as malignant tumor by pathology are admitted to tertiary general hospital, which is a designated hospital for admission to COVID-19;\r&lt;br&gt;2. Stay in hospital for 3 days or more;\r&lt;br&gt;3. Aged 18 or above;\r&lt;br&gt;4. Informed consent and ability to cooperate with research.","Inclusion criteria: o be enrolled, all the following criteria must be met:\r&lt;br&gt;1) the confirmed patient (or legal guardian) agrees to participate in the study and signs the informed consent;\r&lt;br&gt;2) Aged 18-65 years, gender not limited;\r&lt;br&gt;3) the time interval between symptom onset and random enrollment was within 8 days (symptom onset was mainly determined by the time of fever);\r&lt;br&gt;4) real-time fluorescence rt-pcr detection of respiratory tract or blood samples in patients with positive nucleic acid of novel coronavirus;\r&lt;br&gt;5) diagnosis of mild, common or severe cases according to the diagnosis and treatment plan for pneumonia caused by novel coronavirus (trial version 5):\r&lt;br&gt;A. Mild: the clinical symptoms were mild, and no pneumonia was found on imaging;\r&lt;br&gt;B. Common type: symptoms such as fever and respiratory tract, and manifestations of pneumonia can be seen on imaging;\r&lt;br&gt;C. Heavy: meets any of the following:\r&lt;br&gt;A. respiratory distress, respiratory frequency &gt;= 30 times/min;\r&lt;br&gt;B. At rest, oxygen saturation (SaO2) &lt;= 93%;\r&lt;br&gt;C. Arterial partial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;= 300mmHg.","Inclusion criteria: (1) aged 18 to 70 years;\r&lt;br&gt;(2) Light and heavy patients with new coronavirus infection confirmed by etiology.","Inclusion criteria: 1) &gt; 18 years of age;\r&lt;br&gt;2) identify the patients infected with the new coronavirus pneumonia;\r&lt;br&gt;3) the patient completes CT examination;\r&lt;br&gt;4) sign the informed consent.","Inclusion criteria: 1. Pharyngeal swabs are used to detect the positive nucleic acid of the novel coronavirus, or the virus gene sequencing is highly homologous with the known novel coronavirus;\r&lt;br&gt;2. Ages between 18 to 85 years male or female;\r&lt;br&gt;3. Subjects should fully understand the purpose, nature, methods and reactions of the experiment, voluntarily participate in the study and sign the informed consent.","Inclusion criteria: Viral nucleic acid test positive","Inclusion criteria: 1. Aged 18 years old and above;\r&lt;br&gt;2. Meet the novel coronavirus pneumonia (COVID-19) diagnostic criteria. The upper and lower respiratory tract RT-PCR confirmed that 2019-nCoV nucleic acid positive, chest CT imaging examination could be used in conjunction;\r&lt;br&gt;3. SaO2/SpO2=94% under indoor air, or PaO2/FiO2&lt;300mgHg (for severe type patients);\r&lt;br&gt;4. Sign informed consent;\r&lt;br&gt;5. Do not participate in the clinical study of other study drugs within 28 days.","Inclusion criteria: &lt;br&gt;- Women and men with documented respiratory infection with Coronavirus SARS CoV 2\r&lt;br&gt;- Teenager girls and boys aged more than 12 years old\r&lt;br&gt;- Persons who have given their free and informed consent and have signed the written form.\r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: 5&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 10&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 10&lt;br&gt;","Inclusion criteria: see study arms","Inclusion criteria: Patients with highly suspected or confirmed COVID-19 who are candid for hospitalization and starting triple-drug combination.","Inclusion criteria: Laboratory-confirmed COVID-19 cases (2019-nCoV Real-Time RT-PCR ), regardless of the clinical manifestations and history of close contact&lt;br&gt;Both the men and women, aged between 18 to 65 years old&lt;br&gt;Signing informed written consent&lt;br&gt;Highly suspected cases of COVID-19 based on positive findings of chest CT scan","Inclusion criteria: Patients with highly suspected or confirmed COVID-19 infection who are candid forhospitalized and starting triple-drug combination","Inclusion criteria: Positive PCR test for Coronavirus (SARS-COV2)&lt;br&gt;CT Scan finding","Inclusion criteria: Laboratory confirmed COVID-19  with RT-PCR&lt;br&gt;Respiratory rate &gt; 30/min&lt;br&gt;Oxygen saturation &lt; 90%&lt;br&gt;PaO2/FiO2 &lt; 300mmHg","Inclusion criteria: Patients with highly suspected diagnosis of COVID-19&lt;br&gt;Patients with confirmed diagnosis of  COVID-19&lt;br&gt;Patients who are candid for hospitalization&lt;br&gt;Patients  who are candid for starting triple-drug combination","Inclusion criteria: Both genders&lt;br&gt;Age =18 years at time of signing Informed Consent Form&lt;br&gt;Willing and able to provide written informed consent prior to performing study to any assigned treatment arm&lt;br&gt;Must agree not to enroll in another study of an investigational agent prior to completion of study&lt;br&gt;Will be admitted to Shariati hospital and not transferred to another hospital&lt;br&gt;Laboratory (RT-PCR) confirmed infection with 2019-nCoV&lt;br&gt;Lung involvement confirmed with chest CT scan&lt;br&gt;Hospitalized patients with: Fever (Oral temperature = 37.8 ?) and at least one of Respiratory rate &gt;24/min / O2Sat&lt;94% or the Pa02/Fi02 ratio &lt;300mgHg&lt;br&gt;=8 days since illness onset","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1.Meet the definition of severe pneumonia(Comply with any of the followings):\r&lt;br&gt;\r&lt;br&gt;          1. Shortness of breath,RR=30 bpm;\r&lt;br&gt;\r&lt;br&gt;          2. In a resting state:SPO2=93%;\r&lt;br&gt;\r&lt;br&gt;          3. PaO2/FiO2=300mmHg.\r&lt;br&gt;\r&lt;br&gt;        2.2019-nCoV nucleic acid test was positive.\r&lt;br&gt;\r&lt;br&gt;        3.CT of the lung conformed to the manifestation of viral pneumonia.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. dying state (i.e. survival time is less than 24 hours);\r&lt;br&gt;\r&lt;br&gt;          2. progressive malignant tumor with life expectancy less than 6 months;\r&lt;br&gt;\r&lt;br&gt;          3. immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs)\r&lt;br&gt;\r&lt;br&gt;          4. underlying diseases requiring long-term glucocorticoid treatment in the past 6 months\r&lt;br&gt;             or short-term glucocorticoid therapy in the past 4 weeks;\r&lt;br&gt;\r&lt;br&gt;          5. pregnancy\r&lt;br&gt;\r&lt;br&gt;          6. patients with glucocorticoid taboos\r&lt;br&gt;","Inclusion criteria: Patients with highly suspected or confirmed COVID-19 who are candid for hospitalization and starting triple-drug combination","Inclusion criteria: positive result for COVID-19 detection test&lt;br&gt;fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan&lt;br&gt;hospital admission","Inclusion criteria: Patients suspected of Covid-19 (fever + cough) presenting: \r&lt;br&gt;qSOFA &gt;=1 (respiratory rate ? 22, systolic blood pressure ? 100 mmHg, or altered mental status)","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. 14-70 years old\r&lt;br&gt;\r&lt;br&gt;          2. 2019 novel coronavirus pneumonia (severe type)\r&lt;br&gt;\r&lt;br&gt;          3. Subjects voluntarily participate in the clinical trial and sign the informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Disturbance of consciousness\r&lt;br&gt;\r&lt;br&gt;          2. Difficulty swallowing and frequent vomiting\r&lt;br&gt;\r&lt;br&gt;          3. Patients requiring blood transfusion\r&lt;br&gt;\r&lt;br&gt;          4. Pulmonary abscess, hepatitis, cirrhosis, tuberculosis, emphysema and pulmonary\r&lt;br&gt;             infarction\r&lt;br&gt;\r&lt;br&gt;          5. Fungal and other identified pathogens infection\r&lt;br&gt;\r&lt;br&gt;          6. Heart failure existed before diagnosis of novel coronavirus infection\r&lt;br&gt;\r&lt;br&gt;          7. Liver function: alanine aminotransferase &gt; 500 U/L\r&lt;br&gt;\r&lt;br&gt;          8. Patients requiring hemodialysis\r&lt;br&gt;\r&lt;br&gt;          9. Taking anticoagulant drugs due to cardiovascular and cerebrovascular diseases\r&lt;br&gt;\r&lt;br&gt;         10. Other conditions that the investigator considers ineligible for clinical trial\r&lt;br&gt;","Inclusion criteria: positive result for COVID-19 detection test&lt;br&gt;fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan&lt;br&gt;hospital admission","Inclusion criteria: (1) Age 16 or greater at the time of consent&lt;br&gt;(2) Sex;  male or female&lt;br&gt;(3) Outpatient or inpatient: inpatient &lt;br&gt;(4) Meets all of 1), 2), 3) below&lt;br&gt; 1)Has at least one RT-PCR test positive for SARS-CoV2 from pharyngeal or nasopharyngeal swab&lt;br&gt; 2) Has a performance status of 0 or 1&lt;br&gt; 3) Is able to remain inpatient for 15 days&lt;br&gt;(5) Has a negative pregnancy test if the subject is female and pre-menopausal &lt;br&gt;(6) Has provided written consent for participation;  written consents from both the subject and a legal guardian","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged between 18 and 80 years (Including 18and 80years, male or female).\r&lt;br&gt;\r&lt;br&gt;          -  One of them:\r&lt;br&gt;\r&lt;br&gt;               1. Laboratory (RT-PCR) and clinical symptoms confirmed case of novel coronavirus\r&lt;br&gt;                  pneumonia (COVID-19).\r&lt;br&gt;\r&lt;br&gt;               2. Patients diagnosed clinically as suspected cases.\r&lt;br&gt;\r&lt;br&gt;          -  Ability to communicate well with researchers and sign the informed consent Form (ICF)\r&lt;br&gt;             voluntarily.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  ALT=5 times of ULN, level of total bilirubin=3 times of ULN, or Cr=1.5 times of ULN.\r&lt;br&gt;\r&lt;br&gt;          -  Patients with serious severe liver disease.\r&lt;br&gt;\r&lt;br&gt;          -  Excluded who diagnosed as pneumonia patients with novel coronavirus infection of\r&lt;br&gt;             severe type and critical type. ?Diagnostic criteria reference the official guideline\r&lt;br&gt;             \"Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial\r&lt;br&gt;             Version 5) \"?.\r&lt;br&gt;\r&lt;br&gt;          -  Patients with previous history of severe gastrointestinal diseases such as gastric\r&lt;br&gt;             ulcers and bleeding.\r&lt;br&gt;\r&lt;br&gt;          -  Patients with lactose intolerance.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are allergic to the components of this medicine (Major components:\r&lt;br&gt;             Bromhexine Hydrochloride; excipient: starch, lactose, magnesium stearate).\r&lt;br&gt;\r&lt;br&gt;          -  Positive serum pregnancy test result for women with childbearing potential at\r&lt;br&gt;             screening or lactating women.\r&lt;br&gt;\r&lt;br&gt;          -  Other circumstances that the researcher considers inappropriate to participate in this\r&lt;br&gt;             study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to\r&lt;br&gt;             \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial\r&lt;br&gt;             Version 5)\";\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Physician judged the patient was not suitable for this clinical trial.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Laboratory diagnosis:\r&lt;br&gt;\r&lt;br&gt;               -  Respiratory specimen is positive for SARS-CoV-2 nucleic acid by RT-PCR; OR,\r&lt;br&gt;\r&lt;br&gt;               -  The viral gene sequencing of the respiratory specimen is highly homologous to\r&lt;br&gt;                  known novel coronavirus.\r&lt;br&gt;\r&lt;br&gt;          2. Fever:\r&lt;br&gt;\r&lt;br&gt;             Axillary temperature &gt;37.3?\r&lt;br&gt;\r&lt;br&gt;          3. Respiratory variables (meets one of the following criteria):\r&lt;br&gt;\r&lt;br&gt;               -  Respiratory rate: RR =25 breaths/min\r&lt;br&gt;\r&lt;br&gt;               -  Oxygen saturation =93% at rest on room air\r&lt;br&gt;\r&lt;br&gt;               -  PaO2/FiO2 =300 mmHg(1 mmHg=0.133 KPa)\r&lt;br&gt;\r&lt;br&gt;               -  Pulmonary imaging showed that the lesions progressed more than 50% within 24-48\r&lt;br&gt;                  hours, and the patients were managed as severe\r&lt;br&gt;\r&lt;br&gt;          4. HBsAg negative, or HBV DNA =10^4 copy/ml if HBsAg positive; anti-HCV negative; HIV\r&lt;br&gt;             negative two weeks prior to signed Informed Consent Form (ICF)\r&lt;br&gt;\r&lt;br&gt;          5. Appropriate ethics approval and\r&lt;br&gt;\r&lt;br&gt;          6. ICF\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt;18 years; Age &gt;80 years\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breast feeding woman or with positive pregnancy test result\r&lt;br&gt;\r&lt;br&gt;          -  P/F &lt;100 mmHg\r&lt;br&gt;\r&lt;br&gt;          -  Moribund condition (death likely in days) or not expected to survive for &gt;7 days\r&lt;br&gt;\r&lt;br&gt;          -  Refusal by attending MD\r&lt;br&gt;\r&lt;br&gt;          -  Not hemodynamically stable in the preceding 4 hours (MAP =65 mmHg, or SAP &lt;90 mmHg,\r&lt;br&gt;             DAP &lt;60 mmHg, vasoactive agents are required)\r&lt;br&gt;\r&lt;br&gt;          -  Patient on invasive mechanical ventilation or ECMO\r&lt;br&gt;\r&lt;br&gt;          -  Patient in other therapeutic clinical trial within 30 days before ICF\r&lt;br&gt;\r&lt;br&gt;          -  Receive any other ACE inhibitors (ACEI), angiotensin-receptor blockers (ARB) treatment\r&lt;br&gt;             within 7 days before ICF\r&lt;br&gt;\r&lt;br&gt;          -  Chronic immunosuppression: current autoimmune diseases or patients who received\r&lt;br&gt;             immunotherapy within 30 days before ICF\r&lt;br&gt;\r&lt;br&gt;          -  Hematologic malignancy (lymphoma, leukemia, multiple myeloma)\r&lt;br&gt;\r&lt;br&gt;          -  Other patient characteristics (not thought to be related to underlying COVID-19) that\r&lt;br&gt;             portend a very poor prognosis (e.g, severe liver failure, and ect)\r&lt;br&gt;\r&lt;br&gt;          -  Known allergy to study drug or its ingredients related to renin-angiotensin system\r&lt;br&gt;             (RAS), or frequent and/or severe allergic reactions with multiple medications\r&lt;br&gt;\r&lt;br&gt;          -  Other uncontrolled diseases, as judged by investigators\r&lt;br&gt;\r&lt;br&gt;          -  Body weight =85 kg\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1)2019-nCoV nucleic acid test was positive. 2)CT of the lung conformed to the manifestation\r&lt;br&gt;        of viral pneumonia.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients who meet any of the contraindications in the experimental drug labeling\r&lt;br&gt;\r&lt;br&gt;          2. Patients who do not want to participate in this clinical study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. 2019-nCoV nucleic acid test was positive.\r&lt;br&gt;\r&lt;br&gt;          2. CT of the lung conformed to the manifestation of viral pneumonia.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients who meet any of the contraindications in the experimental drug labeling\r&lt;br&gt;\r&lt;br&gt;          2. Patients who do not want to participate in this clinical study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age:18~55 years old, unlimited gender.\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV and accompanied with clinical\r&lt;br&gt;             manifestations.\r&lt;br&gt;\r&lt;br&gt;          3. Patients with newly diagnosed respiratory discomfort who have been hospitalized (The\r&lt;br&gt;             proper diagnosis time is less than 7 days).\r&lt;br&gt;\r&lt;br&gt;          4. Women who have no planned pregnancy in the next six months,and are willing to take\r&lt;br&gt;             effective measures to prevent contraception from the first dose of study drug to 30\r&lt;br&gt;             days after the last dose.\r&lt;br&gt;\r&lt;br&gt;          5. Agree not to participate in other clinical studies within 30 days from the first dose\r&lt;br&gt;             of the study drug to the last dose.\r&lt;br&gt;\r&lt;br&gt;          6. Patients who voluntarily sign informed consent forms.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1.2019-nCoV severe Pneumonia patients.\r&lt;br&gt;\r&lt;br&gt;        Meet the definition of severe pneumonia(Comply with any of the followings):\r&lt;br&gt;\r&lt;br&gt;          1. Respiratory distress ,RR=30 bpm;\r&lt;br&gt;\r&lt;br&gt;          2. In a resting state:SPO2=93%;\r&lt;br&gt;\r&lt;br&gt;          3. PaO2/ FiO2=300mmHg.\r&lt;br&gt;\r&lt;br&gt;             2.2019-nCoV critical and severe Pneumonia patients.Comply with any of the\r&lt;br&gt;             followings:Respiratory failure and need mechanical ventilation;Shock;Patients combined\r&lt;br&gt;             with other organ failure need ICU monitoring and treatment.\r&lt;br&gt;\r&lt;br&gt;             3.Severe liver disease(such as:the ChildPugh score=C;AST &gt; 5 times the upper limit).\r&lt;br&gt;\r&lt;br&gt;             4.Patients who are allergic to the ingredients of ASC09/ritonavir compound tablets.\r&lt;br&gt;\r&lt;br&gt;             5.Patients with definite contraindications in ritonavir tablets.\r&lt;br&gt;\r&lt;br&gt;             6.Female subjects were positive for the pregnancy test during the screening period.\r&lt;br&gt;\r&lt;br&gt;             7.Researcher judges unsuitable for participation in this clinical trial(such as:during\r&lt;br&gt;             the study patients may be transferred to hospital for treatment;patients with multiple\r&lt;br&gt;             underlying diseases, etc)\r&lt;br&gt;","Inclusion criteria:","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory (RT-PCR) confirmed Covid-19 infection in throat swab and/or sputum and/or\r&lt;br&gt;             lower respiratory tract samples;\r&lt;br&gt;\r&lt;br&gt;          -  The interval between the onset of symptoms and randomized is within 7 days. The onset\r&lt;br&gt;             of symptoms is mainly based on fever. If there is no fever, cough or other related\r&lt;br&gt;             symptoms can be used;\r&lt;br&gt;\r&lt;br&gt;          -  White blood cells = 3,500 / l, lymphocytes = 750 / l;\r&lt;br&gt;\r&lt;br&gt;          -  Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)\r&lt;br&gt;             or tuberculosis (TB) test is negative;\r&lt;br&gt;\r&lt;br&gt;          -  Sign the Informed Consent Form on a voluntary basis;\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Subject infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV\r&lt;br&gt;             antibody positive), or HTLV (HTLV antibody positive).\r&lt;br&gt;\r&lt;br&gt;          -  Subject is albumin-intolerant.\r&lt;br&gt;\r&lt;br&gt;          -  Subject with life expectancy less than 4 weeks.\r&lt;br&gt;\r&lt;br&gt;          -  Subject participated in other investigational somatic cell therapies within past 30\r&lt;br&gt;             days.\r&lt;br&gt;\r&lt;br&gt;          -  Subject with positive pregnancy test result.\r&lt;br&gt;\r&lt;br&gt;          -  Researchers consider unsuitable.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Volunteers who have understood and signed the informed consent;\r&lt;br&gt;\r&lt;br&gt;          2. Age =18 years, gender unlimited;\r&lt;br&gt;\r&lt;br&gt;          3. Patients diagnosed with acute severe 2019-nCoV pneumonia:\r&lt;br&gt;\r&lt;br&gt;               1. Laboratory (RT-PCR) confirmed infection with 2019-nCoV.\r&lt;br&gt;\r&lt;br&gt;               2. Lung involvement confirmed with pulmonary CT scan.\r&lt;br&gt;\r&lt;br&gt;               3. At least one of the following conditions should be met: respiratory distress, RR\r&lt;br&gt;                  = 30 times/min; oxygen saturation = 93% in resting state; PaO2/FiO2 = 300mmHg;\r&lt;br&gt;                  respiratory failure and mechanical ventilation are required; shock occurs; ICU\r&lt;br&gt;                  monitoring and treatment is required in combination with other organ failure.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Viral pneumonia with other viruses besides 2019-nCoV.\r&lt;br&gt;\r&lt;br&gt;          2. Patients are not suitable for immunoglobulin therapy.\r&lt;br&gt;\r&lt;br&gt;          3. Participation in other studies.\r&lt;br&gt;\r&lt;br&gt;          4. Other circumstances in which the investigator determined that the patient is not\r&lt;br&gt;             suitable for the clinical trial.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years at time of signing Informed Consent Form.\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with CoVID-19.\r&lt;br&gt;\r&lt;br&gt;          3. Hospitalised with Fever(=36.7? -axilla or oral temperature = 38.0 ? or =38.6C\r&lt;br&gt;             tympanic or rectal) and cough;\r&lt;br&gt;\r&lt;br&gt;          4. No difficulty swallowing oral medications.\r&lt;br&gt;\r&lt;br&gt;          5. Must agree not to enroll in another study of an investigational agent prior to\r&lt;br&gt;             completion of Day 28 of study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Allergies, known to be allergic to research drugs or drug excipients;\r&lt;br&gt;\r&lt;br&gt;          2. Patient weight is less than 40 kg;\r&lt;br&gt;\r&lt;br&gt;          3. Respiratory distress-RR=30 / min on room air,or SPO2= 93%, or PaO2/FiO2 =300mmHg\r&lt;br&gt;             (1mmHg = 0.133kPa)\r&lt;br&gt;\r&lt;br&gt;          4. Shock;\r&lt;br&gt;\r&lt;br&gt;          5. The clinician judges that ICU monitoring treatment is needed;\r&lt;br&gt;\r&lt;br&gt;          6. Patients who have participated in other clinical trials within 1 month;\r&lt;br&gt;\r&lt;br&gt;          7. Known patients with impaired renal function (estimated creatinine clearance &lt;60 mL /\r&lt;br&gt;             min (male: Cr (ml / min) = (140-age)  body weight (kg) / 72  blood creatinine\r&lt;br&gt;             concentration (mg / dl); female: Cr (ml / min) = (140-age)  weight (kg) / 85  blood\r&lt;br&gt;             creatinine concentration (mg / dl));\r&lt;br&gt;\r&lt;br&gt;          8. During the screening or within 24 hours before screening, patients were found to have\r&lt;br&gt;             any of the following laboratory parameter abnormalities (based on local laboratory\r&lt;br&gt;             reference range):-ALT or AST level&gt; 5 times the upper limit of normal range (ULN)\r&lt;br&gt;             or-ALT or AST &gt; 3 times ULN and total bilirubin levels&gt; 2 times ULN;\r&lt;br&gt;\r&lt;br&gt;          9. Being pregnant or breastfeeding, or having a positive pregnancy test at the time of\r&lt;br&gt;             pre-dose inspection, or planning to become pregnant within 3 months of study\r&lt;br&gt;             treatment.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult aged &gt;=18years old;\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed\r&lt;br&gt;             SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral\r&lt;br&gt;             pneumonia.\r&lt;br&gt;\r&lt;br&gt;          -  Criteria for severe or critical ill conditions: Respiratory rate &gt;=30/min; or Rest\r&lt;br&gt;             SPO2&lt;=93%; or PaO2/FiO2&lt;=300mmHg.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Near-death state (expected survival time less than 24 hours);\r&lt;br&gt;\r&lt;br&gt;          -  Malignant tumor;\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or puerperium women;\r&lt;br&gt;\r&lt;br&gt;          -  Patients who refused to participant.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  It conforms to the diagnostic criteria of confirmed cases of COVID-19;\r&lt;br&gt;\r&lt;br&gt;          -  Age from 18-75, regardless gender.\r&lt;br&gt;\r&lt;br&gt;          -  The patient informed consent and sign the informed consent form (if the subject has no\r&lt;br&gt;             capacity, limited capacity and limited expression of personal will, he or she should\r&lt;br&gt;             obtain the consent of his guardian and sign the informed consent at the same time).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Women during pregnancy or lactation;\r&lt;br&gt;\r&lt;br&gt;          -  Allergic constitution, such as those who have a history of allergy to two or more\r&lt;br&gt;             drugs or food, or who are known to be allergic to drug ingredients observed in this\r&lt;br&gt;             study.\r&lt;br&gt;\r&lt;br&gt;          -  Severe complications such as multiple organ failure and shock occurred.\r&lt;br&gt;\r&lt;br&gt;          -  Complicated with severe primary diseases such as heart, brain, liver, kidney and so\r&lt;br&gt;             on.\r&lt;br&gt;\r&lt;br&gt;          -  Patients have mental illness.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who participated in or is currently participating in other clinical trials\r&lt;br&gt;             within the first month of this study.\r&lt;br&gt;","Inclusion criteria:","Inclusion criteria: Head of french Emergency Department","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Aged between 18 and 75 years, extremes included, male or female\r&lt;br&gt;\r&lt;br&gt;          2. Patients diagnosed with mild or common type COVID-19, according to the official\r&lt;br&gt;             guideline \"Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection\r&lt;br&gt;             (Trial Version 6)\"\r&lt;br&gt;\r&lt;br&gt;          3. patients can generally tolerable for treatment recommended by the official guideline\r&lt;br&gt;             \"Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial\r&lt;br&gt;             Version 6)\"\r&lt;br&gt;\r&lt;br&gt;          4. Patients have not been accompanied by serious physical diseases of heart, lung, brain,\r&lt;br&gt;             etc.,Eastern Cooperative Oncology Group score standard:0-1\r&lt;br&gt;\r&lt;br&gt;          5. Ability to understand and the willingness to sign a written informed consent document.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Female subjects who are pregnant or breastfeeding.\r&lt;br&gt;\r&lt;br&gt;          2. patients who are allergic to this medicine\r&lt;br&gt;\r&lt;br&gt;          3. patients meet the contraindications of Huaier granule\r&lt;br&gt;\r&lt;br&gt;          4. Patients with diabetes\r&lt;br&gt;\r&lt;br&gt;          5. Patients have any condition that in the judgement of the Investigators would make the\r&lt;br&gt;             subject inappropriate for entry into this study.\r&lt;br&gt;\r&lt;br&gt;          6. patients can't take drugs orally\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female, 18 years old = age = 75years old;\r&lt;br&gt;\r&lt;br&gt;          2. CT image is characteristic of 2019 novel coronavirus pneumonia;\r&lt;br&gt;\r&lt;br&gt;          3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase\r&lt;br&gt;             chain reaction (RT-PCR);\r&lt;br&gt;\r&lt;br&gt;          4. In compliance with the 2019-nCoV pneumonia diagnosis standard (according to the novel\r&lt;br&gt;             coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation\r&lt;br&gt;             Version 6) issued by the National Health and Medical Commission, and WHO 2019 new\r&lt;br&gt;             coronavirus guidelines standards): (A) increased breathing rate (=30 beats / min),\r&lt;br&gt;             difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen\r&lt;br&gt;             saturation =93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired\r&lt;br&gt;             oxygen (FiO2) =300 mmHg (1mmHg = 0.133kPa);\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with severe allergies or allergies to stem cells;\r&lt;br&gt;\r&lt;br&gt;          2. Patients with serious basic diseases that affect survival, including: blood diseases,\r&lt;br&gt;             cachexia, active bleeding, severe malnutrition, etc.;\r&lt;br&gt;\r&lt;br&gt;          3. Patients with pulmonary obstructive pneumonia, severe pulmonary interstitial fibrosis,\r&lt;br&gt;             alveolar proteinosis, allergic alveolitis, and other known viral pneumonia or\r&lt;br&gt;             bacterial pneumonia;\r&lt;br&gt;\r&lt;br&gt;          4. Continuous use of immunosuppressive agents or organ transplants in the past 6 months;\r&lt;br&gt;\r&lt;br&gt;          5. In vitro life support (ECMO, ECCO2R, RRT);\r&lt;br&gt;\r&lt;br&gt;          6. Expected deaths within 48 hours, uncontrolled infections;\r&lt;br&gt;\r&lt;br&gt;          7. Patients with malignant blood-borne diseases such as HIV or syphilis;\r&lt;br&gt;\r&lt;br&gt;          8. Patient with pregnancy, are planning to become pregnant or breastfeeding;\r&lt;br&gt;\r&lt;br&gt;          9. Patients with poor compliance and unable to complete the full study;\r&lt;br&gt;\r&lt;br&gt;         10. The investigator determines that there may be increased risk of the subject or other\r&lt;br&gt;             conditions that interfere with the clinical trial and the judgment of the results\r&lt;br&gt;             (such as excessive stress, sensitivity or cognitive impairment, etc.);\r&lt;br&gt;\r&lt;br&gt;         11. There are other situations that the researchers think are not suitable to participate\r&lt;br&gt;             in this clinical study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  At least 21 years\r&lt;br&gt;\r&lt;br&gt;          -  Has stayed in Singapore for at least 2 years\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Below 21 years\r&lt;br&gt;\r&lt;br&gt;          -  Has stayed in Singapore for less than 2 years\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years at time of signing Informed Consent Form;\r&lt;br&gt;\r&lt;br&gt;          2. Those who meet the diagnosis of severe new coronavirus pneumonia with laboratory\r&lt;br&gt;             confirmed infection with CoVID-19;\r&lt;br&gt;\r&lt;br&gt;          3. Lung involvement confirmed with chest imaging;\r&lt;br&gt;\r&lt;br&gt;          4. Hospitalized with a Pa02/Fi02 ratio =300mgHg;\r&lt;br&gt;\r&lt;br&gt;          5. 40%&gt; lymphocyte percentage =5%;\r&lt;br&gt;\r&lt;br&gt;          6. No difficulty swallowing oral medications.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Allergies, those who are known to be allergic to research drugs or drug excipients;\r&lt;br&gt;\r&lt;br&gt;          2. The patient weighs less than 40 kg;\r&lt;br&gt;\r&lt;br&gt;          3. Patients with diarrhea;\r&lt;br&gt;\r&lt;br&gt;          4. Shock;\r&lt;br&gt;\r&lt;br&gt;          5. Patients with respiratory failure at the time of enrollment who need invasive\r&lt;br&gt;             mechanical ventilation;\r&lt;br&gt;\r&lt;br&gt;          6. The clinician judges that ICU admission is needed;\r&lt;br&gt;\r&lt;br&gt;          7. Patients who participated in other clinical trials within 1 month;\r&lt;br&gt;\r&lt;br&gt;          8. Known patients with impaired renal function (estimated creatinine clearance &lt;60 mL /\r&lt;br&gt;             min (male: Cr (ml / min) = (140-age)  body weight (kg) / 72  blood creatinine\r&lt;br&gt;             concentration (mg / dl); female: Cr (ml / min) = (140-age)  weight (kg) / 85  blood\r&lt;br&gt;             creatinine concentration (mg / dl));\r&lt;br&gt;\r&lt;br&gt;          9. During the screening or within 24 hours before screening, patients were found to have\r&lt;br&gt;             any of the following laboratory parameter abnormalities (based on the local laboratory\r&lt;br&gt;             reference range): ALT or AST level&gt; 5 times the upper limit of normal range (ULN) or\r&lt;br&gt;             ALT or AST level&gt; 3 times ULN and total bilirubin levels&gt; 2 times ULN;\r&lt;br&gt;\r&lt;br&gt;         10. Being pregnant or breastfeeding, or having a positive pregnancy test at the time of\r&lt;br&gt;             pre-dose inspection, or planning to become pregnant within 3 months after study\r&lt;br&gt;             treatment;\r&lt;br&gt;\r&lt;br&gt;         11. Will be transferred to another hospital which is not the study site within 72 hours.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult aged &gt;=18years old;\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed\r&lt;br&gt;             2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia.\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed with primary hypertension.\r&lt;br&gt;\r&lt;br&gt;          -  Criteria for severe or critical ill conditions: Respiratory rate &gt;=30/min; or Rest\r&lt;br&gt;             SPO2&lt;=93%; or PaO2/FiO2&lt;=300mmHg.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Near-death state (expected survival time less than 24 hours);\r&lt;br&gt;\r&lt;br&gt;          -  Malignant tumor;\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or puerperium women;\r&lt;br&gt;\r&lt;br&gt;          -  ACEI contraindication\r&lt;br&gt;\r&lt;br&gt;          -  Patients who refused to participant.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients diagnosed as COVID-19:\r&lt;br&gt;\r&lt;br&gt;               1. mild patient: fever,respiratory and other symptoms, the manifestation of\r&lt;br&gt;                  pneumonia can be seen on imaging.\r&lt;br&gt;\r&lt;br&gt;               2. severe patients: meet the definition of severe pneumonia(comply with any of the\r&lt;br&gt;                  followings): Shortness of breath,RR=30 bpm;In a resting\r&lt;br&gt;                  state:SPO2=93%;PaO2/FiO2=300mmHg.\r&lt;br&gt;\r&lt;br&gt;          2. Age=18 years old,unlimited gender.\r&lt;br&gt;\r&lt;br&gt;          3. Patients who cannot stop the following drugs during the trial:erythromycin or strong\r&lt;br&gt;             inhibitors of CYP3A4 (such as saquinavir,ketoconazole,itraconazole),nonspecific\r&lt;br&gt;             inhibitors of CYP (such as cimetidine),HIV protease inhibitors (such as ritonavir).\r&lt;br&gt;\r&lt;br&gt;          4. Willing to participate in this study,signed Informed Consent and willing to\r&lt;br&gt;             participate in regular follow-up during the study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Suffer from severe cognitive impairment or mental illness.\r&lt;br&gt;\r&lt;br&gt;          2. Pregnant and lactating women.\r&lt;br&gt;\r&lt;br&gt;          3. Patients taking nitric oxide drugs and nitrates in any dosage form.\r&lt;br&gt;\r&lt;br&gt;          4. Patients with malignant tumors;AMI, stroke or life-threatening arrhythmias within 6\r&lt;br&gt;             months;hereditary pigmented retinitis;heart failure or unstable angina pectoris of\r&lt;br&gt;             coronary heart disease;patients with severe hypotension and hypertension.\r&lt;br&gt;\r&lt;br&gt;          5. Patients who are allergic to the study drug or the researcher believes it is not\r&lt;br&gt;             appropriate.\r&lt;br&gt;\r&lt;br&gt;          6. Participate in other clinical studies at the same time.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Agrees to the collection of oropharyngeal or anal swabs and venous blood per protocol.\r&lt;br&gt;\r&lt;br&gt;          2. Male or non-pregnant female adult =18 years of age at time of enrollment.\r&lt;br&gt;\r&lt;br&gt;          3. Has laboratory-confirmed novel coronavirus infection as determined by polymerase chain\r&lt;br&gt;             reaction (PCR), or other commercial or public health assay in oropharyngeal or anal\r&lt;br&gt;             specimen within 72 hours prior to hospitalization.\r&lt;br&gt;\r&lt;br&gt;          4. Illness of any duration, and at least one of the following:\r&lt;br&gt;\r&lt;br&gt;               1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR\r&lt;br&gt;\r&lt;br&gt;               2. Clinical assessment (evidence of rales/crackles on physical examination) AND SpO2\r&lt;br&gt;                  =93% on room air, OR\r&lt;br&gt;\r&lt;br&gt;               3. Requiring mechanical ventilation and/or supplemental oxygen, OR\r&lt;br&gt;\r&lt;br&gt;               4. Sustained fever in the past 24 hours and unresponsive to NSAID or steroid\r&lt;br&gt;\r&lt;br&gt;          5. Serum IL-6 =3 times the upper limit of normal\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Alanine transaminase/aspartate transaminase (ALT/AST) &gt; 5 times the upper limit of\r&lt;br&gt;             normal.\r&lt;br&gt;\r&lt;br&gt;          2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated glomerular\r&lt;br&gt;             filtration rate (eGFR) &lt; 30 ml /min/1.73 m^2)\r&lt;br&gt;\r&lt;br&gt;          3. Hemoglobin&lt;80 g/L\r&lt;br&gt;\r&lt;br&gt;          4. Leukocytes&lt;2.010^9\r&lt;br&gt;\r&lt;br&gt;          5. Platelets&lt;5010^9\r&lt;br&gt;\r&lt;br&gt;          6. Pregnancy or breast feeding.\r&lt;br&gt;\r&lt;br&gt;          7. Anticipated transfer to another hospital which is not a study site within 72 hours.\r&lt;br&gt;\r&lt;br&gt;          8. Expected life span does not exceed 7 days.\r&lt;br&gt;\r&lt;br&gt;          9. Allergy to any study medication.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All patients &gt;18 years of age with a positive test for SARS-CoV2 are eligble for\r&lt;br&gt;             inclusion.\r&lt;br&gt;\r&lt;br&gt;          -  Healty age-matched volunteers will be included as a control group\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  all patients treated for Covid-19\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Chronology not compatible between the drug and the toxicity\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with mild and severe cases who have been diagnosed with new coronavirus\r&lt;br&gt;             pneumonia according to the \"Pneumonitis Diagnosis and Treatment -\r&lt;br&gt;\r&lt;br&gt;          -  Plan for New Coronavirus Infection\"\r&lt;br&gt;\r&lt;br&gt;          -  Age 18 to 75 years;\r&lt;br&gt;\r&lt;br&gt;          -  Sign the informed consent voluntarily.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  With active tuberculosis, idiopathic pulmonary fibrosis, bronchial asthma,\r&lt;br&gt;             bronchiectasis, pulmonary embolism, patients with chronic respiratory failure or other\r&lt;br&gt;             severe respiratory disease;\r&lt;br&gt;\r&lt;br&gt;          -  According to the \"pneumonia diagnosis and treatment program for new coronavirus\r&lt;br&gt;             infection\" (trial version 6), critically ill patients\r&lt;br&gt;\r&lt;br&gt;          -  With severe patients with disease of heart head blood-vessel, malignant arrhythmia,\r&lt;br&gt;             unstable angina, acute myocardial infarction and death, cardiac function level 3 and\r&lt;br&gt;             above, stroke, cerebral hemorrhage, etc.);\r&lt;br&gt;\r&lt;br&gt;          -  With severe liver and kidney diseases (severe liver disease refers to cirrhosis,\r&lt;br&gt;             portal hypertension and varices bleeding, severe kidney disease including dialysis,\r&lt;br&gt;             kidney transplantation);\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant and lactating women;\r&lt;br&gt;\r&lt;br&gt;          -  Severe cognitive and mental disorders;\r&lt;br&gt;\r&lt;br&gt;          -  Clinical investigators who were participating in other interventions within 1 month\r&lt;br&gt;             prior to inclusion\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  (1) Age =18 years. (2) Laboratory (RT-PCR) confirmed infection with SARS-CoV-2. (3)\r&lt;br&gt;             Lung involvement confirmed with chest imaging.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  No cTnI test on admission\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participants in other clinical trials\r&lt;br&gt;\r&lt;br&gt;          -  patients with malignant tumors\r&lt;br&gt;\r&lt;br&gt;          -  pregnant and lactating women\r&lt;br&gt;\r&lt;br&gt;          -  co-infection with other infectious viruses or bacteria\r&lt;br&gt;\r&lt;br&gt;          -  History of several allergies\r&lt;br&gt;\r&lt;br&gt;          -  Patients with history of pulmonary embolism\r&lt;br&gt;\r&lt;br&gt;          -  any liver or kidney diseases\r&lt;br&gt;\r&lt;br&gt;          -  HIV positive patients\r&lt;br&gt;\r&lt;br&gt;          -  Considered by researchers to be not suitable to participate in this clinical trial\r&lt;br&gt;\r&lt;br&gt;          -  Chronic heart failure with ejection fraction less than 30%.\r&lt;br&gt;","Inclusion criteria: (1) Outpatient and emergency patients of PLA General Hospital;\r&lt;br&gt;(2) The body temperature higher than 37.3 degree C.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients diagnosed with COVID-19\r&lt;br&gt;\r&lt;br&gt;               -  Aged between 18-75 years;\r&lt;br&gt;\r&lt;br&gt;                    -  Willing to sign the informed consent voluntarily.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with active tuberculosis, idiopathic pulmonary fibrosis, bronchial asthma,\r&lt;br&gt;             bronchiectasis, pulmonary embolism, chronic respiratory failure or other serious\r&lt;br&gt;             respiratory diseases; ? patients with serious cardiovascular and cerebrovascular\r&lt;br&gt;             diseases (malignant arrhythmia, unstable angina, acute myocardial infarction, cardiac\r&lt;br&gt;             function grade 3 or above, stroke, cerebral hemorrhage, etc.); ? Patients with serious\r&lt;br&gt;             hepatorenal diseases (serious liver diseases refer to cirrhosis, portal hypertension\r&lt;br&gt;             and varicose bleeding, and serious kidney diseases include dialysis and kidney\r&lt;br&gt;             transplantation); ? tumor patients who have undergone resection, radiotherapy and\r&lt;br&gt;             chemotherapy within 5 years; ? patients who have difficulty in activity due to\r&lt;br&gt;             neuromuscular diseases; ? patients with serious arthritis; ? patients with serious\r&lt;br&gt;             peripheral vascular diseases; ? Pregnant and lactating women; ? with severe cognitive\r&lt;br&gt;             and mental disorders; ? the clinical researchers who were participating in other\r&lt;br&gt;             interventions within one month before selection;\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  18 years old upon study start\r&lt;br&gt;\r&lt;br&gt;          -  Healthcare personnel exposed to patients with COVID-19 respiratory disease:\r&lt;br&gt;             physicians, nurses, chemists, pharmacists, janitors, stretcher-bearer, administrative\r&lt;br&gt;             and respiratory therapists.\r&lt;br&gt;\r&lt;br&gt;          -  Signed consent for randomization to any study arm.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to hydroxychloroquine manifested as anaphylaxis\r&lt;br&gt;\r&lt;br&gt;          -  Current treatment to chloroquine or hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Women with last menstruation date farther than a month without negative pregnancy\r&lt;br&gt;             test.\r&lt;br&gt;\r&lt;br&gt;          -  Women with positive pregnancy test\r&lt;br&gt;\r&lt;br&gt;          -  Breastfeeding women\r&lt;br&gt;\r&lt;br&gt;          -  Chronic hepatic disease history (Child-Pugh B or C)\r&lt;br&gt;\r&lt;br&gt;          -  Chronic renal disease (GFR less or equal to 30)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Patients hospitalized for COVID-19\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        none\r&lt;br&gt;","Inclusion criteria: 1) About one month after the recovery of COVID-19;\r&lt;br&gt;2) No other neurological diseases.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to intensive care\r&lt;br&gt;\r&lt;br&gt;          -  suspected or verified COVID-19\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  Preexisting end-stage kidney failure or dialysis\r&lt;br&gt;\r&lt;br&gt;          -  Under-age\r&lt;br&gt;","Inclusion criteria: Including maternal cases who performed emergency cesarean section in our hospital from January 24, 2020 to March 10, 2020","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients went to the fever clinic with respiratory infectious symptoms\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  none\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. age &gt;18 years old\r&lt;br&gt;\r&lt;br&gt;          2. identify the patients infected with novel coronavirus pneumonia;\r&lt;br&gt;\r&lt;br&gt;          3. the patient completed CT examination;\r&lt;br&gt;\r&lt;br&gt;          4. sign the informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. age &lt; 18;\r&lt;br&gt;\r&lt;br&gt;          2. those who cannot complete cardiopulmonary ultrasound according to the a-ccue process;\r&lt;br&gt;\r&lt;br&gt;          3. the patient or his guardian requests to withdraw from the researcher;\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  pregnant women with laboratory-confirmed 2019-n-CoV\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Signed informed consent\r&lt;br&gt;\r&lt;br&gt;          2. negative pregnancy test in women\r&lt;br&gt;\r&lt;br&gt;          3. COVID-19 confirmed by rtPCR in any respiratory sample.\r&lt;br&gt;\r&lt;br&gt;          4. Severe COVID-19 disease defined as any from the following:\r&lt;br&gt;\r&lt;br&gt;               1. Pulse oximetry less than 91% or a 3% drop from base pulse oximetry or need to\r&lt;br&gt;                  increase supplementary oxygen in chronic hypoxia\r&lt;br&gt;\r&lt;br&gt;               2. Need for mechanical ventilation (invasive or non invasive )\r&lt;br&gt;\r&lt;br&gt;               3. Sepsis/septic shock.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. history of anaphylactic shock to hydroxychloroquine.\r&lt;br&gt;\r&lt;br&gt;          2. History of previous administration of chloroquine or hydroxychloroquine (within 1\r&lt;br&gt;             month)\r&lt;br&gt;\r&lt;br&gt;          3. decision of attending physician by any reason.\r&lt;br&gt;\r&lt;br&gt;          4. History of chronic hepatic disease (Child-Pugh B or C)\r&lt;br&gt;\r&lt;br&gt;          5. History of Chronic renal disease (GFR less than 30)\r&lt;br&gt;","Inclusion criteria: 1. Myopia teenagers who were first fitted with or re-examined orthokeratology lens in our hospital from November 2019 to January 2020 were invited to review the progression of myopia by telephone and text messages;\r&lt;br&gt;2.The cornea is transparent;no history of eye disease,eye trauma or surgery.","Inclusion criteria: Patients should fulfill the diagnosis criteria of rheumatoid arthritis in 2009, systemic lupus erythematosus in 2009, axial spondyloarthritis in 2009 or gout in 2015.","Inclusion criteria: We anticipate collecting 200 COVID-19 serum samples (40 severe patients, 130 non-severe patients and 30 influza patients) in 2-4 hospitals. At present, there are two cooperate unit, Taizhou Hospital of Zhejiang Province and the First Hospital of Jiangxing. Severe patients include three categories: good prognosis, poor prognosis under cytokine storm and poor prognosis without cytokine storm. We will collect serum, urine and feces samples at multiple time points during the course of the disease to conduct multi-omics analysis.","Inclusion criteria: (1) Aged 18-65 years;\r&lt;br&gt;(2) Voluntarily participate in this clinical trial and sign off \"informed consent form\";\r&lt;br&gt;(3) Diagnosed with severe pneumonia of COVID: respiratory distress, RR &gt;30 times / min; resting oxygen saturation of 93% or less; arterial partial pressure of oxygen / oxygen concentration 300mmHg; SARS-CoV-2 nucleic acid test was positive.\r&lt;br&gt;(4) Chest imaging confirm COVID-19 featured changes in lung.","Inclusion criteria: 1) Positive;\r&lt;br&gt;2) There is a CT examination in our hospital.","Inclusion criteria: (1) the medical staff on the frontline of the clinical fight against COVID - 19 epidemic should wear protective equipment such as N95 / KN95 respirator, goggles or mask, protective clothing or isolation clothing when they go to hubei province or fight in the local frontline [5];\r&lt;br&gt;(2) there is no limitation on the gender and age of the participants, and they are willing to participate","Inclusion criteria: 1. Mild or moderate cases who meet the \"Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia\" issued by the National Health And Health Council are trialled in the fifth and sixth editions of clinical diagnosis and diagnostic criteria;\r&lt;br&gt;2. Aged &gt;=18 years;\r&lt;br&gt;3. Patient informed consent.","Inclusion criteria: 1. Diagnosed as COVID-19 confirmed patient with a throat swab test;\r&lt;br&gt;2. Aged &gt;=18 years;\r&lt;br&gt;3. Diagnosed as critical ill patients according to the New Coronavirus Pneumonia Diagnosis and Treatment Plan (the seventh edition);\r&lt;br&gt;4. Complete medical records;\r&lt;br&gt;5. The time from admission to death was 3 days or more.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults healthcare workers (HCW) OR\r&lt;br&gt;\r&lt;br&gt;          -  Chronic patients with at least 2 chronic medical conditions\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  People that have been in contact with people positive for COVID-19 in the previous 14\r&lt;br&gt;             days\r&lt;br&gt;\r&lt;br&gt;          -  People with body temperature &gt;37.5C\r&lt;br&gt;\r&lt;br&gt;          -  People with Dry cough\r&lt;br&gt;\r&lt;br&gt;          -  People with Respiratory distress (Respiratory Rate &gt;25/min or O2 Saturation &lt;92%)\r&lt;br&gt;","Inclusion criteria: 1. Myopia teenagers who have optometry in our hospital from November 2019 to January 2020 were invited to review the progression of myopia by telephone and text messages,including those newly diagnosed patients who have been fitted with orthokeratology lens during this period;\r&lt;br&gt;2.The cornea is transparent;no history of eye disease,eye trauma or surgery.","Inclusion criteria: Eligible participants are residents who were located in Wuhan during the lockdown starting from 23 January 2020 due to the Coronavirus breakout. The study was conducted for 12 days between 20 Feb to 2 March","Inclusion criteria: (1) Have a clear history of contact with confirmed cases;\r&lt;br&gt;(2) Two consecutive positive nucleic acid tests;\r&lt;br&gt;(3) No clinically relevant symptoms;\r&lt;br&gt;(4) Patient voluntary.","Inclusion criteria: Novel coronavirus pneumonia diagnosis and treatment plan (trial version seventh) was revised to meet the diagnostic criteria of the 18-65 year old patients","Inclusion criteria: We did a retrospective review of medical records from surgical patients with COVID-19 pneumonia admitted to Renmin Hospital of Wuhan University from January 13 to March 12, 2020.","Inclusion criteria: Confirmed Covid-19 pneumonia patients (Covid-19 pneumonia treatment plan (Seventh Edition) who were admitted from February 2020 to March, and combined with cTnI elevation.","Inclusion criteria: Medical staff involved in COVID-19 prevention and control.","Inclusion criteria: All adult COVID-19 patients cofirmed PCR or CT scan.","Inclusion criteria: Children at medium/low risk aged 0-18 years who were admitted to the department of pediatrics during the study period","Inclusion criteria: 1. History of contact with confirmed cases;\r&lt;br&gt;2. During the 14-day clinical observation period after contact with the confirmed case;\r&lt;br&gt;3. Nucleic acid test positive twice in a row;\r&lt;br&gt;4. Without any clinically relevant symptoms;\r&lt;br&gt;5. No positive change in chest CT;\r&lt;br&gt;6. Patients willing to participate in study.","Inclusion criteria: Patients with Covid-19 discharged from the hospital meet the following criteria:\r&lt;br&gt;(1) clinical and inpatient data are completely available;\r&lt;br&gt;Must include: blood routine on admission and discharge; chest CT; antibody test results on admission and discharge. Non essential data: inflammatory factors test results;\r&lt;br&gt;(2) confirmed patients. At least once nucleic acid test was positive;\r&lt;br&gt;(3) Up to discharge standard ?, within 3 months after onset;\r&lt;br&gt;(4) Sign informed consent.\r&lt;br&gt;Note: The nucleic acid test must be performed twice and the interval of more than 12 hours is negative, and the corresponding results must be presented.","Inclusion criteria: 1. male and female aged 18-70 years;\r&lt;br&gt;2. positive result of test for 2019 novel coronavirus nucleic acid;\r&lt;br&gt;3. Clinical diagnosed with pneumonia;\r&lt;br&gt;4. onset within 7 days (severe cases can be delayed to 14 days);\r&lt;br&gt;5. the informed consent shall be signed by me or the authorized agent;\r&lt;br&gt;6. subjects who can take oral medication or who receive oral medication;\r&lt;br&gt;7. agree to collect clinical samples;\r&lt;br&gt;8. female subjects of child-bearing age are not pregnant and agree to take effective contraceptive measures within 7 days of the last oral medication to ensure that they are not pregnant;\r&lt;br&gt;9. men agree not to have sex with women for seven days after their last oral medication.","Inclusion criteria: (1) Inpatients in our hospital;\r&lt;br&gt;(2) Age and gender are not limited;\r&lt;br&gt;(3) The PT-PCR test is positive or suspected;\r&lt;br&gt;(4) There is a complete medical record in our hospital medical record system.","Inclusion criteria: 1. Those who meet the above-mentioned diagnostic criteria and have reached the standards of separation and discharge after clinical treatment;\r&lt;br&gt;2. The patient was conscious, without aphasia, mental retardation, literacy, volunteered to participate in the trial, agreed to sign the informed consent and cooperated with the treatment.","Inclusion criteria: Homeopathic patient","Inclusion criteria: 1. The diagnosis of COVID-19 was confirmed;\r&lt;br&gt;2. Patients with invasive mechanical ventilation.","Inclusion criteria: 1. patients with novel coronavirus pneumonia confirmed by pathogenic detection;\r&lt;br&gt;2. Fever, respiratory tract and other symptoms, the change of pneumonia can be seen in imaging;\r&lt;br&gt;3. Aged 18 to 80 years;\r&lt;br&gt;4. Signed informed consent.","Inclusion criteria: (1) a patient who meets the diagnostic criteria of novel coronavirus pneumonia and is confirmed by lung CT or nucleic acid examination;\r&lt;br&gt;(2) stable condition, normal cognitive function, able to understand tests and requirements;\r&lt;br&gt;(3) willing to sign the informed consent.","Inclusion criteria: This retrospective cohort study included a cohorts of adult inpatients (&gt;=18 years old) from Department of Respiratory and Critical Care, The First People's Hospital of Jiangxia District, Wuhan(China) between January 29, 2020 to February 29, 2020. All adult patients who were diagnosed with COVID-19 according to WHO interim guidance were screened.","Inclusion criteria: 1. Patients with severe and critical COVID-19 diagnosed in accordance with the Novel Coronavirus infected Pneumonia Diagnosis and Treatment Plan (Trial Version 6);\r&lt;br&gt;2. Aged &gt;=18 years, both men and women;\r&lt;br&gt;3. Agree to participate in this test and sign the informed consent.","Inclusion criteria: The patients in the confirmed group met the diagnostic criteria of COVI-19.The control group excluded the suspected patients diagnosed with COVID-19; Aged&gt;=18 years.","Inclusion criteria: 1. During the outbreak of new coronavirus pneumonia, patients with fever caused by respiratory infection (body temperature &gt; 37 degree C), whether or not they are suspected or confirmed cases of new coronary pneumonia;\r&lt;br&gt;2. Comply with the diagnostic criteria of TCM for wind-heat and dampness or wind-cold and dampness syndrome;\r&lt;br&gt;3. Aged 18 to 75 years;\r&lt;br&gt;4. Outpatients or inpatients admitted by second-level and above medical institutions;\r&lt;br&gt;5. Voluntarily joined the study, with good compliance and signed informed consent.","Inclusion criteria: 1. Novel coronavirus history before entering the group:\r&lt;br&gt;(1) there were travel history or residential history in Wuhan area or other areas with local cases within 14 days before onset;\r&lt;br&gt;(2) During the 14 days before onset, there were patients with fever or respiratory symptoms from Wuhan or other areas with persistent local cases;\r&lt;br&gt;2. Clinical symptoms and signs;\r&lt;br&gt;3. Laboratory examination and chest CT.","Inclusion criteria: (1) Aged &gt;=18 years;\r&lt;br&gt;(2) 2019-nCoV pneumonia is diagnosed according to the standard of diagnosis and treatment;\r&lt;br&gt;(3) Patient's condition has reached the standard of desolation / discharge specified according to the diagnosis and treatment plan;\r&lt;br&gt;(4) According to the diagnosis standard, the syndrome differentiation of TCM is FeiPiQiXuZheng;\r&lt;br&gt;(5) Volunteer to participate in the study and sign informed consent.","Inclusion criteria: 1. Novel coronavirus pneumonia is diagnosed met the fifth edition of the national health and Health Committee;\r&lt;br&gt;2. Respiratory rate in calm state &gt;=30 times / min; OR Finger pulse oxygen saturation under rest and non oxygen absorption state &lt;=93%; OR PO2/FiO2)&lt;=300mmHg; OR PO2&lt;60mmHg.","Inclusion criteria: 1. patients aged 16-85 male or female; \r&lt;br&gt;2. they were willing to sign the informed consent;\r&lt;br&gt;3. The novel coronavirus nucleic acid was detected by real-time fluorescence RT-PCR in sputum, throat swabs, and lower respiratory tract secretions based on the novel coronavirus infection suspected case standard; Sequencing of viral genes is highly homologous to Known novel coronavirus.","Inclusion criteria: (1) Meet the diagnostic criteria for patients with COVID-19 of the Proposal of Diagnosis and Treatment of COVID-19;\r&lt;br&gt;(2) Aged 18-85 years;\r&lt;br&gt;(3) To agree to participate in the study and sign the informed consent","Inclusion criteria: Diagnosis confirmed Novel Coronavirus Pneumonia (COVID-19)","Inclusion criteria: 1. Patients confirmed with novel coronavirus pneumonia. The Diagnostic criteria refer to \"Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)\";\r&lt;br&gt;2. Those without broad-spectrum antibacterial, antifungal, and antiviral treatment;\r&lt;br&gt;3. Imaging revealed pneumonia in patients with a diagnosis of pathogen: influenza, CAP / HAP bacterial infection, and fungal infection.","Inclusion criteria: 1. Normal and severe cases diagnosed in accordance with the diagnosis for pneumonia of novel coronavirus infection;\r&lt;br&gt;2. Viral nucleic acid test is negative or positive after treatment;\r&lt;br&gt;3. Aged &gt;= 18 years;\r&lt;br&gt;4. Patients with clear consciousness;\r&lt;br&gt;5. Patients who voluntarily participate in the study and sign informed consent.","Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the \"Diagnosis and Treatment Program for COVID-19\"(trial version 6th);\r&lt;br&gt;(2) Aged &gt;= 18 years;\r&lt;br&gt;(3) Agree to participate in the trial, and the patient, the legal guardian or the person in charge of the medical institution signed the informed consent through paper signature, electronic signature of mobile phone software, or voice authorization.","Inclusion criteria: Patients admitted to the hospital","Inclusion criteria: 1. Patients discharged from severe or critical new coronavirus pneumonia;\r&lt;br&gt;2. Adults over 18 years of age who signed the informed consent;\r&lt;br&gt;3. Study participants are willing to accept random assignment to any designated treatment group;\r&lt;br&gt;4. Prior to the completion of this study, participants must agree not to participate in another study.","Inclusion criteria: (1) RT-PCR detection of the respiratory or blood samples shows positive nucleic acid of the novel coronavirus;\r&lt;br&gt;(2) Gene sequence of the virus in respiratory or blood samples are highly homologous to the known coronaviruses;\r&lt;br&gt;(3) The CT images of chest shows radiographic features of pneumonia;\r&lt;br&gt;(4) Patients with severe or critical conditions;\r&lt;br&gt;(5) Aged &gt;=18, male or female;\r&lt;br&gt;(6) The subjects should volunteer to join the study, sign the informed consent, have good compliance and cooperate with the follow-up.","Inclusion criteria: &lt;br&gt;1.\tSubject (=18 years old) or legally authorized representative provides informed consent prior to initiation of any study procedures. When signed informed consent is not possible (e.g. due to restrictions to prevent viral transmission), verbal informed consent in the presence of a witness not related to the investigational research study will be obtained.\r&lt;br&gt;2.\tSubject (or legally authorized representative) understands and agrees to comply with planned study procedures. \r&lt;br&gt;3.\tMale or non-pregnant female adult =18 years of age at time of enrolment. \r&lt;br&gt;4.\tHas laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen as diagnosed within 72 hours prior to randomization.\r&lt;br&gt;5.\tIllness of any duration, and at least one of the following:\r&lt;br&gt;a.\tRadiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or \r&lt;br&gt;b.\tClinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room air, or \r&lt;br&gt;c.\tRequiring mechanical ventilation and/or supplemental oxygen. \r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 100&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 100&lt;br&gt;","Inclusion criteria: A novel coronavirus pneumonia is 25-65 years old. It has no gender limitation. It has clinical symptoms such as cough, chest tightness and fatigue. Physical energy can withstand indoor standing for 20 minutes or 2 times a day.","Inclusion criteria: &lt;br&gt;Participants must have severe disease, multi-system organ dysfunction or critical disease&lt;br&gt;Laboratory-confirmed SARS-CoV-2 infection&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 184&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 276&lt;br&gt;","Inclusion criteria: &lt;br&gt;In order to be eligible to participate in this study, a subject must meet the following criteria:&lt;br&gt;\tAdult (=18 years) &lt;br&gt;\tMale or female&lt;br&gt;\tHospital personnel (expected to) taking care for patients with SARS-CoV-2 infection&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 1000&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 40&lt;br&gt;","Inclusion criteria: &lt;br&gt;\tWritten informed consent&lt;br&gt;\tAge above 18 years&lt;br&gt;\tWomen of childbearing age only: Must agree to practice continuous effective contraception for the duration of the study (a method which results in a failure rate less than 1% per year)&lt;br&gt;\tDisease severe enough to require hospitalization&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 25&lt;br&gt;","Inclusion criteria: &lt;br&gt;1.\tAdult patients, 18 years and above\r&lt;br&gt;2.\tConfirmed SARS-2-CoV-2 infection by PCR\r&lt;br&gt;3.\tAdmitted to the hospital ward or the ICU\r&lt;br&gt;4.\tSubjects (or legally authorized representative) provides written informed consent prior to initiation of the study\r&lt;br&gt;5.\tNo anticipated transfer within 72 hours to a non-study hospital\r&lt;br&gt;\r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 221&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 222&lt;br&gt;","Inclusion criteria: &lt;br&gt;1. Positive virus test for SARS-CoV-2&lt;br&gt;&lt;br&gt;2. Male or female, =18 years of age at the time of consent &lt;br&gt;&lt;br&gt;3. Patients admitted to hospital due to the severity of their COVID-19 disease OR non-hospitalised patients from high-risk co-morbidity groups such as the &gt;65-years of age, or those with hypertension, cardiovascular disease, diabetes or a chronic lung condition&lt;br&gt;&lt;br&gt;4. Provide written informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: 0&lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 100&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 300&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Subjects must have a documented positive test for the COVID-19 virus within 72\r&lt;br&gt;             hours of the administration of study drug\r&lt;br&gt;\r&lt;br&gt;          -  2. Subjects who have no requirement for oxygen (Ordinal Scale for Clinical Improvement\r&lt;br&gt;             score of 3 or less)\r&lt;br&gt;\r&lt;br&gt;          -  3. Subjects must be under observation or admitted to a controlled facility or hospital\r&lt;br&gt;             (home quarantine is not sufficient)\r&lt;br&gt;\r&lt;br&gt;          -  4. Subjects must be receiving standard of care (SOC) for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  5. Subject's spirometry (forced expiratory volume in one second [FEV1] and forced\r&lt;br&gt;             vital capacity [FVC]) must be =70% of predicted value\r&lt;br&gt;\r&lt;br&gt;          -  6. If female, must be either post-menopausal (one year or greater without menses),\r&lt;br&gt;             surgically sterile, or, for female subjects of child-bearing potential who are capable\r&lt;br&gt;             of conception must be: practicing two effective methods of birth control (acceptable\r&lt;br&gt;             methods include intrauterine device, spermicide, barrier, male partner surgical\r&lt;br&gt;             sterilization, and hormonal contraception) during the study and through 30 days after\r&lt;br&gt;             completion of the study. Abstinence is not classified as an effective method of birth\r&lt;br&gt;             control.\r&lt;br&gt;\r&lt;br&gt;          -  7. If female, must not be pregnant, plan to become pregnant, or nurse a child during\r&lt;br&gt;             the study and through 30 days after completion of the study. A pregnancy test must be\r&lt;br&gt;             negative at the Screening Visit, prior to dosing on Day 1.\r&lt;br&gt;\r&lt;br&gt;          -  8. If male, must be surgically sterile or willing to practice two effective methods of\r&lt;br&gt;             birth control (acceptable methods include barrier, spermicide, or female partner\r&lt;br&gt;             surgical sterilization) during the study and through 30 days after completion of the\r&lt;br&gt;             study. Abstinence is not classified as an effective method of birth control.\r&lt;br&gt;\r&lt;br&gt;          -  9. Must have the ability to understand and give informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. No documented infection with SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  2. Patients who are symptomatic and require oxygen (Ordinal Scale for Clinical\r&lt;br&gt;             Improvement score &gt;3) at the time of screening\r&lt;br&gt;\r&lt;br&gt;          -  3. Known history of chronic pulmonary disease (e.g., asthma [including atopic asthma,\r&lt;br&gt;             exercise-induced asthma, or asthma triggered by respiratory infection], chronic\r&lt;br&gt;             pulmonary disease, pulmonary fibrosis, COPD), pulmonary hypertension, or heart\r&lt;br&gt;             failure.\r&lt;br&gt;\r&lt;br&gt;          -  4. Any condition which, in the opinion of the Principal Investigator, would prevent\r&lt;br&gt;             full participation in this trial or would interfere with the evaluation of the trial\r&lt;br&gt;             endpoints.\r&lt;br&gt;\r&lt;br&gt;          -  5. Previous exposure to PUL-042 Inhalation Solution\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult =18 years of age at time of enrolment.\r&lt;br&gt;\r&lt;br&gt;          -  Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other\r&lt;br&gt;             commercial or public health assay in any specimen &lt; 72 hours prior to randomization.\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized patients with illness of any duration, and at least one of the following:\r&lt;br&gt;\r&lt;br&gt;               -  Clinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room\r&lt;br&gt;                  air, OR\r&lt;br&gt;\r&lt;br&gt;               -  Acute respiratory failure requiring mechanical ventilation and/or supplemental\r&lt;br&gt;                  oxygen.\r&lt;br&gt;\r&lt;br&gt;          -  Women of childbearing potential must agree to use contraception for the duration of\r&lt;br&gt;             the study. Acceptable birth methods control are listed in section 7.3\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Refusal to participate expressed by patient or legally authorized representative if\r&lt;br&gt;             they are present\r&lt;br&gt;\r&lt;br&gt;          -  Spontaneous blood ALT/AST levels &gt; 5 times the upper limit of normal.\r&lt;br&gt;\r&lt;br&gt;          -  Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt; 30 mL/min)\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breast-feeding.\r&lt;br&gt;\r&lt;br&gt;          -  Anticipated transfer to another hospital, which is not a study site within 72 hours.\r&lt;br&gt;\r&lt;br&gt;          -  Patients previously treated with one of the antivirals evaluated in the trial (i.e.\r&lt;br&gt;             remdesivir, interferon -1a, lopinavir/ritonavir, hydroxychloroquine) in the past 29\r&lt;br&gt;             days\r&lt;br&gt;\r&lt;br&gt;          -  Contraindication to any study medication including allergy\r&lt;br&gt;\r&lt;br&gt;          -  Use of medications that are contraindicated with lopinavir/ritonavir i.e. drugs whose\r&lt;br&gt;             metabolism is highly dependent on the isoform CYP3A with narrow therapeutic range\r&lt;br&gt;             (e.g. amiodarone, colchicine, simvastatine).\r&lt;br&gt;\r&lt;br&gt;          -  Use of medications that are contraindicated with hydroxychloroquine: citalopram,\r&lt;br&gt;             escitalopram, hydroxyzine, domperidone, pipraquine.\r&lt;br&gt;\r&lt;br&gt;          -  Human immunodeficiency virus infection under highly active antiretroviral therapy\r&lt;br&gt;             (HAART).\r&lt;br&gt;\r&lt;br&gt;          -  History of severe depression or attempted suicide or current suicidal ideation\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Male and female, 18-75 years old\r&lt;br&gt;\r&lt;br&gt;          -  Patients previously diagnosed with novel coronavirus pneumonia: the course of illness\r&lt;br&gt;             is no more than 14 days; if the course of the disease was more than 14 days, patient\r&lt;br&gt;             meets one of the following conditions can also be included in the group: (1) No\r&lt;br&gt;             apparent absorption or progression of chest radiograph was observed within 7 days; (2)\r&lt;br&gt;             respiratory symptoms (chest tightness, or cough, or breathing difficulties); (3) Test\r&lt;br&gt;             for viral nucleic acid positive within 3 days.\r&lt;br&gt;\r&lt;br&gt;          -  informed consent should be signed by the participate or an authorized agent\r&lt;br&gt;\r&lt;br&gt;          -  Agree to clinical samples collection\r&lt;br&gt;\r&lt;br&gt;          -  Female or male subjects of childbearing age agree to take effective contraceptive\r&lt;br&gt;             measures within 3 months of the last oral medication to ensure that female or male\r&lt;br&gt;             partners of childbearing age do not become pregnant\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Severe vomiting or difficulty ingesting medication\r&lt;br&gt;\r&lt;br&gt;          -  Woman who are pregnant or during lactation\r&lt;br&gt;\r&lt;br&gt;          -  Patients received lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody\r&lt;br&gt;             specific antiviral drugs three days before enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Cases of respiratory failure requiring mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  Shock\r&lt;br&gt;\r&lt;br&gt;          -  Combined with other organ failure and requires ICU care\r&lt;br&gt;\r&lt;br&gt;          -  Clinical prognostic non-survival, palliative care, or in deep coma and no have\r&lt;br&gt;             response to supportive treatment within three hours of admission\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Parents/legal guardians or adult participant* is willing and able to give informed\r&lt;br&gt;             consent for participation in the study.\r&lt;br&gt;\r&lt;br&gt;          -  Male or Female, aged 0 - 24 years inclusive.\r&lt;br&gt;\r&lt;br&gt;          -  Parents/legal guardians or adult participants are willing to allow their General\r&lt;br&gt;             Practitioner or relevant NHS databases to be contacted for a full immunisation history\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  If participants do not live in the postcode districts selected by PHE\r&lt;br&gt;\r&lt;br&gt;          -  Medically diagnosed bleeding disorder\r&lt;br&gt;\r&lt;br&gt;          -  Medically diagnosed platelet disorder\r&lt;br&gt;\r&lt;br&gt;          -  Anticoagulation medication\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  If another member of their household is participating who is within 5 years of age of\r&lt;br&gt;             the potential participants age\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age 18 or older.\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed Covid-19 infection\r&lt;br&gt;\r&lt;br&gt;          -  ARDS\r&lt;br&gt;\r&lt;br&gt;          -  ICU patient\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Active Neisseria infection.\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant enrollment in another experimental/off-label immunosuppressive therapy\r&lt;br&gt;             trial.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory (RT-PCR) confirmed infection with 2019-nCoV\r&lt;br&gt;\r&lt;br&gt;          3. PaO2/FiO2 &lt; 300 or SpO2 below 93% breathing ambient air\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Physician makes a decision that trial involvement is not in the patient's best\r&lt;br&gt;             interest, or any condition that does not allow the protocol to be followed safely\r&lt;br&gt;\r&lt;br&gt;          2. Pregnant or positive pregnancy test in a pre-dose examination\r&lt;br&gt;\r&lt;br&gt;          3. Use of high flow nasal cannula\r&lt;br&gt;","\r&lt;br&gt;        Study Participants\r&lt;br&gt;\r&lt;br&gt;        These are of two types:\r&lt;br&gt;\r&lt;br&gt;        A. Adult volunteers (exact age is dependent on countries) working as a healthcare worker or\r&lt;br&gt;        frontline (i.e. patient contact) in a healthcare facility or similar institution\r&lt;br&gt;\r&lt;br&gt;        B. Provided that they are willing to participate in the trial and can be followed\r&lt;br&gt;        adequately for up to 5 months, we may also enrol hospitalised patients or relatives exposed\r&lt;br&gt;        or potentially exposed to the SARS-CoV-2 virus or other high-risk groups\r&lt;br&gt;\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participant is willing and able to give informed consent for participation in the\r&lt;br&gt;             study and agrees with the study and its conduct\r&lt;br&gt;\r&lt;br&gt;          -  Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential\r&lt;br&gt;             antivirals\r&lt;br&gt;\r&lt;br&gt;          -  Adults (exact age is dependent on countries)\r&lt;br&gt;\r&lt;br&gt;          -  Not previously diagnosed with COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Not currently symptomatic with an Acute Respiratory Infection\r&lt;br&gt;\r&lt;br&gt;          -  Participant A. works in healthcare facility or other well characterised high-risk\r&lt;br&gt;             environment, OR B. is an inpatient or relative of a patient in a participating\r&lt;br&gt;             hospital and likely exposed to COVID-19 infection or another high-risk group\r&lt;br&gt;\r&lt;br&gt;          -  Possesses an internet-enabled smartphone (Android or iOS)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines\r&lt;br&gt;\r&lt;br&gt;          -  Contraindication to taking chloroquine as prophylaxis e.g. known epileptic, known\r&lt;br&gt;             creatinine clearance &lt; 10 ml/min\r&lt;br&gt;\r&lt;br&gt;          -  Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines\r&lt;br&gt;\r&lt;br&gt;          -  Taking a concomitant medication (Abiraterone acetate, Agalsidase, Conivaptan,\r&lt;br&gt;             Dabrafenib, Dacomitinib, Enzalutamide, Idelalisib, Mifepristone, Mitotane, tiripentol)\r&lt;br&gt;             which cannot be safely stopped\r&lt;br&gt;\r&lt;br&gt;          -  Known retinal disease\r&lt;br&gt;\r&lt;br&gt;          -  Inability to be followed up for the trial period\r&lt;br&gt;\r&lt;br&gt;          -  Known prolonged QT syndrome (however ECG is not required at baseline)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age: 18-80 years old, male and female;\r&lt;br&gt;\r&lt;br&gt;          2. Covid-19 confirmed cases;\r&lt;br&gt;\r&lt;br&gt;          3. Comply with any of the following:\r&lt;br&gt;\r&lt;br&gt;               -  Dyspnea, RR = 30 times / min;\r&lt;br&gt;\r&lt;br&gt;                    -  In resting state, transcutaneous oxygen saturation = 93%;\r&lt;br&gt;\r&lt;br&gt;                         -  Oxygenation index (PaO2 / FiO2) &lt; 300MMHG;\r&lt;br&gt;\r&lt;br&gt;          4. Pulmonary imaging showed diffuse exudative lesions.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Unable to obtain informed consent;\r&lt;br&gt;\r&lt;br&gt;          2. Patients with severe liver dysfunction (Child Pugh score = C, or AST &gt; 5 times of the\r&lt;br&gt;             upper limit), severe renal dysfunction (estimated glomerular filtration rate = 30ml /\r&lt;br&gt;             min / 1.73 m2), or continuous renal replacement therapy, hemodialysis, peritoneal\r&lt;br&gt;             dialysis;\r&lt;br&gt;\r&lt;br&gt;          3. Patients with hypertension and unsatisfactory control of antihypertensive drugs\r&lt;br&gt;             (sitting systolic blood pressure &gt; 160mmHg, or diastolic blood pressure &gt; 100mmHg) had\r&lt;br&gt;             a history of hypertension crisis or hypertensive encephalopathy;\r&lt;br&gt;\r&lt;br&gt;          4. Patients with heart disease or clinical symptoms that can not be well controlled, such\r&lt;br&gt;             as NYHA class II or above of cardiac insufficiency, unstable angina, myocardial\r&lt;br&gt;             infarction within one year, supraventricular or ventricular arrhythmias need treatment\r&lt;br&gt;             or intervention;\r&lt;br&gt;\r&lt;br&gt;          5. Those with known hereditary bleeding tendency or coagulation dysfunction, those who\r&lt;br&gt;             had received full dose anticoagulant or thrombolytic therapy in the first 10 days of\r&lt;br&gt;             the group, or those who had taken nonsteroidal anti-inflammatory drugs with platelet\r&lt;br&gt;             inhibition in the first 10 days of the group (except those who had preventive use of\r&lt;br&gt;             low-dose aspirin = 325mg / day);\r&lt;br&gt;\r&lt;br&gt;          6. In the first 6 months of the group, the patients who had thrombosis, such as ischemic\r&lt;br&gt;             stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism and other\r&lt;br&gt;             thrombotic diseases, and in the first 6 months of the group, the patients who had\r&lt;br&gt;             serious angiopathy (including aneurysms or arterial thrombosis requiring surgical\r&lt;br&gt;             treatment) were screened;\r&lt;br&gt;\r&lt;br&gt;          7. Patients with unhealed wounds, active gastric ulcer or fracture; patients with\r&lt;br&gt;             gastrointestinal perforation, gastrointestinal fistula, abdominal abscess and internal\r&lt;br&gt;             fistula in the first 6 months of the group; patients with major surgical history\r&lt;br&gt;             (including thoracotomy biopsy), major trauma (such as fracture) or possible surgery in\r&lt;br&gt;             the course of participating in the trial within 28 days before the group;\r&lt;br&gt;\r&lt;br&gt;          8. There were hemoptysis, gastrointestinal bleeding, central nervous system bleeding,\r&lt;br&gt;             nose bleeding and other serious and active bleeding patients within one month before\r&lt;br&gt;             admission;\r&lt;br&gt;\r&lt;br&gt;          9. There were malignant tumors in the past 5 years;\r&lt;br&gt;\r&lt;br&gt;         10. Those allergic to bevacizumab and its components;\r&lt;br&gt;\r&lt;br&gt;         11. Untreated active hepatitis patients and HIV positive patients;\r&lt;br&gt;\r&lt;br&gt;         12. Pregnant women, lactating women and planned pregnant women;\r&lt;br&gt;\r&lt;br&gt;         13. Have participated in other clinical trials or the researchers think it is not suitable\r&lt;br&gt;             to participate in this study.\r&lt;br&gt;","\r&lt;br&gt;        The inclusion criteria are:\r&lt;br&gt;\r&lt;br&gt;          1. age over 60 years;\r&lt;br&gt;\r&lt;br&gt;          2. informed consent to participate.\r&lt;br&gt;\r&lt;br&gt;        The exclusion criteria are:\r&lt;br&gt;\r&lt;br&gt;          1. confirmed COVID-19 infection (active or recovered);\r&lt;br&gt;\r&lt;br&gt;          2. hospitalization at screening for eligibility;\r&lt;br&gt;\r&lt;br&gt;          3. someone was already enrolled in the study from the same community/household (to avoid\r&lt;br&gt;             potential crosstalk between the study arms).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  We identify individuals aged 18 years or older and registered in the current primary\r&lt;br&gt;             care practice for at least one year.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  We exclude individuals with a prior history of influenza and viral pneumonia before\r&lt;br&gt;             study entry.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed SARS-CoV-2 infection\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 patient in stable condition (i.e., not requiring ICU admission).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Tube feeding or parenteral nutrition.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or lactating women\r&lt;br&gt;\r&lt;br&gt;          -  Admission to ICU &gt; 24 hours\r&lt;br&gt;\r&lt;br&gt;          -  participation in another study including any forms of supplementation or disease\r&lt;br&gt;             specific ONS.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Subjects must have documented exposure to COVID-19 and have a documented negative\r&lt;br&gt;             test for the virus within 72 hours of the administration of study drug\r&lt;br&gt;\r&lt;br&gt;          -  2. Subjects must be free of clinical symptoms (fever, cough, shortness of breath) of a\r&lt;br&gt;             potential COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;          -  3. Subjects must be under quarantine in a controlled facility or hospital (home\r&lt;br&gt;             quarantine is not sufficient)\r&lt;br&gt;\r&lt;br&gt;          -  4. Spirometry (forced expiratory volume in one second [FEV1] and forced vital capacity\r&lt;br&gt;             [FVC]) =70% of predicted value\r&lt;br&gt;\r&lt;br&gt;          -  5. If female, must be either post-menopausal (one year or greater without menses),\r&lt;br&gt;             surgically sterile, or, for female subjects of child-bearing potential who are capable\r&lt;br&gt;             of conception must be: practicing two effective methods of birth control (acceptable\r&lt;br&gt;             methods include intrauterine device, spermicide, barrier, male partner surgical\r&lt;br&gt;             sterilization, and hormonal contraception) during the study and through 30 days after\r&lt;br&gt;             completion of the study. Abstinence is not classified as an effective method of birth\r&lt;br&gt;             control.\r&lt;br&gt;\r&lt;br&gt;          -  6. If female, must not be pregnant, plan to become pregnant, or nurse a child during\r&lt;br&gt;             the study and through 30 days after completion of the study. A pregnancy test must be\r&lt;br&gt;             negative at the Screening Visit, prior to dosing on Day 1.\r&lt;br&gt;\r&lt;br&gt;          -  7. If male, must be surgically sterile or willing to practice two effective methods of\r&lt;br&gt;             birth control (acceptable methods include barrier, spermicide, or female partner\r&lt;br&gt;             surgical sterilization) during the study and through 30 days after completion of the\r&lt;br&gt;             study. Abstinence is not classified as an effective method of birth control.\r&lt;br&gt;\r&lt;br&gt;          -  8. Ability to understand and give informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Documented infection with COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  2. Clinical signs and symptoms consistent with COVID-19 infection (fever, cough,\r&lt;br&gt;             shortness of breath) at the time of screening\r&lt;br&gt;\r&lt;br&gt;          -  3. Known history of chronic pulmonary disease (e.g., asthma [including atopic asthma,\r&lt;br&gt;             exercise-induced asthma, or asthma triggered by respiratory infection], chronic\r&lt;br&gt;             pulmonary disease, pulmonary fibrosis, COPD), pulmonary hypertension, or heart\r&lt;br&gt;             failure.\r&lt;br&gt;\r&lt;br&gt;          -  4. Any condition which, in the opinion of the Principal Investigator, would prevent\r&lt;br&gt;             full participation in this trial or would interfere with the evaluation of the trial\r&lt;br&gt;             endpoints.\r&lt;br&gt;\r&lt;br&gt;          -  5. Previous exposure to PUL-042 Inhalation Solution\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 pneumonia patients diagnosed by WHO criteria\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who were younger than 18 years,\r&lt;br&gt;\r&lt;br&gt;          -  Patients who had undergone renal replacement therapy (RRT) before admission,\r&lt;br&gt;\r&lt;br&gt;          -  Patients whose entire stay lasted for less than 48 hours.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  healthy asymptomatic healthcare workers attending hospital (place of work)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  SARS-CoV-2 positive or symptomatic healthcare workers\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Household contact of index case: currently residing in the same household as an\r&lt;br&gt;             individual evaluated at NYP via outpatient, emergency department (ED), or inpatient\r&lt;br&gt;             services who (1) test positive for COVID-19, or (2) are defined as suspected cases, or\r&lt;br&gt;             persons under investigations (PUI), by the treating physician.\r&lt;br&gt;\r&lt;br&gt;          -  Willing to take study drug as directed for 5 days.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt;18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Suspected or confirmed current COVID-19, defined as: (1) temperature &gt; 38 Celsius; (2)\r&lt;br&gt;             cough; (3) shortness of breath; (4) sore throat; or, if available (not required), (5)\r&lt;br&gt;             positive confirmatory testing for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Suspected or confirmed convalescent COVID-19, defined as any of the above symptoms\r&lt;br&gt;             within the prior 4 weeks.\r&lt;br&gt;\r&lt;br&gt;          -  Inability to take medications orally\r&lt;br&gt;\r&lt;br&gt;          -  Inability to provide written consent\r&lt;br&gt;\r&lt;br&gt;          -  Known sensitivity/allergy to hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Current use of hydroxychloroquine for another indication\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Prior diagnosis of retinopathy\r&lt;br&gt;\r&lt;br&gt;          -  Prior diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Major comorbidities increasing risk of study drug including: i. Hematologic\r&lt;br&gt;             malignancy, ii. Advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii.\r&lt;br&gt;             Known history of ventricular arrhythmias, iv. Current use of drugs that prolong the QT\r&lt;br&gt;             interval\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - COVID-19 positive patients admitted in a ward identified by positive PCR on nasal swab\r&lt;br&gt;        samples\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - Patients for which electrocardiogram or transthoracic echocardiography is not technically\r&lt;br&gt;        feasible\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  According to the risk stratification criteria of the Emilia-Romagna Region, Italy\r&lt;br&gt;             (accessed on March 24th, 2020 http://www...), eligible patients will belong to the\r&lt;br&gt;             Scenario 2, and 3a (slightly modified) as follows:\r&lt;br&gt;\r&lt;br&gt;        Scenario 2 Positive nasopharyngeal swab for COVID-19, asymptomatic or paucisymptomatic,\r&lt;br&gt;        aged =70 years and/or with clinical risk factors for poor outcome (clinically relevant\r&lt;br&gt;        chronic lung disease, diabetes and/or heart disease) or - symptomatic with respiratory or\r&lt;br&gt;        systemic symptoms, however clinically stable (MEWS&lt;3) with CT imaging showing viral\r&lt;br&gt;        pneumonia and positive or pending pharyngo-nasal swab for COVID-19: Temperature 38C and/or\r&lt;br&gt;        intensive cough, Respiratory rate &lt; 25 /min, oxygen saturation (pulse oximetry) &gt;95%\r&lt;br&gt;\r&lt;br&gt;        Scenario 3 A\r&lt;br&gt;\r&lt;br&gt;        Positive swab for COVID-19\r&lt;br&gt;\r&lt;br&gt;        - with respiratory and/or systemic symptoms and initial mild respiratory failure e with\r&lt;br&gt;        objective signs of lung involvement; the patient is in stable conditions (MEWS &lt; 3)\r&lt;br&gt;        Temperature&gt;38C and or intensive cough, Respiratory rate =25 /min, or oxygen saturation\r&lt;br&gt;        94- 95% in room air\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  Hepatic failure Child-Pugh C\r&lt;br&gt;\r&lt;br&gt;          -  Enrollment in other pharmacological studies\r&lt;br&gt;\r&lt;br&gt;          -  Ongoing treatment with antiviral drugs that include ritonavir or cobicistat\r&lt;br&gt;\r&lt;br&gt;          -  Previous treatment with antiviral drugs that include ritonavir or cobicistat is NOT an\r&lt;br&gt;             exclusion criteria\r&lt;br&gt;\r&lt;br&gt;          -  Any medical condition or disease which in the opinion of the Investigator may place\r&lt;br&gt;             the patient at unacceptable risk for study participation.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  In case of doubt of interstitial pneumonia with indications for intubation\r&lt;br&gt;\r&lt;br&gt;          -  Positive swab test of SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  Interstitial pneumonia\r&lt;br&gt;\r&lt;br&gt;          -  Signature of informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Unsigned informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Negative swab test of SARS-CoV-2\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult patients (&gt;18 years)\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed COVID-19 infection by real-time PCR from a respiratory or other body sample\r&lt;br&gt;             within 48 hours of testing.\r&lt;br&gt;\r&lt;br&gt;          -  Mild to moderate infection or asymptomatic patients with comorbidities: Symptomatic\r&lt;br&gt;             patients with fever &gt;37.9C or cough or dyspnea or chest pain, not fulfilling severity\r&lt;br&gt;             exclusion criteria. We will include patients regardless of time since symptom onset.\r&lt;br&gt;             In addition, we will include asymptomatic patients with comorbidities including\r&lt;br&gt;             cardiac, pulmonary, diabetes, chronic renal failure or liver disease hospitalized for\r&lt;br&gt;             observation.\r&lt;br&gt;\r&lt;br&gt;          -  Informed consent from patient or legal representative.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Severe infection, defined as need for invasive or non-invasive ventilator support,\r&lt;br&gt;             ECMO or shock requiring vasopressor support.\r&lt;br&gt;\r&lt;br&gt;          -  Unable to take oral medication\r&lt;br&gt;\r&lt;br&gt;          -  Known allergy to HCQ or chloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Prolonged QT, defined as QTc =450 milliseconds for men and as QTc =470 for women\r&lt;br&gt;\r&lt;br&gt;          -  Severely reduced LV function (Ejection fraction&lt;30%)\r&lt;br&gt;\r&lt;br&gt;          -  Retinopathy\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant treatment with azithromycin, flecainide, amiodarone, digoxin,\r&lt;br&gt;             procainamide, propafenone, thioridazine, pimozide.\r&lt;br&gt;\r&lt;br&gt;          -  Chronic chloroquine/ HCQ treatment (within 1 month)\r&lt;br&gt;\r&lt;br&gt;          -  Need for hemodialysis\r&lt;br&gt;\r&lt;br&gt;          -  Participating in another RCT for treatment of COVID-19\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Being between the ages of 18-55\r&lt;br&gt;\r&lt;br&gt;          -  To continue their active education or business life before the social isolation\r&lt;br&gt;             period.\r&lt;br&gt;\r&lt;br&gt;          -  Spending time at home differently from routine life recently\r&lt;br&gt;\r&lt;br&gt;          -  Having a smart phone\r&lt;br&gt;\r&lt;br&gt;          -  Not having visual impairment\r&lt;br&gt;\r&lt;br&gt;          -  Being literate in Turkish\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Mental disability or diagnosed severe psychological discomfort\r&lt;br&gt;\r&lt;br&gt;          -  Being diagnosed with serious systemic disease (cardiovascular, metabolic, pulmonary)\r&lt;br&gt;\r&lt;br&gt;          -  Changing the living conditions in the last 3 months (moving, changing jobs ...)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age&gt; 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  patients with acute respiratory failure related to suspected community acquired\r&lt;br&gt;             pneumonia (viral and non viral) requiring oxygen therapy &lt; 6 L/min (or FiO2&lt; 0.50) (to\r&lt;br&gt;             maintain SpO2 between 90 and 94% SpO2) without criteria for immediate intubation or\r&lt;br&gt;             ICU transfer.\r&lt;br&gt;\r&lt;br&gt;          -  Patients hospital admission &lt; 72 hours\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  shock state,\r&lt;br&gt;\r&lt;br&gt;          -  no SpO2 signal available,\r&lt;br&gt;\r&lt;br&gt;          -  patient agitation,\r&lt;br&gt;\r&lt;br&gt;          -  pH &lt; 7.30 (if blood gas available)\r&lt;br&gt;\r&lt;br&gt;          -  PaCO2 &gt; 50 mmHg, (if blood gas available) or chronic hypercapnia history\r&lt;br&gt;\r&lt;br&gt;          -  Non invasive respiratory support (NIV, High flow Nasal Therapy (HFNT)) at study\r&lt;br&gt;             inclusion\r&lt;br&gt;\r&lt;br&gt;          -  Withdrawal of life support or palliation as the goal of care\r&lt;br&gt;\r&lt;br&gt;          -  patients' or next of kin refusal to participate to the study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All consecutive patients with mild to moderate COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt;18 years,\r&lt;br&gt;\r&lt;br&gt;          -  Clinical diagnosis of COVID19 infection\r&lt;br&gt;\r&lt;br&gt;          -  Patients should present fever, cough and myalgia and weakness and radiological\r&lt;br&gt;             findings of pneumonia.\r&lt;br&gt;\r&lt;br&gt;          -  All patients should be willing and able to provide written informed consent prior to\r&lt;br&gt;             performing study procedures.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age less than 18\r&lt;br&gt;\r&lt;br&gt;          -  History of thrombophlebitis.\r&lt;br&gt;\r&lt;br&gt;          -  Patient with latent tuberculosis infection (Quantiferon test).\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy and lactation.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Signed the informed consents before joining this study\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Dysphagia or symptoms of gastric outlet obstruction, suspected or known intestinal\r&lt;br&gt;             stenosis, history of upper gastrointestinal surgery or abdominal surgery altering\r&lt;br&gt;             gastrointestinal anatomy\r&lt;br&gt;\r&lt;br&gt;          -  Refused abdominal surgery to take out the capsule in case of capsule retention\r&lt;br&gt;\r&lt;br&gt;          -  Implanted pacemaker, except the pacemaker is compatible with MRI\r&lt;br&gt;\r&lt;br&gt;          -  Other implanted electromedical devices or magnetic metal foreign bodies\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or suspected pregnancy\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged between 18 and 75 years, extremes included, male or female\r&lt;br&gt;\r&lt;br&gt;          -  Positivity to covid-19 screening test in molecular biology\r&lt;br&gt;\r&lt;br&gt;          -  In escin group: Low response to standard treatment\r&lt;br&gt;\r&lt;br&gt;          -  Ability to understand and the willingness to sign a written informed consent document\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Female subjects who are pregnant or breastfeeding.\r&lt;br&gt;\r&lt;br&gt;          -  patients with previous history to allergy\r&lt;br&gt;\r&lt;br&gt;          -  patients meet the contraindications of escin\r&lt;br&gt;\r&lt;br&gt;          -  Patients have any condition that in the judgement of the Investigators would make the\r&lt;br&gt;             subject inappropriate for entry into this study.\r&lt;br&gt;\r&lt;br&gt;          -  patients can't take drugs orally\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients undergoing ANY type of surgery in an operating theatre, this includes\r&lt;br&gt;             obstetrics\r&lt;br&gt;\r&lt;br&gt;        AND\r&lt;br&gt;\r&lt;br&gt;        - The patient had COVID-19 infection either at the time of surgery or within 30 days of\r&lt;br&gt;        surgery, based on\r&lt;br&gt;\r&lt;br&gt;        (i) positive COVID-19 lab test or computed tomography (CT) chest scan\r&lt;br&gt;\r&lt;br&gt;        OR\r&lt;br&gt;\r&lt;br&gt;        (ii) clinical diagnosis (no COVID-19 lab test or CT chest performed)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  If COVID-19 infection is diagnosed &gt;30 days after discharge, the patient should not be\r&lt;br&gt;             included.\r&lt;br&gt;","Inclusion criteria: 1. The nucleic acid of novel coronavirus 2019 was positive or the virus gene was highly homologous to the known new coronavirus. \r&lt;br&gt;2. The patient has fever or / and pneumonia;\r&lt;br&gt;3. Aged &gt;=18 years old.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. High risk close contact with a confirmed COVID-19 case during their symptomatic\r&lt;br&gt;             period, including one day before symptom onset, within the past 1-7 days. High risk\r&lt;br&gt;             close contact is defined as any of the following exposures without the consistent\r&lt;br&gt;             appropriate use of recommended personal protective equipment:\r&lt;br&gt;\r&lt;br&gt;               1. Provided direct care for the index case\r&lt;br&gt;\r&lt;br&gt;               2. Had close physical contact with the index case\r&lt;br&gt;\r&lt;br&gt;               3. Lived with the index case\r&lt;br&gt;\r&lt;br&gt;               4. Had close contact (within 2 metres), without direct physical contact, for a\r&lt;br&gt;                  prolonged period of time\r&lt;br&gt;\r&lt;br&gt;               5. Had direct contact with infectious body fluids, including oral secretions,\r&lt;br&gt;                  respiratory secretions, or stool.\r&lt;br&gt;\r&lt;br&gt;          2. Successfully contacted by the study team within 24 hours of study team notification of\r&lt;br&gt;             the relevant index COVID-19 case. This time window is necessary because the efficacy\r&lt;br&gt;             of PEP may be dependent on the timing of its initiation, and because randomization of\r&lt;br&gt;             a ring cannot be delayed while awaiting response from contacts that cannot be rapidly\r&lt;br&gt;             reached.\r&lt;br&gt;\r&lt;br&gt;          3. Age =6 months, since the safety and pharmacokinetic profiles of LPV/r in pediatric\r&lt;br&gt;             patients below the age of 6 months have not been established.\r&lt;br&gt;\r&lt;br&gt;          4. Ability to communicate with study staff in English\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Known hypersensitivity/allergy to lopinavir or ritonavir.\r&lt;br&gt;\r&lt;br&gt;          2. Current use of LPV/r for the treatment or prevention of HIV infection.\r&lt;br&gt;\r&lt;br&gt;          3. Receipt of LPV/r in the context of this trial or any other trial of COVID-19 PEP\r&lt;br&gt;             within 2 days or less prior to the last known contact with the index COVID-19 case.\r&lt;br&gt;             The two day time window is intended to ensure that exposure would not have occurred in\r&lt;br&gt;             the presence of clinically relevant drug levels (five times the elimination half-life\r&lt;br&gt;             of LPV/r, which is estimated at 4-6 hours with prolonged use).\r&lt;br&gt;\r&lt;br&gt;          4. Baseline respiratory tract specimen positive for COVID-19. Randomized participants\r&lt;br&gt;             whose baseline samples subsequently show COVID-19 will have study drug discontinued\r&lt;br&gt;             but still remain under observation.\r&lt;br&gt;\r&lt;br&gt;          5. Current breastfeeding, due to potential for serious adverse reactions in nursing\r&lt;br&gt;             infants exposed to LPV/r\r&lt;br&gt;\r&lt;br&gt;          6. Concomitant medications with prohibited drug interactions with LPV/r that cannot be\r&lt;br&gt;             temporarily suspended/replaced, including but not restricted to: 37\r&lt;br&gt;\r&lt;br&gt;               -  alfuzosin (e.g. Xatral)\r&lt;br&gt;\r&lt;br&gt;               -  amiodarone (e.g. Cordarone)\r&lt;br&gt;\r&lt;br&gt;               -  apalutamide (e.g. Erleada)\r&lt;br&gt;\r&lt;br&gt;               -  astemizole*, terfenadine*\r&lt;br&gt;\r&lt;br&gt;               -  cisapride*\r&lt;br&gt;\r&lt;br&gt;               -  colchicine, when used in patients with renal and/or hepatic impairment\r&lt;br&gt;\r&lt;br&gt;               -  dronedarone (e.g., Multaq)\r&lt;br&gt;\r&lt;br&gt;               -  elbasvir/grazoprevir (e.g., ZepatierTM)\r&lt;br&gt;\r&lt;br&gt;               -  ergotamine* (e.g. Cafergot*), dihydroergotamine (e.g. Migranal), ergonovine,\r&lt;br&gt;                  methylergonovine*\r&lt;br&gt;\r&lt;br&gt;               -  fusidic acid (e.g., Fucidin), systemic*\r&lt;br&gt;\r&lt;br&gt;               -  lurasidone (e.g., Latuda), pimozide (e.g., Orap*)\r&lt;br&gt;\r&lt;br&gt;               -  neratinib (e.g., Nerlynx)\r&lt;br&gt;\r&lt;br&gt;               -  sildenafil (e.g., Revatio)\r&lt;br&gt;\r&lt;br&gt;               -  triazolam (e.g. Halcion), midazolam oral*\r&lt;br&gt;\r&lt;br&gt;               -  rifampin (e.g. Rimactane*, Rifadin, Rifater*, Rifamate*)\r&lt;br&gt;\r&lt;br&gt;               -  St. John's Wort\r&lt;br&gt;\r&lt;br&gt;               -  Tadalafil (e.g. Adcirca)\r&lt;br&gt;\r&lt;br&gt;               -  venetoclax (e.g. Venclexta)\r&lt;br&gt;\r&lt;br&gt;               -  lovastatin (e.g., Mevacor*), lomitapide (e.g., JuxtapidTM) or simvastatin (e.g.,\r&lt;br&gt;                  Zocor)\r&lt;br&gt;\r&lt;br&gt;               -  vardenafil (e.g., Levitra or Staxyn)\r&lt;br&gt;\r&lt;br&gt;               -  salmeterol (e.g., Advair or Serevent)\r&lt;br&gt;\r&lt;br&gt;                    -  denotes products not marketed in Canada\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  age &gt;=18 yrs\r&lt;br&gt;\r&lt;br&gt;          -  positive for reverse transcription polymerase chain reaction (RT-PCR) severe acute\r&lt;br&gt;             respiratory syndrome (SARS)-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  Acute respiratory distress syndrome (ARDS) moderate to severe, according to Berlin\r&lt;br&gt;             definition, lasting less than10 days\r&lt;br&gt;\r&lt;br&gt;          -  Polymerase chain reaction (PCR) increased by 3.5 with respect to baseline or &gt;18 mg/dl\r&lt;br&gt;\r&lt;br&gt;          -  need for mechanical ventilation or continuous positive airway pressure (CPAP)\r&lt;br&gt;\r&lt;br&gt;          -  signed informed consent unless unfeasible for the critical condition\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Moderate to severe ARDS lasting more than 10 days\r&lt;br&gt;\r&lt;br&gt;          -  proven hypersensitivity or allergic reaction to hemoderivatives or immunoglobulins\r&lt;br&gt;\r&lt;br&gt;          -  consent denied\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  suspected COVID-19 patients,\r&lt;br&gt;\r&lt;br&gt;          -  known COVID-19 patients.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  confirmed disease different from COVID-19.\r&lt;br&gt;","\r&lt;br&gt;        Key Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients were diagnosed as severe COVID-19 according to the Coronavirus disease\r&lt;br&gt;             (COVID-19) Treatment Guidance (Six edition)\r&lt;br&gt;\r&lt;br&gt;          2. Patients received a combined treatment of TCM and conventional therapy, or only\r&lt;br&gt;             conventional therapy.\r&lt;br&gt;\r&lt;br&gt;        Key Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age &gt;85 years\r&lt;br&gt;\r&lt;br&gt;          2. After cardiopulmonary resuscitation\r&lt;br&gt;\r&lt;br&gt;          3. Patients combined with other organ failure or conditions need ICU monitoring and\r&lt;br&gt;             treatment, such as severe liver disease, severe renal dysfunction, upper\r&lt;br&gt;             gastrointestinal hemorrhage, disseminated intravascular coagulation.\r&lt;br&gt;\r&lt;br&gt;          4. Respiratory failure and need mechanical ventilation\r&lt;br&gt;","Inclusion criteria: 1. People aged between 18 and 65 years old;\r&lt;br&gt;2. People have electronic social software such as WeChat, QQ and Email.","Inclusion criteria: included in \"Diagnosis and treatment scheme of pneumonia infected by novel coronavirus (trial version 5 or later version)\"","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Sign written informed consent;\r&lt;br&gt;\r&lt;br&gt;          2. Age =18 years;\r&lt;br&gt;\r&lt;br&gt;          3. Conforms to the NCP Critical and Critical Diagnostic Standards, namely \"Pneumonitis\r&lt;br&gt;             Diagnosis and Treatment Scheme for New Coronavirus Infection (Trial Version 6)\".\r&lt;br&gt;             Comprehensive judgment based on epidemiological history, clinical manifestations and\r&lt;br&gt;             etiological examination;\r&lt;br&gt;\r&lt;br&gt;          4. The course of disease is within 14 days after the onset of illness;\r&lt;br&gt;\r&lt;br&gt;          5. Willing to collect nasopharyngeal or oropharyngeal swabs before administration.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients participating in clinical trials of other drugs;\r&lt;br&gt;\r&lt;br&gt;          2. pregnant or lactating women;\r&lt;br&gt;\r&lt;br&gt;          3. ALT / AST&gt; 5 times ULN, or neutrophils &lt;0.5 * 109 / L, or platelets less than 50 * 109\r&lt;br&gt;             / L;\r&lt;br&gt;\r&lt;br&gt;          4. Expected survival time is less than 1 week;\r&lt;br&gt;\r&lt;br&gt;          5. A clear diagnosis of rheumatism-related diseases;\r&lt;br&gt;\r&lt;br&gt;          6. Long-term oral anti-rejection drugs or immunomodulatory drugs;\r&lt;br&gt;\r&lt;br&gt;          7. Patients hypersensitive to NK cells and their preservation solution.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Highly suspected/confirmed infection with SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - Patients that opt-out\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 infected patient\r&lt;br&gt;\r&lt;br&gt;          -  Age 18 years or older\r&lt;br&gt;\r&lt;br&gt;          -  Presence of pneumonia\r&lt;br&gt;\r&lt;br&gt;          -  PaO2/FiO2 &lt; 300 mm Hg or SpO2 &lt; 93% in air ambient or need to supplementary oxygen\r&lt;br&gt;             administration in order to maintain SpO2 range in [94-98%] or lung infiltrates &gt; 50%\r&lt;br&gt;\r&lt;br&gt;          -  Medical insurance\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Presence of do-not-resuscitate order\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Prisoners\r&lt;br&gt;\r&lt;br&gt;          -  Known Naproxen allergy or intolerance\r&lt;br&gt;\r&lt;br&gt;          -  Severe renal failure\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Cohort 1:\r&lt;br&gt;\r&lt;br&gt;          -  Females and males over 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Willing to share demographic data with the sponsor of the study\r&lt;br&gt;\r&lt;br&gt;          -  Willing to follow app use instructions during the course of the study\r&lt;br&gt;\r&lt;br&gt;          -  Willing to complete survey instruments as described in study procedures\r&lt;br&gt;\r&lt;br&gt;          -  Willing to provide electronic informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Able to read and understand the English language well enough to complete electronic\r&lt;br&gt;             informed consent\r&lt;br&gt;\r&lt;br&gt;        Cohort 2:\r&lt;br&gt;\r&lt;br&gt;        Any person present in the vicinity of a HealthMode Cough Monitoring Device\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        No exclusion criteria\r&lt;br&gt;\r&lt;br&gt;        -\r&lt;br&gt;","Inclusion criteria: Healthy group: healthy, without serious disease; \r&lt;br&gt;normal group: diagnosed patients with common NCP; \r&lt;br&gt;severe group: diagnosed patients with severe NCP.","Inclusion criteria: 1. Chinese emergency medical staff on duty from November 2019 to June 2020;\r&lt;br&gt;2. Aged &gt;= 18 years;\r&lt;br&gt;3. Meet ethical standards and be able to sign informed consent.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Case are adults age = 18 years old admitted to hospital with laboratory confirmed\r&lt;br&gt;             COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Controls are patients admitted for community-acquired pneumonia\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who refuse to consent for study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients &gt;/= 18 years old AND\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalised with PCR-confirmed and/or CT-confirmed SARS-CoV-2 disease\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt; 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  No informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Patients on cyclosporine/tacrolimus/sirolimus/everolimus therapy*\r&lt;br&gt;","Inclusion criteria: 1. Patients meet Diagnosis and treatment of novel coronavirus pneumonia (Seventh Edition);\r&lt;br&gt;2. Over 18 years old;\r&lt;br&gt;3. Patients with hypertension,diabetes and chronic kidney disease were treated with ARBs or other drugs;\r&lt;br&gt;4. Complete data;\r&lt;br&gt;5. Agree to participate in the study and cooperate with the follow-up.","Inclusion criteria: 1. Patients with new crowns who meet the criteria for the removal and discharge of \"Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 7)\".\r&lt;br&gt;2. Aged &gt;=18 years;\r&lt;br&gt;3. The limbs function is sound;\r&lt;br&gt;4. No serious dysfunction of vital organs such as lung, liver and kidney;\r&lt;br&gt;5. The patient is clearly conscious, willing and signed the informed consent.","Inclusion criteria: 1. Informed consent;\r&lt;br&gt;2. Aged 20-65 years;\r&lt;br&gt;3. Dental emergency medical staff.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Meeting the criteria for diagnosis of COVID-19, either clinically or as confirmed by\r&lt;br&gt;             positive swap.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Children below 5 years old. Severely ill patients with either terminal disease. Nil\r&lt;br&gt;             per os (NPO) patients with contraindication to nasogastric tube feeding.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. SARS-CoV-2 positive\r&lt;br&gt;\r&lt;br&gt;          2. Age &gt;17 years and &lt; 80 years\r&lt;br&gt;\r&lt;br&gt;          3. P/F &lt; 250 mmHg\r&lt;br&gt;\r&lt;br&gt;          4. Bilateral pneumonia (infiltrates/interstitial)\r&lt;br&gt;\r&lt;br&gt;          5. CRP &gt;10mg/dL (or &gt;100mg/L)\r&lt;br&gt;\r&lt;br&gt;          6. Alternatively to 4-5-6 criteria a diagnosis of ARDS according to the Berlin definition\r&lt;br&gt;             (JAMA 2012)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Heart failure as predominant cause of acute respiratory failure\r&lt;br&gt;\r&lt;br&gt;          -  Decompensated liver cirrhosis\r&lt;br&gt;\r&lt;br&gt;          -  Cancer\r&lt;br&gt;\r&lt;br&gt;          -  Organ transplantation\r&lt;br&gt;\r&lt;br&gt;          -  HIV+\r&lt;br&gt;\r&lt;br&gt;          -  dialysis\r&lt;br&gt;\r&lt;br&gt;          -  long-term oxygen therapy\r&lt;br&gt;\r&lt;br&gt;          -  Idiopathic pulmonary fibrosis\r&lt;br&gt;\r&lt;br&gt;          -  Progressive neurmomuscular disorders (e.g. Duchenne, Pompe, ALS)\r&lt;br&gt;\r&lt;br&gt;          -  immunosupressive treatments\r&lt;br&gt;\r&lt;br&gt;          -  Chronic use of corticosteroids\r&lt;br&gt;\r&lt;br&gt;          -  Use of tocilizumab\r&lt;br&gt;\r&lt;br&gt;          -  pregnancy\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18 years of age\r&lt;br&gt;\r&lt;br&gt;          -  Informed consent\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 confirmed by established testing\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Known glucose-6-phosphate dehydrogenase (G6PD) deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Contra-indication to chloroquine or azithromycin\r&lt;br&gt;\r&lt;br&gt;          -  Already receiving chloroquine or azithromycin\r&lt;br&gt;","\r&lt;br&gt;        Group 1\r&lt;br&gt;\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged 18 to 75 years old\r&lt;br&gt;\r&lt;br&gt;          -  Individuals with a clinical diagnosis of moderate-to-severe chronic plaque psoriasis\r&lt;br&gt;             confirmed by the Investigator\r&lt;br&gt;\r&lt;br&gt;          -  Continuous immunosuppressive therapy (etanercept, adalimumab, infliximab, ustekinumab,\r&lt;br&gt;             secukinumab, ixekizumab, brodalumab, guselkumab, apremilast, methotrexate,\r&lt;br&gt;             ciclsoporin, acitretin) for the past 3 months\r&lt;br&gt;\r&lt;br&gt;          -  Is willing and able to sign informed consent to participate\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients unwilling to undergo noasopharyngeal swab\r&lt;br&gt;\r&lt;br&gt;          -  Inability to give informed consent\r&lt;br&gt;\r&lt;br&gt;        Group 2\r&lt;br&gt;\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged 18 to 75 years old\r&lt;br&gt;\r&lt;br&gt;          -  Partner of a patient with psoriasis enrolled in the study\r&lt;br&gt;\r&lt;br&gt;          -  Is willing and able to sign informed consent to participate\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Personal history of psoriasis\r&lt;br&gt;\r&lt;br&gt;          -  Ongoing immunosuppressive therapy\r&lt;br&gt;\r&lt;br&gt;          -  Patients unwilling to undergo noasopharyngeal swab\r&lt;br&gt;\r&lt;br&gt;          -  Inability to give informed consent\r&lt;br&gt;\r&lt;br&gt;        Group 3\r&lt;br&gt;\r&lt;br&gt;          -  Aged 18 to 75 years old\r&lt;br&gt;\r&lt;br&gt;          -  Individuals with a clinical diagnosis of moderate-to-severe atopic dermatitis\r&lt;br&gt;             confirmed by the Investigator\r&lt;br&gt;\r&lt;br&gt;          -  Continuous therapy with dupilumab for the past 3 months\r&lt;br&gt;\r&lt;br&gt;          -  Is willing and able to sign informed consent to participate\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients unwilling to undergo noasopharyngeal swab\r&lt;br&gt;\r&lt;br&gt;          -  Inability to give informed consent\r&lt;br&gt;","Inclusion criteria: 1. Rheumatic disease;\r&lt;br&gt;2. Residents in Hubei province;\r&lt;br&gt;3. &gt; 18 years old.","Inclusion criteria: novel coronavirus pneumonia patients who admitted into the Wuhan mobile cabin Hospital between 10th February 2020 and 25th February 2020","Inclusion criteria: (1) Aged 18 to 90 years old, male or female;\r&lt;br&gt;(2) Patients with a definite diagnosis of new type of coronavirus pneumonia;\r&lt;br&gt;(3) Expected survival time &gt; 10 days;\r&lt;br&gt;(4) Serology: HIV antibody negative; hepatitis B surface antigen, e antigen negative; hepatitis C antibody negative; female patients with negative pregnancy test; ALT, AST &lt;=2.5 ULN; for patients with liver metastases, ALT, AST &lt;=5 ULN; ALP &lt;=2.5 ULN; serum urea nitrogen and creatinine &lt;=1.5 ULN; serum total bilirubin &lt;1.5 times the upper limit of normal;\r&lt;br&gt;(6) Patients or their legal representatives can understand and voluntarily sign informed consent.","Inclusion criteria: Novel coronavirus 2019-nCoV suspected cases, confirmed cases, excluded cases and clinical cases with negative detection of nucleic acid","Inclusion criteria: 1) Aged 18 to 70 years old;\r&lt;br&gt;2) Infection with new coronavirus pneumonia was confirmed by throat swab nucleic acid test. Patients with severe and critical illness were clinically judged. The symptoms of acute infection have been alleviated after treatment (at least 14 days after onset, no fever for more than 3 days), and the disease is recovering Within three months;\r&lt;br&gt;3) CT examination of patients with multiple fibrotic shadows in both lungs;\r&lt;br&gt;4) Blood routine, liver, and kidney functions are within the controllable range: such as the normal upper limit of plasma total bilirubin and creatinine &lt;=1.5 NUL; AST, ALT, LDH &lt;=2 NUL; sufficient hematopoietic function: such as white blood cells &gt;=4.0x10^9/L, platelets &gt;=100x10^9/L;\r&lt;br&gt;5) Signed informed consent.","Inclusion criteria: (1) Aged 18-70-year-old patients with clear intelligence;\r&lt;br&gt;(2) Non-medical staff and staff who need to participate in epidemic prevention and control;\r&lt;br&gt;(3) Patients with non-new coronary pneumonia infection and treatment and rehabilitation;\r&lt;br&gt;(4) Those who are willing to cooperate with the investigation or after explanation, are willing to cooperate with the investigation and sign the informed consent.","Inclusion criteria: 1. Aged 18 to 75 years old;\r&lt;br&gt;2. mild or normal patients;\r&lt;br&gt;3. not using chloroquine phosphate, lopinavir other than other antiviral drugs;\r&lt;br&gt;4. under the gastroscope, there was mucosal damage and pathological biopsy of 2019-ncov nucleic acid positive;\r&lt;br&gt;5. confirmed cases meeting all the following criteria (the 5th edition of the medical guidelines):\r&lt;br&gt;(1) epidemiological history;\r&lt;br&gt;(2) Clinical manifestations (in accordance with any 2 of the following): fever; In the early stage of the disease, the total number of white blood cells was normal or decreased, or the lymphocyte count was decreased. In the early stage of chest imaging, multiple small plaques and stromal changes were observed, especially in the lung. Then, it developed into multiple ground-glass shadows and infiltrating shadows in both lungs. In severe cases, lung consolidation may occur, and pleural effusion is rare;\r&lt;br&gt;(3) Confirmed: the suspected case has one of the following etiological evidence: respiratory or blood specimens were tested positive for novel coronavirus nucleic acid by real-time fluorescent rt-pcr; Respiratory or blood specimen virus gene sequencing, and known novel coronavirus highly homologous.","Inclusion criteria: From February 4, 2020 to March 12, 2020 novel coronavirus pneumonia patients undergoing emergency endotracheal intubation in the severe isolation ward of the Sino French new town hospital in Tongji Hospital","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with suspected SARS-CoV2/Covid-19 infection\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Unwillingness to participate\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  18 years or older\r&lt;br&gt;\r&lt;br&gt;          -  Suspected or known Covid-19 infection (currently or previously)\r&lt;br&gt;\r&lt;br&gt;          -  Image procedure performed as part of a Covid-19 exam with the images available in\r&lt;br&gt;             DICOM format\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;         Under age 18\r&lt;br&gt;","Inclusion criteria: &lt;br&gt;                1. Is a patient in ED, AMU, HDU, GICU, medical wards, or another location within Southampton General Hospital, University Hospital Southampton NHS Foundation Trust (UHS)&lt;br&gt;                2. Aged =18 years old&lt;br&gt;                3. Can be recruited to the study within 24 hours of presentation to hospital&lt;br&gt;                Plus:&lt;br&gt;                4. Has acute respiratory illness (ARI)*&lt;br&gt;                OR&lt;br&gt;                5. Does not have ARI but is a suspected case of COVID-19 according to the current PHE case definition OR&lt;br&gt;                6. Does not have ARI or fulfil the PHE case definition of a suspected case but testing for SARS-CoV-2 is considered necessary by the responsible clinical team&lt;br&gt;                *An episode of acute respiratory illness is defined as an acute upper or lower respiratory illness (including rhinitis, rhino-sinusitis, pharyngitis, pneumonia, bronchitis and influenza-like illness) or an acute exacerbation of a chronic respiratory illness (including exacerbation of COPD, asthma or bronchiectasis). For the study, acute respiratory illness as a provisional, working, differential or confirmed diagnosis must be made by a treating clinician&lt;br&gt;&lt;br&gt;                Staff testing&lt;br&gt;                Non-hospitalised hospital staff members may be included in the post-implementation phase of the study, if they satisfy the other inclusion and exclusion criteria&lt;br&gt;","Inclusion criteria: 1. Hospitalized between December 2019 and March 2020;\r&lt;br&gt;2. Diagnosed with COVID-19.","Inclusion criteria: Novel coronavirus 2019-nCoV suspected cases, confirmed cases, excluded cases and clinical cases with negative detection of nucleic acid","Inclusion criteria: According to the clinical diagnostic criteria of the seventh or latest edition  \"diagnosis and treatment of pneumonia with novel coronavirus infection\", severe COVID-19 pneumonia was clinically diagnosed.","Inclusion criteria: &lt;br&gt;1.\tAdult =18 years of age at time of enrolment.&lt;br&gt;2.\tHas laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen &lt; 72 hours prior to randomization.&lt;br&gt;3.\tHospitalized patients with illness of any duration, and at least one of the following:&lt;br&gt;\tClinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room air, &lt;br&gt;OR&lt;br&gt;\tRequiring supplemental oxygen, high flow oxygen devices, non invasive ventilation and/or mechanical ventilation&lt;br&gt;4.\tWomen of childbearing potential must agree to use at least one primary form of contraception for the duration of the study. Acceptable birth control methods are listed in section 7.3.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 1700&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 1400&lt;br&gt;","Inclusion criteria: 1. Insomnia diagnosed by DSM-5, but reported a duration of less than 3 months for the current episode;\r&lt;br&gt;2. Insomnia happened after the COVID-19 public health first-level response (after January 25, 2020); Patients with insomnia before, the interval between two episodes must be 3 months or more;\r&lt;br&gt;3. Aged 18-60 years;\r&lt;br&gt;4. ISI &gt; 7;\r&lt;br&gt;5. Educational background is high school and above.","Inclusion criteria: (1) patients with definite diagnosis of novel coronavirus pneumonia and hospitalized at Leishenshan hospital;\r&lt;br&gt;(2) patients aged 18-80 years old;\r&lt;br&gt;(3) patients who signed informed consents, voluntarily and persistently participated in the study and follow-up.","Inclusion criteria: 1. Clinical manifestations of suspected Covid-19 such as fever and dry cough; \r&lt;br&gt;2. Pulmonary CT results indicate suspected Covid-19; \r&lt;br&gt;3. Apparently healthy physical examination subjects with a history of exposure to confirmed Covid-19 patients","Inclusion criteria: 1. Aged 18 to 75 years;\r&lt;br&gt;2. Patients with confirmed cases meeting the following criteria:\r&lt;br&gt;(1) Epidemiology history;\r&lt;br&gt;(2) Clinical manifestations (epidemiological history and in accordance with any of the following 2 items; no clear epidemiology history, conforms to 3 items in clinical manifestations):\r&lt;br&gt;Fever and / or respiratory symptoms;\r&lt;br&gt;In the early stage of the disease, the total leukocyte count was normal or decreased, or the lymphocyte count decreased;\r&lt;br&gt;Early chest imaging showed multiple small plaques and interstitial changes, which were evident in the extraneous lung. Further, multiple ground-glass shadows and infiltration shadows were found in both lungs, and lung consolidation and pleural effusion were rare in severe cases;\r&lt;br&gt;(3) Having one of the following etiological evidence:\r&lt;br&gt;Respiratory tract, blood or fecal samples RT-PCR confirmed infection with 2019-nCoV;\r&lt;br&gt;The virus genes of the above samples were sequenced and highly homologous to the 2019-nCoV;\r&lt;br&gt;3. Patients who meet the following mild and normal criteria;\r&lt;br&gt;Mild: mild clinical symptoms, no signs of pneumonia on imaging;\r&lt;br&gt;Normal: fever, respiratory symptoms, imaging manifestations of pneumonia;\r&lt;br&gt;4.Patients who meet the following criteria of severe and critical severity (one of 3 and 4 is enough):\r&lt;br&gt;(1) Criteria for severe patients (if any of them meet the criteria, they will be involved): Respiratory distress, RR &gt;=30 times/min;            \r&lt;br&gt;(2) In the resting state, the oxygen saturation &lt;=93%;            \r&lt;br&gt;(3) PaO2 / FiO2 &lt;=300 mmHg;           \r&lt;br&gt;(4) Lung imaging showed that the lesions progressed more than 50% in 24-48 hours, which was managed according to heavy duty;            \r&lt;br&gt;Criteria for critical patients (only those who meet the conditions in Article 1 can be selected):            \r&lt;br&gt;(1) respiratory failure and mechanical ventilation is required;           \r&lt;br&gt;(2) shock;           \r&lt;br&gt;(3) Other organ failure should be monitored and treated by ICU.\r&lt;br&gt;5. The antimalarial drugs of chloroquine phosphate and hydroxychloroquine sulfate were not used within 3 months;            \r&lt;br&gt;6. From February 19, 2020, hospitalized patients in Wuhan Tongji Hospital, the First Affiliated Hospital of Nanchang University, the Third Hospital of Beijing Medical University (Wuhan Center), the first hospital of Peking University, the people's Hospital of Peking University, and Haidian Hospital of the Third Hospital of Beijing Medical University.","Inclusion criteria: (1) severe or critical patients with covid-19 pneumonia confirmed by novel coronavirus novel coronavirus diagnosis and treatment plan (seventh Edition);\r&lt;br&gt;(2) 18-85 years old;\r&lt;br&gt;(3) Obtaining informed consent;","Inclusion criteria: 1. aged between 20 to 30 years old;\r&lt;br&gt;2. generally well;\r&lt;br&gt;3. able to understand and sign an informed consent.","Inclusion criteria: 1. Healthy male or female subjects &gt;=18 years old at the date of signing the informed consent;\r&lt;br&gt;2. Male body weight 50kg, female body weight &gt;=45kg, body mass index (BMI) in the range of 19-28kg / m2 (including 19 and 28) (BMI = weight (kg) / height 2 (M2));\r&lt;br&gt;3. The results of physical examination, vital signs, blood routine, urine routine, blood biochemistry, blood coagulation, abdominal B-ultrasound, chest X-ray and other examinations in the screening period must be within the normal range consistent with age and gender, or meet the requirements of the program, or be judged as \"NCS\" if they are beyond the normal range;\r&lt;br&gt;4. 12 lead ECG was normal, QTCF was less than 430ms in men and 450 ms in women; QTc interval was corrected by friderica formula (QTCF = QT / (RR ^ 0.33), RR was the standardized heart rate value, which was obtained by dividing 60 by heart rate);\r&lt;br&gt;5. Pregnancy test is negative in women of childbearing age;\r&lt;br&gt;6. Agree to abstain or take effective non drug contraceptive measures within at least 3 months from screening to the last study drug administration (female subjects also require to start abstinence or take effective non drug contraceptive measures two weeks before entering the study);\r&lt;br&gt;7. Subjects who can communicate well with researchers, understand and comply with the requirements of this study, and understand and sign the informed consent.","Inclusion criteria: 1) Male or female patients aged form 18 to 80 years;\r&lt;br&gt;2) Willing to sign informed consent;\r&lt;br&gt;3) Confirmed cases who meet \"Novel Coronavirus Pneumonia Diagnosis and Treatment Protocol\" revised by the National Health Commission of the Peoples Republic of China.\r&lt;br&gt;4) High-resolution CT indicates interstitial injures in the lungs (honeycomb shadows or grid shadows).","Inclusion criteria: &lt;br&gt;Recent (=2weeks prior to randomization) PCR-Confirmed (GLIMS) COVID-19 infection\r&lt;br&gt;- Presence of acute hypoxic respiratory failure defined as (either or both)\r&lt;br&gt;? saturation below 93% on minimal 2 l/min O2\r&lt;br&gt;? PaO2/FiO2 below 350\r&lt;br&gt;- Admitted to specialized COVID-19 ward\r&lt;br&gt;- Age 18-80\r&lt;br&gt;- Male or Female\r&lt;br&gt;- Willing to provide informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 40&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 40&lt;br&gt;","Inclusion criteria: &lt;br&gt; Age 18 or older\r&lt;br&gt; Both genders\r&lt;br&gt; For women of childbearing age, they should use or be willing to use a double contraceptive method during the study. A urine pregnancy test to exclude pregnancy will be performed prior to study initiation.\r&lt;br&gt; Written consent after information provided by the patient or the legal representative in the event that the patient cannot consent.\r&lt;br&gt; Upper respiratory or lower respiratory tract infection, as in Annexes II and III respectively\r&lt;br&gt; Positive respiratory secretion test for SARS-CoV-2 virus by molecular techniques or positive blood IgM titers&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 60&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 60&lt;br&gt;","Inclusion criteria: &lt;br&gt;- Age &gt;18 years&lt;br&gt;\t- Hospital admission with proven SARS2-Covid19 infection&lt;br&gt;\t- Hypoxemic respiratory failure (SaO2 &lt;92%, PaO2 &lt;8kPa)&lt;br&gt;\t- Ability to give informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 200&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 104&lt;br&gt;","Inclusion criteria: &lt;br&gt;1.\tHospitalised\r&lt;br&gt;2.\tAdults 18 year or older\r&lt;br&gt;3.\tModerately severe disease (NEWS score = 6)\r&lt;br&gt;4.\tSARS-CoV-2 positive nasopharyngeal swab \r&lt;br&gt;5.\tSigned informed consent must be obtained and documented according to ICH GCP, and national/local regulations.\r&lt;br&gt;\r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 40&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 160&lt;br&gt;","Inclusion criteria: &lt;br&gt;1. Hospitalized male or female, = 35 to = 80 years of age\r&lt;br&gt;2. Diagnosed to be COVID-19 POSITIVE(SARS-CoV-2 nucleic acid  qPCR)\r&lt;br&gt;3. Oxygenation criterion:\r&lt;br&gt;    Oxygen saturation =93% (either on Room Air or while the patient is on supplement oxygen)\r&lt;br&gt;4. Respiratory frequency, RR = 25 breaths/min\r&lt;br&gt;5. ALT &lt; 5xULN; bilirubin = 1.5xULN\r&lt;br&gt;6. Presence of at least 1 relevant co-morbid condition (defined as arterial hypertension, diabetes, or coronary artery disease) if age &lt;65 years\r&lt;br&gt;7. Signed Inform Consent Form\r&lt;br&gt;8. Body weight = 85kg\r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 80&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 120&lt;br&gt;","Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent.\r&lt;br&gt;\r&lt;br&gt;          -  Has been previously diagnosed with NTM, Burkholderia spp and Aspergillus spp. or\r&lt;br&gt;             Corona-like viral infection:\r&lt;br&gt;\r&lt;br&gt;               1. NTM, Burkholderia spp and Aspergillus spp defined as positive culture(s) of at\r&lt;br&gt;                  least one species of Mycobacterium avium Complex (MAC) or Mycobacterium abscessus\r&lt;br&gt;                  Complex (MABSCor Burkholderia spp and Aspergillus spp) or Corona-like viral\r&lt;br&gt;                  infection:\r&lt;br&gt;\r&lt;br&gt;               2. History of repeatedly positive cultures (2 or more), irregardless of therapy\r&lt;br&gt;\r&lt;br&gt;          -  Male or female =14 years of age.\r&lt;br&gt;\r&lt;br&gt;          -  Female not pregnant at time of study.\r&lt;br&gt;\r&lt;br&gt;          -  Has an FEV1 = 30 % of predicted. c. Suspected corona-like viral infection\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation on room air &gt;92% at screening.\r&lt;br&gt;\r&lt;br&gt;             a. Able to breathe without supplemental oxygen for 60 minutes\r&lt;br&gt;\r&lt;br&gt;          -  Non-smoker for at least 6 months prior to screening and agrees not to smoke during the\r&lt;br&gt;             study.\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to comply with the treatment schedule and procedures.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Use of an investigational drug within 30 days of screening\r&lt;br&gt;\r&lt;br&gt;          -  History of frequent epistaxis (&gt;1 episode/month)\r&lt;br&gt;\r&lt;br&gt;          -  Significant hemoptysis within 30 days (= 5 mL of blood in one coughing episode or &gt; 30\r&lt;br&gt;             mL of blood in a 24 hour period)\r&lt;br&gt;\r&lt;br&gt;          -  History of reactive pulmonary vascular hypertension\r&lt;br&gt;\r&lt;br&gt;          -  Methemoglobin &gt;3% at screening\r&lt;br&gt;\r&lt;br&gt;          -  Liver function insufficiency (ALT/ AST &gt;3 of normal values)\r&lt;br&gt;\r&lt;br&gt;          -  Hemoglobin &lt;11 g/dl\r&lt;br&gt;\r&lt;br&gt;          -  Thrombocytopenia (platelet count &lt;100,000/mm3) at screening\r&lt;br&gt;\r&lt;br&gt;          -  Prothrombin time international ratio (INR) &gt; 1.3 at screening\r&lt;br&gt;\r&lt;br&gt;          -  Changes to antibiotics (e.g. azithromycin) from 7 days prior to screening through last\r&lt;br&gt;             treatment day. (Subjects may be taking antibiotics or antivirals during this time\r&lt;br&gt;             period, but they cannot start, stop or change doses during this time period)\r&lt;br&gt;\r&lt;br&gt;          -  On supplemental oxygen during gNO treatment (SaO2 &lt; 90% for 50 minutes while resting\r&lt;br&gt;             in a chair).\r&lt;br&gt;\r&lt;br&gt;          -  For women of child bearing potential:\r&lt;br&gt;\r&lt;br&gt;               1. positive pregnancy test at screening or\r&lt;br&gt;\r&lt;br&gt;               2. lactating or\r&lt;br&gt;\r&lt;br&gt;               3. unwilling to practice a medically acceptable form of contraception from screening\r&lt;br&gt;                  to Day 36 (acceptable forms of contraception: abstinence, hormonal birth control,\r&lt;br&gt;                  intrauterine device, or barrier method plus a spermicidal agent)\r&lt;br&gt;\r&lt;br&gt;          -  Presence of a condition or abnormality that in the opinion of the Investigator would\r&lt;br&gt;             compromise the safety of the patient or the quality of the data.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The participants were diagnosed as COVID-19 pneumonia, according to the notice on\r&lt;br&gt;             printing and distributing the diagnosis and treatment plan of pneumonia with new\r&lt;br&gt;             coronavirus infection (trial version 4 or update version) made by National Health\r&lt;br&gt;             Commission of the People's Republic of China;\r&lt;br&gt;\r&lt;br&gt;          -  Participants aged over 18;\r&lt;br&gt;\r&lt;br&gt;          -  Written the informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Hypersensitivity to chloroquine or hydroxychloroquine;\r&lt;br&gt;\r&lt;br&gt;          -  Women during pregnancy;\r&lt;br&gt;\r&lt;br&gt;          -  Severe heart, lung, kidney, brain, blood diseases or other important systemic\r&lt;br&gt;             diseases;\r&lt;br&gt;\r&lt;br&gt;          -  Participants with retinal disease, hearing loss;\r&lt;br&gt;\r&lt;br&gt;          -  Participants with severe neurological and mental illness;\r&lt;br&gt;\r&lt;br&gt;          -  Subjects were considered to be unable to complete the study, or not suitable for the\r&lt;br&gt;             study by researchers.\r&lt;br&gt;\r&lt;br&gt;        Exit criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Subjects asked to withdraw the study\r&lt;br&gt;\r&lt;br&gt;          -  Subject will benefit if withdraw according to researchers' suggestions\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  age more than 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  accord with the clinical diagnosis and/ or etiological diagnosis diagnostic criteria\r&lt;br&gt;             of Novel coronavirus pneumonia (COVID-19).\r&lt;br&gt;\r&lt;br&gt;          -  admitted in the general wards\r&lt;br&gt;\r&lt;br&gt;          -  be able to sign informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  severe immunosuppression (HIV infection, long-term use of immunosuppressive agents\r&lt;br&gt;\r&lt;br&gt;          -  pregnant or lactation period women\r&lt;br&gt;\r&lt;br&gt;          -  glucocorticoids are needed for other diseases\r&lt;br&gt;\r&lt;br&gt;          -  unwilling or unable to participate or complete the study\r&lt;br&gt;\r&lt;br&gt;          -  participate in other study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria of Cohort 1 #4 is adapted from the Flu guideline in China (2018) and\r&lt;br&gt;        community acquired pneumonia (CAP) guideline in China (2016)\r&lt;br&gt;\r&lt;br&gt;        Cohort 1:\r&lt;br&gt;\r&lt;br&gt;        Subjects must meet all of the following inclusion criteria at the time of randomization to\r&lt;br&gt;        be eligible for participation in this study:\r&lt;br&gt;\r&lt;br&gt;          1. Males and Females =18 years old\r&lt;br&gt;\r&lt;br&gt;          2. Diagnosed as influenza (IFV) infection within 3 days before randomization\r&lt;br&gt;\r&lt;br&gt;          3. Requires, at the time of randomization, supplemental oxygen =2 LPM due to hypoxemia\r&lt;br&gt;\r&lt;br&gt;          4. Subjects are severely ill\r&lt;br&gt;\r&lt;br&gt;          5. In the opinion of investigator, subjects will be hospitalized at least 1 week.\r&lt;br&gt;\r&lt;br&gt;          6. If female, subject must not be pregnant or nursing\r&lt;br&gt;\r&lt;br&gt;        Cohort 2:\r&lt;br&gt;\r&lt;br&gt;        Subjects must meet all of the following inclusion criteria at the time of randomization to\r&lt;br&gt;        be eligible for participation in this study:\r&lt;br&gt;\r&lt;br&gt;          1. Males and Females =18 years old\r&lt;br&gt;\r&lt;br&gt;          2. Hypoxemia\r&lt;br&gt;\r&lt;br&gt;          3. Subjects fulfill one of the following conditions:\r&lt;br&gt;\r&lt;br&gt;               1. IFV subjects who are eligible for all inclusion criteria of Cohort 1 except for\r&lt;br&gt;                  acute hypoxemia at enrollment.\r&lt;br&gt;\r&lt;br&gt;               2. Subjects confirmed with non-IFV SAD viral infection.\r&lt;br&gt;\r&lt;br&gt;          4. Same in inclusion criteria #5 to #8 in Cohort 1.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria\r&lt;br&gt;\r&lt;br&gt;        Cohort 1 and 2:\r&lt;br&gt;\r&lt;br&gt;        Subjects who meet any of the following exclusion criteria are not to be enrolled in this\r&lt;br&gt;        study:\r&lt;br&gt;\r&lt;br&gt;          1. Subjects requiring mechanical, Bi-PAP or CPAP ventilation at randomization.\r&lt;br&gt;\r&lt;br&gt;          2. Life expectancy less than 30 days.\r&lt;br&gt;\r&lt;br&gt;          3. Subjects with conscious disturbance (slow response, drowsy, restlessness, anxiety,\r&lt;br&gt;             confusion, twitching or convulsion)\r&lt;br&gt;\r&lt;br&gt;          4. Subjects with unstable hemodynamics such as systolic blood pressure &lt; 90 mmHg or\r&lt;br&gt;             septic shock\r&lt;br&gt;\r&lt;br&gt;          5. Subjects with BUN?7.14 mmol/L\r&lt;br&gt;\r&lt;br&gt;          6. Subjects treated with inhaled anti-viral therapy and washout period ? 48 hours.\r&lt;br&gt;\r&lt;br&gt;          7. If Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) or Alkaline\r&lt;br&gt;             Phosphatase (ALP) are =3x ULN and Total Bilirubin (TB) is =2x ULN.\r&lt;br&gt;\r&lt;br&gt;          8. Female subjects with positive pregnancy test result, breastfeeding or planning to\r&lt;br&gt;             breastfeed at any time through 30 days after the last dose of study drug.\r&lt;br&gt;\r&lt;br&gt;          9. Subjects taking any other investigational drug used to treat for another respiratory\r&lt;br&gt;             infection.\r&lt;br&gt;\r&lt;br&gt;         10. Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion\r&lt;br&gt;             of the principal investigator, would affect subject safety and/or compliance.\r&lt;br&gt;","Inclusion criteria: &lt;br&gt;- Patient majeur\r&lt;br&gt;- Infection COVID-19 confirme par RT-PCR SARS-Cov2 ou,  dfaut, par scanner thoracique en faveur dune pneumopathie virale  prdominance priphrique dans un contexte vocateur\r&lt;br&gt;- Diagnostic port depuis moins de 48h\r&lt;br&gt;- Prsence dau moins un des deux facteurs de risque dvolution complique suivant :\r&lt;br&gt;\t- ge = 75 ans \r&lt;br&gt;\t- oxygnodpendance avec saturation capillaire priphrique en oxygne (SpO2) = 94% en air ambiant ou un ratio pression partielle en oxygne (PaO2) sur fraction en oxygne dans lair inspir (FiO2) = 300 mmHg.\r&lt;br&gt;- Patient affili ou bnficiaire dun rgime de scurit sociale \r&lt;br&gt;- Consentement crit sign du patient ou dun proche ou, en cas dimpossibilit,  procdure dinclusion en urgence\r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 750&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 750&lt;br&gt;","Inclusion criteria: &lt;br&gt;- Patients hospitalized in the intensive care unit infected with SARS-CoV-2, for whom a diagnosis of respiratory SARS-CoV-2 infection was made by nasopharyngeal swab or deep respiratory sampling.&lt;br&gt;- Patient receiving Hydroxychloroquine treatment &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 50&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 50&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The subject has to grant permission to enter into the study by signing and dating the\r&lt;br&gt;             informed consent form before completing any study-related procedure such as any\r&lt;br&gt;             assessment or evaluation not related to the normal medical care of the subject.\r&lt;br&gt;\r&lt;br&gt;          -  Able to give written inform consent and retained one copy of the consent form\r&lt;br&gt;\r&lt;br&gt;          -  Male or female subject, aged between 16 - 100 years old.\r&lt;br&gt;\r&lt;br&gt;          -  Subject diagnosed to be COVID19\r&lt;br&gt;\r&lt;br&gt;          -  Female subject in good health and sexually active was instructed by the investigator\r&lt;br&gt;             to avoid pregnancy during the study and to use condom or other contraceptive measure\r&lt;br&gt;             if necessary. The subject was required to have a negative urine pregnancy test before\r&lt;br&gt;             being eligible for the study. (At each of the subsequent visit, a urine pregnancy test\r&lt;br&gt;             was performed).\r&lt;br&gt;\r&lt;br&gt;          -  Subject judged to be reliable for compliance for taking medication and capable of\r&lt;br&gt;             recording the effects of the medication and motivated in receiving benefits from the\r&lt;br&gt;             treatment.and compliance to quarantine procedure 7-14 days after treatment\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The subject was pregnant or lactating.\r&lt;br&gt;\r&lt;br&gt;          -  The subject was a female at risk of pregnancy during the study and not taking adequate\r&lt;br&gt;             precautions against pregnancy.\r&lt;br&gt;\r&lt;br&gt;          -  The subject had a known hypersensitivity to any of the test materials or related\r&lt;br&gt;             compounds.\r&lt;br&gt;\r&lt;br&gt;          -  The subject was unable or unwilling to comply fully with the protocol.\r&lt;br&gt;\r&lt;br&gt;          -  Treatment with investigational drug (s) within 6 months before the screening visit.\r&lt;br&gt;\r&lt;br&gt;          -  The subject had previously entered in this study.\r&lt;br&gt;\r&lt;br&gt;          -  Patient who planned to schedule elective surgery during the study\r&lt;br&gt;\r&lt;br&gt;          -  The used of other antiviral agents\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Laboratory confirmed COVID19 infection defined with a positive RT-PCR from any\r&lt;br&gt;             specimen and/or detection of SARS-CoV-2 IgM/IgG antibodies.\r&lt;br&gt;\r&lt;br&gt;          2. Hospital admission with at least one of the following:\r&lt;br&gt;\r&lt;br&gt;               1. fever = 36.6 C from axillary site; or = 37.2C from oral site; or = 37.6C from\r&lt;br&gt;                  tympanic or rectal site.\r&lt;br&gt;\r&lt;br&gt;               2. Respiratory rate = 24 bpm\r&lt;br&gt;\r&lt;br&gt;               3. cough\r&lt;br&gt;\r&lt;br&gt;          3. Spontaneous breathing with or without hypoxia of any degree. Gas exchange and\r&lt;br&gt;             ventilation maybe assisted by any continuous continuous airway pressure (CPAP), or any\r&lt;br&gt;             system of Non Invasive Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP)\r&lt;br&gt;             = 10 cmH2O.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Tracheostomy\r&lt;br&gt;\r&lt;br&gt;          2. Therapy with high flow nasal cannula\r&lt;br&gt;\r&lt;br&gt;          3. Any clinical contraindications, as judged by the attending physician\r&lt;br&gt;\r&lt;br&gt;          4. Patients enrolled in another interventional study\r&lt;br&gt;\r&lt;br&gt;          5. Hospitalized and confirmed diagnosis of COVID-19 for more than 72 hours\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years\r&lt;br&gt;\r&lt;br&gt;          2. Scheduled to work with SARS-CoV-2 infected patients for at least 3 days in a week.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Previous documented SARS-CoV-2 infections and subsequent negative SARS-CoV-2 rt-PCR\r&lt;br&gt;             test.\r&lt;br&gt;\r&lt;br&gt;          2. Pregnancy\r&lt;br&gt;\r&lt;br&gt;          3. Known hemoglobinopathies.\r&lt;br&gt;\r&lt;br&gt;          4. Known anemia\r&lt;br&gt;","Inclusion criteria: 1.\tLaboratory-confirmed 2019-nCoV infection by real-time RT-PCR and/or next-generation sequencing\r&lt;br&gt;2.\tAdmission to an intensive care unit\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. At the time of randomization, requires supplemental oxygen =2 LPM due to hypoxemia.\r&lt;br&gt;             Hypoxemia can be defined by meeting at least one of the following criteria:\r&lt;br&gt;\r&lt;br&gt;               -  SpO2 &lt;92% on or off supplemental oxygen\r&lt;br&gt;\r&lt;br&gt;               -  Respiratory failure necessitating mechanical or non-invasive ventilation (CPAP or\r&lt;br&gt;                  Bi-PAP)\r&lt;br&gt;\r&lt;br&gt;               -  Written declaration from Investigator that subject is clinically hypoxemic and\r&lt;br&gt;                  removal of oxygen supplementation would not be considered clinically appropriate\r&lt;br&gt;                  for the purpose of measuring SpO2 while on room air\r&lt;br&gt;\r&lt;br&gt;          2. Immunocompromised, as defined by one or more of the following:\r&lt;br&gt;\r&lt;br&gt;               -  Received an autologous or allogeneic hematopoietic stem cell transplantation\r&lt;br&gt;                  (HSCT) at any time in the past\r&lt;br&gt;\r&lt;br&gt;               -  Received a solid organ transplant at any time in the past\r&lt;br&gt;\r&lt;br&gt;               -  Has been or is currently being treated with chemotherapy for hematologic\r&lt;br&gt;                  malignancies (e.g., leukemia, myeloma, lymphoma) and/or solid tumor malignancies\r&lt;br&gt;                  (e.g., lung, breast, brain cancer) at any time in the past\r&lt;br&gt;\r&lt;br&gt;               -  Has an immunodeficiency due to congenital abnormality (only applicable to\r&lt;br&gt;                  subjects age &lt; 18 years old) or pre-term birth (only applicable to subjects age =\r&lt;br&gt;                  2 years old)\r&lt;br&gt;\r&lt;br&gt;          3. Has, within 3 days prior to randomization, a confirmed LRTI with a sialic acid\r&lt;br&gt;             dependent respiratory virus\r&lt;br&gt;\r&lt;br&gt;          4. If female, subject must meet one of the following conditions:\r&lt;br&gt;\r&lt;br&gt;               -  Not be of childbearing potential or\r&lt;br&gt;\r&lt;br&gt;               -  Be of childbearing potential and have a negative urine/serum pregnancy test and\r&lt;br&gt;                  agrees to practice an acceptable method of contraception\r&lt;br&gt;\r&lt;br&gt;          5. Non-vasectomized males are required to practice effective birth control methods\r&lt;br&gt;\r&lt;br&gt;          6. Capable of understanding and complying with procedures as outlined in the protocol\r&lt;br&gt;\r&lt;br&gt;          7. Provides signed informed consent prior to the initiation of any screening or\r&lt;br&gt;             study-specific procedures\r&lt;br&gt;\r&lt;br&gt;        For COVID-19 sub study:\r&lt;br&gt;\r&lt;br&gt;          1. Be =18 years of age\r&lt;br&gt;\r&lt;br&gt;          2. Provide adequate medical history to permit accurate stratification (but health status\r&lt;br&gt;             may be healthy, high-risk conditions, or immunocompromised).\r&lt;br&gt;\r&lt;br&gt;          3. Prior to SARS CoV 2 infection, has the ability to carry out self-care activities of\r&lt;br&gt;             daily living (basic ADL)\r&lt;br&gt;\r&lt;br&gt;          4. Have lower respiratory tract infection (LRTI) confirmed by CT imaging, with or without\r&lt;br&gt;             contrast, to involve at least 2 lobes of the lung.\r&lt;br&gt;\r&lt;br&gt;          5. Has laboratory-confirmation of the presence of SARS CoV 2 in the respiratory tract by\r&lt;br&gt;             at least one of the following samples\r&lt;br&gt;\r&lt;br&gt;          6. Satisfy inclusion criteria #1, 4, 5, 6, 7 of the main study\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Subjects may not be on hospice care or, in the opinion of the investigator, have a low\r&lt;br&gt;             chance of survival during the first 10 days of treatment\r&lt;br&gt;\r&lt;br&gt;          2. Subjects with Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or\r&lt;br&gt;             Alkaline Phosphatase (ALP) =3x ULN and Total Bilirubin (TBILI) =2x ULN Note: Subjects\r&lt;br&gt;             with ALT/AST/ALP = 3x ULN AND TB =2x ULN that have been chronically stable (for &gt;1\r&lt;br&gt;             year on more than one assessments) due to known liver pathology including malignancy\r&lt;br&gt;             (primary or metastasis), chronic medications, transplantation, or chronic infection\r&lt;br&gt;             will not be excluded\r&lt;br&gt;\r&lt;br&gt;          3. Female subjects breastfeeding or planning to breastfeed at any time through 30 days\r&lt;br&gt;             after the last dose of study drug\r&lt;br&gt;\r&lt;br&gt;          4. Subjects taking any other investigational drug used to treat pulmonary infection.\r&lt;br&gt;\r&lt;br&gt;          5. Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion\r&lt;br&gt;             of the principal investigator, would affect subject safety and/or compliance\r&lt;br&gt;\r&lt;br&gt;          6. Subjects with known hypersensitivity to DAS181 and/or any of its components\r&lt;br&gt;\r&lt;br&gt;          7. Subjects with severe sepsis due to either their baseline SAD-RV infection or a\r&lt;br&gt;             concurrent viral, bacterial, or fungal infection and meet at least one of the\r&lt;br&gt;             following criteria:\r&lt;br&gt;\r&lt;br&gt;               -  Has evidence of vital organ failure outside of the lung (e.g., liver, kidney)\r&lt;br&gt;\r&lt;br&gt;               -  Requires vasopressors to maintain blood pressure\r&lt;br&gt;\r&lt;br&gt;        For COVID-19 sub study:\r&lt;br&gt;\r&lt;br&gt;          1. Subjects requiring invasive mechanical, Bi-PAP or CPAP ventilation at randomization.\r&lt;br&gt;\r&lt;br&gt;          2. Subjects receiving any other investigational or empiric treatment for SARS-2-CoV\r&lt;br&gt;             (either as part of a clinical trial or under emergency approval (approved agents for\r&lt;br&gt;             the management of symptoms, e.g., fever, are permitted).\r&lt;br&gt;\r&lt;br&gt;          3. Subjects who are known HIV-positive (and not undetectable at most recent HIV RNA\r&lt;br&gt;             assessment)\r&lt;br&gt;\r&lt;br&gt;          4. Subjects who are currently taking immunomodulating biologics (e.g, interferons,\r&lt;br&gt;             interleukin)\r&lt;br&gt;\r&lt;br&gt;          5. Subjects with severe sepsis due to either their SARS-CoV-2 infection or a concurrent\r&lt;br&gt;             viral, bacterial, or fungal infection and meeting at least one of the following\r&lt;br&gt;             criteria:\r&lt;br&gt;\r&lt;br&gt;               -  Have evidence of vital organ failure outside of the lung (e.g., liver, kidney)\r&lt;br&gt;\r&lt;br&gt;               -  Require vasopressors to maintain blood pressure\r&lt;br&gt;\r&lt;br&gt;          6. Subjects meeting exclusion criteria #2, 3, 5 and 6 of the main study\r&lt;br&gt;","Inclusion criteria: Participants eligible for inclusion in this study must fulfill all of the following criteria:\r&lt;br&gt;1.\tCompletion of the written informed consent process (signed) with video recording of the verbal consent process;\r&lt;br&gt;2.\tMale or female age 18 to 64 years inclusive, in general good health equivalent to Army Medical Employment Classification J22 or above. Civilian personnel would need to be in good general health as advised by their General Practitioner (GP);\r&lt;br&gt;3.\tNot previously diagnosed with COVID-19;\r&lt;br&gt;4.\tParticipant works in/in association with a healthcare facility or other high-risk environment characterised by high level of contact with persons thought likely to be infected with respiratory viruses;\r&lt;br&gt;5.\tPossess an internet enabled smart phone capable of receiving and responding to alerts;\r&lt;br&gt;6.\tWilling and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures;\r&lt;br&gt;7.\tAgrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals; and\r&lt;br&gt;8.\tAgree to stay in contact with the study site for the duration of the study and up to 2 weeks following the EOS visit (unless deployed), provide updated contact information as necessary.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Admitted to the intensive care unit with proven or suspected infection as the main\r&lt;br&gt;             diagnosis;\r&lt;br&gt;\r&lt;br&gt;          2. Currently treated with a continuous IV infusion of vasopressors (norepinephrine,\r&lt;br&gt;             epinephrine, vasopressin, dopamine, phenylephrine).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. &gt; 24 hours of intensive care unit admission;\r&lt;br&gt;\r&lt;br&gt;          2. Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency;\r&lt;br&gt;\r&lt;br&gt;          3. Pregnancy;\r&lt;br&gt;\r&lt;br&gt;          4. Known allergy to vitamin C;\r&lt;br&gt;\r&lt;br&gt;          5. Known kidney stones within the past 1 year;\r&lt;br&gt;\r&lt;br&gt;          6. Received any intravenous vitamin C during this hospitalization unless incorporated in\r&lt;br&gt;             parenteral nutrition;\r&lt;br&gt;\r&lt;br&gt;          7. Expected death or withdrawal of life-sustaining treatments within 48 hours;\r&lt;br&gt;\r&lt;br&gt;          8. Previously enrolled in this study;\r&lt;br&gt;\r&lt;br&gt;          9. Previously enrolled in a trial with which co-enrolment is not allowed.\r&lt;br&gt;\r&lt;br&gt;        The LOVIT trial has broad eligibility criteria and includes patients with a primary\r&lt;br&gt;        diagnosis of sepsis of any cause (including sepsis caused by viral pathogens as COVID-19).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalised\r&lt;br&gt;\r&lt;br&gt;          -  Adults 18 year or older\r&lt;br&gt;\r&lt;br&gt;          -  Moderately severe disease (NEWS score = 6)\r&lt;br&gt;\r&lt;br&gt;          -  SARS-CoV-2 positive nasopharyngeal swab\r&lt;br&gt;\r&lt;br&gt;          -  Signed informed consent must be obtained and documented according to ICH GCP, and\r&lt;br&gt;             national/local regulations.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Requiring ICU admission at screening\r&lt;br&gt;\r&lt;br&gt;          -  History of psoriasis\r&lt;br&gt;\r&lt;br&gt;          -  Tinnitus, reduced hearing\r&lt;br&gt;\r&lt;br&gt;          -  Visual impairment\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Documented COVID-19 infection as evidenced by positive PCR (or comparable clinical\r&lt;br&gt;             assay) for SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  Less than 48 hours since time of hospital admission OR if hospital-acquired COVID-19\r&lt;br&gt;             is suspected, less than 48 hrs since onset of symptoms\r&lt;br&gt;\r&lt;br&gt;          -  Adolescents and adults age &gt;=16 years\r&lt;br&gt;\r&lt;br&gt;          -  Subject or legally authorized representative able to give informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to hospital\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Any condition that, in the Investigator's opinion, will prevent adequate compliance\r&lt;br&gt;             with study therapy\r&lt;br&gt;\r&lt;br&gt;          -  The following laboratory values at baseline (Day 0):\r&lt;br&gt;\r&lt;br&gt;          -  Serum total bilirubin =3 ULN\r&lt;br&gt;\r&lt;br&gt;          -  Estimated glomerular filtration rate (eGFR) =30 mL/min (based on serum creatinine)\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to Camostat Mesilate\r&lt;br&gt;\r&lt;br&gt;          -  Women who are pregnant or breastfeeding\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age &gt; 70 years\r&lt;br&gt;\r&lt;br&gt;          2. ICU-Admission\r&lt;br&gt;\r&lt;br&gt;          3. Infection or suspected infection with SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1. Age &lt;70 years\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient admitted to a Danish emergency department, lung medical department or medical\r&lt;br&gt;             department\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt;18 years\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized &lt;48 hours\r&lt;br&gt;\r&lt;br&gt;          -  Positive COVID-19 test/diagnosis during the hospitalization\r&lt;br&gt;\r&lt;br&gt;          -  Signes informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  If the patient uses &gt; 5 LO2/min at time of recruitment\r&lt;br&gt;\r&lt;br&gt;          -  Known intolerance/allergy to azithromycin or hydroxychloroquine or hypersensitivity to\r&lt;br&gt;             quinine or 4-aminoquinolinderivates\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Breatfeeding\r&lt;br&gt;\r&lt;br&gt;          -  Neurogenic hearing loss\r&lt;br&gt;\r&lt;br&gt;          -  Psoriasis\r&lt;br&gt;\r&lt;br&gt;          -  Retinopathy\r&lt;br&gt;\r&lt;br&gt;          -  Maculopathy\r&lt;br&gt;\r&lt;br&gt;          -  Changes in vision field\r&lt;br&gt;\r&lt;br&gt;          -  Severe liver disease other than amoebiases\r&lt;br&gt;\r&lt;br&gt;          -  Severe gastrointestinal, neurological or haematological disorders\r&lt;br&gt;\r&lt;br&gt;          -  eGFR &lt; 45 ml/min/1.73m2\r&lt;br&gt;\r&lt;br&gt;          -  Clinically significant cardiac conduction disorders/arrhytmias or prolonged QTc\r&lt;br&gt;             interval\r&lt;br&gt;\r&lt;br&gt;          -  Myasthenia Gravis\r&lt;br&gt;\r&lt;br&gt;          -  Uses Digoxin\r&lt;br&gt;\r&lt;br&gt;          -  Glucose-6-phosphate dehydrogenase defiency\r&lt;br&gt;\r&lt;br&gt;          -  Porphyria\r&lt;br&gt;\r&lt;br&gt;          -  Hypoglycemia at any time since hospitalization\r&lt;br&gt;\r&lt;br&gt;          -  Severe mental illness which significantly impedes cooperation\r&lt;br&gt;\r&lt;br&gt;          -  Severe linguistic problems that significantly impedes cooperation\r&lt;br&gt;\r&lt;br&gt;          -  Treatment with sickle alkaloids\r&lt;br&gt;","Inclusion criteria: &lt;br&gt;- SARS-CoV-2 infection confirmed by real time-PCR &lt;br&gt;- Positive imaging: consolidation, ground glass opacities, or bilateral pulmonary infiltration either by CT-scan or chest x-ray;   &lt;br&gt;- Need of oxygen therapy to maintain SO2&gt;94% OR FiO2/PaO2 &lt; 22 &lt;br&gt;- and at least two of the following laboratory parameters:&lt;br&gt;   * CRP level &gt;70 mg/L or CRP level &gt;= 40 mg/L and doubled within 48 hours (without other confirmed infectious or non-infectious course), &lt;br&gt;   * Lactatdehydrogenase &gt; 250 U/L, &lt;br&gt;   * thrombocytopenia &lt; 120 x 10E9/L, &lt;br&gt;   * lymphocyte count &lt; 0.6 x 10E9/L, &lt;br&gt;   * D-dimer &gt; 1 ug/mL, &lt;br&gt;   * serum ferritin &gt; 300 ug/mL  &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 100&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 100&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1 ) Any adult or child or member of the nursing staff from the study participant hospital\r&lt;br&gt;        who presents an infectious syndrome including the following definition :\r&lt;br&gt;\r&lt;br&gt;        2) Suspect Case:\r&lt;br&gt;\r&lt;br&gt;        Fever above 37.8  C if no antipyretics are taken; And or Cough or pharyngeal pain or other\r&lt;br&gt;        symptom suggestive of respiratory infection. AND at least 1 of the following\r&lt;br&gt;        characteristics:\r&lt;br&gt;\r&lt;br&gt;          -  return from a trip to China, or to a country in which the increase in the incidence of\r&lt;br&gt;             infections in SARS-CoV-2 has been proven;\r&lt;br&gt;\r&lt;br&gt;          -  close contact (sharing the same place of family, professional life, same plane, etc.)\r&lt;br&gt;             with a person defined as a suspected or confirmed case;\r&lt;br&gt;\r&lt;br&gt;          -  Occurring in an establishment having received at least one case of suspected or\r&lt;br&gt;             confirmed infection at SARS-CoV-2.\r&lt;br&gt;\r&lt;br&gt;        Or 3) Confirmed Case: The same clinical definitions, in addition to a positive RT-PCR-type\r&lt;br&gt;        virological diagnostic result specific to SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Anyone who does not meet the above definition.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Suspected cases (formerly observed cases)\r&lt;br&gt;\r&lt;br&gt;        Meet the following 2 at the same time:\r&lt;br&gt;\r&lt;br&gt;        Epidemiological history There was a history of travel or residence in Wuhan within two\r&lt;br&gt;        weeks before the onset of illness; or patients who had had fever from Wuhan with\r&lt;br&gt;        respiratory symptoms within 14 days before the onset of illness, or had clustered onset.\r&lt;br&gt;\r&lt;br&gt;        Clinical manifestations\r&lt;br&gt;\r&lt;br&gt;          1. fever;\r&lt;br&gt;\r&lt;br&gt;          2. It has the imaging characteristics of pneumonia mentioned above;\r&lt;br&gt;\r&lt;br&gt;          3. The total number of white blood cells is normal or decreased, or the lymphocyte count\r&lt;br&gt;             is decreased in the early stage of onset.\r&lt;br&gt;\r&lt;br&gt;               -  2. confirmed cases On the basis of meeting the criteria for suspected cases,\r&lt;br&gt;                  sputum, throat swabs, lower respiratory tract secretions, and other specimens\r&lt;br&gt;                  were tested by real-time fluorescent RT-PCR for positive nucleic acid detection\r&lt;br&gt;                  of new coronavirus; or viral gene sequencing was highly homologous with known new\r&lt;br&gt;                  coronaviruses.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus,\r&lt;br&gt;             rhinovirus, human metapneumovirus, SARS coronavirus, and other known other viral\r&lt;br&gt;             pneumonia;\r&lt;br&gt;\r&lt;br&gt;          -  2. Mycoplasma pneumoniae, chlamydia pneumonia, and bacterial pneumonia; non-infectious\r&lt;br&gt;             diseases such as vasculitis, dermatomyositis, and organizing pneumonia.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age 18 to 80.\r&lt;br&gt;\r&lt;br&gt;          2. Confirmed COVID-19 diagnosis(including the clinically confirmed cases in Hubei).\r&lt;br&gt;\r&lt;br&gt;          3. Accord with any of the following: ? Respiratory distress, RR = 30 breaths/min; ? SpO2\r&lt;br&gt;             = 93% at rest; ? Partial arterial oxygen pressure (PaO2) / Fraction of inspiration O2\r&lt;br&gt;             (FiO2) = 300mmHg (1mmHg = 0.133kPa).\r&lt;br&gt;\r&lt;br&gt;          4. Chest imaging confirms lung involvement and has inflammatory exudation or pleural\r&lt;br&gt;             effusion.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Cannot obtain informed consent.\r&lt;br&gt;\r&lt;br&gt;          2. Severe hepatic dysfunction (Child Pugh score = C, or AST&gt; 5 times the upper limit);\r&lt;br&gt;             Severe renal dysfunction (estimated glomerular filtration rate = 30mL / min / 1.73 m2)\r&lt;br&gt;             or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.\r&lt;br&gt;\r&lt;br&gt;          3. Unsatisfactory controlled hypertension (seated systolic blood pressure&gt; 160mmHg, or\r&lt;br&gt;             diastolic blood pressure&gt; 100mmHg); previous history of hypertension crisis or\r&lt;br&gt;             hypertensive encephalopathy.\r&lt;br&gt;\r&lt;br&gt;          4. Poorly controlled heart diseases, such as NYHA class II and above cardiac\r&lt;br&gt;             insufficiency, unstable angina pectoris, myocardial infarction within 1 year before\r&lt;br&gt;             enrollment, supraventricular or ventricular arrhythmia need treatment or intervention.\r&lt;br&gt;\r&lt;br&gt;          5. Hereditary bleeding tendency or coagulopathy; received full-dose anticoagulant or\r&lt;br&gt;             thrombolytic therapy within10 days before enrollment, or have taken non-steroidal\r&lt;br&gt;             anti-inflammatory drugs with platelet suppression within 10 days before enrollment\r&lt;br&gt;             (Except those who use small doses of aspirin =325mg / day for preventive use).\r&lt;br&gt;\r&lt;br&gt;          6. Thrombosis within 6 months before enrollment. And from those patients, screen who had\r&lt;br&gt;             arterial / venous thromboembolic events, such as, ischemic stroke, transient ischemic\r&lt;br&gt;             attack, deep venous thrombosis, pulmonary embolism, etc. within 1 year ahead of\r&lt;br&gt;             enrollment. Severe vascular disease (including aneurysms or arterial thrombosis\r&lt;br&gt;             requiring surgery) within 6 months before enrollment.\r&lt;br&gt;\r&lt;br&gt;          7. Unhealed wounds, active gastric ulcers or fractures. Gastrointestinal perforation,\r&lt;br&gt;             gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6\r&lt;br&gt;             months before enrollment. Major surgery (including preoperative Chest biopsy) or major\r&lt;br&gt;             trauma (such as a fracture) within 28 days before enrollment. May have surgery during\r&lt;br&gt;             the trial.\r&lt;br&gt;\r&lt;br&gt;          8. Severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous\r&lt;br&gt;             system bleeding, and nosebleeds within 1 month before enrollment.\r&lt;br&gt;\r&lt;br&gt;          9. Malignant tumors within 5 years before enrollment.\r&lt;br&gt;\r&lt;br&gt;         10. Allergic to bevacizumab or its components.\r&lt;br&gt;\r&lt;br&gt;         11. Untreated active hepatitis or HIV-positive patients.\r&lt;br&gt;\r&lt;br&gt;         12. Pregnant and lactating women and those planning to get pregnant.\r&lt;br&gt;\r&lt;br&gt;         13. Participated in other clinical trials, not considered suitable for this study by the\r&lt;br&gt;             researchers.\r&lt;br&gt;","\r&lt;br&gt;        Key Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to provide written informed consent prior to performing study\r&lt;br&gt;             procedures (participants = 18 years of age) or assent (participants = 12 and &lt; 18\r&lt;br&gt;             years of age) prior to performing study procedures. For participants = 12 and &lt; 18\r&lt;br&gt;             years of age, a parent or legal guardian willing and able to provide written informed\r&lt;br&gt;             consent prior to performing study procedures\r&lt;br&gt;\r&lt;br&gt;          -  Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by\r&lt;br&gt;             polymerase chain reaction (PCR) test = 4 days before randomization\r&lt;br&gt;\r&lt;br&gt;          -  Currently hospitalized and requiring medical care for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Peripheral capillary oxygen saturation (SpO2) &gt; 94% on room air at screening\r&lt;br&gt;\r&lt;br&gt;          -  Radiographic evidence of pulmonary infiltrates\r&lt;br&gt;\r&lt;br&gt;        Key Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participation in any other clinical trial of an experimental treatment for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent treatment with other agents with actual or possible direct acting antiviral\r&lt;br&gt;             activity against SARS-CoV-2 &lt; 24 hours prior to study drug dosing\r&lt;br&gt;\r&lt;br&gt;          -  Requiring mechanical ventilation at screening\r&lt;br&gt;\r&lt;br&gt;          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit\r&lt;br&gt;             of normal (ULN)\r&lt;br&gt;\r&lt;br&gt;          -  Creatinine clearance &lt; 50 mL/min using the Cockcroft-Gault formula for participants =\r&lt;br&gt;             18 years of age {Cockcroft 1976} and Schwartz Formula for participants &lt; 18 years of\r&lt;br&gt;             age\r&lt;br&gt;\r&lt;br&gt;        Note: Other protocol defined Inclusion/Exclusion criteria may apply.\r&lt;br&gt;","\r&lt;br&gt;        Key Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Positive for RNA of SARS-CoV-2 from respiratory specimens or blood specimens\r&lt;br&gt;\r&lt;br&gt;          2. Hypoxemic\r&lt;br&gt;\r&lt;br&gt;          3. Severe COVID-19\r&lt;br&gt;\r&lt;br&gt;          4. If female, subject must not be pregnant or nursing.\r&lt;br&gt;\r&lt;br&gt;          5. Non-vasectomized males are required to practice effective birth control methods\r&lt;br&gt;\r&lt;br&gt;          6. Capable of understanding and complying with procedures as outlined in the protocol as\r&lt;br&gt;             judged by the Investigator and able to sign informed consent form prior to the\r&lt;br&gt;             initiation of any screening or study-specific procedures.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. ALT or AST&gt; 8 x ULN\r&lt;br&gt;\r&lt;br&gt;          2. (ALT or AST&gt; 3 x ULN) and (Total bilirubin&gt; 2.5 x ULN or INR&gt; 2.0 x ULN)\r&lt;br&gt;\r&lt;br&gt;          3. Female subjects who have a positive pregnancy test and are breastfeeding\r&lt;br&gt;\r&lt;br&gt;          4. Subjects using any other investigational antiviral drugs during the hospitalization\r&lt;br&gt;             before enrollment.\r&lt;br&gt;\r&lt;br&gt;          5. Subjects participating in other clinical trials\r&lt;br&gt;\r&lt;br&gt;          6. Subjects may be transferred to a non-participating hospital within 72 hours\r&lt;br&gt;\r&lt;br&gt;          7. People who cannot cooperate well due to mental illness, have no self-control, and\r&lt;br&gt;             cannot express clearly\r&lt;br&gt;\r&lt;br&gt;          8. Severe underlying diseases affecting survival\r&lt;br&gt;\r&lt;br&gt;          9. Critical COVID-19 requiring mechanical ventilator at the time enrolled\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  SARS-CoV-2-infection with COVID-pneumonia\r&lt;br&gt;\r&lt;br&gt;          -  vv-ECMO therapy\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  pregnancy, breastfeeding\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Healthy adults aged 18-55 years.\r&lt;br&gt;\r&lt;br&gt;          -  Able and willing (in the Investigator's opinion) to comply with all study\r&lt;br&gt;             requirements.\r&lt;br&gt;\r&lt;br&gt;          -  Willing to allow the investigators to discuss the volunteer's medical history with\r&lt;br&gt;             their General Practitioner and access all medical records when relevant to study\r&lt;br&gt;             procedures.\r&lt;br&gt;\r&lt;br&gt;          -  For females only, willingness to practice continuous effective contraception (see\r&lt;br&gt;             below) during the study and a negative pregnancy test on the day(s) of screening and\r&lt;br&gt;             vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Agreement to refrain from blood donation during the course of the study.\r&lt;br&gt;\r&lt;br&gt;          -  Provide written informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        The volunteer may not enter the study if any of the following apply:\r&lt;br&gt;\r&lt;br&gt;          -  Prior receipt of any vaccines (licensed or investigational) =30 days before enrolment\r&lt;br&gt;\r&lt;br&gt;          -  Planned receipt of any vaccine other than the study intervention within 30 days before\r&lt;br&gt;             and after each study vaccination .\r&lt;br&gt;\r&lt;br&gt;          -  Prior receipt of an investigational or licensed vaccine likely to impact on\r&lt;br&gt;             interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus\r&lt;br&gt;             vaccines).\r&lt;br&gt;\r&lt;br&gt;          -  Administration of immunoglobulins and/or any blood products within the three months\r&lt;br&gt;             preceding the planned administration of the vaccine candidate.\r&lt;br&gt;\r&lt;br&gt;          -  Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV\r&lt;br&gt;             infection; asplenia; recurrent severe infections and chronic use (more than 14 days)\r&lt;br&gt;             immunosuppressant medication within the past 6 months (topical steroids are allowed).\r&lt;br&gt;\r&lt;br&gt;          -  History of allergic disease or reactions likely to be exacerbated by any component of\r&lt;br&gt;             the ChAdOx1 nCoV-19 or MenACWY vaccines.\r&lt;br&gt;\r&lt;br&gt;          -  Any history of hereditary angioedema or idiopathic angioedema.\r&lt;br&gt;\r&lt;br&gt;          -  Any history of anaphylaxis in relation to vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy, lactation or willingness/intention to become pregnant during the study.\r&lt;br&gt;\r&lt;br&gt;          -  History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in\r&lt;br&gt;             situ).\r&lt;br&gt;\r&lt;br&gt;          -  History of serious psychiatric condition likely to affect participation in the study.\r&lt;br&gt;\r&lt;br&gt;          -  Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or\r&lt;br&gt;             prior history of significant bleeding or bruising following IM injections or\r&lt;br&gt;             venepuncture.\r&lt;br&gt;\r&lt;br&gt;          -  Any other serious chronic illness requiring hospital specialist supervision.\r&lt;br&gt;\r&lt;br&gt;          -  Chronic respiratory diseases, including mild asthma\r&lt;br&gt;\r&lt;br&gt;          -  Chronic cardiovascular disease, gastrointestinal disease, liver disease, renal\r&lt;br&gt;             disease, endocrine disorder and neurological illness\r&lt;br&gt;\r&lt;br&gt;          -  Seriously overweight (BMI=40 Kg/m2)\r&lt;br&gt;\r&lt;br&gt;          -  Suspected or known current alcohol abuse as defined by an alcohol intake of greater\r&lt;br&gt;             than 42 units every week.\r&lt;br&gt;\r&lt;br&gt;          -  Suspected or known injecting drug abuse in the 5 years preceding enrolment.\r&lt;br&gt;\r&lt;br&gt;          -  Any clinically significant abnormal finding on screening biochemistry, haematology\r&lt;br&gt;             blood tests or urinalysis.\r&lt;br&gt;\r&lt;br&gt;          -  Any other significant disease, disorder or finding which may significantly increase\r&lt;br&gt;             the risk to the volunteer because of participation in the study, affect the ability of\r&lt;br&gt;             the volunteer to participate in the study or impair interpretation of the study data.\r&lt;br&gt;\r&lt;br&gt;          -  History of laboratory confirmed COVID-19.\r&lt;br&gt;\r&lt;br&gt;          -  New onset of fever or a cough or shortness of breath in the 60 days preceding\r&lt;br&gt;             screening and/or enrolment\r&lt;br&gt;\r&lt;br&gt;          -  Travel history to China since January 2020\r&lt;br&gt;\r&lt;br&gt;          -  Living in the same household as any vulnerable groups at risk of severe COVID-19\r&lt;br&gt;             disease\r&lt;br&gt;\r&lt;br&gt;        Re-Vaccination Exclusion Criteria\r&lt;br&gt;\r&lt;br&gt;          -  Anaphylactic reaction following administration of vaccine\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed cases of Covid-19 (all by RT-PCR from same laboratory)\r&lt;br&gt;\r&lt;br&gt;          -  Mild to severe clinical presentation (identified at the time of admission to ward by\r&lt;br&gt;             National Early Warning Score NEWS-2; mild 0-4; severe 5-6)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Covid-19 critically ill patients (NEWS-2 score &lt;7),\r&lt;br&gt;\r&lt;br&gt;          -  Unable to take oral medication,\r&lt;br&gt;\r&lt;br&gt;          -  Immunocompromised,\r&lt;br&gt;\r&lt;br&gt;          -  Creatinine clearance (CCL) &lt; 30 ml/min,\r&lt;br&gt;\r&lt;br&gt;          -  Aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 5 times Upper limit of\r&lt;br&gt;             normal (ULN),\r&lt;br&gt;\r&lt;br&gt;          -  d-dimer &gt; 2microgram per liter, or\r&lt;br&gt;\r&lt;br&gt;          -  Known comorbid condition like hypertension, cardiovascular disease, diabetes mellites,\r&lt;br&gt;             asthma, COPD, cerebrovascular disorder, malignancy of any type, pregnancy,\r&lt;br&gt;\r&lt;br&gt;          -  BMI less than 18\r&lt;br&gt;\r&lt;br&gt;          -  Smoking history (one pack per day) for past six months\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The participants were diagnosed as COVID-19 pneumonia, according to the notice on\r&lt;br&gt;             printing and distributing the diagnosis and treatment plan of pneumonia with new\r&lt;br&gt;             coronavirus infection (trial version 4 or update version) made by National Health\r&lt;br&gt;             Commission of the People's Republic of China.\r&lt;br&gt;\r&lt;br&gt;          -  Written the informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Hypersensitivity to darunavir, cobicistat, or any excipients\r&lt;br&gt;\r&lt;br&gt;          -  Patients with severe liver injury (Child-Pugh Class C)\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant medications that are highly dependent on CYP3A clearance, and the elevated\r&lt;br&gt;             plasma concentrations are associated with serious or life-threatening events.\r&lt;br&gt;\r&lt;br&gt;          -  Subjects were considered to be unable to complete the study, or not suitable for the\r&lt;br&gt;             study by researchers\r&lt;br&gt;\r&lt;br&gt;        Exit criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Subjects asked to withdraw the study\r&lt;br&gt;\r&lt;br&gt;          -  Subject will benefit if withdraw according to researchers' suggestions\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to intensive care unit (ICU), Peking University Third Hospital since Feb 2020\r&lt;br&gt;\r&lt;br&gt;          -  Adult (aged over 18 years)\r&lt;br&gt;\r&lt;br&gt;          -  Anticipate a length of ICU stay (LOS) of more than 48 hours\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed as 2019 coronavirus disease (COVID-19)\r&lt;br&gt;\r&lt;br&gt;          -  With food intake difficulties (can't intake food by oneself)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  aged under 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Actual ICU LOS of less than 48 hours\r&lt;br&gt;\r&lt;br&gt;          -  Using medications of IL-6 or IL-6R\r&lt;br&gt;\r&lt;br&gt;          -  Overdose\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent not obtained in the prospective cohort\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Admitted to a hospital with symptoms suggestive of COVID-19 infection.\r&lt;br&gt;\r&lt;br&gt;          2. Subject (or legally authorized representative) provides written informed consent prior\r&lt;br&gt;             to initiation of any study procedures.\r&lt;br&gt;\r&lt;br&gt;          3. Understands and agrees to comply with planned study procedures.\r&lt;br&gt;\r&lt;br&gt;          4. Agrees to the collection of oropharyngeal (OP) swabs.\r&lt;br&gt;\r&lt;br&gt;          5. Male or non-pregnant female adult &gt; / = 18 years of age at time of enrollment.\r&lt;br&gt;\r&lt;br&gt;          6. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain\r&lt;br&gt;             reaction (PCR) or other commercial or public health assay in any specimen collected &lt;\r&lt;br&gt;             72 hours prior to randomization.\r&lt;br&gt;\r&lt;br&gt;             Note - 72 hours is not necessarily time from initial diagnosis. If &gt; / = 72 hours\r&lt;br&gt;             since positive PCR, the PCR may be repeated to assess eligibility.\r&lt;br&gt;\r&lt;br&gt;          7. Illness of any duration, and at least one of the following:\r&lt;br&gt;\r&lt;br&gt;               -  Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR\r&lt;br&gt;\r&lt;br&gt;               -  Clinical assessment (evidence of rales/crackles on exam) AND SpO2 &lt; / = 94% on\r&lt;br&gt;                  room air, OR\r&lt;br&gt;\r&lt;br&gt;               -  Requiring supplemental oxygen, OR\r&lt;br&gt;\r&lt;br&gt;               -  Requiring mechanical ventilation.\r&lt;br&gt;\r&lt;br&gt;          8. Women of childbearing potential must agree to either abstinence or use at least one\r&lt;br&gt;             primary form of contraception not including hormonal contraception from the time of\r&lt;br&gt;             screening through Day 29.\r&lt;br&gt;\r&lt;br&gt;          9. Agrees to not participate in another clinical trial for the treatment of COVID-19 or\r&lt;br&gt;             SARS-CoV-2 through Day 29.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Alanine Transaminase (ALT)/Aspartate Transaminase (AST) &gt; 5 times the upper limit of\r&lt;br&gt;             normal.\r&lt;br&gt;\r&lt;br&gt;          2. Estimated glomerular filtration rate (eGFR) &lt; 50 or requiring dialysis.\r&lt;br&gt;\r&lt;br&gt;          3. Pregnancy or breast feeding.\r&lt;br&gt;\r&lt;br&gt;          4. Anticipated transfer to another hospital which is not a study site within 72 hours.\r&lt;br&gt;\r&lt;br&gt;          5. Allergy to any study medication.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        A subject must meet all of the following criteria to be eligible to participate in this\r&lt;br&gt;        study:\r&lt;br&gt;\r&lt;br&gt;          1. Provides written informed consent prior to initiation of any study procedures.\r&lt;br&gt;\r&lt;br&gt;          2. Be able to understand and agrees to comply with planned study procedures and be\r&lt;br&gt;             available for all study visits.\r&lt;br&gt;\r&lt;br&gt;          3. Agrees to the collection of venous blood per protocol.\r&lt;br&gt;\r&lt;br&gt;          4. Male or non-pregnant female, 18 to 55 years of age, inclusive, at time of enrollment.\r&lt;br&gt;\r&lt;br&gt;          5. Body Mass Index 18-35 kg/m^2, inclusive, at screening.\r&lt;br&gt;\r&lt;br&gt;          6. Women of childbearing potential* must agree to use or have practiced true abstinence**\r&lt;br&gt;             or use at least one acceptable primary form of contraception.***, **** Note: These\r&lt;br&gt;             criteria are applicable to females in a heterosexual relationship and child-bearing\r&lt;br&gt;             potential (i.e., the criteria do not apply to subjects in a same sex relationship).\r&lt;br&gt;\r&lt;br&gt;             *Not of childbearing potential - post-menopausal females (defined as having a history\r&lt;br&gt;             of amenorrhea for at least one year) or a documented status as being surgically\r&lt;br&gt;             sterile (hysterectomy, bilateral oophorectomy, tubal ligation/salpingectomy, or\r&lt;br&gt;             Essure(R) placement).\r&lt;br&gt;\r&lt;br&gt;             **True abstinence is 100% of time no sexual intercourse (male's penis enters the\r&lt;br&gt;             female's vagina). (Periodic abstinence [e.g., calendar, ovulation, symptothermal,\r&lt;br&gt;             post-ovulation methods] and withdrawal are not acceptable methods of contraception).\r&lt;br&gt;\r&lt;br&gt;             ***Acceptable forms of primary contraception include monogamous relationship with a\r&lt;br&gt;             vasectomized partner who has been vasectomized for 180 days or more prior to the\r&lt;br&gt;             subject's first vaccination, intrauterine devices, birth control pills, and\r&lt;br&gt;             injectable/implantable/insertable hormonal birth control products.\r&lt;br&gt;\r&lt;br&gt;             ****Must use at least one acceptable primary form of contraception for at least 30\r&lt;br&gt;             days prior to the first vaccination and at least one acceptable primary form of\r&lt;br&gt;             contraception for 60 days after the last vaccination.\r&lt;br&gt;\r&lt;br&gt;          7. Women of childbearing potential must have a negative urine or serum pregnancy test\r&lt;br&gt;             within 24 hours prior to each vaccination.\r&lt;br&gt;\r&lt;br&gt;          8. Male subjects of childbearing potential*: use of condoms to ensure effective\r&lt;br&gt;             contraception with a female partner from first vaccination until 3 months after the\r&lt;br&gt;             last vaccination.\r&lt;br&gt;\r&lt;br&gt;             *Biological males who are post-pubertal and considered fertile until permanently\r&lt;br&gt;             sterile by bilateral orchiectomy or vasectomy.\r&lt;br&gt;\r&lt;br&gt;          9. Male subjects agree to refrain from sperm donation from the time of first vaccination\r&lt;br&gt;             until 3 months after the last vaccination.\r&lt;br&gt;\r&lt;br&gt;         10. Oral temperature is less than 100.0 degrees Fahrenheit (37.8 degrees Celsius).\r&lt;br&gt;\r&lt;br&gt;         11. Pulse no greater than 100 beats per minute.\r&lt;br&gt;\r&lt;br&gt;         12. Systolic blood pressure (BP) is 85 to 150 mmHg, inclusive.\r&lt;br&gt;\r&lt;br&gt;         13. Clinical screening laboratory evaluations (white blood cell (WBC), hemoglobin (Hgb),\r&lt;br&gt;             platelets (PLTs), alanine transaminase (ALT), aspartate transaminase (AST), creatinine\r&lt;br&gt;             (Cr), alkaline phosphatase (ALP), total bilirubin (T. Bili), Lipase, prothrombin time\r&lt;br&gt;             (PT), and partial thromboplastin time (PTT)) are within acceptable normal reference\r&lt;br&gt;             ranges at the clinical laboratory being used.\r&lt;br&gt;\r&lt;br&gt;         14. Must agree to have samples stored for secondary research.\r&lt;br&gt;\r&lt;br&gt;         15. Agrees to adhere to Lifestyle Considerations throughout study duration.\r&lt;br&gt;\r&lt;br&gt;         16. The subject must agree to refrain from donating blood or plasma during the study\r&lt;br&gt;             (outside of this study).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        A subject who meets any of the following criteria will be excluded from participation in\r&lt;br&gt;        this study:\r&lt;br&gt;\r&lt;br&gt;          1. Positive pregnancy test either at screening or just prior to each vaccine\r&lt;br&gt;             administration.\r&lt;br&gt;\r&lt;br&gt;          2. Female subject who is breastfeeding or plans to breastfeed from the time of the first\r&lt;br&gt;             vaccination through 60 days after the last vaccination.\r&lt;br&gt;\r&lt;br&gt;          3. Has any medical disease or condition that, in the opinion of the site PI or\r&lt;br&gt;             appropriate sub-investigator, precludes study participation.*\r&lt;br&gt;\r&lt;br&gt;             *Including acute, subacute, intermittent or chronic medical disease or condition that\r&lt;br&gt;             would place the subject at an unacceptable risk of injury, render the subject unable\r&lt;br&gt;             to meet the requirements of the protocol, or may interfere with the evaluation of\r&lt;br&gt;             responses or the subject's successful completion of this trial.\r&lt;br&gt;\r&lt;br&gt;          4. Presence of self-reported or medically documented significant medical or psychiatric\r&lt;br&gt;             condition(s).*\r&lt;br&gt;\r&lt;br&gt;             *Significant medical or psychiatric conditions include but are not limited to:\r&lt;br&gt;             Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma)\r&lt;br&gt;             requiring daily medications currently or any treatment of respiratory disease\r&lt;br&gt;             exacerbations (e.g., asthma exacerbation) in the last 5 years. Asthma medications:\r&lt;br&gt;             inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and\r&lt;br&gt;             short acting beta agonists, theophylline, ipratropium, biologics.\r&lt;br&gt;\r&lt;br&gt;             Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy,\r&lt;br&gt;             ischemic heart disease) or history of myocarditis or pericarditis as an adult.\r&lt;br&gt;\r&lt;br&gt;             Neurological or neurodevelopmental conditions (e.g., history of migraines in the past\r&lt;br&gt;             5 years, epilepsy, stroke, seizures in the last 3 years, encephalopathy, focal\r&lt;br&gt;             neurologic deficits, Guillain-Barr syndrome, encephalomyelitis or transverse\r&lt;br&gt;             myelitis).\r&lt;br&gt;\r&lt;br&gt;             Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding\r&lt;br&gt;             basal cell and squamous cell carcinoma of the skin, which are allowed.\r&lt;br&gt;\r&lt;br&gt;             An autoimmune disease, including hypothyroidism without a defined non-autoimmune\r&lt;br&gt;             cause, localized or history of psoriasis.\r&lt;br&gt;\r&lt;br&gt;             An immunodeficiency of any cause.\r&lt;br&gt;\r&lt;br&gt;          5. Has an acute illness*, as determined by the site PI or appropriate sub-investigator,\r&lt;br&gt;             with or without fever [oral temperature &gt; / = 38.0 degrees Celsius (100.4 degrees\r&lt;br&gt;             Fahrenheit)] within 72 hours prior to each vaccination.\r&lt;br&gt;\r&lt;br&gt;             *An acute illness which is nearly resolved with only minor residual symptoms remaining\r&lt;br&gt;             is allowable if, in the opinion of the site PI or appropriate sub-investigator, the\r&lt;br&gt;             residual symptoms will not interfere with the ability to assess safety parameters as\r&lt;br&gt;             required by the protocol.\r&lt;br&gt;\r&lt;br&gt;          6. Has a positive test result for hepatitis B surface antigen, hepatitis C virus\r&lt;br&gt;             antibody, or HIV types 1 or 2 antibodies at screening.\r&lt;br&gt;\r&lt;br&gt;          7. Has participated in another investigational study involving any investigational\r&lt;br&gt;             product* within 60 days, or 5 half-lives, whichever is longer, before the first\r&lt;br&gt;             vaccine administration.\r&lt;br&gt;\r&lt;br&gt;             *study drug, biologic or device\r&lt;br&gt;\r&lt;br&gt;          8. Currently enr","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Clinically diagnosed with Corona Virus Disease 2019\r&lt;br&gt;\r&lt;br&gt;          2. Increased interleukin-6\r&lt;br&gt;\r&lt;br&gt;          3. Sign the informed consent\r&lt;br&gt;\r&lt;br&gt;          4. Subjects who can take medicine orally\r&lt;br&gt;\r&lt;br&gt;          5. Agree to collect clinical samples\r&lt;br&gt;\r&lt;br&gt;          6. Female subjects of childbearing age are not pregnant and agree to take effective\r&lt;br&gt;             contraception within 7 days of the last oral medication to ensure that they are not\r&lt;br&gt;             pregnant within 3-6 months\r&lt;br&gt;\r&lt;br&gt;          7. Male patients agree to effective contraception within 7 days of last oral medication.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Cases of severe vomiting that make it difficult to take the drug orally\r&lt;br&gt;\r&lt;br&gt;          2. Allergic to Favipiravir or tocilizumab\r&lt;br&gt;\r&lt;br&gt;          3. Pregnant and lactating women\r&lt;br&gt;\r&lt;br&gt;          4. Subjects received specific antiviral drugs such as lopinavir / ritonavir, ribavirin,\r&lt;br&gt;             arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal antibodies within\r&lt;br&gt;             one week before admission.\r&lt;br&gt;\r&lt;br&gt;          5. Cases of respiratory failure and requiring mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          6. Cases of shock\r&lt;br&gt;\r&lt;br&gt;          7. Combined organ failure requires ICU monitoring and treatment\r&lt;br&gt;\r&lt;br&gt;          8. Predicted clinically that there is no hope of survival, or cases of deep coma that do\r&lt;br&gt;             not respond to supportive treatment measures within three hours of admission\r&lt;br&gt;\r&lt;br&gt;          9. Alanine aminotransferase / Aspartate aminotransferase&gt; 5 times of upper limit of\r&lt;br&gt;             normal\r&lt;br&gt;\r&lt;br&gt;         10. Neutrophils &lt;0.5  10^9 / L, platelets less than 50  10^9 / L\r&lt;br&gt;\r&lt;br&gt;         11. Clear diagnosis of rheumatoid immunity, malignant tumors and other related diseases\r&lt;br&gt;\r&lt;br&gt;         12. Long-term oral anti-rejection drugs or immunomodulatory drugs\r&lt;br&gt;\r&lt;br&gt;         13. Allergic reactions to tocilizumab or any excipients\r&lt;br&gt;\r&lt;br&gt;         14. Patients with active hepatitis, tuberculosis, and definite bacterial and fungal\r&lt;br&gt;             infections\r&lt;br&gt;\r&lt;br&gt;         15. Organ transplant patients\r&lt;br&gt;\r&lt;br&gt;         16. Patients with mental disorders\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female, aged = 18 years\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase\r&lt;br&gt;             chain reaction (RT-PCR) from any diagnostic sampling source; and\r&lt;br&gt;\r&lt;br&gt;          3. CT image is characteristic of 2019 novel coronavirus pneumonia\r&lt;br&gt;\r&lt;br&gt;          4. In compliance with the 2019-nCoV pneumonia diagnosis standard [according to the novel\r&lt;br&gt;             coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation\r&lt;br&gt;             Version 6) issued by the National Health and Medical Commission, and WHO 2019 new\r&lt;br&gt;             coronavirus guidelines standards]: (A) increased breathing rate (=30 beats / min),\r&lt;br&gt;             difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen\r&lt;br&gt;             saturation =93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired\r&lt;br&gt;             oxygen (FiO2) =300 mmHg (1mmHg = 0.133kPa);\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with autoimmune diseases in the past or screening;\r&lt;br&gt;\r&lt;br&gt;          2. Those who have serious basic diseases that affect their survival, including: malignant\r&lt;br&gt;             tumor, hematopathy, malignant fluid, active hemorrhage, severe malnutrition, etc.\r&lt;br&gt;             which have not been controlled and can not be removed due to multiple metastasis;\r&lt;br&gt;\r&lt;br&gt;          3. Known or self-reported HIV or syphilis infected persons;\r&lt;br&gt;\r&lt;br&gt;          4. Have participated in stem cell clinical research;\r&lt;br&gt;\r&lt;br&gt;          5. Pregnant or lactating women or those who have fertility plans in the past year;\r&lt;br&gt;\r&lt;br&gt;          6. The estimated life cycle is less than 48 hours;\r&lt;br&gt;\r&lt;br&gt;          7. Other conditions that the researcher thinks are not suitable for participating in the\r&lt;br&gt;             experiment.\r&lt;br&gt;\r&lt;br&gt;          8. Shock\r&lt;br&gt;\r&lt;br&gt;          9. Continuous use of immunosuppressive agents or organ transplants in the past 6 months;\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 pneumonia patients diagnosed by WHO criteria\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who were younger than 18 years.\r&lt;br&gt;\r&lt;br&gt;          -  Patients whose entire stay lasted for less than 48 hours.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Any person interested in participating in the mindfulness session will be eligible to\r&lt;br&gt;             complete the pre/post surveys and participate in the mindfulness session.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  None\r&lt;br&gt;","\r&lt;br&gt;        Key Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to provide written informed consent, or with a legal representative\r&lt;br&gt;             who can provide informed consent, or enrolled under International Conference on\r&lt;br&gt;             Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the\r&lt;br&gt;             investigator (age =18), or willing and able to provide assent (age =12 to &lt;18, where\r&lt;br&gt;             locally and nationally approved) prior to performing study procedures\r&lt;br&gt;\r&lt;br&gt;          -  Aged = 18 years (at all sites), or aged = 12 and &lt; 18 years of age weighing = 40 kg\r&lt;br&gt;             (where permitted according to local law and approved nationally and by the relevant\r&lt;br&gt;             institutional review board [IRB] or independent ethics committee [IEC])\r&lt;br&gt;\r&lt;br&gt;          -  Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by\r&lt;br&gt;             polymerase chain reaction (PCR) test = 4 days before randomization\r&lt;br&gt;\r&lt;br&gt;          -  Currently hospitalized\r&lt;br&gt;\r&lt;br&gt;          -  Peripheral capillary oxygen saturation (SpO2) = 94% or requiring supplemental oxygen\r&lt;br&gt;             at screening\r&lt;br&gt;\r&lt;br&gt;        Key Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participation in any other clinical trial of an experimental treatment for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent treatment with other agents with actual or possible direct acting antiviral\r&lt;br&gt;             activity against SARS-CoV-2 is prohibited &lt; 24 hours prior to study drug dosing\r&lt;br&gt;\r&lt;br&gt;          -  Evidence of multiorgan failure\r&lt;br&gt;\r&lt;br&gt;          -  Mechanically ventilated (including V-V ECMO) = 5 days, or any duration of V-A ECMO.\r&lt;br&gt;\r&lt;br&gt;          -  Requiring mechanical ventilation at screening\r&lt;br&gt;\r&lt;br&gt;          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit\r&lt;br&gt;             of normal (ULN)\r&lt;br&gt;\r&lt;br&gt;          -  Creatinine clearance &lt; 50 mL/min using the Cockcroft-Gault formula for participants =\r&lt;br&gt;             18 years of age {Cockcroft 1976} and Schwartz Formula for participants &lt; 18 years of\r&lt;br&gt;             age\r&lt;br&gt;\r&lt;br&gt;        Note: Other protocol defined Inclusion/Exclusion criteria may apply.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Any permanent medical or paramedic staff of participating services who have given\r&lt;br&gt;             written consent to participate\r&lt;br&gt;\r&lt;br&gt;          -  Having a social security insurance.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Non-permanent staff (occasional staffing), administrative staff, technical staff of\r&lt;br&gt;             participating services.\r&lt;br&gt;\r&lt;br&gt;          -  Staff who were not active during the inclusion period.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Blood donors whose last donation were between 1 Feb to 31 March, 2019.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Blood donors whose blood test results were positive. Blood donors who were aged above\r&lt;br&gt;             60. Blood donors whose cell phone number was obviously invalid.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Provision of informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Exposure to a COVID19 case within 4 days as either a healthcare worker or household\r&lt;br&gt;             contact, OR\r&lt;br&gt;\r&lt;br&gt;          -  Symptomatic COVID19 case with confirmed diagnosis within 4 days of symptom onset OR\r&lt;br&gt;             symptomatic healthcare worker with known COVID19 contact and within 4 days of symptom\r&lt;br&gt;             onset;\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Current hospitalization\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Retinal eye disease\r&lt;br&gt;\r&lt;br&gt;          -  Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Known chronic kidney disease, stage 4 or 5 or receiving dialysis\r&lt;br&gt;\r&lt;br&gt;          -  Weight &lt; 40 kg\r&lt;br&gt;\r&lt;br&gt;          -  Known Porphyria\r&lt;br&gt;\r&lt;br&gt;          -  Current use of: hydroxychloroquine or cardiac medicines of: flecainide, Tambocor;\r&lt;br&gt;             amiodarone, Cordarone, Pacerone; digoxin or Digox, Digitek, Lanoxin; procainamide or\r&lt;br&gt;             Procan, Procanbid, propafenone, Rythmal)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria (case definition)\r&lt;br&gt;\r&lt;br&gt;          -  Consented adults (age =18 years)\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 suspicious and\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to hospital or already in hospital and\r&lt;br&gt;\r&lt;br&gt;          -  Fever (with or without at the time of randomization) and\r&lt;br&gt;\r&lt;br&gt;          -  SARS (severe acute respiratory syndrome)\r&lt;br&gt;\r&lt;br&gt;               -  shortness of breath (dyspnea) or\r&lt;br&gt;\r&lt;br&gt;               -  image of typical or atypical pneumonia or\r&lt;br&gt;\r&lt;br&gt;               -  oxygen desaturation (SpO2 = 93)\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized patients with known COVID-19 negative PCR or\r&lt;br&gt;\r&lt;br&gt;          -  Clear indication or contraindication for the use of colchicine\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breastfeeding female.\r&lt;br&gt;","\r&lt;br&gt;        1. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or\r&lt;br&gt;             public health assay in any specimen &lt; 48 hours prior to randomization, and requiring\r&lt;br&gt;             hospital admission in the opinion of the attending physician.\r&lt;br&gt;\r&lt;br&gt;          2. Provides written informed consent prior to initiation of any study procedures (or\r&lt;br&gt;             legally authorized representative).\r&lt;br&gt;\r&lt;br&gt;          3. Understands and agrees to comply with planned study procedures.\r&lt;br&gt;\r&lt;br&gt;          4. Agrees to the collection of OP swabs and venous blood per protocol.\r&lt;br&gt;\r&lt;br&gt;          5. Male or female adult =18 years of age at time of enrollment.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Men or women 18 to 80 years of age inclusive, at the time of signing the informed\r&lt;br&gt;             consent\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Had a close contact of a person (index) with known PCR-confirmed SARS-CoV-2 infection\r&lt;br&gt;             or who is currently being assessed for COVID-19. Close contact defined as:\r&lt;br&gt;\r&lt;br&gt;               1. Household contact (i.e., residing with the index case in the 14 days prior to\r&lt;br&gt;                  index diagnosis)\r&lt;br&gt;\r&lt;br&gt;               2. Medical staff, first responders, or other care persons who cared for the index\r&lt;br&gt;                  case without personal protection (mask and gloves)\r&lt;br&gt;\r&lt;br&gt;          -  Less than 4 days since last exposure (close contact with a person with SARS-CoV-2\r&lt;br&gt;             infection) to the index case\r&lt;br&gt;\r&lt;br&gt;          -  Body weight &lt; 100 kg (self-reported)\r&lt;br&gt;\r&lt;br&gt;          -  Access to device and internet for Telehealth visits\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to HCQ or other 4-aminoquinoline compounds\r&lt;br&gt;\r&lt;br&gt;          -  Currently hospitalized\r&lt;br&gt;\r&lt;br&gt;          -  Symptomatic with subjective fever, cough, or sore throat\r&lt;br&gt;\r&lt;br&gt;          -  Current medications exclude concomitant use of HCQ\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant use of other anti-malarial treatment or chemoprophylaxis\r&lt;br&gt;\r&lt;br&gt;          -  History of retinopathy of any etiology\r&lt;br&gt;\r&lt;br&gt;          -  Psoriasis\r&lt;br&gt;\r&lt;br&gt;          -  Porphyria\r&lt;br&gt;\r&lt;br&gt;          -  Known bone marrow disorders with significant neutropenia (polymorphonuclear leukocytes\r&lt;br&gt;             &lt; 1500) or thrombocytopenia (&lt; 100 K)\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant use of digoxin, cyclosporin, cimetidine, or tamoxifen\r&lt;br&gt;\r&lt;br&gt;          -  Known liver disease\r&lt;br&gt;\r&lt;br&gt;          -  Known long QT syndrome\r&lt;br&gt;\r&lt;br&gt;          -  Use of any investigational or non-registered drug or vaccine within 30 days preceding\r&lt;br&gt;             the first dose of the study drugs, or planned use during the study period\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Confirmed SARS-CoV-2 infection, defined as RT-PCR provincial laboratory confirmation.\r&lt;br&gt;\r&lt;br&gt;          2. Self-reported symptoms of SARS-CoV-2 infection including any of the following: fever\r&lt;br&gt;             =37.5C, cough, dyspnea, chest tightness, malaise, sore throat, myalgias, or coryza\r&lt;br&gt;\r&lt;br&gt;          3. Time from a positive test result to day 1 of treatment &lt;96 hours\r&lt;br&gt;\r&lt;br&gt;          4. Time from patient reported first symptoms to day 1 of treatment &lt;12 days\r&lt;br&gt;\r&lt;br&gt;          5. Adults, age 18 and over, with any risk factor for severe disease\r&lt;br&gt;\r&lt;br&gt;          6. Resident of Alberta or if not a resident of Alberta able to provide complete follow-up\r&lt;br&gt;             data\r&lt;br&gt;\r&lt;br&gt;          7. Agrees to use adequate contraception for the duration of the study\r&lt;br&gt;\r&lt;br&gt;          8. Informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Currently or imminently planned admission to hospital\r&lt;br&gt;\r&lt;br&gt;          2. Any contraindication to hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          3. Participation in an ongoing interventional clinical trial within the previous 30 days\r&lt;br&gt;\r&lt;br&gt;          4. Use of hydroxychloroquine (Plaquenil) or chloroquine, lumefantrine, mefloquine, or\r&lt;br&gt;             quinine within the previous 30 days.\r&lt;br&gt;\r&lt;br&gt;          5. Inability to swallow pills or any other reason that compliance with the medical\r&lt;br&gt;             regimen is not likely\r&lt;br&gt;\r&lt;br&gt;          6. Pregnant or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          7. Severe underlying disease where treatment is not likely to be beneficial to the\r&lt;br&gt;             patient.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female, aged at 18 years (including) -75 years old\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory confirmation of SARS-CoV-2 infection by reverse-transcription polymerase\r&lt;br&gt;             chain reaction (RT-PCR) from any diagnostic sampling source\r&lt;br&gt;\r&lt;br&gt;          3. Pneumonia that is judged by computed tomography\r&lt;br&gt;\r&lt;br&gt;          4. In accordance with any one of the following : 1)dyspnea (RR = 30 times / min),\r&lt;br&gt;             2)finger oxygen saturation = 93% in resting state, 3)arterial oxygen partial pressure\r&lt;br&gt;             (PaO2) / oxygen absorption concentration (FiO2) = 300MMHG, 4)pulmonary imaging shows\r&lt;br&gt;             that the focus progress &gt; 50% in 24-48 hours\r&lt;br&gt;\r&lt;br&gt;          5. Interstitial lung damage is judged by computed tomography.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Pregnancy, lactation and those who are not pregnant but do not take effective\r&lt;br&gt;             contraceptives measures;\r&lt;br&gt;\r&lt;br&gt;          2. Patients with malignant tumor, other serious systemic diseases and psychosis;\r&lt;br&gt;\r&lt;br&gt;          3. Patients who are participating in other clinical trials;\r&lt;br&gt;\r&lt;br&gt;          4. Inability to provide informed consent or to comply with test requirements.\r&lt;br&gt;\r&lt;br&gt;          5. Co-Infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory\r&lt;br&gt;             infection virus.\r&lt;br&gt;\r&lt;br&gt;          6. Invasive ventilation\r&lt;br&gt;\r&lt;br&gt;          7. Shock\r&lt;br&gt;\r&lt;br&gt;          8. Combined with other organ failure( need organ support)\r&lt;br&gt;\r&lt;br&gt;          9. Interstitial lung damage caused by other reasons ( in 2 weeks)\r&lt;br&gt;\r&lt;br&gt;         10. The pulmonary imaging revealed the interstitial damage of lungs before the COVID-19\r&lt;br&gt;             confirmed.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged 18-75 years old;\r&lt;br&gt;\r&lt;br&gt;          -  Pneumonia patients with new coronavirus infection were confirmed to be positive by\r&lt;br&gt;             RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and\r&lt;br&gt;             treatment plan for pneumonia with new coronavirus infection (Current Trial Version);\r&lt;br&gt;\r&lt;br&gt;          -  Patients with newly diagnosed respiratory system discomfort who have been hospitalized\r&lt;br&gt;             (the diagnosis time of respiratory system discomfort shall not exceed 7 days);\r&lt;br&gt;\r&lt;br&gt;          -  Women and their partners who have no planned pregnancy for nearly half a year and are\r&lt;br&gt;             willing to take effective contraceptive measures within 30 days from the first\r&lt;br&gt;             administration of the study drug to the last administration;\r&lt;br&gt;\r&lt;br&gt;          -  Agree not to participate in other clinical research within 30 days from the first\r&lt;br&gt;             administration of the study drug to the last administration;\r&lt;br&gt;\r&lt;br&gt;          -  Patients who voluntarily sign informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The pneumonia patients with severe new coronavirus infection met one of the following\r&lt;br&gt;             conditions: respiratory distress, RR &gt;= 30 times / min; or SaO2 / SpO2 &lt;93% in resting\r&lt;br&gt;             state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2)\r&lt;br&gt;             &lt;300MMHG (1mmhg = 0.133kpa);\r&lt;br&gt;\r&lt;br&gt;          -  Pneumonia patients with severe new coronavirus infection meet one of the following\r&lt;br&gt;             conditions: respiratory failure and need mechanical ventilation; or shock; or other\r&lt;br&gt;             organ failure combined with ICU monitoring treatment;\r&lt;br&gt;\r&lt;br&gt;          -  Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);\r&lt;br&gt;\r&lt;br&gt;          -  Patients with contraindications specified in the instructions of ritonavir tablets;\r&lt;br&gt;\r&lt;br&gt;          -  The pregnancy test of female subjects in the screening period was positive;\r&lt;br&gt;\r&lt;br&gt;          -  The researchers judged that it was not suitable to participate in this clinical trial\r&lt;br&gt;             (for example, patients who may be transferred to another hospital during the study\r&lt;br&gt;             period; patients with multiple basic diseases, etc.).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  DoD-affiliated personnel as defined in DoDI 6200.02, which includes\r&lt;br&gt;             emergency-essential civilian employees and/or contractor personnel accompanying the\r&lt;br&gt;             Armed Forces who are subject to the same health risk as military personnel\r&lt;br&gt;\r&lt;br&gt;          -  Have a laboratory-confirmed COVID-19 diagnosis with moderate to severe disease\r&lt;br&gt;             presentation as determined by the principal investigator\r&lt;br&gt;\r&lt;br&gt;          -  Patient or legally authorized representative (LAR) provides written informed consent,\r&lt;br&gt;             except as noted in 21 CFR 50.23\r&lt;br&gt;\r&lt;br&gt;          -  Understands and agrees to comply with planned study procedures\r&lt;br&gt;\r&lt;br&gt;          -  Available for clinical follow-up for duration of the treatment and follow-up period\r&lt;br&gt;\r&lt;br&gt;          -  Woman of childbearing potential must\r&lt;br&gt;\r&lt;br&gt;               -  Have a negative pregnancy test within 24 hours before starting treatment\r&lt;br&gt;\r&lt;br&gt;               -  Agree not to become pregnant during treatment and for 1 months after receiving\r&lt;br&gt;                  remdesivir (Treatment will be a maximum of 10 doses given over a 10-day interval)\r&lt;br&gt;\r&lt;br&gt;               -  Use at least 2 reliable forms of effective contraception, including 1 barrier\r&lt;br&gt;                  method, during treatment and for 1 month after the treatment period\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  ALT/AST = 5 times the upper limit of normal\r&lt;br&gt;\r&lt;br&gt;          -  Stage 4 severe kidney disease or requiring dialysis (i.e. eGFR &lt;30)\r&lt;br&gt;\r&lt;br&gt;          -  Anticipated transfer to another hospital that is not a study site within 72 hours\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to any components of the study medication [GS-5734, sulfobutylether\r&lt;br&gt;             -cyclodextrin sodium (SBECD) and hydrochloric acid and/or sodium hydroxide]\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant antiviral therapy (lopinavir/ritonavir [Kaletra])\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or nursing\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria for a case:\r&lt;br&gt;\r&lt;br&gt;          1. Patients who meet the requirements of the New Coronavirus Infection Diagnosis (Acute\r&lt;br&gt;             respiratory infection symptoms or acute cough alone and positive PCR)\r&lt;br&gt;\r&lt;br&gt;          2. Aged =18 years male or female;\r&lt;br&gt;\r&lt;br&gt;          3. In women of childbearing potential, negative pregnancy test and commitment to use\r&lt;br&gt;             contraceptive method throughout the study.\r&lt;br&gt;\r&lt;br&gt;          4. Willing to take study medication\r&lt;br&gt;\r&lt;br&gt;          5. Willing to comply with all study procedures, including repeat nasal swab at day 3\r&lt;br&gt;\r&lt;br&gt;          6. Able to provide oral and written informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria for a case:\r&lt;br&gt;\r&lt;br&gt;          1. Serious condition meeting one of the following: (1) respiratory distress with\r&lt;br&gt;             respiratory rate &gt;=30 breaths/min; (2) oxygen saturation&lt;=93% on quiet status; (3)\r&lt;br&gt;             Arterial partial pressure of oxygen (PaO2)/oxygen concentration&lt;=300mmHg;\r&lt;br&gt;\r&lt;br&gt;          2. Critically ill patients meeting one of the following: (1) Experience respiratory\r&lt;br&gt;             failure and need to receive mechanical ventilation; (2) Experience shock; (3)\r&lt;br&gt;             Complicated with other organs failure and need intensive care and therapy in ICU;\r&lt;br&gt;\r&lt;br&gt;          3. Participants under treatment with medications likely to interfere with experimental\r&lt;br&gt;             drugs\r&lt;br&gt;\r&lt;br&gt;          4. Unable to take drugs by mouth;\r&lt;br&gt;\r&lt;br&gt;          5. With significantly abnormal liver function (Child Pugh C)\r&lt;br&gt;\r&lt;br&gt;          6. Need of dialysis treatment, or GFR=30 mL/min/1.73 m2;\r&lt;br&gt;\r&lt;br&gt;          7. Participants with psoriasis, myasthenia, haematopoietic and retinal\r&lt;br&gt;             diseases,CNS-related hearing loss or glucose-6-phosphate dehydrogenase deficit\r&lt;br&gt;\r&lt;br&gt;          8. Participants with severe neurological and mental illness;\r&lt;br&gt;\r&lt;br&gt;          9. Pregnant or lactating women;\r&lt;br&gt;\r&lt;br&gt;         10. Inability to consent and/or comply with study protocol;\r&lt;br&gt;\r&lt;br&gt;         11. Individuals with known hypersensitivity to the study drugs.\r&lt;br&gt;\r&lt;br&gt;         12. Persons already treated with any of the study drugs during the last 30 days.\r&lt;br&gt;\r&lt;br&gt;         13. Concomitant administration of enzyme inducers (such as carbamazepine) which could lead\r&lt;br&gt;             to ineffectiveness of darunavir; and those who receive CYP3A4 substrates (such as\r&lt;br&gt;             statins) because of the risk of increased toxicity.\r&lt;br&gt;\r&lt;br&gt;         14. HIV patients (because these are already on antiretroviral treatment)\r&lt;br&gt;\r&lt;br&gt;         15. Any contraindications as per the Data Sheet of Rezolsta or Hydroxychloroquine.\r&lt;br&gt;\r&lt;br&gt;        Inclusion Criteria for a contact:\r&lt;br&gt;\r&lt;br&gt;          1. Patients who meet the definition of a contact according to the Catalan Public Health\r&lt;br&gt;             Department Guidelines\r&lt;br&gt;\r&lt;br&gt;          2. Aged =18 years male or female;\r&lt;br&gt;\r&lt;br&gt;          3. In women of childbearing potential, negative pregnancy test and commitment to use\r&lt;br&gt;             contraceptive method throughout the study.\r&lt;br&gt;\r&lt;br&gt;          4. Willing to take study medication;\r&lt;br&gt;\r&lt;br&gt;          5. Willing to comply with all study procedures;\r&lt;br&gt;\r&lt;br&gt;          6. Able to provide oral, informed consent and/or assent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria for a contact:\r&lt;br&gt;\r&lt;br&gt;          1. With known history of cardiac arrhythmia (or QT prolongation syndrome);\r&lt;br&gt;\r&lt;br&gt;          2. Unable to take drugs by mouth;\r&lt;br&gt;\r&lt;br&gt;          3. With significantly abnormal liver function (Child Pugh C)\r&lt;br&gt;\r&lt;br&gt;          4. Need of dialysis treatment, or GFR=30 mL/min/1.73 m2;\r&lt;br&gt;\r&lt;br&gt;          5. Participants with psoriasis, myasthenia, haematopoietic and retinal\r&lt;br&gt;             diseases,CNS-related hearing loss or glucose-6-phosphate dehydrogenase deficit;\r&lt;br&gt;\r&lt;br&gt;          6. Persons already treated with any of the study drugs during the last 30 days;\r&lt;br&gt;\r&lt;br&gt;          7. Pregnant or lactating women;\r&lt;br&gt;\r&lt;br&gt;          8. Any contraindications as per the Data Sheet of Hydroxychloroquine.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Formally serving medical staff in Taihe Hospital;\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  pregnant women;\r&lt;br&gt;\r&lt;br&gt;          -  severe chronic diseases who are unable to participate in daily routine work;\r&lt;br&gt;\r&lt;br&gt;          -  fever (temperature=37.3  ) and / or respiratory symptoms.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Critical/Intensive care or Neurocritical care admission\r&lt;br&gt;\r&lt;br&gt;          -  Admission for/with acute encephalopathy defined as a rapidly developing (over less\r&lt;br&gt;             than 4 weeks, but usually within hours to a few days) pathobiological process in the\r&lt;br&gt;             brain; including delirium or subsyndromal (DSM V definition) or coma (Glasgow coma\r&lt;br&gt;             scale score &lt; 9)\r&lt;br&gt;\r&lt;br&gt;          -  SARS-COV-2 infection (respiratory or other PCR specimen)\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18 years\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - Opposition to study participation from the patient itself or patient surrogate\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  flu-like symptoms\r&lt;br&gt;\r&lt;br&gt;          -  a viral test order for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  confirmed COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  concern for exposure to COVID-19\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Males and females aged &gt; 18 years;\r&lt;br&gt;\r&lt;br&gt;          2. Probable or confirmed infection by SARS-CoV2 presenting with one of the following:\r&lt;br&gt;\r&lt;br&gt;               -  Need for oxygen supplementation &gt; 4L or,\r&lt;br&gt;\r&lt;br&gt;               -  Need for high oxygen flow nasal catheter, or\r&lt;br&gt;\r&lt;br&gt;               -  Need for non-invasive ventilation, or\r&lt;br&gt;\r&lt;br&gt;               -  Need for mechanical ventilation.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Refusal to provide written informed consent (either the patient or a legal\r&lt;br&gt;             representative);\r&lt;br&gt;\r&lt;br&gt;          2. Hypersensitivity to any of the drugs used in the study (Azithromycin or\r&lt;br&gt;             Hydroxychloroquine);\r&lt;br&gt;\r&lt;br&gt;          3. Patients with long QT syndrome or severe ventricular arrhythmias;\r&lt;br&gt;\r&lt;br&gt;          4. QTc&gt; = 480ms;\r&lt;br&gt;\r&lt;br&gt;          5. Patients without a therapeutic perspective or with a palliative care perspective;\r&lt;br&gt;\r&lt;br&gt;          6. Patients with liver disease or cirrhosis or abnormal liver enzyme tests above three\r&lt;br&gt;             times the upper limit values (alanine aminotransferase -ALT and aspartate\r&lt;br&gt;             aminotransferase - AST);\r&lt;br&gt;\r&lt;br&gt;          7. Renal dysfunction (estimated glomerular filtration rate [eGFR] &lt;30 mL/min/1.73m2,\r&lt;br&gt;             using the MDRD or CKD-EPI methods);\r&lt;br&gt;\r&lt;br&gt;          8. Patients with retinopathy or macular degeneration;\r&lt;br&gt;\r&lt;br&gt;          9. Patients with pancreatitis;\r&lt;br&gt;\r&lt;br&gt;         10. Patients using drugs that prolong the QT interval;\r&lt;br&gt;\r&lt;br&gt;         11. Patients with concomitant use of medications that alter the absorption or excretion of\r&lt;br&gt;             azithromycin or hydroxychloroquine;\r&lt;br&gt;\r&lt;br&gt;         12. Breastfeeding women;\r&lt;br&gt;\r&lt;br&gt;         13. Patients using psychoactive drugs;\r&lt;br&gt;\r&lt;br&gt;         14. Pregnancy.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult (age = 18 years)\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed OR suspected COVID-19,\r&lt;br&gt;\r&lt;br&gt;               -  Confirmed: Positive assay for COVID-19 within the last 10 days\r&lt;br&gt;\r&lt;br&gt;               -  Suspected: Pending assay for COVID-19 WITH high clinical suspicion\r&lt;br&gt;\r&lt;br&gt;          -  Scheduled for admission or already admitted to an inpatient bed\r&lt;br&gt;\r&lt;br&gt;          -  Patients must be enrolled within 48 hours of hospital admission\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to hydroxychloroquine or azithromycin\r&lt;br&gt;\r&lt;br&gt;          -  History of bone marrow transplant\r&lt;br&gt;\r&lt;br&gt;          -  Known G6PD deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Chronic hemodialysis or Glomerular Filtration Rate &lt; 20ml/min\r&lt;br&gt;\r&lt;br&gt;          -  Psoriasis\r&lt;br&gt;\r&lt;br&gt;          -  Porphyria\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone\r&lt;br&gt;\r&lt;br&gt;          -  Known history of long QT syndrome\r&lt;br&gt;\r&lt;br&gt;          -  Current known QTc&gt;500 msec\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or nursing\r&lt;br&gt;\r&lt;br&gt;          -  Prisoner\r&lt;br&gt;\r&lt;br&gt;          -  Weight &lt; 35kg\r&lt;br&gt;\r&lt;br&gt;          -  Severe liver disease\r&lt;br&gt;\r&lt;br&gt;          -  Seizure disorder\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. &lt; 18 years-old, and\r&lt;br&gt;\r&lt;br&gt;          2. Present to a participating ED for care, and\r&lt;br&gt;\r&lt;br&gt;          3. Undergo SARS-CoV-2 testing.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1) Refusal to participate (no informed consent)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients who meet the requirements of the New Coronavirus Infection Diagnosis (Acute\r&lt;br&gt;             respiratory infection symptoms or acute cough alone and positive PCR)\r&lt;br&gt;\r&lt;br&gt;          2. Aged =18 and &lt; 75 years male or female;\r&lt;br&gt;\r&lt;br&gt;          3. In women of childbearing potential, negative pregnancy test and commitment to use\r&lt;br&gt;             contraceptive method throughout the study.\r&lt;br&gt;\r&lt;br&gt;          4. Willing to take study medication\r&lt;br&gt;\r&lt;br&gt;          5. Willing to comply with all study procedures,\r&lt;br&gt;\r&lt;br&gt;          6. Diagnosis of IBD disease, rheumatoid arthritis, seronegative spondyloarthritis or\r&lt;br&gt;             psoriasis for more than 6 months.\r&lt;br&gt;\r&lt;br&gt;          7. Be on stable treatment with biological agents, for a minimum period of 6 months,\r&lt;br&gt;             including treatment with Infliximab, etanercept, adalimumab, certolizumab, golimumab,\r&lt;br&gt;             rituximab, abatacept, tocilizumab, sarilumab, secukinumab, vedolizumab, natalizumab,\r&lt;br&gt;             ustekinumab, tofacit\r&lt;br&gt;\r&lt;br&gt;          8. Able to provide oral and written informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria\r&lt;br&gt;\r&lt;br&gt;          1. Previous infection with SARS-CoV-2.\r&lt;br&gt;\r&lt;br&gt;          2. Current treatment with hydroxychloroquine / chloroquine.\r&lt;br&gt;\r&lt;br&gt;          3. Previous or current treatment with tamoxifen or raloxifene.\r&lt;br&gt;\r&lt;br&gt;          4. Previous eye disease, especially maculopathy.\r&lt;br&gt;\r&lt;br&gt;          5. Known heart failure grade III-IV of the classification of the New York Heart\r&lt;br&gt;             Association).\r&lt;br&gt;\r&lt;br&gt;          6. Any type of cancer (except basal cell) in the last 5 years.\r&lt;br&gt;\r&lt;br&gt;          7. Pregnancy.\r&lt;br&gt;\r&lt;br&gt;          8. Refusal to give informed consent.\r&lt;br&gt;\r&lt;br&gt;          9. Evidence of any other unstable or clinically significant unstable, clinically\r&lt;br&gt;             significant, immunological, endocrine, hematologic, gastrointestinal, neurological,\r&lt;br&gt;             neoplastic, or psychiatric illness.\r&lt;br&gt;\r&lt;br&gt;         10. Instability or mental incompetence, so that the validity of the informed consent or\r&lt;br&gt;             the ability to complete the study is uncertain.\r&lt;br&gt;\r&lt;br&gt;         11. Positive antibodies to the human immunodeficiency virus.\r&lt;br&gt;\r&lt;br&gt;         12. Data on decompensated liver disease:\r&lt;br&gt;\r&lt;br&gt;        to. Aspartate aminotransferase (AST) and / or ALT&gt; 10 x upper limit of normal (LSN).\r&lt;br&gt;\r&lt;br&gt;        b. Total bilirubin&gt; 25 mol / l (1.5 mg / dl). c. International normalized index&gt; 1.4. d.\r&lt;br&gt;        Platelet count &lt;100,000 / mm3. 17. Serum creatinine levels&gt; 135 mol / l (&gt; 1.53 mg / dl)\r&lt;br&gt;        in men and&gt; 110 mol / l (&gt; 24 mg / dl) in women.\r&lt;br&gt;\r&lt;br&gt;        18.Significant kidney disease, including nephrotic syndrome, chronic kidney disease\r&lt;br&gt;        (patients with markers of liver injury or estimated glomerular filtration rate [eGFR] of\r&lt;br&gt;        less than 60 ml / min / 1.73 m2). If an abnormal value is obtained at the first screening\r&lt;br&gt;        visit, the measurement of eGFR may be repeated before randomization within the following\r&lt;br&gt;        time frame: minimum 4 weeks after the initial test and maximum 2 weeks before the planned\r&lt;br&gt;        randomization. Repeated abnormal eGFR (less than 60 ml / min / 1.73 m2) leads to exclusion\r&lt;br&gt;        from the study.Pregnant or lactating women; 19. Inability to consent and/or comply with\r&lt;br&gt;        study protocol; 20. Individuals with known hypersensitivity to the study drugs. 21. Any\r&lt;br&gt;        contraindications as per the Data Sheet of or Hydroxychloroquine.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Positive laboratory test for COVID-19 based on local laboratory standard\r&lt;br&gt;\r&lt;br&gt;          -  Upper respiratory symptoms (cough, rhinorrhea) or fever (&gt;101.5)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Randomization &gt; 72 hours of meeting inclusion criteria\r&lt;br&gt;\r&lt;br&gt;          -  Randomization &gt; 7 days of symptom onset\r&lt;br&gt;\r&lt;br&gt;          -  Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin\r&lt;br&gt;             receptor blocker (ARB)\r&lt;br&gt;\r&lt;br&gt;          -  Prior reaction or intolerance to an ARB or ACE inhibitor, including but not limited to\r&lt;br&gt;             angioedema\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  Those able to have children and not currently taking a protocol-allowed version of\r&lt;br&gt;             contraception: intrauterine device, Depo-formulation of hormonal contraception (e.g.\r&lt;br&gt;             medroxyprogesterone acetate / Depo-Provera), subcutaneous contraceptive (e.g.\r&lt;br&gt;             Nexplanon), daily oral contraceptives with verbalized commitment to taking daily\r&lt;br&gt;             throughout the study, condom use or abstinence during the study. All women of child\r&lt;br&gt;             bearing age enrolled in this fashion will be informed of the teratogenic risks.\r&lt;br&gt;\r&lt;br&gt;          -  Patient reported history or electronic medical record history of kidney disease,\r&lt;br&gt;             defined as:\r&lt;br&gt;\r&lt;br&gt;               1. Any history of dialysis\r&lt;br&gt;\r&lt;br&gt;               2. History of chronic kidney disease stage III or IV\r&lt;br&gt;\r&lt;br&gt;               3. Estimated Glomerular Filtration Rate (eGFR) of &lt; 30ml/min/1.73 m2 (must be have\r&lt;br&gt;                  been measured within 1 month of enrollment)\r&lt;br&gt;\r&lt;br&gt;               4. Other kidney disease that in the opinion of the investigator, would affect\r&lt;br&gt;                  losartan clearance\r&lt;br&gt;\r&lt;br&gt;          -  Patient reported dehydration and significantly decreased urine output in the past 72\r&lt;br&gt;             hours\r&lt;br&gt;\r&lt;br&gt;          -  Most recent systolic blood pressure prior to enrollment &lt;110 mmHg\r&lt;br&gt;\r&lt;br&gt;          -  Patient reported history or electronic medical record history of severe liver disease,\r&lt;br&gt;             defined as:\r&lt;br&gt;\r&lt;br&gt;               1. Cirrhosis\r&lt;br&gt;\r&lt;br&gt;               2. History of hepatitis B or C\r&lt;br&gt;\r&lt;br&gt;               3. Other liver disease that in the opinion of the investigator, would affect\r&lt;br&gt;                  losartan clearance\r&lt;br&gt;\r&lt;br&gt;               4. Documented AST or ALT &gt; 3 times the upper limit of normal within 3 months of\r&lt;br&gt;                  randomization (if available in electronic medical record)\r&lt;br&gt;\r&lt;br&gt;          -  Potassium &gt;5.0 mmol/L (must have been measured within 1 month) of enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent treatment with Aliskiren\r&lt;br&gt;\r&lt;br&gt;          -  Inability to obtain informed consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged between 18 and 60 years.\r&lt;br&gt;\r&lt;br&gt;          -  Able to understand the content of informed consent and willing to sign the informed\r&lt;br&gt;             consent\r&lt;br&gt;\r&lt;br&gt;          -  Able and willing to complete all the secluded study process during the whole 6 months\r&lt;br&gt;             study follow-up period.\r&lt;br&gt;\r&lt;br&gt;          -  Negative in HIV diagnostic test.\r&lt;br&gt;\r&lt;br&gt;          -  Negative in serum antibodies (IgG and IgM) screening of COVID-19.\r&lt;br&gt;\r&lt;br&gt;          -  Normal in lung CT images (no imaging features of COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Axillary temperature =37.0C.\r&lt;br&gt;\r&lt;br&gt;          -  The BMI index is 18.5-30.0.\r&lt;br&gt;\r&lt;br&gt;          -  Negative in Nasopharyngeal swabs / sputum and anal swabs through RT-PCR\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory tests such as hematological examination and clinical biochemistry\r&lt;br&gt;             examination are in the normal range or without meaning judged by clinical doctor.\r&lt;br&gt;\r&lt;br&gt;          -  General good health as established by medical history and physical examination.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Family history of seizure, epilepsy, brain or mental disease\r&lt;br&gt;\r&lt;br&gt;          -  Subject allergic to any component of the investigational vaccine, or a more severe\r&lt;br&gt;             allergic reaction and history of allergies in the past.\r&lt;br&gt;\r&lt;br&gt;          -  Woman who is pregnant, breast-feeding or positive in -HCG (human chorionic\r&lt;br&gt;             gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during\r&lt;br&gt;             the next 6 months\r&lt;br&gt;\r&lt;br&gt;          -  Any acute fever disease or infections.\r&lt;br&gt;\r&lt;br&gt;          -  History of SARS\r&lt;br&gt;\r&lt;br&gt;          -  Major congenital defects or not well-controlled chronic illness, such as asthma,\r&lt;br&gt;             diabetes, or thyroid disease.\r&lt;br&gt;\r&lt;br&gt;          -  Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial\r&lt;br&gt;             infarction, severe hypertension without controllable drugs, etc.\r&lt;br&gt;\r&lt;br&gt;          -  Hereditary angioneurotic edema or acquired angioneurotic edema\r&lt;br&gt;\r&lt;br&gt;          -  Urticaria in last one year\r&lt;br&gt;\r&lt;br&gt;          -  No spleen or functional spleen.\r&lt;br&gt;\r&lt;br&gt;          -  Platelet disorder or other bleeding disorder may cause injection contraindication\r&lt;br&gt;\r&lt;br&gt;          -  Faint at the sight of needles.\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of immunodepressant or corticosteroids, antianaphylaxis\r&lt;br&gt;             treatment, cytotoxic treatment in last 6 months.\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of blood products in last 4 months\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of other research medicines in last 1 month\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of attenuated vaccine in last 1 month\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of inactivated vaccine in last 14 days\r&lt;br&gt;\r&lt;br&gt;          -  Current anti-tuberculosis prophylaxis or therapy\r&lt;br&gt;\r&lt;br&gt;          -  According to the judgement of investigator,various medical, psychological, social or\r&lt;br&gt;             other conditions, those could affect the subjects to sign informed consent.\r&lt;br&gt;","\r&lt;br&gt;        Key Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction\r&lt;br&gt;             (PCR), result from any specimen (or other commercial or public health assay) within 2\r&lt;br&gt;             weeks prior to randomization and no alternative explanation for current clinical\r&lt;br&gt;             condition\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized with illness of any duration with evidence of pneumonia and severe\r&lt;br&gt;             disease, critical disease, multi-system organ dysfunction or immunocompromised at\r&lt;br&gt;             baseline\r&lt;br&gt;\r&lt;br&gt;          -  Ability to provide informed consent signed by study patient or legally acceptable\r&lt;br&gt;             representative\r&lt;br&gt;\r&lt;br&gt;          -  Willingness and ability to comply with study-related procedures/assessments\r&lt;br&gt;\r&lt;br&gt;        Key Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  In the opinion of the investigator, not expected to survive for more than 48 hours\r&lt;br&gt;             from screening\r&lt;br&gt;\r&lt;br&gt;          -  Presence of any of the following abnormal laboratory values at screening: absolute\r&lt;br&gt;             neutrophil count (ANC) less than 2000 mm3, aspartate aminotransferase (AST) or alanine\r&lt;br&gt;             aminotransferase (ALT) greater than 5 x upper limit of normal (ULN), platelets &lt;50,000\r&lt;br&gt;             per mm3\r&lt;br&gt;\r&lt;br&gt;          -  Treatment with anti-IL 6, anti-IL-6R antagonists, or with Janus kinase inhibitors\r&lt;br&gt;             (JAKi) in the past 30 days or plans to receive during the study period\r&lt;br&gt;\r&lt;br&gt;          -  Current treatment with the simultaneous combination of leflunomide and methotrexate\r&lt;br&gt;\r&lt;br&gt;          -  Known active tuberculosis (TB), history of incompletely treated TB, suspected or known\r&lt;br&gt;             extrapulmonary TB, suspected or known systemic bacterial or fungal infections\r&lt;br&gt;\r&lt;br&gt;          -  Patients who have received immunosuppressive antibody therapy within the past 5\r&lt;br&gt;             months, including intravenous immunoglobulin or plans to receive during the study\r&lt;br&gt;             period\r&lt;br&gt;\r&lt;br&gt;          -  Participation in a double-blind clinical research study evaluating an investigational\r&lt;br&gt;             product (IP) or therapy within 3 months and less than 5 half-lives of IP prior to the\r&lt;br&gt;             screening visit (The use of remdesivir, hydroxychloroquine, or other treatments being\r&lt;br&gt;             used for COVID-19 treatments in the context of an open-label study or compassionate\r&lt;br&gt;             use protocol is permitted)\r&lt;br&gt;\r&lt;br&gt;          -  Any physical examination findings, and/or history of any illness, concomitant\r&lt;br&gt;             medications or recent live vaccines that, in the opinion of the study investigator,\r&lt;br&gt;             might confound the results of the study or pose an additional risk to the patient by\r&lt;br&gt;             their participation in the study\r&lt;br&gt;\r&lt;br&gt;          -  Known systemic hypersensitivity to sarilumab or the excipients of the drug product\r&lt;br&gt;\r&lt;br&gt;        NOTE: Other protocol defined inclusion / exclusion criteria may apply\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  SARS-CoV2 Infection diagnosed by rt-PCR\r&lt;br&gt;\r&lt;br&gt;          -  CT-scan confirmed multifocal interstitial pneumonia\r&lt;br&gt;\r&lt;br&gt;          -  Need of oxygen therapy to maintain SO2&gt;93%\r&lt;br&gt;\r&lt;br&gt;          -  Worsening of lung involvement, defined as (one of the following criteria):\r&lt;br&gt;\r&lt;br&gt;               -  Worsening of oxygen saturation &gt;3 percentage points or decrease in PaO2 &gt;10%,\r&lt;br&gt;                  with stable FiO2 in the last 24h\r&lt;br&gt;\r&lt;br&gt;               -  Need of increase FiO2 in order to maintain a stable SO2 or new onset need of\r&lt;br&gt;                  mechanical ventilation in the last 24h\r&lt;br&gt;\r&lt;br&gt;               -  Increase in number and/or extension of pulmonary areas of consolidation\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt;18 ys and &gt;90 ys\r&lt;br&gt;\r&lt;br&gt;          -  Severe heart failure\r&lt;br&gt;\r&lt;br&gt;          -  Bacterial Infection\r&lt;br&gt;\r&lt;br&gt;          -  Haematological neoplasm\r&lt;br&gt;\r&lt;br&gt;          -  Neutrophil count below 1000/mcl\r&lt;br&gt;\r&lt;br&gt;          -  Platelet count below 50000/mcl\r&lt;br&gt;\r&lt;br&gt;          -  ALT&gt; x5UNL\r&lt;br&gt;\r&lt;br&gt;          -  Inability to give informed consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria: (1) Adult patients, &gt;/= 18 year-old; (2) Patients admitted to the ICU;\r&lt;br&gt;        (3) Patients who are intubated and mechanically ventilated; (4) Confirmed diagnosis of\r&lt;br&gt;        SARS-CoV2 by positive rt-PCR.\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria: (1) Patients intubated for more than 72 hours from initiation of the\r&lt;br&gt;        treatment gas; (2) Subjects enrolled in another interventional research study; (3)\r&lt;br&gt;        Physician of record opposed to enrolling the patient due to perceived safety concerns; or\r&lt;br&gt;        any condition that does not allow the protocol to be followed safely.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  ARDS associated with COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;          -  Medical necessity for endotracheal intubation and mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  Physician determination that patient is on maximal conventional medical therapy\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  existing evidence of end-organ (renal, cardiac, hepatic, gastrointestinal failure)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Presumptive positive laboratory test for SARS-CoV-2 or upper respiratory infection\r&lt;br&gt;             with recent exposure to laboratory-proven SARS-CoV-2-infected person\r&lt;br&gt;\r&lt;br&gt;          -  Negative influenza and respiratory virus panel\r&lt;br&gt;\r&lt;br&gt;          -  New or worsening hypoxia (SpO2 &lt;95%) compared to baseline or increasing oxygen\r&lt;br&gt;             requirement\r&lt;br&gt;\r&lt;br&gt;          -  Randomization within 24 hours of initial presentation to a hospital (inclusive of\r&lt;br&gt;             transfer)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Currently taking an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin\r&lt;br&gt;             receptor blocker (ARB)\r&lt;br&gt;\r&lt;br&gt;          -  Prior reaction or intolerance to an ARB or ACEi\r&lt;br&gt;\r&lt;br&gt;          -  Blood pressure less than 110/70 mmHg\r&lt;br&gt;\r&lt;br&gt;          -  Potassium great than 5.0 mEq/L within 4 weeks of study enrollment.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  In females of childbearing age, unwillingness to use birth control for the duration of\r&lt;br&gt;             the study\r&lt;br&gt;\r&lt;br&gt;          -  Estimated Glomerular Filtration Rate (eGFR) of &lt; 30ml/min/1.73 m2 within 4 weeks of\r&lt;br&gt;             study initiation or history of advanced renal disease\r&lt;br&gt;\r&lt;br&gt;          -  AST and/or ALT &gt; 3 times the upper limit of normal within 4 weeks of study enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Severe volume depletion or severe acute kidney injury that, in the opinion of the\r&lt;br&gt;             investigator, would preclude administration of Losartan\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent treatment with Alikirin\r&lt;br&gt;\r&lt;br&gt;          -  Inability to obtain informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Non-English speakers\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  flu-like symptoms: myalgia, cough, fever, sputum\r&lt;br&gt;\r&lt;br&gt;          -  Chest X-Rays\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 biological tests\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  patient refusal\r&lt;br&gt;\r&lt;br&gt;          -  uncertain radiographs\r&lt;br&gt;\r&lt;br&gt;          -  uncertain tests results\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Able to consent and agree to participate in the project after discussing the project\r&lt;br&gt;\r&lt;br&gt;          -  Coming to The Everett Clinic during the operational project duration\r&lt;br&gt;\r&lt;br&gt;          -  Evidence of upper respiratory symptoms suggesting higher risk of testing positive for\r&lt;br&gt;             SARS-CoV-2 virus.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Not able to demonstrate understanding of the study\r&lt;br&gt;\r&lt;br&gt;          -  Not willing to commit to having all four samples collected\r&lt;br&gt;\r&lt;br&gt;          -  Medical history evidencing any of the following\r&lt;br&gt;\r&lt;br&gt;               -  Active nosebleed in the past 24 hours\r&lt;br&gt;\r&lt;br&gt;               -  Nasal surgery in the past two weeks\r&lt;br&gt;\r&lt;br&gt;               -  Chemotherapy treatment with low platelet and low white blood cell counts\r&lt;br&gt;\r&lt;br&gt;               -  Acute facial trauma\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with suspected or confirmed COVID-19 admitted to inpatient units and\r&lt;br&gt;             intensive care units\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Need for oxygen supplementation &gt; 4L/min\r&lt;br&gt;\r&lt;br&gt;          -  Patients using a high-flow nasal catheter\r&lt;br&gt;\r&lt;br&gt;          -  Patients using non-invasive mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  Patients using invasive mechanical ventilation 2. Males and females aged &lt; 18 years 3.\r&lt;br&gt;             Pregnancy 4. Allergy to chloroquine or derivatives 5. Allergy to azythromycin 6.\r&lt;br&gt;             Patients hospitalized for more than 48 hours 7. Patients with respiratory symptoms for\r&lt;br&gt;             more than 14 days\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Clinical and radiological diagnosis of pulmonary infection by COVID-19\r&lt;br&gt;\r&lt;br&gt;          2. Positive microbiological evidence of SARS-CoV-2 infection\r&lt;br&gt;\r&lt;br&gt;          3. Diagnosis of acute respiratory distress syndrome clinical panel in accordance with\r&lt;br&gt;             Berlin 2012 criteria\r&lt;br&gt;\r&lt;br&gt;          4. For Cohort A only: subjects are eligible if they are enrolled and treated within 48\r&lt;br&gt;             hours from the beginning of NIV (non invasive ventilation) or CPAP(continous positive\r&lt;br&gt;             airway pressure)\r&lt;br&gt;\r&lt;br&gt;          5. For Cohort B only: subjects are eligible if they are enrolled and treated within 48\r&lt;br&gt;             hours from the beginning of invasive ventilation\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1. Active infection of bacterial or viral (non COVID-19) origin\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 PCR positive (within 7 days)\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 PCR pending\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 high clinical suspicion\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient without Prior Research Authorization (applicable to Mayo Clinic sites)\r&lt;br&gt;\r&lt;br&gt;          -  Non COVID-19 related admissions\r&lt;br&gt;\r&lt;br&gt;          -  Repeated Admission to ICUs/Hospital\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. &gt; 6 months of age\r&lt;br&gt;\r&lt;br&gt;          2. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other\r&lt;br&gt;             commercial or public health assay in any specimen prior to randomization.\r&lt;br&gt;\r&lt;br&gt;          3. Hospitalized at a participating centre\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Anticipated transfer to another hospital, within 72 hours, which is not a study site\r&lt;br&gt;\r&lt;br&gt;          2. Known allergy to study medication or its components (non-medicinal ingredients)\r&lt;br&gt;\r&lt;br&gt;          3. Currently taking any of the following medications:\r&lt;br&gt;\r&lt;br&gt;               -  alfuzosin (e.g., Xatral)\r&lt;br&gt;\r&lt;br&gt;               -  amiodarone (eg Cordarone)\r&lt;br&gt;\r&lt;br&gt;               -  apalutamide (e.g. Erleada)\r&lt;br&gt;\r&lt;br&gt;               -  astemizole*, terfenadine*\r&lt;br&gt;\r&lt;br&gt;               -  cisapride*\r&lt;br&gt;\r&lt;br&gt;               -  colchicine, when used in patients with renal and/or hepatic impairment\r&lt;br&gt;\r&lt;br&gt;               -  dronedarone (e.g., Multaq)\r&lt;br&gt;\r&lt;br&gt;               -  disulfiram (for those who may need to take the oral solution)\r&lt;br&gt;\r&lt;br&gt;               -  elbasvir/grazoprevir (e.g., ZepatierTM) - used to treat hepatitis C virus (HCV)\r&lt;br&gt;\r&lt;br&gt;               -  ergotamine*, dihydroergotamine\r&lt;br&gt;\r&lt;br&gt;               -  ergonovine, methylergonovine* (used after labour and delivery), such as\r&lt;br&gt;                  Cafergot, Migranal, D.H.E. 45*, Methergine*, and others\r&lt;br&gt;\r&lt;br&gt;               -  fusidic acid (e.g., Fucidin), systemic\r&lt;br&gt;\r&lt;br&gt;               -  lurasidone (e.g., Latuda), pimozide (e.g., Orap*)\r&lt;br&gt;\r&lt;br&gt;               -  metronidazole (for those who may need to take the oral solution)\r&lt;br&gt;\r&lt;br&gt;               -  neratinib (e.g., Nerlynx) - used for breast cancer\r&lt;br&gt;\r&lt;br&gt;               -  sildenafil (e.g., Revatio)\r&lt;br&gt;\r&lt;br&gt;               -  triazolam, oral midazolam\r&lt;br&gt;\r&lt;br&gt;               -  rifampin, also known as Rimactane*, Rifadin, Rifater*, or Rifamate*.\r&lt;br&gt;\r&lt;br&gt;               -  St. John's Wort\r&lt;br&gt;\r&lt;br&gt;               -  Venetoclax\r&lt;br&gt;\r&lt;br&gt;               -  lovastatin (e.g., Mevacor*), lomitapide (e.g., JuxtapidTM) or simvastatin (e.g.,\r&lt;br&gt;                  Zocor)\r&lt;br&gt;\r&lt;br&gt;               -  PDE5 inhibitors vardenafil (e.g., Levitra or Revatio).\r&lt;br&gt;\r&lt;br&gt;               -  salmeterol, also known as Advair and Serevent.\r&lt;br&gt;\r&lt;br&gt;          4. Known HIV infection\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  informed consent was given\r&lt;br&gt;\r&lt;br&gt;          -  age = 18\r&lt;br&gt;\r&lt;br&gt;          -  able to complete the questionnaire in German\r&lt;br&gt;\r&lt;br&gt;          -  country of residence: Germany\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  if at least one of the inclusion criteria is not met\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 positive\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation &lt;92%\r&lt;br&gt;\r&lt;br&gt;          -  Able to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Receiving oxygen by non-rebreather mask\r&lt;br&gt;\r&lt;br&gt;          -  Not currently requiring intubation\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Unable or unwilling to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Cognitive impairment\r&lt;br&gt;\r&lt;br&gt;          -  Rapidly decompensating status requiring urgent or emergent higher level of care\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Patients affected by COVID19 referring to italian outpatient clinics or hospitals\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        -\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Should be at least 18 years of age,\r&lt;br&gt;\r&lt;br&gt;          2. Male or female,\r&lt;br&gt;\r&lt;br&gt;          3. Diagnosed with COVID-19 and confirmed SARS-coV-2 viral infection.\r&lt;br&gt;\r&lt;br&gt;          4. Able to sign the consent form.\r&lt;br&gt;\r&lt;br&gt;          5. Severe COVID-19 (Appendix A), or NIAID 7-point ordinal score 3 to 4 (requiring\r&lt;br&gt;             non-invasive ventilation or oxygen, a SpO2 &lt;/= 94% or tachypnea (respiratory rate &gt;/=\r&lt;br&gt;             24 breaths/min), Appendix B).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with COVID 19 in critical condition or ARDS (Appendix A) or NIAID 7-point\r&lt;br&gt;             ordinal score 2 (Hospitalized, on invasive mechanical ventilation or extracorporeal\r&lt;br&gt;             membrane oxygenation (ECMO)).\r&lt;br&gt;\r&lt;br&gt;          2. Patients with bacterial / fungal infections.\r&lt;br&gt;\r&lt;br&gt;          3. Patients who are pregnant, breastfeeding, or have a positive pregnancy test result\r&lt;br&gt;             before enrollment.\r&lt;br&gt;\r&lt;br&gt;          4. Severe liver damage (Child-Pugh score = C, AST&gt; 5 times the upper limit).\r&lt;br&gt;\r&lt;br&gt;          5. Patients with known severe renal impairment (creatinine clearance = 30 mL / min) or\r&lt;br&gt;             patients receiving continuous renal replacement therapy, hemodialysis, or peritoneal\r&lt;br&gt;             dialysis.\r&lt;br&gt;\r&lt;br&gt;          6. The investigator believes that participating in the trial is not in the best interests\r&lt;br&gt;             of the patient, or the investigator considers unsuitable for enrollment (such as\r&lt;br&gt;             unpredictable risks or subject compliance issues).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Any gender\r&lt;br&gt;\r&lt;br&gt;          2. No age limit\r&lt;br&gt;\r&lt;br&gt;          3. Informed consent for participation in the study (consent can be oral if a written\r&lt;br&gt;             consent cannot be expressed. If the subject is incapable of giving an informed consent\r&lt;br&gt;             and an authorized representative is not available without a delay that would, in the\r&lt;br&gt;             opinion of the Investigator, compromise the potential life-saving effect of the\r&lt;br&gt;             treatment this can be administered without consent. Consent to remain in the research\r&lt;br&gt;             should be sought as soon the conditions of the patient will allow it)\r&lt;br&gt;\r&lt;br&gt;          4. Virological diagnosis of SARS-CoV-2 infection (real-time PCR)\r&lt;br&gt;\r&lt;br&gt;          5. Hospitalized due to clinical/instrumental diagnosis of pneumonia\r&lt;br&gt;\r&lt;br&gt;          6. Oxygen saturation at rest in ambient air =93% or requiring oxygen therapy or\r&lt;br&gt;             mechanical ventilation either non invasive or invasive (intubated)\r&lt;br&gt;\r&lt;br&gt;          7. Patients with criteria #4 and #5 who have been already treated with tocilizumab before\r&lt;br&gt;             registration are eligible for the observational retrospective cohort\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Known hypersensitivity to tocilizumab or its excipients\r&lt;br&gt;\r&lt;br&gt;          2. Known active infections or other clinical condition that contraindicate tocilizumab\r&lt;br&gt;             and cannot be treated or solved according to the judgement of the clinician\r&lt;br&gt;\r&lt;br&gt;          3. ALT / AST&gt; 5 times the upper limit of the normality\r&lt;br&gt;\r&lt;br&gt;          4. Neutrophils &lt;500 / mmc\r&lt;br&gt;\r&lt;br&gt;          5. Platelets &lt;50.000 / mmc\r&lt;br&gt;\r&lt;br&gt;          6. Bowel diverticulitis or perforation\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients admitted to hospital with biological samples positive for SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  Patients admitted to hospital with negative test but clinical and radiological\r&lt;br&gt;             characteristics highly suggestive of SARS-CoV-2 disease\r&lt;br&gt;\r&lt;br&gt;          -  Patients discharged from emergency department with biological samples positive for\r&lt;br&gt;             SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  pregnant women with laboratory-confirmed 2019-n-CoV\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Pregnant women or women who have been pregnant within the last 6 weeks\r&lt;br&gt;\r&lt;br&gt;          2. Able to give informed consent\r&lt;br&gt;\r&lt;br&gt;          3. Diagnosed with COVID-19; or being evaluated for COVID-19 (\"patient under\r&lt;br&gt;             investigation\") since January 1, 2020\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1. &lt;18 years of age.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria, general:\r&lt;br&gt;\r&lt;br&gt;          -  Sufficient German language skills to participate in the assessments.\r&lt;br&gt;\r&lt;br&gt;          -  Providing informed consent for participation.\r&lt;br&gt;\r&lt;br&gt;        Inclusion criteria for the arms \"Online support program\" and \"Waiting condition...\":\r&lt;br&gt;\r&lt;br&gt;        - Having signed up for the online support program provided by selfapy GmbH, Berlin, Germany\r&lt;br&gt;        (www.selfapy.de/corona) aiming at reducing burden in the context of the COVID-19 pandemic.\r&lt;br&gt;\r&lt;br&gt;        Inclusion criteria for the arm \"No intervention...\":\r&lt;br&gt;\r&lt;br&gt;        - Not having signed up for the online support program provided by selfapy GmbH, Berlin,\r&lt;br&gt;        Germany (www.selfapy.de/corona) aiming at reducing burden in the context of the COVID-19\r&lt;br&gt;        pandemic.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients must be 18 years of age or older\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19\r&lt;br&gt;             SARS-CoV-2 RT-PCR testing. Patient is willing and able to provide written informed\r&lt;br&gt;             consent and comply with all protocol requirements.\r&lt;br&gt;\r&lt;br&gt;          -  Patient agrees to storage of specimens for future testing.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Female subjects with positive pregnancy test, breastfeeding, or planning to become\r&lt;br&gt;             pregnant/breastfeed during the study period\r&lt;br&gt;\r&lt;br&gt;          -  Receipt of pooled immunoglobulin in past 30 days\r&lt;br&gt;\r&lt;br&gt;          -  Contraindication to transfusion or history of prior reactions to transfusion blood\r&lt;br&gt;             products\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Infection with COVID-19 diagnosed by positive RT-PCR SARS-CoV-2 or, if not performed,\r&lt;br&gt;             by thorax CT-scan suggesting viral pneumonia of peripheral predominance in a\r&lt;br&gt;             clinically significant context.\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed within the previous 48 hours.\r&lt;br&gt;\r&lt;br&gt;          -  Having at least one of the following two risk factors for complications:\r&lt;br&gt;\r&lt;br&gt;          -  age =75 years old\r&lt;br&gt;\r&lt;br&gt;          -  Peripheral oxygen saturation (SpO2) = 94% while breathing ambient air, or a partial\r&lt;br&gt;             oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio = 300 mmHg.\r&lt;br&gt;\r&lt;br&gt;          -  Patients affiliated with or benefitting from a social security scheme\r&lt;br&gt;\r&lt;br&gt;          -  Written and signed consent of the patient or a relative or, if not possible, emergency\r&lt;br&gt;             inclusion procedure\r&lt;br&gt;\r&lt;br&gt;          -  Electrocardiogram showing absence of QT prolongation greater than 440 ms in men and\r&lt;br&gt;             460 ms in women.\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria\r&lt;br&gt;\r&lt;br&gt;          -  Negative RT-PCR SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  Peripheral capillary oxygen saturation less than or equal to 94% (SpO2=94%) despite\r&lt;br&gt;             oxygen therapy greater than or equal to 3 L/min (= 3 L/min)\r&lt;br&gt;\r&lt;br&gt;          -  Organ failure requiring admission to a resuscitation or high dependency unit\r&lt;br&gt;\r&lt;br&gt;          -  Comorbidity that is life-threatening in the short-term (life expectancy &lt;3 months)\r&lt;br&gt;\r&lt;br&gt;          -  Any reason that makes follow-up at day 28 impossible\r&lt;br&gt;\r&lt;br&gt;          -  Current treatment with hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Absolute contraindication to treatment with hydroxychloroquine (known\r&lt;br&gt;             hypersensitivity, concomitant treatment with risk of torsades de pointe)\r&lt;br&gt;\r&lt;br&gt;          -  Electrocardiogram showing corrected QT prolongation greater than 440 ms in men and 460\r&lt;br&gt;             ms in women.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant, lactating or parturient women\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults = 18 years of age\r&lt;br&gt;\r&lt;br&gt;          -  Approval from the patient's primary service\r&lt;br&gt;\r&lt;br&gt;          -  Admitted as an inpatient to University of Chicago Medicine\r&lt;br&gt;\r&lt;br&gt;          -  Fever, documented in electronic medical record and defined as: T = 38*C by any\r&lt;br&gt;             conventional clinical method (forehead, tympanic, oral, axillary, rectal)\r&lt;br&gt;\r&lt;br&gt;          -  Positive test for active SARS-CoV-2 infection\r&lt;br&gt;\r&lt;br&gt;          -  Radiographic evidence of infiltrates on chest radiograph (CXR) or computed tomography\r&lt;br&gt;             (CT)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent use of invasive mechanical ventilation (patients receiving non-invasive\r&lt;br&gt;             mechanical ventilation [CPAP, BiPap, HHFNC] are eligible)\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent use of vasopressor or inotropic medications\r&lt;br&gt;\r&lt;br&gt;          -  Previous receipt of tocilizumab or another anti-IL6R or IL-6 inhibitor.\r&lt;br&gt;\r&lt;br&gt;          -  Known history of hypersensitivity to tocilizumab.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are actively being considered for a study of an antiviral agent that\r&lt;br&gt;             would potentially exclude concurrent enrollment on this study.\r&lt;br&gt;\r&lt;br&gt;          -  Patients actively receiving an investigational antiviral agent in the context of a\r&lt;br&gt;             clinical research study.\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosis of end-stage liver disease or listed for liver transplant.\r&lt;br&gt;\r&lt;br&gt;          -  Elevation of AST or ALT in excess of 5 times the upper limit of normal.\r&lt;br&gt;\r&lt;br&gt;          -  Neutropenia (Absolute neutrophil count &lt; 500/uL).\r&lt;br&gt;\r&lt;br&gt;          -  Thrombocytopenia (Platelets &lt; 50,000/uL).\r&lt;br&gt;\r&lt;br&gt;          -  On active therapy with a biologic immunosuppressive agent.\r&lt;br&gt;\r&lt;br&gt;          -  History of bone marrow transplantation or solid organ transplant.\r&lt;br&gt;\r&lt;br&gt;          -  Known history of Hepatitis B or Hepatitis C.\r&lt;br&gt;\r&lt;br&gt;          -  Known history of mycobacterium tuberculosis infection at risk for reactivation.\r&lt;br&gt;\r&lt;br&gt;          -  Known history of gastrointestinal perforation or active diverticulitis.\r&lt;br&gt;\r&lt;br&gt;          -  Multi-organ failure as determined by primary treating team\r&lt;br&gt;\r&lt;br&gt;          -  Any other documented serious, active infection besides COVID-19.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant patients\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are unable to discontinue scheduled antipyretic medications, either as\r&lt;br&gt;             monotherapy (e.g., acetaminophen or ibuprofen [aspirin is acceptable]) or as part of\r&lt;br&gt;             combination therapy (e.g., hydrocodone/acetaminophen, aspirin/acetaminophen/caffeine\r&lt;br&gt;             [Excedrin])\r&lt;br&gt;\r&lt;br&gt;          -  CRP &lt; 40 mg/L (or ug/mL)\r&lt;br&gt;\r&lt;br&gt;        Patients will be assigned to Group A if:\r&lt;br&gt;\r&lt;br&gt;        ? C-reactive protein (CRP) = 75 ug/mL\r&lt;br&gt;\r&lt;br&gt;        AND\r&lt;br&gt;\r&lt;br&gt;        Any one of the following criteria are met:\r&lt;br&gt;\r&lt;br&gt;          -  Previous ICU admission\r&lt;br&gt;\r&lt;br&gt;          -  Previous non-elective intubation\r&lt;br&gt;\r&lt;br&gt;          -  Admission for heart failure exacerbation within the past 12 months\r&lt;br&gt;\r&lt;br&gt;          -  History of percutaneous coronary intervention (PCI)\r&lt;br&gt;\r&lt;br&gt;          -  History of coronary artery bypass graft (CABG) surgery\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosis of pulmonary hypertension\r&lt;br&gt;\r&lt;br&gt;          -  Baseline requirement for supplemental O2\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosis of interstitial lung disease (ILD)\r&lt;br&gt;\r&lt;br&gt;          -  Admission for chronic obstructive pulmonary disease (COPD) exacerbation within the\r&lt;br&gt;             past 12 months\r&lt;br&gt;\r&lt;br&gt;          -  Asthma with use of daily inhaled corticosteroid\r&lt;br&gt;\r&lt;br&gt;          -  History of pneumonectomy or lobectomy\r&lt;br&gt;\r&lt;br&gt;          -  History of radiation therapy to the lung\r&lt;br&gt;\r&lt;br&gt;          -  History of HIV\r&lt;br&gt;\r&lt;br&gt;          -  Cancer of any stage and receiving active treatment (excluding hormonal therapy)\r&lt;br&gt;\r&lt;br&gt;          -  Any history of diagnosed immunodeficiency\r&lt;br&gt;\r&lt;br&gt;          -  End-stage renal disease (ESRD) requiring peritoneal or hemodialysis\r&lt;br&gt;\r&lt;br&gt;        All other eligible patients assigned to Group B\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients / caregivers treated at Bordeaux University Hospital for asymptomatic or\r&lt;br&gt;             symptomatic infection by SARS -CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  men and women, adults and minors as well as pregnant or breastfeeding women\r&lt;br&gt;\r&lt;br&gt;          -  patients who died following infection with SARS-CoV-2 (specific criterion for\r&lt;br&gt;             post-mortem biopsies)\r&lt;br&gt;\r&lt;br&gt;          -  Be affiliated with or beneficiary of a social security scheme\r&lt;br&gt;\r&lt;br&gt;          -  Free and informed consent obtained and signed by the patient\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Under guardianship or curatorship\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt; 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Expected ICU stay of &gt; 48 hours\r&lt;br&gt;\r&lt;br&gt;          -  Bilateral Viral Pneumonia\r&lt;br&gt;\r&lt;br&gt;          -  Orotracheal intubation from less than 24 hours\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed or highly suspected COVID-19\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with cancer (all stages) diagnosis\r&lt;br&gt;\r&lt;br&gt;          -  Severe hemodynamic instability (need of vasopressors &gt;1 mcg/Kg/min to maintain a MAP &gt;\r&lt;br&gt;             65 mmHg)\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant women\r&lt;br&gt;\r&lt;br&gt;          -  Immunocompromised patients\r&lt;br&gt;\r&lt;br&gt;          -  Limitations of care\r&lt;br&gt;\r&lt;br&gt;          -  Inclusion in any other interventional trial\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Clinical diagnosis of COVID-19 Disease,\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Medical Physicians in Middle East area\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  none\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Adults &gt;18 years of age\r&lt;br&gt;\r&lt;br&gt;          2. Informed consent\r&lt;br&gt;\r&lt;br&gt;          3. A confirmed diagnosis of SARS-CoV-2 with mild to moderate disease defined as oxygen &gt;\r&lt;br&gt;             90% on room air on or supplemental oxygen not more than 6L\r&lt;br&gt;\r&lt;br&gt;          4. Concomitant medications for the treatment are allowed\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients &lt;18 years\r&lt;br&gt;\r&lt;br&gt;          2. Pregnant females\r&lt;br&gt;\r&lt;br&gt;          3. Invasive ventilator support or non-invasive ventilator support including high flow\r&lt;br&gt;             nasal cannula\r&lt;br&gt;\r&lt;br&gt;          4. COPD or Congestive Heart Failure patients requiring home oxygen\r&lt;br&gt;\r&lt;br&gt;          5. History of lung cancer and radiation to lung or had prior radiation to the chest\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Norwegian adult\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Unable to consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged between 18 and 75 years, extremes included, male or female In conscious patients,\r&lt;br&gt;             ability to understand and the willingness to sign a written informed consent document;\r&lt;br&gt;             in unconscious patients informed consent will be signed from parents or legal tutors.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients that don't sign the informed consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized with COVID-19 pneumonia confirmed per WHO criteria (including a positive\r&lt;br&gt;             PCR of any specimen; e.g., respiratory, blood, urine, stool, other bodily fluid) and\r&lt;br&gt;             evidenced by chest X-ray or CT scan\r&lt;br&gt;\r&lt;br&gt;          -  SPO2 &lt;/=93% or PaO2/FiO2 &lt;300 mmHg\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Known severe allergic reactions to TCZ or other monoclonal antibodies\r&lt;br&gt;\r&lt;br&gt;          -  Active tuberculosis (TB) infection\r&lt;br&gt;\r&lt;br&gt;          -  Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)\r&lt;br&gt;\r&lt;br&gt;          -  In the opinion of the investigator, progression to death is imminent and inevitable\r&lt;br&gt;             within the next 24 hours, irrespective of the provision of treatments\r&lt;br&gt;\r&lt;br&gt;          -  Have received oral anti-rejection or immunomodulatory drugs (including TCZ) with the\r&lt;br&gt;             past 6 months\r&lt;br&gt;\r&lt;br&gt;          -  Participating in other drug clinical trials (participation in COVID-19 anti-viral\r&lt;br&gt;             trials may be permitted if approved by Medical Monitor)\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination\r&lt;br&gt;\r&lt;br&gt;          -  Treatment with an investigational drug within 5 half-lives or 30 days (whichever is\r&lt;br&gt;             longer) of randomization (investigational COVID-19 antivirals may be permitted if\r&lt;br&gt;             approved by Medial Monitor)\r&lt;br&gt;\r&lt;br&gt;          -  Any serious medical condition or abnormality of clinical laboratory tests that, in the\r&lt;br&gt;             investigator's judgment, precludes the patient's safe participation in and completion\r&lt;br&gt;             of the study\r&lt;br&gt;\r&lt;br&gt;          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 10 x upper limit\r&lt;br&gt;             of normal (ULN) detected within 24 hours at screening or at baseline (per local lab)\r&lt;br&gt;\r&lt;br&gt;          -  Absolute neutrophil count (ANC) &lt; 1000/mL at screening and baseline (per local lab)\r&lt;br&gt;\r&lt;br&gt;          -  Platelet count &lt; 50,000/mL at screening and baseline (per local lab)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Adult patients, 18 years and above\r&lt;br&gt;\r&lt;br&gt;          2. Confirmed SARS-2-CoV-2 infection by PCR\r&lt;br&gt;\r&lt;br&gt;          3. Admitted to the hospital ward or the ICU\r&lt;br&gt;\r&lt;br&gt;          4. Subjects (or legally authorized representative) provides written informed consent\r&lt;br&gt;             prior to initiation of the study\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Severe co-morbidity with life expectancy &lt;3 months according to investigators\r&lt;br&gt;             assessment\r&lt;br&gt;\r&lt;br&gt;          2. (Aspartate Transaminase/ Alanine Aminotransferase) ASAT/ALAT &gt; 5 times the upper limit\r&lt;br&gt;             of normal\r&lt;br&gt;\r&lt;br&gt;          3. Acute co-morbidity within 7 days before inclusion such as myocardial infarction\r&lt;br&gt;\r&lt;br&gt;          4. Known intolerance to the available study drugs\r&lt;br&gt;\r&lt;br&gt;          5. Pregnancy, possible pregnancy or breast feeding\r&lt;br&gt;\r&lt;br&gt;          6. Any reason why, in the opinion of the investigators, the patient should not\r&lt;br&gt;             participate\r&lt;br&gt;\r&lt;br&gt;          7. Subject participates in a potentially confounding drug or device trial during the\r&lt;br&gt;             course of the study\r&lt;br&gt;\r&lt;br&gt;          8. Prolonged QT interval (&gt;450 ms)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  People who are feeling sick and have tested positive for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  People who are feeling sick but have not tested positive for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  People who are not feeling sick but want to participate\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;         People who are unwilling or unable to provide informed consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  18 years or older\r&lt;br&gt;\r&lt;br&gt;          -  Moderate to severe COVID-19 associated disease as defined by the WHO\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized patient\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to provide written informed consent prior to performing study\r&lt;br&gt;             procedures\r&lt;br&gt;\r&lt;br&gt;          -  Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other\r&lt;br&gt;             commercial or public health assay\r&lt;br&gt;\r&lt;br&gt;          -  Illness of any duration, and at least one of the following: Radiographic infiltrates\r&lt;br&gt;             by imaging (chest x-ray, CT scan, etc.), or Clinical assessment (evidence of\r&lt;br&gt;             rales/crackles on exam) AND SpO2 = 94% on room air, or Require mechanical ventilation\r&lt;br&gt;             and/or supplemental oxygen.\r&lt;br&gt;\r&lt;br&gt;          -  Febrile defined as temperature = 36.6 C armpit, = 37.2 C oral, or = 37.8 C rectal\r&lt;br&gt;             documented within 48 hours of consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participation in any other clinical trial of an experimental treatment for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent treatment with other agents with actual or possible direct acting antiviral\r&lt;br&gt;             activity against SARS-CoV-2 is prohibited &lt; 24 hours prior to study medication\r&lt;br&gt;             initiation\r&lt;br&gt;\r&lt;br&gt;          -  SOFA &gt;10\r&lt;br&gt;\r&lt;br&gt;          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit\r&lt;br&gt;             of normal (ULN)\r&lt;br&gt;\r&lt;br&gt;          -  Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt; 30)\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant women or women who are breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  Immunocompromised patients taking medication upon screening\r&lt;br&gt;\r&lt;br&gt;          -  Consideration by the investigator, for any reason, that the subject is an unsuitable\r&lt;br&gt;             candidate to receive study treatment\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  16 years or above\r&lt;br&gt;\r&lt;br&gt;          -  Patient requiring hospital admission AND AT LEAST ONE OF\r&lt;br&gt;\r&lt;br&gt;          -  Clinical or Radiological evidence of pneumonia\r&lt;br&gt;\r&lt;br&gt;          -  Acute respiratory distress syndrome\r&lt;br&gt;\r&lt;br&gt;          -  Influenza like illness (defined as fever &gt;37.8oC and at least one of the following\r&lt;br&gt;             respiratory symptoms, which much be of acute onset: persistent cough (with or without\r&lt;br&gt;             sputum), hoarseness, nasal discharge or congestion, shortness of breath, sore throat,\r&lt;br&gt;             wheezing, sneezing)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who have not had the standard PHE COVID-19 test applied\r&lt;br&gt;\r&lt;br&gt;          -  Unwilling or unable to comply with research swab of nose &amp; throat or tracheal fluid\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation &lt;93%\r&lt;br&gt;\r&lt;br&gt;          -  Able to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Not currently requiring intubation\r&lt;br&gt;\r&lt;br&gt;          -  Receiving oxygen by face mask\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Unable or unwilling to provide informed consent, cognitive impairment\r&lt;br&gt;\r&lt;br&gt;          -  Rapidly decompensating status requiring urgent or emergent higher level of care\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Patients &gt;18 years old with laboratory confirmed SARS-CoV-2 infection (RT PCR) AND body\r&lt;br&gt;        temperature &gt;37.5 degrees centigrade AND at least two of: i. sustained coughing, ii.\r&lt;br&gt;        sustained throat pain, iii. anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2&lt;95 mmHg.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  pregnancy, lactation;\r&lt;br&gt;\r&lt;br&gt;          -  known hypersensitivity to colchicine\r&lt;br&gt;\r&lt;br&gt;          -  known hepatic failure\r&lt;br&gt;\r&lt;br&gt;          -  eGFR&lt;20 ml/min\r&lt;br&gt;\r&lt;br&gt;          -  clinical estimation that the patient will require mechanical respiratory support in\r&lt;br&gt;             less than 24 hours\r&lt;br&gt;\r&lt;br&gt;          -  any clinical estimation of the attending physician under which the patient shall be\r&lt;br&gt;             excluded\r&lt;br&gt;\r&lt;br&gt;          -  QTc &gt; 450 msec (colchicine is not known to significantly prolong QTc, but may interact\r&lt;br&gt;             with other medications which prolong QTc).\r&lt;br&gt;\r&lt;br&gt;          -  participation in another clinical trial\r&lt;br&gt;\r&lt;br&gt;          -  under colchicine treatment for other indications\r&lt;br&gt;\r&lt;br&gt;          -  patient who is not likely to comply to study procedures\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Over 18 years of age\r&lt;br&gt;\r&lt;br&gt;          -  Employed by one of the hospitals involved in the study\r&lt;br&gt;\r&lt;br&gt;          -  Provide a signed and dated informed consent form\r&lt;br&gt;\r&lt;br&gt;          -  Pre-randomisation blood collected\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Has any BCG vaccine contraindication\r&lt;br&gt;\r&lt;br&gt;          -  Fever or generalised skin infection (where feasible, randomisation can be delayed\r&lt;br&gt;             until cleared)\r&lt;br&gt;\r&lt;br&gt;          -  Weakened resistance toward infections due to a disease in/of the immune system\r&lt;br&gt;\r&lt;br&gt;          -  Receiving medical treatment that affects the immune response or other\r&lt;br&gt;             immunosuppressive therapy in the last year. These therapies include systemic\r&lt;br&gt;             corticosteroids (more than or equal to 20 mg for more than or equal to 2 weeks),\r&lt;br&gt;             non-biological immunosuppressant (also known as 'DMARDS'), biological agents (such as\r&lt;br&gt;             monoclonal antibodies against tumour necrosis factor (TNF)-alpha).\r&lt;br&gt;\r&lt;br&gt;          -  Has a congenital cellular immunodeficiency, including specific deficiencies of the\r&lt;br&gt;             interferon-gamma pathway\r&lt;br&gt;\r&lt;br&gt;          -  Has a malignancy involving bone marrow or lymphoid systems\r&lt;br&gt;\r&lt;br&gt;          -  Has any serious underlying illness (such as malignancy). Please note: People with\r&lt;br&gt;             cardiovascular disease, hypertension, diabetes, and/or chronic respiratory disease are\r&lt;br&gt;             eligible if not immunocompromised\r&lt;br&gt;\r&lt;br&gt;          -  Known or suspected HIV infection, even if asymptomatic or has normal immune function.\r&lt;br&gt;             This is because of the risk of disseminated BCG infection\r&lt;br&gt;\r&lt;br&gt;          -  Has active skin disease such as eczema, dermatitis or psoriasis at or near the site of\r&lt;br&gt;             vaccination. A different site (other than left arm) can be chosen if necessary\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breastfeeding Although there is no evidence that BCG vaccination is\r&lt;br&gt;             harmful during pregnancy or breastfeeding, it is a contra-indication to BCG\r&lt;br&gt;             vaccination. Therefore, we will exclude women who think they could be pregnant.\r&lt;br&gt;\r&lt;br&gt;          -  Another live vaccine administered in the month prior to randomisation\r&lt;br&gt;\r&lt;br&gt;          -  Require another live vaccine to be administered within the month following BCG\r&lt;br&gt;             randomisation If the other live vaccine can be given on the same day, this exclusion\r&lt;br&gt;             criteria does not apply\r&lt;br&gt;\r&lt;br&gt;          -  Known anaphylactic reaction to any of the ingredient present in the BCG vaccine\r&lt;br&gt;\r&lt;br&gt;          -  BCG vaccine given within the last year\r&lt;br&gt;\r&lt;br&gt;          -  Has previously had a SARS-CoV-2 positive test result\r&lt;br&gt;\r&lt;br&gt;          -  Already part of this trial, recruited at a different hospital\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years.\r&lt;br&gt;\r&lt;br&gt;          2. Healthcare worker based in a primary, secondary or tertiary healthcare setting with a\r&lt;br&gt;             high risk of developing COVID-19 due to their potential exposure to patients with\r&lt;br&gt;             SARS-CoV-2 infection.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        -\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  HIV disease\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction\r&lt;br&gt;             (PCR) or other commercial or public health assay\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult, Age&gt;44 years, competent to provide consent\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed COVID-19, via a positive nucleic acid assay for COVID-19 within the last 7\r&lt;br&gt;             days\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participants already prescribed chloroquine, hydroxychloroquine, or azithromycin\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to hydroxychloroquine or azithromycin\r&lt;br&gt;\r&lt;br&gt;          -  History of bone marrow transplant\r&lt;br&gt;\r&lt;br&gt;          -  Known G6PD (Glucose-6-Phosphate Dehydrogenase Deficiency) deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or\r&lt;br&gt;             Glomerular Filtration Rate &lt; 20ml/min/1.73m2\r&lt;br&gt;\r&lt;br&gt;          -  Liver disease (e.g. Child Pugh score = B or AST (Aspartate Transaminase)&gt;2 times upper\r&lt;br&gt;             limit)\r&lt;br&gt;\r&lt;br&gt;          -  Psoriasis\r&lt;br&gt;\r&lt;br&gt;          -  Porphyria\r&lt;br&gt;\r&lt;br&gt;          -  Known cardiac conduction delay (QTc &gt; 500mSec) or taking any prescription medications\r&lt;br&gt;             known to prolong QT interval\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone\r&lt;br&gt;\r&lt;br&gt;          -  Prisoner\r&lt;br&gt;\r&lt;br&gt;          -  Weight &lt; 35kg\r&lt;br&gt;\r&lt;br&gt;          -  Inability to follow-up - no cell phone or no address or not Spanish or English\r&lt;br&gt;             speaking\r&lt;br&gt;\r&lt;br&gt;          -  Receipt of any experimental treatment for SARS-CoV-2 (off-label, compassionate use, or\r&lt;br&gt;             trial related) within the 30 days prior to the time of the screening evaluation\r&lt;br&gt;\r&lt;br&gt;          -  No symptoms attributable to COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or nursing\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female patients aged 18 years and above;\r&lt;br&gt;\r&lt;br&gt;          2. Hospitalised;\r&lt;br&gt;\r&lt;br&gt;          3. Confirmed or suspected SARS-CoV-2 infection;\r&lt;br&gt;\r&lt;br&gt;          4. National Early Warning Score (NEWS2) greater than or equal to 3 in a single parameter\r&lt;br&gt;             or NEWS2 &gt; 5 overall;\r&lt;br&gt;\r&lt;br&gt;          5. Acute hypoxemic respiratory failure: PaO2/FiO2 ratio less than or equal to 300 OR\r&lt;br&gt;             SpO2/FiO2 ratio &lt; 315 (Kigali Modification)\r&lt;br&gt;\r&lt;br&gt;          6. Provision of written informed consent by the patient OR by the patient's Legal\r&lt;br&gt;             Representative OR professional consultee.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Any of the following contraindications to ibuprofen:\r&lt;br&gt;\r&lt;br&gt;               -  A known hypersensitivity to ibuprofen or any other constituent of the medicinal\r&lt;br&gt;                  product;\r&lt;br&gt;\r&lt;br&gt;               -  Patients who have previously shown hypersensitivity reactions (e.g. asthma,\r&lt;br&gt;                  rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal\r&lt;br&gt;                  anti-inflammatory drugs (NSAIDs);\r&lt;br&gt;\r&lt;br&gt;               -  Patients with a history of, or existing gastrointestinal ulceration/perforation\r&lt;br&gt;                  or bleeding, including that associated with NSAIDs;\r&lt;br&gt;\r&lt;br&gt;               -  Patients with severe hepatic failure;\r&lt;br&gt;\r&lt;br&gt;               -  Patients with acute renal failure;\r&lt;br&gt;\r&lt;br&gt;               -  Patients with severe heart failure.\r&lt;br&gt;\r&lt;br&gt;          2. Participation in any other investigational drug products less than 30 days prior to\r&lt;br&gt;             study enrolment;\r&lt;br&gt;\r&lt;br&gt;          3. Glasgow Coma Score &lt; 12;\r&lt;br&gt;\r&lt;br&gt;          4. Pregnancy;\r&lt;br&gt;\r&lt;br&gt;          5. Any medical history that might, in the opinion of the attending clinician, put the\r&lt;br&gt;             patient at significant risk if he/she were to participate in the trial;\r&lt;br&gt;\r&lt;br&gt;          6. DNAR order/limitation of care.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Males and females, at least 40 years of age, capable and willing to provide informed\r&lt;br&gt;             consent;\r&lt;br&gt;\r&lt;br&gt;          2. Patient must have received a diagnosis of COVID-19 infection within the last 24 hours;\r&lt;br&gt;\r&lt;br&gt;          3. Outpatient setting (not currently hospitalized or under immediate consideration for\r&lt;br&gt;             hospitalization);\r&lt;br&gt;\r&lt;br&gt;          4. Patient must possess at least one of the following high-risk criteria: 70 years or\r&lt;br&gt;             more of age, diabetes mellitus, uncontrolled hypertension (systolic blood pressure\r&lt;br&gt;             =150 mm Hg), known respiratory disease (including asthma or chronic obstructive\r&lt;br&gt;             pulmonary disease), known heart failure, known coronary disease, fever of =38.4C\r&lt;br&gt;             within the last 48 hours, dyspnea at the time of presentation, bicytopenia,\r&lt;br&gt;             pancytopenia, or the combination of high neutrophil count and low lymphocyte count;\r&lt;br&gt;\r&lt;br&gt;          5. Female patient is either not of childbearing potential, defined as postmenopausal for\r&lt;br&gt;             at least 1 year or surgically sterile, or is of childbearing potential and practicing\r&lt;br&gt;             at least one method of contraception and preferably two complementary forms of\r&lt;br&gt;             contraception including a barrier method (e.g. male or female condoms, spermicides,\r&lt;br&gt;             sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study\r&lt;br&gt;             and for 30 days after study completion;\r&lt;br&gt;\r&lt;br&gt;          6. Patient must be able and willing to comply with the requirements of this study\r&lt;br&gt;             protocol.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patient currently hospitalized or under immediate consideration for hospitalization;\r&lt;br&gt;\r&lt;br&gt;          2. Patient currently in shock or with hemodynamic instability;\r&lt;br&gt;\r&lt;br&gt;          3. Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis),\r&lt;br&gt;             chronic diarrhea or malabsorption;\r&lt;br&gt;\r&lt;br&gt;          4. Patient with pre-existent progressive neuromuscular disease;\r&lt;br&gt;\r&lt;br&gt;          5. Estimated Glomerular filtration rate (eGFR), using the MDRD equation for all subjects\r&lt;br&gt;             being considered for enrollment, with a cut-off of &lt; 30 mL/m in/1.73m2;\r&lt;br&gt;\r&lt;br&gt;          6. Patient with a history of cirrhosis, chronic active hepatitis or severe hepatic\r&lt;br&gt;             disease;\r&lt;br&gt;\r&lt;br&gt;          7. Female patient who is pregnant, or breast-feeding or is considering becoming pregnant\r&lt;br&gt;             during the study or for 6 months after the last dose of study medication;\r&lt;br&gt;\r&lt;br&gt;          8. Patient currently taking colchicine for other indications (mainly chronic indications\r&lt;br&gt;             represented by Familial Mediterranean Fever or gout);\r&lt;br&gt;\r&lt;br&gt;          9. Patient with a history of an allergic reaction or significant sensitivity to\r&lt;br&gt;             colchicine;\r&lt;br&gt;\r&lt;br&gt;         10. Patient undergoing chemotherapy for cancer;\r&lt;br&gt;\r&lt;br&gt;         11. Patient is considered by the investigator, for any reason, to be an unsuitable\r&lt;br&gt;             candidate for the study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Subjects must be 18 years of age or older\r&lt;br&gt;\r&lt;br&gt;          -  Close contact* exposure to person with COVID-19 within 96 hours of enrollment (and 120\r&lt;br&gt;             hours of receipt of plasma)\r&lt;br&gt;\r&lt;br&gt;        High risk exposure as defined by CDC: Living in the same household as, being an intimate\r&lt;br&gt;        partner of, or providing care in a nonhealthcare setting (such as a home) for a person with\r&lt;br&gt;        symptomatic laboratory-confirmed COVID-19 infection without using recommended precautions\r&lt;br&gt;        for home care and home isolation\r&lt;br&gt;\r&lt;br&gt;        AND\r&lt;br&gt;\r&lt;br&gt;        Higher risk for severe illness as defined by CDC (any of the following):\r&lt;br&gt;\r&lt;br&gt;          -  65 years of age\r&lt;br&gt;\r&lt;br&gt;               -  Residence in a nursing home or long-term care facility 3.3 -Chronic lung disease\r&lt;br&gt;                  or moderate to severe asthma 3.4 -Heart disease 3.5 -Immunocompromising condition\r&lt;br&gt;                  including cancer treatment\r&lt;br&gt;\r&lt;br&gt;               -  Severe obesity (body mass index [BMI] &gt;40)\r&lt;br&gt;\r&lt;br&gt;               -  Uncontrolled diabetes\r&lt;br&gt;\r&lt;br&gt;               -  Renal failure\r&lt;br&gt;\r&lt;br&gt;               -  Liver disease\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Receipt any blood product in past 120 days\r&lt;br&gt;\r&lt;br&gt;          -  Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion\r&lt;br&gt;             of the principal investigator, would affect subject safety and/or compliance\r&lt;br&gt;\r&lt;br&gt;          -  Symptoms consistent with COVID-19 infection (fevers, acute onset cough, shortness of\r&lt;br&gt;             breath) at time of screening\r&lt;br&gt;\r&lt;br&gt;          -  Nucleic acid testing evidence of COVID-19 infection at time of screening\r&lt;br&gt;\r&lt;br&gt;          -  History of prior reactions to transfusion blood products\r&lt;br&gt;\r&lt;br&gt;          -  Inability to complete therapy with the study product within 24 hours after enrollment\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        All the ED patients positive to or suspected of COVID-19 infection with at least one of the\r&lt;br&gt;        following symptoms:\r&lt;br&gt;\r&lt;br&gt;          -  fever\r&lt;br&gt;\r&lt;br&gt;          -  cough/dyspnea\r&lt;br&gt;\r&lt;br&gt;          -  SpO2 &lt; 95% in ambient air (&lt; 91% if BPCO patient).\r&lt;br&gt;\r&lt;br&gt;          -  positive Quick Walk Test\r&lt;br&gt;\r&lt;br&gt;          -  respiratory symptoms or admission in ED for respiratory reason\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  age &lt; 18 years\r&lt;br&gt;\r&lt;br&gt;          -  intubated patients or patients discharged in ICU in 1 hour from ED arrival\r&lt;br&gt;\r&lt;br&gt;          -  denied consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        diagnosis of pneumonia; Covid-19 test positive; hospitalized subjects; both sexes aged;\r&lt;br&gt;        given informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        age lower than 18 years; pregnancy; breast-feeding.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  SARS-CoV-2 infection confirmed by real time-PCR and\r&lt;br&gt;\r&lt;br&gt;          -  Positive imaging: consolidation, ground glass opacities, or bilateral pulmonary\r&lt;br&gt;             infiltration either by CT-scan or chest x-ray; and\r&lt;br&gt;\r&lt;br&gt;          -  Need of oxygen therapy to maintain SO2&gt;94% OR FiO2/PaO2 &gt; 20 and at least two of the\r&lt;br&gt;             following laboratory measures:\r&lt;br&gt;\r&lt;br&gt;          -  CRP level &gt;70 mg/L\r&lt;br&gt;\r&lt;br&gt;          -  CRP level &gt;= 40 mg/L and doubled within 48 hours (without other confirmed infectious\r&lt;br&gt;             or non-infectious course),\r&lt;br&gt;\r&lt;br&gt;          -  Lactatdehydrogenase &gt; 250 U/L,\r&lt;br&gt;\r&lt;br&gt;          -  thrombocytopenia &lt; 120.000 x 10E9/L,\r&lt;br&gt;\r&lt;br&gt;          -  lymphocyte count &lt; 0.6 x 10E9/L,\r&lt;br&gt;\r&lt;br&gt;          -  D-dimer &gt; 1 ug/mL,\r&lt;br&gt;\r&lt;br&gt;          -  serum ferritin &gt; 300 ug/mL\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  pregnancy suspected or confirmed,\r&lt;br&gt;\r&lt;br&gt;          -  severe heart failure,\r&lt;br&gt;\r&lt;br&gt;          -  suspected or confirmed bacterial infection,\r&lt;br&gt;\r&lt;br&gt;          -  current solid or hematological malignancy,\r&lt;br&gt;\r&lt;br&gt;          -  neutropenia,\r&lt;br&gt;\r&lt;br&gt;          -  ALAT elevation more than three times the laboratory upper limit,\r&lt;br&gt;\r&lt;br&gt;          -  ASA class 5 (after COVID19 admission) or higher at inclusion (prior admission),\r&lt;br&gt;\r&lt;br&gt;          -  severe chronic obstructive pulmonary disease or heart failure (NYHA class II or\r&lt;br&gt;             higher),\r&lt;br&gt;\r&lt;br&gt;          -  pregnant or lactating women,\r&lt;br&gt;\r&lt;br&gt;          -  current treatment with conventional synthetic disease-modifying antirheumatic drugs\r&lt;br&gt;             (DMARDs)/immunosuppressive agents including IL-6 inhibitors, or with Janus kinase\r&lt;br&gt;             inhibitors (JAKi) in the past 30 days or plans to receive during the study period,\r&lt;br&gt;\r&lt;br&gt;          -  current use of chronic oral corticosteroids in a dose higher than prednisone 10 mg or\r&lt;br&gt;             equivalent per day,\r&lt;br&gt;\r&lt;br&gt;          -  previous or active tuberculosis (TB),\r&lt;br&gt;\r&lt;br&gt;          -  HIV infection regardless of immunological status, hepatitis,\r&lt;br&gt;\r&lt;br&gt;          -  evidence of recent (30 days) invasive bacterial or fungal infections,\r&lt;br&gt;\r&lt;br&gt;          -  patients who have received immunosuppressive antibody therapy within the past 5\r&lt;br&gt;             months, including intravenous immunoglobulin or plans to receive during the study\r&lt;br&gt;             period,\r&lt;br&gt;\r&lt;br&gt;          -  IV drug abuse,\r&lt;br&gt;\r&lt;br&gt;          -  history of inflammatory bowel disease,\r&lt;br&gt;\r&lt;br&gt;          -  diverticulitis,\r&lt;br&gt;\r&lt;br&gt;          -  ulcer,\r&lt;br&gt;\r&lt;br&gt;          -  perforated gastrointestinal tract,\r&lt;br&gt;\r&lt;br&gt;          -  participation in any clinical research study evaluating an investigational product\r&lt;br&gt;             (IP) or therapy within 3 months and less than five half-lives of IP prior inclusion to\r&lt;br&gt;             the study,\r&lt;br&gt;\r&lt;br&gt;          -  any physical examination findings and/or history of any illness that, in the opinion\r&lt;br&gt;             of the study investigator, might confound the results of the study or pose an\r&lt;br&gt;             additional risk to the patient by their participation in the study,\r&lt;br&gt;\r&lt;br&gt;          -  inability to give informed consent.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Signed informed consent provided by the patient, or by the patient's legally\r&lt;br&gt;             authorized representative(s), as applicable.\r&lt;br&gt;\r&lt;br&gt;          2. Documented presence of SARS-CoV-2 infection as per hospital routine.\r&lt;br&gt;\r&lt;br&gt;          3. Age &gt; 30 to &lt; 80 years at the time of screening.\r&lt;br&gt;\r&lt;br&gt;          4. Presence of respiratory distress, defined as:\r&lt;br&gt;\r&lt;br&gt;               1. PaO2/FiO2 &lt; 300 mm Hg and &gt;200 mm Hg or\r&lt;br&gt;\r&lt;br&gt;               2. Respiratory Rate (RR) =30 breaths/min or\r&lt;br&gt;\r&lt;br&gt;               3. SpO2 &lt; 93 percent in air at rest. Note: Patients given continous positive airway\r&lt;br&gt;                  pressure (CPAP) ventilator support are eligible for inclusion.\r&lt;br&gt;\r&lt;br&gt;          5. Presence of hyperinflammation defined as:\r&lt;br&gt;\r&lt;br&gt;             a. Lymphocyte counts &lt; 1000 cells/L, and b. Two of the following three criteria: i.\r&lt;br&gt;             Ferritin &gt; 500ng/mL ii. LDH &gt; 300 U/L iii. D-Dimers &gt; 1000 ng/mL\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients in mechanical ventilation or with modified early warning score (MEWS) &gt;4 with\r&lt;br&gt;             evidence of moderate or above ARDS (Berlin definition, namely with PaO2/FiO2 &gt;100, but\r&lt;br&gt;             &lt;200 mm Hg) or severe respiratory insufficiency or evidence of rapid worsening\r&lt;br&gt;             (respiratory distress requiring mechanical ventilation or presence of shock or\r&lt;br&gt;             presence of concomitant organ failure requiring ICU admission). Note: For the\r&lt;br&gt;             evaluation of patient eligibility, temperature will not be considered in the\r&lt;br&gt;             calculation of the total MEWS score since presence of fever is a hallmark of\r&lt;br&gt;             SARS-CoV-s infection\r&lt;br&gt;\r&lt;br&gt;          2. Impairment of cardiac function defined as poorly controlled heart diseases, such as\r&lt;br&gt;             New York heart association (NYHA) class II (mild) and above, cardiac insufficiency,\r&lt;br&gt;             unstable angina pectoris, myocardial infarction within 1 year before enrollment,\r&lt;br&gt;             supraventricular or ventricular arrhythmia need treatment or intervention.\r&lt;br&gt;\r&lt;br&gt;          3. Severe renal dysfunction (estimated glomerular filtration rate = 30 mL/min/1.73 m2) or\r&lt;br&gt;             receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.\r&lt;br&gt;\r&lt;br&gt;          4. Uncontrolled hypertension (seated systolic blood pressure &gt;180 mmHg, or diastolic\r&lt;br&gt;             blood pressure &gt;110mmHg) .\r&lt;br&gt;\r&lt;br&gt;          5. Administration of plasma from convalescent patients who recovered from SARS-CoV-2\r&lt;br&gt;             infection.\r&lt;br&gt;\r&lt;br&gt;          6. Clinical suspicion of latent tuberculosis.\r&lt;br&gt;\r&lt;br&gt;          7. History of hypersensitivity or allergy to any component of the study drug.\r&lt;br&gt;\r&lt;br&gt;          8. Pregnant women.\r&lt;br&gt;\r&lt;br&gt;          9. Existence of any life-threatening co-morbidity or any other medical condition which,\r&lt;br&gt;             in the opinion of the investigator, makes the patient unsuitable for inclusion.\r&lt;br&gt;\r&lt;br&gt;         10. Enrollment in another concurrent clinical interventional study, or intake of an\r&lt;br&gt;             investigational drug within three months or 5 half-lives prior to inclusion in this\r&lt;br&gt;             study, if considered interfering with this study objectives as assessed by the\r&lt;br&gt;             Investigator.\r&lt;br&gt;\r&lt;br&gt;         11. Foreseeable inability to cooperate with given instructions or study procedures.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or\r&lt;br&gt;             public health assay in any specimen &lt; 72 hours and/or CT Scan prior to randomization\r&lt;br&gt;             (Following typical radiological findings (ground glass abnormalities, and absence of\r&lt;br&gt;             lymphadenopathy, pleural effusion, pulmonary nodules, lung cavitation)\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized patients\r&lt;br&gt;\r&lt;br&gt;          -  Illness of any duration and severity (mild, moderate, severe, critical, see annexe 1),\r&lt;br&gt;             with symptoms (fever, cough, respiratory difficulties, shortness of breath), and at\r&lt;br&gt;             least one of the following:\r&lt;br&gt;\r&lt;br&gt;          -  Radiographic infiltrates by imaging (CT scan)\r&lt;br&gt;\r&lt;br&gt;          -  Clinical assessment (evidence of rales/crackles on exam or respiratory rate &gt;25/min)\r&lt;br&gt;             AND SpO2=94% on room air\r&lt;br&gt;\r&lt;br&gt;          -  SpO2=97 % with O2 &gt; 5L/min or Respiratory rate&gt;=30/min\r&lt;br&gt;\r&lt;br&gt;          -  Requiring mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  With any comorbidities (TBD such as acute kidney injury, cardiovascular condition,\r&lt;br&gt;             pulmonary disease, obesity, high blood pressure, diabetes, chronic kidney diseases,\r&lt;br&gt;             haematological diseases, sickle cell diseases, autoimmune and auto-inflammatory,\r&lt;br&gt;             pregnant women, HIV infected, etc)\r&lt;br&gt;\r&lt;br&gt;          -  Male or female adult = 18 years of age at time of enrolment\r&lt;br&gt;\r&lt;br&gt;          -  Patients must be able and willing to comply with study visits and procedures.\r&lt;br&gt;\r&lt;br&gt;          -  Patient agrees to the collection of oropharyngeal and nasal swabs and venous blood per\r&lt;br&gt;             protocol Written informed consent provided by the patient or alternatively by\r&lt;br&gt;             next-of-kin prior to any protocol-specific procedures.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with any condition that the physician judges could be detrimental to the\r&lt;br&gt;             patient participating in this study; including any clinically important deviations\r&lt;br&gt;             from normal clinical laboratory values or concurrent medical conditions (active\r&lt;br&gt;             infection diseases such as severe bacterial infections, aspergillosis, tuberculosis,\r&lt;br&gt;             depending on the tested medication).\r&lt;br&gt;\r&lt;br&gt;          -  Absence of Health Insurance\r&lt;br&gt;\r&lt;br&gt;          -  Subject protected by law under guardianship or curatorship\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria :\r&lt;br&gt;\r&lt;br&gt;        Participants must be =18 years of age Participants must be hospitalized with evidence of\r&lt;br&gt;        pneumonia and have one of the following disease categories: severe disease, multi-system\r&lt;br&gt;        organ dysfunction or critical disease Laboratory-confirmed SARS-CoV-2 infection\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria:\r&lt;br&gt;\r&lt;br&gt;        Unlikely to survive after 48 hours from screening or unlikely to remain at the\r&lt;br&gt;        investigational site beyond 48 hours Presence of neutropenia less than 2000/mm3, aspartate\r&lt;br&gt;        aminotransferase (AST) or ALT greater than 5 X ULN, platelets less than 50,000/mm3 Prior\r&lt;br&gt;        immunosuppressive therapies Use of chronic oral corticosteroids for non-COVID-19 related\r&lt;br&gt;        condition Known or suspected history of tuberculosis Suspected or known active systemic\r&lt;br&gt;        bacterial or fungal infections\r&lt;br&gt;\r&lt;br&gt;        The above information is not intended to contain all considerations relevant to a patient's\r&lt;br&gt;        potential participation in a clinical trial.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Aged 18-90 years\r&lt;br&gt;\r&lt;br&gt;          2. The patient is likely to fulfill the ARDS criteria (Berlin definition) and need\r&lt;br&gt;             intubation, ventilator-assisted or ECMO-assisted treatment within 7 days of admission\r&lt;br&gt;             to hospital\r&lt;br&gt;\r&lt;br&gt;          3. Suspected or verified COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;          4. At least one risk factor for increased mortality in COVID-19: currently published e.g.\r&lt;br&gt;             Smoking, Hypertension, Diabetes, Cardiovascular disease\r&lt;br&gt;\r&lt;br&gt;          5. Documented informed consent according to ICH-GCP and national regulations\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. ARDS caused by other viral infections (negative SARS-CoV-2)\r&lt;br&gt;\r&lt;br&gt;          2. ARDS caused by other non-viral infections or trauma\r&lt;br&gt;\r&lt;br&gt;          3. Known pregnancy or positive pregnancy test in women\r&lt;br&gt;\r&lt;br&gt;          4. Patients with previous lung fibrosis\r&lt;br&gt;\r&lt;br&gt;          5. CT- or Spirometry-verified severe COPD with Emphysema\r&lt;br&gt;\r&lt;br&gt;          6. Contraindication for HBO according to local guidelines\r&lt;br&gt;\r&lt;br&gt;          7. Do Not Resuscitate (DNR) or other restrictions in escalation of level of care\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  turkish physicians\r&lt;br&gt;\r&lt;br&gt;          -  work active in pandemic hospital\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  work in another country\r&lt;br&gt;\r&lt;br&gt;          -  retired physicians\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult (=18 years)\r&lt;br&gt;\r&lt;br&gt;          -  Male or female\r&lt;br&gt;\r&lt;br&gt;          -  Hospital personnel (expected to) taking care for patients with SARS CoV-2 infection\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Known allergy to (components of) the BCG vaccine or serious adverse events to prior\r&lt;br&gt;             BCG administration\r&lt;br&gt;\r&lt;br&gt;          -  Known active or latent Mycobacterium tuberculosis or with another mycobacterial\r&lt;br&gt;             species. A history with- or a suspicion of M. tuberculosis infection.\r&lt;br&gt;\r&lt;br&gt;          -  Fever (&gt;38 C) within the past 24 hours\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Suspicion of active viral or bacterial infection\r&lt;br&gt;\r&lt;br&gt;          -  Vaccination in the past 4 weeks or expected vaccination during the study period,\r&lt;br&gt;             independent of the type of vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Severely immunocompromised subjects. This exclusion category comprises: a) subjects\r&lt;br&gt;             with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic\r&lt;br&gt;             subjects with less than 500 neutrophils/mm3; c) subjects with solid organ\r&lt;br&gt;             transplantation; d) subjects with bone marrow transplantation; e) subjects under\r&lt;br&gt;             chemotherapy; f) subjects with primary immunodeficiency; g) severe lymphopenia with\r&lt;br&gt;             less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine therapies. i)\r&lt;br&gt;             treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone\r&lt;br&gt;             or equivalent for longer than 3 months, or probable use of oral or intravenous\r&lt;br&gt;             steroids in the following four weeks\r&lt;br&gt;\r&lt;br&gt;          -  Active solid or non-solid malignancy or lymphoma within the prior two years\r&lt;br&gt;\r&lt;br&gt;          -  Direct involvement in the design or the execution of the BCG-CORONA study\r&lt;br&gt;\r&lt;br&gt;          -  Expected absence from work of =4 of the following 12 weeks due to any reason\r&lt;br&gt;             (holidays, maternity leave, retirement, planned surgery etc)\r&lt;br&gt;\r&lt;br&gt;          -  Employed to the hospital &lt; 22 hours per week\r&lt;br&gt;\r&lt;br&gt;          -  Not in possession of a smartphone\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults (&gt;= 18 years) admitted to the ICU;\r&lt;br&gt;\r&lt;br&gt;          -  Severe confirmed COVID-19 pneumonia, defined by i) a newly-appeared pulmonary\r&lt;br&gt;             parenchymal infiltrate; and ii) a positive RT-PCR (either upper or lower respiratory\r&lt;br&gt;             tract) for COVID-19 (SARS-CoV-2); iii) and admission to the ICU or intermediate care\r&lt;br&gt;             unit;\r&lt;br&gt;\r&lt;br&gt;          -  Informed consent or emergency procedure.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy ;\r&lt;br&gt;\r&lt;br&gt;          -  Congenital immunodeficiency;\r&lt;br&gt;\r&lt;br&gt;          -  HIV infection with CD4 count below 200/mm3 or unknown in the last year;\r&lt;br&gt;\r&lt;br&gt;          -  High-grade hematological malignancy;\r&lt;br&gt;\r&lt;br&gt;          -  Neutropenia (&lt;1 leucocyte/mL or &lt; 0.5 neutrophil/mL);\r&lt;br&gt;\r&lt;br&gt;          -  Immunosuppressive drugs within the previous 30 days, including anti-cancer cytotoxic\r&lt;br&gt;             chemotherapy and anti-rejection drugs for organ/bone marrow transplant;\r&lt;br&gt;\r&lt;br&gt;          -  Moribund patient or death expected from underlying disease during the current\r&lt;br&gt;             admission;\r&lt;br&gt;\r&lt;br&gt;          -  Patient deprived of liberty or under legal protection measure\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female, aged 18 to 80 years.\r&lt;br&gt;\r&lt;br&gt;          2. Provided informed consent prior to any study specific procedure being conducted.\r&lt;br&gt;\r&lt;br&gt;          3. Virological or serological diagnosis of SARS-CoV-2.\r&lt;br&gt;\r&lt;br&gt;          4. Evidence of viral pneumonia (either CT scan or Chest Ultrasonogram).\r&lt;br&gt;\r&lt;br&gt;          5. Oxygen saturation at rest in ambient air = 95%.\r&lt;br&gt;\r&lt;br&gt;          6. PaO2/FiO2 &lt;300mmHg without oxygen inhalation\r&lt;br&gt;\r&lt;br&gt;          7. Fever defined as temperature = 36.6C armpit, = 37.2C oral, = 37.8C rectal.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Trial Subjects\r&lt;br&gt;\r&lt;br&gt;        Selection Criteria: Inclusion criteria:\r&lt;br&gt;\r&lt;br&gt;        The subject must satisfy the following criteria for entry into the study:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female, aged 18 to 80 years.\r&lt;br&gt;\r&lt;br&gt;          2. Provided informed consent prior to any study specific procedure being conducted.\r&lt;br&gt;\r&lt;br&gt;          3. Virological or serological diagnosis of SARS-CoV-2.\r&lt;br&gt;\r&lt;br&gt;          4. Evidence of viral pneumonia (either CT scan or Chest Ultrasonogram).\r&lt;br&gt;\r&lt;br&gt;          5. Oxygen saturation at rest in ambient air = 95%.\r&lt;br&gt;\r&lt;br&gt;          6. PaO2/FiO2 &lt;300mmHg without oxygen inhalation\r&lt;br&gt;\r&lt;br&gt;          7. Fever defined as temperature = 36.6C armpit, = 37.2C oral, = 37.8C rectal.\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria:\r&lt;br&gt;\r&lt;br&gt;        The subject will be excluded from the study if any of the following applies:\r&lt;br&gt;\r&lt;br&gt;          1. Subjects intubated prior to administration of IMP.\r&lt;br&gt;\r&lt;br&gt;          2. Subjects requiring mechanical ventilation at screening.\r&lt;br&gt;\r&lt;br&gt;          3. Known allergic reaction or intolerant to fish or fish oils.\r&lt;br&gt;\r&lt;br&gt;          4. Known allergic reaction to excipients of IMP.\r&lt;br&gt;\r&lt;br&gt;          5. Subjects who are pregnant or breast-feeding at screening.\r&lt;br&gt;\r&lt;br&gt;          6. Subjects who are taking other fish-oil supplements (e.g. cod liver oil) who are\r&lt;br&gt;             unwilling to stop them for the duration of the study.\r&lt;br&gt;\r&lt;br&gt;          7. Subjects taking warfarin or other anti-coagulants.\r&lt;br&gt;\r&lt;br&gt;          8. Subjects who are taking other agents for the treatment of SARS-CoV-2 showing an\r&lt;br&gt;             improvement in symptoms in the 24 hours prior to study dosing.\r&lt;br&gt;\r&lt;br&gt;          9. Subjects who are participating in other clinical studies at the same time.\r&lt;br&gt;\r&lt;br&gt;         10. Evidence of multi-organ failure.\r&lt;br&gt;\r&lt;br&gt;         11. Subjects with a do not resuscitate code.\r&lt;br&gt;\r&lt;br&gt;         12. Subject is deemed, by the investigator, unlikely to be able to comply with the\r&lt;br&gt;             requirements of the protocol.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        I (first step):\r&lt;br&gt;\r&lt;br&gt;          -  Admission to hospital\r&lt;br&gt;\r&lt;br&gt;          -  Male or non-pregnant female, =60 years of age or =30 years of age plus one or more\r&lt;br&gt;             known risk factors (arterial hypertension, diabetes mellitus, coronary heart disease,\r&lt;br&gt;             heart failure, pre-existing chronic pulmonary disease)\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed SARS-CoV infection\r&lt;br&gt;\r&lt;br&gt;          -  Radiographic evidence compatible with Covid-19 pneumonia (X-ray/CT scan, etc.)\r&lt;br&gt;\r&lt;br&gt;          -  Signed Informed Consent Form\r&lt;br&gt;\r&lt;br&gt;        II (second step; indication for intervention):\r&lt;br&gt;\r&lt;br&gt;          -  CRP =50mg/L plus 3 out of the following 5 criteria need to be fulfilled:\r&lt;br&gt;\r&lt;br&gt;          -  Respiration Rate =25\r&lt;br&gt;\r&lt;br&gt;          -  SpO2 &lt;93% (on ambient air)\r&lt;br&gt;\r&lt;br&gt;          -  PaO2 &lt;65 mmHg\r&lt;br&gt;\r&lt;br&gt;          -  Persistent or increasing dyspnoea as defined by a one point increase on the mMRC\r&lt;br&gt;             dyspnoea scale (over 1 hour)\r&lt;br&gt;\r&lt;br&gt;          -  Persistent or increasing oxygen demand (over 1 hour)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        I (first step):\r&lt;br&gt;\r&lt;br&gt;          -  Patients &gt;80 years of age\r&lt;br&gt;\r&lt;br&gt;          -  Patient included in any other interventional trial\r&lt;br&gt;\r&lt;br&gt;          -  Indication for imminent or immediate transfer to ICU\r&lt;br&gt;\r&lt;br&gt;          -  Treatment with TCZ (or other anti-IL-6R treatment) within 4 weeks prior to baseline\r&lt;br&gt;\r&lt;br&gt;          -  Uncontrolled bacterial superinfection according to investigator\r&lt;br&gt;\r&lt;br&gt;          -  History of severe allergic reaction to TCZ\r&lt;br&gt;\r&lt;br&gt;          -  History of diverticulitis requiring antibiotic treatment or history of colon\r&lt;br&gt;             perforation\r&lt;br&gt;\r&lt;br&gt;          -  History of primary immunodeficiency (e.g. CVID) or progressing malignancy\r&lt;br&gt;\r&lt;br&gt;          -  History of chronic liver disease (&gt;Child-Pugh A, or according to investigator)\r&lt;br&gt;\r&lt;br&gt;        II (second step; contraindication for intervention):\r&lt;br&gt;\r&lt;br&gt;          -  Alanine transaminase/aspartate transaminase (ALT/AST) &gt;5 times of the upper limit of\r&lt;br&gt;             normal\r&lt;br&gt;\r&lt;br&gt;          -  Hemoglobin &lt;80 g/L\r&lt;br&gt;\r&lt;br&gt;          -  Leukocytes &lt;2.0 G/L\r&lt;br&gt;\r&lt;br&gt;          -  Absolute neutrophil count &lt;1.0 G/L\r&lt;br&gt;\r&lt;br&gt;          -  Platelets &lt;50 G/L\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  age 18 years or older;\r&lt;br&gt;\r&lt;br&gt;          -  positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay for COVID-19\r&lt;br&gt;             in a respiratory tract sample;\r&lt;br&gt;\r&lt;br&gt;          -  intubated and mechanically ventilated;\r&lt;br&gt;\r&lt;br&gt;          -  acute onset of ARDS, as defined by Berlin criteria as moderate-to-severe ARDS,3 which\r&lt;br&gt;             includes: (i) having pneumonia or worsening respiratory symptoms, (ii) bilateral\r&lt;br&gt;             pulmonary infiltrates on chest imaging (x-ray or CT scan), (iii) absence of left\r&lt;br&gt;             atrial hypertension, pulmonary capillary wedge pressure &lt;18 mmHg, or no clinical signs\r&lt;br&gt;             of left heart failure, and (iv) hypoxemia, as defined by a PaO2/FiO2 ratio of =200\r&lt;br&gt;             mmHg on positive end-expiratory pressure (PEEP) of =5 cmH2O, regardless of FiO2.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        * Patients receiving or under treatment with corticosteroids\r&lt;br&gt;\r&lt;br&gt;          -  Patients with a known contraindication to corticosteroids,\r&lt;br&gt;\r&lt;br&gt;          -  Decision by a physician that involvement in the trial is not in the patient's best\r&lt;br&gt;             interest,\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy and breast-feeding.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Affiliated with or benefiting from a Social Security system\r&lt;br&gt;\r&lt;br&gt;          -  State of health compatible with a blood sample as defined in the protocol\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Person benefiting from a legal protection measure or unable to express informed\r&lt;br&gt;             consent to participation\r&lt;br&gt;\r&lt;br&gt;          -  For women: pregnancy or breastfeeding in progress\r&lt;br&gt;\r&lt;br&gt;          -  Have had an infectious episode and/or respiratory signs in the 14 days prior to the\r&lt;br&gt;             scheduled visit (CORSER 1 and 2a, 2b)\r&lt;br&gt;\r&lt;br&gt;          -  Have been in contact with a confirmed case of SARS-CoV-2 infection within 14 days\r&lt;br&gt;             prior to the date of the visit.(CORSER 1 and 2a, 2b)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 induced adult ARDS patients admitted to the medical ICU\r&lt;br&gt;\r&lt;br&gt;          -  PaO2/FiO2 is less than 200mmHg or FIO2 = 0.4 is required to maintain SpO2 at 88?93% on\r&lt;br&gt;             HFNC treatment\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. If the patients have a consistent SpO2&lt;80% when on evaluation with a FiO2 of 0.6, or\r&lt;br&gt;             signs of respiratory fatigue (RR &gt; 40/min, PaCO2&gt; 50mmHg / pH&lt;7.30, and obvious\r&lt;br&gt;             accessory respiratory muscle use);\r&lt;br&gt;\r&lt;br&gt;          2. Immediate need for intubation (PaO2/FiO2&lt; 50mmHg or SpO2/FiO2 &lt;90, unable to protect\r&lt;br&gt;             airway or mental status change);\r&lt;br&gt;\r&lt;br&gt;          3. unstable hemodynamic status(SBP&lt;90mmHg, MBP below 65 mmHg or requirement for\r&lt;br&gt;             vasopressor);\r&lt;br&gt;\r&lt;br&gt;          4. unable to collaborate with HFNC/PP with agitation or refuse HFNC/PP.\r&lt;br&gt;\r&lt;br&gt;          5. chest trauma or any contraindication for PP\r&lt;br&gt;\r&lt;br&gt;          6. pneumothorax\r&lt;br&gt;\r&lt;br&gt;          7. age &lt; 18 years\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Must have confirmed and documented Coronaviral (COVID-19) infection history with\r&lt;br&gt;             involvement of lung tissues\r&lt;br&gt;\r&lt;br&gt;          -  Must be clear of any viral shed residual confirmed by negative viral testing protocol\r&lt;br&gt;             accepted by the Center for Disease Control (CDC) and/or the FDA\r&lt;br&gt;\r&lt;br&gt;          -  Must have discharge confirmation from infectious disease managing Provider declaring\r&lt;br&gt;             freedom of viral load or active infection\r&lt;br&gt;\r&lt;br&gt;          -  Must have a written Medical History of Physical and discharge summary (if\r&lt;br&gt;             hospitalized) from appropriate Center or Licensed Medical Provider\r&lt;br&gt;\r&lt;br&gt;          -  Must agree to provide a HRCT LUNG study done at baseline (before), 3 months and 6\r&lt;br&gt;             months\r&lt;br&gt;\r&lt;br&gt;          -  Must be able to provide full Informed Consent (ICF)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Active or positive testing of COVID-19 With Clinical Report and Discharge Summary from\r&lt;br&gt;             Hospital or Treatment Facility\r&lt;br&gt;\r&lt;br&gt;          -  Lung disorder without prior confirmation by approved test protocol of history of\r&lt;br&gt;             COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Patient health or condition deemed dangerous or inappropriate for transport, exceeding\r&lt;br&gt;             acceptable stress for transport or care needed to achieve access to the clinical\r&lt;br&gt;             facility, at the discretion of the Providers\r&lt;br&gt;\r&lt;br&gt;          -  Expected lifespan of &lt; 6 months\r&lt;br&gt;\r&lt;br&gt;          -  Serious of life threatening co-morbidities, that in the opinion of the investigators,\r&lt;br&gt;             may compromise the safety or compliance with the study guidelines and tracking\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients included in the CORIMUNO-19 cohort\r&lt;br&gt;\r&lt;br&gt;          2. Patients belonging to one of the 2 following groups:\r&lt;br&gt;\r&lt;br&gt;               -  Group 1: patients not requiring ICU at admission with moderate and severe\r&lt;br&gt;                  pneumopathy according to the OMS Criteria of severity of COVID pneumopathy.\r&lt;br&gt;\r&lt;br&gt;        Moderate cases :\r&lt;br&gt;\r&lt;br&gt;        Cases meeting all of the following criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Showing fever and respiratory symptoms with radiological findings of pneumonia.\r&lt;br&gt;\r&lt;br&gt;          -  Requiring between 3L/min and 5L/min of oxygen to maintain SpO2 &gt;97% Severe cases\r&lt;br&gt;\r&lt;br&gt;        Cases meeting any of the following criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory distress (?30 breaths/ min);\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation=93% at rest in ambient air; or Oxygen saturation =97 % with O2 &gt;\r&lt;br&gt;             5L/min.\r&lt;br&gt;\r&lt;br&gt;          -  PaO2/FiO2?300mmHg\r&lt;br&gt;\r&lt;br&gt;          -  Group 2: patients requiring ICU based on Criteria of severity of COVID pneumopathy.\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory failure and requiring mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  No do-not-resuscitate order (DNR order)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with exclusion criteria to the CORIMUNO-19 cohort.\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to Sarilumab or to any of their excipients.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Current documented bacterial infection\r&lt;br&gt;\r&lt;br&gt;          -  Patient with any of following laboratory results out of the ranges detailed below at\r&lt;br&gt;             screening should be discussed depending of the medication:\r&lt;br&gt;\r&lt;br&gt;          -  Absolute neutrophil count (ANC) = 1.0 x 109/L\r&lt;br&gt;\r&lt;br&gt;          -  Haemoglobin level: no limitation\r&lt;br&gt;\r&lt;br&gt;          -  Platelets (PLT) &lt; 50 G /L\r&lt;br&gt;\r&lt;br&gt;          -  SGOT or SGPT &gt; 5N\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  all known cardiovascular patients from local Cardiology Clinics, with:\r&lt;br&gt;\r&lt;br&gt;               1. all spectrum of coronary syndromes (chronic to acute) +/- known coronary\r&lt;br&gt;                  angioplasties;\r&lt;br&gt;\r&lt;br&gt;               2. treated arterial hypertension;\r&lt;br&gt;\r&lt;br&gt;               3. known congestive heart failure\r&lt;br&gt;\r&lt;br&gt;          -  AND isolated / quarantined recommendations (due to COVID 19 pandemic).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  refusal / denial to create an electronic account on this dedicated platform;\r&lt;br&gt;\r&lt;br&gt;          -  refusal to accept wearable devices (ecg watches, oximetry).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        ED patients positive to or suspected of COVID-19 infection with at least one of the\r&lt;br&gt;        following symptoms:\r&lt;br&gt;\r&lt;br&gt;          -  fever\r&lt;br&gt;\r&lt;br&gt;          -  cough/dyspnea\r&lt;br&gt;\r&lt;br&gt;          -  respiratory symptoms or ED arrival for respiratory reason and for whom there are the\r&lt;br&gt;             following conditions:\r&lt;br&gt;\r&lt;br&gt;          -  SpO2 &lt; 95% in ambient air or positive Quick Walk Test\r&lt;br&gt;\r&lt;br&gt;          -  PaO2/FiO2 &gt; 200 in ambient air or with Venturi mask, evaluated in 1 hour from ED\r&lt;br&gt;             arrival.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  BPCO patients\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt; 70 years\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant status\r&lt;br&gt;\r&lt;br&gt;          -  Contraindications for CPAP\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Healthy subjects\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Drugs\r&lt;br&gt;\r&lt;br&gt;          -  Surgery\r&lt;br&gt;\r&lt;br&gt;          -  Neurology diseases\r&lt;br&gt;\r&lt;br&gt;          -  Rheumatic diseases\r&lt;br&gt;\r&lt;br&gt;          -  Systemic diseases\r&lt;br&gt;\r&lt;br&gt;          -  Smokers\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - A healthcare worker at high risk for COVID-19 exposure (defined below):\r&lt;br&gt;\r&lt;br&gt;          -  Persons primarily working in emergency departments (physicians, nurses, ancillary\r&lt;br&gt;             staff, triage personnel)\r&lt;br&gt;\r&lt;br&gt;          -  Persons primarily working in intensive care units (physicians, nurses, ancillary\r&lt;br&gt;             staff, respiratory therapists)\r&lt;br&gt;\r&lt;br&gt;          -  Persons performing aerosol generating procedures (i.e. anesthesiologists, nurse\r&lt;br&gt;             anesthetists (CRNAs)\r&lt;br&gt;\r&lt;br&gt;          -  First responders (i.e. EMTs, paramedics)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Active COVID-19 disease\r&lt;br&gt;\r&lt;br&gt;          -  Prior COVID-19 disease\r&lt;br&gt;\r&lt;br&gt;          -  Current fever, cough, shortness of breath\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to chloroquine or hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Prior retinal eye disease\r&lt;br&gt;\r&lt;br&gt;          -  Known Chronic Kidney disease, Stage 4 or 5 or dialysis\r&lt;br&gt;\r&lt;br&gt;          -  Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Weight &lt;40 kg\r&lt;br&gt;\r&lt;br&gt;          -  Prolonged QT syndrome\r&lt;br&gt;\r&lt;br&gt;          -  Current use of hydroxychloroquine, chloroquine, or cardiac medicines of flecainide,\r&lt;br&gt;             amiodarone, digoxin, procainamide, or propafenone\r&lt;br&gt;\r&lt;br&gt;          -  Current use of medications with known significant drug-drug interactions: artemether,\r&lt;br&gt;             lumefantrine, mefloquine, tamoxifen, or methotrexate.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        The following persons may be included:\r&lt;br&gt;\r&lt;br&gt;          -  A patient of any age meeting the European Centre for Disease Control and Prevention's\r&lt;br&gt;             confirmed case definition: \"A person with laboratory confirmation of virus causing\r&lt;br&gt;             COVID-19, irrespective of clinical signs and symptoms\" (and/or high suspicion/actively\r&lt;br&gt;             being treated as CoVID+ cases pending test confirmation)\r&lt;br&gt;\r&lt;br&gt;          -  Household contacts (defined as those sleeping in the same apartment/house as an\r&lt;br&gt;             infected patient) of a patient with laboratory-confirmed COVID-19 (and/or high\r&lt;br&gt;             suspicion/actively being treated as CoVID+ cases pending test confirmation), whether\r&lt;br&gt;             symptomatic or not, and whether testing positive or not during a period of 14 days\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criterion:\r&lt;br&gt;\r&lt;br&gt;          -  Long-term incapacity leading to the inability to provide informed consent while not\r&lt;br&gt;             having a patient representative with the ability to provide informed consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Informed consent from patient or legal representative.\r&lt;br&gt;\r&lt;br&gt;          2. Male or female, aged = 18 years;\r&lt;br&gt;\r&lt;br&gt;          3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase\r&lt;br&gt;             chain reaction (RT-PCR) from any diagnostic sampling source;\r&lt;br&gt;\r&lt;br&gt;          4. At least one of the characteristic symptoms of COVID-19\r&lt;br&gt;\r&lt;br&gt;          5. Hospitalized for up to 36h with non-invasive ventilation or up to 24h with invasive\r&lt;br&gt;             ventilation.\r&lt;br&gt;\r&lt;br&gt;          6. Negative result for pregnancy test (if applicable).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Participating in another RCT in the past 12 months;\r&lt;br&gt;\r&lt;br&gt;          2. Known allergy to HCQ or chloroquine\r&lt;br&gt;\r&lt;br&gt;          3. Any contraindication to HTC or AZT, including retinopathy and prolonged QT,\r&lt;br&gt;\r&lt;br&gt;          4. Severely reduced LV function\r&lt;br&gt;\r&lt;br&gt;          5. Severely reduced renal function;\r&lt;br&gt;\r&lt;br&gt;          6. Pregnancy or breast feeding\r&lt;br&gt;\r&lt;br&gt;          7. Any other clinical condition which, in the opinion of the principal investigator,\r&lt;br&gt;             would not allow safe completion of the protocol and safe administration of the\r&lt;br&gt;             investigational products\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. The patients must be 18 years or older.\r&lt;br&gt;\r&lt;br&gt;          2. Patients who opt in to complete the survey.\r&lt;br&gt;\r&lt;br&gt;          3. Patients must have the capacity to verbally consent for the interview.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1.Patients who under the age of 18 years old.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Classified as having SSc by a physician\r&lt;br&gt;\r&lt;br&gt;          -  PROMIS Anxiety 4a v1.0 T-score greater than or equal to 55\r&lt;br&gt;\r&lt;br&gt;          -  Have regular, reliable internet access\r&lt;br&gt;\r&lt;br&gt;          -  Be fluent in English or French\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Engaged in work from home on a typical day\r&lt;br&gt;\r&lt;br&gt;          -  Receiving counseling or therapy currently\r&lt;br&gt;\r&lt;br&gt;          -  Having a positive test for the COVID-19 virus\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed case: Critically ill patient who meets the operational definition of a\r&lt;br&gt;             suspected case and who has a confirmed diagnosis by the National Network of Public\r&lt;br&gt;             Health Laboratories recognized by the Institute of Epidemiological Diagnosis and\r&lt;br&gt;             Reference (Indre) (Mexico).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  If a negative for SARS-CoV-2 result is obtained from a critically ill patient with a\r&lt;br&gt;             high index of suspicion for COVID-19 virus infection.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who had participated in another observational study in the last 30 days prior\r&lt;br&gt;             to inclusion.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient with CHD as defined in the international classification ACC-CHD\r&lt;br&gt;\r&lt;br&gt;          -  Covid-19 infection over the study period\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria:\r&lt;br&gt;\r&lt;br&gt;        - Patient with genetic heart disease (cardiomyopathy, hereditary rhythmic disease).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who consent to participating in the study or Physician discretion that\r&lt;br&gt;             information to be gained is important to the patient\r&lt;br&gt;\r&lt;br&gt;          -  Patients =18 years old\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Unable to lie flat for study\r&lt;br&gt;\r&lt;br&gt;          -  Patients unwilling to give consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. person who are working as health professional with contact to known COVID positive\r&lt;br&gt;             case\r&lt;br&gt;\r&lt;br&gt;          2. Their first degree relatives (child, spouse or parents)\r&lt;br&gt;\r&lt;br&gt;          3. must be able to swallow tablets\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Already using plaquenil for other reasons (RA etc)\r&lt;br&gt;\r&lt;br&gt;          2. person with the diagnosis of COVID infection\r&lt;br&gt;\r&lt;br&gt;          3. Person with the condition may cause complications with this medication (severe CVD, av\r&lt;br&gt;             block, already has ophtalmological complications, organ failure of any degree etc).\r&lt;br&gt;\r&lt;br&gt;          4. Documented allergic history to chloroquine;\r&lt;br&gt;\r&lt;br&gt;          5. Documented history of hematological system diseases;\r&lt;br&gt;\r&lt;br&gt;          6. Documented history of chronic liver and kidney diseases;\r&lt;br&gt;\r&lt;br&gt;          7. Documented history of cardiac arrhythmia or chronic heart diseases;\r&lt;br&gt;\r&lt;br&gt;          8. Documented history of retina or hearing dysfunction;\r&lt;br&gt;\r&lt;br&gt;          9. Documented history of mental illnesses; 10. Use of digitalis due to the previous\r&lt;br&gt;             disease.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All patient admitted in ICU Lille Hospital and hospitalized in the unit \"Emergent\r&lt;br&gt;             Biological Risk\" (REB) before a suspicion of infection with COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Clinical infectious syndrome: fever (&gt;38C) or hypothermia ( 36C), chill, fever at\r&lt;br&gt;             home\r&lt;br&gt;\r&lt;br&gt;          -  a severe respiratory table defined by:\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen demand &gt; 3 L/min in the presence of significant comorbidity (pregnancy, chronic\r&lt;br&gt;             respiratory disease, chronic heart disease, hemopathy, cirrhosis) or &gt; 6 L/min in the\r&lt;br&gt;             absence of comorbidity\r&lt;br&gt;\r&lt;br&gt;          -  or a respiratory rate &gt; 30 cycles per minute\r&lt;br&gt;\r&lt;br&gt;          -  the need for mechanical, invasive or non-invasive ventilation\r&lt;br&gt;\r&lt;br&gt;          -  the need for humidified high-flow oxygen therapy\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient already included in study for first stay\r&lt;br&gt;\r&lt;br&gt;          -  Cirrhosis CHILD C\r&lt;br&gt;\r&lt;br&gt;          -  Major surgery in the last 7 days Minor patient\r&lt;br&gt;\r&lt;br&gt;          -  Patient under guardianship or curatorship\r&lt;br&gt;\r&lt;br&gt;          -  Refusal to participate\r&lt;br&gt;\r&lt;br&gt;          -  No social security coverage.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Recipient:\r&lt;br&gt;\r&lt;br&gt;          1. COVID-19 Patients\r&lt;br&gt;\r&lt;br&gt;          2. Consent to attend the study\r&lt;br&gt;\r&lt;br&gt;          3. Age 30 to 70 years\r&lt;br&gt;\r&lt;br&gt;          4. Don't be intubated\r&lt;br&gt;\r&lt;br&gt;          5. PaO2 / FiO2 is above 200 or Spo2 is greater than 85%.\r&lt;br&gt;\r&lt;br&gt;        Donator:\r&lt;br&gt;\r&lt;br&gt;          1. Complete recovery from severe COVID-19 disease and hospital discharge\r&lt;br&gt;\r&lt;br&gt;          2. Consent to donate blood to the infected person\r&lt;br&gt;\r&lt;br&gt;          3. Age 30 to 60 years\r&lt;br&gt;\r&lt;br&gt;          4. Has normal CBC test results\r&lt;br&gt;\r&lt;br&gt;          5. Negative COVID-19 RT-PCR test\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Recipient:\r&lt;br&gt;\r&lt;br&gt;          1. A history of hypersensitivity to blood transfusions or its products\r&lt;br&gt;\r&lt;br&gt;          2. History of IgA deficiency\r&lt;br&gt;\r&lt;br&gt;          3. Heart failure or any other factor that prevents the transmission of of 500 ml plasma\r&lt;br&gt;\r&lt;br&gt;          4. Entering the intubation stage\r&lt;br&gt;\r&lt;br&gt;        Donator:\r&lt;br&gt;\r&lt;br&gt;          1. Patients infected with blood-borne viral / infectious diseases\r&lt;br&gt;\r&lt;br&gt;          2. Underlying heart disease, low or high blood pressure, diabetes, epilepsy, and anything\r&lt;br&gt;             that may prohibit blood donation.\r&lt;br&gt;\r&lt;br&gt;          3. Use of banned drugs for blood donation (eg, ethertinate, acitretin, aliotretinoin,\r&lt;br&gt;             isotretinoin, antiandrogens, NSAIDs, etc.)\r&lt;br&gt;\r&lt;br&gt;          4. Use of different drugs\r&lt;br&gt;\r&lt;br&gt;          5. Other prohibited donations based on blood transfusion standards\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Clinical suspicion of COVID-19 requiring contact to a hospital.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age less than 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Previous enrollment in this study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Recent ( = 6 days of flu-like symptoms or malaise yet =16 days of flu-like symptoms or\r&lt;br&gt;             malaise prior to randomization) infection with COVID-19.\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 diagnosis confirmed by antigen detection test and/or PCR and/or positive\r&lt;br&gt;             serology, or any emerging and validated diagnostic laboratory test for COVID-19 within\r&lt;br&gt;             this period.\r&lt;br&gt;\r&lt;br&gt;          -  In some patients, it may be impossible to get a confident laboratory confirmation of\r&lt;br&gt;             COVID-19 diagnosis after 24h of hospital admission because viral load is low and/or\r&lt;br&gt;             problems with diagnostic sensitivity. In those cases, in absence of an alternative\r&lt;br&gt;             diagnosis, and with highly suspect bilateral ground glass opacities on recent (&lt;24h)\r&lt;br&gt;             chest-CT scan (confirmed by a radiologist and pulmonary physician as probable\r&lt;br&gt;             COVID-19), and a typical clinical and chemical diagnosis with signs of cytokine\r&lt;br&gt;             release syndrome, a patient can be enrolled as probable COVID-19 infected. In all\r&lt;br&gt;             cases, this needs confirmation by later seroconversion.\r&lt;br&gt;\r&lt;br&gt;          -  Presence of hypoxia defined as PaO2/FiO2 below 350 while breathing room air in upright\r&lt;br&gt;             position or PaO2/FiO2 below 280 on supplemental oxygen and immediately requiring high\r&lt;br&gt;             flow oxygen device or mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  signs of cytokine release syndrome defined as ANY of the following:\r&lt;br&gt;\r&lt;br&gt;               1. serum ferritin concentration &gt;1000 mcg/L and rising since last 24h\r&lt;br&gt;\r&lt;br&gt;               2. single ferritin above 2000 mcg/L in patients requiring immediate high flow oxygen\r&lt;br&gt;                  device or mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;               3. lymphopenia defined as &lt;800 lymphocytes/microliter) and two of the following\r&lt;br&gt;                  extra criteria\r&lt;br&gt;\r&lt;br&gt;                    -  Ferritin &gt; 700 mcg/L and rising since last 24h\r&lt;br&gt;\r&lt;br&gt;                    -  increased LDH (above 300 IU/L) and rising last 24h\r&lt;br&gt;\r&lt;br&gt;                    -  D-Dimers &gt; 1000 ng/mL and rising since last 24h\r&lt;br&gt;\r&lt;br&gt;                    -  CRP above 70mg/L and rising since last 24h and absence of bacterial\r&lt;br&gt;                       infection\r&lt;br&gt;\r&lt;br&gt;                    -  if three of the above are present at admission, no need to document 24h rise\r&lt;br&gt;\r&lt;br&gt;          -  Chest X-ray or CT scan showing bilateral infiltrates within last 2 days\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to specialized COVID-19 ward or an ICU ward taking care of COVID-19 patients\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18yrs\r&lt;br&gt;\r&lt;br&gt;          -  Male or Female\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to provide informed consent or legal representative willing to\r&lt;br&gt;             provide informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with known history of serious allergic reactions, including anaphylaxis, to\r&lt;br&gt;             any of the study medications, or any component of the product.\r&lt;br&gt;\r&lt;br&gt;          -  mechanical ventilation &gt; 24 h at randomization\r&lt;br&gt;\r&lt;br&gt;          -  clinical frailty scale above 3\r&lt;br&gt;\r&lt;br&gt;          -  active bacterial or fungal infection\r&lt;br&gt;\r&lt;br&gt;          -  unlikely to survive beyond 48h\r&lt;br&gt;\r&lt;br&gt;          -  neutrophil count below 1500 cells/microliter\r&lt;br&gt;\r&lt;br&gt;          -  platelets below 50.000/microliter\r&lt;br&gt;\r&lt;br&gt;          -  Patients enrolled in another investigational drug study\r&lt;br&gt;\r&lt;br&gt;          -  patients on high dose systemic steroids (&gt; 20 mg methylprednisolone or equivalent) for\r&lt;br&gt;             COVID-19 unrelated disorder\r&lt;br&gt;\r&lt;br&gt;          -  patients on immunosuppressant or immunomodulatory drugs\r&lt;br&gt;\r&lt;br&gt;          -  patients on current anti-IL1 or anti-IL6 treatment\r&lt;br&gt;\r&lt;br&gt;          -  signs of active tuberculosis\r&lt;br&gt;\r&lt;br&gt;          -  serum transaminase levels &gt;5 times upper limit of normal\r&lt;br&gt;\r&lt;br&gt;          -  bowel perforation or diverticulitis\r&lt;br&gt;\r&lt;br&gt;          -  pregnant or breastfeeding females (all female subjects deemed of childbearing\r&lt;br&gt;             potential by the investigator must have negative pregnancy test at screening)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criera :\r&lt;br&gt;\r&lt;br&gt;          -  Patient = 18 years old and = 75 years old\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory proved infection by COVID-19 by RT-PCR on a nasopharyngeal sample within 2\r&lt;br&gt;             days\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalization is required according to current local recommendations\r&lt;br&gt;\r&lt;br&gt;          -  Patient affiliated to a social security regime\r&lt;br&gt;\r&lt;br&gt;          -  Patient able to give free, informed and written consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria :\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen flow rate &gt;8l/min at inclusion\r&lt;br&gt;\r&lt;br&gt;          -  Current treatment with any inhaled steroid (any other form of steroid administration\r&lt;br&gt;             does not exclude the patient)\r&lt;br&gt;\r&lt;br&gt;          -  Intensive care unit is required for the patient (based on investigator judgement)\r&lt;br&gt;\r&lt;br&gt;          -  Patient with cognitive impairment which do not guarantee proper use of the treatment\r&lt;br&gt;             by the patient himself\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant (positive -HCG at inclusion) or breastfeeding women\r&lt;br&gt;\r&lt;br&gt;          -  Participation in another interventional drug study involving human participants and\r&lt;br&gt;             concerning COVID-19 infection or being in the exclusion period of a previous study\r&lt;br&gt;             involving human participants\r&lt;br&gt;\r&lt;br&gt;          -  Contraindications to the treatments (history of hypersensitivity)\r&lt;br&gt;\r&lt;br&gt;          -  Patient admitted for isolation, for social reason or due to comorbidities without\r&lt;br&gt;             gravity sign\r&lt;br&gt;\r&lt;br&gt;          -  Long-term patient treated with digitalis, disopyramide, procainamide or phenothiazine\r&lt;br&gt;             that could lengthen the QT space\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All users of the https://www.maladiecoronavirus.fr/ application over the age of 18\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  not applicable\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults aged 18-90\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed laboratory COVID-19 infection by RT-PCR\r&lt;br&gt;\r&lt;br&gt;          -  Meeting severe or critical criteria of COVID-19 infection as defined at treating\r&lt;br&gt;             hospital\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed pneumonia by chest radiograph or computed tomography\r&lt;br&gt;\r&lt;br&gt;          -  Fever defined as temperature = 36.6 C armpit, = 37.2 C oral, or = 37.8 C rectal\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation less than 92%\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Recent use of illicit drugs or alcohol abuse\r&lt;br&gt;\r&lt;br&gt;          -  Known allergy to tradipitant or other neurokinin-1 antagonists\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Known HIV, HBV, or HCV infection\r&lt;br&gt;\r&lt;br&gt;          -  Malignant tumor, other serious systemic diseases\r&lt;br&gt;\r&lt;br&gt;          -  Inability to provide informed consent or to have an authorized relative or designated\r&lt;br&gt;             person provide informed consent, or to comply with the protocol requirements\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Recent (=2weeks prior to randomization) PCR(Polymerase Chain Reaction) -Confirmed\r&lt;br&gt;             COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;          -  Presence of acute hypoxic respiratory failure defined as (either or both)\r&lt;br&gt;\r&lt;br&gt;               -  saturation below 93% on minimal 2 l/min O2\r&lt;br&gt;\r&lt;br&gt;               -  PaO2/FiO2 below 300\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to specialized COVID-19 ward\r&lt;br&gt;\r&lt;br&gt;          -  Age 18-80\r&lt;br&gt;\r&lt;br&gt;          -  Male or Female\r&lt;br&gt;\r&lt;br&gt;          -  Willing to provide informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with known history of serious allergic reactions, including anaphylaxis, to\r&lt;br&gt;             human granulocyte-macrophage colony stimulating factor such as sargramostim,\r&lt;br&gt;             yeast-derived products, or any component of the product.\r&lt;br&gt;\r&lt;br&gt;          -  mechanical ventilation before start of study\r&lt;br&gt;\r&lt;br&gt;          -  patients with peripheral white blood cell count above 25.000 per microliter and/or\r&lt;br&gt;             active myeloid malignancy\r&lt;br&gt;\r&lt;br&gt;          -  patients on high dose systemic steroids (&gt; 20 mg methylprednisolone or equivalent)\r&lt;br&gt;\r&lt;br&gt;          -  patients on lithium carbonate therapy\r&lt;br&gt;\r&lt;br&gt;          -  Patients enrolled in another investigational drug study\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breastfeeding females (all female subjects regardless of childbearing\r&lt;br&gt;             potential status must have negative pregnancy test at screening)\r&lt;br&gt;\r&lt;br&gt;          -  Patients with serum ferritin &gt;2000 mcg/ml (which will exclude ongoing HLH)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Probable or confirmed infection by SARS-CoV2\r&lt;br&gt;\r&lt;br&gt;          -  Moderate/severe ARDS defined by the Berlin criteria (PaO2/FiO2 =200mmHg with PEEP\r&lt;br&gt;             =5cmH20)\r&lt;br&gt;\r&lt;br&gt;          -  Development of moderate/severe ARDS in less than 24h before randomization\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or active lactation\r&lt;br&gt;\r&lt;br&gt;          -  Known history of dexamethasone allergy\r&lt;br&gt;\r&lt;br&gt;          -  Daily use of corticosteroids in the past 15 days\r&lt;br&gt;\r&lt;br&gt;          -  Refractory septic shock with the indication of corticosteroids use or any other\r&lt;br&gt;             clinical indication for corticosteroids\r&lt;br&gt;\r&lt;br&gt;          -  Patient expected to die in the next 24h\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Volunteer to participate in the study\r&lt;br&gt;\r&lt;br&gt;          -  Being pregnant\r&lt;br&gt;\r&lt;br&gt;          -  Aged between 18 - 45\r&lt;br&gt;\r&lt;br&gt;          -  To understand Turkish\r&lt;br&gt;\r&lt;br&gt;          -  Spend most of the day at home\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Risky pregnancy status\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Covid + Patients hospitalized in conventionnal hospitalisation Patients hospitalized in\r&lt;br&gt;        intensive care secondary to COVID-19 : Patient under invasive mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  PaO2 / FiO2 ratio &lt;300\r&lt;br&gt;\r&lt;br&gt;          -  PEEP&gt; = 5 cmH20\r&lt;br&gt;\r&lt;br&gt;          -  PCR SARS-CoV-2 positive in a pharyngeal or respiratory sample\r&lt;br&gt;\r&lt;br&gt;          -  PaO2 / FiO2 ratio&gt; 300\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Minor patient Patient deprived of liberty Patient's refusal to participate in the study\r&lt;br&gt;        Patient for whom therapeutic limitation measures such as non-admission to intensive care\r&lt;br&gt;        have been issued\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Documented COVID19 pneumonia (positive SARS-CoV2 test, bilateral abnormalities/\r&lt;br&gt;             infiltrates on chest x-ray or computed tomography, active fever or documented fever\r&lt;br&gt;             within 24-48 or ongoing anti-pyretic use to suppress fever).\r&lt;br&gt;\r&lt;br&gt;          -  Hypoxia (room air SpO2 &lt;92% or requirement for supplemental oxygen).\r&lt;br&gt;\r&lt;br&gt;          -  Increased serum inflammatory markers (CRP &gt; 5 mg/dl AND LDH &gt;upper limit of normal for\r&lt;br&gt;             local laboratory).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Onset of COVID-19 &gt;14 days\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized &gt;7 days\r&lt;br&gt;\r&lt;br&gt;          -  Mechanically ventilated\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt;18 years-old\r&lt;br&gt;\r&lt;br&gt;          -  Neutropenia (absolute neutrophil count &lt;1,500/mm3)\r&lt;br&gt;\r&lt;br&gt;          -  Serious concomitant illness which in the opinion of the investigator precludes the\r&lt;br&gt;             patient from enrolling in the trial, including (but not limited to):\r&lt;br&gt;\r&lt;br&gt;               -  History of immunodeficiency (congenital or acquired)\r&lt;br&gt;\r&lt;br&gt;               -  History of solid-organ or bone marrow transplant\r&lt;br&gt;\r&lt;br&gt;               -  History of current systemic autoimmune or autoinflammatory disease(s) requiring\r&lt;br&gt;                  systemic immune-modulating drugs\r&lt;br&gt;\r&lt;br&gt;               -  History of myeloproliferative disorder or active malignancy receiving cytotoxic\r&lt;br&gt;                  chemotherapy\r&lt;br&gt;\r&lt;br&gt;               -  Pre-existing severe pulmonary disease (i.e. asthma, COPD, or others)\r&lt;br&gt;\r&lt;br&gt;               -  Pre-existing severe left ventricular systolic dysfunction (i.e. LVEF &lt;35%)\r&lt;br&gt;\r&lt;br&gt;               -  Known active tuberculosis (TB) or history of incompletely treated TB or at high\r&lt;br&gt;                  risk for latent TB (for exposure or prior incarceration)\r&lt;br&gt;\r&lt;br&gt;               -  Concomitant systemic bacterial or fungal infection\r&lt;br&gt;\r&lt;br&gt;               -  Concomitant viral infection other than COVD-19 (e.g. influenza)\r&lt;br&gt;\r&lt;br&gt;               -  History of chronic liver disease with portal hypertension\r&lt;br&gt;\r&lt;br&gt;               -  History of end-stage renal disease on chronic renal replacement therapy\r&lt;br&gt;\r&lt;br&gt;          -  Recent treatment with cell-depleting biological therapies (e.g., anti-CD20) within 12\r&lt;br&gt;             months noncell-depleting biological therapies (such as anti-tumor necrosis\r&lt;br&gt;             factor-alpha [TNF-alpha], anakinra, anti-Interleukin [IL]-6 receptor [e.g.\r&lt;br&gt;             tocilizumab], or abatacept) within 8 weeks (or 5 half-lives, whichever is longer),\r&lt;br&gt;             treatment with alkylating agents within 12 weeks, treatment with cyclosporine A,\r&lt;br&gt;             azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) within 4 weeks\r&lt;br&gt;\r&lt;br&gt;          -  Recent treatment with intramuscular live (attenuated) vaccine within the 4 weeks\r&lt;br&gt;\r&lt;br&gt;          -  Chronic or recent corticosteroid use\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or lactation or newborn\r&lt;br&gt;\r&lt;br&gt;          -  Enrolled in another investigational study using immunosuppressive therapy\r&lt;br&gt;\r&lt;br&gt;          -  Enrolled in a blinded clinical trial of any type\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to Mavrilimumab or any of its excipients\r&lt;br&gt;\r&lt;br&gt;          -  In the opinion of the investigator, unable to comply with the requirements to\r&lt;br&gt;             participate in the study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged 18 years or over.\r&lt;br&gt;\r&lt;br&gt;          -  Able to provide written consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Any participants that withdraw their consent.\r&lt;br&gt;\r&lt;br&gt;          -  A skin condition/reaction preventing wearing the wearable sensor.\r&lt;br&gt;\r&lt;br&gt;          -  The presence of a permanent pacemaker or cardiac defibrillator.\r&lt;br&gt;\r&lt;br&gt;          -  Any form of psychiatric disorder or a condition that, in the opinion of the\r&lt;br&gt;             investigator, may hinder communication with the research team.\r&lt;br&gt;\r&lt;br&gt;          -  Inability to cooperate or communicate with the research team.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria\r&lt;br&gt;\r&lt;br&gt;          1. Hospitalized patient\r&lt;br&gt;\r&lt;br&gt;          2. Laboratory confirmation of SARS-CoV-2 infection &lt;/= 72 hr prior to randomization\r&lt;br&gt;\r&lt;br&gt;          3. Randomization within 72 hr of hospital admission\r&lt;br&gt;\r&lt;br&gt;          4. Negative pregnancy test for reproductive age women\r&lt;br&gt;\r&lt;br&gt;          5. Patient or LAR able to provide informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria, general (all groups)\r&lt;br&gt;\r&lt;br&gt;          1. End stage renal disease (ESRD) NOT undergoing renal replacement therapy\r&lt;br&gt;\r&lt;br&gt;          2. Severe hepatic insufficiency (LFTs &gt; 5 times the upper limit of normal or known ESLD\r&lt;br&gt;             or cirrhosis)\r&lt;br&gt;\r&lt;br&gt;          3. Nausea/vomiting or aspiration risk precluding oral medications unless can be given by\r&lt;br&gt;             gastric tube\r&lt;br&gt;\r&lt;br&gt;          4. Use of another SARS-CoV-2 directed medication empirically or within another clinical\r&lt;br&gt;             trial within the prior week\r&lt;br&gt;\r&lt;br&gt;          5. Pregnancy or breast feeding\r&lt;br&gt;\r&lt;br&gt;          6. Absence of dependable contraception in reproductive age women\r&lt;br&gt;\r&lt;br&gt;          7. Inability to obtain or declined informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria, group specific Group 1 (lopinavir/ritonavir)\r&lt;br&gt;\r&lt;br&gt;          1. Allergy or intolerance to lopinavir/ritonavir\r&lt;br&gt;\r&lt;br&gt;          2. Already taking lopinavir/ritonavir (within 1 month)\r&lt;br&gt;\r&lt;br&gt;          3. Known HIV infection and/or taking antiretroviral therapy for another indication\r&lt;br&gt;\r&lt;br&gt;          4. Co-administration with certain drugs due to CYP3A interactions if taken in &lt; 24 hr\r&lt;br&gt;\r&lt;br&gt;        Group 2 (hydroxychloroquine)\r&lt;br&gt;\r&lt;br&gt;          1. Allergy or intolerance to hydroxychloroquine (or chloroquine)\r&lt;br&gt;\r&lt;br&gt;          2. Already taking hydroxychloroquine or chloroquine (within 1 month)\r&lt;br&gt;\r&lt;br&gt;          3. Recent malaria exposure (within 1 month)\r&lt;br&gt;\r&lt;br&gt;          4. History or current cardiac diseases (heart failure, ventricular arrhythmias, LBBB or\r&lt;br&gt;             RBBB, QTc prolongation)\r&lt;br&gt;\r&lt;br&gt;          5. History of retinopathy\r&lt;br&gt;\r&lt;br&gt;          6. Severe hypoglycemia\r&lt;br&gt;\r&lt;br&gt;          7. Auditory disorders\r&lt;br&gt;\r&lt;br&gt;          8. Known G6PD deficiency\r&lt;br&gt;\r&lt;br&gt;          9. Porphyria or psoriasis\r&lt;br&gt;\r&lt;br&gt;         10. Severe active alcohol use disorder (not in remission)\r&lt;br&gt;\r&lt;br&gt;         11. Seizure disorder\r&lt;br&gt;\r&lt;br&gt;         12. Co-administration of significant hepatotoxic agents (acetaminophen in standard dosing\r&lt;br&gt;             would not be included)\r&lt;br&gt;\r&lt;br&gt;         13. Co-administration with certain drugs due to CYP3A interactions if taken in &lt; 24 hr\r&lt;br&gt;\r&lt;br&gt;        Group 3 (losartan)\r&lt;br&gt;\r&lt;br&gt;          1. Allergy or intolerance to losartan (or ACE inhibitors or other ARBs)\r&lt;br&gt;\r&lt;br&gt;          2. Already taking ACE or ARB (within 1 month)\r&lt;br&gt;\r&lt;br&gt;          3. Hypotension\r&lt;br&gt;\r&lt;br&gt;          4. Hyperkalemia (K &gt;/= 5.0 at time of screening or history of hyperkalemia)\r&lt;br&gt;\r&lt;br&gt;          5. Blood pressure &lt; 110/70 mm Hg or history of hypotension or recent (within 1 month) or\r&lt;br&gt;             recurrent syncope\r&lt;br&gt;\r&lt;br&gt;          6. Severe renal dysfunction (estimated GFR &lt; 30 ml/min at time of screening or history\r&lt;br&gt;             advanced renal disease)\r&lt;br&gt;\r&lt;br&gt;          7. Severe volume depletion or acute kidney injury (AKI)\r&lt;br&gt;\r&lt;br&gt;          8. Known cirrhotic ascites\r&lt;br&gt;\r&lt;br&gt;          9. Known severe aortic or mitral valve stenosis\r&lt;br&gt;\r&lt;br&gt;         10. Known unstented renal artery stenosis\r&lt;br&gt;\r&lt;br&gt;         11. Co-administration with certain drugs due to CYP3A interactions if taken in &lt; 24 hr\r&lt;br&gt;\r&lt;br&gt;        Group 4 (standard care [placebo])\r&lt;br&gt;\r&lt;br&gt;        1. None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Primary case: laboratory-confirmed coronavirus SARS-CoV-2 infection by polymerase\r&lt;br&gt;             chain reaction (PCR), or Family contact: person who lived in the same household as the\r&lt;br&gt;             primary case of COVID-19 when the primary case was symptomatic. A household is defined\r&lt;br&gt;             as a group of people (2 or more) living in the same accommodation (excluding\r&lt;br&gt;             residential institutions such as boarding schools, dormitories, hostels, prisons,\r&lt;br&gt;             other communities hosting grouped people)\r&lt;br&gt;\r&lt;br&gt;          -  Affiliated or beneficiary of a social security system\r&lt;br&gt;\r&lt;br&gt;          -  Informed consent prior to initiation of any study procedures from subject (or legally\r&lt;br&gt;             authorized representative)\r&lt;br&gt;\r&lt;br&gt;          -  State of health compatible with a blood sample as defined in the protocol.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant woman or breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  Inability to consent\r&lt;br&gt;\r&lt;br&gt;          -  Person under guardianship or curatorship\r&lt;br&gt;\r&lt;br&gt;          -  Known pathology or a health problem contraindicated with the collect of blood sample.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult aged &gt;=18years old; Diagnosed with CONVID19. Diagnostic criteria including:\r&lt;br&gt;             Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the\r&lt;br&gt;             manifestation of viral pneumonia.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Near-death state (expected survival time less than 24 hours); Malignant tumor;\r&lt;br&gt;             Pregnancy or puerperium women; Patients who refused to participant.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Female sex\r&lt;br&gt;\r&lt;br&gt;          -  Greater than or equal to 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  English-speaking\r&lt;br&gt;\r&lt;br&gt;          -  Established obstetrics/gynecology (OB/Gyn) patients of Banner University Medical\r&lt;br&gt;             Center - Phoenix (BUMCP)\r&lt;br&gt;\r&lt;br&gt;          -  OB patients must be less than or equal to 34 weeks gestational age\r&lt;br&gt;\r&lt;br&gt;          -  Gyn patients must have had a scheduled gynecologic surgery that was delayed or\r&lt;br&gt;             canceled for at least 30 days from the time of study enrollment due to the COVID-19\r&lt;br&gt;             restrictions\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - No access to a smart phone\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Chinese patients, aged 18 to 70 years old, males or females;\r&lt;br&gt;\r&lt;br&gt;          2. Diagnosis of COVID-19, and confirm by chest CT scan;\r&lt;br&gt;\r&lt;br&gt;          3. According to the diagnosis and treatment plan for the novel coronavirus disease\r&lt;br&gt;             (COVID-19) (trial version 5) issued by the National Health Commission (NHC) on the\r&lt;br&gt;             diagnostic criteria for severe or critical ill COVID-19 patients including the\r&lt;br&gt;             patients with acute respiratory distress syndrome (ARDS), the specific diagnostic\r&lt;br&gt;             criteria are:\r&lt;br&gt;\r&lt;br&gt;             Severely ill patients should meet all of the following:\r&lt;br&gt;\r&lt;br&gt;               -  1. Respiratory distress, RR = 30 times/min.\r&lt;br&gt;\r&lt;br&gt;               -  2. In a resting state (without oxygen supplementation), oxygen saturation = 93%.\r&lt;br&gt;\r&lt;br&gt;               -  3. Partial arterial oxygen pressure (PaO2) / oxygen absorption concentration\r&lt;br&gt;                  (FiO2) = 300 mmHg (1 mmHg = 0.133 kpa). High altitude (above sea level 1000 m)\r&lt;br&gt;                  area should be calibrated for PaO2/FiO2 according to the following method:\r&lt;br&gt;                  PaO2/FiO2*[atmospheric pressure (mmHg)/760]. Patients with obvious progress in\r&lt;br&gt;                  lung lesions by chest CT within 24-48 hours should be counted as the server\r&lt;br&gt;                  cases.\r&lt;br&gt;\r&lt;br&gt;             Critically ill patients should meet one of the following :\r&lt;br&gt;\r&lt;br&gt;               -  1. Respiratory failure, the mechanical ventilation required.\r&lt;br&gt;\r&lt;br&gt;               -  2. Shock.\r&lt;br&gt;\r&lt;br&gt;               -  3. Associated with other organ failure, ICU needed for monitoring and management.\r&lt;br&gt;\r&lt;br&gt;          4. Voluntarily participate in the study, agree to comply with the requirements of the\r&lt;br&gt;             clinical trial protocol, and sign the informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with a history of transplantation of cells or organ(s).\r&lt;br&gt;\r&lt;br&gt;          2. Patients with a history of malignancy or pathology indicating severe atypical\r&lt;br&gt;             hyperplasia.\r&lt;br&gt;\r&lt;br&gt;          3. Patients without life expectancy of 48 hours.\r&lt;br&gt;\r&lt;br&gt;          4. Patients with moderate to severe liver failure (Childs Pugh scores &gt; 12).\r&lt;br&gt;\r&lt;br&gt;          5. Patients with cardiogenic pulmonary edema.\r&lt;br&gt;\r&lt;br&gt;          6. Patients with a history of deep vein thrombosis or pulmonary embolism within 3 months\r&lt;br&gt;             before the screening.\r&lt;br&gt;\r&lt;br&gt;          7. Patients with severe chronic pulmonary diseases, including but not restricted to the\r&lt;br&gt;             patients with WHO grade III or IV pulmonary hypertension or those with chronic\r&lt;br&gt;             pulmonary diseases requiring long-term oxygen therapy.\r&lt;br&gt;\r&lt;br&gt;          8. Patients with unstable ventricular tachycardia or ventricular fibrillation.\r&lt;br&gt;\r&lt;br&gt;          9. Patients with poor coagulation, severe bleeding tendency or active bleeding at\r&lt;br&gt;             present.\r&lt;br&gt;\r&lt;br&gt;         10. Patients with serious dysfunction involved in the major organs or systems (liver,\r&lt;br&gt;             kidney, gastrointestinal, cardiovascular, blood coagulation, central system, etc.)\r&lt;br&gt;             besides the respiratory system are not suitable to participate in the present study.\r&lt;br&gt;\r&lt;br&gt;         11. Patients with a history of severe conditions in any organs or systems.\r&lt;br&gt;\r&lt;br&gt;         12. Patients who are unable to accept other invasive rescue except cardiopulmonary\r&lt;br&gt;             resuscitation.\r&lt;br&gt;\r&lt;br&gt;         13. Patients who are allergic to the main active ingredients or excipients of the\r&lt;br&gt;             investigational drug.\r&lt;br&gt;\r&lt;br&gt;         14. Women who are pregnant, breastfeeding or planning to become pregnant during the study\r&lt;br&gt;             period. Woman of childbearing age who is not willing to use appropriate contraceptive\r&lt;br&gt;             methods through the completion of the clinical study.\r&lt;br&gt;\r&lt;br&gt;         15. Patients whose participation is considered to bring significant risks to the present\r&lt;br&gt;             clinical study, cause confusion in analysis, or significantly interfere with the\r&lt;br&gt;             clinical research results.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:Fulfilling all the following criteria\r&lt;br&gt;\r&lt;br&gt;          1. Aged between 18 and 60 years, male or female.\r&lt;br&gt;\r&lt;br&gt;          2. Hospitalized participants with diagnosis of COVID 19 by Real Time - Polymerase Chain\r&lt;br&gt;             Reaction.\r&lt;br&gt;\r&lt;br&gt;          3. Moderate cases according to the official guideline \"Pneumonia Diagnosis and Treatment\r&lt;br&gt;             Scheme for Novel Coronavirus Infection (Trial Version 6)\".\r&lt;br&gt;\r&lt;br&gt;          4. Confusion, Urea, Respiratory rate, Blood pressure-65 (CURB-65) &gt;= 2.\r&lt;br&gt;\r&lt;br&gt;          5. Sequential Organ Failure Assessment score (SOFA) &lt; 6.\r&lt;br&gt;\r&lt;br&gt;          6. Ability to understand and the willingness to sign a written informed consent document.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Female subjects who are pregnant or breastfeeding.\r&lt;br&gt;\r&lt;br&gt;          2. Patients with prior allergic reactions to transfusions.\r&lt;br&gt;\r&lt;br&gt;          3. Critical ill patients in intensive care units.\r&lt;br&gt;\r&lt;br&gt;          4. Patients with surgical procedures in the last 30 days.\r&lt;br&gt;\r&lt;br&gt;          5. Patients with active treatment for cancer (Radiotherapy or Chemotherapy).\r&lt;br&gt;\r&lt;br&gt;          6. HIV diagnosed patients with viral failure (detectable viral load&gt; 1000 copies / ml\r&lt;br&gt;             persistent, two consecutive viral load measurements within a 3 month interval, with\r&lt;br&gt;             medication adherence between measurements after at least 6 months of starting a new\r&lt;br&gt;             regimen antiretrovirals).\r&lt;br&gt;\r&lt;br&gt;          7. Patients who have suspicion or evidence of coinfections.\r&lt;br&gt;\r&lt;br&gt;          8. End-stage chronic kidney disease (Glomerular Filtration Rate &lt;15 ml / min / 1.73 m2).\r&lt;br&gt;\r&lt;br&gt;          9. Child Pugh C stage liver cirrhosis.\r&lt;br&gt;\r&lt;br&gt;         10. High cardiac output diseases.\r&lt;br&gt;\r&lt;br&gt;         11. Autoimmune diseases or Immunoglobulin A nephropathy.\r&lt;br&gt;\r&lt;br&gt;         12. Patients have any condition that in the judgement of the Investigators would make the\r&lt;br&gt;             subject inappropriate for entry into this study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria Donor:\r&lt;br&gt;\r&lt;br&gt;          -  18 years or older\r&lt;br&gt;\r&lt;br&gt;          -  must have been hospitalized w/COVID-19 respiratory symptoms and confirmation via\r&lt;br&gt;             COVID-19 SARS-CoV-2 RT-PCR testing but are now PCR negative by 2 nasopharyngeal\r&lt;br&gt;             testing\r&lt;br&gt;\r&lt;br&gt;          -  females of child-bearing potential must have a negative serum pregnancy test\r&lt;br&gt;\r&lt;br&gt;          -  subject and/or LAR willing to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  patient agrees to storage of specimens for future testing\r&lt;br&gt;\r&lt;br&gt;        Inclusion Criteria Recipient:\r&lt;br&gt;\r&lt;br&gt;          -  18 years or older\r&lt;br&gt;\r&lt;br&gt;          -  must have been hospitalized w/COVID-19 respiratory symptoms within 3 to 7 days from\r&lt;br&gt;             the beginning of illness\r&lt;br&gt;\r&lt;br&gt;          -  subject and/or LAR willing to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  patient agrees to storage of specimens for future testing\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  18 years or older\r&lt;br&gt;\r&lt;br&gt;          -  receipt of pooled immunoglobulin in past 30 days\r&lt;br&gt;\r&lt;br&gt;          -  contraindication to transfusion or history of prior reactions to transfusion blood\r&lt;br&gt;             products\r&lt;br&gt;\r&lt;br&gt;          -  females who are identified as donors must not be pregnant\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults (age =18 years) undergoing ANY type of vascular surgery in an operating\r&lt;br&gt;             theatre, this includes obstetrics. AND\r&lt;br&gt;\r&lt;br&gt;          -  Either before or after surgery: (i) lab test confirmed COVID-19 infection or (ii)\r&lt;br&gt;             clinical diagnosis of COVID-19 infection (no test performed).\r&lt;br&gt;\r&lt;br&gt;        Therefore this study should capture:\r&lt;br&gt;\r&lt;br&gt;          -  emergency surgery patients with clinical diagnosis or lab confirmation of COVID-19\r&lt;br&gt;             infection before surgery.\r&lt;br&gt;\r&lt;br&gt;          -  emergency surgery patients with clinical diagnosis or lab confirmation of COVID-19\r&lt;br&gt;             infection after surgery.\r&lt;br&gt;\r&lt;br&gt;          -  elective surgery patients with clinical diagnosis or lab confirmation of COVID-19\r&lt;br&gt;             infection after surgery.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Not informed consent signed.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  =18 years old with clinical features consistent with pneumonia or chest infection due\r&lt;br&gt;             to SARS-CoV-2 AND\r&lt;br&gt;\r&lt;br&gt;               -  presenting to the Royal Infirmary of Edinburgh where they are swabbed and triaged\r&lt;br&gt;                  for Covid-19.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Inability to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Age 17 years or less\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18 years old (Sub-studies 2 and 3)\r&lt;br&gt;\r&lt;br&gt;          -  Competent and capable to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Have access to a smart device such as a cell phone, tablet, laptop computer with\r&lt;br&gt;             necessary data/internet accessibility\r&lt;br&gt;\r&lt;br&gt;          -  Subjects meeting the following criteria by Sub-Study\r&lt;br&gt;\r&lt;br&gt;        Sub-Study 1:\r&lt;br&gt;\r&lt;br&gt;          -  Age =40 years since the risk of prolonged disease that progresses to severe COVID-19\r&lt;br&gt;             disease increases with age.\r&lt;br&gt;\r&lt;br&gt;          -  PCR-positive for the SARS-CoV2 virus\r&lt;br&gt;\r&lt;br&gt;          -  (Fever, and cough, or Fever and shortness of breath,\r&lt;br&gt;\r&lt;br&gt;          -  =4 days since the first symptoms of COVID-19 and date of testing\r&lt;br&gt;\r&lt;br&gt;          -  Not taking azithromycin\r&lt;br&gt;\r&lt;br&gt;          -  Not requiring hospitalization and is sent home for quarantine.\r&lt;br&gt;\r&lt;br&gt;          -  Must live within 30 miles of HUP or Penn Presbytarian Medical Center to facilitate\r&lt;br&gt;             drop-off of medication\r&lt;br&gt;\r&lt;br&gt;          -  Must own a working computer, or smartphone and have internet access\r&lt;br&gt;\r&lt;br&gt;          -  Must be willing to fill out a daily symptom diary\r&lt;br&gt;\r&lt;br&gt;          -  Must be available for a daily phone call,\r&lt;br&gt;\r&lt;br&gt;          -  Must take their own temperature twice a day\r&lt;br&gt;\r&lt;br&gt;          -  Must be willing to report the observed symptoms and development of COVID-19 in the\r&lt;br&gt;             co-inhabitants of the residence at which the quarantine will be served.\r&lt;br&gt;\r&lt;br&gt;        Sub-Study 2 Hospitalized non-ICU service patients.\r&lt;br&gt;\r&lt;br&gt;          -  PCR-positive for SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  Patients admitted to a floor bed at Hospital of the University of Pennsylvania or Penn\r&lt;br&gt;             Presbyterian.\r&lt;br&gt;\r&lt;br&gt;          -  One or more of the following risk factors for progression to severe disease including:\r&lt;br&gt;             immunocompromising conditions, structural lung disease, hypertension, coronary artery\r&lt;br&gt;             disease, diabetes, age &gt; 60, ferritin &gt; 850, CRP &gt; 6, D-dimer &gt; 1000 Sub-Study 3\r&lt;br&gt;             Health Care Worker Prevention\r&lt;br&gt;\r&lt;br&gt;          -  Emergency Medicine or Infectious Disease Team physician or nurse at HUP or PPMC\r&lt;br&gt;\r&lt;br&gt;          -  =20 hours per week of clinical work scheduled in the coming 2 months during the\r&lt;br&gt;             COVID-19 pandemic\r&lt;br&gt;\r&lt;br&gt;          -  No fever, cough, or shortness of breath in the past 2 weeks\r&lt;br&gt;\r&lt;br&gt;          -  Willing to report compliance with HCQ in the form of a diary\r&lt;br&gt;\r&lt;br&gt;          -  Patients must be able to swallow and retain oral medication and must not have any\r&lt;br&gt;             clinically significant gastrointestinal abnormalities that may alter absorption such\r&lt;br&gt;             as malabsorption syndrome or major resection of the stomach or bowels.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria &lt;18 years of age\r&lt;br&gt;\r&lt;br&gt;          -  Prisoners or other detained persons\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to hydroxychloroquine Pregnant or lactating or positive pregnancy test\r&lt;br&gt;\r&lt;br&gt;          -  Receiving any treatment drug for 2019-ncov within 14 days prior to screening\r&lt;br&gt;             evaluation (off label, compassionate use or trial related).\r&lt;br&gt;\r&lt;br&gt;          -  Co-enrollment onto another COVID-19 study is not allowed unless there is approval by\r&lt;br&gt;             the Medical Monitor in consultation with the PI and EM and ID sub-I leaders.\r&lt;br&gt;\r&lt;br&gt;          -  Known history of retinal disease including but not limited to age related macular\r&lt;br&gt;             degeneration.\r&lt;br&gt;\r&lt;br&gt;          -  Taking any of the following medications that prolong Qtc:\r&lt;br&gt;\r&lt;br&gt;        Chlorpromazine.Haloperidol, Droperidol, Quetiapine, Olanzapine. Amisulpride. Thioridazine\r&lt;br&gt;\r&lt;br&gt;          -  History of interstitial lung disease or chronic pneumonitis unrelated COVID-19.\r&lt;br&gt;\r&lt;br&gt;          -  Due to risk of disease exacerbation patients with porphyria or psoriasis are\r&lt;br&gt;             ineligible unless the disease is well controlled and they are under the care of a\r&lt;br&gt;             specialist for the disorder who agrees to monitor the patient for exacerbations.\r&lt;br&gt;\r&lt;br&gt;          -  Patients with serious intercurrent illness that requires active infusional therapy,\r&lt;br&gt;             intense monitoring, or frequent dose adjustments for medication including but not\r&lt;br&gt;             limited to infectious disease, cancer, autoimmune disease, cardiovascular disease.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who have undergone major abdominal, thoracic, spine or CNS surgery in the\r&lt;br&gt;             last 2 months, or plan to undergo surgery during study participation.\r&lt;br&gt;\r&lt;br&gt;          -  Patients receiving cytochrome P450 enzyme-inducing anticonvulsant drugs (i.e.\r&lt;br&gt;             phenytoin, carbamazepine, Phenobarbital, primidone or oxcarbazepine) within 4 weeks of\r&lt;br&gt;             the start of the study treatment\r&lt;br&gt;\r&lt;br&gt;          -  History or evidence of increased cardiovascular risk including any of the following:\r&lt;br&gt;\r&lt;br&gt;          -  Left ventricular ejection fraction (LVEF) &lt; institutional lower limit of normal.\r&lt;br&gt;             Baseline echocardiogram is not required.\r&lt;br&gt;\r&lt;br&gt;          -  A QT interval corrected for heart rate using the Frederica formula &gt; 500 msec\r&lt;br&gt;             (Sub-study 2)\r&lt;br&gt;\r&lt;br&gt;          -  Current clinically significant uncontrolled arrhythmias. Exception: Subjects with\r&lt;br&gt;             controlled atrial fibrillation\r&lt;br&gt;\r&lt;br&gt;          -  History of acute coronary syndromes (including myocardial infarction and unstable\r&lt;br&gt;             angina), coronary angioplasty, or stenting within 6 months prior to enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Current = Class II congestive heart failure as defined by New York Heart Association\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  A contact person from confirmed case of SARS-CoV-2 infection\r&lt;br&gt;\r&lt;br&gt;          -  Medical staff exposed from confirmed case of SARS-CoV-2 infection in hospitals\r&lt;br&gt;\r&lt;br&gt;          -  Persons exposed to SARS-CoV-2 in COVID-19 outbreak situation with certain workplaces,\r&lt;br&gt;             religious groups, and military, etc.\r&lt;br&gt;\r&lt;br&gt;               -  Subjects of study include both symptomatic and asymptomatic contacts.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Hypersensitivity to Chloroquine or Hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Those who are contraindicated in Hydroxychloroquine administration according to the\r&lt;br&gt;             permission requirements such as pregnant women, nursing mothers, visual disorders,\r&lt;br&gt;             macular disease, and porphyria, etc.\r&lt;br&gt;\r&lt;br&gt;          -  Human immunodeficiency virus (HIV) infected person\r&lt;br&gt;\r&lt;br&gt;          -  Patients with autoimmune disease (Systemic lupus erythematosus, Mixed connective\r&lt;br&gt;             tissue disease)\r&lt;br&gt;\r&lt;br&gt;          -  Patients with autoimmune rheumatoid inflammatory disease (AIIRD; Autoimmune\r&lt;br&gt;             inflammatory rheumatic diseases - Ankylosing spondylitis, Rheumatic arthritis,\r&lt;br&gt;             Psoriatic arthritis)\r&lt;br&gt;\r&lt;br&gt;          -  Arrhythmia, liver cirrhosis of Child Pugh C, chronic renal failure with eGFR=30mL /\r&lt;br&gt;             min / 1.73m2\r&lt;br&gt;\r&lt;br&gt;          -  A person who is positive in the COVID-19 screening PCR test before starting PEP\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with mild COVID-19 (NEWS scoring system 0-4)\r&lt;br&gt;\r&lt;br&gt;          -  Patient within 7 days from symptom onset or Patient within 48 hous after laboratory\r&lt;br&gt;             diagnosis (SARS-CoV-2 RT-PCR)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Unable to take oral medication\r&lt;br&gt;\r&lt;br&gt;          -  Unable to use inhaler\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  Immunocompromising conditions\r&lt;br&gt;\r&lt;br&gt;          -  Moderate/severe renal dysfunction : creatinine clearance (CCL) &lt; 30 mL/min\r&lt;br&gt;\r&lt;br&gt;          -  Moderate/severe liver dysfunction: AST or ALT &gt; 5 times upper normal limit\r&lt;br&gt;\r&lt;br&gt;          -  Asthma or chronic obstructive lung disease\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  confirmed COVID-19 patients by high-throughput sequencing or real-time\r&lt;br&gt;             reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay for nasal and\r&lt;br&gt;             pharyngeal swab specimens.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. patients with severe illness when admitted;\r&lt;br&gt;\r&lt;br&gt;          2. time interval &gt; 2 days between the admission and examinations;\r&lt;br&gt;\r&lt;br&gt;          3. absent data or delayed results\r&lt;br&gt;","\r&lt;br&gt;        Prevention Study Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Capable of understanding and providing signed informed consent and ability to adhere\r&lt;br&gt;             to the requirements and restrictions of this protocol;\r&lt;br&gt;\r&lt;br&gt;          2. Men and Women = 19 years of age unless local laws dictate otherwise;\r&lt;br&gt;\r&lt;br&gt;          3. English speaking;\r&lt;br&gt;\r&lt;br&gt;          4. Must be willing to use an adequate form of contraception (or abstinence) from the time\r&lt;br&gt;             of the first dose with the IMP until after the last dose of IMP.\r&lt;br&gt;\r&lt;br&gt;          5. Be symptom-free and have a negative COVID-19 test result at baseline.\r&lt;br&gt;\r&lt;br&gt;          6. Work/live in contact with COVID-19 infected patients or scheduled to work in a setting\r&lt;br&gt;             with high likelihood of contact with COVID-19 infected patients.\r&lt;br&gt;\r&lt;br&gt;        Prevention Study Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Prior Tracheostomy;\r&lt;br&gt;\r&lt;br&gt;          2. Concomitant treatment of respiratory support (involving any form of oxygen therapy);\r&lt;br&gt;\r&lt;br&gt;          3. Any clinical contraindications, as judged by the attending physician;\r&lt;br&gt;\r&lt;br&gt;          4. Any symptoms consistent with COVID-19;\r&lt;br&gt;\r&lt;br&gt;          5. Mentally or neurologically disabled patients who are considered not fit to consent to\r&lt;br&gt;             their participation in the study;\r&lt;br&gt;\r&lt;br&gt;          6. Prior COVID-19 infection.\r&lt;br&gt;\r&lt;br&gt;        Treatment Sub study Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Capable of understanding and providing signed informed consent and ability to adhere\r&lt;br&gt;             to the requirements and restrictions of this protocol;\r&lt;br&gt;\r&lt;br&gt;          2. Men and Women = 19 years of age unless local laws dictate otherwise;\r&lt;br&gt;\r&lt;br&gt;          3. English speaking;\r&lt;br&gt;\r&lt;br&gt;          4. Must be willing to use an adequate form of contraception (or abstinence) from the time\r&lt;br&gt;             of the first dose with the IMP until after the last dose of IMP;\r&lt;br&gt;\r&lt;br&gt;          5. Positive COVID-19 test or presentation of clinical symptoms defined as fatigue with\r&lt;br&gt;             either fever &gt;37.2 (oral) and/or a persistent cough.\r&lt;br&gt;\r&lt;br&gt;        Treatment Sub Study Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Prior Tracheostomy;\r&lt;br&gt;\r&lt;br&gt;          2. Concomitant treatment of respiratory support (involving any form of oxygen therapy);\r&lt;br&gt;             Any clinical contraindications, as judged by the attending physician;\r&lt;br&gt;\r&lt;br&gt;          3. Mentally or neurologically disabled patients who are considered not fit to consent to\r&lt;br&gt;             their participation in the study;\r&lt;br&gt;\r&lt;br&gt;          4. Currently hospitalized for symptoms of COVID-19.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female subjects at least 18 years of age at time of consent\r&lt;br&gt;\r&lt;br&gt;          2. Confirmed COVID-19 infection by clinical diagnosis and laboratory testing\r&lt;br&gt;\r&lt;br&gt;          3. In critical condition as indicated by life support measurements\r&lt;br&gt;\r&lt;br&gt;          4. Have one or more of the following laboratory parameters:\r&lt;br&gt;\r&lt;br&gt;               -  lymphocytopenia\r&lt;br&gt;\r&lt;br&gt;               -  elevated IL-6\r&lt;br&gt;\r&lt;br&gt;               -  elevated Troponin I/Troponin T (TnI/T)\r&lt;br&gt;\r&lt;br&gt;               -  elevated myoglobin\r&lt;br&gt;\r&lt;br&gt;               -  elevated C-Reactive Protein (CRP)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age at least 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory confirmed diagnosis of infection with SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to an acute care facility for the treatment of COVID-19 complications\r&lt;br&gt;\r&lt;br&gt;          -  Severe or life threatening COVID-19, or judged by the treating provider to be at high\r&lt;br&gt;             risk of progression to severe or life-threatening disease\r&lt;br&gt;\r&lt;br&gt;          -  Informed consent provided by the patient or healthcare proxy\r&lt;br&gt;\r&lt;br&gt;        Severe COVID-19 is defined by one or more of the following:\r&lt;br&gt;\r&lt;br&gt;          -  dyspnea\r&lt;br&gt;\r&lt;br&gt;          -  respiratory frequency = 30/min\r&lt;br&gt;\r&lt;br&gt;          -  blood oxygen saturation = 93%\r&lt;br&gt;\r&lt;br&gt;          -  partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt; 300\r&lt;br&gt;\r&lt;br&gt;          -  lung infiltrates &gt; 50% within 24 to 48 hours\r&lt;br&gt;\r&lt;br&gt;        Life-threatening COVID-19 is defined as one or more of the following:\r&lt;br&gt;\r&lt;br&gt;          -  respiratory failure\r&lt;br&gt;\r&lt;br&gt;          -  septic shock\r&lt;br&gt;\r&lt;br&gt;          -  multiple organ dysfunction or failure\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All adult patients &gt; 18 years scheduled for a (semi) urgent surgery, hematological or\r&lt;br&gt;             oncological treatment or elektrophysiciological investigations in the Jessa hospital\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients &lt; 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Adult patients who are unable the give informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Language barrier\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Being 65 years old and over\r&lt;br&gt;\r&lt;br&gt;          -  Being in social isolation due to the coronavirus epidemic.\r&lt;br&gt;\r&lt;br&gt;          -  Spending at least 1 week at home different from routine life.\r&lt;br&gt;\r&lt;br&gt;          -  Not to be obstructed from doing physical activities.\r&lt;br&gt;\r&lt;br&gt;          -  To have access to online exercise training.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Having a serious cognitive impairment\r&lt;br&gt;\r&lt;br&gt;          -  Having serious hearing and vision problems\r&lt;br&gt;\r&lt;br&gt;          -  Having vestibular disorders that can cause loss of balance\r&lt;br&gt;\r&lt;br&gt;          -  Having diabetes, hypertension or a neurological disease\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - Age:\r&lt;br&gt;\r&lt;br&gt;        At least 18 years of age at the time of signing the ICF.\r&lt;br&gt;\r&lt;br&gt;        - Type of Subject and Disease Characteristics:\r&lt;br&gt;\r&lt;br&gt;        Documented or confirmed SARS-CoV-2 infection by PCR test nasopharyngeal swab = 2 days\r&lt;br&gt;        before randomization.\r&lt;br&gt;\r&lt;br&gt;        Hospitalized for COVID-19.\r&lt;br&gt;\r&lt;br&gt;        Diagnosed with COVID-19 as defined by having at least 2 of the following signs or symptoms\r&lt;br&gt;        within the past 2 days:\r&lt;br&gt;\r&lt;br&gt;        Fever defined as a body temperature of = 38.0 C oral, or = 38.3 C rectal, forehead or\r&lt;br&gt;        aural (axillary temperatures are not allowable);\r&lt;br&gt;\r&lt;br&gt;        Cough;\r&lt;br&gt;\r&lt;br&gt;        Fatigue;\r&lt;br&gt;\r&lt;br&gt;        Shortness of breath.\r&lt;br&gt;\r&lt;br&gt;        Radiographic evidence (chest x-ray or CT scan) of one the following:\r&lt;br&gt;\r&lt;br&gt;        Ground-glass opacities, or\r&lt;br&gt;\r&lt;br&gt;        Local or bilateral patchy infiltrates, or\r&lt;br&gt;\r&lt;br&gt;        Interstitial pulmonary infiltrates.\r&lt;br&gt;\r&lt;br&gt;        - Sex:\r&lt;br&gt;\r&lt;br&gt;        Male and/or female subjects.\r&lt;br&gt;\r&lt;br&gt;        Contraception use by men or women should be consistent with local regulations regarding the\r&lt;br&gt;        methods of contraception for those participating in clinical studies.\r&lt;br&gt;\r&lt;br&gt;        All subjects (male or female) who are of childbearing potential must agree to use highly\r&lt;br&gt;        effective contraception during the study. Female subjects and male partners of female\r&lt;br&gt;        subjects must continue to use highly effective contraception for 30 days after the last\r&lt;br&gt;        dose of study drug. Female subjects should not donate oocytes during this time. Male\r&lt;br&gt;        subjects and female partners of male subjects must continue to use highly effective\r&lt;br&gt;        contraception for 90 days. Male subjects must agree not to donate sperm during this time.\r&lt;br&gt;\r&lt;br&gt;        Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception\r&lt;br&gt;        for the subject.\r&lt;br&gt;\r&lt;br&gt;        Note: Ethinyl estradiol is the primary estrogen used in hormonal contraceptives. The\r&lt;br&gt;        progestin component consists of norethindrone, levonorgestrel, norgestrel, norethindrone\r&lt;br&gt;        acetate, ethynodiol diacetate, norgestimate, desogestrel, and drospirenone. As BLD-2660 is\r&lt;br&gt;        a weak CYP3A4 inducer, exposure to both the estrogen and progestin components in hormonal\r&lt;br&gt;        contraceptives may be decreased, resulting in an increased risk of pregnancy. As such, it\r&lt;br&gt;        is recommended that subjects who are on hormonal contraceptives for birth control should\r&lt;br&gt;        use an alternate means of contraception (condoms, diaphragms, intrauterine device (IUD),\r&lt;br&gt;        other barrier methods, sexual abstinence, etc.) during participation in the study.\r&lt;br&gt;\r&lt;br&gt;        Women of childbearing potential must have a negative serum pregnancy test at Screening\r&lt;br&gt;        within 72 hours prior to first administration of study drug.\r&lt;br&gt;\r&lt;br&gt;        Women not of childbearing potential must be postmenopausal (defined as cessation of regular\r&lt;br&gt;        menstrual periods for at least 1 year\r&lt;br&gt;\r&lt;br&gt;        - Informed Consent:\r&lt;br&gt;\r&lt;br&gt;        Capable of giving signed informed consent which includes compliance with the requirements\r&lt;br&gt;        and restrictions listed in the ICF and in this protocol\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - Medical Conditions:\r&lt;br&gt;\r&lt;br&gt;        Active bacterial pneumonia infection\r&lt;br&gt;\r&lt;br&gt;        Known active tuberculosis (TB).\r&lt;br&gt;\r&lt;br&gt;        Known history of testing positive for Human Immunodeficiency Virus (HIV) (HIV 1/2\r&lt;br&gt;        antibodies).\r&lt;br&gt;\r&lt;br&gt;        Known active Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known\r&lt;br&gt;        active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.\r&lt;br&gt;\r&lt;br&gt;        Note: No testing for Hepatitis B and Hepatitis C is required unless mandated by local\r&lt;br&gt;        health authority\r&lt;br&gt;\r&lt;br&gt;        History of Child-Pugh B or C cirrhosis.\r&lt;br&gt;\r&lt;br&gt;        History of acute coronary syndrome requiring hospital admission or symptomatic ischemic\r&lt;br&gt;        heart disease within 24 weeks prior to screening.\r&lt;br&gt;\r&lt;br&gt;        Subjects requiring high flow oxygen defined as &gt;50 L/min.\r&lt;br&gt;\r&lt;br&gt;        It is not in the best interest of the subjects to participate, in the opinion of the\r&lt;br&gt;        treating Investigator.\r&lt;br&gt;\r&lt;br&gt;        Female subjects who are pregnant or breastfeeding or expecting to conceive within the\r&lt;br&gt;        projected duration of the study, starting with the screening visit through 90 days after\r&lt;br&gt;        the last dose of study drug.\r&lt;br&gt;\r&lt;br&gt;        - Diagnostic Assessments:\r&lt;br&gt;\r&lt;br&gt;        The following laboratory parameters are excluded:\r&lt;br&gt;\r&lt;br&gt;        Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;5 x upper limit of\r&lt;br&gt;        normal (ULN);\r&lt;br&gt;\r&lt;br&gt;        Creatinine clearance &lt; 50 mL/min.\r&lt;br&gt;\r&lt;br&gt;        - Prior Therapy:\r&lt;br&gt;\r&lt;br&gt;        Requiring, or expected to require mechanical ventilation at screening.\r&lt;br&gt;\r&lt;br&gt;        Concurrent treatment with other agents with actual or possible direct acting antiviral\r&lt;br&gt;        activity against SARS-CoV-2 within 24 hours prior to initiation of study drug dosing (e.g.\r&lt;br&gt;        remdesivir within 6 half-lives).\r&lt;br&gt;\r&lt;br&gt;        Treatment with anti-IL 6, anti-IL-6 receptor antagonists, or with Janus kinase inhibitors\r&lt;br&gt;        (JAKi) in the past 30 days or plans to receive during the study period.\r&lt;br&gt;\r&lt;br&gt;        - Prior/Concurrent Clinical Study Experience:\r&lt;br&gt;\r&lt;br&gt;        Participation in any other clinical study of an experimental drug treatment for COVID-19\r&lt;br&gt;        within 6 half-lives of the experimental treatment.\r&lt;br&gt;\r&lt;br&gt;        Current participation or have participated in a study of an investigational agent or has\r&lt;br&gt;        used an investigational device within 4 weeks prior to the first dose of study drug.\r&lt;br&gt;\r&lt;br&gt;        Note: Subjects participating in an observational study are an exception to this criterion\r&lt;br&gt;        and may qualify for the study with Sponsor approval.\r&lt;br&gt;\r&lt;br&gt;        Note: Subjects who have entered the follow-up phase of an investigational study may\r&lt;br&gt;        participate as long as it has been 4 weeks after the last dose of the previous\r&lt;br&gt;        investigational agent.\r&lt;br&gt;\r&lt;br&gt;        - Other Exclusions:\r&lt;br&gt;\r&lt;br&gt;        Unable to swallow solid oral medication or known malabsorption disorder.\r&lt;br&gt;\r&lt;br&gt;        Subjects who have allergy to BLD-2660 or inactive components of BLD-2660.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Must have positive nasopharyngeal swab for SARS-CoV-2 diagnosed via outpatient testing\r&lt;br&gt;             within the previous 48 hours\r&lt;br&gt;\r&lt;br&gt;          -  Age = 45 years\r&lt;br&gt;\r&lt;br&gt;          -  Not hospitalized at the time of enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Established care with Providence provider\r&lt;br&gt;\r&lt;br&gt;          -  Ability to understand a written or electronic informed consent document\r&lt;br&gt;\r&lt;br&gt;          -  Reliable access to a computer or smartphone that can facilitate study communications\r&lt;br&gt;             via remote messaging or telephone and willingness to provide daily verbal check ins\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Hypersensitivity to chloroquine or hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  History of retinal disease (macular degeneration, diabetic retinopathy, retinal\r&lt;br&gt;             rear/detachment, retinitis pigmentosa)\r&lt;br&gt;\r&lt;br&gt;          -  History of seizure disorder\r&lt;br&gt;\r&lt;br&gt;          -  History of ventricular tachycardia/fibrillation, history of long-QT syndrome, or ICD\r&lt;br&gt;\r&lt;br&gt;          -  Current creatinine clearance &lt;10 ml/min or on hemodialysis (as evidenced in EMR)\r&lt;br&gt;\r&lt;br&gt;          -  Known G6PD deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Current use of the following medications: digoxin, amiodarone, flecainide,\r&lt;br&gt;             procainamide, oral dapsone. If other meds of concern, route to pharmacist to evaluate\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant use of the following only at Pharmacist/Investigator discretion:\r&lt;br&gt;             Abiraterone acetate, agalsidase, conivaptan, dabrafenib, dacomitinib, dapsone\r&lt;br&gt;             (systemic), digoxin, enzalutamide, fexinidazole, flecainide, fusidic acid (systemic),\r&lt;br&gt;             idelalisib, mifepristone, mitotane, pimozide, amiodarone, digoxin, procainamide,\r&lt;br&gt;             propafenone, stiripentol\r&lt;br&gt;\r&lt;br&gt;          -  Currently on hospice\r&lt;br&gt;\r&lt;br&gt;          -  Women of childbearing potential must not be pregnant, and must avoid becoming pregnant\r&lt;br&gt;             while on treatment and for 30 days following treatment discontinuation. Men must avoid\r&lt;br&gt;             fathering a child while on treatment and for 30 days following treatment\r&lt;br&gt;             discontinuation\r&lt;br&gt;\r&lt;br&gt;          -  Any clinical factors such as bleeding, active infection, or psychiatric factors that\r&lt;br&gt;             in the judgment of the investigator would preclude safe participation and compliance\r&lt;br&gt;             with study procedures.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1) Aged 18 or above;\r&lt;br&gt;\r&lt;br&gt;          -  2) Laboratory-confirmed COVID-19 infection;\r&lt;br&gt;\r&lt;br&gt;          -  3) Pre-existing liver cirrhosis based on liver biopsy or clinical findings.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1) Pregnancy or unknown pregnancy status.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age = 18 years old.\r&lt;br&gt;\r&lt;br&gt;          2. Hospitalized patient (or documentation of a hospitalization plan if the patient is in\r&lt;br&gt;             an emergency department) with illness of more than 5 days of duration with evidence of\r&lt;br&gt;             pneumonia by chest radiography / tomography computed chest and meets at least one of\r&lt;br&gt;             the following requirements:\r&lt;br&gt;\r&lt;br&gt;               1. Non-critical patient with pneumonia in radiological progression and / or\r&lt;br&gt;\r&lt;br&gt;               2. Patient with progressive respiratory failure at the last 24-48 hours.\r&lt;br&gt;\r&lt;br&gt;          3. Laboratory confirmed SARS-CoV-2 infection (by PCR) or other commercialized analysis or\r&lt;br&gt;             public health in any sample collected 4 days before the randomization or COVID-19\r&lt;br&gt;             criteria following the defined diagnostic criteria at that time in the center.\r&lt;br&gt;\r&lt;br&gt;          4. Patient with a maximum O2 support of 35%\r&lt;br&gt;\r&lt;br&gt;          5. Be willing and able to comply with the study related procedures / evaluations.\r&lt;br&gt;\r&lt;br&gt;          6. Women of childbearing potential * should have a negative serum pregnancy test before\r&lt;br&gt;             enrollment in the study and must commit to using methods highly effective\r&lt;br&gt;             contraceptives (intrauterine device, bilateral tubal occlusion, vasectomized couple\r&lt;br&gt;             and sexual abstinence).\r&lt;br&gt;\r&lt;br&gt;          7. Written informed consent. In case of inability of the patient to sign the informed\r&lt;br&gt;             consent, a verbal informed consent from the legal representative or family witness (or\r&lt;br&gt;             failing this, an impartial witness outside the investigator team) will be obtained by\r&lt;br&gt;             phone.\r&lt;br&gt;\r&lt;br&gt;        When circumstances so allow, participants should sign the consent form. The confirmation of\r&lt;br&gt;        the verbal informed consent will be documented in a document as evidence that verbal\r&lt;br&gt;        consent has been obtained.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patient who, in the investigator's opinion, is unlikely to survive&gt; 48 hours after the\r&lt;br&gt;             inclusion in the study.\r&lt;br&gt;\r&lt;br&gt;          2. Presence of any of the following abnormal analytical values at the time of the\r&lt;br&gt;             inclusion in the study:\r&lt;br&gt;\r&lt;br&gt;               -  absolute neutrophil count less than 2000 / mm3;\r&lt;br&gt;\r&lt;br&gt;               -  AST or ALT&gt; 5 times the upper limit of normality;\r&lt;br&gt;\r&lt;br&gt;               -  platelets &lt;50,000 per mm3.\r&lt;br&gt;\r&lt;br&gt;          3. In active treatment with immunosuppressants or previous prolonged treatment (more 3\r&lt;br&gt;             months) of oral corticosteroids for a disease not related to COVID-19 at a dose\r&lt;br&gt;             greater than 10 mg of prednisone or equivalent per day.\r&lt;br&gt;\r&lt;br&gt;          4. Known active tuberculosis or known history of tuberculosis uncompleted treatment.\r&lt;br&gt;\r&lt;br&gt;          5. Patients with active systemic bacterial and / or fungal infections.\r&lt;br&gt;\r&lt;br&gt;          6. Participants who, at the investigator's discretion, are not eligible to participate,\r&lt;br&gt;             regardless of the reason, including medical or clinical conditions, or participants\r&lt;br&gt;             potentially at risk of not following study procedures.\r&lt;br&gt;\r&lt;br&gt;          7. Patients who do not have entry criteria in the Intensive Care Unit.\r&lt;br&gt;\r&lt;br&gt;          8. Pregnancy or lactation.\r&lt;br&gt;\r&lt;br&gt;          9. Known hypersensitivity to siltuximab or to any of its excipients (histidine, histidine\r&lt;br&gt;             hydrochloride, polysorbate 80 and sucrose).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Men and non-pregnant women aged 60 or over\r&lt;br&gt;\r&lt;br&gt;          -  Known diagnosis of hypertension\r&lt;br&gt;\r&lt;br&gt;          -  Current use of ACEi or ARB for the treatment of hypertension\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 nave (i.e. not known to be infected)\r&lt;br&gt;\r&lt;br&gt;          -  English speaker\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Known diabetic nephropathy\r&lt;br&gt;\r&lt;br&gt;          -  Known heart failure with reduced ejection fraction\r&lt;br&gt;\r&lt;br&gt;          -  Resistant hypertension (defined as blood pressure that remains above goal despite\r&lt;br&gt;             concurrent use of three anti-hypertensive agents of different classes, one of which\r&lt;br&gt;             should be a diuretic, or as blood pressure that is controlled with four or more\r&lt;br&gt;             medications)\r&lt;br&gt;\r&lt;br&gt;          -  Contraindications or allergies to CCB or Thiazide\r&lt;br&gt;\r&lt;br&gt;          -  Unconscious patients\r&lt;br&gt;\r&lt;br&gt;          -  Current psychiatric in-patients\r&lt;br&gt;\r&lt;br&gt;          -  Patients in an emergency medical setting\r&lt;br&gt;\r&lt;br&gt;          -  Inability to consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults of 18 years and above, both in the UK and internationally where the app has\r&lt;br&gt;             been approved for download from the Apple App store and Google Play. The web-based\r&lt;br&gt;             equivalent to the app will also be made available via a link for those unable to\r&lt;br&gt;             download.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Anyone below the age of 18; anyone unable to provide informed consent.\r&lt;br&gt;","\r&lt;br&gt;        INCLUSION CRITERIA\r&lt;br&gt;\r&lt;br&gt;          1. age &gt;=60 years OR age 18-59 years with one of the following conditions:\r&lt;br&gt;\r&lt;br&gt;               1. chronic lung disease\r&lt;br&gt;\r&lt;br&gt;               2. chronic cardiovascular disease\r&lt;br&gt;\r&lt;br&gt;               3. diabetes\r&lt;br&gt;\r&lt;br&gt;               4. malignancy diagnosed within 5 years prior to enrollment\r&lt;br&gt;\r&lt;br&gt;               5. chronic kidney disease\r&lt;br&gt;\r&lt;br&gt;          2. SARS-CoV-2 infection confirmed in RT-PCR (nasopharyngeal swab)\r&lt;br&gt;\r&lt;br&gt;          3. Hospitalization not required based on clinical judgement\r&lt;br&gt;\r&lt;br&gt;          4. Ability to participate in telemedical care\r&lt;br&gt;\r&lt;br&gt;        EXCLUSION CRITERIA\r&lt;br&gt;\r&lt;br&gt;          1. Lack of written informed consent\r&lt;br&gt;\r&lt;br&gt;          2. Possible failure to comply with the protocol\r&lt;br&gt;\r&lt;br&gt;          3. Chloroquine, hydroxychloroquine or other antiviral therapy within 3 months prior to\r&lt;br&gt;             enrollment\r&lt;br&gt;\r&lt;br&gt;          4. Contraindications to chloroquine (pregnancy, breast-feeding, severe renal\r&lt;br&gt;             insufficiency, amiodarone or anticolvunsants therapy, alcohol disease, haematological\r&lt;br&gt;             disorders, epilepsia, porphyria, liver disease/cirrhosis, retinopathy,\r&lt;br&gt;             fainting/syncope, myasthenia)\r&lt;br&gt;\r&lt;br&gt;          5. HIV infection\r&lt;br&gt;\r&lt;br&gt;          6. Concurrent participation in another interventional clinical trial\r&lt;br&gt;\r&lt;br&gt;          7. Hypersensitivity to chloroquine or drug excipients\r&lt;br&gt;\r&lt;br&gt;          8. Other relevant circumstances/conditions based on clinical judgement\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients included in the CORIMUNO-19 cohort\r&lt;br&gt;\r&lt;br&gt;          2. Patients belonging to one of the 2 following groups:\r&lt;br&gt;\r&lt;br&gt;               -  Group 1: patients not requiring ICU at admission with moderate and severe\r&lt;br&gt;                  pneumopathy according to the OMS Criteria of severity of COVID pneumopathy.\r&lt;br&gt;\r&lt;br&gt;        Moderate cases :\r&lt;br&gt;\r&lt;br&gt;        Cases meeting all of the following criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Showing fever and respiratory symptoms with radiological findings of pneumonia.\r&lt;br&gt;\r&lt;br&gt;          -  Requiring between 3L/min and 5L/min of oxygen to maintain SpO2 &gt;97% Severe cases\r&lt;br&gt;\r&lt;br&gt;        Cases meeting any of the following criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory distress (?30 breaths/ min);\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation=93% at rest in ambient air; or Oxygen saturation =97 % with O2 &gt;\r&lt;br&gt;             5L/min.\r&lt;br&gt;\r&lt;br&gt;          -  PaO2/FiO2?300mmHg\r&lt;br&gt;\r&lt;br&gt;          -  Group 2: patients requiring ICU based on Criteria of severity of COVID pneumopathy.\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory failure and requiring mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  No do-not-resuscitate order (DNR order)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with exclusion criteria to the CORIMUNO-19 cohort.\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to Tocilizumab or to any of their excipients.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Current documented bacterial infection\r&lt;br&gt;\r&lt;br&gt;          -  Patient with any of following laboratory results out of the ranges detailed below at\r&lt;br&gt;             screening should be discussed depending of the medication:\r&lt;br&gt;\r&lt;br&gt;          -  Absolute neutrophil count (ANC) = 1.0 x 109/L\r&lt;br&gt;\r&lt;br&gt;          -  Haemoglobin level: no limitation\r&lt;br&gt;\r&lt;br&gt;          -  Platelets (PLT) &lt; 50 G /L\r&lt;br&gt;\r&lt;br&gt;          -  SGOT or SGPT &gt; 5N\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Negative PCR and negative serology at day 0\r&lt;br&gt;\r&lt;br&gt;          -  Healthcare worker at Hospital Clnic de Barcelona\r&lt;br&gt;\r&lt;br&gt;          -  Female participants: negative for pregnancy test\r&lt;br&gt;\r&lt;br&gt;          -  Willing to participate in the study\r&lt;br&gt;\r&lt;br&gt;          -  Able to sign the informed consent form\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt;18 years\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  Ongoing antiviral or antiretroviral treatment or HIV positive\r&lt;br&gt;\r&lt;br&gt;          -  Ongoing anti-inflammatory treatment (NSAID, corticosteroids)\r&lt;br&gt;\r&lt;br&gt;          -  Ongoing chloroquine or hydroxychloroquine treatment\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed case of SARS-CoV-2 infection (positive PCR) at day 0\r&lt;br&gt;\r&lt;br&gt;          -  Positive serology for SARS-CoV-1 infection at day 0\r&lt;br&gt;\r&lt;br&gt;          -  Impossibility of signing the informed consent form\r&lt;br&gt;\r&lt;br&gt;          -  Rejection of participation\r&lt;br&gt;\r&lt;br&gt;          -  Working less than 5 days a week in the Hospital Clinic of Barcelona.\r&lt;br&gt;\r&lt;br&gt;          -  Any contraindication for hydroxychloroquine treatment:\r&lt;br&gt;\r&lt;br&gt;               -  Hydroxychloroquine hypersensitivity or 4-aminoquinoline hypersensitivity\r&lt;br&gt;\r&lt;br&gt;               -  Retinopathy, visual field or visual acuity disturbances\r&lt;br&gt;\r&lt;br&gt;               -  QT prolongation, bradycardia (&lt;50bpm), ventricular tachycardia, other\r&lt;br&gt;                  arrhythmias, as determined on day 0 ECG or medical history\r&lt;br&gt;\r&lt;br&gt;               -  Potassium &lt; 3 mEq/L or AST or ALT &gt; 5 upper normal limit, as determined on day 0\r&lt;br&gt;                  blood test\r&lt;br&gt;\r&lt;br&gt;               -  Previous myocardial infarction\r&lt;br&gt;\r&lt;br&gt;               -  Myasthenia gravis\r&lt;br&gt;\r&lt;br&gt;               -  Psoriasis or porphyria\r&lt;br&gt;\r&lt;br&gt;               -  Glomerular clearance &lt; 10ml/min\r&lt;br&gt;\r&lt;br&gt;               -  Previous history of severe hypoglycaemia\r&lt;br&gt;\r&lt;br&gt;               -  Ongoing treatment with: antimalarials, antiarrhythmic, tricyclic antidepressants,\r&lt;br&gt;                  natalizumab, quinolones, macrolides, agalsidase alfa and beta.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  UK resident\r&lt;br&gt;\r&lt;br&gt;          -  Age =16 years\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria: none\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Definitely positive COVID-19 patients\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Patients with acute respiratory problems including patients with:\r&lt;br&gt;\r&lt;br&gt;          1. Spo2&lt;60%\r&lt;br&gt;\r&lt;br&gt;          2. Severe respiratory distress\r&lt;br&gt;\r&lt;br&gt;          3. Heamodynamic instabilitty\r&lt;br&gt;\r&lt;br&gt;          4. Acid base disturbance\r&lt;br&gt;\r&lt;br&gt;          5. Severe Anemia Patients with severe hepatic diseases Patients with Nurvous system\r&lt;br&gt;             diseases\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 infection diagnosed by nasopharyngeal sample\r&lt;br&gt;\r&lt;br&gt;          -  Need for supplemental oxygen to maintain oxygen saturation &gt; 93%\r&lt;br&gt;\r&lt;br&gt;          -  12 years of age or older\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Neutrophils &lt; 1 x 10^9/L\r&lt;br&gt;\r&lt;br&gt;          -  Platelets &lt; 50 x 10^9/L\r&lt;br&gt;\r&lt;br&gt;          -  Serum total bilirubin &gt;2.0 x upper limit of normal (ULN)\r&lt;br&gt;\r&lt;br&gt;          -  Aspartate aminotransferase (AST), or alanine aminotransferase (ALT) &gt; 5x ULN\r&lt;br&gt;\r&lt;br&gt;          -  Creatinine clearance (CrCl) &lt; 15 mL/minute\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant women\r&lt;br&gt;\r&lt;br&gt;          -  Known HBV or HIV infection\r&lt;br&gt;\r&lt;br&gt;          -  Signs and symptoms of Varicella Zoster Virus (VZV) infection\r&lt;br&gt;\r&lt;br&gt;          -  Patients requiring invasive mechanical ventilation. Patients requiring non-invasive\r&lt;br&gt;             mechanical ventilation (e.g., BiPAP) are eligible.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who require supplemental oxygen support prior to COVID-19 infection.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are on ruxolitinib or similiar drugs.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults (age =18 years) who are or have been hospitalized and diagnosed with Severe\r&lt;br&gt;             Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection.\r&lt;br&gt;\r&lt;br&gt;          -  SARS-CoV-2 confirmed diagnosis (e.g. polymerase chain reaction [PCR] or other\r&lt;br&gt;             clinically utilized test).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        N/A\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. high probability CT thorax or chest X-ray for viral pneumonia within five days of the\r&lt;br&gt;             day of inclusion\r&lt;br&gt;\r&lt;br&gt;          2. positive COVID-19 nasopharyngeal swab within 10 days of inclusion\r&lt;br&gt;\r&lt;br&gt;          3. 18 years or older\r&lt;br&gt;\r&lt;br&gt;          4. Oxygen saturation of &lt; 93% in ambient air\r&lt;br&gt;\r&lt;br&gt;          5. Signed written informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Contra-indication for lung ultrasound\r&lt;br&gt;\r&lt;br&gt;          -  Other causes of hypoxia or of pulmonary infiltrates on CT thorax or chest X-ray\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. 18-70 years old (including 18 and 70 years old), regardless of gender;\r&lt;br&gt;\r&lt;br&gt;          2. Infection with new coronavirus pneumonia was confirmed by throat swab nucleic acid\r&lt;br&gt;             test. Patients with severe and critical illness were clinically judged. The symptoms\r&lt;br&gt;             of acute infection have been alleviated after treatment (at least 14 days after onset,\r&lt;br&gt;             no fever for more than 3 days), and the disease is recovering Within three months;\r&lt;br&gt;\r&lt;br&gt;          3. CT examination of patients with multiple fibrotic shadows in both lungs;\r&lt;br&gt;\r&lt;br&gt;          4. Blood routine, liver, and kidney functions are within the controllable range: such as\r&lt;br&gt;             the normal upper limit of plasma total bilirubin and creatinine = 1.5 times; AST, ALT,\r&lt;br&gt;             LDH = 2 times the normal upper limit; sufficient hematopoietic function: such as white\r&lt;br&gt;             blood cells =4.0  109 / L, platelets =100  109 / L;\r&lt;br&gt;\r&lt;br&gt;          5. Signed informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Previous history of chronic bronchitis, emphysema, interstitial lung disease or\r&lt;br&gt;             pulmonary heart disease;\r&lt;br&gt;\r&lt;br&gt;          2. Combining with other serious diseases: such as those who have suffered myocardial\r&lt;br&gt;             infarction and uncontrollable diabetes within 6 months, and are considered unsuitable\r&lt;br&gt;             to participate in the trial;\r&lt;br&gt;\r&lt;br&gt;          3. People with active peptic ulcer;\r&lt;br&gt;\r&lt;br&gt;          4. Patients during pregnancy and lactation\r&lt;br&gt;\r&lt;br&gt;          5. Patients with mental illness or others who cannot cooperate effectively;\r&lt;br&gt;\r&lt;br&gt;          6. Researcher judges uncomfortable to participate in trial\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Male and Female patients age 18 years or older\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 confirmed positive test results\r&lt;br&gt;\r&lt;br&gt;          -  High risk for complications including with Medium (5-6) or High (More than or equal to\r&lt;br&gt;             7) NEWS score\r&lt;br&gt;\r&lt;br&gt;          -  Hematology criteria: ANC &gt;500 cells/mcl, HGB &gt;9 g/dl, Platelet count &gt;75,000/mcl\r&lt;br&gt;\r&lt;br&gt;          -  Metabolic criteria: Serum creatinine &lt;2.0 mg/dl or calculated creatinine clearance\r&lt;br&gt;             (using Cockcroft-Gault) &gt;30 ml/min, AST/ALT &lt;5x ULN AND Total Bilirubin WNL (for\r&lt;br&gt;             patients with Gilbert's disease, direct bilirubin &lt;ULN)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 negative test result\r&lt;br&gt;\r&lt;br&gt;          -  Inability to adhere to study protocol requirements\r&lt;br&gt;\r&lt;br&gt;          -  Inability to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Other acute or chronic medical or psychiatric condition that in the judgment of the\r&lt;br&gt;             investigator would make the participant inappropriate to take part in the study\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant and breastfeeding individuals\r&lt;br&gt;\r&lt;br&gt;          -  QTc interval greater than 470 msecs at baseline\r&lt;br&gt;\r&lt;br&gt;          -  History of hypersensitivity to atovaquone and/or azithromycin.\r&lt;br&gt;\r&lt;br&gt;          -  History of known intolerance to atovaquone and/or azithromycin\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female, 18 years old = age = 75years old;\r&lt;br&gt;\r&lt;br&gt;          2. CT image is characteristic of 2019 novel coronavirus pneumonia;\r&lt;br&gt;\r&lt;br&gt;          3. Laboratory confirmation of 2019-nCoV infection by reverse transcription polymerase\r&lt;br&gt;             chain reaction (RT-PCR);\r&lt;br&gt;\r&lt;br&gt;          4. In compliance with the 2019-nCoV pneumonia diagnosis standard (according to the novel\r&lt;br&gt;             coronavirus infection pneumonia diagnosis and treatment program (Trial Implementation\r&lt;br&gt;             Version 6) issued by the National Health and Medical Commission, and WHO 2019 new\r&lt;br&gt;             coronavirus guidelines standards): (A) increased breathing rate (=30 beats / min),\r&lt;br&gt;             difficulty breathing, cyanosis of the lips; (B) in resting state, means oxygen\r&lt;br&gt;             saturation =93%; (C) partial pressure of arterial oxygen (PaO2) / Fraction of inspired\r&lt;br&gt;             oxygen (FiO2) =300 mmHg (1mmHg = 0.133kPa);\r&lt;br&gt;\r&lt;br&gt;          5. Participant or the authorized agent signed the informed consent form.\r&lt;br&gt;\r&lt;br&gt;          6. Agree to collect clinical samples.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Malignant disease in the past five years;\r&lt;br&gt;\r&lt;br&gt;          2. Participant with no hope of survival were clinically predicted and only received\r&lt;br&gt;             hospice care, or those who were in a deep coma and did not respond to supportive\r&lt;br&gt;             treatment measures within three hours of admission.\r&lt;br&gt;\r&lt;br&gt;          3. Participant who are participating in other clinical trials or who have participated in\r&lt;br&gt;             other clinical trials within 3 months.\r&lt;br&gt;\r&lt;br&gt;          4. Cases of severe shock and respiratory failure.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria :\r&lt;br&gt;\r&lt;br&gt;          -  &gt; 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Suspected of COVID-19 infection or having a systematic COVID-19 screening\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria :\r&lt;br&gt;\r&lt;br&gt;          -  Patients on whom the ultrasonographic examination is not feasible for technical\r&lt;br&gt;             reasons (morbid obesity, thoracic extensive subcutaneous emphysema, absorbent\r&lt;br&gt;             subcutaneous infiltrations, ...)\r&lt;br&gt;\r&lt;br&gt;          -  Patients with comorbidities justifying priority intensive care, not linked to the\r&lt;br&gt;             COVID-19 condition\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Signed informed consent, demonstrating that the subject understands the procedures\r&lt;br&gt;             required for the study and the purpose of the study\r&lt;br&gt;\r&lt;br&gt;          2. Healthy male or female subjects 18 years of age or older that are considered to be\r&lt;br&gt;             high-risk individuals. High-risk individuals are defined as all health care workers in\r&lt;br&gt;             hospitals, clinics, and emergency rooms, and medical facilities.\r&lt;br&gt;\r&lt;br&gt;          3. Subjects must agree to practice at least one highly effective method of birth control\r&lt;br&gt;             for the duration of the study\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Refusal to sign informed consent form\r&lt;br&gt;\r&lt;br&gt;          2. Any previous positive test for COVID-19 by PCR\r&lt;br&gt;\r&lt;br&gt;          3. Symptomatic for COVID-19\r&lt;br&gt;\r&lt;br&gt;          4. Diarrhea\r&lt;br&gt;\r&lt;br&gt;          5. Type I or II diabetes\r&lt;br&gt;\r&lt;br&gt;          6. Atherosclerotic Coronary Artery Disease\r&lt;br&gt;\r&lt;br&gt;          7. Any contraindication for treatment with Plaquenil\r&lt;br&gt;\r&lt;br&gt;          8. Any comorbidities which, in the opinion of the investigator, constitute health risk\r&lt;br&gt;             for the subject. These include congestive heart failure, cardiac arrhythmia, prior\r&lt;br&gt;             malignancy other than non-melanoma skin cancer, HIV positive, Hepatitis B Surface\r&lt;br&gt;             Antigen Positive, Hepatitis C, Inflammatory bowel disease, Tuberculosis, and any\r&lt;br&gt;             significant infection. Any other condition that in the investigator's opinion should\r&lt;br&gt;             not be enrolled.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Documented COVID-19 pneumonia: defined as upper respiratory tract specimen\r&lt;br&gt;             (nasopharyngeal swab (NPS) or viral throat swab) positive for COVID-19 and/or imaging\r&lt;br&gt;             at computed tomography scan suggestive of COVID-19 pneumonia\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation (SaO2) of 92% or less without oxygen support, or reduction of 3%\r&lt;br&gt;             from basal value of SaO2, or a ratio of the partial pressure of oxygen (PaO2) to the\r&lt;br&gt;             fraction of inspired oxygen (FiO2) (PaO2/FiO2) below 300.\r&lt;br&gt;\r&lt;br&gt;          -  Any gender\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt;= 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent or as per Ethical Committee indication in case of patients\r&lt;br&gt;             not able to express written informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Onset of COVID-19 pneumonia &gt;14 days\r&lt;br&gt;\r&lt;br&gt;          -  Orotracheal intubation\r&lt;br&gt;\r&lt;br&gt;          -  Uncontrolled systemic infection (other than COVID-19)\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant use of thrombolytic therapy Concomitant systemic anticoagulant therapy\r&lt;br&gt;             (e.g. heparin, warfarin, direct thrombin inhibitors and direct factor Xa inhibitors)\r&lt;br&gt;\r&lt;br&gt;          -  Haemodynamic instability, defined as inability to maintain mean arterial pressure with\r&lt;br&gt;             single pressor support\r&lt;br&gt;\r&lt;br&gt;          -  Hypersensitivity to the active substance or to any of the excipients of the\r&lt;br&gt;             experimental drug\r&lt;br&gt;\r&lt;br&gt;          -  Patients who, based on the investigator's clinical judgement, are not able to receive\r&lt;br&gt;             the treatment\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breastfeeding patient\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  who haven't been exercising before and also not thinking of exercising during the\r&lt;br&gt;             isolation period\r&lt;br&gt;\r&lt;br&gt;          -  Who are willing to exercise during the isolation\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Having a disease that may interfere or aggravated with exercise such as orthopaedic\r&lt;br&gt;             problems, chronic diseases, etc.\r&lt;br&gt;\r&lt;br&gt;          -  Having difficulty of understanding and following video-based exercises\r&lt;br&gt;\r&lt;br&gt;          -  Having diagnose of any kind of psychiatric condition such as major depression, panic\r&lt;br&gt;             attack, etc.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age = 18 years and = 64 years at the time of the assessment\r&lt;br&gt;\r&lt;br&gt;          2. Able and willing to understand the study, adhere to all study procedures, and provide\r&lt;br&gt;             written informed consent\r&lt;br&gt;\r&lt;br&gt;          3. Initial diagnosis of COVID-19 disease as defined by a FDA-cleared molecular diagnostic\r&lt;br&gt;             assay positive for SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          4. Display symptoms of COVID respiratory infection without respiratory distress\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are hospitalized for inpatient treatment or currently being evaluated for\r&lt;br&gt;             potential hospitalization at the time of initiation of informed consent\r&lt;br&gt;\r&lt;br&gt;               1. Patients with a known allergy to Peginterferon Lambda-1a or any component thereof\r&lt;br&gt;\r&lt;br&gt;               2. Room air oxygen saturation of &lt;92%\r&lt;br&gt;\r&lt;br&gt;               3. Participation in a clinical trial with or use of any investigational agent within\r&lt;br&gt;                  30 days before screening, or treatment with interferons (IFN) or immunomodulators\r&lt;br&gt;                  within 12 months before screening\r&lt;br&gt;\r&lt;br&gt;               4. Previous use of Peginterferon Lambda-1a\r&lt;br&gt;\r&lt;br&gt;               5. History or evidence of any intolerance or hypersensitivity to IFNs or other\r&lt;br&gt;                  substances contained in the study medication.\r&lt;br&gt;\r&lt;br&gt;               6. Female patients who are pregnant or breastfeeding. Male patients must confirm\r&lt;br&gt;                  that their female sexual partners are not pregnant.\r&lt;br&gt;\r&lt;br&gt;               7. Current or previous history of decompensated liver disease (Child-Pugh Class B or\r&lt;br&gt;                  C) or hepatocellular carcinoma\r&lt;br&gt;\r&lt;br&gt;               8. Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV)\r&lt;br&gt;\r&lt;br&gt;               9. Significant abnormal laboratory test results at screening.\r&lt;br&gt;\r&lt;br&gt;              10. Significant concurrent illnesses and other comorbidities that may require\r&lt;br&gt;                  intervention during the study\r&lt;br&gt;\r&lt;br&gt;              11. Concurrent use of any of the following medications:\r&lt;br&gt;\r&lt;br&gt;                    1. Therapy with an immunomodulatory agent\r&lt;br&gt;\r&lt;br&gt;                    2. Current use of heparin or Coumadin\r&lt;br&gt;\r&lt;br&gt;                    3. Received blood products within 30 days before study randomization\r&lt;br&gt;\r&lt;br&gt;                    4. Use of hematologic growth factors within 30 days before study randomization\r&lt;br&gt;\r&lt;br&gt;                    5. Systemic antibiotics, antifungals, or antivirals for treatment of active\r&lt;br&gt;                       infection within 14 days before study randomization\r&lt;br&gt;\r&lt;br&gt;                    6. Any prescription or herbal product that is not approved by the investigator\r&lt;br&gt;\r&lt;br&gt;                    7. Long-term treatment (&gt; 2 weeks) with agents that have a high risk for\r&lt;br&gt;                       nephrotoxicity or hepatotoxicity unless it is approved by the medical\r&lt;br&gt;                       monitor\r&lt;br&gt;\r&lt;br&gt;                    8. Receipt of systemic immunosuppressive therapy within 3 months before\r&lt;br&gt;                       screening\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Subject (or authorized legal representative) who can provide written informed consent\r&lt;br&gt;             before beginning any study procedure.\r&lt;br&gt;\r&lt;br&gt;          -  Understand and agree to abide by the study procedures.\r&lt;br&gt;\r&lt;br&gt;          -  Adult #18 years of age at the time of inclusion in the study.\r&lt;br&gt;\r&lt;br&gt;          -  Confirmation of SARS-CoV-2 infection by a microbiological test performed before\r&lt;br&gt;             randomization, no longer than 72 hours.\r&lt;br&gt;\r&lt;br&gt;          -  Severity 3-4 according to the WHO 7-point ordinal scale.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  ALT / AST&gt; 5 times the normal limit\r&lt;br&gt;\r&lt;br&gt;          -  Stage 4 chronic kidney disease (GFR &lt;30) or requiring dialysis.\r&lt;br&gt;\r&lt;br&gt;          -  Presence of comorbidities that imply a poor prognosis (according to clinical\r&lt;br&gt;             judgment).\r&lt;br&gt;\r&lt;br&gt;          -  Advanced dementia.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breastfeeding.\r&lt;br&gt;\r&lt;br&gt;          -  Anticipation of transfer to another center in the 12 hours at the beginning of the\r&lt;br&gt;             study.\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to study medication.\r&lt;br&gt;\r&lt;br&gt;          -  Serious or active bacterial infections or documented sepsis by pathogens other than\r&lt;br&gt;             SARS-CoV-2.\r&lt;br&gt;\r&lt;br&gt;          -  Streptococcus pneumoniae antigenuria positive before study start.\r&lt;br&gt;\r&lt;br&gt;          -  Neutropenia &lt;500 / mm3.\r&lt;br&gt;\r&lt;br&gt;          -  Thrombocytopenia &lt;100,000 / mm3.\r&lt;br&gt;\r&lt;br&gt;          -  History of diverticulosis.\r&lt;br&gt;\r&lt;br&gt;          -  Ongoing skin infection (eg, pyodermitis).\r&lt;br&gt;\r&lt;br&gt;          -  Transplanted patient under immunosuppressive treatment.\r&lt;br&gt;\r&lt;br&gt;          -  Previous evidence of latent untreated tuberculosis.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Evidence of a positive SARS-CoV-2 test and test results received within the previous\r&lt;br&gt;             three days\r&lt;br&gt;\r&lt;br&gt;          -  Not currently hospitalized\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to receive study drug by mail\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to return the internet-based study questionnaires at baseline, day 3,\r&lt;br&gt;             7, and 14 days\r&lt;br&gt;\r&lt;br&gt;          -  No known allergy or other contraindication to macrolides\r&lt;br&gt;\r&lt;br&gt;          -  Age 18 years or older at the time of enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Provision of informed consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        In order to be eligible to participate in this study, an individual must meet all of the\r&lt;br&gt;        following criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female, age &gt; 18 years\r&lt;br&gt;\r&lt;br&gt;          2. Positive COVID 19 test\r&lt;br&gt;\r&lt;br&gt;          3. Respiratory compromise defined by SpO2 &lt;93%\r&lt;br&gt;\r&lt;br&gt;          4. Ability to sign informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        An individual who meets any of the following criteria will be excluded from participation\r&lt;br&gt;        in this study:\r&lt;br&gt;\r&lt;br&gt;          1. Pregnancy\r&lt;br&gt;\r&lt;br&gt;          2. Untreated Pneumothorax\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:Fulfilling all the following criteria\r&lt;br&gt;\r&lt;br&gt;          1. Aged between 18 and 60 years, male or female.\r&lt;br&gt;\r&lt;br&gt;          2. Hospitalized participants with diagnosis for COVID 19 by Real Time - Polymerase Chain\r&lt;br&gt;             Reaction.\r&lt;br&gt;\r&lt;br&gt;          3. Without treatment.\r&lt;br&gt;\r&lt;br&gt;          4. Moderate cases according to the official guideline \"Pneumonia Diagnosis and Treatment\r&lt;br&gt;             Scheme for Novel Coronavirus Infection (Trial Version 6)\".\r&lt;br&gt;\r&lt;br&gt;          5. Confusion, Urea, Respiratory rate, Blood pressure-65 (CURB-65) &gt;= 2.\r&lt;br&gt;\r&lt;br&gt;          6. Sequential Organ Failure Assessment score (SOFA) &lt; 6.\r&lt;br&gt;\r&lt;br&gt;          7. Ability to understand and the willingness to sign a written informed consent document.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Female subjects who are pregnant or breastfeeding.\r&lt;br&gt;\r&lt;br&gt;          2. Patients with prior allergic reactions to transfusions.\r&lt;br&gt;\r&lt;br&gt;          3. Critical ill patients in intensive care units.\r&lt;br&gt;\r&lt;br&gt;          4. Patients with surgical procedures in the last 30 days.\r&lt;br&gt;\r&lt;br&gt;          5. Patients with active treatment for cancer (Radiotherapy or Chemotherapy).\r&lt;br&gt;\r&lt;br&gt;          6. HIV diagnosed patients with viral failure (detectable viral load&gt; 1000 copies / ml\r&lt;br&gt;             persistent, two consecutive viral load measurements within a 3 month interval, with\r&lt;br&gt;             medication adherence between measurements after at least 6 months of starting a new\r&lt;br&gt;             regimen antiretrovirals).\r&lt;br&gt;\r&lt;br&gt;          7. Patients who have suspicion or evidence of coinfections.\r&lt;br&gt;\r&lt;br&gt;          8. End-stage chronic kidney disease (Glomerular Filtration Rate &lt;15 ml / min / 1.73 m2).\r&lt;br&gt;\r&lt;br&gt;          9. Child Pugh C stage liver cirrhosis.\r&lt;br&gt;\r&lt;br&gt;         10. High cardiac output diseases.\r&lt;br&gt;\r&lt;br&gt;         11. Autoimmune diseases or Immunoglobulin A nephropathy.\r&lt;br&gt;\r&lt;br&gt;         12. Patients have any condition that in the judgement of the Investigators would make the\r&lt;br&gt;             subject inappropriate for entry into this study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All gender patients aged = 18 years;\r&lt;br&gt;\r&lt;br&gt;          -  Patients with SARS-CoV-2 infection confirmed by tests (RT-PCR) and pulmonary\r&lt;br&gt;             involvement, hospitalized, at the end of the initial phase of high viral load of\r&lt;br&gt;             COVID-19 (apyretic&gt; 72 hours and / or at least 7 days after onset of symptoms);\r&lt;br&gt;\r&lt;br&gt;          -  Worsening of respiratory exchanges such as to require non-invasive or invasive\r&lt;br&gt;             ventilation support (BCRSS score = 3).\r&lt;br&gt;\r&lt;br&gt;          -  High levels of IL-6 (&gt; 40 pg/mL) or alternatively CRP and/or ferritin and/or D-dimer\r&lt;br&gt;             and/or fibrinogen values higher than the reference values or rapidly increasing;\r&lt;br&gt;\r&lt;br&gt;          -  Signature of informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Alanine aminotransferase and/or Aspartate aminotransferase (ALT / AST) &gt; 5 times\r&lt;br&gt;             compared to normal laboratory values.\r&lt;br&gt;\r&lt;br&gt;          -  Presence of a chronic renal failure = 4 stage (glomerular filtrate values &lt;30\r&lt;br&gt;             ml/min/1.73 m2).\r&lt;br&gt;\r&lt;br&gt;          -  Presence of neutropenia (neutrophils count &lt; 500 / mm3).\r&lt;br&gt;\r&lt;br&gt;          -  Platelet count less than 50 x 103/L.\r&lt;br&gt;\r&lt;br&gt;          -  Documented sepsis from other pathogens other than SARS-CoV-2.\r&lt;br&gt;\r&lt;br&gt;          -  Presence of co-morbidities associated, in clinical judgment, with an unfavourable\r&lt;br&gt;             outcome.\r&lt;br&gt;\r&lt;br&gt;          -  Complicated diverticulitis and / or intestinal perforation.\r&lt;br&gt;\r&lt;br&gt;          -  Skin infection in progress (e.g. dermohypodermitis not controlled by antibiotic\r&lt;br&gt;             therapy).\r&lt;br&gt;\r&lt;br&gt;          -  Immuno-suppressive anti-rejection therapy.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or woman of childbearing age who does not use contraceptive and/or\r&lt;br&gt;             breastfeeding measures.\r&lt;br&gt;\r&lt;br&gt;          -  Previous ischemic attack or myocardial infarction.\r&lt;br&gt;\r&lt;br&gt;          -  NYHA class III or IV heart failure.\r&lt;br&gt;\r&lt;br&gt;          -  Severe depressive syndrome or other psychiatric disease which, in the opinion of the\r&lt;br&gt;             doctor, can preclude patient participation in the study.\r&lt;br&gt;\r&lt;br&gt;          -  Presence of known malignant neoplasms.\r&lt;br&gt;\r&lt;br&gt;          -  Clinically significant history of alcohol abuse or drug addiction which, in the\r&lt;br&gt;             opinion of the doctor, may preclude the subject's participation in the study.\r&lt;br&gt;\r&lt;br&gt;          -  Any condition which, in the opinion of the doctor, precludes the possibility of using\r&lt;br&gt;             the study drug provided for in the RCP.\r&lt;br&gt;\r&lt;br&gt;          -  Any other laboratory condition or parameter that, in the doctor's judgment, precludes\r&lt;br&gt;             the subject's participation in the study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria\r&lt;br&gt;\r&lt;br&gt;          1. Patients 18 years and older\r&lt;br&gt;\r&lt;br&gt;          2. Confirmed SARS-CoV-2 Infection by RT-PCR.\r&lt;br&gt;\r&lt;br&gt;          3. Serious or life-threatening infection defined as:\r&lt;br&gt;\r&lt;br&gt;             Serious:\r&lt;br&gt;\r&lt;br&gt;               1. Dyspnea\r&lt;br&gt;\r&lt;br&gt;               2. Respiratory rate greater than or equal to 30 cycles / minute.\r&lt;br&gt;\r&lt;br&gt;               3. Blood oxygen saturation less than or equal to 93% with an oxygen supply greater\r&lt;br&gt;                  than 60%.\r&lt;br&gt;\r&lt;br&gt;               4. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt; 300\r&lt;br&gt;\r&lt;br&gt;               5. A 50% increase in pulmonary infiltrates defined by computer tomography scans in\r&lt;br&gt;                  24 to 48 hours.\r&lt;br&gt;\r&lt;br&gt;                  Life-threatening infection:\r&lt;br&gt;\r&lt;br&gt;               6. respiratory failure.\r&lt;br&gt;\r&lt;br&gt;               7. septic shock.\r&lt;br&gt;\r&lt;br&gt;               8. dysfunction or multiple organ failure.\r&lt;br&gt;\r&lt;br&gt;          4. Refractory to treatment with azithromycin / hydroxychloroquine or chloroquine /\r&lt;br&gt;             ritonavir / lopinavir defined as: 48 hours with no improvement in the modified\r&lt;br&gt;             parameters such as serious or clinically imminent infection.\r&lt;br&gt;\r&lt;br&gt;          5. Signed Informed consent by the patient or by the person responsible for the patient in\r&lt;br&gt;             the case of critically ill patients (spouse or parents).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with a history of allergic reaction to any type of previous transfusion.\r&lt;br&gt;\r&lt;br&gt;          2. Heart failure patients at risk of volume overload.\r&lt;br&gt;\r&lt;br&gt;          3. Patients with a history of chronic kidney failure in the dialysis phase.\r&lt;br&gt;\r&lt;br&gt;          4. Patients with previous hematological diseases (anemia less than 10 grams of\r&lt;br&gt;             hemoglobin, platelets greater than 100,000 / l).\r&lt;br&gt;\r&lt;br&gt;          5. Any case where the investigator decides that the patient is not suitable for the\r&lt;br&gt;             protocol.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;         Health Care workers with high exposure to COVID-19 patients\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to hydroxychloroquine or bromhexine\r&lt;br&gt;\r&lt;br&gt;          -  History of bone marrow transplant\r&lt;br&gt;\r&lt;br&gt;          -  Known G6PD deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Chronic hemodialysis or Glomerular Filtration Rate &lt; 20ml/min\r&lt;br&gt;\r&lt;br&gt;          -  Psoriasis\r&lt;br&gt;\r&lt;br&gt;          -  Porphyria\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone\r&lt;br&gt;\r&lt;br&gt;          -  Known history of long QT syndrome\r&lt;br&gt;\r&lt;br&gt;          -  Current known QTc&gt;500 msec\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or nursing\r&lt;br&gt;\r&lt;br&gt;          -  Severe liver disease\r&lt;br&gt;\r&lt;br&gt;          -  Seizure disorder\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Must be =18 years at the time of signing the informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Understand and voluntarily sign an informed consent document prior to any study\r&lt;br&gt;             related assessments/procedures\r&lt;br&gt;\r&lt;br&gt;          -  Able to adhere to the study visit schedule and other protocol requirements\r&lt;br&gt;\r&lt;br&gt;          -  Mild COVID-19 with outpatient management as decided by the treating physician\r&lt;br&gt;\r&lt;br&gt;          -  Early warning score for 2019-nCoV infected patients = 5\r&lt;br&gt;\r&lt;br&gt;          -  Females of childbearing potential (FCBP1) must agree\r&lt;br&gt;\r&lt;br&gt;          -  to utilize two reliable forms of contraception simultaneously or practice complete\r&lt;br&gt;             abstinence from heterosexual contact for at least 28 days before starting study drug,\r&lt;br&gt;             while participating in the study (including dose interruptions), and for at least 28\r&lt;br&gt;             days after study treatment discontinuation and must agree to regular pregnancy testing\r&lt;br&gt;             during this timeframe\r&lt;br&gt;\r&lt;br&gt;          -  to abstain from breastfeeding during study participation and 28 days after study drug\r&lt;br&gt;             discontinuation\r&lt;br&gt;\r&lt;br&gt;          -  All subjects must agree to refrain from donating blood while on study drug and for 28\r&lt;br&gt;             days after discontinuation from this study treatment\r&lt;br&gt;\r&lt;br&gt;          -  All subjects must agree not to share medication\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Requirement for oxygen administration\r&lt;br&gt;\r&lt;br&gt;          -  Shortness of breath in resting position\r&lt;br&gt;\r&lt;br&gt;          -  Creatinin &gt; 2.0 mg/dl\r&lt;br&gt;\r&lt;br&gt;          -  Women during pregnancy and lactation\r&lt;br&gt;\r&lt;br&gt;          -  Participation in other clinical trials or observation period of competing trials\r&lt;br&gt;\r&lt;br&gt;          -  Active or clinically significant cardiac disease including congestive heart failure\r&lt;br&gt;             (New York Heart Association Class III or higher)\r&lt;br&gt;\r&lt;br&gt;          -  History or current evidence of clinically significant cardiac arrhythmia except atrial\r&lt;br&gt;             fibrillation or paroxysmal supraventricular tachycardia\r&lt;br&gt;\r&lt;br&gt;          -  Use of concomitant medications that prolong the QT/QTc interval\r&lt;br&gt;\r&lt;br&gt;          -  Physician decision that involvement in the study is not in the patients best interest\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  patients with COVID-19: detection of SARS-CoV-2 by PCR in naso- or oropharyngeal swab\r&lt;br&gt;             or sputum, no age limit\r&lt;br&gt;\r&lt;br&gt;          -  control group: any respiratory tract infection not caused by SARS-CoV-2, no age limit\r&lt;br&gt;\r&lt;br&gt;          -  informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  no respiratory tract infection and no detection of SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  no informed consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Aged between 18 and 60 years.\r&lt;br&gt;\r&lt;br&gt;          -  Able to understand the content of informed consent and willing to sign the informed\r&lt;br&gt;             consent\r&lt;br&gt;\r&lt;br&gt;          -  Able and willing to complete all the secluded study process during the whole 6 months\r&lt;br&gt;             study follow-up period.\r&lt;br&gt;\r&lt;br&gt;          -  Negative in HIV diagnostic test.\r&lt;br&gt;\r&lt;br&gt;          -  Negative in serum antibodies (IgG and IgM) screening of COVID-19.\r&lt;br&gt;\r&lt;br&gt;          -  Axillary temperature =37.0C.\r&lt;br&gt;\r&lt;br&gt;          -  The BMI index is 18.5-30.0.\r&lt;br&gt;\r&lt;br&gt;          -  General good health as established by medical history and physical examination.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Family history of seizure, epilepsy, brain or mental disease\r&lt;br&gt;\r&lt;br&gt;          -  Subject allergic to any component of the investigational vaccine, or a more severe\r&lt;br&gt;             allergic reaction and history of allergies in the past.\r&lt;br&gt;\r&lt;br&gt;          -  Woman who is pregnant, breast-feeding or positive in -HCG (human chorionic\r&lt;br&gt;             gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during\r&lt;br&gt;             the next 6 months\r&lt;br&gt;\r&lt;br&gt;          -  Any acute fever disease or infections.\r&lt;br&gt;\r&lt;br&gt;          -  History of SARS\r&lt;br&gt;\r&lt;br&gt;          -  Major congenital defects or not well-controlled chronic illness, such as asthma,\r&lt;br&gt;             diabetes, or thyroid disease.\r&lt;br&gt;\r&lt;br&gt;          -  Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial\r&lt;br&gt;             infarction, severe hypertension without controllable drugs, etc.\r&lt;br&gt;\r&lt;br&gt;          -  Hereditary angioneurotic edema or acquired angioneurotic edema\r&lt;br&gt;\r&lt;br&gt;          -  Urticaria in last one year\r&lt;br&gt;\r&lt;br&gt;          -  No spleen or functional spleen.\r&lt;br&gt;\r&lt;br&gt;          -  Platelet disorder or other bleeding disorder may cause injection contraindication\r&lt;br&gt;\r&lt;br&gt;          -  Faint at the sight of needles.\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of immunodepressant or corticosteroids, antianaphylaxis\r&lt;br&gt;             treatment, cytotoxic treatment in last 6 months.\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of blood products in last 4 months\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of other research medicines in last 1 month\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of attenuated vaccine in last 1 month\r&lt;br&gt;\r&lt;br&gt;          -  Prior administration of inactivated vaccine in last 14 days\r&lt;br&gt;\r&lt;br&gt;          -  Current anti-tuberculosis prophylaxis or therapy\r&lt;br&gt;\r&lt;br&gt;          -  According to the judgement of investigator,various medical, psychological, social or\r&lt;br&gt;             other conditions, those could affect the subjects to sign informed consent.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  20 years and older\r&lt;br&gt;\r&lt;br&gt;          -  Hospital and RBHS healthcare workers who have regular direct patient contact (=3\r&lt;br&gt;             patients/shift) in emergency rooms or inpatient settings that is expected to continue\r&lt;br&gt;             regularly over the next =3 months and who work =20 hours in the hospital weekly\r&lt;br&gt;             (residents, clinical fellows, attending physicians, nurse practitioners, physician\r&lt;br&gt;             assistants, registered nurses, license practice nurses, medical technicians,\r&lt;br&gt;             respiratory therapists, physical therapists, clinical pharmacists, dentists, dental\r&lt;br&gt;             hygienists, or dental assistants)\r&lt;br&gt;\r&lt;br&gt;          -  Hospital workers who do not have patient contact and non-healthcare from the Rutgers\r&lt;br&gt;             faculty, postdoctoral students, administrators, and staff.\r&lt;br&gt;\r&lt;br&gt;          -  Household members in a subset of the participants who test positive and negative for\r&lt;br&gt;             SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Previous diagnosis with COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or have been diagnosed with a new medical condition in the past 30 days or\r&lt;br&gt;             have had a change in medications in the past 30 days\r&lt;br&gt;\r&lt;br&gt;          -  Participants who have been hospitalized in the past 30 days, had and had an emergency\r&lt;br&gt;             room, urgent care visit, or have had surgery.\r&lt;br&gt;\r&lt;br&gt;          -  Participants who have a fever on the day of their first visit to the study site (for\r&lt;br&gt;             consent, biospecimen collection, etc.).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with proven SARS-CoV-2 infection by an accepted assay with symptoms\r&lt;br&gt;             consistent with COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Ability to measure and quantify viral load by quantitative PCR\r&lt;br&gt;\r&lt;br&gt;          -  Temperature &gt;100.6F\r&lt;br&gt;\r&lt;br&gt;          -  Age 18 to 89\r&lt;br&gt;\r&lt;br&gt;          -  Ability to swallow oral medications\r&lt;br&gt;\r&lt;br&gt;          -  Patients must read, understand and sign IRB approved informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or women who are breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  Two consecutive negative assays for SARS-CoV-2 infection\r&lt;br&gt;\r&lt;br&gt;          -  Patients that lack decision-making capacity will not be approached to participate in\r&lt;br&gt;             this study\r&lt;br&gt;\r&lt;br&gt;          -  Inability to tolerate oral medications\r&lt;br&gt;\r&lt;br&gt;          -  Allergy or prior adverse reaction to either azithromycin or hydroxychloroquine sulfate\r&lt;br&gt;\r&lt;br&gt;          -  QTc interval &gt; 470 mSEC\r&lt;br&gt;\r&lt;br&gt;          -  History of ongoing ventricular cardiac dysrhythmias of grade 2 as described by NCI\r&lt;br&gt;             CTCAE 5.0 criteria\r&lt;br&gt;\r&lt;br&gt;          -  History of serious ventricular arrhythmia (VT or VF &gt; 3 beats in a row)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All subject except excluded group\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  subject diagnosed as COVID-19 positive and their contacts\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Children &lt; 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Admitted in French pediatric wards\r&lt;br&gt;\r&lt;br&gt;          -  With a confirmed COVID-19 infection. ( on Nasal and pharyngeal swab specimens or blood\r&lt;br&gt;             samples tested positive for 2019-nCoV nucleic acid using real-time\r&lt;br&gt;             reverse-transcriptase polymerase-chain-reaction (RT- PCR) assay; or on typical chest\r&lt;br&gt;             CT signs\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Expressed refusal to participate\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 positive inpatient (PCR or other certified test mandatory) 72h at least\r&lt;br&gt;             before randomization.\r&lt;br&gt;\r&lt;br&gt;          -  Inpatient showing at least one of the following criterion: Abnormal respiratory\r&lt;br&gt;             auscultation AND SpO2 &lt; 94% without oxygen therapy, OR Acute Respiratory failure\r&lt;br&gt;             requiring either oxygen therapy or high-flow oxygen therapy or non-invasive respirator\r&lt;br&gt;             and/or invasive respirator.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Inpatient requiring legal protection\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breastfeeding woman\r&lt;br&gt;\r&lt;br&gt;          -  Intensive care inpatient or patient undergoing surgery\r&lt;br&gt;\r&lt;br&gt;        Secondary non inclusion criteria :\r&lt;br&gt;\r&lt;br&gt;        - Unintentional blinding removal.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients between 18-80 years\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed HCoV-19 infection\r&lt;br&gt;\r&lt;br&gt;          -  Temperature above 38.0o C\r&lt;br&gt;\r&lt;br&gt;          -  Pulmonary symptoms and signs, at least one of the following before clinical decision\r&lt;br&gt;             for intubation and respirator treatment:\r&lt;br&gt;\r&lt;br&gt;               1. Respiratory distress, RR = 30/min;\r&lt;br&gt;\r&lt;br&gt;               2. Oxygen saturation = 93% at rest state;\r&lt;br&gt;\r&lt;br&gt;               3. Arterial partial pressure of oxygen (PaO2) / Fraction of inspiration O2 (FiO2) =\r&lt;br&gt;                  300mmHg, 1mmHg=0.133kPa\r&lt;br&gt;\r&lt;br&gt;          -  Pneumonia that is judged by chest radiograph or computed tomography\r&lt;br&gt;\r&lt;br&gt;          -  In respirator and possible for treatment within the first 24 hours\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients that have need for additional immunosuppressive treatment\r&lt;br&gt;\r&lt;br&gt;          -  Patients with any past (within the past 3-5 years) or present malignancy (other than\r&lt;br&gt;             excised basal cell carcinoma).\r&lt;br&gt;\r&lt;br&gt;          -  Co-Infection with other infectious agent.\r&lt;br&gt;\r&lt;br&gt;          -  Females capable of becoming pregnant must have a negative pregnancy test prior to\r&lt;br&gt;             treatment. After inclusion, they must use contraceptives for 2 months following the\r&lt;br&gt;             given stem cell treatment. The pill, spiral, depot injection of progesterone,\r&lt;br&gt;             sub-dermal implantation, hormonal vaginal ring and transdermal patch regarded as safe\r&lt;br&gt;             contraceptives.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are participating in other clinical trials.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients included in the CORIMUNO-19 cohort (NCT04324047)\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 cases not requiring ICU at admission with moderate or severe pneumopathy\r&lt;br&gt;             according to the WHO Criteria of severity of COVID pneumopathy:\r&lt;br&gt;\r&lt;br&gt;               -  Moderate cases: Cases meeting all of the following criteria: [Showing fever and\r&lt;br&gt;                  respiratory symptoms with radiological findings of pneumonia] AND [Requiring\r&lt;br&gt;                  between 3L/min and 5L/min of oxygen to maintain SpO2&gt;97%] OR\r&lt;br&gt;\r&lt;br&gt;               -  Severe cases: Cases meeting any of the following criteria: [Respiratory distress\r&lt;br&gt;                  ( = 30 breaths/ min)] OR [Oxygen saturation=93% at rest in ambient air; or Oxygen\r&lt;br&gt;                  saturation =97 % with O2 &gt; 5L/min] OR [PaO2/FiO2 = 300mmHg]\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with exclusion criteria to the CORIMUNO-19 cohort.\r&lt;br&gt;\r&lt;br&gt;          2. Respiratory failure requiring non invasive or mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          3. Patients requiring intensive care\r&lt;br&gt;\r&lt;br&gt;          4. Do-not-resuscitate order (DNR order)\r&lt;br&gt;\r&lt;br&gt;          5. Known hypersensitivity to sarilumab or to any of their excipients.\r&lt;br&gt;\r&lt;br&gt;          6. Known contra-indication to hydroxychloroquine or chloroquine: including\r&lt;br&gt;             hypersensitivity/allergy, retinopathy, G6PD deficiency and QT prolongation\r&lt;br&gt;\r&lt;br&gt;          7. Known contra-indication to azithromycin: including hypersensitivity/allergy and QT\r&lt;br&gt;             prolongation\r&lt;br&gt;\r&lt;br&gt;          8. Pregnancy or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          9. Current documented bacterial infection.\r&lt;br&gt;\r&lt;br&gt;         10. Patient with any of following laboratory results out of the ranges detailed below at\r&lt;br&gt;             screening should be discussed depending of the medication:\r&lt;br&gt;\r&lt;br&gt;               -  Absolute neutrophil count (ANC) = 1.0 x 109/L\r&lt;br&gt;\r&lt;br&gt;               -  Haemoglobin level: no limitation\r&lt;br&gt;\r&lt;br&gt;               -  Platelets (PLT) &lt; 50 G /L\r&lt;br&gt;\r&lt;br&gt;               -  SGOT or SGPT &gt; 5N\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age =18 years\r&lt;br&gt;\r&lt;br&gt;          2. Currently hospitalized or in an emergency department with anticipated hospitalization.\r&lt;br&gt;\r&lt;br&gt;          3. Symptoms of acute respiratory infection, defined as one or more of the following:\r&lt;br&gt;\r&lt;br&gt;               1. cough\r&lt;br&gt;\r&lt;br&gt;               2. fever (&gt; 37.5 C / 99.5 F)\r&lt;br&gt;\r&lt;br&gt;               3. shortness of breath\r&lt;br&gt;\r&lt;br&gt;               4. sore throat\r&lt;br&gt;\r&lt;br&gt;          4. Laboratory-confirmed SARS-CoV-2 infection within the past 10 days or SARS-CoV-2\r&lt;br&gt;             laboratory test result pending plus a high clinical suspicion for COVID-19 as\r&lt;br&gt;             indicated by fulfilling all of the following:\r&lt;br&gt;\r&lt;br&gt;               1. Cough with duration =10 days\r&lt;br&gt;\r&lt;br&gt;               2. Bilateral pulmonary infiltrates on chest imaging (radiograph, or computed\r&lt;br&gt;                  tomography or ultrasound) or new hypoxemia defined as SpO2 =94% on room air\r&lt;br&gt;\r&lt;br&gt;               3. No alternative explanation for symptoms of acute respiratory infection\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Prisoner\r&lt;br&gt;\r&lt;br&gt;          2. Pregnancy\r&lt;br&gt;\r&lt;br&gt;          3. Breast feeding\r&lt;br&gt;\r&lt;br&gt;          4. Symptoms of acute respiratory infection for &gt;10 days before randomization\r&lt;br&gt;\r&lt;br&gt;          5. &gt;48 hours between meeting inclusion criteria and randomization\r&lt;br&gt;\r&lt;br&gt;          6. Seizure disorder\r&lt;br&gt;\r&lt;br&gt;          7. Porphyria cutanea tarda\r&lt;br&gt;\r&lt;br&gt;          8. Diagnosis of Long QT syndrome\r&lt;br&gt;\r&lt;br&gt;          9. QTc &gt;500 ms on electrocardiogram within 72 hours prior to enrollment\r&lt;br&gt;\r&lt;br&gt;         10. Known allergy to hydroxychloroquine, chloroquine, or amodiaquine\r&lt;br&gt;\r&lt;br&gt;         11. Receipt in the 12 hours prior to enrollment, or planned administration during the\r&lt;br&gt;             5-day study period that treating clinicians feel cannot be substituted for another\r&lt;br&gt;             medication, of any of the following: amiodarone; cimetidine; dofetilide;\r&lt;br&gt;             phenobarbital; phenytoin; sotalol\r&lt;br&gt;\r&lt;br&gt;         12. Receipt of &gt;1 dose of hydroxychloroquine or chloroquine in the 10 days prior to\r&lt;br&gt;             enrollment\r&lt;br&gt;\r&lt;br&gt;         13. Inability to receive enteral medications\r&lt;br&gt;\r&lt;br&gt;         14. Inability to be contacted on Day 15 for clinical outcome assessment\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Adult male and female healthcare workers = 18 to = 75 years of age upon study consent\r&lt;br&gt;\r&lt;br&gt;          2. Healthcare workers with\r&lt;br&gt;\r&lt;br&gt;              One day or more of exposure to suspect and/or positive COVID-19 patients, including\r&lt;br&gt;             but not limited to those working in the Emergency Department or Intensive Care Unit.\r&lt;br&gt;\r&lt;br&gt;             OR\r&lt;br&gt;\r&lt;br&gt;              Unprotected exposure to a known positive COVID-19 patient within 72 hours of\r&lt;br&gt;             screening.\r&lt;br&gt;\r&lt;br&gt;          3. Afebrile with no constitutional symptoms\r&lt;br&gt;\r&lt;br&gt;          4. Willing and able to comply with scheduled visits, treatment plan, and other study\r&lt;br&gt;             procedures\r&lt;br&gt;\r&lt;br&gt;          5. Evidence of a personally signed and dated informed consent document indicating that\r&lt;br&gt;             the subject (or a legally acceptable representative) has been informed of all\r&lt;br&gt;             pertinent aspects of the study prior to initiation of any subject-mandated procedures\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Participation in other investigational clinical trials for the treatment or prevention\r&lt;br&gt;             of SARS-COV-2 infection within 30days\r&lt;br&gt;\r&lt;br&gt;          2. Unwilling to practice acceptable methods of birth control (both males who have\r&lt;br&gt;             partners of childbearing potential and females of childbearing potential) during\r&lt;br&gt;             Screening, while taking study drug, and for at least 30 days after the last dose of\r&lt;br&gt;             study drug is ingested Note: the following criteria follow standard clinical practice\r&lt;br&gt;             for FDA approved indications of this medication\r&lt;br&gt;\r&lt;br&gt;          3. Having a prior history of blood disorders such as aplastic anemia, agranulocytosis,\r&lt;br&gt;             leukopenia, or thrombocytopenia\r&lt;br&gt;\r&lt;br&gt;          4. Having a prior history of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency\r&lt;br&gt;\r&lt;br&gt;          5. Having dermatitis, psoriasis or porphyria\r&lt;br&gt;\r&lt;br&gt;          6. Taking Digoxin, Mefloquine, methotrexate, cyclosporine, praziquantel, antacids and\r&lt;br&gt;             kaolin, cimetidine, ampicillin, Insulin or antidiabetic drugs, arrhythmogenic drugs,\r&lt;br&gt;             antiepileptic drugs, loop, thiazide, and related diuretics, laxatives and enemas,\r&lt;br&gt;             amphotericin B, high dose corticosteroids, and proton pump inhibitors, neostigmine,\r&lt;br&gt;             praziquantel, Pyridostigmine, tamoxifen citrate\r&lt;br&gt;\r&lt;br&gt;          7. Allergies: 4-Aminoquinolines\r&lt;br&gt;\r&lt;br&gt;          8. Pre-existing retinopathy of the eye\r&lt;br&gt;\r&lt;br&gt;          9. Has a chronic liver disease or cirrhosis, including hepatitis B and/or untreated\r&lt;br&gt;             hepatitis\r&lt;br&gt;\r&lt;br&gt;         10. Untreated or uncontrolled active bacterial, fungal infection\r&lt;br&gt;\r&lt;br&gt;         11. Known or suspected active drug or alcohol abuse, per investigator judgment\r&lt;br&gt;\r&lt;br&gt;         12. Women who are pregnant or breastfeeding\r&lt;br&gt;\r&lt;br&gt;         13. Known hypersensitivity to any component of the study drug\r&lt;br&gt;\r&lt;br&gt;         14. A known history of prolonged QT syndrome or history of additional risk factors for\r&lt;br&gt;             torsades de pointe (e.g., heart failure, requires a lab test , family history of Long\r&lt;br&gt;             QT Syndrome), or the use of concomitant medications that prolong the QT/QTc interval\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Confirmed COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;          2. Age =/&gt;40 or diabetes or known coronary disease or hypertension\r&lt;br&gt;\r&lt;br&gt;          3. Requires hospital admission for further clinical management.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Clear evidence of cardiac pathology needing ACS treatment.\r&lt;br&gt;\r&lt;br&gt;          2. Myocarditis with serum Troponin &gt; 5000\r&lt;br&gt;\r&lt;br&gt;          3. Bleeding risk suspected e.g. recent surgery, history of GI bleed, other abnormal blood\r&lt;br&gt;             results (Hb&lt;10g/dl, Plts &lt;100, any evidence of DIC)\r&lt;br&gt;\r&lt;br&gt;          4. Study treatment may negatively impact standard best care (physician discretion).\r&lt;br&gt;\r&lt;br&gt;          5. Unrelated co-morbidity with life expectancy &lt;3 months.\r&lt;br&gt;\r&lt;br&gt;          6. Pregnancy.\r&lt;br&gt;\r&lt;br&gt;          7. Age &lt;18 years and &gt;85 years.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt; 18 years old\r&lt;br&gt;\r&lt;br&gt;               -  Collection of the subject's non-opposition\r&lt;br&gt;\r&lt;br&gt;               -  Patient registration on Vik breast, Vik asthma, Vik migraine, Vik depression\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient unable to formulate non-opposition\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  admission to the intensive care unit,\r&lt;br&gt;\r&lt;br&gt;          -  with a proven COVID infection, responsible for acute respiratory failure\r&lt;br&gt;\r&lt;br&gt;          -  agree with participation to the study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  aged under 18\r&lt;br&gt;\r&lt;br&gt;          -  under legal protection\r&lt;br&gt;\r&lt;br&gt;          -  pregnant or breastfeeding\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Older than 18 years of age and without symptoms associated with corona-virus (or\r&lt;br&gt;             previously tested positive for corona).\r&lt;br&gt;\r&lt;br&gt;          -  Participant is outside their home more than 3 hours a day. E.g.for work or for other\r&lt;br&gt;             activities among other people.\r&lt;br&gt;\r&lt;br&gt;          -  Have not experienced any fever in the last month\r&lt;br&gt;\r&lt;br&gt;          -  Do not normally wear a facial mask for daily work (e.g. healthcare personnel)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Previously tested positive for corona-virus\r&lt;br&gt;\r&lt;br&gt;          -  Have had a fever in the last month\r&lt;br&gt;\r&lt;br&gt;          -  Wear facial mask for work\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  patients hospitalized with suspected SARS-CoV-2 (COVID-19) infection\r&lt;br&gt;\r&lt;br&gt;          -  Eligible for different sampling methods\r&lt;br&gt;\r&lt;br&gt;          -  Beneficiary subject affiliated or entitled to a social security scheme\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Minor patient\r&lt;br&gt;\r&lt;br&gt;          -  Refusal to participate\r&lt;br&gt;\r&lt;br&gt;          -  Patient under guardianship\r&lt;br&gt;\r&lt;br&gt;          -  Patient under guardianship\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breastfeeding woman\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Female and male patients over the age of 18.\r&lt;br&gt;\r&lt;br&gt;          2. Confirmed COVID-19 infection by PCR analysis.\r&lt;br&gt;\r&lt;br&gt;          3. Hospitalized at Hasharon Medical Center.\r&lt;br&gt;\r&lt;br&gt;          4. Display moderate to severe symptoms of respiratory infection.\r&lt;br&gt;\r&lt;br&gt;          5. Willing and able to convey informed consent.\r&lt;br&gt;\r&lt;br&gt;          6. Willing and able to comply with all study procedures\r&lt;br&gt;\r&lt;br&gt;          7. Female patients of childbearing potential and male patients with partners of\r&lt;br&gt;             childbearing potential must agree to use adequate methods of contraception during the\r&lt;br&gt;             study and through 90 days after the last dose of study medication. Female patients of\r&lt;br&gt;             childbearing potential are all those except patients who are surgically sterile, who\r&lt;br&gt;             have medically documented ovarian failure, or who are at least 1 year postmenopausal.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Treatment with interferons, immunomodulators and/or immunosuppressive or B-cell\r&lt;br&gt;             depleting medications within 12 months before screening.\r&lt;br&gt;\r&lt;br&gt;          2. Previous receipt of Piclidenoson.\r&lt;br&gt;\r&lt;br&gt;          3. Patients with respiratory infection requiring invasive or non-invasive ventilatory\r&lt;br&gt;             support (bipap or intubation and mechanical ventilation).\r&lt;br&gt;\r&lt;br&gt;          4. Participation in a clinical trial with use of any investigational drug within 30 days\r&lt;br&gt;             before screening.\r&lt;br&gt;\r&lt;br&gt;          5. History of any of the following diseases or conditions:\r&lt;br&gt;\r&lt;br&gt;               -  Advanced or decompensated liver disease (presence or history of bleeding varices,\r&lt;br&gt;                  ascites, encephalopathy or hepato-renal syndrome)\r&lt;br&gt;\r&lt;br&gt;               -  Immunologically mediated disease (e.g., rheumatoid arthritis, inflammatory bowel\r&lt;br&gt;                  disease, severe psoriasis, systemic lupus erythematosus) that requires use of\r&lt;br&gt;                  systemic corticosteroids in the 6 months before screening.\r&lt;br&gt;\r&lt;br&gt;               -  Gastrointestinal disease which could interfere with the absorption of\r&lt;br&gt;                  Piclidenoson.\r&lt;br&gt;\r&lt;br&gt;               -  Any malignancy within 5 years.\r&lt;br&gt;\r&lt;br&gt;               -  Cardiomyopathy, significant ischemic cardiac or cerebrovascular disease\r&lt;br&gt;                  (including history of angina, myocardial infarction, or interventional procedure\r&lt;br&gt;                  for coronary artery disease), or cardiac rhythm disorder.\r&lt;br&gt;\r&lt;br&gt;               -  QTcF interval on an average of triplicate ECGs =500 msec.\r&lt;br&gt;\r&lt;br&gt;               -  A condition which increases proarrhythmic risk, including hypokalemia,\r&lt;br&gt;                  hypomagnesemia, congenital Long QT Syndrome.\r&lt;br&gt;\r&lt;br&gt;               -  Ongoing or planned use of a concomitant medication that is on the CredibleMedsTM\r&lt;br&gt;                  list of drugs known to cause Torsades de Pointes, unless the patient can be\r&lt;br&gt;                  screened and monitored under the guidelines proposed by Giudicessi (Mayo Clinic\r&lt;br&gt;                  Proceedings 2020).\r&lt;br&gt;\r&lt;br&gt;               -  Chronic pulmonary disease (e.g., chronic obstructive pulmonary disease)\r&lt;br&gt;                  associated with functional impairment.\r&lt;br&gt;\r&lt;br&gt;               -  Pancreatitis.\r&lt;br&gt;\r&lt;br&gt;               -  Severe or uncontrolled psychiatric disorder.\r&lt;br&gt;\r&lt;br&gt;               -  Active seizure disorder defined by either an untreated seizure disorder or\r&lt;br&gt;                  continued seizure activity within the preceding year despite treatment with\r&lt;br&gt;                  anti-seizure medication.\r&lt;br&gt;\r&lt;br&gt;               -  Bone marrow or solid organ transplantation.\r&lt;br&gt;\r&lt;br&gt;               -  Other significant medical condition that may require intervention during the\r&lt;br&gt;                  trial (such as uncontrolled diabetes or thyroid disease), or patients for whom\r&lt;br&gt;                  participation in the trial would increase their risk.\r&lt;br&gt;\r&lt;br&gt;               -  Current alcohol abuse.\r&lt;br&gt;\r&lt;br&gt;               -  Drug abuse within the previous 6 months before screening, with the exception of\r&lt;br&gt;                  cannabinoids and their derivatives.\r&lt;br&gt;\r&lt;br&gt;          6. Any of the following abnormal laboratory test in the 12 months prior to enrollment:\r&lt;br&gt;\r&lt;br&gt;               -  Platelet count &lt;90,000 cells/mm3\r&lt;br&gt;\r&lt;br&gt;               -  White blood cell (WBC) count &lt;3,000 cells/mm3\r&lt;br&gt;\r&lt;br&gt;               -  Absolute neutrophil count (ANC) &lt;1,500 cells/mm3\r&lt;br&gt;\r&lt;br&gt;               -  Hemoglobin &lt;11 g/dL for women and &lt;12 g/dL for men\r&lt;br&gt;\r&lt;br&gt;               -  Estimated creatinine clearance (CrCl) &lt; 50 mL/min by Cockroft-Gault formulation\r&lt;br&gt;\r&lt;br&gt;               -  Bilirubin level = 2.5 mg/dL unless due to Gilbert's syndrome\r&lt;br&gt;\r&lt;br&gt;               -  Serum albumin level &lt;3.5 g/dL\r&lt;br&gt;\r&lt;br&gt;               -  International normalized ratio (INR) =1.5.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. COVID-19 has been diagnosed, and the nucleic acid test of respiratory specimens such\r&lt;br&gt;             as sputum or nasopharyngeal swabs has been negative for two consecutive times after\r&lt;br&gt;             treatment (sampling time interval of at least 24 hours);\r&lt;br&gt;\r&lt;br&gt;          2. The nucleic acid test of specimens such as sputum, throat swabs, blood, feces and\r&lt;br&gt;             other specimens was positive for COVID-19 during screening visits;\r&lt;br&gt;\r&lt;br&gt;          3. Voluntarily participate in research and sign informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Those allergic to fapilavir;\r&lt;br&gt;\r&lt;br&gt;          2. Pregnant or lactating women;\r&lt;br&gt;\r&lt;br&gt;          3. Unstable liver, kidney, and heart diseases;\r&lt;br&gt;\r&lt;br&gt;          4. History of mental disorders, substance abuse or dependence;\r&lt;br&gt;\r&lt;br&gt;          5. Researchers consider it inappropriate to participate in research;\r&lt;br&gt;\r&lt;br&gt;          6. Participating in other clinical research.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Non-severe symptomatic patients who present cough, fever, nasal congestion,\r&lt;br&gt;             gastrointestinal symptoms, fatigue, anosmia, ageusia or alternative signs of\r&lt;br&gt;             respiratory infections.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients presenting severe respiratory and/or multisystemic symptoms compatible with\r&lt;br&gt;             advanced COVID-19 and intercurrent acute or severe chronic diseases (i.e. active\r&lt;br&gt;             cancer).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Completed Informed Consent\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Individual is currently working with a trial participating site where individuals\r&lt;br&gt;             receive healthcare (\"healthcare worker\") or is associated with the site through\r&lt;br&gt;             emergency services\r&lt;br&gt;\r&lt;br&gt;          -  Able to speak and read English or Spanish\r&lt;br&gt;\r&lt;br&gt;          -  At risk for COVID-19 infection through one or more of the following work exposures:\r&lt;br&gt;\r&lt;br&gt;               -  in the Intensive care unit, or\r&lt;br&gt;\r&lt;br&gt;               -  in the Emergency department, or\r&lt;br&gt;\r&lt;br&gt;               -  in Emergency Services, or\r&lt;br&gt;\r&lt;br&gt;               -  in a COVID-19 hospital unit/ward, or\r&lt;br&gt;\r&lt;br&gt;               -  in respiratory services\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Prior diagnosis of COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;          -  Participation in another COVID-19 prophylaxis trial within 30 days of consent\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory illness with new-onset fever (Temperature &gt; 100F) or ongoing cough or\r&lt;br&gt;             dyspnea within 14 days\r&lt;br&gt;\r&lt;br&gt;          -  Known allergy to HCQ or chloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Congenital prolonged QT syndrome\r&lt;br&gt;\r&lt;br&gt;          -  Current or planned use of QT prolonging drugs (e.g. procainamide, disopyramide,\r&lt;br&gt;             mexilitine, flecainide, propafenone, amiodarone, sotalol, cimetidine, dronedarone,\r&lt;br&gt;             dofetilide, levofloxacin, ciprofloxacin, moxifloxacin)\r&lt;br&gt;\r&lt;br&gt;          -  End stage renal disease\r&lt;br&gt;\r&lt;br&gt;          -  Pre-existing retinopathy\r&lt;br&gt;\r&lt;br&gt;          -  Current or planned use of the following for treatment or prevention of COVID-19\r&lt;br&gt;             infection:\r&lt;br&gt;\r&lt;br&gt;               -  Hydroxychloroquine (study drug) or chloroquine\r&lt;br&gt;\r&lt;br&gt;               -  azithromycin\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  greater than 18 years of age\r&lt;br&gt;\r&lt;br&gt;          -  COVID-positive status\r&lt;br&gt;\r&lt;br&gt;          -  Being monitored in an outpatient setting at one of our study sites:\r&lt;br&gt;\r&lt;br&gt;          -  Yale New Haven Hospital (YNHH)\r&lt;br&gt;\r&lt;br&gt;          -  University of Michigan\r&lt;br&gt;\r&lt;br&gt;          -  University of Minnesota\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  inflammatory bowel disease\r&lt;br&gt;\r&lt;br&gt;          -  history of gastric bypass surgery\r&lt;br&gt;\r&lt;br&gt;          -  active Clostridium difficile infection\r&lt;br&gt;\r&lt;br&gt;          -  active particiipation in another COVID-19 interventional trial\r&lt;br&gt;\r&lt;br&gt;          -  any physical or psychological condition that, in the opinion of the investigator,\r&lt;br&gt;             would pose unacceptable risk to the patient or raise concern that the patient would\r&lt;br&gt;             not comply with the protocol procedures.\r&lt;br&gt;\r&lt;br&gt;          -  Reported allergy to potato starch or corn starch or to IL-6 inhibitors, such as\r&lt;br&gt;             Tocilizumab\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All patients with laboratory-confirmed COVID-19 in Wenzhou\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Suspected cases of COVID-19\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Outpatients = 18 years presenting to Cleveland Clinic Health System in Northeast Ohio\r&lt;br&gt;             who test positive for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Women of child bearing potential who have not had a menstrual period within the past\r&lt;br&gt;             30 days, have not had previous sterilization or those who are perimenopausal (less\r&lt;br&gt;             than 1 year) who have a negative pregnancy test\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are found to be COVID-19 positive during hospitalization or during an\r&lt;br&gt;             emergency room visit.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who live outside Ohio.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant women:\r&lt;br&gt;\r&lt;br&gt;        Current known pregnancy Positive pregnancy test (women of child bearing potential who have\r&lt;br&gt;        not had previous sterilization as defined as hysterectomy or tubal ligation)\r&lt;br&gt;\r&lt;br&gt;          -  End stage CKD (Chronic kidney disease)\r&lt;br&gt;\r&lt;br&gt;          -  Advanced liver disease awaiting transplant\r&lt;br&gt;\r&lt;br&gt;          -  History of Calcium Oxalate kidney stones.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults (men and women) age over 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  At least one nasal swab positive for COVID-19 detected by PCR, maximum 7 days prior to\r&lt;br&gt;             treatment\r&lt;br&gt;\r&lt;br&gt;          -  Viral pneumonia confirmed by TDM scan\r&lt;br&gt;\r&lt;br&gt;          -  Patients meeting all of the following 3 criteria:\r&lt;br&gt;\r&lt;br&gt;               -  Requiring more than 3L/min of oxygen\r&lt;br&gt;\r&lt;br&gt;               -  WHO progression scale = 5\r&lt;br&gt;\r&lt;br&gt;               -  No NIV or High flow\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with active cancer and immunocopromised patients\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to nivolumab or to any of their excipients.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Patient with an autoimmune or inflammatory disease (including but not limited to:\r&lt;br&gt;             Crohn's Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus,\r&lt;br&gt;             Grave's disease). Patients with thyroiditis or vitiligo only could be included.\r&lt;br&gt;\r&lt;br&gt;          -  Patient with a history of thymoma\r&lt;br&gt;\r&lt;br&gt;          -  Patient with a history of solid organ transplantation or a bone marrow transplantation\r&lt;br&gt;\r&lt;br&gt;          -  Patients treated with immune checkpoint inhibitors 3 months prior to the study\r&lt;br&gt;\r&lt;br&gt;          -  Patients who had a history of grade 3 or 4 immune-related adverse events with a\r&lt;br&gt;             previous treatment with immune-checkpoint inhibtors\r&lt;br&gt;\r&lt;br&gt;          -  Patients requiring ICU based on Criteria of severity of COVID pneumopathy\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory failure requiring mechanical ventilation or extracorporeal membrane\r&lt;br&gt;             oxygenation\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Presentation to the ED with respiratory symptoms likely caused by COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Patient displays at least one of the following\r&lt;br&gt;\r&lt;br&gt;               1. respiratory rate = 24\r&lt;br&gt;\r&lt;br&gt;               2. new cough\r&lt;br&gt;\r&lt;br&gt;               3. new atypical chest pain\r&lt;br&gt;\r&lt;br&gt;               4. new dyspnea\r&lt;br&gt;\r&lt;br&gt;               5. oxygen saturation &lt; 97% at rest\r&lt;br&gt;\r&lt;br&gt;               6. chest x-ray with new changes consistent with COVID-related airspace disease\r&lt;br&gt;\r&lt;br&gt;          -  Cleared for discharge home by attending physician\r&lt;br&gt;\r&lt;br&gt;          -  Obtained COVID testing (results not required at time of enrollment)\r&lt;br&gt;\r&lt;br&gt;          -  Onset of symptoms =12 days prior to ED visit\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Attending physician estimation (&lt; 50% likelihood) of other more likely non-COVID\r&lt;br&gt;             etiology\r&lt;br&gt;\r&lt;br&gt;          -  Presence of tracheostomy\r&lt;br&gt;\r&lt;br&gt;          -  Requirement of oxygen therapy to maintain resting oxygen saturation of &gt; 94%\r&lt;br&gt;\r&lt;br&gt;          -  Clinical contraindication to use of inhaled nitric oxide\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - Residents in the following surgical specialities: cardiothoracic surgery, colon and\r&lt;br&gt;        rectal surgery, general surgery, gynecology and obstetrics, gynecologic oncology,\r&lt;br&gt;        neurological surgery, ophthalmic surgery, oral and maxillofacial surgery, orthopaedic\r&lt;br&gt;        surgery, otorhinolaryngology, pediatric surgery, plastic and maxillofacial surgery,\r&lt;br&gt;        urology, and vascular surgery\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Undergratuated and postgraduated students\r&lt;br&gt;\r&lt;br&gt;          -  Consultants in surgical areas\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Positive reverse transcription polymerase chain reaction for severe acute respiratory\r&lt;br&gt;             syndrome coronavirus 2\r&lt;br&gt;\r&lt;br&gt;          -  Age 18 and older\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Indian males and females currently living in India, OR\r&lt;br&gt;\r&lt;br&gt;          -  All the employees of Max Super Speciality Hospital, New Delhi, India\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Anyone who has filled the questionnaire once per household\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Capable to and does provide written informed consent;\r&lt;br&gt;\r&lt;br&gt;          -  Able to understand and agrees to comply with planned study procedures and be available\r&lt;br&gt;             for all study visits;\r&lt;br&gt;\r&lt;br&gt;          -  Body Mass Index 18-35 kg/square meter, inclusive, at screening;\r&lt;br&gt;\r&lt;br&gt;          -  Women of childbearing potential must agree to use or have practiced true abstinence or\r&lt;br&gt;             use at least one acceptable primary form of contraception.Note: These criteria are\r&lt;br&gt;             applicable to females in a heterosexual relationship and child-bearing potential\r&lt;br&gt;             (i.e., the criteria do not apply to participants in a same sex relationship).\r&lt;br&gt;\r&lt;br&gt;          -  Women of childbearing potential must have a negative urine or serum pregnancy test\r&lt;br&gt;             within 24 hours prior to initiation of vaccination;\r&lt;br&gt;\r&lt;br&gt;          -  Male participants of childbearing potential: use of condoms to ensure effective\r&lt;br&gt;             contraception with a female partner from first vaccination until 3 months after the\r&lt;br&gt;             last vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Male participants agree to refrain from sperm donation from the time of first\r&lt;br&gt;             vaccination until 3 months after the last vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Pulse no greater than 100 beats per minute;\r&lt;br&gt;\r&lt;br&gt;          -  Systolic blood pressure (BP) is 85 to 150 mmHg, inclusive;\r&lt;br&gt;\r&lt;br&gt;          -  Clinical screening laboratory evaluations (white blood cell (WBC), hemoglobin (Hgb),\r&lt;br&gt;             platelets (PLTs), alanine transaminase (ALT), aspartate transaminase (AST), creatinine\r&lt;br&gt;             (Cr), alkaline phosphatase (ALP), total bilirubin (T. Bili), Lipase, prothrombin time\r&lt;br&gt;             (PT), and partial thromboplastin time (PTT)) are within acceptable normal reference\r&lt;br&gt;             ranges at the clinical laboratory being used;\r&lt;br&gt;\r&lt;br&gt;          -  Agree to have samples stored for secondary research.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Positive pregnancy test either at screening or just prior to vaccine administration.\r&lt;br&gt;\r&lt;br&gt;          -  Female participant who is breastfeeding or plans to breastfeed from the time of the\r&lt;br&gt;             first vaccination through 3 months after the last vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Has acute or chronic inflammatory condition of the gastrointestinal tract including,\r&lt;br&gt;             but not limited to, Crohn's disease, ulcerative colitis, gastritis, proctitis, or any\r&lt;br&gt;             other inflammatory bowel disorder\r&lt;br&gt;\r&lt;br&gt;          -  Has any medical disease or condition that, in the opinion of the site PI or\r&lt;br&gt;             appropriate sub-investigator, precludes study participation (including but not limited\r&lt;br&gt;             to acute, subacute, intermittent or chronic medical disease or condition that would\r&lt;br&gt;             place the participant at an unacceptable risk of injury, render the participant unable\r&lt;br&gt;             to meet the requirements of the protocol, or may interfere with the evaluation of\r&lt;br&gt;             responses or the participant's successful completion of this trial.)\r&lt;br&gt;\r&lt;br&gt;          -  Presence of self-reported or medically documented significant medical or psychiatric\r&lt;br&gt;             condition(s).\r&lt;br&gt;\r&lt;br&gt;          -  Significant medical or psychiatric conditions include but are not limited to:\r&lt;br&gt;\r&lt;br&gt;        Respiratory disease, significant cardiovascular disease, neurological or neurodevelopmental\r&lt;br&gt;        conditions, ongoing malignancy or recent diagnosis of malignancy in the last five years\r&lt;br&gt;        (excluding basal cell and squamous cell carcinoma of the skin, which are allowed), an\r&lt;br&gt;        autoimmune disease, including hypothyroidism without a defined non-autoimmune cause,\r&lt;br&gt;        localized or history of psoriasis, an immunodeficiency of any cause.\r&lt;br&gt;\r&lt;br&gt;          -  Presence of an indwelling prosthetic device or other foreign vaccination\r&lt;br&gt;\r&lt;br&gt;          -  Has a positive test result for hepatitis B surface antigen, hepatitis C virus\r&lt;br&gt;             antibody, or HIV types 1 or 2 antibodies at screening.\r&lt;br&gt;\r&lt;br&gt;          -  Has participated in another investigational study involving any investigational\r&lt;br&gt;             product (study drug, biologic or device) within 60 days, or 5 half-lives, whichever is\r&lt;br&gt;             longer, before the first vaccine administration.\r&lt;br&gt;\r&lt;br&gt;          -  Currently enrolled in or plans to participate in another clinical trial with an\r&lt;br&gt;             investigational agent (including licensed or unlicensed vaccine, drug, biologic,\r&lt;br&gt;             device, blood product, or medication) that will be received during the trial period.\r&lt;br&gt;\r&lt;br&gt;          -  Has a history of hypersensitivity or severe allergic reaction (e.g., anaphylaxis,\r&lt;br&gt;             generalized urticaria, angioedema, other significant reaction) to any previous\r&lt;br&gt;             licensed or unlicensed vaccines.\r&lt;br&gt;\r&lt;br&gt;          -  Chronic use (more than 14 continuous days) of any medications that may be associated\r&lt;br&gt;             with impaired immune responsiveness. Including, but not limited to: systemic\r&lt;br&gt;             corticosteroids exceeding 10 mg/day of prednisone equivalent, allergy injections,\r&lt;br&gt;             immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or other similar or\r&lt;br&gt;             toxic drugs during the preceding 6-month period prior to vaccine administration (Day\r&lt;br&gt;             1). The use of low dose topical, ophthalmic, inhaled and intranasal steroid\r&lt;br&gt;             preparations will be permitted.\r&lt;br&gt;\r&lt;br&gt;          -  Received immunoglobulins and/or any blood or blood products within the 4 months before\r&lt;br&gt;             the first vaccine administration or at any time during the study.\r&lt;br&gt;\r&lt;br&gt;          -  Has any blood dyscrasias or significant disorder of coagulation.\r&lt;br&gt;\r&lt;br&gt;          -  Has any chronic liver disease, including fatty liver.\r&lt;br&gt;\r&lt;br&gt;          -  Has a history of alcohol abuse or other recreational drug (excluding cannabis) use\r&lt;br&gt;             within 6 months before the first vaccine administration.\r&lt;br&gt;\r&lt;br&gt;          -  Received or plans to receive a licensed, live vaccine within 4 weeks before or after\r&lt;br&gt;             each vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Received or plans to receive a licensed, inactivated vaccine within 2 weeks before or\r&lt;br&gt;             after each vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Receipt of any other SARS-CoV-2/COVID-19, or other experimental coronavirus vaccine at\r&lt;br&gt;             any time prior to or during the study.\r&lt;br&gt;\r&lt;br&gt;          -  Known previous laboratory-confirmed SARS-CoV-2/COVID-19 infection.\r&lt;br&gt;\r&lt;br&gt;          -  Known close contact of anyone with laboratory-confirmed SARS-CoV-2/COVID-19 infection\r&lt;br&gt;             within 2 weeks prior to vaccine administration.\r&lt;br&gt;\r&lt;br&gt;          -  Has traveled outside Canada for any duration within 30 days before the first\r&lt;br&gt;             vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  Household contact with any medical condition or taking medications that may result in\r&lt;br&gt;             immunosuppression.\r&lt;br&gt;\r&lt;br&gt;          -  Current use of any antibiotics or probiotic supplements within 7 days prior to\r&lt;br&gt;             vaccination and any anticipated use for 7 days post vaccination.\r&lt;br&gt;\r&lt;br&gt;          -  The participant must agree to refrain from donating blood or plasma during the study.\r&lt;br&gt;\r&lt;br&gt;          -  Oral temperature is greater than or equal to 37.8 degrees Celsius (temporary exclusion\r&lt;br&gt;             criteria).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Valid informed consent.\r&lt;br&gt;\r&lt;br&gt;          -  All Covid 19 positive patients age =18 years who are under care at home for Covid 19\r&lt;br&gt;             infection.\r&lt;br&gt;\r&lt;br&gt;          -  Patients with typical Covid 19 clinical symptoms where a test has not been taken may\r&lt;br&gt;             also be included if a test later is positive.\r&lt;br&gt;\r&lt;br&gt;          -  A good quality WIFI system not influenced by other WIFI systems.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt;18 years.\r&lt;br&gt;\r&lt;br&gt;          -  Covid 19 negative.\r&lt;br&gt;\r&lt;br&gt;          -  Internals in prison.\r&lt;br&gt;\r&lt;br&gt;          -  Individuals living in special homes due to need of care.\r&lt;br&gt;\r&lt;br&gt;          -  Refusal of participation.\r&lt;br&gt;\r&lt;br&gt;          -  Comorbidity that hinder the patient to run the system.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt;18 years admitted to the University of Kansas Health System.\r&lt;br&gt;\r&lt;br&gt;          -  Confirmation of infection with SARS-CoV-2 by PCR testing.\r&lt;br&gt;\r&lt;br&gt;          -  Hypoxic respiratory failure\r&lt;br&gt;\r&lt;br&gt;             o Requiring mechanical ventilation or oxygen, an oxygen saturation (SpO2) =94% or a\r&lt;br&gt;             PaO2/FiO2 (P/F) ratio &lt;300 or tachypnea (respiratory rate =24 breaths/min).\r&lt;br&gt;\r&lt;br&gt;          -  Other concomitant medications such as antivirals and hydroxychloroquine are allowed.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy.\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory failure due to a process other than COVID-19.\r&lt;br&gt;\r&lt;br&gt;          -  Intolerance to ARBs.\r&lt;br&gt;\r&lt;br&gt;          -  Current treatment with an angiotensin receptor blocker (ARB) or angiotensin converting\r&lt;br&gt;             enzyme (ACE) inhibitor.\r&lt;br&gt;\r&lt;br&gt;          -  Current chronic use of medication with known interactions with losartan including\r&lt;br&gt;             NSAIDs (intermittent prior use is acceptable), potassium supplementation aliskiren.\r&lt;br&gt;\r&lt;br&gt;          -  Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic recorded on at least\r&lt;br&gt;             two readings 30 min apart.\r&lt;br&gt;\r&lt;br&gt;          -  Need for vasopressors, unless norepinephrine =0.1 g/kg/min\r&lt;br&gt;\r&lt;br&gt;          -  need for vasopressors.\r&lt;br&gt;\r&lt;br&gt;          -  Hyperkalemia (serum K+ &gt;5.5 mM).\r&lt;br&gt;\r&lt;br&gt;          -  Known cardiac failure (left ventricular ejection fraction =35%), renal insufficiency\r&lt;br&gt;             (Cockcroft-Gault &lt;30 mL/min/1.73 m2 or urinary output &lt;20 mL/h), hepatic failure (LFTs\r&lt;br&gt;             &gt; 5x normal upper limit).\r&lt;br&gt;\r&lt;br&gt;          -  Known renal artery stenosis.\r&lt;br&gt;\r&lt;br&gt;          -  Neurological, psychiatric, endocrine or neoplastic diseases that are judged to\r&lt;br&gt;             interfere with participation in the study.\r&lt;br&gt;\r&lt;br&gt;          -  On another interventional trial (including one for COVID-19) that excludes\r&lt;br&gt;             participation.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  In-patients fulfilling the following criteria:\r&lt;br&gt;\r&lt;br&gt;        SARS-CoV-2 infection In-patient treatment Written informed consent for participation in\r&lt;br&gt;        observational study\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  No explicit medical exclusion criteria are stated to avoid selection bias.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  confirmed COVID-19 defined by a positive RT-PCR to SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  none\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult subjects =18 years of age\r&lt;br&gt;\r&lt;br&gt;          -  Quarantined as suspected COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Asymptomatic upon enrolment\r&lt;br&gt;\r&lt;br&gt;          -  All subjects give written informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - Failure to provide written informed consent\r&lt;br&gt;","Inclusion criteria: Inclusion Criteria:\r&lt;br&gt;\tScore of greater than or equal to 3 on the General Health Questionnaire\r&lt;br&gt;\tAged at least 18 years\r&lt;br&gt;\tSufficient English language comprehension \r&lt;br&gt;\tAccess to teleconferencing platform\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  At least 18 years of age or older\r&lt;br&gt;\r&lt;br&gt;          -  Clinically evident or otherwise confirmed severe pneumonia\r&lt;br&gt;\r&lt;br&gt;          -  SARS-CoV2 infection confirmation (tested positive in last 14 days or test results to\r&lt;br&gt;             be obtained within 24h after enrollment, both with locally available test system).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Known history of COPD\r&lt;br&gt;\r&lt;br&gt;          -  Received new other biologic treatment attempt for COVID-19 in the past 14 days\r&lt;br&gt;\r&lt;br&gt;          -  Received treatment with a viral replication inhibitor in past 3 days\r&lt;br&gt;\r&lt;br&gt;          -  Received organ or bone marrow transplantation in past 3 months\r&lt;br&gt;\r&lt;br&gt;          -  Known mechanically resuscitation in past 14 days\r&lt;br&gt;\r&lt;br&gt;          -  Known severe congestive heart failure (NYHA-Class III - IV)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age over 18\r&lt;br&gt;\r&lt;br&gt;          -  A person diagnosed with COVID-19 in the past 48 hours\r&lt;br&gt;\r&lt;br&gt;          -  Asymptomatic\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  chronic lung disease with chronic hypoxia\r&lt;br&gt;\r&lt;br&gt;          -  Sleep apnea requiring BIPAP / continuous positive airway pressure\r&lt;br&gt;\r&lt;br&gt;          -  Retinal disease\r&lt;br&gt;\r&lt;br&gt;          -  Porphyria\r&lt;br&gt;\r&lt;br&gt;          -  Myastenia gravis\r&lt;br&gt;\r&lt;br&gt;          -  immunodeficiency disorders\r&lt;br&gt;\r&lt;br&gt;          -  Hearing Disorders\r&lt;br&gt;\r&lt;br&gt;          -  Scheduled for general anesthesia\r&lt;br&gt;\r&lt;br&gt;          -  treatment with antibiotics or antiretroviral for any reason\r&lt;br&gt;\r&lt;br&gt;          -  Pulse &lt;50\r&lt;br&gt;\r&lt;br&gt;          -  Known Ventricular arrhythmias\r&lt;br&gt;\r&lt;br&gt;          -  Heart Failure: Systolic or Diastolic\r&lt;br&gt;\r&lt;br&gt;          -  kown QT prolongation\r&lt;br&gt;\r&lt;br&gt;          -  Taking medicines that increase the risk of QT prolongation in combination with\r&lt;br&gt;             CHLOROQUINE.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria :\r&lt;br&gt;\r&lt;br&gt;          -  Participants with diagnosis of COVID-19 via nasopharyngeal swab Polymerase Chain\r&lt;br&gt;             Reaction (PCR)\r&lt;br&gt;\r&lt;br&gt;          -  Time between onset of symptoms and enrollment is 72 hours or less\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Severe COVID-19 requiring inpatient treatment\r&lt;br&gt;\r&lt;br&gt;          -  Women who are pregnant or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent antimicrobial therapy\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline compounds\r&lt;br&gt;\r&lt;br&gt;          -  Hydroxychloroquine use within 2 months before enrollment\r&lt;br&gt;\r&lt;br&gt;          -  History of severe skin reactions such as Sevens-Johnson syndrome and toxic epidermal\r&lt;br&gt;             necrolysis\r&lt;br&gt;\r&lt;br&gt;          -  History of retinopathy\r&lt;br&gt;\r&lt;br&gt;          -  History of arrythmia, concurrent use of anti-arrhythmic drugs, or family history of\r&lt;br&gt;             sudden cardiac death\r&lt;br&gt;\r&lt;br&gt;          -  History of severe renal disease (treatment with dialysis or phosphate binders) or\r&lt;br&gt;             hepatic impairment\r&lt;br&gt;\r&lt;br&gt;        The above information is not intended to contain all considerations relevant to a patient's\r&lt;br&gt;        potential participation in a clinical trial.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalisation in the acute care geriatric unit (Angers UH) or institutionalization\r&lt;br&gt;             in St Nicolas during the isolation measures linked to the SARS-CoV-2 epidemic.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Refusal to participate.\r&lt;br&gt;\r&lt;br&gt;          -  Contraindication posed by the medical team to proposing dematerialized communication.\r&lt;br&gt;","Inclusion criteria: Any person aged 18 or older, confirmed with COVID-19 referred to home rehabilitation services delivered at Flinders medical Centre through the division of rehabilitation, aged and palliative care.","Inclusion criteria: &lt;br&gt;                1. Aged 18 or older&lt;br&gt;                2. Critically ill&lt;br&gt;                3. COVID-19 and acute respiratory distress syndrome (ARDS) according to Berlin-Definition&lt;br&gt;                4. No contra-indication to PiCCO-monitoring&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient enrolled in a PACE organization during the implementation period;\r&lt;br&gt;\r&lt;br&gt;          -  PACE organization contractually receiving pharmacy services from CareKinesis;\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  No drug claims data available for the period of 2019-2020\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult (&gt;18 years) within 24 hours of admission to intensive care unit with proven or\r&lt;br&gt;             suspected COVID-19 infection. For the purpose of this study, intensive care unit is\r&lt;br&gt;             defined as a facility that allow continuous monitoring of vital functions and oxygen\r&lt;br&gt;             administration . It is expected that most patients will have rtPCR test known within\r&lt;br&gt;             24 hours of admission to hospital. Nonetheless, if this is not the case (eg. due to\r&lt;br&gt;             overloaded lab facility, lack of supplies) it is possible to randomise a patient based\r&lt;br&gt;             on a strong clinical suspicion of SARS-Cov-2 infection. In case COVID-19 is not\r&lt;br&gt;             confirmed in retrospect, experimental therapy is withdrawn and the study subject is\r&lt;br&gt;             withdrawn from \"per protocol\" analysis of the primary and secondary outcomes, but\r&lt;br&gt;             remains in \"intention-to-treat\" cohort for the analysis of safety.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  symptoms of febrile disease for =1 week, pregnancy, treatment limitations in place or\r&lt;br&gt;             moribund patients, allergy or intolerance of any study treatment, incl. long QT\r&lt;br&gt;             syndromes, myasthenia gravis, allergies or known deficiency of glucose-6-phosphate\r&lt;br&gt;             dehydrogenase, participation in another outcome-based interventional trial within last\r&lt;br&gt;             30 days, patients taking Hydrochloroquine for other indication than COVID-19.\r&lt;br&gt;","\r&lt;br&gt;        Donor Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age greater or equal to 18\r&lt;br&gt;\r&lt;br&gt;          -  Able to donate blood per blood bank standard guidelines\r&lt;br&gt;\r&lt;br&gt;          -  Prior diagnosis of COVID-19 documented by a laboratory test (confirmed)\r&lt;br&gt;\r&lt;br&gt;          -  Complete resolution of symptoms at least 28 days prior to donation\r&lt;br&gt;\r&lt;br&gt;          -  Female donors who have never been pregnant, previously pregnant female donors negative\r&lt;br&gt;             for HLA antibodies (HLA screening), or male donors\r&lt;br&gt;\r&lt;br&gt;        Donor Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Does not provide consent\r&lt;br&gt;\r&lt;br&gt;          -  Does not meet standard blood bank donation guidelines\r&lt;br&gt;\r&lt;br&gt;          -  Unsuccessful blood donation\r&lt;br&gt;\r&lt;br&gt;        Recipient Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients must be 18 years of age or older\r&lt;br&gt;\r&lt;br&gt;          -  Must have laboratory-confirmed COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Must have severe or immediately life-threatening COVID-19\r&lt;br&gt;\r&lt;br&gt;               -  Severe defined as dyspnea, respiratory frequency = 30/min, blood oxygen\r&lt;br&gt;                  saturation = 93%, partial pressure of arterial oxygen to fraction of inspired\r&lt;br&gt;                  oxygen ratio &lt; 300, and/or lung infiltrates &gt; 50% within 24 to 48 hours\r&lt;br&gt;\r&lt;br&gt;               -  Life-threatening defined as respiratory failure, septic shock, and/or multiple\r&lt;br&gt;                  organ dysfunction or failure. Lower priority should be given to patients with\r&lt;br&gt;                  septic shock or multiple organ dysfunction or failure since their disease may\r&lt;br&gt;                  have progressed to a point where they are not able to benefit from convalescent\r&lt;br&gt;                  plasma therapy.\r&lt;br&gt;\r&lt;br&gt;          -  Must be less than 21 days from the start of illness\r&lt;br&gt;\r&lt;br&gt;          -  Patient is willing and able to provide written informed consent and comply with all\r&lt;br&gt;             protocol requirements. If the patient is not able to consent, we will obtain consent\r&lt;br&gt;             from the power of attorney or a health care proxy for the patient as determined by the\r&lt;br&gt;             Illinois Healthcare Surrogate Act\r&lt;br&gt;\r&lt;br&gt;          -  Patient, power of attorney or health care proxy agrees to storage of specimens for\r&lt;br&gt;             future testing.\r&lt;br&gt;\r&lt;br&gt;          -  Of note, eIND application for each recipient subject will need to be approved before\r&lt;br&gt;             administration of convalescent plasma\r&lt;br&gt;\r&lt;br&gt;        Recipient Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Female subjects with positive pregnancy test, breastfeeding, or planning to become\r&lt;br&gt;             pregnant/breastfeed during the study period\r&lt;br&gt;\r&lt;br&gt;          -  Receipt of pooled immunoglobulin in past 30 days\r&lt;br&gt;\r&lt;br&gt;          -  Contraindication to transfusion or history of prior reactions to transfusion blood\r&lt;br&gt;             products\r&lt;br&gt;\r&lt;br&gt;          -  Patients currently enrolled in other drug trials that preclude investigational\r&lt;br&gt;             treatment with anti-SARS-CoV-2 convalescent plasma\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients admitted to ICU for suspected or proven SARS-Cov-2 infection, defined by\r&lt;br&gt;             positive SARS-Cov-2 PCR or CT scan images\r&lt;br&gt;\r&lt;br&gt;          -  Patient &gt; or= 18 years\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient study refusal\r&lt;br&gt;\r&lt;br&gt;          -  Patient already enrolled in the present study\r&lt;br&gt;\r&lt;br&gt;          -  Patient with respiratory illness with negative COVID-19 CT scan images and negative\r&lt;br&gt;             COVID_19 PCR\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Signed informed consent form (ICF) prior to participation in any study-related\r&lt;br&gt;             activities.\r&lt;br&gt;\r&lt;br&gt;          2. Male or nonpregnant female patients = 18 years at the time of signing ICF.\r&lt;br&gt;\r&lt;br&gt;          3. Laboratory confirmed COVID-19 infection defined with a positive reverse\r&lt;br&gt;             transcription-polymerase chain reaction (RT-PCR) from any specimen and/or detection of\r&lt;br&gt;             SARS-CoV-2 immunoglobulin (Ig)M/IgG antibodies.\r&lt;br&gt;\r&lt;br&gt;          4. Diagnostic confirmation of pneumonia by either chest X-ray or thoracic CT scan\r&lt;br&gt;             (preferable).\r&lt;br&gt;\r&lt;br&gt;          5. Patient with severe acute respiratory syndrome related to COVID-19 under treatment as\r&lt;br&gt;             per hospital protocol during at least 48 hours.\r&lt;br&gt;\r&lt;br&gt;          6. Patients with Sequential Organ Failure Assessment (SOFA) score = 3 at the time of\r&lt;br&gt;             signing ICF.\r&lt;br&gt;\r&lt;br&gt;          7. Patients hospitalized with fever defined as temperature = 37,5 C armpit.\r&lt;br&gt;\r&lt;br&gt;          8. Patients with total lymphocyte count =0,8 x106/mL.\r&lt;br&gt;\r&lt;br&gt;          9. Patients who are showing SpO2 = 92% on room air and/or patient who are showing SpO2 =\r&lt;br&gt;             94% on room air and meet at least one of the following parameters:\r&lt;br&gt;\r&lt;br&gt;               -  No objective clinical improvement at physician's discretion after 48 hours of\r&lt;br&gt;                  front-line standard care for COVID-19;\r&lt;br&gt;\r&lt;br&gt;               -  Decrease in lymphocyte count (any decrease within 48 hours);\r&lt;br&gt;\r&lt;br&gt;               -  Increase in ferritin levels (any increase within 48 hours);\r&lt;br&gt;\r&lt;br&gt;               -  Increase in IL-6 levels (any increase within 48 hours);\r&lt;br&gt;\r&lt;br&gt;               -  Increase in D-dimer levels (any increase within 48 hours);\r&lt;br&gt;\r&lt;br&gt;               -  Increase in CRP levels (any increase within 48 hours);\r&lt;br&gt;\r&lt;br&gt;               -  Increase in LDH levels (any increase within 48 hours);\r&lt;br&gt;\r&lt;br&gt;               -  Increase in ESR levels (any increase within 48 hours).\r&lt;br&gt;\r&lt;br&gt;         10. Life expectancy greater than 10 days.\r&lt;br&gt;\r&lt;br&gt;         11. Willing to take study medication and to comply with all study procedures.\r&lt;br&gt;\r&lt;br&gt;         12. In women of childbearing potential, negative pregnancy test and commitment to use\r&lt;br&gt;             contraceptive method throughout the study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Participation in any other clinical trial of an experimental treatment for COVID-19.\r&lt;br&gt;\r&lt;br&gt;          2. Concurrent treatment with other agents with actual or possible direct acting antiviral\r&lt;br&gt;             activity against SARS-CoV-2 is prohibited &lt; 24 hours prior to study drug dosing,\r&lt;br&gt;             except the commonly used antiviral drugs and/or chloroquine.\r&lt;br&gt;\r&lt;br&gt;          3. Requiring endotracheal intubation, mechanical ventilation, and extracorporeal membrane\r&lt;br&gt;             oxygenation (ECMO) at screening.\r&lt;br&gt;\r&lt;br&gt;          4. Patients being treated with immunomodulators or anti-rejection drugs.\r&lt;br&gt;\r&lt;br&gt;          5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 x upper limit\r&lt;br&gt;             of normal (ULN).\r&lt;br&gt;\r&lt;br&gt;          6. Creatinine clearance &lt; 50 mL/min.\r&lt;br&gt;\r&lt;br&gt;          7. Chronic Obstructive Pulmonary Disease (COPD) or end-stage lung disease that require\r&lt;br&gt;             home oxygen therapy.\r&lt;br&gt;\r&lt;br&gt;          8. Known hypersensitivity to recombinant proteins, or any excipient contained in the drug\r&lt;br&gt;             formulation of study pembrolizumab and tocilizumab.\r&lt;br&gt;\r&lt;br&gt;          9. Treatment with high doses of systemic corticosteroids within 72 hours prior signing\r&lt;br&gt;             the ICF except for inhaled steroids and prior corticosteroid therapy at dose lower\r&lt;br&gt;             than or equal to 10 mg/day methylprednisolone equivalent.\r&lt;br&gt;\r&lt;br&gt;         10. Bowel diverticulitis or perforation.\r&lt;br&gt;\r&lt;br&gt;         11. Diagnosis of immunodeficiency receiving immunosuppressive therapy within seven days\r&lt;br&gt;             prior to study treatment initiation. Active autoimmune disease that has required\r&lt;br&gt;             systemic treatment in past 2 years (i.e., with use of disease modifying agents,\r&lt;br&gt;             corticosteroids, or immunosuppressive drugs).\r&lt;br&gt;\r&lt;br&gt;         12. Current known infection with human immunodeficiency virus (HIV), hepatitis B virus\r&lt;br&gt;             (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV\r&lt;br&gt;             infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a\r&lt;br&gt;             positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA\r&lt;br&gt;             test) are eligible. Patients positive for HCV antibody are eligible only if polymerase\r&lt;br&gt;             chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).\r&lt;br&gt;\r&lt;br&gt;         13. Vaccination with any live virus vaccine within 28 days prior to study treatment\r&lt;br&gt;             initiation.\r&lt;br&gt;\r&lt;br&gt;             Note: Examples of live vaccines include, but are not limited to, the following:\r&lt;br&gt;             measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus\r&lt;br&gt;             Calmette-Gurin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection\r&lt;br&gt;             are generally killed virus vaccines and are allowed; however, intranasal influenza\r&lt;br&gt;             vaccines (e.g., FluMist) are live-attenuated vaccines and are not allowed.\r&lt;br&gt;\r&lt;br&gt;         14. History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation.\r&lt;br&gt;\r&lt;br&gt;         15. Patients have any other concurrent severe medical condition that would, in the\r&lt;br&gt;             Investigator's judgment contraindicate patient participation in the clinical study.\r&lt;br&gt;\r&lt;br&gt;         16. Pregnant women, lactating women and planned pregnant women.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal\r&lt;br&gt;             congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients of high clinical suspicion for COVID-19 with only one negative PRC test for\r&lt;br&gt;             SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;          -  Patients with COVID-19 who do not require hospitalization\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Group 1:\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed with RA, PsA, axSpA, SLE or AT and currently treated with either\r&lt;br&gt;             conventional synthetic disease modifying antirheumatic drugs (csDMARDs), biologic\r&lt;br&gt;             disease modifying antirheumatic drugs (bDMARDs), targeted synthetic disease modifying\r&lt;br&gt;             antirheumatic drugs (tsDMARDs) or prednisolone.\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed with COVID-19 verified by Polymerase Chain Reaction (PCR) or other accepted\r&lt;br&gt;             methods and hospitalized.\r&lt;br&gt;\r&lt;br&gt;          -  NOT diagnosed with disease known to cause either immunodeficiency or modification\r&lt;br&gt;             (Human Immunodeficiency Virus [HIV], lymphoproliferative disease etc.).\r&lt;br&gt;\r&lt;br&gt;          -  Patients (=18 years).\r&lt;br&gt;\r&lt;br&gt;          -  Ability and willingness to give written informed consent.\r&lt;br&gt;\r&lt;br&gt;          -  Ability to cooperate with research staff.\r&lt;br&gt;\r&lt;br&gt;        Group 2:\r&lt;br&gt;\r&lt;br&gt;          -  NOT diagnosed with an inflammatory disease\r&lt;br&gt;\r&lt;br&gt;          -  NOT treated with either csDMARDs, bDMARDs, tsDMARDs during the past 6 months or\r&lt;br&gt;             current oral prednisolone treatment.\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed with COVID-19 verified by PCR or other accepted methods and hospitalized.\r&lt;br&gt;\r&lt;br&gt;          -  NOT diagnosed with disease known to cause either immunodeficiency or modification\r&lt;br&gt;             (HIV, lymphoproliferative disease etc.).\r&lt;br&gt;\r&lt;br&gt;          -  Patients (=18 years).\r&lt;br&gt;\r&lt;br&gt;          -  Ability and willingness to give written informed consent.\r&lt;br&gt;\r&lt;br&gt;          -  Ability to cooperate with research staff.\r&lt;br&gt;\r&lt;br&gt;        Group 3:\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed with RA, PsA, axSpA, SLE or AT and currently treated with either csDMARDs,\r&lt;br&gt;             bDMARDs, tsDMARDs or prednisolone.\r&lt;br&gt;\r&lt;br&gt;          -  NOT hospitalised due to a COVID-19 infection.\r&lt;br&gt;\r&lt;br&gt;          -  NOT diagnosed with disease known to cause either immunodeficiency or modification\r&lt;br&gt;             (HIV, lymphoproliferative disease etc.).\r&lt;br&gt;\r&lt;br&gt;          -  Patients (=18 years).\r&lt;br&gt;\r&lt;br&gt;          -  Ability and willingness to give written informed consent.\r&lt;br&gt;\r&lt;br&gt;          -  Ability to cooperate with research staff.\r&lt;br&gt;\r&lt;br&gt;        Group 4:\r&lt;br&gt;\r&lt;br&gt;          -  Healthy subjects from the Danish Blood Donors.\r&lt;br&gt;\r&lt;br&gt;          -  Patients (=18 years).\r&lt;br&gt;\r&lt;br&gt;          -  NOT diagnosed with an inflammatory disease.\r&lt;br&gt;\r&lt;br&gt;          -  NOT treated with either csDMARDs, bDMARDs, tsDMARDs during the past 6 months or\r&lt;br&gt;             current oral prednisolone treatment.\r&lt;br&gt;\r&lt;br&gt;          -  NOT hospitalised due to a COVID-19 infection.\r&lt;br&gt;\r&lt;br&gt;          -  Ability and willingness to give written informed consent.\r&lt;br&gt;\r&lt;br&gt;          -  Ability to cooperate with research staff.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Suspected covid-19 infection and age 0-18 years\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Age &gt;18 years\r&lt;br&gt;","Inclusion criteria: &lt;br&gt;                1. Healthy adults aged 18 - 55 years&lt;br&gt;                2. Able and willing (in the Investigators opinion) to comply with all study requirements&lt;br&gt;                3. Willing to allow the investigators to discuss the volunteers medical history with their General Practitioner and access all medical records when relevant to study procedures&lt;br&gt;                4. For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination&lt;br&gt;                5. Agreement to refrain from blood donation during the course of the study&lt;br&gt;                6. Provide written informed consent&lt;br&gt;","Inclusion criteria: &lt;br&gt;                1. Any pregnant woman hospitalised who has tested positive for COVID-19 will be included.&lt;br&gt;                2. Aged 16-45 years.&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Judged to be healthy by the Investigator on the basis of medical history, physical\r&lt;br&gt;             examination and vital signs performed at screening.\r&lt;br&gt;\r&lt;br&gt;          -  Able and willing to comply with all study procedures.\r&lt;br&gt;\r&lt;br&gt;          -  Screening laboratory results within normal limits or deemed not clinically significant\r&lt;br&gt;             by the Investigator.\r&lt;br&gt;\r&lt;br&gt;          -  Negative serological tests for Hepatitis B surface antigen (HBsAg), Hepatitis C\r&lt;br&gt;             antibody and Human Immunodeficiency Virus (HIV) antibody screening.\r&lt;br&gt;\r&lt;br&gt;          -  Screening electrocardiogram (ECG) deemed by the Investigator as having no clinically\r&lt;br&gt;             significant findings (e.g. Wolff-Parkinson-White syndrome).\r&lt;br&gt;\r&lt;br&gt;          -  Use of medically effective contraception with a failure rate of &lt; 1% per year when\r&lt;br&gt;             used consistently and correctly from screening until 3 months following last dose, be\r&lt;br&gt;             post-menopausal, be surgically sterile or have a partner who is sterile.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breastfeeding, or intending to become pregnant or father children within\r&lt;br&gt;             the projected duration of the trial from screening until 3 months following last dose.\r&lt;br&gt;\r&lt;br&gt;          -  Is currently participating in or has participated in a study with an investigational\r&lt;br&gt;             product within 30 days preceding Day 0.\r&lt;br&gt;\r&lt;br&gt;          -  Previous exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or\r&lt;br&gt;             receipt of an investigational vaccine product for the prevention of COVID-19, middle\r&lt;br&gt;             east respiratory syndrome (MERS) or severe acute respiratory syndrome (SARS).\r&lt;br&gt;\r&lt;br&gt;          -  Current or history of the following medical conditions:\r&lt;br&gt;\r&lt;br&gt;               -  Respiratory diseases\r&lt;br&gt;\r&lt;br&gt;               -  Hypertension\r&lt;br&gt;\r&lt;br&gt;               -  Malignancy within 5 years of screening\r&lt;br&gt;\r&lt;br&gt;               -  Cardiovascular diseases\r&lt;br&gt;\r&lt;br&gt;          -  Immunosuppression as a result of underlying illness or treatment including:\r&lt;br&gt;\r&lt;br&gt;               -  Primary immunodeficiencies\r&lt;br&gt;\r&lt;br&gt;               -  Long term use (=7 days) of oral or parenteral glucocorticoids\r&lt;br&gt;\r&lt;br&gt;               -  Current or anticipated use of disease-modifying doses of anti-rheumatic drugs\r&lt;br&gt;                  (and biologic disease-modifying drugs\r&lt;br&gt;\r&lt;br&gt;               -  History of solid organ or bone marrow transplantation\r&lt;br&gt;\r&lt;br&gt;               -  Prior history of other clinically significant immunosuppressive or clinically\r&lt;br&gt;                  diagnosed autoimmune disease\r&lt;br&gt;\r&lt;br&gt;          -  Fewer than two acceptable sites are available for intradermal (ID) injection and\r&lt;br&gt;             electroporation (EP) considering the deltoid and anterolateral quadriceps muscles.\r&lt;br&gt;\r&lt;br&gt;          -  Any physical examination findings and/or history of any illness that, in the opinion\r&lt;br&gt;             of the study investigator, might confound the results of the study or pose an\r&lt;br&gt;             additional risk to the patient by their participation in the study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1st Line Consultation in Pediatric Emergencies\r&lt;br&gt;\r&lt;br&gt;          -  All reasons for consultation during working hours\r&lt;br&gt;\r&lt;br&gt;          -  Informed and written consent of a parent holder (only 1 authorized companion) and a\r&lt;br&gt;             child of understanding age\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Refusal of participation by parents/child of decision age\r&lt;br&gt;\r&lt;br&gt;          -  No membership of a social security scheme (beneficiary or entitled)\r&lt;br&gt;\r&lt;br&gt;          -  No understanding of French\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients that have been treated with, and still have, a MAGEC rod.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients that do not have a MAGEC rod implant.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  from covid 19 positive mothers\r&lt;br&gt;\r&lt;br&gt;          -  newborn mothers had not other condition or illness\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  from covid 19 negative mothers\r&lt;br&gt;\r&lt;br&gt;          -  childs\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Healthcare workers of the Department for Visceral Surgery and Medicine\r&lt;br&gt;\r&lt;br&gt;          -  Patients of the Department for Visceral Surgery and Medicine\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  No informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Patients with known COVID-19 infection before hospitalization in the investigators'\r&lt;br&gt;             department\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with diagnosed COVID-19 with confirmatory test\r&lt;br&gt;\r&lt;br&gt;          -  Increase in work of breathing or presence of dyspnea\r&lt;br&gt;\r&lt;br&gt;          -  Presence of lung changes associated with COVID pneumonia by chest imaging\r&lt;br&gt;\r&lt;br&gt;          -  Informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  Thrombocytopenia below 20,000 cells/mm3\r&lt;br&gt;\r&lt;br&gt;          -  Neutropenia below 500 cels/mm3\r&lt;br&gt;\r&lt;br&gt;          -  Known and active infection of HIV, Hepatitis C, Hepatitis B, Herpes Zoster or\r&lt;br&gt;             Mycobacterium Tuberculosis\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Confirmed COVID-19, and the nucleic acid test of respiratory specimens such as sputum\r&lt;br&gt;             or nasopharyngeal swabs is negative twice after the treatment (sampling interval is at\r&lt;br&gt;             least 24 hours);\r&lt;br&gt;\r&lt;br&gt;          2. Negative nucleic acid test of respiratory specimens such as sputum or nasopharyngeal\r&lt;br&gt;             swabs during screening visits;\r&lt;br&gt;\r&lt;br&gt;          3. High-resolution CT of the lung (HRCT) indicates pulmonary fibrosis (thickness of\r&lt;br&gt;             lobular septum, honeycomb-like changes, with or without bronchial / pleural\r&lt;br&gt;             distraction);\r&lt;br&gt;\r&lt;br&gt;          4. Voluntarily participate in research and sign informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Combined with severe heart, lung (diagnosed with interstitial lung disease, bronchial\r&lt;br&gt;             asthma, chronic obstructive pulmonary disease, etc.), liver and kidney disease or with\r&lt;br&gt;             endocrine, rheumatic, neurologic, malignant and other systemic diseases;\r&lt;br&gt;\r&lt;br&gt;          2. Have been diagnosed with connective tissue disease;\r&lt;br&gt;\r&lt;br&gt;          3. Pregnant or lactating women;\r&lt;br&gt;\r&lt;br&gt;          4. History of mental disorders, substance abuse or dependence;\r&lt;br&gt;\r&lt;br&gt;          5. Have used other anti-pulmonary fibrosis drugs in the past 14 days, such as nidanib,\r&lt;br&gt;             pirfenidone, penicillamine, colchicine, tumor necrosis factor alpha blocker, imatinib,\r&lt;br&gt;             glucocorticoid hormones, morphomycodyl esters, azathioprine, cyclophosphamide,\r&lt;br&gt;             interferon-?, and traditional Chinese medicine;\r&lt;br&gt;\r&lt;br&gt;          6. Researchers consider it inappropriate to participate in research;\r&lt;br&gt;\r&lt;br&gt;          7. Participating in other clinical research.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients discharged (deceased or alive) from any hospital center with a confirmed\r&lt;br&gt;             diagnosis or a COVID-19 high suspicion.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  There are no exclusion criteria, except for the patient's explicit refusal to\r&lt;br&gt;             participate.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age: 18 years or older (including 18 years); male or female\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory-confirmed SARS-CoV-2 or COVID-19 infection as determined by polymerase\r&lt;br&gt;             chain reaction (PCR) or other commercial or public health assay.\r&lt;br&gt;\r&lt;br&gt;          -  Bilateral lung infection confirmed by imaging.\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized patients =60 years old with underlying medical comorbidities OR Severe\r&lt;br&gt;             disease that meets one of the following conditions: (i) At rest, finger blood oxygen\r&lt;br&gt;             saturation = 93% or PaO2/FiO2 = 300 mmHg; OR (ii) Requiring non-invasive or invasive\r&lt;br&gt;             mechanical ventilation.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Any previous and/or current clinically significant disease or condition that has not\r&lt;br&gt;             been stable within 3 months prior to enrollment, or acute illness, planned medical/\r&lt;br&gt;             surgical procedure, or any trauma that occurred within 2 weeks prior to enrollment.\r&lt;br&gt;\r&lt;br&gt;          -  Chronic obstructive pulmonary disease (COPD) patients requiring inhaled\r&lt;br&gt;             corticosteroid, long-acting beta-adrenergic agonists, long-acting anticholinergics, or\r&lt;br&gt;             long-term oxygen therapy.\r&lt;br&gt;\r&lt;br&gt;          -  Pulmonary interstitial disease, pulmonary alveolar proteinosis, and pulmonary\r&lt;br&gt;             granulomatosis.\r&lt;br&gt;\r&lt;br&gt;          -  Cardiovascular event in the 3 months prior to study drug administration: acute\r&lt;br&gt;             myocardial infarction or unstable angina pectoris, severe arrhythmia (multiple sources\r&lt;br&gt;             of frequent ventricular premature beat, ventricular tachycardia and ventricular\r&lt;br&gt;             fibrillation); New York Heart Association Classification (NYHA): Class III-Class IV.\r&lt;br&gt;\r&lt;br&gt;          -  Blood system disorders or routine blood analysis test abnormalities: Hemoglobin &lt; 8\r&lt;br&gt;             g/dL; Absolute neutrophil count (ANC) &lt;1500  109/L; Platelets &lt; 50  109/L.\r&lt;br&gt;\r&lt;br&gt;          -  Dependence on glucocorticoid treatment equivalent to methylprednisolone 2 mg/kg/ day\r&lt;br&gt;             or more or long-term use of anti-rejection or immunomodulatory drugs.\r&lt;br&gt;\r&lt;br&gt;          -  Subjects that require ECMO.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breastfeeding females.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age: = 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Persons having given their written consent and accepting a weekly follow-up of 6\r&lt;br&gt;             weeks.\r&lt;br&gt;\r&lt;br&gt;          -  Persons affiliated to a social security scheme or beneficiary of such a scheme.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or lactating woman\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Participant is willing and able to provide informed consent.\r&lt;br&gt;\r&lt;br&gt;          2. Participant is 18-75 years of age.\r&lt;br&gt;\r&lt;br&gt;          3. Participant does not have symptoms of respiratory infection, including cough, fevers\r&lt;br&gt;             (temperature &gt;38.0C), difficulty breathing, shortness of breath, chest pains, malaise,\r&lt;br&gt;             myalgia, headaches, nausea or vomiting, or other symptoms associated with COVID-19.\r&lt;br&gt;\r&lt;br&gt;          4. Participant is willing to provide blood samples for the study.\r&lt;br&gt;\r&lt;br&gt;          5. Subject agrees to all aspects of the study.\r&lt;br&gt;\r&lt;br&gt;          6. The participant has no known allergies or contraindications (as stated in the consent\r&lt;br&gt;             form) to the use of hydroxychloroquine (HCQ) as noted in the exclusion criteria and\r&lt;br&gt;             Pharmacy sections.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Does not meet inclusion criteria.\r&lt;br&gt;\r&lt;br&gt;          2. Participant unable or unwilling to provide informed consent.\r&lt;br&gt;\r&lt;br&gt;          3. Participant has any of the symptoms above or screens positive for possible COVID-19\r&lt;br&gt;             disease.\r&lt;br&gt;\r&lt;br&gt;          4. Participant is currently enrolled in a study to evaluate an investigational drug.\r&lt;br&gt;\r&lt;br&gt;          5. Vulnerable populations deemed inappropriate for study by the site Principal\r&lt;br&gt;             Investigator.\r&lt;br&gt;\r&lt;br&gt;          6. The participant has a known allergy/hypersensitivity or has a medication or\r&lt;br&gt;             co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or\r&lt;br&gt;             renal failure) that prevents the use of HCQ (see pharmacy section).\r&lt;br&gt;\r&lt;br&gt;          7. The participant is a woman of childbearing age whose pregnancy status is unknown and\r&lt;br&gt;             is not willing to use 2 methods of contraception.\r&lt;br&gt;\r&lt;br&gt;          8. The participant is pregnant or nursing.\r&lt;br&gt;\r&lt;br&gt;          9. The participant was diagnosed with retinopathy prior to study entry.\r&lt;br&gt;\r&lt;br&gt;         10. The participant has a diagnosis of porphyria prior to study entry.\r&lt;br&gt;\r&lt;br&gt;         11. The participant has renal failure with a creatinine clearance of &lt;10 ml/min,\r&lt;br&gt;             pre-dialysis or requiring dialysis.\r&lt;br&gt;\r&lt;br&gt;         12. The Participant has a family history of Sudden Cardiac Death.\r&lt;br&gt;\r&lt;br&gt;         13. The participant is currently on diuretic therapy.\r&lt;br&gt;\r&lt;br&gt;         14. The participant has a history of known Prolonged QT Syndrome.\r&lt;br&gt;\r&lt;br&gt;         15. The participant is already taking any of the following medications: Abiraterone\r&lt;br&gt;             acetate, Agalsidase, Amodiaquine, Azithromycin, Conivaptan, Dabrafenib, Dacomitinib,\r&lt;br&gt;             Dapsone (Systemic), Digoxin, Enzalutamide, Fusidic Acid (Systemic), Idelalisib,\r&lt;br&gt;             Lanthanum, Lumefantrine, Mefloquine, Mifepristone, Mitotane, Pimozide, QT-prolonging\r&lt;br&gt;             Agents, Stiripentol).\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 positive patients\r&lt;br&gt;\r&lt;br&gt;          -  Treated at the Health Institute of the State of Mexico (ISEM).\r&lt;br&gt;\r&lt;br&gt;          -  With risk factors to get complicated: age more than 60 years old, diabetes mellitus or\r&lt;br&gt;             obesity grade II or more.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients who have inherent contraindications to each drug.\r&lt;br&gt;","Inclusion criteria: 1. A diagnosis of an ASD according to the fifth edition of Diagnostic and Statistical Manual(DSM-5); 2. Preschool Children (3-7 years);DQ (Development Quotient) &gt; 75; 3. Mothers were conscious and gave informed consent.","Inclusion criteria: 1. suspicion of COVID-19 based on the Novel Coronavirus Pneumonia Prevention and Control Program 7th edition (National Health Commission of China, 2020b);\r&lt;br&gt;2. aged &gt;16 years.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Adults residing in the United States aged 18 years or older proficient in\r&lt;br&gt;             understanding and reading the English language who wish to participate in the fight\r&lt;br&gt;             against COVID-19 by providing self-reported health information.\r&lt;br&gt;\r&lt;br&gt;          2. Ability to complete electronic informed consent process.\r&lt;br&gt;\r&lt;br&gt;          3. Ability to use the internet and check email regularly.\r&lt;br&gt;\r&lt;br&gt;          4. Consent to provide a HIPAA waiver of health information to share protected health\r&lt;br&gt;             information.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1. Inability to provide regular updates to their health status when contacted by the BEAT\r&lt;br&gt;        COVID study personnel via email or SMS.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed or suspected SARS-Cov2 cases\r&lt;br&gt;\r&lt;br&gt;          -  Patients admitted to ICU, defined as a unit in which patients can receive\r&lt;br&gt;             vasopressors.\r&lt;br&gt;\r&lt;br&gt;          -  Monitored by a transpulmonary thermodilution system (PiCCO2 (Pulsion Medical Systems,\r&lt;br&gt;             Feldkirchen, Germany) or EV1000 (Edwards Lifesciences, Irvine, United States of\r&lt;br&gt;             America).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  SARS Cov-2 Negative\r&lt;br&gt;\r&lt;br&gt;          -  Refusal to participate in the study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Positive COVID-19 test\r&lt;br&gt;\r&lt;br&gt;          -  Outpatient\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt;/= 19 y.o.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Allergic reaction to tranexamic acid\r&lt;br&gt;\r&lt;br&gt;          -  History of hypercoagulation disorders (deep venous thrombosis, pulmonary\r&lt;br&gt;             thromboembolism)\r&lt;br&gt;\r&lt;br&gt;          -  Ongoing anticoagulation\r&lt;br&gt;\r&lt;br&gt;          -  History of GI bleeding\r&lt;br&gt;\r&lt;br&gt;          -  History of Seizures\r&lt;br&gt;\r&lt;br&gt;          -  Cardiac or other vascular stents\r&lt;br&gt;\r&lt;br&gt;          -  History of severe renal disease\r&lt;br&gt;\r&lt;br&gt;          -  History of intracranial hemorrhage\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient with COVID-19 confirmed by positive RT-PCR or considered as probable by the\r&lt;br&gt;             in-charge physician,\r&lt;br&gt;\r&lt;br&gt;          -  =18 years old,\r&lt;br&gt;\r&lt;br&gt;          -  Not requiring respiratory assistance and/or other intensive care\r&lt;br&gt;\r&lt;br&gt;          -  Not subject to a limitation of active therapeutics\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  History of pneumonectomy\r&lt;br&gt;\r&lt;br&gt;          -  Any reason making chest ultrasonography impossible\r&lt;br&gt;\r&lt;br&gt;          -  Any reason making 14-day follow-up impossible\r&lt;br&gt;\r&lt;br&gt;          -  Patient opposition to research participation.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Signed informed consent, demonstrating that the subject understands the procedures\r&lt;br&gt;             required for the study and the purpose of the study\r&lt;br&gt;\r&lt;br&gt;          2. Healthy male or female subjects 18 years of age to 55 years of age\r&lt;br&gt;\r&lt;br&gt;          3. Subjects must agree to practice at least one highly effective method of birth control\r&lt;br&gt;             for the duration of the study\r&lt;br&gt;\r&lt;br&gt;          4. Diagnosis of COVID-19 by RT-PCR\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Refusal to sign informed consent form\r&lt;br&gt;\r&lt;br&gt;          2. Negative test for COVID-19 by RT-PCR at screening\r&lt;br&gt;\r&lt;br&gt;          3. Diarrhea (prior to infection)\r&lt;br&gt;\r&lt;br&gt;          4. Any comorbidities which, in the opinion of the investigator, constitute health risk\r&lt;br&gt;             for the subject\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participants that, after receiving appropriate information on the study design,\r&lt;br&gt;             objectives, possible risks and acknowledging they have the right to withdraw from the\r&lt;br&gt;             study consent at any time, sing the informed consent for participation in the study.\r&lt;br&gt;\r&lt;br&gt;          -  Male or female aged 18-65 years.\r&lt;br&gt;\r&lt;br&gt;          -  Health care workers in public or private hospitals in Spain in areas of risk of\r&lt;br&gt;             SARS-CoV-2 transmission.\r&lt;br&gt;\r&lt;br&gt;          -  No previous diagnosis of SARS-CoV-2 (COVID-19) infection plus no symptoms compatible\r&lt;br&gt;             with SARS-CoV-2 (COVID-19) since 1st of March 2020 until the date of enrolment in the\r&lt;br&gt;             study.\r&lt;br&gt;\r&lt;br&gt;          -  Understanding of the aim of the study and, therefore, acknowledging they have not been\r&lt;br&gt;             on any drug aiming at pre exposure prophylaxis against SARS-CoV-2 (COVID-19) since 1st\r&lt;br&gt;             of March 2020. This also includes PrEP for HIV.\r&lt;br&gt;\r&lt;br&gt;          -  Negative pregnancy test during the previous 7 days to start treatments or more than 2\r&lt;br&gt;             years after menopause.\r&lt;br&gt;\r&lt;br&gt;          -  Women of reproductive age and their partners should commit to use and highly effective\r&lt;br&gt;             contraceptive method ( double barrier, hormonal contraception), during the study\r&lt;br&gt;             period and until 6 months after the last dose of treatment.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  HIV infection\r&lt;br&gt;\r&lt;br&gt;          -  Active hepatitis B infection.\r&lt;br&gt;\r&lt;br&gt;          -  Renal failure with estimated glomerular filtration rate (GFR) &lt; 60 ml/min) and\r&lt;br&gt;             patients on Hemodialysis.\r&lt;br&gt;\r&lt;br&gt;          -  Osteoporosis\r&lt;br&gt;\r&lt;br&gt;          -  Myasthenia gravis\r&lt;br&gt;\r&lt;br&gt;          -  Pre-existent maculopathy.\r&lt;br&gt;\r&lt;br&gt;          -  Retinitis pigmentosa\r&lt;br&gt;\r&lt;br&gt;          -  Bradycardia &lt; 50bpm\r&lt;br&gt;\r&lt;br&gt;          -  Weight &lt; 40kg\r&lt;br&gt;\r&lt;br&gt;          -  Participant with any immunosuppressive condition or hematological disease\r&lt;br&gt;\r&lt;br&gt;          -  Treatment with drugs that may prolong QT in the last month before randomization for\r&lt;br&gt;             more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin,\r&lt;br&gt;             domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine,\r&lt;br&gt;             mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol,\r&lt;br&gt;             sparfloxacin, thioridazine, amiodarone.\r&lt;br&gt;\r&lt;br&gt;          -  Breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  Known allergy to any of the medication used in this trial\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Hospitalized male or female\r&lt;br&gt;\r&lt;br&gt;          2. Diagnosed to be COVID-19 POSITIV\r&lt;br&gt;\r&lt;br&gt;          3. Signed Inform Consent Form\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Any patient whose clinical condition is deteriorating rapidly\r&lt;br&gt;\r&lt;br&gt;          2. Known positive Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody\r&lt;br&gt;\r&lt;br&gt;          3. History of sensitivity to any of the study medications, or components thereof or a\r&lt;br&gt;             history of drug or other allergy that, in the opinion of the investigator or Medical\r&lt;br&gt;             Monitor, contraindicates their participation\r&lt;br&gt;\r&lt;br&gt;          4. Pregnant females as determined by positive serum or urine hCG test prior to dosing\r&lt;br&gt;\r&lt;br&gt;          5. Lung transplantation\r&lt;br&gt;\r&lt;br&gt;          6. Pre-existing renal failure, i.e. requiring renal replacement therapy with hemodialysis\r&lt;br&gt;             or peritoneal dialysis\r&lt;br&gt;\r&lt;br&gt;          7. There are other uncontrolled co-morbidities that increase the risks associated with\r&lt;br&gt;             the study drug administration, that are assessed by the medical expert team as\r&lt;br&gt;             unsuitable\r&lt;br&gt;\r&lt;br&gt;          8. Patient in trials for COVID-19 within 30 days before ICF\r&lt;br&gt;\r&lt;br&gt;          9. Immunocompromised patients (chemotherapy, HIV, organ transplants, stem cell\r&lt;br&gt;             transplants)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized\r&lt;br&gt;        because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be\r&lt;br&gt;        included\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - Patients under 18 years\r&lt;br&gt;","Inclusion criteria: 1. Patients with Corona Virus Disease 2019 admitted to Wuhan First Hospital and Wuhan Jinyintan Hospital ICU from January 1, 2020 to March 31, 2020;\r&lt;br&gt;2. Patients diagnosed with Corona Virus Disease 2019 according to WHO diagnostic criteria (including nucleic acid examination and chest CT examination);\r&lt;br&gt;3. Patients whose mechanical ventilation is required, FIO2 is greater than or equal to 60%, and intravenous vasoactive drugs are required to maintain blood pressure.","Inclusion criteria: 1. Aged 18-45 years old men and women;\r&lt;br&gt;2. Inpatients;\r&lt;br&gt;3. According to the novel coronavirus diagnosis and treatment plan (Seventh Edition), it meets the diagnostic criteria of light and general type and achieves discharge standard after treatment;\r&lt;br&gt;4. Signing informed consent.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients included in the CORIMUNO-19 cohort\r&lt;br&gt;\r&lt;br&gt;          2. Patients with C-reactive protein level (CRP) &gt; 25 mg / L the day or the day before the\r&lt;br&gt;             infusion)\r&lt;br&gt;\r&lt;br&gt;          3. Patients belonging to one of the 2 following groups:\r&lt;br&gt;\r&lt;br&gt;               -  Group 1: patients meeting all of the following criteria: 1) Requiring more than\r&lt;br&gt;                  3L/min of oxygen; 2) WHO progression scale = 5; 3) No NIV or High flow\r&lt;br&gt;\r&lt;br&gt;               -  Group 2: patients with respiratory failure AND (requiring mechanical ventilation\r&lt;br&gt;                  OR NIV OR High flow), with a WHO progression scale = 6, and no do-not-resuscitate\r&lt;br&gt;                  (DNR) order\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with exclusion criteria to the CORIMUNO-19 cohort.\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity to Anakinra or to any of their excipients.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Current documented bacterial infection.\r&lt;br&gt;\r&lt;br&gt;          -  Patient with any of following laboratory results out of the ranges detailed below at\r&lt;br&gt;             screening:\r&lt;br&gt;\r&lt;br&gt;               -  Absolute neutrophil count (ANC) = 1.0 x 109/L\r&lt;br&gt;\r&lt;br&gt;               -  Haemoglobin level: no limitation\r&lt;br&gt;\r&lt;br&gt;               -  Platelets (PLT) &lt; 50 G /L\r&lt;br&gt;\r&lt;br&gt;               -  SGOT or SGPT &gt; 5N\r&lt;br&gt;\r&lt;br&gt;               -  Severe renal insufficiency with Glomerular filtration rate &lt; 30 ml / mn\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Subjects enrolled in the trial must meet all of the following criteria.\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed COVID-19 pneumonia or high likelihood of COVID-19 pneumonia as suggested by\r&lt;br&gt;             the presence of: a) bilateral pulmonary infiltrates, b) fever &gt;100 degrees Fahrenheit,\r&lt;br&gt;             c) negative URI PCR for other viral pathogens (if performed per clinical indications),\r&lt;br&gt;             and d) serum procalcitonin =0.25ng/mL\r&lt;br&gt;\r&lt;br&gt;          -  Hypoxia as defined by room air oxygen saturation less than 90% or supplemental oxygen\r&lt;br&gt;             requirement\r&lt;br&gt;\r&lt;br&gt;          -  Presence of at least one additional biomarker that has been shown to predict poor\r&lt;br&gt;             prognosis: a) serum ferritin =500ug/l, b) LDH =250U/L, c) d-dimer =1ug/L, or d)\r&lt;br&gt;             lymphopenia as defined by absolute lymphocyte count &lt;1,000/uL\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Completed informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Subjects who meet ANY of the following criteria are not eligible for enrollment as study\r&lt;br&gt;        participants:\r&lt;br&gt;\r&lt;br&gt;          -  Known allergy or hypersensitivity to sirolimus\r&lt;br&gt;\r&lt;br&gt;          -  Inability or refusal to provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Advanced respiratory support (high flow oxygen = 15 L/min, CPAP, non-invasive or\r&lt;br&gt;             invasive mechanical ventilation)\r&lt;br&gt;\r&lt;br&gt;          -  Active enrollment in other interventional clinical drug trials. Co-enrollment in\r&lt;br&gt;             observational studies and biorepositories is allowed.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant women\r&lt;br&gt;\r&lt;br&gt;          -  Breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  On chronic immunosuppression for other medical conditions such as rheumatological\r&lt;br&gt;             disorders, inflammatory bowel disease, or in patients with organ transplants. A list\r&lt;br&gt;             of these medications is provided in Section 12.3.4\r&lt;br&gt;\r&lt;br&gt;          -  Any clinically significant medical disease which in the opinion of the investigator\r&lt;br&gt;             precludes the patient from enrolling in the trial, including (but not limited to):\r&lt;br&gt;\r&lt;br&gt;               -  History of liver cirrhosis\r&lt;br&gt;\r&lt;br&gt;               -  End stage renal disease or need for renal replacement therapy\r&lt;br&gt;\r&lt;br&gt;               -  Decompensated heart failure\r&lt;br&gt;\r&lt;br&gt;               -  Known active tuberculosis or history of incompletely treated tuberculosis\r&lt;br&gt;\r&lt;br&gt;               -  Uncontrolled systemic bacterial or fungal infections\r&lt;br&gt;\r&lt;br&gt;               -  Active viral infection other than COVID-19\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients admitted to hospital with proven COVID-19 infection with respiratory signs\r&lt;br&gt;             warranting a chest CT scan\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient not agreeing to have his or her data collected for the study\r&lt;br&gt;\r&lt;br&gt;          -  Unconscious patient\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Clinical criteria for suspicion of Covid-19 in an epidemic period: Signs of acute\r&lt;br&gt;             respiratory infection (rhinorrhea, odynophagia, cough, dyspnea, polypnea, signs of\r&lt;br&gt;             struggle, pathological auscultation) or syndrome influenza or acute respiratory\r&lt;br&gt;             distress (hypoxia, polypnoea, signs of respiratory distress).\r&lt;br&gt;\r&lt;br&gt;          -  Consultation in the emergency departement\r&lt;br&gt;\r&lt;br&gt;          -  Non-opposition agree\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory impairment related to another identified cause than Covid-19, in\r&lt;br&gt;             particular a rapid diagnostic test flu-positive\r&lt;br&gt;\r&lt;br&gt;          -  Severe patient from the outset with transfer to intensive care within 12 hours of\r&lt;br&gt;             admission to the Emergency Department\r&lt;br&gt;\r&lt;br&gt;          -  No social security coverage (beneficiary or entitled person)\r&lt;br&gt;\r&lt;br&gt;          -  Poor understanding of French\r&lt;br&gt;\r&lt;br&gt;          -  Refusal to participate\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  12 intubated and mechanically ventilated COVID-19 patients admitted to the ICU at a\r&lt;br&gt;             single time point (29/03/2020).\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. Patient or guardian must provide written informed consent (and assent if\r&lt;br&gt;             applicable) before any study assessment is performed.\r&lt;br&gt;\r&lt;br&gt;          -  2. Male and female patients aged = 18 years.\r&lt;br&gt;\r&lt;br&gt;          -  3. Patients with temperature &gt; 37.3C\r&lt;br&gt;\r&lt;br&gt;          -  4. Patients with respiratory symptoms and/or hypoxia SpO2 &lt; 93%\r&lt;br&gt;\r&lt;br&gt;          -  5. Patients with Covid-19 stage II and stage III\r&lt;br&gt;\r&lt;br&gt;          -  6. Patients with lung imaging showing bi-pulmonary infiltrates (chest X-ray or CT\r&lt;br&gt;             scan).\r&lt;br&gt;\r&lt;br&gt;          -  7. Patients, with a Covid Inflammation Score = 10\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. History of hypersensitivity to any drugs or metabolites of similar chemical classes\r&lt;br&gt;             as ruxolitinib.\r&lt;br&gt;\r&lt;br&gt;          -  2. Uncontrolled active bacterial, fungal, viral, or other infection (besides\r&lt;br&gt;             COVID-19).\r&lt;br&gt;\r&lt;br&gt;          -  3. Active Tuberculosis infection.\r&lt;br&gt;\r&lt;br&gt;          -  4. Known Positivity for HBV, HCV or HIV.\r&lt;br&gt;\r&lt;br&gt;          -  5. Patients who are on long-term use of oral anti-rejection or immunomodulatory drugs\r&lt;br&gt;\r&lt;br&gt;          -  6. Participating in any other interventional clinical trial for COVID-19.\r&lt;br&gt;\r&lt;br&gt;          -  7. Treatment with cytokine-directed agents such as anti-IL6 or anti-IL1R directed\r&lt;br&gt;             antibodies (i.e. tocilizumab, anakinra). Other treatment modalities used in locally\r&lt;br&gt;             adapted SOPs (corticosteroids, chloroquine, hydroxychloroquine, lopinavir-ritonavir)\r&lt;br&gt;             may be given with daily documentation of dose and schedule.\r&lt;br&gt;\r&lt;br&gt;          -  8. ALT or AST &gt; 5 x ULN detected within 24 hours at screening (according to local\r&lt;br&gt;             laboratory reference ranges).\r&lt;br&gt;\r&lt;br&gt;          -  9. ANC &lt; 500/L at screening (according to local laboratory reference ranges).\r&lt;br&gt;\r&lt;br&gt;          -  10. Platelet count &lt; 50,000/L at screening (according to local laboratory reference\r&lt;br&gt;             ranges).\r&lt;br&gt;\r&lt;br&gt;          -  11. Hemoglobin &lt; 6 g/dl (3.73mmol/l)\r&lt;br&gt;\r&lt;br&gt;          -  12. Pregnant or nursing (lactating) women.\r&lt;br&gt;\r&lt;br&gt;          -  13. Female patients of childbearing potential (e.g. are menstruating) and male\r&lt;br&gt;             patients who do not agree to abstinence or, if sexually active, do not agree to the\r&lt;br&gt;             use of highly effective contraception as defined below, throughout the study and for\r&lt;br&gt;             up to 90 days after stopping treatment, OR Female patients of child-bearing potential,\r&lt;br&gt;             defined as all women physiologically capable of becoming pregnant, unless they are\r&lt;br&gt;             using highly effective methods of contraception as defined below, throughout the study\r&lt;br&gt;             and for up to 90 days after stopping treatment.\r&lt;br&gt;\r&lt;br&gt;        Highly effective contraception methods include:\r&lt;br&gt;\r&lt;br&gt;          -  Total abstinence (when this is in line with the preferred and usual lifestyle of the\r&lt;br&gt;             patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal,\r&lt;br&gt;             post-ovulation methods) and withdrawal are not acceptable methods of contraception.\r&lt;br&gt;\r&lt;br&gt;          -  Female sterilization (have had surgical bilateral oophorectomy with or without\r&lt;br&gt;             hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking\r&lt;br&gt;             study treatment. In case of oophorectomy alone, only when the reproductive status of\r&lt;br&gt;             the woman has been confirmed by follow up hormone level assessment.\r&lt;br&gt;\r&lt;br&gt;          -  Male sterilization (at least 6 months prior to screening). The vasectomized male\r&lt;br&gt;             partner should be the sole partner for that patient.\r&lt;br&gt;\r&lt;br&gt;          -  Use of oral, injected or implanted hormonal methods of contraception. Placement of an\r&lt;br&gt;             intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal\r&lt;br&gt;             contraception that have comparable efficacy (failure rate &lt;1%), for example hormone\r&lt;br&gt;             vaginal ring or transdermal hormone contraception (in case of oral contraception,\r&lt;br&gt;             patients should have been using the same pill on a stable dose for a minimum of 3\r&lt;br&gt;             months before Screening).\r&lt;br&gt;\r&lt;br&gt;        Women are considered post-menopausal and not of child bearing potential if they have had 12\r&lt;br&gt;        months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age\r&lt;br&gt;        appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy\r&lt;br&gt;        (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks\r&lt;br&gt;        ago. In the case of oophorectomy alone, only when the reproductive status of the woman has\r&lt;br&gt;        been confirmed by follow up hormone level assessment is she considered not of child bearing\r&lt;br&gt;        potential.\r&lt;br&gt;","\r&lt;br&gt;        Inclusions:\r&lt;br&gt;\r&lt;br&gt;          1. Trauma patients presenting to our institution as trauma activation\r&lt;br&gt;\r&lt;br&gt;          2. Trauma patients presenting to our institution as trauma alerts\r&lt;br&gt;\r&lt;br&gt;        Exclusions:\r&lt;br&gt;\r&lt;br&gt;          1. Patients who require prompt surgical exploration based on physical exam findings\r&lt;br&gt;             (minimize delays in transport to the operating room)\r&lt;br&gt;\r&lt;br&gt;          2. Patients with an open chest injury\r&lt;br&gt;","\r&lt;br&gt;        Patient groups\r&lt;br&gt;\r&lt;br&gt;          1. COVID-19+ (n=140) All patients =18 years old admitted to Barts NHS Trust will be\r&lt;br&gt;             eligible for this group.\r&lt;br&gt;\r&lt;br&gt;          2. COVID-19+ Myocardial injury+ (n=20) All patients =18 years old admitted to Barts NHS\r&lt;br&gt;             Trust who have a diagnosis of COVID-19 and evidence of myocardial injury (troponin\r&lt;br&gt;             &gt;99th centile). We will exclude patients from this cohort who have significant chronic\r&lt;br&gt;             kidney disease (eGFR =30 or on dialysis) or septic shock. We will also exclude\r&lt;br&gt;             patients with a diagnosis of chronic heart failure and obstructive coronary artery\r&lt;br&gt;             disease (treated or untreated).\r&lt;br&gt;\r&lt;br&gt;          3. COVID-19+ Complication+ (n=20) All patients =18 years old admitted to the Barts NHS\r&lt;br&gt;             Trust who have a diagnosis of COVID-19 and who develop a complication directly related\r&lt;br&gt;             to the viral infection. Specifically, we will recruit patients who require admission\r&lt;br&gt;             to ICU, develop acute respiratory distress syndrome (ARDS) or secondary hemophagocytic\r&lt;br&gt;             lymphohistiocytosis (as defined in the referenced paper13).\r&lt;br&gt;","Inclusion criteria: 1. Adult &gt;= 18 years old;\r&lt;br&gt;2. Laboratory confirmed COVID-19 infection (i.e. detection of SARS-CoV-2 virus by RT-PCR in one or more clinical specimens);\r&lt;br&gt;3. Provide direct clinical care to confirmed COVID-19 patients.","Inclusion criteria: All medical team members who completed the sleep therapy questionnaire survey;\r&lt;br&gt;The subject who signed an informed consent form;","\r&lt;br&gt;        Inclusion Criteria\r&lt;br&gt;\r&lt;br&gt;          -  Adult (age = 18 years)\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to the hospital of any participating center\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed SARS-CoV-2 infection with either: positive laboratory test for SARS-CoV-2* ;\r&lt;br&gt;             or positive CT thorax diagnostic for SARS-CoV-2 infection according to the prevailing\r&lt;br&gt;             criteria\r&lt;br&gt;\r&lt;br&gt;          -  Randomization:\r&lt;br&gt;\r&lt;br&gt;               -  Within 24 hours of confirmed in-hospital SARS-CoV-2 infection diagnosis OR\r&lt;br&gt;\r&lt;br&gt;               -  within 24 hours of hospital admission in case of pre-hospital confirmed\r&lt;br&gt;                  SARS-CoV-2 infection.\r&lt;br&gt;\r&lt;br&gt;                    -  In case there is a lack of laboratory tests for SARS-CoV-2 in the\r&lt;br&gt;                       participating center of the potentially eligible patient, a positive\r&lt;br&gt;                       laboratory test for SARS-CoV-2 will be no longer required. In that case, the\r&lt;br&gt;                       potentially eligible patient needs to meet the prevailing criteria for the\r&lt;br&gt;                       diagnosis of SARS-CoV-2 infection of that participating center, such as\r&lt;br&gt;                       typical abnormalities on pulmonary CT in the setting of high clinical\r&lt;br&gt;                       suspicion of SARS-CoV-2 infection.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Admitted to ICU prior to randomization\r&lt;br&gt;\r&lt;br&gt;          -  Currently taking an ARB or angiotensin-receptor-neprilysin-inhibitor (ARNI)\r&lt;br&gt;\r&lt;br&gt;          -  Use of other investigational drugs at the time of enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Prior reaction or intolerance to an ARB or ARNI; or severe intolerance to an ACEi,\r&lt;br&gt;             defined as angio-oedema requiring medical intervention\r&lt;br&gt;\r&lt;br&gt;          -  Systolic blood pressure &lt; 105mmHg or diastolic blood pressure &lt;65mmHg\r&lt;br&gt;\r&lt;br&gt;          -  Potassium greater than 5.5 mEq/L within 4 weeks of study enrollment.\r&lt;br&gt;\r&lt;br&gt;          -  Estimated Glomerular Filtration Rate (eGFR) of &lt; 30ml/min/1.73 m2 within 4 weeks of\r&lt;br&gt;             study initiation\r&lt;br&gt;\r&lt;br&gt;          -  A known history of renal artery stenosis\r&lt;br&gt;\r&lt;br&gt;          -  AST and/or ALT &gt; 3 times the upper limit of normal within 4 weeks of study enrollment.\r&lt;br&gt;             In case of mild to moderate liver dysfunction valsartan dosage will be limited to a\r&lt;br&gt;             maximum of 80mg\r&lt;br&gt;\r&lt;br&gt;          -  Severe liver dysfunction, biliary cirrhosis or cholestasis\r&lt;br&gt;\r&lt;br&gt;          -  Severe volume depletion or severe acute kidney injury that, in the opinion of the\r&lt;br&gt;             investigator, would preclude administration of valsartan\r&lt;br&gt;\r&lt;br&gt;          -  Concurrent treatment with Aliskiren\r&lt;br&gt;\r&lt;br&gt;          -  Inability to obtain informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breastfeeding\r&lt;br&gt;\r&lt;br&gt;          -  In females of childbearing age, unwillingness to use birth control or to be sexually\r&lt;br&gt;             abstinent for the duration of the study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Aged 18-65 years;\r&lt;br&gt;\r&lt;br&gt;          2. Voluntarily participate in this clinical trial and sign off \"informed consent form\";\r&lt;br&gt;\r&lt;br&gt;          3. Diagnosed with severe pneumonia of COVID: respiratory distress, RR &gt;30 times / min;\r&lt;br&gt;             resting oxygen saturation of 93% or less; arterial partial pressure of oxygen / oxygen\r&lt;br&gt;             concentration 300mmHg; SARS-CoV-2 nucleic acid test was positive.\r&lt;br&gt;\r&lt;br&gt;          4. Chest imaging confirm COVID-19 featured lesions in lung.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Receive any clinical trial drug treatment for COVID-2019 within 30 days before the\r&lt;br&gt;             screening assessment;\r&lt;br&gt;\r&lt;br&gt;          2. Severe liver disease (e.g., Child Pugh score &gt;=C or AST&gt; 5 times of the upper limit);\r&lt;br&gt;\r&lt;br&gt;          3. Patients with known severe renal insufficiency (estimated glomerular filtration rate\r&lt;br&gt;             &lt;=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy,\r&lt;br&gt;             hemodialysis, peritoneal dialysis;\r&lt;br&gt;\r&lt;br&gt;          4. Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other\r&lt;br&gt;             respiratory infection viruses;\r&lt;br&gt;\r&lt;br&gt;          5. Female patients who have no sexual protection in the last 30 days prior to the\r&lt;br&gt;             screening assessment;\r&lt;br&gt;\r&lt;br&gt;          6. Pregnant or lactating women or women using estrogen contraception;\r&lt;br&gt;\r&lt;br&gt;          7. Patients who are planning to become pregnant during the study period or within 6\r&lt;br&gt;             months after the end of the study period;\r&lt;br&gt;\r&lt;br&gt;          8. Other conditions that the researchers consider not suitable for participating in this\r&lt;br&gt;             clinical trial.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        All subjects participating in this clinical study must meet all of the following criteria:\r&lt;br&gt;\r&lt;br&gt;          1. According to the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 5),\r&lt;br&gt;             under the premise of meeting the diagnostic criteria of moderate COVID-19, the\r&lt;br&gt;             subjects should meet one of the following three conditions:\r&lt;br&gt;\r&lt;br&gt;             ? Respiratory rate (RR): = 20 times/min;\r&lt;br&gt;\r&lt;br&gt;             ? In the state of air absorption and rest, the peripheral oxygen saturation is lower\r&lt;br&gt;             than 95%;\r&lt;br&gt;\r&lt;br&gt;             ? Arterial partial pressure of oxygen (PaO2)/FiO2: = 400 mmHg (1mmHg=0.133 kPa).\r&lt;br&gt;\r&lt;br&gt;          2. =18 years old and =85 years old subjects with normal autonomous judgment, regardless\r&lt;br&gt;             of gender and region;\r&lt;br&gt;\r&lt;br&gt;          3. Subjects voluntarily participate in the study and have signed the informed consent\r&lt;br&gt;             form.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Have other significant diseases other than COVID-19, that is, a disease that,\r&lt;br&gt;             according to the investigator's judgment, can cause the subject to be at risk due to\r&lt;br&gt;             participation in the study, or affect the study results and the ability of the subject\r&lt;br&gt;             to participate in the study.\r&lt;br&gt;\r&lt;br&gt;          2. Women who are pregnant or breastfeeding or plan to be pregnant during the study.\r&lt;br&gt;\r&lt;br&gt;          3. Subjects with one of the following respiratory diseases:\r&lt;br&gt;\r&lt;br&gt;               1. Asthma: Based on the investigator's judgment, the subjects are currently\r&lt;br&gt;                  diagnosed with asthma.\r&lt;br&gt;\r&lt;br&gt;               2. Subjects with a long-term history of COPD and medication or imaging evidence of\r&lt;br&gt;                  significant lung structural damage (e.g., giant pulmonary bullae).\r&lt;br&gt;\r&lt;br&gt;             Other respiratory diseases: Subjects with other active pulmonry diseases, such as\r&lt;br&gt;             active tuberculosis, lung cancer, wet bronchiectasis (the high-resolution CT shows\r&lt;br&gt;             bronchiectasis, with yellow sputum every day), sarcoidosis, idiopathic interstitial\r&lt;br&gt;             pulmonary fibrosis (IPF), primary pulmonary arterial hypertension, and uncontrolled\r&lt;br&gt;             sleep apnea (the severity of the disease will affect the implementation of c)the study\r&lt;br&gt;             according to the investigator's judgment), complicated with pneumothorax, pleural\r&lt;br&gt;             effusion, pulmonary embolism, bronchial asthma, tumor, and fever of unknown origin,\r&lt;br&gt;             etc.\r&lt;br&gt;\r&lt;br&gt;             d)Lung volume reduction: Subjects received lung volume reduction, lobectomy, or\r&lt;br&gt;             bronchoscopic lung volume reduction (endobronchial occlusion, airway bypass,\r&lt;br&gt;             endobronchial valve, steam thermal ablation, biological sealant and airway implant)\r&lt;br&gt;             within 6 months.\r&lt;br&gt;\r&lt;br&gt;             e)Subjects in critical or unstable conditions. Critical (meeting any of the following\r&lt;br&gt;             symptoms): 1. Respiratory failure occurs and mechanical ventilation is needed; 2.\r&lt;br&gt;             Shock occurs; 3. With other organ failure, ICU monitoring and treatment is needed.\r&lt;br&gt;\r&lt;br&gt;             f)Risk factors for pneumonia: immunosuppressive diseases (HIV), severe neurological\r&lt;br&gt;             disease affecting upper respiratory tract control, or other risk factors that the\r&lt;br&gt;             investigator believes can cause a significant risk of pneumonia in subjects.\r&lt;br&gt;\r&lt;br&gt;          4. Subjects with serious primary diseases of heart, liver, kidney, hematopoietic system\r&lt;br&gt;             and other important organs or systems.\r&lt;br&gt;\r&lt;br&gt;          5. Subjects with mental disorder and cognitive impairment.\r&lt;br&gt;\r&lt;br&gt;          6. Subjects who do not follow the study steps.\r&lt;br&gt;\r&lt;br&gt;          7. Patients with doubts about the effectiveness of informed consent: Subjects with mental\r&lt;br&gt;             illness, mental retardation, poor motivation, drug abuse (including drugs and alcohol)\r&lt;br&gt;             or other disease history restricting the effectiveness of informed consent in this\r&lt;br&gt;             study.\r&lt;br&gt;\r&lt;br&gt;          8. Use of non-expectorants and antioxidants, including large doses of vitamin C and\r&lt;br&gt;             vitamen E.\r&lt;br&gt;\r&lt;br&gt;          9. Subjects who are not suitable for participation in this study in the judgment of\r&lt;br&gt;             investigator.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Able to provide informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  None\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient is 18 to 80 years old female.\r&lt;br&gt;\r&lt;br&gt;          -  Patient must have histologically confirmed either type of gynecological malignancies.\r&lt;br&gt;\r&lt;br&gt;          -  Chemotherapy must be essential for the patient.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Diagnosed or suspected patients with covid-19 pneumonia, according to the symptom,\r&lt;br&gt;             nucleic acid tests, antibody tests for SARS-CoV-2, or CT scan of the lungs.\r&lt;br&gt;\r&lt;br&gt;          -  Patient has a prior SARS-CoV-2 infection without clinical cure for 28 days.\r&lt;br&gt;\r&lt;br&gt;          -  Patient has close contact with diagnosed or suspected SARS-CoV-2 infected person\r&lt;br&gt;             within 14 days.\r&lt;br&gt;\r&lt;br&gt;          -  Patient has inadequate general condition, severe complication or organ dysfunction not\r&lt;br&gt;             fit for chemotherapy (based on the judgment of researchers).\r&lt;br&gt;\r&lt;br&gt;          -  Patient or the family refuses to sign the informed consent.\r&lt;br&gt;\r&lt;br&gt;          -  Patient does not cooperate in following up.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  The inclusion criteria are laboratory confirmed Covid-19 positive male or female\r&lt;br&gt;             subjects in the age range of 18-70 years, already admitted in the hospital.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Edentulous patients, patients with low Glasgow coma score, intubated,\r&lt;br&gt;             immune-compromised, history of radiotherapy or chemotherapy will be excluded. Patients\r&lt;br&gt;             with known pre-existing chronic mucosal lesions such as lichen planus will also be\r&lt;br&gt;             excluded.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Dysfunctional worry related to Covid-19 defined as reporting almost constant worry\r&lt;br&gt;             about the topic (e.g. risk of getting ill, consequences for health, economy, family,\r&lt;br&gt;             etc.) and at least one of the following negative consequences of worrying:\r&lt;br&gt;\r&lt;br&gt;               1. Trouble sleeping due to Covid-19 worries\r&lt;br&gt;\r&lt;br&gt;               2. Constantly checking the news and social media to follow developments about\r&lt;br&gt;                  Covid-19\r&lt;br&gt;\r&lt;br&gt;               3. Difficulties concentrating on other things (work, family, hobbies, etc.) due to\r&lt;br&gt;                  worries about Covid-19\r&lt;br&gt;\r&lt;br&gt;               4. Marked loss of productivity due to worries about Covid-19\r&lt;br&gt;\r&lt;br&gt;               5. Difficulties finding joy in everyday situations because of worry about Covid-19\r&lt;br&gt;\r&lt;br&gt;          -  = 16 years of age\r&lt;br&gt;\r&lt;br&gt;          -  Resident in Sweden\r&lt;br&gt;\r&lt;br&gt;          -  Able to provide digital informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Daily access to a computer or other device with internet connection\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Non Swedish-speaking\r&lt;br&gt;\r&lt;br&gt;          -  Severe depression, defined as &gt;28 points on the MADRS-S\r&lt;br&gt;\r&lt;br&gt;          -  Suicidal risk defined as 5 points or above on item 9 on the MADRS-S\r&lt;br&gt;","Inclusion criteria: 1. Meet the history of COVID-19 confirmed in accordance with the diagnosis and treatment plan of COVID-19(trial seventh edition);\r&lt;br&gt;2. Meet the discharge standards of COVID-19(trial seventh edition);\r&lt;br&gt;3. Meet the diagnosis standard of qi deficiency and phlegm stasis syndrome;\r&lt;br&gt;4. Patients aged 18-70 years old, 28 days after discharge, still have abnormal manifestations on lung CT;\r&lt;br&gt;5. Patients willing to sign informed consent.","Inclusion criteria: 1. Confirmed cases: positive nucleic acid test;\r&lt;br&gt;2. Aged 25-65 years;\r&lt;br&gt;3. Asexual difference;\r&lt;br&gt;4. Clinical stage (light, common type);\r&lt;br&gt;5. Immunology standard: peripheral blood lymphocyte was higher than the lower limit of normal;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Voluntarily participating in the clinical study; fully understanding and being fully\r&lt;br&gt;             informed of the study and having signed the Informed Consent Form (ICF); willingness\r&lt;br&gt;             and capability to complete all the study procedures;\r&lt;br&gt;\r&lt;br&gt;          2. Age 18-75 years (inclusive) at the time of signing ICF;\r&lt;br&gt;\r&lt;br&gt;          3. Being confirmed with COVID-19-Moderate type according to Competent Authority and\r&lt;br&gt;             Italian Ministry of Health guidelines and to the recommendations reported in Appendix\r&lt;br&gt;             1 to the present protocol. Based on comprehensive analysis and judgement taking into\r&lt;br&gt;             account both the epidemiological history and clinical manifestations, the diagnosis is\r&lt;br&gt;             to be confirmed for suspected cases/clinically diagnosed cases with all of the\r&lt;br&gt;             following etiological evidences:\r&lt;br&gt;\r&lt;br&gt;               -  Positivity in RT-PCR 2019-nCov test on respiratory tract specimens;\r&lt;br&gt;\r&lt;br&gt;               -  High homology with known gene sequence of 2019-nCov in viral gene sequencing on\r&lt;br&gt;                  respiratory tract specimens; Note: The above criterion would be subject to any\r&lt;br&gt;                  update of the Competent Authority and Italian Ministry of Health guidelines and\r&lt;br&gt;                  to the recommendations reported in Appendix 1 to the present protocol. In case\r&lt;br&gt;                  any new etiologically detection methods/criteria or any new detectable specimens\r&lt;br&gt;                  become available after confirmed diagnosis, the new methods or new specimens may\r&lt;br&gt;                  or may not be used at the discretion of the investigator.\r&lt;br&gt;\r&lt;br&gt;             Note: Sputum specimen is preferred for RT-PCR test of 2019-nCov nucleic acid; the\r&lt;br&gt;             specific type of respiratory tract specimen (e.g., nasopharyngeal swabs, sputum, lower\r&lt;br&gt;             respiratory tract secretions) is to be selected based on the conditions of the local\r&lt;br&gt;             laboratory.\r&lt;br&gt;\r&lt;br&gt;             The type of specimen and detection method for 2019-nCov should remain consistent for\r&lt;br&gt;             the same subject receiving study treatment.\r&lt;br&gt;\r&lt;br&gt;          4. Chest imaging (CT as first option or X-ray if CT not possible)-documented pneumonia;\r&lt;br&gt;             if CT cannot be performed, Pneumonia confirmed by X-ray may be used. The method of\r&lt;br&gt;             chest imaging pneumonia diagnosis must be consistent all through the study period.\r&lt;br&gt;\r&lt;br&gt;          5. Patients with pyrexia (axillary =37? or oral =37.5?, or axillary or rectal=38?) or\r&lt;br&gt;             either respiratory rate &gt;24/min and &lt;30/min or cough; For not hospitalized patients,\r&lt;br&gt;             the Investigator should maintain the detection method consistent all through the study\r&lt;br&gt;             period. In addition, the Investigator should maintain the data collection and quality\r&lt;br&gt;             compliant with GCP requirements.\r&lt;br&gt;\r&lt;br&gt;          6. The interval between symptoms onset and randomization is no more than 10 days;\r&lt;br&gt;             symptoms onset is primarily based on pyrexia, and can be based on cough or other\r&lt;br&gt;             related symptoms for patients without experiencing pyrexia following onset;\r&lt;br&gt;\r&lt;br&gt;          7. For female subjects: evidence of post-menopause, or, for pre-menopause subjects,\r&lt;br&gt;             negative pre-treatment serum or urine pregnancy test. Menopause is defined as\r&lt;br&gt;             amenorrhea for at least 12 months without other medical cause, with the following\r&lt;br&gt;             age-specific requirements:\r&lt;br&gt;\r&lt;br&gt;               -  For female subjects aged &lt;50 years: menopause for at least 12 months following\r&lt;br&gt;                  withdrawal of exogenous hormonal therapy, with LH or FSH within the\r&lt;br&gt;                  post-menopausal ranges, or having undergone any contraceptive surgery (bilateral\r&lt;br&gt;                  oophorectomy or hysterectomy);\r&lt;br&gt;\r&lt;br&gt;               -  For female subjects aged =50 years: menopause for at least 12 months following\r&lt;br&gt;                  withdrawal of exogenous hormonal therapy, or having undergone\r&lt;br&gt;                  radiotherapy-induced oophorectomy with amenorrhea&gt;1 year, or having undergone\r&lt;br&gt;                  chemotherapy-induced menopause with amenorrhea&gt;1 year, or having undergone any\r&lt;br&gt;                  contraceptive surgery (bilateral oophorectomy or hysterectomy).\r&lt;br&gt;\r&lt;br&gt;          8. Eligible subjects of child-bearing age (male or female) must agree to take effective\r&lt;br&gt;             contraceptive measures (including hormonal contraception, barrier methods or\r&lt;br&gt;             abstinence) with his/her partner during the study period and for at least 7 days\r&lt;br&gt;             following the last study treatment;\r&lt;br&gt;\r&lt;br&gt;          9. Not participating in any other interventional drug clinical studies before completion\r&lt;br&gt;             of the present study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Where, in the opinion of the investigator, participation in this study will not be in\r&lt;br&gt;             the best interest of the subject, or any other circumstances that prevent the subject\r&lt;br&gt;             from participating in the study safely;\r&lt;br&gt;\r&lt;br&gt;          2. Refractory nausea, vomiting, or chronic gastrointestinal disorders, inability to\r&lt;br&gt;             swallow the study drug or having undergone extensive bowel resection which may affect\r&lt;br&gt;             adequate absorption of Favipiravir;\r&lt;br&gt;\r&lt;br&gt;          3. Severe liver disease: underlying liver cirrhosis or alanine aminotransferase\r&lt;br&gt;             (ALT)/aspartate aminotransferase (AST) elevated over 5 times the ULN;\r&lt;br&gt;\r&lt;br&gt;          4. Gout/history of gout or hyperuricemia (above the ULN);\r&lt;br&gt;\r&lt;br&gt;          5. Oxygen saturation (SPO2)=93% or arterial oxygen partial pressure (PaO2)/ fraction of\r&lt;br&gt;             inspired O2 (FiO2)=300 mmHg;\r&lt;br&gt;\r&lt;br&gt;          6. Known allergy or hypersensitivity to Favipiravir;\r&lt;br&gt;\r&lt;br&gt;          7. Known severe renal impairment [creatinine clearance (CcCl) &lt;30 mL/min] or having\r&lt;br&gt;             received continuous renal replacement therapy, hemodialysis or peritoneal dialysis;\r&lt;br&gt;             CcCl is to be calculated by the following Cockcroft-Gault formula only when the serum\r&lt;br&gt;             creatinine is&gt;1.5ULN\r&lt;br&gt;\r&lt;br&gt;          8. Possibility of the subject being transferred to a non-study hospital within 72h;\r&lt;br&gt;\r&lt;br&gt;          9. Pregnant or lactating women;\r&lt;br&gt;\r&lt;br&gt;         10. Having used Favipiravir or participated in any other interventional drug clinical\r&lt;br&gt;             study within 30 days prior to first dose of study drug.\r&lt;br&gt;\r&lt;br&gt;        Note: Considering that COVID-19 requires immediate treatment, absence of severe\r&lt;br&gt;        hepatic/renal disorders (e.g., cirrhosis, long-term dialysis) in the medical record can be\r&lt;br&gt;        used as an evidence for eligibility determination. It is recommended that hepatic function\r&lt;br&gt;        and creatinine be examined whenever possible.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  endometriosis patients\r&lt;br&gt;\r&lt;br&gt;          -  no psychiatric illness\r&lt;br&gt;\r&lt;br&gt;          -  no antidepressant use\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  women who had not endometriosis\r&lt;br&gt;\r&lt;br&gt;          -  no extra health conditions\r&lt;br&gt;\r&lt;br&gt;          -  women younger than 18 and older than 45\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Patients eligible for inclusion in this Treatment Plan have to meet all of the following\r&lt;br&gt;        criteria:\r&lt;br&gt;\r&lt;br&gt;        Written patient informed consent or assent must be obtained prior to start of treatment.\r&lt;br&gt;\r&lt;br&gt;          -  Patients aged = 6 years\r&lt;br&gt;\r&lt;br&gt;          -  Patients clinically diagnosed with SARS-CoV-2 infection, either through positive serum\r&lt;br&gt;             antibodies (IgM or IgG); or by PCR; or by other approved diagnostic methodology.\r&lt;br&gt;             Patients with presumptive diagnosis of COVID-19 (other respiratory causes ruled out\r&lt;br&gt;             and SARS-CoV-2 test pending) may be included.\r&lt;br&gt;\r&lt;br&gt;          -  Adult and adolescent patients (=12years), who meet one of the below criteria\r&lt;br&gt;\r&lt;br&gt;               -  Respiratory frequency = 30/min\r&lt;br&gt;\r&lt;br&gt;               -  Oxygen saturation = 93% on room air (FiO2=0.21)\r&lt;br&gt;\r&lt;br&gt;               -  Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2)\r&lt;br&gt;                  &lt;300mmHg(1mmHg=0.133kPa) (corrective formulation should be used for higher\r&lt;br&gt;                  altitude regions (over 1000m).\r&lt;br&gt;\r&lt;br&gt;        AND\r&lt;br&gt;\r&lt;br&gt;        -- Patients with lung imaging showing pulmonary infiltrates (chest X-ray or CT scan)\r&lt;br&gt;\r&lt;br&gt;        Pediatric patients (=6-&lt;12 years) who meet one of the below criteria (where appropriate):\r&lt;br&gt;\r&lt;br&gt;          -  Shortness of breath\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation &lt;92% on room air (Fi)2=0.21)\r&lt;br&gt;\r&lt;br&gt;          -  Labored breathing (e.g. wheezing, flaring of nostrils, three concave sign), cyanosis,\r&lt;br&gt;             intermittent apnea.\r&lt;br&gt;\r&lt;br&gt;          -  Lethargy or convulsions\r&lt;br&gt;\r&lt;br&gt;          -  Refusal to eat or difficulty with feeding; signs of dehydration\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients eligible for this Treatment Plan must not meet any of the following criteria:\r&lt;br&gt;\r&lt;br&gt;          -  History of hypersensitivity to any drugs or metabolites of similar chemical classes as\r&lt;br&gt;             ruxolitinib\r&lt;br&gt;\r&lt;br&gt;          -  Presence of severely impaired renal function defined by serum creatinine &gt; 2 mg/dL\r&lt;br&gt;             (&gt;176.8 mol/L), or have estimated creatinine clearance &lt; 30 ml/min measured or\r&lt;br&gt;             calculated by Cockroft Gault equation or calculated by the updated bedside Schwartz\r&lt;br&gt;             equation.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or nursing (lactating) women.\r&lt;br&gt;\r&lt;br&gt;          -  Patients who are NOT able to understand and to comply with treatment instructions and\r&lt;br&gt;             requirements unless health care proxy is able to provide consent.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Nursing home resident with Covid disease RT-PCR or Chest CT or rapid test\r&lt;br&gt;\r&lt;br&gt;          -  Nursing home resident with Covid-19 disease symptoms :\r&lt;br&gt;\r&lt;br&gt;          -  fever\r&lt;br&gt;\r&lt;br&gt;          -  cough\r&lt;br&gt;\r&lt;br&gt;          -  dyspnea\r&lt;br&gt;\r&lt;br&gt;          -  SPO2&lt;95% in ambient air (or &lt;91% in COPD patient)\r&lt;br&gt;\r&lt;br&gt;          -  Diarrhea\r&lt;br&gt;\r&lt;br&gt;          -  Fall or balance disorder\r&lt;br&gt;\r&lt;br&gt;          -  Confusion\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt; 75 years\r&lt;br&gt;\r&lt;br&gt;          -  Patient in respiratory distress\r&lt;br&gt;\r&lt;br&gt;          -  No consent\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with acute respiratory failure due to COVID-19 who have initiated NIV or CPAP\r&lt;br&gt;             based on assistant clinician decision\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with imediate indication to invasive mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  Patients with any formal contraindication to noninvasive respiratory support\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Age above 18 years\r&lt;br&gt;\r&lt;br&gt;          -  Women of childbearing age only: Must agree to practice continuous effective\r&lt;br&gt;             contraception for the duration of the study (a method which results in a failure rate\r&lt;br&gt;             less than 1% per year)\r&lt;br&gt;\r&lt;br&gt;          -  Disease severe enough to require hospitalization\r&lt;br&gt;\r&lt;br&gt;          -  QTc interval lower than 450 msec\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Respiratory rate &gt;24/min\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy (tested with a pregnancy test) or lactation\r&lt;br&gt;\r&lt;br&gt;          -  Weight &lt;50 kg\r&lt;br&gt;\r&lt;br&gt;          -  Hemodynamic/rhythm instability\r&lt;br&gt;\r&lt;br&gt;          -  Acute myocardial infarction Type 1\r&lt;br&gt;\r&lt;br&gt;          -  Use of concomitant medications that prolong the QT/QTc interval.\r&lt;br&gt;\r&lt;br&gt;          -  Any regular concomitant medication which is contraindicated in the use together with\r&lt;br&gt;             HCQ\r&lt;br&gt;\r&lt;br&gt;          -  Hypersensitivity to Hydroxychloroquine, Chloroquine or other 4-Aminoquinolines\r&lt;br&gt;\r&lt;br&gt;          -  Pre-existing retinopathy or maculopathy\r&lt;br&gt;\r&lt;br&gt;          -  Known Glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, Favism)\r&lt;br&gt;\r&lt;br&gt;          -  Haematopoietic systems diseases\r&lt;br&gt;\r&lt;br&gt;          -  Myasthenia gravis\r&lt;br&gt;\r&lt;br&gt;          -  Any other significant disease, disorder or finding which, in the opinion of the\r&lt;br&gt;             investigator, may significantly increase the risk to the volunteer because of\r&lt;br&gt;             participation in the study, affect the ability of the volunteer to participate in the\r&lt;br&gt;             study or impair interpretation of the study data\r&lt;br&gt;\r&lt;br&gt;        Additionally, clinical evaluation and laboratory values inform eligibility of the patient\r&lt;br&gt;        based on the judgement of the study team. These may include: total bilirubin, transaminase\r&lt;br&gt;        level, albumin concentration, haematological parameters, troponin and BNP levels,\r&lt;br&gt;        creatinine, creatinine kinase levels.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  physicians working in endoscopy units worldwide\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  physicians not working in endoscopy units worldwide\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. men and woman age 18 and older;\r&lt;br&gt;\r&lt;br&gt;          2. Not hospitalized;\r&lt;br&gt;\r&lt;br&gt;          3. Has recently tested SARS-CoV-2 (COVID-19 virus) positive.\r&lt;br&gt;\r&lt;br&gt;          4. Currently symptomatic with one or more of one or more of the following symptoms:\r&lt;br&gt;             fever, cough, myalgia, mild dyspnea, diarrhea, vomiting, anosmia (inability to smell),\r&lt;br&gt;             ageusia (inability to taste), sore throat.\r&lt;br&gt;\r&lt;br&gt;          5. Able to provide informed consent.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Illness severe enough to require hospitalization or already meeting study's primary\r&lt;br&gt;             endpoint for clinical worsening.\r&lt;br&gt;\r&lt;br&gt;          2. Unstable medical comorbidities including, but not limited to: Severe underlying lung\r&lt;br&gt;             disease (COPD on home oxygen, interstitial lung disease, pulmonary hypertension),\r&lt;br&gt;             decompensated cirrhosis, Congestive heart failure (stage 3 or 4 per patient report\r&lt;br&gt;             and/or medical records).\r&lt;br&gt;\r&lt;br&gt;          3. Immunocompromised (solid organ transplant, BMT, AIDS, on biologics and/or high dose\r&lt;br&gt;             steroids (&gt;20mg prednisone per day)\r&lt;br&gt;\r&lt;br&gt;          4. Unable to provide informed consent (eg moderate-severe dementia diagnosis)\r&lt;br&gt;\r&lt;br&gt;          5. Unable to perform the study procedures\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  between the ages of 18-65\r&lt;br&gt;\r&lt;br&gt;          -  works from home\r&lt;br&gt;\r&lt;br&gt;          -  works in the office before isolation\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  have any systemic disease that may affect on musculoskeletal system such as\r&lt;br&gt;             fibromyalgia, myofacial pain syndrome, etc.\r&lt;br&gt;\r&lt;br&gt;          -  have any vision problem\r&lt;br&gt;\r&lt;br&gt;          -  have difficulty of understanding and following online survey\r&lt;br&gt;\r&lt;br&gt;          -  have any physical disability\r&lt;br&gt;\r&lt;br&gt;          -  have self-reported computer use for less than four hours on a typical workday\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Suspected cases of COVID-19, due to clinical and radiological data, during the\r&lt;br&gt;             epidemic;\r&lt;br&gt;\r&lt;br&gt;          2. Adult aged 18 or over, at the time of inclusion\r&lt;br&gt;\r&lt;br&gt;          3. Not having severe acute respiratory syndrome (SARS), that is, not using mechanical\r&lt;br&gt;             ventilation or supplemental oxygen, peripheral oxygen saturation&gt; 94% in room air, and\r&lt;br&gt;             having a respiratory rate below 24 incursions per minute.\r&lt;br&gt;\r&lt;br&gt;          4. Patients with comorbidities only, due to the increased risk of developing SARS\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        1. Patients with chronic use of drugs known to prolong QTc interval.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All clients and health care worker of WFBH are eligible for enrollment.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Health care workers who do not receive medical services through WFBH will not be\r&lt;br&gt;             enrolled.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adults admitted to hospital with suspected or confirmed acute COVID-19 infection who\r&lt;br&gt;             are believed to be =50 years old are eligible. Acute COVID-19 infection is suspected\r&lt;br&gt;             in the presence of a fever and at least one symptom of respiratory disease e.g. cough,\r&lt;br&gt;             difficulty breathing, signs of hypoxia, requiring hospitalization. The clinician may\r&lt;br&gt;             suspect COVID-19 infection if i) the patient lives in or has recently travelled to an\r&lt;br&gt;             area with COVID-19 transmission; ii) the patient had recent contact with a confirmed\r&lt;br&gt;             or probable COVID-19 case, or iii) no alternative diagnosis fully explains the\r&lt;br&gt;             clinical presentation. Patients hospitalised without symptoms of acute COVID-19\r&lt;br&gt;             infection should not be recruited even if they test positive for COVID-19.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Women known to be pregnant and patients already receiving or with a definite\r&lt;br&gt;             indication or contraindication for any of the trial treatments are excluded. Patients\r&lt;br&gt;             who are very severely frail (completely dependent and approaching end of life who\r&lt;br&gt;             typically they could not recover even from a mild illness) or terminally ill should\r&lt;br&gt;             not be recruited. Patients with a clinical indication for or contraindication to any\r&lt;br&gt;             of the trial drugs should not be recruited\r&lt;br&gt;","Inclusion criteria: -\tPatients (=18 years of age) admitted to the hospital with confirmed COVID-19 and not needing admission to MC or ICU&lt;br&gt;-\tPatient has moderate to severe COVID-19. This will be defined as patients with NEWS-2 score = 5. &lt;br&gt;-\tWilling and able to give written informed consent","Inclusion criteria: Patients need to have a smartphone and install the app that is provided to them through their own hospital.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Age 18 years or older\r&lt;br&gt;\r&lt;br&gt;          2. Hospitalization with a suspected diagnosis of COVID-19, based on: (a) A compatible\r&lt;br&gt;             clinical presentation with a positive laboratory test for SARS-CoV-2, or (b)\r&lt;br&gt;             Considered by the primary team to be a Person Under Investigation due to undergo\r&lt;br&gt;             testing for COVID-19 in addition to compatible pulmonary infiltrates on chest x-ray\r&lt;br&gt;             (mutilobar, intersticial or ground glass opacities).\r&lt;br&gt;\r&lt;br&gt;          3. Use of ACEI or ARB as an outpatient prior to hospital admission.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Systolic blood pressure &lt;100 mmHg.\r&lt;br&gt;\r&lt;br&gt;          2. Systolic blood pressure &gt; 180 mmHg or &gt;160 if unable to substitute ACEIs/ARBs for\r&lt;br&gt;             another antihypertensive class, per the investigator's discretion.\r&lt;br&gt;\r&lt;br&gt;          3. Diastolic blood pressure &gt; 110 mmHg\r&lt;br&gt;\r&lt;br&gt;          4. Known history of heart failure with reduced ejection fraction (EF &lt;40%) on their most\r&lt;br&gt;             recent echo and/or clinical heart failure with unknown EF (i.e. no echo in\r&lt;br&gt;             approximately the past year).\r&lt;br&gt;\r&lt;br&gt;          5. Serum K&gt;5.0 mEq/L on admission.\r&lt;br&gt;\r&lt;br&gt;          6. Known pregnancy or breastfeeding.\r&lt;br&gt;\r&lt;br&gt;          7. eGFR &lt;30 mL/min/1.73m2\r&lt;br&gt;\r&lt;br&gt;          8. &gt;50% increase in creatinine (to a creatinine &gt;1.5 mg/dl) compared to most recent\r&lt;br&gt;             creatinine in the past six months, if available\r&lt;br&gt;\r&lt;br&gt;          9. Urine protein-to-creatitine ratio &gt; 3 g/g or proteinuria &gt; 3 g/24-hours within the\r&lt;br&gt;             past year\r&lt;br&gt;\r&lt;br&gt;         10. Ongoing treatment with aliskiren or sacubitril-valsartan.\r&lt;br&gt;\r&lt;br&gt;         11. Inability to obtain informed consent from patient.\r&lt;br&gt;\r&lt;br&gt;         12. Inability to read and write or lack of access to a smart phone, computer or tablet\r&lt;br&gt;             device at the time of evaluation.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All patients visiting the ER of Sheba Medical Center between January 1 - March 31 in\r&lt;br&gt;             the following years: 2017, 2018, 2019, 2020\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients less than 18 years of age\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Confirmed SARS-CoV-2 (COVID-19) infection by a positive test result\r&lt;br&gt;\r&lt;br&gt;          2. Either gender\r&lt;br&gt;\r&lt;br&gt;          3. Symptomatic for example fever, dry Cough, difficulty to breathe\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Confirmed absence of SARS-CoV-2 (COVID-19) infection by a negative test result\r&lt;br&gt;\r&lt;br&gt;          2. Have chronic conditions such as heart disease, liver and kidney failure\r&lt;br&gt;\r&lt;br&gt;          3. Pregnant or currently lactating\r&lt;br&gt;\r&lt;br&gt;          4. Immunocompromise and/or systemic disease(s)\r&lt;br&gt;\r&lt;br&gt;          5. On other antiviral drugs\r&lt;br&gt;\r&lt;br&gt;          6. History of allergy to any of the drugs to be administered in this study\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Participants =18 years of age with SARS-CoV-2 infection confirmed by PCR before\r&lt;br&gt;             randomization\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to provide written informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized and requiring medical care for COVID-19, (status 3 or 4 of 7-point\r&lt;br&gt;             ordinal clinical status scale)\r&lt;br&gt;\r&lt;br&gt;          -  SpO2 =93% on room air\r&lt;br&gt;\r&lt;br&gt;          -  Evidence of pulmonary infiltrate on chest X ray/and or CT scan\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt;18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  Inability to take oral medication\r&lt;br&gt;\r&lt;br&gt;          -  Inability to provide informed written consent\r&lt;br&gt;\r&lt;br&gt;          -  Known hypersensitivity towards 4-aminoquinolines, e.g. hydroxychloroquine and/or\r&lt;br&gt;             camostat\r&lt;br&gt;\r&lt;br&gt;          -  Use of hydroxychloroquine, chloroquine and or camostat within 6 months prior to\r&lt;br&gt;             baseline\r&lt;br&gt;\r&lt;br&gt;          -  Patients with known retinopathy or macular degeneration Patients with known\r&lt;br&gt;             glucose-6-phosphate dehydrogenase (G6PD) deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Prolonged QTc-interval in baseline ECG (&gt;500 ms)\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant medication associated with QTc-interval prolongation, which cannot be\r&lt;br&gt;             withdrawn prior to study drug administration\r&lt;br&gt;\r&lt;br&gt;          -  Major comorbidities, possibly leading to increased unwanted side effects of study\r&lt;br&gt;             drugs:\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Are hospitalized with pneumonia, and presumed or confirmed COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Are able and willing to give signed informed consent (legally authorized\r&lt;br&gt;             representative can provide informed consent if needed)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Female participants must not be pregnant and/or lactating\r&lt;br&gt;\r&lt;br&gt;          -  Have Acute Respiratory Distress Syndrome (ARDS) or will require immediate intermittent\r&lt;br&gt;             mandatory ventilation (IMV), or are ineligible for IMV\r&lt;br&gt;\r&lt;br&gt;          -  Have any concurrent serious medical condition (for example active malignancies on\r&lt;br&gt;             chemotherapy, post organ transplant, dialysis) or concomitant medication that would\r&lt;br&gt;             preclude participation in the study\r&lt;br&gt;\r&lt;br&gt;          -  Are moribund irrespective of the provision of treatments\r&lt;br&gt;\r&lt;br&gt;          -  Have a known history or show evidence of human immunodeficiency virus (HIV) and/or\r&lt;br&gt;             hepatitis\r&lt;br&gt;\r&lt;br&gt;          -  Receiving full-dose anticoagulation therapy with warfarin or other anticoagulants\r&lt;br&gt;\r&lt;br&gt;          -  Have recently undergone major surgery or central venous access device placement\r&lt;br&gt;\r&lt;br&gt;          -  Have a significant bleeding disorder or vasculitis\r&lt;br&gt;\r&lt;br&gt;          -  Have experienced a thromboembolic event\r&lt;br&gt;\r&lt;br&gt;          -  Have symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac\r&lt;br&gt;             arrhythmia\r&lt;br&gt;\r&lt;br&gt;          -  Have a serious, nonhealing wound, peptic ulcer, or bone fracture\r&lt;br&gt;\r&lt;br&gt;          -  Have liver cirrhosis\r&lt;br&gt;\r&lt;br&gt;          -  Have a known sensitivity to monoclonal antibodies (mAbs) or other therapeutic proteins\r&lt;br&gt;\r&lt;br&gt;          -  Have a history of hypertensive crisis or hypertensive encephalopathy or current,\r&lt;br&gt;             poorly controlled hypertension\r&lt;br&gt;","\r&lt;br&gt;        Inclusion criteria:\r&lt;br&gt;\r&lt;br&gt;          -  &gt;18 years\r&lt;br&gt;\r&lt;br&gt;          -  Accept study\r&lt;br&gt;\r&lt;br&gt;          -  live with an addiction\r&lt;br&gt;\r&lt;br&gt;        Exclusion criteria:\r&lt;br&gt;\r&lt;br&gt;        - not being able to answer the questionnaire\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient over the age of 18;\r&lt;br&gt;\r&lt;br&gt;          -  Diagnostic COVID-19 by RT-PCR;\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalisation in resuscitation for the management of complications related to\r&lt;br&gt;             COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Implanted ECMO-VV during hospitalisation;\r&lt;br&gt;\r&lt;br&gt;          -  Patient agreeing to participate in the study\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Sujet under guardianship or trusteeship\r&lt;br&gt;\r&lt;br&gt;          -  Sujet under safeguard of justice\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Willing to participate on this study by signing the informed consent\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  No\r&lt;br&gt;","Inclusion criteria: &lt;br&gt;\tAll types of locally advanced and metastatic malignancy\r&lt;br&gt;\tMale/female participants\r&lt;br&gt;\tAge&gt;18 y.o. \r&lt;br&gt;\tSigned informed consent for participation in the study \r&lt;br&gt;\tNo restriction on Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) Performance Status \r&lt;br&gt;\tSubject should not have received a prior systemic anti-viral treatment for Covid19 disease. \r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 800&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 200&lt;br&gt;","Inclusion criteria: &lt;br&gt;-Recent (=6 days of flu-like symptoms or malaise yet =16 days of flu-like symptoms or malaise prior to randomization) infection with COVID-19.\r&lt;br&gt;-COVID-19 diagnosis confirmed by antigen detection test and/or PCR and/or positive serology, or any emerging and validated diagnostic laboratory test for COVID-19 within this period.\r&lt;br&gt;-In some patients, it may be impossible to get a confident laboratory confirmation of COVID-19 diagnosis after 24h of hospital admission because viral load is low and/or problems with diagnostic sensitivity. In those cases, in absence of an alternative diagnosis, and with highly suspect bilateral ground glass opacities on recent (&lt;24h) chest-CT scan (confirmed by a radiologist and pulmonary physician as probable COVID-19), and a typical clinical and chemical diagnosis with signs of cytokine release syndrome, a patient can be enrolled as probable COVID-19 infected. In all cases, this needs confirmation by later seroconversion.\r&lt;br&gt;-Presence of hypoxia defined as\r&lt;br&gt;PaO2/FiO2 below 350 while breathing room air in upright position or PaO2/FiO2 below 280 on supplemental oxygen and immediately requiring high flow oxygen device or mechanical ventilation\r&lt;br&gt;-signs of cytokine release syndrome defined as\r&lt;br&gt;ANY of the following\r&lt;br&gt;-serum ferritin concentration &gt;1000 mcg/L and rising since last 24h\r&lt;br&gt;-single ferritin above 2000 mcg/L in patients requiring immediate high flow oxygen device or mechanical ventilation\r&lt;br&gt;-lymphopenia defined as &lt;800 lymphocytes/microliter and two of the following extra criteria\r&lt;br&gt;Ferritin &gt; 700 mcg/L and rising since last 24h\r&lt;br&gt;-increased LDH (above 300 IU/L) and rising since last 24h\r&lt;br&gt;-D-Dimers &gt; 1000 ng/mL and rising since last 24h\r&lt;br&gt;-CRP above 70 mg/L and rising since last 24h and absence of bacterial infection\r&lt;br&gt;-if three of the above are present at admission, no need to document 24h rise\r&lt;br&gt;-Chest X-ray and/or CT scan showing bilateral infiltrates within last 2 days\r&lt;br&gt;-Admitted to specialized COVID-19 ward or an ICU ward taking care of COVID-19 patients\r&lt;br&gt;-Age = 18 years\r&lt;br&gt;-Male or Female\r&lt;br&gt;-Willing and able to provide informed consent or legal representative willing to provide informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 171&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 171&lt;br&gt;","\r&lt;br&gt;        Donor Eligibility Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age 18-60\r&lt;br&gt;\r&lt;br&gt;          -  A history of a positive nasopharyngeal swab for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  At least 14 days from resolution of COVID-19-associated symptoms\r&lt;br&gt;\r&lt;br&gt;          -  Two negative nasopharyngeal swabs done at least 24 hours apart for COVID-19 RNA\r&lt;br&gt;\r&lt;br&gt;          -  Covid-19 neutralizing antibody &gt;1:64\r&lt;br&gt;\r&lt;br&gt;          -  Adequate venous access for apheresis\r&lt;br&gt;\r&lt;br&gt;          -  Meets donor eligibility criteria in accordance to Hackensack University Medical Center\r&lt;br&gt;             (HUMC) Collection Facility at the John Theurer Cancer Center (JTCC) and all regulatory\r&lt;br&gt;             agencies as describes in SOP 800 01\r&lt;br&gt;\r&lt;br&gt;          -  Required testing of the donor and product must be performed in accordance to FDA\r&lt;br&gt;             regulations (21 CFR 610.40), and the donation must be found suitable (21 CFR 630.30)\r&lt;br&gt;\r&lt;br&gt;        Recipient Eligibility Criteria:\r&lt;br&gt;\r&lt;br&gt;        Recipients age &gt;18 years old, are assigned to one of two clinical tracks, track 2 or 3,\r&lt;br&gt;        based on COVID-19 disease severity.\r&lt;br&gt;\r&lt;br&gt;        Track 2:\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized, moderate symptoms requiring medical care for COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;          -  Symptoms may include fever, dyspnea, dehydration among others\r&lt;br&gt;\r&lt;br&gt;          -  Hypoxemia may be present but is not a requirement\r&lt;br&gt;\r&lt;br&gt;        Track 3:\r&lt;br&gt;\r&lt;br&gt;         Requiring mechanical ventilation for the care of COVID-19 infection\r&lt;br&gt;\r&lt;br&gt;        Recipient exclusion criteria:\r&lt;br&gt;\r&lt;br&gt;          -  History of severe transfusion reaction to plasma products\r&lt;br&gt;\r&lt;br&gt;          -  Infusion of immune globulin within the previous 30 days\r&lt;br&gt;\r&lt;br&gt;          -  AST or ALT &gt; 10 x upper limit of normal\r&lt;br&gt;\r&lt;br&gt;          -  Requirement for vasopressors\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19-associated acute kidney injury requiring dialysis\r&lt;br&gt;","Inclusion criteria: Suspected or proven novel Coronavirus (nCoV) infection as main reason for admission or presentation to hospital or clinic.","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        -1. Patients with age above 18 years and any gender with definite Dx of covid19 and\r&lt;br&gt;        pneumonia in the ward according to the clinical, laboratory, and imaging criteria.\r&lt;br&gt;\r&lt;br&gt;        2. Understands and agrees to comply with planned study procedures.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Patients with hypersensitivity or severe adverse effects to Ivermectin\r&lt;br&gt;\r&lt;br&gt;          2. Renal impairment\r&lt;br&gt;\r&lt;br&gt;          3. Hepatic impairment.\r&lt;br&gt;\r&lt;br&gt;          4. Pregnancy or a desire to become pregnant (drug considered pregnancy category c)\r&lt;br&gt;\r&lt;br&gt;          5. Breast feeding.\r&lt;br&gt;\r&lt;br&gt;          6. Patient with covid 19 positive and mild no pneumonia\r&lt;br&gt;\r&lt;br&gt;          7. Children under the age of five or those who weigh less than 15 kilograms\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Adult inpatients &gt;18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Positive PCR COVID-19 testing\r&lt;br&gt;\r&lt;br&gt;          -  CT evidence of interstitial opacity\r&lt;br&gt;\r&lt;br&gt;          -  Oxygen saturation &lt;90% on room air\r&lt;br&gt;\r&lt;br&gt;          -  pO2 = 55-70.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Increased oxygen requirements\r&lt;br&gt;\r&lt;br&gt;          -  Hemodynamic instability (MAP&lt;65)\r&lt;br&gt;\r&lt;br&gt;          -  Bradycardia (HR&lt;50)\r&lt;br&gt;\r&lt;br&gt;          -  History of seizure disorder\r&lt;br&gt;\r&lt;br&gt;          -  Pneumothorax\r&lt;br&gt;\r&lt;br&gt;          -  GFR&lt;30\r&lt;br&gt;\r&lt;br&gt;          -  Hemodialysis\r&lt;br&gt;\r&lt;br&gt;          -  Refractory anxiety/claustrophobia\r&lt;br&gt;\r&lt;br&gt;          -  Current pregnancy\r&lt;br&gt;\r&lt;br&gt;          -  Uncorrectable hypoglycemia\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Male or female adult = 18 years of age at time of enrollment.\r&lt;br&gt;\r&lt;br&gt;          2. Subjects with mild-to-moderate symptoms of respiratory illness caused by coronavirus\r&lt;br&gt;             2019 infection as defined below:\r&lt;br&gt;\r&lt;br&gt;             Mild (uncomplicated) Illness:\r&lt;br&gt;\r&lt;br&gt;               -  Diagnosed with COVID-19 by a standardized RT-PCR assay AND\r&lt;br&gt;\r&lt;br&gt;               -  Mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise,\r&lt;br&gt;                  headache, muscle pain, or malaise, but with no shortness of breath AND\r&lt;br&gt;\r&lt;br&gt;               -  No signs of a more serious lower airway disease AND\r&lt;br&gt;\r&lt;br&gt;               -  RR&lt;20, HR &lt;90, oxygen saturation (pulse oximetry) &gt; 93% on room air\r&lt;br&gt;\r&lt;br&gt;             Moderate Illness:\r&lt;br&gt;\r&lt;br&gt;               -  Diagnosed with COVID-19 by a standardized RT-PCR assay AND\r&lt;br&gt;\r&lt;br&gt;               -  In addition to symptoms above, more significant lower respiratory symptoms,\r&lt;br&gt;                  including shortness of breath (at rest or with exertion) OR\r&lt;br&gt;\r&lt;br&gt;               -  Signs of moderate pneumonia, including RR = 20 but &lt;30, HR = 90 but less than\r&lt;br&gt;                  125, oxygen saturation (pulse oximetry) &gt; 93% on room air AND\r&lt;br&gt;\r&lt;br&gt;               -  If available, lung infiltrates based on X-ray or CT scan &lt; 50% present\r&lt;br&gt;\r&lt;br&gt;          3. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered\r&lt;br&gt;             not clinically significant by the Principal Investigator.\r&lt;br&gt;\r&lt;br&gt;          4. Subject (or legally authorized representative) provides written informed consent prior\r&lt;br&gt;             to initiation of any study procedures.\r&lt;br&gt;\r&lt;br&gt;          5. Understands and agrees to comply with planned study procedures.\r&lt;br&gt;\r&lt;br&gt;          6. Women of childbearing potential must agree to use at least one medically accepted\r&lt;br&gt;             method of contraception (e.g., barrier contraceptives [condom, or diaphragm with a\r&lt;br&gt;             spermicidal gel], hormonal contraceptives [implants, injectables, combination oral\r&lt;br&gt;             contraceptives, transdermal patches, or contraceptive rings], or intrauterine devices)\r&lt;br&gt;             for the duration of the study.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Subjects showing signs of acute respiratory distress syndrome (ARDS) or respiratory\r&lt;br&gt;             failure necessitating mechanical ventilation at the time of screening;\r&lt;br&gt;\r&lt;br&gt;          2. History of severe chronic respiratory disease and requirement for long-term oxygen\r&lt;br&gt;             therapy;\r&lt;br&gt;\r&lt;br&gt;          3. Subjects showing signs of clinical jaundice at the time of screening;\r&lt;br&gt;\r&lt;br&gt;          4. History of moderate and severe liver disease (Child-Pugh score &gt;12);\r&lt;br&gt;\r&lt;br&gt;          5. Subjects requiring Renal Replacement Therapy (RRT) at the time of screening;\r&lt;br&gt;\r&lt;br&gt;          6. History of severe chronic kidney disease or requiring dialysis;\r&lt;br&gt;\r&lt;br&gt;          7. Any uncontrolled active systemic infection requiring admission to an intensive care\r&lt;br&gt;             unit (ICU); Note: Subjects infected with chronic hepatitis B virus or hepatitis C\r&lt;br&gt;             virus will be eligible for the study if they have no signs of hepatic decompensation.\r&lt;br&gt;\r&lt;br&gt;             Note: Subjects infected with HIV-1 will be eligible for the study with undetectable\r&lt;br&gt;             viral load and are on a stable ART regimen. Investigators are required to review the\r&lt;br&gt;             subjects' medical records to confirm HIV-1 RNA suppression within the previous 3\r&lt;br&gt;             months.\r&lt;br&gt;\r&lt;br&gt;             Note: Empirical antibiotic treatment for secondary bacterial infections is allowed\r&lt;br&gt;             during the course of study.\r&lt;br&gt;\r&lt;br&gt;          8. Patients with malignant tumor, or other serious systemic diseases;\r&lt;br&gt;\r&lt;br&gt;          9. Patients who are participating in other clinical trials;\r&lt;br&gt;\r&lt;br&gt;         10. Patients who have a history of allergic reactions attributed to compounds of similar\r&lt;br&gt;             chemical or biologic composition to leronlimab (PRO 140) are not eligible; and\r&lt;br&gt;\r&lt;br&gt;         11. Inability to provide informed consent or to comply with test requirements\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - to. Covid 19 positives b. Some of the characteristic symptoms of covid 19: fever,\r&lt;br&gt;        odynophagia, respiratory distress.\r&lt;br&gt;\r&lt;br&gt;        c. Age between 18 years and 80 years\r&lt;br&gt;\r&lt;br&gt;        Criteria Exclusion:\r&lt;br&gt;\r&lt;br&gt;          -  to. Covid 19 negatives b. Kidney failure IV / VI. c. Congestive heart failure. d.\r&lt;br&gt;             Patients taking anticoagulants, particularly warfarin sodium\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with diagnosis of Covid-19 .\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients refuse to participate in the study\r&lt;br&gt;","\r&lt;br&gt;        -  INCLUSION CRITERIA:\r&lt;br&gt;\r&lt;br&gt;        In order to be eligible to participate in this study, an individual must meet all of the\r&lt;br&gt;        following criteria:\r&lt;br&gt;\r&lt;br&gt;          -  18 years of age and older.\r&lt;br&gt;\r&lt;br&gt;          -  Able to read and write English.\r&lt;br&gt;\r&lt;br&gt;          -  Able to provide informed consent online using study website.\r&lt;br&gt;\r&lt;br&gt;        EXCLUSION CRITERIA:\r&lt;br&gt;\r&lt;br&gt;        There are no exclusion criteria for this study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  patients under investigation for COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  patients that are positive for COVID-19 at UMMC and Bethesda\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        - ultrasound contraindication such as overlying skin wound\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  = 18 years of age\r&lt;br&gt;\r&lt;br&gt;          -  Histologically confirmed cancer\r&lt;br&gt;\r&lt;br&gt;          -  Receive systemic therapy (including chemotherapy, targeted small-molecule therapy,\r&lt;br&gt;             anticancer monoclonal antibody, immunotherapy, endocrine therapy, or investigational\r&lt;br&gt;             agent) (either exclusively or in combination with other anticancer therapy) between\r&lt;br&gt;             February 14, 2020 and March 31, 2020 (Note: Patients whose systemic treatment\r&lt;br&gt;             administration was initially planned for this period but was modified, delayed,\r&lt;br&gt;             stopped, or withheld due to COVID-19 measures are also eligible for inclusion)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Insufficient understanding of the Dutch language\r&lt;br&gt;\r&lt;br&gt;          -  Severe cognitive impairment\r&lt;br&gt;\r&lt;br&gt;          -  Acute psychiatric crisis\r&lt;br&gt;\r&lt;br&gt;          -  Not able to give informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed or clinically suspected COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Endocrine therapy in (neo)adjuvant setting (Note: Patients whose (neo)adjuvant\r&lt;br&gt;             systemic treatment was initially planned as chemotherapy, targeted small-molecule\r&lt;br&gt;             therapy, anticancer monoclonal antibody, immunotherapy, or investigational agent\r&lt;br&gt;             (either exclusively or in combination in combination with other anticancer therapy)\r&lt;br&gt;             but was modified to endocrine therapy due to COVID-19 measures are also eligible for\r&lt;br&gt;             inclusion)\r&lt;br&gt;","Inclusion criteria: &lt;br&gt; Age equal to or above 18 years&lt;br&gt; Male or female gender&lt;br&gt; In case of women, unwillingness to remain pregnant during the study period.&lt;br&gt; Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent&lt;br&gt; Confirmed infection by SARS-CoV-2 virus using molecular techniques as defined by the World Health Organization11&lt;br&gt; Organ dysfunction defined as the presence of at least one of the following conditions: &lt;br&gt; - Total SOFA score greater than or equal to 2; &lt;br&gt; - Involvement of the lower respiratory tract&lt;br&gt; Laboratory documentation of MAS or immune dysregulation. MAS is documented by the findings of any serum ferritin greater than 4,420ng/ml. immune dysregulation is documented by the combination of two findings: a) serum ferritin equal to or lower than 4,420ng/ml; and b) less than 5,000 receptors of the membrane molecule of HLA-DR on the cell membrane of blood CD14-monocytes or less than 30 MFI of HLA-DR on the cell membrane of blood CD14-monocytes as counted by flow cytometry.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 20&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 20&lt;br&gt;","Inclusion criteria: Patients admitted to ICU at the Royal Brisbane &amp; Women's Hospital with suspected or proven severe COVID-19 infection, prescribed hydroxychloroquine as part of their routine management.","Inclusion criteria: &lt;br&gt;                1. Aged at least 18 years&lt;br&gt;                2. Hospitalised&lt;br&gt;                3. SARS-CoV-2 infection&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed)\r&lt;br&gt;\r&lt;br&gt;          -  Tympanic Temperature of =37.5 AND at least one of the following: Cough, Sputum\r&lt;br&gt;             production, nasal discharge, myalgia, headache or fatigue) on admission.\r&lt;br&gt;\r&lt;br&gt;          -  Time of onset of the symptoms should be acute ( Days = 10)\r&lt;br&gt;\r&lt;br&gt;          -  NEWS2 = 1 on admission (National Early Warning Score 2)\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Refusal to participate expressed by patient or legally authorized representative if\r&lt;br&gt;             they are present\r&lt;br&gt;\r&lt;br&gt;          -  Patients with prolonged QT or PR intervals, Second or Third Degree heart block,\r&lt;br&gt;             Arrhythmias including torsade de pointes\r&lt;br&gt;\r&lt;br&gt;          -  Patients using drugs with potential interaction with Hydroxychloroquine +\r&lt;br&gt;             Lopinavir/Ritonavir, Interferon- 1a? Interferon- 1b.\r&lt;br&gt;\r&lt;br&gt;          -  Pregnant or lactating women.\r&lt;br&gt;\r&lt;br&gt;          -  History of alcohol or drug addiction in the past 5 years.\r&lt;br&gt;\r&lt;br&gt;          -  Blood ALT/AST levels &gt; 5 times the upper limit of normal on laboratory results.\r&lt;br&gt;","Inclusion criteria: Diagnosis of IBD: Crohns disease, ulcerative colitis or indeterminate colitis established using standard criteria (we will ask for the details of patient's gastroenterologist, and these will be verified by our team); \r&lt;br&gt;Distress: at least mild distress on K10 (scores 20-29); \r&lt;br&gt;Age: 18 years and older; \r&lt;br&gt;Other: Australians, able to read and write in English, with access to internet to participate in online intervention, able to download Zoom and available to participate for approx. 30 minutes for 4 consecutive days (likely in the evening).","Inclusion criteria: &lt;br&gt;                1. Healthcare professionals&lt;br&gt;                2. &gt;18 years of age&lt;br&gt;                3. Willing to participate&lt;br&gt;","Inclusion criteria: &lt;br&gt;                Current inclusion criteria as of 26/03/2020:&lt;br&gt;                1. Adults &gt; 18 years&lt;br&gt;                2. Admitted to ICU for respiratory support requiring intubation and ventilation for &gt;24 hours&lt;br&gt;                AND EITHER:&lt;br&gt;                3. Positive influenza or SARS-CoV-2 PCR from nasal, throat swab, BAL or other respiratory specimen taken either &lt; 7 days pre, or &lt; 3 days post, admission to ICU&lt;br&gt;                OR&lt;br&gt;                4. Influenza or SARS-CoV-2 suspected but PCR results awaited  under these circumstances the patient can be provisionally enrolled, but later excluded if no specimens taken within either &lt; 7 days pre, or &lt; 3 days post admission to ICU positive as above&lt;br&gt;&lt;br&gt;                Previous inclusion criteria:&lt;br&gt;                1. Adults &gt;  18 years&lt;br&gt;                2. Admitted to intensive care for respiratory support requiring intubation and ventilation for &gt; 24 hours&lt;br&gt;                AND EITHER:&lt;br&gt;                3. Positive influenza PCR from nasal, throat swab, BAL or other respiratory specimen taken within 48 hours (of admission to ICU  pre or post&lt;br&gt;                OR&lt;br&gt;                4. Influenza suspected but influenza PCR results awaited  under these circumstances the patient can be provisionally enrolled, but later excluded if no specimens taken within 48 hours pre/post admission to ICU is positive as above&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Male or female aged 18 - 89 years at time of enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Hospitalized (or documented plan to hospitalize if patient is in the emergency\r&lt;br&gt;             department) with symptoms suggestive of COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Illness of any duration that meets each of the following:\r&lt;br&gt;\r&lt;br&gt;               1. Evidence of pneumonia, including radiographic infiltrates by imaging (chest\r&lt;br&gt;                  x-ray, CT scan, etc.) or clinical assessment (rales/crackles on exam)\r&lt;br&gt;\r&lt;br&gt;               2. Requires supportive care, including non-invasive supplemental oxygen\r&lt;br&gt;\r&lt;br&gt;          -  Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or\r&lt;br&gt;             public health assay within 7 days of enrollment\r&lt;br&gt;\r&lt;br&gt;          -  Understands and agrees to comply with planned study procedures\r&lt;br&gt;\r&lt;br&gt;          -  Provides informed consent signed by study patient or legally acceptable representative\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Absolute lymphocyte count is less than 500 cells/mm\r&lt;br&gt;\r&lt;br&gt;          -  Absolute neutrophil count is less than 1000 cells/mm\r&lt;br&gt;\r&lt;br&gt;          -  Hemoglobin level is less than 8 g/dL\r&lt;br&gt;\r&lt;br&gt;          -  Estimated GFR is less than 60 mL/min/1.73 m2\r&lt;br&gt;\r&lt;br&gt;          -  ALT or AST is over 5 times the upper limit of normal\r&lt;br&gt;\r&lt;br&gt;          -  Treatment with other JAK inhibitors, OAT3 inhibitors, biologic disease-modifying\r&lt;br&gt;             anti-rheumatic drugs (DMARDs), anti-IL-6 or anti-IL-6R antibodies, or potent\r&lt;br&gt;             immunosuppressants such as azathioprine. and cyclosporine concurrently or within the\r&lt;br&gt;             past 5 days. Note: recent or concurrent treatment with hydroxychloroquine or\r&lt;br&gt;             chloroquine is allowable, as these are 'non-biologic' DMARDs with potential antiviral\r&lt;br&gt;             activity.\r&lt;br&gt;\r&lt;br&gt;          -  History of HIV infection and on active immunosuppressant therapy\r&lt;br&gt;\r&lt;br&gt;          -  Current hematological or solid organ malignancy and on active immunosuppressant\r&lt;br&gt;             therapy\r&lt;br&gt;\r&lt;br&gt;          -  Active tuberculosis (TB) infection or known or suspected systemic bacterial or fungal\r&lt;br&gt;             infection\r&lt;br&gt;\r&lt;br&gt;          -  Pregnancy or breast feeding\r&lt;br&gt;\r&lt;br&gt;          -  Known allergy to baricitinib\r&lt;br&gt;\r&lt;br&gt;          -  In the opinion of the investigator, they are unlikely to survive for &gt;48 hours from\r&lt;br&gt;             screening\r&lt;br&gt;\r&lt;br&gt;          -  Any physical examination findings and/or history of any illness that, in the opinion\r&lt;br&gt;             of the investigator, might confound the results of the study or pose an additional\r&lt;br&gt;             risk to the patient by their participation in the study\r&lt;br&gt;\r&lt;br&gt;        Additional Exclusion Criteria for Phase 2 only:\r&lt;br&gt;\r&lt;br&gt;         Invasive oxygen supplementation, including mechanical ventilation and extracorporeal\r&lt;br&gt;        membrane oxygenation (ECMO)\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. NCP with severe acute respiratory distress syndrome with ratio of partial pressure\r&lt;br&gt;             of arterial oxygen over fraction of inspired oxygen (PaO2:FiO2)&lt;150 and PEEP &gt;10cmH2O\r&lt;br&gt;\r&lt;br&gt;          -  2. Driving pressure&gt; 20cmH2O\r&lt;br&gt;\r&lt;br&gt;          -  3. RR&gt;30bpm\r&lt;br&gt;\r&lt;br&gt;          -  4.PaCO2&gt;55cmH2O and/or PH&gt;7.3\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  1. poor venous vascular condition and unavaible for central venous catheter placement\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed\r&lt;br&gt;             diagnosis of COVID-19\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19positive(+) ARDS as defined according to the Berlin Definition\r&lt;br&gt;\r&lt;br&gt;          -  ratio of partial pressure arterial oxygen and fraction of inspired oxygen (PaO2/ FiO2)\r&lt;br&gt;             =100\r&lt;br&gt;\r&lt;br&gt;          -  Bilateral opacities consistent with pulmonary edema on frontal chest radiograph\r&lt;br&gt;\r&lt;br&gt;          -  requirement for positive pressure ventilation via an endotracheal tube or non-invasive\r&lt;br&gt;             ventilation\r&lt;br&gt;\r&lt;br&gt;          -  no clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial\r&lt;br&gt;             Wedge Pressure (PAOP) less than or equal to 18 mmHg.\r&lt;br&gt;\r&lt;br&gt;          -  = 7 days from the initiation of mechanical ventilation at the time of randomization. -\r&lt;br&gt;             Patients must be enrolled within 96 hours of onset of ARDS -\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19negative(-) ARDS\r&lt;br&gt;\r&lt;br&gt;          -  Age less than 18 years\r&lt;br&gt;\r&lt;br&gt;          -  More than 7 days since initiation of mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;          -  more than 96 hours since meeting ARDS criteria\r&lt;br&gt;\r&lt;br&gt;          -  patient, surrogate or physician not committed to full intensive care support.\r&lt;br&gt;\r&lt;br&gt;          -  pregnancy\r&lt;br&gt;","Inclusion criteria: 1. Age 18 years and over\r&lt;br&gt;2. Confirmed SARS-CoV-2 by nucleic acid testing in the past 12 days\r&lt;br&gt;3. Able to be randomised within 12 days of symptom onset\r&lt;br&gt;4. Expected to be remain an inpatient for at least 48 hours from the time of randomisation\r&lt;br&gt;","Inclusion criteria: Adult (18+ years old) patients with \r&lt;br&gt;(a) confirmed COVID-19 symptoms and\r&lt;br&gt;(b) symptom onset within the past five days.","Inclusion criteria: &lt;br&gt;                1. Adults = 18 years&lt;br&gt;                2. Admitted to hospital with suspected or proven COVID-19&lt;br&gt;                3. On 40% oxygen (or greater) with SpO2 &lt;94%&lt;br&gt;                4. Plan for escalation to intubation if needed&lt;br&gt;","Inclusion criteria: &lt;br&gt;                1. Adults (aged =18 years) hospitalized with definite COVID-19&lt;br&gt;                2. Not already receiving any of the study drugs&lt;br&gt;                3. Without known allergy or contraindications to any of them (in the view of the physician responsible for their care)&lt;br&gt;                4. Without anticipated transfer within 72 h to a non-study hospital&lt;br&gt;&lt;br&gt;                Patients invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Any employee of Lake Forrest Memorial Hospital presenting to work\r&lt;br&gt;\r&lt;br&gt;          -  Age greater than 18 years-old\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age less than 18 years-old\r&lt;br&gt;\r&lt;br&gt;          -  Non-employee\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients:\r&lt;br&gt;\r&lt;br&gt;               -  Age&gt;18y\r&lt;br&gt;\r&lt;br&gt;               -  Admission to the participating ICUs for any cause of acute respiratory failure\r&lt;br&gt;                  during the COVID-19 pandemic\r&lt;br&gt;\r&lt;br&gt;               -  Having received invasive or noninvasive mechanical ventilation\r&lt;br&gt;\r&lt;br&gt;               -  Non-opposition to participate to the telephone interviews.\r&lt;br&gt;\r&lt;br&gt;        Family members:\r&lt;br&gt;\r&lt;br&gt;          -  Age&gt;18y\r&lt;br&gt;\r&lt;br&gt;          -  Non-opposition to participate to the telephone interviews\r&lt;br&gt;\r&lt;br&gt;          -  One family member per patient: the family member the most implicated in the patient's\r&lt;br&gt;             care\r&lt;br&gt;\r&lt;br&gt;        Healthcare providers:\r&lt;br&gt;\r&lt;br&gt;          -  All nurses and physicians (including those in training) in the participating ICUs\r&lt;br&gt;             during the COVID-19 pandemic\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients:\r&lt;br&gt;\r&lt;br&gt;               -  Language barrier to be able to respond to the telephone interview\r&lt;br&gt;\r&lt;br&gt;               -  Cognitive disorders disabling patients to respond to the telephone interview\r&lt;br&gt;\r&lt;br&gt;               -  Person under legal protection (1121-8 of CSP, Public Health Code) Failure to\r&lt;br&gt;                  obtain the non-opposition\r&lt;br&gt;\r&lt;br&gt;        Family members:\r&lt;br&gt;\r&lt;br&gt;          -  Language barrier to be able to respond to the telephone interview\r&lt;br&gt;\r&lt;br&gt;          -  Person under legal protection (1121-8 of CSP, Public Health Code)\r&lt;br&gt;\r&lt;br&gt;          -  Failure to obtain the non-opposition\r&lt;br&gt;\r&lt;br&gt;        Healthcare providers:\r&lt;br&gt;\r&lt;br&gt;        Failure to obtain the non-opposition\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18 years old\r&lt;br&gt;\r&lt;br&gt;          -  Telephone consultation\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  New patient in the department\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore\r&lt;br&gt;             throat, myalgia, nasal congestion, diarrhea\r&lt;br&gt;\r&lt;br&gt;          -  Moderate COVID-19 is defined as &gt; 2 of the following in non-intubated patients: any\r&lt;br&gt;             symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with\r&lt;br&gt;             bilateral ground glass opacities or bilateral consolidations, SpO2 &lt;90% up to 5L Nasal\r&lt;br&gt;             Cannula (NC)\r&lt;br&gt;\r&lt;br&gt;          -  No additional signs or symptoms of severe COVID-19.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines\r&lt;br&gt;\r&lt;br&gt;          -  History of Diabetic Ketoacidosis (DKA)\r&lt;br&gt;\r&lt;br&gt;          -  History of acute pancreatitis\r&lt;br&gt;\r&lt;br&gt;          -  Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) &lt; 30\r&lt;br&gt;             ml/min/1.73 m2\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        T1DM diabetes, as per ADA guidelines, History of DKA, History of acute pancreatitis;\r&lt;br&gt;        Chronic or Acute Renal Failure with eGFR &lt; 30 ml/min/1.73 m2\r&lt;br&gt;","Inclusion criteria: (1) patients diagnosed with COVID-19;\r&lt;br&gt;(2) patients after discharge;\r&lt;br&gt;(3) patients aged 18 to 80 years old;\r&lt;br&gt;(4) patients voluntarily agree to join the cohort and cooperate with treatment and evaluation.","Inclusion criteria: 1. Discharged patients with COVID-19 pneumonia;\r&lt;br&gt;2. With dyspnea symptom (mMRC 2~3);\r&lt;br&gt;3. Aged 18~75 years old;\r&lt;br&gt;4. Have and can use smart phone (study subjects or family members);\r&lt;br&gt;5. Obtain the consent of the subjects or legal representative and sign the informed consent.","Inclusion criteria: Patients diagnosed with severe new coronavirus pneumonia from January to March 2020","Inclusion criteria: 1. Students cursing through the first year to internship (sixth year).\r&lt;br&gt;2. Students currently registered in medical school system of University Mayor de San Andres (UMSA)","Inclusion criteria: 1. Aged 18 years old;\r&lt;br&gt;2. diagnosed with viral pneumonia such as new coronavirus;\r&lt;br&gt;3. voluntary informed consent","Inclusion criteria: Cases of cesarean section in Women's Hospital Medical School of Zhejiang University from January 24, 2020 to March 31, 2020","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Aged 21 to 80 years.\r&lt;br&gt;\r&lt;br&gt;          2. History of close contact or exposure to positive COVID-19 cases in the same household.\r&lt;br&gt;\r&lt;br&gt;          3. Absence of symptoms resembling COVID-19 (e.g., fever and acute respiratory or\r&lt;br&gt;             gastrointestinal symptoms)\r&lt;br&gt;\r&lt;br&gt;          4. Able to give informed consent.\r&lt;br&gt;\r&lt;br&gt;          5. Able to comply with study procedures and follow-up\r&lt;br&gt;\r&lt;br&gt;          6. Singapore citizen, permanent resident or long-term pass-holder.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          1. Pregnant at time of screening or breastfeeding.\r&lt;br&gt;\r&lt;br&gt;          2. Known allergy or hypersensitivity to HCQ or other aminoquinoline compounds.\r&lt;br&gt;\r&lt;br&gt;          3. Already on HCQ for different indications (e.g., rheumatological diseases, malaria\r&lt;br&gt;             prophylaxis)\r&lt;br&gt;\r&lt;br&gt;          4. Diagnosis of other systemic viral or bacterial infection.\r&lt;br&gt;\r&lt;br&gt;          5. Use of systemic immunosuppressant agents within 90 days of enrollment (e.g.,\r&lt;br&gt;             corticosteroids and immunomodulatory therapy)\r&lt;br&gt;\r&lt;br&gt;          6. History of immunocompromised state.\r&lt;br&gt;\r&lt;br&gt;          7. History of psychiatric illness.\r&lt;br&gt;\r&lt;br&gt;          8. History of psoriasis or porphyria.\r&lt;br&gt;\r&lt;br&gt;          9. History of cardiac disease.\r&lt;br&gt;\r&lt;br&gt;         10. Other major comorbidities that contraindicate the use of HCQ: i. Hematologic\r&lt;br&gt;             malignancy, ii. Stage 4-5 chronic kidney disease or end-stage renal failure, iii.\r&lt;br&gt;             history of ventricular arrhythmias, iv. current use of drugs that prolong the QT\r&lt;br&gt;             interval\r&lt;br&gt;\r&lt;br&gt;         11. History of severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal\r&lt;br&gt;             necrolysis.\r&lt;br&gt;\r&lt;br&gt;         12. Bradycardia &lt;50beats/min.\r&lt;br&gt;\r&lt;br&gt;         13. Uncorrected hypokalemia or hypomagnesemia.\r&lt;br&gt;\r&lt;br&gt;         14. Person diagnosed with COVID-19 infection and if he is living in the same household as\r&lt;br&gt;             index case, only he will be excluded but rest of the members of the household will be\r&lt;br&gt;             included.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient age =18 years, competent to provide consent\r&lt;br&gt;\r&lt;br&gt;          -  Within 48 hours of positive nucleic acid test for SARS-CoV-2\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient already prescribed chloroquine or hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  Allergy to hydroxychloroquine\r&lt;br&gt;\r&lt;br&gt;          -  History of bone marrow or solid organ transplant\r&lt;br&gt;\r&lt;br&gt;          -  Known G6PD deficiency\r&lt;br&gt;\r&lt;br&gt;          -  Chronic hemodialysis, peritoneal dialysis, continuous renal replacement therapy or\r&lt;br&gt;             Glomerular Filtration Rate &lt; 20ml/min/1.73m2\r&lt;br&gt;\r&lt;br&gt;          -  Known liver disease (e.g. Child Pugh score = B or AST&gt;2 times upper limit)\r&lt;br&gt;\r&lt;br&gt;          -  Psoriasis\r&lt;br&gt;\r&lt;br&gt;          -  Porphyria\r&lt;br&gt;\r&lt;br&gt;          -  Known cardiac conduction delay (QTc &gt; 500mSec) or taking any prescription medications\r&lt;br&gt;             known to prolong QT interval\r&lt;br&gt;\r&lt;br&gt;          -  Concomitant use of digitalis, flecainide, amiodarone, procainamide, or propafenone\r&lt;br&gt;\r&lt;br&gt;          -  Seizure disorder\r&lt;br&gt;\r&lt;br&gt;          -  Prisoner\r&lt;br&gt;\r&lt;br&gt;          -  Weight &lt; 35kg\r&lt;br&gt;\r&lt;br&gt;          -  Inability to follow-up - no cell phone or no address or not Spanish or English\r&lt;br&gt;             speaking\r&lt;br&gt;\r&lt;br&gt;          -  Receipt of any experimental treatment for SARS-CoV-2 (off-label, compassionate use, or\r&lt;br&gt;             trial related) within the 30 days prior to the time of the screening evaluation\r&lt;br&gt;\r&lt;br&gt;          -  Patient or another member of patient's household has been already enrolled in this\r&lt;br&gt;             study.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patients with PCR confirmed COVID disease\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent by patient or legal patient representative\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt;18\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Patient in which a \"no ICU admission\" or \"no invasive ventilation\" restriction was\r&lt;br&gt;             implemented at the time of screening for the study\r&lt;br&gt;\r&lt;br&gt;        Donors: Eligibility for plasma donation\r&lt;br&gt;\r&lt;br&gt;        Inclusions Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  A history of COVID infection that was documented by PCR\r&lt;br&gt;\r&lt;br&gt;          -  Known ABO-Resus(D) blood group\r&lt;br&gt;\r&lt;br&gt;          -  A negative screening for irregular antibodies\r&lt;br&gt;\r&lt;br&gt;          -  Asymptomatic for at least 24 hours\r&lt;br&gt;\r&lt;br&gt;          -  Donors will be restricted to those who had a symptomatic COVID infection defined as\r&lt;br&gt;             documented fever 38.0 or higher C for at least 48 hours.\r&lt;br&gt;\r&lt;br&gt;          -  Written informed consent regarding the plasmapheresis procedure\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt;18 years\r&lt;br&gt;\r&lt;br&gt;          -  Weight &lt;45kg\r&lt;br&gt;\r&lt;br&gt;          -  Medical history of heart failure\r&lt;br&gt;\r&lt;br&gt;          -  History of transfusion with red blood cells, platelets or plasma\r&lt;br&gt;\r&lt;br&gt;          -  Born as a female person. The reason for this is a higher incidence of transfusion\r&lt;br&gt;             related acute lung injury (TRALI) after plasma transfusion from a female donor\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Age 18 to 65 (inclusive)\r&lt;br&gt;\r&lt;br&gt;          -  Confirmed COVID-19 infection by a FDA-approved molecular based assay (including those\r&lt;br&gt;             under emergency use authorization) of respiratory or blood specimens;\r&lt;br&gt;\r&lt;br&gt;          -  If symptomatic with COVID-19, must have evidence of improvement of symptoms and a\r&lt;br&gt;             duration of at least 4 weeks from the onset of symptoms to day of enrollment;\r&lt;br&gt;\r&lt;br&gt;          -  If asymptomatic, must have a duration of at least 4 weeks from first positive\r&lt;br&gt;             molecular based COVID-19 assay to day of enrollment\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  &lt;18 years or &gt;65 years old\r&lt;br&gt;\r&lt;br&gt;          -  No confirmed diagnosis of COVID-19\r&lt;br&gt;","Inclusion criteria: 1. Aged 18-75 years old;\r&lt;br&gt;2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (Current Trial Version);\r&lt;br&gt;3. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;4. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration;\r&lt;br&gt;5. Patients who voluntarily sign informed consent.","Inclusion criteria: 1. Patients aged 14-75 years;\r&lt;br&gt;2. Real-time fluorescence rt-pcr detection of novel coronavirus nucleic acid positive in respiratory or blood specimens;\r&lt;br&gt;3. The respiratory tract specimen or blood specimen virus gene sequencing, and novel coronavirus highly homologous patients.","Inclusion criteria: (1) Comply with the diagnostic criteria for general type COVID-19 in the \"Diagnosis and Treatment Program for COVID-19\"(trial version 6th);\r&lt;br&gt;(2) Patients =18 years of age with tracheal intubation;\r&lt;br&gt;(3) Agree to participate in the trial, and the patient, the legal guardian or the person in charge of the medical institution signed the informed consent through paper signature, electronic signature of mobile phone software, or voice authorization.","Inclusion criteria: Clinical diagnosis of COVID-19&lt;br&gt;Intubation for mechanical respiratory support (including&lt;br&gt;ECMO) &lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Individual currently works in a setting where individuals receive healthcare\r&lt;br&gt;             (\"healthcare worker\") in the United States (including emergency medical services)\r&lt;br&gt;\r&lt;br&gt;          -  Age = 18\r&lt;br&gt;\r&lt;br&gt;          -  Able to speak and read English or Spanish\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        * There are no specific exclusion criteria for this study. Participants must meet inclusion\r&lt;br&gt;        criteria.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Male and female residents of LTCFs at least 65 years of age.\r&lt;br&gt;\r&lt;br&gt;          -  Willing and able to provide written informed consent and comply with the requirements\r&lt;br&gt;             of the protocol.\r&lt;br&gt;\r&lt;br&gt;          -  At least one symptomatic laboratory-confirmed viral respiratory infection identified\r&lt;br&gt;             in the LTCF within 7 days prior to enrollment.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Alzheimer's disease, dementia, or other mental incapacity which precludes\r&lt;br&gt;             comprehension of the study requirements or symptom diary.\r&lt;br&gt;\r&lt;br&gt;          -  Subjects expected to require hospitalization within the 6-week treatment period.\r&lt;br&gt;\r&lt;br&gt;          -  Subjects who experienced a previous episode of acute upper respiratory tract\r&lt;br&gt;             infection, otitis, bronchitis or sinusitis or received antibiotics for these\r&lt;br&gt;             conditions or antiviral therapy for influenza within two weeks prior to and including\r&lt;br&gt;             study day 1.\r&lt;br&gt;\r&lt;br&gt;          -  Receipt of any dose of NTZ within 7 days prior to screening.\r&lt;br&gt;\r&lt;br&gt;          -  Treatment with any investigational drug or vaccine within 30 days prior to screening\r&lt;br&gt;             or unwilling to avoid them during the course of the study.\r&lt;br&gt;\r&lt;br&gt;          -  Known sensitivity to NTZ or any of the excipients comprising the study medication.\r&lt;br&gt;\r&lt;br&gt;          -  Subjects unable to swallow oral tablets or capsules.\r&lt;br&gt;\r&lt;br&gt;          -  Subjects taking medications considered to be major CYP2C8 substrates.\r&lt;br&gt;\r&lt;br&gt;          -  Subjects who, in the judgment of the Investigator, will be unlikely to comply with the\r&lt;br&gt;             requirements of this protocol.\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  All genders\r&lt;br&gt;\r&lt;br&gt;          -  Age &gt; 18 yrs and &lt; 90 yrs\r&lt;br&gt;\r&lt;br&gt;          -  Must have laboratory confirmed COVID-19\r&lt;br&gt;\r&lt;br&gt;          -  Must provide informed consent\r&lt;br&gt;\r&lt;br&gt;          -  Must have severe or immediately life-threatening COVID-19,\r&lt;br&gt;\r&lt;br&gt;        Severe disease is defined as:\r&lt;br&gt;\r&lt;br&gt;          -  dyspnea,\r&lt;br&gt;\r&lt;br&gt;          -  respiratory frequency = 30/min,\r&lt;br&gt;\r&lt;br&gt;          -  blood oxygen saturation = 93%,\r&lt;br&gt;\r&lt;br&gt;          -  partial pressure of arterial oxygen to fraction of inspired oxygen ratio &lt; 300\r&lt;br&gt;\r&lt;br&gt;          -  lung infiltrates &gt; 50% within 24 to 48 hours\r&lt;br&gt;\r&lt;br&gt;        Life-threatening disease is defined as:\r&lt;br&gt;\r&lt;br&gt;          -  respiratory failure,\r&lt;br&gt;\r&lt;br&gt;          -  septic shock\r&lt;br&gt;\r&lt;br&gt;          -  multiple organ dysfunction or failure\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  No gender exclusion\r&lt;br&gt;\r&lt;br&gt;          -  Age &lt; 18 yrs and &gt; 90 yrs\r&lt;br&gt;\r&lt;br&gt;          -  COVID-19 negative\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        All mission critical personnel enrolled to the DiLorenzo Tricare Health Clinic or Pentagon\r&lt;br&gt;        Flight Medicine Clinic unable to telework or appropriately socially distance with access to\r&lt;br&gt;        the Pentagon during the declared public health crisis.\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        Known recovered COVID-19 patient, G6PD deficient individuals, individuals with significant\r&lt;br&gt;        QT abnormalities, non-compliant patients, and patients who refuse randomization or consent.\r&lt;br&gt;","Inclusion criteria: 1. Aged &gt;18 years old;\r&lt;br&gt;2. patients diagnosed COVID-19.","Inclusion criteria: Patients confirmed to be infected with SARS-CoV-2.","Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria:&lt;br&gt;- Age = 18 years.&lt;br&gt;&lt;br&gt;For patients:&lt;br&gt;- Diagnosed by their treating physician with RA, PsA, or AS.&lt;br&gt;&lt;br&gt;For controls:&lt;br&gt;- Belonging to family or close friend of patient (of the same gender). &lt;br&gt;&lt;br&gt;For the sub-study:&lt;br&gt;- A confirmed infection with SARS-CoV-2 by the GGD or typical COVID-19 complaints and contact with someone who is also suspected for an infection with SARS-CoV-2.","Inclusion criteria: Age (=18 years)&lt;br&gt;Proven(PCR) or suspected (based on clinical signs and imaging) COVID-19 infection-&lt;br&gt;Referral or admission for internal, emergency or respiratory medicine-&lt;br&gt;Certified sonographerpresent","Inclusion criteria: SARS-CoV 2 PCR positive patients at the intensive care","Inclusion criteria: Able to fill in the questionnaire in Dutch","\r&lt;br&gt;        Inclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;          -  Any faculty, staff, or trainee from Duke pulmonary and critical care that consents to\r&lt;br&gt;             being in the study\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        -\r&lt;br&gt;","\r&lt;br&gt;        Inclusion Criteria (each of the following):\r&lt;br&gt;\r&lt;br&gt;          1. Adults (aged =18 years)\r&lt;br&gt;\r&lt;br&gt;          2. Confirmed diagnosis of COVID-19\r&lt;br&gt;\r&lt;br&gt;          3. Hospitalized in the ICU for illness related to COVID-19\r&lt;br&gt;\r&lt;br&gt;          4. Died or discharged from the hospital, or at least 14 days of survival data available\r&lt;br&gt;             from the time of ICU admission\r&lt;br&gt;\r&lt;br&gt;        Exclusion Criteria:\r&lt;br&gt;\r&lt;br&gt;        -None\r&lt;br&gt;","Inclusion criteria: Positive for COVID 19 with pulmonary involvement - severe\r&lt;br&gt;Admission or being considered for admission to intensive care unit","Inclusion criteria: &lt;br&gt;Subjects meeting all of the following criteria will be considered for enrolment into the study:\r&lt;br&gt;1.\tAge = 18 year/old \r&lt;br&gt;2.\tChronically treated with RAS blockers (ACE inhibitors or ARBs on the last prescription prior to admission with a treatment duration = 1 month))\r&lt;br&gt;3.\tDiagnosis of COVID-19 confirmed by the presence of SARS-CoV-2 on any biological sample with any detection method\r&lt;br&gt;4.\tPatients hospitalized in a non-ICU\r&lt;br&gt;5.\tPregnancy test at inclusion visit for women of childbearing potential\r&lt;br&gt;6.\tWomen of childbearing potential must agree to use adequate contraception according to Recommendations related to contraception and pregnancy testing in clinical trials, by Clinical Trial Facilitation Group (CTFG)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 277&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 277&lt;br&gt;","Inclusion criteria: All pregnant women admitted to a participating hospital with COVID-19 during pregnancy","Inclusion criteria: \tAged 18 to 75 years.\r&lt;br&gt;\tLaboratory confirmed SARS-CoV2 infection. \r&lt;br&gt;\tAdvised to self-manage COVID-19 in the community by the regional public health team. \r&lt;br&gt;\tIn the Investigators opinion, is able and willing to comply with all trial requirements.\r&lt;br&gt;\tBaseline Flu PRO score &gt;1.3\r&lt;br&gt;\tAble to receive and commence randomised treatment via courier the day after consent was obtained. \r&lt;br&gt;","Inclusion criteria: - Age &gt;18 years&lt;br&gt;- Hospital admission with proven SARS2-Covid19 infection&lt;br&gt;- Hypoxemic respiratory failure (SaO2 &lt;92%, PaO2 &lt;8kPa)&lt;br&gt;- Ability to give informed consent","Inclusion criteria: &lt;br&gt;Patients with SARS-CoV-2 infection and:\r&lt;br&gt;1.\tage = 18 years and = 75 years\r&lt;br&gt;2.\tSARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal \r&lt;br&gt;                    swap)\r&lt;br&gt;3.\tsevere disease defined by at least one of the following:\r&lt;br&gt;  a.\trespiratory rate = 30 breaths / minute under ambient air\r&lt;br&gt;  b.\trequirement of any type of ventilation support\r&lt;br&gt;  c.\tneeds ICU Treatment\r&lt;br&gt;4.                 Written informed consent by patient or legally authorized representative\r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 77&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 29&lt;br&gt;","Inclusion criteria: &lt;br&gt;- Positive CoV-2 SARS test on nasopharyngeal swab&lt;br&gt;- Onset of symptoms &lt; 72 hours prior to nasopharyngeal swabbing&lt;br&gt;- Age = 65 years old&lt;br&gt;- Valid, ambulatory person, fully capable of understanding the challenges of the tria&lt;br&gt;- No hospitalization criteria according to current recommendations&lt;br&gt;- Signed informed consent&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 1057&lt;br&gt;","Inclusion criteria: &lt;br&gt;1. Patient aged &gt; 18&lt;br&gt;2. Patient affiliated to a health insurance plan&lt;br&gt;3. Patient who has given their free, informed and written consent or patient for whom an independent doctor has given their signed consent as part of an emergency procedure&lt;br&gt;4. Serum Potassium&gt; 3,5 mmol / L&lt;br&gt;5. Patient diagnosed COVID positive by RT-PCR and / or scanner&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 80&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 42&lt;br&gt;","Inclusion criteria: \tConsenting adult patients adult male or female, age 18 years or older. Laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or another commercial or public health assay\r&lt;br&gt;\tHospitalized with a SARS-CoV-2 infection of any duration\r&lt;br&gt;\tAbility to provide informed consent signed by study patient or legally acceptable representative\r&lt;br&gt;\tWillingness and ability to comply with study-related procedures/assessments\r&lt;br&gt;\tHave an oxygen saturation (SaO2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (PaO2) to the fraction of inspired oxygen (FiO2) (Pao2: Fio2) at or below 300 mg Hg. \r&lt;br&gt;\tNo chronic kidney disease (CKD) defined by stage II or higher using the Kidney Disease Improving Global Outcomes (KDIGO) classification\r&lt;br&gt;","Inclusion criteria: &lt;br&gt;                All participants must:&lt;br&gt;                1. Be aged 18 years and above&lt;br&gt;                2. Have a sufficient level of English comprehension to understand and complete questionnaires&lt;br&gt;&lt;br&gt;                Poor sleepers:&lt;br&gt;                1. Must have difficulties in falling asleep, staying asleep, or awakening too early at least three nights per week, for a time period of between two weeks and three months&lt;br&gt;                2. Must have distress or impairment caused by sleep loss&lt;br&gt;                3. Both 1. and 2. must occur despite the individual having an adequate opportunity for sleep&lt;br&gt;&lt;br&gt;                Good sleepers:&lt;br&gt;                1. No current sleep problems&lt;br&gt;","Inclusion criteria: &lt;br&gt;consenting adults (age =18) hospitalised with definite COVID-19, not already receiving any of the study drugs&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 500&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 2000&lt;br&gt;","Inclusion criteria: &lt;br&gt;? Patients of both sexes with an age greater than or equal to 18 years.&lt;br&gt;? Patients with a diagnosis of SARS-CoV-2 infection confirmed by RT-PCR.&lt;br&gt;? Patients with grade 4, 5 or 6 clinical status according to the WHO classification.&lt;br&gt;- Grade 4: Hospitalized patients requiring oxygen therapy.&lt;br&gt;- Grade 5: Hospitalized patients requiring high-flow oxygen therapy, non-invasive mechanical ventilation, or both.&lt;br&gt;- Grade 6: Hospitalized patients requiring extracorporeal membrane oxygenation or invasive mechanical ventilation.&lt;br&gt;? Patients with IL-6 levels equal to or greater than 3 times the value of normality&lt;br&gt;? Potentially fertile patients should have a negative pregnancy test in serum (beta-HCG) or urine (evaluated between 2 and 1 days prior to administration of the study medication).&lt;br&gt;? Patients who offer sufficient guarantees of adherence to the protocol.&lt;br&gt;? Patients who give their written informed consent to participate in the study&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 60&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 60&lt;br&gt;","Inclusion criteria: &lt;br&gt;                1. Present to the UZH COVID-19 Testing Center for SARS-CoV-2 testing following a phone-based triage assessing their eligibility for SARS-CoV-2 testing&lt;br&gt;                2. Provide consent for study participation&lt;br&gt;","Inclusion criteria: &lt;br&gt;                1. Participant is willing and able to give informed consent for participation in the study&lt;br&gt;                2. Participant is willing to comply with all trial procedures&lt;br&gt;                3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 7 days of inclusion&lt;br&gt;                4. Patients aged =65 with or without comorbidity, and patients aged =50 years with the following listed comorbidities:&lt;br&gt;                4.1. Known weakened immune system due to serious illness or infection (e.g. chemotherapy)&lt;br&gt;                4.2. Known heart disease&lt;br&gt;                4.3. Known asthma or lung disease&lt;br&gt;                4.4. Known diabetes not treated with insulin&lt;br&gt;                4.5. Known mild hepatic impairment&lt;br&gt;                4.6. Known stroke or neurological problem&lt;br&gt;","Inclusion criteria: &lt;br&gt;1. Absence of SARS-CoV-2 infection (COVID-19) due to the absence of a symptoms of acute respiratory infection or a diagnostic test with a negative result.&lt;br&gt;&lt;br&gt;2. Men or women 18 years of age or older at the time of signing the informed consent.&lt;br&gt;&lt;br&gt;3. For fertile women, negative pregnancy test and written commitment to use a reliable contraceptive method for the duration of the study and for 3 months after the end of treatment.&lt;br&gt;&lt;br&gt;4. Health care workers active at the center.&lt;br&gt;&lt;br&gt;5. Informed consent signed&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 2163&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;","Inclusion criteria: &lt;br&gt;- Patients of both sexes&lt;br&gt;- Patients = 18 years with COVID and comorbidities (COPD, asthma, heart disease, HT, diabetes, neoplasia, chronic liver disease or with immunosuppressive treatment), without pneumonia or over 60 with COVID&lt;br&gt;- SARS-CoV-2 infection confirmed by PCR test&lt;br&gt;- Radiographic evidence of not presenting pneumonia&lt;br&gt;- O2 saturation&gt; 92%&lt;br&gt;- Respiratory Rate &lt;20 rpm&lt;br&gt;- Willing and able to sign the written informed consent before carrying out the study procedures. Exceptionally, oral consent is admitted, preferably before independent witnesses, documenting it in the medical record and provided that it can later be ratified.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 62&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 62&lt;br&gt;","Inclusion criteria: &lt;br&gt;- Major patient (age = 18 years old);&lt;br&gt;- Hospitalized in intensive care;&lt;br&gt;- Severe pneumonia COVID-19 with Berlin criteria for ARDS (PaO2/FiO2&lt;300 and PEP&gt;5).&lt;br&gt;- Intubated for less than 8 days ;&lt;br&gt;- Expected duration of mechanical ventilation is &gt;48 hours;&lt;br&gt;- Carrying an arterial catheter;&lt;br&gt;- Affiliated with or beneficiary of a health insurance social protection scheme&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 50&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 50&lt;br&gt;","Inclusion criteria: &lt;br&gt;People in close contact with adults diagnosed with COVID-19 who sign the informed consent. Close contact is defined as those who live at home with an infected person, who have had intimate relationships or whose job is less than two meters from the infected person.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 100&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 100&lt;br&gt;","Inclusion criteria: Laboratory confirmation of COVID-19 was performed at The First Affiliated Hospital of Yangtze University according to WHO interim guidelines,10 while ARDS diagnosis was performed according to the Berlin definitions. \r&lt;br&gt;all COVID-19 patients who developed ARDS and who received mechanical ventilation. Included cases were confirmed ARDS patients according to their medical charts, had two consecutive arterial blood gas analysis (ABGA) with oxygenation index (OI), partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) &lt; 300 mmHg (with positive end-expiratory pressure, PEEP &gt;=5 cm H2O), had bilateral radiographic opacities on computed tomography (CT) that could not be explained by effusions, pulmonary collapse, or nodules, and had respiratory failure that could not be explained by cardiogenic pulmonary edema.","Inclusion criteria: 1. Patients with clinically confirmed rosacea and certain  autoimmune?diseases (such as LE, dermatomyositis, RA, Sjogren syndrome or UCTD);\r&lt;br&gt;2. Have exposure to people with SARS-CoV-2 infection or diagnosed as COVID-19; Or, living in the epidemic regions of SARS-CoV-2; Or, have ever gone to the epidemic regions; Or, have ever contacted with people from the epidemic regions.","Inclusion criteria: &lt;br&gt;- Age = 18 years&lt;br&gt;- Negative PCR and negative serology at day 0&lt;br&gt;- Healthcare worker at Hospital Clinic of Barcelona&lt;br&gt;- Female participants: negative for pregnancy test&lt;br&gt;- Willing to participate in the study&lt;br&gt;- Able to sign the informed consent form&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 435&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 5&lt;br&gt;","Inclusion criteria: 1. Aged above 18 years;\r&lt;br&gt;2. Able to understand the content of informed consent and willing to sign the informed consent;\r&lt;br&gt;3. Able and willing to complete all the secluded study process during the whole follow-up period of 6 months.\r&lt;br&gt;4. Negative in HIV diagnostic test;\r&lt;br&gt;5. Axillary temperature &lt;=37.0 degree C;\r&lt;br&gt;6. Negative in serum antibodies (IgG and IgM) screening of COVID-19.\r&lt;br&gt;7. The BMI index 18.5-30.0;\r&lt;br&gt;8. General good health as established by medical history and physical examination.","Inclusion criteria: (1) RT-PCR or / and NGS method can be used to detect novel coronavirus nucleic acid in nasopharyngeal swabs, sputum and other lower respiratory tract secretions, blood, feces and other specimens; (2) novel coronavirus specific IgM Positive antibody; (3) New coronavirus-specific IgG antibody positive; (4) The body generally allows participation in this clinical study (5) The participants can understand and sign the informed consent.","Inclusion criteria: (1)Complete sample information, including sample number, gender, age, sampling time, and clinical diagnosis background information\r&lt;br&gt;(2)New coronavirus-infected pneumonia confirmed cases (including partial recovery cases), excluded cases, etc. (Confirmed cases should include patients with different disease processes (such as early, middle, late treatment / recovery patients, etc.)\r&lt;br&gt;(3)Consecutive samples collected at different times from some patients with pneumonitis infected by the new coronavirus were included, including samples from each stage of the new coronavirus nucleic acid and antigen / antibody from negative to positive\r&lt;br&gt;(4)The samples were selected as inpatients and outpatient patients for clinical needs.The remaining samples can be tested by clinical units or stored as frozen samples.","Inclusion criteria: We collected 33 cases of COVID-19 from wenzhou central hospital.After interferon treatment, serum, fece and sputum samples of patients were collected of patients at different time. The nucleic acid virus clearance for 4 weeks or more was divided into one group, and another group was less than 4 weeks. The samples of these patients at different time periods were inactivated, and then multi-group analysis was performed","Inclusion criteria: Subject previously participated in the PIENTER 3 study (2016/17) and had indicated that they could be approached for a follow-up study.","Inclusion criteria: Pregnant women who tested positive on SARS-CoV-2, regardless of the presence or absence of any clinical symptoms","Inclusion criteria: -Age (=18 years)-&lt;br&gt;Proven(PCR) or suspected (based on clinical signs) COVID-19 infection-&lt;br&gt;Referralor admission for internal, emergency or respiratory medicine-&lt;br&gt;Certified sonographerpresent","Inclusion criteria: ? Patients 18 years and older&lt;br&gt;? Patients with a diagnosis of COVID-19 based on a compatible clinical presentation AND a positive SARS-CoV-2 PCR on a respiratory sample such as a nasopharyngeal swab, sputum, or BAL fluid&lt;br&gt;? Clinical features compatible with hyperinflammation:&lt;br&gt;- Hypoxia, without other explanation for hypoxia than COVID-19 OR&lt;br&gt;- ferritin &gt;2000 g/L or doubling of serum ferritin in 20-48 hours&lt;br&gt;Hypoxia is defined according to ASTCT CRS Consensus grading: grade II. [Lee DW, et al. BBMT 2019;25(4):625-638] Inclusion of patients already requiring oxygen administration prior to COVID-19 should be discussed with the study team.&lt;br&gt;? Written informed consent.&lt;br&gt;? Patient is capable of giving informed consent.","Inclusion criteria: &lt;br&gt; COVID-19 infected patient \r&lt;br&gt; Age 18 years or older \r&lt;br&gt; Presence of pneumonia \r&lt;br&gt; PaO2/FiO2 &lt; 300 mm Hg or SpO2 &lt; 93% in air ambient or need to supplementary oxygen administration in order to maintain SpO2 range in [94-98%] or lung infiltrates &gt; 50% \r&lt;br&gt; Medical insurance&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 292&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 292&lt;br&gt;","Inclusion criteria: &lt;br&gt;1. At least 18 years of age or older\r&lt;br&gt;2. Clinically evident or otherwise confirmed severe pneumonia as evidenced by at least one of the following criteria:\r&lt;br&gt; Chest X-ray or CT-scan or MRI with pulmonary infiltrates consistent with pneumonia\r&lt;br&gt; Clinical history in past 14 days of newly developed severe shortness of breath (&gt; 29 BR / minute) in the absence of oxygen supply or spontaneous peripheral oxygenation = 92 with need for oxygen supply, or need for non-invasive or invasive ventilation (in conjunction with a positive test for SARS-CoV-2 infection)\r&lt;br&gt;3. Oxygenation Index at time of enrollment (PaO2 / FiO2) = 250 and = 100 in supine position\r&lt;br&gt;4. SARS-CoV-2 infection confirmation (tested positive in last 14 days or test results to be obtained within 24h after enrollment, both with locally available test system).\r&lt;br&gt;5. No use OR stop of any corticosteroid treatment at time point of enrollment (topical treatment and systemic dose of = 10mg prednisone / day equivalent allowed)\r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 65&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 65&lt;br&gt;","Inclusion criteria: &lt;br&gt;-\tAdult Healthcare workers (HCWs) (physicians, nurses, assistant nurses, dentists, physiotherapists, and midwives)&lt;br&gt;-\tHCWs involved at the time of enrolment in the care of patients with confirmed or suspected SARS-CoV-2 infection in hospital settings in outpatient care settings or in geriatric long-term care facilities&lt;br&gt;-\tHCWs tested negative for HIV&lt;br&gt;-\tHCW affiliated to the French health insurance system&lt;br&gt;-\tHCW women of childbearing age with an effective contraception (ethinylestradiol-containing contraceptive pills are not regarded as effective in the context of LPV/r treatment) &lt;br&gt;-\tWilling to comply to study design and the follow-up&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 1200&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;","Inclusion criteria: &lt;br&gt;I1. Age 18 or older at the time of enrolment.\r&lt;br&gt;I2. Histologically or cytologically confirmed diagnosis of advanced or metastatic hematological or solid tumor (hematological or solid tumor, any type and any localization).\r&lt;br&gt;I3. Documented diagnosis of COVID-19 (diagnostic test performed in a certified laboratory) or symptoms of COVID-19 associated with radiological signs of pneumonia as described by Shi et al.;\r&lt;br&gt;I4. Cohort 2: patients with pneumonia confirmed by chest imaging, and an oxygen saturation (Sao2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) (Pao2:Fio2) at or below 300 mg Hg. \r&lt;br&gt;...See the protocol&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 147&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range 126&lt;br&gt;","Inclusion criteria: &lt;br&gt;1.Age = 18 years \r&lt;br&gt;2.Admitted to ICU within 48 hours\r&lt;br&gt;3.Confirmed or highly suspected COVID-19 infection \r&lt;br&gt;4.Acute hypoxemic respiratory failure (PaO2 &lt;70 mmHg or SpO2&lt;90% on room air or tachypnea&gt;30/min or labored breathing or respiratory distress; need for oxygen flow &gt;=6L/min) \r&lt;br&gt;5.\tAny treatment intended to treat the SARS-CoV-2 infection (either as a compassionate use or in the context of a clinical trial, i.e remdesivir, lopinavir/ritonavir, favipiravir, hydroxychloroquine and any other new drug with potential activity). \r&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 400&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 150&lt;br&gt;","Inclusion criteria: &lt;br&gt;Inclusion criteria: &lt;br&gt;&lt;br&gt;Patients admitted to the HUB with COVID-19 infection confirmed by fluorescent RT-PCR who meet all of the following criteria: &lt;br&gt;1 New-onset radiological infiltrates (either by plain chest radiography, computed tomography or chest ultrasound) attributed to COVID-19, &lt;br&gt;2. Respiratory failure (PaO2/FiO2 &lt; 300 or satO2/FiO2 &lt; 220) attributed to 1, &lt;br&gt;3.PCR &gt; 100 mg/L and/or D-Dimer &gt; 1000 g/L and/or Ferritin &gt; 1000 ug/L attributed to 1, &lt;br&gt;4. Age = 18 years. &lt;br&gt;5. The subject, his legal representative or closest relative (in case of the subject's incapacity due to the seriousness of the clinical situation) that gives informed consent&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 44&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 40&lt;br&gt;","Inclusion criteria: &lt;br&gt;1. Subject (or authorized legal representative) who can provide written informed consent before beginning any study procedure.&lt;br&gt;2. Understand and agree to abide by the study procedures.&lt;br&gt;3. Adult =18 years of age at the time of inclusion in the study.&lt;br&gt;4. Confirmation of SARS-CoV-2 infection by a microbiological test performed before randomization, no longer than 72 hours.&lt;br&gt;5. Gravity 3-4 according to the WHO 7-point ordinal scale:&lt;br&gt;- Severity 3. Hospitalized, which does not require supplemental oxygen&lt;br&gt;- Severity 4. Hospitalized, requiring supplemental oxygen&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 276&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;","Inclusion criteria: &lt;br&gt;\tParticipants that after receiving appropriate information on the study design, objectives, possible risks and acknowledging that they have the right to withdraw from the study consent at any time sing the informed consent for participation in the study. &lt;br&gt;\tMale or female aged 18-65 years. &lt;br&gt;\tHealth care workers in public or private hospitals in Spain in an areas of risk of SARS-CoV-2 transmission. &lt;br&gt;\tNot previous diagnosis of SARS-CoV-2 (COVID-19) infection plus no symptoms of SARS-CoV-2 (COVID-19) since 1st of March 2020 until the date of enrolment in the study. &lt;br&gt;\tUnderstand the aim of the study and have not been on any previous active pre exposure prophylaxis treatment against SARS-CoV-2 (COVID-19) since 1st of March 2020 until the date of enrolment in the study.  This include PrEP for HIV.&lt;br&gt;\tNegative PCR rapid test for SARS-CoV-2 (COVID-19) at enrolment.  &lt;br&gt;\tParticipant willing and able to give informed consent for participation in the study&lt;br&gt;\tNegative pregnancy test during the previous 7 days to start treatments or more than 2 years after menopause. &lt;br&gt;\tWomen of reproductive age and their partners should commit to use and highly effective contraceptive method (such sterilisation, double barrier, hormonal  contraception), during the study period and until 6 months after the last dose of treatment.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 4000&lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;","Inclusion criteria: &lt;br&gt;Participants must be hospitalized with illness consistent with COVID-19 pneumonia by chest imaging and/or clinical examination and with moderate to severe disease\r&lt;br&gt;Laboratory-confirmed SARS-CoV-2 infection\r&lt;br&gt;Onset of COVID-19 symptoms  =5 days before randomization \r&lt;br&gt;Women of childbearing potential must have a negative highly sensitive\r&lt;br&gt;pregnancy test at screening and should agree to use an acceptable\r&lt;br&gt;contraceptive method&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 175&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 175&lt;br&gt;","Inclusion criteria: &lt;br&gt;1. Diagnosis of SARS-CoV-2 by testing the polymerase chain reaction performed on a respiratory sample;&lt;br&gt;2. Pneumonia confirmed by radiological imaging test;&lt;br&gt;3. ARDS Criteria:&lt;br&gt;    (i) bilateral infiltrates;&lt;br&gt;    (ii) PO2/FiO2 &lt;300 mmHg; And&lt;br&gt;    (iii) reasonable clinical exclusion of heart cause (requires all).&lt;br&gt;4. Verbal consent of the patient.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range 39&lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range 65&lt;br&gt;"],["Exclusion criteria: Patients diagnosed with pneumonia of age &lt;15 years diagnosed according to\"guideline of the diagnose and treatment of 2019-nCoV (tested)\" published by National Health Committees of Peoples' Republic Country;  Suspected patient with viral nucleic acid-negative 2019-nCoV infection.","Exclusion criteria: 1. Female patients during pregnancy; \r&lt;br&gt;2. Patients with known allergy to chloroquine; \r&lt;br&gt;3. Patients with haematological diseases; \r&lt;br&gt;4. Patients with chronic liver or kidney diseases at the end stage; \r&lt;br&gt;5. Patients with arrhythmia and chronic heart disease; \r&lt;br&gt;6. Patients with retinal disease, hearing deficiency or hearing loss; \r&lt;br&gt;7. Patients with psychiatric diseases; \r&lt;br&gt;8. Patients taking digitalis due to underlying diseases.",null,"Exclusion criteria: Absolutely forbidden criteria for ECMO application","Exclusion criteria: 1. Hypersensitive to immunoglobulin;\r&lt;br&gt;2. Have immunoglobulin A deficiency.","Exclusion criteria: No exclusion criteria","Exclusion criteria: 1. Patients with respiratory failure, acute necrotizing encephalopathy, septic shock, multiple organ dysfunction, and other serious clinical conditions requiring monitoring and treatment when enrolled;\r&lt;br&gt;2. Pregnant, preparing or lactating women;\r&lt;br&gt;3. Patients with severe heart, cerebrovascular and liver, kidney, hematopoietic system diseases and mental illness;\r&lt;br&gt;4. Patients with tuberculosis, measles, AIDS and other infectious diseases;\r&lt;br&gt;5. Patients with known allergies to western medicine or traditional Chinese medicine ingredients used in this research;\r&lt;br&gt;6. Patients with gastrointestinal bleeding who cannot take Chinese medicine;\r&lt;br&gt;7. Patients who use oral Chinese medicine within 4 weeks.","Exclusion criteria: 1. Unable to receive traditional Chinese medicine treatment.\r&lt;br&gt;2. Cases where complete diagnosis and treatment information is not available.","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment","Exclusion criteria: Suspected patients with inability to collect deep sputum, throat swabs, or nose swabs from alveolar lavage.",null,null,null,"Exclusion criteria: 1. Patients without any clinical or chest imaging manifestations;\r&lt;br&gt;2. Those with severe nasal diseases affecting the sampling;\r&lt;br&gt;3. Inability to understand or follow research protocols for severe mental illness;\r&lt;br&gt;4. Invasive ventilation with endotracheal intubation.","Exclusion criteria: N/A","Exclusion criteria: 1. Patients with cognitive disorder or known mental illness;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Patients with active tuberculosis, pulmonary abscess or chronic respiratory failure;\r&lt;br&gt;4. Patients with tumor;\r&lt;br&gt;5. Patients with severe liver or kidney diseases;\r&lt;br&gt;6. Patients with severe cardiovascular or cerebrovascular diseases;\r&lt;br&gt;7. Patients who are participating in clinical trials of other drugs, or known to be allergic to therapeutic drugs.","Exclusion criteria: N/A","Exclusion criteria: 1. Pregnant or lactating women, allergic to the research drug; \r&lt;br&gt;2. Combined with cardiovascular, liver, kidney and hematopoietic systems and other serious primary diseases, mental illness;\r&lt;br&gt;3. Those with observational factors affecting efficacy; \r&lt;br&gt;4. Those who do not meet the inclusion criteria, do not use the prescribed drugs, can not determine the efficacy or incomplete information and other effects of efficacy or safety judgment.","Exclusion criteria: 1. Pregancy or lactating women;\r&lt;br&gt;2. People with allergies or allergies to traditional Chinese medicine  \r&lt;br&gt;3. Severe Primary disease such as uncontrolled and metastasis malignancy, hematopathy, HIV;\r&lt;br&gt;4. Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis;\r&lt;br&gt;5. Previous immunodepressant within 6 months before study entry or Receipt of a solid-organ or bone marrow transplant;\r&lt;br&gt;6. Severe mental illness or inability to cooperate with investigators.","Exclusion criteria: 1. Patients who have received immunotherapy (such as PD-1 / L1, CTLA4, etc.) and inflammatory factor modulators (such as Ulinastatin) within one month.\r&lt;br&gt;2. Patients who have used antibacterial drugs such as macrolides within one week.\r&lt;br&gt;3. Patients who have received other anti-2019-nCOV potentially effective drugs such as Lopinavir and Ritonavir within one week.\r&lt;br&gt;4. Those who have undergone organ transplantation or surgery planning within 6 months.\r&lt;br&gt;5. Patients with coma or intestinal obstruction can not eat or take medicine.\r&lt;br&gt;6. With severe illness affected survival, including uncontrolled malignant tumors that have been metastatic and can not be removed, blood diseases, cachexia, active bleeding, severe malnutrition, HIV, etc..\r&lt;br&gt;7. Pregnant and lactating women, subjects (including male subjects) have a pregnancy plan (including sperm donation, egg donation plan) within the next 6 months or are unable to take effective contraceptive measures.\r&lt;br&gt;8. Patients with allergies or allergies to macrolide drugs, lopinavir / ritonavir tablets.\r&lt;br&gt;9. Patients with contraindications to using lopinavir / ritonavir tablets who plan or are using drugs that interact with the drug (including: highly dependent on CYP3A clearance and increased plasma concentrations can be severe and / or Life-threatening events [narrow therapeutic index] drugs, CYP3A inducers [see the instructions for details]), and can not be stopped or switched to other drugs.\r&lt;br&gt;10. Elevated alanine aminotransferase (ALT) / glutaminase (AST) is more than five times the upper limit of normal, total bilirubin is three times the upper limit of normal, or child-Pugh grade C cirrhosis.\r&lt;br&gt;11. Extracorporeal life support (ECMO, ECCO2R, RRT).\r&lt;br&gt;12. Critical patients with an estimated survival time of &lt; 48 h.\r&lt;br&gt;13. Participants in other clinical research in the past  month.\r&lt;br&gt;14. At the investigator's discretion, patients were deemed unsuitable for inclusion.","Exclusion criteria: 1. Pregancy or lactating women;\r&lt;br&gt;2. People with allergies or allergies to components of Truncated Torsion formula; \r&lt;br&gt;3. Patients with serious basic diseases such as malignant tumor, cirrhosis, chronic renal failure (uremic stage), hematological disease, HIV, etc.;\r&lt;br&gt;4. Patients with obstructive pneumonia caused by lung tumor, pulmonary fibrosis, alveolar proteinosis and allergic alveolitis;\r&lt;br&gt;5. Patients with long-term use of hormone, immunosuppressant and other drugs;\r&lt;br&gt;6. Severe mental illness or inability to cooperate with investigators.","Exclusion criteria: 1. Severe pneumonia requires mechanical ventilationcritically severe cases;\r&lt;br&gt;2. Estimated Time of Death is less than 48 hours;\r&lt;br&gt;3. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;\r&lt;br&gt;4. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation. Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;\r&lt;br&gt;5. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;\r&lt;br&gt;6. Mental state unable to cooperate, suffering from mental illness, unable to control, unable to express clearly\r&lt;br&gt;7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;\r&lt;br&gt;8. Patients with a history of substance abuse or dependence;\r&lt;br&gt;9. Pregnant or lactating women;\r&lt;br&gt;10. Patients who participated in other clinical trials within the last 3 months;\r&lt;br&gt;11. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.",null,null,null,null,"Exclusion criteria: 1. Rest or unattended staff;\r&lt;br&gt;2. Staff with respiratory symptoms;\r&lt;br&gt;3. Staff who need the necessary isolation.","Exclusion criteria: 1. CT image quality does not meet the analysis criteria;\r&lt;br&gt;2. Pregnant and lactating women.","Exclusion criteria: 1. Patients with respiratory failure, acute necrotizing encephalopathy, septic shock, multiple organ dysfunction, and other serious clinical conditions requiring monitoring and treatment when enrolled;\r&lt;br&gt;2. Pregnant, preparing or lactating women;\r&lt;br&gt;4. Patients with severe heart, cerebrovascular and liver, kidney, hematopoietic system diseases and mental illness;\r&lt;br&gt;3. Patients with tuberculosis, measles, AIDS and other infectious diseases;\r&lt;br&gt;5. Patients with known allergies to western medicine or traditional Chinese medicine ingredients used in this research;\r&lt;br&gt;6. Patients with gastrointestinal bleeding who cannot take Chinese medicine;\r&lt;br&gt;7. Patients who use oral Chinese medicine within 4 weeks.","Exclusion criteria: 1. Female patients during pregnancy; \r&lt;br&gt;2. Patients with known allergy to chloroquine; \r&lt;br&gt;3. Patients with haematological diseases; \r&lt;br&gt;4. Patients with chronic liver or kidney diseases at the end stage; \r&lt;br&gt;5. Patients with arrhythmia and chronic heart disease; \r&lt;br&gt;6. Patients with retinal disease, hearing deficiency or hearing loss; \r&lt;br&gt;7. Patients with psychiatric diseases; \r&lt;br&gt;8. Patients taking digitalis due to underlying diseases.","Exclusion criteria: Participants who have used fluoroquinolone antibiotics within 1 week","Exclusion criteria: (1) Those who cannot take Chinese traditional medicine decoction;\r&lt;br&gt;(2) mentally ill subjects who are not easy to control;\r&lt;br&gt;(3) those who are pregnant or breast-feeding;\r&lt;br&gt;(4) those who use other Chinese medicines;\r&lt;br&gt;(5) those who are not considered suitable to participate in this trial by researchers.","Exclusion criteria: N/A","Exclusion criteria: 1. Patients who refuse to sign informed consent;\r&lt;br&gt;2. Clinical data is seriously missing or unable to ensure the authenticity of data.","Exclusion criteria: Severe novel coronavirus pneumonia patients who cannot provide exhaled breath samples.","Exclusion criteria: 1. Known to receive hormone therapy orally or intravenously; \r&lt;br&gt;2. Hormone therapy is needed due to concomitant disease upon admission; \r&lt;br&gt;3. Patients with diabetes are receiving oral medication or insulin therapy; \r&lt;br&gt;4. Known contraindications to dexamethasone or other excipients (such as refractory hypertension; epilepsy or delirium and glaucoma); \r&lt;br&gt;5. Known active gastrointestinal bleeding in the past 3 months;\r&lt;br&gt;6. Known difficulties in correcting hypokalemia; \r&lt;br&gt;7. Known secondary bacterial or fungal infections;\r&lt;br&gt;8. Known immunosuppressive status (such as chemotherapy / radiotherapy / HIV infection within one month after surgery);\r&lt;br&gt;9. The clinician thinks that participating in the trial may cause patient damage (such as severe lymphocyte reduction); \r&lt;br&gt;10. The patient may be transferred to a non-participating hospital within 72 hours.","Exclusion criteria: 1. Staff and pharmacists in the administrative, logistics and medical technology departments;\r&lt;br&gt;2. Regulatory students, interns, re-employment, external employment and labor dispatch personnel;\r&lt;br&gt;3. Those who refused to participate in this survey.","Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;\r&lt;br&gt;(2) Preparing pregnant, pregnant and lactating women;\r&lt;br&gt;(3) Patients with allergies (referring to allergies to two or more medicines, foods or known ingredients in this study);\r&lt;br&gt;(4) Patients with mental illness, or have no cognitive ability;\r&lt;br&gt;(5) Patients with an estimated survival time of less than 48 hours from the start of screening;\r&lt;br&gt;(6) Those who have been intubated or mechanically ventilated at the time of screening;\r&lt;br&gt;(7) Obvious symptoms of heart, liver, kidney or various other systems, ALT, AST exceed 1.5 times the upper limit of normal value;\r&lt;br&gt;(8) Believed to be not suitable to participate in clinical trials by investigator.","Exclusion criteria: 1. Pregnant or lactating women, or pregnant;\r&lt;br&gt;2. Those who are allergic to the drug ingredients of this program;\r&lt;br&gt;3. Severe cardiovascular diseases, such as severe center of gravity dysfunction, second or third degree atrioventricular block, etc.;\r&lt;br&gt;4. Severe hepatic insufficiency: defined as the upper limit of ALT &gt; 2 times normal value or AST &gt; 2 times normal value;\r&lt;br&gt;5. Severe renal insufficiency: defined as creatinine &gt; 1.5 times the upper limit of normal value;\r&lt;br&gt;6. Have asthma, COPD serious respiratory disease;\r&lt;br&gt;7. Serious blood diseases, such as coagulation disorders, systemic bleeding, platelet diseases, etc;\r&lt;br&gt;8. Serious endocrine system diseases, such as type II diabetes;\r&lt;br&gt;9. Patients with malignant tumor;\r&lt;br&gt;10. Patients taking antiedematous drugs for a long time;\r&lt;br&gt;11. Major operation history;\r&lt;br&gt;12. Other clinical researchers.","Exclusion criteria: (Subjects cannot enter the study if they meet any of the following conditions):\r&lt;br&gt;1. Patients with a history of allergy to chloroquine phosphate, lopinavir, and ritonavir;\r&lt;br&gt;2. Patients with hematological diseases;\r&lt;br&gt;3. Patients with chronic liver and kidney disease and reaching the end stage;\r&lt;br&gt;4. Patients with arrhythmia and chronic heart disease;\r&lt;br&gt;5. Patients known to have retinal disease, hearing loss or hearing loss;\r&lt;br&gt;6. Patients with known mental illness;\r&lt;br&gt;7. Patients who must use digitalis because of the original underlying disease;\r&lt;br&gt;8. Pancreatitis;\r&lt;br&gt;9. Hemophilia;\r&lt;br&gt;10. Broad bean disease;\r&lt;br&gt;11. Female patients during pregnancy.","Exclusion criteria: None","Exclusion criteria: 1) pneumonia patients with severe or critical new coronavirus infection;\r&lt;br&gt;2) daily treatment of asthma, any other chronic respiratory disease;\r&lt;br&gt;3) patients with confirmed history of diabetes and HbA1C &gt;=8.0%;\r&lt;br&gt;4) those allergic to the known ingredients of the drug;\r&lt;br&gt;5) pregnant or nursing women;\r&lt;br&gt;6) patients with severe mental illness;\r&lt;br&gt;7) patients who have participated in other clinical trials within the past 1 month.","Exclusion criteria: 1. Aged &lt;18 years;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Allergic to the test drug;\r&lt;br&gt;4. The underlying disease is very serious, and the expected survival time is less than 6 months (such as advanced malignant tumors);\r&lt;br&gt;5. COPD or end-stage lung disease requires home oxygen therapy;\r&lt;br&gt;6. Expected survival time does not exceed 48 hours;\r&lt;br&gt;7. Participated in other clinical intervention trials in the past 3 months;\r&lt;br&gt;8. Suffering from autoimmune diseases;\r&lt;br&gt;9. History of organ, bone marrow or hematopoietic stem cell transplant Received radiotherapy and chemotherapy for malignant tumors within 10.6 months;\r&lt;br&gt;11. HIV-infected patients or acquired immune deficiency diagnosed within the past year (CD4 T cells &lt;= 200 / mm3);\r&lt;br&gt;12. Patients receiving anti-HCV treatment;\r&lt;br&gt;13. 90 days with retinal detachment or eye surgery;\r&lt;br&gt;14. Permanent blindness in one eye;\r&lt;br&gt;15. History of iritis, endophthalmitis, scleritis, or retinitis;\r&lt;br&gt;16. The doctor in charge considers it inappropriate to participate in this study.","Exclusion criteria: (1) Impaired consciousness or mental illness cannot cooperate with treating the observer.\r&lt;br&gt;(2) Those with severe organ dysfunction.\r&lt;br&gt;(3) Pregnant women.","Exclusion criteria: Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with immune system diseases or cancers etc.)","Exclusion criteria: Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.","Exclusion criteria: 1. People with allergies and allergies to experimental drugs; \r&lt;br&gt;2. Combined with other malignant tumors; \r&lt;br&gt;3. Patients with hematological diseases, coagulopathy and autoimmune diseases; \r&lt;br&gt;4. Combined with severe cardiovascular diseases, Patients with vascular disease, hematopoietic system disease, and neuropathy; \r&lt;br&gt;5. Participated in other clinical researchers 3 months before the trial.","Exclusion criteria: 1. Patients who are participating in other drug clinical trials;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;\r&lt;br&gt;4. Definite diagnosis of rheumatic immune-related diseases;\r&lt;br&gt;5. Long-term oral anti-rejection or immunomodulatory drugs;\r&lt;br&gt;6. Hypersensitivity to tocilizumab or any excipients;\r&lt;br&gt;7. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.","Exclusion criteria: ?Allergic constitution, ie, allergic history to 2 or more kinds of medicine or food, or to the medicines of our study.\r&lt;br&gt;?Patients who do not agree with taking traditional Chinese medicine.","Exclusion criteria: 1) Known or suspected to be allergic to the components of vMIP.\r&lt;br&gt;2) Confirmed hepatitis B, C, AIDS and other viral infections.\r&lt;br&gt;3) Acute respiratory distress syndrome (ARDS) was found.\r&lt;br&gt;4) According to the judgment of the researchers, there are other conditions that are not suitable for the experiment.\r&lt;br&gt;5) Pregnant, lactating women or during the trial period and within 6 months after the end of the family planning.\r&lt;br&gt;6) Have participated in other clinical trials or are using experimental drugs within 12 weeks before administration.","Exclusion criteria: (1) known or suspected allergy to the components of Azivudine tablets;\r&lt;br&gt;(2) patients with malabsorption syndrome or any other condition that affects gastrointestinal absorption and requires intravenous nutrition or unable to take oral medication;\r&lt;br&gt;(3) patients who is currently receiving anti-hiv treatment;\r&lt;br&gt;(4) patients with one of the following conditions: respiratory failure and mechanical ventilation;Shock;Combined with other organ failure, intensive care unit(ICU) was needed.\r&lt;br&gt;(5) women who are pregnant or breast-feeding or have a family planning plan during the trial period and within 6 months after the end of the trial;\r&lt;br&gt;(6) participating in another clinical trials or using experimental drugs within 12 weeks prior to administration;\r&lt;br&gt;(7)  there are other conditions that are not suitable for participating in this experiment evaluated by the investigator.","Exclusion criteria: 1. Pregnant and nursing women;\r&lt;br&gt;2. Patients with severe liver disease and severe renal dysfunction.","Exclusion criteria: (1) Patients who can not guarantee compliance of using TCM during the treatment period, or patients who are difficult to take medicine by oral or nasal route.\r&lt;br&gt;(2) Patients who have been more than 7 days since definite diagnosis.\r&lt;br&gt;(3) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19.\r&lt;br&gt;(4) Maternal, or patients with a positive urine pregnancy test.\r&lt;br&gt;(5) Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study.","Exclusion criteria: N/A","Exclusion criteria: 1. Clear evidences?of bacterial infection;\r&lt;br&gt;2. Serious primary diseases judged by researchers,such as heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract,?may affect the patients' participation in the trial or the outcome of the study;\r&lt;br&gt;3. Family history of mental illness or mental illness;\r&lt;br&gt;4. Allergic constitution or multi drug allergy;\r&lt;br&gt;5. Pregnant or lactating women.","Exclusion criteria: (1) diseases need to be differentiated from 2019-ncov, such as influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial pulmonary virus, SARS coronavirus and other known viral pneumonia, mycoplasma pneumoniae, chlamydia pneumonia, bacterial pneumonia and non-infectious diseases;\r&lt;br&gt;(2) suspected case of 2019-ncov with no confirmed patient;\r&lt;br&gt;(3) the clinical stage was mild: the clinical symptoms were mild, and no pneumonia was observed on imaging;\r&lt;br&gt;(4) clinical stage: common type: fever, respiratory tract and other symptoms, and imaging findings of pneumonia;\r&lt;br&gt;(5) have any known disease that seriously affects the immune system, such as a history of infection with the human immunodeficiency virus (HIV), or malignant tumors of the blood system or solid organs, or splenectomy;\r&lt;br&gt;(6) other circumstances that the researcher considers inappropriate to participate in this study.","Exclusion criteria: (1) Patients whose estimated survival time does not exceed 48 hours from the start of screening;\r&lt;br&gt;(2) Tracheal intubation and mechanical ventilation have been performed during screening;\r&lt;br&gt;(3) Other problems that doctor's judgment is not suitable for the study.","Exclusion criteria: Patients with other serious organ diseases or mental illness.","Exclusion criteria: 1. Suspected cases and confirmed cases;\r&lt;br&gt;2. Patients with severe heart, brain, liver, kidney and other visceral diseases or other serious metabolic disorders and tumors;\r&lt;br&gt;3. People who could not complete the study for other reasons;\r&lt;br&gt;4. Pregnant or lactating women.","Exclusion criteria: 1. Pregnant or lactating women;\r&lt;br&gt;2. The patients had mental disorder, drug abuse or dependence history, allergy to research drugs, and participated in other clinical studies within 3 months;\r&lt;br&gt;3. Potential violation of test compliance or any other situation affecting safety and effectiveness evaluation.","Exclusion criteria: 1. pregnant woman patients;\r&lt;br&gt;2. Documented allergic history to chloroquine; \r&lt;br&gt;3. Documented history of hematological system diseases;\r&lt;br&gt;4. Documented history of chronic liver and kidney diseases; \r&lt;br&gt;5. Documented history of cardiac arrhythmia or chronic heart diseases; \r&lt;br&gt;6. Documented history of retina or hearing dysfunction; \r&lt;br&gt;7. Documented history of mental illnesses; \r&lt;br&gt;8. Use of digitalis due to the previous disease.","Exclusion criteria: 1) Any situation that makes the programme cannot proceed safely; \r&lt;br&gt;2) patients who have used Kaletra or remdesivir; \r&lt;br&gt;3) no clinical or chest imaging manifestations; \r&lt;br&gt;4) In the state of no oxygen at rest, the patient's SPO2 &lt;= 94% or the oxygenation index is less than 300mmHg respiratory rate &gt;= 24/min; \r&lt;br&gt;5) Patients who need to be admitted to ICU judged by clinicians; \r&lt;br&gt;6) Known allergy or hypersensitivity reaction to lopinavir / ritonavir; \r&lt;br&gt;7) Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 3 times the upper limit of normal; \r&lt;br&gt;8) Drugs that are forbidden to be treated with lopinavir / ritonavir and cannot be replaced or stopped during the study period, such as afzosin, amiodarone, fusidic acid, astemizole, terfenadine, piperazine, dihydroergomethane, ergometrine Alkali, ergotamine, methylergometrine, cisapride, lovastatin, simvastatin, sildenafil, vartanafi, midazolam, triazolam, St. John's wort (Hypericum perforatum extract), etc.; \r&lt;br&gt;9) Pregnancy: positive pregnancy test for women of childbearing age; \r&lt;br&gt;10) lactating women did not stop lactation; \r&lt;br&gt;11) Known HIV infection, because of concerns about the development of resistance to lopinavir/rionavir if used without combination with other anti-HIV drugs; \r&lt;br&gt;12) Patient likely to be transferred to a non-participating hospital within 72 hours.","Exclusion criteria: (1) The critically ill patients in the diagnosis and treatment program of pneumonia with new coronavirus infection issued by the National Health Commission;\r&lt;br&gt;(2) It is not suitable for patients who take traditional Chinese medicine decoction;\r&lt;br&gt;(3) Those with other serious organ diseases or mental diseases;\r&lt;br&gt;(4) Those who are allergic to or have contraindications to the drugs involved in the study scheme.","Exclusion criteria: (1) Patients are not suitable to take Chinese medicine decoction.\r&lt;br&gt;(2) Patients have other serious organ disease or mental illness;\r&lt;br&gt;(3) Patients allergy or have contraindications to the drugs involved in the research program.","Exclusion criteria: 1. Age&gt; 75 years.\r&lt;br&gt;2. After CPR.\r&lt;br&gt;3. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).","Exclusion criteria: Children, pregnant women","Exclusion criteria: 1. Chronic lung diseases requiring long-term oxygen therapy;\r&lt;br&gt;2. Long-term application of glucocorticoids due to underlying diseases;\r&lt;br&gt;3. Based on the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;\r&lt;br&gt; Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory diseases affecting clinical trial evaluation, Chest CT confirmed that patients with severe pulmonary interstitial lesions, bronchiectasis and other underlying lung diseases;\r&lt;br&gt;4. Breastfeeding or pregnancy test result is positive during screening or test;\r&lt;br&gt;5. Allergic constitution (persons who are allergic to more than 2 types of substances), persons who are allergic to similar drugs in the past or those who are known to be allergic to the ingredients and auxiliary materials in the test drugs;\r&lt;br&gt;6. The investigator decides that it is not in the best interest of the subject to participate in the study, or that the subject has any situation in which the protocol cannot be fully followed.","Exclusion criteria: Patients over 80 years of age or less than 12 years of age (trial 3 and less than 18 years old); patients with contraindications to study drugs; cancer patients, life expectancy &lt;6 months; participants in other clinical trials in the past three months; pregnant women, breastfeeding Women.","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; \r&lt;br&gt;2. Pregnant or lactating women; \r&lt;br&gt;3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; \r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months, or who have other conditions not suitable for clinical study.","Exclusion criteria: 1. Infected with other viruses such as HCV, HIV, and syphilis;\r&lt;br&gt;2. Used non-steroidal anti-inflammatory drugs within 3 days before enrollment;\r&lt;br&gt;3. Have severe liver disease;\r&lt;br&gt;4. Those who are known to be allergic to the test drug and its ingredients;\r&lt;br&gt;5. Any of the following risk factors: \r&lt;br&gt;1) Chronic respiratory diseases such as chronic dual lung disease, acute bronchial respiratory disease; \r&lt;br&gt;2) Severe cardiovascular diseases such as congenital hypertension, congestive heart failure, coronary artery disease, except hypertension; \r&lt;br&gt;3) Nervous system and neuromuscular diseases, such as cerebral palsy, epilepsy, stroke,Intellectual Disability, muscular dystrophy or spinal cord injury, etc .; \r&lt;br&gt;4) Severe blood system diseases such as sickle cell disease; \r&lt;br&gt;5) Malignant tumor.\r&lt;br&gt;6. Pregnancy or breastfeeding,or positive pregnancy test in a predose examination;\r&lt;br&gt;7. Patients who participated in other clinical trials within the last 3 months;\r&lt;br&gt;8. Patients who are pregnant or in lactation period.","Exclusion criteria: 1. Patients who are unable to complete the questionnaire;\r&lt;br&gt;2. Patients and healthy people who are not willing to participate in the survey.","Exclusion criteria: Serious cognitive or mental disorder.","Exclusion criteria: 1) patients were judged not suitable to participate in the study; \r&lt;br&gt;2) patients were not suitable to use Chinese patent medicine.","Exclusion criteria: 1. Patients with severe novel coronavirus pneumonia;\r&lt;br&gt;2. Patients with severe basic diseases;\r&lt;br&gt;3. Patients who have mental confusion, pregnant or lactating women, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.","Exclusion criteria: 1. Those with allergies;\r&lt;br&gt;2. Patients with a history of severe cardio-cerebral vascular disease, diabetes, mental and neurological diseases, severe liver and renal insufficiency;\r&lt;br&gt;3. History of hip or knee trauma or surgery;\r&lt;br&gt;4. Patients who abuse drugs;\r&lt;br&gt;5. Those who are in the acute phase of chronic diseases;\r&lt;br&gt;6. Patients with other malignant diseases and a survival time of less than 12 months;\r&lt;br&gt;7. pregnancy,lactating women;\r&lt;br&gt;8. Poor compliance and unable to follow up on time;\r&lt;br&gt;9. Participants in clinical trials of other drugs or devices within the past 3 months.","Exclusion criteria: 1. Patients with severe primary diseases such as heart, lung, liver, kidney, brain, and hematopoietic system;\r&lt;br&gt;2. pregnant or lactating women;\r&lt;br&gt;3. Patients with mental illness;\r&lt;br&gt;4. Those who are participating in other clinical trials or taking other Chinese herbal medicines.","Exclusion criteria: Researchers believe that patients are not suitable for any other situation in this study.","Exclusion criteria: 1. Patients with a significant disease or condition other than the new coronavirus pneumonia, that is, a disease that, according to the investigator's judgment, may cause the subject to be at risk due to participation in the study, or affect the results of the study and the ability of the subject to participate in the study.\r&lt;br&gt;2. Women who are pregnant or nursing or plan to become pregnant during the study.\r&lt;br&gt;3. Have one of the following respiratory diseases:\r&lt;br&gt;1) Asthma: Based on the investigator's judgment, the subject is currently diagnosed with asthma.\r&lt;br&gt;2) Subjects with a previous history of COPD or long-term medication or imaging that showed significant lung structural damage (eg, giant pulmonary bullae).\r&lt;br&gt;3) Other respiratory diseases: subjects with other active lung diseases, such as active tuberculosis, lung cancer, wet bronchiectasis (high-resolution CT shows bronchiectasis, yellow sputum every day), sarcoidosis, idiopathic Interstitial Pulmonary Fibrosis (IPF), Primary Pulmonary Arterial Hypertension, Uncontrolled Sleep Apnea (ie, the severity of the disease will affect the implementation of the study at the investigator's discretion), combined with pneumothorax, pleural effusion and pulmonary embolism , Bronchial asthma, tumors, fever of unknown origin, etc.\r&lt;br&gt;4) Lung volume reduction: Lung volume reduction, lobectomy, or bronchoscopic lung volume reduction within 6 months (bronchial obstruction, airway bypass, bronchial valve, steam thermal ablation, biological sealant, Implants).\r&lt;br&gt;5) Patients who are critically ill or unstable. Definition of Severe Pneumonia: \r&lt;br&gt;A. Increased breathing rate ( &gt;= 30 beats / min), difficulty breathing; \r&lt;br&gt;B. Peripheral blood oxygen saturation &lt;= 93% when inhaling air, or arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) &lt;= 300mmHg; \r&lt;br&gt;C. Lung imaging showed multi-leaf disease or lesion progression&gt; 50% within 48 hours; \r&lt;br&gt;D. Combined with pneumothorax.\r&lt;br&gt;6) Pneumonia risk factors: immunosuppression (HIV), severe neurological disease affecting upper respiratory tract control, or other risk factors that the investigator believes may put the subject at a significant risk of pneumonia.\r&lt;br&gt;4. Complicate serious primary diseases such as heart, liver, kidney, and hematopoietic system.\r&lt;br&gt;5. People with mental disorders and cognitive impairment.\r&lt;br&gt;6. Non-compliance: Subjects who did not comply with the study procedures, including non-compliance completion logs.\r&lt;br&gt;7. Questions about the effectiveness of informed consent: subjects with a history of psychosis, mental retardation, poor motivation, substance abuse (including drugs and alcohol), or other medical conditions that limit the effectiveness of informed consent in this study.\r&lt;br&gt;8. Those who use non-expectorant antioxidant drugs, including large doses of vitamin C and vitamin E.\r&lt;br&gt;9. Researchers consider it inappropriate to participate in this research.","Exclusion criteria: 1. Patients without any clinical and chest imaging findings;\r&lt;br&gt;2. Supplementation with vitamin D or calcium within one week before admission\r&lt;br&gt;3. Patients with severe failure with chronic organ dysfunction;\r&lt;br&gt;4. Malignant tumors; diseases of the immune system; radiation and chemotherapy.\r&lt;br&gt;5. Pregnancy: The pregnancy test is positive for women of childbearing age; the breastfeeding women have not stopped breastfeeding.","Exclusion criteria: 1. Patients complicated with active tuberculosis, malignant arrhythmia, acute myocardial infarction and stroke;\r&lt;br&gt;2. pregnant and lactating women;\r&lt;br&gt;3. Patients complicated with severe cognitive and mental disorders;\r&lt;br&gt;4. Clinical investigators who are participating in other interventions within one month prior to enrollment;\r&lt;br&gt;5. Those who are known to be allergic to therapeutic drugs.","Exclusion criteria: 1) Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases that cannot be removed, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;\r&lt;br&gt;2) Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis;\r&lt;br&gt;3) Previous immunosuppressive agents within 6 months before study entry or recipients of a solid-organ or bone marrow transplant;\r&lt;br&gt;4) Pregnant or lactating women;\r&lt;br&gt;5) Researchers believe that patients may have other factors affecting the efficacy or safety evaluation of this study.","Exclusion criteria: no exclusion criteria.","Exclusion criteria: An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients in Xin-Guan-2 formula.","Exclusion criteria: No","Exclusion criteria: 1. Critical type: If one of the following conditions is met\r&lt;br&gt;(1) Respiratory failure occurs and mechanical ventilation is needed;\r&lt;br&gt;(2) Shock occurred;\r&lt;br&gt;(3) Patients with other organ failure need ICU monitoring treatment;\r&lt;br&gt;2. Severe type: If one of the following conditions is met\r&lt;br&gt;(1) Respiratory distress, RR &gt;= 30 beats / min;\r&lt;br&gt;(2) In resting state, finger oxygen saturation (SaO2) &lt;= 93%;\r&lt;br&gt;(3) Partial pressure of arterial oxygen (PaO2) / concentration of oxygen inhaled (FiO2)&lt;= 300mmHg;\r&lt;br&gt;3. Those who have a history of allergy to this class of drugs and / or severe allergic constitution;\r&lt;br&gt;4. The results of laboratory tests are abnormal:\r&lt;br&gt;(1) Hematological dysfunction is defined as:\r&lt;br&gt;1) Platelet (PLT) count &lt;100x10^9/L;\r&lt;br&gt;2) Hemoglobin (Hb) level &lt;90g/L;\r&lt;br&gt;(2) Abnormal liver function is defined as:\r&lt;br&gt;1) Level of total bilirubin(TBil) &gt;2 ULN;\r&lt;br&gt;2) The levels of aspartate aminotransferase (AST) and Alanine transaminase (ALT)&gt;3 ULN;\r&lt;br&gt;3) Definition of renal dysfunction:\r&lt;br&gt;Serum creatinine&gt;1.5 ULN, or calculated creatinine clearance&lt;50ml/min;\r&lt;br&gt;4) Definition of abnormal blood coagulation:\r&lt;br&gt;International normalized ratio(INR) &gt;1.5 ULN, and the prothrombin time ((PT)) or activated partial thromboplastin time (aPTT) 1.5 ULN, unless the subject is receiving anticoagulant therapy;\r&lt;br&gt;5. Abidor was used before inclusion(Tablets, capsules, granules);\r&lt;br&gt;6. Women who are nursing or pregnant;\r&lt;br&gt;7. Serum or urine pregnancy tests were positive for women of child-bearing age;\r&lt;br&gt;8. Immunodeficient patient(Patients with malignant tumors, Organ or bone marrow transplant, HIV patient, those who took immunosuppressive drugs within 3 months before the screening test );\r&lt;br&gt;9. With the following history of present illness:\r&lt;br&gt;(1) Neurological and neurodevelopmental disorders, These include diseases of the brain, spinal cord, peripheral nerves and muscles(Such as cerebral palsy, epilepsy, stroke, mental retardation, moderate to severe developmental delay, muscular malnutrition or spinal cord injury );\r&lt;br&gt;(2) Circulation system disease( congenital heart disease, Congestive heart failure or coronary artery disease);\r&lt;br&gt;(3) Severe heart disease or a history of clinically significant arrhythmias that the researchers believe will affect participants' safety (According to the ECG or medical history);\r&lt;br&gt;10. Other patients considered ineligible for this study were considered ineligible by the investigators.","Exclusion criteria: Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with immune system diseases or cancers etc.)","Exclusion criteria: 1. Severe or critically severe patients;\r&lt;br&gt;2. Clear evidence of bacterial infection; \r&lt;br&gt;3. Patients with severe primary diseases such as heart, kidney, lung, endocrine, blood, metabolism, and gastrointestinal tract, etc., may affect participation in the trial or may affect the outcome of the study by the judgment of the researcher;\r&lt;br&gt;4. Patients who have a family history of mental illness or have had a mental illness; \r&lt;br&gt;5. Patients who are allergic constitution or allergy to multiple drug; \r&lt;br&gt;6. pregnant or lactating women.","Exclusion criteria: 1. Pregnant woman patients;\r&lt;br&gt;2. Documented allergic history to any of chloroquine phosphate, ritonavir and lopinavir;\r&lt;br&gt;3. Documented history of hematological system diseases;\r&lt;br&gt;4. Documented history of chronic liver and kidney diseases;\r&lt;br&gt;5. Documented history of cardiac arrhythmia or chronic heart diseases;\r&lt;br&gt;6. Documented history of retina or hearing dysfunction;\r&lt;br&gt;7. Documented history of mental illnesses;\r&lt;br&gt;8. Use of digitalis due to the previous disease;\r&lt;br&gt;9. Onging pancreatitis;\r&lt;br&gt;10. Documented history of hemophilia;\r&lt;br&gt;11. Documented history of glucose-6 phosphate dehydrogenase (G-6-PD) deficiency.","Exclusion criteria: 1. Pregnant or lactating women;\r&lt;br&gt;2. There are comorbidities that affect the judgment of the efficacy, such as those with malignant tumors or long-term immunosuppressants;\r&lt;br&gt;3. The investigator believes that the patient has other conditions that are not suitable for enrollment;\r&lt;br&gt;4. Allergic to dimethyl sulfoxide (DMSO), dextran 40 or human albumin;\r&lt;br&gt;5. Contraindicated signs of artificial liver therapy","Exclusion criteria: 1. History of tumor;\r&lt;br&gt;2. Vascular embolism and pulmonary hypertension;\r&lt;br&gt;3. Suspected or established history of alcohol, drug or drug abuse;\r&lt;br&gt;4. Female patients of child-bearing age who are pregnant, breast-feeding or have a recent family planning;\r&lt;br&gt;5. Patients who have participated in or are participating in other drug trials within one month;\r&lt;br&gt;6. Patients considered unfit to participate in this clinical trial.","Exclusion criteria: 1. The patient has other immune system, blood system, heart, liver, kidney and other important organs of the disease;\r&lt;br&gt;2. Accompanied by chronic diseases, such as malignant tumors, chronic obstructive pulmonary disease;\r&lt;br&gt;3. have a history of mental illness;\r&lt;br&gt;4. pregnant and nursing women;\r&lt;br&gt;5. less than 18 years old;\r&lt;br&gt;6. Studying drug allergies or contraindications;\r&lt;br&gt;7. Patients participating in other clinical trials;\r&lt;br&gt;8. The researchers consider other reasons not appropriate for clinical subjects.","Exclusion criteria: 1. Any situation which the protocol cannot be carried out safely;\r&lt;br&gt;2. Patient refuses to receive invasive tracheal support (if needed);\r&lt;br&gt;3. Pregnant or lactating women:childbearing age women with positive pregnancy test, breastfeeding, miscarriage or within 2 weeks after delivery.Postmenopausal and hysterectomy women do not need a pregnancy test;\r&lt;br&gt;4. Patients with chronic liver and kidney disease and reaching end-stage;\r&lt;br&gt;5. Previous history of allergic reactions to Fapiravir or Lopinavir and Ritonavir;\r&lt;br&gt;6. Currently or in the past 28 days, participated in another clinical trial against novel coronavirus treatment;\r&lt;br&gt;7. After the investigator's judgment, the subjects could not participate the study protocol, follow-up or self-evaluation after enrollment.","Exclusion criteria: 1. Have any known disease that seriously affects the immune system, such as a history of infection with the human immunodeficiency virus (HIV), or malignant tumors of the blood system or solid organs, or splenectomy;\r&lt;br&gt;2. Other circumstances that the researcher considers inappropriate to participate in this study.","Exclusion criteria: 1. Severe pneumonia requires mechanical ventilationcritically severe cases;\r&lt;br&gt;2. Estimated Time of Death is less than 48 hours;\r&lt;br&gt;3. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;\r&lt;br&gt;4. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation . Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;\r&lt;br&gt;5. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;6. Mental state unable to cooperate, suffering from mental illness, unable to control, unable to express clearly\r&lt;br&gt;7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;\r&lt;br&gt;8. Patients with a history of substance abuse or dependence;\r&lt;br&gt;9. Pregnant or lactating women;\r&lt;br&gt;10. Patients who participated in other clinical trials within the last 3 months;\r&lt;br&gt;11. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.","Exclusion criteria: 1. Patients with severe 2019-nCoV pneumonia met one of the following conditions: respiratory distress, RR &gt;= 30 times / min; or SaO2 / SpO2 &lt;= 93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;= 300MMHG (1mmhg = 0.133kpa);\r&lt;br&gt;2. Patients with critical 2019-nCoV pneumonia met one of the following conditions: respiratory failure and mechanical ventilation required; or shock; or combined with other organ failure required ICU monitoring treatment;\r&lt;br&gt;3. Severe liver disease (such as child Pugh score &gt;= C, AST &gt; 5 times upper limit);\r&lt;br&gt;4. Patients were allergic to the components of ASC09 / ritonavir compound tablets;\r&lt;br&gt;5. Patients with definite contraindications in the label of ritonavir tablets;\r&lt;br&gt;6. Female subjects pregnancy test was positive during the screening period;\r&lt;br&gt;7. Patients who are taking HIV protease inhibitor drugs;\r&lt;br&gt;8. Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with multiple basic diseases, etc.).","Exclusion criteria: The investigator considers that the subject has other conditions that make him/her unsuitable to participate in the clinical trial or other special circumstances.","Exclusion criteria: 1. Allergic constitution, known to be allergic to balosavir or farpiravir or pharmaceutical excipients;\r&lt;br&gt;2. Body weight &lt;40 kg;\r&lt;br&gt;3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or admitted to the ICU due to complications;\r&lt;br&gt;4. Has known kidney dysfunction determined as CLcr&lt;60 mL/min;\r&lt;br&gt;5. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 5 times the upper limit of normal; or increase in ALT or AST is more than 3 ULN and increase in total bilirubin more than 2 ULN;\r&lt;br&gt;6. In the investigator's judgment, there are other factors that may cause the subject to be forced to terminate the study, such as other serious illnesses, serious laboratory abnormalities, and other factors that may affect the safety of the subject or the collection of test data and blood samples.","Exclusion criteria: No exclusion criteria.","Exclusion criteria: 1. Hypersensitive to study drug;\r&lt;br&gt;2. Body weight &lt;40 kg;\r&lt;br&gt;3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or admitted to the ICU due to complications;\r&lt;br&gt;4. Has known kidney dysfunction determined as CLcr&lt;60 mL/min;\r&lt;br&gt;5. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 5 times the upper limit of normal; or increase in ALT or AST is more than 3 ULN and increase in total bilirubin more than 2 ULN;\r&lt;br&gt;6. Pregnancy or breastfeeding,or positive pregnancy test in a predose examination, or have a plan to be pregnant within 3 months after the study.","Exclusion criteria: 1. Allergic history to study medicines;\r&lt;br&gt;2. ALT/AST &gt;5 UNL or Child-Pugh Class C;\r&lt;br&gt;3. Severely ill patients with life expectance &lt;48 hours;\r&lt;br&gt;4. Contraindication of DRV or thymosin;\r&lt;br&gt;5. Pregnancy testing positive for child-bearing woman;\r&lt;br&gt;6. Known HIV infection;\r&lt;br&gt;7. not adequate to be enrolled.","Exclusion criteria: 1. Clinical suspected or confirmed cases [Refer to the recommendations for diagnosis and treatment of 2019-nCoV infection in children in Hubei Province (trial version 1)]\r&lt;br&gt;2. Those who have received other traditional Chinese medicine, proprietary Chinese medicines or immunomodulators to prevent new coronavirus pneumonia;\r&lt;br&gt;3. Participants in clinical trials of other drugs in the past 12 weeks;\r&lt;br&gt;4. People with other serious primary diseases such as cardiovascular and cerebrovascular diseases, liver and kidney or hematopoietic diseases, genetic metabolic diseases;\r&lt;br&gt;5. Those who are known to be allergic to the test drug and its ingredients;\r&lt;br&gt;6. Other constitutions in TCM constitution theory.","Exclusion criteria: (1) with severe liver or kidney failure or other serious underlying diseases; \r&lt;br&gt;(2) Pregnant and lactating women; \r&lt;br&gt;(3) Persons who are participating in other clinical trials.","Exclusion criteria: 1) ARDS caused by other viral infections; \r&lt;br&gt;2) ARDS caused by other non-viral infections (such as trauma); \r&lt;br&gt;3) WHO grade III or IV pulmonary hypertension; \r&lt;br&gt;4) Patients with malignant tumors of the lungs and other systems; \r&lt;br&gt;5) Positive blood pregnancy test in lactating women or screening women; \r&lt;br&gt;6) Idiopathic IgA deficiency; \r&lt;br&gt;7) Cardio-cerebrovascular events in the near future (3 months); \r&lt;br&gt;8) patients with lung transplantation; \r&lt;br&gt;9) HIV positive patients; \r&lt;br&gt;10) Tester excluding from the investigator's judgment a history or current evidence of any disease, treatment, or laboratory abnormality that may confuse the results of the study, interfere with the participant's participation in the study process, or are not in the best interest of the participant to participate in the study.","Exclusion criteria: 1. ARDS was developed after infection without antiviral treatment;\r&lt;br&gt;2. suffering from HBV, HIV, pancreatitis, intrahepatic bile duct stones or having the previous history mentioned above ;\r&lt;br&gt;3. severe heart, liver, kidney and respiratory diseases before infection;\r&lt;br&gt;4. history of metabolic and endocrine diseases such as osteoporosis;\r&lt;br&gt;5. pregnant or nursing women;\r&lt;br&gt;6. those who are unable to cooperate in mental state, suffer from mental disease, have no self-control and cannot express clearly;\r&lt;br&gt;7. participating in other clinical trials.","Exclusion criteria: Doctor's judgment is not suitable for the study.","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; \r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; \r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Patients who have mental confusion, who with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.","Exclusion criteria: 1. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease; \r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Patients with mental confusion, with a history of drug abuse or dependence, who allergic to study medication, who have participated in another clinical trial within 3 months,or who have other conditions not suitable for clinical study.","Exclusion criteria: 1) Pregnant or lactating women;\r&lt;br&gt;2) Severe basic diseases that affect survival;\r&lt;br&gt;3) Other problems thant doctor's judgment is not suitable for the study;\r&lt;br&gt;4) Patients have difficulty in taking TCM standard decoctions.","Exclusion criteria: 1. Pregnancy or lactation;\r&lt;br&gt;2. Previous serious chronic basic diseases;\r&lt;br&gt;3. Previous allergy to traditional Chinese medicine;\r&lt;br&gt;4. Newly diagnosed 2019-nCOV pneumonia.","Exclusion criteria: NA","Exclusion criteria: With other serious physical or mental illnesses.","Exclusion criteria: 1. In the six months before the diagnosis of 2019-nCoV acute respiratory disease, the patient was clearly diagnosed as a psychiatric disorder, including depression, bipolar disorder and so on; \r&lt;br&gt;2. Patients with psychotic symptoms;\r&lt;br&gt;3. A history of suicide attempt in the 6 months before the study, or a score of  more than 3 on item 3 (suicide item) of the HAMD17 scale;\r&lt;br&gt;4. The total score of Hamilton depression scale (HAMD17) is more than 24 or the total score of Hamilton anxiety scale (HAMA14)is more than 21 at baseline;\r&lt;br&gt;5. The patient is diagnosed with organic mental disorder caused by a systemic disease or a neurological disorder,with a history of severe and unstable physical illness;\r&lt;br&gt;6. The patient is undergoing psychotherapy or has received psychotherapy 12 weeks prior to screening; \r&lt;br&gt;7. The patient had alcohol abuse within 30 days prior to screening or alcohol or drug dependence within 6 months prior to screening;\r&lt;br&gt;8. The patient use antipsychotics, antidepressants, and anti-anxiety drugs within 6 months prior to screening;\r&lt;br&gt;9. The researchers believe there are other conditions in the patient that are not suitable for this clinical trial.","Exclusion criteria: 1. Pregnancy or lactating women;\r&lt;br&gt;2. People with allergies or allergies to Shenfu injection and its components;\r&lt;br&gt;3. Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases that cannot be removed, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;\r&lt;br&gt;4. Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis;\r&lt;br&gt;5. Previous immunosuppressive agents within 6 months before study entry or recipients of a solid-organ or bone marrow transplant;\r&lt;br&gt;6. Extracorporeal life support (ECMO, ECCO2R, RRT);\r&lt;br&gt;7. Expected to die within 48 hours;\r&lt;br&gt;8. Patients who are considered by the investigator to be unsuitable subjects for this study.","Exclusion criteria: (1) It is known or suspected that it is allergic to the components of azvudine tablets;\r&lt;br&gt;(2) Light or severe patients;\r&lt;br&gt;(3) Patients with dysabsorption syndrome, or any other condition that affects gastrointestinal absorption, or who are unable to take drugs orally;\r&lt;br&gt;(4) Severe liver diseases (such as child Pugh score&gt;=C, TBIL&gt;=2 times the upper limit of normal value, ALT/AST&gt;=5 ULN, or HBsAg positive;\r&lt;br&gt;(5) Patients with severe renal insufficiency (eGFR&lt;=30ml/min/1.73m2) or undergoing continuous renal replacement therapy, hemodialysis and peritoneal dialysis;\r&lt;br&gt;(6) Women during pregnancy and lactation or having family planning during the trial period / within 6 months of the end of the trial;\r&lt;br&gt;(7) Other factors that are not suitable for entering the trial (According to the judgment of the researcher).",null,null,"Exclusion criteria: 1) Any situation where the solution cannot be carried out safely;\r&lt;br&gt;2) Allergic constitution, allergic to plasma or drugs;\r&lt;br&gt;3) Being too old with severe underlying diseases that affect survival, including uncontrolled clinically significant heart, lung, kidney, digestive, hematological, neuropsychiatric, immune, metabolic, or malignant tumors, Severe malnutrition, etc.;\r&lt;br&gt;4) Patients with severe respiratory failure, heart failure, and multiple organ failure;\r&lt;br&gt;5) Participants in other clinical trials.","Exclusion criteria: 1) Patients with particularly severe pneumonia caused by novel coronavirus infection.\r&lt;br&gt;2) Patients whose initial onset time exceeds 5 days.\r&lt;br&gt;3) Patients with severe primary respiratory disease.\r&lt;br&gt;4) It is difficult to administer to patients by oral or nasal feeding.\r&lt;br&gt;5) Pregnant women, as well as patients with other malignancies such as malignant tumors, mental illnesses, and patients who are not considered suitable for study.",null,"Exclusion criteria: none","Exclusion criteria: 1. Any situation which the protocol cannot be carried out safely;\r&lt;br&gt;2. Patient refuses to receive invasive tracheal support (if needed);\r&lt;br&gt;3. Pregnant or lactating women:childbearing age women with positive pregnancy test, breastfeeding, miscarriage or within 2 weeks after delivery.Postmenopausal and hysterectomy women do not need a pregnancy test;\r&lt;br&gt;4. Patients with chronic liver and kidney disease and reaching end-stage;\r&lt;br&gt;5. Previous history of allergic reactions to Fapiravir or Lopinavir and Ritonavir;\r&lt;br&gt;6. After the investigator's judgment, the subjects could not participate the study protocol, follow-up or self-evaluation after enrollment.","Exclusion criteria: (1) Diagnosed with other known viral pneumonia,like influenza virus, parainfluenza virus, adenovirus, respiratory syncytical virus, rhinovirus, human metapneumovirus and SARS coronavirus, etc.;\r&lt;br&gt;(2) Diagnosed with mycoplasma pneumonia, chlamydial pneumonia and bacterial pneumonia;\r&lt;br&gt;(3) Diagnosed with vasculitis, dermatomyositis, organizing pneumonia and other noninfectious diseases;\r&lt;br&gt;(4) pregnant or breastfeeding woman;\r&lt;br&gt;(5) Known to be allergic to this medicine ingredient;\r&lt;br&gt;(6) Patients with serious underlying disease, and researchers considered inappropriate to participate.","Exclusion criteria: 1. Exclude participants who disagree;\r&lt;br&gt;2. Exclude those who cannot cooperate.","Exclusion criteria: 1. Pregnancy or lactating women;\r&lt;br&gt;2. People with allergies or allergies to Xuebijing injection and its components;\r&lt;br&gt;3. Severe basic diseases that affect survival, including: uncontrolled malignant tumors with multiple metastases that cannot be removed, hematological diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;\r&lt;br&gt;4. Obstructive pneumonia caused by lung tumors, severe pulmonary interstitial fibrosis, alveolar proteinosis, allergic reaction alveolitis;\r&lt;br&gt;5. Previous immunosuppressive agents within 6 months before study entry or recipients of a solid-organ or bone marrow transplant;\r&lt;br&gt;6. Extracorporeal life support (ECMO, ECCO2R, RRT);\r&lt;br&gt;7. Expected to die within 48 hours.",null,"Exclusion criteria: none","Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;\r&lt;br&gt;(2) Preparing pregnant, pregnant and lactating women;\r&lt;br&gt;(3) Patients with allergies (referring to allergies to two or more medicines, foods or known ingredients in this study);\r&lt;br&gt;(4) Patients with mental illness, or have no cognitive ability;\r&lt;br&gt;(5) Patients with an estimated survival time of less than 48 hours from the start of screening;\r&lt;br&gt;(6) Those who have been intubated or mechanically ventilated at the time of screening;\r&lt;br&gt;(7) Obvious symptoms of heart, liver, kidney or various other systems, ALT, AST exceed 1.5 times the upper limit of normal value;\r&lt;br&gt;(8) Believed to be not suitable to participate in clinical trials by investigator.","Exclusion criteria: The doctor believes that the subject is not suitable to continue the clinical study;","Exclusion criteria: 1. pregnancy or lactation;\r&lt;br&gt;2. history of psychiatric disorders(serious anxiety and depression,schizophrenia);\r&lt;br&gt;3. take sedatives in the past week.","Exclusion criteria: 1) Patients who may be transferred to other hospitals that are not included in the trial within 72 hours; \r&lt;br&gt;2) G-6PD defect (Favism); \r&lt;br&gt;3) Pregnancy, especially early pregnancy; \r&lt;br&gt;4) Patients who continually use immunosuppressant, or are organ transplant recipients within 6 months; \r&lt;br&gt;5) Hyperthyroidism; \r&lt;br&gt;6) Patients with medical ozone allergy; \r&lt;br&gt;7) Patients who are receiving other clinical trials.","Exclusion criteria: 1. Allergic constitution (persons who are allergic to more than 2 kinds of substances), people who are allergic to similar drugs in the past or those who are known to be allergic to the ingredients and auxiliary materials in the test drugs;\r&lt;br&gt;2. Patients who have participated in other clinical trials in the past 3 months;\r&lt;br&gt;3. Patients not suitable for the clinical trials judged by researchers.","Exclusion criteria: 1. Patients who have been treated with glucocorticoids;\r&lt;br&gt;2. Patients who have received invasive ventilator-assisted ventilation treatment;\r&lt;br&gt;3. Patients with shock;\r&lt;br&gt;4. Patients combined with organ failure and needed ICU monitoring;\r&lt;br&gt;5. Other situations that researchers think not-suitable for enrollment.","Exclusion criteria: Diagnosis confirmed not coronavirus disease-19.","Exclusion criteria: (1) It is difficult to administer to patients by oral or nasal feeding;\r&lt;br&gt;(2) Pregnant women, as well as patients with other malignancies such as malignant tumors, mental illnesses, and patients who are not considered suitable for study.","Exclusion criteria: Exclusion criteria for the severe NCP group were the same as those for the acutely exacerbated NCP group:\r&lt;br&gt;1. Have a history of drug dependence or substance abuse;\r&lt;br&gt;2. female patients who are pregnant or lactating;\r&lt;br&gt;3. People with allergies or known allergies to research drugs and excipients;\r&lt;br&gt;4. In patients with impaired liver function, alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increases more than five times the upper limit of normal;\r&lt;br&gt;5. Patients with renal impairment (dialysis treatment patients or eGFR &lt;60mL / min);\r&lt;br&gt;6. Those who meet the diagnostic criteria of ARDS:\r&lt;br&gt;(1) acute onset;\r&lt;br&gt;(2) oxygenation index (PaO2 / FiO2) &lt;=200mmHg [1mmHg = 0.133kPa, regardless of the positive end-expiratory pressure (PEEP) level];\r&lt;br&gt;(3) positive X A chest radiograph showed patchy shadows in both lungs;\r&lt;br&gt;(4) pulmonary artery incarceration pressure &lt;=18mmHg, or no clinical evidence of increased left atrial pressure.\r&lt;br&gt;7. Patients with significantly impaired cardiac function: those with A and NYHA heart failure classification = Grade II or LVEF &lt;=lower limit of normal value; those with ECG in leads B and 12 suggesting conduction block or acute myocardial infarction requiring urgent treatment;\r&lt;br&gt;8. Combining other serious diseases that affect patient survival, such as malignant tumors;\r&lt;br&gt;9. the use of immunosuppressants or diseases that seriously affect the immune system, such as human immunodeficiency virus infection;\r&lt;br&gt;10. Combining other infections that are severe and uncontrollable (bacteria, chlamydia, deep fungi, etc.);\r&lt;br&gt;11. Those with diarrhea&gt; 4 times / day;\r&lt;br&gt;12. People who have difficulty swallowing oral drugs;\r&lt;br&gt;13. Situations in which other researchers find it inappropriate to participate in research.","Exclusion criteria: 1. Previous or current allergic history to human plasma protein products or excipients (sodium citrate) contained in this product;\r&lt;br&gt;2. Patients diagnosed as severe COVID-19;\r&lt;br&gt;3. Patients diagnosed as infection of influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS virus and other known viral pneumonia; Patients diagnosed as mycoplasma pneumonia, chlamydia pneumonia and bacterial pneumonia;\r&lt;br&gt;4. Subjects who had suffered or suffered from deep vein thrombosis, pulmonary embolism or arterial embolism within 1 year before signing the informed transfusion form or currently;\r&lt;br&gt;5. Patients with severe heart disease, including myocardial infarction and chronic cardiac insufficiency (NYHA grades III and IV);\r&lt;br&gt;6. Researchers judge that patients with severe liver and kidney diseases who are not suitable for clinical trial;\r&lt;br&gt;7. Patients with positive HBsAg antigen (or nucleic acid test) or HCV antibody (or nucleic acid test) or HIV antibody (or nucleic acid test) or Treponema pallidum antibody;\r&lt;br&gt;8. Pregnant women or breast-feeding women or women of childbearing age or male subjects in childbearing age are unwilling to take contraceptive measures during the study period;\r&lt;br&gt;9. Participated in clinical trials for other drugs or medical devices within 1 month before signing the informed transfusion form;\r&lt;br&gt;10. Suffering from mental illness, obvious mental disorder or epilepsy; Patients with acute diseases; Patients with current or previous malignant tumor diseases; Incapable of behavior or cognition;\r&lt;br&gt;11. Alcoholics, drug addicts, drug abusers and addicts;\r&lt;br&gt;12. Poor compliance or any circumstances that other researchers believe are not suitable for inclusion (e.g. Expected survival time is less than 3 months).","Exclusion criteria: age&lt;18 year; missing baseline and follow-up data","Exclusion criteria: 1. Hypersensitive to suramin or 2 or more drugs or food; \r&lt;br&gt;2. Body weight &lt;40 kg; \r&lt;br&gt;3. Considered as severe disease: has an ongoing respiratory deficiency and subjected to invasive mechanical ventilation; or presence of shock; or admitted to the ICU due to complications; \r&lt;br&gt;4. Has known kidney dysfunction determined as CLcr&lt;60 mL/min; \r&lt;br&gt;5. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 5 times the upper limit of normal; or increase in ALT or AST is more than 3 ULN and increase in total bilirubin more than 2 ULN; \r&lt;br&gt;6. Pregnancy or breastfeeding, or positive pregnancy test in a predose examination, or have a plan to be pregnant within 3 months after the study;\r&lt;br&gt;7. Physician judged the patient was not suitable for this clinical trial (for example, patient with severe abnormality laboratory indexes; patient with multiple basic diseases, etc.).","Exclusion criteria:  People with allergies and allergies to experimental drugs;","Exclusion criteria: None","Exclusion criteria: 1. severe vomiting and difficulty in taking oral medication or absorbing in oral medication;\r&lt;br&gt;2. pregnant and nursing women;\r&lt;br&gt;3. subjects received lopinavir/ridonavir, ribavirin, monoclonal antibodies and other specific antiviral drugs in the week prior to admission;\r&lt;br&gt;4. subjects exist respiratory failure requiring mechanical ventilation;\r&lt;br&gt;5. subjects of shock;\r&lt;br&gt;6. subjects combined with other organ failure requires intensive care unit;\r&lt;br&gt;7. subjects with no clinical expectation of survival and only give end-of-life care, or those in a deep coma who did not respond to supportive treatment within three hours of admission.","Exclusion criteria: Subjects who meet one of the following conditions will not be eligible for the trial:\r&lt;br&gt;1. pregnant or lactating women;\r&lt;br&gt;2. Malignant tumors, patients with other severe systemic diseases and mental illness;\r&lt;br&gt;3. Those who have recently participated in other clinical trials;\r&lt;br&gt;4. There is evidence of drug addiction within one year before joining the trial;\r&lt;br&gt;5. Unable or unwilling to provide informed consent or comply with test requirements;\r&lt;br&gt;6. Combined with HIV, tuberculosis, influenza virus, adenovirus and other respiratory infections.","Exclusion criteria: disagree to consent or infected with COVID-19","Exclusion criteria: 1. Pregnant women;\r&lt;br&gt;2. Patients with a history of angina pectoris, myocardial infarction and other serious cardiovascular diseases;\r&lt;br&gt;3. The researchers judged that this study was not in the interests of patients.","Exclusion criteria: 1. Combining basic diseases such as hypertension, diabetes, and coronary heart disease;\r&lt;br&gt;2. Malignant tumor or with a history of malignant tumor;\r&lt;br&gt;3. pregnant or lactating women;\r&lt;br&gt;4. suffer from severe mental illness;\r&lt;br&gt;5. History of unstable angina pectoris or myocardial infarction within 6 months; coronary angiography suggested severe stenosis of the main branches of the coronary arteries;\r&lt;br&gt;6. History of cerebral infarction or cerebral hemorrhage within 6 months;\r&lt;br&gt;7. People who are intolerant or allergic to rhG-CSF;\r&lt;br&gt;8. Patients were judged unsuitable for inclusion in the trial.","Exclusion criteria: Patients who refuse to sign informed consent form","Exclusion criteria: 1. The physician decides that participating in this study is not in the best interest of the subject or that there exist a circumstance in which the agreed protocol cannot be safely followed;\r&lt;br&gt;2. People who have allergic reactions or allergies to antiviral oral solution or Wuzhifangguanfang decoction;\r&lt;br&gt;3. Those who do not meet the national diagnostic criteria for close contacts of new coronary pneumonia;\r&lt;br&gt;4. Confirmed cases of new coronavirus pneumonia;\r&lt;br&gt;5. People with mental disorders who cannot communicate normally;\r&lt;br&gt;6. Pregnant woman;\r&lt;br&gt;7. People who do not agree to participate;","Exclusion criteria: Patients can not follow-up;\r&lt;br&gt;Investigator considering inappropriate","Exclusion criteria: 1. Any situation that does not allow the program to proceed safely; \r&lt;br&gt;2. The patient may be transferred to a non-participating hospital within 72 hours; \r&lt;br&gt;3. Those who have continued to use immunosuppressive agents or organ transplants for the past 6 months; \r&lt;br&gt;4. Glucose-6-phosphate dehydrogenation Enzyme deficiency (faba bean disease) 5; \r&lt;br&gt;5. Patients treated with any of the antiviral drugs listed in the protocol during hospitalization before enrollment; \r&lt;br&gt;6. Those participating in other clinical trials. \r&lt;br&gt;7. Those who are allergic to ozone or hypersensitive.","Exclusion criteria: Diagnosis confirmed not coronavirus disease-19.","Exclusion criteria: Patients who the researchers determined not suitable for this study.","Exclusion criteria: NA","Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:\r&lt;br&gt;1) Respiratory failure occurs and requires mechanical ventilation;\r&lt;br&gt;2) Shock occurs;\r&lt;br&gt;3) Combined failure of other organs requires ICU monitoring and treatment;\r&lt;br&gt;2. Those who are allergic to blood products or plasma components and auxiliary materials (sodium citrate);\r&lt;br&gt;3. There is multiple organ failure, and the estimated survival time is less than 3 days;\r&lt;br&gt;4. Those who tested positive for HIV antibodies before enrollment;\r&lt;br&gt;5. Women who are pregnant or breastfeeding or have a birth plan within the past year;\r&lt;br&gt;6. Participants in other clinical trials within 3 months before screening;\r&lt;br&gt;Poor adherence or other conditions that the investigator believes are not suitable for inclusion (such as poor physical condition).","Exclusion criteria: 1. Patients who are participating in other drug clinical trials;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;\r&lt;br&gt;4. Expected survival is less than 1 week;\r&lt;br&gt;5. Patients diagnosed with rheumatic immune related diseases;\r&lt;br&gt;6. Take orally anti rejection drugs or immunomodulatory drugs for a long time;\r&lt;br&gt;7. Hypersensitive to adalimumab or any excipients;\r&lt;br&gt;8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections","Exclusion criteria: No","Exclusion criteria: 1. Plan for pregnant,breast-feeding or pregnant;\r&lt;br&gt;2. Hospitalized for other reasons within 14 days before the election;\r&lt;br&gt;5. Combined with serious diseases of heart, lung, brain, liver, kidney, blood system;\r&lt;br&gt;6. Has fever, runny nose, diarrhea and other respiratory and digestive symptoms.","Exclusion criteria: (1) Hyperthyroidism; \r&lt;br&gt;(2) Favism; \r&lt;br&gt;(3) Pregnancy; \r&lt;br&gt;(4) Abnormal coagulation, thrombocytopenia, active bleeding;\r&lt;br&gt;(5) People with medical ozone allergy or hypersensitivity; \r&lt;br&gt;(6) Severe anemia; \r&lt;br&gt;(7) Hypocalcemia; \r&lt;br&gt;(8) Unstable period of severe cardiovascular disease; \r&lt;br&gt;(9) Uncontrolled diabetes.","Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR 30 times / min; or SaO2 / SpO2 &lt;93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;300MMHG (1mmhg = 0.133kpa);\r&lt;br&gt;2. Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;\r&lt;br&gt;3. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);\r&lt;br&gt;4. Patients with contraindications specified in the instructions of ritonavir tablets;\r&lt;br&gt;5. The pregnancy test of female subjects in the screening period was positive;\r&lt;br&gt;6. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).","Exclusion criteria: No","Exclusion criteria: 1. Previous cheset trauma and surgery;\r&lt;br&gt;2. Previous severe emphysema and chronic obstructive pulmonary disease.","Exclusion criteria: Medical staff with contact history outside the operating room.","Exclusion criteria: 1. Investigator makes a decision that trial participation is not in patients' best interest, or any condition that does not allow the protocol to be followed safely;\r&lt;br&gt;2. As judged by investigator historic or current diseases that may have impact on the subjects participation of the study or the study outcome. These diseases include but not limited to cadiac diease and arrhythmia and QT prolongation), neurological disease psychiatric disease,active bleeding, serious malnutrition and endocrine disease; currently complicated with serious respiratory disease or that seriously affect immune system, such as flu, COPD, asthma, HIV infection, blood system disease, or splenectomy, organ transplantation etc.;\r&lt;br&gt;3. Severe liver disease (AST&gt;3 ULN);\r&lt;br&gt;4. Patients with known severe renal impairment (estimated glomerular filtration rate &lt;=60 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis;\r&lt;br&gt;5. QT elongation;\r&lt;br&gt;6. Allergic to chloroquine or hydroxychloroquine;\r&lt;br&gt;7. Pregnant or breastfeeding, or positive pregnancy test in a predose examination;\r&lt;br&gt;8. Will be transferred to another hospital within 72 hours;\r&lt;br&gt;9. Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within the 14 days prior to the time of the screening evaluation.","Exclusion criteria: 1. Highly allergic constitution or history of severe allergy, especially plasma allergy;\r&lt;br&gt;2. The doctor believes that there are other reasons not to include the healer.","Exclusion criteria: 1. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening;\r&lt;br&gt;2. Males or females who have a birth plan or are unwilling to take reliable contraceptive measures for contraception within 90 days from signing the informed consent to the last dose;\r&lt;br&gt;3. Other circumstances that the researchers consider inappropriate for participation in this study.","Exclusion criteria: 1. Patients who have been admitted to the hospital for reasons other than pneumonia\r&lt;br&gt;2. Patients with mental illness have been identified or have been clearly diagnosed with emotional disorders\r&lt;br&gt;3. Minors","Exclusion criteria: (1) The PI considers that the patient is not suitable to participate the study or  the patient may be unsafe if he participate the study;\r&lt;br&gt;(2) Patients with serious liver disease, grade C according to child-pugh;\r&lt;br&gt;(3) Patients with severe renal impairment (glomerular filtration rate &lt;=30mL/min/1.73m2) or who have received continuous renal replacement therapy, hemodialysis or peritoneal dialysis;\r&lt;br&gt;(4) Patients with severe anemia, Hgb &lt; 60g/L.\r&lt;br&gt;(5) Pregnant women or women with pregnancy test positive or breastfeeding women;\r&lt;br&gt;(6) Patients with allergy history of Triazavirin or its components;\r&lt;br&gt;(7) Confused to sign the informed consent;\r&lt;br&gt;(8) Patients may be transferred to another hospital within 72h;\r&lt;br&gt;(9) Received any experimental treatment for novel coronavirus infection within 30 days prior to screening.","Exclusion criteria: 1. patients with dysphagia or gastrointestinal obstruction;\r&lt;br&gt;2. Patients with autoimmune diseases, or with extremely low immunity, or with other diseases requiring systemic use of immunosuppressive drugs or hormone therapy;\r&lt;br&gt;3. Human immunodeficiency virus (HIV) positive or active hepatitis b or c infection;\r&lt;br&gt;4. Pregnant or nursing women;\r&lt;br&gt;5. After evaluation, the researcher believes that the study is not conducive to patients and is not suitable for other conditions of study participation.","Exclusion criteria: Pneumonia caused by other pathogens","Exclusion criteria: (1) Subject has a history of tumor\r&lt;br&gt;(2) Female patients of childbearing age during pregnancy, lactation or recent birth planning\r&lt;br&gt;(3) Highly allergic constitution or history of severe allergies\r&lt;br&gt;(4) Coagulation disorders such as hemophilia\r&lt;br&gt;(5) Those with positive serological tests such as AIDS, syphilis, etc.\r&lt;br&gt;(6) Patients who have participated in or are participating in other drug trials within one month\r&lt;br&gt;(7) Patients who the investigator refused to participate in this clinical trial\r&lt;br&gt;(8) There is a large area of pulmonary vascular embolism and severe pulmonary hypertension","Exclusion criteria: Unable to access the nCapp platform","Exclusion criteria: None","Exclusion criteria: No","Exclusion criteria: 1. Patients who are participating in other drug clinical trials;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. ALT / AST&gt; 5 ULN, neutrophils &lt;0.5, platelets less than 50;\r&lt;br&gt;4. Expected life&lt;1 week;\r&lt;br&gt;5. Definite diagnosis of asthma-related diseases;\r&lt;br&gt;6. Long-term oral anti-rejection or immunomodulatory drugs;\r&lt;br&gt;7. Hypersensitivity to tocilizumab or any excipients;\r&lt;br&gt;8. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.","Exclusion criteria: 1. Patients with other serious diseases such as lung diseases, cardiovascular and cerebrovascular diseases, hematopoietic diseases, autoimmune diseases, digestive system, or mental illness;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Participate in other forms of exercise during the trial","Exclusion criteria: 1. Patients with other serious diseases such as lung diseases, cardiovascular and cerebrovascular diseases, hematopoietic diseases, autoimmune diseases, digestive system, or mental illness;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Participate in other forms of exercise during the trial","Exclusion criteria: 1. In the opinion of the researchers, the participation of the trial is not in the best interests of the patients, or any situation is not in line with the situation that the trial scheme is allowed to be followed safely;\r&lt;br&gt;2. According to the judgment of the investigator, the diseases previously or now may affect the patients' participation in the trial or the outcome of the study, including but not limited to: malignant tumors, autoimmune diseases, liver and kidney diseases, cardiovascular system diseases (including but not limited to having a clear history of heart disease, cardiac arrhythmia and ECG QT Patients with prolonged interval), nervous system diseases, mental system diseases, active bleeding, severe malnutrition and endocrine diseases; patients with severe respiratory system diseases or diseases seriously affecting the immune system, such as: influenza, COPD, asthma, human immunodeficiency virus (HIV) infection, or blood system diseases, or splenectomy, organ transplantation, etc.;\r&lt;br&gt;3. Severe liver disease (AST &gt; 3 times of upper limit);\r&lt;br&gt;4. Patients with known renal insufficiency (estimated glomerular filtration rate &lt;= 60ml / min / 1.73 m2 or continuous renal replacement therapy, hemodialysis, peritoneal dialysis;\r&lt;br&gt;5. Extended QT interval in ECG;\r&lt;br&gt;6. Allergic to chloroquine or hydroxychloroquine;\r&lt;br&gt;7. Pregnant or lactating or positive pregnancy test during pre medication examination;\r&lt;br&gt;8. Transfer to another hospital within 72 hours;\r&lt;br&gt;9. Receive any trial treatment drug for 2019-ncov within 14 days prior to screening evaluation (off label, compassionate use or trial related).","Exclusion criteria: 1. Malignant disease in the past five years;\r&lt;br&gt;2. The clinical prediction is that there is no hope for survival, only cases of hospice care, or cases of deep coma that do not respond to supportive treatment measures within three hours of admission;\r&lt;br&gt;3. Subjects who are participating in other clinical trials or within 3 months;\r&lt;br&gt;4. Cases of very severe shock and respiratory failure.","Exclusion criteria: 1. critically ill patients based on the New Protocol for Diagnosis and Treatment of NCP;\r&lt;br&gt;2. Patients with eye diseases (such as cataract, conjunctivitis, glaucoma)\r&lt;br&gt;3. Severe liver disease (such as  AST &gt; 3 ULN);\r&lt;br&gt;4. Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;=30ml/min/1.73m2) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis;\r&lt;br&gt;5. Pregnant or breast-feeding women;\r&lt;br&gt;6. Patients may be transferred to non-designated hospitals within 72 hours;\r&lt;br&gt;7. Patients who have participated in other clinical trials in the past 7 days;\r&lt;br&gt;8. Allergic constitution, such as those who are allergic to two or over twodrugs ,with history of food allergies, or known to be allergic to the ingredients of this drug;\r&lt;br&gt;9. In the opinion of the investigator, subjects who are not suitable for enrollment or with any factors that affect the outcome of the trial.","Exclusion criteria: 1) Cases with severe vomiting and difficulty in taking drugs orally or causing difficulty in taking drugs after oral administration;\r&lt;br&gt;2) Pregnant and lactating women;\r&lt;br&gt;3) The subjects received specific antiviral drugs such as lopinavir / lidonavir, ribavirin and monoclonal antibody within one week before admission;\r&lt;br&gt;4) Cases with no hope of survival, hospice care only, or deep coma and no response to supportive treatment within three hours after admission;\r&lt;br&gt;5) Cases of deep shock and respiratory failure;\r&lt;br&gt;6) Severe liver diseases (such as child Pugh score &gt;= C, AST more than 5 times of the upper limit of normal);\r&lt;br&gt;7) Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;= 30ml / min / 1.73m2) or undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis;\r&lt;br&gt;8) Patients with known allergic reactions or contraindications to chloroquine phosphate;\r&lt;br&gt;9) The doctor decided that it was not in the best interests of the subjects to participate in the study, or there was any situation in which the agreement could not be followed safely.","Exclusion criteria: pregnant or lactating women","Exclusion criteria: No","Exclusion criteria: 1)One of the following conditions:\r&lt;br&gt;Respiratory distress, RR &gt;= 30 times/min;\r&lt;br&gt;At rest, oxygen saturation is less than 93%;\r&lt;br&gt;Atrial  arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;= 300mmHg (1mmHg=0.133kPa);\r&lt;br&gt;Respiratory failure is present and mechanical ventilation is required;\r&lt;br&gt;Shock;\r&lt;br&gt;Combined with other organ failure requires intensive care unit.\r&lt;br&gt;2)Severe influenza and influenza patients with complications (such as secondary bacterial pneumonia, pneumonia caused by other pathogens and other viral pneumonia);Or the patient is hospitalized with severe influenza;\r&lt;br&gt;3)Patients with other upper respiratory tract infections: asthma requiring daily treatment, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases affecting clinical trial evaluation. Imaging  confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;\r&lt;br&gt;4)It is expected to be transferred to a non-study hospital within 72 hours;\r&lt;br&gt;5)Past or present diseases may affect the outcome of the study, such as unresectable malignant tumors, hematological diseases, active bleeding, malignant fluid, liver and kidney diseases, nervous system diseases, endocrine system diseases, etc Suffering from diseases that seriously affect the immune system, such as HIV infection, splenectomy, organ transplantation, etc.;\r&lt;br&gt;6)A woman who is pregnant or breastfeeding;\r&lt;br&gt;7)Test drug components allergy, or allergic constitution;\r&lt;br&gt;8)Patients with a history of substance abuse;\r&lt;br&gt;9)Participants in other clinical trials in the last 3 months;\r&lt;br&gt;10)The investigator considers it inappropriate to participate in this clinical trial.","Exclusion criteria: Patients who is enrolled in other clinical trial\r&lt;br&gt;who had diagnosed as macular degeneration of retinawere or defects of visual field;\r&lt;br&gt;who was allergic to 4-aminoquinoline compounds or is prescribed any drug had interactions with hydrocholoroquine\r&lt;br&gt;emergency or critically ill patients who can not received oral drugs\r&lt;br&gt;pregnancy or lactation\r&lt;br&gt;severe heart disease, digestive disease,neurological or ocular disease,or porphyrin;\r&lt;br&gt;WBC less than 2.0*10^9/L,hemoglobin 60g/L,liver enzyme or creatine higher than 3 times of ULT,or heart marker elevated,\r&lt;br&gt;unsuitable to participate this trial by investigator or in other special circumstances.","Exclusion criteria: (1) advanced and trainee nurses; \r&lt;br&gt;(2) nurses during the investigation period due to leave (sickness, affairs, pregnancy, etc.) reasons not post.","Exclusion criteria: (1) Positive for other pathogens such as A, B, Mycoplasma, Adenovirus;\r&lt;br&gt;(2) Respiratory failure occurs, requiring mechanical ventilation;\r&lt;br&gt;(3) People with metal or pacemaker;\r&lt;br&gt;(4) active tuberculosis;\r&lt;br&gt;(5) Massive pulmonary fibrosis;\r&lt;br&gt;(6) Those with shock;\r&lt;br&gt;(7) Those who have bleeding tendency or active bleeding in the lungs;\r&lt;br&gt;(8) Patients with multiple organ failure who need ICU monitoring and treatment;\r&lt;br&gt;(9) Patients with tumor and severe basic diseases;\r&lt;br&gt;(10) pregnant or lactating women;\r&lt;br&gt;(11) Patients with active tuberculosis;\r&lt;br&gt;(12) Those with other contraindications to ultrashort wave;\r&lt;br&gt;(13) Patients with severe cognitive impairment who cannot follow the instructions to complete the treatment;\r&lt;br&gt;(14) Those without signed informed consent;\r&lt;br&gt;(15) Researchers believe that other reasons are not suitable for clinical trials.","Exclusion criteria: Pregnant women.","Exclusion criteria: 1. Aged &lt;18 years;\r&lt;br&gt;2. Patients with systemic disease and severe liver and kidney dysfunction were excluded.","Exclusion criteria: Patients that the researchers determined not suitable for this study","Exclusion criteria: 1. The serious NCP patients who can neither swallow medicines nor take medicine via stomach tube, and the critical serious NCP patients;\r&lt;br&gt;2. Those with severe hypo-immunity due to, but not limited to, one of the following reasons:\r&lt;br&gt;1) HIV/AIDS,  the condition is still unstable in the process of mediation and /or the  last detection value of CD4 plus T lymphocyte is less than 200;\r&lt;br&gt;2) Those who received organ transplantation and are given systematic immune treatment;\r&lt;br&gt;3) Long-term systematic administration of corticosteroids is defined as daily intake of over 40 mg of Prednisone or equivalent in 14 days before the first medication;\r&lt;br&gt;4. Patients who are unable to take medicines orally or via stomach tube;\r&lt;br&gt;5. Patients who are allergic to the test medicines;\r&lt;br&gt;6. Those with poor communication skills, understanding, cooperation or compliance and those cannot follow protocol to complete the study;\r&lt;br&gt;7. Those suffered with serious diseases such as malignancy, mental diseases and so on, or those ineligible to participate the study according to investigators judgement.","Exclusion criteria: 1. The physician decides that participating in the trial is not in the best interest of the patient, or does not meet any conditions for safe follow-up in the protocol;\r&lt;br&gt;2. People with heart disease such as cardiac block;\r&lt;br&gt;3. People with eye diseases such as retina and cornea;\r&lt;br&gt;4. Severe liver disease (such as Child Pugh score &gt;= C or AST &gt; 5 times the upper limit);\r&lt;br&gt;5. Pregnancy or breastfeeding, or a positive pregnancy test during the pre-dose check;\r&lt;br&gt;6. Patients with known severe renal insufficiency (estimated glomerular filtration rate &lt;= 30mL / min / 1.73m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis.","Exclusion criteria: 1)One of the following conditions:\r&lt;br&gt;Respiratory distress, RR &gt;= 30 times/min;\r&lt;br&gt;At rest, oxygen saturation is less than 93%;\r&lt;br&gt;Artial arterial oxygen pressure (PaO2)/oxygen absorption concentration (FiO2) &lt;= 300mmHg (1mmHg=0.133kPa);\r&lt;br&gt;Respiratory failure is present and mechanical ventilation is required;\r&lt;br&gt;Shock;\r&lt;br&gt;Combined with other organ failure requires intensive care unit;\r&lt;br&gt;It is expected to be transferred to a non-study hospital within 72 hours.\r&lt;br&gt;2)Severe influenza and influenza patients with complications (such as secondary bacterial pneumonia, pneumonia caused by other pathogens and other viral pneumonia);Or the patient is hospitalized with severe influenza;\r&lt;br&gt;3)Patients with other upper respiratory tract infections: asthma requiring daily treatment, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases affecting clinical trial evaluation.Imaging confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;\r&lt;br&gt;4)Past or present diseases may affect the outcome of the study, such as unresectable malignant tumors, hematological diseases, active bleeding, malignant fluid, liver and kidney diseases, nervous system diseases, endocrine system diseases, etc.;\r&lt;br&gt;5)Suffering from diseases that seriously affect the immune system, such as HIV infection, splenectomy, organ transplantation, etc.;\r&lt;br&gt;6)A woman who is pregnant or breastfeeding;\r&lt;br&gt;7)Test drug components allergy, or allergic constitution;\r&lt;br&gt;8)Patients with a history of substance abuse;\r&lt;br&gt;9)Participants in other clinical trials in the last 3 months;\r&lt;br&gt;10)The investigator considers it inappropriate to participate in this clinical trial.","Exclusion criteria: 1. Involving in other drug clinical trial;\r&lt;br&gt;2. Pregnant or breastfeeding;\r&lt;br&gt;3. Presence of other serious diseases that may be life threatening, such as cancer;\r&lt;br&gt;4. Expected life is less than 24 hours;\r&lt;br&gt;5. Allergy to ALA or drugs of similar chemical classes (Vitamin B),previous history of intolerance to recommended target doses of alpha-LA;\r&lt;br&gt;6. diagnosed with diseases of immune system.",null,"Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infection caused by basic diseases such as primary immunodeficiency disease, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease and pulmonary dysplasia;\t\r&lt;br&gt;2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory system bacterial infection such as suppurative tonsillitis, acute bronchitis, sinusitis, otitis media or other respiratory diseases affecting the evaluation of clinical trials. Or with Chest CT confirmed the presence of serious interstitial lung disease, bronchiectasis and other basic lung diseases;\r&lt;br&gt;3. critically ill patients based on the New Protocol for Diagnosis and Treatment of NCP;\r&lt;br&gt;4. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 ULN);\r&lt;br&gt;5. Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;=30ml/min/1.73m2) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis;\r&lt;br&gt;6. Pregnant or breast-feeding women;\r&lt;br&gt;7. Patients may be transferred to non-designated hospitals within 72 hours;\r&lt;br&gt;8. Patients who have participated in other clinical trials in the past 7 days;\r&lt;br&gt;9. Allergic constitution, such as those who are allergic to two or over twodrugs ,with history of food allergies, or known to be allergic to the ingredients of this drug;\r&lt;br&gt;10. In the opinion of the investigator, subjects who are not suitable for enrollment or with any factors that affect the outcome of the trial.",null,null,null,null,"Exclusion criteria: 1. Heart rate: heart rate &lt;40 or &gt;130 times/min;\r&lt;br&gt;2. New myocardial ischemia or arrhythmia;\r&lt;br&gt;3. Severe liver and kidney dysfunction or the appearance of new progressive liver and kidney dysfunction;\r&lt;br&gt;4. Oxygen saturation &lt;=93%;\r&lt;br&gt;5. Patients with tracheotomy;\r&lt;br&gt;6. Other complications not suitable for respiratory rehabilitation;\r&lt;br&gt;7. Can not cooperate with the training of cognitive impairment, consciousness disorder patients","Exclusion criteria: 1. Heart rate: Heart rate &lt;40 or&gt; 130 beats / min;\r&lt;br&gt;2. New onset of myocardial ischemia or arrhythmia;\r&lt;br&gt;3. Blood pressure: mean arterial pressure (MAP) &lt;65mmHg or&gt; 110mmHg;\r&lt;br&gt;4. Body temperature: &gt;=38.5 degree C;\r&lt;br&gt;5. Blood oxygen saturation &lt;=93%;\r&lt;br&gt;6. Hemodynamic instability;\r&lt;br&gt;7. Severe liver and kidney dysfunction or newly emerging progressive liver and kidney dysfunction;\r&lt;br&gt;8. Tracheal intubation or tracheotomy patients, mechanical ventilation patients;\r&lt;br&gt;9. There are other complications that are not suitable for respiratory rehabilitation;\r&lt;br&gt;10. Patients with cognitive impairment or conscious impairment who cannot cooperate with training.",null,null,null,"Exclusion criteria: 1) patients in coma, unable to carry out voluntary activities and social activities;\r&lt;br&gt;2) patients with mental illness or adverse reactions caused by drugs;\r&lt;br&gt;3) patients with serious diseases such as cardiovascular, cerebrovascular, liver and kidney damage.",null,null,null,null,"Exclusion criteria: (1) Patients with severe primary diseases such as heart, brain, liver, kidney and hematopoietic system;\r&lt;br&gt;(2) Those with malignant changes in the lungs;\r&lt;br&gt;(3) Persons with a mental, intellectual or language impairment;\r&lt;br&gt;(4) pregnant women, lactating women and those who have pregnancy requirements in the last 6 months;\r&lt;br&gt;(5) Those who are unable to fill in the questionnaire materials using mobile phones, computers, etc.;\r&lt;br&gt;(6) Those who are unwilling to receive moxibustion, or who are allergic to moxibustion or Wenwen cream;\r&lt;br&gt;(7) Those who are participating in other clinical trials.\r&lt;br&gt;Patients who meet any of the above are excluded.","Exclusion criteria: 1. If the researcher judges that a previous or current disease may affect the outcome of participating in the trial or study: severe lung disease, diabetes, cardiovascular and cerebrovascular disease, liver and kidney disease, malignant tumor, neuropsychiatric disease and other diseases that seriously affect survival;\r&lt;br&gt;2. Suffering from diseases that seriously affect the immune system: such as HIV infection, splenectomy, organ transplantation, etc.;\r&lt;br&gt;3. Pregnant and lactating women;\r&lt;br&gt;4. Those who are allergic to moxibustion or Chinese medicine, or allergies;\r&lt;br&gt;5. Hyperthermia, irritability Patients with intense heat;\r&lt;br&gt;6. local skin damage caused by the application is not suitable;\r&lt;br&gt;7. those who have participated in other clinical trials within the past 3 months;\r&lt;br&gt;8. researchers who are not suitable to participate in this clinical trial.","Exclusion criteria: The cases of artifacts caused by poor breath-holding coordination or operator factors are excluded","Exclusion criteria: (1) Exclude influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus,rhinovirus, human metapneumovirus, boca virus, and other known viral respiratory infections;\r&lt;br&gt;(2) Exclude pneumonia caused by atypical microorganisms such as mycoplasma pneumoniae and legionella,bacterial pneumonia, fungal pneumonia, and tuberculosis;\r&lt;br&gt;(3) Exclude children with basic diseases who have invasive fungal infections;\r&lt;br&gt;(4) Exclude children with no clear infectious etiology, who have non-infectious diseases such as vasculitis, dermatomyositis, idiopathic interstitial lung disease, and organizing pneumonia;\r&lt;br&gt;(5) The guardian does not agree to sign the informed consent or collect information.","Exclusion criteria: 1. Patients with serious heart and lung, liver and kidney functions and central nervous system diseases;\r&lt;br&gt;2. Pregnant or lactating patients.","Exclusion criteria: 1.With vomiting, diarrhea or other contraindications;\r&lt;br&gt;2.refuse to traditional Chinese medicine.",null,"Exclusion criteria: Patients with severe cardiovascular disease, lung disease, sleep disorder, psychological disease, musculoskeletal system disease and other sports contraindications.","Exclusion criteria: 1. Cannot take medicine by mouth;\r&lt;br&gt;2. Those who are allergic to bismuth potassium citrate capsules or who have taken bismuth preparations within 1 month;\r&lt;br&gt;3. Critical patients meet one of the following conditions:\r&lt;br&gt;(1) Respiratory failure occurs and requires mechanical ventilation;\r&lt;br&gt;(2) Shock occurs;\r&lt;br&gt;(3) ICU monitoring and treatment is required for other organ failure;\r&lt;br&gt;4. Patients with long-term hemodialysis and known severe renal impairment (glomerular filtration rate &lt;30ml / min / 1.73m2) or patients receiving continuous renal replacement therapy, hemodialysis or peritoneal dialysis;\r&lt;br&gt;5. Pregnant woman and lactation period;\r&lt;br&gt;6. The patient may be transferred to a non-participating hospital within 72 hours;\r&lt;br&gt;7. Researchers deem unsuitable and cannot implement the protocol.","Exclusion criteria: 1. Other pneumonia;\r&lt;br&gt;2. Known to be allergic to traditional Chinese medicine ingredients, or patients with allergies;\r&lt;br&gt;3. Women during lactation and pregnancy, or have a positive urine pregnancy test.",null,null,null,"Exclusion criteria: Allergy to any medicine\r&lt;br&gt;Pregnancy","Exclusion criteria: No","Exclusion criteria: 1. AST and ALT&gt; 1.5 x ULN at visit 1;\r&lt;br&gt;2. bilirubin&gt; 1.5 x ULN at visit 1;\r&lt;br&gt;3. At visit 1, calculated by CockcroftGault formula, creatinine clearance &lt;30 mL / min;\r&lt;br&gt;4. Patients with potential chronic liver disease (Child Pugh A, B or C liver injury);\r&lt;br&gt;5. Previous treatment with nidanib or pirfenidone;\r&lt;br&gt;6. One month before the screening visit (Visit 1) or 6 half-lives (whichever is greater) were treated with other research drugs;\r&lt;br&gt;7. Diagnosis of IPF based on ATS/ERS/JRS/ALAT2011 guidelines (p11-07084);\r&lt;br&gt;8. Significant pulmonary hypertension (PAH) defined by any of the following criteria:\r&lt;br&gt;(1) Clinical / echocardiographic evidence of previously significant right heart failure;\r&lt;br&gt;(2) History including right heart catheterization showing a cardiac index &lt;=2 l / min / m2;\r&lt;br&gt;(3) Prostaglandin required Parenteral administration of Treprostinil for PAH 9. Other clinically significant pulmonary abnormalities that the investigators believe;\r&lt;br&gt;10. Major extrapulmonary physiological limitations (eg, chest wall deformity, large pleural effusion);\r&lt;br&gt;11. Cardiovascular disease, any of the following diseases:\r&lt;br&gt;(1) Severe hypertension within 6 months of visit 1, uncontrollable after treatment (&gt;=160 / 100 mmHg)\r&lt;br&gt;(2) Myocardial infarction within 6 months of visit 1, Unstable angina pectoris within 6 months of Visit 1;\r&lt;br&gt;12. History of severe central nervous system (CNS) events;\r&lt;br&gt;13. Known allergy to test drug;\r&lt;br&gt;14. Other diseases that may interfere with the testing process or that the investigator judges may interfere with the trial participation or may put patients at risk when participating in the trial;\r&lt;br&gt;15. Women who were pregnant, lactating or planning to become pregnant in this trial;\r&lt;br&gt;16. Patients are unable to understand or follow the trial procedures, including completing the questionnaires themselves without assistance.","Exclusion criteria: Severe liver and kidney damage, pulmonary tuberculosis, congenital heart disease, autoimmune disease, interstitial pneumonia, bacterial pneumonia, malignant tumor, history of psychiatric disease","Exclusion criteria: 1. Pneumonia caused by other viruses, except for 2019-nCov;\r&lt;br&gt;2. Clear bacterial infection;\r&lt;br&gt;3. Subjects who have used antiviral drugs and may need another antiviral treatment during the study;\r&lt;br&gt;4. There are serious non-infectious pulmonary diseases, including tuberculosis, pulmonary edema and pulmonary embolism;\r&lt;br&gt;5. Severe liver and kidney dysfunction;\r&lt;br&gt;6. Participating in other clinical studies within 30 days before administration;\r&lt;br&gt;7. Allergic to type 1 interferon;\r&lt;br&gt;8. Pregnant or lactating women;\r&lt;br&gt;9.In any other case, if the investigator thinks it is not suitable for the trial, or it may increase the risk of the subject or interfere with the clinical trial.","Exclusion criteria: (1) known or suspected allergies to the components of azivudine tablets;\r&lt;br&gt;(2) women who are breast-feeding during pregnancy or have a family plan during the trial period and within 6 months after the end of the trial;\r&lt;br&gt;(3) participating in other clinical trials or taking experimental drugs within 12 weeks prior to administration\r&lt;br&gt;(4) severe liver disease (TBIL&gt;=2 times normal upper limit; ALTAST&gt;=5 times normal upper limit);\r&lt;br&gt;(5) patients with severe renal insufficiency or receiving continuous renal replacement therapy or peritoneal dialysis\r&lt;br&gt;(6) Other conditions that not appropriate to be enrolled into this study based on investigator's advise.","Exclusion criteria: 1. Pneumonia caused by other pathogens; \r&lt;br&gt;2. Not receiving antiviral treatment.","Exclusion criteria: 1. Patients with serious heart and lung, liver and kidney functions and central nervous system diseases;\r&lt;br&gt;2. Pregnant or lactating patients;\r&lt;br&gt;3. Cancer patients.","Exclusion criteria: anyone who are reluctant or unable to answer the questionnaire","Exclusion criteria: 1. Patients undergoing general gastroscopy;\r&lt;br&gt;2. With trachea dysfunction;\r&lt;br&gt;3. pregnant women, children, age more than 80 years;\r&lt;br&gt;4. Patients with difficulty in intubation.","Exclusion criteria: (1) Known to be allergic to the ingredients contained in the research medication, or patients with allergies;\r&lt;br&gt;(2) Unwilling to cooperate with the information collector;\r&lt;br&gt;(3) Patients with mental illness, or cognitive impairment;\r&lt;br&gt;(4) Women who are breastfeeding or pregnant, or who have a positive urine pregnancy test, or who do not agree to contraception within 3 months of participating in the test;\r&lt;br&gt;(5) Other patients that the investigator considers unsuitable to participate in this study","Exclusion criteria: none","Exclusion criteria: 1. refuse to participate in the questionnaire survey\r&lt;br&gt;2. with mental disorders","Exclusion criteria: 1. The subject has a history of substance abuse (defined as the use of any illicit drug) or alcohol abuse within the first year of screening;\r&lt;br&gt;2. The subject suffers from active psychosis, which the researcher believes may interfere with their compliance with the study process;\r&lt;br&gt;3. Subjects are unable to participate in all study visits or follow study procedures;\r&lt;br&gt;4. The subject is a staff member of the research center or a member of his or her immediate family or relatives (such as spouse, parents, children, siblings) performing the study or the subject is compelled to agree to participate in the study;\r&lt;br&gt;5. Female subjects during lactation, or female subjects with positive results of serum pregnancy test during screening, or female subjects with positive results of urine pregnancy test before drug administration;\r&lt;br&gt;6. Have participated in other clinical research projects;\r&lt;br&gt;7. Subjects have hypersensitivity reactions or allergic reactions to the stem cell preparation or its components;\r&lt;br&gt;8. The subject suffers from any unstable or uncontrolled cardiovascular, lung, liver, kidney, gastrointestinal, urogenital, hematology, coagulation, immunology, endocrine/metabolic or other medical conditions that the investigator considers to interfere with the outcome of the study or endanger the subject's safety;\r&lt;br&gt;9. The subject has a history of malignant tumor;\r&lt;br&gt;10. Subjects have a history of severe neurological disorders, including stroke, multiple sclerosis, brain tumors, or neurodegenerative diseases.","Exclusion criteria: 1. CT image quality does not meet the analysis criteria;\r&lt;br&gt;2. Pregnant and lactating women.","Exclusion criteria: 1. With local skin infection, trauma and other contraindications;\r&lt;br&gt;2. Patients who refuse massage.","Exclusion criteria: No","Exclusion criteria: 1. Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc.;\r&lt;br&gt;2. Obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumor;\r&lt;br&gt;3. Continuous use of immunosuppressive agents or organ transplants in the past 6 months;\r&lt;br&gt;4. Use in vitro life support (ECMO, ECCO2R);\r&lt;br&gt;5. Patients are expected to die within 48 hours;\r&lt;br&gt;6. Patients with acute kidney injury and AKI stage 2 or above;\r&lt;br&gt;7. Any potential violation of test compliance or any other circumstance affecting safety and effectiveness evaluation that may exist, which the researchers believe is not suitable for patients participating in the study.","Exclusion criteria: no","Exclusion criteria: Nurses who were diagnosed with any mental disorders and who were infected by nCoV were excluded from the study.","Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR &lt;=30 times / min; or SaO2 / SpO2 &lt;=93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;=300MMHG (1mmhg = 0.133kpa);\r&lt;br&gt;2. Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;\r&lt;br&gt;3.Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);\r&lt;br&gt;4. Patients with contraindications specified in the instructions of danorevir and ritonavir tablets;\r&lt;br&gt;5. Patients who have taken or are taking protease inhibitor drugs;\r&lt;br&gt;6. The pregnancy test of female subjects in the screening period was positive;\r&lt;br&gt;7. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).","Exclusion criteria: (1) novel coronavirus pneumonia is a disease or condition beyond the pneumonia. That is, according to the researchers' judgement, the subjects will be at risk for taking part in the research, or will have an impact on the results of the study and the ability of the subjects to participate in the study;\r&lt;br&gt;(2) A woman who is pregnant or breastfeeding or who plans to be pregnant during the study period;\r&lt;br&gt;(3) Combined with heart, liver, kidney, hematopoietic system and other important organs or systems of serious primary diseases;\r&lt;br&gt;(4) Severe and critical patients: respiratory distress, RR &gt;=30 times / min; in resting state, oxygen saturation &lt;= 93%; arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt; 300MMHG; respiratory failure, mechanical ventilation; shock; other organ failure requiring ICU monitoring and treatment;\r&lt;br&gt;(5) Patients over 70 years old;\r&lt;br&gt;(6) Patients with mental disorders and cognitive disorders;\r&lt;br&gt;(7) Those who have poor compliance, are unwilling to participate in the project or do not sign the informed consent during their stay in the hospital. There are doubts about the validity of informed consent: subjects with mental illness, mental retardation, poor motivation, drug abuse (including drugs and alcohol) or other disease history restricting the validity of informed consent in this study;\r&lt;br&gt;(8) Patients with glucocorticoid;\r&lt;br&gt;(9) The researchers think it is not suitable to participate in this study.","Exclusion criteria: blood disease, hepatosis, maglinant tumor, other diseases affecting coagulation function. and taking anticoagulation drugs.","Exclusion criteria: 1. No malnutrition;\r&lt;br&gt;2. Patients who had received antiviral drugs, immunosuppressive drugs and cytotoxic drugs 2 weeks before diagnosis;\r&lt;br&gt;3. patients with hypertriglyceridemia (TG): Serum TG &gt; 3.0mmol/l;\r&lt;br&gt;4. patients with severe liver and kidney dysfunction;\r&lt;br&gt;5. pregnant women; 6.tumor patients.","Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;\r&lt;br&gt;2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation . Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;\r&lt;br&gt;3. Severe pneumonia requires mechanical ventilation;\r&lt;br&gt;4. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;5. Pregnant or lactating women;\r&lt;br&gt;6. Patients who participated in other clinical trials within the last 3 months;\r&lt;br&gt;7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;\r&lt;br&gt;8. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.","Exclusion criteria: (1) Age &lt; 18 or &gt; 65; \r&lt;br&gt;(2) Patients with severe heart, brain, lung, kidney dysfunction, endocrine disease, hematopoiesis system disease or other serious diseases and psychosis; \r&lt;br&gt;(3) Pregnant and lactating women.","Exclusion criteria: 1. Patients who are unable to complete the questionnaire;\r&lt;br&gt;2. Patients and healthy people who are not willing to participate in the survey.","Exclusion criteria: Non Novel coronavirus suspected infection and Confirmed patients","Exclusion criteria: 1) Liver and kidney dysfunction (alt, AST &gt; 2 times the upper limit of normal reference value or / and serum creatinine &gt; 2 times the upper limit of normal reference value);\r&lt;br&gt;2) Psychosis, or cognitive impairment;\r&lt;br&gt;3) Those who are unwilling to cooperate with information collection.","Exclusion criteria: Pregnancy;Sudden death disease, such as fatal heart disease patients.","Exclusion criteria: 1. Patients with other serious pulmonary diseases, cardiovascular and cerebrovascular diseases, diabetes mellitus, tumor, hematopoiesis, autoimmune diseases, digestive system diseases, skin diseases, psychosis, etc.;\r&lt;br&gt;2. Patients who cannot complete the treatment;\r&lt;br&gt;3. Pregnant or lactating women.","Exclusion criteria: 1) Any situation where the solution cannot be carried out safely;\r&lt;br&gt;2) Allergic constitution, allergic to one or more foods or drugs;\r&lt;br&gt;3) Severe basic diseases affecting survival, including uncontrolled clinically significant heart, lung, kidney, digestive, hematological, neuropsychiatric diseases, immune diseases, metabolic diseases or malignant tumors, severe malnutrition;\r&lt;br&gt;4) pregnant or lactating women;\r&lt;br&gt;5) The patient may be transferred to a non-participating hospital within 72 hours;\r&lt;br&gt;6) Those who have continued to use immunosuppressive agents or organ transplants in the past 6 months;\r&lt;br&gt;7) Within 15 days before enrollment, during the hospitalization period, any patient who is being treated with antiviral drugs other than this program during treatment;\r&lt;br&gt;8) People who cannot cooperate with mental state, suffer from mental illness, have no self-control, and cannot express clearly;\r&lt;br&gt;9) History of HBV, HCV, TPPA, HIV, and pancreatitis before infection;\r&lt;br&gt;10) Those who are participating in other clinical trials.","Exclusion criteria: 1. People with serious or uncontrolled concomitant diseases, including sensory, vascular, heart, liver, kidney, gastric, intestinal, endocrine, etc.;\r&lt;br&gt;2. Having received Vaccine in the 4 weeks before entry or Planning to receive vaccine during the study;\r&lt;br&gt;3. Hypersensitivity to tocilizumab;\r&lt;br&gt;4. Pregnant or positive of the pregnancy test, lactating women;\r&lt;br&gt;5. Other reasons to exclude from the study.","Exclusion criteria: Exclusion criterion: those who do not agree to participate.","Exclusion criteria: Cancelled","Exclusion criteria: NONE","Exclusion criteria: 1) Children (less than 14 years old);\r&lt;br&gt;2) lack of important case information (such as blood routine, C-reactive protein, epidemic history, chest CT, etc.).","Exclusion criteria: (1) Patients with known or suspected to be allergic to the components of the test drug; \r&lt;br&gt;(2) Patients with known hepatitis B, C, AIDS and other viral infections;\r&lt;br&gt;(3) Patients with severe or severe clinical classification who have experienced complications such as respiratory failure and acute respiratory distress syndrome (ARDS);\r&lt;br&gt;(4) Patients who have participated or are participating in other drug clinical trials within 2 weeks before screening;\r&lt;br&gt;(5) Pregnancy: Positive pregnancy test for Female patients;\r&lt;br&gt;(6) Patients may be transferred to non-participating hospitals within 72 hours; \r&lt;br&gt;(7) Patients with respiratory infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and lung development;\r&lt;br&gt;(8) Patients being treated with other Chinese medicine;\r&lt;br&gt;(9) Believed to be not suitable to participate in clinical trials by investigator.","Exclusion criteria: 1. Suspected cases and confirmed cases;\r&lt;br&gt;2. Patients with severe heart, brain, liver, kidney and other visceral diseases or other serious metabolic disorders and tumors;\r&lt;br&gt;3. People who could not complete the study for other reasons;\r&lt;br&gt;4. Pregnant or lactating women.","Exclusion criteria: 1. Patients with identified allergies to 4-aminoquinoline and lopinavir/litonavir;\r&lt;br&gt;2. Patients with server diseases of the blood system;\r&lt;br&gt;3. Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit;\r&lt;br&gt;4. Patients with alcoholism or are taking hepatotoxic drugs;\r&lt;br&gt;5. Patients with renal impairment (estimated glomerular filtration rate [eGFR]&lt; 30 mL/min/1.73m2, using the MDRD method);\r&lt;br&gt;6. Patients with 6-phosphate dehydrogenase deficiency;\r&lt;br&gt;7. History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level ?-?;\r&lt;br&gt;8. QTc &gt;= 480ms;\r&lt;br&gt;9. Uncorrected patients with hypokalemia or hypokalemia;\r&lt;br&gt;10. Patients with retinopathy, fundus lesions, macular degeneration;\r&lt;br&gt;11. Patients with psychiatric disorders;\r&lt;br&gt;12. Patients with pancreatitis;\r&lt;br&gt;13. Patients with server auditory damage;\r&lt;br&gt;14. Pregnant or breastfeeding women or female with positive pregnancy test at child-bearing age;\r&lt;br&gt;15. Patients with medication that affect drug absorption, metabolism and excretion, that can induce QT interval prolongation, or drugs that can increase adverse reactions, etc.;\r&lt;br&gt;16. Patients were not eligible for this trial based on Investigator's considerationsPatients with a history of malignant tumor in the last 5 years.","Exclusion criteria: 1 Patients with identified allergies to 4-aminoquinoline and lopinavir/litonavir;\r&lt;br&gt;2 Patients with server diseases of the blood system;\r&lt;br&gt;3 Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit;\r&lt;br&gt;4 Patients with alcoholism or are taking hepatotoxic drugs;\r&lt;br&gt;5 Patients with renal impairment (estimated glomerular filtration rate [eGFR]&lt; 30 mL/min/1.73m2, using the MDRD method);\r&lt;br&gt;6 Patients with 6-phosphate dehydrogenase deficiency;\r&lt;br&gt;7 History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level ?-?;\r&lt;br&gt;8 QTc=480ms\r&lt;br&gt;9 uncorrected patients with hypokalemia or hypokalemia\r&lt;br&gt;10Patients with retinopathy, fundus lesions, macular degeneration;\r&lt;br&gt;11 Patients with psychiatric disorders;\r&lt;br&gt;12? Patients with pancreatitis;\r&lt;br&gt;13? Patients with server auditory damage;\r&lt;br&gt;14? Pregnant or breastfeeding women or female with positive pregnancy test at child-bearing age;\r&lt;br&gt;15? Patients with medication that affect drug absorption, metabolism and excretion, that can induce QT interval prolongation, or drugs that can increase adverse reactions, etc.;\r&lt;br&gt;16? Patients were not eligible for this trial based on Investigator's considerationsPatients with a history of malignant tumor in the last 5 years.","Exclusion criteria: 1. Known to be allergic to hydroxychloroquine or 4-aminoquinoline;\r&lt;br&gt;2. Patients with severe renal insufficiency (EGFR &lt; = 30 ml / min / 1.73 m2) and RRT;\r&lt;br&gt;3. Severe liver disease (child Pugh score &gt; =C,Ast &gt; 5 times of the upper limit);\r&lt;br&gt;4. Suffering from retinopathy;\r&lt;br&gt;5. History of epilepsy;\r&lt;br&gt;6.G6PD deficiency;\r&lt;br&gt;7. Pregnancy or lactation;\r&lt;br&gt;8. Patients taking tamoxifen;\r&lt;br&gt;9. Doctors judged that this study was not in the interests of patients;\r&lt;br&gt;10. Transfer to another hospital which is not the study site within 72 hours;\r&lt;br&gt;11. Receive any trial treatment drug (off label, compassionate use or trial related) for 2019-ncov within 30 days prior to screening evaluation.","Exclusion criteria: Patients with any of the following were excluded from the study:\r&lt;br&gt;1. Patients with previous allergy to 4-aminoquinoline compounds;\r&lt;br&gt;2. Patients with previous severe retinal or visual field related diseases;\r&lt;br&gt;3. Patients with severe liver damage;\r&lt;br&gt;4. Patients with impaired renal function (creatinine clearance &lt;=50 mL / min);\r&lt;br&gt;5. Patients weighing &lt;35kg;\r&lt;br&gt;6. Patients exposed to other study drugs within 30 days before administration;\r&lt;br&gt;7. Being pregnant or breastfeeding. Or have a pregnancy plan (including partner) within one month.","Exclusion criteria: (1) Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia;\r&lt;br&gt;(2) Severe primary diseases that affect survival, including: uncontrolled malignant tumors, hematological diseases, and HIV that have not been metastasized in multiple places;\r&lt;br&gt;(3) Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and allergic alveolitis caused by lung tumors;\r&lt;br&gt;(4) Women who are breastfeeding or pregnant;\r&lt;br&gt;(5) Those who are known to be allergic to the ingredients contained in the research medication, or patients with allergies;\r&lt;br&gt;(6) Those who have continued to use immunosuppressive agents or organ transplants in the past 6 months;\r&lt;br&gt;(7) Patients who have participated in other drug clinical trials within 3 months before the screening test;\r&lt;br&gt;(8) The investigator judges that he or she cannot complete or should not participate in the study (expected death within 48 hours, and the patient refuses active treatment)","Exclusion criteria: NO.","Exclusion criteria: 1. Expected to die within 48 hours;\r&lt;br&gt;2. Patients with asthma attack, purulent tonsillitis, acute and chronic bronchitis, sinusitis, otitis media, and other respiratory diseases affecting clinical trial evaluation; and chest CT confirmed the existence of severe pulmonary interstitial disease, bronchiectasis, obstructive pulmonary disease With lung disease;\r&lt;br&gt;3. Patients with respiratory infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and lung development;\r&lt;br&gt;4. At the discretion of the investigator, previous or present chronic or severe illness may affect participation in the trial or affect the outcome of the study, including but not limited to the gastrointestinal system, cardio-cerebral vascular system, liver, kidney, hematopoietic system, lymph System, endocrine system, immune system, malignant tumor, severe malnutrition, nervous system and endocrine system and other diseases; and currently suffering from human immunodeficiency virus (HIV) infection, splenectomy, organ transplantation and other diseases that seriously affect the immune system By;\r&lt;br&gt;5. People who cannot co-operate with mental state, suffer from mental illness, cannot control themselves, and cannot express;\r&lt;br&gt;6. Patients with poorly controlled hypertension: low pressure &gt;=110 mmHg or high pressure &gt;= 180 mmHg;\r&lt;br&gt;7. Patients with ALT, AST &gt;= 1.5 times the upper limit of normal value, and Scr&gt; upper limit of normal value;\r&lt;br&gt;8. People with a specific history of allergies (such as asthma, measles, eczema, etc.), or allergies (such as those allergic to two or more drugs, foods such as milk and pollen), or those who are allergic to the components of cough syrup and cough capsule;\r&lt;br&gt;9. Patients with a history of drug abuse or dependence within 6 months before randomization;\r&lt;br&gt;10. Those who have used any Chinese and Western medicine for cough and phlegm elimination within 24 hours before random enrollment;\r&lt;br&gt;11. Female patients during pregnancy and lactation;\r&lt;br&gt;12. Patients who have participated or are participating in other drug clinical trials within 3 months before screening;\r&lt;br&gt;13. Researchers consider others unsuitable to participate in this clinical trial.","Exclusion criteria: 1. Patients with severe pneumonia requiring mechanical ventilation and severe new coronavirus infection with pneumonia;\r&lt;br&gt;2. Death is expected within 48 hours;\r&lt;br&gt;3. There is clear evidence of bacterial infection in respiratory tract infections caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease, pulmonary dysplasia and other basic diseases;\r&lt;br&gt;4 subjects with the following conditions: daily treatment of asthma, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases that affect clinical trial evaluation.Chest CT confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;\r&lt;br&gt;5. According to the researcher's judgment, the previous or current diseases may affect the patient's participation in the trial or the outcome of the study, including malignant diseases, autoimmune diseases, severe malnutrition, liver and kidney diseases, blood diseases, nervous system diseases, and endocrine diseases;He is suffering from serious diseases that affect the immune system, such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc.\r&lt;br&gt;Unable to cooperate in mental state, suffering from mental disease, unable to control, unable to express clearly;\r&lt;br&gt;Allergic constitution (such as allergic to two or more drugs or food) or history of allergy to this product and conventional treatment drugs;\r&lt;br&gt;8. A history of substance abuse or dependence;\r&lt;br&gt;9. Pregnant or nursing women;\r&lt;br&gt;10. Other researchers consider it inappropriate to participate in clinical trials.","Exclusion criteria: 1. Meets any contraindications of ARB;\r&lt;br&gt;2. Meets any contraindications of Jinyebaidu Granule;\r&lt;br&gt;3. Pregnant women, lactating women, severe renal insufficiency.","Exclusion criteria: (1) Patients are diagnosed as a case of severe NCIP;\r&lt;br&gt;(2) Patients are pregnant or breastfeeding women; \r&lt;br&gt;(3) Patients have aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 5UNL or creatinine clearance &lt;50 ml / min; \r&lt;br&gt;(4) Patients are allergic or intolerant to the proposed antiviral therapeutic drugs;\r&lt;br&gt;(5) Patients are HIV-positive; \r&lt;br&gt;(6) Patients with hemoglobin disease\r&lt;br&gt;(7) Patients have severe heart disease, brain disease, lung disease, kidney disease, tumor or other severe systemic diseases;\r&lt;br&gt;(8) Patients are not willing to provide signed informed consent.","Exclusion criteria: 1. Patients who are unable to complete the questionnaire;\r&lt;br&gt;2. Patients  who are not willing to participate in the survey.","Exclusion criteria: Patients with any of the following were excluded from the study:\r&lt;br&gt;1. Patients with previous allergy to 4-aminoquinoline compounds;\r&lt;br&gt;2. Patients with previous severe retinal or visual field related diseases;\r&lt;br&gt;3. Patients with severe liver dysfunction and patients with renal dysfunction (creatinine clearance rate &lt;= 50 mL / min);\r&lt;br&gt;4. Patients weighing &lt;35kg;\r&lt;br&gt;5. Patients exposed to other study drugs within 30 days before administration;\r&lt;br&gt;6. Being pregnant or breastfeeding. Or have a pregnancy plan (including partner) within one month.","Exclusion criteria: 1. Severe liver disease (such as child Pugh score &gt;= C, AST &gt; 5 times upper limit);\r&lt;br&gt;2. The patients were allergic to the components in asc09 / ritonavir compound tablets;\r&lt;br&gt;3. Patients with contraindications specified in the instructions of ritonavir tablets;\r&lt;br&gt;4. The pregnancy test of female subjects in the screening period was positive;\r&lt;br&gt;5. Patients have treat with HIV protease inhibitor;\r&lt;br&gt;6. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).","Exclusion criteria: 1. Patients are allergic or intolerant to therapeutic drugs;\r&lt;br&gt;2. Pregnancy or lactating women;\r&lt;br&gt;3. Researchers believe that patients may have other factors affecting the efficacy or safety evaluation of this study.","Exclusion criteria: 1. Known allergic to hydroxychloroquine or 4-aminoquinoline;\r&lt;br&gt;2. Severe renal impairment (eGFR &lt;= 30 mL/min/1.73 m2), and those with RRT;\r&lt;br&gt;3. Severe liver disease (Child Pugh score &gt;= C, AST&gt;5 times upper limit);\r&lt;br&gt;4. Pre-existing retinopathy of the eye;\r&lt;br&gt;5. History of epilepsy;\r&lt;br&gt;6. G6PD deficiency;\r&lt;br&gt;7. Pregnant or breastfeeding; \r&lt;br&gt;8. Patients taking tamoxifen;\r&lt;br&gt;9. The study not in patients' best interests judged by the physician.",null,"Exclusion criteria: No","Exclusion criteria: 1. Children and pregnant women; \r&lt;br&gt;2. Serious cardiopulmonary diseases (chronic obstructive pulmonary disease, acute coronary syndrome, dilated cardiomyopathy, congenital heart disease, chronic pulmonary hypertension, etc.); \r&lt;br&gt;3. End stage of malignant tumor.",null,null,null,null,null,"Exclusion criteria: (1) Patients allergic to antiviral drugs;\r&lt;br&gt;(2) Pregnant or lactating women;\r&lt;br&gt;(3) Patients whose GPT or total bilirubin is higher than the upper limit of normal value before antiviral drug use.","Exclusion criteria: 1) Patient or family member does not agree to sign informed consent;\r&lt;br&gt;2) Patients with previous or existing history of DVT;\r&lt;br&gt;3) The investigator believes that the patient has other conditions that are not suitable for enrollment;","Exclusion criteria: 1) &lt; 18 years old or &gt;=80 years old; \r&lt;br&gt;2) pregnant and lactating women; \r&lt;br&gt;3) patients with mental illness.","Exclusion criteria: (1) Combined with high blood pressure, diabetes, coronary heart disease and other underlying disease; \r&lt;br&gt;(2) Combined with malignant tumor or a medical history of malignant tumor; \r&lt;br&gt;(3) Pregnant or lactating women; \r&lt;br&gt;(4) Suffering from severe mental illness; \r&lt;br&gt;(5) Medical history of unstable angor pectoris or myocardial?infarction within 6 months, coronary arteriography; it indicates severe stenosis of the main branch of the coronary artery; \r&lt;br&gt;(6) Medical history of cerebral infarction or cerebral hemorrhage within 6 months; \r&lt;br&gt;(7) Intolerant or allergic to interferon preparations; \r&lt;br&gt;(8) The investigator determined that the patients were not eligible for the trial.","Exclusion criteria: 1. Patients with serious primary diseases such as severe mental and psychological disorders, heart and brain vessels diseases, liver and kidney diseases, endocrine diseases, hematopoietic system diseases and malignant tumors;\r&lt;br&gt;2. Patients are known to be allergic to trail drugs or a certain Chinese medicine of this study;\r&lt;br&gt;3. Women are breastfeeding, pregnant or preparing for pregnancy;\r&lt;br&gt;4. Patients participating in other clinical studies.",null,null,"Exclusion criteria: Patients with hypersensitivity to plasma products; patients with severe transfusion reactions in the past; patients with acute pulmonary edema, congestive heart failure, pulmonary embolism, malignant hypertension, polycythemia vera, extreme renal failure and other diseases.","Exclusion criteria: No","Exclusion criteria: 1. Pregnant and lactating women; \r&lt;br&gt;2. Patients with mental illness.","Exclusion criteria: No","Exclusion criteria: (1) Chronic obstructive pulmonary disease; \r&lt;br&gt;(2) Cardiorenal insufficiency; \r&lt;br&gt;(3) Pregnant women","Exclusion criteria: 1. pregnancy;\r&lt;br&gt;2. blood purification treatment prior to admission;\r&lt;br&gt;3. patients had other indications for blood purification treatment including hyperkalemia, acute kidney failure, and so on;\r&lt;br&gt;4. allergic to dimethyl sulfoxide, dextran or Heparin;\r&lt;br&gt;5. currently active malignant tumor or under Immunosuppressive therapy.","Exclusion criteria: (1) known or suspected allergies to the components of azivudine tablets;\r&lt;br&gt;(2) women who are breast-feeding during pregnancy or have a family plan during the trial period and within 6 months after the end of the trial;\r&lt;br&gt;(3) participating in other clinical trials or taking experimental drugs within 12 weeks prior to administration;\r&lt;br&gt;(4) severe liver disease (TBIL&gt;=2 times normal upper limit; ALTAST&gt;=5 times normal upper limit);\r&lt;br&gt;(5) patients with severe renal insufficiency or receiving continuous renal replacement therapy or peritoneal dialysis \r&lt;br&gt;(6) Other conditions that not appropriate to be enrolled into this study based on investigator's advise.","Exclusion criteria: (1) Exclude influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, boca virus, and other known viral respiratory infections;\r&lt;br&gt;(2) Exclude pneumonia caused by atypical microorganisms such as  Mycoplasma pneumoniae, Legionella, fungal pneumonia, and tuberculosis;\r&lt;br&gt;(3) Exclude children with basic diseases who have invasive fungal infections;\r&lt;br&gt;(4) Exclude children with no clear infectious etiology who have non-infectious diseases such as vasculitis, dermatomyositis, idiopathic interstitial lung disease, and organizing pneumonia;\r&lt;br&gt;(5) Exclude If the guardian of the child does not agree to sign the informed consent form or collect information.","Exclusion criteria: 1) &lt;14 years of age;\r&lt;br&gt;2) pregnant women;\r&lt;br&gt;3) ICU hospital stay &lt;24 hours;\r&lt;br&gt;4) The necessary clinical information is incomplete.","Exclusion criteria: 1. Age &lt;14 years;\r&lt;br&gt;2. Pregnant;\r&lt;br&gt;3. Patient is irritable during NIV treatment, and still cannot tolerate NIV after adequate health education and nursing guidance;\r&lt;br&gt;4. Intubation-mechanical ventilation without previous NIV treatment;\r&lt;br&gt;5. Patient or legal representative refuses to participate in this clinical study;\r&lt;br&gt;6. Patient or legal representative refuses intubation and/or mechanical ventilation.","Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR 30 times / min; or SaO2 / SpO2 &lt;93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;300MMHG (1mmhg = 0.133kpa);\r&lt;br&gt;2. Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;\r&lt;br&gt;3. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);\r&lt;br&gt;4. Patients with contraindications specified in the instructions of ritonavir tablets;\r&lt;br&gt;5. The patient who previous or ongoing use of protease inhibitors;\r&lt;br&gt;6. The pregnancy test of female subjects in the screening period was positive;\r&lt;br&gt;7. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).?","Exclusion criteria: The patients disagreed for sample collection will be excluded.","Exclusion criteria: On-the-job college students and graduate students.","Exclusion criteria: COVID-19 group: \r&lt;br&gt;1. Patients without self-awareness; \r&lt;br&gt;2. Patients who used drugs that can affect metabolism in the past 2 weeks, such as antibiotics (penicillins, erythromycin), hormones (deoxycortisol, dexamethasone), non-steroidal anti-inflammatory drugs (aspirin, sanitin), etc. \r&lt;br&gt;3. Patients with significant abnormalities in lung ventilation;\r&lt;br&gt;4. Pregnant or lactating women;\r&lt;br&gt;5. Patients with other metabolic disorders and any acute disease symptoms in the past 2 weeks.\r&lt;br&gt;Similar symptoms group \r&lt;br&gt;1. Patients without knowledge;\r&lt;br&gt;2. With previous medical history of COVID-19.\r&lt;br&gt;3. Patients with other metabolic disorders and any acute disease symptoms in the past 2 weeks;\r&lt;br&gt;4. Patients with significant abnormalities in lung ventilation.","Exclusion criteria: Participants who are not suitable to be included in the project evaluated by the researchers.","Exclusion criteria: (1)People who complicated with mental illness\r&lt;br&gt;(2) people who can't use smart phones\r&lt;br&gt;(3)people who can't recognize or clearly read Chinese characters\r&lt;br&gt;(4)people who can't understand Chinese characters","Exclusion criteria: 1. Any situation where the programme cannot be carried out safely;\r&lt;br&gt;2. Patients who have used interferon or remedesivir;\r&lt;br&gt;3. No clinical manifestations and chest imaging findings;\r&lt;br&gt;4. Known allergy or hypersensitivity to interferon (including asthma);\r&lt;br&gt;5. Disabled in patients with uncontrolled autoimmune diseases;\r&lt;br&gt;6. Patients with severe heart disease, decompensated liver disease, renal insufficiency (CrCL &lt;50ml / min), and those with abnormal bone marrow function are prohibited;\r&lt;br&gt;7. Epilepsy and impaired central nervous system function;\r&lt;br&gt;8. Pregnancy: Positive pregnancy test for women of childbearing age;\r&lt;br&gt;9. Breastfeeding women have not stopped breastfeeding;\r&lt;br&gt;10. The patient may be transferred to a non-participating hospital within 72 hours.","Exclusion criteria: 1. Patients with cardiopulmonary resuscitation at the end of the disease; \r&lt;br&gt;2. Pregnant women.","Exclusion criteria: pregnant or lactating women","Exclusion criteria: (1) Female patients during pregnancy or lactation;\r&lt;br&gt;(2) Patients allergic to lipoic acid or similar drugs (B vitamins), previously intolerant to the recommended dose of lipoic acid;\r&lt;br&gt;(3) Patients who are taking part in clinical trials of other drugs;\r&lt;br&gt;(4) Patients are taking other foods or drugs with antioxidant effect, such as vitamin C, vitamin E, etc.\r&lt;br&gt;(5) Patients with other serious diseases that may threaten life, such as cancer.","Exclusion criteria: 1. Patients with mild and critical novel coronavirus pneumonia;\r&lt;br&gt;2. Acute respiratory disease caused by non- novel coronavirus pneumonia;\r&lt;br&gt;3. Patients with diabetes and hypertension accompanied by severe primary immunodeficiency disease acquired immunodeficiency syndrome congenital respiratory malformation congenital heart disease pulmonary dysplasia and other diseases;\r&lt;br&gt;4. Patients with obvious abnormal heart, liver and kidney disease or serious other system diseases such as digestive system urogenital system blood system hemorrhagic disease central nervous system psychiatric diseases in acute stage, and endocrine and metabolic diseases;\r&lt;br&gt;5. People who are known to be allergic to the ingredients in the research drug, or patients with allergies; \r&lt;br&gt;6. Women who are breastfeeding, pregnant, or have a positive urine pregnancy test;\r&lt;br&gt;7. Patients who are participating in other clinical trials or patients who have participated in other drug clinical trials within 1 month;\r&lt;br&gt;8. Researchers find the patient inappropriate to be involved in the trial.","Exclusion criteria: (1) Known or suspected allergy to the components of zedoary turmeric oil injection, or allergic constitution;\r&lt;br&gt;(2) Mild and severe patients.\r&lt;br&gt;(3) Combined with severe liver disease (such as Child-Pugh score &gt;=C, TBIL &gt;=2 times the upper limit of normal, ALT/AST &gt;=5 times the upper limit of normal);\r&lt;br&gt;(4) Combined with severe renal insufficiency (eGFR &lt;=30 mL/min/1.73 m2) or undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis;\r&lt;br&gt;(5) Pregnant and lactating women or have fertility plans during the trial and within 6 months after the end of the trial;\r&lt;br&gt;(6) Participated in other clinical trials within 3 months before enrollment;\r&lt;br&gt;(7) According to the investigator's judgment, there are other conditions that are not suitable for participating in this trial.","Exclusion criteria: None","Exclusion criteria: 1) Patients with mild, severe or critical novel coronavirus disease;\r&lt;br&gt;2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;3) Those who are allergic to the research drug and its main ingredients;\r&lt;br&gt;4) pregnant or lactating women;\r&lt;br&gt;5) Those who have difficulty taking medicine orally.","Exclusion criteria: 1. Respiratory failure explained with other lung conditions, including influenza virus, bacterial infection, fungi infection, non-infectious causes;\r&lt;br&gt;2. Comorbidities including lupus, vasculitis, APS et al.\r&lt;br&gt;3. Concurrent use of anti-IL6 receptor antibody;\r&lt;br&gt;4. Malignancy;\r&lt;br&gt;5. Pregnancy;\r&lt;br&gt;6. Potential tranfer to other hospital during the trial;\r&lt;br&gt;7. Other potential conditions determined by the investigators.","Exclusion criteria: 1. according to the clinical classification of severe and critical cases in the sixth edition of Diagnosis and treatment of pneumonia with 2019-ncov infection issued by the National Health Commission.\r&lt;br&gt;Note: those who comply with any of the following provisions shall not be included:\r&lt;br&gt;Heavy duty:\r&lt;br&gt;(1) Respiratory Distress, Rr &gt;=3/Min; \r&lt;br&gt;(2) At rest, oxygen saturation &lt;=93% ; \r&lt;br&gt;(3) Arterial Partial Oxygen Pressure (PAO2) / oxygen uptake concentration (FIO2)&lt;=300 MMHG 10.133 KPA\r&lt;br&gt;Critical type: \r&lt;br&gt;(1) Respiratory Failure with Mechanical Ventilation; \r&lt;br&gt;(2) Go into shock;. \r&lt;br&gt;(3) Patients with other organ failure need intensive care in ICU.\r&lt;br&gt;2. merger other virus like HCV, HIV, syphilis and so on infection person;\r&lt;br&gt;3. Chest radiography or CT confirmed interstitial lesions and other diseases;\r&lt;br&gt;4. combined with severe liver and kidney damage, ALT, AST, Tbil or any of the above items; 1.5 times the upper limit of normal value, or CR &amp; GT;\r&lt;br&gt;5. those diagnosed as immunodeficient or who have taken immunosuppressive drugs or glucocorticoid within 3 months;\r&lt;br&gt;6. Known history of allergy to experimental drugs or their excipients\r&lt;br&gt;7. The risk factors are as follows:\r&lt;br&gt;(1) chronic obstructive pulmonary disease, chronic respiratory disease such as asthma;\r&lt;br&gt;(2) serious cardiovascular diseases such as congenital heart defect, heart failure and coronary artery disease, except hypertension;\r&lt;br&gt;(3) neurological and neuromuscular diseases such as cerebral palsy, epilepsy, stroke, mental retardation, muscular dystrophy or spinal cord injury;\r&lt;br&gt;(4) serious hematological diseases such as sickle cell disease;\r&lt;br&gt;(5) malignant tumors;\r&lt;br&gt;8. Female subjects who were pregnant, lactating or positive in pregnancy during the screening period or during the trial; male and female patients with reproductive potential who were unwilling to use an effective, protocol-prescribed method of contraception during the study period;\r&lt;br&gt;9. persons with Infectious Disease and mental illness;\r&lt;br&gt;10. Who have been in clinical trials for other drugs in the last 3 months;\r&lt;br&gt;11. The researchers did not consider it appropriate to participate in this clinical trial.","Exclusion criteria: 1. Patients who are allergic to corticosteroid;\r&lt;br&gt;2. Patients who are diagnosed with adrenal insufficiency;\r&lt;br&gt;3. Severe immunosuppression, one of the following: infection with human immunodeficiency virus and CD4 cell count below 350 cells per microliter, immunosuppressive therapy after solid organ transplantation, neutropenia (less than 500 cells Per microliter) and so on;\r&lt;br&gt;4. Patients with cystic fibrosis or active tuberculosis;\r&lt;br&gt;5. Patients with gastrointestinal bleeding in the past three months;\r&lt;br&gt;6. Incomplete clinical data;\r&lt;br&gt;7. Participated in other clinical research;\r&lt;br&gt;8. Patients who cannot understand and execute the survey plan;\r&lt;br&gt;9. Patients who abandoned treatment.","Exclusion criteria: 1. COVID-19 suspected or confirmed patients:\r&lt;br&gt;(1) Those who refuse to cooperate;\r&lt;br&gt;(2) Pregnant women;\r&lt;br&gt;(3)Patients with mental disorders and cognitive dysfunction.\r&lt;br&gt;2. non-COVID healthy residents:\r&lt;br&gt;(1) Those who refuse to cooperate;\r&lt;br&gt;(2) Patients with mental disorders and cognitive dysfunction.\r&lt;br&gt;3. medical staff:\r&lt;br&gt;(1) Those who refuse to cooperate;\r&lt;br&gt;(2) non-working staff;\r&lt;br&gt;(3) Patients with mental disorders and cognitive dysfunction.","Exclusion criteria: ? Doctors decided that it was not in the best interests of the subjects to participate in the study, or there was any situation that could not follow the agreement safely; ? there was a history of pulmonary embolism; ? there were patients with human immunodeficiency virus (HIV) infection; ? there were severe organ failure; such as severe liver disease (such as child Pugh score = grade C, AST more than 5 times of the upper limit of normal; or severe renal insufficiency (estimated glomerular filtration rate = 30ml / min / 1.73m2) or patients undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis; severe shock or other situations that clinicians think are not suitable for use. (Note: due to the newly discovered disease, clinicians can't give up the hope of treatment at will based on the principle of rescuing the dead and supporting the wounded) ? pregnant and lactating women, or positive pregnancy test before medication; ? human immunodeficiency virus (HIV) infected patients; ? Patients with malignant tumors, except those with cervical carcinoma in situ, skin non metastatic squamous or basal cell carcinoma who have been treated completely; ? any experimental treatment for lung injured cells or stem cells within 28 days before screening and evaluation.","Exclusion criteria: (1) Patients during pregnancy;\r&lt;br&gt;(2) Complicated liver, kidney, and metabolic diseases;\r&lt;br&gt;(3) Have other serious primary cardiovascular disease, kidney disease, liver disease, hematological changes, or serious diseases that affect its quality of life, such as malignant tumors, AIDS, etc.;\r&lt;br&gt;(4) Have or suspect a history of alcohol, drug abuse, etc.;\r&lt;br&gt;(5) People with mental illness or manic disorder, or unwilling to accept research measures, or unwilling to cooperate with others;\r&lt;br&gt;(6) Those who have participated in other clinical studies and influenced the results of this survey.","Exclusion criteria:  infection caused by other pathogens","Exclusion criteria: Patients not suitable for study judged by researchers.","Exclusion criteria: 1. Respiratory failure explained with other lung conditions, including influenza virus, bacterial infection, fungi infection, non-infectious causes;\r&lt;br&gt;2. Comorbidities including lupus, vasculitis, APS et al.;\r&lt;br&gt;3. Concurrent use of anti-IL6 receptor antibody;\r&lt;br&gt;4. Malignancy;\r&lt;br&gt;5. Pregnancy;\r&lt;br&gt;6. there is potential of transfer to other hospital during the trial;\r&lt;br&gt;7. Other potential conditions determined by the investigators.","Exclusion criteria: 1) patients in coma, unable to carry out voluntary activities and social activities; \r&lt;br&gt;2) patients with mental illness or adverse reactions caused by drugs; \r&lt;br&gt;3) patients with serious diseases such as cardiovascular, cerebrovascular, liver and kidney damage.","Exclusion criteria: 1. Intubation required immidiately in case of cardiac arrest or asphyxia; 2. Pregnancy, severe chronic respiratory, uncontrolled gastric reflux disease and any nasopharyngeal anatomical obstacle; 3. Those patients has intubated in ICU.","Exclusion criteria: 1.diabetic ketoacidosis, hyperosmolar hyperglycemic status, or severe recurrent hypoglycemia occurred within 3 months;\r&lt;br&gt;2.previous history of cardiovascular disease, malignant tumor, mental illness or severe liver and kidney dysfunction.","Exclusion criteria: 1. General anesthesia surgery patients;\r&lt;br&gt;2. Medical staff with contact history outside the operating room.","Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:\r&lt;br&gt;1) Respiratory failure occurs and requires mechanical ventilation;\r&lt;br&gt;2) Shock occurs;\r&lt;br&gt;3) Combined failure of other organs requires ICU monitoring and treatment;\r&lt;br&gt;2. Those who are allergic to blood products or plasma components and auxiliary materials (sodium citrate);\r&lt;br&gt;3. There is multiple organ failure, and the estimated survival time is less than 3 days;\r&lt;br&gt;4. Those who tested positive for HIV antibodies before enrollment;\r&lt;br&gt;5. Women who are pregnant or breastfeeding or have a birth plan within the past year;\r&lt;br&gt;6. Participants in other clinical trials within 3 months before screening;\r&lt;br&gt;7.Poor adherence or other conditions that the investigator believes are not suitable for inclusion (such as poor physical condition).","Exclusion criteria: suspected or diagnosed isolation of nurses","Exclusion criteria: NO","Exclusion criteria: Observational study, no exclusion criteria","Exclusion criteria: Exclude patients with influenza, adenovirus and other upper respiratory tract infections","Exclusion criteria: 1. Patients with other malignant tumors requiring treatment;\r&lt;br&gt;2. Severe cardiovascular and metabolic diseases beyond the control of combination with other drugs \r&lt;br&gt;3. Patients with clinical symptoms of brain dysfunction or serious mental illness who cannot understand or follow the study protocol;\r&lt;br&gt;4. Endotracheal intubation with invasive ventilation;\r&lt;br&gt;5. Patients who cannot guarantee completion of necessary treatment plan and follow-up observation;\r&lt;br&gt;6. Women of child-bearing age who are positive in pregnancy test or do not stop breastfeeding in lactation period;\r&lt;br&gt;7. Patients with other infections at the time of enrollment;\r&lt;br&gt;8. Other circumstances that prevent the protocol from proceeding safely.","Exclusion criteria: 1. Critical case with the following situation:\r&lt;br&gt; i. Patients with respiratory failure and needing mechanical ventilation;\r&lt;br&gt; ii. Patients with shock;\r&lt;br&gt; iii. Patients with other organ failures and needing ICU monitoring and treatment;\r&lt;br&gt;2. Patients who have other respiratory tract infection;\r&lt;br&gt;3. Patients used Liu Shen Capsule  within 1 month before screening;\r&lt;br&gt;4. Allergic constitution patients, who are allergic to the drugs used in this research;\r&lt;br&gt;5. Lactating or pregnant females, or urine pregnancy test was positive or did not agree to use contraception 3 months after the trial;\r&lt;br&gt;6. Immunodeficiency (such as a malignant tumor, solid organ or bone marrow transplant, aids, using immunosuppressive drugs within 3 months before screening);\r&lt;br&gt;7. Severe liver insufficiency (ALT or AST &gt; 5ULN, or ALT or AST &gt; 3ULN with BIL &gt; 3ULN); Severe renal insufficiency (Ccr &lt; 50ml/min, estimated by Scr);\r&lt;br&gt;8. Patients who do-not-resuscitate;\r&lt;br&gt;9. The researchers consider the patients are not suitable.","Exclusion criteria: (1) Combining basic diseases such as hypertension, diabetes, and coronary heart disease,which were judged unsuitable for inclusion in the trial by researchers.\r&lt;br&gt;(2) Malignant tumor or with a history of malignant tumor;\r&lt;br&gt;(3) pregnant or lactating women;\r&lt;br&gt;(4) suffer from severe mental illness;\r&lt;br&gt;(5) History of unstable angina pectoris or myocardial infarction within 6 months; coronary angiography suggested severe stenosis of the main branches of the coronary arteries;\r&lt;br&gt;(6) History of cerebral infarction or cerebral hemorrhage within 6 months;\r&lt;br&gt;(7) People who are intolerant or allergic to interferon preparations;\r&lt;br&gt;(8)Other patients  were judged unsuitable for inclusion in the trial by researchers.","Exclusion criteria: No","Exclusion criteria: Exclude patients with severe and critical 2019-nCoV pneumonia","Exclusion criteria: 1. Patients without any clinical and chest radiographic findings.\r&lt;br&gt;2. Patients not providing written informed consent.","Exclusion criteria: 1. Respiratory tract infection caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease, abnormal lung development and other basic diseases, with clear evidence of bacterial infection;\r&lt;br&gt;2. Subjects with the following conditions: daily treatment of asthma, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases that affect clinical trial evaluation.Chest CT confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;\r&lt;br&gt;3. Severe pneumonia requiring mechanical ventilation;\r&lt;br&gt;4. In the judgment of the investigator, the previous or current diseases may affect the patient's participation in the trial or the outcome of the study, including malignant diseases, autoimmune diseases, liver and kidney diseases, blood diseases, nervous system diseases, and endocrine diseases;The patient is suffering from serious diseases that affect the immune system, such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc.;\r&lt;br&gt;5. Pregnant or lactating women;\r&lt;br&gt;6. Patients who participated in other clinical trials within the last 3 months;\r&lt;br&gt;7. Allergic constitution, such as a history of allergy to two or more drugs or food, or a known allergy to the ingredients of the drug;\r&lt;br&gt;8. The investigator considers that there are any factors that are inappropriate for inclusion or affect the evaluation of the efficacy.","Exclusion criteria: 1.The doctor believes that the patient is not suitable to participate in this trial, including those who may not cooperate, do not comply with the requirements of the procedure, or participate in this trial may put the patient in an unsafe situation.\r&lt;br&gt;2.Pregnant or lactation periods women;\r&lt;br&gt;3.Immunoglobulin allergy;\r&lt;br&gt;4.Immunoglobulin A deficiency;\r&lt;br&gt;5.There are diseases that may increase the risk of thrombosis, such as cold globulinemia, severe refractory hypertriglyceridemia, clinically defined monoclonal gamma globulinemia, etc.\r&lt;br&gt;6.High titer of anti-novel coronavirus antibody RBDIgG (higher than 1) could be detected.\r&lt;br&gt;7.Received any experimental treatment for novel coronavirus infection within 30 days before screening;\r&lt;br&gt;8.The researchers judged that the patients had the following life-threatening conditions, including, but not limited to, Phammer F &lt; 100mmHg, near-death state or expected survival time less than 24 hours, severe septic shock or disseminated intravascular coagulation ((DIC)), etc\r&lt;br&gt;9.Severe congestive heart failure, or other relative contraindications for plasma transfusion determined by researchers.",null,"Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infections caused by basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and abnormal lung development;\r&lt;br&gt;2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory tracts diseases that affecting clinical trial evaluation . Chest CT confirmed that patients with basic pulmonary diseases such as severe pulmonary interstitial lesions and bronchiectasis;\r&lt;br&gt;3. Severe pneumonia requires mechanical ventilation;\r&lt;br&gt;4. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;5. Pregnant or lactating women;\r&lt;br&gt;6. Patients who participated in other clinical trials within the last 3 months;\r&lt;br&gt;7. An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients of the drug;\r&lt;br&gt;8. The investigator believes that there are any factors that are not suitable for enrollment or affect the evaluation of the efficacy.",null,"Exclusion criteria: If one of the following situations occurs, it is not recommended to take the traditional Chinese medicine preparation recommended by this plan:\r&lt;br&gt;(1) Has fever, cough, fatigue, stuffy nose, runny nose, dry throat, thirst, poor stool or diarrhea, little sputum or sputum, chest tightness, abdominal distension, constipation and other discomfort symptoms;\r&lt;br&gt;(2) Patients with severe primary diseases of the cardiovascular, cerebrovascular, lung, kidney and hematopoietic system;\r&lt;br&gt;(3) pregnant or lactating women;\r&lt;br&gt;(4) History of allergy to prescription drugs.","Exclusion criteria: 1. Complicated active tuberculosis, malignant arrhythmia, acute myocardial infarction, stroke, etc.\r&lt;br&gt;2. pregnant and lactating women;\r&lt;br&gt;3. Combining severe cognitive and mental disorders;\r&lt;br&gt;4. Clinical researchers who are participating in other interventions within 1 month before being selected;\r&lt;br&gt;5. Those who are known to be allergic to treatment drugs;\r&lt;br&gt;6. Those who are critically ill.\r&lt;br&gt;7. The researcher thinks that others are not suitable for enrollment.","Exclusion criteria: 1. The patients refused to cooperate in investigation;\r&lt;br&gt;2. The patients were out of contact;\r&lt;br&gt;3. The patients was unable to receive the investigation or could not understand the content of investigation;\r&lt;br&gt;4. The patients was under 18 years old and without the help from guardians;\r&lt;br&gt;5. The patients hided the truth on purpose.","Exclusion criteria: 1. Cases of severe vomiting that make it difficult to take the drug orally;\r&lt;br&gt;2. Allergic to Favipiravir or tocilizumab;\r&lt;br&gt;3. Pregnant and lactating women;\r&lt;br&gt;4. Subjects received specific antiviral drugs such as lopinavir / ritonavir, ribavirin, arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal antibodies within one week before admission;\r&lt;br&gt;5. Cases of respiratory failure and requiring mechanical ventilation;\r&lt;br&gt;6. Cases of shock;\r&lt;br&gt;7. Combined organ failure requires ICU monitoring and treatment;\r&lt;br&gt;8. Predicted clinically that there is no hope of survival, or cases of deep coma that do not respond to supportive treatment measures within three hours of admission;\r&lt;br&gt;9. Alanine aminotransferase / Aspartate aminotransferase&gt; 5 times of upper limit of normal;\r&lt;br&gt;10. Neutrophils &lt;0.5  10^9 / L, platelets less than 50 x 10^9/L;\r&lt;br&gt;11. Clear diagnosis of rheumatoid immunity, malignant tumors and other related diseases\r&lt;br&gt;12. Long-term oral anti-rejection drugs or immunomodulatory drugs;\r&lt;br&gt;13. Allergic reactions to tocilizumab or any excipients;\r&lt;br&gt;14. Patients with active hepatitis, tuberculosis, and definite bacterial and fungal infections;\r&lt;br&gt;15. Organ transplant patients;\r&lt;br&gt;16. Patients with mental disorders.",null,"Exclusion criteria: To rule out anyone not living in Jingzhou during the outbreak.","Exclusion criteria: no","Exclusion criteria: 1. CT imaging data with poor quality;\r&lt;br&gt;2. Incomplete etiological or clinical data.",null,null,null,"Exclusion criteria: 1. Gestational female patients;\r&lt;br&gt;2. Patients with other malignant diseases such as malignant tumours, chronic liver or kidney diseases, and reaching the end stage;\r&lt;br&gt;3. Patients with known psychiatric disorders;\r&lt;br&gt;4. Patients withdrawing from other clinical trial within 4 weeks.","Exclusion criteria: (1) before the application or hospital admission corticosteroids; \r&lt;br&gt;(2) malignancies;\r&lt;br&gt;(3) the presence of severely impaired immune function, immunodeficiency diseases; \r&lt;br&gt;(4) 7 days before admission row major surgery or severe trauma; \r&lt;br&gt;(5) with asthma; \r&lt;br&gt;(6) COVID-19 undiagnosed patients.","Exclusion criteria: Stage 1 and stage 2: subjects who cannot cooperate; Patients with fever, cough and expectoration in recent 2 weeks; Patients with underlying diseases.\r&lt;br&gt;Stage 3:\r&lt;br&gt;1. Patients who cannot cooperate with the throat swab examination;\r&lt;br&gt;2. Three patients who are not consistent with clinical manifestations at the same time and not suspected of novel coronavirus;\r&lt;br&gt;3. Patients considered inappropriate by the researcher;\r&lt;br&gt;4. Patients with severe or unstable vital signs with novel coronavirus.","Exclusion criteria: Not applicable","Exclusion criteria: Patients with negative detection of new coronavirus nucleic acid","Exclusion criteria: 1. Pregnancy;\r&lt;br&gt;2. Patients with advanced malignant tumor;\r&lt;br&gt;3. Suspected cases.","Exclusion criteria: mild COVID-19 infection without intrapulmonary lesions","Exclusion criteria: 1. people who are allergic to pifenidone capsules;\r&lt;br&gt;2. the researchers judged that the compliance of the subjects was not good;\r&lt;br&gt;3. those who cannot take drugs through gastrointestinal tract;\r&lt;br&gt;4. any significant clinical or laboratory abnormalities that may affect the safety assessment, such as: serum creatinine &gt; 2mg/dL or 176.8mmol sputum alt, AST &gt;=2.5 ULN or TBIL &gt;=1.5 ULN;\r&lt;br&gt;5. patients with severe liver disease;\r&lt;br&gt;6. pregnant and lactating patients;\r&lt;br&gt;7. patients with severe nephropathy or requiring dialysis treatment;\r&lt;br&gt;8. those who need to take fluvoxamine at the same time (a drug for the treatment of depression or obsessive-compulsive disorder).","Exclusion criteria: (1) patients allergic to the prescription of traditional Chinese medicine;\r&lt;br&gt;(2) infants and young children unable to take traditional Chinese medicine decoction;\r&lt;br&gt;(3) patients with unconsciousness or loss of consciousness;\r&lt;br&gt;(4) pregnant and lactating patients, or positive urine pregnancy test;\r&lt;br&gt;(5) according to the judgment of the doctor in the study, it is not suitable for the patients who take qingfei detoxification mixture.","Exclusion criteria: N/A","Exclusion criteria: Unsigned or unwilling to sign informed consent","Exclusion criteria: The family refused","Exclusion criteria: All mild patients need to be isolated and treated in mobile cabin hospitals. After admission, patients were given antiviral and symptomatic treatment according to their condition and symptoms, and patients with fever were given antibiotics at the same time. Besides, the patient was instructed to exercise and psychological intervention, all drugs were presented in Supplementary Table S1. During the hospital stay, decide whether you need a chest CT or chest radiograph based on the patient's condition. When the patient has no fever for three days and the respiratory symptoms are relieved, start nucleic acid tests and chest radiographs or CT scans of the lungs. The decision to be discharged based on whether the test results meet discharge criteria.","Exclusion criteria: (1) Patients who cannot guarantee medication compliance during treatment, and patients who have difficulty in oral administration;\r&lt;br&gt;(2) Patients more than 7 days after diagnosis;\r&lt;br&gt;(3) Patients with severe primary respiratory diseases, or patients with other pathogenic microbial pneumonia that needs to be identified with NCP; \r&lt;br&gt;(4) pregnant women, those with positive urine pregnancy tests;\r&lt;br&gt;(5) Combined with other systemic malignant diseases such as malignant tumors and mental diseases;\r&lt;br&gt;(6) Patients with other serious diseases such as uremia and severe heart failure;\r&lt;br&gt;(7) Those who are allergic to the test drugs or who are intolerant to taking the drugs;\r&lt;br&gt;(8) Patients that the investigator considers unsuitable to participate in the study.","Exclusion criteria: 1. Discharge cases that cannot be contacted by WeChat or telephone;\r&lt;br&gt;2. Discharge cases with language and other barriers, inability to communicate effectively, or failure to receive follow-up for various reasons.","Exclusion criteria: (1) CT result is negative;\r&lt;br&gt;(2) Incomplete clinical data.","Exclusion criteria: 1) Ordinary covid-19 pneumonia is not in conformity with the standard diagnostic criteria.            \r&lt;br&gt;2) Patients with allergy to traditional Chinese medicine and allergic constitution;           \r&lt;br&gt;3) Patients with malignant tumor, cirrhosis, chronic renal failure (uremic stage), blood system disease, HIV and other serious basic diseases;            \r&lt;br&gt;4) Long term use of hormone, immunosuppressant and other drugs to treat patients;            \r&lt;br&gt;5) Suffering from serious mental illness or being unable to cooperate with the trial;            \r&lt;br&gt;6) Pregnant and lactating women.","Exclusion criteria: CT negative results","Exclusion criteria: 1. Too young to understand the research or to cooperate with the research;\r&lt;br&gt;2. Non-neoplastic coronary pneumonia patients;\r&lt;br&gt;3. Impaired consciousness, affecting its understanding and expression;\r&lt;br&gt;4. Those who cannot cooperate with research or cannot express because of malignant basic disease or critical illness of this disease;\r&lt;br&gt;5. People with a history of mental illness;\r&lt;br&gt;6. Those who cannot follow up in the field and those who fall off naturally during observation.","Exclusion criteria: 1. Any situation that makes the programme cannot proceed safely;\r&lt;br&gt;2. Known allergy or hypersensitivity reaction to lopinavir / ritonavir;\r&lt;br&gt;3. Increase in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) is more than 5 times the upper limit of normal;\r&lt;br&gt;4. Use of medications that are contraindicated with lopinavir / ritonavir and that cannot be replaced or stopped during the study period, such as CYP3A inhibitors;\r&lt;br&gt;5. Pregnancy: positive pregnancy test for women of childbearing age;\r&lt;br&gt;6. Known HIV infection, because of concerns about the development of resistance to lopinavir/rionavir if used without combination with other anti-HIV drugs;\r&lt;br&gt;7. Patient likely to be transferred to a non-participating hospital within 72 hours;\r&lt;br&gt;8. Researchers consider unsuitable.","Exclusion criteria: &lt;br&gt;                General REMAP-CAP Exclusion Criteria:&lt;br&gt;                1. Healthcare-associated pneumonia:&lt;br&gt;                a. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days&lt;br&gt;                b. Resident of a nursing home or long-term care facility.&lt;br&gt;                2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.&lt;br&gt;                3. Previous participation in this REMAP within the last 90 days&lt;br&gt;&lt;br&gt;                AB Domain Specific Exclusion Criteria&lt;br&gt;&lt;br&gt;                Received more than 48 hours of IV antibiotic treatment for this index illness&lt;br&gt;                 More than 24 hours has elapsed since ICU admission&lt;br&gt;                 Known hypersensitivity to all of the study drugs in the site randomization schedule&lt;br&gt;                 A specific antibiotic choice is indicated, for example:&lt;br&gt;                o Suspected or proven concomitant infection such as meningitis&lt;br&gt;                o Suspected or proven infection with resistant bacteria where agents being trialed would not be expected to be active. This includes cystic fibrosis, bronchiectasis or other chronic suppurative lung disease where infection with Pseudomonas may be suspected but does not include patients with suspected methicillin-resistant staphylococcus aureus (MRSA) infection (see MRSA below).&lt;br&gt;                o Febrile neutropenia or significant immunosuppression (including organ or bone marrow transplantation, human immunodeficiency virus (HIV) Infection with CD4 cell count &lt;200 cells/L, systemic immunosuppressive, systemic corticosteroids comprising prednisolone, or equivalent, =20mg/day for &gt; 4 preceding weeks).&lt;br&gt;                o Suspected melioidosis (tropical sites during melioidosis season  see melioidosis below)&lt;br&gt;                o There is sufficient microbiological information to guide specific antibacterial therapy&lt;br&gt;                 The treating clinician believes that participation in the domain would not be in the best interests of the patient&lt;br&gt;&lt;br&gt;                AB Specific Intervention Exclusion Criteria&lt;br&gt;                1.\tKnown non-serious hypersensitivity to penicillins will result in exclusion from receiving interventions that include piperacillin and amoxicillin&lt;br&gt;                2.\tKnown non-serious hypersensitivity to cephalosporins will result in exclusion from receiving interventions that include ceftriaxone and ceftaroline&lt;br&gt;                3.\tKnown serious hypersensitivity to beta-lactams, including penicillins or cephalosporins, will result in exclusion from interventions that include piperacillin, amoxicillin, ceftriaxone, and ceftaroline.&lt;br&gt;                4.\tKnown hypersensitivity to moxifloxacin or levofloxacin will result in exclusion from moxifloxacin or levofloxacin intervention&lt;br&gt;                5.\tKnown serious hypersensitivity to the macrolide will result in exclusion from interventions that include piperacillin, amoxicillin, ceftriaxone, and ceftaroline.&lt;br&gt;                6.\tKnown or suspected pregnancy will result in exclusion from moxifloxacin or levofloxacin and ceftaroline interventions.&lt;br&gt;&lt;br&gt;                Corticisteroid domain Specific Exclusion Criteria&lt;br&gt;                 Known hypersensitivity to hydrocortisone&lt;br&gt;                 Intention to prescribe systemic corticosteroids for a reason that is unrelated to the current episode of CAP (or direct compli","Exclusion criteria: 1. Pregnant or lactating women;\r&lt;br&gt;2. Patients with malignant tumor, other serious systemic diseases and psychosis;\r&lt;br&gt;3. Patients who have recently or are participating in other clinical trials;\r&lt;br&gt;4. There was evidence of drug addiction within one year before the trial;\r&lt;br&gt;5. Inability or unwillingness to provide informed consent or comply with test requirements;\r&lt;br&gt;6. Combined with HIV, tuberculosis, influenza virus, adenovirus and other respiratory tract infection virus infection;\r&lt;br&gt;7. Other conditions judged by the researcher as unsuitable for participating in the clinical study.","Exclusion criteria: 1. Exclude medical staff who are not in clinical work due to sick leave;\r&lt;br&gt;2. Exclude medical staff who worked in the clinical setting for less than half a month recently.\r&lt;br&gt;3. Exclude if the medical staff and family members do not agree to complete the informed consent form or do not agree to provide relevant information.","Exclusion criteria: none","Exclusion criteria: (1) Aged &lt;18 years;\r&lt;br&gt;(2) pneumonia patients whose novel coronavirus nucleic acid test were negative ;","Exclusion criteria: No","Exclusion criteria: none","Exclusion criteria: 1) Aged &lt;14 years; \r&lt;br&gt;2) Pregnant; \r&lt;br&gt;3) COVID-19 as an complication on other major diseases;\r&lt;br&gt;4) Insufficient medical information.","Exclusion criteria: (1) Infection with influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial pneumonovirus, SARS coronavirus and other known viral pneumonia patients;\r&lt;br&gt;(2) Patients with mycoplasma pneumoniae, chlamydia pneumonia and bacterial pneumonia;\r&lt;br&gt;(3) Patients with non-infectious diseases, such as vasculitis, dermatomyositis and mechanical pneumonia;\r&lt;br&gt;(4) Clinical diagnosis of SARS- Cov-2 virus nucleic acid test negative in respiratory tract swab.","Exclusion criteria: Patients who meet any of the following criteria are not eligible for this study: \r&lt;br&gt;1. The clinical data are insufficient and the required clinical data cannot be collected;\r&lt;br&gt;2. The age of the patient is below 12 years old.","Exclusion criteria: None.","Exclusion criteria: (1) Those who do not meet the inclusion criteria of this study;\r&lt;br&gt;(2) Complicated with severe primary heart, liver, and kidney disease;\r&lt;br&gt;(3) Patients during perioperative period (within 7 days after operation);\r&lt;br&gt;(4) Immune dysfunction diseases (such as systemic lupus erythematosus) in the active phase;\r&lt;br&gt;(5) Those who lack clinical data or cannot obtain accurate data.","Exclusion criteria: There were no hospitalized patients, no CT patients.","Exclusion criteria: Patients who are younger than 18 years , who have severe liver or kidney dysfunction,or patients with other condition evaluated by doctors were excluded from this study.","Exclusion criteria: 1. Incomplete medical records, especially medication information,which may affect the evaluation\r&lt;br&gt;2. Those which the researchers deemed inappropriate","Exclusion criteria: Missing clinical data.","Exclusion criteria: Non-definitively diagnosed cases","Exclusion criteria: 1. Transfers to Huoshen shan or Leishen shan hospital;\r&lt;br&gt;2. Patient with only one laboratory test.","Exclusion criteria: none",null,"Exclusion criteria: 1. A pregnant or lactating woman; \r&lt;br&gt;2. With other major diseases, such as serious heart, lung, liver, kidney damage or psychiatric patients. Participants should not take part in the study under any of the above circumstances. The Research Hospital and the applicant unit will not bear the responsibility if they intentionally conceal the medical history and medication history.","Exclusion criteria: (1) Death is expected within 48 hours;\r&lt;br&gt;(2) Basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation , congenital heart disease, gastroesophageal reflux disease, congenital pulmonary airway malformation and more with  the exact evidence of bacterial infection;\r&lt;br&gt;(3)  Patients with the following conditions: Daily treatment of asthma, chronic respiratory disease, bacterial infections of the respiratory system such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media, etc that affect clinical trial evaluation. Chest CT confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases;\r&lt;br&gt;(4) As judged by the researcher, past or present diseases may affect the participation of patients in the research outcome, including malignant diseases, autoimmune diseases, severe malnutrition, liver and kidney diseases, hematological diseases, nervous system diseases, endocrine diseases and serious diseases affecting the immune system such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc.\r&lt;br&gt;(5) Mental state unable to cooperation: suffering from mental illness, unabling to control or  express clearly;\r&lt;br&gt;(6) Allergic constitution (such as allergic to two or more drugs or food) or history of alleric to this product and conventional treatment drugs;\r&lt;br&gt;(7) History of substance abuse or dependence;\r&lt;br&gt;(8) Pregnant or nursing women;\r&lt;br&gt;(9) Participants in clinical trials of other drugs in the past 3 months;\r&lt;br&gt;(10) Researchers believe that patients are not suitable for any other situation in this study.","Exclusion criteria: 1) Age &lt; 14 years;\r&lt;br&gt;2) Pregnant women;\r&lt;br&gt;3) Incomplete information of necessary clinical data.","Exclusion criteria: Pregnant woman","Exclusion criteria: 1. Renal replacement therapy has been performed;\r&lt;br&gt;2. Relative / absolute contraindications of blood purification;\r&lt;br&gt;3. Pregnant women, participating in other clinical trials, etc.","Exclusion criteria: 1. Patients who refused to participate in the project;\r&lt;br&gt;2. Patients developed symptoms caused by other pathogens rather than the 2019-nCoV, and there was no evidence show that patients were infected with 2019-nCoV.","Exclusion criteria: People with anxiety or depression prior to the COVID-19 outbreak.","Exclusion criteria: (1) Past medical history of pulmonary embolism;\r&lt;br&gt;(2) Patients infected with human immunodeficiency virus (HIV);\r&lt;br&gt;(3) Patients with malignant tumors: Patients with cervical carcinoma in situ, skin non metastatic squamous or basal cell carcinoma after complete treatment are excluded;\r&lt;br&gt;(4) pregnant and lactating women;\r&lt;br&gt;(5) Other situations that the clinician considers unsuitable.","Exclusion criteria: 1. not qualified for novel coronavirus pneumonia diagnostic criteria;\r&lt;br&gt;2. Pregnant or lactating women who are allergic to the drug;\r&lt;br&gt;3. Patients with severe primary diseases and psychosis, such as cardiovascular, liver, kidney and hematopoietic system;\r&lt;br&gt;4. There are factors influencing the observation of curative effect;\r&lt;br&gt;5. Those who do not meet the inclusion criteria, fail to use the medicine according to the regulations, fail to determine the curative effect or incomplete data, which affect the judgment of curative effect or safety.","Exclusion criteria: none","Exclusion criteria: severe patients and juveniles","Exclusion criteria: People with severe mental disorders","Exclusion criteria: Mild and critical new coronavirus pneumonia","Exclusion criteria: (1) Patients who were eventually diagnosed with other bacterial or viral infections;\r&lt;br&gt;(2) Patients whose data could not be obtained for special reasons.","Exclusion criteria: 1. Pregnant women;\r&lt;br&gt;2. Combined with severe basal diseases such as malignant tumor, cirrhosis and HIV;\r&lt;br&gt;3. Patients with lung tumor, interstitial fibrosis, alveolar proteinosis, and allergic alveolitis.","Exclusion criteria: Not eligible for novel coronavirus pneumonia","Exclusion criteria: 1. declared clinical death or discharged after admission within 24 hour;\r&lt;br&gt;2. important data missing.","Exclusion criteria: (1) Other viral pneumonia (influenza virus parainfluenza virus adenovirus respiratory syncytial virus rhinovirus human metapneumovirus SARS Coronavirus) was excluded;\r&lt;br&gt;(2) Serious mental illness or history of depression;\r&lt;br&gt;(3) Suspected allergy to any of the following substances or contraindications for the application of any of the following substances include the active ingredients of the test drug and emergency medicine and other ingredients contained in the test drug or emergency medicine;\r&lt;br&gt;(4) Pregnant and lactating women who plan to be pregnant or cannot use reliable contraceptive measures;\r&lt;br&gt;(5) Any concomitant disease that may interfere with the procedure or evaluation of the trial or other conditions that the investigator considers unsuitable for inclusion in the trial.","Exclusion criteria: 1. Cases with severe vomiting and difficulty in taking drugs orally or causing difficulty in taking drugs after oral administration;\r&lt;br&gt;2. Pregnant and lactating women;\r&lt;br&gt;3. The subjects participated other clinical trials within 30 days before admission;\r&lt;br&gt;4. Cases with no hope of survival, hospice care only, or deep coma and no response to supportive treatment within three hours after admission;\r&lt;br&gt;5. Cases of deep shock and respiratory failure;\r&lt;br&gt;6. Severe liver diseases (such as child Pugh score &gt;= C, AST more than 5 times of the upper limit of normal);\r&lt;br&gt;7. Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;= 30ml / min / 1.73m2) or undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis;\r&lt;br&gt;8. Patients with known allergic reactions or contraindications to chloroquine phosphate;\r&lt;br&gt;9. The doctor decided that it was not in the best interests of the subjects to participate in the study, or there was any situation in which the agreement could not be followed safely.","Exclusion criteria: 1. Family members refuse to extubate;","Exclusion criteria: 1. Medical worker who is diagnosed with COVID-19,suspected to COVID-19 or segregated due to COVID-19;\r&lt;br&gt;2. Occupation is not medical wokers such as manager,secretary or support staff who is work in medical institution;\r&lt;br&gt;3. Medical worker who is suffering from mental and psychological illness;\r&lt;br&gt;4. Medical worker who visit doctor due to discomfort dring the past 14 days;\r&lt;br&gt;5. Medical worker refuse to be investigated.","Exclusion criteria: 1. With other parts of the infection occurred within 7 days after discontinuation of antibiotic therapy, including urinary tract infections, bloodstream infections, biliary tract infections, central nervous system infections, and so on;\r&lt;br&gt;2. The drainage tube of important organs can not be extracted within 14 days;\r&lt;br&gt;3. Patients or relatives request to suspend the trial.","Exclusion criteria: 1. Aged&lt;14 years;\r&lt;br&gt;2. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).","Exclusion criteria: 1. younger than 18 years old;\r&lt;br&gt;2. do not fulfill the criteria of critical cases;\r&lt;br&gt;3. declared clinical death or discharged after ICU admission within 24 hour;\r&lt;br&gt;4. important data missing.","Exclusion criteria: 1. Hemodynamic instability: Cardiac pacemaker inserted in the last 2 days or life-threatening arrhythmias or circulatory disorders (use of large doses of vasoactive drugs);\r&lt;br&gt;2. Intracranial pressure &gt;30 mm Hg or cerebral perfusion pressure &lt;60 mmHg;\r&lt;br&gt;3. Massive hemoptysis requiring an immediate surgical or interventional radiology procedure;\r&lt;br&gt;4. Tracheal surgery or sternotomy during the previous 15 days;\r&lt;br&gt;5. Serious facial trauma or facial surgery;\r&lt;br&gt;6. Deep venous thrombosis treated for less than 2 days;\r&lt;br&gt;7. Anterior chest wall placed closed thoracic drainage device;\r&lt;br&gt;8. Open wound of abdominal cavity;\r&lt;br&gt;9. Unstable spine;\r&lt;br&gt;10. femur or pelvic fractures;\r&lt;br&gt;11. Pregnant women;\r&lt;br&gt;12. Use of extracorporeal membrane oxygenation (ECMO) before inclusion;\r&lt;br&gt;13. Chronic respiratory failure requiring oxygen therapy or non-invasive ventilation(NIV);\r&lt;br&gt;14. Previous inclusion in the present study;\r&lt;br&gt;15. Opposition from next of kin.","Exclusion criteria: 1. If the patient received any antifungal treatment (excluding fluconazole or up to 7 days of selective digestion purification therapy) within 14 days prior to randomization, or if there was evidence of IFI; \r&lt;br&gt;2. aged &lt; 14 years;\r&lt;br&gt;3. pregnant or lactating women;\r&lt;br&gt;4. allergy or hypersensitivity to any research drug or excipient;\r&lt;br&gt;5. participate in another clinical study or treat with an experimental drug 28 days prior to registration or use an accompanying drug therapy that the investigator considers likely to interfere with the study target.","Exclusion criteria: Severe patients","Exclusion criteria: 1. Aged&lt;14 years; \r&lt;br&gt;2. Pneumothorax; \r&lt;br&gt;3. Severe asthma or COPD.","Exclusion criteria: 1. Patients who are not willing to fill in the scale;\r&lt;br&gt;2. Patients without the ability to fill in the scale  autonomously.","Exclusion criteria: no","Exclusion criteria: 1. The patient has a history of alcohol or narcotic drug abuse, or a history of mental illness (such as schizophrenia, obsessive-compulsive disorder, depression), antagonistic personality, bad motivation, doubt, or other emotional or intellectual problems that may affect participation in this study The status of informed effectiveness;\r&lt;br&gt;2. Patients cannot cooperate with the relevant examinations of this project and do not agree with the informed consent form\r&lt;br&gt;3. The required information is incomplete;\r&lt;br&gt;4. pregnancy;\r&lt;br&gt;5. There are contraindications for sputum induction. Those who induce sputum by atomization may cause diseases, including:\r&lt;br&gt;(1) Severe chest and lung diseases: such as acute asthma, acute exacerbation of COPD, pneumothorax, massive pleural effusion, acute or chronic respiratory failure;\r&lt;br&gt;(2) a large amount of pericardial effusion;\r&lt;br&gt;(3) cardiac function level III or above.","Exclusion criteria: 1. Viral pneumonia with other viruses besides 2019-nCoV;\r&lt;br&gt;2. Patients are not suitable for immunoglobulin therapy;\r&lt;br&gt;3. Participation in other studies;\r&lt;br&gt;4. Other circumstances in which the investigator determined that the patient is not suitable for the clinical trial.","Exclusion criteria: The patients were diagnosed with Coronavirus Disease (COVID-19) before surgery.","Exclusion criteria: Patients in non plateau areas","Exclusion criteria: 1. Suspected patients unable to collect nasopharyngeal swabs;\r&lt;br&gt;2. Pneumonia caused by other pathogens.","Exclusion criteria: (1) Patients who were eventually diagnosed with other bacterial or viral infections; \r&lt;br&gt;(2) Patients whose data could not be obtained for special reasons.","Exclusion criteria: 1. Critical new pneumonia infection that meets one of the following conditions: respiratory failure occurs and requires mechanical ventilation; shock; combined organ failure requires ICU monitoring and treatment\r&lt;br&gt;2. Known allergies to Ixekizumab or antiviral drugs;\r&lt;br&gt;3. ALT / AST&gt; 5 times ULN, neutrophils &lt;0.5x10^9/L, Platelets less than 50x10^9/L;\r&lt;br&gt;4. Patients with impaired renal function: serum creatinine &gt;=2 mg/dl (176 umol/l);\r&lt;br&gt;5. Combined with severe underlying diseases, the expected life cycle is less than 3 months;\r&lt;br&gt;6. Active hepatitis, patients with definite severe bacterial and fungal infections, tuberculosis infection, and HIV infection;\r&lt;br&gt;7. Clear diagnosis of malignant tumors such as lymphoproliferative diseases;\r&lt;br&gt;8. Known active Crohn's disease;\r&lt;br&gt;9. Pregnant or lactating women;\r&lt;br&gt;10. Participated in other interventional clinical trials in the past 3 months;\r&lt;br&gt;11. Other conditions that the researcher considers unsuitable.","Exclusion criteria: (1) other psychiatric disorders;\r&lt;br&gt;(2) complicating with sever medical disorder on nervous, cardiovascular, respiratory system;\r&lt;br&gt;(3) taking antidepressants, psychoactive drugs, steroids, drugs that affect heart rate and blood pressure;\r&lt;br&gt;(4) be in the Lactation or pregnancy.","Exclusion criteria: Confirmed cases who had the organ transplantation were excluded following the latest guideline of diagnostic and treatment Covid-19 issued by China Health Committee.","Exclusion criteria: 1. Aged &gt; 75 years old and &lt; 18 years old;\r&lt;br&gt;2. Patients who are contraindicated or allergic to this study drug (lung-clearing and detoxification decoction and ulinastatin for injection);\r&lt;br&gt;3. Patients with previous tumor, severe liver disease, pulmonary fibrosis, tuberculosis, autoimmune diseases, and treatment with glucocorticoids and immunosuppressive agents;\r&lt;br&gt;4. The diagnostic criteria for severe patients with novel coronavirus pneumonia were [novel coronavirus infection pneumonia treatment scheme 5.0].","Exclusion criteria: (1) Female patients during pregnancy or lactation;\r&lt;br&gt;(2) Patients with allergy to Exocarpium Citri Grandis preparation, patients with intolerance to the recommended dose of Exocarpium Citri Grandis were previously applied;\r&lt;br&gt;(3) Patients who are taking part in clinical trials of other drugs;\r&lt;br&gt;(4) Patients are taking other foods or drugs with antitussive and antiasthmatic effects.\r&lt;br&gt;(5) There are other serious diseases that may threaten life, such as cancer.","Exclusion criteria: 1. Previous medication information was not recorded;\r&lt;br&gt;2. The patients' medical records  were incomplete after admission.","Exclusion criteria: 1. Patients with mental abnormality or unwilling to participate in this study;\r&lt;br&gt;2. Patients participating in other clinical trials.","Exclusion criteria: 1. Exclusion of COVID-19 infection in children;\r&lt;br&gt;2. Dead children;\r&lt;br&gt;3. Sign to reject this project.","Exclusion criteria: 1. There is clear evidence of bacterial infection in respiratory tract infection caused by basic diseases such as primary immunodeficiency disease, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease and pulmonary dysplasia;\r&lt;br&gt;2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory system bacterial infection such as suppurative tonsillitis, acute bronchitis, sinusitis, otitis media or other respiratory diseases affecting the evaluation of clinical trials. Or with Chest CT confirmed the presence of serious interstitial lung disease, bronchiectasis and other basic lung diseases;\r&lt;br&gt;3. critically ill patients based on the New Protocol for Diagnosis and Treatment of NCP;\r&lt;br&gt;4. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 ULN);\r&lt;br&gt;5. Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;=30ml/min/1.73m2) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis;\r&lt;br&gt;6. Pregnant or breast-feeding women;\r&lt;br&gt;7. Patients may be transferred to non-designated hospitals within 72 hours;\r&lt;br&gt;8. Patients who have participated in other clinical trials in the past 7 days;\r&lt;br&gt;9. Allergic constitution, such as those who are allergic to two or over twodrugs, with history of food allergies, or known to be allergic to the ingredients of this drug;\r&lt;br&gt;10. In the opinion of the investigator, subjects who are not suitable for enrollment or with any factors that affect the outcome of the trial.","Exclusion criteria: 1) &lt; 18 years old or = 80 years old; \r&lt;br&gt;2) pregnant and lactating women; \r&lt;br&gt;3) patients with severe primary diseases such as cardiovascular, liver, kidney and hematopoietic system.","Exclusion criteria: (1) pregnant or breast-feeding women;\r&lt;br&gt;(2) ALT/AST &gt; 5 times ULN, neutrophils &lt; 0.5x10^9/L, platelets less than 50x10^9/L;\r&lt;br&gt;(3) definite diagnosis of rheumatoid immunity, malignant tumor and other related diseases;\r&lt;br&gt;(4) patients with long-term oral immunoregulatory drugs or who had used large doses of glucocorticoids within 14 days;\r&lt;br&gt;(5) allergic reactions to adamumab or tozumab;\r&lt;br&gt;(6) active hepatitis, tuberculosis, associated with specific severe bacterial and fungal infections, organ transplantation or mental disorders;\r&lt;br&gt;(7) received Il-6 monoclonal antibody or TNFa monoclonal antibody within 14 days.","Exclusion criteria: 1. Participation in the study is not in accordance with the rights and interests of the patient based on PIs judgement, or any other circumstances that investigators consider inappropriate for participation;\r&lt;br&gt;2. Low body weight patients (females&lt;45kg, males&lt;57kg);\r&lt;br&gt;3. With bleeding or bleeding associated with severe coagulation disorders (except for disseminated intravascular coagulation unrelated to heparin therapy), with a history of severe type II heparin-induced thrombocytopenia, whether or not caused by unfractionated heparin or low-molecular-weight heparin (significantly reduced by platelet count previously), active peptic ulcer or organ damage with bleeding tendency, clinically significant active bleeding , cerebral hemorrhage;\r&lt;br&gt;4. Have any situation that treatment with low molecular heparin is required;\r&lt;br&gt;5. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening;\r&lt;br&gt;6. Males or females who have a birth plan or are unwilling to take reliable contraceptive measures for contraception within 90 days from signing the informed consent to the last dose;\r&lt;br&gt;7. With severe liver disease: patient with basic diseases of liver cirrhosis , or alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increased more than 5 times of the normal upper limit;\r&lt;br&gt;8. Patients known to have severe renal impairment [creatinine clearance (CcCl) &lt; 30 ml/min], or to receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis;\r&lt;br&gt;9. At rest without oxygen inhalation, SPO2 &lt;=93%, or PaO2/ FiO2 &lt;=300 mmHg;\r&lt;br&gt;10. Patients allergic to enoxaparin, heparin or its derivatives, including other low-molecular-weight heparins.","Exclusion criteria: 1. Participation in the study is not in accordance with the rights and interests of the patient based on PIs judgement, or any other circumstances that investigators consider inappropriate for participation;\r&lt;br&gt;2. With bleeding or bleeding associated with severe coagulation disorders (except for disseminated intravascular coagulation unrelated to heparin therapy), with a history of severe type II heparin-induced thrombocytopenia, whether or not caused by unfractionated heparin or low-molecular-weight heparin (significantly reduced by platelet count previously), active peptic ulcer or organ damage with bleeding tendency, clinically significant active bleeding , cerebral hemorrhage;\r&lt;br&gt;3. Have any situation that treatment with low molecular heparin is required;\r&lt;br&gt;4. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening;\r&lt;br&gt;5. Males or females who have a birth plan or are unwilling to take reliable contraceptive measures for contraception within 90 days from signing the informed consent to the last dose;\r&lt;br&gt;6. With severe liver disease: patient with basic diseases of liver cirrhosis , or alanine aminotransferase (ALT) / aspartate aminotransferase (AST) increased more than 5 times of the normal upper limit;\r&lt;br&gt;7. Patients known to have severe renal impairment [creatinine clearance (CcCl) &lt; 30 ml / min], or to receive continuous renal replacement therapy, hemodialysis or peritoneal dialysis;\r&lt;br&gt;8. At rest without oxygen inhalation, SPO2 &lt;=93%, or PaO2/ FiO2 &lt;=300 mmHg; \r&lt;br&gt;9. Patients allergic to enoxaparin, heparin or its derivatives, including other low-molecular-weight heparins.","Exclusion criteria: 1. With contraindications of Ulinastatin Injection;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Patients taking other urinary trypsin inhibitors;\r&lt;br&gt;4. Not suitable to participate in the clinical trial by investigator's judgement.","Exclusion criteria: 1. Age&lt;14 years;\r&lt;br&gt;2. Accompanied by other serious organ dysfunction (including severe liver and kidney dysfunction, upper gastrointestinal bleeding, DIC, etc.).","Exclusion criteria: People with a history of mental illness or a genetic history of familial psychosis, people with previous mental disorders, sequelae of traumatic brain injury, patients with drug and alcohol abuse, or people with other mental illnesses.","Exclusion criteria: 1. Those who are allergic to Xuebijing injection and its components;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. Serious basic diseases affecting survival, including: malignant tumor, hematopathy, HIV, etc;\r&lt;br&gt;4. Expected death within 48 hours;\r&lt;br&gt;5. Patients who are participating in other clinical trials;\r&lt;br&gt;6. The researchers think other reasons are not suitable for clinical trials","Exclusion criteria: 1. Patients who are unable to establish proper vascular access;\r&lt;br&gt;2. Patients with hemodynamic instability;\r&lt;br&gt;3. With severe coagulation dysfunction;\r&lt;br&gt;4. With active bleeding, especially intracranial hemorrhage;\r&lt;br&gt;5. Pregnant patients;\r&lt;br&gt;6. Patients not suitable for this study judged by researchers.","Exclusion criteria: recently diagnosed as a confirmed COVID-19 case","Exclusion criteria: Persons who do not meet the inclusion criteria","Exclusion criteria: Doctors and researchers consider that the patient inappropriate to enroll in the study.","Exclusion criteria: 1. Pneumonia caused by other etiology; \r&lt;br&gt;2. Patients with incomplete data.","Exclusion criteria: Patients with difficult airways;Patients who need to remain tracheal intubation to return to the ward after surgery;After signing the informed consent, those who were conscious and awake during the perioperative period refused to continue to participate in the test.","Exclusion criteria: Patients with severe hemodynamic instability, unfavorable to change body position; Patients with severe deformity of the thorax or massive subcutaneous emphysema that cannot be examined by lung ultrasound; Patients who did not check all 10 points of the BLUE-plus regimen.","Exclusion criteria: The investigator considers that the subject has other conditions that make him/her unsuitable to participate in the clinical trial or other special circumstances.","Exclusion criteria: 1. The subject has a history of substance abuse (defined as the use of any illicit drug) or alcohol abuse within the first year of screening;\r&lt;br&gt;2. The subject suffers from active psychosis, which the researcher believes may interfere with their compliance with the study process;\r&lt;br&gt;3. Subjects are unable to participate in all study visits or follow study procedures;\r&lt;br&gt;4. The subject is a staff member of the research center or a member of his or her immediate family or relatives (such as spouse, parents, children, siblings) performing the study or the subject is compelled to agree to participate in the study;\r&lt;br&gt;5. Female subjects during lactation, or female subjects with positive results of serum pregnancy test during screening, or female subjects with positive results of urine pregnancy test before drug administration;\r&lt;br&gt;6. Have participated in other clinical research projects;\r&lt;br&gt;7. Subjects have hypersensitivity reactions or allergic reactions to the stem cell preparation or its components;\r&lt;br&gt;8. The subject suffers from any unstable or uncontrolled cardiovascular, lung, liver, kidney, gastrointestinal, urogenital, hematology, coagulation, immunology, endocrine/metabolic or other medical conditions that the investigator considers to interfere with the outcome of the study or endanger the subject's safety;\r&lt;br&gt;9. The subject has a history of malignant tumor;\r&lt;br&gt;10. Subjects have a history of severe neurological disorders, including stroke, multiple sclerosis, brain tumors, or neurodegenerative diseases.","Exclusion criteria: Employees who go out for further study or leave, people with previous mental disorders, and sufferers who recently undergo a major injury to work or family life, were excluded in this survey.","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;\r&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment.","Exclusion criteria: 1. Allergic to vitamin C;\r&lt;br&gt;2. Cardiogenic dyspnea;\r&lt;br&gt;3. Life expectancy&lt;24h;\r&lt;br&gt;4. Pregnant and/or lactating female;\r&lt;br&gt;5. There is a state of tracheotomy or home oxygen therapy in the past;\r&lt;br&gt;6. Previously complicated with interstitial lung disease, malignant tumors,diffuse alveolar hemorrhage, diabetic ketoacidosis, or an active kidney stone;\r&lt;br&gt;7. Participating in other clinical trials;\r&lt;br&gt;8. Researchers believe patients are not suitable for clinical trials for other reasons.","Exclusion criteria: (1) Those who were not treated with drugs during hospitalization;\r&lt;br&gt;(2) Patients with active tuberculosis;\r&lt;br&gt;(3) Organ transplant patients;\r&lt;br&gt;(4) Patients with mental disorders.","Exclusion criteria: (1) asthma requiring daily treatment, any other chronic respiratory disease\r&lt;br&gt;(2) patients with severe mental illness and severe neurosis.?\r&lt;br&gt;(3) the risk stratification of exercise rehabilitation was assessed as high-risk patients or those who were restricted from activities for other reasons;\r&lt;br&gt;(4) patients with severe renal insufficiency and liver insufficiency;\r&lt;br&gt;(5) patients with severe copd, cor pulmonale or respiratory failure;\r&lt;br&gt;(6) severe hematopoietic system, tumor and other serious primary diseases;\r&lt;br&gt;(7) those who practice traditional Chinese medicine skills (ba duan jin, tai chi, wu qin xi or other fitness qigong) within 14 days.\r&lt;br&gt;There are speech, cognitive impairment and other effects of communicators.\r&lt;br&gt;(8) the sixth trial version of the reference diagnosis and treatment scheme is for patients with severe or critical criteria;","Exclusion criteria: no","Exclusion criteria: 1. With other serious primary pulmonary diseases (such as active pulmonary tuberculosis, pneumothorax, pleural effusion, pulmonary embolism and neuromuscular diseases affecting respiratory and motor function);\r&lt;br&gt;2. Severe primary diseases, belong to heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract, may affect the patients' participation in the study or the outcome of the study;\r&lt;br&gt;3. A family history of mental illness or a history of mental illness;\r&lt;br&gt;4. Allergic constitution or known drug allergy;\r&lt;br&gt;5. Pregnant or lactating women and those with recent pregnancy plans;\r&lt;br&gt;6. Bedridden for various reasons.","Exclusion criteria: 1. Patients who are participating in clinical trials of other drugs;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. ALT / AST &gt; 2-fold ULN;\r&lt;br&gt;4. Expected survival time &lt; 1 week;\r&lt;br&gt;5. With serious liver disease;\r&lt;br&gt;6. Patients taking orally anti-tumor drugs or immunomodulatory drugs for a long time;\r&lt;br&gt;7. Patients who are participating in other clinical trials;\r&lt;br&gt;8. The researchers think that other reasons are not suitable for clinical trials.","Exclusion criteria: (1) Known or suspected to be allergic to the components of GD31;\r&lt;br&gt;(2) Mild or critical patients in clinical classification;\r&lt;br&gt;(3) Severe liver diseases (such as child Pugh score &gt;=C, TBIL &gt;=2 ULN, AST &gt;=5 ULN), or HBsAg positive\r&lt;br&gt;(4) Patients with severe renal insufficiency (estimated glomerular filtration rate &lt;=30ml/min/1.73m2) or undergoing continuous renal replacement therapy, hemodialysis and peritoneal dialysis;\r&lt;br&gt;(5) Pregnant or lactating women or women with birth plan during or within 6 months after the trial;\r&lt;br&gt;(6) According to the judgment of the researcher, there are other situation of the patient that are not suitable for attending the trial;\r&lt;br&gt;(7) Patients who had received chloroquine treatment within 4 weeks.","Exclusion criteria: 1) Patients with mild, severe or critical novel coronavirus disease;\r&lt;br&gt;2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;\r&lt;br&gt;3) Those who are allergic to the research drug and its main ingredients;\r&lt;br&gt;4) pregnant or lactating women;\r&lt;br&gt;5) Those who have difficulty taking medicine orally.","Exclusion criteria: 1. Patients with presence, coagulopathy or hypotension;\r&lt;br&gt;2. Pregnant and lactating women;\r&lt;br&gt;3. People with allergies or allergies to Xuebijing Injection and its components;\r&lt;br&gt;4. Severe basic diseases that affect survival, including: uncontrolled malignant tumors that have metastasized and cannot be removed, blood diseases, cachexia, active bleeding, severe malnutrition, HIV, etc.;\r&lt;br&gt;5. Pulmonary tumors caused by obstructive pneumonia, severe interstitial fibrosis, alveolar proteinosis, allergic alveolitis;\r&lt;br&gt;6. Continued use of immunosuppressive agents or organ transplants in the last 6 months;\r&lt;br&gt;7. Extracorporeal life support (ECMO, ECCO2R, RRT);\r&lt;br&gt;8. Expected deaths within 48 hours;\r&lt;br&gt;9. Clinicians judge inappropriate.","Exclusion criteria: 1. Investigator believes that subjects should not be included (patients are severely uncooperative);\r&lt;br&gt;2. Not suitable for inclusion in subjects (clinically considered fully healthy patients or light);\r&lt;br&gt;3. Patients who cannot auscultate clearly with non-invasive or invasive ventilation (patients who can still auscultate are not excluded);\r&lt;br&gt;4. Pregnant women and children.","Exclusion criteria: 1. Patients with severe primary diseases such as heart, kidney, lung, endocrine, blood, metabolism, and gastrointestinal tract, etc., may affect participation in the trial or may affect the outcome of the study by the judgment of the researcher;\r&lt;br&gt;2. Patients who have a family history of mental illness or have had a mental illness; \r&lt;br&gt;3. Patients who are allergic constitution or allergy to multiple drug; \r&lt;br&gt;4. Pregnant or lactating women.","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment.","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment","Exclusion criteria: 1. Serious/critically ill patients with novel coronavirus(COVID-19) pneumonia or patients that clinician consider that he/she shall be treated in ICU;\r&lt;br&gt;2. With pneumonia infected by other virus;\r&lt;br&gt;3. With one of following abnormal laboratory parameters( judged per local Laboratory reference range):\r&lt;br&gt;-ALT or AST&gt;5 ULN or;\r&lt;br&gt;-ALT or AST &gt;3 ULN, and total bilirubin&gt;2 ULN;\r&lt;br&gt;4. Previous or current disease, judged by investigator, may affect his/her participation in this study or outcome of the study, including but not limited to malignant tumor,autoimmune disease,liver and kidney disease, cardiovascular disease(including but not limited to \r&lt;br&gt;5. definate history of cadiac diease and arrhythmia and QT prolongation),neurological disease psychiatric disease,active bleeding,serious malnutrition and endocrine disease; currently complicated with serious respiratory disease or that seriously affect immune system, such as HIV,blood system disease, or splenectomy, organ transplantion etc.;\r&lt;br&gt;6. Need to receive digitalis for original disease;\r&lt;br&gt;7. May be transfered to non-study hospital;\r&lt;br&gt;8. Allergy to study drug phosphoric chloroquine;\r&lt;br&gt;9. With history of grug abuse and drug dependency;\r&lt;br&gt;10. Pregant or lactating women;or planing to be pregnant within 3 months after study;\r&lt;br&gt;11. One that the investigator consider not applicable for this study.","Exclusion criteria: If subject meet one of the following exclusion critera, he/she cannot be enrolled in this study:\r&lt;br&gt;1. Be dysphagia and cannot receive drud by oral administration;\r&lt;br&gt;2. Complicated with pneumonia infected by other virus;\r&lt;br&gt;3. Allergy to or intolerance to study drug phosphoric chloroquine;\r&lt;br&gt;4. With significantly abnormal liver function( judged per local Laboratory reference range):\r&lt;br&gt;-ALT/AST&gt;5 times ULN or;\r&lt;br&gt;-ALT/AST&gt;3 times ULN, and total bilirubin&gt;2 times ULN or;\r&lt;br&gt;-need dDialysis treatment, or GFR=30 mL/min/1.73 m2.\r&lt;br&gt;5. With definate history of cadiac diease and arrhythmia and QT prolong;\r&lt;br&gt;6. Need to receive digitalis for original diease;\r&lt;br&gt;7. With history of grug abuse and drug dependency;\r&lt;br&gt;8. Pregant or lactating women;\r&lt;br&gt;9. One that the investigator consider not applicable for this study.","Exclusion criteria: 1. Serious/critically ill patients with novel coronavirus(COVID-19) pneumonia or patients that clinician consider that he/she shall be treated in ICU;\r&lt;br&gt;2. With pneumonia infected by other virus;\r&lt;br&gt;3. With one of following abnormal laboratory parameters( judged per local Laboratory reference range):\r&lt;br&gt;-ALT or AST&gt;5 ULN or;\r&lt;br&gt;-ALT or AST &gt;3 ULN, and total bilirubin&gt;2 ULN;\r&lt;br&gt;4. Previous or current disease, judged by investigator, may affect his/her participation in this study or outcome of the study, including but not limited to malignant tumor, autoimmune disease, liver and kidney disease, cardiovascular disease (including but not limited to definate history of cadiac diease and arrhythmia and QT prolongation), neurological disease psychiatric disease, active bleeding,serious malnutrition and endocrine disease; currently complicated with serious respiratory disease or that seriously affect immune system, such as HIV, blood system disease, or splenectomy, organ transplantion etc.;\r&lt;br&gt;5. Need to receive digitalis for original disease;\r&lt;br&gt;6. May be transfered to non-study hospital;\r&lt;br&gt;7.Those who had taken phosphoric chloroquine or hydroxychloroquine within one week before participating in the study\r&lt;br&gt;8. Allergy to study drug phosphoric chloroquine or hydroxychloroquine;\r&lt;br&gt;9. With history of grug abuse and drug dependency;\r&lt;br&gt;10. Pregant or lactating women;or planing to be pregnant within 3 months after study;\r&lt;br&gt;11. One that the investigator consider not applicable for this study.","Exclusion criteria: 1. Patients without any clinical or chest imaging manifestations;\r&lt;br&gt;2. Those with severe nasal diseases affecting the sampling;\r&lt;br&gt;3. Inability to understand or follow research protocols for severe mental illness;\r&lt;br&gt;4. Invasive ventilation with endotracheal intubation;\r&lt;br&gt;5. Patients with frequent vomiting;","Exclusion criteria: 1. The doctor believes that the patient is not suitable to participate in this trial, including those who may not cooperate, do not comply with the requirements of the procedure, or participate in this trial may put the patient in an unsafe situation.\r&lt;br&gt;2. Pregnant or lactation periods women;\r&lt;br&gt;3. Immunoglobulin allergy;\r&lt;br&gt;4. Immunoglobulin A deficiency;\r&lt;br&gt;5. The clinical symptoms are mild or reach the standard of severe or critical.\r&lt;br&gt;Mild symptoms:\r&lt;br&gt;Clinical symptoms are mild and no pneumonia on imaging.\r&lt;br&gt;Severe patients meet any of the following:\r&lt;br&gt;1) respiratory distress, RR &gt;=30 beats / min;\r&lt;br&gt;2) in resting state, oxygen saturation &lt;=93%;\r&lt;br&gt;3) partial pressure of oxygen in arterial blood (PaO2) / oxygen concentration (FiO2) \r&lt;br&gt;&lt;=300mmHg (1mmHg=0.133kPa)\r&lt;br&gt;Critically ill patients meet any of the following:\r&lt;br&gt;1) respiratory failure and need mechanical ventilation;\r&lt;br&gt;2) shock;\r&lt;br&gt;3) patients with other organ failure need ICU monitoring treatment.\r&lt;br&gt;6. There are diseases that may increase the risk of thrombosis, such as cold globulinemia, severe refractory hypertriglyceridemia, clinically defined monoclonal gamma globulinemia, etc.\r&lt;br&gt;7. High titer of anti-novel coronavirus antibody RBDIgG (higher than 1) could be detected.\r&lt;br&gt;8. Received any experimental treatment for novel coronavirus infection within 30 days before screening;\r&lt;br&gt;9. The researchers judged that the patients had the following life-threatening conditions, including, but not limited to, Phammer F &lt; 100mmHg, near-death state or expected survival time less than 24 hours, severe septic shock or disseminated intravascular coagulation ((DIC)), etc.,\r&lt;br&gt;10. Severe congestive heart failure, or other relative contraindications for plasma transfusion determined by researchers.","Exclusion criteria: 1. Those who have not completed effective psychological consultation and assessment;\r&lt;br&gt;2. Researchers who are unwilling to participate in this survey;\r&lt;br&gt;3. The investigator is unwilling to continue during the evaluation process.","Exclusion criteria: anyone who is  reluctant or unable to answer the questionnaire","Exclusion criteria: no exclusion criteria","Exclusion criteria: 1. Cases of patients with tumor or mental disorder or immunosuppressive disease; \r&lt;br&gt;2. A case of a pregnant or lactating woman; \r&lt;br&gt;3. Incomplete case.","Exclusion criteria: 1. Cases of patients with tumor or mental disorder or immunosuppressive disease;\r&lt;br&gt;2. A case of a pregnant or lactating woman;\r&lt;br&gt;3. Incomplete case.","Exclusion criteria: Participants in other clinical trials within 4 weeks before the start of this study","Exclusion criteria: 1. Sever cases with shock, acute respiratory distress syndrome;\r&lt;br&gt;2. Multiple organ failure;\r&lt;br&gt;3. Pregnant or lactating women;\r&lt;br&gt;4. Cases with malignant disease, autoimmune disease or sever diseases of immune immune system, such as: HIV infection;\r&lt;br&gt;5. Major organ transplantation;\r&lt;br&gt;6. Other conditions that are not suitable for enrollment.","Exclusion criteria: 2020.01.01 Patients who have tested negative for new coronavirus in our hospital",null,"Exclusion criteria: 1. People with high-risk exposure who are unwilling to participate in this survey;\r&lt;br&gt;2. People with high-risk exposure who want to withdraw from the research during the study.",null,"Exclusion criteria: (1) patients with severe heart, liver, kidney and other complications or other serious primary disease or mental illness;\r&lt;br&gt;(2) patients whose survival time is not expected to exceed 48 hours from screening;\r&lt;br&gt;(3) endotracheal intubation and mechanical ventilation had been performed during screening;\r&lt;br&gt;(4) any influence on inclusion judged by the researcher.","Exclusion criteria: 1. Patients with allergic history to 4-aminoquinoline (such as chloroquine, hydroxychloroquine, piperaquine, aminophenquine, etc.) and similar drugs (such as primaquine, etc.) were identified;\r&lt;br&gt;2. Patients with blood system diseases;\r&lt;br&gt;3. Patients with hearing impairment;\r&lt;br&gt;4. Patients with known severe liver disease, basic disease of liver cirrhosis or ALT / AST increased more than 2 times of the upper limit of normal;\r&lt;br&gt;5. Patients who drink alcohol or are taking hepatotoxic drugs;\r&lt;br&gt;6. Patients with known impairment of renal function (estimated glomerular filtration rate [EGFR] &lt; 30ml / min / 1.73m2, estimated by MDRD method);\r&lt;br&gt;7. Patients with known 6-phosphate dehydrogenase deficiency;\r&lt;br&gt;8. In the past 6 months, there were history of acute myocardial infarction, unstable angina, serious arrhythmia (multiple frequent ventricular premature, ventricular tachycardia, ventricular fibrillation), NYHA class III-IV;\r&lt;br&gt;9.QTc&gt;=450ms;\r&lt;br&gt;10. Patients with uncorrected hypokalemia and hypomagnesemia;\r&lt;br&gt;11. Patients with known retinopathy, fundus disease and macular disease;\r&lt;br&gt;12. Patients known to have mental illness;\r&lt;br&gt;13. Patients with pancreatitis;\r&lt;br&gt;14. Female patients in pregnancy, childbearing age with positive pregnancy test or lactation;\r&lt;br&gt;15. Taking drugs that affect drug absorption, metabolism and excretion, can prolong QTc interval, can affect drug efficacy or increase adverse reactions;\r&lt;br&gt;16. Patients with a history of malignancy in the last 5 years;\r&lt;br&gt;17. Patients with skin diseases (including skin rash, dermatitis, psoriasis);\r&lt;br&gt;18. The novel coronavirus pneumonia diagnosis and treatment scheme (latest edition) has been adopted in the standard treatment of 2 and 2 or more antiviral drugs;\r&lt;br&gt;19. The researchers judged that it was not suitable to participate in this clinical trial.","Exclusion criteria: 1. The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:\r&lt;br&gt;1) Respiratory failure occurs and requires mechanical ventilation;\r&lt;br&gt;2) Shock occurs;\r&lt;br&gt;3) Combined failure of other organs requires ICU monitoring and treatment;\r&lt;br&gt;2. Those who are allergic to blood products or plasma components and auxiliary materials (sodium citrate);\r&lt;br&gt;3. There is multiple organ failure, and the estimated survival time is less than 3 days;\r&lt;br&gt;4. Those who tested positive for HIV antibodies before enrollment;\r&lt;br&gt;5. Women who are pregnant or breastfeeding or have a birth plan within the past year;\r&lt;br&gt;6. Participants in other clinical trials within 3 months before screening;\r&lt;br&gt;7.Poor adherence or other conditions that the investigator believes are not suitable for inclusion (such as poor physical condition).","Exclusion criteria: 1. Allergic to vitamin C; \r&lt;br&gt;2. Cardiogenic dyspnea; \r&lt;br&gt;3. Life expectancy&lt;24h; \r&lt;br&gt;4. Pregnant and/or lactating female; \r&lt;br&gt;5. There is a state of tracheotomy or home oxygen therapy in the past; \r&lt;br&gt;6. Previously complicated with interstitial lung disease, malignant tumors,diffuse alveolar hemorrhage, diabetic ketoacidosis, or an active kidney stone; \r&lt;br&gt;7. Participating in other clinical trials; \r&lt;br&gt;8. Researchers believe patients are not suitable for clinical trials for other reasons.","Exclusion criteria: With acute cardio-cerebrovascular liver and kidney function damage, or combined with other important organ injury;","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc .;\r&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment","Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure;\r&lt;br&gt;2. Pregnant or lactating women;\r&lt;br&gt;3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;\r&lt;br&gt;4. The investigator believes that the patient has other conditions that are not suitable for enrollment","Exclusion criteria: Physician judged the patient was not suitable for this clinical trial.",null,"Exclusion criteria: 25(OH)D level not available",null,"Exclusion criteria:  Under 18 years of age, suffering from autoimmune diseases","Exclusion criteria: none","Exclusion criteria: (1) Those who are allergic to pirfenidone;\r&lt;br&gt;(2) The investigator judges that the subject's compliance is poor.\r&lt;br&gt;(3) Patients with severe liver disease;\r&lt;br&gt;(4) pregnant and lactating patients;\r&lt;br&gt;(5) Those who have severe kidney disease or need dialysis treatment;\r&lt;br&gt;(6) Those who need to take fluvoxamine at the same time","Exclusion criteria: (1) limited sample size;                                                                          \r&lt;br&gt;(2) Lack of sample information;\r&lt;br&gt;(3) unable or failure to detect due to human error;\r&lt;br&gt;(4) Abnormal results or failure in detection due to instrument or non-reagent quality problems.","Exclusion criteria: no","Exclusion criteria: 1) Patients with severe respiratory movement artifacts \r&lt;br&gt;2) Children, pregnant women and lactating women;","Exclusion criteria: 1) Have other severe psychological diagnosis;\r&lt;br&gt;2) Have suicidal ideation and plan during the past 2 week;\r&lt;br&gt;3) Not willing to let their legal guardian know their participation;\r&lt;br&gt;4) Currently taking psychiatric medication;\r&lt;br&gt;5) Receiving counseling service elsewhere.","Exclusion criteria: 1. Other major mental disorders;\r&lt;br&gt;2. Weakness affects participation in the experiment;\r&lt;br&gt;3. Communication barriers;\r&lt;br&gt;4. Already participated in regular cognitive training;\r&lt;br&gt;5. Take psychotropic or other drugs that are known to affect mood;\r&lt;br&gt;6. History of major neurological deficits, including history of stroke, transient ischemic attack or traumatic brain injury.","Exclusion criteria: (1) Patients who are unwilling to cooperate during the treatment; \r&lt;br&gt;(2) Patients with neocoronary pneumonia converted to critically ill during the treatment; \r&lt;br&gt;(3) Patients with mental illness who have severe primary diseases such as hematopoietic system, liver, cardiovascular, lung and kidney; \r&lt;br&gt;(4) Those who are allergic to alcohol and tape.","Exclusion criteria: (1) had participated in other clinical trials within 4 weeks before the start of this study;\r&lt;br&gt;(2) used albumin and immunoenhancer drugs within 15 days before operation;\r&lt;br&gt;(3) had a history of coronavirus infection, direct or indirect exposure, had fever, cough;\r&lt;br&gt;(4) had previous immune deficiency;\r&lt;br&gt;(5) had congenital metabolic abnormalities and other diseases;\r&lt;br&gt;(6) Patients with autoimmune diseases and infections;\r&lt;br&gt;(7) pregnant and lactating women;\r&lt;br&gt;(8) who were not willing to participate in the study for any reason.","Exclusion criteria: No","Exclusion criteria: Patients who died within 24h after admission.","Exclusion criteria: (1) those who do not meet the above inclusion criteria;\r&lt;br&gt;(2) pregnant and lactating women;\r&lt;br&gt;(3) severe basic diseases of the liver (Child Pugh score &gt;=C, AST &gt; 5 times the upper limit);\r&lt;br&gt;(4) serious renal damage basic diseases (estimated glomerular filtration rate &lt;=30 ml/min / 1.73 m2, or is undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis);\r&lt;br&gt;(5) people who accepted any 2019 - nCoV experimental treatment within 30days prior to evaluation;\r&lt;br&gt;(6) people who are allergic to lactococcus lactis or pharmaceutical excipients.","Exclusion criteria: 1. aged &gt;75 years old.\r&lt;br&gt;2. after cardiopulmonary resuscitation;\r&lt;br&gt;3. accompanied by other severe organ dysfunction (including severe liver and kidney dysfunction, massive upper gastrointestinal bleeding, DIC, etc.).","Exclusion criteria: 1. Pregnant women or lactating women;\r&lt;br&gt;2. Severe liver function damage (child-pugh grade C);\r&lt;br&gt;3. Severe renal impairment (Ccr&lt;=15ml/min);\r&lt;br&gt;4. Have any coexisting medical conditions or diseases that the investigator determines may impair the conduct of the study;\r&lt;br&gt;5. Social and mental disability, no legal capacity/restricted capacity;\r&lt;br&gt;6. Refuse to sign the informed consent;\r&lt;br&gt;7. VTE score &lt;4;\r&lt;br&gt;8. Higher blood risk factors.","Exclusion criteria: Undetected T lymphocyte count within 48 hours of admission","Exclusion criteria: Patients with inadequate clinical information",null,null,null,"Exclusion criteria: Confirmed cases who had an organ transplantation were excluded, following the latest guideline of diagnostic and treatment Covid-19 issued by China Health Committee.","Exclusion criteria: 1. Patients diagnosed with the critical type of COVID-19 [in accordance with the diagnostic criteria of the Notice on Printing and Distributing COVID-19 Diagnosis and Treatment Plan (Trial Implementation Version 6th) issued by the National Health and Medical Commission], and with unstable vital signs;\r&lt;br&gt;2. Patients with severe primary disease of liver, kidney, hematological and endocrine system;\r&lt;br&gt;3. Pregnant or lactating women;\r&lt;br&gt;4. Patients with a history of psychosis, substance abuse or dependence;\r&lt;br&gt;5. Those who participate in other clinical trials within 3 months when screening;\r&lt;br&gt;6. Patients with other diseases being treated with medications and affecting the study observation;\r&lt;br&gt;7. Other patients that considered unsuitable for the clinical trial by the investigators.","Exclusion criteria: No","Exclusion criteria: Age &lt;14 years old","Exclusion criteria: None","Exclusion criteria: 1. Patients who are using invasive mechanical ventilation for respiratory support;\r&lt;br&gt;2. Patients with recent hemodynamic instability requiring maintenance of vasoactive drugs and determined by the investigator to be unsuitable to participate in this clinical study;\r&lt;br&gt;3. Patients with other severe basic lung diseases, such as active tuberculosis, bronchiectasis, chronic obstructive pulmonary disease, pulmonary hypertension, and damaged lungs, etc., and the researchers judge that they are not suitable to participate in this clinical study;\r&lt;br&gt;4. Complicated with severe vascular diseases, such as severe cardiac dysfunction (cardiac function ?, ?), or suffered from acute coronary syndrome, acute cerebrovascular event, deep vein thrombosis or pulmonary embolism within 6 months before enrollment, and Researchers judge it inappropriate to participate in this study;\r&lt;br&gt;5. Poorly controlled hypertension, diabetes, severe liver, kidney, coagulation dysfunction, or the effects of other diseases, and it is not appropriate for the study to be judged by the researcher;\r&lt;br&gt;6. Those with malignant tumors or pathology suggesting a history of severe atypical hyperplasia;\r&lt;br&gt;7. Positive test for human immunodeficiency virus (HIV) antibody, hepatitis C virus antibody, Treponema pallidum antibody, and patients with active infectious diseases that other researchers consider unsuitable to participate in this study;\r&lt;br&gt;8. Have a history of severe drug allergies, or are allergic to the main active ingredients or excipients of clinical research products;\r&lt;br&gt;9. Those who have previously received cell therapy or organ transplants;\r&lt;br&gt;10. Women who are pregnant or nursing or plan to become pregnant during the study, or women or men of childbearing age who are unwilling to take contraception throughout the study;\r&lt;br&gt;11. Patients who have been treated with other clinical research products within 28 days before starting treatment, and the researcher determines that the relevant clinical research products will interfere with the evaluation of the safety and effectiveness of this clinical research product;\r&lt;br&gt;12. The investigator believes that patients participating in this study are not in the best interest or are not suitable for other conditions such as poor compliance.","Exclusion criteria: 1. Patients who are difficult to be administered orally or by nasal feeding, those who are allergic to the test drug and those who are intolerant to the drug;\r&lt;br&gt;2. The compliance of medication cannot be guaranteed during the treatment\r&lt;br&gt;3. Patients with severe primary respiratory diseases, or pneumonia caused by other pathogen.\r&lt;br&gt;4. Patients with serious diseases, malignant tumors or mental diseases;\r&lt;br&gt;5. Pregnant women, urine pregnancy test positive;\r&lt;br&gt;6. Participated in other drug trials in the past month;\r&lt;br&gt;7. The investigator judged that the patient was not suitable for the study.","Exclusion criteria: (1) Female patients who are pregnant or planning to become pregnant within 7 months;\r&lt;br&gt;(2) ALT is higher than 10 times the upper limit of normal value, or total bilirubin is highter than 2 times the upper limit of normal value, or the stage of decompensation of cirrhosis, or has had decompensation of cirrhosis;\r&lt;br&gt;(3) The number of peripheral blood leukocytes and/or platelets is lower than the lower limit of normal value;\r&lt;br&gt;(4) There are serious important organs such as cardiovascular,lung,kidney,brain lesions and fundus lesions;\r&lt;br&gt;(5) Combined with autoimmune disease,mental illness,diabetes,and abnormal thyroid function (hyperthyroidism or hypothyroidism);\r&lt;br&gt;(6) Those diagnosed or suspected of malignant tumors;\r&lt;br&gt;(7) Those who are using immunosuppressive drugs or after organ transplantation or who are preparing to undergo organ transplantation;\r&lt;br&gt;(8) Drug addicts or people with HIV infection;\r&lt;br&gt;(9) Those who are allergic to interferon;\r&lt;br&gt;(10) There are other situations in which interferon is not suitable for use by the doctor in charge;\r&lt;br&gt;(11) Men who did not take effective contraception during and after the treatment period.","Exclusion criteria: 1. Family history of seizure, epilepsy, brain or mental disease;\r&lt;br&gt;2. Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past;\r&lt;br&gt;3. Woman who is pregnant, breast-feeding or positive in -HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months;\r&lt;br&gt;4. Any acute fever disease or infections;\r&lt;br&gt;5. History of SARS;\r&lt;br&gt;6. Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease;\r&lt;br&gt;7. Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.;\r&lt;br&gt;8. Hereditary angioneurotic edema or acquired angioneurotic edema;\r&lt;br&gt;9. Urticaria in last one year;\r&lt;br&gt;10. No spleen or functional spleen;\r&lt;br&gt;11. Platelet disorder or other bleeding disorder may cause injection contraindication;\r&lt;br&gt;12. Faint at the sight of needles;\r&lt;br&gt;13. Prior administration of immunodepressant or corticosteroids,antianaphylaxis treatment, cytotoxic treatment in last 6 months;\r&lt;br&gt;14. Prior administration of blood products in last 4 months;\r&lt;br&gt;15. Prior administration of other research medicines in last 1 month;\r&lt;br&gt;16. Prior administration of attenuated vaccine in last 1 month;\r&lt;br&gt;17. Prior administration of inactivated vaccine in last 14 days;\r&lt;br&gt;18. Current anti-tuberculosis prophylaxis or therapy;\r&lt;br&gt;19. According to the judgement of investigator,various medical, psychological,social or other conditions, those could affect the subjects to sign informed consent.","Exclusion criteria: No","Exclusion criteria: Exclusion criteria (subjects cannot enter the study if they meet any of the following conditions):\r&lt;br&gt;(1) There was no rapid immunoassay;\r&lt;br&gt;(2) Subjects who could not cooperate with information collection were excluded.","Exclusion criteria: Suspected patients with COVID19, not confirmed by the laboratory","Exclusion criteria: 1. Patients who are using warfarin or with bleeding disorders or bleeding tendencies;\r&lt;br&gt;2. Those who refuse to sign the informed consent;","Exclusion criteria: (1) Patients with severe mental illness who could not cooperate with treatment; \r&lt;br&gt;(2) Maternal patients; \r&lt;br&gt;(3) Pediatric patients; \r&lt;br&gt;(4) Suicide death cases; \r&lt;br&gt;(5) Transferred to hospital halfway and failed to obtain final course outcome Cases; \r&lt;br&gt;(6) Cases with recurrence reported after discharge.","Exclusion criteria: 1. Cases of severe vomiting or difficulty in ingesting medication;\r&lt;br&gt;2. Pregnant and lactating women;\r&lt;br&gt;3. Lopinavir/ridonavir, ribavirin, interferon and monoclonal antibody were received 3 days before enrollment;\r&lt;br&gt;4. Cases of respiratory failure requiring mechanical ventilation;\r&lt;br&gt;5. Cases of shock;\r&lt;br&gt;6. Complications of other organ failure require ICU care;\r&lt;br&gt;7. Patients were clinically predicted with no hope of survival and only received hospice care, or those who were in a deep coma and did not respond to supportive treatment measures within three hours of admission.","Exclusion criteria: 1. Patients who have contraindications to specimen collection, such as: coagulopathy, rectal tumors, anal canal disease, severe cardiopulmonary dysfunction, etc .;\r&lt;br&gt;2. Patients with mental illness cannot cooperate with sampling;\r&lt;br&gt;3. The patient did not agree to participate in the study.","Exclusion criteria: (1) Allergic to fabiravir or abidol;\r&lt;br&gt;(2) ALT/AST increased 5 times higher than the upper limit of normal, or with child Pugh C;\r&lt;br&gt;(3) Severe patients with expected survival time &lt; 48 hours;\r&lt;br&gt;(4) Pregnancy;\r&lt;br&gt;(5) HIV positive;\r&lt;br&gt;(6) Considered unsuitable by researchers.","Exclusion criteria: Mild and critical new coronavirus pneumonia","Exclusion criteria: 1. Intubation required immidiately in case of cardiac arrest or asphyxia;\r&lt;br&gt;2. Pregnancy, severe chronic respiratory, uncontrolled gastric reflux disease and any nasopharyngeal anatomical obstacle;\r&lt;br&gt;3. Those patients has intubated in ICU.","Exclusion criteria:  a history of neurologic and psychiatric deficits","Exclusion criteria: (1) Reexamine CT;\r&lt;br&gt;(2) The CT image can not be analyzed caused by respiratory movement ;\r&lt;br&gt;(3) Patients with pleural effusion or atelectasis.","Exclusion criteria: The clinical classification of patients with severe novel coronavirus infection is to meet any of the following:\r&lt;br&gt;1) Respiratory failure occurs and requires mechanical ventilation;\r&lt;br&gt;2) Shock occurs;\r&lt;br&gt;3) Combined failure of other organs requires ICU monitoring and treatment;\r&lt;br&gt;2. Those who are allergic to blood products or plasma components and auxiliary materials (sodium citrate);\r&lt;br&gt;3. There is multiple organ failure, and the estimated survival time is less than 3 days;\r&lt;br&gt;4. Those who tested positive for HIV antibodies before enrollment;\r&lt;br&gt;5. Women who are pregnant or breastfeeding or have a birth plan within the past year;\r&lt;br&gt;6. Participants in other clinical trials within 1 months before screening;\r&lt;br&gt;7.Poor adherence or other conditions that the investigator believes are not suitable for inclusion (such as poor physical condition).","Exclusion criteria: 1. Gestational female patients;\r&lt;br&gt;2. Patients with allergic constitution, specifically with a history of allergies to these three intervention drugs;\r&lt;br&gt;3. Patients with other malignant diseases such as malignant tumours, chronic liver or kidney diseases, and reaching the end stage;\r&lt;br&gt;4. Patients with known psychiatric disorders;\r&lt;br&gt;5. Patients withdrawing from other clinical trial within 4 weeks.","Exclusion criteria: 1. Allergy to drugs and excipients used in this study;\r&lt;br&gt;2. Pregnant and lactating women and women of child-bearing years did not agree to use contraception during the experiment;\r&lt;br&gt;3.Have malignant tumor or hypercoagulant state;\r&lt;br&gt;4. Suffer from mental illness and can't cooperate well;\r&lt;br&gt;5. Those who have participated in or are participating in clinical trials of other drugs during the course of the disease;\r&lt;br&gt;6. Other conditions considered inappropriate for inclusion by the researcher.","Exclusion criteria: 1) According to the researcher's judgment, the diseases that have been or have suffered may affect the patients to participate in the trial;\r&lt;br&gt;2) Those who are allergic to the known ingredients of this medicine;\r&lt;br&gt;3) Pregnant or lactating women;\r&lt;br&gt;4) Patients who have participated in other clinical trials in the past 3 months;\r&lt;br&gt;5) The researcher believes that there is anything unsuitable for enrollment.","Exclusion criteria: 1. sNCP caused by other non-viral infections (such as trauma);\r&lt;br&gt;2. WHO grade III or IV pulmonary hypertension;\r&lt;br&gt;3. Malignant tumor in lung and other systems;\r&lt;br&gt;4. Lactating women or screening women with positive blood pregnancy test;\r&lt;br&gt;5. Idiopathic IgA deficiency;\r&lt;br&gt;6. Recent cardiovascular and cerebrovascular events (3 months);\r&lt;br&gt;7. Lung transplanted patients;\r&lt;br&gt;8. HIV positive patients;\r&lt;br&gt;9. According to the researcher's judgment, these subjects will be excluded because of some causes, such as any disease, treatment, or laboratory abnormal history or current evidence, which may confound the results of the study, interfere with the subject's participation in the study procedure, or be not in the best interest of the subject's participation in the study.","Exclusion criteria: Undiagnosed NCP patients","Exclusion criteria: 1. Patients with congenital heart disease, primary and other secondary cardiomyopathy, severe arrhythmia, frequent atrial fibrillation, and serious image quality artifacts;\r&lt;br&gt;2. Contraindications of MRI: there are ferromagnetic metal foreign bodies in the body (such as cardiac pacemaker, nerve stimulator, artificial metal heart valve, aneurysm clip, intraocular metal foreign body, inner ear implant, metal prosthesis, metal prosthesis, metal joint, etc.); see the informed consent of enhanced MRI for details;\r&lt;br&gt;3. The patients with claustrophobia had recently developed allergic diseases such as measles and allergic dermatitis;\r&lt;br&gt;4. Contraindications of gadolinium contrast agent: estimated glomerular filtration rate (EGFR) &lt;30 ml/min/1.73 m2; previous adverse reactions or other drug allergy history of gadolinium contrast agent injection.","Exclusion criteria: 1. Confirmed or suspected novel coronavirus pneumonia infection;\r&lt;br&gt;2. KPS &gt; 30 points.","Exclusion criteria: You cannot be enrolled if you meet any of the following criteria:\r&lt;br&gt;1) any situation that cannot allow the program to proceed safely;\r&lt;br&gt;2) allergic constitution, allergic to more than one kind of food or medicine;\r&lt;br&gt;3) patients with severe basic diseases that affect survival, including uncontrolled clinically significant heart, lung, kidney, digestion, blood diseases, neuropsychiatric diseases, immune diseases, metabolic diseases, malignant tumors, and severe malnutrition;\r&lt;br&gt;4) pregnant or lactating women;\r&lt;br&gt;5) patients may be transferred to non-participating hospitals within 72 hours;\r&lt;br&gt;6) patients who have been on immunosuppressive agents or organ transplants for nearly 6 months;\r&lt;br&gt;7) critically ill patients diagnosed according to the diagnosis and treatment plan for pneumonia caused by novel coronavirus infection (trial fifth edition);\r&lt;br&gt;8) those who are unable to cooperate in mental state, suffer from mental illness, have no self-control and cannot express clearly;\r&lt;br&gt;9) a history of HBV, HCV, TPPA, HIV and pancreatitis before infection;\r&lt;br&gt;10) participants in other clinical trials.","Exclusion criteria: (1) any situation in which the program cannot proceed safely;\r&lt;br&gt;(2) allergic constitution;\r&lt;br&gt;(3) serious basic diseases affecting survival, including uncontrolled malignant tumors with multiple metastases that cannot be resected, blood diseases, malignant fluid, active bleeding, severe malnutrition, HIV, etc.;\r&lt;br&gt;The main organ function is abnormal\r&lt;br&gt;(4) liver function was obviously abnormal: ALT/AST increased by more than 5 times the normal upper limit, increase of total bilirubin more than 2 times of normal upper limit;\r&lt;br&gt;(5) obstructive pneumonia, severe pulmonary fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumors;\r&lt;br&gt;(6) pregnancy: positive pregnancy test for women of child-bearing age;\r&lt;br&gt;(7) the patient may be transferred to a non-participating hospital within 72h;\r&lt;br&gt;(8) continuous use of immunosuppressants or organ transplants within the past 6 months;\r&lt;br&gt;(9) in vitro life support patients (ECMO, ECCO2R, RRT);\r&lt;br&gt;(10) expected survival no more than 48 hours.","Exclusion criteria: 1. those who cannot complete cardiopulmonary ultrasound according to the a-ccue process;\r&lt;br&gt;2. the patient or his guardian requests to withdraw from the researcher;","Exclusion criteria: 1. Patients with mental illness who cannot cooperate with the sampling;\r&lt;br&gt;2. Patients judged by the researchers as unsuitable for the study.","Exclusion criteria: Viral nucleic acid test negative","Exclusion criteria: 1. Aged less than 18 years old;\r&lt;br&gt;2. Other serious medical diseases such as malignant tumor, heart, liver and kidney disease, uncontrollable metabolic disease, etc;\r&lt;br&gt;3. Not suitable for gastrointestinal administration;\r&lt;br&gt;4. Pregnant or lactating women;\r&lt;br&gt;5. Those who are allergic to the ingredients of this product;\r&lt;br&gt;6. Mental state can not cooperate with the observer or cognitive impairment;\r&lt;br&gt;7. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times ULN);\r&lt;br&gt;8. Patients with known severe renal impairment (creatinine clearance rate &lt;=30 ml/min) or continuous renal replacement therapy, hemodialysis, peritoneal dialysis.","Exclusion criteria: &lt;br&gt;- Pregnant woman \r&lt;br&gt;-Child less than 12 years-old \r&lt;br&gt;-Known hypersensitivity to chloroquine or hydroxy chloroquine.\r&lt;br&gt;-Feeding\r&lt;br&gt;-Retinopathy\r&lt;br&gt;-Known deficit in G6PD\r&lt;br&gt;-Refusal to participate in the study\r&lt;br&gt;-Patient with known QT prolongation  &lt;br&gt;","Exclusion criteria: minor","Exclusion criteria: History of drug allergy&lt;br&gt;Pregnancy and lactation &lt;br&gt;Uncontrolled baseline diseases including neuropsychiatric disorders, diabetes, thyroid disorders, heart disease, baseline liver failure","Exclusion criteria: 5 days or more after the onset of illness&lt;br&gt;Pregnancy&lt;br&gt;Breastfeeding&lt;br&gt;History of drug allergy&lt;br&gt;Complicated cases with bacterial infection&lt;br&gt;Patients in recovery phase&lt;br&gt;Critical and severe cases such as ARDS&lt;br&gt;Clinical evidence for respiratory insufficiency at the time of hospitalization (SaO2 =90% or PaO2 &lt; 8 kPa) in the patient breathing room air without oxygen therapy&lt;br&gt;Comorbidities (e.g. renal failure, liver failure, CHF, cerebrovascular and cardiovascular major diseases, chronic pulmonary disease, malignancy, endocrine and metabolic diseases, any immunodeficiency disorders such as AIDS, encephalopathy, neuropathy )","Exclusion criteria: History of drug allergy&lt;br&gt;Uncontrolled baseline diseases including neuropsychiatric disorders, diabetes, thyroid disorders, heart disease&lt;br&gt;Pregnancy and lactation&lt;br&gt;Baseline liver failure","Exclusion criteria: Patient who use warfarin&lt;br&gt;Patient who ACEI (captopril. enalapril,...  )","Exclusion criteria: Chronic kidney Disease&lt;br&gt;Pregnancy or breastfeeding&lt;br&gt;Drug allergy history&lt;br&gt;Pneumonia due to influenza virus, bacterial pneumonia, fungal pneumonia, and noninfectious causes&lt;br&gt;Chronic liver disease&lt;br&gt;Acute kidney injury","Exclusion criteria: History of drug allergy&lt;br&gt;Pregnancy&lt;br&gt;Lactation","Exclusion criteria: Known allergic reaction to Sofosbuvir or Daclatasvir&lt;br&gt;Pregnant or breastfeeding, or positive pregnancy test&lt;br&gt;Receipt of any experimental treatment for COVID-19 prior to the time of the screening evaluation&lt;br&gt;Heart rate &lt; 60/min&lt;br&gt;Taking Amiodarone&lt;br&gt;Evidence of multiorgan failure&lt;br&gt;Requiring mechanical ventilation at screening&lt;br&gt;eGFR&lt; 50 mL/min",null,"Exclusion criteria: History of drug allergy&lt;br&gt;Pregnancy","Exclusion criteria: past history of hypersensitivity to lopinavir, ritonavir, hydroxychloroquine or oseltamivir&lt;br&gt;pregnancy","Exclusion criteria: None",null,"Exclusion criteria: pregnancy&lt;br&gt;lactation","Exclusion criteria: (1) 7 days or more since the onset of COVID-19, as diagnosed by fever, pneumonia or other relevant findings&lt;br&gt;(2) Performance status of 2 or greater&lt;br&gt;(3) Advanced liver function abnormalities classified as grade C by the Child-Pugh criteria&lt;br&gt;(4) End-stage renal disease requiring dialysis&lt;br&gt;(5) Altered mental status&lt;br&gt;(6) Pregnant or planning pregnancy&lt;br&gt;(7) If female, not agreeable to using oral contraceptive, intrauterine contraceptive device, mechanical contraceptive methods such as pessaries and condoms, or combinations thereof, during favipiravir administration and 90 days thereafter&lt;br&gt;(8) If male, has a female partner who is not agreeable to the contraceptive methods described in (7) &lt;br&gt;(9) If male, not agreeable to using condoms during favipiravir administration and 90 days thereafter&lt;br&gt;(10) History of hereditary xanthine oxidase deficiency&lt;br&gt;(11) History of hypouricemia (less than 1 mg/dL) or xanthine urolithiasis&lt;br&gt;(12) History of gout or active treatment of gout or hyperuricemia&lt;br&gt;(13) History of immunocompromising conditions such as HIV positivity&lt;br&gt;(14) Deemed ineligible as determined by the principal investigator or a co-investigator",null,null,null,null,null,null,"Exclusion criteria: 1.\tPatients treated with mechanical ventilation for other concomitant causes&lt;br&gt;2.\tPatients treated with ECMO for other concomitant causes",null,null,null,null,null,"Exclusion criteria: Those who refused to participate in the study by opt-out","Exclusion criteria: Only one response per hospital or ED",null,null,null,null,null,null,null,null,null,null,null,null,"Exclusion criteria: (1) younger than 12 years old;\r&lt;br&gt;(2) refuse to sign informed consent.",null,null,null,"Exclusion criteria: 1) POSITIVE;\r&lt;br&gt;2) Those who cannot cooperate to complete the magnetic resonance examination.",null,"Exclusion criteria: Incomplete case data.",null,null,null,null,"Exclusion criteria: History of eye surgery,trauma,other eye diseases,family history of glaucoma,etc.","Exclusion criteria: 1. Pregnant or breast-fed women;\r&lt;br&gt;2. age &lt; 18 years;\r&lt;br&gt;3. Participating in any clinical trail in 12 weeks before signing informed consent form;\r&lt;br&gt;4. refuse to sign the informed consent form;\r&lt;br&gt;5. individuals who suffer from severe diseases, or serious complications which affect disease and/ or psychological assessment;\r&lt;br&gt;6. patients cannot finish questionnaires;\r&lt;br&gt;7. employees and related people of investigators and research center;\r&lt;br&gt;8. Individuals who are unsuitable to take part in this study due to consideration of researchers.","Exclusion criteria: Death was excluded. Cases with BMI mismatch were excluded","Exclusion criteria: (1) Receive any clinical trial drug treatment for COVID-2019 within 30 days before the screening assessment;\r&lt;br&gt;(2) Severe liver disease (e.g., Child Pugh score &gt;=C or AST&gt; 5 times of the upper limit);\r&lt;br&gt;(3) Patients with known severe renal insufficiency (estimated glomerular filtration rate &lt;=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis;\r&lt;br&gt;(4) Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses;\r&lt;br&gt;(5) Female patients who have no sexual protection in the last 30 days prior to the screening assessment;\r&lt;br&gt;(6) Pregnant or lactating women or women using estrogen contraception;\r&lt;br&gt;(7) Patients who are planning to become pregnant during the study period or within 6 months after the end of the study period;\r&lt;br&gt;(8) Other conditions that the researchers consider inappropriate for participating in this clinical trial.","Exclusion criteria: 1) Those with poor CT image quality;\r&lt;br&gt;2) Patients who are unwilling to participate in the study.","Exclusion criteria: No","Exclusion criteria: 1. Combining patients with severe primary respiratory diseases, or with other pathogenic microbial pneumonia that needs to be identified in relation to COVID-19;\r&lt;br&gt;2. Combining systems such as heart, brain, lung, liver and kidney syllading with severe primary diseases, as well as mental illness;\r&lt;br&gt;3. Those who are unconscious and unable to cooperate;\r&lt;br&gt;4. People who cannot accept music because of hearing impairment;\r&lt;br&gt;5. Combining patients with other serious diseases such as uremia and severe heart failure;\r&lt;br&gt;6. The researchers did not consider it appropriate for patients to participate in the study.","Exclusion criteria: 1. Suspected patients;\r&lt;br&gt;2. Pregnancy and lactation.",null,"Exclusion criteria: History of eye surgery,trauma,other eye diseases,family history of glaucoma,etc.","Exclusion criteria: Participants who were not located in Wuhan when we conducted the study and those who did not practice mindfulness or mind-wandering exercise over the next 10 days.","Exclusion criteria: (1) Patients have clinical symptoms or CT positive changes;\r&lt;br&gt;(2) Patients have no willingness to participate in the study;\r&lt;br&gt;(3) Patients with unconsciousness.","Exclusion criteria: (1) Basic diseases: Patients with severe diabetes, cardiopulmonary insufficiency, chronic kidney disease, chronic liver failure, cirrhosis, etc. before onset; tumor patients; patients with azotemia;\r&lt;br&gt;(2) Not willing to participate in the experiment;","Exclusion criteria: not in this period","Exclusion criteria: Patients not suitable for study judged by researchers","Exclusion criteria: Medical staff without informed consent.","Exclusion criteria: other viral pneumonia and COVID-19 in children.","Exclusion criteria: 1. Patients at h high risk of SARS-CoV-2 infection;\r&lt;br&gt;2. The guardian does not agree to sign the informed consent or the guardian does not agree to collect information.","Exclusion criteria: 1. Have clinical symptoms or CT positive changes;\r&lt;br&gt;2. Patients no willingness to participate in the study;\r&lt;br&gt;3. Patients with consciousness disorders.","Exclusion criteria: Pregnant women; less than 18 years old; serious diseases (cardiovascular diseases, respiratory diseases, digestive diseases, etc); patients with tumor; patients who can not cooperate","Exclusion criteria: 1. severe vomiting and difficulty in taking oral medication or in taking oral medication;\r&lt;br&gt;2. pregnant and nursing women;\r&lt;br&gt;3. subjects received lopinavir/ridonavir, ribavirin, monoclonal antibodies and other specific antiviral drugs in the week prior to admission;\r&lt;br&gt;4. cases of respiratory failure requiring mechanical ventilation;\r&lt;br&gt;5. cases of shock;\r&lt;br&gt;6. combined with other organ failure requires intensive care unit;\r&lt;br&gt;7. patients with no clinical expectation of survival and only end-of-life care, or those in a deep coma who did not respond to supportive treatment within three hours of admission.","Exclusion criteria: (1) Patients who are negative for multiple PT-PCR tests and cannot be diagnosed;\r&lt;br&gt;(2) Patients with incomplete medical records;\r&lt;br&gt;(3) There are patients who other researchers believe are not suitable for inclusion in this study.","Exclusion criteria: 1. Cases of clinical treatment of pneumonia;\r&lt;br&gt;2. Those who cannot understand the content of the scale and cannot evaluate the curative effect;\r&lt;br&gt;3. Suicide-prone by the doctor;\r&lt;br&gt;4. pregnant women, those with severe cardiovascular and cerebrovascular, liver, kidney, hematopoietic system and other diseases;\r&lt;br&gt;5. Those who do not cooperate with the treatment plan;\r&lt;br&gt;6. The researcher thinks that others are not suitable for enrollment.","Exclusion criteria: Patients in hospital, complicated with other acute and severe diseases, etc","Exclusion criteria: 1. Patients with cardiac arrest before endotracheal intubation;\r&lt;br&gt;2. Patients with severe medical record information registration defects;\r&lt;br&gt;3. Patients whose condition is not stable and whose prognosis cannot be determined.","Exclusion criteria: 1) novel coronavirus pneumonia is not in conformity with the standard diagnostic criteria.            \r&lt;br&gt;2) The age is less than 18 years old or more than 80 years old;            \r&lt;br&gt;3) Patients with allergy to traditional Chinese medicine and allergic constitution;            \r&lt;br&gt;4) Patients with malignant tumor, cirrhosis, chronic renal failure (uremic stage), blood system disease, HIV and other serious basic diseases;            \r&lt;br&gt;5) Long term use of hormone, immunosuppressant and other drugs to treat patients;            \r&lt;br&gt;6) Suffering from serious mental illness or being unable to cooperate with the trial            \r&lt;br&gt;7) Pregnant and lactating women.","Exclusion criteria: (1) patients with severe basic diseases and intolerance such as cardiopulmonary function;\r&lt;br&gt;(2) patients combined with diseases affecting the assessment; with communication and cognitive impairment, unclear consciousness and unable to cooperate with the experiment.","Exclusion criteria: Age &lt; 18 years old, clinical data missing.","Exclusion criteria: 1. Those who cannot receive Chinese medicine treatment;\r&lt;br&gt;2. Patients with allergies to certain traditional Chinese medicine decoctions or traditional Chinese medicine injections;\r&lt;br&gt;3. Cases where complete diagnosis and treatment information cannot be obtained;\r&lt;br&gt;4. Any other chronic respiratory diseases, respiratory bacterial infections such as purulent tonsillitis, acute tracheobronchitis, sinusitis, otitis media, and other respiratory diseases affecting clinical trial evaluation;\r&lt;br&gt;5. Accompanied by basic diseases such as severe primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, and abnormal lung development;\r&lt;br&gt;6. Expected survival time is less than 1 week.\r&lt;br&gt;Note: Anyone who meets any of the above exclusion criteria cannot be included in this test.","Exclusion criteria: 1. Those who do not meet the inclusion criteria;\r&lt;br&gt;2. Without the informed consent of the patient;\r&lt;br&gt;3. Unable to cooperate with the information collection due to illness or other reasons.","Exclusion criteria: 1. Known allergies to the components of this study;\r&lt;br&gt;2. Non-fever non-new coronary pneumonia diagnosed or suspected;\r&lt;br&gt;3. Fever caused by other non-infectious causes;\r&lt;br&gt;4. Patients with tuberculosis, bronchial asthma, chronic obstructive pulmonary disease, and respiratory failure;\r&lt;br&gt;5. Patients who are unwilling to take traditional Chinese medicine preparations;\r&lt;br&gt;6. Women during pregnancy and lactation who have fertility requirements in the last 3 months;\r&lt;br&gt;7. Participating in clinical trials of other drugs;\r&lt;br&gt;8. Other reasons led the researchers to consider it inappropriate to participate in this study.","Exclusion criteria: 1. Having one of the following infections (influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human partial lung virus, SARS coronavirus and other known viral pneumonia);\r&lt;br&gt;2. Mycoplasma pneumoniae, Chlamydia pneumoniae and bacterial pneumonia;\r&lt;br&gt;3. There are non infectious diseases, such as vasculitis, dermatomyositis and organic pneumonia.","Exclusion criteria: (1) Known or suspected allergy to the components of the study drug;\r&lt;br&gt;(2) Acute infection of other viruses and bacteria has not been cured;\r&lt;br&gt;(3) The function of liver and kidney was abnormal (ALT/AST&gt;=2 times of the upper limit of normal value, SCr&gt;1.5 times of the upper limit of normal value);\r&lt;br&gt;(4) Participating in clinical trials of other drugs;\r&lt;br&gt;(5) Pregnant and lactating women; or can not take effective contraceptive measures during the trial;\r&lt;br&gt;(6) According to the judgment of the researcher, there are other situations that are not suitable for the experiment.","Exclusion criteria: 1. Aged &lt; 7-year-old;\r&lt;br&gt;2. previous arrhythmia;\r&lt;br&gt;3. previous chronic respiratory failure caused by other diseases, such as heart failure, thoracic deformity, structural lung disease, etc.;\r&lt;br&gt;4. hemodynamic instability;\r&lt;br&gt;5. severe immune deficiency or recent use of immunosuppressive agents;\r&lt;br&gt;6. allergic patients;\r&lt;br&gt;7. estimated survival time less than 3 days;\r&lt;br&gt;8. dropout on the halfway as well as lose of follow-up.","Exclusion criteria: 1. Pregnant or lactating women;\r&lt;br&gt;2. patients with malignant tumor, other serious systemic diseases and psychosis; \r&lt;br&gt;3. patients with severe liver dysfunction; \r&lt;br&gt;4. recent or participating in other clinical trials; \r&lt;br&gt;5. evidence of drug addiction within one year before joining the trial;\r&lt;br&gt;6. unable or unwilling to provide informed consent or comply with the trial requirements;\r&lt;br&gt;7. Combined with other infectious diseases.","Exclusion criteria: (1) Critical patients;\r&lt;br&gt;(2) TCM diagnosis of yang deficiency syndrome, manifested as limb warm, thin stools, chills, etc.;\r&lt;br&gt;(3) Patients who cannot guarantee compliance during treatment, and patients who are difficult to administer by oral or nasal route;\r&lt;br&gt;(4) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19;\r&lt;br&gt;(5) Pregnant and mothers, those who have a pregnancy plan, and those who have a positive urine pregnancy test;\r&lt;br&gt;(6) Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the study;\r&lt;br&gt;(7) People who have been allergic to Chinese medicine or intolerant to taking medicine.\r&lt;br&gt;(8) Patients are participating in other COVID-19 clinical trials.","Exclusion criteria: no exclusion critereia","Exclusion criteria: 1. A coma, MODS or death occurred on admission;\r&lt;br&gt;2. The estimated survival time is &lt;7 days;\r&lt;br&gt;3. The patient's medical history is not detailed and relatives cannot be contacted.","Exclusion criteria: 1. Pneumonia caused by other reasons;\r&lt;br&gt;2. Have contraindications that can not participate in sports activities;\r&lt;br&gt;3. Mental disorders, cognitive impairments etc. can not cooperate with researchers subjectively;\r&lt;br&gt;4. Patients with serious illnesses, such as heart, liver, kidney, endocrine diseases and hematopoietic system disease;\r&lt;br&gt;5. Pregnant or lactating women.","Exclusion criteria: (1) Critical patients;\r&lt;br&gt;(2) Patients who can not guarantee compliance of using TCM during the treatment period, or patients who are difficult to take medicine by oral or nasal route;\r&lt;br&gt;(3) Patients with severe primary respiratory disease or other pathogenic microbial pneumonia that needs to be identified with COVID-19;\r&lt;br&gt;(4) Pregnant or parturient women. Patient who have a pregnancy plan or a positive urine pregnancy test;\r&lt;br&gt;(5) Patients with other systemic malignant diseases such as malignant tumors, mental illnesses, etc., which the researchers consider unsuitable for participation in the trial;\r&lt;br&gt;(6) Patients who have been allergic or intolerant to taking TCM.","Exclusion criteria: NO","Exclusion criteria: 1. Pneumonia caused by other reasons;\r&lt;br&gt;2. Have contraindications that can not participate in sports activities;\r&lt;br&gt;3. Mental disorders, cognitive impairments etc. can not cooperate with researchers subjectively.","Exclusion criteria: (1) Subjects who have any active autoimmune disease or history of autoimmune disease;\r&lt;br&gt;(2) Subjects who received immunosuppressive therapy by using immunosuppressant, or systemic or absorbable topic hormone therapy (temprednisone or other therapeutic hormones with a dosage &gt;10 mg/day) within 14 days prior to the administration of the studied drug;\r&lt;br&gt;(3) Severe allergic reaction to other monoclonal antibodies;\r&lt;br&gt;(4) Women in pregnancy or lactation;\r&lt;br&gt;(5) Human immunodeficiency virus (HIV) infection;\r&lt;br&gt;(6) Subjects with abnormal coagulation, bleeding tendency or undergoing thrombolysis or anticoagulation;\r&lt;br&gt;(7) Subjects with any known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders or thrombocytopenia);\r&lt;br&gt;(8) Subjects who have previously received other PD-1 antibody therapy or other immunotherapy for PD-1/PD-L.","Exclusion criteria: &lt;br&gt;1. ALT/AST &gt; 5 times the upper limit of normal. \r&lt;br&gt;2. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt; 30)  \r&lt;br&gt;3. Pregnancy or breast feeding. \r&lt;br&gt;4. Allergy to any study medication\r&lt;br&gt;5. Any medical condition which would impose an unacceptable safety hazard by participation to the study.\r&lt;br&gt;6. Study drug specific exclusion criteria:\r&lt;br&gt;\t- for itraconazole: heart failure ,  concomitant treatment with lopinavir/ritonavir, and potent CYP450 inducers such as rifampicin, rifabutin, carbamazepine, phenobarbital, phenytoin.\r&lt;br&gt;&lt;br&gt;","Exclusion criteria: He has been suffering from respiratory system disease, unstable condition, risk of falling, severe other organ disease or mental disease, cognitive or language communication disorders.","Exclusion criteria: &lt;br&gt;Unlikely to survive for &gt;48 hours from screening&lt;br&gt;Presence of neutropenia less than 2000/mm3, AST or ALT greater than 5 X ULN, platelets less than 50,000/mm3&lt;br&gt;Prior immunosuppressive therapies&lt;br&gt;Use of chronic oral corticosteroids for non-COVID-19 related condition&lt;br&gt;Past or current history of autoimmune or inflammatory disease(s)&lt;br&gt;Known or suspected history of tuberculosis&lt;br&gt;Suspected or known active systemic bacterial or fungal infections&lt;br&gt;","Exclusion criteria: &lt;br&gt;A potential subject who meets any of the following criteria will be excluded from participation in this study:&lt;br&gt;\tKnown allergy to (components of) the BCG vaccine or serious adverse events to prior BCG administration  &lt;br&gt;\tKnown active or latent Mycobacterium tuberculosis or with another mycobacterial species.  A history with- or a suspicion of M. tuberculosis infection. &lt;br&gt;\tFever (&gt;38 C) within the past 24 hours &lt;br&gt;\tPregnancy &lt;br&gt;\tSuspicion of active viral or bacterial infection &lt;br&gt;\tVaccination in the past 4 weeks or expected vaccination during the study period, independent of the type of vaccination.&lt;br&gt;\tSeverely immunocompromised subjects. This exclusion category comprises: a) subjects with known infection by the human immunodeficiency virus (HIV-1); b) neutropenic subjects with less than 500 neutrophils/mm3; c) subjects with solid organ transplantation; d) subjects with bone marrow transplantation; e) subjects under chemotherapy; f) subjects with primary immunodeficiency; g) severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine therapies. i) treatment with oral or intravenous steroids defined as daily doses of 10mg prednisone or equivalent for longer than 3 months, or probable use of oral or intravenous steroids in the following four weeks &lt;br&gt;\tActive solid or non-solid malignancy or lymphoma within the prior two years&lt;br&gt;\tDirect involvement in the design or the execution of the BCG-CORONA study&lt;br&gt;\tExpected absence from work of =4 of the following 12 weeks due to any reason (holidays, maternity leave, retirement, planned surgery etc)  &lt;br&gt;\tEmployed to the hospital &lt; 22 hours per week&lt;br&gt;\tNot in possession of a smartphone &lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;\tRespiratory rate &gt;24/min&lt;br&gt;\tPregnancy or lactation&lt;br&gt;\tWeight &lt;50 kg&lt;br&gt;\tHemodynamic/rhythm instability&lt;br&gt;\tAcute myocardial infarction Type 1&lt;br&gt;\tUse of concomitant medications that prolong the QT/QTc interval.&lt;br&gt;\tAny other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;1.\tSevere co-morbidity with life expectancy &lt;3 months according to investigators assessment\r&lt;br&gt;2.\tASAT/ALAT &gt; 5 times the upper limit of normal\r&lt;br&gt;3.\tAcute co-morbidity within 7 days before inclusion such as myocardial infarction\r&lt;br&gt;4.\tKnown intolerance to the available study drugs\r&lt;br&gt;5.\tPregnancy, possible pregnancy or breast feeding\r&lt;br&gt;6.\tAny reason why, in the opinion of the investigators, the patient should not participate\r&lt;br&gt;7.\tSubject participates in a potentially confounding drug or device trial during the course of the study \r&lt;br&gt;8.\tProlonged QT interval (&gt;450 ms)\r&lt;br&gt;\r&lt;br&gt;9.\tAlready receiving any of the study drugs&lt;br&gt;","Exclusion criteria: &lt;br&gt;1. &gt; 24 hours after confirmation of SARS-CoV-2 infection &lt;br&gt;&lt;br&gt;2. Any condition, including findings in the patients medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation.&lt;br&gt;&lt;br&gt;3. Current or previous participation in another clinical trial where the patient has received a dose of an IMP containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.&lt;br&gt;&lt;br&gt;4. Ventilated or in intensive care&lt;br&gt;&lt;br&gt;5. Inability to use a nebuliser with a mouthpiece.&lt;br&gt;&lt;br&gt;6. History of hypersensitivity to natural or recombinant IFN- or to any of the excipients in the drug preparation.&lt;br&gt;&lt;br&gt;7. Pregnancy.&lt;br&gt;&lt;br&gt;",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Exclusion criteria: 1. Have a clear history of celecoxib allergy;\r&lt;br&gt;2. Serious nausea, vomiting, diarrhea and other clinical manifestations affect the oral or absorption of the drug;\r&lt;br&gt;3. Taking drugs that may interact with celecoxib at the same time;\r&lt;br&gt;4. Patients with serious basic diseases, such as heart disease (including history of angina pectoris or coronary heart disease of myocardial infarction, atrioventricular block), lung, kidney, liver, etc., or mental diseases that cannot be treated together;\r&lt;br&gt;5. History of peptic ulcer;\r&lt;br&gt;6. Pregnant and lactating women;\r&lt;br&gt;7. Suspected or confirmed that there is still a history of alcohol, drug abuse or drug abuse;\r&lt;br&gt;8. Participated in other drug trials in the past month.",null,null,null,null,"Exclusion criteria: 1. a history of neurologic and psychiatric deficits \r&lt;br&gt;2. medical-care worker","Exclusion criteria: No",null,null,null,null,"Exclusion criteria: Uninfected group: with severe disease of heart, liver, lung, kidney or other organs; \r&lt;br&gt;normal group: those who refused to join this trial;\r&lt;br&gt;severe group: those who refused to join this trial.","Exclusion criteria: 1. Have been diagnosed with psychologic illness;\r&lt;br&gt;2. Taking antipsychotic drugs;\r&lt;br&gt;3. Participating in clinical trials of other drugs.",null,null,"Exclusion criteria: 1. Missing or incomplete medical records;\r&lt;br&gt;2. 28 day follow-up is incompleted;\r&lt;br&gt;3. Co-infection with influenza or other viruses;\r&lt;br&gt;4. Discontinuation of antihypertensive or chronic kidney disease treatment is more than 48 hours;\r&lt;br&gt;5. ACEIs were used during the treatment.","Exclusion criteria: 1. Heart rate&gt; 120 beats / min or &lt;40 beats / min;\r&lt;br&gt;2. Blood pressure &lt;90/60 mmHg or&gt; 140/90 mmHg;\r&lt;br&gt;3. Blood oxygen saturation is &lt;=90% or the change from baseline value is decreased by&gt; 4%;\r&lt;br&gt;4. Respiratory frequency&gt; 40 times / minute;\r&lt;br&gt;5. Pregnant women or other special groups.","Exclusion criteria: 1. Never worked on first-line clinical duty in the dental emergency department;\r&lt;br&gt;2. Having a history of mental illness;\r&lt;br&gt;3. Drug abusers.",null,null,null,null,"Exclusion criteria: 1. unclear diagnosis;\r&lt;br&gt;2. participants are not able to understand or cooperate;\r&lt;br&gt;3. malignancy;\r&lt;br&gt;4. pregnancy or abortion;\r&lt;br&gt;5. breast-feeding.","Exclusion criteria: Patients refusing to participate in the experiment","Exclusion criteria: 1. With any autoimmune disease;\r&lt;br&gt;2. with malignant tumors;\r&lt;br&gt;3. Participated in other clinical studies within three months before entering the group;\r&lt;br&gt;4. Severe allergic history, allergic to T cell therapy products or other biological agents;\r&lt;br&gt;5. Pregnant, planning to become pregnant or lactating women;\r&lt;br&gt;6. Patients with severe systemic diseases who are not suitable for entering the study, including but not limited to severe liver dysfunction, severe coagulation disorders, severe mental diseases, etc.;\r&lt;br&gt;7. Previously received other stem cell therapy, had received CIK cell therapy within two months;\r&lt;br&gt;8. Researchers believe that other conditions should not be included in this trial.","Exclusion criteria: (1) The time of sample collection or case information is not clear;\r&lt;br&gt;(2) Sample size less than 200 uL;\r&lt;br&gt;(3) Samples with severe hemolysis, lipemia and jaundice;\r&lt;br&gt;(4) The researchers believe that the sample does not meet the test requirements.","Exclusion criteria: 1) Previous history of chronic bronchitis, emphysema, interstitial lung disease or pulmonary heart disease;\r&lt;br&gt;2) Combining with other serious diseases: such as those who have suffered myocardial infarction and uncontrollable diabetes within 6 months, and are considered unsuitable to participate in the trial;\r&lt;br&gt;3) People with active peptic ulcer;\r&lt;br&gt;4) Patients during pregnancy and lactation;\r&lt;br&gt;5) Patients with mental illness or others who cannot cooperate effectively;\r&lt;br&gt;6) Researcher judged unsuitable to participate.","Exclusion criteria: (1) Patients with mental, cognitive, expression and basic writing disorders;\r&lt;br&gt;(2) Patients with severe heart, lung and blood vessels who need to stay in bed for a long time;\r&lt;br&gt;(3) Patients who are not willing to participate by themselves or their families;\r&lt;br&gt;(4) Patients or family members cannot cooperate with the implementer;\r&lt;br&gt;(5) Those who cannot obtain complete data;\r&lt;br&gt;(6) Suspected personnel and confirmed isolated patients","Exclusion criteria: 1. in pregnancy, breast-feeding female patients;\r&lt;br&gt;2. to determine the history of chloroquine phosphate, rabeprazole drug allergy patients;\r&lt;br&gt;Patients suffering from diseases of the blood system;\r&lt;br&gt;3. patients suffering from chronic liver and kidney diseases and reaching the terminal stage;\r&lt;br&gt;4. Serious heart, lung dysfunction and mental illness;\r&lt;br&gt;5. Patients with known retinal diseases, hearing loss or hearing loss;\r&lt;br&gt;6. Patients who have to take digitalis drugs for existing underlying diseases;\r&lt;br&gt;7. Merger of other digestive tract diseases;\r&lt;br&gt;8. Combine ribavirin;\r&lt;br&gt;9. Involved in other processing clinical drug trials.","Exclusion criteria: ?????????\r&lt;br&gt;Incomplete medical history",null,null,"Exclusion criteria: &lt;br&gt;                1. Not fulfilling all the inclusion criteria&lt;br&gt;                2. Declines nasal/pharyngeal swabbing&lt;br&gt;                3. Consent declined or consultee consent declined&lt;br&gt;                4. Already recruited to the study in the last 30 days&lt;br&gt;","Exclusion criteria: 1. Missing critical clinical data;\r&lt;br&gt;2. &lt; 12 years old.","Exclusion criteria: (1) The time of sample collection or case information is not clear;\r&lt;br&gt;(2) Sample size less than 200 uL;\r&lt;br&gt;(3) Samples with severe hemolysis, lipemia and jaundice;\r&lt;br&gt;(4) The researchers believe that the sample does not meet the test requirements.","Exclusion criteria: NO","Exclusion criteria: &lt;br&gt;1.\tRefusal to participate expressed by patient or legally authorized representative if they are present&lt;br&gt;2.\tLiver enzymes ALT/AST &gt; 5 times the upper limit of normal.&lt;br&gt;3.\tStage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR &lt; 30 mL/min)&lt;br&gt;4.\tPregnancy or breast-feeding.&lt;br&gt;5.\tAnticipated transfer to another hospital, which is not a study site within 72 hours.&lt;br&gt;6.\tPatients treated with one of the antivirals evaluated in the study (i.e. remdesivir, interferon -1a, lopinavir/ritonavir, hydroxychloroquine) in the past 29 days&lt;br&gt;7.\tContraindication to any study medication including allergy&lt;br&gt;8.\tUse of medications that are contraindicated with lopinavir/ritonavir i.e. drugs whose metabolism is highly dependent on the isoform CYP3A with narrow therapeutic range (e.g. amiodarone, colchicine, simvastatine)&lt;br&gt;9.\tUse of medications that are contraindicated with hydroxychloroquine: citalopram, escitalopram, hydroxyzine, domperidone, pipraquine.&lt;br&gt;10.\tHuman immunodeficiency virus infection under highly active antiretroviral therapy (HAART).&lt;br&gt;11.\tHistory of severe depression or attempted suicide or current suicidal ideation.&lt;br&gt;&lt;br&gt;&lt;br&gt;","Exclusion criteria: 1. Another mental disorder meets the DSM-5 criteria, including substance use disorders (except for nicotine dependence);\r&lt;br&gt;2. Another sleep disorder meets the DSM-5 criteria;\r&lt;br&gt;3. Current using hypnotic drugs;\r&lt;br&gt;4. Individuals who are pregnant or lactating; Individuals who are plan to become pregnant within 3 months;\r&lt;br&gt;5. Individuals with organ failures such as heart, liver, lung, and kidney, and organic diseases of the brain;\r&lt;br&gt;6. Accept cognitive-behavioral therapy or taking antidepressants, antipsychotics in the past two weeks;\r&lt;br&gt;7. Traveling across 2 time zones in the past 2 months or planning travel in the next 3 months; Shift workers.","Exclusion criteria: (1) patients without definite diagnosis of novel coronavirus pneumonia;\r&lt;br&gt;(2) combined with a end-stage disease with a life expectancy of less than 1 year;\r&lt;br&gt;(3) intolerance to cardiopulmonary monitoring recorder;\r&lt;br&gt;(4) regular follow-up is not possible.","Exclusion criteria: lack of NAT or serologically specific antibody detection","Exclusion criteria: 1. Patients with server diseases of the blood system;\r&lt;br&gt;Patients with identified severe liver disease, underlying cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit;\r&lt;br&gt;Patients with renal impairment (estimated glomerular filtration rate [eGFR]&lt; 30 mL/min/1.73m2, using the MDRD method);\r&lt;br&gt;2. History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level III-IV;\r&lt;br&gt; 3. QTc &gt;= 480ms;\r&lt;br&gt; 4. Uncorrected patients with hypokalemia or hypokalemia;\r&lt;br&gt; 5. Patients with psychiatric disorders;\r&lt;br&gt; 6. Patients with pancreatitis;\r&lt;br&gt; 7. Pregnant or breastfeeding women or female with positive pregnancy test at child-bearing age.","Exclusion criteria: (1) Patients who are participating in clinical trials of other drugs;\r&lt;br&gt;(2) Pregnant or lactating women;\r&lt;br&gt;(3) ALT / AST &gt; 5-fold ULN, neutrophil &lt; 0.5x10^9/L, platelet &lt; 50x10^9/L;\r&lt;br&gt;(4) The diagnosis of rheumatic immune related diseases was clear;\r&lt;br&gt;(5) Long term oral anti rejection drugs or immunomodulatory drugs;\r&lt;br&gt;(6) Hypersensitive reaction to mAb or any adjuvant;\r&lt;br&gt;(7) Active tuberculosis patients with definite bacterial and fungal infection;\r&lt;br&gt;(8) Patients with organ transplantation history within three months;\r&lt;br&gt;(9) There was a history of PCI in the past 60 days;\r&lt;br&gt;(10) COPD with end-stage chronic diseases, including NYHA heart failure above grade III, chronic kidney disease with CCR &lt; 40 ml / min or requiring family oxygen therapy.","Exclusion criteria: Druring pregnancy or breastfeeding.","Exclusion criteria: 1. Patients with allergic constitution or known allergy to study drug / similar drug;\r&lt;br&gt;2. Patients who often use sedatives, sleeping pills or other addictive drugs; patients who have a history of drug abuse or positive drug abuse screening within 12 months before the first administration;\r&lt;br&gt;3. Alcoholics or patients who drink more than 14 units of alcohol per week (1 unit = 360ml of beer or 45ml of spirits or 150ml of wine with 40% of alcohol), patients who are addicted to smoking or quit smoking for less than 3 months, patients who are positive in alcohol breath test and nicotine test, and can not be banned from smoking or alcohol during the test period;\r&lt;br&gt;4. Patients who used any prescription medicine or Chinese herbal medicine supplement within one month before the first administration; patients who used any over-the-counter medicine (OTC), food supplement (including vitamins, calcium tablets, etc.) within two weeks before the first administration; patients who used contraceptive within two weeks before the first administration;\r&lt;br&gt;5. Patients who participated in other clinical trials and took the study drug within 3 months before the first administration;\r&lt;br&gt;6. The patients who participated in blood donation (including component blood donation) or lost 400ml blood within 3 months before the first administration, and the patients who participated in blood donation (including component blood donation) or lost 200ml blood within 1 month before screening, or received blood transfusion;\r&lt;br&gt;7. There was a history of autonomic nervous dysfunction and / or current history (such as recurrent syncope, palpitation, etc.) within 3 years before the first administration;\r&lt;br&gt;8. Patients with previous history of cardiovascular, liver, kidney, lung, digestive tract, nervous system diseases, and any history or condition that may significantly affect drug absorption, distribution, metabolism and excretion. Any medical history or condition that may be hazardous to the subjects participating in the trial. Researchers should consider the following medical history or conditions: inflammatory gastroenteritis, gastroesophageal reflux, gastrointestinal or rectal bleeding; history of pancreatic injury or pancreatitis; major surgical history such as gastrectomy, gastroenterostomy, or enterotomy; history of acute and chronic renal insufficiency, history of kidney transplantation;\r&lt;br&gt;9. Screening the patients with severe vomiting and diarrhea in the previous week;\r&lt;br&gt;10. Pregnant and lactating female subjects and those of childbearing age who could not use contraception as required;\r&lt;br&gt;11. Hepatitis B surface antigen positive, hepatitis C antibody positive, syphilis antibody positive, HIV antibody positive;\r&lt;br&gt;12. Patients who have special requirements for diet and fail to comply with the provided diet and corresponding regulations;\r&lt;br&gt;13. Subjects who refused to stop using any drink or food containing methylxanthine, such as coffee, tea, cola, chocolate, etc., 48 hours before the first administration until the end of the study;\r&lt;br&gt;14. Subjects who refused to discontinue any drink or food containing grapefruit 7 days before the first administration until the end of the study;\r&lt;br&gt;15. Subjects with difficulty in venous blood collection or intolerability to venipuncture;\r&lt;br&gt;16. Subjects with other unsuitable factors (including but not limited to the inability to understand the research requirements, poor compliance, weakness, etc.) judged by the researcher.","Exclusion criteria: 1) Pregnant or lactating women;\r&lt;br&gt;2) High-resolution CT before the onset of the disease suggests the presence of interstitial injures in lungs;\r&lt;br&gt;3) Acute interstitial lung injures caused by other reasons (within two weeks);\r&lt;br&gt;4) Invasive ventilator assisted ventilation;\r&lt;br&gt;5) Multiple organ dysfunction syndrome.","Exclusion criteria: &lt;br&gt;- Patients with known history of serious allergic reactions, including anaphylaxis, to human granulocyte-macrophage colony stimulating factor such as sargramostim, yeast-derived products, or any component of the product.\r&lt;br&gt;- mechanical ventilation before start of study\r&lt;br&gt;- patients with peripheral white blood cell count above 25.000 per microliter and/or active myeloid malignancy\r&lt;br&gt;-patients on high dose systemic steroids (&gt; 20 mg methylprednisolone or equivalent)\r&lt;br&gt;-patients on lithium carbonate therapy\r&lt;br&gt;- Patients enrolled in another investigational drug study\r&lt;br&gt;- Pregnant or breastfeeding females (all female subjects regardless of childbearing potential status must have negative pregnancy test at screening)\r&lt;br&gt;- Patients with serum ferritin &gt;2000 mcg/ml (which will exclude ongoing HLH)&lt;br&gt;","Exclusion criteria: &lt;br&gt; Under 18 years of age\r&lt;br&gt; Denial of written consent\r&lt;br&gt; Any patient case where it has been decided not to rejuvenate\r&lt;br&gt; Serum AST values greater than 5 times the upper normal range\r&lt;br&gt; QTc interval in rest electrocardiogram greater than 500msecs\r&lt;br&gt; Pregnancy or lactation. Urgent pregnancy test to exclude pregnancy before inclusion in the study&lt;br&gt;","Exclusion criteria: &lt;br&gt;- Pre-existing chronic pulmonary disease&lt;br&gt;\t- Former diagnosis of Interstitial pulmonary disease&lt;br&gt;\t- Former diagnosis of COPD 4 or FEV1&lt;30%pred&lt;br&gt;\t- Previous DLCO &lt;45%&lt;br&gt;\t- Total lung capacity (TLC) &lt; 60% of predicted&lt;br&gt;\t- Lung cancer with non-surgical treatment in last year &lt;br&gt;\t- Home oxygen treatment&lt;br&gt;\t- Active treatment of hematological or non-hematological cancer with targeted, \timmuno- or chemotherapy in the last year &lt;br&gt;\t- Chronic or acute renal failure, defined as eGFR &lt;30ml/min&lt;br&gt;\t- Inability to provide informed consent&lt;br&gt;\t- Any subject who had received any investigational medication within 1 \tmonth prior \tto the start of this study or who is scheduled to receive another investigational drug \tduring the course of this study&lt;br&gt;\t- Active liver disease, porphyria or elevations of serums transaminases &gt;3 x \tULN \t(upper limit of normal) or bilirubin &gt; 1.5 x ULN&lt;br&gt;\t- History or suspicion of inability to cooperate adequately.&lt;br&gt;\t- White blood count &lt; 4.0^109/l&lt;br&gt;\t- Hemoglobin &lt; 6.0 mmol/l&lt;br&gt;\t- Thrombocytes &lt; 100^109/l&lt;br&gt;\t- Pregnant female subjects&lt;br&gt;\t- Breastfeeding female subjects&lt;br&gt;","Exclusion criteria: &lt;br&gt;1.\tRequiring ICU admission at screening\r&lt;br&gt;2.\tHistory of psoriasis\r&lt;br&gt;3.\tTinnitus, reduced hearing\r&lt;br&gt;4.\tVisual impairment\r&lt;br&gt;5.\tKnown adverse reaction to hydroxychloroquine sulphate\r&lt;br&gt;6.\tPregnancy\r&lt;br&gt;7.\tProlonged QT interval (&gt;450 ms)\r&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;1. Patients whose clinical condition is deteriorating rapidly or any patient for whom the investigator does not consider there is a reasonable expectation that they will be able to complete the study.\r&lt;br&gt;2. Known positive Hepatitis B surface antigen, Hepatitis C antibody or HIV antibody\r&lt;br&gt;3. Current or chronic history of liver disease (Child Pugh score = 10), or known hepatic or biliary abnormalities (with the excep-tion of Gilbert's syndrome or asymptomatic gallstones).\r&lt;br&gt;4. The patient has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).\r&lt;br&gt;5. Patients requiring high doses of loop diuretics (i.e. &gt; 240 mg fu-rosemide daily) with significant intravascular volume depletion, as assessed clinically.\r&lt;br&gt;6. History of sensitivity to any of the study medications, or compo-nents thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.\r&lt;br&gt;7. Pregnant females as determined by positive serum or urine hCG test prior to dosing.\r&lt;br&gt;8. Lactating females.\r&lt;br&gt;9. Unwillingness or inability to follow the procedures outlined in the protocol.\r&lt;br&gt;10. History of sensitivity to heparin or heparin-induced thrombocy-topenia.\r&lt;br&gt;11. Unstable Hemoglobin (Hb &lt; 7) at time of drug infusion (i.e. Hb must be &gt; 7 mg/dL at the time of drug infusion. Transfusion is permitted to increase Hb levels to allow entry into the study.\r&lt;br&gt;12. Malignancy or other irreversible condition for which 6 month mortality is estimated to be &gt;50%.\r&lt;br&gt;13. Arterial blood pH less than 7.2 or serum HCO3- &lt;15 (if ABG not available) before infusion is started.\r&lt;br&gt;14. Known severe chronic pulmonary disease:\r&lt;br&gt;      - known FEV1/FVC less than 45% predicted, or\r&lt;br&gt;      - known chronic hypercapnia (PaCO2 &gt; 45 mmHg) or chronic hypoxemia [(PaO2&lt;55 mmHg) on FiO2 =0.21, or supplemental oxygen therapy prior to this admission], or\r&lt;br&gt;      - known FEV1 &lt;15 ml/kg (e.g. 1L for 70 kg person), or\r&lt;br&gt;      - known radiographic evidence of chronic interstitial infil-tration, or\r&lt;br&gt;      - known hospitalization within the past six months for respiratory failure (PaCO2 &gt; 50 mmHg or PaO2 &lt; 55 mmHg, or oxygen saturation &lt;88% on FiO2 = 0.21)\r&lt;br&gt;      - known chronic restrictive, obstructive, neuromuscular, chest wall, or pulmonary vascular disease resulting in severe exercise restriction (i.e. unable to climb stairs or perform household duties), known secondary polycythemia,  \r&lt;br&gt;        severe pulmonary hypertension, or ventilator dependency\r&lt;br&gt;15. Known vasculitis with diffuse alveolar hemorrhage\r&lt;br&gt;16. Lung transplantation\r&lt;br&gt;17. Pre-existing renal failure, i.e. requiring renal replacement ther-apy with hemodialysis or peritoneal dialysis\r&lt;br&gt;18. There are other uncontrolled co-morbidities that increase the risks associated with the study drug administration, that are as-sessed by the medical expert team as unsuitable\r&lt;br&gt;19. Patient in trials for COVID-19 within 30 days before ICF\r&lt;br&gt;20. Unstable hemodynamics in the preceding 4 hours (MAP = 65 mmHg, or SAP &lt; 90 mmHg, DAP &lt; 60 mmHg, and vaso-active agents required)\r&lt;br&gt;21. Immunocompromised patients (chemotherapy, HIV, organ transplants, stem cell transplants),\r&lt;br&gt;22. Receive any Angiotensin-Converting-Enzyme inhibitor (ACEi) or renin inhibitor treatment within 7 days before ICF&lt;br&gt;","Exclusion criteria: &lt;br&gt;",null,null,null,null,"Exclusion criteria: &lt;br&gt;- RT-PCR SARS-Cov2 ngative\r&lt;br&gt;- Saturation capillaire priphrique en oxygne infrieure ou gale  94% (SpO2 =94%) malgr une oxygnothrapie suprieure ou gale  3L/min (= 3L/min)\r&lt;br&gt;- Dfaillance dorgane ncessitant une admission en ranimation ou unit de soins-continus\r&lt;br&gt;- Comorbidit engageant le pronostic vital  court terme (esprance de vie &lt; 3 mois)\r&lt;br&gt;- Toute raison rendant le suivi  J28 impossible\r&lt;br&gt;- Traitement en cours par hydroxychloroquine\r&lt;br&gt;- Contre-indication absolue au traitement par hydroxychloroquine (hypersensibilit connue, traitement concomitant  risque de torsades de pointe)\r&lt;br&gt;- ECG chez les patients  risque mettant en vidence un allongement du QT corrig suprieure  440 ms chez lhomme et 460 ms chez la femme.\r&lt;br&gt;- Femme enceinte, allaitante ou parturiente \r&lt;br&gt;- Personne prive de libert par dcision judiciaire ou administrative \r&lt;br&gt;- Personne faisant lobjet de soins psychiatriques sous la contrainte\r&lt;br&gt;- Personne faisant lobjet dune mesure de protection lgale\r&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;- Hypersensitivity to the active substances or to any of the following excipients: lactose monohydrate, povidone, corn starch, magnesium stearate.&lt;br&gt;- Retinopathies&lt;br&gt;- Combination with citalopram, escitalopram, hydroxyzine, domperidone and piperazine due to increased risk of ventricular rhythm disturbances, including torsades de pointes. &lt;br&gt;- Patient with known QT prolongation&lt;br&gt;- Known deficit in G6PD&lt;br&gt;",null,null,null,"Exclusion criteria: 1.\tPatients treated with mechanical ventilation for other concomitant causes.\r&lt;br&gt;2.\tPatients treated with ECMO for other concomitant causes\r&lt;br&gt;",null,"Exclusion criteria: Participants fulfilling any of the following criteria are not eligible for inclusion in this study:\r&lt;br&gt;1. History of allergy or intolerance to chloroquine, vitamin C or any excipients.\r&lt;br&gt;2. Contraindication to taking chloroquine as chemoprophylaxis e.g. known epileptic, creatinine clearance &lt; 10 mL/min, known prolonged QT syndrome, diabetes.\r&lt;br&gt;3. Those having previously received hydroxychloroquine for skin conditions or rheumatological diseases, chloroquine for malaria, tamoxifen, amiodarone or other drugs that may affect the retina within 30 days or 5 half-lives (whichever is longer) of study start.\r&lt;br&gt;4. Taking a concomitant medication (abiraterone acetate, agalsidase, amodiaquine, conivaptan, dabrafenib, dacomitinib, dapsone (systemic), enzalutamide, fusidic acid (systemic), idealisib, lanthanum, lumefantrine, mefloquine, MiFEPRIStone, Mitotane, Pimozide, QT-prolonging agents, or stiripentol) which cannot be safely stopped.\r&lt;br&gt;5. Participants who, in the opinion of the Investigator, do not have the ability to complete the study.\r&lt;br&gt;For other eligibility criteria considerations, the Investigator is referred to the IB (ADFMIDI IB) for detailed information regarding warnings, precautions, contraindications, AEs, and other significant data pertaining to the use of chloroquine.",null,null,null,null,null,"Exclusion criteria: &lt;br&gt;Age &lt;18 years, pregnancy suspected or confirmed, severe heart failure, suspected or confirmed bacterial infection, current solid or haematological malignancy, neutropenia, ALAT elevation more than three times the laboratory upper limit, ASA class 5 (after COVID19 admission) or higher at inclusion (prior admission), severe chronic obstructive pulmonary disease or heart failure (NYHA class II or higher), current treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs)/immunosuppressive agents including IL-6 inhibitors, or with Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during the study period, current use of chronic oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, previous or active tuberculosis (TB), HIV infection regardless of immunological status, hepatitis, evidence of recent (30 days) invasive bacterial or fungal infections, patients who have received immunosuppressive antibody therapy within the past 5 months, including intravenous immunoglobulin or plans to receive during the study period, IV drug abuse, history of inflammatory bowel disease, diverticulitis, ulcer, perforated gastrointestinal tract, participation in any clinical research study evaluating an investigational product (IP) or therapy within 3 months and less than five half-lives of IP prior inclusion to the study, any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study, inability to give informed consent.&lt;br&gt;",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Exclusion criteria: Exclusion Criteria:\r&lt;br&gt;\tCurrent psychosis\r&lt;br&gt;\tImminent suicidal risk\r&lt;br&gt;\tCurrent substance dependence (but not abuse) \r&lt;br&gt;No access to internet-based access to teleconferencing facility\r&lt;br&gt;",null,null,null,null,"Exclusion criteria: Prospective participants are excluded from the study if they decline the offer to participate in the study experimental arm.","Exclusion criteria: 1. Pregnant",null,null,null,null,null,null,null,null,"Exclusion criteria: &lt;br&gt;                1. Prior receipt of any vaccines (licensed or investigational) &lt; = 30 days before enrolment&lt;br&gt;                2. Planned receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination&lt;br&gt;                3. Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data&lt;br&gt;                4. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate&lt;br&gt;                5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent severe infections and chronic use of (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)&lt;br&gt;                6. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine&lt;br&gt;                7. Any history of hereditary angioedema or idiopathic angioedema&lt;br&gt;                8. Any history of anaphylaxis in relation to vaccination&lt;br&gt;                9. Pregnancy, lactation or willingness/intention to become pregnant during the study&lt;br&gt;                10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)&lt;br&gt;                11. History of serious psychiatric condition likely to affect participation in the study&lt;br&gt;                12. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture&lt;br&gt;                13. Any other serious chronic illness requiring hospital specialist supervision&lt;br&gt;                14. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week&lt;br&gt;                15. Suspected or known injecting drug abuse in the 5 years preceding enrolment&lt;br&gt;                16. Any clinically significant abnormal finding on screening biochemistry, haematology blood tests or urinalysis&lt;br&gt;                17. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data&lt;br&gt;                18. History of laboratory confirmed COVID-19&lt;br&gt;                19. New onset of fever and a cough or shortness of breath in the 30 days preceding screening and/or enrolment&lt;br&gt;","Exclusion criteria: 1. Any woman not meeting the criteria.",null,null,null,null,null,null,null,null,null,null,null,null,"Exclusion criteria: 1. The child was combined with other acute and chronic somatic diseases, hereditary diseases, and hearing and hearing impairment; 2. The parents of the child refused to cooperate after the investigator explained; 3. The child could not participate in the full study; 4. The child was participating or was participated in related experimental research projects in the last 8 months.","Exclusion criteria: Exclusion criteria: incomplete case data.",null,null,null,null,null,null,null,null,"Exclusion criteria: 1. Patients who have received treatment in the ICU due to death or transfer out within 24 hours;\r&lt;br&gt;2. The medical record information is seriously missing, according to the case report form, the data is missing more than 50% of patients.","Exclusion criteria: 1. Participated in other clinical trials 4 weeks before the start of this study;\r&lt;br&gt;2. Patients with hypertension, diabetes or other chronic diseases;\r&lt;br&gt;3. People with other system basic diseases;\r&lt;br&gt;4. Patients with other pathogens before or at the time of admission;\r&lt;br&gt;5. Patients who recur after discharge;\r&lt;br&gt;6. Pregnant or lactating women;\r&lt;br&gt;7. Those who do not sign the informed consent.",null,null,null,null,null,null,null,null,"Exclusion criteria: Refusal to consent","Exclusion criteria: N/A",null,null,null,null,null,null,null,"Exclusion criteria: 1. Patients with primary and secondary cardiovascular, cerebrovascular, renal, endocrine, neurological and blood system diseases, tumors and tuberculosis;\r&lt;br&gt;2. Patients who have participated in or are participating in other clinical trials within one month;\r&lt;br&gt;3. Patients with mental disorders who can not express their feelings;\r&lt;br&gt;4. There are other situations that are not suitable to be included in the study.","Exclusion criteria: 1. With complications of multiple organ failure;\r&lt;br&gt;2. Patients with malignant tumor;\r&lt;br&gt;3. Pregnant women;\r&lt;br&gt;4. HIV positive.",null,null,null,null,null,null,null,null,null,null,null,null,"Exclusion criteria: -\tSevere Covid-19 defined as NEWS-2 score &gt;5 or admission to the ICU needing ventilation or pressure support. &lt;br&gt;-\tContra-indications for hydroxychloroquine or chloroquine&lt;br&gt;-\tKnown pregnancy, not using adequate contraception and having a chance of being pregnant (unless a negative pregnancy test is documented) or breast-feeding&lt;br&gt;-\tUnable to take oral medication (chloroquine and hydroxychloroquine can be administered through tube feeding and is considered oral administration)&lt;br&gt;-\tIdentified allergies to 4-aminoquinoline&lt;br&gt;-\tSevere diseases of the blood system &lt;br&gt;-\t6-phosphate dehydrogenase deficiency &lt;br&gt;-\tHistory of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level III-IV&lt;br&gt;-\tCorrected QT interval (QTc) = 480ms on baseline electrocardiogram. (The treatment guideline states: An electrocardiogram is made before start chloroquine and hydroxychloroquine)&lt;br&gt;-\tUncorrected severe hypokalaemia (&lt; 2,5 mmol/l) or uncorrected severe hypomagnesemia (&lt; 0.6 mmol/l) &lt;br&gt;-\tPancreatitis&lt;br&gt;-\tConcomitant medication that affect drug absorption, metabolism and excretion, that can induce QT interval prolongation: &lt;br&gt;o\tAmiodarone, disopyramide, flecainide, ibutailide, kinidine, sotalol, &lt;br&gt;o\tchlorpromazine, citolapram, escitalopram, haloperidol, pimozide, &lt;br&gt;o\tazitromycine, claritromycine, erytromycine, moxifloxacine, trimethoprim/sulfamethoxazole, &lt;br&gt;o\tDimperidon, ondansetron,&lt;br&gt;o\tMethadon, &lt;br&gt;o\tAnagrelide, arseentrioxide, droperidol, pentamidine, sevofluraan, vandetanib. &lt;br&gt;-\tRefusal to participate expressed by patient or legally authorized representative if they are present &lt;br&gt;","Exclusion criteria: No possession of smartphone or tablet, no understanding of Dutch language.",null,null,null,null,null,null,null,null,"Exclusion criteria: &lt;br&gt;\tPatients with known allergy to hydroxychloroquine or chloroquine,  \r&lt;br&gt;\tPatients with known allergy to azithromycine, erythromycine, or all antibiotics belonging to the macrolide family. \r&lt;br&gt;\tPatients currently treated with Tamoxifen\r&lt;br&gt;\tPatients with known contra-indication to treatment with the study drug, including retinopathy, G6PD deficiency, QT prolongation and severe hepato-cellular insufficiency. \r&lt;br&gt;\tPregnant or breastfeeding women. Women of childbearing potential (WOCBP, as defined in appendix 2) should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.  If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\r&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;-Patients with known history of serious allergic reactions, including anaphylaxis, to any of the study medications, or any component of the product.\r&lt;br&gt;-mechanical ventilation &gt; 24 h at randomization\r&lt;br&gt;-clinical frailty scale above 3\r&lt;br&gt;-active bacterial or fungal infection\r&lt;br&gt;-unlikely to survive beyond 48h\r&lt;br&gt;-neutrophil count below 1500 cells/microliter\r&lt;br&gt;-platelets below 50.000/microliter\r&lt;br&gt;-Patients enrolled in another investigational drug study\r&lt;br&gt;-patients on high dose systemic steroids (&gt; 8 mg methylprednisolone or equivalent for more than 1 month) for COVID-19 unrelated disorder\r&lt;br&gt;-patients on immunosuppressant or immunomodulatory drugs\r&lt;br&gt;-patients on current anti-IL1 or anti-IL6 treatment\r&lt;br&gt;-signs of active tuberculosis\r&lt;br&gt;-serum transaminase levels &gt;5 times upper limit of normal, unless there are clear signs of cytokine release syndrome defined by LDH &gt;300 IU/L and ferritin &gt;700 ng/ml\r&lt;br&gt;-history of (non-iatrogenic) bowel perforation or diverticulitis\r&lt;br&gt;- Pregnant or breastfeeding females (all female subjects deemed of childbearing potential by the investigator must have negative pregnancy test at screening)&lt;br&gt;",null,"Exclusion criteria: Confirmed diagnosis of a pathogen unrelated to the objectives of this study and no indication or likelihood of co-infection with a relevant pathogen\r&lt;br&gt;\r&lt;br&gt;Refusal by participant, parent, or appropriate representative.\r&lt;br&gt;\r&lt;br&gt;Any other reason, as determined by the Lead Investigator or treating clinician, that the patient should not be included in the study, in-line with ICH GCP (E6 R2) requirements and the Australian Code for Responsible Conduct of Research (2018).\r&lt;br&gt;",null,null,null,null,null,null,null,null,"Exclusion criteria: &lt;br&gt; Age below 18 years&lt;br&gt; Denial for written informed consent&lt;br&gt; Any stage IV malignancy&lt;br&gt; Any do not resuscitate decision&lt;br&gt; Active tuberculosis (TB) as defined by the co-administration of drugs for the treatment of TB&lt;br&gt; Infection by the human immunodeficiency virus (HIV)&lt;br&gt; Any primary immunodeficiency&lt;br&gt; Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg prednisone or greater the last 15 days.&lt;br&gt; Any anti-cytokine biological treatment the last one month&lt;br&gt; Medical history of systemic lupus erythematosus&lt;br&gt; Medical history of multiple sclerosis or any other demyelinating disorder.&lt;br&gt; Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study&lt;br&gt;","Exclusion criteria: Individuals aged &lt;18 years old.","Exclusion criteria: &lt;br&gt;                1. Patients will be excluded if they have a medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial&lt;br&gt;                2. In addition, if the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms, then the patient will be excluded from randomisation to that arm&lt;br&gt;",null,"Exclusion criteria: Severe distress based on K10 (scores 30-50 very high distress) as these participants would require a more intensive therapeutic approach.","Exclusion criteria: Does not meet inclusion criteria","Exclusion criteria: &lt;br&gt;                1. Respiratory failure not the primary reason for ICU admission&lt;br&gt;                2. History of proven/ probable invasive pulmonary aspergillosis&lt;br&gt;",null,null,null,null,"Exclusion criteria: 1. Currently admitted to an Intensive Care Unit (ICU)\r&lt;br&gt;2. Currently receiving intensive respiratory support (invasive or non-invasive ventilation or humidified high flow nasal oxygen)\r&lt;br&gt;3. Currently taking LPV/r OR hydroxychloroquine\r&lt;br&gt;4. Known allergy or hypersensitivity to LPV/r OR hydroxychloroquine\r&lt;br&gt;5. Use of medications that are contraindicated with LPV/r OR hydroxychloroquine that cannot be replaced or stopped during the study period. https://www.covid19-druginteractions.org/.\r&lt;br&gt;6. Currently on other investigational agents with targeted antiviral effects\r&lt;br&gt;7. Known cirrhosis or ALT or AST greater than 5x upper limit of normal\r&lt;br&gt;8. Previous participation in the trial\r&lt;br&gt;9. Known pregnancy\r&lt;br&gt;10. Known HIV infection not on antiretroviral therapy \r&lt;br&gt;11. QTc greater than or equal to 470 for males, QTc greater than or equal to 480 for females\r&lt;br&gt;12. Treating team deems enrolment in the study is not in the best interests of the patient\r&lt;br&gt;13. Unable to provide consent\r&lt;br&gt;14. Death is deemed to be imminent and inevitable within the next 24 hours","Exclusion criteria: \tKnown iodine sensitivity \r&lt;br&gt;\tPreviously diagnosed thyroid disease\r&lt;br&gt;\tPreviously diagnosed kidney disease\r&lt;br&gt;\tKnown to be pregnant or currently breastfeeding \r&lt;br&gt;","Exclusion criteria: &lt;br&gt;                1. Planned intubation and mechanical ventilation imminent within 1 hour&lt;br&gt;                2. Known or clinically apparent pregnancy&lt;br&gt;                3. Any absolute contraindication to CPAP or HFNO&lt;br&gt;                4. Decision not to intubate due to ceiling of treatment or withdrawal of care anticipated&lt;br&gt;                5. Equipment for both CPAP and HFNO not available&lt;br&gt;","Exclusion criteria: &lt;br&gt;                1. Any of the available study drugs are contra-indicated (e.g. because of patient characteristics, chronic liver or heart disease, or some concurrent medication)&lt;br&gt;                2. Pregnant&lt;br&gt;                3. Declined to participate in the study&lt;br&gt;",null,null,null,null,"Exclusion criteria: (1) body temperature&gt;38 degree C\r&lt;br&gt;(2) heart rate at rest&gt;120 cpm or &lt;40 cpm,SBP&lt;90mmHg or &gt;180mmHg,respiratory rate&lt;25 cpm. Or the above vital signs change significantly;\r&lt;br&gt;(3) continuous oxygen therapy is required;\r&lt;br&gt;(4) patients with myocarditis, pulmonary hypertension, congestive heart failure, acute renal failure, fresh venous thromboembolic disease, unstable fractures, who are not suitable for exercise;\r&lt;br&gt;(5) Patients with disturbance of consciousness, cognitive impairment, mental disorder, severe balance disorder, severe osteoarticular diseases, who cannot cooperate with treatment and evaluation;\r&lt;br&gt;(6) Other conditions that do not cooperate with rehabilitation treatment.","Exclusion criteria: 1. Dyspnea scale mMRC 0~1 or 4;\r&lt;br&gt;2. Resting heart rate&gt;100bpm;\r&lt;br&gt;3. Adjusting dosage of drugs which affect cardiopulmonary function or heart rate (such as: trimetazidine, salbutamol, beta-blocker);\r&lt;br&gt;4. Combined uncontrolled chronic disease, such as uncontrolled hypertension (resting BP=160100mmHg), uncontrolled diabetes (random blood glucose&gt;16.7 mmol/l, HbA1C&gt;7.0%);\r&lt;br&gt;5. Combined severe organic disease, such as unstable hemodynamic heart disease, heart failure with limited movement (previous diagnosis, or have clinical symptoms of heart failure, after consultation by cardiologist);\r&lt;br&gt;6. Cerebrovascular disease occurred within the past 6 months;\r&lt;br&gt;7. Active stage of digestive ulcer, thyroid dysfunction, or active tuberculosis;\r&lt;br&gt;8. Chronic kidney disease &gt;=stage 3 (eGFR&lt;60ml/min);\r&lt;br&gt;9. Have received intra-articular drug injection or surgical treatment in the lower extremity within the past 6 months;\r&lt;br&gt;10. Poor compliance, unable to cooperate with assessment or training;\r&lt;br&gt;11. Unable to walk independently with auxiliary;\r&lt;br&gt;12. Combined mental disease that prevents patients from living independently or receiving treatment;\r&lt;br&gt;13. Alcohol abuse or illegal drug use history;\r&lt;br&gt;14. Pregnancy, nursing or preparing for pregnancy (including male subjects);\r&lt;br&gt;15. Have participated in other clinical trials within the past 3 months.","Exclusion criteria: Patients not suitable for study judged by researchers","Exclusion criteria: 1. Staff who are not pursuing a career at Medical school at UMSA \r&lt;br&gt;2. Incomplete information in the questionnaire.","Exclusion criteria: 1) left heart failure pulmonary edema;\r&lt;br&gt;2) pregnancy and lactation or perinatal period;\r&lt;br&gt;3) liver failure MELD score &gt;40;\r&lt;br&gt;4) a history of deep vein thrombosis or pulmonary embolism in the past 3 months;\r&lt;br&gt;5) cases that the researcher judged to be unsuitable for the group.","Exclusion criteria: incomplete case date",null,null,null,null,"Exclusion criteria: 1. The pneumonia patients with severe new coronavirus infection met one of the following conditions: respiratory distress, RR&gt;=30 times / min; or SaO2 / SpO2 &lt;93% in resting state; or arterial partial pressure of oxygen (PaO2) / concentration of oxygen (FiO2) &lt;300MMHG (1mmhg = 0.133kpa);\r&lt;br&gt;2. Pneumonia patients with severe new coronavirus infection meet one of the following conditions: respiratory failure and need mechanical ventilation; or shock; or other organ failure combined with ICU monitoring treatment;\r&lt;br&gt;3. Severe liver disease (such as child Pugh score &gt;=C, AST &gt; 5 times upper limit);\r&lt;br&gt;4. Patients with contraindications specified in the instructions of danoprevir and ritonavir tablets;\r&lt;br&gt;5. Patients who plan to take protease inhibitors other than danoprevir and ritonavir simultaneously during the trial.\r&lt;br&gt;6. The pregnancy test of female subjects in the screening period was positive;\r&lt;br&gt;7. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).","Exclusion criteria: 1. Pregnant women;\r&lt;br&gt;2. Previous history of drug and alcohol abuse;\r&lt;br&gt;3. Inability to communicate or comply with research requirements;\r&lt;br&gt;4. Patients with acquired immune deficiency syndrome;\r&lt;br&gt;5. Patients with malignant tumors.","Exclusion criteria: 1.Serious basic diseases affecting survival, including: uncontrolled malignant tumor with multiple metastases that cannot be removed, hematological diseases, cachexia, active hemorrhage, severe malnutrition, AIDS, etc.;\r&lt;br&gt;2.Obstructive pneumonia, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis caused by lung tumor;\r&lt;br&gt;3.Use in vitro life support (ECMO, ECCO2R);\r&lt;br&gt;4.Patients with bronchial asthma, peptic ulcer, and patients allergic to acetylcysteine;\r&lt;br&gt;5.Any potential violation of test compliance or any other circumstance affecting safety and effectiveness evaluation that may exist, which the researchers believe is not suitable for patients participating in the study.","Exclusion criteria: None",null,null,null,null,"Exclusion criteria: 1. Patients without complete clinical data;\r&lt;br&gt;2. Give up treatment and discharge patients automatically.","Exclusion criteria: 1. Patients who refused to participate in the project; \r&lt;br&gt;2. Patients developed symptoms caused by other pathogens rather than the SARS-CoV-2, and there was no evidence show that patients were infected with SARS-CoV-2.","Exclusion criteria: Patients who meet the following criteria will be excluded from the study:&lt;br&gt;- Language problems precluding the completion of the questionnaire;&lt;br&gt;- Likelihood of absence in the next 6 months;&lt;br&gt;- Lack of informed consent.","Exclusion criteria: -Pre-existing pulmonary disease or heart failure&lt;br&gt;-Absence of COVID infection","Exclusion criteria: SARS-CoV 2 PCR negative OR no SARS-CoV 2 PCR","Exclusion criteria: Younger than 8 years old",null,null,"Exclusion criteria: Moribund or for palliative care","Exclusion criteria: &lt;br&gt;Subjects presenting with any of the following will not be included in the study:\r&lt;br&gt;1.\tShock requiring vasoactive agents \r&lt;br&gt;2.\tAcute respiratory distress syndrome requiring invasive mechanical ventilation\r&lt;br&gt;3.\tCirculatory assistance\r&lt;br&gt;4.\tHistory of malignant hypertension according to the definition of the 2018 ESC/ESH guidelines on hypertension\r&lt;br&gt;5.\tUncontrolled blood pressure despite the use of five antihypertensive drugs \r&lt;br&gt;6.\tHistory of nephrotic syndrome\r&lt;br&gt;7.\tHistory of hospitalization for hemorrhagic stroke in the past 3 months\r&lt;br&gt;8.\tRAS blockers therapy previously stopped &gt; 48h\r&lt;br&gt;9.\tNo affiliation to the French Health Care System Scurit Sociale\r&lt;br&gt;10.\tInability to obtain informed consent&lt;br&gt;","Exclusion criteria: Suspected COVID-19 not subsequently confirmed on PCR, serology or imaging","Exclusion criteria: \tKnown pregnancy or planning to become pregnant during the study period\r&lt;br&gt;\tCurrently breastfeeding\r&lt;br&gt;\tKnown maculopathy or retinal disorder.\r&lt;br&gt;\tKnown cardiac disease/dysrhythmia or prolonged QTc\r&lt;br&gt;\tKnow renal disease\r&lt;br&gt;\tKnown hepatic disease\r&lt;br&gt;\tKnown hypomagnesaemia or hypokalaemia. \r&lt;br&gt;\tCurrently using hydroxychloroquine or any 4-aminoquinoline.\r&lt;br&gt;\tUse of medications prolonging QTc including: Class IA (quinidine, procainamide, disopyramide) and III (amiodarone, sotalol, ibutilide, dofetilide) antiarrythmics, macrolides, methadone, fluoroquinolones, domperidone, fluconazole, ondansetron, tacrolimus, tramadol, anti-retrovirals.\r&lt;br&gt;\tCurrent use of tamoxifen, digoxin, tricyclics, SSRIs, antipsychotics, halfantrine, cyclosporin and anti-epileptic medications\r&lt;br&gt;\tCurrent use of oral hypoglycaemics including glipizide, glyburide, gliclazide, glimepiride, repaglinide, nateglinide, metformin, rosiglitazone, pioglitazone, acarbose, miglitol, voglibose, sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin, dapagliflozin, canagliflozin, bromocriptine. \r&lt;br&gt;\tSensitivity or allergy to 4-aminoquinilone compounds or any excipients used in the study\r&lt;br&gt;\tUnable to access digital consent forms or maintain remote contact with the study team\r&lt;br&gt;\tHave any other condition which, at the investigators discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.\r&lt;br&gt;","Exclusion criteria: 1. Pre-existing chronic pulmonary disease, including:&lt;br&gt;? Known diagnosis of Interstitial Lung disease&lt;br&gt;? Former diagnosis of COPD 4 or FEV1&lt;30%pred&lt;br&gt;? DLCO &lt;45%&lt;br&gt;? Total lung capacity (TLC) &lt; 60% of predicted&lt;br&gt;? Lung cancer with non-surgical treatment in last year&lt;br&gt;2. Home oxygen treatment&lt;br&gt;3. Pre-existing heart failure with a known left ventricular ejection fraction &lt;40%&lt;br&gt;4. Active treatment of hematological or non-hematological cancer with targeted, immuno- or chemotherapy in the last year&lt;br&gt;4. Inability to provide informed consent&lt;br&gt;5. Any subject who had received any investigational medication within 1 month prior to the start of this study or who is scheduled to receive another investigational drug during the course of this study&lt;br&gt;6. Active liver disease, porphyria or elevations of serums transaminases &gt;3 x ULN (upper limit of normal) or bilirubin &gt; 1.5 x ULN&lt;br&gt;7. History or suspicion of inability to cooperate adequately.&lt;br&gt;8. White blood count &lt; 4.0^109/l&lt;br&gt;9. Hemoglobin &lt; 6.0 mmol/l&lt;br&gt;10. Thrombocytes &lt; 100^109/l&lt;br&gt;11. Pregnant female subjects&lt;br&gt;12. Breastfeeding female subjects","Exclusion criteria: &lt;br&gt;1.\tAccompanying diseases other than COVID-19 with an expected survival time of \r&lt;br&gt;                    less than 12 months\r&lt;br&gt;2.\tIn the opinion of the clinical team, progression to death is imminent and \r&lt;br&gt;                    inevitable within the next 48 hours, irrespective of the provision of treatment\r&lt;br&gt;3.\tInterval &gt; 72 hours since start of ventilation support\r&lt;br&gt;4.\tNot considered eligible for extracorporeal oxygenation support  (even in case of \r&lt;br&gt;                     severe ARDS according to Berlin classification with Horovitz-Index &lt; 100 mg Hg) \r&lt;br&gt;5.\tChronic obstructive lung disease (COPD), stage 4\r&lt;br&gt;6.\tLung fibrosis with UIP pattern in CT and severe emphysema\r&lt;br&gt;7.\tChronic heart failure NYHA = 3 and/or pre-existing reduction of left ventricular \r&lt;br&gt;                    ejection fraction to = 30%\r&lt;br&gt;8.\tCardiovascular failure requiring = 0.5 g/kg/min noradrenaline (or equivalent) or \r&lt;br&gt;                     requiring more than two types of vasopressor medication\r&lt;br&gt;9.\tLiver cirrhosis Child C\r&lt;br&gt;10.\tLiver failure: Bilirubin &gt; 5 x ULN and elevation of ALT or AST (&gt; 10 x ULN)\r&lt;br&gt;11.\tAny history of adverse reactions to plasma proteins\r&lt;br&gt;12.\tKnown deficiency of immunoglobulin A\r&lt;br&gt;13.\tPregnancy\r&lt;br&gt;14.\tBreastfeeding women\r&lt;br&gt;15.\tVolume overload until sufficiently treated\r&lt;br&gt;16.\tPulmonary edema\r&lt;br&gt;17.\tParticipation in another clinical trial for treatment of COVID-19\r&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;- Inability to make a decision to participate (dementia, guardianship)&lt;br&gt;- Long QT syndrome, or QTc space &gt; 500 ms &lt;br&gt;- Presence of a pace maker&lt;br&gt;- Hyperkalemia &gt; 5.5 mmol/L or hypokalemia &lt; 3.5 mmol/L &lt;br&gt;- Treatment with piperazine, halofantrine, dasatinib, nilotinib.citalopram, escitalopram, hydroxyzine, domperidone, potent inhibitors of cytochrome P450 CYP3A4 isoenzyme, potent inducers of cytochrome P450 CYP3A4 isoenzyme. &lt;br&gt;- Hypersensitivity to any of the test drugs or chloroquine and other 4-aminoquinolines, amodiaquine, mefloquine, glafenine, floctafenine, antrafenine, ARB2 or sartan.&lt;br&gt;- Hepatic porphyria, known obstructive hepato-biliary disease, liver failure (stage = Child-Pugh B), stage 4 or 5 chronic kidney disease (DFG &lt;30 mL/min/1.73 m) or person on dialysis, retinopathy, lactose hypersensitivity, abnormalities in galactose metabolism, lactase deficiency, malabsorption syndrome, known glucose-6-phosphate dehydrogenase deficiency, symptomatic gout/hyperuricemia.&lt;br&gt;&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;1. Patient under guardianship or curatorship&lt;br&gt;2. Patient with plausible alternate diagnosis&lt;br&gt;3. ARDS evolving for more than 4 days&lt;br&gt;4. Contraindication to the HCQ&lt;br&gt;5. Contraindication to DXM&lt;br&gt;6. Uncontrolled septic shock&lt;br&gt;7. Untreated active infection or treated less than 24 hours&lt;br&gt;8. Long-term patient treated with corticosteroids (&gt; 20 mg / day) or HCQ&lt;br&gt;9. Immunocompromised patients: AIDS, bone marrow or solid organ transplant recipients&lt;br&gt;10. Pregnant women&lt;br&gt;","Exclusion criteria: \tAge less than 18yo or pregnant or lactating female\r&lt;br&gt;\tAllergy to Zn\r&lt;br&gt;\tSevere hepatic impairment defined as Child C liver disease. \r&lt;br&gt;\teGFR equal to or less than 30 mL/min/1.73 m2 (defined using CKD-EPI SCr formula)\r&lt;br&gt;\tHistory of any organ transplant which requires active immunosuppressive treatment which can interfere with kidney function\r&lt;br&gt;\tIf a patient required cardiopulmonary resuscitation (CPR) within 14 days \r&lt;br&gt;\tDNR (do not resuscitate) DNI (do not intubate) orders \r&lt;br&gt;\tDeath is deemed imminent or inevitable during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment \r&lt;br&gt;\tAlready receiving dialysis (either acute or chronic) or imminent need of dialysis at the time of enrolment \r&lt;br&gt;\tPatients with known HIV infection\r&lt;br&gt;\tPatients with a known or suspected history of oxalate nephropathy or hyperoxaluria, scurvy, chronic iron overload, G-6PD deficiency \r&lt;br&gt;\tClinician expects to prescribe Zinc for another indication\r&lt;br&gt;\tPatients with known haemochromatosis.","Exclusion criteria: &lt;br&gt;                Poor sleepers:&lt;br&gt;                1. Long-term (i.e. chronic) sleep problems (&gt; 3 months)&lt;br&gt;","Exclusion criteria: &lt;br&gt;known allergy or contra-indications to investigational products&lt;br&gt;anticipated transfer within 72 hours to a non-study hospital.&lt;br&gt;","Exclusion criteria: &lt;br&gt;? Patients with acute bleeding.&lt;br&gt;? Patients with thrombolytic treatment and anticoagulant treatment at therapeutic doses.&lt;br&gt;? Patients with an active malignant tumor.&lt;br&gt;? Patients with severe systemic or neuropsychiatric diseases.&lt;br&gt;? Patients with hypersensitivity to the active substance or to any of the excipients of the study drug.&lt;br&gt;? Patients who are participating in other clinical trials.&lt;br&gt;? Patients with an inability to understand informed consent.&lt;br&gt;? Pregnant patientsb, in the postpartum period or in the period of active lactation.&lt;br&gt;Physically fertile patients, UNLESS they are using a highly effective contraceptive method&lt;br&gt;","Exclusion criteria: &lt;br&gt;                1. Unable to follow study procedures&lt;br&gt;                2. Insufficient knowledge of the German, English, French, or Italian language&lt;br&gt;                3. Aged &lt;16 years&lt;br&gt;","Exclusion criteria: &lt;br&gt;                1. Pregnancy&lt;br&gt;                2. Breastfeeding&lt;br&gt;                3. Known severe hepatic impairment&lt;br&gt;                4. Known severe renal impairment&lt;br&gt;                5. Known porphyrias&lt;br&gt;                6. Type 1 diabetes or insulin-dependent Type 2 diabetes mellitus&lt;br&gt;                7. Known G6PD deficiency&lt;br&gt;                8. Known myasthenia gravis&lt;br&gt;                9. Known severe psoriasis&lt;br&gt;                10. Known severe neurological disorders (especially those with a history of epilepsy  may lower seizure threshold)&lt;br&gt;                11. Previous adverse reaction to, or currently taking, hydroxychloroquine&lt;br&gt;                12. Known retinal disease&lt;br&gt;                13. Judgement of the recruiting clinician deems ineligibility&lt;br&gt;","Exclusion criteria: &lt;br&gt;1. Health care workers previously treated with hydroxycloroquine in the 60 days before.&lt;br&gt;&lt;br&gt;2. Health care workers participating  in another clinical study where they received an investigational drug in the 24 weeks before to signing the informed consent.&lt;br&gt;&lt;br&gt;3. Pregnant or lactating women.&lt;br&gt;&lt;br&gt;4. Postmenopausal women &lt;br&gt;&lt;br&gt;5. Psoriasis.&lt;br&gt;&lt;br&gt;6. Retinopathy, maculopathy or changes in the visual field, regardless of its origin.&lt;br&gt;&lt;br&gt;7. Neurogenic hearing impairment.&lt;br&gt;&lt;br&gt;8. Myasthenia gravis.&lt;br&gt;&lt;br&gt;9. Disease of the hematopoietic system.&lt;br&gt;&lt;br&gt;10. Glucose-6-phosphate dehydrogenase deficiency (eg hemolytic anemia or favism).&lt;br&gt;&lt;br&gt;11. Hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives.&lt;br&gt;&lt;br&gt;12. Inability to take oral medication.&lt;br&gt;&lt;br&gt;13. Diagnosis of any other pathology that, in the investigator's opinion, may increase the subject's risk or reduce the possibilities of obtaining satisfactory data to achieve the objectives of the study.&lt;br&gt;&lt;br&gt;14. Consumption of alcohol or any other drug that could disable him in the judgment of the investigator to participate in the study.&lt;br&gt;&lt;br&gt;15. Other circumstances or difficulties that, in the investigator's opinion, may increase the subject's risk or reduce the possibilities of obtaining satisfactory data to achieve the study's objectives.&lt;br&gt;","Exclusion criteria: &lt;br&gt;- Participation in any other clinical trial with an experimental treatment for COVID-19&lt;br&gt;- Hypersensitivity to the active substance, to 4-aminoquinoline compounds or to any of the excipients included in section 6.1 of the hydroxychloroquine data sheet&lt;br&gt;- Hypersensitivity to azithromycin, erythromycin, any other macrolide or ketolide antibiotic or to any of the excipients listed in section 6.1 of the azithromycin SmPC&lt;br&gt;- psoriasis&lt;br&gt;- Patients with glucose-6-phosphate dehydrogenase deficiency&lt;br&gt;- Any contraindication according to the Technical Data Sheet of Hydroxychloroquine and Azithromycin&lt;br&gt;- pneumonia&lt;br&gt;- Myasthenia gravis&lt;br&gt;- Pre-existing maculopathy of the eye&lt;br&gt;- Presence of changes in acuity or visual field&lt;br&gt;- QT +/- 450 extension&lt;br&gt;- ALT or AST&gt; 5 x ULN&lt;br&gt;- Creatinine clearance &lt;50 ml / min&lt;br&gt;- Positive pregnancy test&lt;br&gt;- Woman with breastfeeding&lt;br&gt;- Active treatment with: artemeter / lumefantrine, mefloquine, natilizumab, live attenuated virus vaccines, pimecrolimus, tacrolimus (topical), mosifloxacin, and agalsidase alpha and beta&lt;br&gt;- Refusal by the patient to accept the commitment to comply with the procedures indicated during the research process&lt;br&gt;","Exclusion criteria: &lt;br&gt;- Known hypersensitivity to Dornase alfa or any of the excipients;&lt;br&gt;- Pregnant or nursing woman;&lt;br&gt;- Patient with legal pro&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;-Patients &lt;18 years.&lt;br&gt;-Patients with symptoms suggestive of SARS-CoV-2 infection.&lt;br&gt;-Women who are pregnant or who intend to become pregnant for the next three months after taking the drug.&lt;br&gt;-Patients allergic to mefloquine or other quinine or quinidine-type medications.&lt;br&gt;-Patients with a neurological history (seizures, epilepsy, etc.).&lt;br&gt;-Patients with a previous history of psychiatric illnesses (depression, anxiety, suicide attempt).&lt;br&gt;-Patients with cardiac pathologies or relevant chronic diseases that in the judgment of the clinician recommend the non-inclusion of the patient in the study.&lt;br&gt;-Patients in treatment with other medications such as valproic acid, antiarrhythmics, antihistamines H1, beta-blockers, calcium channel blockers, chloroquine, halofantrine, phenothiazines, quinidine and quinine.&lt;br&gt;","Exclusion criteria: Cases were excluded as they sustained a pulse oxygen saturation (SpO2) more than 95%. Additionally, patients with pulse oxygen saturation (SpO2) of more than 95% after oxygen therapy ( at a flow rate of 3 liters per minute) were excluded from the study. Patients with oxygenation index higher than 300 mmHg were also excluded from the study.","Exclusion criteria: The patient himself/herself cannot finish the survey, while no caregiver who is familiar with patients condition is available.","Exclusion criteria: &lt;br&gt;- Age &lt;18 years&lt;br&gt;- Pregnancy or breastfeeding&lt;br&gt;- Ongoing antiviral or antiretroviral treatment or HIV positive&lt;br&gt;- Ongoing anti inflammatory treatment (NSAID, corticosteroids)&lt;br&gt;- Ongoing chloroquine or hydroxychloroquine treatment&lt;br&gt;- Confirmed case of SARS-CoV-2 infection (positive PCR) at day 0&lt;br&gt;- Positive serology for SARS-CoV-1 infection at day 0&lt;br&gt;- Impossibility of signing the informed consent form&lt;br&gt;- Rejection of participation&lt;br&gt;- Working less than 5 days a week in the Hospital Clinic of Barcelona.&lt;br&gt;- Any contraindication for hydroxychloroquine treatment (9):&lt;br&gt;o Hydroxychloroquine hypersensitivity or 4-aminoquinoline hypersensitivity&lt;br&gt;o Retinopathy, visual field or visual acuity disturbances&lt;br&gt;o QT prolongation, bradycardia (&lt;50bpm), ventricular tachycardia, other arrhythmia, as determined on day 0 ECG or medical history&lt;br&gt;o Potassium &lt; 3 mEq/L or AST or ALT &gt; 5 upper normal limit, as determined on day 0 blood test&lt;br&gt;o Previous myocardial infarction&lt;br&gt;o Myasthenia gravis&lt;br&gt;o Psoriasis or porphyria&lt;br&gt;o Glomerular clearance &lt; 10ml/min&lt;br&gt;o Previous history of severe hypoglycaemia&lt;br&gt;o Ongoing treatment with: antimalarials, antiarrhythmic, tricyclic antidepressants, natalizumab, quinolones, macrolides, agalsidase alfa and beta.&lt;br&gt;","Exclusion criteria: 1. Family history of seizure, epilepsy, brain or mental disease;\r&lt;br&gt;2. Subject allergic to any component of the investigational vaccine, or a more severe allergic reaction and history of allergies in the past;\r&lt;br&gt;3. Woman who is pregnant, breast-feeding or positive in -HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months;\r&lt;br&gt;4. Any acute fever disease or infections;\r&lt;br&gt;5. History of SARS;\r&lt;br&gt;6. Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease;\r&lt;br&gt;7. Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension without controllable drugs, etc.;\r&lt;br&gt;8. Hereditary angioneurotic edema or acquired angioneurotic edema;\r&lt;br&gt;9. Urticaria in last one year;\r&lt;br&gt;10. No spleen or functional spleen;\r&lt;br&gt;11. Platelet disorder or other bleeding disorder may cause injection contraindication;\r&lt;br&gt;12. Faint at the sight of needles;\r&lt;br&gt;13. Prior administration of immunodepressant or corticosteroids,antianaphylaxis treatment, cytotoxic treatment in last 6 months;\r&lt;br&gt;14. Prior administration of blood products in last 4 months;\r&lt;br&gt;15. Prior administration of other research medicines in last 1 month;\r&lt;br&gt;16. Prior administration of attenuated vaccine in last 1 month;\r&lt;br&gt;17. Prior administration of inactivated vaccine in last 14 days;\r&lt;br&gt;18. Current anti-tuberculosis prophylaxis or therapy;\r&lt;br&gt;19. According to the judgement of investigator,various medical, psychological,social or other conditions, those could affect the subjects to sign informed consent.","Exclusion criteria: (1) Suspected patients with COVID-19; (2) Close contacts with COVID-19; (3) General physical conditions are not allowed to participate in this clinical study. (4) The participants can not understand and sign informed consent.","Exclusion criteria: (1)Unclear sample collection time or information\r&lt;br&gt;(2)Insufficient sample size due to mistakes in the test operation\r&lt;br&gt;(3)Contaminated sample.","Exclusion criteria: COVID-19 test negative in patients","Exclusion criteria: There are no exclusion criteria.","Exclusion criteria: Women &lt;18 years old","Exclusion criteria: -Other Pre-existing pulmonary disease or heart failure-&lt;br&gt;Absence of COVID infection","Exclusion criteria: ? Pregnancy&lt;br&gt;? allergy to tocilizumab","Exclusion criteria: &lt;br&gt; Presence of do-not-resuscitate order \r&lt;br&gt; Pregnancy\r&lt;br&gt;  Prisoners\r&lt;br&gt;  Naproxen allergy or intolerance \r&lt;br&gt; Severe renal failure&lt;br&gt;","Exclusion criteria: &lt;br&gt;1. Oxygenation Index at time of enrollment (PaO2 / FiO2) &lt; 100 or &gt; 250 in supine position\r&lt;br&gt;2. Intubated &gt; 48h at time point of enrollment\r&lt;br&gt;3. Patients who demonstrate an improvement in past 24h prior to enrollment in oxygenation and ventilation / support parameters which indicate an expected resolution of lung dysfunction in the next 24h without additional intervention according to judgment of the investigator with one or more of the following parameters present:\r&lt;br&gt; Improvement in oxygenation index of &gt; 30% relative to previous measure (last 24h in supine position)\r&lt;br&gt; Extubation if intubated before\r&lt;br&gt;4. Known history of COPD\r&lt;br&gt;5. Known history of chronic dialysis OR received renal replacement therapy in past 14 days\r&lt;br&gt;6. Received new other biologic treatment attempt for COVID-19 in the past 14 days\r&lt;br&gt;7. Received treatment with a viral replication inhibitor in past 3 days\r&lt;br&gt;8. Known hypersensitivity to IFX-1 or any other ingredient of the study medication\r&lt;br&gt;9. Known pregnancy\r&lt;br&gt;10. Received organ or bone marrow transplantation in past 3 months\r&lt;br&gt;11. Known mechanically resuscitation in past 14 days\r&lt;br&gt;12. Patient moribund or expected to die in next 12h according to the judgment of the investigator\r&lt;br&gt;13. Patients otherwise considered restricted from receiving full supportive care (including ICU support)\r&lt;br&gt;14. Existing diagnosis of progressed cancer or other life-limiting disease with life expectancy &lt; 6 months\r&lt;br&gt;15. Known to have received anti-cancer therapy for oncological disease in past 4 weeks\r&lt;br&gt;16. Known severe congestive heart failure (NYHA-Class III - IV)\r&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;-\tHCWs with positive SARS-CoV-2 RT-PCR of nasopharyngeal swab at the inclusion visit.&lt;br&gt;-\tHCW with past history of confirmed SARS-CoV-2 infection &lt;br&gt;-\tHCW with positive SARS-CoV-2 serology at the inclusion visit (if the serology is available at inclusion time, if SARS-CoV-2 serology is not available, it will be a secondary exclusion criteria) &lt;br&gt;-\tHCW with comorbidities such as chronic HCV infection treated by direct antiviral drugs or with hypothyroidism that need hormonal substitution, or retinopathy or known to have hypercholesterolemia hypertriglyceridemia&lt;br&gt;-\tPregnant HCW&lt;br&gt;-\tBreastfeeding HCW&lt;br&gt;-\tHCW taking comedications known to have interactions with LPV/r according to the official characteristics of the product&lt;br&gt;See sessions 4.3 Contraindications and 4.5 Interaction with other medicinal products and other forms of interaction&lt;br&gt;Lopinavir and ritonavir are both inhibitors of the P450 isoform CYP3A in vitro. Co-administration of LPV/r and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse reactions. LPV/r does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).&lt;br&gt;LPV/r has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation. This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products&lt;br&gt;-\tHCW taking comedications known to have interactions with hydroxychloroquine according to the official characteristics of the product&lt;br&gt;","Exclusion criteria: &lt;br&gt;E1. For cohort 1 only : Patient currently receiving therapy with an anti- PD-1, anti- PD-L1, or anti-CTLA4.\r&lt;br&gt;E2. For cohort 2 only: Patient currently receiving therapy with an anti- IL-6 or anti-IL-6R. \r&lt;br&gt;E3. Contraindication to treatment with nivolumab (cohort 1 only) or to tocilizumab (cohort 2 only) as per respective SPC, including known hypersensitivity to one of these study drugs or severe hypersensitivity reaction to any monoclonal antibody.\r&lt;br&gt;E4. Patient known to have intolerance or hypersensitivity to chloroquine or any quinoline derivates (e.g., quinine, chloroquine, mefloquine).\r&lt;br&gt;...See the protocol&lt;br&gt;","Exclusion criteria: &lt;br&gt;1. Patient moribond\r&lt;br&gt;2. Grossesse ou allaitement\r&lt;br&gt;3. Corticothrapie  long terme  une dose de 0,5 mg / kg / j ou plus\r&lt;br&gt;4. Infection bactrienne, fongique ou parasitaire active et non traite\r&lt;br&gt;5. Absence de consentement clair crit du patient ou d'un reprsentant lgal, le cas chant\r&lt;br&gt;6. Hypersensibilit  la Dexamethasone ou lun de ces excipients \r&lt;br&gt;\r&lt;br&gt;Pour les patients non ventils mcaniquement, les critres de non-inclusion supplmentaires sont:\r&lt;br&gt;7. Facteurs anatomiques empchant l'utilisation d'une canule nasale\r&lt;br&gt;8. Hypercapnie indiquant une VNI (paCO2 = 50 mmHg)\r&lt;br&gt;&lt;br&gt;","Exclusion criteria: &lt;br&gt;Exclusion criteria: &lt;br&gt;1. Imminent death (life expectancy = 24h). &lt;br&gt;2. Contraindication for the use of tacrolimus according to the summary of product charactheristics . &lt;br&gt;3. Known adverse reactions to treatment &lt;br&gt;4. Have participated in a clinical trial in the last 3 months.&lt;br&gt;","Exclusion criteria: &lt;br&gt;1. ALT / AST&gt; 5 times the normal limit&lt;br&gt;2. Stage 4 chronic kidney disease (GFR &lt;30) or requiring dialysis.&lt;br&gt;3. Presence of comorbidities that imply a poor prognosis (according to clinical judgment).&lt;br&gt;4. Advanced dementia.&lt;br&gt;5. Pregnancy or breastfeeding.&lt;br&gt;6. Forecast of transfer to another center in the 12 hours at the beginning of the study.&lt;br&gt;7. Allergy to study medication.&lt;br&gt;8. Serious or active bacterial infections or documented sepsis by pathogens other than SARS-CoV-2.&lt;br&gt;9. Streptococcus pneumoniae antigenuria positive before study start.&lt;br&gt;10. Neutropenia &lt;500 / mm3.&lt;br&gt;11. Plateletpenia &lt;100,000 / mm3.&lt;br&gt;12. History of diverticulosis.&lt;br&gt;13. Ongoing skin infection (eg, pyodermitis).&lt;br&gt;14. Transplanted patient under immunosuppressive treatment.&lt;br&gt;15. Previous evidence of latent untreated tuberculosis.&lt;br&gt;","Exclusion criteria: &lt;br&gt;\tHIV infection&lt;br&gt;\tActive hepatitis B infection. Infeccin activa por virus de la hepatitis  B &lt;br&gt;\tRenal failure with estimated glomerular filtration rate (GFR) &lt; 60 ml/min) and patients on Hemodialysis. &lt;br&gt;\tOsteoporosis&lt;br&gt;\tMyasthenia gravis&lt;br&gt;\tPre-existent maculopathy. &lt;br&gt;\tRetinitis pigmentosa&lt;br&gt;\tBradycardia &lt; 50bpm &lt;br&gt;\tWeight &lt; 40kg &lt;br&gt;\tParticipant with any immunosuppressive condition or haematological disease&lt;br&gt;\tTreatment with drugs that may prolong QT in the last month before randomization for more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone.&lt;br&gt;\tPregnancy or fertility desire during the estudy periodo r the following 6 months. &lt;br&gt;\tBreastfeeding  &lt;br&gt;\tKnown allergy to any of the medication used in this trial &lt;br&gt;\tSelf-medication practice to prevent SARS-2-CoV infection&lt;br&gt;","Exclusion criteria: &lt;br&gt;Unlikely to survive for &gt;48 hours from screening\r&lt;br&gt;Participants  with critical disease or multi-organ failure \r&lt;br&gt;Any contraindication to HCQ or intolerance to HCQ \r&lt;br&gt;Any medical condition or concomitant therapy that may put the particpants at risk if they are treated with HCQ\r&lt;br&gt;Pregnant or breastfeeding women\r&lt;br&gt;Use of antiarrhythmic medications and medications known to prolong\r&lt;br&gt;QT interval or cause Torsades de Pointes (TdPs)\r&lt;br&gt;Participants with history of congenital or acquired long QT, arrhythmia,\r&lt;br&gt;family history of long QT or sudden cardiac death, or any other cardiac\r&lt;br&gt;condition that, by the judgement of the Investigator, would put the\r&lt;br&gt;patient at higher risk for QTc prolongation or sudden cardiac death\r&lt;br&gt;Participants with the following ECG findings at screening: QTcF &gt;470\r&lt;br&gt;msec for women or &gt;450 msec for men or heart rate &lt;50 beats/minute\r&lt;br&gt;Participants with known glucose-6-phosphate dehydrogenase (G6PD)\r&lt;br&gt;deficiency&lt;br&gt;","Exclusion criteria: &lt;br&gt;1. Age &lt;18 years;&lt;br&gt;2. Less than 5 days from the onset of symptoms to randomization;&lt;br&gt;3. Pregnancy;&lt;br&gt;4. Hypersensitivity or known allergy to methylprednisolone;&lt;br&gt;5. Bacterial infection: not drained abscess, intravascular infection, bacterial pneumonia, septic shock, disseminated fungal infection;&lt;br&gt;6. Participation in another trial in the previous 30 days;&lt;br&gt;7. Acquired immunodeficiency syndrome;&lt;br&gt;8. Previous use of corticosteroids (cumulative dose of prednisone [or equivalent] of more than 300 mg in the last 21 days; or more than 15 mg/day in the last 7 days before randomization);&lt;br&gt;9. Cytotoxic treatment in the last 3 weeks;&lt;br&gt;10. Known or suspected adrenal insufficiency;&lt;br&gt;11. Lung or bone marrow transplant;&lt;br&gt;12. Severe liver disease.&lt;br&gt;"],["2019-nCoV Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","2019 Novel Coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus Infections","Cardiovascular Death; Major Adverse Cardiovascular Events","Virus; Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","severe novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Pneumonia Caused by Human Coronavirus (Disorder)","2019-nCoV","2019-nCoV","2019-nCoV","novel coronavirus pneumonia (COVID-19); mental health status","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Emotional  disorder","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019 Novel Coronavirus Infection (CoVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","new coronavirus pneumonia","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia  (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Epilepsy, Chronic diseases, Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (NCP)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (NCP)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19) in children","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","new coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Mental health; Novel coronavirues pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19) with mild to moderate anxiety and depression","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus","2019 nCoV, PD-1","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Coronavirus Infections;Respiratory Infection Virus","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Pneumonia, Viral;Pneumonia, Ventilator-Associated","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus Disease 2019","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia(COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","anxiety and depression; novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Pneumonia caused by new coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Anxiety; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","pneumonitis caused by novel coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","NO","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019-nCoV","Novel Coronavirus Pneumonia (COVID-19)","Neonatal Infection;Perinatal Problems;Infectious Disease","Susceptibility to Viral and Mycobacterial Infection","COVID-19 Thalidomide","COVID-19 Thalidomide","2019-nCov pneumonia","Novel Coronavirus Pneumonia (COVID-19)","2019-nCoV","2019 Novel Coronavirus Pneumonia;COVID-19","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","2019-nCov;Remdesivir","2019-nCoVs Infection Pneumonia","2019 Novel Coronavirus Pneumonia","Pulmonary Fibrosis Due to 2019-nCoV","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19);U07.100x001","pediatric COVID19","Coronavirus Disease (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus","Coronavirus","Novel Coronavirus Pneumonia","Coronavirus Disease 2019","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","psychological status","Digestive endoscopy gastroscopy; Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","psychological health; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); children","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","job burnout; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Geriatrics; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","cytokine release syndrome of new coronavirus pneumonia (COVID-19)","Biopsychosocial health; novel coronavirus pneumonia (COVID19)","Cancelled","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Infectious Disease (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019 novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Infection","Novel Coronavirus Infection Pneumonia","Novel Coronavirus Pneumonia;Pneumonia;Pirfenidone","2019 Novel Coronavirus Pneumonia","Coronavirus","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Coronavirus Disease 2019;Novel Coronavirus Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019 novel coronavirus pneumonia(COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","sleep disorders","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Lung injury","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","influenza","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","suspected novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Coronavirus","Novel Coronavirus Pneumonia  (COVID-19)","Pneumonia Caused by Human Coronavirus","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19;Recombinant Human Interferon a1","Novel Coronavirus Pneumonia (COVID-19)","psychological well-being; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Coronavirus;N95;Medical Mask","Mental Disorder","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Fibrosis after Severe Coronavirus Disease 2019 (COVID-19) Pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Severe Community Acquired Pneumonia &lt;br&gt;\n                MedDRA version: 20.1\n                Level: LLT\n                Classification code 10010120\n                Term: Community acquired pneumonia\n                System Organ Class: 100000004862\n            ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Rheumatic disease; Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19;Endotracheal Intubation","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Anxiety; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19); mental health status","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); psychosomatic medicine","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Somatopsychic illness; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","End-stage renal disease; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Corona Virus Disease 2019(COVID-19)","Novel Coronavirus Pneumonia (COVID-19); Kidney disease in children","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Mental health; Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Sleep; Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel common type of coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019-nCoV pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (NCP)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)N; psychosomatic medicine","malignant  tumor","Novel Coronavirus (COVID-19) Infected Diseases","novel coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Vitamin C;Pneumonia, Viral;Pneumonia, Ventilator-Associated","novel coronavirus pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (NCP)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Stress, Psychological","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Severe COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); Anxiety Disorder","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","cancer","2019-nCOV Disease","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Treat and Prevent Covid-19 Infection","Pneumonitis","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); myocardial injury, arrythmias","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","sleep disorders","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","malignant tumor; Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","2019 - nCoV pneumonia","Novel Coronavirus Pneumonia (COVID-19)","Patients with documented respiratory infection with coronavirus SARS COV 2;Therapeutic area: Diseases [C] - Virus Diseases [C02]",";J12.8 - Other viral pneumonia","COVID-19 pneumonia.","COVID-19. &lt;br&gt;COVID-19;U07.1","COVID-19 pneumonia.","Novel Cronavirus Disease (COVID-19). &lt;br&gt;?????? ?????? ?????;COVID-19","COVID-19 pneumonia. &lt;br&gt;Coronavirus infection, unspecified;B34.2","COVID-19 pneumonia.","COVID-19. &lt;br&gt;COVID-19;U07.1","2019-nCoV Severe Pneumonia","COVID-19 pneumonia.","patients infected with COVID-19 &lt;br&gt;Coronavirus","Covid-19 cases management during epidemic phase &lt;br&gt;Covid-19; Emergency; Quality; ;Covid-19; Emergency; Quality;","COVID-19 Complicated With Refractory Intestinal Infections","patients infected with COVID-19 &lt;br&gt;Coronavirus","COVID-19 infection &lt;br&gt;COVID-19 infection","Novel Coronavirus Pneumonia;2019-nCoV","Novel Coronavirus Pneumonia","COVID-19","2019-nCoV","2019-nCoV","2019-nCoV Pneumonia","COVID-19","Pathogen Infection Covid-19 Infection","2019-nCoV;Immunoglobulin of Cured Patients","CoVID-19;Chinese Medicine","SARS-CoV-2;Outcome, Fatal","COVID-19","COVID-19","Preparedness and responsiveness of french Hospital and ED by electronic survey.\r\nHead of Emergency Department will be questionned. &lt;br&gt;Covid-19, Preparedness, Responsiveness, Emergency, Quality, Organization, Formation, Resources, Management, Interoperability;Covid-19, Preparedness, Responsiveness, Emergency, Quality, Organization, Formation, Resources, Management, Interoperability","COVID-19","COVID-19","Coronavirus;Depression;Anxiety;Stress","COVID-19;Severe Pneumonia;Chinese Medicine","2019-nCoV","COVID-19","Covid-19;SARS;Cytokine Storm;Cytokine Release Syndrome;Tocilizumab","Coronavirus;SARS","Coronavirus;Iatrogenic Disease;Acute Kidney Injury;ARDS, Human","Corona Virus Disease 2019,COVID-19","COVID-19;Cardiovascular Diseases","Use of Stem Cells for COVID-19 Treatment","fever; Novel Coronavirus Pneumonia (COVID-19)","Coronavirus Disease-2019","COVID-19;Severe Acute Respiratory Syndrome","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","COVID-19;Organ Dysfunction Syndrome Sepsis;Organ Dysfunction Syndrome, Multiple;Septic Shock;Acute Kidney Injury;Acute Respiratory Distress Syndrome","Cesarean delivery","COVID-19","Novel Coronavirus Pneumonia","Infection Viral","COVID-19;Severe Acute Respiratory Syndrome","Myopia","Rheumatic diseases; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19); medical adhesive-related skin injury","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus Infections","Myopia; Novel Coronavirus Pneumonia (COVID-19)","Sleep, stress and anxiety","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Chronic diseases such as hypertension, diabetes, malignant tumor, immunosuppressive state, etc","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia  (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","novel coronavirus disease (COVID-19)","COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10038700\nTerm: Respiratory infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia  (COVID-19)","Corona virus infection &lt;br&gt;MedDRA version: 20.1\nLevel: PT\nClassification code 10053983\nTerm: Corona virus infection\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-CoV-2  infection &lt;br&gt;MedDRA version: 20.0\nLevel: HLT\nClassification code 10047490\nTerm: Virus identification and serology\nSystem Organ Class: 100000004848\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Acute coronavirus disease 2019 &lt;br&gt;MedDRA version: 20.1\nLevel: PT\nClassification code 10053983\nTerm: Corona virus infection\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-COV-2 infection &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10037373\nTerm: Pulmonary disorder\nSystem Organ Class: 100000004855\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19","Corona Virus Infection","Novel Coronavirus Pnuemonia","Serogroup C Meningococcal Meningitis;Diphtheria;COVID-19","Coronavirus","Coronavirus;SARS (Severe Acute Respiratory Syndrome)","COVID19;Coronavirus;Acute Respiratory Illnesses","COVID-19 Pneumonia","SARS-CoV-2;Coronavirus;COVID-19;2019-nCoV;2019nCoV","Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","COVID-19","COVID-19","COVID-19;Acute Kidney Injury;Kidney Function","Health Care Worker Patient Transmission;Coronavirus;Coronavirus Infections;Immunological Abnormality","COVID-19;Corona Virus Infection","COVID-19;Myocardial Injury;Myocarditis","Coronavirus Infections;Pneumonia, Viral","Hospitalized Patients With Covid-19 Pneumonia","COVID-19","Healthy People","Coronavirus;Pneumonia;Oxygen Toxicity","Pharmacological Action","Gastrointestinal Disease;Infectious Disease","Coronavirus Infections","COVID-19;Coronavirus;Surgery","Novel Coronavirus Pneumonia (COVID-19)","Coronavirus Infections;Post-exposure Prophylaxis","COVID-19","Coronavirus;Epidemic Disease;Pneumonia, Viral","COVID-19","sleep disorders","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","COVID-19; Cardiovascular Diseases","COVID-19","COVID-19;Coronavirus Infections;Hay Fever;Asthma;Chronic Obstructive Pulmonary Disease;Influenza;Common Cold;Respiratory Tract Infections;Healthy","Novel Coronavirus Pneumonia (COVID-19)","depression","Coronavirus Infections","Coronavirus Infections","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Severe Acute Respiratory Syndrome (SARS) Pneumonia;Coronavirus Infections;ARDS, Human","Coronavirus;Severe Acute Respiratory Syndrome","Coronavirus Infection","rheumatic disease; Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Corona Virus Disease 2019","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Cervical spondylosis","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Cardiovascular Diseases;Cardiovascular Risk Factor;SARS","COVID-19","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;Coronavirus infection, unspecified site","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19 \n\n- Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen &lt; 72 hours prior to randomization.\n- Illness of any duration, and at least one of the following:\nClinical assessment (evidence of rales/crackles on exam) AND SpO2 = 94% on room air, OR\nRequiring mechanical ventilation and/or supplemental oxygen.\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Acute Insomnia","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Acute hypoxic respiratory failure of COVID-19 patients &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10074615\nTerm: Hypoxic respiratory failure\nSystem Organ Class: 100000004855\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Possible prevention of pneumonia from SARS-CoV-2 in patients staying home and improving symptoms of SARS-CoV-2 pneumonia in patients treated in hospital &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10035738\nTerm: Pneumonia viral NOS\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Covid19 is characterized by hypoxemic respiratory failure, caused by extensive vascular leak and pulmonary edema early in the course of disease.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","SARS-COV-2 infection &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10037373\nTerm: Pulmonary disorder\nSystem Organ Class: 100000004855\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Severe COVID-19 POSITIVE hospitalized male or female, between 35 and = 80 years of age;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 infection;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Respiratory Tract Infections;Corona Virus Infection","Pneumonia, Pneumocystis;Coronavirus;COVID-19","COVID-19;Novel Coronavirus Pneumonia","Influenza Infection;SAD-RV Infection and COVID-19","Patient atteint du Covid-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","covid-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10070267\nTerm: SARS virus test positive\nSystem Organ Class: 100000004848\n &lt;br&gt;MedDRA version: 21.1\nLevel: PT\nClassification code 10022519\nTerm: Intensive care\nSystem Organ Class: 10042613 - Surgical and medical procedures\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","SARS-COV-2 Infections;COVID-19","Coronavirus Infections;Pneumonia, Viral;Acute Respiratory Distress Syndrome","Coronavirus Infections;Healthcare Associated Infection","2019 SARS-CoV-2 Infection and coronavirus disease (COVID-19);Respiratory Infection; &lt;br&gt;2019 SARS-CoV-2 Infection and coronavirus disease (COVID-19) &lt;br&gt;Respiratory Infection;Infection - Studies of infection and infectious agents;Respiratory - Other respiratory disorders / diseases","Lower Respiratory Tract Infection;Parainfluenza;Immunocompromised;COVID-19","COVID-19 Infection; &lt;br&gt;COVID-19 Infection;Infection - Other infectious diseases","Sepsis;Vitamin C;Intensive Care Unit;COVID-19;Pandemic;Coronavirus","Corona Virus Infection","Corona Virus Infection","COVID-19;Elderly Patients;Critical Illness;Survival;Old Age","Virus Diseases;Infection Viral;Corona Virus Infection","SARS-CoV-2 infection &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10070267\nTerm: SARS virus test positive\nSystem Organ Class: 100000004848\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Infection Viral","New Coronavirus","Coronavirus Infections","COVID-19","COVID-19","Coronavirus;COVID-19;SARS-CoV Infection;Respiratory Failure;Cytokine Storm","Coronavirus","COVID19","Pneumonia, Pneumocystis;Coronavirus","Critically Ill;Coronavirus Infections","Corona Virus Infection","Corona Virus Infection;Immunisations","COVID-19","COVID-19 Pneumonia","COVID-19;Hypertension","Migraine Disorders;Stress;Anxiety","COVID-19","Sars-CoV2","Blood Donation","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection;Coronavirus;Coronavirus Infections","COVID-19","SARS-CoV-2 Infection;COVID-19","COVID-19;Corona Virus Infection;SARS (Severe Acute Respiratory Syndrome)","COVID-19","Corona Virus Disease 2019(COVID-19)","COVID-19","Coronavirus Disease 2019","COVID-19","2019 Novel Coronavirus Infection","COVID-19;Encephalopathy;Critically Ill","COVID-19;SARS-CoV-2;Coronavirus;Influenza -Like Illness;Lower Resp Tract Infection;Upper Resp Tract Infection","Coronavirus Infections;Pneumonia, Viral","COVID-19","COVID-19;SARS-CoV-2 Infection;Pediatric ALL;Pneumonia, Viral;Pandemic Response","COVID 19;Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection","COVID-19","COVID-19","SARS Pneumonia","SARS (Severe Acute Respiratory Syndrome);Coronavirus","Acute Respiratory Distress Syndrome;Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS);Corona Virus Infection","Corona Virus Infection;Acute Respiratory Distress Syndrome;SARS-CoV Infection","COVID-19;Pneumonia, Viral;Influenza With Pneumonia;Flu Symptom;Flu Like Illness;Pneumonia, Interstitial;Pneumonia, Ventilator-Associated;Pneumonia Atypical","Infections, Respiratory;Fever;Cough","Coronavirus Infections","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection","Coronavirus","COVID-19","Anxiety Related to the COVID-19 Pandemic","COVID-19","COVID-19;Hypertension;Cardiovascular Diseases","Severe Coronavirus Disease (COVID-19)","COVID-19 Pneumonia","Coronavirus Infections","Infection Viral","Pregnancy;Coronavirus;COVID-19","COVID-19;Psychosocial Stress;Mental Health","Coronavirus","Coronavirus","COVID-19","Infection Viral","Coronavirus;Respiratory Failure;Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere;SARS-CoV-2","COVID-19","COVID-19","SARS-COV2;Severe Acute Respiratory Syndrome;COVID-19","Coronavirus","Coronavirus","COVID-19 Pneumonia","SARS-CoV Infection;COVID 19;Acute Respiratory Distress Syndrome ARDS","Coronavirus","COVID-19","Acute Disease;Coronavirus;Respiratory Viral Infection","Coronavirus Infection","Corona Virus Disease 19 (Covid 19)","Coronavirus Disease 2019 (COVID-19);Febrile Respiratory Illness;Corona Virus Infection;COVID-19","COVID 19","HIV/AIDS;COVID-19;SARS-CoV-2","COVID-19","Coronavirus;Respiratory Distress Syndrome;SARS-CoV Infection","Corona Virus Infection","Coronavirus;Convalescence","Early CPAP Ventilation in COVID-19 Patients","Pneumonia, Viral;Hypertension;Diabetes Mellitus;Obesity;Cardiovascular Diseases;Obstructive Lung Disease","Corona Virus Disease","SARS-CoV-2","Corona Virus Infection","Corona Virus Infection","Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS);Cytokine Storm;Infection Viral","COVID-19;Physician-Patient Relations","COVID-19","Covid19;Pneumonia","SARS-CoV-2","SARS-CoV-2 Infection","Acute Respiratory Distress Syndrome Caused by COVID-19","SARS (Severe Acute Respiratory Syndrome);COVID-19","Prone Positioning;High Flow Nasal Cannula;Acute Respiratory Distress Syndrome;Corona Virus Infection","Pulmonary Alveolar Proteinosis;COPD;Idiopathic Pulmonary Fibrosis;Viral Pneumonia;Coronavirus Infection;Interstitial Lung Disease","Corona Virus Infection","Angina Pectoris;Acute Coronary Syndrome;Coronary Syndrome;Coronary Artery Disease;Angioplasty;Stent Restenosis;Hypertension;Heart Failure, Systolic;Depression, Anxiety;Covid-19;Isolation, Social","CPAP Ventilation;COVID-19;Emergency Departments","Disease, Infectious;Respiratory Disease;Safety Issues;Effectiveness","COVID-19;Corona Virus Infection;ARDS;Acute Respiratory Distress Syndrome","SARS-CoV-2 Viral Kinetics and Host Immune Responses","COVID-19","Cancer;COVID-19","Scleroderma;Scleroderma, Systemic;Systemic Sclerosis","Coronavirus Infections;COVID-19;Viral Pneumonia Human Coronavirus","Congenital Heart Disease;Covid-19","COVID-19","Pneumonitis;Coronavirus Infection","Infection Viral;Coronavirus;ARDS;Pneumonia","Coronavirus Infections","COVID-19","COVID-19","Covid-19 Infection;Hospitalization in Respiratory Disease Department","COVID-19","Coronavirus Infection","COVID-19","Coronavirus Infection;Pneumonia, Viral;Acute Respiratory Distress Syndrome","Covid-19;Coronavirus Infection;Pregnancy Related","COVID 19","COVID-19","Coronavirus","SARS-CoV-2 Infection","Coronavirus Infections;Severe Acute Respiratory Syndrome;SARS-CoV Infection","Coronavirus","Perceived Stress;Anxiety;Sleep Disturbance","COVID-19;Acute Respiratory Distress Syndrome;Virus; Pneumonia;Acute Lung Injury","Coronavirus;Coronavirus Infection","Pneumonia, Interstitial","Vascular Surgical Procedures;COVID-19;Postoperative Complications","COVID-19;Respiratory Disease","COVID-19","Contact Person From COVID-19 Confirmed Patient","COVID-19","Coronavirus;Machine Learning","Corona Virus Infection","COVID-19","COVID19","COVID 19","Telerehabilitation","Sars-CoV2","COVID-19;Corona Virus Infection;SARS-CoV-2;2019-nCoV;2019 Novel Coronavirus","COVID-19;Liver Cirrhosis","COVID-19","Hypertension;COVID-19","COVID-19","COVID-19","Corona Virus Infection","COVID-19","COVID-19","COVID-19","COVID-19;Pneumonia","COVID-19;Coronavirus","COVID-19 Pneumonia;Lung Ultrasound","COVID-19;Nintedanib;Safety;Effect of Drugs","Covid19","COVID-19","2019-nCoV (COVID-19);Interstitial Pneumonia","COVID-19","Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure","Social Isolation;Physical Inactivity;Well-Being","COVID-19","COVID-19","COVID-19;SARS-CoV-2","COVID-19","Coronavirus;Coronavirus Infection","COVID-19 Pneumonia","COVID-19","Hydroxychloroquine;Antimalarials;Enzyme Inhibitors;Antirheumatic Agents","COVID-19","COVID-19;SARS-CoV-2","COVID-19","Coronavirus;SARS-CoV-2","SARS-CoV-2;COVID-19","COVID-19","COVID-19","Covid19;SARS-CoV Infection","Respiratory Tract Diseases","COVID19;SARS-CoV-2 Infection","Coronavirus;Acute Respiratory Infection;SARS-CoV Infection","COVID-19","COVID-19","Stress, Psychological","COVID;Acute Respiratory Distress Syndrome","COVID-19","COVID-19","COVID-19;Coronavirus Infection","COVID-19","Patients Infected With COVID-19","COVID-19","COVID-19","Follow-up;COVID-19;Infectious Diseases;Respiratory","COVID;Corona Virus Infection","COVID19- Infection With SARS-CoV-2 Virus","COVID19","COVID","Coronavirus;Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere","COVID-19","COVID-19","COVID 19","COVID-19","COVID","SARS-CoV-2","COVID19","Anxiety;Depression;COVID-19; &lt;br&gt;Anxiety &lt;br&gt;Depression &lt;br&gt;COVID-19;Mental Health - Anxiety;Mental Health - Depression;Infection - Other infectious diseases","COVID-19 Pneumonia","COVID-19","Coronavirus Infection","Coronavirus","COVID-19;Requiring home rehabilitation service; &lt;br&gt;COVID-19 &lt;br&gt;Requiring home rehabilitation service;Public Health - Health service research;Physical Medicine / Rehabilitation - Other physical medicine / rehabilitation;Infection - Other infectious diseases","COVID-19 (SARS-CoV-2 infection) and acute respiratory distress syndrome (ARDS) &lt;br&gt;Infections and Infestations","COVID;Drug Effect;Drug Interaction;Adverse Drug Event","COVID-19;Respiratory Failure","Coronavirus","Pneumonia, Viral;Critically Ill;Corona Virus Infection","COVID-19;Pneumonia, Viral","Cardiovascular Diseases;COVID","Rheumatoid Arthritis;Psoriatic Arthritis;Axial Spondyloarthritis;Systemic Lupus Erythematosus;Giant Cell Arteritis","Pediatric Respiratory Diseases;COVID;Fatigue Post Viral","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations","COVID-19 (SARS-CoV-2 infection) in pregnant women &lt;br&gt;Pregnancy and Childbirth","Coronavirus Infection","Coronavirus;COVID;Infection Viral","MAGEC Rod","Covid19;Newborn Morbidity","SARS-CoV-2","COVID-19;Severe Acute Respiratory Syndrome Coronavirus 2","COVID-19","COVID 19","Coronavirus Disease 2019 COVID-19","Suspicion of Infection With SARS-CoV-2","COVID-19;Coronavirus;Coronavirus Infections;SARS-CoV 2","Coronavirus Infection","Autism Spectrum Disorder","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Coronavirus;SARS-CoV-2;COVID-19;Acute Respiratory Distress Syndrome;Shock;Acute Circulatory Failure;Left Ventricular Dysfunction;Fluid Overload","COVID-19","COVID;Coronavirus Infection","COVID-19","Coronavirus Infection","COVID-19","COVID;Acute Coronary Syndrome;Myocardial Infarction;Myocarditis;Venous Thromboembolism;Deep Vein Thrombosis;Pulmonary Embolism","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Corona Virus Infection","COVID-19","Pneumonia, Viral;COVID-19","Infection Viral;Coronavirus;COVID-19","COVID-19;Deep Vein Thrombosis (DVT)/Thrombophlebitis","Covid-19","COVID;Trauma;Ultrasound","Cardiovascular Disease Acute;Cardiomyopathies;COVID","Novel Coronavirus Pneumonia (COVID-19)","sleep disorder","Respiratory Distress Syndrome, Adult;SARS-CoV-2","COVID-19","COVID-19","Liver Diseases;Liver Cancer;COVID19","Gynecological Cancer","Intraoral Viral Load in Covid-19 Patients","Dysfunctional Worry","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Endometriosis;Covid19","Severe/Very Severe COVID-19 Illness","Coronavirus Infection","Respiratory Failure;Covid-19","COVID-19, Hydroxychloroquine Sulfate","COVID-19","COVID 19;Coronavirus","Musculoskeletal Pain","COVID-19;SARS-CoV Infection;Severe Acute Respiratory Syndrome (SARS) Pneumonia;Clinical Trial","Coronavirus;COVID","Covid-19","COVID-19","COVID-19","COVID-19","Emergency Service, Hospital;General Surgery","COVID 19","COVID","COVID-19;Pneumonia","Addiction, Substance;COVID-19","Respiratory Distress Syndrome","Mental Stress;Mental Health Wellness 1;Depression;Anxiety;Behavior Problem;Emotional Problem","Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies.;Therapeutic area: Diseases [C] - Cancer [C04]","COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome.;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19","COVID-19 (known or suspected);serious acute respiratory infection (SARI), known or suspected; &lt;br&gt;COVID-19 (known or suspected) &lt;br&gt;serious acute respiratory infection (SARI), known or suspected;Respiratory - Other respiratory disorders / diseases;Infection - Other infectious diseases","COVID 19","COVID-19","Coronavirus Disease 2019","COVID-19","Characteristics Diseases;Outcome, Fatal","Healthy Volunteer;Mood Disorder;Anxiety Disorder;Preexisting Medical Condition","Coronavirus Infection;COVID;Covid-19;SARS-CoV-2","Cancer","Organ dysfunction by the novel SARS-Cov-2 virus &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10035738\nTerm: Pneumonia viral NOS\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19; &lt;br&gt;COVID-19;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Severe Acute Respiratory Syndrome, COVID-19 (SARS coronavirus 2 [SARS-CoV-2] infection) &lt;br&gt;Infections and Infestations","COVID-19","inflammatory bowel disease;Crohn's disease;ulcerative colitis;indeterminate colitis;COVID-19; &lt;br&gt;inflammatory bowel disease &lt;br&gt;Crohn's disease &lt;br&gt;ulcerative colitis &lt;br&gt;indeterminate colitis &lt;br&gt;COVID-19;Oral and Gastrointestinal - Inflammatory bowel disease;Oral and Gastrointestinal - Crohn's disease;Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon;Mental Health - Anxiety;Mental Health - Depression;Infection - Other infectious diseases","Individual resilience and work sense of coherence and the development of mental symptoms during a pandemic scenario &lt;br&gt;Not Applicable","Aspergillosis &lt;br&gt;Infections and Infestations &lt;br&gt;Aspergillosis","COVID-19","COVID-19;ECMO","Solid Organ Transplant Rejection;COVID-19","ARDS, Human;COVID-19","COVID-19 (SARS-CoV-2); &lt;br&gt;COVID-19 (SARS-CoV-2);Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","COVID-19 Positive; &lt;br&gt;COVID-19 Positive;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Respiratory failure in patients with known or suspected COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Respiratory &lt;br&gt;COVID-19 (SARS-CoV-2 infection)","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)","COVID-19","Corona Virus Infection;Post-traumatic Stress Disorder","Efficacy, Self;Satisfaction, Patient;Telemedicine","Coronavirus Infection;Type 2 Diabetes","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","Cesarean management and maternal and","Coronavirus Infection;Hydroxychloroquine Adverse Reaction","Coronavirus Infection;Coronavirus;Infectious Disease","COVID-19","COVID-19;Coronavirus Infection;Corona Virus Infection","Novel Coronavirus Pneumonia (COVID-19)","renal injuries","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Health Care Worker (HCW);COVID-19","COVID-19;Viral Respiratory Illnesses","SARS-CoV-2;COVID;Coronavirus","COVID-19","Novel Coronavirus Pneumonia 2019 (COVID-19)","COVID-19","Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis","SARS-CoV2 infection","Lower respiratory tract infections","SARS-CoV-2","COVID-19","Coronavirus Infection","COVID-19;Acute respiratory distress syndrome;Pneumonia; &lt;br&gt;COVID-19 &lt;br&gt;Acute respiratory distress syndrome &lt;br&gt;Pneumonia;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Adult patients with a diagnosis of COVID-19 requiring hospitalization in a non-ICU and on prior therapy with RAS blockers;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Pregnancy;COVID-19 infection; &lt;br&gt;Pregnancy &lt;br&gt;COVID-19 infection;Reproductive Health and Childbirth - Childbirth and postnatal care;Reproductive Health and Childbirth - Complications of newborn;Reproductive Health and Childbirth - Fetal medicine and complications of pregnancy;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","COVID-19; &lt;br&gt;COVID-19;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Covid19 positive pneumonitis with need for hospital admission","Patients with SARS-CoV-2 infection and:\r\n1.\tage = 18 years and = 75 years\r\n2.\tSARS-CoV-2 infection confirmed by PCR (BAL, sputum, nasal and/or pharyngeal \r\n                    swap)\r\n3.\tsevere disease defined by at least one of the following:\r\n  a.\trespiratory rate = 30 breaths / minute under ambient air\r\n  b.\trequirement of any type of ventilation support\r\n  c.\tneeds ICU treatment\r\n &lt;br&gt;MedDRA version: 20.1\nLevel: LLT\nClassification code 10047475\nTerm: Viral pneumonia, unspecified\nSystem Organ Class: 100000004862\n &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10070267\nTerm: SARS virus test positive\nSystem Organ Class: 100000004848\n &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10021433\nTerm: Immunization\nSystem Organ Class: 100000004865\n &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10054540\nTerm: Passive immunization\nSystem Organ Class: 100000004865\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","severe acute respiratory syndrome coronavirus 2(SARS-CoV 2);Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]","Acute Respiratory Distress Syndrome (ARDS) caused by SARS-Cov-2 infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 infection;Acute respiratory distress syndrome; &lt;br&gt;COVID-19 infection &lt;br&gt;Acute respiratory distress syndrome;Infection - Other infectious diseases;Respiratory - Other respiratory disorders / diseases","Acute insomnia &lt;br&gt;Mental and Behavioural Disorders","COVID-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19;Therapeutic area: Body processes [G] - Immune system processes [G12]","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;COVID-19 (SARS-CoV-2 infection)","COVID-19 (SARS-CoV-2 infection) &lt;br&gt;Infections and Infestations &lt;br&gt;Coronavirus infection, unspecified site","SARS-CoV-2 infection &lt;br&gt;MedDRA version: 20.0\nLevel: PT\nClassification code 10049924\nTerm: Infection prophylaxis\nSystem Organ Class: 10042613 - Surgical and medical procedures\n;Therapeutic area: Health Care [N] - Environment and Public Health [N06]","COVID-19 infection &lt;br&gt;MedDRA version: 20.0\nLevel: PT\nClassification code 10070255\nTerm: Coronavirus test positive\nSystem Organ Class: 10022891 - Investigations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Patients on mechanical ventilation, inpatient resuscitation for ARDS, secondary to COVID-19 infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 infection is being spread around the world with more than 400.000 cases. The spred of the disease is being a world health problem.;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia (COVID-19); Acute respiratory distress syndrome (ARDS)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Novel Coronavirus Pneumonia (COVID-19)","COVID-19","Novel Coronavirus Pneumonia (COVID-19)","Novel Coronavirus Pneumonia (COVID-19)","COVID-19, SARS-CoV-2","COVID-19 during pregnancy","SARS-CoV2 Infection","COVID-19 with Hypoxia","COVID-19 Infection;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Severe pneumonia in context of COVID-19\r\n &lt;br&gt;MedDRA version: 21.1\nLevel: PT\nClassification code 10035737\nTerm: Pneumonia viral\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Healthcare workers &lt;br&gt;MedDRA version: 21.1\nLevel: LLT\nClassification code 10008434\nTerm: Chemoprophylaxis NOS\nSystem Organ Class: 100000004865\n &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10061986\nTerm: SARS\nSystem Organ Class: 100000004862\n;Therapeutic area: Not possible to specify","Patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit;Therapeutic area: Diseases [C] - Cancer [C04]","acute hypoxemic respiratory failure (AHRF);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]","Hospitalized patients with severe pneumonia secondary  to COVID-19. &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n &lt;br&gt;MedDRA version: 20.0\nLevel: PT\nClassification code 10070255\nTerm: Coronavirus test positive\nSystem Organ Class: 10022891 - Investigations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID19;Therapeutic area: Diseases [C] - Virus Diseases [C02]","COVID-19 &lt;br&gt;MedDRA version: 20.0\nLevel: LLT\nClassification code 10051905\nTerm: Coronavirus infection\nSystem Organ Class: 100000004862\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Coronavirus infection &lt;br&gt;MedDRA version: 20.1\nLevel: PT\nClassification code 10053983\nTerm: Corona virus infection\nSystem Organ Class: 10021881 - Infections and infestations\n;Therapeutic area: Diseases [C] - Virus Diseases [C02]","Adult respiratory distress syndrome (ARDS) secondary to SARS-CoV-2;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]"],["survival group:none;died:none;","Case series:Treated with conventional treatment combined with Chloroquine Phosphate;","Drug: arbidol,400mg,tid;Drug: arbidol,200mg,tid;Drug: Conventional treatment group","Case series:Extracorporeal Membrane Oxygenation;","experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;","control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment;control group :western medicine symptomatic treatment  ;","Case series:Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;","Experimental group:Conventional treatment+Anti-aging Active Freeze-dried Powder Granules;Control group:Conventional treatment;","Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&amp;#32;product&amp;#32;of&amp;#32;SARS-CoV-2.;","Drug: Arbidol;Drug: Lopinavir and Ritonavir Tablets",null,null,"Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: &lt;br&gt;1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-CoV-2; &lt;br&gt;2. Gene sequencing of respiratory or blood samples is highly homologous with SARS-CoV-2.;Index test:SARS-CoV-2&amp;#32;nucleic&amp;#32;acid&amp;#32;test:&amp;#32;1.&amp;#32;nasopharyngeal&amp;#32;samples;&amp;#32;2.&amp;#32;oropharyngeal&amp;#32;samples;","case series:N/A;","Experimental group:TCM based on symptomatic treatment;Control group:Placebo TCM based on symptomatic treatment;","Gold Standard:Guidelines for novel coronavirus pneumonia (fifth edition);Index test:Diagnosis&amp;#32;model&amp;#32;based&amp;#32;on&amp;#32;Artificial&amp;#32;Intelligence&amp;#32;(Epidemiological&amp;#32;history,&amp;#32;clinical&amp;#32;information,&amp;#32;laboratory&amp;#32;examination,&amp;#32;hospitalization&amp;#32;profile,&amp;#32;pulmonary&amp;#32;function&amp;#32;examination,&amp;#32;blood&amp;#32;gas&amp;#32;test,&amp;#32;chest&amp;#32;plain&amp;#32;film,&amp;#32;chest&amp;#32;CT,&amp;#32;complications,&amp;#32;final&amp;#32;classification,&amp;#32;disease&amp;#32;stage).;","TCM Group:herbal medicine and conventional treatment;QFPD decoction group:QFPD decoction and conventional treatment;SFJD capsuale group:SFJD capsuale and conventional treatment;control group:conventional treatment;","experimental group:Truncated Torsion' Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","Experimental group:Carrimycin;Control group:Lopinavir and Ritonavir Tablets;","experimental group:Truncation and Torsion Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","experimental group:Polyinosinic-Polycytidylic Acid Injection and conventional therapy;control group:conventional therapy;","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir);Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules","Other: basic treatment;Drug: Arbidol","Other: Standard care;Drug: Intravenous Immunoglobulin","Drug: lopinavir/ritonavir group;Drug: ASC09/ritonavir group","Case series:Not applicable.;","case series:N/A;","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment ;control group:western medicine symptomatic treatment ;","Conventional treatment group:The conventional treatment group will be treated according to the guidance of the Diagnosis and Treatment Scheme of COVID-19 published by the National Health Commission.;Experimental group:conventional treatment combined with Chloroquine Phosphate.;","Experimental group:Regulating intestinal flora + conventional treatment;Control group:conventional treatment;","Experimental group:honeysuckle decoction;Control group:placebo;","Case series:Nil;","Case series:Nil;","Gold Standard:RT-PCR of the novel coronavirus;Index test:Exhaled&amp;#32;breath&amp;#32;detection&amp;#32;by&amp;#32;mass&amp;#32;spectrometry;","control group:Standard treatment;experimental group:Standard treatment and methylprednisolone for injection;","Case series:Nil;","Experimental group:Conventional Treatment &amp; Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;","General patients treated with normal treatment:Normal Treatment;General patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;Severe patients control group 1:Normal treatment plus hormonotherapy;Severe patients control group 2:Normal Treatment;Severe patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;","experimental group:Chloroquine Phosphate;control group:Lopinavir / Ritonavir;","Gold Standard:Nucleic acid detection method of novel Coronavirus pneumonia ;Index test:IgM/IgG;","Chinese traditional medicine group 1:Traditional Chinese medicine qingfei prescription treatment;Chinese traditional medicine group 2:Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment;Control group:Conventional treatment;","Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days;PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion;Conventional treatment group:Conventional treatment;","Control group:Western medicine basic treatment;Experimental group:Western medicine basic treatment combined with traditional Chinese medicine;","Normal group:No;Severe group:No;","Case series:Traditional Chinese Medicine;","Control group :Western medicine routine treatment plan;Intervention group :Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","control group:conventional therapy;Experience group:conventional  therapy+tocilizumab;","Experimental group:Xinguan-1 formula+Standard treatment;Control group:Standard treatment;","Case series:Conventional standardized treatment and vMIP atomized inhalation;","Experimental group:Oral administration of 5 tablets of 1mg Azvudine tablets daily;Control group:According to the \"Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)\" issued by National Health Commission of People's Republic of China, the subjects were given corresponding treatment.;","Case series:variety treatments;","experimental group:TCM and general treatment;control group:general treatment;","Case series:Nil;","Control group:Health education+Basic treatment of western medicine;Experimental group:Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine;","control group :Conventional treatment ;Experimental group :conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;","control group:basic western medical therapies;experimental group:Reduning injection combined with basic western medical therapies;","Treatment group:Integrated Traditional Chinese and Western Medicine;","Observation  group:TCM prevention;Health  education unit:Health  education;","Experimental group:Conventional treatment + take Ba-Bao-Dan;Control group:Conventional treatment;","Experimental group:chloroquine;control group:conventional management;","experimental group:conventional standardized treatment and Lopinavir-Ritonavir;control group:Conventional standardized treatment;","(ordinary) Western medicine group:Use the (ordinary)  western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(ordinary) Chinese and Western Medicine Group:Use the (ordinary)   TCM clinical prescription combined with the western medicine  treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Western medicine group:Use the (severe) TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Chinese and Western Medicine Group:Use the(severe)TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;","treament group:Chinese medicine decoction;placebo group:placebo;","Case series:NA;","Experimental group:Routine treatment + Babaodan 6 capsules, bid orally;Control group:Conventional treatment;","experimental group:Xiyanping injection;control group:alpha-interferon;","Experimental group:Traditional Chinese Medicine;control group:Basic treatment of modern medicine;","experimental group:Traditional Chinese Medicine+psychological intervention;\t Control group:Traditional Chinese Medicine;Control group:psychological intervention;","experimental group \t:TCM decoctions+basic western medical therapies ;control group :basic western medical therapies ;","experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;control group:clinical standard antiviral treatment;","Epilepsy group:N/A;Health Control group:N/A;","Case series:NA;","control group:western medical therapies;Experimental group:Conventional medicine + TCM;","Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended.;","A:Critical Treatment in Critical Period + Ankylosaurus;B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy;C:Critical Treatment in Critical Period;","Suspected patient control group:Routine respiratory disease treatment;Suspected patient Treatment group:Oral Chinese medicine treatment based on control group;Common NCP patient control group:treatment according to the guideline;Common NCP patient Treatment group:Oral Chinese medicine treatment based on control group;Severe NCP patient:Oral Chinese medicine treatment and treatment according to the guideline;","non-severe group and severe gorup:N/A;","Experimental group:Hydrogen-Oxygen Nebulizer;Control group:Oxygen concentrator;","Vitamin D deficiency group:N/A;Vitamin D normal group:N/A;","Group 1:TCM syndrome differentiation treatment+ Western medicine treatment;Group 2:Western medicine treatment;","Experimental Group:Combined Treatment of Chinese medicine and western medicine;Control Group:Western medicine treatment;","doctors group:Psychological intervention;nurses group:Psychological intervention;suspected cases group:Psychological intervention or drug intervention;cases group:Psychological intervention or drug intervention;","Experimental group:Xinguan-2 formula+Standard treatment;Control group:Standard treatment;","Case series:N/A;","Experimental group:Arbidol tablets + basic treatment;Control group:Basic treatment;","Gold Standard:Clinical outcome;Index test:early&amp;#32;warning&amp;#32;and&amp;#32;prediction&amp;#32;system;","Experimental group:health education, follow-up condition management by team of family doctors, Chinese medicine treatment;Control group:health education, follow-up condition management by team of family doctors;","mild-moderate chloroquine group:oral chloroquine phosphate;mild-moderate Lopinavir/ritonavir group:oral Lopinavir/ritonavir;mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir;severe-chloroquine group :oral chloroquine phosphate  ;severe- Lopinavir/ritonavir group:oral Lopinavir/ritonavir;","experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations;control gorup A:Conventional treatment;Experimental Group B1:Artificial liver therapy+conventional treatment;Experimental Group B2:Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+conventional treatment;Control Gorup A:Conventional treatment;","Experimental group:umbilical cord mesenchymal stem cells;control group:convention treatment;","Control group:Routine treatment (Pure western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection;Investigation group:(Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection(routine treatment)+Qing-Wen Bai-Du-Yin formula granules;","Group A:alpha-Interferon atomization;Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization;","control group:Conventional treatment;experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group;","Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.;Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.;High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment.;Control group:Routine treatment;","Experimental group:Conventional standardized treatment and ASC09/Ritonavir;Control group:Conventional standardized treatment and Lopinavir/Ritonavir;","experimental group 1:Hydroxychloroquine 0.1 oral 2/ day;experimental group 2:Hydroxychloroquine 0.2 oral 2/ day;Placebo control group:Starch pill oral 2/ day;","Experimental group 1:current antiviral treatment+Baloxavir Marboxil  tablets;Experimental group 2:current antiviral treatment+fabiravir tablets;Control group:current antiviral treatment;","single arm:Chinese medicine treatment combined with western medicine treatment;","A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.;B:Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days.;C:Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days.;","DRV/c group:DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD) ;LPV/r group:LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD);other group:Conventional treatment containing thymosin (1.6 mg SC QOD) ;","Experimental group:Isolation and oral  Gubiao Jiedu Ling Chinese medicine;Control group:Isolated observation;","Experimental group:Traditional Chinese medicine soup;Control group:Western antiviral;","Two groups:Different stem cell doses;","experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination;Historical Control:LPV/r;","Case series:according to guidelines;","experimental group:TCM decoctions+basic conventional therapy;Control group:basic conventional therapies;","experimental group:shadowboxing +conventional treatment;Control group:conventional treatments;","experimental group:Pulmonary rehabilitation+Conventional treatment;control group:Conventional treatment;","control group:basic western medical therapies;experimental group:TCM standard decoctions+basic western medical therapies;","Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM intervention;Community suspected control group:Placebo;Hospital suspected TCM intervention group:TCM intervention;Hospital suspected control group:Placebo;","Case series:Nil;","1:Simplify cognitive behavior;2:Supportive psychotherapy;","Psychological Intervention Group:\"Intelligent Psychosomatic Regulation System\" Intervention;Control Group :General Treatment ;","Experimental:Conventional treatment and Shenfu injection;control:Conventional treatment;","Case series:FNC;","Biological: 2019-nCoV PCR","Other: standard treatment;Drug: Thymosin+standard treatment;Drug: PD-1 blocking antibody+standard treatment","Experimental group:Routine treatment + plasma treatment;Control group:Routine treatment;","Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;","Other: Standard care;Drug: methylprednisolone therapy","Case series:N/A;","Control group:Keep ritonavir/ritonavir treatment;Experimental group:Favipiravir;","Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;","Case series:Nil;","Group 1:Xuebijing Injiection;Group 2:Conventional treatment;","Biological: UC-MSCs","Gold Standard:Clinical outcome and Viral nucleic acid detection;Index test:critical&amp;#32;care&amp;#32;ultrasound&amp;#32;examination;","Experimental Group:Conventional Treatment &amp; Low Dose  Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks);Control Group:Conventional Treatment+Placebo  i.m.(once another day, 3 times per week, 2 weeks);","Case series:Nil;","Adolescent group:NA;Childbearing group:NA;Climacterium group:NA;","control group:conventional treatment;mild ill patients:conventional treatment and ozonated autohemotherapy;severe/critical ill patients:conventional treatment and ozonated autohemotherapy;","Combination therapy group:Xiyanping injection+ conventional treatment;Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon;","Case series:Basic symptomatic therapy combined with glucocorticoid therapy;","Severe group:None;Critical group:none;Light group:None;Common group:None;","Experimental group:Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment;Control group:Western medicine basic treatment;","severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;","Case series:Anti-2019-nCoV virus inactivated plasma;","Case series:Nil;","Case series:Suramin( IV.);","Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","Exercise prescription group:Exercise prescription;Control group:None;","Experimental group :Oral leflunomide;Control group:Oral placebo;","Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;","Case series:Humanistic care;","1:inhalate the mycobacterium vaccae for injection;2:inhalate  Physiological saline;","Experimental group:rhG-CSF, 5ug/kg, combinated with standard treatment;Control group:standard treatment;","case series:none;","Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral \"Wu-Zhi-Fang-Guan-Fang\" decoction;Control group:Routine quarantine measures;","Humanistic care:Humanistic care+routine regimen;Control group:routine regimen;","control group with common NCP:conventional treatment;experimental group with common NCP:conventional treatment combined with ozone therapy;experimental group with severe NCP:conventional treatment combined with ozone therapy;control group with severe NCP:conventional treatment;experimental group with critical NCP:conventional treatment combined with ozone therapy;control group with critical NCP:conventional treatment;","Severe group:None;Non-severe group:None;","Case series:Nil;","Case series:NA;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;","Experimental group:Iv injection of Wharton's Jelly mesenchymal stem cells (110^6/kg), cell suspension volume: 40ml;Control group:Iv 40ml saline;","Case series:Nil;","Experimental group:ozonated autohemotherapy;Control group:Standard medical treatment;","Ganovo / ritonavir group:Ganovo/ ritonavir oral;Pegasys group:Pegasys injection;Novaferon group:Novaferon  intramuscular injection+Spray inhalation;Coriolus group:Coriolus  oral;Comparator:TCM+Spray inhalation;","Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;","Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;","general anesthesia group vs. intraspinal anesthesia group:N/A;Health care goup:N/A;","Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day ;Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ;Control group:Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan ;","Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended;control group:conventional therapy;","Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d.;High-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d.;","pneumonia patients group:N/A;medical staff group:N/A;","Experimental group:Basic treatment combined Triazavirin;Control group:Basic treatment combined Triazavirin placebo;","Mild Group:probiotics;Severe Group:probiotics;","Case series:Nil;","Case series:mesenchymal stem cells therapy;","Training:None;Vaidation:None;","college students:none;","Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;","control group:conventional therapy;Experience group:conventional therapy and Tranilast;","Control group:Conventional treatment;Experimental group:Conventional treatment +acupressure+Liuzijue qigong;","Control group:Conventional treatment;Experimental group:Conventional treatment pius Dao Yin;","Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day   ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days;Routine treatment group:Recommended treatment plan for novel coronavirus pneumonia severe and critical cases;","experimental group:mesenchymal stem cells;control group:saline;","experimental group.:Recombinant Human Interferon a1b Eye Drops ;Control group:placebo drop;","Experimental group:Chloroquine Phosphate;Control group:No;","Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;","COVID-19 pregnant women and normal pregnant women and infants born to them:None;","experimental group:routine treatment and Kangbingdu granules;control group:routine treatment ;","hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day;control group:conventional therapy;","Case series:Nil;","Experimental group:ultra short wave  Electrotherapy;control:standard medical therapy;","Gold Standard:Diagnostic criteria for severe novel coronavirus pneumonia.;Index test:early&amp;#32;warning&amp;#32;and&amp;#32;prediction&amp;#32;system.;","common group:N/A;severe group:N/A;critical group:N/A;","Gold Standard:Pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of Hubei province: including clinical diagnosis and Pathogenic nucleic acid test of pharynx swab.;Index test:expression&amp;#32;of&amp;#32;sars-cov-2&amp;#32;nucleic&amp;#32;acid&amp;#32;in&amp;#32;vaginal&amp;#32;secretions;","Experimental group:atic treatment medicines;Control group:Symptomatic treatment medicines;","A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;","experimental group:Routine treatment and Shenqi Fuzheng Injection;control group:Routine treatment ;","control group:conventional therapy and placebo;Experience group:conventional therapy and ALA;","Drug: Remdesivir placebo;Drug: Remdesivir","Control group:Treated according to the New Protocol for Diagnosis and Treatment of NCP(5th edition), without using traditional Chinese medicine;Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid;Experimental group 2:Basic treatment + high dose of honeysuckle oral liquid 180 ml each time, tid;",null,"Other: mobile internet survey on self-test","Drug: thalidomide;Drug: placebo","Drug: placebo;Drug: Thalidomide","one group:Rehabilitation Lung Health Eight - Stage Exercise ;","Group 1:Eight lung exercises for rehabilitation;Group 2:Free activities;",null,"Drug: Placebo;Biological: UC-MSCs","Other: nCapp, a cell phone-based auto-diagnosis system","Control group:Conventional integrated traditional Chinese and western medicine treatment and western medicine psychological intervention treatment;Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medicine psychological intervention therapy and traditional chinese medicine psychological intervention therapy;","Drug: Remdesivir placebo;Drug: Remdesivir","Drug: Meplazumab for Injection","Drug: Xiyanping injection;Drug: Lopinavir / ritonavir, alpha-interferon nebulization","Drug: N-acetylcysteine+Placebo;Drug: N-acetylcysteine+ Fuzheng Huayu Tablet","Case series:moxibustion;","Case series:routine treatment+indirect moxibustion;","Gold Standard:Postive result of SARS-CoV-2 nucleic acid examination;Index test:Diagnostic&amp;#32;Assistance&amp;#32;Decision&amp;#32;Support&amp;#32;System;","Monitor cases, suspected cases and diagnosed cases:No;","Light and common type group:Conventional treatment;Severe group:Conventional treatment;Western medicine treatment group:Give routine western medicine treatment;Chinese and western medicine combined treatment group:Traditional Chinese medicine is combined with conventional western medicine treatment.;Non-invasive mechanical ventilation group:Give noninvasive mechanical ventilation and respiratory support;Nasal high flow oxygen therapy group:Give nasal high flow oxygen therapy respiratory support;","Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;","Drug: Fingolimod 0.5 mg","Case series:rehabilitation and Lung eight-segment exercise;Control group:Keep the initial life style;","Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;","Exposure group:Western medicine routine treatment+triple energizer treatment;Control group:Conventional medicine routine treatment;","Other: Comprehensive treatment",null,"Biological: NK Cells","Case series:Combination of Tocilizumab, IVIG and CRRT;","Gold Standard:COVID-19 viral PCR;Index test:MicroRNA;","Pirfenidone group:Conventional standard treatment + Pirfenidone 400mg three times a day;Control group:Conventional standard treatment;","Case series:traditional Chinese medicine;","Group 2:Once for two days;Group 3:Once for one day;Group 1:Control Group;","Case series:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment;","Case series:NA;","Mild group:Conventional treatment;Serere group:intensive care;","Case series:N/A;","The experimental group:Wear a self-made \"gastroscope mask\" during gastroscopy;Control group:Without self-made \"gastroscope mask\" during gastroscopy;","Case series: Prescription based on syndrome differentiation of TCM and Routine treatment of Western Medicine;","Case series:Nil;","Intervention group:Psychological intervention;","Case series:mesenchymal stem cells therapy;","case series:N/A;","Two groups:Chinese massage versus control;","Case series:Retrospective analysis;","High inflammation oXiris CRRT treatment group:oXiris CRRT treatment;High inflammation Conventional treatment group:Conventional treatment;Low inflammation conventional treatment group:Conventional treatment;","Burnout positive group versus burnout negative group:NO;","Case series:Nil;","Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;","Experimental group:Conventional drug therapy plus hydrogen inhalation;Control group:Conventional drug therapy;","Case series:Nil;","Experimental group:enteral nutrition emulsion, tpf-t 200ml Bid;Control group:No intervention;","Routine treatment +  Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day \t;Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Exocrine group:Aerosol inhalation of exosomes;Control group:Blank;","the elderly population:none;","Gold Standard:Detection of novel coronavirus by fluorescence RT-PCR;Index test:Detection&amp;#32;of&amp;#32;viral&amp;#32;nucleic&amp;#32;acids&amp;#32;in&amp;#32;eye&amp;#32;swabs,&amp;#32;throat&amp;#32;swabs,&amp;#32;oral&amp;#32;saliva,&amp;#32;feces,&amp;#32;urine&amp;#32;and&amp;#32;plasma;","Case series:Integration of traditional Chinese and Western Medicine;","Case series:Nil;","Experimental group:Conventional treatment &amp; Acupuncture;Control Group:Conventional treatment;","Experimental group 1:Routine treatment + Kanguan No. 1;Control group (Mild patients):Routine treatment;Experimental group 2:Routine treatment + Kanguan No. 2;Control group (general patient):Routine treatment;Experimental group 3:Routine treatment + Kanguan No. 3;Control group (severe patients):Routine treatment;","Case series:conventional therapy+tocilizumab;","General population:Health Advice based on survey results;",null,"Experimental group:Exercise prescription;Control group:none;","Case series:Nil;","Experimental group:Conventional therapy and Pediatric Huatanzhike granules;Control group:Conventional therapy;","Experimental group:recombinant human interferon a1b spray;Control group:Blank;","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day 1-3:500mg BID; Day 4-5:250mg BID;","Experimental group:Chloroquine phosphate;","Experimental group:Conventional treatent and hydroxychloroquine;Control group:Conventional treatment;","Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;","Case series:Nil;","Kesuting syrup group:conventional therapy and Kesuting syrup, p.o., 20ml, three times a day;Keqing capsule group:conventional therapy and Keqing capsule, p.o., three pills once, three times a day;control group:conventional therapy;","experimental group:routine treatment, Jinyebaidu granule, po, 1-2 bags once, 3 times a day;;control group:routinel treatment, treatment according to the fifth version  of the diagnosis and treatment protocol, no use of traditional Chinese medicine.;","Case series:Nil;","arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;","Case series:Nil;","Low-dose group:Low-dose hydroxychloroquine and conventional therapy;Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy;High-dose group:High-dose hydroxychloroquine and conventional therapy;control group:conventional therapy;","control group 1:Lopinavir / Ritonavir (Kaletra)  and IFN aerosol inhalation;control group 2:Abidol and IFN aerosol inhalation.;Experimental group:ASC09/ Ritonavir (ASC09F)  and IFN aerosol inhalation;","Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kgd for 3 days.;Control group:Without any glucocorticoid therapy;","Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;","Drug: basic treatment;Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;Drug: Carrimycin","Case series:No;","Case series:N/A;","Drug: Interferon Beta-1B;Drug: Ribavirin;Drug: Lopinavir/ritonavir","Diagnostic Test: New screening strategy;Diagnostic Test: Standard screening strategy","Drug: pirfenidone","Biological: MSCs","Biological: MSCs-derived exosomes","Case series:None;","Case series:clustering nusing progremm;","Case series:Nil;","experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U  bid and Lopinavir 200 mg, 2 capsules at a time, bid;","experimental group:Ma-Xing-Gan-Shi decoction and Conventional Western Medicine Treatment;control group:placebo and Conventional Western Medicine Treatment;","Other: CT score","Drug: T89","Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;","Case series:observation;","case series:N/A;","Case series:Nil;","Experimental group:Lung rehabilitation training+Conventional treatment;Control group:Conventional treatment;","Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment;","Azvudine Plus Symptomatic treatment:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment&amp;#32;","monitor cases, suspected cases and diagnosed cases:Provide psychological intervention for children with severe stress response;","Case series:no;","Group 2:conservation mechanical ventilation group;Group 1:aggressive mechanical ventilation;","Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment;","Case series:reverse transcription polymerase chain reaction;","Medical students group; Non-medical students group:None;","Gold Standard:Nucleic acid test;Index test:Nano-nasal&amp;#32;COVID-19&amp;#32;diagnostic&amp;#32;screening&amp;#32;model;","Patients with COVID-19 VS Healthy controls; Severe group VS Mild group:None;","cross-sectional study:no;","Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;","CRRT group:CRRT;Control group:Routine treatment, CRRT only when there are emergency indications;","Control group:Western medicine treatment;Experimental group:integrate Chinese and conventional medicine  treatment;","Lipoic acid group:Routine Therapy and administration of Lipoic acid injection;Blank control group:Routine Therapy and administration of placebo;","Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;","Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 days, observation until 21 days or discharge;Control group:Conventional treatment, no control drug;","Patients in Wuhan versus Sichuan:none;","Control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan.;Experimental group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + Yiqi Huashi Jiedu Fang (same as above), decoction of decoction machine, 300mL;","Case series:oXiris membrane;","Case series:diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water;","Early corticosteroid intervention group:Early corticosteroid intervention;Middle-late corticosteroid intervention group:Middle-late corticosteroid intervention;Control group:No corticosteroid;","COVID-2019 patients in Tongji Hospital:none;COVID-2019 patients in Mobile field hospital:none;Medical staff in Tongji Hospital:none;Control:none;","treatment group1:HUMSCs: intravenous infusion, 5  10E7 cells / time, once / week, twice / course;treatment group 2:HUMSCs: intravenous infusion, 5  107 cells / time, 1 time / week, 2 times / course, a total of 2 courses;            Exosomes: intravenous administration, 180mg / time, 1 time / day, 7 days / course, 2 courses in total;control group:The control group was given the same amount of placebo (stem cell solvent);","PRE-GROUP1:Taking Chinese medicine preventive decoction;PRE-GROUP2:General prevention methods;TRE-GROUP1:TCM syndrome differentiation treatment+ Western medicine treatment;TRE-GROUP2:Western medicine treatment;","ACEIs/ARBs:NA;","Case series:NA;","Case series:cytokine removal therapy with Cytosorb;","Control group:TCM + Conventional medicine treatment + conventional medicine's psychological intervention;Experimental group:Integrated Chinese and Conventional medicine treatment + conventional medicine's psychological intervention + TCM psychological intervention;","Group 2:SMO Assisted tracheal intubation;Group 1:Assisted tracheal intubation via nasal high-flow oxygen inhalation;","Case series:Nil;","patient group:Under surgical and anesthesia;Health care team:Anesthesiologists for NCP patients;","Case series:Anti-SARS-CoV-2 virus inactivated plasma;","Case series:Nil;","Case series:Nil;","Case series:NA;","Experimental group:pulmonary training;control group:Conventional medication;","Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group:  Routine treatment;","group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy;","Treatment group:nebulization of recombinant super-compound interferon (rSIFN-co);Control group:nebulization of  interferon a;","Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g,  tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water;","Experimental group:Western medicine routine treatment combined with traditional Chinese medicine treatment;Control group:Western medicine routine treatment;","Case series:Nil;","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan;","Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;",null,"Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;",null,"Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention;","Case series:traditional Chinese medicine and Western medicine treatment;","Case series:Nil;","Group 1:Favipiravir Combined With Tocilizumab;Group 2:Favipiravir;Group 3:Tocilizumab;","Drug: Recombinant human interferon a1","Case series:None;","Observation group:Positive Psychological Guidance Group Counseling;","Case series:None;","Drug: Lopinavir/ritonavir treatment;Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection","Device: N95 respirator;Device: Medical Mask","Other: Exposed to the novel coronavirus disease 2019","Control group:Routine medicines and food;Experimental group:Taking Newgen beta-gluten probiotic composite powder;","Ordinary COVID-19 patients:Nil;Heavy COVID-19 patients:Nil;","Case series:Nil;","Case series:Not applicable;","The triple combination antiviral therapy:abidor,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);The dual combination antiviral therapy:,lopinavir/ritonavir plus recombinant interferon alpha-2b(rIFN alpha-2b);","Case series:dexmedetomidine;","Case series:Nil;","Experimental group:Pirfenidone;Control group:Blank;","Case series:qingfei detoxification decoction (mixture);","Case series:N/A;","Case series:none;","Case series:Nil;","Case series:none;","Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);","Case series:Nil;","Gold Standard:RT-PCR test results;Index test:Typing&amp;#32;and&amp;#32;prediction&amp;#32;accuracy&amp;#32;of&amp;#32;artificial&amp;#32;intelligence&amp;#32;models;","Group 2:Truncated Torsion' Formula and Routine treatment of Western Medicine;Group 1:Routine treatment of Western Medicine;","Gold Standard:RT-PCR test results;Index test:Artificial&amp;#32;intelligence&amp;#32;model;","Case series:Psychological intervention;","intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;","&lt;br&gt;                Product Name: LEVOFLOXACIN&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: LEVOFLOXACIN&lt;br&gt;                CAS Number: CAS 138199-7&lt;br&gt;&lt;br&gt;                Product Name: HYDROCORTISONE&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: HYDROCORTISONE&lt;br&gt;                CAS Number: 50-23-7&lt;br&gt;&lt;br&gt;                Product Name: CEFTRIAXONE&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: CEFTRIAXONE&lt;br&gt;                CAS Number: 73384-59-5&lt;br&gt;&lt;br&gt;                Product Name: AZITHROMYCIN&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: AZITHROMYCIN&lt;br&gt;                CAS Number: 83905-01-5&lt;br&gt;&lt;br&gt;                Product Name: CLARITHROMYCIN&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: CLARITHROMYCIN&lt;br&gt;                CAS Number: 81103-11-9&lt;br&gt;                Other descriptive name: CLARITHROMYCIN LACTOBIONATE&lt;br&gt;&lt;br&gt;                Product Name: ERYTHROMYCIN&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: ERYTHROMYCIN&lt;br&gt;                CAS Number: 3847-29-8&lt;br&gt;&lt;br&gt;                Product Name: AMOXICILLINE-CLAVULANTE&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: AMOXICILLIN&lt;br&gt;                CAS Number: 34642-77-8&lt;br&gt;                INN or Proposed INN: POTASSIUM CLAVULANATE&lt;br&gt;                CAS Number: 61177-45-5&lt;br&gt;&lt;br&gt;                Product Name: AZITHROMYCIN&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: AZITHROMYCIN MONOHYDRATE&lt;br&gt;                CAS Number: 121470-24-4&lt;br&gt;&lt;br&gt;                Product Name: CLARITHROMYCIN&lt;br&gt;                Pharmaceutical Form:&lt;br&gt;                INN or Proposed INN: CLARITHROMYCIN&lt;br&gt;                CAS Number: 81103-11-9&lt;br&gt;&lt;br&gt;                Product Name: PIPERACILLIN-TAZOBACTAM&lt;br&gt;                Ph","High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);","Case series:Nil;","Gold Standard:PCR Nucleic acid detection;Index test:high-throughput&amp;#32;novel&amp;#32;coronavirus&amp;#32;(2019-nCoV)&amp;#32;screening&amp;#32;detection&amp;#32;kit;","Case series:Nil;","Case series:Nil;","\t Case series:none;","Case series:none;","Case series:N/A;","Case series:Nil;","Case series:No;","non-cancer COVID-19 versus cancer with COVID-19:none;","Case series:Nil;","severe patients:none;","Case series:Nil;","Case series:Nil;","Case series:Nil;","discharge group:no;","Gold Standard:Epidemiological history + CT + clinical manifestations + sars-cov-2 nucleic acid positive;Index test:Elisa&amp;#32;analysis&amp;#32;of&amp;#32;validation&amp;#32;factors,&amp;#32;inflammatory&amp;#32;factors,&amp;#32;adhesion&amp;#32;factors;","Other: severe covid-19 pneumonia with ET","Population under risk:Chushifangyi prescription;","control group:Routine supportive treatment;experimental group:TCM decoction intervention + routine supportive treatment;","NIV group:no;MV group:no;","Case series:none;","Case series:Early initiation of blood purification;","Case series:No;","Case series:no;","MSC group:Intravenous infusion of MSC based on conventional treatments;","Case series:Western medicine plus Qingfei Paidu decoction;","Case series:Nil;","Case series:Nil;","4 groups:N/A;","Case series:Nil;","Group 1:Traditional Chinese medicine and routine treatment of western medicine;Group 2:Routine treatment of western medicine;","Case series:The use of fiberoptic bronchoscopy;","two groups:no intervention;","Case series:no;","Case series:Traditional Mongolian Medicine;","Experimental group:chloroquine phosphate ;Control group:none;","Case series:external diaphragmatic pacing;","Observation group:Medical workers in Hubei province;Control group:Non-Hubei medical staffNon-Hubei medical staff;","case series:no;","ECMO group:ECMO therapy;the conventional treatment group:no;","Case series:no;","transnasal high-flow oxygen therapy:prone position ventilation;noninvasive mechanical ventilation:prone position ventilation ;invasive mechanical ventilation:prone position ventilation;","Exposed group:Prophylactic antifungal therapy;Control group:Diagnostic antifungal therapy;","in hospital:Virus detection in semen;Recovered:Hormones and sperm quality;","case series:no;","Case series:filling in the  scale;","case series:no;","Gold Standard:Patients with mild or light COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;Index test:1.&amp;#32;throat&amp;#32;swab&lt;br&gt;2.&amp;#32;induced&amp;#32;sputum;","Experimental group:Immunoglobulin of cured patients;Control group:gama-Globulin;","Case series:Laboratory examination and pulmonary CT;","Case series:Nil;","Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR&amp;#32;product&amp;#32;of&amp;#32;SARS-CoV-2.;","Integrated traditional Chinese and western medicine group:Traditional Chinese medicine and routine treatment of western medicine;Western medicine group:Routine treatment of western medicine;","experimental group:Ixekizumab and antiviral therapy;control group:antiviral therapy;","Group 1:mindfulness therapy;Group 2:cognitive behavioral therapy;Group 3:exercise therapy;Group 4:Without treatment, online assessment per two weeks;","Case series:Nil;","experimental group:Oral Chinese medicine \"qingfei detoxification soup\" + intravenous injection of ulinastatin 200000 U Bid.;","Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;","Gold Standard:Clinical outcome;Index test:artificial&amp;#32;intelligence&amp;#32;prediction&amp;#32;model;","Case series:Noninvasive hemodynamic monitoring;","Infection without renal injury group:none;Infection with proteinuria group:Bailing Capsule;Infection with hematuria group:Bailing Capsule;Infection with impaired renal function group:Bailing Capsule, Renal replacement therapy;","Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients can be sent out of the group immediately to receive the treatment&amp;#;Experimental group 1:Basic treatment + honeysuckle oral liquid at a low dose of 60ml / time, three times a day;Experimental group 2:Basic treatment + honeysuckle oral liquid high dose group, honeysuckle oral liquid120ml / time, three times a day.;","Two groups:Nil;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used;control group:Follow the guidelines for standard treatment;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","Experimental group:Conventional treatent and Ulinastatin;Control group:Conventional treatent ;","case series:no;","Case series:Psychological counseling;","Experimental group:On the basis of routine treatment, add 100ml of normal saline and 50ml of Xuebijing injection twice a day;;Control group:conventional therapy;","Case series:CRRT;","Gold Standard:2019 nCOV detection;Index test:SARS-CoV-2 IgM;","1:Throat swab virus nucleic acid test combined with low-dose chest CT;2:Throat swab virus nucleic acid test combined with low-dose chest CT;","Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.610E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.610E8/kg) were injected twice every other day.;","Gold Standard:Clinical outcomes;Index test:MEWS&amp;#32;and&amp;#32;other&amp;#32;scores;","Group A:Sevoflurane anesthesia maintenance, common extubation;Group B:Sevoflurane anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;Group C:Propofol anesthesia maintenance, common extubation;Group D:Propofol anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;","Gold Standard:Chest CT examination;Index test:Lung&amp;#32;ultrasound&amp;#32;examination;","experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.;control group:antiviral treatment was selected as: a-interferon and Ardibdol;","Case series:no;","Case series:Nil;","Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;","Case series:high-dose Vitamin C+Standard treatment;","Case series:Nil;","treatment group :Ba duanjin;","case series:Nil;","Control group :Health education and   symptomatic treatment;Comprehensive treatment group:Health education+Comprehensive TCM treatment;","Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment;","Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes; D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.;","Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of Western medicine + Lianhua Qingwen Capsule (0.35 g per capsule) orally, 4 capsules each time;Compound Yuxingcao Mixture Group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + compound Yuxingcao mixture orally, 30mL each time, 3 times a day.;","Routine treatment group:Conventional treatment of 2019-nCoV pneumonia;Dipyridamole treatment group:Conventional treatment of 2019-nCoV pneumonia and Dipyridamole;","Case series:Nil;","Group 2:Western medicine conventional treatment;Group 1:TCM treatment;","High dose group:High-dose NK cells (&gt;5x10^9)and mesenchymal stem cells(&gt;5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every two days for a total of three times;Preventive dose group:Preventive dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every week for a total of one time;","Experimental group:Conventional treatment followed by Intravenous infusion of  Umbilical Cord Blood Mononuclear Cells preparations;Control group:Conventional treatment;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)\";Placebo:2 tablets placebo BID;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: 1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-Cov-2; 2. Gene sequencing of respiratory or blood samples is highly homologous with SARS-Cov-2. ;Index test:SARS-Cov-2&amp;#32;nucleic&amp;#32;acid&amp;#32;test:&amp;#32;1.morning&amp;#32;sputum&amp;#32;samples;&amp;#32;2.&amp;#32;oropharyngeal&amp;#32;samples&amp;#32;;","eperimental group:Conventional treatment and convalescent plasma therapy;control group:conventional treatment;","Case series:NA;","tumor patients group:no;","case series:N/A;","Chinese medicine treatment cohort:traditional Chinese medicine;Integrated Chinese and western medicine treatment cohort:Chinese medicine and western medicine;Western medicine treatment cohort:western medicine;","Case series:N/A;","Group 1:Baduanjin;Group 2:Auricular acupressure;","experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*1071*108/kg body weight of NK cells each day.;control group:Sodium Potassium Magnesium Calcium and Glucose Injection.;","Case series:Nil;","Drug: Sterile Water for Injection;Drug: VC","Two cohorts:Arbidol cohort versus without Arbidol cohort;","Drug: Hydroxychloroquine sulfate;Drug: Lopinavir/ritonavir","1:meditation+Standard treatment of traditional Chinese and Western Medicine;2:Standard treatment of traditional Chinese and Western Medicine;","Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution;control group:Water for injection atomization inhalation combined with standard therapy;","Experimental group:Conventional treatment and anti-SARS-CoV-2 virus inactivated plasma;Control group:Conventional treatment and Ordinary plasma;","Experimental group:High-dose Vitamin C;Control group:Routine treatment;","Gold Standard:Nucleic acid detection method of COVID-19;Index test:IgM/IgG&amp;#32;detection&amp;#32;method&amp;#32;of&amp;#32;COVID-19;","Experimental group :Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations;Control group:Conventional treatment ;","Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;","Case series:NA;","Biological: Dental pulp mesenchymal stem cells","Case series:Nil;",null,"Case series:Nil;","Case series:none;","Pirfenidone group:Support treatment with oral taken Pirfenidone capsule;Support treatment group:Support treatment ;","Diagnosed Group:Nil;Suspending Group:Nil;","COVID-19  patients:no;","Gold Standard:Clinical outcomes;Index test:the&amp;#32;diagnosis&amp;#32;and&amp;#32;prognosis&amp;#32;prediction&amp;#32;AI&amp;#32;model;","SFBT group:Internet based SFBT;Waiting Group:Wait ;","Group 1:psychological support;Group 2:cognitive behavioral therapy;","Experimental group:normal treatment and auricular point pressing;control group:normal treatment;","Group 2:thymosin;Group 1:BaZhen soup;","SARS-COV-2 RNA Positive group:None;SARS-COV-2 RNA Negative group:None;","Case series:Nil;","Case series:oral CSA0001;","Case series:Nil;","1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;","Critical group/ Ordinary group:no;","Case series:Nil;",null,"Biological: Pathogen-specific aAPC",null,"Case series:Nil;","Group 1:Liuzijue exercise;Group 2:Respiratory muscle training;Group 3:Liuzijue exercise combined with respiratory muscle training;","COVID-19 patients:Nil;","Case series:Nil;","the patients of 2019 new coronavirus pneumonia:None;","Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion interval 1 week (+/-2 days) from the last time.;","experimental group:Toujiequwen Granules and basic treatment ;control group:basic treatment with or without antiviral therapy ;","A:Long-acting interferon alpha-2a (135ug) + ribavirin;B:Abidol + ribavirin;","1:Low dose (5E10vp);2:Middle dose (1E11vp);3:High dose (1E11vp);","Case series:Nil;","Case series:Nil;","COVID-19 patients:Retrospective analysis;","Gold Standard:Clinical outcome;Index test:Based&amp;#32;on&amp;#32;proteomics,&amp;#32;genomics,&amp;#32;and&amp;#32;epigenomics&amp;#32;to&amp;#32;detect&amp;#32;molecular&amp;#32;markers&amp;#32;in&amp;#32;peripheral&amp;#32;blood&amp;#32;of&amp;#32;patients&amp;#32;with&amp;#32;mild&amp;#32;and&amp;#32;severe&amp;#32;COVID-19&amp;#32;infection,&amp;#32;in&amp;#32;order&amp;#32;to&amp;#32;establish&amp;#32;an&amp;#32;early&amp;#32;molecular&amp;#32;marker&amp;#32;prediction&amp;#32;model&amp;#32;to&amp;#32;predict&amp;#32;the&amp;#32;prognosis&amp;#32;of&amp;#32;patients.;","Gold Standard:Other parts samples or other methods for virus detection;Index test:Upper&amp;#32;Respiratory&amp;#32;Tract&amp;#32;Virus&amp;#32;Detection;","Experimental group 1:the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group;Experimental group 2:the oral trial drug favipiravir tablets;Control group:the oral placebo treatment;","Case series:Nil;","Experimental group:Farpiravir tablets;Control group:Abidole tablets;",null,"experimental group:high-fow therapy by nasal cannulae (HFNC);control group:bag- valve mask oxygenation (SMO);","cross-sectional study:Nil;","Gold Standard:RT-PCR test;Index test:artificial&amp;#32;intelligence&amp;#32;triage&amp;#32;system;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food;","1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;","Experimental group:Increased Compound Houttuynia Mixture in real world situations;Control group:None(People who do not receive Compound Houttuynia Mixture in real world situations);","Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;","Case series:no;","Gold Standard:Clinical outcome, meet the guideline of novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV.;Index test:First&amp;#32;pass&amp;#32;perfusion&amp;#32;imaging&amp;#32;parameters&amp;#32;(slope,&amp;#32;tip,&amp;#32;PT)&amp;#32;and&amp;#32;delayed&amp;#32;enhancement&amp;#32;ratio&amp;#32;(%);&amp;#32;quantitative&amp;#32;T1&amp;#32;\\&amp;#32;T2&amp;#32;values,&amp;#32;ECV&amp;#32;and&amp;#32;pseudocolor&amp;#32;images&amp;#32;were&amp;#32;obtained&amp;#32;by&amp;#32;t1mapping&amp;#32;\\&amp;#32;T2&amp;#32;mapping.&amp;#32;Meanwhile,&amp;#32;the&amp;#32;degree&amp;#32;of&amp;#32;myocardial&amp;#32;edema&amp;#32;and&amp;#32;fat&amp;#32;replacement&amp;#32;was&amp;#32;analyzed.&amp;#32;Myocardial&amp;#32;creatine&amp;#32;metabolism&amp;#32;was&amp;#32;analyzed&amp;#32;by&amp;#32;MRS,;","tumor patients group:N/A;non tumor patients group:N/A;","Mild Type Group A:antiviral therapy and Chinese medicine treatment;Mild Type Group B:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;Common and Heavy Type Group C:antiviral therapy and Chinese medicine treatment;Common and Heavy Type Group C:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;","Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / ritonavir tablets (Kaletra) twice a day, twice each time, 7-14 days.;intervention C:On the basis of routine medical treatment, combined with Novafron and Kaletra, the usage and course of treatment are the same as above.;","observational:Ultrasonic monitoring;","control group:None;Experimental group (mild and normal type in patients with new coronavirus pneumonia):3% hydrogen peroxide gargle;","Case series:Nil;","Experimental group:oral hydroxychloroquine sulfate tablets;Control group:Conventional treatment meet the Guideline;","&lt;br&gt;Trade Name: Plaquenil 200 mg, comprim pellicul&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;","Intervention 1: no or mild symptoms of common cold, SARS-CoV-2 negative Intervention 2: mild COVID-19 Intervention 3: severe COVID-19 Intervention 4: severe viral pneumonia, SARS-CoV-2 negative","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + oseltamivir +lopinavir/ritonavir), patients will receive interferon , sub-type 1b with dose of 250 mcg subcutaneously every other day for 14 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (hydroxychloroquine + oseltamivir +Lopinavir/ritonavir) for at least 5 days.","Intervention 1: Intervention group: Hospitalized patients will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments recommended by the corona county committee. Intervention 2: Control group: Hospitalized patients will receive standard treatment according to the national guidelines for the treatment of COVID-19. Intervention 3: Intervention group:  Outpatients (self-quarantine at their home) will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments recommended by the corona county committee.","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + Oseltamivir +Lopinavir/ritonavir), patients will receive interferon B, sub type 1a (CinnaGen Company) with dose of 44 mcg subcutaneously every other day for 14 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (hydroxychloroquine + Oseltamivir +Lopinavir/ritonavir) for at least 5 days.","Intervention 1: Intervention group: Treatment group which received Noscapine   mg, tds. Intervention 2: Control group: Group receiving Placebo with no API.","Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus Interferon beta-1a 44 mg every other day S.C for 10 days.","Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (Tab hydroxychloroquine 400 mg single dose + Cap oseltamivir 75 mg twice daily + Tab lopinavir/ritonavir 200/50 mg two tablets twice daily for at least 5 days), patients will receive one tablet of Sofosbuvir/ledipasvir 400/100 mg (Danesh Pharmaceutical Development Company) daily for 10 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (Tab hydroxychloroquine 400 mg single dose + Cap oseltamivir 75 mg twice daily + Tab lopinavir/ritonavir 200/50 mg two tablets twice daily for at least 5 days).","Intervention 1: Control group: Standard of care treatment according to the national guidelines for the treatment of COVID-19. Intervention 2: Intervention group: Sovodak, Company: Rojan, Daily single oral tablet containing 400mg of Sofosbovir and 60mg of Daclatasvir + Standard of care treatment.","Drug: Methylprednisolone;Drug: Methylprednisolone","Intervention group: Patients in this group will receive triple-drug regimen including hydroxychloroquine 200 mg two tablets singe dose + cap oseltamivir 75 mg twice daily + lopinavir/ritonavir 200/50 mg two tablets twice daily or atazanavir/ritonavir 300/100 mg daily for at least 5 days..","oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir","Patients suspected of Covid-19 infection with severity criteria","Other: placebo;Other: washed microbiota transplantation","oral administration of favipiravir","Immediate favipiravir arm: Favipiravir administered orally between Day 1 and Day 10, 1800 mg twice a day on Day 1 followed by 800 mg twice a day from Day 2&lt;br&gt;Delayed favipiravir arm: Favipiravir administered orally between Day 6 and Day 15, 1800 mg twice a day on Day 6 followed by 800 mg twice a day from Day 7","Drug: Recombinant Human Interferon a2b Spray;Drug: Arbidol Hydrochloride Granules;Drug: Bromhexine Hydrochloride Tablets","Combination Product: systemic treatment","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Drug: Abidol hydrochloride;Drug: Abidol Hydrochloride combined with Interferon atomization","Drug: Abidol hydrochloride;Drug: Oseltamivir;Drug: Lopinavir/ritonavir","Drug: Oseltamivir;Drug: Ritonavir+Oseltamivir;Drug: ASC09F+Oseltamivir",null,"Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Drug: Immunoglobulin of cured patients;Drug: ?-Globulin","Other: standard western medicine treatment;Other: Chinese medicine treatment;Drug: YinHu QingWen Decoction(low dose);Drug: YinHu QingWen Decoction",null,"Drug: TCM prescriptions",null,"Head of departmenet or nurse supervisor of all emergency departments in France","Drug: Huaier Granule","Biological: UC-MSCs;Other: Placebo","Behavioral: Use of social media during COVID-19","Drug: Yinhu Qingwen Granula;Drug: Yin Hu Qing Wen Granula(low does);Other: standard medical treatment",null,"Drug: Sildenafil citrate tablets","Drug: Tocilizumab;Other: Standard of care;Procedure: Continuous renal replacement therapy",null,"Drug: Any drug used to treat Covid-19","Drug: Tetrandrine","Other: non","Biological: WJ-MSCs","Case series:no;","Other: oxygen treatment","Drug: Placebo oral tablet;Drug: Hydroxychloroquine",null,"mild recovery:none;severe recovery:none;control:none;",null,"Cesarean section:Case Series;","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform",null,"Other: pregnant women with laboratory-confirmed 2019-n-CoV","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Case series:orthokeratology lens;","Case series:None.;","Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,&amp;#32;metabolomics&amp;#32;and&amp;#32;other&amp;#32;markers,&amp;#32;mass&amp;#32;spectrometer;","hDPSCs group:Routine treatment + Intravenous injection of human dental pulp stem cells;Control group:Routine treatment + Placebo;","Gold Standard:Clinical outcome by diagnosis results of imaging doctors and clinicians;Index test:new&amp;#32;artificial&amp;#32;intelligence-based&amp;#32;prognosis&amp;#32;assessment&amp;#32;system;","Case series:none;","Group M:Play sleep-aid music on the cell phone at the same time as basic therapy, listen to it once every night at 22 o'clock, and the patient falls asleep with the music. A total of 2 weeks of treatment.;Group C:No music, the use of basic treatment, in accordance with the \"new coronavirus infection pneumonia diagnosis and treatment program\" trial fifth, sixth, seventh version of the provisions of the implementation.;","Case series:Nil;","Device: VivaDiag COVID-19 lgM/IgG Rapid Test","Case series:Nil;","mindfulness intervention group:Mindfulness practice;control group:mind-wandering practice;","Case series:Nil;","Control group:regular treatment;Experimental group:Compound amino acid combined with routine treatment;","Case series:Nil;","Case series:Nil;","Case series:Nil;","Survival and D:none;","Case series:Nil;","Case series:NO;","Case series:Nil;","Experimental treatment group:Oral chloroquine phosphate tablets (treatment group);control group:Oral placebo group (control group);","Case series:?;","1:Blank;2:Moxibustion treatment;","Homeopathic patient:The popular science education;","Case series:Nil;","Experimental group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment + acupoint application (Zusanli + Feishu);control group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment;","Case series:Nil;","Case series:none;","Case series:standard treatment + syndrome differentiation and treatment of TCM;","confirmed group:none;control group:none;","CM group:Xinguan No. 2 / Xinguan No. 3 alone or + regular treatment;WM group:Regular Ttreatment;","Suspected case treatment group:TCM formula 1 or TCM formula 2;Suspected case control group:null;Confirmed case  treatment group:Western medicine+(TCM formula 3 or TCM formula 4 or TCM formula 5 or TCM formula 6);Confirmed case control group:Western medicine;","Experimental group:On the basis of rehabilitation treatment, the subjects in the experimental group take Gu-Shen Ding-Chuan-Wan;Control group:standard treatment;","Experimental group:Bufonis venenum injection;Control group:0.9% N.S.;","treatment group:combination of  Lopinavir/ritonavir (Kaletra) Tablets and interferon;control group:Routine medical treatment,;","Experimental group:Hua-Shi Bai-Du granules;control group:conventional treatment of western medicine;","Light group:N/A;Common group:N/A;Severe group:N/A;Critical group:N/A;","COVID-19 group:NA;Healthy people:NA;","Case series:6-minute walk training;","experimental group:TCM formula and general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);control group:general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);","Case series:Nil;","experimental group:Health education+ pulmonary rehabilitation;control group:Health educatio;","Experimental group:PD-1 mAb + Standard treatment;Control group:Standard treatment;","&lt;br&gt;Product Name: itraconazole&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: ITRACONAZOLE&lt;br&gt;CAS Number: 84625-61-6&lt;br&gt;&lt;br&gt;Product Name: itraconazole&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: ITRACONAZOLE&lt;br&gt;CAS Number: 84625-61-6&lt;br&gt;&lt;br&gt;","experimental group:Fitness Qigong Yangfei prescription;control group:general advice and related psychological comfort.;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Current Sponsor code: SAR153191&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: BCG vaccine (BCG-Vaccin SSI [Nederlands VaccinStatens Serum Instituut]) Danish strain 1331.&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Concentrate and solvent for solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Quensyl&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Interferon beat-1a (IFN-1a)&lt;br&gt;Product Code: SNG001&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;Current Sponsor code: SNG001&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;Pharmaceutical form of the placebo: Nebulisation solution&lt;br&gt;Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","Drug: Placebo;Drug: PUL-042 Inhalation Solution","Other: Standard of care;Drug: Hydroxychloroquine;Drug: Interferon Beta-1A;Drug: Lopinavir/ritonavir;Drug: Remdesivir","Drug: favipiravir tablets+chloroquine phosphatetablets tablets;Drug: Favipiravir tablets;Drug: Placebo","Procedure: venepuncture","Drug: Eculizumab","Drug: Nitric Oxide Gas","Drug: Placebo;Drug: Chloroquine or Hydroxychloroquine","Drug: Bevacizumab","Behavioral: General health education;Behavioral: Personalized health education","Drug: ACE inhibitor","Dietary Supplement: isocaloric/isonutrigenous ONS;Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants","Drug: PUL-042 Inhalation Solution;Drug: Placebo",null,"Diagnostic Test: COPAN swabbing and blood sample collection","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Diagnostic Test: Electrocardiogram and transthoracic echocardiography","Drug: Colchicine","Dietary Supplement: Vitamin C","Other: The control group will not receive hydroxychloroquine;Drug: Hydroxychloroquine","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","Device: Automated oxygen administration - FreeO2;Other: Standard administration of oxygen flow","Drug: Baricitinib","Device: Non-contact MCE system","Drug: standard therapy;Drug: Escin","Procedure: Surgery","Experimental group:Celebrex capsules 200mg / time twice a day for 7 days;control group:routine treatment;","Drug: Lopinavir/ritonavir","Other: hyperimmune plasma","Diagnostic Test: Lung ultrasound","Drug: Traditional Chinese Medicine Prescription","cross-sectional study:no;","ordinary group versus severe group versus critical group versus deceased patients group:no;","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells",null,"Drug: 2: Standard of care;Drug: 1: Naproxen",null,"Control group :Isolate PBMC to extract tRNA ;normal group:Isolate PBMC to extract tRNA;severe group:Isolate PBMC to extract tRNA;","Case series:N/A;","Other: No intervention","Other: Patient sampling","ARBs Group:Treatment of ARBs;non-ARBs Group:other treatments;","Experimental group:Rehabilitation Nursing Program;Control group:Routine rehabilitation care;","Medical personnel group:N/A;","Dietary Supplement: Natural Honey;Other: Standard Care","Drug: Methylprednisolone;Other: standard care","Drug: Chloroquine;Drug: Azithromycin","Diagnostic Test: Nasopharyngeal swab","Rheumatic disease with COVID-19:N/A;Rheumatic disease without COVID-19:N/A;","eye patch and earplugs:Nil;eye patch:Nil;","Experimental group:Conventional medication + Infusion of mesenchymal stem cells;Control group:Conventional medication;","Gold Standard:PCR Nucleic acid detection;Index test:2019-nCov IgG;","Nintedanib group:Nintedanib;Control group:Placebo;","Case series:Questionnaire survey without intervention;","experimental group:Rabeprazole plus chloroquine;control group :Lopinavir + rabeprazole;",null,"Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","Other: No intervention","Patients will have a nose and throat swab collected and tested immediately using the QIAstat-Dx Respiratory n-CoV Panel. Results are available in one hour and will be communicated immediately to clinical and infection control teams. There is no patient follow up but clinical outcome data are collected retrospectively from case notes and hospital information systems for the duration of hospitalisation, up to 30 days post-intervention.","COVID-19 with risk factors:N/A;COVID-19 without risk factors:N/A;","Gold Standard:PCR Nucleic acid detection;Index test:2019-nCov IgM;","Case series:Nil;","&lt;br&gt;Trade Name: MYLAN&lt;br&gt;Product Name: lopinavir/ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;&lt;br&gt;Trade Name: REBIF&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Remdesivir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Group 1:single-shot CBT-I;Group 2:Sleep Hygiene;","Control:NA;Noninvasive cardiopulmonary monitoring group:Wear non-invasive multi-channel cardiopulmonary monitor;","Gold Standard:Viral nucleic acid detection;Index test:specific&amp;#32;serological&amp;#32;detection;","Mild:No;severe:No;","Group 1:Routine treatment + Infusion of convalescent plasma;Group 2:Routine treatment;","experiment group:Cold outdoor environment;experiment group :temperature measuring distance;","Different dose groups:Injection dose;","Experimental group:Conventional treatment regimen + MSC treatment;Control group:Conventional treatment regimen;","&lt;br&gt;Trade Name: Leukine&lt;br&gt;Product Name: Leukine&lt;br&gt;Pharmaceutical Form: Powder for nebuliser solution&lt;br&gt;INN or Proposed INN: SARGRAMOSTIM&lt;br&gt;CAS Number: 123774-72-1&lt;br&gt;Concentration unit: g microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Leukine&lt;br&gt;Product Name: Leukine&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: SARGRAMOSTIM&lt;br&gt;CAS Number: 123774-72-1&lt;br&gt;Concentration unit: g microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: UNIKINON Tablets 200mg/tab&lt;br&gt;Product Name: UNIKINON Tablets 200mg/tab&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CHLOROQUINE PHOSPHATE&lt;br&gt;Other descriptive name: CHLOROQUINE PHOSPHATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Imatinib mesilate &lt;br&gt;Product Name: Imatinib mesilate&lt;br&gt;Product Code: L01XE01&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulfate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Recombinant human angiotensin-converting enzyme 2&lt;br&gt;Product Code: APN01&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: APN01 / GSK2586881&lt;br&gt;Other descriptive name: GSK2586881&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 20 ml (400 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 20 ml (400 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 10 ml (200 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 10 ml (200 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 4 ml (80 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 4 ml (80 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Drug: Hydroxychloroquine","Drug: Methylprednisolone","Drug: DAS181;Drug: Placebo","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Sulfate d'hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-800&lt;br&gt;&lt;br&gt;","Drug: Oral","Drug: Nitric Oxide","Drug: Inhaled nitric oxide gas","In patients in patients with 2019-nCoV who require admission to the intensive care unit mechanical ventilation and extracorporeal membrane oxygenation (ECMO). It is expected that this study will not require individual patient consent. This study is in effect a large-scale clinical audit during a global health emergency, as all data is already recorded as part of routine clinical care, therefore justifying participant enrolment using a waiver of consent. Retrospective data will be sourced from all collaborating hospitals across Australia from January 2020 to March 2020. Whereas, international hospitals will provide their retrospective data between January 2019 and march 2020. Prospective data will be collected in Australian and International hospitals until completion of COVID-19 global epidemic, as judged by the World Health Organization. The total duration of observation per participant will be until hospital discharge or 28 days post intensive care unit admission, whichever comes first. The study will combine prospective observation, and retrospective observations sourced from clinical charts. &lt;br&gt;","Drug: DAS181;Drug: Placebo;Drug: DAS181 COVID-19;Drug: DAS181 OL","Oral 500mg chloroquine phosphate tablets prophylactic weekly regimen against COVID-19 over 10 week trial period followed with plasma chloroquine levels.","Drug: Vitamin C;Other: Control","Drug: Hydroxychloroquine Sulfate","Drug: Camostat Mesilate;Drug: Placebo oral tablet",null,"Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Placebo oral tablet;Drug: Placebo oral tablet","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: Roactemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Sarilumab&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Other descriptive name: Kevzara&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Other: nosocomial infection/hospital acquired infection","Diagnostic Test: Recombinase aided amplification (RAA) assay","Drug: Bevacizumab Injection","Drug: Remdesivir;Drug: Standard of Care","Drug: DAS181","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber);Device: vv-ECMO only (no cytokine adsorption)","Biological: ChAdOx1 nCoV-19;Biological: MenACWY Placebo","Drug: Hydroxychloroquine 200 Mg Oral Tablet;Drug: Azithromycin 500Mg Oral Tablet;Dietary Supplement: Glucose tablets","Drug: Darunavir and Cobicistat","Other: Nutrition support","Other: Placebo;Drug: Remdesivir","Biological: mRNA-1273","Drug: Favipiravir Combined With Tocilizumab;Drug: Favipiravir;Drug: Tocilizumab","Biological: NestCell;Biological: NestCell",null,"Behavioral: Mindfulness session(s)","Drug: Remdesivir;Drug: Standard of Care","Other: blood sample","Other: Questionnaire with precaution information;Other: Experimental: Questionnaire without precaution information","Drug: Hydroxychloroquine;Other: Placebo","Drug: Colchicine;Other: Local standard of care","Drug: Chloroquine phosphate","Drug: Hydroxychloroquine Sulfate;Drug: Ascorbic Acid","Drug: Hydroxychloroquine","Biological: MSCs;Biological: Saline containing 1% Human serum albumin(solution of MSC)","Drug: Ganovo+ritonavir+/-Interferon nebulization","Drug: Remdesivir","Drug: Antiviral treatment and prophylaxis;Other: Standard Public Health measures","Drug: recombinant human interferon Alpha-1b;Drug: thymosin alpha 1","Other: Follow up",null,"Drug: Hydroxychloroquine + azithromycin;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine;Drug: Azithromycin","Other: Exposure (not intervention) - SARS-CoV-2 infection","Drug: Hidroxicloroquina;Drug: Control group","Drug: Losartan;Other: Placebo","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Drug: Sarilumab;Drug: Placebo","Drug: Tocilizumab","Drug: Nitric Oxide Gas","Drug: Aviptadil by intravenous infusion + maximal intensive care;Drug: Normal Saline Infusion + Maximal intensive care","Drug: Losartan;Other: Placebo","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals","Drug: Hydroxychloroquine Oral Product;Drug: Hydroxychloroquine + azithromycin",null,"Other: observational","Drug: Lopinavir/ritonavir","Diagnostic Test: Online Questionnaire","Device: GO2 PEEP MOUTHPIECE",null,"Drug: CD24Fc;Drug: Placebo","Drug: Tocilizumab Injection","Other: Observational Study","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19;Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Behavioral: Guided online support program;Behavioral: WHO recommendations (waiting condition)","Biological: Convalescent Plasma","Drug: Hydroxychloroquine;Drug: Placebo","Drug: Tocilizumab;Drug: Tocilizumab","Other: biological samples collection","Drug: Angiotensin 1-7;Drug: Placebos","Drug: Deferoxamine","Other: survey","Device: CT-V","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Diagnostic Test: Biomarkers expression","Drug: Tocilizumab (TCZ);Drug: Placebo","Drug: Hydroxychloroquine;Drug: Remdesivir;Other: (Standard of Care) SoC","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate;Drug: Baricitinib (janus kinase inhibitor);Drug: Sarilumab (anti-IL-6 receptor)","Diagnostic Test: SAMBA II (Diagnostic for the Real World);Diagnostic Test: Public Health England Gold Standard;Diagnostic Test: Cambridge Validated Viral Detection Method;Diagnostic Test: Radiological Detection","Device: bidirectional oxygenation mouthpiece","Drug: Colchicine;Drug: Standard treatment","Drug: BCG Vaccine","Drug: Low-dose chloroquine/hydroxychloroquine;Drug: Mid dose chloroquine or hydroxychloroquine;Drug: High does chloroquine or hydroxychloroquine;Drug: Placebo","Other: No intervention","Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Ibuprofen","Drug: Colchicine;Drug: Placebo oral tablet","Biological: Anti- SARS-CoV-2 Plasma;Biological: SARS-CoV-2 non-immune Plasma",null,null,"Drug: RoActemra iv;Drug: RoActemra sc;Drug: Kevzara sc;Other: Standard medical care","Biological: Emapalumab;Biological: Anakinra",null,"Drug: Sarilumab SAR153191;Drug: Placebo","Drug: Hyperbaric oxygen","Behavioral: turkish physicians","Drug: BCG Vaccine;Drug: Placebo","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin;Other: Usual antibiotic treatment","Drug: Eicosapentaenoic acid gastro-resistant capsules","Drug: Tocilizumab (TCZ);Drug: Placebo","Drug: Dexamethasone","Other: Human Biological samples","Device: high flow nasal cannula (HFNC);Procedure: Prone positioning (PP)","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Centricyte 1000;Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;Drug: Liberase Enzyme (Roche);Drug: Sterile Normal Saline for Intravenous Use","Drug: Sarilumab","Other: Tele-medicine platform","Device: CPAP treatment","Device: Inspiratory training device;Device: Expiratory training device","Drug: Hydroxychloroquine;Other: Placebo","Other: NA (no intervention)","Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin Tablets",null,"Other: SPIN-CHAT Program",null,null,"Device: Caption AI","Drug: Plaquenil 200Mg Tablet",null,"Biological: Convalescent Plasma",null,"Other: Usual Care;Drug: Anakinra;Drug: Siltuximab;Drug: Tocilizumab","Drug: 2: Usual practice + SYMBICORT RAPIHALER;Other: 1: Usual practice","Device: Web application users","Drug: Tradipitant;Drug: Placebo","Drug: Sargramostim;Other: Control","Drug: Dexamethasone","Other: Survey","Other: blood draw","Drug: Mavrilimumab","Device: SensiumVitals wearable sensor","Drug: lopinavir/ritonavir;Drug: Hydroxychloroquine Sulfate;Drug: Losartan;Drug: Placebos","Procedure: Human biological samples","Other: retrospective analysis","Other: \"Calm\" is a mindfulness meditation mobile app","Biological: CAStem","Drug: Plasma;Drug: Hydroxychloroquine;Drug: Azithromycin","Biological: high-titer anti-Sars-CoV-2 plasma;Other: oxygen therapy","Procedure: Vascular surgery","Diagnostic Test: Breath test","Drug: Hydroxychloroquine Sulfate 400 mg twice a day;Drug: Hydroxychloroquine Sulfate 600 mg twice a day;Drug: Hydroxychloroquine Sulfate 600 mg once a day;Drug: Placebo oral tablet","Drug: Hydroxychloroquine as post exposure prophylaxis;Other: Others(No intervention)","Drug: Ciclesonide Metered Dose Inhaler [Alvesco];Drug: Hydroxychloroquine","Diagnostic Test: Machine learning model","Drug: NORS (Nitric Oxide Releasing Solution);Drug: NORS (Nitric Oxide Releasing Solution)","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells","Biological: COVID-19 convalescent plasma","Other: Questionnaire","Other: Telerehabilitation","Drug: BLD-2660","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin C",null,"Drug: Siltuximab;Drug: Methylprednisolone","Drug: Thiazide or Thiazide-like diuretics;Drug: Calcium Channel Blockers;Drug: ACE inhibitor;Drug: Angiotensin receptor blocker","Other: No Intervention","Drug: Chloroquine phosphate;Other: Telemedicine","Drug: Tocilizumab","Drug: Hydroxychloroquine;Drug: Placebos",null,"Drug: Levamisole Pill + Budesonide+Formoterol inhaler;Drug: Lopinavir/Ritonavir + hydoxychloroquine","Drug: Ruxolitinib",null,"Diagnostic Test: Lung ultrasound","Drug: Nintedanib 150 MG;Other: Placebo","Drug: Atovaquone/Azithromycin","Biological: UC-MSCs;Other: Placebo","Other: Pulmonary ultrasound","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin C;Dietary Supplement: Vitamin D;Dietary Supplement: Zinc","Drug: Defibrotide Injection","Other: Video based aerobic exercise","Drug: Peginterferon Lambda-1a;Other: Standard of Care Treatment","Drug: Tocilizumab;Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Azithromycin;Drug: Placebos","Device: hyperbaric oxygen therapy (HBOT)","Drug: Plasma",null,"Biological: Convalescent Plasma","Drug: Hydroxychloroquine Sulfate;Drug: Bromhexine 8 MG","Drug: Hydroxychloroquine;Drug: Placebo","Other: this study is non- interventional","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector);Other: Placebo","Other: Non-Interventional","Combination Product: Hydroxychloroquine Sulfate + Azithromycin;Drug: Hydroxychloroquine Sulfate","Other: Questionnaire;Diagnostic Test: IgG","Other: hospitalized children with Covid19","Procedure: Auricular neuromodulation;Procedure: Control","Drug: Stem Cell Product","Drug: Sarilumab;Drug: Azithromycin;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine;Drug: Placebo","Drug: Hydroxychloroquine","Drug: Aspirin 75mg;Drug: Clopidogrel 75mg;Drug: Rivaroxaban 2.5 MG;Drug: Atorvastatin 40mg;Drug: Omeprazole 20mg","Other: questionnaire assesment","Biological: blood sampling","Other: Surgical facial mask","Diagnostic Test: COVID-19 diagnostic test","Drug: Piclidenoson","Drug: Favipiravir","Dietary Supplement: Vitamin D","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Dietary Supplement: Bob's Red Mill;Dietary Supplement: Control - Amioca powder (Amylopectin)",null,"Dietary Supplement: Ascorbic Acid;Dietary Supplement: Zinc Gluconate;Dietary Supplement: Ascorbic Acid and Zinc Gluconate;Other: Standard of Care","Drug: Nivolumab Injection","Drug: Nitric Oxide Gas;Other: Inhaled Supplemental Oxygen","Behavioral: COVID-surgRES questionaire",null,null,"Biological: bacTRL-Spike;Other: Placebo","Device: Biosensors","Drug: Losartan","Other: Prospective oberservational registry","Other: observation","Device: BIOVITALS","There are two arms to this trial. Arm 1: Problem Management Plus. Arm 2: Enhanced Treatment as Usual. Therapy is administered once-weekly 60 minute sessions by clinical psychologists over 6 weeks delivered via teleconferencing to groups of 4 people at a time. Problem Management Plus is a program developed by the World Health Organization. Across sessions the clinical psychologist will teach the following stress coping strategies: anxiety reduction, problem solving, behavioral activation, and accessing social support. This will occur will via educational sessions, group discussions via teleconference, and handouts. The duration of the study for any participant will conclude after a 2-month follow-up assessment, resulting in participation duration of 15 weeks.","Drug: Best supportive Care (BSC) + IFX-1;Drug: Best supportive care only","Drug: chloroquine;Other: standard care","Drug: Hydroxychloroquine SAR321068;Drug: Placebo",null,"The primary aim of this study is to evaluate the efficacy and efficiency of two telerehabilitation interventions. The intervention consists of a rehabilitation intervention which focuses more on participation in usual activities and is offered via a coaching model to a virtual group of people. The intervention components are: identifying patient goals with therapist (1:1); and participation in virtual groups (up to 4 participants per session) with physiotherapist and occupational therapists which focus on increasing participation in life roles and usual activities. &lt;br&gt;The 1:1 session will last for approximately 45 minutes and will be followed by commencement of group sessions within 5 days.&lt;br&gt;Groups adopt a coaching model where the therapist talks about common challenges, facilitates discussion and sharing of experiences and ideas and the group brainstorm and plan next steps together. The group sessions will last approximately 45 minutes and will be delivered 3 times per week for up to 4 weeks. &lt;br&gt;Adherence will be measured using attendance logs. &lt;br&gt;&lt;br&gt;","According to the standard of the ICU for COVID-19 and non-COVID-19 patients, routine data of patients with COVID-19 and ARDS including PiCCO-monitoring will be documented from the day of intubation until extubation. All measurements were repeated at least once per day.","Other: Simulation of Repurposed Drugs for COVID-19","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Placebo","Biological: anti-SARS-CoV-2 convalescent plasma","Other: No intervention","Drug: Tocilizumab;Biological: Pembrolizumab (MK-3475)","Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values","Other: COVID-19 infection",null,"&lt;br&gt;                Volunteers will initially be required to complete an online screening. This is an initial confirmation of eligibility. Volunteers will initially be invited for a screening visit. Prior to attending they will have received written information about the study and had time to consider it. At the screening visit a doctor will explain about the study and answer any questions they may have. If the volunteer decides to take part, they will be asked to sign a consent form. The doctor will then check whether the volunteer is eligible to take part. This will involve taking a medical history, performing a physical examination, taking blood tests, urine tests, and measuring blood pressure and temperature.&lt;br&gt;                The doctor will then write to the volunteers own GP to enquire about their medical health. If all the inclusion criteria are met and none of the exclusion criteria are present then the volunteer is invited to return for vaccination. Due to the need for rapid delivery of this study, there will be minimal flexibility around appointment dates.&lt;br&gt;&lt;br&gt;                Before vaccination, volunteers will be asked about their recent health to ensure that they are still medically fit. They will have blood tests taken and participants in groups 1 and 2 will be randomised (1:1) to receive either ChAdOx1 nCoV-19 or saline placebo. Group 3 participants will not be randomised and therefore not blinded.&lt;br&gt;&lt;br&gt;                Participants from group 1 or 3 will be vaccinated first. The first volunteer to receive the IMP will be vaccinated ahead of any other participants. The investigators and/or chair of DSMB will assess there are no safety concerns within 48 hours (24h) post vaccination. The next 3 volunteers will be vaccinated with the IMP at least 1 hour apart. The inve","&lt;br&gt;                Research design:&lt;br&gt;                This cohort study will use the UK Obstetric Surveillance System (UKOSS) to identify women hospitalized with pandemic novel coronavirus infection in pregnancy throughout a 6-month period. Participants will receive their usual management and information will be collected subsequently, detailing their treatment and outcomes. Research participants will not be contacted directly and no personally identifiable information (names, addresses or dates of birth will be collected.&lt;br&gt;&lt;br&gt;                Cohort identification:&lt;br&gt;                Infected women will be identified through the UKOSS network of nominated reporting clinicians in each consultant-led maternity unit in the UK. Nominated reporting clinicians will be asked to report all pregnant women with confirmed pandemic novel coronavirus infection admitted to their unit. In view of the need for rapid and ongoing data analysis and production of guidance, we will use a specific web-based rapid reporting and data collection system for this study to enable UKOSS nominated clinicians to report cases as they occur. In addition, nominated clinicians will be sent a standard UKOSS reporting card each month to further enhance case ascertainment.&lt;br&gt;&lt;br&gt;                Comparison group identification:&lt;br&gt;                Information about comparison women will be obtained from previously conducted UKOSS studies. Previous UKOSS studies have collected detailed demographic, pregnancy and delivery information about a cohort of over 1200 women giving birth in the UK identified from the same hospitals as infected women. This pragmatic approach has been adopted to allow risk factors for severe outcomes of pandemic influenza or novel coronavirus to be identified while minimizing the data collection burden on","Drug: INO-4800;Device: CELLECTRA 2000","Diagnostic Test: nasopharyngeal swab","Device: MAGEC Spine Rod;Diagnostic Test: Titanium blood test","Other: newborns from covid 19 positive mothers",null,"Drug: Ruxolitinib Oral Tablet","Drug: Anluohuaxian","Combination Product: Observational (registry)","Drug: TJ003234;Drug: Placebo","Diagnostic Test: Serological tests will be applied on patients blood sampling","Drug: Hydroxychloroquine - Daily Dosing;Drug: Hydroxychloroquine - Weekly Dosing;Other: Placebo oral tablet;Diagnostic Test: Monitoring Visit - Baseline;Diagnostic Test: Monitoring Visit - Week 4;Diagnostic Test: Monitoring Visit - Week 8;Other: Weekly Assessment","Drug: Nitazoxanide 500 MG;Drug: Hydroxychloroquine","Experimental group:WeChat-based parenting education;Control groop:Electronic Manual + Teaching Plan;","Case series:Nursing care;",null,"Device: Transpulmonary thermodilution;Device: Echocardiography","Drug: Tranexamic acid tablets;Drug: Placebo oral tablet","Procedure: Follow-up at 14 days","Drug: Hydroxychloroquine;Drug: Azithromycin;Dietary Supplement: vitamin C;Dietary Supplement: Vitamin D;Dietary Supplement: Zinc","Drug: Emtricitabine/tenofovir disoproxil;Drug: Hydroxychloroquine;Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo;Drug: Placebo: Hydroxychloroquine","Drug: RhACE2 APN01;Drug: Physiological saline solution",null,"survival group:none;death group:none;","Case group:N/A;control group:N/A;","Drug: Anakinra","Drug: Sirolimus;Drug: Placebo","Other: No special intervention",null,null,"Drug: Ruxolitinib 10 MG","Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation","Biological: COVID-19 exposure","Patient:Surface swab and air sample collection;Healthcare providers:Surface swab from personal protective equipment;","For the mild new coronary pneumonia: General Ward Group:Nil;For the severe new coronary pneumonia: ICU Group:Nil;Support staff: Logistics group:Nil;","Drug: Valsartan (Diovan);Drug: Placebo oral tablet","Biological: allogeneic human dental pulp stem cells (BSH BTC &amp; Utooth BTC);Other: Intravenous saline injection (Placebo)","Device: oxyhydrogen;Device: Oxygen","Diagnostic Test: Collection of breath sample","Drug: Chemotherapy","Drug: Gargle/Mouthwash","Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic","Experimental Group:Xiaotan Sanjiefang granule;Control Group:placebo (contain 5% test drug);","common type :Immunotherapy with recombinant chimeric DC vaccine;Latent period group:Immunotherapy with recombinant chimeric DC vaccine;Normal control group:Immunotherapy with recombinant chimeric DC vaccine;Blank vaccine control group:0.9%NS;","Drug: Favipiravir;Other: Placebo",null,"Drug: Ruxolitinib","Other: telehealth applications","Other: Monitoring for aggravation;Other: Evaluate HACOR score effectivity in this patients","Drug: Hydroxychloroquine Sulfate;Drug: Placebo","Other: Practice details","Drug: Fluvoxamine;Drug: Placebo",null,"Drug: Chloroquine Diphosphate;Drug: Placebo oral tablet",null,"Drug: Aspirin;Drug: Losartan;Drug: Simvastatin","All treatment arms contain standard supportive care during hospital and:&lt;br&gt;1.\tChloroquine arm: loading dose 600mg as chloroquine base followed by 300mg 12 hours later followed by 300mg twice a day; total treatment duration 5 days (same dose as LCI guideline) &lt;br&gt;2.\tHydroxychloroquine arm: loading dose 400mg bid followed by 200mg twice a day; total treatment duration 5 days (same dose as LCI guideline)&lt;br&gt;3.\tNo antiviral treatment arm",null,"Other: Discontinuation of ARB/ACEI;Other: Continuation of ARB/ACEI","Other: COVID-19 Pandemic","Drug: Hydroxychloroquine;Drug: Oseltamivir;Drug: Azithromycin","Drug: Camostat Mesilate;Drug: Placebo;Drug: Hydroxychloroquine","Drug: LY3127804;Drug: Placebo",null,null,null,"&lt;br&gt;Trade Name: Plaquenil 200mg&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;Trade Name: Azithromycine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Kineret&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ANAKINRA&lt;br&gt;CAS Number: 143090-92-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;Trade Name: SYLVANT&lt;br&gt;Product Name: SYLVANT&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Siltuximab&lt;br&gt;CAS Number: 541502-14-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;","Biological: Convalescent Plasma","Exposure to COVID-19.&lt;br&gt;&lt;br&gt;Participant involvement is required, including but not limited to extra nasopharyngeal swabs, blood draws, as well as possible surveys (local site intervention is bound to ISARIC protocol).&lt;br&gt;There may be follow-up after discharge, at 3 and 6 month timepoints (protocol is evolving).","Drug: Ivermectine;Drug: Hydroxychloroquine Sulfate;Drug: Placebos","Device: Hyperbaric Oxygen Therapy","Drug: Placebos;Drug: Leronlimab (700mg)","Drug: chlorine dioxide 3000 ppm","Other: Follow up",null,"Diagnostic Test: Point-of-Care Ultrasonography (POCUS)","Other: Survey administration","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Anakinra&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;&lt;br&gt;","Based on preclinical and non-randomised studies, the Royal Brisbane and Womens Hospital Intensive Care Unit clinical Consultant Medical Staff, in agreement with the Infectious Diseases Department and the Pharmacy Department, have decided that all patients admitted to the ICU with COVID-19 infection should receive hydroxychloroquine as standard care. Therefore, hydroxychloroquine is NOT considered a trial intervention for the purpose of this study.&lt;br&gt;&lt;br&gt;The dose of hydroxychloroquine used for COVID-19 infection is extrapolated from that in common use for malaria and other approved indications. However, the organ dysfuction that accompanies critical illness suggests dosing is likely to require adjustment. This study will adjust the dose of hydroxychloroquine using therapeutic drug monitoring (TDM) to a goal concentration known to be safe. The observation period for TDM will be a total of up to 10 days or until the time of ICU discharge, which ever is sooner.&lt;br&gt;&lt;br&gt;As is routine practice at the RBWH ICU, TDM will be led by the senior ICU pharmacist after initiation of therapy. Trough venous blood samples (3 ml) will be taken via an indwelling arterial cannula. The first TDM should ideally occur before the administration of the FIRST MAINTENANCE DOSE, provided the appropriate loading dose schedule has been completed. Sampling thereafter can occur every 24-48 hours to confirm the appropriateness of ongoing dosing as guided by the Pharmacy and Medical Team. Blood samples will be transported to Queensland Pathology on the Herston Campus for drug analysis. Prescribing of initial and ongoing/revised dosing will remain the responsibility of medical officers, whilst fidelity of the intervention will be maintained through pharmacy dosing adjustment notes which are subjected to","&lt;br&gt;                RECOVERY is a randomised trial among adults hospitalised for COVID-19. Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs lopinavir + ritonavir vs interferon 1 vs low-dose corticosteroids vs hydroxychloroquine. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.&lt;br&gt;&lt;br&gt;                RECOVERY has an adaptive trial design. The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The DMC will assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.&lt;br&gt;&lt;br&gt;                Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs Lopinavir-Ritonavir vs Interferon 1 vs Low-dose Corticosteroids vs Hydroxychloroquine.&lt;br&gt;                For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.&lt;br&gt;&lt;br&gt;                Drug dosage and duration:&lt;br&gt;                Lopinavir 400 mg + ritonavir 100 mg: by mouth (or nasogastric tube) every 12 hours for 10 days or unti","Drug: Hydroxychloroquine;Drug: Lopinavir / Ritonavir;Drug: Interferon Beta-1A;Drug: Interferon Beta-1B","Expressive/gratitude writing intervention  This group will participate in the adapted evidenced-based 4-day writing program (Pennebaker 1997). Participants will meet with the facilitator (a researcher with a Psychology degree) using Zoom in a group format four times in one week for approx. 30 minutes (25 minutes of writing time). Daily e-mail reminders will be sent during the 4 days of writing. Session structure  1 min to complete the distress VAS measure (before), 5 minutes write any reflection from last session, 15 minutes spent writing about your thoughts and feelings, 5 minutes writing about the things you are grateful for, 1 min to complete the distress VAS measure (after). The instruction each day will be (adapted from Pennebaker): &lt;br&gt;Please write about your thoughts and feelings about your IBD and the recent situation with COVID-19. Try to select something that you had a strong reaction to  perhaps this was a thought that was challenging or unpleasant. Feel free to really let go and explore your very deepest emotions and thoughts. You might tie your topic to your relationships with others, including parents, lovers, friends or relatives, to your past, your present, your future, or to who you have been, who you would like to be, or who you are now. All of your writing will be completely confidential. Please dont worry about spelling, sentence structure, or grammar. Feel free to type or write by hand. &lt;br&gt;Participants will not be asked to share their writing with the study investigators, to ensure free expression.&lt;br&gt;","&lt;br&gt;                Matched longitudinal internet-based survey with pre-existing, validated self-questionnaires (Work-SoC, PHQ-9, IES-6, PVD, SFI, CD-RISC 10), at 3 time periods of 2 weeks over 6 months, with the option to prolong depending on the development of the pandemic.&lt;br&gt;&lt;br&gt;                Semi-structured interviews with focus groups after the last period of the survey.&lt;br&gt;","&lt;br&gt;                After consent and enrolment patients in the influenza cohort will undergo a single-draw set of baseline blood tests. This will include peripheral blood mononuclear cells and Paxgene DNA. Approximately 30-40 ml of blood will be taken. BAL will only be performed at the discretion of the treating team as per standard clinical care. Surplus BAL samples from participants will be stored for analysis after the influenza season. Leftover serum will also be stored.&lt;br&gt;&lt;br&gt;                Data Collection&lt;br&gt;                Clinical data will be collected from the electronic hospital records at baseline, during the patients ICU stay, and after ICU discharge - up to 90 days or hospital discharge (whichever is longer).&lt;br&gt;&lt;br&gt;                Data Analysis&lt;br&gt;                The researchers will use the collected clinical and microbiological data and BAL/blood galactomannan results to determine the primary and secondary outcome measures, with input from the study statistician for the multivariable analyses.&lt;br&gt;&lt;br&gt;                Retrospective Diagnostic Evaluation&lt;br&gt;                Once the prospective study is complete, stored BAL/blood samples will be tested retrospectively in parallel by two tests: galactomannan EIA (the current gold standard biomarker test for IA) and by the AspLFD (the new test we wish to validate). This will be done after the influenza season so results will have no implications for participants. The BAL/blood AspLFD results will be compared against the IA status of the patient to evaluate test performance against the AspICU definition.&lt;br&gt;&lt;br&gt;                Planned Sub-studies&lt;br&gt;                These will be subject to further funding and are laboratory studies to help us understand why certain patients with influenza might be at greater risk of developing IA. This will i","Drug: Baricitinib","Device: Low flow ECMO driving by CVVH machine",null,"Procedure: ECMO Implantation","Intervention 1&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Lopinavir/ritonavir&lt;br&gt;Intervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;Intervention 2&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Hydroxychloroquine&lt;br&gt;Intervention Description: 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;Intervention 3&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Lopinavir / ritonavir plus hydroxychloroquine&lt;br&gt;Intervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days plus hydroxychloroquine 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;","Intervention is an aqueous buffered solution of 0.5% povidone-iodine (PVP-I) contained in a 30 mL bottle closed with a traditional nasal spray pump.&lt;br&gt;Subjects will receive a single dose to their nasal passages, administered by the investigator. &lt;br&gt;The amount a subject receives consists of 6 x 140L pump actuations (3 into each nostril), being 0.84 mL total volume.","&lt;br&gt;                Patients will be randomised in a 1:1:1 ratio to:&lt;br&gt;                Arm 1: Continuous positive airway pressure (CPAP), administered according to local protocol/guidelines. Administration will be left to clinical discretion.&lt;br&gt;                Arm 2: High flow nasal oxygen (HFNO) will be administered according to local protocol/guidelines. Administration will be left to clinical discretion.&lt;br&gt;                Arm 3: Standard care. Standard oxygen therapy according to local protocol/guidelines.&lt;br&gt;","&lt;br&gt;                Adults (aged =18 years) recently hospitalized, or already in the hospital, with definite COVID-19 and, in the view of the responsible doctor, no contra-indication to any of the study drugs will be randomly allocated between five groups:&lt;br&gt;                1. Local standard of care alone&lt;br&gt;                OR local standard of care plus one of&lt;br&gt;                2. Remdesivir (daily infusion for 10 days)&lt;br&gt;                3. Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)&lt;br&gt;                4. Lopinavir + ritonavir (orally twice daily for 14 days)&lt;br&gt;                5. Lopinavir + ritonavir ((orally twice daily for 14 days) plus interferon-beta (daily injection for 6 days)&lt;br&gt;&lt;br&gt;                Follow-up is until death or discharge from hospital.&lt;br&gt;                Randomization is performed at one central global location through an online portal.&lt;br&gt;","Device: Non-contact ECG","Behavioral: PTSD;Behavioral: Burnout","Other: Satisfaction evaluation","Drug: Linagliptin;Drug: Insulin regimen","intervention group:exercise;Control group:Blank;","Experimental group:exercise rehabilitation under remote monitoring;Control group:patient education;","Case series:Nil;","Case series:None;","NK cell group:NK cells were injected by intravenous drip once a day for 2 to 3 times in total, each dose was 4 10^7 pieces /kg body weight,100ml normal saline suspension;Control group:100ml normal saline intravenous drip;","Case series:cesarean section;","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Biological: Convalescent plasma","Procedure: Blood draw","Case series:Danorevir sodium tablets,/ritonavir oral;","Case series:no intervention;","Experimental group:Acetylcysteine inhaled via tracheal tube;Control group:Placebo (saline) inhaled via tracheal tube;",null,null,"Drug: Nitazoxanide;Drug: Placebo","Biological: Convalescent Plasma","Drug: Hydroxychloroquine;Dietary Supplement: Placebo","Novel coronavirus pneumonia:none;","Case series:NA;",null,"Lung Ultrasound","During routine daily laboratory rounds blood will be stored at -80 C until biomarkers will be assayed later.","Infotainment intervention with (social) media and influencers.","Behavioral: Crisis management coaching","Other: No intervention","Patients with pulmonary infection and COVID 19 will have their respiratory management during ICU admission decided in one of two ways&lt;br&gt;Method 1. Lung ultrasound will be used to make management decisions - this is a non-invasive way of ultrasounding the lungs &lt;br&gt;One hospital site will use method 1&lt;br&gt;Three hospitals will use method 2&lt;br&gt;Both methods are currently standard at the respective hospitals&lt;br&gt;The comparator treatment will be decided by the attending intensivist. The treatment will be different in every patient. Depending on the results of the auscultation and waveform analysis, a different method of mechanical ventilation or respiratory physiotherapy may be chosen. &lt;br&gt;&lt;br&gt;Respiratory physiotherapy may be different in each case but will consist of either ventilator hyperinflation, positioning or manual techniques. The senior respiratory physiotherapist will decide the type of physiotherapy treatment delivered based on COVI 19 guidelines. &lt;br&gt;This will be from admission to ICU to 28 days post hospital discharge","&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","All women infected with SARS-CoV 2 (novel coronavirus) infection or who were diagnosed with COVID-19 during pregnancy. Observation will continue throughout pregnancy up until 6 weeks postpartum. In addition to standard care, women will be asked to complete a questionnaire after discharge to include postpartum and neonatal outcomes.","Oral administration of Hydroxychloroquine capsules for five days. &lt;br&gt;Day 1: 800mg (4 capsules) Hydroxychloroquine stat&lt;br&gt;Days 2 - 5: 400mg (2 capsules) Hydroxychloroquine once daily&lt;br&gt;Adherence to trial treatment will be assessed through the study diaries which will require the participant to complete the time of administration and number of tablets taken each day. Participants will not be required to return used study treatments to the research office but encouraged to dispose of any unused medication via their community pharmacy or general practice.","Imatinib or placebo","&lt;br&gt;Trade Name: Fresh frozen plasma (FFP) with marketing authorisation in Germany issued by PEI&lt;br&gt;&lt;br&gt;Product Name: For example \"Gefrorenes Frischplasma / Apherese DRK Blutspendedienst\"&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL 200 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Imatinib Teva 400 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: IMATINIB&lt;br&gt;CAS Number: 152459-95-5&lt;br&gt;Other descriptive name: IMATINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: AVIGAN 200mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: FAVIPIRAVIR&lt;br&gt;Other descriptive name: FAVIPIRAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: MICARDIS 20mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TELMISARTAN&lt;br&gt;CAS Number: 144701-48-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: DEXAMETHASONE MYLAN 20mg/5mL &lt;br&gt;Product Name: DEXAMETHASONE&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;Trade Name: PLAQUENIL 200MG&lt;br&gt;Product Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","COVID-19 symptomatic confirmed hospitalized adult patients will be enrolled as soon as possible after fulfilling the criteria for randomisation. Patients will be allocated in a 1:1 ratio to either the treatment group receiving intravenous zinc chloride (0.5mg/kg/d) or to control group, receiving saline placebo alone. &lt;br&gt;Pharmaceutical grade Zinc Chloride stock solution obtained from an Australian company (Phebra Pty Ltd) will be diluted in 250ml of normal saline and infused, resulting in a final dosage of 0.5mg/kg/d. Patients will be administered zinc for seven days. To standardise administration time, zinc infusions will commence around 9am but anywhere between 8am to 12pm in the morning is adequate. Zinc chloride will be administered via central venous or peripheral access over 3-6 hrs.&lt;br&gt;We will monitor fidelity to the intervention by review of nursing documentation in the intravenous fluid given section of the electronic fluid balance chart. Note will be made of what was given, time commenced, volume given, time completed.&lt;br&gt;","&lt;br&gt;                This is an interventional study where good sleepers will be recruited as a wait-list control, where they will receive the treatment after a delay of one week. An additional group of good sleeper participants will be recruited who will not receive the intervention. An equal number of participants will be recruited to each group and healthy good sleepers and individuals with sleep problems will be recruited at a 2:1 ratio (estimated n = 40:20 participants).&lt;br&gt;&lt;br&gt;                The study is single-centre and the study will be run entirely online.&lt;br&gt;&lt;br&gt;                Participants who are in the two intervention groups (poor sleep and wait-list control good sleepers) will be provided with an online version of a self-help leaflet. A printed version of this leaflet has been used in previous treatment studies conducted by our research group. Briefly, this self-help leaflet aims to improve sleep by identifying and addressing sleep-related dysfunctional thinking by providing education about sleep, providing techniques to distract from intrusive worrisome thoughts at night, and providing guidelines for sleep-related stimulus control.&lt;br&gt;&lt;br&gt;                The duration of treatment will be one week and the follow-up period is at the end of the treatment period. Participants will be randomised using online software (where good sleepers will be randomised to treatment or no treatment).&lt;br&gt;","&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Current Sponsor code: REMDESIVIR&lt;br&gt;Other descriptive name: REMDESIVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Chloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Interfern b 1A&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;CAS Number: 220581-49-7&lt;br&gt;Current Sponsor code: Interferon beta-1a&lt;br&gt;Other descriptive name: Interferon beta-1a&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 152-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: DEFITELIO&lt;br&gt;Product Name: DEFITELIO&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: DEFIBROTIDE&lt;br&gt;CAS Number: 83712-60-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;                Patients presenting to the UZH COVID-19 Testing Center for SARS-CoV-2 testing will be enrolled in the cohort study. All patients will undergo routine testing at the testing center. The cohort study-specific follow-up and prospective data collection will depend on the test result.&lt;br&gt;&lt;br&gt;                Patients tested positive for SARS-CoV-2 will receive three calls at 7, 14 and 60 days after their visit to the testing center. Information will be collected about the disease course and current health status, as well as further health care contacts. Further information about the disease course, hospitalization and patient outcomes will be collected from patient records obtained from general practitioners and treating physicians in hospitals.&lt;br&gt;&lt;br&gt;                Patients tested negative for SARS-CoV-2 will receive one call at 14 days after their visit to the testing center. Information will be collected about the disease course and current health status, as well as further health care contacts and retesting. If retested, further information about the second test result will be collected from general practitioners and treating physicians in hospitals. Biological samples obtained for viral testing will additionally be analyzed for further respiratory pathogens.&lt;br&gt;","&lt;br&gt;                The trial will initially be two-arm, comparing usual care to usual care with hydroxychloroquine treatment.&lt;br&gt;&lt;br&gt;                The trial will be implemented in the first instance in practices that are already part of the RCGP RSC Network. Currently, over 500 practices are part of this network, with 100 already offering a sentinel viral swabbing service which is being scaled up and due to the pandemic, all practices in the UK have been asked to join the RCGP RSC Network.&lt;br&gt;&lt;br&gt;                A platform trial, in contrast to say a  traditional two-arm design, allows multiple arms to be considered simultaneously, and interventions can be dropped and replaced as evidence emerges for effectiveness or lack of it. The intent is to establish an on-going trial infrastructure within a master protocol that uses all the data already accumulated for the assessment of current and subsequently introduced interventions. New interventions will only be added after submission to the appropriate approval bodies.&lt;br&gt;&lt;br&gt;                The PRINCIPLE trial will begin as a 1:1 randomised trial of usual care plus study-specific medication (in the first instance hydroxychloroquine) versus usual care alone but the study design has the capability to add additional interventions over time. The evaluation of any new interventions will be governed by the master protocol, including adaptive and decision criteria. In addition, the inclusion of any new interventions will require supplementary appendices to the protocol and SAP.&lt;br&gt;&lt;br&gt;                The initial drug is hydroxychloroquine sulphate 200 mg tablets. The tablets are for oral administration. One tablet (200 mg) hydroxychloroquine to be taken twice daily for 7 days by mouth (14 tablets in total). This is the standard therapeutic dose for its n","&lt;br&gt;Trade Name: Hidroxicloroquina Aristo&lt;br&gt;Product Name: Hidroxicloroquina sulfato&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: 81939&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Hidroxicloroquina Aristo&lt;br&gt;Product Name: Hidroxicloroquina sulfato&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: 81939&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ibuprofen&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: IBUPROFEN&lt;br&gt;CAS Number: 15687-27-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;Trade Name: Hidroxicloroquina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Azitromicina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Azithromycin&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Other descriptive name: AZITHROMYCIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Paracetamol&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Paracetamol&lt;br&gt;CAS Number: 103-90-2&lt;br&gt;Other descriptive name: PARACETAMOL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Pulmozyme 2500 U/2,5ml, solution pour inhalation par nbuliseur&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lariam&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: MEFLOQUINE&lt;br&gt;CAS Number: 53230-10-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","mild, moderate, severe ARDS:Nil;","Patients with LE and are taking hydroxychloroquine:N/A;Patients with LE and are not taking hydroxychloroquine:N/A;Patients with dermatomyositis and are taking hydroxychloroquine:N/A;Patients with dermatomyositis and are not taking hydroxychloroquine:N/A;Patients with RA and are taking hydroxychloroquine:N/A;Patients with RA and are not taking hydroxychloroquine:N/A;Patients with rosacea and are taking hydroxychloroquine:N/A;Patients with rosacea and are not taking hydroxychloroquine:N/A;","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine Sulfate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","1:Middle dose (1E11vp);2:Low dose (5E10vp);3:placebo;","1:none;","Gold Standard:clinical outcome; nucleic acid test;Index test:antigen reagent;","Gold Standard:Clinical outcome, novel coronavirus nucleic acid test, clinical symptoms, lung CT;Index test:Proteomics,&amp;#32;metabolomics&amp;#32;and&amp;#32;other&amp;#32;markers,&amp;#32;mass&amp;#32;spectrometer;","Not applicable","None","Lung Ultrasound and CT-scan","Patients in this study are treated with intravenous tociluzumab: 8 mg/kg (maximum dose 800 mg), which can be repeated at the same dose after 8 hours if the hypoxia has not improved. This is the approved dose for cytokine release syndrome.","&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: NAPROXEN&lt;br&gt;Other descriptive name: NAPROXEN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: IFX-1&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: -&lt;br&gt;CAS Number: -&lt;br&gt;Current Sponsor code: IFX-1&lt;br&gt;Other descriptive name: -&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lopinavir/Ritonavir&lt;br&gt;Product Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: GNS561&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Not available&lt;br&gt;CAS Number: 1914148-72-3&lt;br&gt;Current Sponsor code: GNS561&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 50 - 200-&lt;br&gt;&lt;br&gt;Trade Name: Opdivo&lt;br&gt;Product Name: Nivolumab&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: NIVOLUMAB&lt;br&gt;CAS Number: NIVOLUMAB&lt;br&gt;Current Sponsor code: ET17-093&lt;br&gt;Other descriptive name: NIVOLUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dexamethasone 20 mg/5mL&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: DEXAMETHASONE&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Medicinal Oxygen&lt;br&gt;Product Name: Medicinal Oxygen&lt;br&gt;Pharmaceutical Form: Medicinal gas, liquefied&lt;br&gt;INN or Proposed INN: Medicinal Oxygen&lt;br&gt;Other descriptive name: Medicinal Oxygen&lt;br&gt;Concentration unit: % (V/V) percent volume/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Metilprednisolona&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 20-125&lt;br&gt;&lt;br&gt;Trade Name: Modigraf&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.1-0.2&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 648-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Truvada&lt;br&gt;Product Name: Truvada&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TENOFOVIR DISOPROXIL FUMARATE&lt;br&gt;CAS Number: 202138-50-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: EMTRICITABINE&lt;br&gt;CAS Number: 143491-57-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 245-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Hydroxychloroquine&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL 200 mg, comprim pellicul&lt;br&gt;Product Code: SAR390530&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: SAR321068&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Solu-Modern 1 g polvo y disolvente para solucin inyectable&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection/infusion&lt;br&gt;INN or Proposed INN: Metilprednisolona (como succinato de sodio)&lt;br&gt;CAS Number: 2375-03-3&lt;br&gt;Current Sponsor code: Pfizer, SL&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;"],["duration of in hospital;in hospital mortality;the 28s day' mortality after admission;duration of ICU stay;","Length of hospital stay;","mortality","inhospital length;inhospital mortality;ECMO treatment length;28th day mortality after admission;","Fatality rate;","Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms;","Lung function;","Conversion rate of mild and common type patients to severe type;Mortality Rate;","Time to disease recovery;","SEN, SPE, ACC, AUC of ROC;","The rate of virus inhibition","Cardiovascular Death","GHQ-12(general health questionnaire-12)","detection of SARS-CoV-2 nucleic acid;SEN;","28-day mortality and 90-day mortality.;","St. George's Respiratory Questionnaire;","Chest CT findings;Epidemiological history;Laboratory examination;Pulmonary function test;SEN, SPE, ACC, AUC of ROC;","Length of hospital stay;fever clearance time;","14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;","Body temperature returns to normal time;Pulmonary inflammation resolution time (HRCT);Mouthwash (pharyngeal swab) at the end of treatment COVID-19 RNA negative rate;","14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;","Time to Clinical recovery;","Time to complete remission of 2019-nCoV infection-associated symptoms","Virus negative conversion rate in the first week","Lower Murray lung injury score;Lower Murray lung injury score;Clinical improvement based on the 7-point scale","The incidence of composite adverse outcome","PSQI;","imaging feature;","Number of worsening events;","Length of hospital stay;","Length of admission;mortality rate;","rate of cure;","clinical features and risk factors;validity and reliability of the model;","Incidence of co-infection;","Sensitivity of detection of NCP;Specificity of detection of NCP;","ECG;Chest imaging;Complications;vital signs;NEWS2 score;","Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;","Time of viral nucleic acid turns negative;Antipyretic time;","Chest imaging (CT);","Length of stay;Length of severe;oxygenation index during treatment;all-cause mortality in 28 days;Peripheral blood cell count (including white blood cells, lymphocytes, neutrophils, etc.);procalcitonin;C-reactive protein;Inflammatory factors (including IL-6, IL-10, TNF-a, etc.);Lymphocyte subsets and complement;Coagulation indicators (prothrombin time, activated partial prothrombin time, fibrinogen, D-dimer, platelet count);Virus nucleic acid;","Positive/Negtive;SEN, SPE, ACC, AUC of ROC;","TCM symptom score;Antifebrile time;The time and rate of transition of new coronavirus to Yin;","Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomization;","TCM symptoms efficacy;","TCR sequencing;BCR sequencing;HLA sequencing;","Time for body temperature recovery;Chest CT absorption;Time of nucleic acid test turning negative;","Antipyretic time;Pharyngeal swab nucleic acid negative time;Blood gas analysis;Traditional Chinese medicine syndrome score;","cure rate;","Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;","2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation;","time and rate of temperature return to normal;;time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.);time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms;time and rate of pulmonary imaging improvement;time and rate of change to negative COVID-19 nucleic acid test;time and rate of improvement of oxygenation measurement;improvement time and rate of CD4 count;rate of mild/modorate type to severe type, rate of severe type to critical type;length of hospitalization;mortality;","Time to clinical recovery;","Rate of conversion to severe or critical illness;","length of stay;length of stay in ICU;Antibiotic use;Hospital costs;Organ function support measures;Organ function;","the negative conversion ratio;the proportion of general patients with advanced severe disease;confirmed rate of suspected cases;","PSI;","Antipyretic time;","Cure rate;The cure time;The rate and time at which the normal type progresses to the heavy type;Rate and time of progression from heavy to critical type and even death;","CD4+;CD3+;HAMA;HAMD;STAI;","Clinical and laboratory indicators;Viral load;chest CT;serum cell factor;","viral negative-transforming time;30-day cause-specific mortality;","The incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 = 94% or respiratory frequency = 24 times / min in the state of resting without oxygen inhalation;","Recovery time;Ratio and time for the general type to progress to heavy;Ratio and time of severe progression to critical or even death;","Relief of clinical symptoms and duration;","Inpatient mortality;","28-day survival;Inflammatory factor levels;","vital signs (Body temperature, blood pressure, heart rate, breathing rate);Respiratory symptoms and signs (Lung sounds, cough, sputum);Etiology and laboratory testing;PaO2/SPO2;Liquid balance;Ventilator condition;Imaging changes;","Chest CT;Routine blood test;liver and renal function;TCM syndrome;","Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;ocial support rate scale, SSRS;","pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;","Time to Clinical recovery;","Physical and mental health;","Clinical characteristics;TCM syndrome;","CURB-65;PSI score;Mechanical ventilation time;Length of stay in hospital;","Time for body temperature recovery;Chest X-ray absorption;","CT of lung;CT and MRI of hip;","blood routine examination;CRP;PCT;Chest CT;Liver and kidney function;Etiology test;","incidence;mortality;","the condition worsens and develops into severe or critical condition;the condition improves significantly and reaches the discharge standard;The overall treatment time is no longer than 14 days;","ROX index;","Duration of PCR normalization;Clinical symptom score;","Critically ill patients (%);","Physical examination;Nucleic acid;Oxygenation index;GAD-7;PHQ-9;SASRQ;PSQI;Lymphocyte subsets;","Time to completely antipyretic time:completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Main symptom relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of breath all remission/disappear.;","Epidemiological history;haematological;First symptom;blood glucose;blood glucose;prognosis;Blood gas analysis;complication;","Virus negative conversion rate in the first week;","Lymphocyte subpopulation analysis;Cytokine detection;Single cell sequencing of bronchial lavage fluid cells;","Incidence of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;days of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;","virus nucleic acid negative-transforming time;","Mortality in patients;","pulmonary function;Novel coronavirus pneumonic nucleic acid test;","CT scan of the lungs;Nucleic acid detection of throat secretion;","Declining speed of Novel Coronavirus by PCR;Negative Time of Novel Coronavirus by PCR;Incidentce rate of chest imaging;Incidence rate of liver enzymes;Incidence rate of kidney damage;","PSI;","Time to disease recovery;","The incidence of composite adverse outcome within 14 days after admission: Defined as (one of them) SPO2&lt;= 93% without oxygen supplementation, PaO2/FiO2 &lt;= 300mmHg or RR &lt;=30 breaths per minute.;","The time when the nucleic acid of the novel coronavirus turns negative;T cell recovery time;","Time to viral negativity by RT-PCR;Time to clinical improvement;","blood routine;urine routines;CRP;PCT;ESR;creatase;troponin;myoglobin;D-Dimer;arterial blood gas analysis;Nucleic acid test for 2019-nCoV ;chest CT;Biochemical complete set;","Time to viral negativityby RT-PCR;Time to clinical improvement: Time from start of study drug to hospital discharge or to NEWS2&lt;2 for 24 hours.;","Time to conversion of 2019-nCoV RNA result from RI sample;","body temperature;Whole blood count and five classifications;C-reactive protein;","Chest CT scan;Nucleic acid of novel coronavirus;Routine blood test;Routine urine test;Stool routine test;","Time to leave ventilator on day 28 after receiving MSCs infusion;","Patient survival rate;","all available outcome;","pulmonary function;Antipyretic time;Time of virus turning negative;","pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;Incidence of adverse events;","pulmonary function;St Georges respiratory questionnaire, SGRQ;","Antipyretic time;Time of virus turning negative;","Viral nucleic acid detection;CT Scan of the Lungs;Blood routine examination;Temperature;Height;Weight;","TCM syndroms;","State anxiety;","the score of Hamilton depression scale;the score of Hamilton anxiety scale;the score of Self-Rating Depression Scale;the score of Self-Rating Anxiety Scale;the score of Athens Insomnia Scale;","pneumonia severity index (PSI);Incidence of new organ dysfunction;","The novel coronavirus nucleic acid negative rate;","Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab","lung injury score","Cure rate;Mortality;","the rate of remission;","Lower Murray lung injury score;Lower Murray lung injury score","the daily treatment intensity;","Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination;","Body temperature;TCM syndrome integral;Murray lung injury score;The transition time of novel coronavirus nucleic acid;MuLBSTA score;","Distribution of 'B' line around lungs of both lungs;Whether there is peripulmonary focus;","pneumonia severity index (PSI);","Oxygenation index","28day mortality;","CD8+ T cells numbers;CD4+ T cell numbers;NK cell numbers;Fatality rate;Clinical recovery time;Critical (severe or critical) conversion rate;","SARS-CoV2 Nucleic Acid Quantification;","menstruation changes;TCM body constitution score;","Chest CT;Whole blood cell analysis;Recovery rate;Oxygenation index;Inflammatory response index;","Clinical recovery time;","Cortisol;ACTH;Form of Adrenal tissue;","M mode echocardiography;two-dimensional echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;","TCM symptom score;Becomes negative time of COVID-19;Cure / mortality rate;","Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;","The changes of clinical symptom, laboratory and radiological data ;Oxyhemoglobin saturation.;dyspnea;Body temperature;Radiological characteristic sign;Blood routine;C-reaction protein;lymphocyte count;Liver function: TBIL(total bilirubin), AST(alanine aminotransferase) and ALT(aspartate aminotransferase);Neutralization antibody level;","Acute kidney injury;","clinical cure rate;Incidence of mechanical ventilation by day28;All-cause mortality by day28;Incidence of ICU admission by day28;","Release rate of discharge standards for isolation;Change in Critical Illness;Traditional Chinese medicine syndrome score;","Mood index;","The days from positive to negative for viral nucleic acid testing;","Clinical index;","Self-rating depression scale;","viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;Others (liver function, kidney function, myocardial enzyme);","Clinical symptoms;Blood routine;the viral load of 2019-nCOV of throat swab;TBNK cell subsets;TH1/TH2 Cytokine;Chest CT;","ICU hospitalization days;Death rate;","Proportion of COVID-19 close contacts who have developed as confirmed cases;","recovery time;","Chest imaging;RNA test of COVID-19;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;Completely antipyretic time: completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Blood oxygen saturation;Time to 2019-nCoV RT-PCR negativity: defined as the last test time for two consecutive negative respiratory viral nucleic acid tests (sampling interval of at least 1 day);Liver, renal  and heart  function;","Death;Recovered;Discharged;","menstruation changes;","NA;","Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);","TTCI (Time to Clinical Improvement);","The nucleic acid of the novel coronavirus is negative;CT scan of ground glass shadow disappeared;","psychological scale;Intestinal flora abundance, etc;Upper respiratory flora abundance, etc;","Recovery rate;","Rate of composite advers outcomes:SpO2,PaO2/FiO2, respiratory rate;","Quality of life;Anxiety assessment;Depression assessment;Major symptoms improved;","Three-dimensional ultrasound;Two-dimensional ultrasound;Respiration related parameters;Doppler ultrasound;","CT image of lung of close contact medical staff;Human body temperature of close contact medical staff;Anxiety Scale of of close contact medical staff;","Clinical recovery time;","SARS-CoV-2 DNA;SARS-CoV-2  antibody levels;thoracic spiral CT;","Time to Clinical Recovery;","Self-Rating Anxiety Scale;Self-Rating Depression Scale;Posttraumatic stress disorder checklist,;Questionnaire for Simple Responses;","Time to Clinical recovery;","gut microbiome;Fecal metabolomics;Blood routine;albumin;serum potassium;CRP;ALT;AST;urea;Cr;urea nitrogen;D-Dimer;ESR;IgG;IgM;IgA;hepatitis B surface antigen;2-microglobulin;IFN-gama;IL-6;TNF-beta;IL-10;IL-2;IL-4;IL-13;IL-12;chest CT;abdominal CT;ECG;Weight;height;body temperature;respiratory rate;Heart Rate;Blood Pressure;Defecate frequency;Bristol grading;","Clinical characteristics;","Coronavirus nucleic acid markers negative rate;Symptoms improved after 4 treatments;Inflammation (CT of the chest);","Accuracy;","Mental health status;","hospital stay;Discharge rate;Site-specific hospital metastasis rate or severe conversion rate;Body temperature normalization time;Clinical symptoms disappearance rate;","cure rate;","lung function;ADL;6min walk;","Length of hospital stay;","Clinical recovery time;Clinical recovery time;Changes in viral load of upper and lower respiratory tract samples compared with the baseline;","Improved respiratory system function (blood oxygen saturation) recovery time;","Arterial Blood Oxygen Saturation;TTCR,Time to Clinical recovery;temperature;respiratory rate;Lung CT;","Time to Clinical Recovery;","TCM syndrome;","CoVID-19 Perinatal Outcomes;","Disappearance rate of fever symptoms;","oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis;","HSCS;SCSQ;GHQ-12;","the rate of Coronary virus nucleic acid negative at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;Symptom recovery at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;","Cytokine detection;Lymphocyte subpopulation analysis ;SEN, SPE, ACC, AUC of ROC;","blood cell count;C-reactive protein (CRP);arterial blood-gas analysis;markers of myocardial injury;coagulation profile;serum biochemical test;brain natriuretic peptide(BNP);blood lipid;fibrinogen(FIB), D-Dimer.;","SARS-COV-2 nucleic acid;SEN, SPE, ACC, AUC of ROC;","Time to Clinical recovery;Butyrate in feces;","Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus;","Recovery time;","SOFA;","Time to Clinical recoveryTime to Clinical Recovery (TTCR)","Recovery time;Pneumonia psi score;","The SARS-CoV-2 infection of neonates born to mothers with COVID-19;The death of newborns with COVID-19","positive number diagnosed by national guideline in the evaluated population","Time to Clinical recoveryTime to Clinical Recovery (TTCR)","Time to Clinical Improvement (TTCI)","PCL;HRQL;IPAQ;PASE;","Post-traumatic stress disorder checklist;Clinical prognostic outcome;Il-6;Health-related quality of life inventory;","The incidence of long-term adverse outcomes.;The improvement rate of 2019-nCoV.;The cure rate of 2019-nCoV.","Oxygenation index (PaO2/FiO2);Pneumonia severity index","Accuracy of nCapp COVID-19 risk diagnostic model","Psychological status;Treatment compliance;To evaluate the difference in isolation and rehabilitation of patients after discharge;","Time to Clinical Improvement (TTCI) [Censored at Day 28]","2019 nCoV nucleic acid detection","Clinical recovery time","High-resolution computed tomography (HRCT) score;Lung function including FVC, FVC as a percentage of projected value and DLco","mood assessment;","pulmonary iconography;","CT;SEN, SPE, ACC, AUC of ROC;","Epidemiological characteristics;clinical features;Treatment outcome;","Epidemiological and clinical characteristics;","temperature;respiratory symptoms;","The change of pneumonia severity on X-ray images","PCL;PSQI;FSI;","Pharynx swabs, lower respiratory tract samples (sputum/endotracheal aspiration/alveolar lavage), and anal swabs rt-pcr of novel coronavirus nucleic acid negative conversion rate.;","Lung CT;TCM symptoms;","Survival rate","Positive rate of 2019 Novel Coronavirus RNA","Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0;Improvement of clinical symptoms including respiratory frequency;Improvement of clinical symptoms including duration of fever","Inhospital time;","SEN, SPE, ACC, AUC of ROC;","K-bld questionnaire survey;Refers to the pulse oxygen;chest CT;blood gas;","blood RNA;","Viral load;Clinical features;Inflammation;Pulmonary imaging;","Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time.;","cure rate;virus negative rate;time of virus negative;","Epidemiological and clinical characteristics;","GHQ-20;","During the operation, the patient's volume of local exhaled air from the mouth and nose, the patient's heart rate, respiratory rate and blood oxygen saturation;","Critically ill patients (%);Mortality Rate;","Blood Routine;Liver function;Blood electrolyte;Anticoagulation index;Lung CT;Viral RNA;","Psychological questionnaire;","Time to disease recovery;Exacerbation (transfer to RICU) time;","imaging feature;","Temperature;Respiratory symptoms;","Clinical indicators;","Inflammation factor;","no;","Quality of Life;Epidemic Prevention Medical Protective Equipment related Skin Lesion and Management Scale;","Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;","temperature;respiratory rate;Blood oxygen saturation;Cough symptom;Lung CT;Fatality rate;","INR;PT;TT;APTT;FIB;DD;","NRS 2002 score;BMI;triceps skinfold thickness (TSF);prealbumin;total albumin;leucocyte count;CRP;lymphocyte percentage;TNF- alpha;IL-6;","Clearance rate and time of main symptoms (fever, fatigue, cough);","Lung CT;","health status;Mental health status;","SEN, SPE, ACC, AUC of ROC;","Clinical symptoms;TCM syndrome;Lung imaging;Time of nucleic acid turning negative;","Clinical characteristics;","Length of hospital stay;Discharge time of general type;Discharge time of severe type;","Routine physical examination;Vital signs: breathing, body temperature (armpit temperature);Blood routine;C-reactive protein;Liver and kidney function test;Myocardial enzyme content;ESR;T cell subsets;Cytokine;Liver, gallbladder, thyroid, and lymph node imaging;Chest CT;Infectious disease test;","the relive of CRS;","Quality of life;Socio-demographcis and others;","Cancelled;","Mood index;","ROC;calibration curve;","COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);;Lung CT observation of inflammation absorption;;Proportion of cases with progressive disease;","Blood routine examination;Chest CT;Arterial Blood Oxygen Saturation;","Time to Clinical Recovery, TTCR;","TTCI (Time to Clinical Improvement);","viral negative-transforming time;30-day cause-specific mortality;co-infections;Time from severe and critical patients to clinical improvement;","Negative conversion rate of COVID-19 nucleic acid;Lung inflammation absorption ratio;","Clinical recovery time;Pneumonia Severity Index (PSI) score;","Clinical symptoms;Test result;Examination result;","cough;","Validity observation index;","The proportion of patients diagnosed with 2019-ncov viral pneumonia;","The time to 2019-nCoV RNA negativity in patients;","exposed factors;latent period;preventive measures;","Negative conversion rate of 2019-nCoV nucleic acid ;Lung inflammation absorption ratio;","time to recovery.;","SOFA score;","Time to clinical recovery;","Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment;Pulmonary inflammation resolution time (HRCT) (day);Fever to normal time (day)","Worsening condition;Death;Heart fatty acid binding protein;","Lung ultrasound index;Right ventricular function ultrasound index;Left ventricular function ultrasound index;","Time to negative NPS","Screening accuracy","K-BILD;blood gas;Finger pulse oxygen;chest CT","Size of lesion area by chest radiograph or CT;Side effects in the MSCs treatment group","Adverse reaction (AE) and severe adverse reaction (SAE);Time to clinical improvement (TTIC)","ALT;","Unplanned shutdowns;","viral load;virus genotyping;Classification of lymphocytes;","Clinical therapeutic course;Pathogenic detectio;Chest CT;Laboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.);","Time to Clinical Recovery (TTCR);","7-day mortality","The proportion of patients with normal level of oxygen saturation(=97%);The time to oxygen saturation recovery to normal level (=97%)","Tempreture;Virus nucleic acid detection;","intrusion;avoidance;","Immunity function;cytokines;viral load;","clinic outcome;","Pulmonary function;6 minutes walking distance;The Short Form -36 Healthy Survey;","Mortality;","Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time;","Child Stress Disorders Checklist evaluation;Achenbach children's behavior checklist evaluation;children's severe emotional disorder and psychological crisis during inpatient treatment;","in-ICU mortality;mortality of 28 days;","28-day mortality;ICU 14-day mortality;","Rate of composite advers outcomes: SPO2, PaO2/FiO2 and respiratory rate;","A cycle threshold value (Ct-value);","PSS-14;","Volatile organic compounds, VOCs;SEN, SPE, ACC, AUC of ROC;","Pulmonary image findings;Relevant clinical manifestations of COVID-19;Oxygen saturation in resting state;Arterial partial pressure of oxygen/ Oxygen absorption concentration;Length of hospital stay;Viral genome information;Host genome information;Expression level of host cytokines;Conventional laboratory testing index;","Pittsburgh sleep quality index;","Incidence of side effects;","Chest imaging;Oxygenation index;Extravascular pulmonary water;pulmonary vascular permeability index, PVPI;Inflammatory factors;Tissue kallikrein;","TCM syndrome;","Progression rate from mild to critical/severe;","fever clearance time;Effective rate of TCM symptoms;","Real-time fluorescent RT-PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start of medication, determined according to clinical needs);Time to clinical improvement;Change in size of lesion area by chest CT;Time to fever subsidence, defined as the time at which a subject with fever at enrollment has returned to normal temperature for at least 72 hours;","length of stay;length of stay in ICU;Hospital costs;Hospital costs;Antibiotic use;Organ function support measures;","lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;","28 day mortality;","Cure rate;","The time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens (such as throat swabs) or blood specimens change to negative.;","Nuclei acid test of SARS-CoV-2 of conjunctival swab;Nuclei acid test of SARS-CoV-2 of throat swab;Nuclei acid test of SARS-CoV-2 of peripheral blood sample;Eye symptoms;Clinical symptoms;","PaO2 / FiO2 or respiratory rate (without oxygen);Frequency of respiratory exacerbation;Observe physical signs and symptoms and record clinical recovery time;The number and range of lesions indicated by CT and X-ray of lung;Time for cough to become mild or absent;Time for dyspnea to become mild or no dyspnea;Frequency of oxygen inhalation or noninvasive ventilation, frequency of mechanical ventilation;Inflammatory cytokines (CRP / PCT / SAA, etc.);Frequency of serious adverse events;","disease incidence;Duration of PCR normalization;Distribution pattern of TCM syndromes;","ratio of severe cases;","Cardiac injury;Death in hospital and/or Endotracheal Intubation Deaths during hospitalization;Admitted to the ICU;Composite end points of cardiovascular events( nonfatal heart failure, nonfatal myocardial infarction, nonfatal stroke or cardiovascular death);Stroke;Heart failure;Myocardial infarction;Other cardiovascular health related endpoints;","28 day mortality;","Psychological status;","SpO2 during intubation;the total time of intubation;Mask ventilation for SpO2 &lt; 90%;","time in range;","CT image of lung;","Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;","Mental status;Social support;","Clinical characteristics;","cure rate;duration of hospitalization;days of treatment;","MRC breathlessness scale;6MWD;","Safety;","Main symptom relief time;","Clinical symptoms;Blood routine;Biochemical and myocardial enzymes;C-reactive protein;Erythrocyte sedimentation rate;Inflammatory cytokines;Chest CT;Etiology Inspection;Vital signs;","CRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine examination;chest CT;creatase;","Severe conversion rate;Oxygenation index;2019-nCoV nucleic acid test;Chest CT;","Cytokines;","Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;","the number of days between randomised grouping and clinical improvement;","Numbers of participants with different Clinical outcomes;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1","Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;","Mortality;The time interval of Nucleic acid detection become negative","Inccidence of 2019-nCoV pneumonia;","Improvement of symptoms;","nosocomial infection ratio of SARS-Cov-2;","Clinical cure rate;","The incidence of side effects;The incidence of side effects;The incidence of side effects","mental health status and influence factors;","Symptom Checklist 90;","chest CT images;","Clinical recovery time","RT-PCR confirmed COVID-19 infection","The prevalence and incidence changes of common mental disorders","serum albumin;siderophilin;prealbumin;lung CT scanning result;","Laboratory inspection index;Oxygen therapy case;Film degree exam;","CT;","Transmission dynamics of COVID-19 in Hong Kong;Characteristics of super-spreading events;Effectiveness of public health measures;","white blood cell;lymphocyte;creatinine;CRP;","CK-MB;CTnI;neuron-specific enolase,NSE;BUN;scr.;lactic acid;","Death;","HRCT pulmonary fibrosis score;","temperature;Systemic symptom;Respiratory symptoms;Chest imaging changes;Detection of novel coronavirus nucleic acid two consecutive negative time;","RT-PCR test for SARS-CoV-2;","Single cell sequencing;","Maternal and neonatal morbidity;","Discharge rate;","Average discharge time;WBC;ALT, AST, gama-GT, BUN, Cr, CK-MB;turn serious/crisis ratio;","Clinical outcomes after discharge;","Precision;SEN, SPE, ACC, AUC of ROC;","14 day outcome of the subjects, including: recovery, improvement, turning critical, death. ;Lung CT;","sensitivity;SPE;","SCL-90 scale;","Clinical improvement time of 28 days after randomization;The 7-point scale;7 points: death;6 points: admission to ECMO and / or mechanical ventilation;5 points: Hospitalized for non-invasive ventilation and / or high-flow oxygen therapy;4 points: hospitalization for oxygen therapy;3 points: Hospitalization does not require oxygen therapy;2 points: discharged but not restored to normal functional status;1 point: discharged to normal function;","Timepoint(s) of evaluation of this end point: 90 Days from the date of enrolment.;Primary end point(s): The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by all-cause mortality at 90 days.;&lt;br&gt;                Main Objective: The primary objective of this REMAP is, for adult patients with severe CAP who are admitted to an ICU, to identify the effect of a range of interventions to improve outcome as defined by the occurrence of death during the index hospital admission censored 90 days from the date of enrolment.&lt;br&gt;            ;Secondary Objective: The secondary objectives are to determine, for adult patients with severe CAP who are admitted to an ICU, the effect of interventions on ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator free days (VFDs) censored at 28 days, organ failure free days (OFFDs) censored at 28 days, other endpoints as indicated for specific domains, and, where feasible or specified in a DSA, survival at 6 months, health related quality of life (HRQoL) assessed after 6 months using the EQ5D and disability assessed after 6 months using the World Health Organization Disability Assessment Schedule (WHODAS).",null,"Epidemiological characteristics;SARS-CoV-2 IgM, IgG antibody titer test result;","RNA of 2019-nCov;SPE, SEN, ACC, AUC of ROC;","Laboratory inspection index;Imaging examination results(chest CT);performance of intubation;therapeutic schedule;prognosis;","Liver function;","ymphocyte subsets;","Mortality of ICU 28-day;","Ocular  Symptoms;","Clinical features;","Epidemiological features;","lynphocyte;cytokine;cancer history;order of severity;","Quantitative CT characteristic;","age;sex;comorbidities;chest-CT examination;standard blood counts;albumin;pre-albumin;hemoglobin;alanine transaminase;aspartate transaminase;creatinine;glucose;lipids;procalcitonin;C-reactive protein;coagulation function;nutritional risk screening;body weight;body height;prognosis;","time  and rate of cure; proportion and time of patients who progressed to severe disease;","blood biochemistry;","mortality;effective rate;","discharg time;",null,"Success rate of intubation;Infection rate of Anesthesiologist","Confirmed 2019-ncov pneumonia;","The time for the positive nucleic acid of the novel coronavirus to turn negative;Incidence of deterioration;The defervescence time;Chest CT;Primary symptom remission rate;","Dose of analgesic and sedative drugs;28-day mortality rate;","28-day prognosis;","death;Number of failure organs;Length of hospital stay;","Epidemiological characteristics;clinical features;Treatment outcome;","anxiety;","Oxygenation index (arterial oxygen partial pressure (PaO2) / oxygen concentration (FiO2));Conversion rate from serious to critical patients;Conversion rate and conversion time from critical to serious patients;Mortality in serious and critical patients;","2019-ncov-RNA;Chest CT;Routine blood test;Blood biochemistry;TCM symptom;","Psychological assessment;","SARS-CoV-2;","PSQI;PPHQ-9;GAD-7;PTSDChecklist-Civilian Version,PCL-C;","Clinical characteristics according to TCM;","Mortality rate;","cytology;proteomics;chest X-ray;Oxygenation index;","the clinical, laboratory and the radiologic characteristics;","Critical illness ratio;","nucleic acids probing;blood routine;blood biochemistry;Urine Routine;Blood Gas Analysis;CT;","Time to Clinical Recovery;","Length of stay in ICU;Diaphragm movement;","Chinese health status scale;Self-rating Anxiety Scale;Self-rating Depression Scale;","ICU hospitalization days;The recurrence rate of infection;","Inpatient mortality;ICU hospital stay;","in-ICU mortality;","PaO2;PaCO2;","14-days mortality;28-days mortality;","SARS-CoV-2 virus;sex hormones;sperm quality;","mortality;ICU hospital stay;mechanical ventilation time;mortality of 28 days;","Levels of anxiety, stress and depression;","Tempreture;cough;dyspnea;Blood Routine;Aterial Blood Gas;Chest CT Scan;","detection of SARS-CoV-2 RNA;SEN, SPE, ACC, AUC of ROC;","Time to Clinical Improvement (TTCI);","SAA;Detection of respiratory pathogen serotype;Lymphocyte subgroup detection;IgM and IgG detection;Pulmonary CT;","Blood oxygen saturation;","Sensitivity, specificity and accuracy;","Mortality rate;Common-severe conversion rate;Length of hospital stay.;","Lung CT;","PHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACTH;cortisol;24-hour ECG;Magnetic resonance spectroscopy;","Abnormalities on chest CT;Exposure to source of transmission within past 14 days;","blood RT;ABG;blood clotting function;liver and kidney function;","Cough Score;Expectoration score;","cure rate;propotion of progression;SEN, SPE, ACC, AUC of ROC;","all-cause death;fatal arrhythmias;","temperature;heart rate;respiratory rate;blood pressure;Urine volume;blood routine;C-reactive protein;erythrocyte sedimentation rat;pulmonary CT;liver function;coagulation function;renal function;immunoglobulin;complement;T cell subsets;electrolytes;Urine analysis;microalbuminuria;COVID-19 nucleic acid;COVID-19 antibody;renal ultrasound;24-hour urine protein;Tc-DTPA renal dynamic imaging;eGFR;","Recovery time;Pneumonia psi score;","Lymphocyte grouping;","chest computerized tomography;Nucleic acid detection of novel coronavirus;TNF-alpha;IL-6;IL-10;","Time to Virus Eradication;","Time to Virus Eradication;","blood gas;SOFA score;","Pulmonary function;Cardiac function;neural function;","Comprehensive psychological assessment;Mental toughness;Solution;","The percentage of patients who convert to moderate one;The rate of shock;Endotracheal intubation ratio;Time spent on the ventilator;mortality;Time of virus nucleic acid test turning negative;","CRP;IL-6;TNF-alpha;IL-8;","false positive rate of SARS-CoV-2 IgM antibody;SEN, SPE, ACC, AUC of ROC;","CT image features;Fever;Throat swab virus nucleic acid tes;lymphocyte;","Status of immune function;The time of nucleic acid turns to negative;Length of stay in-hospital;","In-hospital mortality;ACC, SEN, SPE, ROC;","cough;agitation;","Lung ultrasound;Chest computed tomography (CT);Respiratory and oxygenation indicators;Prognostic indicators (length of stay, mortality);","The time when the nucleic acid of the novel coronavirus turns negative;Conversion to heavy/critical type;","Time to disease recovery;Time and rate of coronavirus become negative;","sleep status and related factors of insomnia;","IFN-gama;TNF-alpha;Blood routine index;Time and rate of coronavirus become negative;immunoglobulin;Exacerbation (transfer to RICU) time;Clearance rate and time of main symptoms (fever, fatigue, cough);","Ventilation-free days;mortality;","treatment effect;",null,"Outcome;","CT Scan-Chest;","Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative;","The negative conversion rate and negative conversion time of novel coronavirus nucleic acid;","lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;","Complete Blood Count;CRP;blood coagulation;D-dimer;Virological examination of pharyngeal swab;Pulmonary imaging;","ascultation;","Medical imaging improvement rate in patients during recovery period;","Time to disease recovery;","Time to disease recovery;","Time of conversion to be negative of novel coronavirus  nucleic acid;","Mortality rate;","Time of conversion to be negative of novel coronavirus nucleic acid;","detection of SARS-Cov-2 nucleic acid;SEN, ACC;","Time to clinical recovery after randomization;","SDS;SAS;PSQI;","impact on the treatment of tumor patients;","Clinical characteristics;Clinical outcomes;","Imaging;","Disease Severity;Imaging;Syndrome Features of TCM;","GAD-7;","Time and rate of novel coronavirus become negative.;","DEATH;","Ventilation-free days","2019-nCoV RNA;2019-nCoV antibody;Chest CT;","Viral load","Self-rating depression scale;self-rating anxiety scale;Athens Insomnia Scale;","Temperature returns to normal for more than 3 days;Respiratory symptoms improved significantly;Pulmonary imaging showed that acute exudative lesions were significantly improved;Negative for two consecutive tests of respiratory pathogenic nucleic acid (sampling interval at least 1 day);","Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;","Ventilation-free days;mortality;","Positive/Negtive;False positive of rate  ;","Time to disease recovery;","Time to disease recovery;","Patients general information: epidemiological indicators such as age, gender, address, telephone, exposure history, past medical history, and BMI;Clinical symptoms;Patients' signs;blood routine examination;Urine routine test;stool routine examination;Blood biochemistry;myocardial enzyme spectrum;full set of coagulation;blood gas analysis;cytokine profile;T lymphocyte subsets;ESR;CRP;PCT;complete set of self-immunity test;Etiology related inspections;Chest X-ray;lung CT;Patients' treatment history;Patients' Prognosis;the cause of death;Others;","Disppear time of ground-glass shadow in the lungs","25(OH)D;","Stress","T lymphocyte subsets;","Neonatal outcome;","HRCT score;","Metagenomics Sequencing;","demographic information;exposure history;clinical  symptoms;Laboratory examination;radiological  findings;treatment;disease progression;","SEN, SPE, ACC, AUC of ROC;","GAD-7;STAI-Y (C);","Pittsburgh sleep quality index;Self-rating anxiety scale;Self-rating depression scale;CD-RISC scale;","insomnia;anxiety;depression;comfort;","postoperative complication;occupancy rate of intensive care unit;2-year tumor-free survival and overall survival;","Serum SARS-COV-2 RNA;Swallow swab SARS-COV-2 RNA;feces SARS-COV-2 RNA;Sputum SARS-COV-2 RNA;Urine SARS-COV-2 RNA;","clincical characteristics;","nuclear acid test of faeces;nuclear acid test of the upper respiratory tract;IgM;IgG;CT test of lung;glutamic oxalacetic transaminase;glutamic-pyruvic transaminase;total bilirubin;direct bilirubin;urea nitrogen;lactic dehydrogenase;creatinine;lymphocyte;C-reactive protein;procalcitonin;erythrocyte sedimentation rate;","hospital mortality;","The biochemical indicators;","T lymphocyte count;","Clinical Characteristics, Treatments and Prognosis;","28 day mortality","Proportion of subjects with positive T cell response;Frequency of serious vaccine events;Frequency of vaccine events","survival status","Abnormalities on chest CT;","Maximal inspiratory pressure;Respiratory muscle evaluation;","Length of hospital stay;","Clinical characteristics and risk factors;","Nucleic acid;","Pulmonary function evaluation;Changes in blood gas analysis;Evaluation of activity;Evaluation of dyspnea;CT changes from baseline;","syndrome;nucleic acid of nCoV-19;","COVID-19 nucleic acid negative conversion rate;Causal mortality;All-cause mortality;","adverse reactions 7 days post injection;","Venous Thrombosis;","Immune response multiomics;","Time to negative conversion of severe acute respiratory syndrome coronavirus 2;","RNA;DNA;","PT-PCR test;SEN, SPE, ACC, AUC of ROC;","improvement or recovery of respiratory symptoms;viral nucleic acid shedding;","RNA of  Coronavirus;","Clinical recovery rate of day 7;","prognosis;","the lowest SpO2 during intubation;","Pittsburgh sleep quality index;hospital anxiety and depression scale;","CT image;sensitivity;Specificity;Time efficiency;","Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);","Albumin;Cellular immune indicators (total lymphocyte count (TLC) and T lymphocyte subsets (CD3, CD4));","SP02;lesions of lung CT;temperature;Blood routine;Inflammatory biomarkers;","Compared with the control group, the positive rate of NCP nucleic acid test on subjects used Compound Houttuynia Mixture.;","Changes of serum inflammatory factors;Patient death risk;Drug related adverse reactions and events;","Blood routine test;","First pass perfusion i;Delayed enhancement;T1 /T2 mapping;Extracellular volume;MRS;CEST;","psychological states;","The time required for RNA Yin conversion of novel coronavirus in respiratory or blood specimens was compared between treatment groups The difference of;","novel coronavirus nucleic acid clearance rate;","auto B line method;Semi-automatic manual measurement of line B;CT image score;NEWS score;hospital time;ICU time;Critical time;Hospital costs;mechanical ventilation time;prognosis of the patient;","novel coronavirus nucleic acid;","detection of virus nucleic acid;","Viral nucleic acid test;","Main Objective: To shorten the period of virus carrying and thus contagion;Secondary Objective: To evaluate the clinical effectiveness of treatment on time to apyrexia, normalization of respiratory rate, and average length of hospital stay and mortality.;Primary end point(s): Results of SARS-COV2 virus detection ;Timepoint(s) of evaluation of this end point: Day 1, Day 4, Day 7 and Day 14","genetic and epigenetic risk profiles","Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.;Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.","Response to the treatment (Significant clinical improvement). Timepoint: At baseline and on the third, fifth, seventh, and tenth days after starting the treatment. Method of measurement: According to the clinical, paraclinical and laboratory findings. Clinical improvement: normalization of the body temperature (=37.2  C), respiratory rate (=24 breaths per minute), oxygen saturation (&gt; 94% at room temperature) and cough (zero or mild) that persist for at least 24 hours. Cough will measure on a qualitative scale based on the patient's report . Other outcome variables will measure during clinical examination.;Complications of the treatment. Timepoint: Daily, until the tenth day. Method of measurement: Interview and patient's record.","Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.;Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.","Cough. Timepoint: Daily. Method of measurement: Clinical finding.;O2 Saturation. Timepoint: daily. Method of measurement: Pulse Oximeter.;Radiographic features Findings. Timepoint: Before/After. Method of measurement: Radiography- CT SCAN.","Clinical response to therapy. Timepoint: Daily. Method of measurement: Clinical symptoms.","Response to the treatment (improvement of patients' chief complaint, abnormal paraclinic and radiologic findings). Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Gastrointestinal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Cutaneous complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Neurological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Renal complications. Timepoint: Daily. Method of measurement: Interview and patient's record.;Hematological complications. Timepoint: Daily. Method of measurement: Interview and patient's record.","Clinical recovery (composite) within 14 days from initiation of study treatment until normalization of fever (=37.2 C oral), respiratory rate (=24/minute on room air), and oxygen saturation (=94% on room air),  sustained for at least 24 hours. Timepoint: daily up to 14 days after starting the trial. Method of measurement: Clinical examination.","Rate and time of entering the critical stage;Rate of disease remission","Clinical response. Timepoint: Every other day. Method of measurement: Evaluation of clinical signs and symptoms.;Paraclinical response. Timepoint: Every other day. Method of measurement: Laboratory and radiological findings.;Adverse drug reactions. Timepoint: Every other day. Method of measurement: Interview and laboratory data.","expected value and 95% CI of ratio of C-reactive protein before versus after the treatment","ED time interval [Timeframe hospital exit Time between ED arrival and hospital admission]\t\t\t","Number of participants with improvement from severe type to common type","expected value and 95% CI of ratio of C-reactive protein before versus after the treatment","Proportion of subjects with clearance of SARS-CoV2 in nasopharyngeal swab on Day 6","Rate of aggravation;Time to clinical recovery after treatment","recovery","Viral load over time;Time course of body temperature (fever)","Time for lung recovery;Rate of disease remission","Rate of disease remission;Time for lung recovery","Rate of comprehensive adverse outcome","1.\tDate of ECMO discontinuation&lt;br&gt;2.\tDate of invasive mechanical ventilation discontinuation&lt;br&gt;3.\tDate of ICU Discharge&lt;br&gt;4.\tDate of Hospital Discharge&lt;br&gt;5.\tMortality at 28 days&lt;br&gt;6.\tMain cause of death","Lower Murray lung injury score;Clinical improvement based on the 7-point scale","Time to Clinical Improvement (TTCI)","Mean clinical recovery time (hours)","all-cause mortality","Chest CT absorption;The relief / disappearance rate of main symptoms","none","Prepredness measurement [Timeframe at response date electronic survey with electronic questionnaire]\t\t\t","Mortality rate","Size of lesion area by chest imaging;Blood oxygen saturation","Depression, Anxiety and Stress Scale;Assessment of COVID-19 situation","changes in the ratio of PaO2 to FiO2 from baseline","Occupancy rate in the intensive care unit (ICU);Mechanical Ventilation;Death","Time of entering the critical stage;Rate of entering the critical stage;Rate of disease remission","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14","Change in viral expression in association to organspecific biomarkers","Renal failure","Survival rate","The risk factors analysis for the death;The myocardial injury incidence","RT-PCR results;CT Scan;Clinical outcome","temperature;novel coronavirus;Influenza virus;","Incidence of respiratory failure","Symptomatic COVID-19 infection rate","Severe COVID-19","brain volume;white matter;brain function;","Acute Kidney Injury","fever;Chest CT;cough;;Anesthesia during cesarean section;Adverse reactions;Apgar score for neonates; Intraoperative blood loss;diagnosis of COVID-19 during perioperative;the medical observations of anesthesiologists participating in anesthesia management;","Sensitivity, spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform","characteristics of cardiopulmonary ultrasound","Maternal and perinatal outcomes","All-cause hospital mortality","Axle length;Visual acuity;corneal diopter;Tear film rupture time;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;","medication possession ratio;selfrating anxiety scale;selfrating depression scale;Disease activity score-28;Systemic lupus erythematosus disease activity index;Ankylosing spondylits disease activity score;Visual analogue scale;","proteomics;metabonomics;SEN, SPE, ACC, AUC of ROC;","TTCI;","sensitivity;accuracy;specificity;","Incidence of medical adhensive-related injury;","Self-assessment of sleep quality;Efficient of sleep improvement;","Time of death;The hospitalization time;","Number of patients with contrasting results;Overall Number of patients negative for COVID-19;Overall Number of patients positive for COVID-19;Number of patients with positive test with a positive PCR for COVID-19;Number of patients with constant negative results","eye axial length;corneal diopter;Tear film rupture time;Visual acuity;Visual fatigue;habits of using eyes;Accommodative Amplitude;Adjustment sensitivity;Adjustment lag;Negative relative adjustment;Positive relative adjustment;Fusion function;","Anxiety level;Sleep;","Demographic data;Epidemiological characteristics;Routine laboratory testing;Viral nucleic acid test;Patient reports symptoms daily;","Hospital stay or death ratio of experimental group / death ratio of control group;","Rate of COVID-19, distribution, time of onset and outcome;","ECG;","mental state;","clinical features of COVID-19 patients and risk factors of death;","Epidemiological characteristics;clinical features;Treatment outcome;","IgG antibody;IgM antibody;Throat swab virus nucleic acid test;","RT-PCR test for Covid-19;CT image;Covid-19 antibody test;","Clearance time of virus RNA;","PT-PCR test;","TCM Syndrome Scale;","Patient satisfaction;","Clinical features and prognosis;","Quantitative table of main symptom grading;Quantitative table of lung physical signs grading;","Modified dyspnea index scale;St.George's Respiratory Questionnaire;Self-Rating Depression Scale;","mortality;","fatality rate;the ratio of patients transforming from severe/critical to light;Non-invasive/invasive mechanical ventilation time;","traditional Chinese medicine symptom;","Body temperature returns to normal time;After the medication, the disappearance rate of TCM symptoms;","Incidence of COVID-19 pneumonia;COVID-19 pneumonia rate of improvement;","The change of TCM syndrome integral of deficiency of Fei-Pi-Qi-Xu Zhen;The results and changes of fatigue assessment scale at each time point;","PO2/FiO2;ROX INDEX;","time till the SARS-CoV-2 clearance;","Inflammation absorption on Chest CT;","Two-dimensional ultrasound;M mode echocardiography;Doppler ultrasound;two-dimensional speckle tracking;three-dimensional echocardiography;","Patients' general information: epidemiological indicators such as age, gender, address, telephone, past medical history, and BMI;Division of disease;Metabolomics;Laboratory inspection;Imaging examination;Etiological examination;The remaining observation indicators are supplemented according to clinical needs.;","walking distance;oxygen saturation;heart rate;","The time to 2019-nCoV RNA negativity in patients;","Epidemiological and clinical characteristics;","pulmonary function;","Neutrophil count;Lymphocyte count;Monocyte / macrophage count;Monocyte / macrophage function test;NK cell count;DC cell count;PD-1( immunosuppressive biomarker );PD-L1(immunosuppressive biomarker );CTLA4 (immunosuppressive biomarker );CD79;Blnk;Il7r;T lymphocyte count;CD4+ T lymphocyte count;CD8+ T lymphocyte count;B lymphocyte count;NK cell count;Proportion of navie CD4+ T lymphocytes to CD4+ T lymphocytes;Proportion of memory CD4+ T lymphocyte to CD4+ T lymphocytes;Proportion of CD4+ T lymphocyte subsets to CD4+ T lymphocytes;Proportion of CD8+ CD28+ subsets to CD8 + T lymphocytes;Activation ratio of CD8+ T lymphocytes;Ratio of CD4+ T lymphocytes to CD8+ T lymphocytes;","Timepoint(s) of evaluation of this end point: Day 15;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale): &lt;br&gt;1.\tNot hospitalized, no limitations on activities &lt;br&gt;2.\tNot hospitalized, limitation on activities; &lt;br&gt;3.\tHospitalized, not requiring supplemental oxygen; &lt;br&gt;4.\tHospitalized, requiring supplemental oxygen; &lt;br&gt;5.\tHospitalized, on non-invasive ventilation or high flow oxygen devices; &lt;br&gt;6.\tHospitalized, on invasive mechanical ventilation or ECMO; &lt;br&gt;7.\tDeath.;Secondary Objective: To evaluate clinical efficacy of different investigational therapeutics as compared to the control arm as assessed by Clinical Severity, Oxygenation, Ventilation, Hospitalisation.;Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the standard of care in patients hospitalized with COVID-19.","Oxygen Inhalation Frequency;Oxygen Intake Time;cough;Degree of expiratory dyspnoea;","Timepoint(s) of evaluation of this end point: Baseline to Day 29;Primary end point(s): Phase 2: time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner&lt;br&gt;Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale;Secondary Objective: Evaluate the clinical efficacy of sarilumab compared to the control arm by clinical severity, changes in the National Early Warning Score 2, duration of predefined symptoms and signs, duration of supplemental oxygen dependency, incidence of new mechanical ventilation use, the duration of new mechanical ventilation use, need for admission into ICU, duration of hospitalization,  28-day mortality rate.&lt;br&gt;Secondary safety objectives are to evaluate the safety of sarilumab compared to the control arm as assessed by incidence of: SAEs, Grade 4 neutropenia (ANC&lt;500/mm3) with concurrent severe or life-threatening bacterial, invasive fungal, or opportunistic infection, Grade =2 infusion related reactions, Grade =2 hypersensitivity reactions, Increase in ALT =3X ULN (for patients with normal baseline) or &gt;3X ULN and at least 2-fold increase from baseline value (for patients with abnormal baseline), Invasive bacterial or fungal infections of clinical significance with confirmed diagnosis ;Main Objective: Phase 2: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19&lt;br&gt;Phase 3: To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19  &lt;br&gt;","Timepoint(s) of evaluation of this end point: Between day 0 up to day 180 after inclusion;Primary end point(s): Number of days of unplanned absenteeism for any reason ;Secondary Objective: To reduce hospital admission, ICU admission or death in HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.;Main Objective: To reduce absenteeism among HCW with direct patient contacts during the epidemic phase of SARS-CoV-2.","Timepoint(s) of evaluation of this end point: One interim analysis for evaluating the primary efficacy endpoint is planned for this study. The interim analysis will be done when 40% of events have accrued.  In case the interim analysis shows a HR &gt; 1.93 (nominal p &lt; 0.0018), efficacy is shown and the trial may be stopped.  Final analysis upon completion of the trial and final database lock.;Primary end point(s): Primary efficacy endpoint: Viral clearance defined as time to sustained SARS-CoV-2-specific RNA copy number =100, measured by real time reverse-transcription polymerase chain reaction in throat swabs&lt;br&gt;&lt;br&gt;&lt;br&gt;;Secondary Objective: Exploratory objectives are to assess the effect of infection and HCQ treatment on clinical outcome, cardiac function, mucosal, humoral and cellular immune response including single cell phenotype and RNA expression, effect on anti-viral defense, assessment of chronic symptoms and quality of life. ;Main Objective: Primary objective: Effect of HCQ on in vivo viral clearance.","Timepoint(s) of evaluation of this end point: Please see above;Primary end point(s):  The primary endpoint will be in-hospital mortality. The primary endpoint will be the same as the primary endpoint in the core WHO protocol.;Secondary Objective: Not applicable;Main Objective: 1.\tTo investigate the effect of Remdesivir and Hydroxychloroquine in COVID 19 infection in relation to the defined primary and secondary endpoints.&lt;br&gt;2.\tTo compare the effect of early versus late intervention with Remdesivir and Hydroxychloroquine in relation to time from symptom debut and in relation to disease severity when included.&lt;br&gt;3.\tTo analyse markers that can give prognostic information and information on pathogenic mechanisms in COVID 19 infection with particular focus on ICU patient characteristics compared with patientstreated at the hospital ward. &lt;br&gt;4.\tTo establish the safety of the study drugs.&lt;br&gt;","Main Objective: To assess whether SNG001 is well tolerated, and can prevent or accelerate recovery of lower respiratory tract illness in patients with SARS-CoV-2 infection.;Secondary Objective: To understand more about the biology of how SNG001 affects patients and the virus infection, this will be done by assessing changes in biomarkers in blood and sputum if they are available.;Primary end point(s): Primary Endpoint:&lt;br&gt;Change in condition measured using the Ordinal Scale for Clinical Improvement during the dosing period.&lt;br&gt;&lt;br&gt;The Ordinal Scale for Clinical Improvement is a World Health Organisation recommended scale for use in COVID-19 trials.&lt;br&gt;;Timepoint(s) of evaluation of this end point: The dosing period is 14 days. Changes in the ordinal scale during the dosing period will be assessed.","Severity of COVID-19","Percentage of subjects reporting each severity rating on a 7-point ordinal scale","Time of Improvement or recovery of respiratory symptoms;Number of days virus nucleic acid shedding;Frequency of Improvement or recovery of respiratory symptoms","Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds;Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds;Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds",null,"SARS-free patients at 14 days","Symptoms severity of COVID-19;Number of symptomatic COVID-19 infections","The time from randomization to clinical improvement","Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases","Incidence of influenza","Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial;Change from baseline serum Tumor necrosis factor-a concentration at end of the trial;Change from baseline serum C-reactive protein concentration at end of the trial;Change from baseline serum Interleukin-6 concentration at end of the trial;Change from baseline Serum ferritin level at end of the trial;Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial","Prevention of COVID-19","Rate of Acute Kidney Injury","Seroconversion to SARS-CoV-2 positivity","Number of participants with symptomatic, lab-confirmed COVID-19.","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay","Hospital discharge;Clinical improvement","In-hospital mortality","Number patients developing severe infection or death","Beck Depression Scale;Health-Related Quality of Life SF-12 Scale;International Physical Activity Questionnaire (IPAQ)","Duration of interventions;The number of interventions","The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.","Technical success","Clinical status evaluated in agreement with guidelines;Mortality rate","30-day mortality","Prostaglandin E2;","Microbiologic evidence of infection","death","Lung ultrasound grading system for COVID-19 pneumonia","Length of hospital stay (days)","PSQI;","Chest computed tomography (CT);","Side effects in the treatment group;Clinical response","The incidence of cardiovascular complications in patients with COVID-19","Mortality all causes at day30","Dataset size","CRP;SAA;IL-6;PCT;tRNA;","The score of PHQ-9;","Microbiological;Virological;Clinical","Host genetic variation;Immune host response at local level;Immune host response at systemic level;Clinical Features","Incidence of ARDS;Mortality within 28 days;","6minu tewalkingtest,6MWT;mMRC;Rating of Perceived Exertion Scale;SAS;","ASDS;PSS;PHQ;GAD;","Rate of recovery from positive to negative swaps;Fever to normal temperature in days;Resolution of lung inflammation in CT or X ray","Composite primary end-point;death;Admission to ICU;Endotracheal intubation (invasive mechanical ventilation)","Inpatients: Invasive mechanical ventilation or mortality;Outpatients: Hospital Admission or Death","Point prevalence of COVID-19 infection","Infection;","Quality of sleep;","Chest Imaging;lung function;ADL;","2019-nCov IgG;","FVC;","Phone time before and during the outbreak;Physical exercise time before and during the outbreak;Symptoms worsened in patients with previous cervical spondylosis since the outbreak;Symptoms in people with no previous symptoms of cervical spondylosis since the outbreak;","2019-ncov nucleic acid yin rate;Blood 2019-ncov nucleic acid positive;Positive 2019-ncov nucleic acid in feces;Nasopharyngeal swab positive for 2019-ncov nucleic acid;","Success rate of intubation;Exposure classification of glottis;","All-cause mortality","CT or Xray images from COVID-19 patients","Time from COVID-19 test being requested to the result being available to clinical teams in minutes and hours, recorded during hospitalisation","Blood cell number;Biochemical markers;Metabolic markers;","SPE, SEN, ACC, AUC of ROC;","Cure rate;improvement rate;","Timepoint(s) of evaluation of this end point: Day 15;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale):&lt;br&gt;1.\tNot hospitalized, no limitations on activities&lt;br&gt;2.\tNot hospitalized, limitation on activities;&lt;br&gt;3.\tHospitalized, not requiring supplemental oxygen;&lt;br&gt;4.\tHospitalized, requiring supplemental oxygen;&lt;br&gt;5.\tHospitalized, on non-invasive ventilation or high flow oxygen devices;&lt;br&gt;6.\tHospitalized, on invasive mechanical ventilation or ECMO;&lt;br&gt;7.\tDeath.&lt;br&gt;&lt;br&gt;;Secondary Objective: Evaluate clinical efficacy of different investigational therapeutics as compared to the control arm as assessed by:&lt;br&gt;&lt;br&gt;-Clinical Severity (Ordinal scale, National Early Warning Score (NEWS), Oxygenation, Mechanical Ventilation)&lt;br&gt;-Hospitalization : duration of hospitalization (days). &lt;br&gt;-Mortality&lt;br&gt;-Evaluate the safety of different investigational therapeutics through 28 days of follow-up as compared to the control arm&lt;br&gt;-Evaluate the virologic efficacy of different investigational therapeutics as compared to the control arm as assessed ;Main Objective: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19.&lt;br&gt;\tThe primary endpoint is subject clinical status (on a 7-point ordinal scale) at day 15 &lt;br&gt;","Sleep diary;The insomnia severity index;Sleep visual analogue scale;","Exposure time in the medical cabin;Hospitalization period;Detection rate of arrhythmia;","SARS-CoV-2 antibody;SEN, SPE, ACC, AUC of ROC;","Safety;Effectiveness;","hospital mortality;","body surface temperature;","Safety and tolerance;","Electrocardiogram;St George's Respiratory Questionnaire Score;High resolution CT for chest;Blood gas analysis;Percutaneous blood oxygen saturation;6 min walking distance;Pulmonary function VCmax;Blood routine;Liver and kidney function;Cytokine analysis;Immunoglobulin;Lymphocyte subsets;Coagulation;Myocardial enzymes;Serum ferritin;Procalcitonin;IL-6;Lactic acid;D-Dimer;CRP;","Timepoint(s) of evaluation of this end point: day 5;Primary end point(s): To measure the effectiveness of sargramostim on restoring lung homeostasis, the primary endpoint of this intervention is measuring oxygenation after 5 DAYS of inhaled (and intravenous) treatment through assessment of pretreatment (day 0) and post-treatment (day 5) ratio of PaO2/FiO2 and through measurement of the P(A-a)O2 gradient, which can easily be performed in the setting of clinical observation of patients admitted to the COVID -19 ward or ICU COVID-19 unit. During the 5 day treatment period, we will perform daily measurements of oxygen saturation (pulse oximetry) in relation to FiO2, and the slope of alterations in this parameters could also be an indicator that our hypothesis is correct.;Secondary Objective: - to study if early intervention with sargramostim is safe (number of AEs/SAEs)&lt;br&gt;- to study if early intervention with inhaled sargramostim affects clinical outcome defined by&lt;br&gt;duration of hospital stay, 6-point ordinal scale, clinical sign score, SOFA score, NEWS2 score&lt;br&gt;- to study if early intervention with sargramostim affects the rate of nosocomial infection&lt;br&gt;- to study if early intervention with inhaled sargramostim affects progression to mechanical ventilation and/or ARDS&lt;br&gt;- to study if treatment with sargramostim affects all-cause mortality rate at 4 and 20 weeks post inclusion&lt;br&gt;-to study if treatment with sargramostim affects features of secondary haemophagocytic lymphohistiocytosis, defined by HS score&lt;br&gt;- to study if treatment with sargramostim has a favourable effect on long term 10-20 week follow up&lt;br&gt;;Main Objective: The primary objective is to investigate whether the administration of inhaled sargramostim (Leukine) at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure .","Timepoint(s) of evaluation of this end point: Days 1, 2-7, 8;Primary end point(s):  Recording of co-administered drugs, vital signs, absolute blood cell count (if any), biochemical markers (if any), microbiological tests and antibiotics (if any)&lt;br&gt; Pneumonia symptoms ratings for patients with lower respiratory infection (Appendix V)&lt;br&gt; Recording of adverse reactions (AEs) or serious adverse reactions (SAEs);Secondary Objective:  Comparison of the primary endpoint with respective patients not receiving the treatment&lt;br&gt; Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment&lt;br&gt; Frequency of AEs and SAEs;Main Objective: Achieving one of two goals on day 8 visit from study initiation:&lt;br&gt; 50% reduction in symptom score for patients with lower respiratory tract infection&lt;br&gt; Lack of progression to lower respiratory tract infection in patients enrolled in the study due to upper respiratory tract infection&lt;br&gt;&lt;br&gt;Patients leaving the hospital alive before day 8 visit are considered to have reached the primary endpoint. Patients who die before the day 8 visit are considered to have failed at the primary endpoint.","Timepoint(s) of evaluation of this end point: 28 days;Primary end point(s): Composite outcome of death / need for invasive ventilation / need for ECMO ;Secondary Objective: The secondary objective is to evaluate the pharmacokinetics of a 10-day course of oral imatinib in patients with severe Covid19 pneumonitis.;Main Objective: To test whether treatment with oral imatinib reduce disease burden and consumption of medical resources.","Timepoint(s) of evaluation of this end point: 96 hours.;Primary end point(s): Rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR  in samples collected at baseline, 48 and 96 hours after randomization;Secondary Objective: \tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on rate of decline in SARS-CoV-2 viral load in nasopharyngeal samples as assessed by RT-PCR from baseline to 96 hours&lt;br&gt;\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on changes in NEWS score&lt;br&gt;\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on admission rate to ICU&lt;br&gt;\tAssess the impact of early treatment with chloroquine in patients with established COVID-19 on in hospital mortality&lt;br&gt;;Main Objective: To assess whether early treatment with chloroquine in patients with established COVID-19 will significantly reduce replication rate of SARS-CoV-2.","Timepoint(s) of evaluation of this end point: Continioulsy over the duration of the trial;Primary end point(s): The primary endpoint is a composite endpoint of all cause-death or invasive mechanical ventilation up to 28 days or hospital discharge.;Secondary Objective: To assess efficacy of APN01 using log transformed levels of Lactate dehydrogenase (LDH) as a surrogate marker for organ damage.&lt;br&gt;To evaluate the safety of APN01 in patients with severe COVID-19&lt;br&gt;To monitor other biomarker changes (e.g. IL-6, AngII) in patient with severe COVID-19 treated with APN01&lt;br&gt;&lt;br&gt;;Main Objective: To assess clinical efficacy of APN01 using a composite outcome of all cause-death or need of invasive mechanical ventilation up to 28 days","Primary end point(s): ;Secondary Objective: ;Main Objective:","Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5;The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7;The mortality rate of subjects at weeks 2","the incidence of treatment failure in 14 days","Percent of subjects who have returned to room air;Percent change of subjects return to baseline oxygen requirement","Timepoint(s) of evaluation of this end point: Le critre de jugement principal est le dcs quelle quen soit la cause ou le recours  une intubation et ventilation invasive dans les 14 jours (J14) suivant linclusion et le dbut du traitement (J0).;Primary end point(s): Le critre de jugement principal est le dcs quelle quen soit la cause ou le recours  une intubation et ventilation invasive dans les 14 jours (J14) suivant linclusion et le dbut du traitement (J0).;Secondary Objective: Les objectifs secondaires sont :&lt;br&gt;&lt;br&gt;1) valuer lefficacit de lhydroxychloroquine versus placebo chez les patients COVID-19 sur : &lt;br&gt;a- lvolution clinique via lchelle OSCI (Ordinal Scale for Clinical Improvement) pour COVID-19 de lOMS&lt;br&gt;b- la mortalit toute cause &lt;br&gt;c- le portage viral &lt;br&gt;d- lincidence des accidents thrombo-emboliques veineux &lt;br&gt;&lt;br&gt;2) valuer lefficacit de lhydroxychloroquine versus placebo dans le sous-groupe des personnes ges de 75 ans ou plus sur :&lt;br&gt;a- lvolution clinique via lchelle OSCI pour COVID-19 de lOMS &lt;br&gt;b- la mortalit toute cause&lt;br&gt;&lt;br&gt;3) valuer la tolrance de lhydroxychloroquine versus placebo sur la survenue dvnements indsirables graves&lt;br&gt;&lt;br&gt;Objectifs ancillaires &lt;br&gt;valuer, dans un sous-groupe de patients COVID-19, limpact de lhydroxychloroquine versus placebo sur lvolution des cytokines et des marqueurs biologiques de limmunit, de linflammation et de lhmostase&lt;br&gt;;Main Objective: Lobjectif principal est dvaluer lefficacit de lhydroxychloroquine versus placebo sur le taux de dcs ou de recours  une ventilation invasive chez les patients ayant une infection COVID-19  haut risque daggravation.","Timepoint(s) of evaluation of this end point: daily for 10 days;Primary end point(s): determination of the blood concentration of hydroxychloroquine by liquid chromatography coupled with mass spectrometry.;Secondary Objective:  - Describe the relationship between HCQ concentration and cardiac toxicity.&lt;br&gt;- To describe the pharmacokinetic (concentration) and pharmacodynamic (viral load) relationship of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.&lt;br&gt;- To define the best modalities of administration of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2  based on the PK/PD relationship.;Main Objective: to describe the pharmacokinetics of hydroxychloroquine in resuscitation patients infected with SARS-CoV-2.","SARS-CoV-2 eradication time","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation","COVID-19 diagnosis","Mortality&lt;br&gt;[At hospital discharge or 28 days post intensive care unit admission, whichever comes later. ]","Percent of subjects who Return to Room Air (RTRA) (main study);Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)","Number of sick days (SDS) during the study period: The number of sick days will be obtained from participants medical records as defined as the number of days deemed 'not fit for duty/work' by their reviewing medical professional, and will be compared between participants randomised to chloroquine and vitamin C.[12 weeks post-commencement of the IMP. Study to commence Apr 2020.]","Number of deceased participants or with persistent organ dysfunction","Rate of decline in SARS-CoV-2 viral load","Days to clinical improvement from study enrolment","Survival","Number of days alive and discharged from hospital within 14 days","Timepoint(s) of evaluation of this end point: Up to 28 days;Primary end point(s): Time to independence from supplementary oxygen therapy in days ;Secondary Objective: Not applicable;Main Objective: To investigate  the effect of different types of IL-6 inhibition versus no adjuvant treatment compared to standard of care in patients with severe SARS-CoV-2 pneumonia.","nosocomial infection","Detection sensitivity is greater than 95%;Detection specificity is greater than 95%","Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio;Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11","Improved clinical status;Return to room air","interleukin-6 (IL-6) level after 72 hours","Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases;Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)","National Early Warning Score equal to zero","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7","28-day all cause mortality","Percentage of subjects reporting each severity rating on an 8-point ordinal scale","Frequency of solicited local reactogenicity adverse events (AEs);Frequency of any medically-attended adverse events (MAAEs);Frequency of any new-onset chronic medical conditions (NOCMCs);Frequency of any serious adverse events (SAEs);Frequency of any unsolicited adverse events (AEs);Frequency of solicited systemic reactogenicity adverse events (AEs);Grade of any unsolicited adverse events (AEs);Grade of solicited local reactogenicity adverse events (AEs);Grade of solicited systemic reactogenicity adverse events (AEs)","Clinical cure rate","Disappear time of ground-glass shadow in the lungs","Rate of Death","Helpfulness of the session;Platform effectiveness","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14","Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff","Differences of attitude about blood donation towards different questionnaires","Incidence of COVID19 Disease among those who are asymptomatic at trial entry;Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry","All-cause mortality","Viral clearance time","Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection;Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection","Composite of hospitalization, invasive mechanical ventilation or death within 30 days","Size of lesion area and severity of pulmonary fibrosis by chest CT","Rate of composite adverse outcomes",null,"Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases","new-onset COVID-19","prevalence","Number of participants who experience inpatient admission","Evaluation of the clinical status","COVID Ordinal Outcomes Scale at 14 days","Clinical characteristics of children with SARS-CoV-2;Factors associated with severe COVID-19 outcomes","Incidence rate of new COVID-19 cases in both arms;Prevalence of COVID-19 cases in both arms;Mortality rate secondary to COVID-19 cases in both groups;Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups","Hospital Admission","Safety indexes of adverse reactions","Percent change in C-reactive protein (CRP) levels;Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal","arrest in deterioration of pulmonary function;improving in pulmonary function","Change of arterial oxygenation at 48 hours from enrollment","Mortality;PaO2:FiO2 ratio","Sequential Organ Failure Assessment (SOFA) Respiratory Score","COVID-19 positive X-Rays;COVID-19 negative X-Rays","Accuracy of patient administered tests","Evaluation of the clinical status","Cohort A: reduction of the need of invasive ventilation or 30-day mortality;Cohort B: reduction of mortality","ICU and hospital mortality of COVID-19 patients","Efficacy of Intervention","Characteristics of COVID-19-related anxiety;COVID-19-related anxiety symptoms","Change in Oxygen Saturation by Pulse Oximetry","Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents;Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents","Improvement of COVID-19 disease status","One-month mortality rate","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","Maternal and perinatal outcomes","Clinical presentation;Disease prognosis outcomes;Pregnancy outcomes;Obstetric outcomes;Neonatal outcomes;Modes of transmission of COVID-19","Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score","RNA in SARS-CoV-2;ICU Admissions;Hospital Mortality;Hospital Length of Stay (LOS)","Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.","Clinical response;Biochemical response","COVID-19 desease description;COVID-19 desease description","ventilator free days","Mortality rate","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","Predictive association between CT-V, PBM score and disease progression","Rate of COVID-19 infection","Biomarkers expression;Liver Biomarkers expression","Clinical Status Assessed Using a 7-Category Ordinal Scale","In-hospital mortality","Define Natural Symptom Course","Clinical status of subject at day 15 (on a 7 point ordinal scale).","SAMBA COVID-19 POC PCR Test","Pulse oximetry level","CRP increase to 3 x upper limit of normal;Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&amp;D committee;Maximal concentration of cardiac troponin","COVID-19 disease incidence;Severe COVID-19 disease incidence","Symptomatic COVID-19;Peak severity of COVID-19 over the study period","Mortality","Hospitalization within 14 days of enrollment","Disease progression;Time to mechanical ventilation","Number of participants who die or require hospitalization due to COVID-19 infection","Cumulative incidence of composite outcome of disease severity","Death or need of intubation","rate of recovery","Time to independence from supplementary oxygen therapy","Treatment success","Survival;WHO progression scale COVID 19","Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner;Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale","PO2/FiO2 (Safety);PO2/FiO2 (Efficacy);Early Warning Score (NEWS) (Safety);Early Warning Score (NEWS) (Efficacy);Immunological response (Efficacy);Mechanical ventilation (Efficacy)","Evaluation of covid-19 knowledge level of turkish physicians","Health Care Workers absenteeism","Number of antibiotic free days","Evaluation of EPA-FFA efficacy compared to standard of care","Number of patients with ICU admission;Number of patients with intubation;Number of patients with death","60-day mortality","Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.","Treatment failure;Intubation rate","Incidence of Treatment-Emergent Adverse Events","Survival without needs of ventilator utilization at day 14.;WHO progression scale &lt;=5 at day 4;Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14;WHO progression scale &lt;=7 at day 4","Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients;Number of patients included in this platform","Death or need of intubation","COVID-19 disease diagnosis","COVID-19-free survival","Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days;Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability","Number of participants who fill out the survey and participate in the semi-structured interviews.","Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0","Hospital mortality","Population characteristics","Percent of patient echos that are not interpretable;Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction);Time to acquire images as measured by time stamps","Protection against COVID-19","Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU","Mortality changes in day 10;Mortality changes in day 30;Changes of C-reactive protein;Changes of C-reactive protein;Changes of C-reactive protein;Changes of Interleukin 6;Changes of Interleukin 6;Changes of Interleukin 6;Changes of tumor necrosis factor-a;Changes of tumor necrosis factor-a;Changes of tumor necrosis factor-a;Changes of PaO2/FiO2 Ratio;Changes of PaO2/FiO2 Ratio;Changes of PaO2/FiO2 Ratio","FLUS findings and respiratory failure","Time to Clinical Improvement","Time (in days) to clinical improvement within 30 days after randomization","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/;To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/","Proportion of participants with normalization of fever and oxygen saturation by day 14","Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure","Ventilator-free days","International Physical Activity Questionnaire;Pittsburgh Sleep Quality Index;Perceived Stress Scale;Numerical Pain Rating Scale","overactivity of the renin / aldosterone system","Time to resolution of fever","Deterioration resulting in healthcare review","National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)","Evaluation of the extent of the virus transmission within households","Time to negative conversion of severe acute respiratory syndrome coronavirus 2","Perceived Stress Scale;Perceived Stress Scale;Perceived Stress Scale","Adverse reaction (AE) and severe adverse reaction (SAE);Changes of lung imaging examinations","Change in Viral Load;Change in Immunoglobulin M COVID-19 Titers;Change in Immunoglobulin G COVID-19 Titers","reduction in oxygen and ventilation support","30-days mortality","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.","Median release from quarantine time;Rate of hospital discharge;Rate of infection","The rate of COVID-19","Rate of SARS-CoV-2 eradication at day 14 from study enrollment","Predictive performance","Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19;Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19",null,null,"Prevalence of symptoms;Prevalence of positive Sars CoV-2 PCR;Prevalence of positive radiological findings","Physical Activity Scale for the Elderly;Nottingham Health Profile;Loneliness Scale for the Elderly","Antiviral Activity;Improvement of oxygenation","Total Hospitalization;Total Mechanical Ventilation","All-cause mortality of COVID-19 patients with liver cirrhosis","Proportion of patients requiring ICU admission at any time within the study period.","Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)","Physical health symptoms;Lack of physical health symptoms","COVID-19-related hospitalization or all-cause death","Survival without needs of ventilator utilization at day 14.;WHO progression scale &lt;=5 at day 4;Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14;WHO progression scale at day 4","Confirmed cases of a COVID-19","Incidence of suspected, probable or confirmed COVID-19","Clear chest CT-scan;PCR test","Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more);Number of adverse events","Natural history of COVID-19: Characteristics of COVID-19;Natural history of COVID-19: Participant demographics;Natural history of COVID-19: Treatment use;Time point of clinical response","Accuracy of the diagnosis of interstitial syndrome by lung ultrasound;Inter-observer variability","Changes in forced vital capacity (FVC)","Virology Cure Rate","The immune function (TNF-a ?IL-1?IL-6?TGF-?IL-8?PCT?CRP);Blood oxygen saturation","Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity","Prevention of COVID-19 measured by negative testing with RT-PCR;Safety as determined by blood pressure readings;Safety as determined by presence of side effects","to able to reduce the progression of acute respiratory failure","World Health Organization Quality of Life Questionnaire Bref","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","In-hospital mortality;Need for mechanical ventilation in the Intensive Care Unit","Hospitalization","Mortality","Change in Viral Load;Change in Immunoglobulin M COVID-19 antibodies Titers;Change in Immunoglobulin G COVID-19 antibodies Titers","Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.","Side effects","Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.;Polymerase chain reaction assay (PCR) negative at day 30.;Polymerase chain reaction assay (PCR) negative at day 60.","Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment","Clinical course of COVID-19;Analysis of development of antibodies to SARS-CoV-2;Estimation of viral load;Detection of viral coinfections;Measurement of cytokine and chemokine response;Characterisation of virus-host-interaction;Identification of disease patterns in proteome;Analysis of change in lymphocyte subtypes;Analysis of histological changes in severe lung disease;Detection of bacterial coinfections","Occurrence of adverse reactions;Anti SARS-CoV-2 S antibody response(ELISA);Neutralizing antibody response to SARS-CoV-2","Prevalence;Incidence","Changes in patients viral load;Second evaluation of changes in patients viral load","Measure frequency of people suffered from unusual flu-like symptoms before December 2019","Percentage of children with severe or critical form.","Comparison of the percentage of clinically improved inpatients between D0 and D14","Changes in clinical critical treatment index","Need for ventilation (including invasive and non invasive ventilation), intensive care or death","COVID Ordinal Outcomes Scale on Day 15","Rate of COVID-19 positive conversion","All-cause mortality at 30 days after admission","quantify and qualify distress over a large population in times of pandemic crisis.","ACE2 level change over time","Reduction in COVID-19 infection frequency","Positive or negative character of the three tests;Positive or negative character of the three tests","Duration of viral shedding in days;Time to clinical recovery (TTCR) in days;Treatment-emergent adverse events (AEs)","Viral nucleic acid test negative conversion rate","Composite of cumulative death (i.e. mortality) for all causes and for specific causes.","Number of participants testing positive for COVID-19 infection","Rates of hospitalization for a COVID-19 related complication","days to cure;Days of turning negative on RT-PCR test","Symptom Reduction","Time to clinical improvement","Rates of return visits to the ED","Measure of the impact of COVID Emergency on surgical specialist training programs","Suitable for discharge","COVID-19 positive case","Frequency of Adverse Events","Stop home isolation;NEWS score","Number of participants with treatment-related adverse events as assessed by protocol definition of AE","Chest x-ray;Chest CT;Supportive care - ICU;Supportive care - oxygen therapy;Supportive care - ventilation;Medication;Therapeutic strategies;Lab parameters;Intra-hospital complications;Vital status at discharge","symptoms of COVID-19 in older patients","Time to diagnosis of COVID-19 by RT-PCR in subjects","Anxiety and depression represent a composite primary outcome, as measured by the Hospital Anxiety and Depression scale.[Pretreatment (week 1), posttreatment (week 7), primary follow-up (week 15). ]","Change in PaO2/FiO2","change in virus duration (viral shedding);change in the number of patients going from asymptomatic to moderately disease","Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available);Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)","Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).","Integration to community as measured on the Reintegration to Normal Living Index (RNLI) -  A 11-item questionnaire-based instrument that measures the degree to which individuals achieve reintegration into normal social activities (such as recreation, movement in the community, and interaction in family or other relationships). [Baseline, &lt;br&gt;Three (3) months following baseline assessment. ]","Extravascular lung water index EVLWI measured using TPTD (PiCCO; Pulsion Medical Systems; Feldkirechen Germany) daily from intubation until extubation","To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.;To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.;To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.;To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.","Proportion of alive patients free off mechanical ventilation","Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients;Type of respiratory support","Mortality at day 28","Percentage of patients with normalization of SpO2 =96%","Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.","Disease activity","Risk Factors;Immunulogical mechanisms;Long term outcome","&lt;br&gt;                1. Efficacy of candidate vaccine measured by virologically confirmed (PCR positive) symptomatic cases of COVID-19 over the course of 6 months&lt;br&gt;                2. Safety of candidate vaccine measured by the occurrence of serious adverse events (SAEs) over the course of 6 months&lt;br&gt;","Incidence of pandemic COVID-19 in pregnancy assessed as proportion of pregnant women hospitalised with confirmed COVID-19 disease per 100,000 maternities during the study period","Percentage of Participants with Adverse Events (AEs);Percentage of Participants with Administration (Injection) Site Reactions;Percentage of Participants with Adverse Events of Special Interest (AESIs);Change from Baseline in Antigen-Specific Binding Antibody Titers;Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-?) Cellular Immune Response","Prevalence of positivity of COVID-19 virus measured by rt-PCR","Titanium level","Evaluation of apgar status of newborns from covid 19 positive mothers","Fraction of healthcare workers infected with SARS-CoV-2","Recovery of Pneumonia","Changes in high-resolution computer tomography of the lung;Change in 6-minute walking distance","Death","Proportion (%) of subjects experiencing deterioration in clinical status;Treatment Emergent Adverse Events","The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.;The positivity (Yes/No) of the serological test.","Reduction in the number of COVID-19 infections in healthcare workers.","Mechanical ventilation requirement","Psycho Educational Profile,PEP;Self-Rated Anxiety Scale,SAS;Self-Rated Depression Scale,SDS;Parenting Stress Index-Short Form,PSI-SF;","Fever;","Health Outcomes","Body temperature;Blood pressure;Pulse (heart rate);Respiratory rate;Data provided by transpulmonary thermodilution-CI;Data provided by transpulmonary thermodilution-GEDV;Data provided by transpulmonary thermodilution-EVLW;Data provided by transpulmonary thermodilution-PVPI;Incidence of abnormal laboratory test results","Hospitalization","Risk of unfavourable outcome at D14","Successful treatment as determined by Negative Test and resolution of symptoms;Safety of Quintuple Therapy","Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)","Cause of death or invasive mechanical ventilation","Determine the incidence of cardiomyopathies and venous thromboembolism","survival;","Colour Sonography;electrocardiogram;Pulmonary function(TLC, FVC, FEV1, DLCO);","Survival without needs of ventilator utilization at day 14;WHO progression scale = 5;Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) or withdrawal of NIV or high flow (for &gt; 48h), at day 14;Decrease of at least one point in WHO progression scale score","Progression to advanced respiratory support","Characteristics of pulmonary ultrasound for Covid-19 patients","Rate of secondary aggravation","to investigate the prevalence and identify possible risk factors of the occurrence of a DVT in these patients at the ICU.","overall response rate in reversal of hyperinflammation","Correlation of FAST+ pulmonary findings with active COVID infection","T-cell immunophenotype","Environment viral load;","PSQI;","first occurrence of intensive care unit admission, mechanical ventilation or death","TTCI","Recovery time","Breath volatile organic compound profiles;Utility of breath profiles for disease diagnosis or prognosis","SARS-CoV-2 infection","Intraoral viral load","The self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)","Lung CT Score;","Shorten the duration of the disease;Antipyretic rate;Severe rate;Time of virus nucleic acid turning negative;Negative rate of viral nucleic acid;Time for improvement of lung image;PCT;CRP;IL-17;WBC;Lymphocyte subtype analysis;Blood gas analysis;","Time from randomization to clinical recovery","Covid 19 Anxiety levels in Endometriosis Patients",null,"Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).","HACOR score efficacy;HACOR score addaptation","Effect of HCQ on in vivo viral clearance","Effect of GI societies recommendations on prevention of SARS-CoV-2 infection;To measure the percentage change in performed endoscopic procedure in response to COVID-19","Time to clinical worsening","The Rapid Office Strain Assessment (ROSA)","Proportion of patients with onset of severe acute respiratory syndrome (SARS)","Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina;Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina","Death","-\tComposite endpoint with disease progression defined as a NEWS2score = 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.","Number of people that download the app and choose to check their health, perform the self-assessment and use the 7 day self-reported symptoms diary for one or more days.","Hierarchical composite endpoint","Rates of emergency visits needing surgical consult;The ratio of severe presentations to non-severe presentations","Laboratory Result;Clinical Outcome","Not hospitalized","Number of Ventilator Free Days","Evolution of consumption;Evolution of consumption","Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them","Depression;Anxiety symptoms;Stress related problems;Behavior and emotional problem among children and adolescents","Main Objective: To determine the prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (Part A).&lt;br&gt;To evaluate the Covid-19 disease mortality rate in cancer patients treated by hydroxychloroquine and azithromycin (Part B).&lt;br&gt;;Secondary Objective: To evaluate the safety, Covid-19 disease severity, response to cancer treatment, Progression-free survival (PFS), cancer mortality, and Overall Survival (OS) of cancer patients infected by SARS-Cov2.&lt;br&gt;To follow the evolution of SARS-CoV-2 infection and viral load in different compartments (nasal epithelia, blood and urine) during the course of therapy.&lt;br&gt;To evaluate the impact of mutation shifts in SARS-CoV-2 genotype (in sever cases only).&lt;br&gt;To follow the humoral and cellular immune responses to the virus, to cancer and control antigens during infection with SARS-CoV-2.&lt;br&gt;To deconvolute SARS-CoV-2-specific MHC class I and II binding epitopes to follow T cell responses with tetramers and Elispot assays, as well as cancer antigens (NY-ESO-1, MAGEn, preprocalcitonin, actinin...)-specific responses.&lt;br&gt;;Primary end point(s): The primary endpoints of the study are for the: &lt;br&gt;o\tPart A: prevalence at first visit and 12 weeks cumulative incidence (in a competing risk model with mortality) of SARS-CoV-2 positive subjects (RT-PCR)&lt;br&gt;o\tPart B: Covid-19 disease specific mortality;Timepoint(s) of evaluation of this end point: 12 weeks and 12 month (mortality)","Main Objective: Study if blockade of IL-6 +/- IL-1 to block the cytokine storm and acute lung injury in comparison with usual care reduces time to clinical improvement as defined by an increase of more than 2 on the 6 point ordinal scale or discharge from the hospital;Secondary Objective: -to investigate whether treatment with either tocilizumab, siltuximab, anakinra or combinations thereof&lt;br&gt;-improves oxygenation&lt;br&gt;-causes defervescence, measured as time to first fever-free 48h period&lt;br&gt;-improves features of secondary haemophagocytic lymphohistiocytosis&lt;br&gt;-improves features of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6 and IL-1&lt;br&gt;-affects clinical outcome in relation to IL-6 and IL-1 levels&lt;br&gt;-affects the rate of nosocomial infection&lt;br&gt;-affects progression to mechanical ventilation, high oxygen delivery device, and/or ARDS in non-ventilated patients&lt;br&gt;-affects length of dependency of ventilation in ventilated patients&lt;br&gt;-affects all-cause mortality rate at 4 and 20 weeks post inclusion&lt;br&gt;-affects long term 10-20 week follow up clinical status and lung function&lt;br&gt;-is safe (number of AEs/SAEs)&lt;br&gt;-When there is a significant association between IL-6 blockade and time to clinical improvement, tocilizumab and siltuximab will be compared versus usual care ;Primary end point(s): Time to clinical improvement (defined as the time from randomization to either an improvement of two points on a six-category ordinal scale measured daily till day 28 or discharge from the hospital or death)&lt;br&gt;1. Death&lt;br&gt;2. Hospitalized, on invasive mechanical ventilation or ECMO;&lt;br&gt;3. Hospitalized, on non-invasive ventilation or high flow oxygen devices;&lt;br&gt;4. Hospitalized, requiring supplemental oxygen&lt;br&gt;5. Hospitalized, not requiring supplemental oxygen&lt;br&gt;6. Not hospitalized;Timepoint(s) of evaluation of this end point: 28 days","For patients hospitalized for COVID-19 but not intubated;Primary objective for patients with COVID-19 already intubated","Describe the clinical features of COVID-19.&lt;br&gt;&lt;br&gt;(This is verbatim from submitted protocol)[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints. ];Describe the response to treatment, including supportive care and novel therapeutics, based on data linkage to medical records. (composite primary outcome)&lt;br&gt;&lt;br&gt;(This is verbatim from submitted protocol)&lt;br&gt;[Due to the nature of the evolving pandemic, there is no timeline for the assessment of primary timepoints.]","Number of cured patients","Decrease incidence of intubation by 30% or greater","Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)","negative testing of covid19","Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group;Clinical manifestations of Coronavirus Disease 2019 (COVID-19);Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort;Radiological features of Coronavirus Disease 2019 (COVID-19) cohort","NIMH COVID Study survey - adult responses","POCUS Score - Lungs;POCUS Score - Heart","Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs = 29).;Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21Depression); in terms of proportions (0-4 vs = 5).;Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21Anxiety); in terms of proportions (0-3 vs = 4).;Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21Stress); in terms of proportions (0-7 vs = 8).","Main Objective: Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be allocated to immunotherapy treatment according to their needs.  ;Secondary Objective: Not applicable;Primary end point(s): The study primary endpoint is composite and contains the achievement of at least one of the following goals or both goals after 7 days (study visit of day 8):&lt;br&gt; At least 25% decrease of baseline total SOFA score or increase of the pO2/FiO2 ratio by at least 50%&lt;br&gt; Clinical improvement of lung involvement&lt;br&gt;Patients discharged from hospital alive before study visit of day 8 are considered achieving the primary endpoint. Patients dying before study visit of day 8 are considered non-achieving the primary endpoint.;Timepoint(s) of evaluation of this end point: Visit study day 8","Dose adjustment required to attain a steady-state target trough hydroxychloroquine concentration of 0.24mg/L using TDM (proportion of patients / magnitude of adjustments)&lt;br&gt;&lt;br&gt;Dose adjustment data will be collected and maintained by the senior ICU clinical pharmacist.[Up to the point of ICU discharge, in the first 10 days after commencement of initial HCQ dose, ]","Number of hospitalised patients who died within 28 days of randomisation, data collected via a secure web-based case report form","Time to clinical improvement","Distress measured on Kessler Psychological Distress Scale (K10)[Baseline, post-intervention (within one week since the completion of the intervention, primary endpoint), 3 months post-intervention]","COVID-19 Anxiety (adapted SARS-Anxiety-Scale) at 3 time periods of 2 weeks over 6 months","&lt;br&gt;                1. Incidence and risk factors for invasive aspergillosis (IA) in the study cohort (as per modified AspICU criteria):&lt;br&gt;                1.1. Diagnostic classification of Influenza-associated aspergillosis (IAA) during ICU admission as per modified AspICU criteria, determined at the end of ICU stay&lt;br&gt;                1.2. Risk factors to be elicited from baseline clinical data points collected at enrolment (within three days of ICU admission) and ICU therapeutics/interventions collected at the end of ICU stay&lt;br&gt;","Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs);Phase 2: Cumulative incidence of serious adverse events (SAEs);Phase 2: Changes in white blood cell count (CBC) through Day 15;Phase 2: Changes in hemoglobin through Day 15;Phase 2: Changes in platelets through Day 15;Phase 2: Changes in creatinine through Day 15;Phase 2: Changes in glucose through Day 15;Phase 2: Changes in prothrombin time (PT) through Day 15;Phase 2: Changes in total bilirubin through Day 15;Phase 2: Changes in ALT through Day 15;Phase 2: Changes in AST through Day 15;Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS);Phase 2: Changes in hemoglobin through End of Study (EOS);Phase 2: Changes in platelets through End of Study (EOS);Phase 2: Changes in creatinine through End of Study (EOS);Phase 2: Changes in glucose through End of Study (EOS);Phase 2: Changes in prothrombin time (PT) though End of Study (EOS);Phase 2: Changes in total bilirubin through End of Study (EOS);Phase 2: Changes in ALT through End of Study (EOS);Phase 2: Changes in AST through End of Study (EOS);Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15","PaCO2;Driving Pressure;Tidal volume","Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19","28 day all cause mortality","Proportion of participants alive and not having required intensive respiratory support (invasive or non-invasive ventilation or humidified high flow nasal oxygen flow) at 15 days after enrolment.&lt;br&gt;&lt;br&gt;This outcome is assessed by the number of patients who are not admitted into the intensive care unit (ICU)&lt;br&gt;&lt;br&gt;[15 days after enrolment]","Impact of Nasodine on the reduction in virus in the nasal passages of subjects who are shedding the virus.  Virus concentration is  measured by PCR analysis of cell culture medium 96 hours after inoculation with a post-treatment nasal swab and compared to an equivalent culture inoculated with swab collected prior to treatment.[Endpoint is swab taken 5 minutes after dosing and compared against a swab taken 5 minutes prior to dosing.]","Composite outcome comprising tracheal intubation or mortality within 30 days. Mortality will be reported from hospital records up until discharge and tracked after discharge. Intubation will be obtained from hospital data.","All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study","ECG changes associated with COVID-19","PTSD Family members sup 22","Efficiency of the telephone consultation","Changes in Glucose Llevels","cardiopulmonary function;motor function;","Total distances of 6 minutes walk test;","clinical characteristics and risk factors of death;inflammatory factors;","attitudes toward COVID-19;Consciousness awareness toward COVID-19;","Monitoring of adverse events within 24 hours after infusion (including infusion related events and severe adverse reactions associated with non-primary disease);","Perioperative fever;Perioperative cough;Outcome of lung CT;Operative time;Volume of Postpartum hemorrhage;postoperative hospitalization;Stay in isolation ward;Apgar score of newborn;Neonatal admission to NICU;Medical observation of personnel involved in the operation;","positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.","Duration of viral shedding","Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first","Number of antibodies against coronaviruses isolated and identified from patient samples","Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;","NGAL;MAU;cystatin C;Beta 2-MG;","Lung CT after 3 days;Lung CT after 7 days;Oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), PaO2/FiO2;Hospital stay;Novel coronavirus nucleic acid detection;Recurrence rate;","mortality and end of mechanical respiratory support.","Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis;Distribution of COVID-19 risk factors by participant characteristics;Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization);Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study;Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment","Symptomatic laboratory-confirmed COVID-19;Symptomatic laboratory-confirmed VRI","Mortality;Viral Load;Serum Antibody Titers","Incidence","mortality;",null,"Our primary study parameter is the percentage of participants with a positive IgM or IgG response admitted to the hospital.","Patients will receive regular care as indicated by the treating physician. LUS is performed immediately in  the  Emergency  Department  or after  admissionto  the hospital. SARS-CoV-2  PCR testing  will  be performed along with standard laboratory testing and other microbiological tests to detect pathogens that cause respiratory tract infection.CT-scan during admission is only performed if this is clinically indicated or protocol during COVID outbreak.","28-day mortality","Elevation of proper hygiene behaviour (behavioural change)","Change in stress level as measured by survey","14-Day Mortality","Mortality[During Intensive care unit stay &lt; 14 days];Mortality[28 day post discharge from ICU];Length of stay intensive care unit from patient medical record[Discharge from intensive care]","Main Objective: To compare the effect of discontinuation versus continuation of RAS blockers on the clinical course of patients with confirmed COVID-19 infection leading to hospitalization;Secondary Objective: 1.\tEvaluate the cardiovascular safety of RAS blockers discontinuation in patients hospitalized for COVID-19 by a composite endpoint of MACE.&lt;br&gt;2.\tEvaluate the efficacy of RAS blockers discontinuation in patients hospitalized for COVID-19 by the secondary efficacy endpoints.&lt;br&gt;;Primary end point(s): Primary endpoint: &lt;br&gt;Time to clinical improvement from day 0 to day 28.&lt;br&gt;Clinical improvement is defined as an improvement of two points  on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first,  as recommended by the WHO R&amp;D Blueprint expert group (3).&lt;br&gt;&lt;br&gt;The seven-category ordinal scale consisted of the following categories: &lt;br&gt;1.\tnot hospitalized with resumption of normal activities &lt;br&gt;2.\tnot hospitalized, but unable to resume normal activities&lt;br&gt;3.\thospitalized, not requiring supplemental oxygen &lt;br&gt;4.\thospitalized, requiring supplemental oxygen&lt;br&gt;5.\thospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both&lt;br&gt;6.\thospitalized, requiring ECMO, invasive mechanical ventilation, or both&lt;br&gt;7. death. ;Timepoint(s) of evaluation of this end point: 28 days","Maternal mortality from COVID-19[During pregnancy until 6 weeks postpartum];Perinatal mortality (stillbirth, neonatal death)[During pregnancy and until day 28 in the neonate]","Efficacy of Hydroxychloroquine in the community-based management of COVID-19 assessed by the mean daily InFLUenza Patient-Reported Outcome (FLU-PRO) illness severity score[Day 5 of treatment administration]","time to liberation from ventilation and supplemental oxygen and alive during a 28day period after randomization","Main Objective: To improve survival &lt;br&gt;&lt;br&gt;AND&lt;br&gt;&lt;br&gt;remove criteria of severe COVID-19 (CoV-2 infection) within 21 days after randomization;Secondary Objective: - Time to clinical improvement on WHO R&amp;D Blueprint seven-category ordinal scale by 2 &lt;br&gt;- Adverse events &lt;br&gt;- Case fatality rate on days 21, 35 and 60&lt;br&gt;- Length of hospital stay&lt;br&gt;- Length of ICU stay &lt;br&gt;- Duration of ventilation Support / ECMO&lt;br&gt;- Time until negative SARS-CoV-2 PCR&lt;br&gt;- Predictive value of comorbidities and inflammation markers &lt;br&gt;- Feasibility of collection of plasma units &lt;br&gt;- Kinetics of anti-SARS-CoV-2 antibodies in plasma of patients = plasma donors who recovered &lt;br&gt;   from a SARS-CoV-2 infection&lt;br&gt;- Titer of anti-SARS-CoV-2 in transfused plasma units&lt;br&gt;- Impact of donor characteristics on anti-SARS-CoV-2 humoral response&lt;br&gt;- Course of anti-SARS-CoV-2 titer in patients &lt;br&gt;- Effect of timing of plasma transfusions on outcome&lt;br&gt;;Primary end point(s): Composite endpoint of:&lt;br&gt;&lt;br&gt;- Survival &lt;br&gt;&lt;br&gt;AND&lt;br&gt;&lt;br&gt;- no longer fulfilling criteria of severe COVID-19 within 21 days after randomization&lt;br&gt;&lt;br&gt;All criteria must be met in order to fulfill the primary endpoint.&lt;br&gt;;Timepoint(s) of evaluation of this end point: Treatment group: Day 21&lt;br&gt;&lt;br&gt;Control group: Days 14 and 21","Main Objective: The main objective of this trial is To estimate the efficacy of several specific experimental treatments, compared to standard care, to prevent hospitalization or death at D14 in adults over 65 years of age, with documented SARS-CoV-2 infection, with symptoms lasting less than 72 hours and not meeting any hospitalization criteria.;Secondary Objective: To estimate :&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2, to prevent death on D28&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2, to prevent hospitalization on D28&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent hospitalization in intensive care on D28&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2 to suppress nasopharyngeal viral carriage, compared to standard care&lt;br&gt;- the effectiveness of experimental treatments against SARS-CoV-2, compared to standard care, to prevent a loss of autonomy on D14 and D28&lt;br&gt;- the tolerance of experimental treatments against SARS-CoV-2&lt;br&gt;- Study the factors associated with the worsening of the disease&lt;br&gt;- Evaluate the feasibility and acceptability of the trial and the care model implemented&lt;br&gt;- Assess the relationship between the concentration of each drug and the effectiveness of each treatment;Primary end point(s): Proportion of participants with an occurrence of hospitalization and/or death between D0 and D14 in each arm;Timepoint(s) of evaluation of this end point: day 14 after inclusion","Main Objective: Assess, in patients with ARDS caused by COVID-19, the efficacy of dexamethasone (DXM) associated with hydroxychloroquine (HCQ) compared to HCQ alone on mortality at 28 days;Secondary Objective: Assess, in patients with ARDS causedd by COVID-19, the efficacy of DXM associated with HCQ compared to HCQ alone on :&lt;br&gt;- the ventilator-free days&lt;br&gt;- mortality in intensive care unit&lt;br&gt;- mortality on D60&lt;br&gt;- the occurrence of infectious complications ;Primary end point(s): Mortality on D28&lt;br&gt;;Timepoint(s) of evaluation of this end point: the 28th day after the start of treatment&lt;br&gt;","In non-ventilated patients- Mean change in the worst (highest) level of oxygenation (oxygen flow in litres/min). This will be assessed by the nursing documentation in the participant's electronic record of the flow rate of oxygen delivered and the delivery method (ie nasal prongs, Hudson mask, or non-breather mask). &lt;br&gt;In ventilated patients- Mean change in the worst (lowest) PaO2 /FiO2 ratio (in mmHg). This will be assessed by nursing documented PaO2 and FiO2 levels in the patient chart.[Worst recorded level of oxygenation during the 7 days of intervention.];Feasibility will be assesses by the following measures:&lt;br&gt; The primary assessment of our ability to blind treatment of the HDIVZn in a 250-ml saline preparation&lt;br&gt; Drug availability from supplier, storage and timely delivery to a patient&lt;br&gt; Good clinical practice documentation of drug prescription on Cerner (an electronic medical record), delivery to ICU by project research officer, double signing by nursing staff&lt;br&gt; Appropriate preparation of drug- onsite refrigeration storage, preparation with SOPs, maintenance of sterile conditions, protocol compliance, breaches, and variation, documentation processes including patient retention and follow-up rates&lt;br&gt; Determine the per-patient cost to estimate subsequent pivotal trial costs&lt;br&gt; Assess the process for efficient and effective data entry and analysis&lt;br&gt;These will be assessed by our research investigators on a regular basis and data collected in the case report forms.[During 7 days of intervention]","Insomnia severity measured using the Insomnia Severity Index at one week post-intervention","Main Objective: The aim of this core protocol is to compare the effects on major outcomes in hospital of the local standard of care alone versus the local standard of care plus one of four alternative anti-viral agents. &lt;br&gt;&lt;br&gt;The primary objective of this large international randomised trial is to provide reliable estimates on any effects of these anti-viral treatments on in-hospital mortality in moderate and in severe COVID;Secondary Objective: The secondary objectives are to assess any effects of these anti-viral treatments on hospital duration and receipt of ventilation or intensive care, and to identify any serious adverse reactions.;Primary end point(s): The primary outcome is all-cause mortality, subdivided by severity of disease at the time of randomisation.;Timepoint(s) of evaluation of this end point: At discharge or death.","Main Objective: To determine the efficacy of the intravenous infusion of Defibrotide (Defitelio) to reduce mortality in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.;Secondary Objective: To assess the safety of intravenous Defibrotide (Defitelio) infusion in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.&lt;br&gt;? To analyze the effects of the intravenous infusion of Defibrotide (Defitelio) on the clinical state of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.&lt;br&gt;? Assess the capacity of intravenous infusion of Defibrotide (Defitelio) to improve the radiological response of patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6 according to the WHO classification.&lt;br&gt;? Study the action of Defibrotide (Defitelio) on risk biomarkers in patients with SARS-CoV-2 infection with grade 4, 5 or 6 clinical status according to the WHO classification.;Primary end point(s): Mortality rate 30 days after starting treatment.;Timepoint(s) of evaluation of this end point: 15, 30 ,60 days","Hospital admission for any reason among patients who tested positive for SARS-CoV-2 within 30 days following initial consultation for SARS-CoV-2 testing. Information will be collected from participants via follow-up phone calls at days 7, 14, and 60 after consultation, as well as via patient records from general practitioners and/or treating physicians in hospitals after 60 days.","The need for hospital admission or death, for patients aged =50 years with comorbidity, and aged =65 with or without comorbidity and suspected COVID-19 infection during time of prevalent COVID-19 infections, measured by hospital admission or mortality related to suspected COVID-19 within 28 days","Main Objective: To assess the efficacy of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals by negative PCR.;Secondary Objective: To assess the safety of hydroxychloroquine as chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.&lt;br&gt;&lt;br&gt;To assess the efficacy of personal protective equipment against SARS-CoV-2 (COVID-19) infection in healthcare professionals;Primary end point(s): Diagnosis of SARS-CoV-2 COVID-19 infection;Timepoint(s) of evaluation of this end point: - At the end of prophylaxis treatment&lt;br&gt;- Fourteen days after the last dose of treatment","Main Objective: Demonstrate the therapeutic effectiveness of Hydroxychloroquine associated with Azithromycin treatment for symptom control and negative viral load, in patients with comorbidities without pneumonia and COVID-19 infection.;Secondary Objective: - Evaluate the safety of the treatment&lt;br&gt;- Assess tolerance of treatment;Primary end point(s): Proportion of patients with negative viral load by CODV-19 [SARS-CoV-2 (PCR)] at 6 days after the start of treatment;Timepoint(s) of evaluation of this end point: 30 DAYS","Main Objective: To evaluate the efficacy of intratracheal administration of dornase alfa (Pulmozyme) on the evolution of ventilatory parameters at D7;Secondary Objective: 1) all-cause mortality at D28&lt;br&gt;2) the clinical evolution at D28 ;&lt;br&gt;3) the duration of mechanical ventilation;&lt;br&gt;4) the number of days without mechanical ventilation at D28;&lt;br&gt;5) the length of stay in intensive care ;&lt;br&gt;6) the concentrations of blood markers of inflammation over time;&lt;br&gt;7) NET concentrations in bronchial secretions over time&lt;br&gt;8) the occurrence of adverse events;Primary end point(s): Comparison between the two treatment arms of the evolution of the PaO2/FiO2 ratio between D0 (inclusion) and D7;Timepoint(s) of evaluation of this end point: D7","Main Objective: To determine the protective efficacy of mefloquine prophylaxis against placebo in close contacts of people with COVID-19.;Secondary Objective: -Establish if the preventive administration of mefloquine attenuates the clinical manifestations of COVID-19 in people who become infected.&lt;br&gt;-Evaluate the safety of prophylactic mefloquine in this setting.;Primary end point(s): COVID-19 infection.;Timepoint(s) of evaluation of this end point: The patient will be evaluated weekly for 30 days from enrollment in the study to rule out / confirm COVID-19 infection.","partial pressure of arterial oxygen;","Incidence of SARS-CoV-2 infection (including confirmed SARS-CoV-2 detection, but might asymptomatic);Incidence of COVID-19 pneumonia;","Main Objective: To compare the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of COVID-19 disease during an epidemic period.;Secondary Objective: 1) To assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period.&lt;br&gt;&lt;br&gt;2) To evaluate the safety of PrEP with hydroxychloroquine in adults.&lt;br&gt;&lt;br&gt;3) To describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection.&lt;br&gt;&lt;br&gt;4) To identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection.&lt;br&gt;&lt;br&gt;5) To set up a repository (biobank) of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection.;Primary end point(s): Confirmed cases of a COVID-19 (defined by symptoms compatible with COVID-19 and/or a positive PCR for SARS-CoV-2) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative PCR for SARS-CoV-2 at day 0.;Timepoint(s) of evaluation of this end point: 6 months","Adverse reactions 0-14 days post vaccination;Anti-S antibody IgG titer on day 28 post vaccination;Anti-SARS-CoV-2 neutralizing antibody titer on day 28 post vaccination;","semen;feces;blood;urine;","new coronavirus nucleocapsid (N) antigen;SEN, SPE, ACC, AUC of ROC;","proteomics;metabonomics;S antibody IgG;S antibody IgM;S-RBD antibody IgG;S-RBD antibody IgM;N antibody IgG;N antibody IgM;SEN, SPE, ACC, AUC of ROC;","To assess achieved immunity against COVID-19 across the different age groups in The Netherlands by testing a representative part of&lt;br&gt;the Dutch population for the presence of SARS-Cov-2 specific antibodies in serum","-To describe the clinical presentation (symptoms) of pregnant women who tested positive on SARS-CoV-2&lt;br&gt;-To describe the clinical course of COVID-19 infection during pregnancy","Diagnostic accuracyof LUSand CT in COVID-19 patients","30-day mortality (from randomization)","Main Objective: To demonstrate the superiority of naproxen treatment addition to standard of care compared to standard of care in term of 30-day mortality;Secondary Objective: To demonstrate the effect of naproxen treatment to in-hospital mortality, morbidity, virus concentration;Primary end point(s): 30-day mortality all causes;Timepoint(s) of evaluation of this end point: 30 days","Main Objective: The primary objective of Phase II is:&lt;br&gt; To explore the effect of IFX-1 on COVID-19 related severe pneumonia (hypothesis generating)&lt;br&gt;&lt;br&gt;The primary objective of Phase III is&lt;br&gt; To demonstrate the efficacy of IFX-1 to improve of symptoms and outcome of severe COVID-19 pneumonia (confirmative)&lt;br&gt;;Secondary Objective: The secondary objectives of Phase II and Phase III are:&lt;br&gt; To assess and define other parameters of efficacy&lt;br&gt; To assess the safety of IFX-1&lt;br&gt;;Primary end point(s): Phase II: &lt;br&gt;The primary endpoint in Phase II is the relative change (%) from baseline (day 1 prior to study drug administration at  1h of randomization) in Oxygenation Index (PaO2 / FiO2) in supine position at day 3, 5, 9, and 15.&lt;br&gt;&lt;br&gt;Phase III: &lt;br&gt;The primary, secondary, and other endpoints for Phase III are the same as those for Phase II if not adjusted according to recommendations of the expert committee.&lt;br&gt;;Timepoint(s) of evaluation of this end point: Day 3, 5, 9 and 15","Secondary Objective: 1. To evaluate the occurrence of adverse events in each arm,&lt;br&gt;2. To evaluate the discontinuation rates of the investigational drug in each arm,&lt;br&gt;3. To evaluate the adherence of participants to study drug,&lt;br&gt;4. To evaluate the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,&lt;br&gt;5. To evaluate the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm, at to 2,5 months after randomization,&lt;br&gt;6. To evaluate the incidence of severe cases of SARS-CoV-2 infection in each arm. ;Primary end point(s): The primary endpoint is the occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs) &lt;br&gt;An infection by SARS-CoV-2 is defined by either:&lt;br&gt; a positive specific RT-PCR on periodic systematic nasopharyngeal swab during follow-up&lt;br&gt;OR&lt;br&gt; a positive specific RT-PCR on a respiratory sample in case of onset of symptoms consistent with COVID-19 during follow-up&lt;br&gt;OR&lt;br&gt; a seroconversion to SARS-CoV-2 after randomization.;Timepoint(s) of evaluation of this end point: Day: 7, 14, 21, 28, 35, 42, 49, 57, 71 after the start of the drug;Main Objective: To explore whether a 2-month treatment with either LPV/r or hydroxychloroquine may reduce the incidence of symptomatic or asymptomatic infection by SARS-CoV-2, as compared to their placebo in healthcare workers exposed to SARS-CoV-2.","Main Objective: The main objective is to compare versus standard of care short-term mortality rates in advanced or metastatic cancer patients who are positive for COVID-19 treated with a chloroquine analog (GNS561), an anti-PD1 (nivolumab) or an anti-IL-6R antibody (tocilizumab).;Secondary Objective: The secondary objectives will be to describe in each arm of the study:&lt;br&gt; Time to clinical improvement&lt;br&gt; Clinical status at days 7, 14 and 28&lt;br&gt; Mean change in clinical status from baseline to days 7, 14 and 28 &lt;br&gt; Overall survival &lt;br&gt; Length of stay in Intensive Care Unit and in Resuscitation Unit&lt;br&gt; Duration of mechanical ventilation or high flow oxygen devices&lt;br&gt; Duration of hospitalization&lt;br&gt; Rate of throat swab negativation at days 7, 14 and 28&lt;br&gt; Quantitative SARS-CoV-2 virus in throat swab at days 7, 14 and 28&lt;br&gt; Quantitative SARS-CoV-2 virus in blood at days 7, 14 and 28&lt;br&gt; Rate of secondary infection by other documented pathogens (bacteria, fungi)&lt;br&gt; Biological parameters (hematological parameters and markers of inflammation)&lt;br&gt; Safety of experimental treatments.&lt;br&gt;And to perform Cost-Effectiveness Analyses (CEA) with Incremental Cost-Effectiveness Ratios (ICERs) expressed in cost per Life Year Gained.&lt;br&gt;;Primary end point(s): The primary endpoint will be the 28-day survival rate, defined by the proportion of patients still alive 28 days after randomization. &lt;br&gt;;Timepoint(s) of evaluation of this end point: 28-day","Main Objective: The main objective is to assess the impact of dexamethasone on overall mortality at day-60 after randomization in patients admitted in ICU for severe COVID-19 infection.&lt;br&gt;In non mechanical ventilation (MV) patients, the additional objective is to assess whether oxygen support based on either HFNO or CPAP modality in COVID-19 related AHRF reduces the need for mechanical ventilation at day-28.&lt;br&gt;;Secondary Objective: For the study of the effect of corticosteroids, secondary objectives include: &lt;br&gt;1.To compare the evolution of the viral load in the respiratory tract &lt;br&gt;2.To compare the occurrence of healthcare-associated infections &lt;br&gt;3.To compare the exposition to mechanical ventilation &lt;br&gt;4.To compare the evolution of SOFA score &lt;br&gt;5.To compare the exposition to renal replacement therapy &lt;br&gt;6.To compare the lengths of ICU and hospital-stay&lt;br&gt;&lt;br&gt;For the study of the effect of oxygen support modalities, secondary objectives are, to compare each of oxygen support group to the control group in terms of: &lt;br&gt;1.overall survival&lt;br&gt;2.occurrence of healthcare-associated infections &lt;br&gt;3.length of ICU and hospital-stay&lt;br&gt;;Primary end point(s): , the primary endpoint is the time-to-death from all causes within the first 60 days after randomization.and the  time to need for mechanical ventilation (MV);Timepoint(s) of evaluation of this end point: october 2020","Main Objective: Main objective: &lt;br&gt;- To study the time (days) to reach clinical stability after randomization in hospitalized patients with severe pneumonia secondary  to COVID-19, and elevated inflammatory parameters.;Secondary Objective: Clinical &lt;br&gt;-time to reach an afebrile state during 48 hours. &lt;br&gt;-time to reach PaO2/FiO2 &gt;400 and/or SatO2/FiO2 &gt;400 &lt;br&gt;-time until you reach a FR = 24 rpm for 48 hours &lt;br&gt;-time to D-dimer normalization (&lt;250 ug/L) &lt;br&gt;-time until PCR is normalized (&lt;5mg/L). &lt;br&gt;-time to normalisation of ferritin (&lt;400ug/L). &lt;br&gt;-impact of immunosuppressive treatment on viral dynamics using quantitative PCR. &lt;br&gt;-duration of treatment with tacrolimus. &lt;br&gt;-duration of the inpatient stay. &lt;br&gt;-Percentage of patients requiring artificial respiratory support&lt;br&gt;-duration of artificial respiratory support needs to be maintained. &lt;br&gt;-mortality Incidence COVID at 28 and 56 days&lt;br&gt;-mortality incidence all-cause at 28 and 56 days &lt;br&gt;-relapses of COVID-19 pneumonia at 28 and 56 days&lt;br&gt;-Analysis of expanded cytokine profile (day 0 and every 7 days)&lt;br&gt;Safety&lt;br&gt;-side effects according to the severity attributed to tacrolimus during its administration. &lt;br&gt;-side effects according to the severity attributed to other treatments administered;Primary end point(s): Primary endpoint  (for the main objective of effectiveness): &lt;br&gt;- Time (days) to clinical stability after initiation of trial treatment in hospitalised patients with severe pneumonia secondary to COVID-19 and elevated inflammatory parameters;Timepoint(s) of evaluation of this end point: Throughout the study until clinical stability","Main Objective: To evaluate in-hospital mortality or mechanical ventilation in the Intensive Care Unit (ICU), or need for a rescue dose of tocilizumab in patients with confirmed infection by COVID-19 in treatment with hydroxychloroquine and azithromycin combined or non-tocilizumab.;Secondary Objective: To assess the clinical efficacy of tocilizumab in COVID-19 infection compared to the control arm by:&lt;br&gt;&lt;br&gt;Clinical severity:&lt;br&gt;Patient score according to the WHO 7-point ordinal scale&lt;br&gt;National Early Warning Score (NEWS)&lt;br&gt;Oxygen therapy&lt;br&gt;Mechanic ventilation&lt;br&gt;Hospitalization&lt;br&gt;Mortality at 15, 30 and 90 days&lt;br&gt;&lt;br&gt;To assess the safety of the intervention 30 days after treatment compared to the control arm.&lt;br&gt;&lt;br&gt;To assess the safety of the intervention at 90 days of treatment compared to the control arm.&lt;br&gt;- Cumulative incidence of serious adverse effects (SAEs).&lt;br&gt;- Cumulative incidence of grade 3 and 4 adverse effects (AEs).&lt;br&gt;- Discontinuation or suspension of treatment for any reason.&lt;br&gt;- Changes in the white blood cell count, hemoglobin, platelets, creatinine, glucose, total bilirubin, AST, ALT, GGT, LDH, C-reactive protein, D-dimer, troponin, ferritin, fibrinogen, KL-6 during follow-up.;Primary end point(s): In-hospital mortality or need for mechanical ventilation in the Intensive Care Unit.;Timepoint(s) of evaluation of this end point: During hospitalization","Main Objective: To assess the efficacy of a daily single dose of TDF (300 mg)/FTC (200 mg), a daily single dose of HC (200 mg), daily single dose of TDF (300 mg)/FTC (200 mg) plus HC (200 mg) or placebo, during 12 weeks in: (1) reducing the incidence of symptomatic disease and (2) reducing the clinical severity of the coronavirus infection (COVID-19) among hospital healthcare workers aged 18 to 65 years who are exposed to coronavirus infection (COVID-19) in Spain.;Secondary Objective: not applicable;Primary end point(s): number of symptomatic confirmed infections by SARS-CoV-2 (COVID-19);Timepoint(s) of evaluation of this end point: 12 weeks treatment + 4 weeks F/U","Main Objective: Evaluate the effect of hydroxychloroquine (HCQ) + standard of care as compared to standard of care only on oxygen saturation/fraction of inspired oxygen (SpO2/FiO2) ratio  in adult patients hospitalized with moderate to severe Coronavirus Disease 2019 (COVID-19) ;Secondary Objective: Evaluate the clinical efficacy of HCQ + standard of care as compared to standard of care only in adult patients hospitalized with moderate to severe COVID-19&lt;br&gt;Evaluate the effect of HCQ + standard of care as compared to standard of care only on the virologic load in nasopharynx as assessed by quantitative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) counts in adult patients hospitalized with moderate to severe COVID-19  &lt;br&gt;Evaluate the safety of HCQ + standard of care as compared to standard of care ;Primary end point(s): 1. Phase 2: Change in SpO2/FiO2 ratio from baseline  to  Day 15.&lt;br&gt;2. Phase 3 (may be reassessed after review of phase 2): Change in SpO2/FiO2 ratio from baseline to Day 15;Timepoint(s) of evaluation of this end point: 1, 2. Baseline to Day 15","Main Objective: To evaluate the efficacy of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary tp SARS-CoV-2 .;Secondary Objective: To evaluate the safety of methylprednisolone treatment, added to the standard treatment, in patients with ARDS secondary to SARS-CoV-2.;Primary end point(s): The primary end point of efficacy will be death for any cause in the first 28 days after randomization.;Timepoint(s) of evaluation of this end point: The first 28 days after randomization."],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"30/04/2020",null,null,null,null,null,null,null,null,null,"31/08/2021",null,null,null,null,null,"31/01/2021","30/04/2020",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"01/04/2021",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"30/04/2020",null,null,null,null,null,null,null,null,"31/12/2020","31/12/2022",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"30/06/2021",null,null,"01/01/2021","05/08/2021",null,null,null,null,null,null,"05/05/2021","25/03/2021",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"06/04/2022",null,null,"31/12/2020","24/03/2021",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null],["No","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","No","Yes","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","Yes","Yes","No","Yes","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","Yes","No","No","No","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","Yes","No","No","Yes","No","Yes","No","Yes","No","Yes","No","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","No","Yes","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","Yes","No","No","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","No","No","Yes","No","Yes","Yes","Yes","No","Yes","No","No","No","Yes","Yes","Yes","Yes","No","Yes","No","No","No","Yes","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","No","Yes","Yes","No","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","No","Yes","No","No","No","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","No","No","No","No","Yes","Yes","Yes","Yes","Yes","No","No","No","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","Yes","No","Yes","No","Yes","Yes","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","No","No","No","No","Yes","No","No","No","No","No","Yes","Yes","No","No","No","Yes","No","No","Yes","No","Yes","No","No","No","No","Yes","No","No","Yes","No","No","Yes","Yes","No","No","No","No","No","No","No","No","No","Yes","No","Yes","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","No","No","No","Yes","Yes","No","No","No","No","Yes","Yes","Yes","Yes","No","Yes","No","Yes","No","No","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","No","No","No","No","No","Yes","Yes","No","No","No","No","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","No","No","No","No","No","No","No","Yes","No","Yes","No","No","No","Yes","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","No","Yes","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","No","No","No","No","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","Yes","Yes","No","Yes","Yes","No","No","No","Yes","No","No","No","No","No","No","Yes","No","Yes","No","No","Yes","No","Yes","Yes","No","No","No","No","Yes","No","No","Yes","No","Yes","Yes","Yes","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","No","No","No","No","Yes","Yes","No","No","Yes","Yes","Yes","Yes","No","No","Yes","No","No","No","No","No","No","Yes","No","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","No","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","Yes","Yes","Yes","Yes","No","No","Yes","No","Yes","Yes","Yes","Yes","No","No","Yes","No","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","Yes","No","Yes","No","Yes","Yes","No","Yes","Yes","No","No","Yes","No","No","No","Yes","No","Yes","Yes","No","Yes","Yes","Yes","Yes","Yes","Yes","No","No","No","Yes","No"],["False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","False","True","True","False","True","False","False","True","False"],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"child",null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"parent","parent",null,"parent",null,null,"parent",null],[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>TrialID<\/th>\n      <th>Last Refreshed on<\/th>\n      <th>Public title<\/th>\n      <th>Scientific title<\/th>\n      <th>Acronym<\/th>\n      <th>Primary sponsor<\/th>\n      <th>Date registration<\/th>\n      <th>Date registration3<\/th>\n      <th>Export date<\/th>\n      <th>Source Register<\/th>\n      <th>web address<\/th>\n      <th>Recruitment Status<\/th>\n      <th>other records<\/th>\n      <th>Inclusion agemin<\/th>\n      <th>Inclusion agemax<\/th>\n      <th>Inclusion gender<\/th>\n      <th>Date enrollement<\/th>\n      <th>Target size<\/th>\n      <th>Study type<\/th>\n      <th>Study design<\/th>\n      <th>Phase<\/th>\n      <th>Countries<\/th>\n      <th>Contact Firstname<\/th>\n      <th>Contact Lastname<\/th>\n      <th>Contact Address<\/th>\n      <th>Contact Email<\/th>\n      <th>Contact Tel<\/th>\n      <th>Contact Affiliation<\/th>\n      <th>Inclusion Criteria<\/th>\n      <th>Exclusion Criteria<\/th>\n      <th>Condition<\/th>\n      <th>Intervention<\/th>\n      <th>Primary outcome<\/th>\n      <th>results date posted<\/th>\n      <th>results date completed<\/th>\n      <th>results url link<\/th>\n      <th>Retrospective flag<\/th>\n      <th>Bridging flag truefalse<\/th>\n      <th>Bridged type<\/th>\n      <th>results yes no<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","columnDefs":[{"className":"dt-right","targets":8},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="fontes-oms" class="section level3">
<h3>Fontes OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-cfc3b74095dc2eda5088" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-cfc3b74095dc2eda5088">{"x":{"filter":"none","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10"],["ChiCTR","ClinicalTrials.gov","EU Clinical Trials Register","ANZCTR","ISRCTN","Netherlands Trial Register","IRCT","JPRN","TCTR","German Clinical Trials Register"],[602,438,42,13,12,12,8,5,2,1]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Source Register<\/th>\n      <th>n<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","columnDefs":[{"className":"dt-right","targets":2},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
</div>

</div>

<script>

$(document).ready(function () {

  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');

  // initialize mathjax
  var script = document.createElement("script");
  script.type = "text/javascript";
  script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
  document.getElementsByTagName("head")[0].appendChild(script);

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    theme: "cosmo",
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460
  });
});
</script>

</body>
</html>
